**P01**

**REPRODUCTIVE GENETICS**

**P01.001A An unusual number of high mutations expand in the male germline in tyrosine kinase receptors**

*Irene Tiemann-Boege*, Ingrid Hartl, Sofia Moura, Renato Salazar

1Biophysics, Linz, Austria.

**Background/Objectives:** The higher risk of older fathers having an affected offspring with early or late-onset rare disorders has been quite unsettling; but unfortunately, the methods have been limited to better characterize this phenomenon. So far, studies have focused on well-characterized mutations mainly identified in the receptor tyrosine kinase receptor (RTK) signalling pathway [1-3].

**Methods:** The establishment of duplex sequencing opened exciting new possibilities in ultra-rare variant detection with a very high accuracy for a sequencing-based method [4, 5]. This is the first study that has used this sequencing approach to explore this type of mutagenesis directly in sperm in the FGFR3 gene.

**Results:** We found mutations associated with congenital disorders at increased frequencies and identified new unreported selfish mutations expanding with age [6]. We further characterized the expansion of these in the male germline with droplet digital PCR and analysed the change in receptor signalling [7, 8].

**Conclusion:** Our work sheds light into different mutational mechanisms potentially affecting the receptor kinase activity.

**References:** 1 Arnheim, N. et al. Annu Rev Genomics Hum Genet 2016.
2 Goriely, A. et al. Am J Hum Genet 2012.
3 Shinde, D. N. et al. Hum Mol Genet 2013.
4 Kennedy, S. R. et al. PLoS Genet 2013.
5 Salk, J. J. et al. Nat Rev Genet 2018.
6 Salazar, R. et al. bioRxiv 2021.04.26.441422 2022.
7 Lanzestrofer, P. et al. PLoS One 2014.
8 Motsch, V. et al. Sci Rep 2019.

**Grants:** FWF1250, FWF30867000, REGGEN ATCZ207.

**Conflict of Interest:** Irene Tiemann-Boege Johannes Kepler University Linz, principal investigator, Ingrid Hartl Johannes Kepler University Linz, Sofia Moura: None declared, Renato Salazar: None declared.

**P01.002.B Using accurate duplex sequencing to explore the connection between elevated germline mutation rates, sperm selection, and male (sub)fertility**

*Jason Kunisaki*, Suchita Lulla, Xichen Nie, Joemly Ramsay, Yixuan Guo, Joshua Horns, Jim Hotaling, Kenneth Aston, Aaron Quinlan

1University of Utah School of Medicine, Human Genetics, Salt Lake City, United States; 2University of Utah School of Medicine, Oncological Sciences, Salt Lake City, United States; 3University of Utah School of Medicine, Surgery, Salt Lake City, United States; 4University of Utah School of Medicine, Biomedical Informatics, Salt Lake City, United States.

**Background/Objectives:** Elevated germline de novo mutation rates can impact health and fertility, especially in the context of male subfertility. In 2020, we associated elevated paternal germline mutation rates with reduced lifespans, mirroring the somatic theory of aging. Similarly, studies of subfertile men report elevated individual and familial cancer risks compared to
Abstracts from the 55th European Society of Human Genetics Conference

University Gießen, Gießen, Germany; Clinic for Urology, Paediatric Veterinary Anatomy, Histology and Embryology, Justus Liebig University, Alexander Busch, D. Fietz, Adrian Pilatz, Anders Juul, Sabine Urology and Andrology, Justus Liebig University Gießen, Gießen, Germany; Department of Growth and Reproduction, Rigshospitalet, Amsterdam, Netherlands, Hans Ivar Hanekv

Background/Objectives: Impaired testicular descent is a common cause for undescended testes in boys. Heterozygous variants in INSL3 and RXFP2 are proposed as associated with cryptorchidism but those variants are ongoing.

Methods: Analysis of germline mutation rates frequently involves the use of whole-genome sequencing from pedigrees. However, this strategy suffers from high sequencing error rates (10^-3) and the indirect determination of mutations in sperm. To account for this, we use TwinStrand Duplex Sequencing (TDS) on bulk sperm and blood samples to accurately detect true mutations in individual gametes as those occurring on complementary DNA strands, reducing our per-nucleotide error rate to <10^-9.

Results: Studying a normozoospermic individual’s bulk sperm and blood, we obtained high (≤50,000X) coverage across our sequencing panel. We estimate sperm and blood mutation rates of ~2e-7 (95% CI: 3.2-4.8e-7) and ~2.3e-7 (95% CI: 2.1-2.6e-7), respectively.

Conclusion: We find mutation rates in sperm to be elevated compared to those inferred from pedigree studies, and in line with expectations based on per-cell-division error rates. This supports a hypothesis that sperm with elevated mutation rates are selected against during capacitation and/or fertilization which has significant implications for IVF and ICSI procedures that bypass these processes. We will share results from additional samples to explore the link between mutation rates, male fertility, and health.

References:

Grants:

Conflict of Interest: None declared.

P01.004.D Associations between epigenetic biomarkers of aging and infertility

Yunsung Lee, Jan Bohlin, Christian Magnus Page, Haakon Egedevit Nustad, Jennifer Ruth Harris, Per Magnus, Astanand Jugessur, Maria Christine Magnus, Siri Höberg, Hans Ivar Hanekv

Background/Objectives: As more individuals in developed countries postpone parenthood, more experience infertility and use assisted reproductive technologies (ART). While the effect of increased chronological age on the risk of infertility is well known, the relationships between epigenetic biomarkers of aging and male or female infertility are understudied.

Methods: Using 1,945 mother-father pairs from the Norwegian Mother, Father and Child Cohort Study, we compared five epigenetic biomarkers of aging between 1,000 couples who conceived by coitus and 894 couples who conceived by ART – in vitro-fertilization (IVF, n = 525) and intracytoplasmic sperm injection (ICSI, n = 369).

Results: We found a significant difference in one epigenetic biomarker of a pace of aging, the standardized Dunedin Pace of Aging methylation (DunedinPoAm), between non-ART and IVF mothers (0.208, P-value = 0.0004) after adjustment for chronological age and potential confounders. Further, we detected elevated DunedinPoAm in mothers with tubal factor infertility (0.326, P-value = 0.0001), ovulation factor (0.248, P-value = 0.0075) and unexplained infertility (0.245, P-value = 0.0014) compared to non-ART mothers. No differences in epigenetic biomarkers of aging between non-ART and ICSI fathers were found. DunedinPoAm also showed stronger associations with smoking, education, and parity than other epigenetic biomarkers of aging.

Conclusion: In conclusion, DunedinPoAm captured a difference in the pace of epigenetic aging between non-ART and IVF mothers, indicating an association between female epigenetic aging and infertility.

References:

Grants: Research Council of Norway (Women’s fertility, project no. 320656 and Centres of Excellence Funding Scheme, project no. 262700) and the European Research Council under the European Union’s Horizon 2020 research, grant no. 947684.

Conflict of Interest: Yunsung Lee: None declared, Jon Bohlin: None declared, Christian Magnus Page: None declared, Haakon Egedevit Nustad: None declared, Jennifer Ruth Harris: None declared, Per Magnus Research Council of Norway. Centres of Excellence Funding Scheme (project no. 262700), Astanand
Jugessur: None declared, Maria Christine Magnus European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement number 947684). Siri Håberg Research Council of Norway. Women’s fertility (project no. 320656) and Centres of Excellence Funding Scheme (project no. 262700), Hans Ivar Hanevik Research Council of Norway. Women’s fertility (project no. 320656).

P01.005.A Aftermath of long-term cigarette smoking on telomere length and mitochondrial DNA copy number in human cumulus cells prior to In Vitro Fertilization

Fani Konstantinidou1,2, Maria Cristina Budani3, Francesca Gonzella1,2, Gian Mario Tiboni4, Liborio Stuppia1,2, Valentina Gatta1,2

1G. d’Annunzio” University of Chieti-Pescara, School of Medicine and Health Sciences, Chieti, Italy; 2G. d’Annunzio” University of Chieti-Pescara, Unit of Molecular Genetics, Center for Advanced Studies and Technology (CAST), Chieti, Italy; 3G. d’Annunzio” University of Chieti-Pescara, Department of Medical, Oral and Biotechnological Sciences, Chieti, Italy.

Background/Objectives: The female reproductive system represents a sensitive target of the harmful effects of cigarette smoke, with folliculogenesis as mostly affected by this exposure. Some of the main causes of ovarian injury can be represented by cigarette smoke-induced oxidative stress (OS), abnormal crosstalk between oocyte and granulosa-cells and increased cell death [1]. Studies have shown that smoking can also result in telomere shortening and mitochondrial dysfunction in human reproduction [2]. Based on these premises, we estimated the effect of tobacco smoking on telomere length and mitochondrial DNA (mtDNA) copy number in cumulus cells (CCs) of healthy smoking and non-smoking women (<35 years of age) enrolled from Assisted Reproductive Technology protocols.

Methods: DNA was manually extracted from CCs of all subjects and subsequently quantified. 96-well plates were prepared in order to perform dual quantification qPCR assays using telomere, mtDNA and a single copy reference primer sets, as well as a reference genomic DNA sample. Results were deemed significant when showing a fold change >1.4 or <0.7 and a P-value < 0.05 of smokers compared to corresponding controls.

Results: Statistical analysis indicated a significantly lower relative telomere length and mtDNA copy number (p-value ~ 0.014/0.012) of the target sample to the reference sample in CCs relative telomere length and mtDNA copy number (p-value ~ 0.014/0.012) of the target sample to the reference sample in CCs.

Conclusion: We discovered an association between BMP15 rs41308602 polymorphism and POI in Bulgarian patients and lack of association for FSHR polymorphisms with this condition.

References:

P01.007.C A GWAS of parental allelic interactions associated with subfertility

Siri Næerland Skodvin1, Miriam Gjerdevik1, Julia Romanowska1,2, Christian Magnus Page1,3,4, Yunsung Lee1, Astanand Jugessur1,2, Haakon Gjessing1

1Norwegian Institute of Public Health, Centre for Fertility and Health, Oslo, Norway; 2University of Bergen, Department of Global Public Health and Primary Care, Bergen, Norway; 3University of Oslo, Section for Statistics and Data science, Department of Mathematics, Faculty of Mathematics and Natural Sciences, Oslo, Norway; 4University of Oslo, PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, Oslo, Norway.

Background/Objectives: Subfertility is a heterogeneous phenotype, the causes of which are often unclear. One hypothesis is that the joint contribution of risk alleles in the parents may partly explain subfertility. We, therefore, performed a GWAS to study parental allelic interactions.

Methods: In the 29,199 pregnancies available for analysis in the Norwegian Mother, Father and Child Cohort Study (MoBa), 609 newborns were conceived using assisted reproductive technology (ART). We used ART as proxy for subfertility and analyzed interaction effects using logistic regression and a multiplicative

Abstracts from the 55th European Society of Human Genetics Conference 347
Abstracts from the 55th European Society of Human Genetics Conference

348

dose-response model, adjusting for principal components, age, and BMI.

Results: Our results revealed interaction effects between maternal and paternal SNPs and use of ART. Entries in various public gene databases indicated that several of the identified genes are highly expressed in tissues relevant for the phenotype studied here. For example, the gene for coiled-coil domain containing 171 (CCDC171, 9p22.3) is expressed in both testis and endometrium. Two other genes, DENN domain containing 6B (DENND6B, 22q13.33) and karyopherin subunit beta 1 (KPNB1, 17q21.32), are also expressed in testis.

Conclusion: Our results point to several significant interaction effects between maternal and paternal SNPs in genes that are highly relevant to subfertility. Further replications are necessary to confirm these findings.

References: Magnus et al. Cohort profile update: the Norwegian Mother and Child Cohort study (MoBa). Int J Epidemiol. 2016.

Gissing & Lie. Case-parent Triads: Estimating Single-and Double-dose Effects of Fetal and Maternal Disease Gene Haplotypes. Annals of human genetics. 2006.

Grants: Norwegian Research Council (grant 262700).

Conflict of Interest: None declared.

P01.008.D Establishment of the nPGT-A programme in two IVF centres

Antonio Urbano1;2;3, Marina Sánchez1;3, Isabel Ochando1;2;3, Mireia Poveda1;3, Juan Iníguez2;3, Estefanía Montoya1;3, Rosario Vazquez1;3, Juan Manuel Moreno5;4, Jose Jesús López-Gálvez5;4, JOAQUIN RUEDA1;2;3

1Unidad de Genética. Hospital HLA Vistahermosa, Alacant, Spain; 2Universidad Miguel Hernández (UMH), Departamento de Histología y Anatomía, UMH, Alicante, Spain; 3San Juan de Alicante, Spain; 4Cátedra de Biomedicina Reproductiva Vistahermosa, UMH, Alicante, Spain, Alacant, Spain; 5UR Vistahermosa, UR Grupo Internacional de Reproducción Asistida, Alacant, Spain; 6UR IMED Valencia, UR Grupo Internacional de Reproducción Asistida, Burjassot, Spain.

Background/Objectives: Preimplantation genetic testing for aneuploidy (PGT-A) selects euploid embryos, improving the results in in vitro fertilisation (IVF) cycles. The evolution of next-generation sequencing (NGS) has made it possible to reduce the amount of genetic material needed to obtain reliable results. NGS allows analysis of spent culture medium (SMC) to determine embryo ploidy, with even better concordance with embryo ploidy than trophectoderm biopsy (1). Non-invasive PGT-A (nPGT-A) promises to be one of the main tools for embryo selection, as it provides insight into embryo ploidy without altering embryo development at all. Our objective is to determine the best protocol for nPGT-A.

Methods: We established a nPGT-A programme in 2 IVF centres. We determined concordance, FPR and FNR. Centre A establishes a standard protocol for remove granulosa cells from oocyte and Centre B establishes a strict protocol for remove granulosa cells.

Results: Control: 47 SMC from vitrified embryos. Concordance 95.74% SMC vs TE, FNR of 2.13% and FPR 2.13%.

Centre A: 34 fresh SMC, 52.94% concordance, 38.24% FNR and 8.82% FPR.

Centre B: 16 fresh SMC. 100% concordance and 0% FPR and FNR.

Conclusion: nPGT-A is one of the best techniques for embryo selection, but it is necessary to establish a strict protocol for the removal of granulosa cells from the oocyte and/or embryo to ensure consistent results.

References: 1. Huang L, Bogale B, Tang Y, Lu S, Sunney X, Racowsky C. Noninvasive preimplantation genetic testing for aneuploidy in spent medium may be more reliable than trophectoderm biopsy. 2019:1-8. https://doi.org/10.1073/pnas.1907472116.

Grants: UMH-Citolab1.19A.

Conflict of Interest: None declared.

P01.009.A Experimental validation of PRD-like homeobox genes expressed in bovine oocytes and early IVF embryos

Bärş Yaşar1;2, Nina Boskovic1;2;3, Eeva-Mari Jouhilahti4, Piibe Villi1, Thomas Burglin5, Shintaro Katayama2;4;6, Tönis Org1;7, Juha Kere2;4;6, Ants Kurg1

1Institute of Molecular and Cell Biology, University of Tartu, Department of Biotechnology, Tartu, Estonia; 2Karolinska Institutet, Department of Biosciences and Nutrition, Huddinge, Sweden; 3Helsinki University Hospital, University of Helsinki, Department of Obstetrics and Gynecology, Helsinki, Finland; 4Stem cells and Metabolism and Biomedicum Stem Cell Centre, Faculty of Medicine, University of Helsinki, Research Programs Unit, Helsinki, Finland; 5University of Basel, Department of Biomedicine, Basel, Switzerland; 6Folkhålsan Research Center, Helsinki, Finland; 7Estonian Genome Centre, University of Tartu, Institute of Genomics, Tartu, Estonia.

Background/Objectives: Identification of genes involved in embryonic genome activation (EGA) in humans revealed a role of PRD-like homeobox genes during early embryo development. In this study we investigate bovine (Bos taurus) oocytes and pre-implantation embryos in order to clarify the possible roles of PRD-like homeobox genes in EGA.

Methods: Bovine oocytes/embryos were used to prepare cDNA by STRT-N which was followed by PCR for subsequent TOPO cloning and Sanger sequencing.

Results: We analysed RNA-seq data derived from a bovine model system to investigate the transcriptome in germlinal vesicle and metaphase II oocytes, and in embryos at the four-, eight-, 16-cell, and blastocyst stages. This revealed the expression of a similar set of early embryo PRD-like homeodomain transcription factors previously identified in humans. In addition, evolutionary comparisons of oocyte and early embryo transcription factors helped predict gene structures and the genomic location of these PRD-like homeobox genes. cDNA cloning allowed the validation of these genes in bovine as candidate igniters of EGA.

Conclusion: Orthologues of human PRD-like homeobox genes, ARFX, DUXX, NOBOX, LEUTX, TPRX1, and TPRX2 were experimentally identified in bovine at the transcript level. A TPRX duplicate, TPRX3, which was earlier predicted but not confirmed, was also shown to be expressed in bovine.

References: Töönen, V. et al. Novel PRD-like homeodomain transcription factors and retrotransposon elements in early human development. Nat Commun 6, 8207 (2015).

Grants: This work is funded from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 813707.

Conflict of Interest: None declared.

P01.010.B SizeMatters: a novel algorithm for fetal-fraction estimation based on fragment-size distributions

Jesper Eiffeldt1;2, Camilla Holmgren2, Malin Tirfing2, Anna Lindstrand1;2, Erik Iwarsson1;2, Agne Lieden1;2

1Karolinska Institute, Molecular medicine and surgery, Solna, Sweden; 2Karolinska University hospital, Clinical genetics, Solna, Sweden.

Background/Objectives: Non-invasive prenatal testing (NIPT) for trisomy 13,18, and 21 is performed on cell free DNA (cfDNA) extracted from peripheral blood from the pregnant woman. The
P01.011.C Shedding light on Endometriosis (EM) disease: Whole Exome Sequencing (WES) and new genes discovery in a fully clinical characterized Italian cohort

Aurora Santin1, Paola Tesolin1, Beatrice Spedicati1, Gabriella Zito2, Federico Romano3, Anna Morgan3, Maria Pina Concas3, Giuseppe Rici3, Giorgia Giroto3

1University of Trieste, Department of Medicine, Surgery and Health Sciences, Trieste, Italy; 2Institute for Maternal and Child Health – I.R.C.C.S. “Burlo Garofolo”, Department of Obstetrics and Gynecology, Trieste, Italy; 3Institute for Maternal and Child Health – I.R.C.C.S. “Burlo Garofolo”, Medical Genetics, Trieste, Italy.

Background/Objectives: EM is a multifactorial disease, involving the proliferation of endometrial epithelium and stromal tissue outside the uterine cavity. Despite its prevalence, little is known about the genetic factors involved.

Methods: To date, 50 EM adult women with a deep clinical evaluation (i.e., second-level ultrasound echography) were recruited and WES was performed. WES focused on a first list of 285 known EM genes and later on new candidates. Likely pathogenic variants have been selected and their frequency checked in 1000 controls, requiring large training sets and homogenous data. As such, there is a need to develop robust computational tools for the estimation of FF in both male and female fetuses. Herein, we present a novel algorithm (SM) based on a machine-learning consensus approach for FF estimation from DNA fragment size distribution in shallow genome sequencing data (sGS).

Methods: We develop the SM-algorithm, combining multilayer perceptron regression, support-vector machine, and multiple linear regression in a machine-learning framework.

Results: We analysed 4000 pregnancies using the SM-algorithm for FF estimation based on sGS data and fragment size distribution and compared it to current leading methods for sGS FF estimation. The SM-algorithm was able to successfully estimate FF, providing high concordance with FFY (median absolute error (MAE) = 0.9), significant correlation with trisomy 21 signal (r = 0.75), and final NIP test quality (fail < 1%).

Conclusion: Our novel algorithm for FF estimation provides a FF estimation in both male and female fetuses.

References: None.

Grants: None.

Conflict of Interest: None declared.

P01.012.D Design and validation of a next-generation sequencing workflow for simultaneous detection of aneuploidy, ploidy, and common pathogenic microdeletions within Preimplantation Genetic Testing (PGT)

Matteo Filiguzzi1, Silvia Caroselli1, Francesco Cogo2, Paola Zambon2, Cristina Patassini2, Dany Bakalova2, Federico Favero3, Attilio Anastasi3, Francesco Capodanno4, Andrea Gallinelli4, Danilo Cinamom5, Laura Rienzi6, Filippo Maria Ubaldi7, Carmen Rubio8, Jose Miravit-Valenciano9, Jorge Jimenez Almazan9, David Blesa10, Carlos Simon10, Antonio Cabalbo1

1Igenomix Italia, Reproductive Genetics, Rome, Italy; 2Igenomix Italia, Reproductive Genetics, Marostica, Italy; 3Igenomix UK, Reproductive Genetics, Guildford, United Kingdom; 4Arc-Ster, ART center, Mestre, Italy; 5Hospital “del Delta”, Pathophysiology of Human Reproduction Center, Lagasanto, Italy; 6GeneraLife, ART center, Rome, Italy; 7Igenomix Spain, Reproductive Genetics, Valencia, Spain.

Background/Objectives: Standard methodologies employed in preimplantation genetic testing allow to identify chromosomal aneuploidies but not to determine embryo ploidy status nor the presence of microdeletions (MD). Transferring embryos with these abnormalities can result in miscarriage, molar pregnancy, or multiple congenital anomalies, requiring later-stage invasive prenatal diagnosis. Our objective is the development of a novel NGS-based framework to resolve current limitations.

Methods: PGT-A products were reamplified and sequenced using a custom AmpliSeq panel targeting 357 genomic regions harboring high frequency SNPs and/or associated to 8 pathogenic microdeletions (-4p = Wolf-Hirschhorn, -8q = Langer-Giedion, -1p = 1p36 deletion, -22q = DiGeorge, -15q = Prader-Willi/Angelman, -11q = Jacobsen, -17p = Smith-Magenis). Sequencing data were analyzed by a bioinformatic algorithm which accounts for sequencing noise through gaussian-mixture modeling of B-allelic ratios measured at each SNP locus and estimates the likelihood of different ploidy levels and of the presence of MD.

Results: Ploidy was correctly determined in 233/234 cases, with only one diploid sample misclassified as triploid (PPV = 94.1%, NPV = 100%). Microdeletions could be consistently detected with high reliability (PPV = 98.5%, NPV = 99.5%) in 6 out of 8 microdeletion regions. Detection in -1p and -4p was less reliable due to the presence of recurrent haplotype blocks in the population, as confirmed by the analysis of a dataset of 2504 whole genome sequencing from 1KGP database.

Conclusion: This study provides, for the first time, detection of common pathogenic microdeletions and ploidy status from a single trophectoderm biopsy, expanding PGT clinical validity. This new assay will also help elucidate fundamental biological and clinical questions related to the genetics of implantation failure and pregnancy loss of apparently euploid embryos.

References: None declared.

Conflict of Interest: Matteo Filiguzzi Igenomix Italy, Silvia Caroselli Igenomix Italy, Francesco Cogo Igenomix Italy, Paola Zambon Igenomix Italy, Cristina Patassini Igenomix Italy, Dany Bakalova Igenomix UK, Federico Favero Arc-Ster, Attilio Anastasi: None declared, Francesco Capodanno: None declared, Andrea Bakalova Igenomix UK.
Gallinelli: None declared, Danilo Cimadomo GeneralLife, Laura Rienzi GeneralLife, Filippo Maria Ubaldi GeneralLife, Carmen Rubio Igenomix Spain, Jose Miravet-Valenciano Igenomix Spain, Jorge Jimenez Almazan Igenomix Spain, David Blesa Igenomix Spain, Carlos Simon Igenomix Spain, Antonio Capalbo Igenomix Italy.

P01.013.A Actionable secondary findings in infertile men and their clinical significance

Kristiina Lillepea1, Laura Kasak1, Liina Nagirnaja2, Kenneth Aston3, Don Conrad2, Margus Punab1;4;5, Maris Laan1

1University of Tartu, Institute of Biomedicine and Translational Medicine, Tartu, Estonia; 2Oregon Health & Science University, Oregon National Primate Research Center, Division of Genetics, Beaverton, OR, United States; 3University of Utah School of Medicine, Department of Surgery, Division of Urology, Andrology and IVF Laboratory, Salt Lake City, UT, United States; 4University of Tartu, Institute of Clinical Medicine, Tartu, Estonia; 5Tartu University Hospital, Andrology Center, Tartu, Estonia.

Background/Objectives: Whole exome sequencing (WES) has been increasingly used in medicine for patients with suspected genetic disorders. WES also enables the identification of secondary findings (SFs) – genetic variants in disease-causing genes that are unrelated to the patient’s primary condition but are still medically actionable. The prevalence of SFs in the general population is 1–3%; data of SFs in specific clinical conditions is limited. This study aimed to describe SFs in non-obstructive azoospermia (NOA) patients.

Methods: GEMINI1 represents a multi-center study aiming to map the genetic composition of NOA. We evaluated SFs across 85 genes in a cohort of 836 GEMINI participants from six countries. Recommendations from the American College of Genetics and Genomics (ACMG), the Geisinger Health System’s MyCode and the Clinical Genome Resource were used to compile the gene list.

Results: Based on the ACMG guidelines for the interpretation of genetic variants, we identified 27 SFs in 21 genes in 30 patients (3.6%, 30/836). The majority of these patients carried SFs in genes linked to familial cancer syndromes, followed by cardiac conditions. Moreover, 11 patients with SFs (37%, 11/30) carried variants in genes linked to spermatogenic failure in knockout mice. Clinico-molecular diagnoses were confirmed in multiple cases during a retrospective evaluation of patients with SFs.

Conclusion: Every 28th analyzed NOA patient carried a medically actionable SF. Disclosure of SFs is valuable in genetic disease prevention and intervention, and long-term health management of andrology patients.

References: 1. Nagirnaja et al. (2021) N Engl J Med; 385:707-719.

Grants: Estonian Research Council IUT34-12, PRG1021; NIH R01HD078641, F50HD096723.

Conflict of Interest: None declared.

PO01.014.B Asymptomatic male carriers of long copy number variants are predisposed to spermatogenic failure

Triin Kikas1, Laura Kasak1, Margus Punab2,3, Maris Laan1

1Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia; 2Andrology Centre, Tartu University Hospital, Tartu, Estonia; 3Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.

Background/Objectives: Infertility affects 7-10% of all men. About 60% of these cases remain idiopathic. Among other genetic factors, a burden of copy number variants (CNVs) has been suggested to increase the risk for spermatogenetic failure. Only a limited number of genome-wide studies have been conducted on the subject.

Methods: All study participants were recruited at the Andrology Center of Tartu University Hospital (2000-2015). The study group consists of azoosperma (no sperms, n = 73), severe (sperm count per ejaculate <10 mln, n = 83) or moderate oligozoosperma (10-39 mln, n = 58) and normozoosperma (≥39 mln, n = 63) cases. All individuals were genotyped using Illumina HumanOmniExpress-24-v1.0/v1.1 BeadChips. Calling of autosomal CNVs (>100bp) from the genotyping data was performed with three algorithms (GADA, QuantiSNP, and CNstream) (1). CNVs detected by at least two programs were included in the analysis.

Results: No difference was detected between the groups for the mean number (7.2-7.4) and length (101-120kb) of CNVs per subject. CNVs longer than >1Mb (n = 33) were located in pericentric regions and near telomeres. Three loci overlapped with known pathogenic CNV regions (1q21.1, 7p22.2, 14q32.33). A recurrent CNV within the CSMD1 gene (n = 4) was detected only in azoosperma and severe oligozoospermia cases, supporting its reported link to spermatogenic failure (2).

Conclusion: Large pericentromeric and subtelomeric CNVs may affect spermatogenesis through meiotic and mitotic chromosomal missegregation. CNVs located within genes showing enhanced testicular expression may compromise normal spermatogenesis.

References: 1. Kasak et al (2015) Sci Rep 5:8342. 2. Lee et al (2019) Nat Commun 10:4626.

Grants: PRG1021 (Estonian Research Council).

Conflict of Interest: None declared.

P01.015.C Novel STAR2D8 and STAR2D9 mutations identified in 46,XY gonadal dysgenesis patients lend support to these genes as DSD candidates

Ludmila Livshits1, Dmytro Sirokha1, Alexandra Gorodna1, Nataliya Zelinska2, Jadwiga Jaruzelska3, Kamila Kusz-Zamelczyk3, Serge Net4

1Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine, Laboratory of Human Genomics, Kyiv, Ukraine; 2Ukrainian Scientific and Practical Center for Endocrine Surgery, Transplantation of Endocrine Organs and Tissues, Ministry of Health of Ukraine, Kyiv, Ukraine; 3Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland; 4Faculty of Medicine, University of Geneva, Department of Genetic Medicine and Development, Geneva, Switzerland.

Background/Objectives: Investigating mutation in genes, affecting gonad development is essential for understanding the genetic mechanisms causing Disorders/Differences in Sex Development. The aim of the research was to identify novel DSD genetic variants using whole exome sequencing (WES).

Methods: The WES was performed for two unrelated 46,XY SRY positive patients with gonadal dysgenesis.

Results: In first patient the hemizygous missense mutation NM_001142503.2 c.2659C>T (p.Arg887Cys) (rs766188656) in STAR2D8 gene (MAF = 0.0000251) was identified and confirmed as pathogenic using bioinformatic tools. After analysis of second patient two deferent mutations in compound heterozygous state were identified in STAR2D9 gene: NM_020759.3 c.5585_5590del (p.Ser1862_Thr1863del) (rs766188656) in STAR2D8 gene (MAF = 0.0000251) combined with NM_020759.3 c.3514C>T (p.Arg1172Cys) (rs12594837) – missense mutation (MAF = 0.00837). The analysis of genetic background which were performed for both patients did not reveal any pathogenic variants implicated in DSD phenotype. All detected mutant variants were inherited from healthy parents – heterozygous carriers and were not previously implicated in the pathogenesis of any disease. Bioinformatic analysis revealed that
mutant variant in STARD8 and both mutations in STARD9 genes located in positions that are conserved in primates.

Conclusion: Based on the results obtained in current study, previous reports of STARD gene family mutations in DSD patients, expression patterns of STARD8 and STARD9 genes and steroidogenic properties of those protein products we conclude that STARD8 and STARD9 considered as 46,XY DSD causing genes.

References:

Grants: Study was funded by the Swiss National Science Foundation, grant number SCOPES IZ73Z0_152347/1 and National Academy of Sciences of Ukraine [0121U110054].

Conflict of Interest: None declared.

P01.016.D Using marginal analysis to optimise the number of tested genes for reproductive genetic carrier screening

Leslie Burnett1,2, Matthew Hobbs3, Heather Gordon1

1Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia; 2University of NSW, Sydney, School of Clinical Medicine, St Vincent’s Campus, Darlinghurst, Sydney, Australia; 3University of Sydney, Northern Clinical School, Royal North Shore Hospital, St Leonards, Sydney, Australia.

Background/Objectives: Genomic technologies now permit carrier testing using very large panels, or even the entire exome. Including more genes increases diagnostic sensitivity, but at higher cost. We have explored if there is an optimum number of genes for clinical utility and cost effectiveness.

Methods: We used a comprehensive list of 1,300 genes causative of autosomal recessive and X-linked recessive conditions relevant to carrier screening. From data in the Genome Aggregation Database (gnomAD), for both total population as well as major population subgroups, we extracted the allele frequency (AF) in these genes for all known single nucleotide variants (SNV) and indel variants that have been reported as Pathogenic or Likely Pathogenic in ClinVar. We also considered a notional population subgroup, in which the AF was set equal to the highest encountered AF in any other population subgroup. Using marginal analysis techniques, we calculated the number of genes needing to be incorporated into a carrier screening panel to achieve 90%, 95% or 99% of theoretical maximal diagnostic sensitivity.

Results: To achieve the stated fraction of theoretical maximal diagnostic sensitivity, the number of genes needing to be included in a screening panel was found to be:

| Diagnostic sensitivity | 90% | 95% | 99% |
|------------------------|-----|-----|-----|
| Couples                | 84  | 160 | 381 |
| Individuals            | 383 | 546 | 842 |

Conclusion: To achieve generally accepted levels of diagnostic sensitivity, the number of genes needing inclusion in a screening panel is much smaller than the total number of genes potentially available for testing. This has significant policy implications for both cost and public health benefits of carrier screening.

References:

Grants: None declared.

Conflict of Interest: None declared.

P01.019.C Familial Mayer-Rokitansky-Küster-Hauser syndrome

Hagit Daum1, Ayala Frumkin1, Vardiella Meiner2, Iris Harel3, Dvora Bauman4

1Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Israel; 2Faculty of Medicine, Ashkelon, Israel; 3Barzilai Medical Center, OBGYN, Ashkelon, Israel; 4Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Israel, OBGYN, Jerusalem, Israel.

Background/Objectives: Mayer-Kröniantsky-Küster-Hauser (MRKH) syndrome is characterized by congenital agenesis/aplasia of the uterus and part of the vagina in women with a normal 46,XX karyotype. Most cases are sporadic and do not have a molecular diagnosis, although individual case reports have been described in association with copy number variants or candidate genes (WNT9B, LHX1, GREB1L, 1q21.1 deletion, 22q11.21 duplication etc.). We describe a dominantly inherited case of MRKH, in which a
mother with MRKH had a biological daughter with the same syndrome through a surrogate pregnancy.

**Methods:** We used G-banded chromosomal analysis in order to confirm a 46,XX karyotype, and exome sequencing in order to investigate single nucleotide variants (SNV). Copy number variants were inferred from read depth analysis of the exome data.

**Results:** Chromosome analysis on the mother and daughter with MRKH revealed a female karyotype with a deletion of chr2q37 in both. The deletion was found to be de novo in the mother. Exome sequencing, undertaken in the daughter, confirmed the ~4Mb deletion and did not demonstrate pathogenic or likely pathogenic variants. Similar deletions have been described in the literature in association with a spectrum of neuro-physical findings but never with MRKH.

**Conclusion:** Our data suggest that deletion of 2q37 may be associated with MRKH. The developing options of surrogacy and uterine transplantation stress the importance of genetic investigation for MRKH patients.

**References:**

**Grants:** Internal fund of the Hebrew University of Jerusalem and Hadassah Medical Center.

**Conflict of Interest:** Hagit Daum Mentoring Grant of the Hebrew university and Hadassah Medical Center. Pi: Hagit Daum. Ayala Frumkin: None declared. Vardiella Meiner: None declared. Iris Harel: None declared. Dvora Bauman: None declared.

**P01.020.D A Novel Cause of Male Infertility and Hypergonadotropic Hypogonadism: Inhibin-A Deficiency Due to Loss of Function Variations of INHA**

*Esra Arslan Ateş,* Mehmet Ełtan, Bahadir Şahin, Busra Gürpinar Tosun, Tuba Seven Menevse, bilgen bilge geçkinli, Andy Greenfield, Serap Turan, Abdullah Bereket, Tulay Guran

1Marmara University Pendik Training and Research Hospital, Genetic Diseases Diagnostic Center, Istanbul, Turkey; 2Marmara University School of Medicine, Department of Pediatric Endocrinology and Diabetes, Istanbul, Turkey; 3Marmara University School of Medicine, Department of Urology, Istanbul, Turkey; 4Marmara University School of Medicine, Medical Genetics, Istanbul, Turkey; 5MRC Harwell Institute, Mammalian Genetics Unit, Oxfordshire, United Kingdom.

**Background/Objectives:** The human INHA gene encodes the inhibin subunit alpha protein, which is common to both inhibin A and B. The functional importance of inhibins in male sex development, sexual function, and reproduction remain largely unknown. Todate no clinical manifestation were related to INHA gene variations. Here we report for the first time two male siblings sharing the same clinical features associated with homozygous INHA pathogenic variations.

**Methods:** The medical documents were examined for clinical, biochemical, and imaging data. Genetic analysis was performed using next-generation and Sanger sequencing methods.

**Results:** Two brothers were referred to us because of gynecomastia, testicular pain, and having a history of hypospadias. They were born to a consanguineous parents and no similar cases were reported in the family. Biochemistry revealed low serum testosterone, high gonadotropin and anti-Mullerian hormone, and very low/undetectable inhibin concentrations, where available. Both patients had azospermia in spermogram. We have identified a homozygous 2bp deletion (c.208_209delAG, R70Gfs*3), which leads to a truncated INHA protein in both patients, and confirmed heterozygosity in the parents. The external genital development, pubertal onset and progression, reproductive functions, serum gonadotropins, and sex hormones of mother and father, who were heterozygous carriers of the identified mutation were normal.

**Conclusion:** Homozygosity for pathogenic INHA variations causes decreased prenatal and postnatal testosterone production and infertility in males, while the heterozygous female and male carriers of INHA variations do not have any abnormality in sex development and reproduction.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P01.023.C Copy number variant (CNV) analysis in couples with recurrent miscarriages**

*Evelina Dagyte,* Algirdas Utkus

1Vilnius University, Faculty of Medicine, Institute of Biomedical Sciences, Department of Human and Medical Genetics, Vilnius, Lithuania.

**Background/Objectives:** Recurrent miscarriage (RM) is an important global health issue and carries psychological and financial burden for affected couples. Anotomy factors, antiphospholipid syndrome, endocrinological and chromosomal abnormalities are the most commonly recognized aetologies for RM. Aetiology of RM remains idiopathic in 40-60 % of couples. The aim of this study was to evaluate copy-number variation (CNV) characteristics in couples with RM and compare to the Lithuanian population cohort.

**Methods:** Microarray analysis was performed for couples with unexplained RM (anatomy factors, antiphospholipid syndrome, chromosomal and endocrinological abnormalities were excluded) to detect CNVs. Genotyping was performed with Illumina HumanCytoSNP-12 v2.1 arrays using the standard Illumina Infinium HD Ultra Assay Protocol Guide.

**Results:** In total, 68 RM patients were tested and 72 CNVs were detected. The average number of CNVs per patient was 1.1 (1.67 in Lithuanian population cohort). No CNVs were identified in approximately 40 % of patients (30-40 % in Lithuanian population cohort). CNV regions (CNVRs) presented >1 individual (criteria met in approximately 40 % of patients (30-40 % in Lithuanian population cohort). For more detailed results, the study continues to involve more patients.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P01.024.D DNA methylation in newborns conceived by assisted reproductive technology**

*Robert Lyle,* Christian Page, Yunsung Lee, Haakon Nustad, Maria Christine Magnus, Kristine Løkås Haftorn, Ellen Carlersen, William Denault, Jon Bohlin, Astanand Jugessur, Per Magnus, Haakon Gjessing, Siri Håberg

1Oslo University Hospital, Department of Medical Genetics, Oslo, Norway; 2University of Oslo, Department of Mathematics, Oslo, Norway; 3University of Oslo, Department of Medical Genetics, Oslo, Norway; 4University of Bristol, MRC Integrative Epidemiology Unit, Bristol, United Kingdom; 5Bristol Medical School, Population Health Sciences, Bristol, United Kingdom; 6University of Chicago, Department of Human Genetics, Chicago, United States; 7Norwegian Institute of Public Health, Department of Method Development and Analytics, Oslo, Norway; 8University of Bergen, Department of Global Public Health and Primary Care, Bergen, Norway.

**Background/Objectives:** Assisted reproductive technology (ART) may affect fetal development through epigenetic mechanisms as
the timing of ART procedures coincides with the extensive epigenetic remodeling occurring between fertilization and embryo implantation. However, it is unknown to what extent ART procedures alter the fetal epigenome. Underlying parental characteristics and subfertility may also play a role.

Methods: Here we identify differences in cord blood DNA methylation, measured using the Illumina EPIC platform, between 962 ART conceived and 983 naturally conceived singleton newborns.

Results: We show that ART conceived newborns display widespread differences in DNA methylation, and overall less methylation across the genome. There were 607 genome-wide differentially methylated CpGs. We find differences in 176 known genes, including genes related to growth, neurodevelopment, and other health outcomes that have been associated with ART. Both fresh and frozen embryo transfer show DNA methylation differences. Associations persist after controlling for parents’ DNA methylation, and are not explained by parental subfertility.

Conclusion: Our results support the hypothesis that ART procedures influence DNA methylation in fetal life. The epigenetic differences between ART and naturally conceived children were not explained by parental DNA methylation or parental subfertility. Longitudinal assessments of DNA methylation are necessary to establish whether ART-induced differences in DNA methylation persist and influence later health outcomes.

References:

Grants:

Conflict of Interest: None declared.

P01.025.A Genome sequencing reveals causative CHH structural and single nucleotide variants in consanguineous families

Yassine Zouaghi1,2, Saba Irshad3, Ambrin Fatima3, mariam shahid3, Nida Najmi4, Fernanda De Azevedo Correa1,2, Ansar Muhammad5, Saba Irshad3, Ambrin Fatima3, mariam shahid3, Nida Najmi4, Fernanda De Azevedo Correa1,2, Ansar Muhammad5, Saba Irshad3, Ambrin Fatima3, mariam shahid3, Nida Najmi4, Fernanda De Azevedo Correa1,2, Ansar Muhammad5

1University of Lausanne, Lausanne, Switzerland; 2Lausanne University Hospital, Service of Endocrinology, Diabetology and Metabolism; Lausanne, Switzerland; 3Aga Khan University, Department of Biological and Biomedical Sciences, Karachi, Pakistan; 4The Aga Khan University Hospital (AKUH), Department of Obstetrics and Gynecology, Karachi, Pakistan; 5Hospital Ophthalmic Jules-Gonin - Fondation Asile Des Aveugles, Ophthalmology Department of the University of Lausanne, Lausanne, Switzerland; 6Medigenome, Genève, Switzerland.

Background/Objectives: Congenital hypogonadotropic hypogonadism (CHH) is a rare genetic disorder that causes incomplete or absent puberty leading to infertility due to defects in secretion or action of gonadotropin-releasing hormone. CHH is very heterogeneous phenotypically, and its genetics are complex. More than 25 genes have been associated with it explaining up to 50% of cases. Discovering new causative genes, or new variants in known genes may give hope to the families.

Methods: We have performed WES on seven euploid miscarried tissues from couples with recurrent EPL.

Results: Compound heterozygous pathogenic variants in CPLAN1 (c.1819delIT and c.5820+3_5820+6delAAGT) and DHR7 (c.964+1G>C and c.452G>A) genes were detected in two miscarriages. The variants were confirmed with Sanger sequencing and the partners in both families were heterozygous carriers. The compound heterozygosity in CPLAN1 was also confirmed in a second miscarriage from the same couple. Pathogenic variants in CPLAN1 and DHR7 genes cause Joubert syndrome 17 and Smith-Lemli-Opitz syndrome, respectively. Both are multi-systemic disorders associated with variable clinical severity and, besides in patients, have been confirmed in pregnancy losses and/or fetuses with ultrasound abnormalities.

Conclusion: In conclusion, our study shows a high percentage of autosomal recessive disorders (2/7 or 28.5%) as a cause of EPL. Increased number of WES analysis in recurrent euploid miscarriages could improve our understanding of the etiology of EPL and relevant biological processes. The knowledge of genetic causes responsible for EPL allows for genetic counselling and gives hope to the families.

References:

Grants:

Conflict of Interest: None declared.

P01.028.D Genetic variation in genes linked to telomere length in Estonian non-obstructive azoospermia patients

Anna-Grete Juchnewitsch1, Laura Kasak1, Liina Nagimaja2, Kenneth Aston3, Don Conrad4, Margus Punab1,4,3, Maris Loan1

1University of Tartu, Institute of Biomedicine and Translational Medicine, Tartu, Estonia; 2Oregon Health & Science University, Division of Genetics, Oregon National Primate Research Center, Beaverton, Oregon, USA; 3Genetics Research Center, Tartu, Estonia; 4Institute of Biomedicine, University of Tartu, Tartu, Estonia; 5University of Tartu, Institute of Biomedicine and Translational Medicine, Tartu, Estonia; 6Oregon Health & Science University, Division of Genetics, Oregon National Primate Research Center, Beaverton, Oregon, USA.

Abstracts from the 55th European Society of Human Genetics Conference 353
Abstracts from the 55th European Society of Human Genetics Conference

Background/Objectives: Intact telomeric structures are important in protecting chromosomes from damage. Association between telomere length and risk to chronic diseases has become an engaging topic. Sperm quality has been correlated with shorter telomeres and rare variants in genes implicated in meiotic telomere complex can have an impact on telomere length in the scientific literature. We investigated the suggested potential causative link between rare variants in genes linked to telomere length and spermatogenic failure.

Methods: Exomes of 85 idiopathic NOA cases from Estonia were sequenced in collaboration with the GEMINI (Genetics of Male Infertility Initiative) project. A list of 66 genes associated with telomere length in the scientific literature was compiled. Rare variants were identified and their possible pathogenicity was evaluated based on the ACMG guidelines.

Results: In our study group, no likely pathogenic/pathogenic rare variants in 66 candidate genes were identified. However, two autosomal dominant genes (pLI > 0.8) PEL1 and TERF1 carried two heterozygous missense variants of uncertain significance (VUS). Among these TERF1 is also implicated in the male reproductive system.

Conclusion: None of 85 Estonian NOA cases could be explained by causative variants in the analyzed genes modulating telomere length. The study may have been limited by an insufficient number of patients given a high heterogeneity of monogenic NOA and uncertainties in evaluating the effect of variants.

References: 1. Darmishonnejad et al Andrologia 52, e13546 (2020). 2. Salas-Huetos et al Human Genetics 140:217-227(2021).

P01.029.A Role of progesterone receptor genetic variants rs4754732 and rs1942836 in spontaneous premature birth

Jasenka Wagner1, Mirta Kadivnik2, Andrijana Muller2, Kristina Kralkic2, Nena Arvaj1, Siniša Sijanović1

1Faculty of Medicine, J.J. Strossmayer University Osijek, Department of Medical Biology and Genetics, Osijek, Croatia; 2Clinic of Obstetrics and Gynecology, University Hospital Center Osijek, Osijek, Croatia; 3Faculty of Medicine, J.J. Strossmayer University Osijek, Department of Medical Statistics and Informatics, Osijek, Croatia.

Background/Objectives: To evaluate the roles of two selected genetic variations in fetal and maternal progesterone receptor gene (PGR) and to identify women who may have higher or lower odds for spontaneous premature birth compared to the general population.

Methods: A preliminary case-control study with two groups of pregnant women (with term and premature delivery, 219 in total) and two groups of newborns (term and preterm, 219 in total) was performed. Two single nucleotide polymorphisms (SNPs) of the progesterone receptor gene (rs4754732 and rs1942836) were genotyped.

Results: Our results suggest that women who gave birth to male newborns with CC or CT rs4754732 genotype have 2.5 higher chance for preterm birth (OR = 2.5; 95%CI 1.09 – 5.6; P = 0.03; Fisher’s Exact Test). We also found that women older than 35 whose newborns have CC or CT rs1942836 genotype have 5.3 higher chance for preterm birth (OR = 5.3; 95%CI 1.05 – 26.2; P = 0.04; Fisher’s Exact Test).

Conclusion: Our study suggests that patients with selected genetic variants of the progesterone receptor gene could have greater odds for premature birth compared to general population. Replication studies with a larger population of different ethnicity are needed in order to confirm these findings.

References:

Grants: None declared.

P01.030.B Does aneuploidy discordance between trophectoderm and spent culture medium suggest embryo mechanism of self-correction?

Anna Stychalska1, Wojciech Sierka1, Joanna Smolen-Dzirba1, Anna Kokot1, Natalia Jodłowiec-Lubańska2, Klaudia Simka-Lampa1, Urszula Wroblewska1, Patrycja Piotrowska1, Adam Pudełko1, Emilia Morawiec1, Anna Bednarska-Czerwińska1, Simone Palini1

1Gyncentrum Genetic Laboratory, Sosnowiec, Poland; 2“Cervesi” Hospital Cattolica, IFV unit, Cattolica, Italy.

Background/Objectives: Investigating the utility of spent culture media (SCM) and mixture of SCM and blastocyst fluid (BF) in non invasive preimplantation genetic testing for aneuploidy (PGT-A).

Methods: Embryo was cultured until day 4, then washed and transferred to fresh medium. Trophectoderm (TE) biopsied from embryo day 6 has been tested for PGT-A in our routine procedure. SCM and mix of SCM + BF were collected prior to TE biopsy. Testing was performed with the use of Illumina VeriSeq NGS platform and MiSeq system.

Results: Comparison of chromosome 8 changes is presented in table.

| Material | Start cyto | End cyto | Type of change | Copy# |
|----------|------------|----------|----------------|-------|
| Trophodectoderm | pter | q24.13 | Gain | 2.66 |
| Spent coulter medium | q24.13 | qter | Gain | 6 |
| SCM+BF | pter | q24.13 | Loss | 1 |
| | q24.13 | qter | Gain | 4 |

TE analysis showed partial gain of chromosome 8 (pter->q24.13). In SCM we found gain of remaining part of chr8 (q24.13->qter). Sample of mix (SCM+BF) showed DNA gain of chr8 (q24.13->qter) and loss of chr8 (pter->q24.13).

Conclusion: Human embryo ability of self-correction has been discussed widely. Repairing mechanisms may result from increased aneuploidy cells death and release of fragmented DNA into culture media. We tested cell-free embryo DNA released from the blastocyst to SCM and mix of SCM + BF during cell cleavage (day 4 to day 6). We have observed chromosomal status after breakage occurred in mitotic cell division of chromosome 8 in embryo. Discordance between results in collected samples may be evidence for embryo undergoing self-correction mechanism.

References:

Grants: WND-RPSL.01.02.00-24-0477/19-007.
P01.032.D Novel variant curation strategies and preclinical technology to improve diagnosis of differences of sex development

Emmanuèle Délot1,2, Surajit Bhattacharya3, Hayk Barseghyan1,2,3, Eric Vilain1,2

1George Washington University, Genomics and Precision Medicine, Washington, D.C., United States; 2Children’s National Research Institute, Center for Genetic Medicine Research, Washington, D.C., United States; 3Bionano Genomics Inc, San Diego, United States.

Background/Objectives: Despite being collectively among the most frequent congenital developmental conditions, differences of sex development (DSD) lack recognition and research funding. As a result, what constitutes optimal management remains uncertain. Identification of the individual conditions is challenging and molecular diagnosis frequently not achieved, which may have psychosocial and health-related repercussions for individuals and their families. While research genome sequencing of samples from the DSD-TRN repository contributed to the description of the new GUBS syndrome (OMIM 618820) and diagnosed previously unsolved cases, network-wide diagnosis rate remains under 50%.

Methods: New pre-clinical genomic approaches have the potential to increase diagnostic yield through ascertainment of under-recognized etiology such as mosaic, structural, non-coding, or epigenetic variants. We undertook a study to determine the usefulness of Optical Genome Mapping for clinical DSD diagnosis and etiology discovery. As interpretation of now widespread exome sequencing requires expert interpretation rarely available in clinical settings, we also examined variants in ClinVar for 32 DSD genes.

Results: OGM identified 7 common DSD so far. We showed that curation of DSD gene variants in clinical databases used by algorithms to classify variants is currently insufficient even for the best validated DSD genes.

Conclusion: To address this gap, a special-interest group on the Franklin.genoox.com platform, opened to interested curators worldwide, integrates curation of DSD-specific variants into the genetic data analysis platform, with variant classification available through the free Franklin interface. Analysis of DSD-TRN registry data also shows that practice needs to evolve to prioritize early genetic testing.

References: PMID33513338.

Grants: NICHD R01HD093450.

Conflict of Interest: Emmanuèle Délot Estranged spouse has consultancy, Bionano Genomics. Stock/stock options in Bionano Genomics, current value $12,000 USD.

P01.033.A Polygenic risk score for recurrent pregnancy loss in LUCAR study, Ukraine

Yevheniya Sharhorodska1,2, Zhanna Balikhnyarova2,3, Anna Ulrich2,3, Vincent Pascart4, Liliia Chorna1, Ivan Shymanska1, Harmen M Draisma3, Danuta Zastawna1, Oleg-Roman Gnateyko1, Holyna Makukh1, Marika Kaakinien2,3, Inga Prokopenko1,2

1Institute of hereditary pathology, National Academy of Medical Sciences, Lviv, Ukraine; 2University of Surrey, Department of Clinical Genetics, Guildford, United Kingdom; 3Imperial College London, Department of Clinical and Experimental Medicine, London, United Kingdom; 4University of Lille, Lille, France.

Background/Objectives: The loss of 2+ sequential pregnancies before 24 weeks of gestation is defined as recurrent pregnancy loss (RPL). In RPL etiology, endocrine, immunological, anatomical and other factors could drive individual susceptibility, still ~50% of RPL cases remain idiopathic. We assessed the predictive ability of a polygenic risk score (PRS) for RPL in the LUCAR study (Lviv Ukrainian Cohort for Advancing Reproductive Health) from the Western Ukraine.

Methods: LUCAR includes 350 idiopathic RPL cases/458 controls with at least one healthy child, all having the genome-wide association study (GWAS) data imputed to TopMED and RPL association analyses performed using log-additive model. We used summary statistics from recurrent miscarriage (RM) GWAS meta-analysis (Laisk et al., PMID:33239672) and PRS software PRSice-2.

Results: In LUCAR, the unweighted common variant PRS was not associated with independent SNP sets after LD clumping, did not increase the RPL risk (Table). The lead variants from the Laisk et al., rs146350366 and rs7859844, did not affect RPL susceptibility.

Conclusion: Despite the previous meta-analysis showing good predictive ability of the PRS for RPL, we were unable to replicate this in dataset from Western Ukraine. We believe this highlights the commonly observed problem of low portability of PRS derived in one population to another, and an urgent need for well-powered GWAS for RPL in world-wide populations.

References:

Grants:

Conflict of Interest: None declared.

P02

PRENATAL GENETICS

P02.001.B Exome sequencing for structurally normal fetuses - yields and dilemmas

Hagar Mor-Shaked1, Hagit Daum1, Tamar Harel1, Avital Eilat1, Duha Fahham1, Shiri Gershon-Naamat1, Chaggai Rosenbluh1, Orly Elpeleg2, Vardella Meiner1

1Hadassah-Hebrew University Medical Center, Human Genetics, Jerusalem, Israel.

Background/Objectives: There is a growing body of literature regarding the yield of chromosomal microarray analysis (CMA) in structurally normal fetuses (1-3). We aimed to assess the empirical data as to the yield of exome sequencing (ES) in this population.
**Methods:** From February 2017 to January 2022, 1,298 fetuses were subjected to ES; 374 of them were structurally normal (28.8%). Only pathogenic and likely pathogenic (P/LP) variants, per the American College of Medical Genetics and Genomics (ACMG) classification, were reported. Additionally, ACMG secondary findings relevant to childhood were reported.

**Results:** Five fetuses (5/374; ~1.33%) had a P/LP variants indicating a moderate to severe disease: Wilson disease, Enhanced S-cone syndrome, Legius and Muenke syndromes (upon affected genes ATP7B, NR2E3, SPRED1 and FGFR3 respectively). One fetus had a paternally inherited pathogenic variant in RET.

**Conclusion:** Our data suggest that offering only CMA for structurally normal fetuses may provide false reassurance. Prenatal ES mandates restrictive analysis, and careful management combined with pre and post-test genetic counselling.

**References:**
1. Stern S, Haochen N, Meiner V, et al. Universal chromosomal microarray analysis reveals high proportion of copy number variants in low risk pregnancies. Ultrasound Obstet Gynecol. 2020.
2. Sagi-Dain L, Cohen Vig L, Kahana S, et al. Chromosomal microarray vs. NIPS: analysis of 5541 low-risk pregnancies. Genet Med. 2019.
3. Moshonov R, Hod K, Azaria B, Abadi-Korek I, Berger R, Shohat M. Benefit versus risk of chromosomal microarray analysis performed in pregnancies with normal and positive prenatal screening results: A retrospective study. PLoS One. 2021;16(4):e0250734.

**Conflict of Interest:** None declared.

---

**P02.002.C DES-NIPT study: Global approach to detect inherited paternal variants in NIPT samples using deep exome sequencing**

**Ieva Miceikaite**1, Charlotte Brasch-Andersen1,2, Qin Hao2, Christina Fagerberg1,2, Britta Schlott Kristiansen2, Pernille Toring2, Geske Sidsel Bak2, Lene Spering2, Martin Larsen1,2

1. University of Southern Denmark, Human Genetics, Department of Clinical Research, Faculty of Health Sciences, Odense, Denmark; 2. Odense University Hospital, Department of Clinical Genetics, Odense, Denmark; 3. Odense University Hospital, Fetal Medicine Unit, Department of Obstetrics and Gynecology, Odense, Denmark.

**Background/Objectives:** Deep sequencing has now enabled detection of sequence variants and diagnosis of specific monogenic diseases by non-invasive prenatal testing (NIPT), using tailor-made assays for each pregnancy. However, a comprehensive non-invasive genome-wide diagnostic approach suitable for all cases and all known monogenic disorders is needed.

The aim of this study was to utilize high-throughput deep exome sequencing (DES) on cfDNA as a global approach to detect inherited paternal sequence variants, allowing the detection of known dominant monogenic disease variants and enabling paternal variant exclusion in recessive disease diagnostics.

**Methods:** For our pilot study, we included 16 pregnancies with high-risk criteria for genetic testing. The gestational age ranged 14-21 weeks. We obtained plasma, parental blood and invasive fetal samples (trio), and applied DES. We performed bioinformatic evaluation of the results from trio and DES-NIPT analysis. To estimate DES-NIPT sensitivity and precision, we compared paternal variants found in the overlapping exonic regions in both the NIPT and the invasive sample, where variants from invasive samples were the reference.

**Results:** We achieved a mean alignment target coverage of 537x. Using the paternal allele frequency in NIPT samples, we estimated fetal fraction, which ranged 5.13-18.77%. The sensitivity and precision of our approach to detect all inherited paternal variants from plasma samples were 98.19% and 99.41%, respectively.

**Conclusion:** Using DES-NIPT approach, we can detect and exclude inherited paternal variants from NIPT samples with high sensitivity and precision. This potentially allows the detection of the majority known inherited monogenic disorders early in the pregnancy and non-invasively.

**References:**
1. Stern S, Haochen N, Meiner V, et al. Universal chromosomal microarray analysis reveals high proportion of copy number variants in low risk pregnancies. Ultrasound Obstet Gynecol. 2020.

**Conflict of Interest:** None declared.

---

**P02.004.A Valuable insights after one year whole exome sequencing in a fetal/prenatal setting**

**Sarah Delbaere**1, Machteld Baetens1, Candy Kumps3, Ellen Roets2, Noortje Van Oostrum1, Bert Callewaert1, Sandra Janssens1, Olivier Vanacker1, Björn Menten1

1. Center for Medical Genetics Ghent, Ghent University Hospital, Ghent University, Department of Biomolecular Medicine, Gent, Belgium; 2. Women’s Clinic, Ghent University Hospital, Department of Obstetrics, Gent, Belgium.

**Background/Objectives:** The aim of this study is to evaluate the implementation of whole exome sequencing (WES) for fetuses with congenital anomalies in a diagnostic workflow.

**Methods:** A fast-WES track for prenatal testing was implemented, with a maximal turn-around-time of 8 weeks. Depending on the fetus’s abnormalities, targeted gene panel or Mendelioane analysis was performed in-silico, the latter comprising all human disease-linked genes. The variant analysis strategy was optimized to efficiently identify the causal variant, by focusing on de novo, X-linked or biallelic inheritance. National Belgian guidelines have been established to standardize the testing and reporting strategy.

**Results:** Over the period of one year, 59 structurally abnormal fetuses with normal copy number variant (CNV) analysis were investigated via exome sequencing. The overall diagnostic yield was 16.9%; in 10 out of 59 fetuses, a class 4 or 5 variant could be identified. When comparing analysis in on-going versus terminated pregnancies or miscarriages, diagnostic yield was 17.9% (5/28) and 15.6% (5/32) respectively. Diagnostic yield for targeted gene panels was 13% (3/23), which is less compared to 18.4% (7/38) for Mendelioane analysis. Additional CNV analysis on the WES data using the ExomeDepth algorithm revealed a small intragenic ASCCI homozogeous deletion in a fetus with heterozygous carrier parents. Furthermore, two inherited pathogenic incidental findings were reported (APOB and BRIP1).

**Conclusion:** These results proof an important contribution of WES within prenatal and fetal context to obtain a high number of molecular diagnoses and can broaden the understanding of aberrant fetal phenotypes and their underlying genetic cause.

**References:**
1. Stern S, Haochen N, Meiner V, et al. Universal chromosomal microarray analysis reveals high proportion of copy number variants in low risk pregnancies. Ultrasound Obstet Gynecol. 2020.

**Conflict of Interest:** None declared.

---

**P02.005.B C-terminal cFLIP disruption in humans causes intrauterine multisystem anomalies due to aberrant cell death response switch**

**Ivana Lessel**1, Leonie Piehl1, Kira Kirchner1, Thilo Diehl2, Christian Kubisch1, Davor Lessel1

1. University Medical Center Hamburg-Eppendorf, Institute of Human Genetics, Hamburg, Germany; 2. University Medical Center Hamburg-
Eppendorf, Department of Neonatology and Pediatric Intensive Care Medicine, Hamburg, Germany.

Background/Objectives: Pregnancy losses are mostly attributable to chromosomal abnormalities although recent studies also identified selected Mendelian disorders responsible for stillbirth. However, in the majority of cases the underlying cause of foetal death remains elusive. Here, we studied a consanguineous family with history of recurrent early miscarriages and two foetuses who presented with severe intrauterine multi-system anomalies, resulting in early demise.

Methods: Next-generation sequencing and segregation analyses were used to identify candidate variants. Functional characterization was performed in a dual-cellular model utilizing cell viability analyses, immunoblotting, immunoprecipitation, caspase activity assays, RNA-sequencing and methylation profiling.

Results: We identified a homozygous frameshift variant in CFLAR resulting in C-terminally truncated cFLIP, a master regulator of multiple cell death pathways. In-vitro analyses of the identified variant revealed enhanced binding to unprocessed procaspase-8, which correlated with abrogated caspase-8 activity, thus disclosing the inability to execute CASP8-mediated extrinsic apoptosis. Furthermore, we observed enhanced binding to RIPK1 and phosphorylated-RIPK1, which correlated with an enhanced aberrant execution of the RIPK1-RIPK3-MLKL phosphorylation cascade upon apoptotic stimuli. Thus, aberrant necroptosis induction concomitant with impaired ability to execute apoptosis during embryonic development underlies the cFLIP-deficiency. Moreover, integrative transcriptome and epigenome analysis of patient-derived fibroblasts revealed compensatory, pro-survival silencing of RIPK3 and CASP10.

Conclusion: Above identifying a novel Mendelian cause for foetal death and linking for the first time a pathogenic CFLAR variant to a human disease, we further expand the knowledge underlying the molecular switch between apoptosis and necroptosis, and provide the first direct evidence for the importance of necroptosis inhibition for proper human embryonic development.

References:

Grants:

Conflict of Interest: Ivana Lessel full time, Leonie Piehl full time, Kira Kirchner full time, Thilo Diehl full time, Christian Kubisch full time, Davor Lessel full time, 1. Deciphering molecular mechanisms of CHAMP1 deficiency-associated developmental delay, German Research Foundation (Deutsche Forschungsgemeinschaft, DFG). 2. The role of RNA interference in human neurodevelopment, Werner-Otto Foundation. 3. Identification and characterization of highly penetrant risk genes in testicular germ cell tumors, German Cancer Aid (Deutsche Krebshilfe).
4. Elucidating the role of stress granules associated translational control in aging and aging-associated diseases, Fritz Thyssen Foundation. 5. The RNA helicase DHX30: Physiological function and role in a neurodevelopmental disorder, German Research Foundation (Deutsche Forschungsgemeinschaft, DFG). 6. Genomic context analysis of clinically-relevant disease-associated variants in zinc finger proteins (mis-ZFs), German Academic Exchange Service (Deutscher Akademischer Austauschdienst, DAAD), The Champ1 Research Foundation, Member of the Scientific Advisory Board, https://champ1foundation.org/scientific-advisory-board/ AGO2 Association, Member of the Scientific Advisory Board, https://ago2.org/en.

P02.006.C Increased nuchal translucency (NT). Can we do more? Prenatal trio exome sequencing of >150 cases revealed unexpected findings in fetuses with increased NT

Heinz Gabriel1, Björn Schulte1, Martin Ritthaler1, Saskia Biskup1

Abstracts from the 55th European Society of Human Genetics Conference

Veritas Intercontinental, Barcelona, Spain; Synlab Diagnostics Globales, Esplugues de Llobregat, Spain.

Background/Objectives: Ultrasound diagnosis allows for the detection of half of all major structural anomalies. As a soft marker, nuchal translucency (NT) is associated with a spectrum of structural anomalies. Mostly, NT measurement is offered as part of screening for chromosomal abnormalities. About 20% of fetuses with increased NT will have a chromosomal abnormality. Noonan syndrome is considered the most frequently reported syndrome associated with increased NT. Prenatal panel testing for Noonan syndrome genes is nowadays widely offered in cases with increased NT. Aside from these Noonan syndrome genes, there are only a limited number of gene for which increased NT is documented.

Methods: In this study, we performed prenatal trio exome sequencing in cases with increased NT.

A cohort of 158 fetuses with increased NT were analysed by trio exome sequencing. The mean turn-around-time (TAT) was 12 days.

Results: We detected (likely) pathogenic variants in 46 cases (29%). Noonan syndrome genes were found in 11 cases. In 22 cases pathogenic variants were found in genes which are not to be known to be associated with increased NT so far.

Conclusion: Our data demonstrate that prenatal testing should not be limited to chromosomal aberrations, or RASopathies/Noonan syndrome, in cases with increased NT. Increased NT can be found in a wide range of syndromic conditions and might be one of the earliest detectable phenotypic features in the first trimester. We have shown the value of trio exome sequencing for the prenatal genetic diagnosis of fetuses with increased NT.

References:

Grants:

Conflict of Interest: Heinz Gabriel full time, Björn Schulte full-time, Martin Ritthaler full-time, Saskia Biskup full-time.

P02.007.D Prenatal WES for rapid detection of copy number variants and single gene disorders in uncultured samples

Vincenzo Cirigliano1, Elisabet Lloveras2, Elena Ordonez2, Isabel Castilla1, Mireia Lechuga1, Mafalda Almeida1, Cristina Perez2, Miriam Leon1,1,1

1Praxis fuer Humangenetik/CeGaT Tuebingen, Tuebingen, Germany.

Background/Objectives: aCGH is currently the first line test in prenatal diagnosis. However, most cases with normal results require additional tests targeting specific indications or whole exome sequencing. We evaluated an optimized WES capture assay to detect both CNVs and SNVs in a single assay aiming to assess its performance for genomewide detection of CNVs in uncultured prenatal samples.

Methods: DNA extracted from uncultured amniotic fluids (17) and CVSs (8) were selected with pathogenic CNVs of different sizes reported by aCGH. Samples were sequenced using an improved whole exome capture of 51 Mb designed to allow genomewide CNV detection and optimised for coverage of a wide subset of genes related with fetal structural abnormalities and developmental delay.

Results: All samples passed sequencing QC metrics, full concordance between WES and aCGH results was observed with an expectable slight difference in CNVs breakpoints locations. CNVs ranged between 13.8Kb and 52.9Mb in size: 17 cases with a unique event, 4 cases with 1 gain and 1 loss, two more samples had 2 and 3 losses. One rare case of chromothripsis, with 8 duplications along different regions of the same chromosome was also correctly classified.
Conclusion: WES can be used to identify pathogenic CNVs in uncultured prenatal samples. CNVs testing as first analysis step on sequencing data has the advantage of allowing rapid inclusion of SNVs/indels detection in multiple genes if required. While reducing time/costs for the analyses, this single test approach has the potential to increase the overall diagnostic yield in prenatal diagnosis.

References:

Grants:

Conflict of Interest: None declared.

P02.008.A A positive noninvasive prenatal testing result for sex chromosome aneuploidies. What could we expect?

Radostina Raynova1, Stoyan Bichev2, Katerina Vladimirova2, Kameliya Kercheva4, Violeta Dimitrova3, Irena Bradinova2, Ivanka Dimova3, Alexey Savov1

1National Genetic Laboratory, University Hospital of Obstetrics and Gynecology, Medical University, Sofia, Bulgaria; 2National Genetic Laboratory, University Hospital of Obstetrics and Gynecology, Medical University, Sofia, Bulgaria, Sofia, Bulgaria; 3University Hospital of Obstetrics and Gynecology, Medical University, Sofia, Bulgaria, Sofia, Bulgaria; 4SAGBAL "Dr. Shtereve", Sofia, Bulgaria.

Background/Objectives: Non-invasive prenatal testing (NIPT) for detection of fetal aneuploidy risk has been widely adopted in clinical practice due to its high positive predictive value (PPV) for common aneuploidies, involving chromosomes 21, 18, 13. However, PPV for sex chromosome aneuploidies (SCA) is as lower as 57.6 %. NIPT remains classified as a screening, non-diagnostic test with standard recommendations that any positive NIPT result be followed by confirmatory diagnostic testing.

Methods: We present three cases referred to our Laboratory for confirmation of positive results for SCA from NIPT: 1) for Jacobs syndrome (47, XYY), 2) Turner syndrome (45, X) and 3) a deletion of 9.71 Mb on Xp11.4-Xp11.23. Amniocenteses were performed and DNA was extracted from uncultured amniocytes. Commercial QF-PCR kit and MLPA probe mix were used and samples were analyzed on ABI 3130. Karyotyping was performed on cultured amniocytes using standard protocol.

Results: For the first case, QF-PCR showed a XXY profile instead of a XYY, and the karyotype was 46, X(Y)[12]/47,XXY[18]. Monosomy X was excluded for the second case, karyotype was 46, X, del(Y)(q12). The Xp deletion of the third case wasn’t confirmed by MLPA probe mix P034; the QF-PCR result was consistent with Turner syndrome.

Conclusion: The confirmation of a positive NIPT result for SCA demands an integral approach for the elucidation of the case and thus facilitating the counseling and patients’ decision making.

References: None.

Grants: None.

Conflict of Interest: None declared.

P02.009.B Exome sequencing in prenatal diagnosis: results from 156 cases

Emmanuelle Ranza1, Xavier Blanc1, Federico Santoni1, Katayoun Afshar2, Guerry Frederic2, Bernard Conrad2, Isabelle Eperon2, Cécile Tissot2, Cécile Deluen3, Tanguy Araud3, Loïc Baerlocher3, Yasmine Sayegh-Martin3, Anne-Claude Müller-Brochut4, Christian Bisch4, Wawrzyniec Rieder5, Joel Fluss6, Jean-Marie Pellegrinelli5, Marta Carrasco7, Thibaud Quibel8, Sylvie Lacroix8, Philippe Extermann9, Graziano Pescia10, Romaine Robyr Susini10, Stylianos Antonarakis11

1National Genetic Laboratory, University Hospital of Obstetrics and Gynecology “Maichin Dom”, Medical University, Sofia, Bulgaria, Obstetrics and Gynecology, Sofia, Bulgaria; 2Pediatric clinic, UMHAT “Alexandrovska”, Sofia, Medical University of Sofia, Pediatric, Sofia, Bulgaria.

Background/Objectives: Exome sequencing (ES) has become a standard test for undiagnosed developmental disorders, now increasingly used in prenatal diagnosis.

Methods: We report here our experience with 156 consecutive prenatal cases through ES. The most common fetal signs were: increased nuchal translucency (25 %), congenital heart defect (21.8 %), skeletal malformations (18.6 %) and brain abnormalities (9.6 %). After performing a-CGH, 28 cases had solo and 128 trio ES.

Results: In 21.8 % of cases, we have identified a pathogenic or likely pathogenic variant (as per the ACMG guidelines) likely causative of the fetal phenotype. The diagnostic yield was 34.5 % for skeletal malformations, 15.4 % for nuchal translucency, 11.8 % for congenital heart defect, and 33.3 % for brain anomalies. In 29 of the solved cases, the pathogenic variants were SNVs, while 2 were pathogenic structural variants (SV). Furthermore, the trio ES has identified in three cases complete uniparental disomies UPD6, UPD16 and UPD17, all including isodisomic segments with likely causative recessive genes.

Conclusion: ES is a powerful method for the identification of causative variants in prenatal; trio sequencing reduces the turn-around time and increases the diagnostic yield. The VUS remain a challenge and guidelines are needed to assist in the interpretation and disclosure of the results.

The discovery of novel mendelian genes and the introduction of additional laboratory and computational methods such as long-read sequencing and improvement of SV detection may further increase the diagnostic yield.

References: None.

Grants: None.

Conflict of Interest: Emmanuelle Ranza Medigenome, Medigenome, Xavier Blanc Medigenome, Federico Santoni Medigenome, Katayoun Afshar Medigenome, Guerry Frederic Genesupport, Bernard Conrad Genesupport, Genesupport, Isabelle Eperon Dianecho, Cécile Tissot Clinique des Grannettes, Cécile Deluen Genesupport, Tanguy Araud Genesupport, Loïc Baerlocher Gene support, Yasmine Sayegh-Martin Centre Jean-Violette, Centre Jean-Violette, Anne-Claude Müller-Brochut GynEcho, Christian Bisch Dianecho, Wawrzyniec Rieder Dianecho, Joel Fluss HUG, Jean-Marie Pellegrinelli HUG, Marta Carrasco: None declared, Thibaud Quibel Echogenomics, Sylvie Lacroix Echogenomes, Philippe Extermann Dianecho, Dianecho, Graziano Pescia Genesupport, Genesupport, Romaine Robyr Susini Echogenomes, Echogenome, Stylianos Antonarakis Medigenome, Medigenome.

P02.010.C Frequency of cystic fibrosis in fetuses with echogenic bowel in Bulgarian population

Nadya Yaneva1, Guergana Petrova2, Irena Bradinova1, Kameliya Kercheva1, Radostina Raynova1, Alexey Savov1

1National Genetic Laboratory, University Hospital of Obstetrics and Gynecology “Maichin Dom”, Medical University, Sofia, Bulgaria, Obstetrics and Gynecology, Sofia, Bulgaria; 2Pediatric clinic, UMHAT “Alexandrovska”, Sofia, Medical University of Sofia, Pediatric, Sofia, Bulgaria.

Background/Objectives: Cystic fibrosis (CF) is the most common life-limiting condition with autosomal recessive inheritance. The at birth prevalence of CF in Bulgaria was estimated to be 1:3,600 live
births. According to prenatal ultrasound evaluations 0.5-9.9% of cases with fetal echogenic bowel (FEB) are affected with CF. Recent studies revealed that detected echogenic bowel is associated with CF, chromosome abnormalities, congenital CMV infections, intrauterine growth retardation, and even fetal or neonatal death. However, the relation between the presence of FEB and cystic fibrosis is still scarcely studied. The purpose of this study was to assess the frequency of occurrence of cystic fibrosis in cases with fetal echogenic bowel.

**Methods:** 101 cases with FEB, detected during a routine ultrasound examination were screened for transmembrane conductance regulator (CFTR) mutations with Sanger sequencing at National Genetic Laboratory.

**Results:** Of the 101 cases studied, in 9 cases only one parent was carrier for CFTR mutation. Additionally, in 7 cases both parents were carriers of CFTR mutation. In five of these cases the fetuses had CF. Only one pregnancy was terminated. Other four was confirmed postnatally. In the other two cases the fetuses were negative.

**Conclusion:** We observed relatively high frequency of occurrence of CF in fetuses with echogenic bowel (5%, 5/101). However, the presence of CFTR mutation in the parents is not mandatory associated with the presence of CFTR mutation and CF in their fetus. For this reason after screening for carrier status of the parents, we recommend prenatal diagnosis for fetal CF when FEB is detected.

**References:** None.

**Grants:** None.

**Conflict of Interest:** None declared.

**P02.011.D Genetic variants identified in Slovenian families with apparent non-syndromic oro-facial cleft phenotypes**

**Lara Slavec**1,2, Ksenija Geršak1,2, Andreja Eberlin4, Nataša Karas Kuželčik2

1University Medical Centre Ljubljana, Department of Obstetrics and Gynaecology, Research Unit, Ljubljana, Slovenia; 2University of Ljubljana, Faculty of Pharmacy, Department of Clinical Biochemistry, Ljubljana, Slovenia; 3University of Ljubljana, Faculty of Medicine, Department of Gynaecology and Obstetrics, Ljubljana, Slovenia; 4University Medical Centre Ljubljana, Department of Maxillofacial surgery, Ljubljana, Slovenia.

**Background/Objectives:** Orofacial clefts (OFCs) are common congenital anomalies that manifest as cleft lip and/or cleft palate. Most OFCs are non-syndromic (nsOFCs), but can also occur in various syndromes (syOFCs). The majority of syOFCs have a known, monogenic cause, while nsOFCs usually have a complex aetiology. In some syOFCs, the presence of additional anomalies is not obvious, thus they often remain undiagnosed as such. Examples of such syOFCs are Van der Woude syndrome (VWS; IRF6 mutations), and X-linked cleft palate (CPX; TBX22 mutations). Moreover, there is increasing evidence that mutations in single genes may be implicated in some families with nsOFCs.

**Methods:** We recruited 35 Slovenian multiplex families. Using whole-exome sequencing (WES) and Sanger sequencing, we firstly screened the proband of each family for causal variants in IRF6, GRHL3, and TBX22. In probands without any relevant variants in these three genes, we filtered WES data for 72 additional genes. Family segregation was checked for each identified variant.

**Results:** We genetically confirmed the diagnosis of VWS in five families. We identified four (likely) pathogenic variants in IRF6: two stop-gain, one frameshift, and one missense variant. In one family, we identified the deletion of TBX22 and confirmed CPX. We have also found one nsOFC family with deletions in coding regions of ARHGAP29.

**Conclusion:** With a two-step approach in gene selection and analysis, we identified families with syOFCs and found a mono- genic mutation in a family with nsOFCs. We present the first genetic study performed on Slovenian patients with apparent nsOFCs.

**References:**

**Grants:** Slovenian Research Agency (J3-8207, MRS1882).

**Conflict of Interest:** None declared.

**P02.012.A Is nuchal translucency of 3.0-3.49 mm an indication for NIPT or microarray-still needs a debate**

**Magda Rybak-Krzyzsowska1,2, Anna Madetko-Talowska2, Katarzyna Szewczyk2, Mirosław Bik-Multanowski3, Agata Sakowicz3, David Stejskal1, Marie Trková4, Dagmar Smetanova5, Silvia Serafini6, Hildeberto Correia7, Julián Nevado8, Fe Amalia García Santiago9, María Angeles Mori9, Lena Rutkowska9, Agata Kuchínska9, Agnieszka Gach9, Hubert Huras1, Madgalena Kola1, Małgorzata Srebnik1**

1Department of Obstetrics and Perinatology University Hospital, Kraków, Poland; 2Hi-Gen Centrum Medyczne, Krakow, Poland; 3Department of Medical Genetics, Institute of Paediatrics, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland; 4Department of Medical Biotechnology, Medical University of Lodz, Łódź, Poland; 5Centre of Medical Genetics and Reproductive Medicine GENNET, Prague, Czech Republic; 6Unidade de Citogenética, Departamento de Genética Humana, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal; 7Instituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz-IdiPaz and Centro de Investigación Básica en Red de Enfermedades Raras (CIBERER), Madrid, Spain; 8ITHACA, International Research Network in Rare Diseases. Hospital Universitario La Paz, Madrid, Spain; 9Department of Genetics, Polish Mother’s Memorial Hospital Research Institute, Łódź, Poland; 10Department of Clinical Genetics, Erasmus MC, Rotterdam, Netherlands.

**Background/Objectives:** Nowadays, fetal nuchal translucency (NT) values of >3.5 mm constitute an indication for invasive testing, optimally followed by chromosomal microarray. In our analysis, we wanted to evaluate the occurrence of clinically relevant sub-microscopic chromosomal aberrations in fetuses with the NT range from 3.0 to 3.49 mm, which would be missed by currently available non-invasive prenatal tests (NIPT).

**Methods:** A retrospective analysis of 271 fetuses with NT between 3.0 and 3.49 mm and increased risk after combined test in five cohorts of pregnant women referred for invasive testing and chromosomal microarray was performed: Czech Republic (n = 152), Poland (Cracow n = 48, Lodz n = 7) Portugal (n = 46) and Spain (n = 18).

**Results:** A chromosomal aberration was identified in 1:5 fetuses (19.19%; 52/271). In 15.13% (41/271) of cases trisomy 21, 18 or 13 was found. In 0.74% (2/271) sex chromosome aneuploidy was found. In 1.13% (3/271) of cases copy number variant (CNV) >10Mb was detected, which would potentially also be detected by NIPT. The residual risk for missing a clinically relevant (sub)microscopic chromosomal aberration in the presented cohorts is 1:45 (2.21%; 6/271).

**Conclusion:** Our results indicate that a significant number of fetuses with increased risk after combined test and presenting NT of 3.0-3.49 mm carry a clinically relevant chromosomal abnormality other than common trisomy. Invasive testing should be offered and counselling on NIPT should include the resolution limitation that may result in NIPT false negative results in a substantial percentage of fetuses.

**References:**

**Grants:**

**Conflict of Interest:** None declared.
P02.013.B Sodium channel gene variants in fetuses with abnormal sonographic findings

Andrea Hadjipanteli1, athina theodosiou2, ioannis papaevripidou2, paola evangelidou2, angelas alexandrou2, nicole salameh2, violette anastasiadou1, Yiannis Kallikas3, LUDMILA KOUSOULIDOU2, carolina sismani2

1The Cyprus Institute on Neurology and Genetics, Cytogenetics and Genomics, Nicosia, Cyprus; 2The Cyprus Institute on Neurology and Genetics, Cytogenetics and Genomics, Nicosia, Cyprus; 3Archibishop Makarios III hospital, Nicosia, Cyprus; 4AAK Ultrasound and Fetal Medicine Centre, Nicosia, Cyprus.

Background/Objectives: Voltage-gated sodium channels (VGSCs) are responsible for the initiation and propagation of action potentials in the brain and muscle. Pathogenic variants in genes encoding VGSC may therefore cause epileptic encephalopathies and congenital myopathies resulting in severe phenotypes. This study presents two cases of sodium channelopathies in pregnancies with abnormal ultrasound findings; identified as part of a larger cohort study.

Methods: Fetal samples with abnormal sonographic findings accompanied by normal karyotype and array-CGH results were included in the study. Trio-based whole-exome sequencing was accompanied by normal karyotype and array-CGH results were included in the study. Trio-based whole-exome sequencing was performed, followed by Sanger sequencing for the confirmation of pathogenic variants.

Results: Two unrelated fetuses presented pathogenic variants in genes encoding the alpha subunit of VGSCs. A known de novo heterozygous missense variant was identified in the gene SCN2A (c.751G>A; p.Val251Ile) in a fetus with intrauterine growth retardation, hand clenching, ventriculomegaly and other structural findings that neonatally also exhibited refractory epilepsy, spasms, and MRI abnormalities. The second fetus was compound heterozygous for two parentally inherited novel missense variants in the gene SCN4A (c.4340T>C; p.Phe1447Ser), (c.3798G>C; p.Glu1266Asp). The fetus presented a severe prenatal phenotype including talipes, fetal hydrops, hypoplastic lungs, polyhydramnios, ear abnormalities and other. Both probands died soon after their birth.

Conclusion: Our results suggest a potentially crucial role of the sodium channel gene family in fetal development since non-functional VGSCs have been associated with severe fetal phenotypes and early lethality. New genotype-in utero phenotype associations related to this gene family may ultimately result in new additions to preconception and prenatal diagnostic panels.

References:
Grants: -
Conflict of Interest: None declared.

P02.014.C Diagnostic yield and implications of exome sequencing analysis, including the use of copy number variant analysis pipeline, for pregnancy management in a series of 46 fetuses with structural anomalies

Sebastien Moutton1,2, Ines Harzallah3, Laure Raymond1, Jérémie Mortreux1, Nada Houcinat1, Marine Dancer1, Vanna Geromel1, Radoslava Sarareva-Lamri1, Angeline Preto1, Luc Druant1, Marc Nouchy1, Fabienne Prieur2, Marine Lebrun1, Francis Ramond1, Rodolphe Dard3, Aude Tessier1, Benjamin Dauriat1, Valentin Marquet1, Constance Wells4, Caroline Dellier1, Elise Schoefer5, Leila Frigere1, Patrice Bouvagnet1, Renaud Touraine1, Marie-Emmanuelle Naud-Barreyre1

1Laboratoire Eurofins Biomnis, Département de génétique, Lyon, France; 2Maison de Santé Protestant de Bordeaux Bagatelle, Centre Pluridisciplinaire de Diagnostic PréNatal, Talence, France; 3CHU de Saint-Etienne, Service de génétique médicale, Saint Etienne, France; 4CH Poissy-Saint-Germain-en-Laye, Service de génétique médicale, Poissy, France; 5CHU de Limoges, Service de génétique médicale, Limoges, France; 6CHU de Montpellier, Service de génétique médicale et foetopathologie, Montpellier, France; 7CHRU de Strasbourg, Service de génétique médicale, Strasbourg, France; 8CHU de Martinique, Centre Pluridisciplinaire de Diagnostic PréNatal, Fort de France, France.

Background/Objectives: During the past years, exome sequencing has been used more and more widely and contributed to increased diagnostic yield in many fields of human genetics including developmental disorders (25-40% according to the studies, the design, the limitation to diagnosis or extension to research). Its use has been progressively implemented in a prenatal setting, first to assess the yield in these particular patients, and second to assess its usefulness in pregnancy management.

Methods: Between June 2020 and November 2021, 46 exome analyses were asked for fetuses with structural anomalies (at the same time or after normal chromosomal microarray result), questioning the prognosis. Prescriptions came from several French multidisciplinary centers for prenatal diagnosis. Exome data were produced by Eurofins Biomnis laboratory and analyzed by 2 or 3 independent molecular geneticists, medical geneticists and/or scientists followed by meetings before reporting the results.

Results: In 11/46 = 24% of cases, a conclusive diagnosis could be made, with implications in pregnancy management in 5/11 = 45%, leading to opt for termination in 3 cases and to reassure in 2 cases (and 3 additional cases where the molecular diagnosis confirmed the suspicion by imaging and helped decision-making of termination). One diagnosis was an intragenic GPC3 duplication not seen by chromosomal microarray. In at least 16 until 29/35 un conclusive results, the negativity contributed to the continuation of the pregnancy.

Conclusion: Although the cohort remains quite small, this study suggests that exome sequencing could be useful in selected prenatal situations, as reported in still not so numerous other studies.

References: -
Grants: -
Conflict of Interest: None declared.

P02.015.D Designing a quantitative PCR assay for fetal RhD genotyping from maternal plasma derived cell-free fetal DNA (cfDNA)

Suvi Parvainen1, Ville Veikkolainen2

1University of Turku, Life Technologies, Turku, Finland; 2PerkinElmer Wallac Oy, Turku, Finland.

Background/Objectives: Hemolytic disease of the fetus and newborn (HDFN) is typically caused by maternal alloimmunization against antigens of RhD positive red blood cells. During pregnancy, these anti-RhD antibodies can induce the destruction of fetal RhD positive red blood cells and lead to HDFN. Maternal alloimmunization can be prevented with antenatal and postnatal anti-D prophylaxis treatment, which is often routinely performed for all RhD negative mothers. However, fetal RhD genotyping allows anti-D prophylaxis to be targeted only for women carrying RhD positive fetus. Therefore, unnecessary anti-D prophylaxis treatments can be avoided. The aim of the study was to develop a multiplexed, quantitative PCR (qPCR) assay for fetal RhD genotyping using maternal plasma derived cell-free fetal DNA (cfDNA) as sample material.

Methods: The fetal RhD genotyping assay was designed for simultaneous detection of RhD gene exons 5, 7 and 10, in addition to an internal control gene. Dry qPCR chemistry was utilized to enable simplified qPCR workflow. The assay was confirmed to
be compatible with cfDNA samples extracted with PerkinElmer Vanadis Extract® system.

**Results:** The assay was able to distinguish RhD positive and negative cfDNA samples and showed similar performance with both liquid and dried qPCR chemistry. The presence of fetal DNA in the maternal cfDNA samples was demonstrated by amplification of male-specific sex-determining region Y (SRY) gene.

**Conclusion:** Dried qPCR chemistry enables a simple and time-saving workflow, which can be easily combined with other prenatal cfDNA screening. Further clinical testing is required to determine clinical sensitivity and specificity.

**References:**

**Grants:** In collaboration with PerkinElmer Wallac Oy.

**Conflict of Interest:** Suvi Parviainen This Master’s Thesis study was done as collaboration with PerkinElmer Wallac Oy and University of Turku. I am currently working full-time at PerkinElmer Wallac Oy as Subject Matter Expert (customer support). Ville Veikko lainen Employee at PerkinElmer (Senior R&D Scientist).

---

**P02.016.A LARS1-related disorder presenting as recurrent severe early onset fetal growth restriction attributed to placental and immune disease**

**Dana Brabbing-Goldstein**, Sharon Perlman, Illi Bazak, Gabriel Arie Lidzbarsky, Yael Kilim, Lina Basel-salmon, Rivka Sukenik-Haley

**1Raphael Recanati Genetic Institute, Rabin Medical Center-Beilinson Hospital, Petach Tikva, Israel; 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 3Ultrasound Unit, Helen Schneider Women’s Hospital, Rabin Medical Center, Petach Tikva, Israel; 4Paediatric Genetics Clinic, Schneider Children’s Medical Center of Israel, Petach Tikva, Israel; 5Felsenstein Medical Research Center, Petach Tikva, Israel; 6Genetic Institute, Meir Medical Center, Kfar Saba, Israel.

**Background/Objectives:** While the yield of chromosomal microarray in isolated fetal growth restriction (FGR) has been established, the added value of whole exome sequencing (WES) in such cases is unknown. We report recurrent severe early onset FGR in three of the five pregnancies in one family related to infantile liver failure syndrome type 1 (OMIM 615438).

**Methods:**

**Results:** Fetal autopsy showing hepatocyte hemosiderosis and placental pathology showing >50% necrosis of villi, multiple cysts and synechia, raised suspicion of both gestational alloimmune liver disease and thrombophilia. However, FGR fully reoccurred albeit IVIG and antithrombotic treatment. Fetal chromosomal microarray analysis was normal. Quatro WES revealed that two affected fetuses were compound heterozygotes for paternal truncating (c.1144G>T;p.Glu382Ter) and maternal missense (c.1511C>T;p.La504Val) variants in the LARSI gene (NM_020117.11) which is related to autosomal recessive infantile liver failure syndrome type 1. The variants co-segregated in a third affected fetus but not in a healthy daughter.

**Conclusion:** Aminoacyl-tRNA synthetase deficiency, including LARSI-related condition, cause multisystemic disorders mostly affecting growth and nervous system. Inefficient translation and consequential decreased cell proliferation may explain the FGR phenotype. The family’s genetic diagnosis will allow prenatal diagnosis or preimplantation genetic testing in future pregnancies and will help to avoid unnecessary treatments. This report highlights the importance of incorporating WES in the evaluation of early severe isolated FGR, as genetic diagnosis may completely change medical interventions and shed light on the expected outcome. Further studies are needed to evaluate the prevalence of single gene disorders in isolated FGR.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

---

**P02.017.B The role of a multidisciplinary team in managing variants of uncertain clinical significance in prenatal genetic diagnosis**

Karina Diderich, Jasmin Klapwijk, Myrthe van den Born, Martina Wilke, Marieje Joosten, Diane Van Opstal, Hennie Brüggenwirth, Malgorzata Srebnik

**1Erasmus MC, Clinical Genetics, Rotterdam, Netherlands.**

**Background/Objectives:** The aim of this study was to evaluate the role of the multidisciplinary team (MDT), the elements that facilitate rapid management of variants of unknown clinical significance (VUS) in prenatal diagnosis, and which types of VUS were considered for reporting.

**Methods:** We reviewed the frequency of MDT meetings and factors contributing towards decision making on reporting VUS after prenatal exome sequencing.

**Results:** The crucial elements that facilitate rapid VUS management were regular meetings, appropriate expertise, professional connections with other experts (ad hoc present) and psychological team safety. The following VUS were considered for reporting: possibly matching the fetal phenotype, associated with severe disorders when a functional test is available (e.g. enzymatic test), possibly associated with a disorder where early post-partum diagnosis and treatment are crucial for a better prognosis.

**Conclusion:** In order to protect prospective parents from the burden of VUS, the professionals should limit reporting them. Apart from using software filters and building professional guidelines, this can be achieved by sharing professional experience and responsibility in a MDT setting. Moreover, we noted that emotional distress caused by communicating uncertain information to the prospective parents can only be borne when supported by psychological team safety.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

---

**P02.018.C CHRB – a tool for identification and visualization of chromosomal abnormalities in preimplantation embryos using next-generation sequencing data**

Tim Nguyen, Zainul Arifin, Vivienne Tan, Beatrice Pak, Arnold Tan, Simin Wong, Henry Yang, Caroline Lee, Mahesh Choolani, Peng Cheang Wong, Samuel Chong

**1National University of Singapore, Singapore, Singapore.**

**Background/Objectives:** Current commercial solutions for pre-implantation genetic testing of aneuploidies (PGT-A) using next generation sequencing (NGS) data entail the use of specific proprietary analysis software, which preclude analysis of NGS data generated from other sources. We have developed and evaluated CHRB, a tool for identifying CHromosomal ABnormalities in preimplantation embryos using NGS data.

**Methods:** Single-cell and five-cell replicates from aneuploid and segmentally unbalanced cell lines were whole genome amplified using SurePlex and subjected to Nanopore single-molecule sequencing, followed by CHRB analysis and visualization. An aliquot of each Sureplex-amplified sample was also sequenced using a leading commercial NGS-based PGT-A solution (Illumina VeriSeq PGS) and analyzed using its proprietary analysis software (BlueFuse Multi).
Results: Using Nanopore sequencing and CHRAB analysis and visualization, the expected cell-line specific aneuploidy was detected in 84 of 88 (95.45%) single- and multi-cells tested, and the expected segmental imbalance (≥10 Mb) was detected in 88 of 90 (97.78%) single- and multi-cells tested. The corresponding percentages obtained using the commercial PGT-A solution were 95.45% (84 of 88 single- and multi-cells with an aneuploidy) and 98.89% (89 of 90 single- and multi-cells with a segmental imbalance of ≥10 Mb). Detection sensitivity for smaller segmental imbalances of <10 Mb was significantly lower on both platforms.

Conclusion: We have developed a bioinformatics tool for aneuploidy and segmental imbalance detection from single- and multi-cell NGS data, with accuracy comparable to commercial platforms.

References:
Grants:
References:
Conflict of Interest: None declared.

P02.019.D Perlman Syndrome: A prenatal and genetic diagnostic challenge
Kim Van Berkel1, Elise Vantroux1, Ileen Slegers1, Astrid Leus2, Stefanie Brock2, Boyan Dimitrov1
1UZ Brussel, Centre for Medical Genetics, Brussels, Belgium; 2UZ Brussel, Department of Pathology, Brussels, Belgium.

Background/Objectives: Perlman syndrome (PS) is a very rare congenital overgrowth syndrome, with a prevalence estimated to be less than 1/1,000,000. Generally the diagnosis is based on neonatal clinical appearance and histologic findings. For a long time the genetic basis of PS was unknown with an assumed autosomal recessive inheritance. Since 2012 mutations in DIS3L2 gene have been found to be associated to PS. Some cases have been described prenatally, but precise diagnosis in a prenatal setting remains difficult to obtain due to overlap with other overgrowth syndromes. Both prenatal imaging and genetic diagnostic technologies have enormously evolved over the past decade and are being implemented in prenatal diagnosis today, enhancing diagnostic yield.

Methods: Here, we present a prenatal case of PS, with phenotyping by subsequent ultrasound and MRI examinations and molecular diagnosis by NGS, with an overview of existing literature. Accurate prenatal phenotyping of PS and comparison with Beckwith-Wiedemann and Simpson-Golabi-Behmel syndrome was made.

Results: Confirmed prenatal diagnosis of PS was obtained by subsequent high resolution imaging with next generation sequencing (NGS) on amniotic fluid sample, showing 2 pathogenic variants in the DIS3L2 gene, not yet described in existing literature.

Conclusion: Since knowledge of the concerned gene and use of new technologies, for imaging as well as genetic analysis, the diagnosis of PS can be made prenatally. This is of great value during prenatal counseling of pregnant couples, as PS is known to have a poor prognosis.

References: Astuti D et al Nature Genet. 2012. Grants:
Conflict of Interest: None declared.

P02.021.B Expanded NIPS does not significantly increase the detection rate of abnormal genetic findings in pregnancies with normal ultrasound
Lena Sagı-Daın1, Didt Maya2, Liat Sheelo Salzer2, lina basel-salmon2
1Carmel Medical Center, Haifa, Israel; 2Rabin Medical Center Golda Hasharon Campus, Petach Tikva, Israel.

Background/Objectives: Non-invasive prenatal screening (NIPS) is currently widely used in many countries. The common NIPS technique is focused on trisomies 13, 18, 21 and sex-chromosomal aberrations (S-NIPS), while many laboratories offer expansion to include common microdeletions as well as genome-wide aberrations sized over 7Mb. We aimed to evaluate the theoretical yield of NIPS expansions compared to the commonly used 5-NIPS, based on chromosomal microarray analysis (CMA) results of pregnancies with normal ultrasound.

Methods: CMA results of pregnancies with normal ultrasound (including soft markers and abnormal maternal serum screening) were recorded. We have calculated the detection rate of 5-NIPS detectable aberrations and compared those to rates of findings detectable by 5-NIPS plus common microdeletions (1p36.3-1p36.2, 4p16.3-4p16.2, 5p15.3-5p15.1, 15q11.2-15q13.1, and 22q11.2), and genome-wide NIPS-detectable findings (including variants >7Mb).

Conflict of Interest: None declared.

References:
Grants:

P02.020.A Prenatal Trio-Exome-Analysis reveals not yet published prenatal manifestations of rare diseases
Uwe Ahting1, Melanie Isar2, Bernt Schulze2, Markus Stumm1, Konstanze Hoernagel1
1MVZ-Martinsried GmbH, Human Genetics, Planegg, Germany; 2MedicoGen Genetics GmbH, Molekulargenetik, Berlin, Germany; 3Medico Humangenetik Berlin Lichtenberg, Humangenetik Hannover, Hannover, Germany.

Background/Objectives: Between 7-2021 and 12-2021 we performed 79 prenatal trio exome analyses with 23 positive results (29.5%) with a turnaround time of 12.05 days on average. In all cases, indication has been ultrasound abnormalities. Most frequently leading symptoms were increased nuchal translucency (n = 19), skeletal (n = 14), brain (n = 14), and heart (n = 13) abnormalities. Most pathogenic variants found in association with skeletal abnormalities were de novo and located in known disease genes. In some cases, pathogenic variants were associated with prenatal manifestations of rare diseases not published so far. Here we present two case reports.

Methods: Prenatal trio exome analysis.

Results: Case 1: Fetus with cerebella vermis hypoplasia, choroid plexus cyst and micrognathia in 19th week of pregnancy. Trio exome analysis demonstrated a frameshift variant in CNOT3 (disease IDDSADF, OMIM #: 618672), already published as pathogenic. Postnatal manifestations of IDDSADF are small chin, short stature, hypotonia, cerebellar abnormalities. Prenatal manifestations are not published yet.

Case 2: Fetus with increased nuchal translucency and cystic hygroma in 13th week of pregnancy. Trio exome analysis provided a probably pathogenic missense variant in KCNT2 (disease DEES7, OMIM #: 617771). Postnatal manifestations of DEES7 are global developmental delay, hypotonia, intellectual disability and seizures. Hitherto only fatal hiccup has been mentioned in one case report.

Conclusion: Notwithstanding the possibility of spurious correlations, the two presented cases reveal so far unreported prenatal manifestations of rare diseases. More to be found. In addition prenatal trio exome analysis increases the diagnostic yield of genetic prenatal investigation, especially if increased nuchal translucency is present.

References:
Grants:
Conflict of Interest: None declared.
Results: Of the 8,605 pregnancies, 44 (0.51%) 5-NIPS detectable findings were noted, ranging from 1.56% in 642 pregnancies with abnormal maternal serum screening, 0.63% in 318 pregnancies with soft markers, 0.62% in 4,378 women aged over 35 years, to 0.15% in younger women. Three cases of common microdeletions were detected in the overall cohort (0.03%), as well as six genome-wide-NIPS detectable findings (0.07%), yielding a non-significant difference compared to 5-NIPS.

Conclusion: NIPS expansion to common microdeletions as well as to genome-wide-findings does not significantly increase the detection rate compared to 5-NIPS. These results facilitate informed decisions of couples regarding prenatal genetic screening using NIPS technology in comparison to CMA from invasive fetal sample.

References:

Grants:

Conflict of Interest: None declared.

P02.022.C A rare case of fetoplacental discrepancy: a normal result in chorionic villi in contrast to de novo unbalanced translocation 46,XX,der(6)(t(6;17) in amniotic fluid

Lucie Lišková1, Vlasta Čejnova1, Monika Stára1, Vjaceslav Harmas1, Lilly Dejová1, Lenka Vancová1, Jana Lastuvková1
1Masaryk Hospital in Ústí nad Labem, o.z., Krajská zdravotní, a.s., Department of Medical Genetics, Ústí nad Labem, Czech Republic.

Background/Objectives: We present a gravidity with different levels of mosaicism. The mosaicism of cell line with der(6) was detected together with abnormal cell line with der(6) in karyotype, whereas in the other types of tissues the normal cell was de

ized by FISH analysis: amniotic fluid, fetus tissue, cord blood; 90%, 66%, 17.5% of interphase nuclei, respectively.

Methods: Prenatal ultrasound, aCGH, karyotyping and FISH.

Results: Microarray analysis of native chorionic villi showed a normal female profile of the fetus. The aneuploidy (at 16 WG) was performed due to other fetal ultrasound findings: ascites, hyperdense lung and hyperechogenic fetal bowel. Cytological analysis of cultured amniocytes revealed an abnormal karyotype: 46,XX,der(6) which was confirmed by microarray: arr[GRCh37] 6q26q27(162799322_170884575)x1,17q12q25.3(47109888_81044533)x3. De novo unbalanced translocation was determined in the fetus: 46,XX,der(6)(t(6;17))q(26q27.3), where the 8 Mb terminal deletion of long arm of chromosome 6 and 34 Mb terminal duplication of chromosome 17 were determined. Karyotypes of both parents were normal. The gravidity was terminated and the samples of placenta, amniotic fluid, cord blood and skin were analyzed. Cytological analysis of placenta confirmed a normal karyotype, whereas in the other types of tissues the normal cell line was detected together with abnormal cell line with der(6) in different levels of mosaicism. The mosaicism of cell line with der(6) was defined by FISH analysis: amniotic fluid, fetus tissue, cord blood; 90%; 66%, 17.5% of interphase nuclei, respectively.

Conclusion: The mosaicism of normal cell line 46,XX together with abnormal cell line with de novo unbalanced autosomal translocation is extremely rare and need’t be detected in CVS.

References:

Grants:

Conflict of Interest: None declared.

P02.022.D False positivity and false negativity as a standard part of noninvasive prenatal testing

Gabriel Minarik1,2, Michaela Hyblova1,2, Martina Sekelska1,2, Erika Tomkova2, Katarina Tothova2, Dagmar Landlova2, Peter Krizan1,3
1Medirex Group Academy n.p.o., Department of genomics, Nitka, Slovakia; 2Trisomy test Ltd., Nitka, Slovakia; 3Medirex Inc., Department of genetics, Bratislava, Slovakia.

Background/Objectives: Noninvasive prenatal testing (NIPT) is becoming highly accepted as a routine prenatal screening tool in most of developed countries. With advanced versions of NIPT tests covering aneuploidies of all chromosomes and subchromosomal aberrations false positives and false negatives appear more frequently.

Methods: To get comprehensive information about the reason of NIPT result false negatives as qPCR, aCGH, FISH, karyotyping in diagnostic settings were used additionally to original low coverage whole genome sequencing based NPT.

Results: After 19159 NIPT performed in routine clinical laboratory 9 analyses were reported as false negative (2) and false positive (7), in statistics focused solely on chromosomes 21, 18 and 13 trisomies, representing less than 0.05% of cases. When focusing on all chromosomes and also subchromosomal aberrations the frequency of such false results is even higher. From the portfolio of potential biological reasons we detected and confirmed by molecular methods cases related to confined placental mosaicism, true fetal mosaicism, maternal aberration in full and mosaic state, precancerous maternal aberration, incorrect previous anamnestic data. As technical reasons grey zone result, insufficient coverage and syndrome specific information were detected.

Conclusion: False negative and false positive NIPT results are reported every day all over the world and need to be addressed with comprehensive supplementary diagnostic testing. Consensus about its routine usage is needed and international guidelines should reflect this need too.

References:

Grants: This work was supported by the OPII programme as the project - Center for biomedical research – BIOMEDIIER, ITMS 313011W428, co-financed by the ERDF.

Conflict of Interest: Gabriel Minarik part-time employee of Medirex Group Academy n.p.o and Trisomy test Ltd., principal investigator of running grants, Michaela Hyblova part-time employee of Medirex Group Academy n.p.o and Trisomy test Ltd., collaborator on several grants, Martina Sekelska part-time employee of Medirex Group Academy n.p.o and Trisomy test Ltd., collaborator on several running grants, Erika Tomkova full-time employee of Medirex Inc., Katarina Tothova full-time employee of Medirex Inc., Dagmar Landlova full-time employee of Medirex Inc., Peter Krizan part-time employee of Medirex Inc. and Medirex Group Academy n.p.o.

P02.024.A Clinical implementation of a custom oligonucleotide array-CGH. Experience in the largest cohort of Spanish prenatal samples (>5300 samples)

Olaya Villa Marcos1, Marina Viñas-Jornet1, Noemi Sousa1, Nerea Alvarez1, Neus Forés1, Manel García-Aragonés1, Luis Pérez-Jurado2, Lluís Armengol1
1Quantitative Genomics Medicine Laboratories, qGenomics, Microarray, Esplugues del Llobregat, Spain; 2Universitat Pompeu Fabra, Hospital del Mar – IMIM, and CIBER de Enfermedades Raras (CIBERER), Genetics unit, Barcelona, Spain.

Background/Objectives: The implementation of genomic array in prenatal routines, when accompanied by pre- and post-test genetic counseling, has demonstrated its utility by fulfilling the longstanding need for a diagnostic test with a higher resolution and higher diagnostic yield than its predecessor, the conventional karyotype.
Methods: Array CGH was performed in 5388 prenatal samples (3972 amniotic fluids, 1131 corions and 285 fetal samples), using a custom 60K oligonucleotide-based microarray (qChip® CM) designed to maximize the detection of clinically relevant copy-number alterations, and minimize the detection of variants of unknown significance (VOUS). As a general rule, VOUS with unclear phenotypic effect according to current knowledge, and some susceptibility variants are not reported.

Results: We identified a total of 363 pathogenic or likely pathogenic alterations (detection rate: 6.73%) and 76 VOUS (1.41%). As expected, the greatest pathogenic detection rate (7.28%, 326/4477) was among fetuses with ultrasound anomalies, while detection rate was 4.06% (37/911) in normal ultrasound gestations. When both parental samples were available, the vast majority of the VOUS were inherited from a non-affected parent (90.24%) and could be reclassified as likely benign.

Conclusion: Our series reinforces the clinical utility of prenatal microarray testing: it nearly doubles the diagnostic yield of conventional karyotype (153/363 with variants <10Mb), with no significant increase in the frequency of VOUS that could interfere in decision making. In our experience, we highlight the importance of implementing aCGH in prenatal routines, for all gestations with an indication of invasive fetal sampling.

References:

Grants:

Conflict of Interest: None declared.

P02.027.D Use of prenatal exome sequencing in fetuses with ultrasound anomalies

Maria Segura-Puimendon1, Marta Carreño1, Raquel García1, Lidia Carreño1, Hector San Nicolás1, César Arjona1, Celia Sintas1, Olaya Villa Marcos1, Marina Viñas-Jornet1, Mónica Valls1, Nina Bosch1, LLuis Armengol1

1qGenomics, NGS Clinical Department, Esplugues de Llobregat, Spain.

Background/Objectives: Whole exome sequencing (WES) is an established diagnostic tool in postnatal settings for individuals with a suspected genetic condition. Recently, it is increasingly used as a diagnostic tool in prenatal settings as well. We present here our experience using this technology in fetuses with ultrasound anomalies.

Methods: WES was performed in 350 fetal samples with ultrasound anomalies. 248 samples were from evolutive pregnancies and 102 were from legal interruptions or stillbirths. Segregation studies were performed in cases with a candidate variant when possible.

Results: Common reasons for referral were skeletal anomalies, polymalformated fetuses, cerebral anomalies or specific syndrome suspicion. Pathogenic or likely pathogenic variants were identified in n = 56 (16%) of samples. In n = 64 (18.2%) cases, variants of unknown significance were identified. In more than half of the cases (58%) no candidate variant was identified. Diagnostic yield was higher in fetuses with skeletal anomalies, where pathogenic or likely pathogenic variants were identified in (n = 19) 33% of cases, and in fetuses with increased nuchal translucency or hydrops (Noonan syndrome suspicion), where a pathogenic variant was found in 23.5% (n = 13) of the samples.

Conclusion: Exome sequencing is a valuable diagnostic tool in fetuses with ultrasound anomalies, especially when skeletal anomalies are present or when Noonan syndrome is suspected.

References:

Grants:

Conflict of Interest: None declared.

P02.028.A Two novel variants in the POR gene causing Antley-Bixler syndrome type 2 detected prenatally in a foetus with abnormal ultrasound findings

Jana Lastuvkova1, Miroslav Brestak2, Pavel Votyka3, Petra Peldova4, Vlasta Cejnova4, Lucie Liskova1, Vjaceslav Harmas1

1Masaryk Hospital, o.z., Krajska zdravotni, a.s., Department od Medical Genetics, Usti nad Labem, Czech Republic; 2Prague Prenatal Diagnosis Centre, ProfiG2, Prague, Czech Republic; 32nd Faculty of Medicine,
Charles University in Prague and Motol University Hospital, Department of Biology and Medical Genetics, Prague, Czech Republic.

Background/Objectives: Antley-Bixler syndrome (ABS) is a rare severe form of syndromic craniosenosis.

Type 1 ABS is autosomal dominant due to heterozygous pathogenic variants in the FGR2 gene, type 2 ABS is autosomal recessive due to biallelic pathogenic variants in the POR gene. Phenotypic features include craniosenosis, characteristic facial features, proptosis, skeletal anomalies and wide range of organ malformations.

We present a case of ABS type 2 detected on the basis of prenatal ultrasound examination.

Methods: Prenatal ultrasound, aCGH, targeted NGS panel of 89 genes associated with craniosenosis.

Results: Atypical head shape of foetus was seen on ultrasound in the 21st week of pregnancy. Combined screening of the 1st trimester was negative but level of PAPP-A was extremely high - 41.112 MoM. Specialized ultrasound examination confirmed turiccephaly, deformity of the cerebral hemispheres, hypertelorism, low set ears and talipes varus. Craniosenosis was suspected. Parents decided to terminate pregnancy.

Autopsy of the foetus showed turiccephaly, frontal bones agenesis, hypertelorism, proptosis, low set ears, lack of thumbs and arachnodactyly forefingers on both feet. Examination of the targeted NGS gene panel revealed 2 novel heterozygous probably pathogenic variants in the POR gene - c.1898+1del/c.450>A p.(Asp150Glu). Each variant is present in one of the parents.

Conclusion: This case demonstrates the importance of collaboration between precision ultrasound diagnostics and modern laboratory methods (NGS) in elucidating the causes of rare serious foetal disorders. We believe this is the first case of prenatal detection of ABS type 2 in the Czech Republic.

References:

Grants: NA.
Conflict of Interest: None declared.

P03
SENSORY DISORDERS (EYE, EAR, PAIN)

P03.001.B Accurate clinical evaluation and high throughput technologies for the molecular characterization of hereditary hearing loss in a large cohort of Italian patients

Anna Morgan1, Stefania Lenarduzzi1, Beatrice Spedicati2, Paola Tesolin3, Aurora Santin1, Elisa Rubinato1, Giorgia Girotto1,2

1Institute for Maternal and Child Health – IRCCS “Burlo Garofolo”, Trieste, Italy; 2University of Trieste, Department of Medicine, Surgery and Health Sciences, Trieste, Italy.

Background/Objectives: HL is the most prevalent sensory disorder, affecting ~6% of the world’s population. From a genetic perspective, HL is a challenging disease because of its genetic heterogeneity and clinical variability with different onset of symptoms complicating the molecular diagnosis.

Methods: We applied a multi-step approach for testing 290 syndromic and non-syndromic HL families (negative to GJB2 mutation), which included:

1. an accurate clinical evaluation,
2. the assessment of STRC-CATSPER2 and OTOA Copy Number Variants (CNV) via Multiplex Ligation-dependent Probe Amplification (MLPA),
3. Whole Exome Sequencing (WES) in patients negative to steps 2-3.
4. Whole Genome Sequencing (WGS) in a subset of families negative to 2-3.

Results: MLPA and WES led to the characterization of ~41% of cases. In particular, data analysis allowed to 1) confirm the relevant role of CNVs in the STRC gene, with ~5.9% of patients carrying a pathogenic deletion, 2) discover six new disease genes (e.g. PSIP1, TBL1Y, SPATC1L, PLS1, SLC12A2, MYOSC), and 3) shed the light on unexpected scenarios, such as the presence of dual molecular diagnosis, further exploring the complexity of HL. In negative cases to steps 2-3 we proceeded with WGS, searching for new possible causative alleles, including deep intronic and structural variants, starting from patients carriers of one pathogenic variant in recessive HL genes (e.g. SLC26A4).

Conclusion: Our approach led to an overall detection rate of ~41% in the Italian population. Furthermore, we expect WGS to unveil other possible disease mechanisms, deepening the knowledge of the biological mechanisms of HL.

References: None declared.

Grants: None.
Conflict of Interest: None declared.

P03.002.C A comprehensive WGS-based pipeline for the identification of new candidate genes in inherited retinal dystrophies

Elena Fernández-Suárez1,2, Maria González-del Pozo1,2, Nereida Bravo-Gil1,2, Cristina Méndez-Vidal1,2, Marta Martín-Sánchez1, María Mena1,2, Enrique Rodríguez-de la Rúa1,2, Manuel Ramos-Jiménez2, María Jose Morillo Sanchez2, Salud Borrego1,2, Guillermo Antiónd1,2

1Virgen del Rocío University Hospital/CSIC/University of Seville, Department of Maternofetal Medicine, Genetics and Reproduction/Institute of Biomedicine of Seville, Seville, Spain; 2Center for Biomedical Network Research on Rare Diseases (CIBERER), Seville, Spain; 3University Hospital Virgen Macarena, Department of Ophthalmology, Seville, Spain; 4Institute of Health Carlos III, Retics Patología Ocular, OFTARED, Madrid, Spain; 5University Hospital Virgen Macarena, Department of Clinical Neurophysiology, Seville, Spain.

Background/Objectives: To enhance the use of Whole Genome Sequencing (WGS) in clinical practice, it is still necessary to standardize data analysis pipelines. Herein, we aimed to define a WGS-based algorithm for the accurate variant interpretation in inherited retinal dystrophies (IRD).

Methods: This study comprised 429 phenotyped individuals divided into three cohorts: i) the training cohort with 209 genetically diagnosed IRD individuals was used to perform a statistical comparison of 14 pathogenicity predictors, redefine cutoffs and design the algorithm; ii) the validation cohort, consisting of 50 additional IRD individuals, 109 hereditary cancer patients and 47 with neurological diseases, allowed to select the optimal combination of predictors and to evaluate its translational value and iii) the discovery cohort including WGS data of 14 individuals from 7 genetically undiagnosed IRD families that were analysed applying our optimised workflow.

Results: The statistical analysis disclosed the most effective combination of predictors for non-splicing (CADDv1.6, MAPP, Grantham, and SIFT) and splicing (SpliceAI and NNS) variants. The pipeline validation showed high sensitivity, detecting 90% of causal variants in all the pathologies tested. This approach allowed identifying variants in candidate genes for IRD, such as CFA2P20, in the discovery cohort families. Moreover, our results showed a 90% reduction of variants to be manually reviewed applying the customized cutoffs instead of the literature values.
protein 20, CFAP20, encodes for a highly conserved protein that causes a ciliary phenotype in both in-vitro and in-vivo models, suggesting its likely implication in human ciliopathies. On the other hand, CFAP20 (Bug22) depletion causes a ciliary phenotype, and studies have demonstrated that CFAP20 mRNA was highest in the retina. Specifically, in silico mutagenesis experiments also predicted conformational changes secondary to hydrogen-bonds loss. Additionally, CFAP20 is known to interact with the RP-associated protein, NPHP3. These findings led us to propose CFAP20 as a candidate gene for non-syndromic retinitis pigmentosa (RP).

Methods: Two members of one consanguineous non-syndromic RP family underwent WGS using Illumina’s HiSeqX platform. Segregation analysis was conducted by Sanger sequencing. The retinal expression and localization of human CFAP20 were evaluated by real-time-qPCR and immunohistochemistry using retinal sections from healthy donors. CFAP20 clinical impact was further investigated using 3D-modeling and protein-protein interaction networks.

Results: An in-house data analysis pipeline allowed the identification of one homozygous variant in CFAP20 (c.337C>T; p.Arg113Trp) segregating with the disease. Comparison of the relative mRNA levels between different tissues showed that CFAP20 mRNA was highest in the retina. Specific immunolabeling was observed in the photoreceptors layer. Our in-silico mutagenesis experiments also predicted conformational changes secondary to hydrogen-bonds loss. Additionally, CFAP20 was found to interact with the RP-associated protein, ARL2BP.

Conclusion: Although additional studies are needed, this work led us to propose CFAP20 as a candidate gene for non-syndromic RP and is expected to expand the mutational landscape of ciliary genes associated with human diseases.

References: PMIDs: 24414207; 20118210; 24574454; 31763178; 23849777.

Grants: ISICIII-ERDF/ESF (P118-00612; P121-00244; F119/00091), Andalusian Government (PEER_0501_2019), F.Isabel Gemio/F.Cajasol (FGEMIO-2019-01).

Conflict of Interest: None declared.

P03.003.D Evaluation of CFAP20 as a candidate gene for autosomal recessive non-syndromic retinitis pigmentosa

Maria Gonzalez-del Pozo1,2, Elena Fernández-Suárez1,2, Nereida Bravo-Gil1,2, Cristina Méndez-Vidal1,2, Marta Martín-Sánchez1, Marcella Mend1,2, Enrique Rodríguez-de la Rúa1,2, Manuel Ramos-Jiménez1, María Jose Morillo Sanchez2, Salud Borrego1,2, Guillermo Antinol1,2

Background/Objectives: The cilia and cilia-related genes associated with human diseases. The cilia and ciliopathies, have a very high power and cost-effective tool to identify rare mutations which are not reported. This makes the HearPanel-IdA a powerful and cost-effective tool to identify rare mutations causing HI.

Methods: We explored the variants responsible for deafness in a total of 450 unrelated patients affected by severe to profound early onset HI from North African (Algeria, Mauritania, Morocco, Tunisia) and Middle East (Jordan) countries. To this purpose, we developed a targeted exome high throughput sequencing of 156 known deafness genes (HearPanel-IdA), followed by qPCR analysis and only retained predicted pathogenic variants.

Results: This allowed us to ascertain molecular diagnosis for a total of 391/450 patients (86.9%). Remarkably, we found 63/450 patients (14%) with variants in Usher syndrome (USH) genes of whom 40 had been clinically diagnosed as Usher. In the other 23 patients, subsequent clinical exams established the existence of a retinitis pigmentosa. Moreover, a total of 213 predicted pathogenic variants were identified in 49 known deafness genes of which 84 (39.4%) never reported. This makes the HearPanel-IdA a powerful and cost-effective tool to identify rare mutations causing HI.

Conclusion: The use of HearPanel-IdA as a routine investigation should not only facilitate the detection of rare mutations in uncommon HI genes, but also contribute significantly to the early diagnosis of specific forms of syndromic HI such as Usher syndrome, for which early cochlear implantation is of utmost importance because of the secondary sight loss.

References:

Zied Riahi1, Sophie Boucher2, Fabienne Wong Jun Tai3, Amrit Estivo1, Magali Niasme-Grare4, Yosra Bouyacoub5, Samia Abdi6, Malika Dahman5, Sonia Talbi6, Rhamma mkouaf6, Ghita Amalou5, Soukaina Elharichi5, Mima Mustafa5, Malak Salame7, Ely Cheikh Moota7, Moua Hadram6, chine chezareddine5, Marrakchi Jihe10, Rim Zainine1, Houda Chahed1, Besbes Ghazi10, Medjiba Tabet2, Ridha Mirad2, Ichraf Kraoua2, Ikhem Turki2, Ahmed Hourmeida1, Abdelhamid Barak2, Fatima Ammar-Khodja2, Akila Zenati2, Mohamed Makrelouf2, Sonia Abdelhak3, Christine Petit1, Cristel Bonet1

1Institut de l’audition, Institut Pasteur, INSERM, Paris, France; 2Service d’ORL, Centre Hospitalier Universitaire (CHU) d’Angers, Faculté de Médecine, Angers, France; 3Service de Biochimie et Biologie Moléculaire, Hôpital d’Enfants Armand-Trousseau, AP-HP, Paris, France; 4Laboratoire de biochimie génétique, Service de biologie - CHU de Bob El Ouad, Université d’Alger 1; 5Laboratoire central de biologie, CHU Frantz Fanon, Faculté de médecine, Université Saad Dahleb, Béja, Algiers, Algeria; 6Équipe de Genétique, Laboratoire de Biologie Cellulaire et Moléculaire, Faculté des Sciences Biologiques, Université des Sciences et de la Technologie Houari Boumediène (USTHB), El Alia, Bab-Ezzouar, Algiers, Algeria; 7Institut Pasteur de Tunis, LR16IP05, Biomedical Genomics and Oncogenetics Laboratory, Tunis, Tunisia; 8Human Molecular Genetics Laboratory, Institut Pasteur du Maroc, Casablanca, Morocco; 9University of Sheffield, Department of Biomedical Science, Sheffield, United Kingdom; 10Unité de Recherche sur les Biomarqueurs dans la Population Mauritanienne, Université des Sciences, de Technologie, et de Médecine (USTM), Nouakchott, Mauritania; 11Hôpital La Rabta, Otorhinolaryngology Diseases, Tunis, Tunisia; 12Hôpital Charles Nicolle, Congenital and Hereditary Diseases, Tunis, Tunisia; 13Institut National de Neurologie, Tunis, Tunisia; 14Laboratoire de biochimie génétique, Service de biologie - CHU de Bob El Oued, Université d’Alger 1, Algiers, Algeria.

Conclusion: Given the lack of consensus on the use of prediction tools, we offer a translational strategy for accurate WGS data prioritization in the clinical setting.

References: PMIDs: 24618965; 20238084.

Grants: ISICIII-ERDF/ESF (P118-00612; P121-00244; F119/00091), Andalusian Government (PEER_0501_2019), F.Isabel Gemio/F.Cajasol (FGEMIO-2019-01).

Conflict of Interest: None declared.
P03.006.C Deciphering the genetic architecture of inherited retinal diseases in the Iranian population by integrated exome sequencing

Miriam Bawens1, Kristof Van Schil2, Marieke De Bruyne2, Mattias Van Heetvelde1, Quinten Mahieu1, Toon Rosseel1, Ebrahim Al Hajj3, Sarah Van Malderen1, Reza Maroofiyan4, Fatemeh Suri5, Elfride De Baere1

1Center for Medical Genetics Ghent, Ghent University and Ghent University Hospital, Ghent, Belgium; 2Center for Medical Genetics Antwerp, Universiteit Antwerpen, Antwerp, Belgium; 3Vrije Universiteit Brussel, Brussels, Belgium; 4Institute of Neurology, Department of Neuromuscular Diseases, University College London, London, United Kingdom; 5Ophthalmic Epidemiology Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Background/Objectives: To uncover the underlying molecular causes of inherited retinal disease (IRD) in 105 unrelated families of Iranian descent, an integrated approach consisting of whole exome sequencing (WES) and autozygosity mapping was used.

Methods: WES was performed in 105 Iranian IRD families, predominantly originating from a consanguineous background (77%). Data-analysis was performed using the in-house Sequplorer tool. Copy number variants (CNVs) were assessed via ExomeDepth. Variants were validated, classified (ACMG/ACGS guidelines) and segregation analysis was performed. AutoMap was used to determine runs of homozygosity (ROHs).

Results: By interrogating 290 known IRD genes using a WES-based analysis, we obtained a molecular diagnosis for 85% of the cohort. In total, 103 (likely) disease-associated variants were identified in 42 genes, 58 of which are novel variants. ABCA4, EYS, AIP1 and CRB1 were the four most implicated genes. In addition, the importance of structural variation (SV) in IRD was demonstrated, with CNVs identified in 8% of the cohort, including novel CNVs in CDHR1, CHM and RD3. Homozygous nonsense and missense deleterious variants were found in novel retina-expressed candidate IRD genes, including PFKFB2 and QRFPR.

Conclusion: This integrated study using WES and an in-depth analysis of the variants provides insight into the genetic architecture of IRD in Iran. We provided 85% of patients with a molecular diagnosis, expanded the molecular spectrum of IRD in Iran by the identification of novel variants in the majority of patients. Finally, autozygome-guided exome sequencing revealed several novel candidate genes for IRD in unsolved cases.

References:
Grants: FWO1802220N.
Conflict of Interest: None declared.

P03.007.DTransient receptor potential ankyrin 1 (TRPA1) channel: rare variants in chronic neuropathic pain patients

Erika Salvi1, Margherita Marchi1, Ekdalia Mehmeti1, Mirna Andelic2, Daniele Cazzato2, Grazia Devigili2, Ilaria D’Ambato1, Raffaella Lombardi1, Daniele Cartelli1, Monique Gerrits2, Milena Słęczkowska3, Rayaz Malik7,8, Catharina Faber9, Giuseppe Lauria Pinter1,10

1Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Neurology Unit, Milano, Italy; 2School of Mental Health and Neuroscience, Maastricht University, Department of Neurology, Maastricht, Netherlands; 3Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Neurophysiology Unit, Milano, Italy; 4Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Movement Disorders Unit, Milano, Italy; 5Maastricht University Medical Center, Department of Clinical Genetics, Maastricht, Netherlands; 6Maastricht University, Department of Toxicogenomics, Maastricht, Netherlands; 7University of Manchester and NIHR/Wellcome, Faculty of Biology, Medicine and Health, Manchester, United Kingdom; 8Weill CornellMedicine-Qatar, Qatar Foundation, Research Division, Doha, Qatar; 9Maastricht University Medical Centre, School of Mental Health and Neuroscience, Maastricht, Netherlands; 10University of Milan, Department of Biomedical Technology and Translational Medicine, Milano, Italy.

Background/Objectives: Chronic neuropathic pain is amongst the most common non-communicable disorders, with a significant impact on patients’ quality of life. The aim of this study is to assess the incidence of rare mutations in patients with neuropathic pain (NeuP).

Methods: We collected 480 patients complaining NeuP, and 216 healthy controls (HC) aged over 50. Subjects were classified according to symptoms distribution as “length-dependent”, “non-length-dependent” and “atypical” and analysed by target NGS of 107 genes involved in pain signalling. Rare genetic variants were selected and classified following ACGS recommendations.

Results: TRPA1 showed a significant overrepresentation of rare variants with functional or disrupting impact on the protein in NeuP patients compared to HC. We found that mutated samples with rare functional or disruptive variants were 2.92 times more frequent than in HC (2.85%). TRPA1 variants are mainly clustered in the N-terminal domain containing the ankyrin repeats, involved in channel function and regulation. Among patients harboring TRPA1 mutations, 18 (69%) has non-length-dependent NeuP, 10 (38%) reported cold-induced or cold-accentuated pain, 12 (46%) neuropathic itch and 14 (48%) electric shock-like pain.

Conclusion: TRPA1 encodes for a polymodal Ca2+ channel, involved in pain and inflammation, activated by potentially noxious stimuli, chemicals, and cold. The only genetic disease associated with TRPA1 is Familial Episodic Pain Syndrome. High-throughput studies on SNPs frequency found no association with NeuP susceptibility. Focusing on rare high-impact mutations, our study suggests that TRPA1 could increase the risk for complex painful conditions.

References:
Grants: GRANT AGREEMENT NO.602273 PROPANE STUDY–FP7-HEALTH-2013-INNOVATION-1.
Conflict of Interest: Erika Salvi: None declared, Margherita Marchi: None declared, Ekdalia Mehmeti: None declared, Mirna Andelic: None declared, Daniele Cazzato: None declared, Grazia Devigili: None declared, Ilaria D’Ambato: None declared, Raffaella Lombardi: None declared, Daniele Cartelli: None declared, Monique Gerrits: None declared, Milena Słęczkowska: None declared, Rayaz Malik: None declared, Catharina Faber Dr. Faber reports grants from European Union’s Horizon 2020 research and innovation programme Marie Skłodowska-Curie grant for PAIN-Net, Molecule-to-man pain network (grant no. 721841), grants from Gifols and Lamepro for a trial on IVIg in small fibre neuropathy, grants from Princes Beatrice Sierfonds, Steering committees/advisory board for studies in small fibre neuropathy of Biogen/Convergence, Vertex, Lilly and OliPass, Giuseppe Lauria Pinter: None declared.

P03.008.A Molecular characterization of inherited retinal degenerations in a Swiss patient cohort

Katrina Kaminska1,2, Francesca Cancellieri1,2, Quinodoz Mathieu1,2,3, Giacomo Calzetti1,2, Benoît György1,2, Lucas Janeschitz-Kriegi1,3, Hendrik Scholl1,2, Carlo Rivolta1,2

1Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Neurology Unit, Milano, Italy; 2School of Mental Health and Neuroscience, Maastricht University, Department of Neurology, Maastricht, Netherlands; 3Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Movement Disorders Unit, Milano, Italy; 4Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Movement Disorders Unit, Milano, Italy; 5Maastricht University Medical Center, Department of Clinical Genetics, Maastricht, Netherlands; 6Maastricht University, Department of Toxicogenomics, Maastricht, Netherlands; 7University of Manchester and NIHR/Wellcome, Faculty of Biology, Medicine and Health, Manchester, United Kingdom; 8Weill Cornell Medicine-Qatar, Qatar Foundation, Research Division, Doha, Qatar; 9Maastricht University Medical Centre, School of Mental Health and Neuroscience, Maastricht, Netherlands; 10University of Milan, Department of Biomedical Technology and Translational Medicine, Milano, Italy.
Abstracts from the 55th European Society of Human Genetics Conference

**Background/Objectives:** Inherited retinal degenerations (IRDs) are a group of disorders known for their genetic and clinical heterogeneity, which make molecular diagnosis a challenging process.

**Methods:** We collected approximately 200 DNA samples from more than 170 families with IRDs and other ocular disorders, ascertained by the Department of Ophthalmology at the University of Basel, and we developed a robust workflow based on the next generation sequencing (NGS) to identify the genetic determinants for these conditions. All patients underwent an ophthalmic examination performed by an IRD specialist, and their DNA was extracted from whole blood or saliva samples. Whole Exome Sequencing (WES) was performed for at least one affected individual from each family.

**Results:** Thus far, NGS analysis of 109 probands enabled the identification of causative variants in 37 known disease genes for 80 individuals, leading to an overall molecular characterization rate of 73%. Most identified mutations were single nucleotide variants (SNVs) and small deletion or insertions, whereas 6% of mutations were copy number variants (CNVs). Interestingly, mutations in intronic regions contributed to the diagnosis of 17 patients (>20% of all solved cases), with 3 deep intronic variants identified by an extensive analysis.

**Conclusion:** Integration of a research approach into analytical pipeline, together with the precise description of the clinical phenotype, lead to a high molecular diagnostic rate for patients with IRDs. Molecular diagnosis is crucial for the development of future gene therapies and proper genetic counseling of all patients.

**References:**

- **Grants:** The Swiss National Science Foundation, grant #204285.
- **Conflict of Interest:** None declared.

**P03.010.C Visual acuity GWAS in children identify novel genes and pathways**

**Krzysztof Marianski**, Judith Schmitz, Filippo Abbondanza, Michelle Luciano, Silvia Paracchini

1University of St Andrews, School of Medicine, St Andrews, United Kingdom; 2Georg-August-University Göttingen, Biological Personality Psychology, Göttingen, Germany; 3University of Edinburgh, Department of Psychology, Edinburgh, United Kingdom.

**Background/Objectives:** Visual acuity (VA) is a measure of the eyes’ ability to distinguish between shapes and overall detail of objects. Reduction in VA is associated with myopia, reading disability (RD) and lower quality of life. Genetics of VA are not well understood due to most of the genome wide association studies (GWAS) related to vision, focusing on myopia or age-related macular degeneration, predominantly in adults.

**Methods:** We performed GWAS for VA on children aged 11.5 years old, from the ALSPAC data (N=6,680), calculated polygenic risk scores and applied novel, non-standard post GWAS analyses tools - FINDOR and Downstreamer. FINDOR uses functional annotations to reweight GWAS summary statistics p-values and Downstreamer prioritises genes and pathways that would not normally be analysed for GWAS loci. Neither tool uses any phenotypic information.

**Results:** We report the first GWAS for VA in children. The top hit (NPLOC4 locus) was previously associated in GWAS for vision outcomes in adults and we find that having a higher polygenic risk for ADHD and RD is correlated with worse VA. Post-hoc analysis showed significant enrichments of genes and pathways related to vision. FINDOR re-weighted p-values resulted in six additional SNPs reaching statistical significance. Downstreamer prioritised two genes, namely PDE6G and RFSN, both important in sensory functions.

**Conclusion:** Our GWAS and post-GWAS analyses for VA resulted in significant associations despite a small sample size. This indicates the potential of VA as a useful phenotype for dissecting the genetics of vision.

**References:**

- **Grants:** None declared.
- **Conflict of Interest:** None declared.

**P03.012.A Spectrum of ABCA4 variants in Slovenian patients with Stargardt disease**

**Jana Sajovic**, Andrej Meglic, Martina Jarc-Vidmar, Vlasta Hadalini, Zelja Corradi, Frans P.M. Cremers, Jana Zernant, Rando Alinkets, Damjan Glavac, Alex Maves, Marija Volk, Borut Peterlin, Marko Hawlina, Ana Fakin

1Eye Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia; 2Department of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands; 3Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, Netherlands; 4Department of Ophthalmology, Columbia University, New York, United States; 5Department of Molecular Genetics, Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; 6Clinical Institute of Medical Genetics, University Medical Centre Ljubljana, Ljubljana, Slovenia.

**Background/Objectives:** There are >1290 known pathogenic variants in ABCA4 causing heterogeneous phenotypes. This study aims to report the genetic and clinical characteristics of the Slovenian ABCA4 cohort.

**Methods:** Study included 75 patients (28 male; median age at the last exam 32 years, range 8-75). Genetic analysis was done with next-generation sequencing, deep intronic regions were included in 65/75. Phenotype analysis included age at disease onset, Snellen decimal best corrected visual acuity (VA), pattern and full-field electroretinography (ERG), and fundus autofluorescence (FAF) appearance.

**Results:** 63 (84%) patients had ≥2 identified variants, whereas 12 (16%) had 1 identified variant. Most frequent variants were p.(Asn1868Ile) (11% alleles), p.(Gly1961Glu) (11%), p.[(Leu541-Pro;Ala1038Val)] (10%), p.(Arg681*) (7%) and c.5714+5G>A (7%). The latter was more frequent than in a multicentric study of 279 patients (2%) (1). 7/52 different variants were novel. Median age at onset was 15 years (range 5-60). Late-onset (>40 years) was present in 28%. Median VA was 0.16 (range counting fingers-1.0). According to ERG, generalized retinal dysfunction (ERG group 2 or 3) was present in 52%. Abnormalities on FAF extended beyond the vascular arcades in 60%. Patients with late-onset had a higher frequency of foveal sparing (44%) than other patients (9%). However, frequency of missense variants was similar between the two groups (72% vs 67%).

**Conclusion:** Slovenian ABCA4 cohort has a specific spectrum of ABCA4 variants. 13% of variants were novel, while c.5714+5G>A was relatively more frequent than in other cohorts. Around one-third of patients had late-onset disease, which may be misdiagnosed as age-related macular degeneration.

**References:** (1). PMID:29925512.

- **Grants:** None declared.
- **Conflict of Interest:** Jana Sajovic Eye Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia, Andrej Meglic Eye Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia, Martina Jarc-Vidmar Eye Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia, Vlasta Hadalini: None declared, Zelja
P03.013.B Biallelic variants in KITLG cause Waardenburg syndrome type 2, albinism-deafness syndrome and oculocutaneous albinism

Katta Girisha1,2, Barbara Vona3,4, Daniel Schwartzbaum5, Alejandro A. Rodriguez6, Solange S. Lewis7, Mehran Beiraghi8, Periyasamy Radhakrishnan9, Nazim Bozan11, Ramazan Akin9, Mohammad Doosti10, Ramachandran Manju6, Duygu Duman12, Claire J. Sineni12, Sheela Nampoothiri11, Ehsan Ghayoor Karimiani8,12,13, Henry Houlden14, Guney Bademci5,15, Mustafa Tekin5,15, Soa Douzgou HOUGE16,17, Reza Marooofian14

1Department of Medical Genetics, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, India, Manipal, India; 2Suma Genomics Private Limited, Manipal Universal Technology Business Incubator Manipal, Karnataka, India, Manipal, India; 3Institute of Human Genetics, University Medical Center Göttingen, Göttingen, Germany, Göttingen, Germany; 4Institute for Auditory Neuroscience and InnerEarLab, University Medical Center Göttingen, Göttingen, Germany, Göttingen, Germany; 5Department of Molecular Genetics, Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; 6Department of Otolaryngology, Faculty of Health Sciences, Ankara University, Ankara, Turkey, Ankara, Turkey; 7Department of Paediatric Genetics, Amrita Institute of Medical Sciences and Research Centre, Kochi, India, Kochi, India; 8Department of Medical Genetics, Radboud University Medical Center, Nijmegen, The Netherlands, Frans P.M. Cremer Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands, Jana Zernant Department of Ophthalmology, Columbia University, New York, New York, United States, Rando Allikmets Department of Ophthalmology, Columbia University, New York, New York, United States, Damjan Glavac Department of Molecular Genetics, Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia, Marija Volk Clinical Institute of Medical Genetics, University Medical Centre Ljubljana, Ljubljana, Slovenia, Borut Peterlin Clinical Institute of Medical Genetics, University Medical Centre Ljubljana, Ljubljana, Slovenia, Marko Hafiela Eye Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia, Ana Fakin Eye Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.

Background/Objectives: Familial progressive hyper- and hypopigmentation. We expand this spectrum to include a recessive disorder presenting with a hypomelanosis spectrum with or without hearing impairment.

Methods: We characterized the largest case series with biallelic KITLG variants identified through precision phenotyping, multiple sequencing approaches and extensive networking.

Results: We expand the KITLG-related hypomelanosis spectrum to include different patterns of distal depigmentation, partial depigmentation resembling Tietz albinism-deafness syndrome and complete depigmentation reminiscent of oculocutaneous albinism. We speculate that loss-of-function KITLG variants cause oculocutaneous albinism while those with possible residual function cause Waardenburg syndrome type 2 or albinism-deafness syndrome.

Conclusion: We expand the understanding of the mode of inheritance of Waardenburg syndrome type 2 to include autosomal recessive transmission. This work defines KITLG as a new molecular cause of autosomal recessive albinism-deafness syndrome and oculocutaneous albinism.

References:

Funding was provided by the Bio-CARE Woman Scientist Award, Department of Biotechnology, Ministry of Science and Technology, Government of India (grant no. BT/Bio-CARE/07/ 9889/2013–14) (SSL and KMG), the John T. and Winifred M. Hayward Foundation (to MT), and the German Research Foundation Collaborative Research Center 889 (BV).

Conflict of interest: Katta Girisha Founding director of Suma Genomics Pvt. Ltd., Barbara Vona: None declared, Daniel Schwartzbaum: None declared, Alejandro A. Rodriguez: None declared, Solange S. Lewis: None declared, Mehran Beiraghi Toosi: None declared, Periyasamy Radhakrishnan Scientist and Laboratory Director, Suma Genomics Private Limited, Nazim Bozan: None declared, Ramazan Akin: None declared, Mohammad Doosti: None declared, Ramachandran Manju: None declared, Duygu Duman: None declared, Claire J. Sineni: None declared, Sheela Nampoothiri: None declared, Ehsan Ghayoor Karimiani: None declared, Henry Houlden: None declared, Guney Bademci: None declared, Mustafa Tekin: None declared, Sofia Douzgou HOUGE: None declared, Reza Marooofian: None declared.

P03.014.C Dysregulated microRNA in skin epidermis contributes to small fiber neuropathy pathophysiology

Mirna Andelic1,2, Erika Salvi1, Margherita Marchi1, Daniele Cazzato3, Stefania Marcuzzo4, Daniele Cartelli5, Janneke Hoeijmakers2, Catharina Faber6, Raffaella Lombardi7, Giuseppe Laura Pinter8

1Fondazione IRCCS Istituto Neuromedico “Carlo Besta”, Neurology Unit, Milan, Italy; 2School of Mental Health and Neuroscience, Maastricht University, Department of Neurology, Maastricht, Netherlands; 3Fondazione IRCCS Istituto Neuromedico “Carlo Besta”, Neuroimmunology and Neuromuscular Diseases Unit, Milan, Italy; 4Fondazione IRCCS Istituto Neuromedico “Carlo Besta”, Neuroimmunology and Neuromuscular Diseases Unit, Milan, Italy; 5Fondazione IRCCS Istituto Neuromedico “Carlo Besta”, Neuroimmunology and Neuromuscular Diseases Unit, Milan, Italy; 6Università degli Studi di Milano, Department of Biotechnol- ogy and Translational Medicine, Milano, Italy.

Background/Objectives: Small fiber neuropathy (SFN) is a multifactorial condition defined by impairment of peripheral nerve fibres often accompanied by pain. Lately, miRNAs are emerging as key fine-tuning regulators in complex neurodegenerative diseases, particularly associated with regulation of axon guidance and cross-talk. Our study aimed to investigate miRNA profiles of painful SFN patients and their possible correlation with underlying disease mechanisms.
Methods: Total RNA was isolated from skin epidermis. Unbiased miRNA expression quantification was performed using microfluidic array containing 754 miRNAs. Discovery and validation profiling involved 23 painful SFN patients and 15 healthy controls. We applied the relative threshold (Crt) method and NormFinder software was used to determine the optimal normalization gene. Results were expressed as relative quantification with healthy control tissue as reference group. Moreover, target and functional enrichment analyses were performed to explore possibly affected biological processes and molecular functions.

Results: We identified a miRNA as significantly downregulated in SFN patients respect to controls. The validation revealed an optimal diagnostic accuracy (AUC = 96.4%). Functional enrichment analysis showed involvement in biological processes and pathways that are closely related to nociception signaling cascade triggering various cellular responses and pain-related channel trafficking. Specifically, miRNA’s effect on target genes such as TRPV1, MAPK1, NTRK1 dysregulates inflammatory mediator regulation of TRP channels, cAMP and MAPK signaling pathways.

Conclusion: Our proof-of-concept study of miRNA profiling of human epidermis provided novel hints on epigenetic regulation of epidermal innervation and chronic neuropathic pain, while adding value to the dysfunction of axon-cell network in the contest of SFN.

References: None.

Grants: PAIN-Net (grant no. 721841).

Conflict of Interest: Mirna Andelic: None declared, Erika Salvi: None declared, Margherita Marchi: None declared, Daniele Cazzato: None declared, Stefania Marcuzzo: None declared, Daniele Cartelli: None declared, Janneke Hoeijmakers: None declared, Catharina Faber Grants from European Union’s Horizon 2020 research and innovation programme Marie Skłodowska-Curie grant for PAIN-Net, Molecule-to-man pain network (grant no. 721841), grants from Grifols and Lamepro for a trial on IVIg in small fibre neuropathy, Grants from Princes Beatrix Spierfonds, Mirna Andelic: None declared, Erika Salvi: None declared, Margherita Marchi: None declared, Daniele Cazzato: None declared, Stefania Marcuzzo: None declared, Daniele Cartelli: None declared, Janneke Hoeijmakers: None declared, Catharina Faber

P03.016.A Achromatopsia: The curious case of triallelic inheritance

Ratna Tripathy1, Rainer König2, Mojgan Drasda3, Nuha Al Zaabi2

1Bioscientia Institute for Medical Diagnostics GmbH, Human Genetics, Ingelheim, Germany; 2College of Medicine and Health Science, United Arab Emirates University, Department of Pediatric, Al Ain, United Arab Emirates.

Background/Objectives: Achromatopsia is a retinal disorder characterized by reduced or complete loss of color vision, reduced visual acuity, pendular nystagmus, and congenital photophobia (1). Affected patients show limited or complete lack of cone photoreceptor activity, caused in the majority of cases by biallelic variants in the CNGA3 or CNGB3 genes (2, 3), encoding CNGB channel subunits that heterodimerize to mediate membrane hyperpolarization in response to light. A recent study by Burkard et al (2018) looked into the controversial p.R403Q hypomorphic variant in CNGB3, which in a biallelic state shows high variability, reduced penetrance, with high frequency in unaffected individuals. The authors showed that a triallelic co-occurrence of heterozygous pathogenic CNGA3 variant, in individuals with the homozygous CNGB3 p.R403Q variant, contributes to an exacerbated retinopathy (3).

Methods: We present a four-year-old boy with visual defects since age of six months, preferring dark or dimly lit rooms, showing nystagmus, and defective color discrimination. We performed whole exome sequencing to identify a possible genetic cause.

Results: The analysis lead to the identification of a new triallelic combination of the homozygous hypomorphic CNGB3 p.R403Q variant with the monoallelic known pathogenic CNGA3 variant p.A323P, which can explain the phenotype of the boy.

Conclusion: Along with broadening the list of triallelic variant combinations for achromatopsia, with this case, we aim to raise awareness in the clinical genetics community of the presence and importance of digenic-triallelic inheritance, which has implications for diagnosis, prognosis, and genetic counseling.

References: PMID: (1) 20301591, (2) 9662398, (3) 10958649, (4) 30418171.

Grants: Conflict of Interest: None declared.

P03.017.B Retinitis pigmentosa caused by mutations in the ush2a gene: clinical trend comparison and genotype-phenotype correlations

Luigi Monti1,2, Nicole Balducci3, Antonio Ciardella4, Sara Taormina1,2, Sofia Cesarini2, Elena Olivucci1,2, Elena Luppi1,2, Mina Grippa1, Enrico Ambrosini1, Giovanna Sartor1, Francesca Montanari1,2, Giulia Severi2, Sara Miccoli4, Claudio Graziano4, Cesare Rossi3, Daniela Turchetti1,2, Marco seri2,1

1Alma Mater Studiorum University of Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, Bologna, Italy; 2IRCCS Azienda Ospedaliera Universitaria di Bologna, U.O. Genetica Medica, Bologna, Italy; 3Ophthalmology Unit, S.Orsola-Malpighi Hospital, University of Bologna, Department of Medical and Surgical Sciences, Bologna, Italy; 4AUSL della Romagna, U.O. Genetica Medica, Cesena, Italy.

Background/Objectives: Mutations in the USH2A gene are responsible for both isolated and syndromic (Usher syndrome type Ila) retinitis pigmentosa. We studied genotype-phenotype correlations and compared clinical prognosis between Usher syndrome type Ila and non-syndromic RP.

Methods: Clinical data, visual acuity (VA), visual field (VF), retinal imaging and electrophysiologic features were extracted from medical records of patients affected, with non-syndromic RP (n 6) and Usher syndrome type Ila (n 25). The patients were carriers of at least one pathogenetic USH2A mutation and they underwent to counseling in the medical genetics unit of University of Bologna (2003-2021). Statistical analysis has been performed (Student’s t-test, Chi-squared test, Fisher’s exact test).

Results: Participant groups had similar distributions of gender and similar ethnicity. Usher syndrome type Ila patients demonstrated earlier symptoms than non-syndromic RP (14 vs 27 years, P = 0.04), earlier clinical diagnosis (24 vs 43 years, P = 0.01), earlier molecular diagnosis (37 vs 58 years, P = 0.04) and earlier visual impairment (40 vs 56 years for VF, 45 vs 68 years for VA, P = 0.02). Truncating mutations are associated with earlier symptoms (13 vs 20) and with syndromic phenotype. We found novel variants (4 missense, 2 frameshift, 1 splicing) in both groups and suspected pathogenicity has been raised for other (n 3).

Conclusion: Patients with Usher syndrome type Ila have symptoms and severe visual impairment earlier than non-syndromic RP. One truncating mutation seems to predispose to worse clinical trend, two truncating mutations in USH2A is associated with syndromic phenotype.

References: Grants: Conflict of Interest: None declared.
PO3.019.D Functional characterization of potential spliceogenic PAX6 variants in aniridia combining minigenes and long-reads sequencing

Carolina Ruiz-Sanchez1, Alejandra Tamayo1,2, Gonzalo Nuñez Moreno1,2,3, Tudor Pastae1, Carmen Ayuso1,2, Pablo Minguez1,2,3, Marta Corton1,2

1Health Research Institute - Fundación Jiménez Díaz (IIS-FJD), Genetics Department, Madrid, Spain; 2Center for Biomedical Research on Rare Diseases - CIBERER, Madrid, Spain; 3Health Research Institute - Fundación Jiménez Díaz (IIS-FJD), Bioinformatic Unit, Madrid, Spain.

Background/Objectives: PAX6 is a highly-conserved transcription factor involved in ocular development. Several aniridia-associated exonic and intronic variants located in the hotspot exon 6 of PAX6 generate aberrant splicing patterns involving 5 cryptic donors. We aim to functionally study the potential spliceogenic effect of other variants affecting this exon.

Methods: Potential spliceogenic variants located in exon 6 were selected from our aniridia cohort or mutational databases based on in silico splicing analysis and further characterized in vitro. Then, a minigene was generated from the pSPL3 vector containing the full sequences between exons 5 to 7 of the PAX6 gene. Directed mutagenesis was used to introduce the selected variants in the PAX6_exon 5-7 minigene. Mutated and wild-type minigenes were transfected in HEK293 cells and total RNA was extracted. Finally, the splicing isoforms were analysed by RT-PCR using Oxford Nanopore long-read and Sanger sequencing.

Results: After an in silico analysis of 120 PAX6 variants, 6 of them showing potential splicing effects were analysed using in vitro minigenes. Four showed aberrant splicing patterns, including intronic retentions and partial or total exon skipping. Two of them, initially considered variants of uncertain significance, were reclassified as probably pathogenic.

Conclusion: In silico and in vitro minigenes assays are a good approach to test the involvement of different genetic variants in the splicing process. In additon, this functional characterization is useful to deepen into the pathogenicity of aniridia-causing variants.

References:
Grants: Spanish Health Institute Carlos III (PI17_01164 and PI20_00851) and Spanish National Organization of the Blind (ONCE).
Conflict of Interest: None declared.

PO3.020.A Rare missense variants and deletions in α-tectorin may drive a change in tectorial membrane stability in familial Meniere's disease

Pablo Román-Naranjo1,2,3,4, Alberto M. Parra-Perez1,2,3, Alba EscaleraBalsera1,2,3, Andrés Soto-Varela1,2,3, Álvaro Gallego-Martínez1,2,3, Ismael Aran1,2, Nicolás Perez-Fernandez2,3, David Baechinger4, Andreas H. Eckhard5, Rocío Gonzalez-Aguado1, Lidia Frejo1,2,3, Antonio Lopez-Escame1,2,3,4

1GENYO. Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government, Otology & Neurotology Group CTS 495, Department of Genomic Medicine, Granada, Spain; 2Centro de Investigación Biomédica en Red en Enfermedades Raras, CIBERER, Sensorineural Pathology Programme, Madrid, Spain; 3Instituto de Investigación Biosanitaria ibs.Granada, Hospital Universitario Virgen de las Nieves, Universidad de Granada, Department of Otolaryngology, Granada, Spain; 4University of Granada, Division of Otolaryngology, Department of Surgery, Granada, Spain; 5Complexo Hospitalario Universitario, Division of Oto-neurology, Department of Otorhinolaryngology, Santiago de Compostela, Spain; 6Universidad de Santiago de Compostela, Spain.

Background/Objectives: Meniere’s disease (MD) is an inner ear disease characterized by low frequency sensorineural hearing loss associated with vertigo and aural fullness. Familial aggregation has been found in 9-10% of MD patients showing, mostly, an autosomal dominant inheritance with incomplete penetrance. Nevertheless, other inheritance patterns have been proposed, such as recessive and digenic inheritance involving rare variants in OTOG and MYO7A genes. This study aimed to search for relevant genes not previously linked to MD.

Methods: Exome sequencing was performed in 99 individuals diagnosed with MD. Candidate variants were classified according to the ACMG/AMP guidelines and their effects were evaluated by protein modeling. Audiometric evaluations were retrieved, and a case report was made of each family to assess genotype-phenotype correlations.

Results: TECTA gene was highlighted as candidate for four multicase MD families and two additional families with one MD patient and relatives with partial syndromes. Four rare missense variants and two frameshift deletions were found in heterozygous state segregating the MD phenotype. These variants could affect the stability of α-tectorin based on the predicted protein model.

Conclusion: Several MD families were identified carrying rare variants and deletions in the TECTA gene, which encodes one of the main proteins of the tectorial membrane (TM). The TM is an extracellular matrix localized over the sensory epithelium mediating the mechanical stimulation of cochlear hair cells. Modifications on the TM stability and the micromechanics involved in the sound-evoked motion of stereocilia may drive MD.

References:
Grants: H2020-SC1-2019-848261 (UNITI), CECEU PY20-00303 (EPIMEN), European Regional Funds B-CTS-68-LGR20 (M3N-OMIC) and the Schmieder-Bohrisch Foundation.
Conflict of Interest: None declared.

PO3.021.B Investigation of gene variations in inherited retinal dystrophies via next-generation sequencing

Şenol Demir1, esra arslan ages2, bilgen bilge geckinli3, ohmet aman1

1marmara university school of medicine, medical genetics, istanbul, Turkey; 2marmara university pendik training and research hospital, genetic diseases diagnosis center, istanbul, Turkey.

Background/Objectives: Inherited Retinal dystrophies(IRD) are a group of progressive degenerative disorders of the retina with clinical and genetic heterogeneity. Common presentations include night blindness and peripheral vision abnormalities. Among retinal dystrophies most common sub-type is retinitis pigmentosa. In addition Leber congenital amaurosis, Usher syndrome, Stargardt disease are the other rare subtypes. This study aims to determine the effectiveness of the multigene panel testing in retinal dystrophies and to reveal genetic etiology of the IRD patients.

Methods: Thirty probands having retinal dystrophy with specific examination findings were included in this study. After evaluation of clinical and family histories, probands were screened using a custom designed retinal disorders panel including 140 genes via next-generation sequencing (NGS). The family members
of the probands carrying pathogenic variations were screened via Sanger Sequencing.

**Results:** Among 30 cases, 14 were born to consanguineous parents and IRD family history was reported in 8 cases. Onset of the ages of the probands ranged between 3 months-48 years. We detected in 21 (70%) probands biallelic pathogenic variations, which of 5 were novel, in CYP4V2 (n = 4), ABCA4 (n = 4), USH2A (n = 3), RDH12 (n = 2), PROM1, ABHD12, TTC8, BBS1, RP1, CRB1, MAK, GRK1 genes.

**Conclusion:** The detection of 5 novel pathogenic variations has contributed to the expansion of the mutation spectrum. Also, the diagnosis of 70% of the patients supports that the NGS panel is an effective diagnostic method in IRD. Defining molecular etiology of IRD is important in terms of screening at risk family members and giving appropriate genetic counseling for preimplantation genetic diagnosis opportunities.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P03.022.C Cryptic chromosomal rearrangements disrupting the PAX6 locus identified in aniridia cases based on long-read whole-genome sequencing**

Alejandra Damián1,2, Gonzalo Nuñez Moreno1,2,3, Claire Jubin4, Alejandra Tamayo1,2, Marta Rodriguez de Alba1,2, Jean-François Deleuze5, Pablo Mínguez1,2,3, Carmen Ayuso1,2, Marta Corton1,2

1Fundación Jiménez Díaz University Hospital Health Research Institute (IIS-FJD)-Universidad Autónoma de Madrid (UAM), Department of Genetics & Genomics, Madrid, Spain; 2Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain; 3Fundación Jiménez Díaz University Hospital Health Research Institute (IIS-FJD)-Universidad Autónoma de Madrid (UAM), Bioinformatic Unit, Madrid, Spain; 4National Center of Human Genomics Research (CNRGH) Université Paris-Saclay, Evry, France.

**Background/Objectives:** Haploinsufficiency of the transcription factor PAX6 is the main responsible for aniridia, a disorder mainly characterized by iris and fovea hypoplasia. 11p13 microdeletions altering PAX6 or its 3' regulatory regions were found in ~25% of aniridia patients. However, only few complex chromosomal rearrangements have been involved in aniridia which can be attributed to the inherent difficulty of detecting structural variants (SVs) involving repetitive/low-complexity regions. Long-read sequencing (LRS) techniques may overcome these limitations. Our objective was to assess the presence of cryptic SVs in our "PAX6-negative" cases suffering from aniridia using LRS approaches.

**Methods:** Long-read genome sequencing was conducted in two previously unsolved sporadic patients of our aniridia cohort after short-reads sequencing and CGH arrays. Libraries were prepared using high-weight molecular DNA following Oxford Nanopore Technologies protocols and sequenced at 30x on a PromethION. Detected SVs were validated using Sanger sequencing and/or FISH analysis.

**Results:** LRS analysis revealed a 4.9 Mb inversion in 11p13 involving the intrinsic 7 of the canonical PAX6 isoform disrupting its linear structure. In a second patient, LRS revealed breakpoints for an apparently balanced translocation t(6;11) that affects the centromeric region on 6p11.1 and the downstream regulatory region (DRR) of PAX6 on the 11p13 region.

**Conclusion:** We first report two cases of cryptic balanced chromosomal SVs disrupting directly PAX6 or its regulatory elements. We demonstrate here how LRS can provide insight into hidden sources of variation.

**References:**

**Grants:** H2020 EasiGenomics program (PID10291), PI20_00851 and Spanish National Organization of the Blind (ONCE).

**Conflict of Interest:** None declared.

**P03.023.D Burden of rare coding variants in connexin genes involving Meniere Disease**

Alba Escalera-Balsera1,2,3, Pablo Román-Naranjo1,2,3,4, Marisa Flook1,2,3, Paula Robles-Bolivar1,2,3, Alberto M. Parra-Perez1,2,3,4, Alvaro Gallego-Martinez1,2,3, José Antonio Lopez-Escamez1,2,3,4

1Otology & Neurotology Group CT5495, GENYO, Centre for Genomics and Oncological Research, Pfizer University of Granada Andalusian Regional Government, Department of Genomic Medicine, Granada, Spain; 2Sensorineural Pathology Programme, Centro de Investigación Biomédica en Red en Enfermedades Raras, CIBERER, Madrid, Spain; 3Instituto de Investigación Biosanitaria Ibs.GRANADA, Hospital Universitario Virgen de las Nieves, Universidad de Granada, Department of Otolaryngology, Granada, Spain; 4Division of Otolaryngology, University of Granada, Department of Surgery, Granada, Spain.

**Background/Objectives:** Gap junctions consist of connexin proteins forming hemichannels in the sensory epithelia. Mutations in GJB2, GJB6 and GJB3 cause genetic deafness and hearing loss. Meniere Disease (MD) is an inner ear disorder characterized by episodic vertigo and associated with sensorineural hearing loss, tinnitus and/or aural fullness.

**Methods:** Whole Exome Sequencing (WES) was performed in 313 patients with MD. Gene Burden Analysis was done filtering the variants by a Minor Allele Frequency<0.05 and using gnomAD database as reference population. Connexin genes expressed in the mammalian inner ear were retrieved for further analyses. The pathogenicity of each variant was estimated and the protein stability changes were studied using PremPS and DynaMut2.

**Results:** An enrichment of rare missense variants was found in 2 genes expressed in the inner ear: GJB5 (OR = 29.53) and GJB2 (OR = 13.77). GJA10 presents an enrichment in rare stop-gain variants (OR = 2.28). GJB5 (OR = 103.28) and GJC2 are enriched in rare frameshift, inframe insertion and deletion variants (OR = 22.73). Functional analysis revealed biological processes involved in gap junctions, cell communication or transmembrane transport.

**Conclusion:** We have found a burden of rare missense variants, stop-gain variants and indels in patients with MD in 4 genes: GJB5 (CX31.1), GJD2 (CX36), GJA10 (CX62) and GJC2 (CX47). Further studies, including segregation analysis, are needed to confirm the role of these variants in MD.

**References:**

**Grants:** European Union’s Horizon 2020 Research and Innovation Programme, Grant Agreement Number 848261.

**Conflict of Interest:** None declared.

**P03.024.A PACS1-related syndrome: three cases with colobomas further delineating the phenotype**

Simon Boussion1,2, Thomas Smo2,3, Perrine Brunelle2,3, Mélanie Rama3, Séverine Drunat4, Pierre Blanc5, François Ennould6, Sabine Defoort7, Vasily Smirnov7, Jamal Ghoumid1,2, Florence Petit1,2, Catherine Vincent-Delorme1

1CHU Lille, Clinique de Génétique Médicale “Guy Fontaine”, Lille, France; 2Univ.Lille, RADEME, EA7364, Lille, France; 3CHU Lille, Institut de Génétique Médicale, Lille, France; 4Hôpital Robert Debré, AP-HP, Service de Génétique Médicale, Paris, France; 5Seqoia-FMG2025, Laboratoire de biologie médicale multisites, Paris, France; 6CHU Lille, Service d’Ophthalmologie, Lille, France; 7CHU Lille, Explorations de la Vision et de Neuro-Ophthalomologie, Lille, France.
Background/Objectives: PACS1 gene (MIM #607492) is related to Schuurs-Hoeijmakers syndrome (MIM #615009), a condition characterized by the association of intellectual disability, recognizable facial appearance, and a wide range of congenital abnormalities. Here we report 3 patients with coloboma and developmental delay due to the recurrent PACS1 missense variant.

Methods: After clinical examination, NGS sequencing was performed (WGS for patient 1, gene panels for patients 2 and 3).

Results: The first proband is a 3 years old male presenting with congenital bilateral iris, chorioretinal and papillary coloboma, ectopia lentis, hypotonia, cryptorchidism. The second proband is a 9 years old female presenting with congenital bilateral chorioretinal coloboma, microphthalmia, right iris coloboma, hypotonia. The third proband is a 6 years old male presenting with congenital iris and chorioretinal coloboma, hypotonia, cryptorchidism. Cerebral MRI showed diffuse cortical atrophy, dysplastic corpus callosum, vermis hypoplasia. All 3 patients evolved towards global developmental delay. The same pathogenic de novo heterozygous variant in PACS1 (c.607C>G, p.(Arg203Trp)) has been identified in all 3 patients.

Conclusion: PACS1 encodes the Phosphofurin Acid Cluster Sorting Protein 1, a trans-golgi-membrane trafficking regulator. So far, 61 patients with Schuurs-Hoeijmakers syndrome have been published, carrying the p.(Arg203Trp) heterozygous missense or rarely the p.(Arg203Gln) missense in PACS1. Intellectual disability is constant but congenital malformations are variable. Iris and chorioretinal colobomas are rare (9% and 13% respectively). Our patients present with coloboma at the forefront of the clinical description, further delineating the phenotype and highlighting the variable expressivity of this condition. PACS1 implication should be considered in patients with congenital coloboma.

References:

Grants:

Conflict of Interest: None declared.

P03.025.B Longitudinal follow-up of Slovenian patients with RPGR associated retinitis pigmentosa

Vlasta Hadalin1, Maša Marija Buscarino1, Jana Sajovic1, Marija Volk1, Martina Jarc-Vidmar1, Manca Tekavcic Pompe1, Marko Howlina1, Ana Fakin1

1Eye Hospital University Medical Centre Ljubljana, Ljubljana, Slovenia; 2Clinical Institute of Medical Genetics, University Medical Centre Ljubljana, Slovenia, Ljubljana, Slovenia.

Background/Objectives: To report the variant spectrum and longitudinal follow-up data of Slovenian RPGR-retinitis pigmentosa (RP) patients.

Methods: The study included 13 subjects (7 males) from 6 RPGR-RP families. Age at onset, logMAR best corrected visual acuity (BCVA), visual fields and fundus autofluorescence (FAF) were analyzed. Eyes with milder degree were taken for the analysis to best reflect the functional impairment.

Results: Genetic analysis revealed two reported (c.1217dupT(Ser407fs), c.2236_2237delGA(p.Glu746ArgfsTer23)) and four novel variants (c.457G>A(p.Ala153Thr), c.1245+704_1415-2286del, c.G1978G>A(p.Glu660Ter), c.2340_2341delAG(p.Arg780SerfsTer54)). Median age at onset in males was 3 years (0-18). At first exam median age of 16 years (0-61), median BCVA was 0.3 logMAR (0.15-2.0). All had constricted visual fields and hyperautofluorescence rings on FAF. At the last follow-up median age of 39 years (4-71), median BCVA was 0.48 logMAR (0.0-2.30). FAF showed ring constriction, transitioning to patch in 2/7 cases. Median age at onset in females was 22.5 years (5-66). At first exam median age of 40 years (6-66), median BCVA was 0.0 logMAR (0.0-0.30). One had normal/near-normal autofluorescence, 2 radial pattern, 1 focal pigmentary retinopathy and 2 male phenotype with partial AF ring. At the last follow-up at median age of 45 years (10-66), median BCVA was 0.10 logMAR (0.0-0.20). In 2 cases with male phenotype partial AF ring constituted.

Conclusion: RPGR-RP-causing variants in Slovenian cohort include 4/6 (67 %) novel variants, suggesting a distinct genetic background of the RPGR alleles in Slovenian population. Longitudinal follow-up of RPGR-RP patients showed disease progression in all males and 5/6 (83%) females.

References:

Grants:

Conflict of Interest: None declared.

P03.026.C Impaired bestrophin channel activity in a iPSC-RPE model of Best Vitelliform Macular dystrophy (BVMD) from an early onset patient carrying the P77S dominant mutation

Amna Navinés-Ferrer1,2, Sheila Ruiz-Nogales1,2, Pilar Mendez1,2, Esther Pomares1,2

1Fundació de Recerca de l’Institut de Microcirurgia Ocular, Departament de Genètica, Barcelona, Spain; 2Institut de Microcirurgia Ocular, IMO Grupo Miranza, Barcelona, Spain.

Background/Objectives: Best Vitelliform Macular dystrophy (BVMD) is the most prevalent of the distinctive retinal dystrophies caused by mutations in BEST1 gene. This gene, which encodes for a homopentameric calcium-activated ion channel, is crucial for the homeostasis and function of the retinal pigment epithelia (RPE), the cell type responsible for recycling the visual pigments generated by photoreceptor cells. In BVMD patients, mutations in this gene induce functional problems in the RPE cell layer with an accumulation of lipofuscin that evolves into cell death and loss of sight.

Methods: In this work, we employ iPSC-RPE cells derived from a patient with the p.Pro77Ser dominant mutation to determine the correlation between this mutation and the ocular phenotype. To this purpose, gene and protein expression and localization are evaluated in iPSC-RPE cells along with functional assays like photoreceptor cells.

Results: Our cell model shows no differences in gene expression, protein expression/localization or phagocytosis capacity. There are no signs of apoptosis but the iPSC-RPE presents an increased chloride entrance that would explain the patient’s phenotype.

Conclusion: The molecular mechanisms underlying this dominant mutation from a BVMD patient widen the understanding of this pathology and open the door for a better diagnosis and prognosis of the disease.

References: Domingo-Prim et al., Generation of Best disease-derived induced pluripotent stem cell line (FRIMO006-A) carrying a novel dominant mutation in BEST1 gene.

Grants:

Conflict of Interest: None declared.

P03.030.C Targeted retinal dystrophy panel as a reliable tool for genetic diagnostics of retinal disorders in Polish patients

Ewa Matczyńska1,2, Anna Wąsowska1,2, Marta Beć1, Przemysław Łyszkiewicz1, Robert Szymańczak1, Ewa Suchecka1, Monika Jurkowska1, Maria Jędrzejowska1, Sławomir Teper1, Anna Boguszewska-Chachulska1

1Genomed S.A., Warsaw, Poland; 2Medical University of Silesia, Chair and Clinical Dept. of Ophthalmology, Zabrze, Poland.

Background/Objectives: A developed targeted panel approach for genetic diagnosis of inherited retinal dystrophies (IRD) was...
successfully implemented in the routine diagnostics of Polish IRD patients. Here we present the results for the second part of Polish patients group subjected to IRD genetic diagnosis using the established method.

**Methods:** A group of Polish patients with clinical symptoms of retinal dystrophies (N = 182) were subjected to an NGS analysis using a custom panel capturing coding regions of 270 IRD genes (RetNet), developed with the Roche NimbleGen SeqCap EZ. Bioinformatic analysis was performed with the GATKV4 and CoNvADING (for CNV analysis), using the GRCh38 reference genome. Variant analysis and interpretation were completed according to ACMG guidelines using the in-house variant interpretation tool - BroVar.

**Results:** The NGS data presented a satisfactory level of QC data metrics with mean target coverage in a range of 200-250x, heterozygote SNP calling sensitivity level above 0.997, and fraction of target bases covered >20x between 0.996 and 0.997. An IRD diagnosis was confirmed in 109 cases (59.8%). In several cases, the disease confirmation was enabled by CNVs or deep intronic variants calls. In further 29 patients only one pathogenic/likely pathogenic variant was identified in the context of AR disease.

**Conclusion:** The results of the application of the existing targeted retinal dystrophy panel are promising. Further increase in the method sensitivity is expected in the second version of the approach, which would broaden the targeted gene list, include more deep intronic clinvar variants and target the mtDNA using additional spike-in.

**References:**

**Grants:**

**Conflict of Interest:** Ewa Matczyńska Employed in Genomed S.A., Anna Wąsowska Employed in Genomed S.A., Marta Beć Employed in Genomed S.A., Przemysław Łyszkiewicz Employed in Genomed S.A., Robert Szymańczak Employed in Genomed S.A., Ewa Suchecka Employed in Genomed S.A., Monika Jurkowska Employed in Genomed S.A., Anna Boguszewska-Chachulska Genomed S.A. CEO.

**P04**

INTERNAL ORGANS & ENDOCRINOLOGY (LUNG, KIDNEY, LIVER, GASTROINTESTINAL)

**P04.001.D Genetic polymorphisms and susceptibility to urinary tract infection among paediatric and adult populations: a systematic review and meta-analysis**

**Jiakun Yu**, Kristina Allen-Brady, Romana Cuffola, Felice Sorrentino, John Chua, Harmeet Sidhu, Marianne Koch, Philippe Violette, Rufus Cartwright

1Imperial College London, School of Medicine, London, United Kingdom; 2The University of Utah, Utah, United States; 3Stoke Mandeville Hospital, Aylesbury, United Kingdom; 4Department of Obstetrics & Gynecology-Policlinico Riuniti Foggia, Foggia, Italy; 5Frimley Health NHS Foundation Trust, Frimley, United Kingdom; 6LONDON NORTH WEST UNIVERSITY HEALTHCARE NHS TRUST, London, United Kingdom; 7Medical University of Vienna, Vienna, United Kingdom; 8McMaster University, Ontario, Canada.

**Background/Objectives:** The lifetime risk of UTI is known to be highly heritable. Associations have also been observed across the life course from paediatric UTI to recurrent UTI in adulthood, suggesting lifelong susceptibility factors. We conducted a systematic review to identify all genetic polymorphisms tested for an association with UTI in children and adults, and to assess their strength, consistency, and risk of bias.

**Methods:** PubMed, HuGE Navigator and Embase were searched from 01/Jan/2005 to 01/Sep/2021, using a combination of genetic and phenotype key words. Fixed and random effects meta-analyses were conducted using co-dominant models of inheritance in metan. The interim Venice criteria were used to assess their credibility.

**Results:** 1283 studies were screened, with 42 included in the analysis (18 adult papers and 24 paediatric papers). All possible meta-analyses summarised in Table 1 (paediatric samples) and Table 2 (adult samples). These meta-analyses demonstrated significant pooled associations for paediatric UTI with variation in ACE, CXCR1, IL8, TGF, TLR4, VDR and VEGF. These meta-analyses also demonstrated a significant pooled association for adult UTI with variation in AC and CXCR1. All significant pooled associations were graded as providing at most weak epidemiological credibility.

| Gene | SNP identifier | n studies | n participants | Pooled OR | 95% CI | p | F (%) | Venice Grade |
|------|----------------|-----------|----------------|-----------|--------|----|-------|-------------|
| ACE  | rs1744368 | 3 | 1962 | 0.14 | 0.09-0.20 | 0.001 | 70.6 | weak |
| CXCR1| rs2234671  | 2 | 566 | 0.51 | 0.30-0.86 | 0.01 | 89.7 | weak |
| TGF  | rs8073  | 2 | 1389 | 1.09 | 0.92-1.30 | 0.29 | 84.9 | - |
| TLR4 | rs8177374 | 3 | 2883 | 1.01 | 0.85-1.22 | 0.85 | 0 | - |
| TLR2 | rs744168 | 2 | 1992 | 1.08 | 0.93-1.40 | 0.55 | 88.4 | - |
| TLR4 | rs9848700 | 4 | 2006 | 0.95 | 0.85-1.04 | 0.28 | 65.5 | - |
| TLR2 | rs743709 | 2 | 1642 | 1.25 | 1.05-1.46 | 0.11 | 0 | - |
| TLR4 | rs812293 | 2 | 2002 | 1.12 | 0.77-1.65 | 0.53 | 0 | - |
| TLR2 | rs5743618 | 2 | 1900 | 1.10 | 0.96-1.26 | 0.15 | 0 | - |

**Table 1:** Pooled associations for paediatric UTI

**Table 2:** Pooled associations for adult UTI

**Conclusion:** This systematic review provides a current synthesis of the known genetic architecture of UTI in childhood and adulthood, and should provide important information for researchers planning or analysing future genetic association studies. Although, overall, the credibility of pooled associations was weak, the consistency of findings for rs2234671 (CXCR1) in both populations suggests a key role in UTI pathogenesis.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P04.002.A KIF12 variants and disturbed hepatocyte polarity in children with a phenotypic spectrum of cholestatic liver disease**

**Amelie Stalke**, Malte Sgodda, Tobias Cantz, Britta Skawran, Elke Layinka, Björn Hartleben, Ulrich Baumann, Eva-Doreen Pfister

1Hannover Medical School, Department of Human Genetics, Hannover, Germany; 2Hannover Medical School, Pediatric Gastroenterology
and Hepatology, Hannover, Germany; 3Hannover Medical School, Translational Hepatology and Stem Cell Biology, Department of Gastroenterology, Hepatology and Endocrinology, REBIRTH-Center for Translational Regenerative Medicine, Hannover, Germany; 4University Children’s Hospital Essen, Department for Pediatric Nephrology, Gastroenterology, Endocrinology and Transplant Medicine, Essen, Germany; 5Hannover Medical School, Institute of Pathology, Hannover, Germany.

Background/Objectives: Recently, KIF12 has been identified as a cholestasis-associated candidate gene(1,2). As KIF12 is a member of a microtubule-associated motor protein family involved in intracellular transport, KIF12-associated cholestasis is assumed to be a result of disturbed cell polarity. We describe six cases with likely pathogenic KIF12 variants from four unrelated families, their different phenotypes and our investigations to study hepatocyte polarity.

Methods: Children with familial cholestasis and a likely pathogenic variant in the KIF12 gene were identified by exome sequencing. Segregation was analysed by testing parents and siblings. Immunofluorescence imaging of apical markers MRP2 and BSEP, basolateral marker OATP1B1, tight junction protein ZO-1 and KIF12 itself was performed on patient’s liver tissue sections.

Results: We detected two homozygous KIF12 variants in five patients ((NM_138424.1) 4 patients: c.655C>T p.(Arg219*); 1 patient: c.482-4_500del p.?). Segregation analyses confirmed autosomal recessive inheritance. The patients’ clinical manifestations ranged from neonatal cholestasis with complete clinical remission, or absent clinical symptoms to a progressive course, underdiagnosed. Cases, KIF12-associated cholestatic liver diseases are potentially underdiagnosed.

Conclusion: Our results strongly support pathogenic KIF12 variants as cause for familial cholestatic liver disease and suggest that these variants result in functional cell polarity disturbance. Due to its wide clinical presentation with even asymptomatic cases, KIF12-associated cholestatic liver diseases are potentially underdiagnosed.

References: 1.PMID: 30250217; 2.PMID:30976738. Grants: DFG#43387263; BMBF (HChol)#01GM1904B. Conflict of Interest: None declared.

P04.003.B Elevated polygenic burden for brain haemorrhage related traits in kidney donors

Kane Collins1,2,3; Edmund Gilbert1,2; Peter Conlon1,4; Gianpiero Cavalleri1,2; Elhussein Elhassan5; Graham Lord5
1Royal College of Surgeons in Ireland, School of Pharmacy and Biomolecular Sciences, Dublin, Ireland; 2SFI FutureNeuro Research centre, Dublin, Ireland; 3SFI Centre for research training in Genomics Data Science, Galway, Ireland; 4Beaumont Hospital, Dublin, Ireland; 5The University of Manchester, Faculty of Biology, Medicine and Health, Manchester, United Kingdom.

Background/Objectives: Brain haemorrhage (BH) is a common cause of death among kidney donors, but little research has been done to investigate polygenic risk scores (PRSs) for BH and related traits in kidney donors. A PRS estimates the cumulative effect of common genetic variation on an individual’s disease status.

Methods: We had 2,122 genotyped donor-recipient pairs from across the UK and Ireland and 5,519 ancestry matched controls. We calculated PRSs for stroke, Intracranial Aneurysm (IA) and hypertension. We compared PRSs between the donors who died of intracranial haemorrhage (DDICH) (1,303 individuals) and controls. We then used PRS to predict case/control status.

Results: PRS for stroke explained the greatest amount of variance in case/control status between DDICH and controls (6.7%, p: 8.1 x 10^-6), with still significant values for the other PRSs (IA: 5.3%, hypertension: 0.24%). A null model using just sex and principal components to predict case/control status achieved an AUC of 0.63, while models using just hypertension, IA and stroke PRSs achieved AUCs of 0.54, 0.61 and 0.67 respectively. A combined model with all the PRSs and covariates achieved an AUC of 0.74.

Conclusion: These observations support the hypothesis that DDICH carry an increased burden for traits related to BH. PRSs can play a part in being able to distinguish DDICH from the general population. These findings could have utility in testing relatives of DDICH to determine if they share the same risk for ICH.

References: Grants: Science Foundation Ireland grant number 18/CRT/6214. Conflict of Interest: Kane Collins Full time, Science Foundation Ireland Grant number 18/CRT/6214. UKIRTC was supported by grants awarded from the Wellcome Trust (090355/A/09/Z, 090355/B/09/Z and 088849/Z/09/Z, “WTC3”), Edmund Gilbert Full time, Peter Conlon Full time, Gianpietro Cavalleri Full time, Elhussein Elhassan Full time, Graham Lord Full time.

P04.005.D Genetic complexity of congenital hypopituitarism: oligogenic inheritance may explain the variable expression and incomplete penetrance of deleterious GL12 variants in congenital hypopituitarism

Francisco Javier Rodríguez-Contreras1, Purificación Ros Pérez2, Fe Amalia García Santiago3, Elena Vallespín4,5; Angela Del Pozo Mate6,5; Mario Solís6, Isabel Gonzalez-Casado1, Karen E. Heath2,5; Angel Campos-Barros6,5
1Centro de Salud Galapagar, Pediatrics, Galapagar, Madrid, Spain; 2Hospital Universitario Puerta de Hierro, Pediatrics, Majadahonda, MADRID, Spain; 3Institute of Medical & Molecular Genetics (INGEMM), IdiPAZ, Hospital Universitario La Paz, Prenatal Genetics & Fetal Medicine, Madrid, Spain; 4Institute of Medical & Molecular Genetics (INGEMM), IdiPAZ, Hospital Universitario La Paz, Molecular Ophthalmogenetics, Madrid, Spain; 5Instituto de Salud Carlos III (ISCIII), CIBER de Enfermedades Raras (CIBERER) U753, Madrid, Spain; 6Institute of Medical & Molecular Genetics (INGEMM), IdiPAZ, Hospital Universitario La Paz, Bioinformatics, Madrid, Spain; 7Hospital Universitario La Paz, Pediatric Endocrinology, Madrid, Spain; 8Institute of Medical & Molecular Genetics (INGEMM), IdiPAZ, Hospital Universitario La Paz, Molecular Endocrinology Division, Madrid, Spain.

Background/Objectives: Pathogenic GL12 variants are implicated in the etiology of the broad clinical spectrum of congenital hypopituitarism (CHYP), showing a highly variable expressivity and incomplete penetrance.

Aims: Genotype-phenotype correlations in a cohort of patients with CHYP and deleterious GL12 variants.

Methods: Subjects: 114 patients with CHYP (n = 72), septo-optic dysplasia (SOD; n = 33) or isolated GH deficiency (n = 9).

Molecular analysis: Targeted NGS (HYPOPIT_V3 panel) of 310 genes implicated in the etiology of CHYP and hypothalamic-pituitary development.

Results: Deleterious GL12 variants were identified in 11/114 (9.6%), all of them with CHYP. These included 4 truncating variants [p.(Arg1226*), p.(Leu709Trpfs*15), p.(Ser267*) and p.(Ser859-Profs*53)] (ACMG: pathogenic). All had pituitary hypoplasia, 75%
had ectopic neurohypophysis, and those with truncating variants had both conditions. 10/11 were GH and TSH deficient and 8/11 were also ACTH deficient. Other associated traits observed included postaxial polydactyly, ogival palate, bulbous nose, nephrourological dysplasia, and holoprosencephaly, with midfacial hypoplasia and hypotelorism being the most pervasive among the studied relatives (n = 25) of the 11 probands. All of them (11/11) also presented with a burden of additional deleterious variants in multiple genes involved in the regulation of pituitary development signaling pathways (SHH, BMP/TGFβ, FGF, WNT, NOTCH, NODAL).

Conclusion: All probands with GLI2 variants presented deleterious variants in other genes involved in pituitary development and function, suggesting the possibility of a complex multifactorial genetic component.

This may explain the highly variable expressivity and incomplete penetrance observed, which seems determined by the burden of additional inherited variants in other relevant genes.

References:

Grants: PI18/00402, ISCIII, to A.C.B.
Conflict of Interest: None declared.

Background/Objectives: The complement system regulator CD55

Results: The CD55 p.Ser199Leu variant is known as the Cromer Dr(a-) blood type variant. The variant is highly prevalent in BJs (carrier frequency: 1:17).

References:

Grants: WO/2018/217638, which does not include any royalties.
Conflict of Interest: None declared.

P04.007.B CD55-deficiency in Jews of Bukharan descent is caused by the Cromer Dr(a-) blood type variant

Alina Kurolap1, David Hagin2,3, Tal Freund2, Sigal Fishman2,4, Noa Henig5, Eli Brazowski5, Josepha Yeshaya5, Tova Naiman1, elon pras1, Jacob N. Ablin5, Hagit Baris Feldman1,3

1Tel Aviv Sourasky Medical Center, The Genetics Institute and Genomics Center, Tel Aviv-Yafo, Israel; 2Tel Aviv Sourasky Medical Center, Allergy and Clinical Immunology Unit, Department of Medicine, Tel Aviv, Israel; 3Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel; 4Tel Aviv Sourasky Medical Center, The Gastroenterology Institute, Tel Aviv, Israel; 5Tel Aviv Sourasky Medical Center, The Institute of Pathology, Tel Aviv, Israel; 6American Medical Genetics LaboratoryHerzllya, Herzlya, Israel; 7Sheba Medical Center, The Danek Gertner Institute of Human Genetics, Ramat Gan, Israel; 8Tel Aviv Sourasky Medical Center, Internal Medicine H, Tel Aviv, Israel.

Background/Objectives: The complement system regulator CD55 was initially found to carry the Cromer blood group antigens, and its complete loss-of-function was recently revealed to cause a severe monogenic syndrome characterized by protein-losing enteropathy and susceptibility to venous thromboembolism.

Methods: Patient 1 was diagnosed using flow cytometry and targeted Sanger sequencing. Patient 2 was diagnosed by unrelated exome sequencing. Additional testing on Patient 1 samples included RNA analysis and B-cell immunophenotyping. A population screen was performed using enzymatic restriction method.

Results: Both patients are Bukharan Jewish (BJ) and presented with CD55-deficiency of variable severity; testing revealed homozygosity for the CD55:c.596C>T:p.Ser199Leu variant. RNA analysis confirmed that this missense variant causes aberrant splicing and deletion of 44bp in exon 5, leading to premature termination and low CD55 protein levels. Furthermore, Patient 1 exhibited a mildly abnormal B-cell immunophenotyping profile. The variant is highly prevalent in BJs (carrier frequency: 1:17).

Conclusion: The CD55 p.Ser199Leu variant is known as the Cromer Dr(a-) genotype, yet this is the first report in terms of CD55-deficiency. The phenotypic variability, ranging from abdominal pain on a high-fat diet to the full CD55-deficiency phenotype, is likely related to modifiers affecting the proportion of the variant that is able to escape aberrant splicing. The high frequency in the BJ population suggests that many similar patients are un- or mis-diagnosed. Establishing the diagnosis of CD55-deficiency in a timely manner may have critical effects on patient management and quality-of-life, since treatment with the complement inhibitor eculizumab is highly effective in ameliorating disease manifestations.

References:

Grants: None declared.
Conflict of Interest: None declared.

P04.006.A Clinical and genetic features in two patients carrying PAX2 variants

Deimante Brazdžionaitė1, Ilona Rudminiene2, Migle Gudynaite2, Rasa Strupaitė2, Gabija Mazur2, Marius Miglino3, Algirdas Utukas1

1Department of Human and Medical Genetics, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania; 2Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania; 3Center of Eye diseases, Clinic of Ear, Nose, Throat and Eye diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

Background/Objectives: Pathogenic variants in PAX2 have been associated with a spectrum of kidney and eye disorders, including isolated renal hypoplasia, papillorenal syndrome (renal coloboma syndrome) and focal segmental glomerulosclerosis.

Methods: We report clinical, pathology and genetic data of 2 unrelated adult male patients carrying previously reported heterozygous mutations in PAX2 gene.

Results: 27-years-old patient 1 referred to clinical geneticist with suspicion of hereditary cystic kidney disease. At 11 years, he was diagnosed with bilateral multicystic kidney dysplasia, now presenting with proteinuria and chronic kidney disease (CKD 3 stage). Patient’s father, grandmother had unspecified kidney disease. A kidney-focused NGs panel analysis identified heterozygous nonsense pathogenic c.685C>T, p.(Arg229*) variant in PAX2. Later ocular evaluation revealed bilateral optic disc dysplasia.

36-years-old patient 2 referred to clinical geneticist after his diagnosis was confirmed with bilateral kidney hypoplasia, caused by heterozygous missense pathogenic c.250G>A, p.(Gly84Ser) variant in PAX2. Patient presented with persistent proteinuria, and chronic kidney disease. A kidney-focused NGS panel analysis identified heterozygous nonsense pathogenic c.250G>A, p.(Gly84Ser) variant. RNA analysis confirmed the full loss-of-function was recently revealed to cause a severe monogenic syndrome characterized by protein-losing enteropathy and susceptibility to venous thromboembolism.

Conclusion: Hereditary kidney diseases are rare and still underdiagnosed due to variable expressivity and wide range of clinical manifestations even within single families. Reported patients demonstrate this variability and expand knowledge about disorders, caused by PAX2 mutations, reported in literature. It also suggests that ocular evaluation should be performed for a better clinical diagnosis, when kidney pathology is present.
Fishman: None declared. Noa Henig: None declared, Eli Brazowski: None declared, Josepha Yeshaya: None declared, Tova Naiman: None declared, elon pras: None declared, Jacob N. Ablin: None declared, Hagit Baris Feldman Patent with Alexion Pharmaceuticals on ecuclizumab treatment protocol for CD55-deficiency (WO/2018/217638), which does not include any royalties, Advisory board member for the CS-inhibitor Pozelimab clinical trial by Regeneron Pharmaceuticals.

P04.008.C Asthma exacerbations in the UK Biobank: a Genome-Wide Association Study
Ahmed Edris Mohamed1,2, Katherine Fawcett3, Ian P. Hall3, Martin D Tobin2, Lies Lahousse1

1Faculty of Pharmaceutical Sciences, Ghent University, Department of Bioanalysis, Ghent, Belgium; 2University of Leicester, Genetic Epidemiology Group, Department of Health Sciences, Leicester, United Kingdom; 3University of Nottingham, Faculty of Medicine & Health Sciences, Nottingham, United Kingdom.

Background/Objectives: Asthma exacerbations affect morbidity and mortality of the disease, and increase the burden to both patient and healthcare system. We aimed to assess the effects of genetic variants on asthma exacerbation risk in UK Biobank participants with asthma.

Methods: Within the UK Biobank study, individuals with asthma were identified as those self-reporting doctor-diagnosed asthma, or with a code for asthma in hospital inpatient and/or General Practitioners (GP) records. Exacerbations were identified as either asthma-related hospitalization, GP record of asthma exacerbation, or an Oral Corticosteroid (OCS) burst prescription. A logistic regression model adjusted for age, sex, and smoking status was used to assess the association between genome-wide imputed SNPs and risk of an asthma exacerbation.

Results: We identified 11,604 individuals with asthma with at least one exacerbation (cases), and 37,890 individuals with asthma with no recorded exacerbations (controls). While no least one exacerbation (cases), and 37,890 individuals with asthma with no recorded exacerbations (controls). While no

P04.010.A The value of genomic testing for the kidney patient and for pre-transplantation donor evaluation
Georgia Christopoulou1, Stavroula Samara2, Aikaterini Oikonomaki1, Vassilis Filiopoulos2, Stathis Tsikas2, Christina Melexopoulou2, Ioannis Boletis2, Pantelis Constantoulakis1

1Genotypos M.S.A., Athens, Greece; 2National and Kapodistrian University of Athens, School of Medicine, “Laikon” University Hospital, Nephrology Department and Renal Transplant Unit, Athens, Greece.

Background/Objectives: The spectrum of kidney genetic disease is extremely broad and phenotypes are variable and overlapping, involving extra-kidney manifestations in some disease groups. Elucidating potential genetic causes is challenging due to the number of genes involved and unknown disease mechanisms. Exome sequencing (ES) may unveil the genetic background in patients, allowing definitive diagnosis and/or timely interventions while it may provide valuable information for kidney-donor candidates.

Methods: Thirty-three individuals (kidney-patients/donor-candidates) were referred to our lab, by a single reference clinic for ES,
performed on DNA extracted from peripheral blood; libraries preparation was performed with Clinical Exome (Sophia Genetics) or Whole Exome (Twist Bioscience) and sequenced on Illumina NextSeq-550 (Illumina). Bioinformatics analyses were conducted by SOPHIA DDM® bioinformatics pipelines.

**Results:** Pathogenic/likely pathogenic variants were detected in 19 patients: 10 in collagen-genes, 5 PKD1 and 1 INF2 confirming suspected diagnosis i.e., Alport syndrome, autosomal dominant polycystic kidney disease and focal segmental glomerulosclerosis, respectively. All cases were consistent with biopsy, imaging and urine/blood tests. Copy number variation analysis revealed a NPHP1 homozygous deletion (nephronophthisis) and a COL4A5 heterozygous deletion (Alport syndrome). In 9 cases results were negative either failing to elucidate genetic disease or clearing genetic burden for 5 kidney-donor candidates. In 5 cases, variants of unknown significance were detected giving eligibility to 1 donor, rejecting 2.

**Conclusion:** ES permitted timely, accurate diagnosis confirmation for kidney-patients allowing appropriate intervention, maintenance treatment or transplantation programming. Further, it provided valuable information for donor-candidates regarding their and the recipient's best interest. Incorporating exome sequencing in Nephrology may lead to higher-quality healthcare.

**References:**

**Grants:**

**Conflict of Interest:** Georgia Christopoulou Full time employee: Genotyping M.S.A., Stavroula Samara Full time employee: Genotyping M.S.A., Alkaterini Oikonomaki Full time employee: Genotyping M.S.A., Vassilis Filippoupolos: None declared, Stathis Tsiakas: None declared, Christina Melexopoulou: None declared, Ioannis Boletis: None declared, Pantelis Constantoulakis Full time employee: Genotyping M.S.A.

**P04.011.B Novel pathogenic ALG8 variants and evidence for somatic loss of heterozygosity in 542 autosomal dominant polycystic liver disease patients**

**Melissa M. Boerrigter**, Rone H.M. te Morsche, Anja Geerts, Anne Hoores, J.P.H. Drent

**Radboud University Medical Center, Department of Gastroenterology and Hepatology, Nijmegen, Netherlands; Ghent University Hospital, Department of Gastroenterology and Hepatology, Ghent, Belgium; Ghent University Hospital, Department of Pathology, Ghent, Belgium.

**Methods:** We performed whole exome sequencing in a cohort of 60 genetically undiagnosed ADPLD patients and targeted sequencing of all ALG8 exons using MiniSeq in 482 genetically undiagnosed ADPLD patients. We performed expression analysis by immunohistochemistry on liver cyst tissue with a hepatocyte-specific, a cholangiocyte-specific, and an ALG8 antibody.

**Results:** We screened 542 ADPLD patients and identified 8 heterozygous variants in ALG8 (nonsense n = 4, frameshift n = 2, splice site n = 1, missense n = 1) in 16 ADPLD patients. A 19-member family included 4 patients with severe ADPLD who shared the novel ALG8 variant c.160C>T p.(Gln54*). This variant was also present in 7 asymptomatic family members with 0-2 liver cysts. The 7 other variants were found in 1 small family and 10 singletons. All patients had mild to severe ADPLD and 0-6 kidney cysts that did not affect renal functioning. We found evidence for somatic loss of heterozygosity, as ALG8 immunoreactivity was absent in the cyst lining and cyst bordering hepatocytes of a patient carrying the c.1501delG variant.

**Conclusion:** Our results are consistent with a pathogenic role of ALG8 in ADPLD. Loss of heterozygosity of ALG8 in liver cyst lining is a key event in the pathogenesis of ADPLD.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P04.013.C Clinical exome sequencing as a valuable diagnostic tool for glomerulopathies: a cohort study**

Angelo Corso Faini, Valeria Bracciama, Silvia Kalantari, Giulia Margherita Brach del Prever, Martina Callegari, Lucia Peruzzi, Roberto Fenoglio, Dario Roccatello, Tiziana Vaisitti, Antonio Amoroso, Silvia Deaglio

**1Transplant Regional Center-Piedmont, Immunogenetics and Transplant Biology, AO UdC della Salute e della Scienza, Department of Medical Sciences, University of Turin, Turin, Italy; 2Nephrology Dialysis and Transplantation, Regina Margherita Children’s Hospital, Turin, Italy; 3SCU Nephrology and Dialysis (ERKnet member)-CMID, Center of Research of Immunopathology and Rare Diseases, San Giovanni Hospital, Turin, Italy; 4Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.

**Background/Objectives:** The diagnosis of glomerulopathies remains a hard task, as different diseases can present with similar characteristics and biopsy evidence is often non-specific. In this complex scenario, genetic analyses may play an important role.

**Methods:** Adult and pediatric patients were recruited from multiple centers of the Piedmont region (Italy), exploiting a pre-existing transplantation network. When referred to our center, patients had already undergone nephrological counselling and suspicion of glomerulopathy was raised. Clinical exome sequencing (CES) was performed, and analysis was restricted to a panel of genes associated with glomerulopathies.

**Results:** CES was performed on a diagnostic cohort of 166 patients. Alport syndrome scored the highest percentage of solved cases (59%), followed by glomerulonephritis (35%), non-nephrotic proteinuria (29%), FSGS (12%) and nephrotic proteinuria (19%). Of note, 54% of clinically undiagnosed glomerulopathies were solved. Overall, results show a diagnostic rate of 36% which is in line with published data.

**Conclusion:** Our data confirm genetic analysis is a valuable diagnostic resource when a precise glomerulopathy is suspected and ¬ unexpectedly ¬ also when the clinical suspicion is less defined. Analysis by CES i) shows a high diagnostic rate; ii) allows a precise diagnosis avoiding invasive procedures (biopsy); iii) prevents ineffective treatment; iv) speeds up the enrollment in transplantation awaiting lists and v) allows to determine recurrence risk, post-transplantation prognosis and living-donor eligibility. Taken together, our results strongly support genetic analysis as a first-line diagnostic tool in kidney disease.

**References:** 1. Connaughton at. el, Kidney Int., 2019,95(4):914-928.

**Grants:** Ministero dell’Istruzione, Progetto strategico di Eccellenza Deparmentale #D15D18000410001.

**Conflict of Interest:** None declared.

**P04.013.D Clinical exome sequencing (CES) as a tool for genetic diagnosis of Autosomal Dominant Polycystic Kidney Disease (ADPKD)**

Valeria Bracciama, Angelo Corso Faini, Silvia Kalantari, Giulia Margherita Brach del Prever, Martina Callegari, Lucia Peruzzi,}

**References:**

1. Connaughton et. al, Kidney Int., 2019,95(4):914-928.

**Grants:** Ministero dell’Istruzione, Progetto strategico di Eccellenza Deparmentale #D15D18000410001.

**Conflict of Interest:** None declared.
Robert Fenoglio1, Dario Roccatello2,3, Silvia Deaglio1, Antonio Amoroso1, Tiziana Vaisiti1

1Transplant Regional Center-Piedmont, Immunogenetics and Transplant Biology, AOU Città della Salute e della Scienza & Department of Medical Sciences, University of Turin, Turin, Italy; 2Nephrology Dialysis and Transplantation, Regina Margherita Children’s Hospital, Turin, Turin, Italy; 3SCU Nephrology and Dialysis (ERKnet member)-CMID, Center of Research of Immunopathology and Rare Diseases, San Giovanni Hospital, Turin, Italy; 4Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.

Background/Objectives: Autosomal dominant polycystic kidney disease (ADPKD #175620, #178350, #606666) is the most common inherited nephropathy and is predominantly caused by mutations in PKD1 and PKD2. Genetic testing of PKD1 is challenging for the presence of homologous pseudogenes with genetic and allelic heterogeneity. Due to phenocopies, diagnostic criteria are unable to provide a definitive diagnosis. We propose NGS-based strategy for genetic diagnosis of patients with ADPKD.

Methods: CES was performed in 121 subjects with clinical suspicion of PKD. Patients were recruited by the hospitals of the Piedmont region (Italy). PKD1 and PKD2 were analyzed and for negative cases additional cystogenes were investigated. Identified variants were segregated and validated by Sanger sequencing.

Results: Causative variants in PKD1 and PKD2 were identified in 78 patients, 56% of them presenting family history. 31 cases resulted negative or conclusive. Most of the diagnostic genetic variants affected PKD1 (78%) and PKD2 (9%). 20 patients had more than one variant in the same gene or the 2 different cystogenes. Furthermore, we identified 12 possible alternative diagnoses among which 5 patients with biallelic mutations in PKHD1 and two patients with variants in TSC1 and DYSTK, respectively.

Conclusion: Identification of the specific molecular basis of a disease is essential to avoid genetic misdiagnosis, unnecessary and invasive therapies and for early detection of renal and extrarenal comorbidities. The broad phenotypic and genetic heterogeneity of cystic kidney diseases make CES a time- and cost-efficient diagnostic approach for these indications.

References: Connc-Le Gall, et al., Lancer. 2019.

Grants: Ministero dell’Istruzione, Progetto strategico di Eccellenza Dipartimentale #D15D18000410001.

Conflict of Interest: None declared.

P04.014.A Transcriptomic landscape of pancreatic neuroendocrine tumours

Olesja Rogoza1, Helvijs Niedra1, Rihards Saksis1, Alja Gerina-Berzina2, Sofija Vilsova2, Julie Earl1, Ignacio Ruiz Caracuel3, Bozena Smolkova3, Georgina Kolenkova3, Peter Dubovans6, Peter Makovicky3, Eythimios Koniaris3, Agapi Kataki8, Vita Rovita1

1Latvian Biomedical Research and Study Centre, Research Group of Molecular and Functional Genomics, Riga, Latvia; 2Pauls Stradins Clinical University Hospital, Oncology Clinic, Riga, Latvia; 3Ramón y Cajal Health Research Institute (IRYCS), Ramón y Cajal University Hospital, Madrid, Spain; 4Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia; 5National Cancer Institute, Department of Pathology, Bratislava, Slovakia; 6National Cancer Institute, Department of Surgical Oncology of Slovak Medical University, Bratislava, Slovakia; 7Hippokraterion General, Hospital of Athens, Department of Pathology, Athens, Greece; 8Hippokraterion General, Hospital of Athens, First Department of Propaedeutic Surgery, Athens, Greece.

Background/Objectives: Pancreatic neuroendocrine tumours (PanNETs) arise from the neuroendocrine cells in pancreatic islets and account for approximately 12% of digestive system NETs, with an overall 5-year survival rate of 85%. PanNETs are heterogeneous lesions, classified according to cell proliferation rate and differentiation grade. In this study, we aimed to create a well-defined cohort of PanNETs and characterize the transcriptomic landscape on a molecular level to discover novel markers and therapeutic strategies for better tumour management options.

Methods: PanNET FFPE samples used in this study were obtained from different consortium members from Greece, Slovakia, and Spain. RNA was then extracted from FFPE samples and libraries prepared. Transcriptome sequencing was then carried out on DNASEQ-G400 platform (MG1) to identify differentially expressed genes (DEGs) in tumour and non-tumour tissues.

Results: We have sequenced transcriptomes of 72 PanNET FFPE samples and detected different transcriptome profiles that distinguish tumour and non-tumour tissues of the pancreas. In total, we were able to find 265 DEGs. Among these were insulin regulation pathway genes and other markers related to tumour pathogenesis pathways, cell proliferation, and invasion, for example, I5L1, SYCN, KLK1, CUYD1 and others.

Conclusion: The results of the PanNET transcriptomic landscape highlight the heterogeneity of PanNETs, which is dependent on various tumour characteristics. Transcriptome analysis is valuable for understanding PanNET tumour biology, which will help to discover new markers and develop new therapeutic approaches for PanNETs.

References: [Grants: European Regional Development Fund project “Establishing an algorithm for the early diagnosis and follow-up of patients with pancreatic neuroendocrine tumours (NEXT)” grant number 1.1.1.5/ERANET/20/03.]

Conflict of Interest: None declared.

P04.015.B Four years’ experience in cystic fibrosis neonatal screening in Luxembourg: 2018-2021

Marizela Kullisic1, Dominique BourgeoisJ1, Anna-Maria Charatsi2,3, Meriem Mastour2,3, Caroline Eisele4, Flore Nzuangue4, Isabel De La Fuente Garcia5, Barbara KLINK6, Patricia Borde4

1Laboratoire national de santé (LNS), National Center of Genetics, Dudelange, Luxembourg; 2Centre Hospitalier de Luxembourg (CHL), Paediatric Department, Kannerklinik, Luxembourg, Luxembourg; 3Centre Hospitalier de Luxembourg (CHL), Pneumology Department, Luxembourg, Luxembourg; 4Laboratoire national de santé (LNS), Department of Medical Biology, Dudelange, Luxembourg.

Background/Objectives: Cystic fibrosis (CF) newborn screening (NBS) was introduced in Luxembourg in January 2018. Biochemical and genetic testing is centralized at the Laboratoire national de santé (LNS) and we present the results of the first 4 years.

Methods: Immunoreactive Trypsinogen (IRT) is assessed for all newborns (app 7000/year) on day 3 of life (D3). In case of high IRT-D3 (≥60ng/mL), CFTR genetic testing using the CF-EU2v1 (Yourgene Health) kit to detect 50 frequent CFTR pathogenic variants is performed, and a second IRT test on day 21 (D21). Patients screened positive (one or two pathogenic variant detected and/or IRT-D21 ≥40ng/mL) are referred to the Paediatric National CF centre for sweat testing and further multi-disciplinary clinical follow-up. In case of positive sweat test without confirmed molecular diagnosis, complete CFTR gene sequencing is performed.

Results: IRT-D3 level was above the threshold in 0.6% newborns in 2018, 0.97% in 2019, 1.38% in 2020 and 1.32% in 2021. CF was diagnosed in 10 infants (n = 3; n = 4; n = 2; n = 1 respectively). The positive predictive value (PPV) was 15%. All patients had at least one CFTR pathogenic variant detected by the kit (55% of them were F508del). In four cases, the second rare CF-causing
variant was detected by sequencing (4382delA, E664X, I502T, S489L). The incidence of CF was 1/2454 live births.

**Conclusion:** CF NBS in Luxembourg is in line with current recommendations for standards of CF care. To improve the PPV, we will adapt the protocol and consider cases with no mutation and IRT-D3<100ng/ml as screened negative.

**References:**

**Conflict of Interest:** None declared.

**P04.017.D Genetic revision of the Hungarian cystic fibrosis registry**

Anna Dedek1, Katalin Koczok1, Beáta Besseneyel1, László Madar1, Zsuzsanna Szics1, Gabriella Csorba1, Istvan Balogh1,2

1University of Debrecen, Department of Laboratory Medicine, Division of Clinical Genetics, Debrecen, Hungary; 2University of Debrecen, Department of Human Genetics, Debrecen, Hungary.

**Background/Objectives:**

To develop a diagnostic strategy for cystic fibrosis and to facilitate mutation-specific treatments, the genetic revision of the Hungarian cystic fibrosis Registry was performed.

**Methods:** 528 patients’ data and samples were used for the revision. First we reviewed the patients’ existing genetic findings. Wherever necessary, a comprehensive three-level genetic analysis of the CFTR gene was done.

**Results:** According to our study, of the 528 patients present in the Registry 395 (74.8%) had two pathogenic CFTR mutation. We completed and corrected 94 patients’ previously incomplete genetic status. 73 different pathogenic variants were detected, in which 6 aberrations were not previously reported. The five most common mutations were: F508del (68.3%); CFTRdel2,3 (3.7%); G542X (3.2%); 2184insA (2.7%); W1282X (2.3%). Based on genotype and age, 192 patients (36.4%) are eligible for the available ivacaftor-elixaclaf combination therapy. Soon ivacaftor-elixaclaf combination will be an option for 364 (68.9%) patients.

**Conclusion:** Due to the revision, we could identify the patients who can benefit from mutation-specific drugs instead of symptomatic therapy. In addition, the obtained data have been used to map the Hungarian distribution of mutations in the CFTR gene, which will help to develop a diagnostic strategy.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P04.018.A Gene expression profiling through Whole Transcriptome Sequencing predicts novel mechanisms in Hirschsprung Associated Enterocolitis**

Francesca Rosamilia1, FRANCESCA CALCATERA2,3, Francesco Caroli4, Marta Rusmini5, Alice Grossi5, Alessio Pini Prato6, domenico maffiolo2,3, Isabella Ceccherini2, francesca iantieri1

1University of Genoa, Health Science Department (DISSAL), Biostatistics Unit, Genoa, Italy; 2University of Milan, Department of Medical Biotechnologies and Translational Medicine, Milan, Italy; 3IRCCS Humanitas Research Hospital, Laboratory of Clinical and Experimental Immunology, Milan, Italy; 4IRCCS Istituto Giannina Gaslini, University of Genoa, UOC Genetica Medica, Genoa, Italy; 5IRCCS Istituto Giannina Gaslini, UOSD, Laboratory of Genetics and Genomics of Rare Diseases, Genoa, Italy; 6Azienda Ospedaliera SS Antonio E Biagio E Cesare Arrigo, Umberto Bosio Center for Digestive Diseases, The Children Hospital, Alessandria, Italy.

**Background/Objectives:** Hirschsprung (HSCR) associated Enterocolitis (HAE) is a common life-threatening complication in HSCR, likely due to a gut immune system impairment. We have recently identified a HAE associated susceptibility variant in the Oncostatin-M receptor gene, also implied in Inflammatory Bowel Diseases (IBDs), through Whole-Exome Sequencing on HSCR and HAE patients. This study also confirmed the immune system impairment in HAE, however no data is available on possibly different gene expression in HAE versus HSCR patients.

**Methods:** We have carried out a transcriptome analysis on Intraepithelial lymphocytes (IEL) derived from biopsies of the gut of 6 HAE patients, 6 HSCR-only patients, and 4 paediatric patients affected by neither Hirschsprung nor inflammatory related diseases. For the sequencing, the Ion AmpliSeq Transcriptome Human Gene Expression Kit was used.

**Results:** We found a clear clustering between the three different groups of patients. Several transcripts were nominally significantly over- and under-expressed in HAE vs HSCR-only patients, among which several transcripts also involved in IBDs pathogenesis. Very preliminary results showed an enrichment in immune and inflammatory pathways in the HAE group, although further analyses are still in progress.

**Conclusion:** We have identified several differentially expressed genes between HSCR patients that had developed HAE vs those without HAE occurrence, including genes or pathways already affected in several intestinal pathological conditions. This could lead to the identification of key factors in the HAE pathogenesis, possibly shared with other intestinal inflammatory diseases.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P04.019.B Association between arterial hypertension and liver-related outcomes using polygenic risk scores – a population-based study**

Fredrik Åberg1, Katri Kantojärvi2, Ville Tapio Männistö3, Anna But4, Veikko Salomaa5, Teemu Niiranen6, Martti Färkkilä6, Panu Luukkonen7,8,9, Satu Männistö2, Annamari Lundqvist2, Markus Perola2, Antti Jula2

1Helsinki University Hospital, Transplantation and Liver Surgery Clinic, Helsinki, Finland; 2Finnish Institute for Health and Welfare, Helsinki, Finland; 3University of Eastern Finland and Kuopio University Hospital, Department of Medicine, Kuopio, Finland; 4Helsinki University Hospital, Abdominal Center, Helsinki, Finland; 5Turku University Hospital and University of Turku, Department of Medicine, Turku, Finland; 6Helsinki University and Helsinki University Hospital, Abdominal Center, Helsinki, Finland; 7Minerva Foundation Institute for Medical Research, Helsinki, Finland; 8University of Helsinki and Helsinki University Hospital, Department of Medicine, Helsinki, Finland; 9Yale University, Department of Internal Medicine, New Haven, United States.

**Background/Objectives:** Arterial hypertension (HTA) is associated with liver disease, but the causality remains unclear. We investigated whether genetic predisposition to HTA is associated with incident liver disease in the general population, and if antihypertensive medication modifies this association.

**Methods:** Participants of the Finnish health-examination surveys, FINRISK 1992-2012 and Health 2000, were followed for incident liver-related outcomes (ICD-10 codes: K70-K77, C22.0) and initiation of antihypertensive medication through the linkage with nationwide registers. Polygenic risk scores (PRS) for systolic (SP) and diastolic (DBP) blood pressure were derived from GWAS where over 1 million people were studied (Evangelou et al. 2018). PRSs...
were calculated with PRS-CS method. Cox regression analyses were adjusted for multiple confounders.

**Results:** In the fully-adjusted Cox regression models, both measured systolic blood pressure and clinically defined HTA were associated with increased risk of liver-related outcomes. Similarly, the PRSs for systolic and diastolic blood pressure were associated with liver-related outcomes. Recent initiation of antihypertensive medication was associated with reduced rates of liver-related outcomes in persons with high genetic HTA risk.

**Conclusion:** HTA and a genetic predisposition for HTA are associated with liver-related outcomes in Finnish population. New initiation of antihypertensive medication attenuates this association in persons with a high genetic risk for HTA.

**References:** Evangelou E. et al. 2018. https://doi.org/10.1038/s41588-018-0205-x.

**Grants:** Mary and Georg Ehrnrooth Foundation, Medicinska Understödföreningen Liv och Hälsa, Finska Läkaresällskapet, Academy of Finland (#338544) and Sigrid Jusélius Foundation.

**Conflict of Interest:** None declared.

**P04.020.C Whole Exome Analysis to identify related genes that predispose to the progression of Non-Alcoholic Fatty Liver (NAFL) to Non-Alcoholic Steatohepatitis (NASH)**

Chiara Catalano¹, Carla Debernardi¹, Gian Paolo Caviglia¹, Elisabetta Casalone¹, Chiara Rosso¹, Angelo Armandi², Alessandra Allione¹, Alessia Russo¹, Elisabetta Bugianesi¹, Giuseppe Matullo¹,²

¹University of Turin, Department of Medical Sciences, Turin, Italy; ²AOU Città della Salute e della Scienza, Medical Genetics Unit, Turin, Italy;

**Background/Objectives:** Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease that includes a wide range of liver damage ranging from simple steatosis (non-alcoholic fatty liver; NAFL) to non-alcoholic steatohepatitis (NASH)(1). The genetic factors underlying the progression from NAFL to NASH remain partially explored. We performed Whole Exome Sequencing (WES) analysis to better characterize the genetic landscape of NAFL vs NASH.

**Methods:** The study includes patients with biopsy-proven NAFLD enrolled at the Liver Unit of the Department of Medical Sciences, University of Turin. DNA samples from 157 patients (111 NASH; 46 NAFL) were used for WES analysis (Illumina Novaseq6000).

**Results:** For variant analysis, we filtered based on the pathogenic/likely-pathogenic status according to ClinVar’s clinical annotation and Allele Frequency (Max AF) less than 5%. Preliminary results on a subset of 112 patients (76 NASH; 36 NAFL) revealed that NASH subjects have on average fewer mutations than NAFL subjects (Wilcoxon test p-value = 0.014). We identified 113 genes exclusively mutated in NASH patients. The majority of them is involved in pathways such as DNA repair, primary cilia formation and lipid metabolism, which are all linked to the pathophysiology of the progressive form of the disease.

**Conclusion:** WES analysis allows the detection of novel genetic alterations that could be useful to identify genes and pathways that may help in risk stratification in patients with NAFLD.

**References:** 1)Armandi, et al. Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease. Metabolites 2021.

**Grants:** Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR) Project “Dipartimenti di Eccellenza 2018–2022”.

**Conflict of Interest:** None declared.

**P04.021.D Genetics of transient congenital hypothyroidism**

Nikolina Zdraveska¹, Violeta Anastasovska¹,², Mirjana Kocova²

¹Ss. Cyril and Methodius University in Skopje (UKIM), University Children Hospital, Skopje, Macedonia; ²Ss. Cyril and Methodius University in Skopje (UKIM), Skopje, Macedonia.

**Background/Objectives:** The etiology of transient congenital hypothyroidism (TCH) is heterogeneous and can result from maternal thyroid autoimmune disease, antithyroid medications, iodine deficiency or iodine excess iodine in the perinatal period or due to a genetic cause usually related to mild thyroid dyshormonogenesis.

**Methods:** The study cohort included 11 patients with TCH from unrelated families including 9 cases with normal sized eutopic thyroid gland and 2 cases with goiter. All patients had CH without extrathyroidal manifestations. Genomic DNA was extracted from peripheral blood leukocytes using standard techniques, and Sanger sequencing was used to screen for TSHR, DUOX2, and DUOX2A genes were screened for mutations in all coding exons and exon/intron boundaries amplified by PCR specific primers. In cases for whom peretechnetate scan data were lacking, SLC5A5 (NIS) was also screened.

**Results:** Heterozygous DUOX2 variants were identified in 18% of the TCH cases. The p.E1546G mutation was previously reported to be associated with transient CH. An additional novel heterozygous DUOX2 variant p.D1440N was detected affecting a conserved amino acid within the NAPDH-oxidase domain in which other pathogenic mutations have been identified, supporting the phenotype characteristics of mild, goitrous CH. Two novel monogenic TSHR mutations were identified p.L453P and p.E107D. TSHR variants were associated with mild CH and normal sized thyroid gland. In both cases TSH normalization was readily achieved after levothyroxine initiation without requiring supra-physiological FT4 levels.

**Conclusion:** Identification of genetic causes of TCH is important for delineation form permanent forms and possible earlier re-evaluation, as infants with TCH usually receive thyroid hormone replacement.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P04.022.A A comprehensive stepwise approach to study a large group of Egyptian referral patients with disorders of sex development (DSD)**

Mona Mekkawy¹, Inas Mazen², Alaa Kamel¹, Heba Hassan², Mona Essawi³, Mohamad Abdelhamid³, Ola Eid¹, Amal Mahmoud¹, Aya Elaidy¹, Shereen Adel¹, Hala Soliman¹, Ken McElreavey⁴, anu bashamboo⁵

¹National Research Centre, Human Cytogenetics, Cairo, Egypt; ²National Research Centre, Clinical genetics, Cairo, Egypt; ³National Research Centre, Medical Molecular genetics, Cairo, Egypt; ⁴Institut Pasteur, Developmental Genetics and Stem Cell Biology, Paris, France; ⁵Institut Pasteur, Developmental Genetics and Stem Cell Biology, Paris, France.

**Background/Objectives:** Disorders of sexual development (DSD) include conditions affecting urogenital development, associated with atypical chromosomal, gonadal, or phenotypic sex. The phenotype variability result from a wide range of genetic alterations that may be chromosomal, CNVs, monogenic, digenic or polygenic (Mazen et al., 2021). The study aimed to improve the diagnostic strategy of DSD patients by applying a stepwise approach.

**Methods:** The study included 599 Egyptian DSD patients, over a period of 6 years. They underwent clinical examination, hormonal and imaging studies, cytogenetic and FISH analysis and
Sanger sequencing. Detection of copy number variations (CNV) using MLPA was applied on 35 patients. Whole exome sequencing (WES) was applied on 18 patients and chromosomal microarray (CMA) was conducted for five patients with associated anomalies. This study was approved by NRC Ethics Committee.

Results: Sex chromosomal abnormalities were found in 41%, while autosomal abnormalities were detected in 2.3%. Sanger sequencing identified pathogenic variants in 33.7%. MLPA identified deletions of SOX9 in two patients. The detection rate of WES reached 66.7%, while CMA analysis revealed pathogenic copy number variations in two patients.

Conclusion: The study reports a large number of DSD patients from the same ethnic group with a wide cytogenetic spectrum and characteristic mutational profile with novel and rare variants.

References: Mazen I, Mekkawy M, Kamel A, et al. (2021) Advances in genomic diagnosis of a large cohort of Egyptian patients with disorders of sex development. Am J Med Genet A. 185:1666-1677.

Grants: STDF–IRD Joint Innovative Projects Fund, Grant/Award Number: 4632.

In house NRC projects: 2013-2019.

Conflict of Interest: None declared.

P04.024.C NEK8-associated nephropathies: do autosomal dominant forms exist?

Cybel Mehawe1, Eliane Choueiry1, ramy ghabiř2, sima tokajian3, Andre Megarbane1,2,4

1Lebanese American University, Department of Human Genetics, Gilbert and Rose-Marie Chagoury School of Medicine, Byblos, Lebanon; 2University of Balamand, Department of Clinical Pediatrics, Pediatric Nephrology Unit, Saint George University Hospital, Beirut, Lebanon; 3Lebanese American University, Department of Natural Sciences, School of Arts and Sciences, Byblos, Lebanon; 4Institut Jérôme Lejeune, Paris, Lebanon.

Background/Objectives: Nephronophthisis (NPHP) is a group of autosomal recessive renal diseases characterized by a reduced ability of the kidneys to concentrate solutes, chronic tubulointerstitial nephritis and cystic kidney disease. It represents the most common genetic cause of childhood renal failure. To date, around 20 different genes, encoding primary cilia proteins, have been linked to NPHP. These contribute to one third of cases with NPHP while the majority of patients remain molecularly undiagnosed.

Methods: Whole exome sequencing (WES) was carried out on a two-year-old Lebanese boy with infantile NPHP characterized by multicystic kidney dysplasia, kidney insufficiency and enlarged kidneys in addition to chronic anemia. The candidate variant, detected by WES, was then tested in the patient and his parents by Sanger sequencing. Copy number variations analysis (CNV) was subsequently performed in the proband.

Results: Our studies enabled the detection of a heterozygous de-novo variant in NEK8 (NM_178170: pArg45Trp) in the proband. CNV analysis excluded the presence of big deletions or insertions in this gene.

Conclusion: In conclusion, here we report a de-novo heterozygous variant in the NEK8 gene in infantile NPHP. This variant was detected at a de-novo state in a patient presenting with the same clinical features as the proband (and reported in VarSome). This suggests that autosomal dominant forms of NEK8-linked nephropathies may exist. Reporting further patients is essential to confirm these findings and assess whether dominant forms of the disease are restricted to a specific mutational spot or are linked to variants scattered throughout the NEK8 gene.

References: NA.

Grants: NA.

Conflict of Interest: None declared.

P04.025.D Lipid metabolism is altered in alpha-1 antitrypsin deficiency derived-patients organoids

Sara Perez-Luz1, Joaana Lalchandani1, Nerea Matamala1, Iago Justo2, Alberto Marcaccuso2, Cristina Garfia2, Loreto Hierro Llanillo3, Gema Gomez-Mariano3, Beatriz Martinez-Delgado1

1Instituto de Investigación de Enfermedades Raras, Molecular Genetics, Madrid, Spain; 2Hospital 12 de Octubre, Madrid, Spain; 3Hospital La Paz, Madrid, Spain.

Background/Objectives: Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder due to mutations in SERPINA1 gene presenting clinical manifestations in liver and lungs. More than 90% of severe deficiency patients are homozygous for PIz (Glu342Lys) mutation located in exon 5, which produces an altered protein (AAT-Z) prone to accumulate in hepatocytes. The aggregated polymers avoid protein secretion into the circulation, resulting in plasma levels 10% to 15% of the levels of normal M homozygous while they related to different hepatic alterations such as fibrosis, hepatocarcinome or lipid alterations.

Methods: We have used hepatic organoids derived from patient homozygous for the Z mutation and HepG2 cells over-expressing Z-AAT to verify the relationship among AAT-Z protein and lipid accumulation by detecting neutral lipids using oil red O staining. In addition, we performed a lipidomic analysis to determine the lipidic species accumulated in our model as well as a transcriptomic study to reveal differential expressed genes, which could explain the aforementioned results.

Results: Our results show how Z-AAT protein accumulation triggered an increase in lipid content in hepatocytes and identified specifically three species presenting a more notably increment as measured by mass spectrography. Furthermore, the transcriptomic analysis expose several genes somehow related to lipid metabolism whose variation suggest involvement in such lipid deposits.

Conclusion: AAT polymers are associated to intracellular lipid accumulation mainly because the altered expression of lipogenic genes without ruling out the possibility that lipid accumulation could be cause, as well as consequence, and hence responsible of some clinical features associated with DAAT.

References: NA.

Grants: AESI/PI/307/20.

Conflict of Interest: None declared.

P04.027.B Benefits of whole exome sequencing to advance the genetic diagnosis in patients with differences (disorders) of sex development

Hannes Syryn1, Hannah Verdin1, Julie Van De Velde1, Marianne Becker2, Cécile Bracet3, Marieke den Brinker4, Sylvia Depoorter1, Julie Fudvoye5, Daniel Klink2, Philippe Lysy6, Guy Massa6, Nele Reynaert7, Anne Roehrs1, Willem Staels2,1, Marlies Van Loocke3,2, Martine Cools1, Elfride De Baere1

1Ghent University Hospital, Center for Medical Genetics, Department of Biomolecular Medicine, Ghent, Belgium; 2Centre Hospitalier de Luxembourg, Pediatric Endocrinology and Diabetology (DECCP), Luxembourg, Luxembourg; 3Hôpital Universitaire des Enfants Reine Fabiola, Paediatric Endocrinology Unit, Brussels, Belgium; 4Antwerp University Hospital, Department of Paediatric Endocrinology, Antwerp, Belgium; 5General Hospital Sint-Jan Bruges-Ostend, Department of Child Endocrinology, Bruges, Belgium; 6CHU de Liège, Department of Pediatrics, Liège, Belgium; 7ZNA Queen Paola Children’s Hospital, Division of Pediatric Endocrinology and Diabetes,

Conflict of Interest: None declared.
Antwerp, Belgium; 8 Cliniques universitaires Saint Luc, Pediatric Endocrinology, Brussels, Belgium; 9 Jessa Hospital, Department of Pediatric Endocrinology and Diabetology, Hasselt, Belgium; 10 University Hospitals Leuven, Department of Paediatric Endocrinology, Leuven, Belgium; 11 University Hospital of Brussels, Division of Pediatric Endocrinology, Jette, Belgium; 12 Ghent University Hospital, Department of Internal Medicine and Pediatrics, Ghent, Belgium.

Background/Objectives: Differences of sex development (DSD) are heterogeneous conditions affecting the development of chromosomal, gonadal or anatomical sex. Although over 75 genes have been associated with DSD, the diagnostic yield of whole exome sequencing (WES) studies is typically not higher than 35% in a clinical setting. Here, we investigated the benefits of WES for the genetic diagnosis in patients with DSD.

Methods: Between 2016 and 2022, 144 unrelated index patients with a clinical diagnosis of DSD or the broader DSD umbrella underwent WES-based panel testing interrogating the coding regions of 130 genes implicated in DSD, primary ovarian insufficiency and hypogonadotropic hypogonadism. Variants were extracted and classified according to the ACMG guidelines. Copy number variant (CNV) analysis was performed using the ExomeDepth algorithm.

Results: In 13% of patients, we identified a likely pathogenic (LP) or pathogenic (P) rare variant in 12 distinct DSD genes, including AR (6), NR5A1 (2), WT1 (2), ATRX, CYP21A2, DHX37, HSD3B2, HSD17B3, RXFP2, SRD5A2, SRY, and TXNRD2. The majority are sequence variants; four defects are CNVs identified using ExomeDepth. Interestingly, in two brothers displaying bilateral cryptorchidism with a heterozygous missense variant, corroborating its role in familial bilateral cryptorchidism.

Conclusion: We demonstrate the benefit of WES-based genetic testing of DSD in a clinical context. The low detection rate emphasizes the need for more stringent inclusion criteria on the one hand and for advanced genome analysis to solve missing heritability in this condition.

References:

Grants: BESPEED, FWO1802220N, FWO1801018N.
Conflict of Interest: None declared.

P04.028.C Unique pipeline for the assessment of novel genetic variants leads to confirmation of PCD diagnosis

Nina Stevanovic1, Marina Andjelkovic1, Anita Skakic1, Vesna Spasovski1, Maja Stojilkovic1, Marina Parezanovic1, Milena Ugrin1, Sonja Pavlovic1

1 Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.

Background/Objectives: Primary ciliary dyskinesia (PCD) is a disease caused by impaired ciliary motility and mainly affects the lungs and reproductive organs. Inheritance is autosomal recessive and X-linked with more than 40 disease-causing genes, whereas PCD patients have diverse clinical manifestations, thus making diagnosis difficult. The utility of next-generation sequencing (NGS) technology for diagnostic purposes allows a better understanding of the PCD genetic background. However, the identification of specific disease-causing variants is challenging. The objective of this study was to create a unique guideline that will enable the standardization of the assessment of novel variants within PCD associated genes.

Methods: The study included designing a pipeline for the classification of the rare genetic variants detected using NGS. The pipeline included in silico (translation, 3D-model, protein-protein interactions, sequence conservation, posttranslational modifications) and functional analysis (expression analysis, Western Blot) of the variants.

Results: The designed pipeline consists of three steps: sequencing, detection, and identification of genes/variants; classification of variants according to their effect; and variant characterization using in silico structural and functional analysis. The pipeline was validated by the analysis of the variants detected in a disease-causing gene (DNA1) and the novel candidate gene (SPAG16).

Conclusion: The application of the pipeline resulted in the identification of disease-causing variants, as well as pathogenicity validation, through the analysis on transcriptional, translational, and posttranslational levels. The application of created pipeline leads to the confirmation of PCD diagnosis and enables a shift from candidate to disease-causing gene.

References:

Grants: This work was funded by MESTD, Republic of Serbia (451-03-68/2022-14/200042).
Conflict of Interest: None declared.

P04.029.D TSHB R75G is a founder variant and prevalent cause of low or undetectable TSH in Indian Jews

Marina Eskin-Schwartz1,2, David Shaki3,4, Noam Hadar5, Emily Bosin6, Lior Carmor2,3, Samuel Retefoff6, Eli Hershkovitz2,3, Ohad Shmuel Birk1,2,3, Alon Haim2,8

1 Soroka Medical Center, Genetics Institute, Beer Sheva, Israel; 2 Ben-Gurion University of the Negev, the Faculty of Health Sciences, Beer Sheva, Israel; 3 Soroka Medical Center, Pediatric Endocrinology Unit, Beer Sheva, Israel; 4 Ben-Gurion University of the Negev, the Faculty of Health Sciences, Beer Sheva, Israel; 5 Ben-Gurion University of the Negev, the Morris Kahn Laboratory of Human Genetics, the Faculty of Health Sciences and National Institute for Biotechnology in the Negev, Beer Sheva, Israel; 6 Soroka Medical Center, Endocrinology Laboratory, Beer Sheva, Israel; 7 The University of Chicago, Departments of Medicine and Pediatrics and the Committee on Genetics, Chicago, Illinois, United States; 8 Soroka Medical Center, Pediatric Endocrinology Unit, Beer Sheva, Israel.

Background/Objectives: Bi-allelic loss-of-function mutations in TSHB, encoding the beta-subunit of TSH, cause congenital hypothyroidism. Homozygosity for the TSHB p.R75G variant, previously described in South Asian individuals, does not alter TSH function, but abrogates its detection by some immune-detection-based platforms, leading to erroneous diagnosis of hyperthyroidism. We set out to identify and determine carrier rate of the p.R75G variant among clinically euthyroid Bene Israel Indian Jews, to examine possible founder origin of this variant worldwide and to determine phenotypic effects of its heterozygosity.

Methods: Molecular genetic studies of Bene Israel Jews and comparative studies with South Asian cohort were performed. TSHB p.R75G variant was tested by Sanger sequencing and RFLP. Haplotype analysis in the vicinity of the TSHB gene was performed using SNP arrays.

Results: Clinically euthyroid individuals with low or undetectable TSH levels from three apparently unrelated Israeli Jewish families of Bene Israel ethnicity, originating from the Mumbai region of India, were found heterozygous or homozygous for the p.R75G TSHB variant. Extremely high carrier rate of the p.R75G variant among clinically euthyroid Bene Israel Indian Jews, to examine possible founder origin of this variant worldwide and to determine phenotypic effects of its heterozygosity.

Methods: Molecular genetic studies of Bene Israel Jews and comparative studies with South Asian cohort were performed. TSHB p.R75G variant was tested by Sanger sequencing and RFLP. Haplotype analysis in the vicinity of the TSHB gene was performed using SNP arrays.

Results: Clinically euthyroid individuals with low or undetectable TSH levels from three apparently unrelated Israeli Jewish families of Bene Israel ethnicity, originating from the Mumbai region of India, were found heterozygous or homozygous for the p.R75G TSHB variant. Extremely high carrier rate of the p.R75G TSHB in Bene Israel Indian Jews (~4%) was observed. A haplotype block of 239.7kB in the vicinity of TSHB shared by Bene Israel and individuals of South Asian origin was detected.

Conclusion: Our findings highlight the high prevalence of the R75G TSHB variant in euthyroid Bene Israel Indian Jews, demonstrate that heterozygosity of this variant can cause erroneous detection of subnormal TSH levels, and show that R75G TSHB is an ancient founder variant, delineating shared ancestry of its carriers.

References:

Grants: BESPEED, FWO1802220N, FWO1801018N.
Conflict of Interest: None declared.
Conflict of Interest: None declared.

P04.030.A Genotype-phenotype correlation in patients with PHEX-related hypophosphatemia: identification of novel variants and a case of mosaicism

Irene Ambrosetti1,2, Giulia Olivucci1,2, Claudio Graziano3, Giulia Lanzoni1, Giulia Severi1, Enrico Ambrosini1, Sofia Cesarini1,2, Elena Bonora2, Cesare Rossi1, Marco Seri1,2

1O.U. Genetica Medica - IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 2Dipartimento di Scienze Mediche e Chirurgiche, Alma Mater Studiorum - Università di Bologna, Italy, Bologna, Italy; 3U.O. Genetica Medica - AUSL della Romagna - Cesena (FC), Cesena, Italy.

Background/Objectives: X-linked hypophosphatemia (XLH) is an X-linked dominant disorder caused by inactivating mutations in the PHEX gene. The clinical phenotype ranges from isolated hypophosphatemia to severe manifestations of rickets, such as bowing of the lower extremities, bone pain, low stature, and dental anomalies.

Methods: Medical records from 2008 to 2021 were retrospectively reviewed to collect clinical, biochemical and molecular findings for patients carrying pathogenic PHEX variants, detected through Sanger or Next Generation Sequencing on DNA extracted from peripheral blood lymphocytes.

Results: We report a series of seven unrelated patients from our clinical center carrying pathogenic PHEX variants. In particular, we identified one intragenic deletion and five distinct nonsense or frameshift variants (one of which was present in two unrelated patients); three of the variants we identified were novel and one was present as a somatic mosaicism in a male patient. To our knowledge, only 12 cases of somatic mosaicism for a PHEX mutation in hemizygous males have been reported in the literature; we reviewed their clinical and biochemical features, confirming the wide phenotypic variability among mosaic male patients with XLH.

Conclusion: While some reports suggested a dosage effect, with a milder clinical phenotype in mosaic males, our case and a review of the literature show a broad range of severity in these patients, overlapping that of male and female patients with germline mutations.

References:

Grants:

Conflict of Interest: None declared.

P04.031.B Exome sequencing in adult nephropathy of unknown origin: a population study

Alice DOREILLE1,2, Yannis Lombardi1, Hugo Garcia1, Radoslava Sarasva-Lamri3, Marine Dancer2, Laure Raymond4, Laurent Mesnard1,2

1Tenon Hospital, Paris, France; 2Medipole, Dumbéa Sur Mer, New Caledonia; 3Eurofins Biomnis, Lyon, France; 4ATIR, Dumbéa, New Caledonia.

Background/Objectives: Despite the importance of an etiological diagnosis, up to 20% of nephropathies remain of undetermined origin. Increased availability of genome-wide testing, such as exome sequencing (ES), may allow many cases of undetermined kidney disease to be reclassified. Here, we report the largest French cohort of ES in adult nephropathy.

Methods: Between September 2018 and February 2021, 538 unrelated patients underwent an ES (Twist Human Exome kit, 100 base pair-end sequenced on NextSeq500- Illumina). CNV research was done from the same assay, calling was based on model built by GATK4. Variant co-segregation was investigated by Sanger sequencing in relatives when needed.

Results: Of 538 unrelated patients, ES resulted in a molecular diagnosis in 135 patients (diagnostic yield of 25%). Seven patients had a conclusive result with identification of a pathogenic CNV (5% of positive diagnoses). The mean age of the patients was 43 years (± 13). 80% of the patients were analysed in solo exome. The genetic diagnosis had various consequences: allowing for a pre-symptomatic diagnosis (63%), assisting in the selection of a potential related living donor (7.5%), not considering immunosuppressive therapy (11%), ruling-out potential recurrence on the graft (20%), prescribing further investigations in the context of retrophenotyping (36%).

Conclusion: With a high diagnostic yield, major clinical and therapeutic consequences and a measured cost, our study shows the interest of ES with analysis integrating CNV detection in indeterminate adult nephropathies. The diagnoses made were often unexpected, validating the interest of a genome-wide approach.

References:

Grants:

Conflict of Interest: None declared.

P04.032.C Exome sequencing in isolated population: new insights into nephropathies of unknown origin in New Caledonia

David De Saint Gilles1, nicolas quinin2, Marine Dancer2, Nadège BATAIL1, yves doussy3, thomas lamy2, Laure Raymond4, Laurent Mesnard1, Alice DOREILLE1

1Tenon Hospital, Paris, France; 2Medipole, Dumbéa Sur Mer, New Caledonia; 3Eurofins Biomnis, Lyon, France; 4ATIR, Dumbéa, New Caledonia.

Background/Objectives: Recently, exome sequencing (ES) has shown a good diagnostic yield in adult nephrology. New Caledonia has a very high incidence of Chronic Kidney Disease (CKD) with a clear predominance of indeterminate nephropathies (40%) and a young population (60% of dialyzed patients < 65 y/o). Given its insularity, genetics offer very interesting perspectives for New Caledonian patients with nephropathy of unknown origin.

Methods: Since November 2019, ES is offered to adult patients with CKD of unclear origin with early-onset (< 45 y/o) or with a family history of kidney disease, regardless of age.

Results: From November 2019 to January 2022, 84 unrelated patients received a solo ES as a first-line exploration. The sequenced population was predominantly of Melanesian (60%) and Polynesian (30%) origin. ES identified pathogenic diagnostic variants in 15 patients (19%). Twenty-two patients (26%) presented a variant of unknown significance (VUS). None of the 84 patients carried APOL1 risk alleles. This exome-wide approach had major consequences (allow a new look on the whole clinical picture, description of new pathogenic variants, selection of a related living donor for 15 patients, a renal biopsy could be avoided in one relative).

Conclusion: With a diagnostic yield of 19% and major clinical impact, nephropathies of unknown origin in New Caledonia appear as an interesting indication of ES. As the Oceanian populations are absent from Gnomad most variants required co-segregation and retrophenotyping studies to reach ACMG 4/5 rank. Thus an important number of variants remained VUS.

References:

Grants:

Conflict of Interest: None declared.
P04.033.D Stringent variant assessment in pulmonary fibrosis reveals a stronger genetic predisposition in female than in male patients

Samuel Wilkinson1, Amy Slater2, Matthew Edwards3, Shibu John4, Deborah Morris-Rosendahl5

1Royal Brompton & Harefield NHS Foundation Trust, Clinical Genetics and Genomics, London, United Kingdom; 2Royal Brompton & Harefield NHS Foundation Trust, Clinical Genetics and Genomics, London, United Kingdom; 3Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom; 4Royal Brompton & Harefield NHS Foundation Trust, Clinical Genetics and Genomics, London, United Kingdom; 5Royal Brompton & Harefield NHS Foundation Trust, Clinical Genetics and Genomics, London, United Kingdom.

Background/Objectives: Pulmonary fibrosis (PF) is a severely progressive and fatal fibrotic interstitial lung disease, with a late age of onset (55-75 years) and an average survival rate of 3 years post diagnosis. The phenotype is strongly associated with a reduction in telomere length and pathogenic variants in telomere-associated genes, have been found in approximately 8-15% of familial PF cases. Genetic testing provides diagnostic accuracy when considering lung transplantation.

Methods: 16 patients (9%, 11 female and 5 male) were referred for genetic testing and sequenced on our custom “Resipgene” panel for inherited respiratory conditions. Analysis was bioinformatically targeted to 25 genes associated with familial pulmonary fibrosis (FPF).

Results: Sixteen patients (9%, 11 female and 5 male) were found to have a pathogenic or likely pathogenic variant in the RET1, TERT, PARIN or SFTP C genes; 48 patients (27%, 27 female, 21 male) harboured at least one variant of uncertain significance (VUS). The MUC5B rs3570590 risk-associated variant was detected in 23.6% of PF patients, compared to 18.94% in patients with a non-ILD respiratory condition.

Conclusion: Female patients appear more likely to have a genetic cause to their PF than male patients. Functional studies are required to refine the pathogenicity of the many VUSs detected. The presence of the MUC5B risk allele at a significantly higher frequency in PF patients than in patients with other respiratory conditions, was confirmed.

References:

Grants:
Conflict of Interest: None declared.

P02

SKELETAL, CONNECTIVE TISSUE, ECTODERMAL AND SKIN DISORDERS

P05.001.B Disruption of zfhx4 leads to defects in zebrafish craniofacial development matching human characteristics of nonsyndromic cleft lip with or without palate

Selina Hözel1,2, Nina Ishorst1,2, Carola Greve1,2, Franziska Degenhardt1,2, Özür Yilmaz2, Tobias Lindenberg2, Dmitriy Drichel2, Carlo Ma9, Michael Nothnagel5,7, Jayne Y. Herir-Kwa3, Joris A. Veltman5,8, Berina Zametica1, Teresa Kruse1,2, Stefanie Nowak1, Carine Carel1,2, Iris van Rooij1, Kerstin Ludwig1, Benjamin Odermatt1, Elisabeth Mangold1

1Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany; 2Institute of Anatomy, Division of Neuroanatomy, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany; 3LOEWE Centre for Translational Biodiversity Genomics, Frankfurt am Main (current address), Frankfurt am Main, Germany; 4Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Essen, University of Duisburg-Essen (current address), Duisburg, Germany; 5Cologne Center for Genomics, University of Cologne, Cologne, Germany; 6Institute for Genomic Statistics and Bioinformatics, University of Bonn, School of Medicine and University Hospital Bonn, Bonn, Germany; 7University Hospital Cologne, Cologne, Germany; 8Department of Human Genetics, Donners Institute, Radboud University Medical Center, Nijmegen, Netherlands; 9Institute of Genetic Medicine, Newcastle University, Newcastle-upon-Tyne, United Kingdom; 10Department of Orthodontics, University of Cologne, Cologne, Germany; 11Department of Human Genetics, KU Leuven, Leuven, Belgium; 12Orthodontics, University Hospitals KU Leuven, Leuven, Belgium; 13Department for Health Evidence, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, Netherlands.

Background/Objectives: Nonsyndromic cleft lip with or without palate (nsCL/P) is a frequent congenital anomaly with high heritability estimates.1,2 Despite the discovery of several common nsCL/P risk loci, major fractions of its complex congenital background yet remain unrevealed.3

Methods: In order to identify copy number variants that might be causal for nsCL/P we reanalyzed an exome sequencing dataset comprising 50 Central European nsCL/P trios. Here, we identified a heterozygous 86 kb de novo deletion that affects exons 3-11 of 11 of the ZFHX4 gene. ZFHX4 encodes the transcription factor Zinc Finger Homeobox 4 which recently has been shown to be enriched for de novo mutations in patients with nonsyndromic orofacial clefting.4 To functionally characterize the role of ZFHX4 in craniofacial development, we knocked down the zebrafish orthologue zfhx4 in wild type zebrafish larvae (zfl) by a translational blocking morpholino (TB MO).

Results: Cartilage staining of TB MO injected zfl at 4 days post-fertilization showed underdeveloped and abnormally shaped cartilaginous jaw and ethmoid plate structures, and therefore matched human characteristics of nsCL/P. Moreover, preliminary data of transient CRISPR/Cas9 zfhx4 F0-knockout in zfl replicated these observations.

Conclusion: In conclusion, our human genetic findings and subsequent functional studies in zfl indicate the importance of ZFHX4 in the process of craniofacial development and confirm its role as susceptibility gene for nsCL/P.

References: 1Mangold, et al., 2011. Trends Mol Medo. 2Groen, et al., 2011. Epidemiology,. 3Welzenbach, et al., 2021. HGG Advances,. 4Bishop, et al., 2020. Am J Hum Genet. Grants: S.H.: BonnNI Q-614.1254.; E.M.: DFG, MA 2546/6-1.; K.U.L.: DFG, LU 1944/3-1.

Conflict of Interest: None declared.

P05.002.C LRP4 intracellular variant may lead to high bone mass with bone fragility: a functional analysis

Caroline Caetano da Silva1, Genevieve Baudat2, Adrien Bloch1, Manon Ricquebourg1, Kevin Valmorin1, Martine Cohen-Solal1, Corinne Collet1

1INSERM U1132, Paris, France; 2INSERM UMR 1163, IMAGINE Institute, Necker Enfants Malades Hospital, Paris, France; 3UF de Genetique Moleculaire, Hôpital Robert Debré, Département de Génétique, Paris, France.

Background/Objectives: The LRP4 receptor is associated to bone and musculoskeletal diseases.1 We identified a novel
missense variant located in the intracellular domain in LRP4 in a 6-years-old patient, with an atypical bone phenotype characterized by osteocondensation and fractures. Another patient presented a rare LRP4 variant in extracellular domain with high bone mass, without fractures. Our goal was to confirm the pathogenicity of the variants and to unravel the disregulates pathways.

Methods: A CRISPR-Cas9 approach was used to generate mutated osteosarcoma cells (U2OS) for functional analysis.

Results: We generated two heterozygous mutant cell lines, one in intracellular domain c.5317_5320delp.(Thr1773Argfs*3) and other in the extracellular domain c.4699_4727delp.(Arg1567Glnfs*7). Both mutant cells presented a slight decrease in apoptosis compared to control. An increased mineralization was observed in the intracellular mutant, as well as higher RUNX2 and ALPL expression by RT-qPCR. The extracellular mutant had a lower mineralization/differentiation and an increase in BMP2 expression. RNAseq analysis in both mutant cells revealed 1700 and 1400 under and over expressed genes for intracellular mutant and 100 and 40 under and over expressed genes for extracellular mutant.

Conclusion: Mineralization and expression of target genes differ according to the variant localization, showing that the pathways and the pathogenicity are not the same. This approach will allow to study new functions of LRP4 in bone.

References: 1. Shen, et al. “LRP4 in neuromuscular junction and bone development and diseases.” Bone (2015). https://doi.org/10.1016/j.bone.2015.05.012.

Grants: European Union’s Horizon 2020, grant agreement 766347.

Conflict of Interest: None declared.

P05.003.D Developmental genomics on split-hand/foot malformation, further indication of allelic series and gene dosage effects

Ruizhi Duan1, Hadia Hijazi1,2, Haowei Du1, Jawid Fatih1, Christopher Grochowski1, Shalnini Jhangiani3, Jennifer Posey1, Zeynep Coban Akdemir1,4, V. Reid Sutton1, Claudia Carvalho1,5, Davut Pehlivan1,6, James Lupski1,3,6,7

1Baylor College of Medicine, Department of molecular and human genetics, Houston, United States; 2Johns Hopkins University, McKusick-Nathans Institute of Genetic Medicine, Baltimore, United States; 3Baylor College of Medicine, Human Genome Sequencing Center, Houston, United States; 4UTH Health School of Public Health, Houston, United States; 5Pacific Northwest Research Institute, Seattle, United States; 6Texas Children’s Hospital, Houston, United States; 7Baylor College of Medicine, Department of Pediatrics, Houston, United States.

Background/Objectives: Split-hand/foot malformation (SHFM) is a rare form of congenital limb anomaly with unclear molecular etiology, presumably because of a failure to maintain the central portion of apical ectodermal ridge (AER) during limb bud proximal-distal (P/D) axial development.

Methods: Family-based genomics and rare variant analyses were implemented using exome sequencing (ES) combined with whole-genome array-based comparative genomic hybridization (aCGH) to investigate 5 SHFM cases that originated from diverse world geographical populations.

Results: We identified one novel pathogenic variant of WNT10B in two unrelated Turkish families; one family with a de novo 7Mb large chromosomal deletion encompassing the entire HOXD territory; two families involving copy number gain of Chr17p13.3 including BHLHA9. Notably, breakpoint junction analyses for all three CNV alleles provided evidence for microhomology-mediated break-induced replication (MMBIR) as the putative molecular mutational mechanism facilitated by Alu/Alu-mediated rearrangement (AAMR). In contrast to heterozygous duplication of BHLHA9 associated with SHFLD3, homozygous duplication CNV was observed in association with the Gollop-Wolfgang Complex, implicating semi-dominant inheritance.

Conclusion: Genes acting on limb patterning are sensitive to a gene dosage effect and often associated with an allelic series. Novel variant identifications involving these genes/loci provide potential insights that further elucidate the developmental genomics of SHFM. We extend a gene dosage model which could potentially, in an adjuvant way, assist interpreting the interconnections among allelic series, clinical phenotypical severity, and reduced penetrance of the BHLHA9-related CLM spectrum.

References: da Rocha et al. Clinical Genetics. 2021; 100(5):615-623.

Grants: BHCMG, UM1 HG006542; BCM-GREGoR; U01 HG011758; NIH R01 NS1050.

Conflict of Interest: Ruizhi Duan: None declared, Hadia Hijazi: None declared, Haowei Du: None declared, Jawid Fatih: None declared, Christopher Grochowski: None declared, Shalnini Jhangiani: None declared, Jennifer Posey J.E.P. was supported by NIH K08 HG008986, and is the principal investigator of Baylor College of Medicine Genomics Research Elucidates Genetics of Rare (BCM-GREGoR; U01 HG011758), Zeynep Coban Akdemir: None declared, V. Reid Sutton: None declared, Claudia Carvalho: None declared, Davut Pehlivan D.P. is supported by the International Rett Syndrome Foundation (IRSF grant #3701-1), James Lupski United States (U.S.) National Human Genome Research Institute (NHGRI) and National Heart Lung and Blood Institute (NHLBI) to the Baylor-Hopkins Center for Mendelian Genomics (BHC MG, UM1 HG006542) and Baylor College of Medicine Genomics Research Elucidates Genetics of Rare (BCM-GREGoR; U01 HG011758), U.S. National Institute of Neurological Disorders and Stroke (NINDS) (R35NS105078 to J.R.L.); and Muscular Dystrophy Association (MDA). (512848 to J.R.L.) and Spastic Paraplegia Foundation (SPF) (to J.R.L.), J.R.L. has stock ownership in 23andMe, J.R.L. is a paid consultant for Regeneron Genetics Center; The Department of Molecular and Human Genetics at Baylor College of Medicine receives revenue from clinical genetic testing conducted at Baylor Genetics (BG); J.R.L. serves on the Scientific Advisory Board (SAB) of BG, J.R.L. is a co-inventor on multiple United States and European patents related to molecular diagnostics for inherited neuropathies, eye diseases, genomic disorders and bacterial genomic fingerprinting.

P05.004.A Weill-Marchesani syndrome: natural history and genotype-phenotype correlation from 18 cases

Pauline Marzin1,2, jean-luc alessandri2, Klaus Dieterich3, Christine Francannet5, Sandra Mercier6, Caroline Michel1,2, Oana Moldovan7, Gianmaria Miolo8, Massimilano Rossi9, Sophie Rondeau10, Valérie Comnier-Daire1,2

1Institut Imagine, AP-HP, Hôpital Necker-Enfants Malades, Fédération de Génétique e, Paris, France; 2Université de Paris, UMR1163, INSERM, Paris, France; 3CHU de la Réunion - Hôpital Félix Guyon, Bellepierre, Pôle Femme-Mère-Enfants, Saint-Denis, France; 4Univ. Grenoble Alpes, Inserm, U1209, CHU Grenoble Alpes, Institut of Advanced Biosciences, Grenoble, France; 5CHU de Clermont-Ferrand - Hôpital d’Enfants, Service de génétique médicale, Pôle Femme et Enfant, Clermont-Ferrand, France; 6CHU de Nantes - Hôtel Dieu, Service de génétique médicale - Unité de Génétique clinique, Nantes, France;
Background/Objectives: Weill-Marchesani syndrome (WMS) belongs to the acromelic dysplasia group, defined by short stature, brachydactyly and progressive joint stiffness. WMS is characterized by ophthalmological abnormalities such as microspherophakia, severe myopia secondary to lens shape anomaly, and lens ectopia. Cardiovascular defects have been reported. Monoallelic variants in FBN1 are associated with a dominant WMS, while biallelic variations in ADAMTS10, ADAMTS17 and LTBP2 are responsible for recessive WMS. These four genes code for components of the extracellular matrix.

Objectives: Natural history description of WMS and genotype-phenotype correlation establishment.

Methods: Retrospective multicenter study. Inclusion criteria: clinical diagnosis of WMS with identified mutations.

Results: 18 individuals, 11 females and 7 males, with a mean age of 20 years (from 1.5 to 59 years) were included. Eight have a mutation in FBN1 without specific localization, 6 in ADAMTS10, 4 in ADAMTS17, none in LTBP2. All individuals presented with eye anomalies including lens ectopia (10/18), high myopia (9/18), microspherophakia (8/18), glaucoma (5/18), and cataract (4/18). 10/18 have a short stature (-2 to -4 DS), 12/18 myopia (9/18), microspherophakia (8/18), glaucoma (5/18), and cataract (4/18). 10/18 have a short stature (-2 to -4 DS), 12/18 brachydactyly. 7/18 individuals have cardiac defect such as valvulopathy (pulmonary stenosis 2/7, aortic stenosis 1/7, mitral insufficiency 3/7, mitral thickening 1/7). Other manifestations included: recurrent laryngitis (1), hepatomegaly (1), carpal tunnel syndrome detected at 22 years of age (1).

Conclusion: Apart from ophthalmological findings which are mandatory for diagnosis, phenotype of WMS seems to be more variable than initially described, notably, only half of patients presented with short stature. No genotype-phenotype correlation emerges from this cohort.

References:

Grants:

Conflict of Interest: None declared.

PO05.005.B Potential therapeutic targets for hypermobile Ehlers-Danlos syndrome from proteome and secretome analyses of patients’ dermal fibroblasts

Valeria Cinquina1, Nicola chiarelli1, Nicoletta Zoppi1, Daniele Capitanio2, Virginia Bassi1, Marina Venturini2, Cecilia Gelfi2, Marco Ritelli1, Marina Colombi1

1University of Brescia, Department of Molecular and Translational Medicine, Brescia, Italy; 2University of Milan, Department of Biomedical Sciences for Health, Milan, Italy; 3Spedali Civili University Hospital, Department of Clinical and Experimental Sciences, Brescia, Italy.

Background/Objectives: Hypermobile Ehlers-Danlos syndrome (hEDS) is a connective tissue disorder without a known genetic etiology and specific therapies, which is mainly characterized by generalized joint hypermobility and musculoskeletal complaints. Patients’ dermal fibroblasts exhibit a widespread extracellular matrix (ECM) disarray and myofibroblast-like characteristics including α-SMA cytoskeleton organization. Control fibroblasts treated with hEDS cells-derived conditioned media (hEDS-CM) acquire this pathological phenotype.

Methods: A comprehensive proteomic study based on top-down and bottom-up approaches was performed by comparing the intra- and extracellular proteome of patients’ and controls’ fibroblasts. We also performed in vitro studies to define the effect of the matrix metalloproteinases (MMPs) inhibitor doxycycline on ECM organization and fibroblast-to-myofibroblast transition (FMT).

Results: Cellular proteome analyses unveiled protein changes essential to actin cytoskeleton dynamics, energy metabolism and redox balance, proteostasis, intracellular trafficking and secretion. Secretome profiling of hEDS-CM mainly revealed an MMPs dysfunction as a possible disease driver by causing a detrimental feedback loop of excessive ECM degradation coupled with myofibroblast differentiation. Doxycycline-mediated MMPs inhibition rescued in patients’ cells a control-like ECM organization and induced a partial reversal of their myofibroblast-like phenotype. Furthermore, the addition of doxycycline to hEDS-CM abolishes its capability to induce in control cells ECM disarray and FMT.

Conclusion: Altogether, these data provide evidence on several putative disease targets for the development of therapeutic strategies with a potential benefit for patients’ management.

References:

Grants: This research was funded by The Ehlers-Danlos Society (grant numbers: 2018.02c. LOI.26; Molecular Studies in hEDS and HSD $1 Million Grant).

Conflict of Interest: Valeria Cinquina: None declared, Nicola chiarelli: None declared, Nicoletta Zoppi: None declared, Daniele Capitanio: None declared, Virginia Bassi: None declared, Marina Venturini: None declared, Cecilia Gelfi: None declared, Marco Ritelli: None declared, Marina Colombi Principal investigator funded by The Ehlers-Danlos Society (grant numbers: 2018.02c. LOI.26; Molecular Studies in hEDS and HSD $1 Million Grant).

PO05.006.C Mutation spectrum in Bulgarian patients with skeletal tissue disorders, revealed by clinical exome sequencing

Ivanka Dimova1, Kalina Mihova2, Kunka Kamenarova2, Nevyan Ivanova2, Darina Kachakova-Yordanova2, Radka Kaneva2

1Medical University Sofia, Sofia, Bulgaria; 2Medical University Sofia, Molecular Medicine Center, Sofia, Bulgaria.

Background/Objectives: Identifying a molecular diagnosis for an individual with a skeletal dysplasia can lead to improved clinical care, guide future medical management and treatment, and inform assessment of risk for familial recurrence. We aimed in revealing the type and frequency of genetic mutations in Bulgarian patients with skeletal tissue disorders.

Methods: We performed next generation sequencing (NGS) by using TruSight One kit (clinical exome) and MiSeq platform of Illumina in 26 patients with clinical diagnosis, suspicious for skeletal tissue disorder.

Results: We found pathogenic and likely pathogenic variants in 10 and 2 patients, respectively. Six were missense mutation, 3 – nonsense, 2 - frameshift and 1 splicing variant. The highest frequency of mutations was detected for Osteogenesis imperfecta. The Table below represents our findings.

Abstracts from the 55th European Society of Human Genetics Conference
Conclusion: We put genetic diagnosis in 46% of the patients with clinical diagnosis of skeletal tissue disorder by using clinical exome sequencing. These findings demonstrate the utility of NGS testing for individuals with a suspected skeletal dysplasia or growth disorder.

References: Scocchia, A., et al. Diagnostic utility of next-generation sequencing-based panel testing in 543 patients with suspected skeletal dysplasia. Orphanet J Rare Dis 16, 412 (2021).

Grants: D01-285-17.12.2019.
D01-395-18.12.2020.
D01-302-17.12.2021.

Conflict of Interest: None declared.

P05.007.D The familiar and the sporadic form of Trichorhinophalangeal syndrome - case reports

Lenka Horáková1, Gabriela Kříčková1, Monika Koudová1, Marie Trková1, Ivo Mařík2, Jitka Stekrová1, Katerina Hirschfeldova1

1GENNET - Center of Medical genetics and reproductive medicine, Prague, Czech Republic; 2Ambulatory Centre for Defects of Locomotor Apparatus, Prague, Czech Republic; 3First Faculty of Medicine Charles University, The Institute of Biology and Medical Genetics, Prague, Czech Republic.

Background/Objectives: Trichorhinophalangeal syndrome type I (TRPS I) is a rare autosomal dominant disorder caused by mutation in the TRPS1 gene coding a transcriptional repressor of GATA genes. TRPS1 haploinsufficiency reduces activity of genes regulating the growth of bone and cartilage with clinical picture of TRPS I: abnormal bones in the fingers and toes, joint abnormalities, distinctive facial features and other symptoms (fine, sparse hair, pear-shaped nose, prominent ears, brachydactyly, cone shaped epiphyses of the phalanges, dystrophic nails, short stature, small breasts, hip dysplasia). We report 2 cases. The first case is the 16 years old girl with growth retardation and typical facial features. The proband’s mother manifested the same facial signs and. The 2nd sporadic case is 12 years old girl with similar facial signs, disproportion between leg length and scoliosis.

Methods: In the first case we carried out a NGS amplicon analysis of TRPS1 gene. In the second case SNP array (OmnExpress-24 v1.3 chip, Illumina) was performed and result was confirmed by MLPA (Salsa MLPA KIT Illumina P-228 TRPS1-LGS).

Results: In the first case a missense mutation c.2761C>T (p. Arg921Ter) in exon 6 of TRPS1 gene of maternal origin and in the second case de novo 155kb microdeletion involving exons 3-5 of TRPS1 gene were found.

Conclusion: Correct diagnosis based on characteristic facial features in combination with targeted genetic testing is essential for confirmation of diagnosis with adequate follow up and therapeutic care and is very important for possibility to provide appropriate genetic counselling.

References:

Grants:

Conflict of Interest: None declared.

P05.008.A Molecular characterization and investigation of the role of genetic variation in phenotypic variability and response to treatment in a large pediatric Marfan syndrome cohort

Josephina (Jeannette) Meester1, Silke Peeters1, Lotte Van Den Heuvel1, Aline Verstraeten1, Lot Van Laer1, Bart Loeyes1,2

1University of Antwerp and Antwerp University Hospital, Center of Medical Genetics, Antwerp, Belgium; 2Radboud University Medical Center, Department of Human Genetics, Nijmegen, Netherlands.

Background/Objectives: In a large cohort of 373 paediatric patients with Marfan syndrome (MFS) with a severe cardiovascular phenotype, we explored the proportion of patients with MFS with a pathogenic FBN1 variant and analysed whether the type/location of FBN1 variants was associated with specific clinical characteristics and response to treatment. Patients were recruited on the basis of the following criteria: aortic root z-score > 3, age 6 months to 25 years, no prior or planned surgery, and aortic root diameter < 5 cm.

Methods: Targeted resequencing and deletion/duplication testing of FBN1 and related genes were performed.

Results: We identified (likely) pathogenic FBN1 variants in 91% of patients. Ectopia lentis was more frequent in patients with dominant-negative (DN) variants (61%) than in those with haploinsufficient variants (27%). For DN FBN1 variants, the prevalence of ectopia lentis was highest in the N-terminal region (84%) and lowest in the C-terminal region (17%). The association with a more severe cardiovascular phenotype was not restricted to DN variants in the neonatal FBN1 region (exon 25-33) but was also seen in the variants in exons 26 to 49. No difference in the therapeutic response was detected between genotypes.

Conclusion: Important novel genotype-phenotype associations involving both cardiovascular and extra-cardiovascular manifestations were identified, and existing ones were confirmed. These findings have implications for prognostic counseling of families with MFS.

References: PMID: 35058154.

Grants: FWO Flanders: 12X8520N and G044720N.

Conflict of Interest: None declared.

P05.009.B Serum calcification propensity T50 associates with disease severity in patients with pseudoxanthoma elasticum

Lukas Nollet1,2,3, Matthias Van Gils1,2,3, Suzanne Fischer4, Laurence Campens4, Swapna Karthik5, Andreas Pasch6,7,8, Julie De Zeytijd9, Bart Leroy1,9,10, Daniel Devos1,2, Tine De Backer1, Paul Coucke1,2, Olivier Vanacker1,2,3

1University of Antwerp and Antwerp University Hospital, Center of Medical Genetics, Antwerp, Belgium; 2Radboud University Medical Center, Department of Human Genetics, Nijmegen, Netherlands; 3European Journal of Human Genetics (2023) 31:345 – 709

Abstracts from the 55th European Society of Human Genetics Conference
Background/Objectives: Pseudoxanthoma elasticum (PXE) is a currently intractable Mendelian disorder characterized by progressive ectopic calcification in the skin, eyes and arteries. Therapeutic trials in PXE are severely hampered by the lack of reliable biomarkers. Serum calcification propensity T50 is a novel blood test measuring the functional anti-calcifying buffer capacity of serum. Here, we evaluated T50 in PXE patients aiming to investigate its determinants and suitability as a potential biomarker for disease severity.

Methods: Fifty-seven PXE patients were included and demographic, clinical, imaging and biochemical data were collected from medical health records. PXE severity was assessed using Phenodex scores. T50 was measured using a validated, nephelometry-based assay. Multivariate models were then created to investigate T50 determinants and associations with disease severity.

Results: Mean age of patients was 45.2 years, 68.4% was female and mean serum T50 was 347 minutes. Multivariate regression analysis identified serum fetuin-A (p < 0.001), phosphorus (p = 0.007) and magnesium levels (p = 0.034) as significant determinants of T50, while no correlations were identified with serum calcium, eGFR, plasma PPI levels or ABCC6 genotype. After correction for covariates, T50 was found to be an independent predictor of ocular (p = 0.013), vascular (p = 0.013) and overall disease severity (p = 0.016) in PXE.

Conclusion: In this cross-sectional cohort study, shorter serum T50 – indicative of higher calcification propensity – associated with a more severe phenotype in PXE patients. This study indicates for the first time that serum T50 might be a reliable and clinically relevant biomarker in PXE and may act as a surrogate endpoint in future therapeutic trials.

References:

Grants:

Conflict of Interest: Lukas Nollet: None declared, Matthias Van Gils: None declared, Suzanne Fischer: None declared, Laurence Campens: None declared, Swapna Karthik Swapna Karthik is an employee of Calcison AG, Swapna Karthik is a stockholder of Calcison AG., Andreas Pasch Andreas Pasch is an employee of Calcison AG, Andreas Pasch is a stockholder of Calcison AG., Julie De Zaeytijdt: None declared, Bart Leroy: None declared, Daniel Devos: None declared, Tine De Backer: None declared, Paul Coucke: None declared, Olivier Vanacker: None declared.

P05.010.C Genetic and functional studies of novel candidate genes for Psoriatic Arthritis Mutilans

Sailan Wang1, Pernilla Nikamo1, Raquel Vaz1, Fulya Taylan1, Jesper Eisenfeld1, Xiaowei Zheng1, Leena Laasonen1, Isabel Tapia-Paez1, Mona Stahle1

1Karolinska institutet, Stockholm, Sweden.

Background/Objectives: Psoriatic arthritis mutilans (PAM) is the most severe and rare clinical subtype of psoriatic arthritis (PsA) characterized by severe destruction of the distal joints. The prevalence of PAM in the Nordic countries is estimated to 3.69 cases per million inhabitants.

Methods: In this project, we aim to study the genetic basis of PAM in a unique Nordic PAM cohort consisting of 61 well-characterized patients1 by the whole genome sequence (WGS) and whole exome sequence (WES).

Results: Using next generation sequencing we found three very rare variants in the same gene in four unrelated patients. The gene found suggest involvement of the Reactive oxygen species (ROS) in development of PAM. To measure ROS generation in patients’ blood we are using the very sensitive Electron Paramagnetic Resonance (EPR) method. In addition, we are creating cell models to study the effects of the mutations in global expression, and we plan to use zebrafish models to study the consequences of these variants in vivo.

Conclusion: In summary, identifying the genetic cause of PAM is very valuable as it gives affected individuals the opportunity for diagnosis, important information about prognosis and treatment.

References:

1.Gudbjornsson, B et al. “Psoriatic arthritis mutilans (PAM) in the Nordic countries: demographics and disease status. The Nordic PAM study.” Scandinavian journal of rheumatology vol. 42,5 (2013): 373-8. https://doi.org/10.3109/03009742.2013.771211.

Grants: 1) KI- China Scholarship Council (CSC202008320311 to Sailan Wang). 2) 2021: Sällsyntafonden. Funding: 35 000 SEK. Role: solo applicant.

Conflict of Interest: None declared.

P05.011.D Expanding the allelic and locus heterogeneity of Multiple osteochondromas

Artem Borovikov1, Nailiya Galeeva1, Tatiana Markova1, Elena Zinina1, Tatiana Nagomova1, Ekaterina Zakharova1, Aysulu Muratzina1, Ilya Kanivets2,3, Sergey Korostelev2, Maria Orlova1, Aleksander Polyakov1, Elena Dadali1, Olga Schagina1

1Research Centre for Medical Genetics, Moscow, Russian Federation; 2Genomed LTD, Moscow, Russian Federation; 3FSBEI FPE RMACPE MOH Russia, Moscow, Russian Federation.

Background/Objectives: Multiple osteochondromas (MO) is a skeletal dysplasia characterized by the growth of two or more osteochondromas, caused by pathogenic nucleotide variants in EXT1 or EXT2 genes in 70%-90% of patients. Another rarer disease characterized by multiple osteochondromas but with additional enchondromas is metachondromatosis, associated with the loss-of-function variants in the PTPN11 gene. The clinical similarity of the two diseases suggests that atypical forms of metachondromatosis can be misdiagnosed as MO. This study aims to characterize the genotype profile of the Russian population and find additional molecular causes in patients with MO.

Methods: DNA sequencing (Sanger Method and NGS panel) and MLPA analysis were performed to identify SNV and CNV in the sample of 348 patients from 153 families. Patients were divided into groups according to the severity of the disease, using a three-degree clinical scale with two subgroups.

Results: Germline pathogenic or likely pathogenic variants were identified in 137 (89%) families. 122 unique disease-causative variants (53 novel and 69 known) and 15 recurrent (4 novel) were identified including frameshift (34,4%), nonsense (26,2%), missense (12,3%), splicing (15,5%) variants, genomic rearrangements (5,7%) and in-frame deletion (0,8%). In 16 families with the clinical picture of MO with no significant findings in EXT1 and EXT2 genes, five loss-of-function variants in the PTPN11 gene were found.

Conclusion: Our work expanded the allelic and locus heterogeneity of MO and showed that some of the undiagnosed patients with MO could have pathogenic variants in the PTPN11 gene.
P05.013.A A biallelic gain-of-function variant in MSGN1 causes a new skeletal dysplasia syndrome

Asuman Koparir1, Caroline Lekszas1, Kemal Kesenoglu2, Aboulfazl Rad3, Atefeh Hasanazadeh4, Ehsan Ghayoor Karimian5, Nakul Narendran6, Ertugrul Ozbudak7,8, Barbara Vona1,4,9,10, Thomas Haaf1

1Institute of Human Genetics, Julius Maximilians University Würzburg, Würzburg, Germany; 2Division of Developmental Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, United States; 3Department of Otolaryngology-Head & Neck Surgery, Sabzevar University of Medical Sciences, Sabzevar, Iran; 4Department of Medical Genetics, Next Generation Genetic Polyclinic, Sabzevar University of Medical Sciences, Sabzevar, Iran; 5Department of Genetic Medicine, Medical University of Vienna, Vienna, Austria; 6Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, United States; 7Department of Medical Genetics, Next Generation Genetic Polyclinic, Sabzevar University of Medical Sciences, Sabzevar, Iran; 8Department of Otolaryngology-Head & Neck Surgery, Sabzevar University of Medical Sciences, Sabzevar, Iran; 9Institute for Auditory Neuroscience and InnerEarLab, University Medical Center Göttingen, Göttingen, Germany; 10Institute of Human Genetics, University Medical Center Göttingen, Göttingen, Germany.

Background/Objectives: Mesogenin1 (MSGN1, OMIM: *612209), a basic-Helix–Loop–Helix transcription factor, is expressed in the presomitic mesoderm (PSM) and plays a crucial role in formation of PSM progenitor cells during somitogenesis. We aimed at identifying the molecular basis of a patient with severe skeletal dysplasia in a single family through utilization of whole-exome sequencing and subsequent Sanger sequencing.

Methods: The proband displays short stature and multiple skeletal problems, including mesomelic dysplasia of the arms with complete humero-radio-ulna synostosis, arched clavicles, pelvic dysplasia, short and thin fibulae, proportionally short vertebrae, hyperlordosis and mild kyphosis. To test the pathogenicity of the detected mutation, we overexpressed either wild-type (WT) or the mutant msgn1 in zebrafish via mRNA injection and analyzed tbxta (i.e., Tbrachyury/ntl) expression in the tailbud. Results: A novel homozygous c.374G>T (p.Arg125Leu) missense variant was detected in MSGN1 (NM_001105569.2) in a patient. MSGN1 resides in a ~13.2 Mb homologous interval on chromosome 2. We found overexpression of WT or the mutant msgn1 significantly reduces tbxta expression in the tailbud compared to uninjected WT embryos (p < 0.0001). In addition, we also found the mutant msgn1 has a more severe effect than WT msgn1 (p = 0.0186, Kruskal-Wallis), causing a gain-of-function.

Conclusion: In contrast to loss-of-function effect, gain-of-function of MSGN1 explains mild affected vertebrae of the proband. Furthermore, as somite segments from 9 to 13 are known to contribute to the forelimb muscle, these might potentially be related with mesomelic shortening in our case. Our findings highlight a new skeletal dysplasia syndrome caused by a gain-of-function mutation in MSGN1.

References:

Grants:

Conflict of Interest: None declared.

P05.013.B A biallelic gain-of-function variant in MSGN1 causes a new skeletal dysplasia syndrome

Asuman Koparir1, Caroline Lekszas1, Kemal Kesenoglu2, Aboulfazl Rad3, Atefeh Hasanazadeh4, Ehsan Ghayoor Karimian5, Nakul Narendran6, Ertugrul Ozbudak7,8, Barbara Vona1,4,9,10, Thomas Haaf1

1Institute of Human Genetics, Julius Maximilians University Würzburg, Würzburg, Germany; 2Division of Developmental Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, United States; 3Department of Otolaryngology-Head & Neck Surgery, Sabzevar University of Medical Sciences, Sabzevar, Iran; 4Department of Medical Genetics, Next Generation Genetic Polyclinic, Sabzevar University of Medical Sciences, Sabzevar, Iran; 5Department of Pediatric Medicine, Cincinnati, United States; 6Division of Developmental Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, United States; 7Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, United States; 8Institute of Human Genetics, University Medical Center Göttingen, Göttingen, Germany; 9Institute for Auditory Neuroscience and InnerEarLab, University Medical Center Göttingen, Göttingen, Germany.

Background/Objectives: Mesogenin1 (MSGN1, OMIM: *612209), a basic-Helix–Loop–Helix transcription factor, is expressed in the presomitic mesoderm (PSM) and plays a crucial role in formation of PSM progenitor cells during somitogenesis. We aimed at identifying the molecular basis of a patient with severe skeletal dysplasia in a single family through utilization of whole-exome sequencing and subsequent Sanger sequencing.

Methods: The proband displays short stature and multiple skeletal problems, including mesomelic dysplasia of the arms with complete humero-radio-ulna synostosis, arched clavicles, pelvic dysplasia, short and thin fibulae, proportionally short vertebrae, hyperlordosis and mild kyphosis. To test the pathogenicity of the detected mutation, we overexpressed either wild-type (WT) or the mutant msgn1 in zebrafish via mRNA injection and analyzed tbxta (i.e., Tbrachyury/ntl) expression in the tailbud. Results: A novel homozygous c.374G>T (p.Arg125Leu) missense variant was detected in MSGN1 (NM_001105569.2) in a patient. MSGN1 resides in a ~13.2 Mb homologous interval on chromosome 2. We found overexpression of WT or the mutant msgn1 significantly reduces tbxta expression in the tailbud compared to uninjected WT embryos (p < 0.0001). In addition, we also found the mutant msgn1 has a more severe effect than WT msgn1 (p = 0.0186, Kruskal-Wallis), causing a gain-of-function.

Conclusion: In contrast to loss-of-function effect, gain-of-function of MSGN1 explains mild affected vertebrae of the proband. Furthermore, as somite segments from 9 to 13 are known to contribute to the forelimb muscle, these might potentially be related with mesomelic shortening in our case. Our findings highlight a new skeletal dysplasia syndrome caused by a gain-of-function mutation in MSGN1.

References:

Grants:

Conflict of Interest: None declared.

P05.014.C MN1-related disorders in two Bulgarian patients

Mila Sleptsova1, Tihomir Todorov1, Slavena Atemin1,2, Mihaela Miladenova1,2, Daniela Avdjieva-Tzavella2, Albena Todorova1,2

1Genetic Medico-Diagnostic Laboratory “Genica”, Sofia, Bulgaria; 2Department of Medical Chemistry and Biochemistry, Medical University Sofia, Sofia, Bulgaria.

Background/Objectives: Pathogenic variants in the MN1 gene are a known cause of CEBALID syndrome, which is characterised mainly by craniofacial and structural brain abnormalities, and global developmental and variable intellectual delay. Predominantly nonsense and frameshift variants have been reported as pathogenic so far. The syndrome is with autosomal dominant inheritance (Mak et al., 2019). We report two patients which presented with similar clinical characteristics and were found to carry heterozygous variants in the MN1 gene.

Methods: Whole Exome Sequencing was performed for both patients and a panel of genes was analysed. Variants flagged through the analysis were confirmed and segregated in the patients’ families via Sanger sequencing.

Results: The first case is a patient with craniofacial dysostosis, low-set ears, polyolyscin kidney dysplasia and congenital intellectual delay. The following variant in MN1 was found in a heterozygous state: c.3743G>A, p.Trp1248Ter. The segregation analysis confirmed the variant occurs de novo.

The second case is a patient which presents with craniofacial malformations. The c.2486C>A, p.Ser829Tyr variant was found in a heterozygous state. The segregation analysis confirmed the variant occurs de novo.

Conclusion: Those cases provide insight into the diversity of MN1 variants that could be disease-causing. Although no missense variants have been reported as pathogenic so far, functional studies might be worth looking into.

References:

Grants:

Conflict of Interest: None declared.
mislocalization in the cytosol, seeming to fail to enter the nucleus. RNAseq data on HaCaT cells downregulated for the endogenous SNRPE show an alteration of many physiological processes and a reduction in KRT81 expression levels, previously linked to monilethrix.

**Conclusion:** The mechanism by which mutations in SNRPE cause hypotrichosis is still unclear. However, mutant forms of SNRPE are probably unable to exert their function. Down-regulation of SNRPE in HaCaT affects the expression of KRT81, known to cause monilethrix.

**References:** 1 Pasternack et al., 2013. Grants: MR/N0137941/1;MC_UU_00011/1;MC_UU_00011/1;MR/T002239/1;SBF004/1079.

**Conflict of Interest:** None declared.

**P05.016.A Age-specific effects of body size on fracture risk in later life: A lifecourse Mendelian randomization study**

Grace Marion Power1, Jonathan Tobias1,2, Timothy M. Frayling3, Jessica Tyrrell4, April Hartley5, Jon Heron6, George Davey Smith7, Tom G. Richardson1

1University of Bristol, MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol, United Kingdom; 2University of Bristol, Musculoskeletal Research Unit, Bristol, United Kingdom; 3University of Exeter, Genetics of Complex Traits, College of Medicine and Health, Exeter, United Kingdom.

**Background/Objectives:** Musculoskeletal conditions, including fractures, can have severe and long-lasting consequences. Higher body mass index in adulthood is widely acknowledged to be protective for most fracture sites. However, the association between weight and bone health is complex and confounding bias may have distorted earlier findings. Employing a lifecourse Mendelian randomization (MR) approach, this investigation explores how prepubertal and adult body size independently influence fracture risk in later life.

**Methods:** Using data from a large UK-based prospective cohort, univariable and multivariable MR were conducted to simultaneously estimate the effects of age-specific genetic proxies for body size (n = 453,169) on the odds of fracture in later life (n = 416,795). A two-step MR framework was additionally applied to elucidate potential mediators.

**Results:** Univariable and multivariable MR indicated strong evidence that higher body size in childhood reduced fractures in later life (OR, 95% CI: 0.89, 0.82 to 0.96, P = 0.005 and OR, 95% CI: 0.76, 0.69 to 0.85, P = 1x10-6, respectively). Conversely, higher body size in adulthood increased fracture risk (OR, 95% CI: 1.08, 1.01 to 1.16, P = 0.023 and OR, 95% CI: 1.26, 1.14 to 1.38, P = 2x10-6, respectively). Two-step MR analyses suggested that the effect of higher body size in childhood on reduced fracture risk was mediated by its influence on higher estimated bone mineral density in adulthood.

**Conclusion:** This investigation provides novel evidence that higher body size in childhood reduces fractures in later life and higher body size in adulthood is a risk factor, opposing findings from earlier research. Protective effect estimates previously observed are likely attributed to childhood effects.

**References:** Grants: MR/N0137941/1;MC_UU_00011/1;MC_UU_00011/1;MR/T002239/1;SBF004/1079.

**Conflict of Interest:** Grace Marion Power GMP is employed part-time by Clifton Insight outside of this work. Jonathan Tobias: None declared, Timothy M. Frayling: None declared, Jessica Tyrrell: None declared, April Hartley: None declared, Jon Heron: None declared, David Davey Smith: None declared, Tom G. Richardson TGR is employed part-time by Novo Nordisk outside of this work.

**P05.018.C Satisfaction with resilient denture liner versus acrylic resin telescopic prostheses for patients with ectodermal dysplasia: A non randomized crossover clinical trial**

Yasmine H. Mohsen1, Mohamed Abdel Kader1, Nouran Abdel Nabi2, Iman A. W. Radip
Background/Objectives: Ectodermal dysplasia is a rare genetic disorder that manifests dry skin, sparse hair, xerostomia, complete or partial anodontia of deciduous and/or permanent teeth and malformed teeth. The crowns are usually conical anteriorly. The roots are stunted having a huge pulp chamber. Enamel usually forms a delicate layer, decreasing in thickness towards cervical line. Xerostomia is mostly present due to absence of salivary glands or reduction in their number. Alveolar ridges are commonly flat due lack of tooth formation, it is the main reason for the low vertical dimension of the face and the senile appearance of the patient. These oral features can hinder proper restoration of teeth.

Methods: In this non-randomized clinical trial, ectodermal dysplasia patients with partial anodontia were recruited. Overdentures were constructed for the patients, that were later relined opposing to the teeth with a soft liner. Follow up was done 1 week and 3 months following denture delivery and denture relining. After each stage, patient satisfaction, retention, and periodontal health parameters were assessed. Patient satisfaction was assessed with a validated, reliable questionnaire.

Results: A statistical significant difference was found between the groups regarding retention (P = 0.025), probing depth (P < 0.001), and gingival index (P = 0.011) favouring the acrylic resin coping-retained overdentures 3 months after overdenture delivery.

Conclusion: The resilient denture liner-retained maxillary complete overdenture improved patient satisfaction and tooth mobility of anterior teeth, while minimally jeopardizing the periodontal condition of the abutment teeth in children with ectodermal dysplasia.

References:

Grants: Supported by a research grant from the National Research Centre, Cairo, Egypt.

Conflict of Interest: Yasmine H. Mohsen National research centre, Mohamed Abdel Kader: None declared, Nouran Abdel Nabi: None declared, Iman A. W. Radi: None declared.

P05.019.D Identification of a novel deep intronic variant in CRTAP by genome sequencing as the cause of osteogenesis imperfecta

Gandham SriLakshmi Bhavani1, Prajna Udupa1, Shalini Nayak1, Neethukrishna Kausthubham1, Ashwin Dala2, Katta Girisha1

1Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Department of Medical Genetics, Manipal, India; 2Centre for DNA Fingerprinting and Diagnostics, Diagnostics Division, HYDERABAD, India.

Background/Objectives: CRTAP is one of the 21 genes known to be associated with Osteogenesis Imperfecta (OI). Biallelic variants in CRTAP (cartilage-associated protein) cause autosomal recessive OI type VII. CRTAP forms a complex with P3H1 in the endoplasmic reticulum and binds to pro-alpha collagen chains to mediate post-translational modification of collagen triple helix.

Methods: Detailed clinical evaluation and a complete skeletal survey were performed. We did exome sequencing followed by genome sequencing to identify the genetic aetiology. RNA was extracted from the fetal fibroblasts for transcript analysis.

Results: Antenatal sonography at 19 weeks of gestation showed shortening of long bones and rocker bottom feet. Perinatal pathological evaluation showed protruding thoracic cage, depressed nasal bridge with anteverted nares, and long philtrum. Radiographic findings were short and bowed legs with multiple fractures at different stages of healing, and generalized osteopenia. Exome sequencing did not reveal any significant pathogenic variants. Genome sequencing identified a deep intronic homogenous variant in intron 3, c.794-1403A>G. RNA studies revealed that it affects splicing and results in two different abnormal transcripts. The detected variant generates the novel splice donor site and utilizes upstream acceptor sites resulting in the formation of two different transcripts of 68 bp and 75 bp cryptic exons in CRTAP mRNA.

Conclusion: The deep intronic variant is associated with alteration of splicing, leading to the generation of two abnormal transcripts. This novel splicing effect in CRTAP is likely cause of lethal form of OI in the fetus.

References:

Grants: 

Conflict of Interest: None declared.

P05.020.A Pathogenic LEF1 variants disrupt WNT signaling to osteogenesis imperfecta associated with limb malformations

Salem Alawbethani1,2, Maria Asif1,2,3, William Dufour4,5, Anne-Sophie Jourdain6,7, Geneviève Baujat8, Christian Becker1, Birgit Budde1, Lyndon Gallacher5,9, Theodoros Georgomanolis1, Jamal Ghomim5, Wolfgang Höhne10, Stanislas Lyonnet1, Iman Ali Baddik10, Sylvie Manouvrier-Hanu6, Susanne Motameny1, Angelika A Noege6,7, Lynn Pais11, Clemence Vanlerbergh6,8, Prerana Wagle12, Sue White8,9, Marjolaine Willems13, Peter Nürnberg1,2, Fabienne Escande4,6, Florence Petit8,9, Muhammad Saajid Hussain1,2,3

1CCG - Cologne Center for Genomics, Köln, Germany; 2Center for Biochemistry, Medical Faculty, University of Cologne, Cologne, Germany; 3Center for Molecular Medicine Cologne, Köln, Germany; 4University of Lille, Lille, France; 5Chu De Lille, Lille, France; 6Chu, Lille, France; 7Necker Hospital, Paris, France; 8Victorian Clinical Genetics Services, Parkville, Australia; 9University of Melbourne, Parkville, Australia; 10Department of Pediatrics, Faculty of Medicine and Health Sciences, University of Aden, Aden, Yemen; 11Broad Institute of MIT and Harvard, Cambridge, United States; 12Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany; 13Hospital Center University De Montpellier, Montpellier, France.

Background/Objectives: Ectrodactyly ectodermal dysplasia without cleft lip/palate (MIM 129810) is reported with clinical manifestations of split-hand/foot malformation accompanied by ectodermal anomalies like hypotrichosis and abnormal dentition. This disorder has received insufficient attention in the past. We aim to delineate the underlying genetic determinants of this disorder.

Methods: Whole exome and transcriptome sequencing, Pull down assay, Immunoblotting, Immunofluorescence.

Results: We recruited 12 individuals from 5 unrelated families manifesting a syndrome with variable expression of limb malformations and/or ectodermal dysplasia. The phenotypic spectrum includes various limb malformations, such as radial ray defects, polydactyly or split hand/foot, and ectodermal dysplasia in some individuals. We identified four novel LEF1 variants — monoallelic in 11 affected individuals and biallelic in one. We have shown that out of four, only the p.Met23dup impaired interaction with β-catenin due to its location in a highly conserved β-catenin binding domain of LEF-1. Whole transcriptomic profiling further confirmed that Wnt/β-catenin signaling pathway is impaired. We have seen significant differential expression of transcripts already known as downstream targets of the Wnt/β-catenin signaling pathway.
pathway and HOX family — both Wnt and HOX are crucial for embryonic developmental events.

**Conclusion:** Our functional data show that two molecular mechanisms are at play: haploinsufficiency or loss of DNA-binding are responsible for a mild to moderate phenotype, while loss of β-Catenin binding due to biallelic variants is associated with a severe phenotype. Our findings establish mono- and biallelic variants in LEF1 as a cause for a syndrome comprising limb malformations and ectodermal dysplasia.

**References:**

**Grants:** CHU Lille, CMMC, DAAD, NHGRI, NHLBI.

**Conflict of Interest:** None declared.

**P05.022.C Body mass index and the risk of rheumatic disease: clinical practice, as an abnormality justifiable in the context of ISS and could be limited to patients with signs of LWD, whereas it was zero in patients with ISS. Thus this analysis seems questionable in the context of ISS and could be limited to patients with significant signs of LWD (i.e. a positive "Rappold revisited" score\(^\text{1}\)).

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P05.022.C Body mass index and the risk of rheumatic disease: linear and nonlinear Mendelian randomization analyses**

Torgny Karlsson\(^1\), Fatemeh Hadizadeh\(^1\), Mathias Rask-Andersen\(^1\), Åsa Johansson\(^1\), Weronica Ek\(^1\)

\(^1\)Uppsala University, Department of Immunology, Genetics and Pathology and Science for Life Laboratory, Uppsala, Sweden.

**Background/Objectives:** While the association between obesity and risk of rheumatic disease is well established, the causal relation is not fully established. Here we estimate the causal effect of body mass index (BMI) on the risk of developing five types of rheumatic disease.

**Methods:** Linear and nonlinear mendelian randomization (MR) was used to estimate the effect of BMI on the risk of developing rheumatic disease and to identify sex-specific effects. Primary MR analyses were performed in 361,952 participants from the UK Biobank cohort.

**Results:** We found that a one standard deviation increase in BMI increases the risk for rheumatoid arthritis (IRR = 1.52; 95% CI = 1.36-1.69), osteoarthritis (IRR = 1.49; 1.43-1.55), psoriatic arthropathy (IRR = 1.80; 1.31-2.48), gout (IRR = 1.73; 1.56-1.92), and inflammatory spondylitis (IRR = 1.34; 1.14-1.57). BMI was also found to be a stronger risk factor for psoriatic arthropathy (sex-interaction P = 3.3 × 10⁻⁴) and gout (P = 4.3 × 10⁻³) in females compared to males. Nonlinear effects of BMI were identified for osteoarthritis and gout in males, and for gout in females. The nonlinearity for gout was more extreme in males compared to females, and was similar to what was observed for urate levels.

**Conclusion:** Higher BMI causes an increased risk for rheumatic disease, an effect that is more pronounced in females compared to males for both gout and psoriatic arthropathy. These results give further insight into etiology and pathology of rheumatic disease.

**References:**

**Grants:** This work was supported by the Swedish Research Council, the Marcus Borgström’s, Åke Wibergs, and M Rudbergs foundations, Vleugels foundation and Hedströms foundation.

**Conflict of Interest:** None declared.

**P05.023.D MED12 somatic mutation in Paget’s disease of bone**

Nerea Gestoso-Uzal\(^1, 2, 3\), Luis Antonio Corchete\(^2, 3\), Ana-Belén Herrero\(^1, 2, 3\), Javier del Pino-Montes\(^2, 4\), Juan Francisco Blanco-Bueno\(^2, 3\), Rogello González-Sarmiento\(^1, 2, 3\)

\(^1\)Molecular Medicine Unit, Department of Medicine, University of Salamanca, Salamanca, Spain; \(^2\)Biomedical Research Institute of Salamanca (IBSAL), University Hospital of Salamanca-USAL-CSIC, Salamanca, Spain; \(^3\)Institute of Molecular and Cellular Biology of Cancer (IBMCC), University of Salamanca-CSIC, Salamanca, Spain; \(^4\)Rheumatology Service, University Hospital of Salamanca-IBSAL, Salamanca, Spain; \(^5\)Traumatology and orthopedic surgery service, University Hospital of Salamanca-IBSAL, Salamanca, Spain.

**Background/Objectives:** Paget’s disease of bone (PDB) is a metabolic bone disease characterized by an increase in bone turnover in a disorganized way. Germline mutation in SQSTM1 gene constitutes the most important known genetic factor predisposing to PDB, but it can not explain the etiopathogenesis of all the patients. Moreover, PDB is a focal disorder that does not affect to all the bone tissue. The aim of this study was to identify somatic mutations that can determine the development of PDB.

**Methods:** DNA was extracted from both pagetic and normal bone tissue from one PDB patient following a standard phenol/chloroform procedure. Whole exome sequencing was performed to identify pagetic bone-exclusive mutations.

**Results:** We identified 40 somatic variants in the pagetic bone that did not appear in the normal tissue, including 11 exonic variants. We found just one nonsense mutation, c.103C>T; p.E35*, in MED12 gene. Somatic mutation of MED12 gene has been associated with uterine myomas, characterized by uncontrolled but benign cell proliferation. Moreover, it has been reported that MED12 mutation causes a blockade of autophagy, as it occurs with reported mutations in SQSTM1\(^1\).

**Conclusion:** Our results suggest that somatic alteration of MED12 gene could be responsible of PDB development.

**References:**

**Grants:** This study was funded by FIS-FEDER: PI18/01476.

**Conflict of Interest:** None declared.
P05.024.A Syntaxin-18 defects in human and zebrafish cause traffic jams and unravel key roles in early bone development

Brecht Guillemin1, Hanna De Saffel1, Jan Willem Bek1, Piyanoot Tapaneeypaphan1, Adelbert De Clercq1, Tamara Jarayseh1, Sophie Debaenst1, Andy Willaert1, Peter Byers2, Paul Coucke1, Bettina Blaumiers3, Delfien Syx4, Fransiska Malfait1, Sofie Symoens1

1Center for Medical Genetics Ghent, Department of Biomolecular Medicine, Ghent, Belgium; 2University of Washington, Department of Laboratory Medicine and Pathology - Department of Medicine, Seattle, United States; 3University of Antwerp, Department of Medical Genetics, Antwerp, Belgium.

Background/Objectives: Membrane fusion is a key process in all living organisms. SNAREs are required for fusogenic action, where they zipper up at the juncture of membranes, enabling fusion and cargo transfer. Syntaxin-18 (STX18), an endoplasmic reticulum-resident SNARE, is crucial for membrane fusion events, vesicular transport and secretion of collagens. Currently, STX18 is not linked to any human disease.

Methods: Whole exome sequencing (WES) was applied for a fetus with lethal osteogenesis imperfecta, presenting with multiple fractures, abnormal cartilage formation, tibial bowing, irregularly formed mandible, and severe cranial undermineralization. Protein modelling and overexpression studies were performed and stx18 zebrafish crisprants (uppercut18) were generated using CRISPR/Cas9.

Results: WES revealed a homozygous missense variant p.Arg10Pro in STX18, affecting a critical residue in the cytoplasmic resident SNARE, is crucial for membrane fusion events, vesicular cargo transfer. Syntaxin-18 (STX18), an endoplasmic reticulum-resident SNARE, is crucial for membrane fusion events, vesicular transport and secretion of collagens. Currently, STX18 is not linked to any human disease.

Conclusion: Our study provides evidence for a link between genetic defects in STX18 and human bone disease, expanding the phenotype of the SNAREopathies, and our in vivo data describes for the first time an essential role for syntaxin-18 during skeletal development and its involvement in neurological pathways.

References: https://doi.org/10.1126/science.1161748, https://doi.org/10.7554/eLife.02784, https://doi.org/10.1016/j.ydbio.2016.11.010.

Grants: Research Foundation Flanders (1TQ5920N, 1842318N), Ghent University.

Conflict of Interest: None declared.

P05.025.B Comprehensive molecular screening using NGS custom gene panel identifies ultra-rare types of Osteogenesis imperfecta and OI-like disorders

KINGA SALACIŃSKA1,lena Rutkowska1, Iwona Pinkier1, Dominik Salachna1, Izabela Michalus2, Elżbieta Jakubowska-Pietkiewicz3, Łukasz Kępcyński1, Agnieszka Gach1

1Polish Mother’s Memorial Hospital - Research Institute, Department of Genetics, Lodz, Poland; 2Polish Mother’s Memorial Hospital - Research Institute, Department of Endocrinology and Metabolic Diseases, Lodz, Poland; 3Medical University of Lodz, Department of Paediatric Propedeutics and Bone Metabolic Diseases, Lodz, Poland.

Background/Objectives: Osteogenesis imperfecta (OI) is a rare connective tissue disorder, presenting genetic and phenotypic heterogeneity. The molecular etiology reaches XXI types, of which types I-IV (90% of patients) are associated with mutations in genes encoding collagen type I. Other cases are caused by aberrations in one out of 17 non-collagen genes influencing collagen biosynthesis or related molecular pathways, which prevalence is below 1 per 1,000,000 births or remains unknown.

Methods: The study included 158 patients suspected with Osteogenesis imperfecta, aged 6 months to 44 years, presenting a broad spectrum of clinical manifestation. NGS custom gene panel, encompassing all known genes for OI types I-XIX and OI-like disorders, was performed.

Results: We have identified 9 families with pathogenic mutations located in six non-collagen genes (IFTM5, SERPINF1, FKBP10, WNT1, P4HB, LRP5) associated with an ultra-rare OI type V, VI, XI, XV and OI-like disorders as Cole-Carpenter syndrome, Primary Osteoporosis, Idiopathic Juvenile Osteoporosis. This unique group of patients constituted 7% of the study population with a proven molecular diagnosis of congenital bone fragility. Of 10 non-collagen variants, four have not been reported previously.

Conclusion: Obtained results reflect phenotypic and genetic variety of skeletal disorders, as primary patients with mutations in non-collagen genes were classified as having OI type I (LRP5, WNT1, P4HB), type III (FKBP10, IFTM5) and type IV (SERPINF1, IFTM5). Thus, comprehensive molecular screening is crucial for correct diagnosis, genetic counselling and appropriate treatment.

References: PMID: 24715559; PMID: 20301472; OMIM Database.

Grants: Young Scientist Grant 2016/IV/S7-MN.

Conflict of Interest: None declared.

P05.026.C Biallelic loss of function variants in EXOC6B are associated with impaired primary ciiloigenesis and cause spondylo-epi-metaphyseal dysplasia with joint laxity type 3

Pelin Simsek-Kiper1, Prince Jacob2, Priyanka Upadhyay2, ekim taskiran3, Vishal Singh Guleria2, rmed individuals have been reported hitherto and the underlying mechanism is yet to be elucidated.

Methods: Using exome sequencing, we identified c.2122+15447-2197-59588del and c.4011>T>G biallelic variants in EXOC6B in two individuals from unrelated families with different ethnicities. Immunofluorescence and immunoblotting assays were performed in proband 1 (P1), and osteogenic differentiation assay and total mRNA sequencing in proband 2 (P2). RT-PCR and RT-qPCR were performed for both in patient derived fibroblasts.

Results: P1 at age 3 years demonstrated lepadactyly (sleender metacarpals and metatarsals), delayed carpal ossification, lumbar lordosis with bilateral hip, and knee dislocations. P2 at age 13 years had intellectual disability with central nervous system
anomalies including hydrocephalus, hypoplastic mesencephalon, and thin corpus callosum in addition to the known features of SEMD1L3. Increased levels of EXOC6B mRNA, absent protein in fibroblast-derived cell lysates, shortening of primary cilia length with minor variability of primary cilia frequency in P1 as compared to control derived fibroblasts were observed. The expression of EXOC6B mRNA and osteogenic differentiation potential was reduced in dermal fibroblasts of P2 as compared to that of control fibroblasts. Pathways related to the extracellular matrix were also disturbed in P2.

Conclusion: Our study provides the first evidence of the impairment of exocytosis potentially deregulating primary ciliogenesis in two subjects with SEMD1L3 that might represent yet another ciliopathy with central nervous system involvement and joint dislocations.

References:

Grants: India Alliance Fellowship (IA/CRC/20/1/600002).

Conflict of Interest: None declared.

P05.027.D Genetic anomalies and diagnostic yield in an 11-year birth cohort of craniosynostosis patients

Linda Gaillard1, Anne Goyerde2, Annelies de Klein2, Irene Mathijssen1, Marieke van Dooren2

1Erasmus Medical Center-Sophia Children’s Hospital, University Medical Center, Department of Plastic, Reconstructive and Hand Surgery, Rotterdam, Netherlands; 2Erasmus Medical Center-Sophia Children’s Hospital, University Medical Center, Department of Clinical Genetics, Rotterdam, Netherlands.

Background/Objectives: Craniosynostosis is a rare congenital anomaly, defined by premature fusion of one or more cranial sutures. Craniosynostosis can occur in isolation or as part of a clinical syndrome. The genetic cause of craniosynostosis may impact the clinical course and treatment of patients with craniosynostosis. Knowledge on the genetic etiology therefore is key to ensure adequate counseling and to improve clinical management of craniosynostosis patients. In line with this, the Dutch craniosynostosis guideline recommends genetic diagnostic testing in patients with craniosynostosis. In this case report, we present an unusual cause of craniosynostosis.

Methods: We conducted a retrospective cohort study among patients who presented at the outpatient clinic of the Erasmus University Medical Center, The Netherlands. We included all patients, born between 2010-2021, with radiologically confirmed craniosynostosis and assessed diagnostic yield of genetic testing.

Results: We included 993 patients (n = 334 female/659 male), of whom 856 presented with single-suture craniosynostosis (449 sagittal, 268 metopic, 116 unicoronal, 14 unilambdoid, 9 frontosphenoidal) and 136 patients presented with multisutural craniosynostosis, and one unknown (preliminary results).

Conclusion: This study will discuss the prevalence of chromosomal and monogenic (likely) pathogenic variants and provide an update on the diagnostic yield of genetic testing in our 11-year birth cohort craniosynostosis patients. Finally, we will compare the diagnostic yield for different types of craniosynostosis with the long term aim of improving genetic testing strategies and counseling.

References:

Grants:

Conflict of Interest: None declared.

P05.028.A The stop-loss variant c.690A>G in RAB33B results in milder phenotype of Smith-McCort dysplasia-2

Ashwin Dalal1,2, Prince Jacob2, Katta Girisha2, Prajna Udupa2, debashish ghosh2, Gandham SriLakshmi Bhavani2, hitesh shah2

1Centre for DNA Fingerprinting and Diagnostics - CDFD, Hyderabad, India; 2Kasturba Medical College, Manipal, Manipal, India.

Background/Objectives: Smith-McCort dysplasia-2 (SMC-2) is a rare spondylo-epiphyseal-metaphyseal dysplasia, caused by biallelic loss of function variants in RAB33B. RAB33B has dual functions in membrane trafficking and in the autophagy process. Studies investigating the dynamics of the autophagy with relation to RAB33B in patients with SMC2 have not been reported.

Methods: We identified a biallelic stop-loss variant, c.690A>G in RAB33B in two siblings (P1 and P2) by exome sequencing. Functional studies were done using immunofluorescence, immunoblotting, and qPCR in fibroblast cells of P1 and P2.

Results: P1 and P2 at age 13 years and 15 years respectively presented with short trunk, barrel-shaped chest, brachydactyly, plump interphalangeal joints, limited extension of elbow joints, and progressive joint pain. Convex vertebral endplates, reduced hip joint spaces, short metacarpals (4th and 5th), abnormal carpal bone morphology were observed in their radiographs. The mutant RAB33B showed loss of its Golgi body localization which led to aggregation of collagens in cytosol. Abundance of cytoplasmic RAB33B led to increased flux of autophagy, causing accelerated clearance of the aggregated collagen by aggrephagy. Thus, the equilibrium of RAB33B localization to Golgi body and phagophore membrane is modulated by the mutant RAB33B, leading to differential crosstalk of Golgi body-RAB33B-autophagosome in the patient fibroblasts.

Conclusion: Mislocalization of mutant RAB33B at Golgi body with simultaneous increased autophagy probably underlie the milder phenotype of SMC-2. Our work highlights the emerging role of autophagy in collagen degeneration and in skeletal dysplasia.

References:

Grants:

Conflict of Interest: None declared.

P05.029.B Inversion of LMX1B - a novel cause of nail-patella syndrome in a Swedish family

Hillevi Lindelöf1,2, Eva Horemuzova1, Ann Nordgren1,2, Ulrika Voss3, Anna Hammarström1,2, Giedre Grigelioniene1,2

1Karolinska Institutet, Department of molecular medicine and surgery, Stockholm, Sweden; 2Karolinska University Hospital, Department of Clinical Genetics, Stockholm, Sweden; 3Karolinska University Hospital, Department of Pediatric Radiology, Stockholm, Sweden.

Background/Objectives: Nail-patella syndrome (OMIM #161200) is a rare autosomal dominant disorder with an estimated prevalence of 1 in 50 000. The characteristic clinical findings are different nail and skeletal abnormalities including underdeveloped nails, hypoplastic or absent patellae and iliac horns. It is caused by missense or truncating variants in LMX1B, resulting in haploinsufficiency. In this case report, we present an unusual cause of
NPS in a family of five affected individuals where Sanger sequencing failed to detect any pathogenic variants in the LMX1B gene.

**Methods:** We describe a large inversion disrupting the LMX1B gene in five affected family members with mild but variable clinical features of nail-patella syndrome.

**Results:** Whole genome sequencing revealed an inversion stretching approximately 4.2 Mb and disrupting LMX1B and ABL1 which was confirmed by Sanger sequencing of the breakpoints.

**Conclusion:** This expands the molecular spectrum of nail-patella syndrome, indicating that genomic rearrangements should be considered a possible cause in patients where standard genetic investigations fail to detect any pathogenic variants in LMX1B.

**References:** Sweeney, E., Fryer, A., Mountford, R., Green, A., & McIntosh, I. (2003). Nail patella syndrome: a review of the phenotype aided by developmental biology. J Med Genet, 40(3), 153-162.

**Grants:** The Swedish Rare Diseases Research foundation (Sällysantofonden), Sällskapet Barnavård and Karolinska Institutet, Swedish Research Council, through the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, Promobilia Foundation and Frimurare Barnhusfond foundation in Stockholm.

**Conflict of Interest:** None declared.

**P05.031.D de novo c.784G>A variant in LMNA disturbs nuclear proteostasis and results in progeroid manifestations**

**Shruti Pande**¹, **Debasish Kumar Ghosh**¹, **Jeevan Kumar**³, **Dhanya Yesodharan**², **Sheela Nampoothiri**², **Periyasamy Radhakrishnan**³, **Chilikala Gangi Reddy**⁶, **Akash Ranjan**⁶, **Katta Girisha**¹,⁵

¹Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Department of Medical Genetics, Udupi, India; ²Amrita Institute of Medical Sciences and Research Centre Cochin, Kerala, India, Department of Pediatric Genetics, Cochin, India; ³Suma Genomics Private Limited Manipal, Udupi, India; ⁴Computational and Functional Genomics Group Centre for DNA Fingerprinting and Diagnostics Hyderabad, Telangana, India, Hyderabad, Telangana, India; ⁵Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Department of Medical Genetics, UDUPI, India.

**Background/Objectives:** Variants in LMNA lead to collapse of nuclear systems network and underlie some disorders of premature aging, including Hutchinson-Gilford progeria syndrome.

**Methods:** We identified a de novo heterozygous nonsynonymous variant, c.784G>A (LMNA²⁶²K) in exon 4 of LMNA (NM_170707.4) in a sixteen-years old male by exome sequencing. We performed immunocytochemistry to see expression and localization of the mutant LMNA and immunoblotting to quantify the mutant LMNA in patient fibroblasts. To study the LMNA secondary structure, recombinant wild type and mutant were cloned and circular dichroism spectroscopy, atomic force microscopy, dynamic light scattering and isothermal titration calorimetry were performed. Computation tools and molecular dynamics simulation were used to assess the stability of LMNA²⁶²K.

**Results:** The proband had micrognathia, sparse scalp hair, eyebrows and eyelashes, narrow nasal bridge with broad nasal tip and dental crowding. His fibroblasts showed nuclear aggregates of the mutant LMNA with its mislocalization from the nuclear envelope. Structural destabilization of mutant region results in the clustering of multiple hydrophobic residues, making LMNA unstable and prone to aggregation. LMNA²⁶²K also disrupts the consensus binding site of E2-SUMO ligase UBE2I, further reducing the clearance of mutant LMNA in patient fibroblasts. Aggregates of LMNA²⁶²K temporally sequester HSPA1A1, PSMD8, MRE11 and KU80, resulting in impaired nuclear proteostasis and loss of DNA damage repair response in proband fibroblasts.

**Conclusion:** LMNA²⁶²K in the rod2 domain causes structure-function destabilization of LMNA, leading to nuclear proteotoxicity in premature aging.

**References:**

**Grants:** India Alliance (IA/CRC/20/1/600002) funded this work.

**Conflict of Interest:** Shruti Pande: None declared, Debasish Kumar Ghosh: None declared, Jeevan Kumar: None declared, Dhanya Yesodharan: None declared, Sheela Nampoothiri: None declared, Periyasamy Radhakrishnan: None declared, Chilikala Gangi Reddy: None declared, Akash Ranjan: None declared, Katta Girisha: Suma Genomics, Private Limited, Manipal (Director).

**P05.032.A A novel SLC35D1 variant causing milder phenotype of Schneckenbecken dysplasia in a large pedigree**

**Leyla Ozer**¹, **Suleyman Aktuna**¹, **Ervim Unsal**¹, **volkan baltaci**¹

¹Mikrogen Genetik Tani Merkezi, Genetics, ANKARA, Turkey.

**Background/Objectives:** SLC35D1 gene mutations causes Schneckenbecken dysplasia (SD) which is an rare autosomal recessive disorder and characterized by the snail-like pelvis, flattening of vertebral bodies, short and broad long bones with a dumbbell-like appearance, thoracic hypoplasia. Here we reported a family with novel SLC35D1 variant and milder phenotype of SD (1, 2).

**Methods:** The clinical features of 5 patients were represented in Table 1. Whole exome sequencing was done using the NextSeq500 Sequencer. The detected variant which was predicted as the causative variant was validated by Sanger sequencing in the proband and her parents. Sanger sequencing were studied for the other affected individuals in the family.

**Results:** Whole Exome sequencing of the proband revealed a homozygous missense variant of SLC35D1 gene; c.401T>C. A, p.Met134Thr. Affected sibling and her cousins with same phenotype have homozygous missense variant too. The parents and their healthy girl are heterozygous carriers.

**Conclusion:** Patients with mild phenotypic findings who carry SLC35D1mutation were reported for the first time in this study. This report will have significant consequences since it has the largest SD family with alive patients (ages ranged 4-31 years old) reported to date.

**References:** 1. Song Z. Roles of the nucleotide sugar transporters (SLC35 family) in health and disease. Molecular Aspects of Medicine. 2013; 34: 590–600. 2. Furuichi T et al. Identification of loss-of-function mutations of SLC35D1 in patients with Schneckenbecken dysplasia, but not with other severe spondyloepiphysial dysplasias group diseases. J Med Genet. 2009 ; 46(8): 562–568.

**Grants:** Table 1. Clinical features of the patients.

| Age | Gender | Specific clinical features |
|-----|--------|---------------------------|
| 12  | F      | Short stature, short limbs, mild scoliosis, hypoplasia of middle phalanges of fingers, palmar creases, hyperconvex nails, hoophoof-like nails, karaya-like nails, strabismus, congenital heart defect |
| 15  | F      | Short stature, short hands and feet, clinodactyly, pes planus |
| 19  | M      | Short stature, strabismus, congenital heart disease, hypoplastic ribs, thoracic kyphosis |
| 24  | M      | Short stature, strabismus, congenital heart disease, hypoplastic ribs, thoracic kyphosis |
| 31  | M      | Short stature, strabismus, congenital heart disease, hypoplastic ribs, thoracic kyphosis |

**Conflict of Interest:** None declared.
P05.033.B Mapping active regulatory signals at early embryonic stage of face development

Catia Attanasio1, Marion Leleu2, Alexandre Reynaud3

1KU Leuven, Human Genetics, Leuven, Belgium; 2University of Lausanne, Bioinformatics Competence Center, Lausanne, Switzerland; 3University of Lausanne, Center for Integrative Genomics, Lausanne, Switzerland.

Background/Objectives:
While craniofacial malformations are among the most common congenital anomalies in humans at frequency 1/1600, their genetic causes remain largely unknown. Previous studies have shown that deletion or mutation of craniofacial enhancers modifies the activity of craniofacial gene(s) and affects face morphology. To reveal the complex regulatory networks that control craniofacial development and gain insights into the effect of non-coding variation, we mapped 3D interactions between craniofacial enhancers and genes.

Methods: We isolated the four facial prominences, i.e., mandible, maxillary, lateral and medial nasal prominences of E11.5 mouse embryo and performed Capture Hi-C to identify chromatin interactions at all gene promoters.

Results: We identified an average of 163’000 interactions per tissue, for a total of 327’459 unique loops. These are chiefly cis-interactions, which account for >98% of all detected interactions, with a median distance of interacting fragments of 280kb. Chromatin interactions between a gene and an intergenic space account for 77% of all detected interactions. Importantly, enrichment analyses of matched tissue and developmental stage epigenomics data (e.g. H3K27ac binding sites) show a significant enrichment of craniofacial regulatory sequences in our interacting fragments, supporting the biological significance of these craniofacial interactions’ maps. We recapitulate previously reported interactions, reveal new interesting regulatory landscape of craniofacial genes and link GWAS non-coding lead SNPs for craniofacial phenotypes to candidate target gene(s).

Conclusion: Our data provide a starting point to disentangle the gene regulatory signals controlling craniofacial development and point toward new candidate regions for determining the genetic origins of many craniofacial-associated disorders.

References:
Grants: PRO-Femmes grant (UNIL, Switzerland).
Conflict of Interest: None declared.

P05.034.C Multiple epiphyseal dysplasia: A diagnostic challenge with genetic heterogeneity

Tuğba Nur Doğar1, ekim taskıran2, gizem ürel-demir1,3, beren karaosmanoglu2, gozde imren2, güney yilmaz2, Yasemin Alanay2,3, Gulen Eda Utine1, Koray Boduroğlu2, Pelin Simsek-Kiper1

1Hacettepe university, department of pediatrics, division of pediatric genetics, ankara, Turkey; 2Hacettepe university, department of medical genetics, ankara, Turkey; 3mersin city research and training hospital, department of pediatrics, division of pediatric genetics, mersin, Turkey; 4hacettepe university, department of orthopedics, ankara, Turkey; 5Acibadem university, department of pediatrics, division of pediatric genetics, istanbul, Turkey.

Background/Objectives: Multiple epiphyseal dysplasia (MED) is a rare genetic skeletal disorder with clinical and genetic heterogeneity. MED is caused by mutations in the genes encoding important cartilage extracellular matrix proteins, enzymes, and transporter proteins including COMP, MATN3, COL9A1, COL9A2, COL9A3, CANT1 and SLC26A2. Disproportionate short stature, joint pain, and early-onset osteoarthritis are the main clinical features (1). In this study we aimed to investigate the clinical and molecular findings along with natural course of the disease in a group of patients with MED.

Methods: The molecular etiology was investigated with Sanger sequencing and whole exome sequencing. The clinical findings of mutation positive patients were reviewed.

Results: A total of 36 patients with a clinical diagnosis of MED was evaluated and the genetic etiology was revealed in 20 (55.5%); 11 were male and 9 were female. COMP (n = 12, 60%), MATN3 (n = 6, 30%) and SLC26A2 (n = 2, 10%) mutations were detected in a decreasing order. The most frequent complaints for referral were difficulty in walking, fatigue and joint pain. Proportionate short stature was detected in 9/15 of patients. Orthopedic follow-up was required in most of the patients. In patients with SLC26A9 mutations characteristic findings of double layered patella and pes equinovarus were not present.

Conclusion: MED is genetically heterogenous yet with unidentified gene mutations in the etiology. The diagnosis should be considered even in the absence of characteristic clinical findings. Multidisciplinary follow-up is mandatory.

References: 1. Dennis EP, Greenhalgh-Maychell PL, Briggs MD. Multiple epiphyseal dysplasia and related disorders: Molecular genetics, disease mechanisms, and therapeutic avenues. Dev Dyn. 2021;250(3):345-359.

Grants: Conflict of Interest: None declared.

P05.035.D Further delineating the clinical spectrum of p.Arg444Cys variant in LRPS: a case report and a systematic review of the literature

Elena Luppi1,2, Guido Zavatta2,3, Nicole Balducci4, Dario Cocciadiferro4, Uberto Pagotto2,3, Marco ser1,2

1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Medical Genetics Unit, Bologna, Italy; 2Alma Mater Studiorum University of Bologna, Department of Medical and Surgical Sciences (DIMEC), Bologna, Italy; 3IRCCS Azienda Ospedaliero-Universitaria di Bologna, Unit of Endocrinology and Prevention and Care of Diabetes, Bologna, Italy; 4IRCCS Azienda Ospedaliero-Universitaria di Bologna, Ophthalmology Unit, Bologna, Italy; 5Bambino Gesù Children’s Hospital, IRCCS, Translational Cytoendocrinology Research Unit, Rome, Italy.

Background/Objectives: The LRPS protein plays a key role in retinal vasculature development and helps regulate bone mineral density (BMD) homeostasis. Loss-of-function variants in LRPS were associated with familial exudative vitreoretinopathy (FEVR), osteoporosis-pseudoglioma syndrome and early-onset osteoporosis/osteopenia.

We describe the clinical and genetic features of a family with osteopenia as the presenting feature, displaying the p.Arg444Cys variant in LRPS.

Methods: Clinical and familial data were based on physical examination and medical records. Next-generation sequencing of an in-silico panel encompassing 20 genes correlated with bone fragility and detection of index mutation were performed with Twist Custom Panel (clinical exome-twist Bioscience) kit.

A systematic review of the p.Arg444Cys variant in LRPS, according to PRISMA guidelines, was performed.

Results: Our proband is a 36-year-old male who suffered from scoliosis and recurrent vertebral fractures even during bisphosphonate treatment. The genetic testing revealed the heterozygous variant c.1330C>T (p.Arg444Cys) in the LRPS gene (NM_002335.4), segregating in his father and his 30-year-old sister. Both of them experienced less severe osteopenia and denied visual impairment, supporting the variant’s role in reduced BMD.
Ophthalmic examination excluded signs of vitreoretinopathy in our proband and his father.

We systematically review 1384 records and we found four studies reporting the same variant. To our knowledge, the p.Arg444Cys variant was previously identified only in patients with FEVR with or without osteopenia.

**Conclusion:** We reported a patient displaying the p.Arg444Cys variant in LRP5 and familial low BMD without eye involvement, expanding the clinical spectrum of this variant. Further clinical and biochemical assessment of the other family carriers are ongoing.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P05.036.A Genetic basis of cleft lip and palate**

_Eleonoré Pairet_1,2, Peyman Ranji3, Raphaël Helaers3, Vera Lucia Gil-da-Silva-Lopes3, Benedicte Boyer4, Elin Malek Abrahimians4, Naima Deggou4, Sara Castelain4, Nicole Revencu2,4, Miikka Vikkula1

1De Duve Institute UCLouvain, Human Molecular Genetics, Woluwe-Saint-Lambert, Belgium; 2Cliniques universitaires Saint-Luc (UCLouvain), Center for Human Genetics, Bruxelles, Belgium; 3UNICAMP Universidade Estadual de Campinas, Medical Genetics, Campinas, Brazil; 4Cliniques universitaires Saint-Luc (UCLouvain), Centre labio-palatin Albert de Coninck, Bruxelles, Belgium.

**Background/Objectives:** Cleft lip and/or palate (CL/P) is the most common cranio-facial malformation often divided into syndromic CL/P (syCL/P) and non-syndromic CL/P (nsCL/P). In general, patients with syCL/P follow Mendelian inheritance, whilst those with nsCL/P are thought to have a complex etiology.

**Methods:** We analyzed 81 a priori non-syndromic index CL/P patients from a continuously growing cohort of 1400 CL/P patients using ExomeDepth. We unraveled pathogenic or likely pathogenic variants in 12 families in COL2A1, CTNND1, TP63, CHD7, PHF8, IRF6, and GHRL3. We also identified, and validated by molecular karyotyping, a deletion in TP63 in 2 siblings.

**Conclusion:** We confirmed mutations in 16 % of index cases by WES, providing an accurate diagnosis as well as the possibility of genetic counseling. In some cases, we identified pathogenic variants in syCL/P genes in a priori nsCL/P cases, demonstrating that patients with CL/P without cardinal signs or familial history of a syndrome may still carry a mutation in a gene linked to syCL/P. We also identified a new phenotype in blepharocheilodontic syndrome 2: imperforate anus. These results show that WES is an important tool for identifying the genetic cause of CL/P. For the remaining patients for which we have not identified pathogenic variants in candidate genes, we will enlarge our research towards the rest of the genes in the human genome to identify new genes for clefs.

**References:**

**Grants:** FNRS n°40000521.

**Conflict of Interest:** None declared.

**P05.036.B Novel SDR9C7 mutation causes lamellar ichthyosis in a Spanish patient**

_Carlos Gutiérrez-Cerrajero1,2,3, Nerea Gestoso-Uzal1,2,3, Daniel Salate Granado1,2, Janet Sotolongo-Ravelo1, David Diez-Castro1,2, Ana-Belén Herrera1,2,3, Ángela Hernández-Martín4, Rogelio González-Sarmiento1,2,3_

1Molecular Medicine Unit, Department of Medicine, University of Salamanca, Salamanca, Spain; 2Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain; 3Institute of Molecular and Cellular Biology of Cancer (IBMCC), Salamanca, Spain; 4Department of Dermatology, Niño Jesús Hospital, Madrid, Spain.

**Background/Objectives:** Ichthyoses are a group of diseases characterized by dry, scaly skin and a disruption of skin barrier function(1). Lamellar ichthyosis (LI) is a severe variant (1) and SDR9C7 has recently been identified as one of the causal genes for LI. To date, four mutations in SDR9C7 have been linked to LI: two in Lebanese families in 2016, one in a Japanese woman in 2016 and one in a Pakistani family in 2017. Here we present a new mutation in a Spanish patient.

**Methods:** The patient was admitted to Hospital Niño Jesús in Madrid. Genomic DNA was extracted from peripheral blood by standard phenol/chloroform protocol, mutations were found using whole-exome sequencing and validated by Sanger sequencing. Candidate mutations were analysed using the predictors SIFT and Polyphen, as well as the databases ClinVar and Varsome.

**Results:** The patient shows ichthyosis with dark scales and sporadic superficial desquamation, hyperactivity and microcephaly. Whole exome sequencing revealed the patient was homozygous for mutation c.95G>A, p.Gly32Asp in SDR9C7 and Sanger sequencing validated it. The parents were heterozygous for this mutation. This mutation was not included in ClinVar, but SIFT, Polyphen and Varsome predicted its effect to be pathogenic or likely pathogenic.

**Conclusion:** We report the discovery of a novel mutation in SDR9C7 that causes LI. This is the first mutation discovered worldwide and the first in a European patient.

**References:** 1. V. Oji et al., J. Am. Acad. Dermatol. 63, 607–641 (2010).

**Grants:** This project was funded by FIS-FEDER P120/01569.

**Conflict of Interest:** None declared.

**P05.038.C Novel RIPK4 variants cause ectodermal dysplasia and alter cell-cell adhesion**

_Chiara De Luca1, Rosanna Monetto1, Elisabetta Botti2, Manuel Belli3, Maria Grazia Palmerini1, Marco Salvatore1, Lucia Militti2, Arianna Di Daniele1, Elena Cicchetti1, Daniele Castiglia6, Francesco Brancati1, Paola Fortugno7_

1University of L’Aquila, L’Aquila, Italy; 2University of Rome Tor Vergata, Rome, Italy; 3University of L’Aquila, L’Aquila, Italy; 4Istituto superiore di sanità, Rome, Italy; 5ASL1 Abruzzo, L’Aquila, Italy; 6Istituto dermatopatia dell’Immacolata IRCCS, Rome, Italy; 7IRCCS San Raffaele Pisana, Rome, Italy.

**Background/Objectives:** Ectodermal Dysplasia Syndactyly Syndrome (EDSS1) is caused by mutations in PVR/L4 encoding nectin-4, a component of adherens junctions. EDSS1 shares cutaneous hyperkeratosis associated to syndactyly of hands and feet suggestive of EDSS1. After excluding PVR/L4 variants, exome sequencing revealed biallelic likely pathogenic variants in RIPK4, inherited from heterozygous unaffected parents. Reverse phenotyping revealed that one brother was born with “closed eyes” (ankyloblepharon) and...
oral synchiaes, surgically treated at birth, typically seen in RIPK4-related disorders. Functional studies showed that RIPK4 deficiency impaired cell adhesion organization downregulating PVR/nectin-4 expression through IRF6 transcription factor. Also, PKP1/DSG1/DSP altered expression or localization was detected and desmosomes showed abnormal morphology at electron microscopy.

**Conclusion:** This work further expands the clinical spectrum seen in RIPK4-pathies highlighting epithelial fusions as diagnostic handles for the disease. In adults, the phenotype coincides with EDSS1. Such clinical overlap is mirrored at functional level, as outlined by this newly uncovered RIPK4-IRF6-nectin-4 axis.

**References:** Online Mendelian Inheritance in Man, OMIM.

**Grants:** GR2013-02356227 and RC2020-2756828.

**Conflict of Interest:** Chiara De Luca full-time, Rosanna Monetta full-time, Elisabetta Botti full-time, Manuel Belli full-time, Maria Grazia Palmieri full-time, Marco Salvatore full-time, Lucia Militti: None declared. Arianna Di Daniele: None declared, Elena Cicchetti: None declared. Daniele Castiglia full-time, RC2020-2756828, Francesco Brancati full-time, GR2013-02356227, Paola Fortugno full-time.

**P05.039.D A unique COL2A1 phenotype as a result of partial gene deletion**

**Sena Çetin**1,2, Mustafa Gunes1,2, Filiz Ozen2, Elif Yilmaz Gulec1,2

1Istanbul Medeniyet University Medical School, Department of Medical Genetics, Istanbul, Turkey; 2Istanbul Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Department of Medical Genetics, Istanbul, Turkey.

**Background/Objectives:** Monoallelic COL2A1 (OMIM *120140) pathogenic variants cause various syndromes associated with several skeletal and ocular disorders such as achondrogenesis, chondrodysplasia, SED congenita, Spondyloepiphysial dysplasia, Kniest dysplasia, Stickler syndrome type I, avascular necrosis of the femoral head.

**Methods:** A 24-year-old male patient referred with the complaint of short stature, skeletal deformities, arthralgia in weight bearing joints, easy fatiguability and high degree myopia. The patient and his skeletal survey were evaluated and multigene panel was performed and followed by multiplex ligation-dependent probe amplification (MLPA) assay.

**Results:** The patient had acro-mesomelic short stature with short and deformed forearms, legs, hands and feet. X-ray images showed bilateral thickened and short metatarsal and metacarpal bones, bilateral short ulnas, shortened and wide phalanxes. Pelvis MRI showed bilateral avascular necrosis of the femoral heads. Ophthalmologic examination revealed retinal detachment due to high degree myopia. Heterozygous deletion between exons 51-54 was detected in MLPA performed as a result of suspected CNVs detected in exon sequencing.

**Conclusion:** To date, the majority of variants reported in COL2A1 are single nucleotide changes. Only 2 cases with COL2A1 whole exon deletion have been reported, which have the phenotype of Stickler Syndrome Type I(1). Our case is unique having a novel phenotype, which possess overlapping features of various COL2A1 related disorders with a monoallelic large deletion.

**References:** (1) Richards, Allan J et al. "Stickler syndrome and the vitreous phenotype: mutations in COL2A1 and COL11A1." Human mutation vol. 31,6 (2010): E1461-71. https://doi.org/10.1002/humu.21257.

**Grants:** None declared.

**Conflict of Interest:** None declared.

**P05.040.A Sudden cardiac death - a new phenotypic aspect of PLACK syndrome?**

Ceren Damla Durmaz1,2, Aysel Ünal2

1Hacettepe University, School of Medicine, Department of Medical Genetics, Ankara, Turkey; 2University of Health Sciences, Gazi Yasargil Training and Research Hospital, Department of Medical Genetics, Diyarbakir, Turkey.

**Background/Objectives:** PLACK syndrome (Peeling skin, Leukonychia, Acral punctate keratoses, Cheilitis and Knuckle pads syndrome, OMIM 616295) is an extremely rare genodermatosi caused by biallelic mutations in CAST. Here, we report a previously unreported CAST variant in a family with PLACK syndrome which may reveal an unexplored aspect of this syndrome for the first time: the sudden cardiac death (SCD).

**Methods:** Whole exome sequencing (WES) was employed to explore the molecular etiology of a dermatological phenotype comprised of punctate palmpoplantar keratoderma, angular cheilitis and hyperkeratosis of the knees in two sisters (4 and 8 years old).

**Results:** A novel homozygous nonsense mutation (NM_001042440.5: c.1759C>T; p.Gln587Ter) in CAST was identified in both sisters, which segregated with the dermatological phenotype in family. During the follow-up, dilated cardiomyopathy became evident in the proband and resulted in SCD similar to her two affected brothers who died suddenly at 3 and 4 years. WES did not reveal any other pathogenic variants that may explain cardiomyopathy/sudden cardiac death.

**Conclusion:** CAST encodes calpastatin, an endogenous inhibitor of calpain. Calpain responds to increased Ca\(^{2+}\) in myocardial cells, leading to myocyte death by cleaving structural and functional proteins of myocytes during cardiac ischemia, which is inhibited by calpastatin. Although SCD/cardiomyopathy is not a known feature present in the seven reported families with PLACK syndrome, considering the function of CAST in myocardium, SCD/cardiomyopathy may be a hidden phenotypic feature of the syndrome. Whether this phenotype is specific to the variant identified here is yet to be explored.

**References:** PMID:24333421.

**Grants:** None declared.

**Conflict of Interest:** None declared.

**P05.041.B Identification of candidate mutations related to adolescent idiopathic scoliosis in the Caucasian population - focusing on post-zygotic alternations**

Monika Horbacz1, Marek Roklowski2, Marcin Ceynowa2, Rafal Pankowski2, Arkadiusz Piotrowski1

1Medical University of Gdansk, International Research Agenda 3P-Medical Laboratory, Gdansk, Poland; 2Medical University of Gdansk, Department of Orthopedic Surgery, Gdansk, Poland.

**Background/Objectives:** Adolescent idiopathic scoliosis is a multidimensional and multicausal spine deformity with frequency from 1-4 % in general population. Most studies focused on germline mutation analysis, omitting post-zygotic variation leading to pathological effects in organisms. Post-zygotic changes pop up in the human body de novo during a lifetime and usually is not inherited. “Benign” diseases research shows that a combination of germline and somatic variation that explore in the human body early in a lifetime may negatively impact and speed up the manifestation of the disease.

**Methods:** Whole-exome sequencing were performed to determine scoliosis-related genes in the Caucasian population of 32 adolescent patients with severe scoliosis, with a significant focus on mosaic variations. Types of biological material used: blood and articular processes.

**Results:** We identified recurrent missense germline and somatic variants located in OBSCN, NEB and other genes.
Conclusion: Mentioned genes encode proteins that are fundamental components in the assembly and functioning of vertebrate striated muscles. Germline and somatic variations coexistence across them might cause muscle weakness and correlate with scoliosis manifestation and its advanced level.

References: Cheng, J. C. et al. Nat. Rev. Dis. Prim. 1, (2015).
Forsberg, L. A. et al. Nat. Rev. Genet. 18, 128–142 (2017).
Mustjoki, S. et al. N. Engl. J. Med. 384, 2039–2052 (2021).
Murphy, S. et al. Expert Rev. Proteomics 16, 241–256 (2019).

Grants: Project POWR.03.05.00-00-2082/18 co-financed by the European Union through the European Social Fund under the Operational Programme Knowledge Education Development 2014–2020.

Conflict of Interest: None declared.

P05.042.C A case with spondyloenchondrodysplasia with immune dysregulation (SPENCDI) caused by a novel missense ACP5 mutation

nuray azzurk1, Dilek Uludag Alkaya2, Gokcen Karamik1, banu nur1, Beyhan Tüysüz2, ercan mihci1

1Akdeniz University School of Medicine, Pediatric Genetics, Antalya, Turkey; 2Istanbul University Cerrahpasa Faculty of Medicine, Pediatric Genetics, Istanbul, Turkey.

Background/Objectives: Spondyloenchondrodysplasia with immune dysregulation (SPENCDI) is a rare autosomal recessive immunoosseous dysplasia, characterized by enchondromatous metaphyseal and vertebral lesions with immune dysfunction and neurologic involvement. SPENCDI is caused by biallelic mutations in the ACP5 gene which encodes tartrate-resistant acid phosphatase, a protein functioning in the type I interferon pathway. Here, we present a case with a novel variant in the ACP5 gene.

Methods: The patient is a 7-year-old male who initially presented with short stature and gait disturbance at the age of 5. He is the first child of consanguineous parents born at term. At the age of 2, he presented to hospital with toe walking, the neurological examination exhibit spasticity and hyperreflexia. Brain Spinal MRI and EMG were normal. At the age of 5, his height was 95 cm (~3.2 SD), skeletal survey revealed metaphyseal irregularities and platyspondyly. Cranial CT revealed calcifications in the basal ganglia. He was hospitalized for autoimmune hemolytic anemia at age 7. Bone marrow aspiration, autoimmune and immunological screenings were normal.

Results: Whole-exome sequencing analysis displayed a homozygous missense variant of c.389G>T (p.Trp130Leu) in the ACP5 gene, later confirmed by sanger sequencing. It was predicted as a "pathogenic" change conforming ACMG criteria in VARSOME database and wasn't reported in the literature. Parents were found to be heterozygous carriers of the variant.

Conclusion: SPENCDI is a clinically heterogeneous disease with distinctive skeletal findings and pleiotropic extra-osseous phenotype. We aimed to raise awareness of SPENCDI, which has multisystem involvement and a significant risk of morbidity and mortality.

References: https://doi.org/10.1007/s10875-016-0252-y.

Grants: None.

Conflict of Interest: None declared.

P05.043.D Identification of effector cell types for orofacial clefting through integration of murine single-cell expression data and GWAS results

Anna Siewert1, Julia Welzenbach1, Benedikt Reiz2, Elisabeth Mangold1, Henning Dickten1, Kerstin Ludwig1

1Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Genomics, Bonn, Germany; 2FASTGenomics, Comma Soft AG, Bonn, Germany.

Background/Objectives: Orofacial clefting (OFC) is among the most common human birth defects. Although about 60 risk loci have been identified to date, the functional consequences of the identified variants are still largely unknown, as are the cell types in which the candidate genes exhibit their effects. We here analyzed the gene expression patterns of OFC candidate genes in recently published single-cell RNA sequencing (scRNA-seq) data from embryonic mice.

Methods: We re-analyzed scRNA-seq data from the mouse face (~8,000 cells at E11.5[1] and whole embryos (~1.4 million cells E9.5–E13.5)[2] using Seurat v4 and scCATCH. The analyses were reproducibly run on the FASTGenomics platform.

Results: We observed predominant expression of OFC candidate genes in epithelial cells (e.g. Irf6, Grhl3, Tafap2a), and in a combination of chondrocytes, osteoblasts and progenitor cells of connective tissue, jaw and teeth (e.g. Fgf1r, Fgf10, Mmp16). Furthermore, we found that Irf6, Grhl3 and Tafap2a are co-expressed in an epithelial cell sub-population and additional OFC candidate genes are specifically expressed in Irf6+ epithelial cells.

Conclusion: Epithelial cells are involved in processes of proliferation and patterning of the mesenchyme and are therefore one of the crucial cell types during craniofacial development. Our results further suggest a distinct epithelial cell sub-population in which OFC candidate genes are active during this developmental timeframe. We will follow this up by studying a more systematic enrichment of OFC candidate genes on a cell-type and single-cell level using single-cell disease relevance scores[3].

References: [1] Li et. al 2019. [2] Cao et. al 2019. [3] Zhang et. al 2021.

Grants: None.

Conflict of Interest: Anna Siewert: None declared, Julia Welzenbach: None declared, Benedikt Reiz Comma Soft AG, Elisabeth Mangold: None declared, Henning Dickten Comma Soft AG, Kerstin Ludwig: None declared.

P05.044.A Exploring genotype-phenotype correlations, penetrance and expressivity of HOXD13 associated synpolydactyly in a cohort of 17 families with HOXD13 variants

Annika Gottschalk1, Henrike Szczakiel2,3, Wiebke Hülsemann4, Sarina Schwartzmann1, Angela Abad Perez5, Malte Spielmann6, Stefan Mundlos1,2, Denise Horn1, Martin Atta Mensah1,7

1Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institut für Medizinische Genetik und Humangenetik, Berlin, Germany; 2Max Planck Institute for Molecular Genetics, RG Development & Disease, Berlin, Germany; 3Berlin Institute of Health at Charité – Universitätsmedizin Berlin, BfH Biomedical Innovation Academy, BfH Charité Junior Clinician Scientist Program, Berlin, Germany; 4Kinderklinik, Kinderklinikum Wilhelmstift, Handchirurgie, Hamburg, Germany; 5Universität zu Lübeck, Institut für Humangenetik Lübeck, Lübeck, Germany; 6Max Planck Institute for Molecular Genetics, Human Molecular Genomics Group, Berlin, Germany; 7Berlin Institute of Health at Charité – Universitätsmedizin Berlin, BfH Biomedical Innovation Academy, BfH Charité Digital Clinician Scientist Program, Berlin, Germany.

Background/Objectives: The homeobox transcription factor HOXD13 is an important regulator of embryonic limb development. Mutations leading to haploinsufficiency of HOXD13 typically expand a polyalanine repeat in exon 1 – cause synpolydactyly.
type 1. How these contribute to genotype-phenotype correlations, penetrance and expressivity of HOXD13 associated synpolydactyly remains mostly illusory. We present a large cohort of 43 affected individuals from 17 families with HOXD13 variants.

**Methods:** 41 patients with synpolydactyly suggestive of HOXD13 haploinsufficiency were selected for analysis of HOXD13 (NM_000523.4) by Sanger sequencing, microsatellite analysis and next generation sequencing.

**Results:** We identified 15 causative variants and 2 variants of uncertain significance in HOXD13. The most frequent variants (12/17) were repeat expansions of the alanine stretch (5 expansions by 8 and 7 by 7 alanines). Additionally, we identified 3 (likely) pathogenic variants (one frameshift, one stop-gain, one single amino acid deletion) and 2 missense variants of uncertain significance. Pedigree and/or segregation analysis of these index patients revealed a total of 43 affected individuals. The observed phenotypes ranged from unaffected carriers to severe osseous synpolydactyly with pheno- typic heterogeneity occurring not only across but also within families and asymmetrically affected individuals. We could also corroborate a previously suggested genotype-phenotype correlation of longer alanine repeat expansions with more severe phenotypes.

**Conclusion:** In a large cohort of 43 affected individuals from 17 families with HOXD13-associated synpolydactyly we could identify variable penetrance and expressivity of HOXD13 variants and confirm a positive correlation of alanine repeat expansion length and phenotypic severity.

References:

Grants:

Conflict of Interest: None declared.

**P05.045.B Incontinentia pigmenti female with the NEMOdel4-10 deletion in the IKBKG/NEMO gene in a mosaic form**

**Ezio Spinosi**¹, Michele Salvia¹, Carmela Casale¹, Alessandra Pescatore¹, Annalaura Torella²-³, Giulio Piluso², Vincenzo Nigro²-³, Vincenzo Piccolo⁴, Andrea Dicociatti⁴, Maya El Hachem⁵, Matilde Valeria Ursini¹, Francesca Fusco¹

¹Institute of Genetics and Biophysics “Adriano Buzzati-Traverso” IGB-CN, Naples, Italy; ²Dipartimento di Medicina di Precisione, Università della Campania “Luigi Vanvitelli”, Naples, Italy; ³Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy; ⁴Dermatology Unit, University of Campania Luigi Vanvitelli, Naples, Italy; ⁵Dermatology Unit, Bambino Gesù. Children’s Hospital—IRCCS, Rome, Italy.

**Background/Objectives:** Incontinentia pigmenti (IP; OMIM#308300) is an X-linked dominant disease, generally lethal in male, caused by mutations in IKBKG/NEMO gene, essential for NF-kB activation. The IP phenotype is characterized by typical skin lesions and by neuroectodermal defects that contribute to a wide variability of severity of disease.

Here we report the case of IP female with neurological and ocular impairment, carrying the recurrent deletion in NEMO/IKBKG gene as a somatic mutation. Moreover, the patient showed also a de novo pathogenic variant c.1708_1709del, p.Ser570fs*27 in MED13L gene.

**Methods:** An IP female patient with severe form of IP, confirmed by skin biopsy, was analyzed in the IP locus on DNA from blood and the presence of NEMOdel4-10 was detected by long- range PCR and quantified by QPCR.

**Results:** The IP locus analysis revealed the presence of de novo NEMOdel4-10 deletion and excluded the presence of the risk alleles for IP (MER67dup, NEMOPdel). Somatic mosaicism was strongly supported by quantitative analysis of the ratio of allele mutated versus wild-type allele in genomic DNA from blood. Consistent with somatic mosaicism, the sample of patient had lower ratios of mutant versus wild-type allele compared to the fully heterozygote IP female control.

**Conclusion:** Postzygotic genetic mosaics for the IKBKG/NEMO mutation are reported only in IP male, indeed the IP phenotype is almost entirely restricted to females heterozygous for IKBKG/ NEMO gene mutation. This is the first report demonstrating mosaicism as a cause of IP in female. To note that the contribute of constitutive alteration in MED13L gene (NM_015335.5: c.1708_1709del) will be discussed.

References:

Grants:

Conflict of Interest: None declared.
Background/Objectives: Skeletal dysplasia are heterogeneous group of genetic disorders affecting skeletal development. Progress in molecular genetic testing and up-to-date knowledge from pre-clinical trials have been leading to novel therapeutic approaches for genetic skeletal disorders despite the challenges of drug development in rare diseases. Timely diagnosis and patients’ information availability is crucial for early and proper application of new treatment options.

Methods: We systematically analyzed data from the internal electronic database of our genetic service in order to create an internal sub-register of patients with genetic skeletal disorders.

Results: In the past six years, 137 patients with suspected genetic skeletal disorders have been referred to the Department of Clinical Genetics, University Children’s Hospital in Belgrade. Next generation sequencing was performed for 64 patients with suspected heterogeneous skeletal dysplasia, among them there are confirmed cases of very rare or severe skeletal diseases. Also, single gene sequencing or specific mutation analysis was performed for 27 patients according to clinical suspicion. Other patients are clinically monitored or their proposed genetic testing is in progress. We categorized all patients according to the latest classification of genetic skeletal disorders. The FGF3 chondrodysplasia group has 19 pediatric patients, with three familial cases of achondroplasia.

Conclusion: The Internal Skeletal Dysplasia Registry should allow for better monitoring of data and visibility results of genetic testing for these patients so that they are timely included specific treatments in the context of personalised medicine in the future.

References: Non applicable.

Grants: Non applicable.

Conflict of Interest: None declared.

P05.049.B A progeroid syndrome with severe osteogenesis imperfecta segregates with an intronic TAPT1 homozygous variant that creates a knockout allele

nasrin sadat nabavizadeh1,2,3, Ankkatrina Bressin1, PohHui Chia1, Ricardo Moreno Traspos1, Nathalie Escande-Bellard1,2, Carine Bonnard1, Zoheir Hotjar1, Scott Drutman5, Jean-Laurent Casanova5,6,7, Mohammad Shboul8, Andreas Mayor1, Bruno Reversade1,2,9

1Laboratory of Human Genetics & Therapeutics, Genome Institute of Singapore, A*STAR, Singapore., Singapore, Singapore; 2Division of Genetics, Department of Cell and Molecular Biology & Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran; 3Medical Genetics Department, Koç University School of Medicine, Istanbul, Turkey; 4Max Planck Institute for Molecular Genetics, Berlin, Germany; 5St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, New York, United States; 6Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France; 7University of Paris, Imagine Institute, Paris, France; 8Department of Medical Laboratory Sciences, Jordan University of Science and Technology, Irbid, Jordan., Irbid, Jordan; 9Institute of Molecular and Cell Biology, A*STAR, 61 Biopolis Drive, Proteos, Singapore., Singapore, Singapore.

Background/Objectives: Exome sequencing has introduced a paradigm shift for the identification of germline variations responsible for Mendelian diseases. However, non-coding regions, which make up 98% of the genome, contain structural, regulatory, and transcribed information that cannot be captured. The lack of functional annotation for intronic and intergenic variants makes RNA sequencing a powerful companion diagnostic.

Methods: Here, we identified five patients with a recessive Osteogenesis Imperfecta (OI) syndrome characterized by bone defects and neonatal progeria. We integrated results obtained from homozygosity mapping, genome and RNA sequencing to find the causative gene.

Results: We delineated a non-coding TAPT1 mutation (c.1237-52G>A) that segregated with the disease. This private mutation, which is predicted to serve as an alternative splicing branchpoint, results in exon 12 skipping and creates a protein-null allele. Functional studies performed on patients’ fibroblasts support the notion that 1) TAPT1 resides in the ER/Golgi, 2) it is not an essential receptor for human Cytomegalovirus (HCMV) and 3) controls pathways involved in collagen and extracellular matrix biology.

Conclusion: Overall, our work highlights the power of transcriptomic approaches in identifying genetic defects as well as in illuminating the molecular mechanisms and underlying dysregulated pathways in human diseases.

References:
Grants: This work was supported by a Strategic Positioning Fund on Genetic Orphan Diseases (GODAFIT) and a Use-Inspired Basic Research (UIBR) grant from Agency for Science, Technology and Research (A*STAR) in Singapore to B.R. This work was also funded by the Max Planck Society (to A.M.) and the Deutsche Forschungsgemeinschaft (DFG, grant 148415292 to A. M.)

Conflict of Interest: nasrin sadat nabi vazadeh: None declared, Annkatrin Bressin: None declared, Poh Hui Chia: None declared, Ricardo Moreno Traspas: None declared, Nathalie Escande-Beillard: None declared, Carine Bonnard: None declared, Zohreh Hojati: None declared, Scott Druutman: None declared, Jean-Laurent Casanova: None declared, mohammad Shboul: None declared, Andreas mayor: None declared, Bruno Reversade Principle investigator.

P06

CARDIOVASCULAR DISORDERS

P06.001.C Diagnostic yield of a NGS panel in a Brugada syndrome cohort

Eline Simons1, Ewa Sielionwczyk1, Maarik Bastiaansen1, Ilyas Louarroudi1, Bart Loeyt3, Maarik Aloets1

1University of Antwerp, Center of Medical Genetics, Edegem, Belgium.

Background/Objectives: Brugada syndrome (BrS) is a rare inherited cardiac arrhythmia disorder affecting 1/2000 individuals. Its diagnosis requires presence of a spontaneous or sodium channel blocker induced ST-segment elevation on an electrocardiogram (ECG). BrS patients are at risk for ventricular fibrillations which could lead to sudden cardiac death. In general, only for 25-30% of the patients a genetic diagnosis can be established in one of the BrS associated genes, of which 20-25% carry a variant in the SCN5A gene.

Methods: We collected clinical history, ECG parameters and genetic results of 294 BrS patients (61% male) screened with a diagnostic panel for inherited primary electrical disorders covering initially 51 and in a later version 60 genes.

Results: In total, 43.5% of patients carried a variant of uncertain significance (VUS, class 3; n = 102) or (likely) pathogenic variant (class 4 and 5; n = 26) following the ACMG guidelines. Most of the class 4/5 variants are found in the SCN5A gene (23/26), whereas the remainder were identified in KCNQ1/LMNA/SCN2B. 43.9% of patients had a Shangai score above 3.5 (definite BrS) of which 14.7% carried a class 4/5 variant. Only 4.2% of patients with a Shangai score between 2 and 3 carried a (likely) pathogenic variant. Of the 22.4% of patients with a familial history, 20% carried a class 4/5 variant.

Conclusion: The overall diagnostic yield in our cohort is 8.8%, increasing to 15% in BrS patients with a definite diagnosis, or 20% in clear familial patients, which is slightly lower than reported in literature.

References:

Grants: Research Foundation Flanders.

Conflict of Interest: None declared.

P06.002.D Clinical characteristics, genetic findings and arrhythmic outcomes of patients with catecholaminergic polymorphic ventricular tachycardia across the globe

Danny Radford1,2, Emma Coakley-Youngs1,2, Meltem Altinsoy1,2,3, sharen lee2, elham mahmoudi2,4, Levent pay2, Göksel Çinier2, pawel matusik2,7, George Bazoukis2,8, Sebastian Garcia-Zamora2, Jeremy Man Ho Hui2, Yan Hiu Athena Lee2, Konstantinos Letsas8, Ziliang

Background/Objectives: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare cardiac ion channelopathy. This study examined the clinical characteristics, genetic basis and arrhythmic outcomes of CPVT patients globally.

Methods: PubMed was systematically searched for case reports or series on CPVT. Clinical characteristics, genetic findings and primary outcome of spontaneous ventricular tachycardia/ventricular fibrillation (VT/VF) were analysed.

Results: A total of 442 patients (mean presentation age: 15±12-years-old, 52% male) were included. On presentation, 368 patients (83%) were initially symptomatic and 214 (48%) had VT. PVCs were present in 356 patients (81%) and WT was present in 352 patients (80%). Genetic tests were performed on 257 (58%) patients with a yield of 98%. RyR2, CASQ2, TERCL and KCNJ2 mutations were found in 232 (89%), 27 (10%), 2 (0.8%) and 1 (0.4%) patients, respectively. Out of 336 patients, 302 (90%) were prescribed beta-blockers, 88 (29%) were prescribed flecainide, 82 (27%) were prescribed propranolol, 26 (9%) were prescribed atenolol, 24 (8%) were prescribed verapamil, 4 (1%) were prescribed propafenone. Out of 442, implantable-cardioverter defibrillator (ICD) were inserted for 120 (27%) patients and sympathectomy was performed on 32 (7%) of patients. On follow-up, 73 patients (38%) had VT/VF.

Conclusion: This is the first systematic review and meta-analysis of CPVT cases globally. Most patients had symptoms on initial presentation and approximately half had VT as the presenting complaint. RyR2 mutations accounts for the majority (83%) of the CPVT cases, followed by CASQ2 (10%), then TERCL and KCNJ2 mutations (1%). Most patients received beta-blocker therapy. 7% had sympathectomy and 27% had ICDs implanted.

References: None.

Grants: None.

Conflict of Interest: None declared.

P06.003.A Association of the genetic variation in the long non-coding RNA FENDRR with the risk of developing Hypertrophic Cardiomyopathy

Elías Cuesta Llovona1, Rebeca Lorca1, Isael David Duarte Herrera1, Belén Alonso1, Sara Iglesias Alvarez1, Jose Julian Rodriguez Reguero1, Elecer Coto1, Juan Gómez1

1Central University Hospital of Asturias, Oviedo, Spain.

Background/Objectives: Hypertrophic Cardiomyopathy (HCM) is the most common hereditary heart disease. However, in around 40-60% of cases no pathogenic variants are identified in the exome. Studies suggest that there are other genetic factors that
could explain part of the risk of developing HCM. A group of candidate genes to be evaluated are those that encode lncRNAs. The aim of this study was to evaluate the possible association of lncRNAs with the risk of developing HCM.

Methods: We sequence a total of 238 index cases of HCM (58 ± 16 years old, 63% male) and 212 controls (70 ± 7 years old; 45% male) through a panel of 10 lncRNAs coding genes that have been associated with cardiovascular disease (H19, KCNQ1OT1, MYH7, CARMEN, FENDRR, TINCR, ANRIL, MIAT, PTMD1, MALAT1) with semiconductor chips and the Ion GeneStudio S5 Sequencer (Ion Torrent). The Chi-square test were used to compare allelic frequencies in the polymorphisms identified.

Results: We observed that FENDRR rs39527 A>G, G, rs39529 G>C and rs40384 T>C polymorphisms were significantly associated with the risk of developing HCM in our cohort (0.006 patients vs 0.03 controls; p = 0.0274; OR: 0.2381; IC: 0.0660-0.8594).

Conclusion: In summary, this study identified the significant protective effect of the rare allele in the FENDRR rs29527, rs39529 and rs40384 polymorphisms on this disease in a Spanish population. These variants could involve a change in the structure of FENDRR that would modify the regulation of gene expression controlled by this lncRNA. However, the functional relevance of this change requires experimental validation.

References:

Grants: FIS PI17/00648.

Conflict of Interest: None declared.

P06.005.C Pathogenic variants are distributed among different genes when comparing adult LQTS patients to infants

Alexander Moscu-Gregor1, Christoph Marshall1, Sabine Lippert1, Sebastian Eck1, Konstanze Hörntagel1, Imma Rost1

1MVZ Martinsried GmbH, Medicover Group, Martinsried, Germany.

Background/Objectives: Congenital long-QT-syndrome (LQTS) is a rare heart disease characterized by a prolonged ventricular repolarization leading to a QTC of more than 460 ms. Patients are usually between 5 and 18 years old when diagnosed. However, little is known about the genetic background of severe LQTS in the very young (especially neonates/infants). This raises the question which variants in which genes are responsible for the early manifestation.

Methods: Between January 2017 and December 2021, 1391 index patients with suspected LQTS were referred to our laboratory for genetic testing. All the genes for which there was at least limited evidence of association with LQTS were examined. The patients were sorted by age (neonate/infant/toddler/>4 years), and it was determined which genes were affected in each age group.

Results: Of the 36 toddlers examined, 8 were confirmed genetically positive. All 8 patients carried variants exclusively in the KCNQ1 gene, indicating that this gene is overrepresented when compared to the 1271 older (>4 years) patients (∼45% of positive cases). Additionally, pathogenic variants of one gene were detected in neonates or infants with severe LQTS only: CACNA1C.

Conclusion: In the very young patients (<4 years), the variants are distributed among different genes than in adults. This can be used for variant classification according to ACMG/ACGS guidelines. Criterion PP4, which refers to phenotype specificity, could be assigned to CACNA1C variants if a severe LQTS phenotype is present in a neonate/infant. Moreover, PP4 could be modified to a moderate or strong pathogenic criterion for KCNQ1 variants detected in toddlers.

References:

Conflicts of Interest: None declared.

P06.006.D Heart transcriptome profile of a novel transgenic mouse model for arrhythmogenic cardiomyopathy

Martina Calore1, Sofia Compagna2, Sara Vencato2, Robin Colpaert1, Claudia Sacchetti1, Alessandra Lorenzon2, Tommaso Becchi2, Nicola Facchinello3, Chiara Romualdi4, Leon de Wind5, Paola Braghetta1, Libero Vitiello5, Alessandra Rampazzo2

1Maastricht University, Department of Molecular Genetics, Maastricht University, The Netherlands, Maastricht, Netherlands; 2Padova University, Department of Biology, University of Padova, Italy; Padova, Italy; 3Padova University, Department of Molecular Medicine, University of Padova, Italy, Padova, Italy.

Background/Objectives: Arrhythmogenic cardiomyopathy (ACM) is one of the most commonly inherited cardiomyopathies, characterized by the progressive substitution of the myocardium with fibrofatty tissue (1). Clinically, ACM is characterized by ventricular arrhythmias, syncope, and sudden cardiac death and shows wide phenotypic heterogeneity (1). Of the known disease genes, desmosomal proteins plakophilin-2 (PKP2), desmoplakin (DSP), and desmoglein-2 (DSG2) are most commonly mutated (2). To study the pathogenic mechanisms of ACM, we generated a novel mouse model for the disease.

Methods: We generated transgenic mice overexpressing desmoglein-2 carrying the p.G100R mutation (TgG) found in an affected patient. To establish the transcriptomic ACM signature, we performed RNA seq on cardiac samples from 6 month-old TgG and control mice.

Results: TgG mice present several of the clinical features of ACM, such as fibrous replacement, and increased distance between cardiomyocyte membranes. Importantly though, we did not detect the same reductions of the canonical Wnt/b-catenin signalling pathway reported in other ACM models, indicating that additional pathways must be perturbed in TgG. Enrichment analysis and network construction identified upregulation of immune- and extracellular matrix-related processes, as well as epigenetic mechanisms, such as histone acetyltransferase activity. By contrast, downregulated processes included the MAPK and TGF-β pathways.

Conclusion: Collectively, these findings identified numerous processes potentially altered in TgG mice that could pave the way for further studies focused on ACM pathogenic mechanisms.

References: (1) Thieme et al., N Engl J Med (1988) 318:129–131988. (2) Calore et al., Cell Tissue Res (2015)360:491–500.

Grants: Hartstichting DCVA2017-2018ARENA-PRIME, Beat the beat donation.

Conflict of Interest: None declared.

P06.007.A Identification of rare genetic variants associated with stroke outcome

Estefanía Alcaide1,2,3,4, Nuria Martínez-Gil1,2,3,4, Georgia Escaramiz4,6, Uxue Lazcano7, Marina Mola-Caminal1, Cristófol Vives-Bauza8, Jordi Jiménez6, Israel Fernández-Cadenas9, Susanna Balcells1,2,3,4, Raquel Rabionet1,2,3,4

1Universitat de Barcelona, Genètica, Microbiologia i Estadística, Barcelona, Spain; 2Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Spain; 3Institut de Recerca Sant Joan de Déu (IRSJD), Barcelona, Spain; 4CIBERER, Barcelona, Spain; 5CIBERER-ESP, Barcelona, Spain; 6Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain; 7Hospital Del Mar, Servei de Neurologia, Barcelona, Spain; 8Universitat de les Illes Balears, Biologia, Palma de

Conflict of Interest: None declared.
Mallorca, Spain; 5Hospital de la Santa Creu i de Sant Pau, Barcelona, Spain.

Background/Objectives: Stroke is a cerebrovascular disease that may lead to an important adult disability. There is a large variability in the functional outcome after a stroke, which may be in part regulated by genetic factors. With the aim to further investigate the genetics of stroke outcome, we performed exome sequencing followed by targeted resequencing in a set of 702 patients.

Methods: A pilot study was performed with 90 exomes of extreme stroke recovery scores (modified Rankin Scale (mRS) at 90 days 0-1 vs 3-5) and target genes involved in functional outcome were selected. 702 samples were sequenced by targeted next-generation sequencing using a capture assay that included these targets along with selected regions based on previous GWAS results. Here, we performed continuous (mRS 0-6) and dichotomic (mRS 0-1 vs 3-5 and 0-1 vs 3-6) analyses with Bayesian-based rare variant association (BATI) adjusting for multiple testing and selecting rare variants with a CADD score >20.

Results: These analyses highlighted coding rare variants in CNTN5 and VNN2 genes. Coding variants in VNN2, a protein that may act in cell adhesion and migration of neutrophils, were significantly enriched in cases with better outcome. In contrast, rare variants in CNTN5, a protein involved in synaptogenesis, are associated with a poor outcome.

Conclusion: CNTN5 and VNN2 appear to be linked to stroke outcome. Further functional experiments are needed to understand how mutations in these genes lead to differences in recovery.

References: 1Susak et al., PLoS Comput Biol. 2021 17(2):e1007784.

Grants: “La Fundación de la Marató de TV3” (Reg.70/307_Proj.201726).

Conflict of Interest: None declared.

P06.008.C Penetrance and disease expression of (likely) pathogenic variants associated with inherited cardiomyopathies in the general population

Mimount Bourfiss1, Marion van Vugt1, Abdulrahman Alasiri1, Bram Rujsink1,2, Jessica Van Setten1, Amand Schmidt1,2, Dennis Dooijes4, Esther Puyol-Antón1, Birgitta Velthuis1, Peter van Tintelen1, Anneline te Riele1,2, Annette Baas1, Folkert Asselbergs1,3,4

1University Medical Center Utrecht, Department of Cardiology, Utrecht, Netherlands; 2King’s College London, London, United Kingdom; 3University College London, London, United Kingdom; 4University Medical Center Utrecht, Department of Genetics, Utrecht, Netherlands; 5University Medical Center Utrecht, Department of Radiology, Utrecht, Netherlands; 6Netherlands Heart Institute, Utrecht, Netherlands.

Background/Objectives: (Likely) pathogenic variants associated with arrhythmogenic cardiomyopathy (ACM), dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM) are recommended to be reported as secondary findings in genome sequencing studies. This provides opportunities for early diagnosis, but also fuels uncertainty in variant carriers (G+), since disease penetrance is incomplete. We assessed the prevalence and disease expression of G+ in the general population.

Methods: We calculated the prevalence of (likely) pathogenic variants associated with ACM, DCM and/or HCM extracted from two databases in the UK Biobank. Furthermore, we analysed the frequency of cardiomyopathy/heart failure diagnosis in individuals carrying these variants (G+). In undiagnosed individuals, we analysed early signs of disease expression.

Results: We found a prevalence of 1:578, 1:251 and 1:149 for (likely) pathogenic variants associated with ACM, DCM and HCM respectively. Compared to controls, cardiovascular mortality was higher in DCM G+, but similar in ACM and HCM G+. More specifically, cardiomyopathy or heart failure diagnosis were more frequent in DCM G+ and HCM G+, but comparable in ACM G+. In contrast, ACM G+ had more ventricular arrhythmias. Left ventricular ejection fraction was reduced in undiagnosed DCM G+ individuals.

Conclusion: In the general population, (likely) pathogenic variants associated with ACM, DCM or HCM are not uncommon. Although G+ have increased mortality and morbidity, disease expression in these carriers from the general population remains low (1.2-4%). Decisions on application of cascade screening and frequency of cardiological examination should be based on multiple factors, such as the gene, variant type and family history.

References:

Grants: Conflict of Interest: Mimount Bourfiss: None declared, Marion van Vugt: None declared, Abdulrahman Alasiri: None declared, Bram Rujsink: None declared, Jessica Van Setten: None declared, Amand Schmidt Servier and Pfizer funding for unrelated work, Dennis Dooijes: None declared, Esther Puyol-Antón: None declared, Birgitta Velthuis: None declared, Peter van Tintelen: None declared, Anneline te Riele: None declared, Annette Baas: None declared, Folkert Asselbergs: None declared.

P06.009.CUsing genotyping and whole-exome sequencing data to improve genetic risk prediction in deep venous thrombosis

Valeria Lo Faro1, Therese Johansson1,2, Åsa Johansson1

1Uppsala University, Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala, Sweden; 2Womher, Uppsala University, Centre for Women’s Mental Health during the Reproductive Lifespan, Uppsala, Sweden.

Background/Objectives: Deep venous thrombosis (DVT) is the formation of blood clots in the deep veins. Blood clots traveling to the lung can cause organ damage or sudden death. More than 60% of DVT risk is influenced by genetic factors, such as the Leiden mutation in F5 (FVL). Characterizing the genetic contribution and stratifying individuals based on their genetic makeup can favourably impact risk prediction.

Methods: We performed a genome-wide association study and constructed a polygenic risk score (PRS) in the 60% (N = 284,591) of the UK Biobank cohort. The remaining 40% (N = 198,362) was employed to evaluate the PRS, and to perform gene-based test on exome-sequencing data to investigate effects by rare variants.

Results: We identified and replicated a new variant (rs11604583) near TRIM51 gene, and a rare variant (rs187725533), associated with 2.2-fold higher risk of DVT, in CREB3L1 gene. The top PRS decile was associated with 3.4-fold risk of DVT, an effect that was still 2.3-fold, when excluding FVL carriers. Cumulative risk of DVT at the age of 70 years for FVL carriers in the top PRS decile is of 10%, contraposed to 5% for non-carriers.

Conclusion: We showed that common and rare variants influence DVT risk, and that the PRS improve risk prediction on top of FVL. This suggests that individuals classified with high PRS score could benefit from early genetic screening.

References: Stone et al. “Deep vein thrombosis: pathogenesis, diagnosis, and medical management.” Cardiovasc Diagn Ther (2017).

Grants: This work was funded by the Swedish Heart-Lung foundation (nr.20200687).

Conflict of Interest: None declared.
P06.010.D Clinical utility of genetic testing in pediatric patients with polymorphic ventricular tachycardia

Magdalena Pełć1, Dorota Jurkiewicz1, Paweł Kowalski1, Agnieszka Madej-Pilarczyk1, Joanna Kosińska2, Małgorzata Rydzanicka3, Piotr Stawiński1, Maria Posadowska4, Katarzyna Pregowska5, Monika Brzezińska6, Albizia Ciara1, Dorota Piektowska-Abramczuk1, Paulina Halat-Wolska1, Beata Chalupeczyńska5, Marzena Gawlik4, Dorota Siestrzykowska1, Dorota Wicher1, Krystyna Chrzanska1, Rafał Płoski1, Katarzyna Bieganowska4

1The Children’s Memorial Health Institute, Department of Medical Genetics, Warsaw, Poland; 2Warsaw Medical University, Department of Medical Genetics, Warsaw, Poland; 3Institute of Physiology and Pathology of Hearing, Department of Genetics, Warsaw, Poland; 4The Children’s Memorial Health Institute, Department of Cardiology, Warsaw, Poland.

Background/Objectives: Primary electrical disorders affect the myocyte transmembrane ion channels and predispose to malignant arrhythmias, including polymorphic ventricular tachycardia (PVT), which is rare in children. Genetically determined channelopathies, such as catecholaminergic PVT (CPVT), long/short QT (LQTS/SQTS) and Brugada syndromes, may be the cause of these arrhythmias. They present with incomplete penetrance and variable expressivity.

Methods: Next generation sequencing (NGS) analysis of genes associated with inherited arrhythmia conditions was performed in 33 Polish patients with documented PVT.

Results: Sixteen patients had a clinically significant variant in: RYR2, KCNH2, KCNJ2, CALM1, SCN5A or 1p13.2 duplicating KCND3. In one CPVT patient two novel biallelic RYR2 variants co-occurred, and in another with LQTS co-occurrence of RYR2 and KCNH2 defects implied digenic etiology. Additionally, in two probands a rare variant of unknown significance (VUS), favoring pathogenetic, in MYBPC3 was noted. Five known VUS in KCNH2, SCN5A, SCN10A, TRPM4 were denoted possibly benign due to high frequency in an in-house Polish database.

Conclusion: Genetic testing has an essential role in PVT diagnosis, influencing risk stratification, preventive and therapeutic management and genetic counseling. NGS-based testing in PVT patients provides good diagnostic yield (~55%), however variant classification criteria should consider the unique characteristics of primary arrhythmias and population aspects. In PVT patients, concomitance of two or more pathogenic variants (biallelic/digenic) may occur, resulting in exacerbation of the phenotype, and phenotypic overlap may be observed in RYR2 or SCN5A-positive cases. Rarely, PVT may be associated with underlying cardiomyopathy.

References:
Grants: Partially supported: CMHL-M31/18.
Conflict of Interest: None declared.

P06.012.B Family screening of relatives with vascular Ehlers-Danlos syndrome, an asset in preventing arterial events

Jean-Michaël Mazzella1, Boris Oehmichen1, Clarisse Billon12, Michael Frank1, Xavier Jeunemaitre12, Tristan Mirault12

1Assistance Publique-Hôpitaux de Paris, Hôpital Évropéen Georges Pompidou, Centre de Référence des Maladies Vasculaires Rares, Paris, France; 2University of Paris, INSERM, U970 PARCC, Paris, France.

Background/Objectives: Vascular Ehlers-Danlos syndrome (vEDS) is a rare inherited disorder leading to mainly arterial complications, due to pathogenic COL3A1 variations. Ong et al (Lancet 2010) showed that the introduction of celiprolol significantly reduced arterial events. Screening of relatives allows specific and multidisciplinary management, but the benefit of celiprolol in those without arterial events remains uncertain. We wanted to evaluate the occurrence of arterial events during vEDS relatives follow-up.

Methods: All vEDS relatives diagnosed in our department since 2004 were included. We retrospectively analyzed several criteria (duration of follow-up, presence of arterial events, introduction and dose of celiprolol…).

Results: n = 72 relatives had at least one outpatient visit. Arterial events were found in n = 36 (50%), symptomatic (n = 20) or silent (n = 16). Median age was 44.5yrs vs. 23.0yrs for n = 36 without any arterial event (p < 0.05). During follow-up, n = 7 (19%) had a first arterial event at 29yrs and were all treated with celiprolol. Duration of treatment was 3yrs at the onset of the first silent event and 10yrs for the first symptomatic event. Celiprolol was introduced in n = 27 (75%) after genetic diagnosis disclosure. Treated relatives had a follow-up duration about 4yrs vs. 2yrs for the untreated ones (p = 0.01).

Conclusion: These results confirm the importance of family screening of vEDS relatives. Despite the introduction of celiprolol, some relatives have presented an arterial event during follow-up. However, our data are probably too low to assess the occurrence of events. A study on probands without arterial events at first outpatient visit could confirm the benefit of celiprolol in all vEDS patients.

References:
Grants:
Conflict of Interest: None declared.

P06.014.D Cardiovascular and Connective Tissue Disorder features in FLNA-related PVNH patients: progress towards a refined delineation of this syndrome

Clarisse Billon12, Salma Adham3, Natalia Hernandez Poblete4, Anne Legrand12, Michael Frank1, Laurent Chiche5, Stephane Zulli6, Karelle Benistan1, Laurent Savole6, Khoaula Zaafraane Khachnoua9, Anne-Claire Brehin10, Laurence Bail11, Tiffany Busa12, Melanie FRADIN13, Chloe Quelin13, Bertrand Chesneau14, Denis Wahl6, Patricia Fergelot8, Cyril GOIZET7, Tristan Mirault12, Xavier Jeunemaitre12, Juliette Albuissier12,15

1AP-HP, Hôpital Européen Georges Pompidou, Genetics Department, National Referral Center for Rare Vascular Diseases, Paris, France; 2Université de Paris, INSERM, U970 PARCC, Paris, France; 3University Hospital Center Saint Eloi Hospital, Vascular department, Montpellier, France; 4Chu Bordeaux - Site Pellegrin, Department of Medical Genetics, Bordeaux, France; 5University Hospitals Pitéi Sâlpêtrière - Charles Foix, Department of Vascular and Endovascular Surgery, Tertiary Aortic Center, Paris, France; 6Hospital Center Regional And University De Nancy Hospital Central, Vascular Medicine Division And Regional Competence Center for Rare Vascular And Systemic Autoimmune Diseases, Nancy, France; 7Raymond Poincaré University Hospital - (AP-HP), Centre de Référence des Syndromes d’Ehlers-Danlos non Vasculaires, Garches, France; 8Bicêtre Hospital, Service de Pneumologie, Le Kremlin-Bicêtre, France; 9Hospital L’archet, Medical Genetics Unit 2, Nice, France; 10Hospital Center University De Rouen, Normandy Center for Genomic and Personalized Medicine, Rouen, France; 11Marseille University Hospital Timone, Regional reference center in Marfan and Related Syndroms, Aortic Center, Marseille, France; 12Marseille University Hospital Timone, Département de Génétique Médicale, Marseille, France; 13South Hospital, Service de Génétique Clinique, Centre de Référence Maladies Rares CLAD-Ouest, Rennes, France; 14Hospital Center University De Toulouse, Département de Génétique Médicale, Centre de Référence du syndrome de Marfan et des syndromes apparentés.
Background/Objectives: FLNA Loss-of-Function (LoF) causes periventricular nodular heterotopia type 1 (PVNH1), an acknowledged cause of seizures of various types. Neurological symptoms are inconstant, and cardiovascular (CV) defects or connective tissue disorders (CTD) have regularly been associated. We aimed at refining the description of CV and CTD features in patients with FLNA LoF and depicting the multisystemic nature of this condition.

Methods: We retrospectively evaluated FLNA variants and clinical presentations in FLNA LoF patient with at least one CV or CTD feature, from three cohorts: ten patients from the French Reference Center for Rare Vascular Diseases, 23 patients from the national reference diagnostic lab for flaminopathies-A, and 59 patients from literature review.

Results: Half of patients did not present neurological symptoms. Most patients presented a syndromic association combining CV and CTD features. CV anomalies, mostly aortic aneurysm and/or dilation were present in 75% of patients. CTD features were present in 75%. Variants analysis demonstrated an enrichment of coding variants in the CH1 domain of FLNA protein.

Conclusion: In FLNA LoF patients, the absence of seizures should not be overlooked. When considering a diagnosis of PVNH1, the assessment for CV and CTD anomalies is of major interest as they represent interlinked features. We recommend systematic study of FLNA within CTD genes panels, regardless of the presence of neurological symptoms.

References:

Grants:

Conflict of Interest: None declared.

P06.015.A Genome-wide epistasis for cardiovascular severity in Marfan study design: patient organization driven research

Lotte Van Den Heuvel1,2,3 Josephina (Jeannette) Meester1,2, Silke Peeters1,2, romain alderweireldt4, Aline Verstraeten1,2, Paul Coucke3, Bart Loeys1,2

1University of Antwerp, Antwerpen, Belgium; 2Antwerp University Hospital, Edegem, Belgium; 3Ghent University, Ghent, Belgium; 4Foundation 101 Genomes, Brussel, Belgium.

Background/Objectives: Marfan syndrome (MFS) is an autosomal dominant connective tissue disorder with manifestations in the ocular, skeletal and cardiovascular system. Morbidity and mortality are mostly determined by aortic disease. Although mutations in FBN1 are the well-established genetic cause of MFS, there is a poor correlation with regards to phenotypical outcome, especially cardiovascular. Wide intra- and interfamilial phenotypical variability is observed, but the underlying mechanisms remain largely elusive. Consequently, the identification of genetic variation that modifies these effects will add important novel insights.

Methods: A worldwide collaborative project driven by researchers and a Belgian patient organization, ‘Foundation 101 Genomes’ (F101G), was established to maximize the number of patients to study the genetic basis of phenotypical variability. RNA-sequencing will be integrated with WGS to reveal MFS aortopathy genetic modifiers, which will be validated using CRISPR/Cas9 in iPSC-VSMC models.

Results: Our research institutions already gathered DNA and PBMCs of 35 patients carrying the most common FBN1 missense variant (p.Ile2585Thr:c.7754T>C). International collaborations yield at least 200 patients carrying this specific variant. Together with F101G, we created a website to guide patients to participate in our research.

Conclusion: Despite the large number of patients already included, more patients are needed to identify genetic modifiers for MFS aortopathy. Understanding how mother nature by itself modifies the outcome of the primary FBN1 mutation will individualize current treatment protocols to deliver true precision medicine and offer promising new leads to novel therapeutic strategies.

References:

Grants:

Conflict of Interest: None declared.

P06.016.B Casq2 deletion: a zebrafish model of CPVT

Ewa Sieliwonczyk1, Bert Vandoendriessche1, Charlotte Claes1, Evy Mayeur2, Maaike Alaerts1, Bart Loeys3, Dorien Schepers1

1Center of Medical Genetics, Faculty of Medicine and Health Sciences, University of Antwerp and Antwerp University Hospital, Edegem, Belgium; 2Laboratory for Molecular, Cellular and Network Excitability, University of Antwerp, Antwerp, Belgium.

Background/Objectives: Autosomal recessive mutations in CASQ2 are the second most common genetic defect identified in catecholaminergic polymorphic ventricular tachycardia (CPVT), one of the most lethal inherited cardiac arrhythmias. Recent findings suggest an autosomal dominant inheritance is also possible for CASQ2. We developed a zebrafish knockout model, which will be used to further explore this hypothesis.

Methods: The casq2 knockout was generated on the background of a transgenic zebrafish line expressing cardiac dual voltage and calcium reporters (Ace2N-mNeon and R-GECO) with CRISPR/Cas9. Loss of expression was confirmed by RT-qPCR. The voltage and calcium signals were measured with a Leica SP8 light sheet microscope at 3 days post-fertilization, after overnight exposure to the adenylyl cyclase activator forskolin.

Results: The casq2 knockout line contains a 5 base pair deletion in exon 2. Casq2-/- embryos showed a decreased heart rate at baseline compared to wildtype. Delayed afterdepolarizations (DADs) induced by forskolin were observed significantly more often in casq2-/- embryos (table 1).

Table 1:

| Casq2-/- 5μM Forskolin | DAs | No DAs | p-value |
|------------------------|-----|--------|--------|
| 8 (57%)                 | 6 (43%) | 0.018 (Fisher’s exact test) |
| Casq2-/-+/ 5μM Forskolin | 2 (12%) | 15 (88%) |        |

Conclusion: The casq2 knockout is the first zebrafish model of the classical CPVT genes. Similar to the human phenotype, we observe bradycardia at rest and a sensitivity to DADs upon stimulation. This model will provide a promising opportunity for further testing of CASQ2 inheritance patterns.

References: (1) Ng K, et al. Circulation, 2020. 142(10):932. PMID:32693635.

Grants: Fund for Scientific Research, Flanders (FWO) and the Antwerp University Research Fund (BOF).

Conflict of Interest: None declared.
P06.017.C A trans-ancestry Mendelian Randomisation study to estimate the causal effects of cardiometabolic factors on coronary artery disease in British Pakistanis and Bangladeshi

Diana Dunca1, Qin Qin Huang2, Neneh Sallah3, Hilary Martin4, Thomas Lumbers5, Karoline Kuchenbäcker5

1University College London, UCL Genetics Institute, London, United Kingdom; 2Wellcome Sanger Institute, Department of Human Genetics, Cambridge, United Kingdom; 3University College London, Institute of Health Informatics, London, United Kingdom; 4Wellcome Sanger Institute, Department of Human Genetics, Cambridge, United Kingdom; 5University College London, Division of Psychiatry, London, United Kingdom.

Background/Objectives: British people with South-Asian ancestry have a higher risk of coronary artery disease (CAD) than other ancestry groups. Statistical power can be a limiting factor when extending Mendelian Randomisation (MR) analyses to non-European populations, because ancestry-matched GWASs for risk factors (RFs) of interest might not be sufficiently large.

Methods: We compared different strategies for trans-ancestry MR to assess the effect of cardiometabolic RFs (BMI, triglycerides, HDL-cholesterol, LDL-cholesterol, systolic and diastolic blood pressure) on the risk of CAD in 22,000 British Pakistani and Bangladeshi (BPB) individuals from the Genes&Health cohort. We used an ancestry-matched sample to derive instruments in a two-sample MR of CAD in Genes&Health, with summary statistics for RFs from the BPB group in the UK Biobank. However, insufficient number of genome-wide significant instruments were identified in the UK Biobank BPB population. Therefore, we used a less stringent p-value threshold (p < 5x10^-5) for selecting instruments, incorporating results from large European GWASS, and using a subset of loci with evidence of transferability.

Results: We found that most of the associations were not significant in the ancestry-matched MR. We found a risk increasing effect for LDL-cholesterol and risk reducing effect for HDL-cholesterol when using the variants from the large European GWASs, and also for the subset of loci that were transferable. The associations for BMI with CAD were significant only for transferable loci.

Conclusion: Incorporating findings from European GWAS can increase power for MR in other ancestry groups. We demonstrated the importance of considering transferability of RF loci to ensure causal inference.

References:
No.206194,No.116074,MR,S003754/1.

Conflict of Interest: None declared.

P06.018.D Whole exome/genome sequencing joint analysis in a family with oligogenic familial hypercholesterolemia

Youmna Ghaleb1,2, Sandy Elbitar1,2, Anne Philipp3, Petra El Khoury1,2, Yara Azar1,2, Mariangela Andrianirina4, Alexia Loste4, Yara Abou-khali1,2,4, Gaël Nicolas5,5, Marie Le Borgne1,2, Philippe Moulign6,7, Mathilde Di Filippo7,8, Sybil Charriere6,7, Michel Farinier9, Cécile Yelnik10,11, Valérie Carreau12, Jean-François Deleuze13, Jean-Pierre Varret14,15, Alexa Derksen16,17, Geneviève Bernard15,17,18, Marie-Soleil Kingdom; 5University College London, Division of Psychiatry, London, United Kingdom; 6Laboratory of Biochemistry and Molecular Therapeutics (LBTM), Faculty of Pharmacy, Pole Technologie-Santé (PTS), Saint-Joseph University, Beirut, Lebanon; 7Université de Paris, Institut Cochin, INSERM U1016, CNRS UMR-8104, Paris, France, Paris, France; 8Université de Paris and Université Sorbonne Paris Nord, Paris, France, Paris, France; 9EA 7460 Physiopathologie et Epidémiologie Cérébro-Cardiovasculaires (PEC2), Université de Bourgogne-Franche Comté, Dijon, France, Dijon, France; 10Institut de Médecine Interne et Immunologie Clinique Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO) CHU de Lille, Lille, France, Lille, France; 11U1167 Risk Factors and Molecular Determinants of Aging-Related Diseases Inserm CHU de Lille Univ, Lille, France, Lille, France, 12Department of Endocrinology and Prevention of Cardiovascular Disease, Institute of Cardio Metabolism and Nutrition (ICAN), La Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Paris, France; 13Department of Cardiology and INSERM UMR 1295, Toulouse Rangueil University Hospital, Toulouse, France, Toulouse, France; 14Nutrition Department, Institut Pasteur de Lille, 59019 Lille Cedex, France, Lille, France; 15Child Health and Human Development Program, Research Institute of the McGill University Health Centre, Montréal, Québéc, Canada, Montréal, Canada; 16Translational Proteomics Laboratory, Institut de Recherches Cliniques de Montréal, Montréal, Québéc, Canada, Montréal, Canada; 17Department of Neurology and Neurosurgery, McGill University, Montréal, Québec, Canada, Montréal, Canada; 18Division of Medical Genetics, Department of Specialized Medicine, McGill University Health Centre, Montréal, Québéc, Canada, Montréal, Canada; 19Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, Canada, Montréal, Canada; 20Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany, Bonn, Germany; 21Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine, 91057, Evry, France and Laboratory of Excellence GENMED (Medical Genomics), Evry, France; 22Centre d’Etude du Polymorphisme Humain, Fondation Jean Dausset, Paris, France, Paris, France, 23Amboise Paré University Hospital, APHP., Department of Biochemistry and Molecular Genetics, Paris, France; 24Genetic Department, AP-HP, Hôpital Bichat, F-75018 Paris, France, Paris, France.

Background/Objectives: Autosomal Dominant Hypercholesterolemia (ADH) is a genetic disorder caused by pathogenic variants in LDLR, APOB, PCSK9 and APOE genes. We sought to identify a new candidate gene responsible of the ADH phenotype in patients with no pathogenic variants in known ADH causing genes.

Methods: We performed linkage analysis, whole exome and whole genome sequencing in one French family, with affected and non-affected members presenting a high ADH polygenic risk score (wPRS). We also performed functional studies in HEK293T cells of the four LRP6 mutants.

Results: Linkage analysis, whole exome and whole genome sequencing in one French family, with affected and non-affected members presenting a high ADH polygenic risk score (wPRS) allowed us to identify p.(Pro398Ala) in CYP7A1, p.(Val1382Phe) in LRP6 and p.(Ser202His) in LDLRAP1. Six other variants were identified in 6 from 160 unrelated ADH probands: p.(Ala1313Val) and p.(Aps347Asn) in CYP7A1, p.(Tyr972Cys), p.(Thr1479Ile) and p.(Ser1612Phe) in LRP6 and p.(Ser202LeufsTer19) in LDLRAP1. All these six probands presented a moderate wPRS. Serum analysis of carriers of p.(Pro398Ala) variant in CYP7A1 showed no differences in bile acids synthesis when compared to non-carriers sera.
Functional studies in HEK293T cells of the four LRP6 mutants showed contradictory results. None of the family members heterozygous carriers of the LDLRAP1 p.(Ser202His) variant alone presented ADH.

Conclusio: Altogether, each variant alone does not seem to contribute sufficiently to the elevation of LDL-C and it is the oligogenic combination of two or three variants that is necessary to reveal the ADH phenotype.

References:
Grants:
Conflict of Interest: None declared.

P06.019.A Contribution of SCN5A copy number variations to the genetic diagnosis of Brugada syndrome

Laura Cazón1, Luis De la Higuera Romero1, Marlene Perez Barbeito1, Rosalía Peteiro1, Iria Gómez Diaz1, Paula Rebolo1, Paula Velez1, María Sanchez1, Anahi Sanluis Verdes1, Guillermo Smith Ramos1, Emilia Maneiro1, Xusto Fernandez1, Almudena Amor1, María Valverde1, Soledad García Hernández2,3, Ivonne Cárdenas Reyes1, Martín Ortiz Genga1, Juan Pablo Ochoa2

Background/Objectives: Loss-of-function variants in SCN5A are identified in 15-25% of Brugada syndrome (BrS) cases. Most of them are single-nucleotide variants, small insertions / deletions, and splicing errors, whereas information on copy number variations (CNVs) is still limited. The objective of this study is to determine the contribution of CNVs to the genetic diagnosis of BrS.

Methods: A total of 977 consecutive unrelated probands with suspected BrS were genotyped by next-generation-sequencing (NGS) using a panel of genes that included SCN5A. Filtering and classification of NGS data was performed using a custom pipeline; CNVs were detected using a read depth approach and confirmed by orthogonal molecular techniques.

Results: Actionable variants in SCN5A were identified in 128 probands (13%): 83 were pathogenic/likely pathogenic and 47 variants of unknown significance but favoring pathogenic. CNV analysis could be performed in 88 (90.9%) of the probands and revealed six carriers of CNVs in SCN5A (table 1).

Conclusio: SCN5A CNVs were detected in 0.6% of the BrS probands, but they represented 7.2% of pathogenic / likely pathogenic variations identified in our cohort. This result emphasizes the importance of a complete genetic study including CNVs in the diagnosis of BrS.

References:
Grants:
Conflict of Interest: None declared.

P06.020.B Spontaneous coronary artery dissection: role of the genetic background in pathogenesis and management

Marta Casula1, Lucia Trevisan2,3, Fabio Gotta4, Daniela Marchetti4, Laura Pezzoli4, Antonio Zingarelli3, Paola Mandich2,3, Maria Iascone4

1Università degli Studi di Genova, genoa, Italy; 2Università degli Studi di Genova, dinogmi, Genova, Italy; 3IRCCS Ospedale Policlinico San Martino, Genova, Italy; 4ASST Papa Giovanni XXIII, Laboratorio di Genetica Medica, Bergamo, Italy.

Background/Objectives: Spontaneous coronary artery dissection (SCAD) is a rare, non-atherosclerotic disease of the coronary vascular tunics, frequently starting as an acute coronary syndrome. Recent genetic studies on SCAD have identified a possible correlation with inherited connective tissue disorders and a possible predisposition linked to CGG repeat expansion in FMR1 gene. This study explored rare genetic factors that may contribute to the pathogenetic mechanisms underlying SCAD.

Methods: After the SCAD event between January 2010 and February 2021, fourteen patients referred to the Cardiology Department of IRCCS Policlinico San Martino underwent clinical genetic evaluation, whole-exome sequencing analyses (trio or singleton), and FRAXA analyses. This study was approved by local Ethical Committee.

Results: Although none of the 14 patients enrolled showed clinical features associated with connective tissue disorders, in the 21% of our cohort, we identified variants in genes involved in the formation and in the integrity of connective tissue. We also detected an intermediate allele in the FMR1 gene in one patient and a de novo variant in a new candidate gene in another one.

Conclusion: Despite the small number of patients analysed, we identified several genetic risk factors for SCAD and a promising novel candidate gene. Although further studies are needed, this work could contribute to give insight into the pathogenetic pathways of this rare condition.

References: Tassanakijpanich N. et al, Cardiovascular problems in the Fragile X premutation; Front Genet. 2020. Amrani-Midoun A. et al, Recent advances on the genetics of spontaneous coronary artery dissection; CircGenomPrecisMed 2021. Grants: This project was not supported by any grant. Conflict of Interest: None declared.

P06.021.C Polygenic risk scores predict overweight and obesity in the Dutch population

Bahar Sedaghati-khayat1, Linda Broer1, Annemiek Verkerk1, André Uitterlinden1,2, Joyce Van Meurs1,2, Jeroen van Rooij1

European Journal of Human Genetics (2023) 31:345 – 709
Background/Objectives: Obesity, the fifth leading risk of global deaths, has grown to epidemic proportions. Its etiology is largely unknown but it has a substantial hereditary component. Global GWAS have identified 941 genetic variants influencing body-mass index explaining 6% of heritability. This study combined these variants into a polygenic risk score (PRS) to assess obesity-risk in a Dutch Caucasian population cohort.

Methods: The PRS was tested in 11,209 participants of the Rotterdam Study (mean±SD age = 65.7±10.2 years) to predict BMI as a continuous and categorical outcome (under-weight, normal-weight, overweight, obese, and morbid-obese). We evaluated the risk conveyed by PRS as a linear instrument (per 1 SD) and categorical (highest 10% vs. middle 50% of the PRS distribution).

Results: The PRS was associated with BMI (beta-estimate = 0.9 [95% confidence interval 0.7-1.1] p < 1 x 10^-16). One SD increase of the PRS significantly increased the risk of being underweight, over-weight, obese and morbid-obese by 0.8, 1.3, 1.8 and 2.2 fold times, respectively. Similarly, the top 10% of the population with the highest BMI-PRS showed increased risks of 1.1, 1.5, 2.6 and 4.5 for these BMI categories, respectively. The risk increased exponentially in the PRS distribution tails, up to 8.2 of the top 1% PRS for morbid-obese vs. normal-weight.

Conclusion: These results confirm that the PRS significantly impacts BMI in a Dutch Caucasian elderly population. Identifying the biological pathways affected by an individual’s genetic background could aid in targeted and personalized intervention strategies long before the onset of obesity. BMI-PRS utility is being investigated as part of the Genotyping on all patients (GOALL) project.

References:

Grants:

Conflict of Interest: None declared.

P06.022.D Novel loss of function KCNA5 pathogenic variants in pulmonary arterial hypertension

Natalia Gallego1,2,3, Alba Vera-Zambrano4,5,6, Mauro Lago-Docampo7,8, Juan Felipe Franco-González9, Daniel Morales-Cano10,11, Alejandro Cruz-Utrilla12,13, Marta Villegas4,14, Pilar Escrivano-Subias12,13, Jair Tenorio1,2,3, Francisco Perez Vizcaíno4,14, Diana Valverde Pérez4,5,6, Teresa González8,9, Angel Cogollo4,14

1Institute of Medical and Molecular Genetics (INGEMMI)-IdiPAZ, Madrid, Spain; 2CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain; 3TITACCA, European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability, Hospital Universitario La Paz, Madrid, Spain; 4Department of Pharmacology and Toxicology, School of Medicine, University Complutense of Madrid, Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid, Spain; 5Department of Biochemistry, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain; 6Instituto de Investigaciones Biomédicas “Alberto Sols” CSIC-UAM, Madrid, Spain; 7CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain; 8CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain; 9CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain; 10Instituto de Investigación Sanitaria Galicia Sur (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain; 11Department of Structural and Chemical Biology, Centre for Biological Research Margarita Salas, CIB-CSIC, Madrid, Spain; 12Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; 13Experimental Pathology of Atherosclerosis Laboratory, Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain; 14CIBER Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.

Background/Objectives: Reduced expression and/or activity of Kv1.5 channels (encoded by KCNA5) is a common hallmark in human or experimental pulmonary arterial hypertension (PAH).

Methods: Potassium currents were recorded by patch-clamp technique in HEK293 cells transfected with WT or mutant Kv1.5 cDNA. Flow cytometry, western blot and confocal microscopy techniques were used for measuring protein expression and cell apoptosis in HEK293 and human pulmonary artery smooth muscle cells (hPASMC).

Results: KCNA5 variants (namely, p.Arg184Pro and p.Gly384Arg) resulted in a loss of potassium channel function as assessed by electrophysiological and molecular modelling analysis. The p.Arg184Pro variant also resulted in a pronounced reduction of Kv1.5 expression. Transfection with p.Arg184Pro or p.Gly384Arg variants decreased apoptosis of hPASMCs compared with the WT, demonstrating that KCNA5 dysfunction in both variants affects cell viability. Thus, in addition to affect channel activity, both variants were associated with a clear impairment in a key PASMC process linked to the disease. The estimated prevalence of dysfunctional KCNA5 variants in the PAH population analysed was around 0.8%.

Conclusion: Our data indicates that some KCNA5 mutations present in PAH patients have critical consequences for channel function. This encourages the idea that KCNA5 pathogenic variants may be developing a contributing factor for PAH.

References:

Grants: P118/01233, FCHP unrestricted grant.

Conflict of Interest: None declared.

P06.023.A Genetic testing outcomes in a cohort of 21,159 children with heart disease

Robert Nussbaum1, Flavia Facio2, Ana Morales2, Asia Mitchell2, John Garcia1, Dianalee McKnight3, Tom Callis4, Chad Moretz2, Matteo Vatta4, Swareop Aradhya2

1Invitae, San Francisco, United States; 2Invitae, Medical Affairs, San Francisco, United States; 3Invitae, Systems Development, San Francisco, United States; 4Invitae, CNP US Sales, San Francisco, United States; 5Invitae, Health Economics and Outcomes Research, San Francisco, United States; 6Invitae, Clinical Operations, San Francisco, United States.

Background/Objectives: Pediatric heart conditions affect 1/77 US children. Guidelines recommend cardiogenetic testing in children and at-risk relatives. We investigated outcomes in a large pediatric cohort undergoing genetic testing for a wide range of cardiogenetic conditions.

Methods: Probands <18 years had next generation sequencing and deletion/duplication analysis for cardiogenetic conditions (up to 224 genes). A positive result was defined as a single pathogenic/likely pathogenic (P/LP) variant in a gene associated with an autosomal dominant or X-linked disorder, or two P/LP variants in a gene associated with a recessive disorder. Outcomes were compared to cardiogenetic testing results of 61,368 adults by t-tests with multiple comparison correction.

Results: 21,159 probands were tested (median = 10.03 years, SD = 5.75) and positive result were reported in 16.6%. Cascade testing was pursued in 3.9% of families (mean 3.48 relatives/
family: 59.1% aged <10 years). Positive results were more frequent in children than in adults (16.6% vs 15.3%), and were particularly enriched in genes associated with syndromic disorders relative to non-syndromic ones (41.4% vs 29.7%). Families with probands aged <10 had cascade testing more often in comparison to those with older probands (4.6%: p = 0.0069).

Conclusion: One in six children referred for cardigenetic testing received a positive result, highlighting opportunities for management. Cascade testing was pursued more often than in families with probands <10 years in comparison to those with adult probands. These findings provide rationale for family-based care to identify patients who can benefit from genetics-guided interventions.

References:
Grants:
Conflict of Interest: Robert Nussbaum: None declared, Flavia Facio Invitae, Ana Morales Invitae, Asia Mitchell Invitae, John Garcia Invitae, Dianalee McKnight Invitae, Tom Callis Invitae, Chad Moretz Invitae, Matteo Vatta Invitae, Swooop Aradhy Invitae.

P06.024.B Identification of novel loss-of-function genes associated with carotid intima-media thickness

Abdulrahman Alasiri1,2, Marion van Vugt1, Jessica Van Setten1, Folkert Asselbergs1,2,3, Sander van der Laan1,3,4, Vardiella Meiner1, Ben Goult6, Vasso naama elefant

1University Medical Center Utrecht, Department of Cardiology, Utrecht, Netherlands; 2King Abdullah International Medical Research Center, Medical Genomics Research Department, Riyadh, Saudi Arabia; 3University College London, Health Data Research UK and Institute of Health Informatics, Utrecht, Netherlands; 4University College London, Institute of Cardiovascular Science, Utrecht, Netherlands; 5University Medical Center Utrecht, Central Diagnostic Laboratory, Utrecht, Netherlands.

Background/Objectives: Ultrasound measurement of the carotid intima-media thickness (cIMT) of the carotid artery is frequently employed as a biomarker for subclinical atherosclerosis and the extent of vascular remodelling. Large-scale genetic studies identified common genetic risk factors for cIMT. Here, we aimed to identify loss-of-function (LoF) genes that are inactive in one or two copies (i.e. full knockouts) associated with cIMT.

Methods: We used LoFTK (https://github.com/CirculatoryHealth/LoFTK) to annotate LoF genes from UK Biobank exomes and UCC-SMART imputed genotypes. We performed LoF-wide association studies (LoFWAS) in both cohorts and conducted a meta-analysis to identify genes associated with cIMT. We explored tissue- and cell-specific expression in carotid atherosclerotic plaques.

Results: We identified four genes associated with cIMT in our meta-analysis. Three of these genes (PPP1R21, HSD3B2 and ULK2) were inactive in one copy, while one gene (KIR3DL1) was a full knockout. Single-cell RNA sequencing revealed cellular subtype-specific expression patterns of PPP1R21, ULK2, and KIR3DL1 in carotid plaques.

Conclusion: We identified 4 novel genes associated with cIMT. Our study provides insights into LoF genes and cIMT that underpin the genetic and biological mechanisms of atherosclerosis.

References:
Grants:
Conflict of Interest: None declared.

P06.026.D Phenotypic and genetic factors modifying the risk of developing cardiomyopathy symptoms for PLN-p.Arg14del carriers

Esteban Lopera-Mayas1,2, Shuang Li1, Remco de Bouwer1, Ilja Nolte2, Justin van Brein1, Jan Jongbloed1,4, Morris Swertz1,4, Harold Snieder2, Lude Franke1, R.A. de Boer3, Cisca Wijmenga1, Patrick Deelen1, Paul van der Zwaag1, Serena Sanna1,3,5

1University of Groningen, University Medical Center Groningen, Department of Cardiology, Groningen, Netherlands; 2University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, Netherlands; 3University of Groningen, University Medical Center Groningen, Department of Cardiology, Groningen, Netherlands; 4University of Groningen, University Medical Center Groningen, Genomics Coordination Center, Groningen, Netherlands; 5National Research Council (CNR), Institute for Genetic and Biomedical Research (IRGB), Cagliari, Italy.

Background/Objectives: The phospholamban (PLN) p.Arg14del Dutch founder variant has been associated with dilated and arrhythmogenic cardiomyopathy. Some carriers show life-threatening symptoms, while others remain asymptomatic or show only mild symptoms at old age. To understand the mechanisms behind this incomplete penetrance, we aimed to identify protective factors in asymptomatic PLN-Arg14del carriers in a large population cohort.

Methods: We conducted exome sequencing analysis on peripheral blood of two family members, followed by Sanger sequencing for segregation in additional family members. cDNA analysis from blood and fibroblast samples was used to determine the consequence of a variant of interest.

Results: A rare novel heterozygous variant in the TLN1 gene (c.7188+2T>C) was identified in all three family members with SCLS. This variant causes in-frame skipping of exon54 and is predicted to affect the c-terminal actin binding domain in the Talin-1 protein (domain ABS3).

Conclusion: Talin-1 (TLN1) has a key role in cell adhesions via the linkage of integrins to the actin cytoskeleton and by activation of integrins. Studies have shown that Talin-1 regulates VE-Cadherin localization, which plays an important role in endothelial cell barrier function. Based on our findings we suggest that pathogenic variants in TLN1 underlie SCLS. Future studies are warranted to further investigate the mechanism of the disease and to explore possible therapeutic options.

References:
Grants:
Conflict of Interest: None declared.
Methods: We identified 74 (0.2%) carriers in 36,339 genotyped individuals of the Dutch Lifelines cohort, of which 48 were asymptomatic according to their ECG and questionnaires. We interrogated 38 quantitative measurements and 97 polygenic scores (PGS) of cardio-metabolic traits, performed a GWAS, and a rare variant burden analysis in 82 risk loci. We used the non-standard approach of comparing asymptomatic carriers to asymptomatic non-carriers, and confirmed the results by comparing each group to symptomatic carriers.

Results: Compared to the asymptomatic non-carriers, the asymptomatic carriers showed lower QRS (p = 0.002), an effect that replicated in another Lifelines subset (N = 20,221) and in the ACM patient registry (N = 592). Furthermore, symptomatic carriers showed a higher correlation between PGSPR and PR (p = 0.022) and between PGSSQRS and QRS (p = 1.9x10^{-5}). These results indicate symptomatic PLN-Arg14del carriers have an increased sensitivity for common genetic variation affecting cardiac rhythm.

Conclusion: We have used a population cohort to identify protective factors for PLN-Arg14del carriers. These results can improve risk prediction models for cardiac outcomes and guide future studies on genetic diseases with incomplete penetrance.

References: 1van der Zwaag et al, Eur J Heart Fail 2012. 2Scholtens et al, Int J Epidemiol 2015. Grants: UMCG-HAP-2017-2 324.

Conflict of Interest: None declared.

P06.027.A NGS analysis in a patient with conduction disorders and dilated cardiomyopathy: a case report of R222Q SCN5A variant, benefiting from mutation specific target therapy

Martina Callegari1, Francesca Bianchi2, Valeria Bracciamà1, Giulia Margherita Brach del Prever1, Angela Corsa Faini1, Silvia Kalantari1, Tiziana Vaisitti1, Stefano Grossi1, Antonio Amoroso1, Silvia Deaglio1

1Transplant Regional Center-Piedmont, Immunogenetics and Transplant Biology, AOU Città della Salute e della Scienza, Department of Medical Sciences, University of Turin, Torino, Italy; 2Division of Cardiology, Mauriziano Umberto I Hospital, Turin, Italy.

Background/Objectives: Mutations in SCN5A, which encodes the alpha-subunit of cardiac sodium channel Nav1.5, are reported non-only in patients with Brugada Syndrome but also in those with dilated cardiomyopathy (DCM). In these patients, cardiac dilatation is preceded by conduction system abnormalities. Genetic diagnosis in these cases can determine therapeutic choices with consequences on patient's quality of life and survival.

Methods: We performed Next Generation Sequencing (NGS) analysis as part of the routine work-out of a 53-year-old woman with a history of ventricular extrasystoles (burden > 50%) since the age of 20, syncopal sinus pauses with required PM implantation, with a history of ventricular extrasystoles (burden > 50%) since the analysis as part of the routine work-out of a 53-year-old woman.

Results: We identified a heterozygous pathogenic variant (p.Arg222Gln) in SCN5A, previously reported to be responsive to sodium channel blockers. Hydroquinidine treatment led to normalization of ventricular cell potentials. Patient showed almost complete regression of arrhythmic manifestations and NYHA class improvement.

Conclusion: Identification of R222Q in SCN5A was fundamental for the patient's prognosis. This paradigmatic case underlines the importance of NGS analysis for optimal therapeutic management of patients with conduction disorders and DCM. For these patients, genetic studies should be considered integral components of the diagnostic phase.

References: Mann SA et al, JACC 2012.

Conflict of Interest: None declared.

P06.028.B Yield of 3 years of diagnostic testing of TNNI3K in Arrhythmia and Cardiomyopathy Patients

Karolina Andrzejczyk1, Caroline Pham1, Kaylin Palm1, Leander Beekman1, Alexa Vermeer2, Janneke Nijman2, Imke Christiaans3, Doris Škorić-Milosavljević2, Ronald Lekkane Dit Deprez2, Philip Janssen2, Niels Vos2, Svitlana Podliesna1, Connie R. Bezzina1, Elisabeth Lodder1,2

1Amsterdam University Medical Center, Clinical and Experimental Cardiology, Amsterdam, Netherlands; 2Amsterdam University Medical Center, Human Genetics, Amsterdam, Netherlands; 3University Medical Center Groningen, Clinical Genetics, Groningen, Netherlands.

Background/Objectives: Genetic variants in TNNI3K have been associated with supraventricular arrhythmias (SVTs), conduction disease (CCD), and dilated cardiomyopathy (DCM) in a limited number of papers thus far. The yield in diagnostic screening of this gene in cardiac diseases has not yet been evaluated, we here aim to fill this gap. As pathogenic variants in TNNI3K have been shown to affect the level of autophosphorylation, we evaluated this for identified variants.

Methods: We collected and analysed clinical data of individuals with variants in TNNI3K. These variants were identified by i) systematic clinical genetic screening of gene panels in patients with cardiomyopathies and/or arrhythmias between 08-2018 and 12-2021 at the Amsterdam UMC, and ii) collaboration with multiple centres in the Netherlands. Functional in vitro studies were performed to assess the effects of the identified variants on TNNI3K auto-phosphorylation.

Results: We identified 19 rare coding variants in TNNI3K in 24 probands. Among these two novel likely pathogenic variants (p.H592T and p.I512T) were found in eight families. Individuals harbouring these variants demonstrated SVTs, CCD, DCM, and/or out-of-hospital cardiac arrest. Functional studies revealed significantly increased auto-phosphorylation levels in both TNNI3K variants.

Conclusion: Screening of rare variants in TNNI3K adds to the diagnostic yield for cardiac diseases. However, considering the current lack of validation of the functional tests, co-segregation analysis is paramount for the classification of identified variants.

References: The Diverse Roles of TNNI3K in Cardiac Disease and Potential for Treatment. Doi: Caroline Pham, Noelia Muñoz-Martín, Elisabeth Lodder.

Grants: Netherlands Organisation for Scientific Research (VIDI-91718361).

Conflict of Interest: None declared.

P06.029.C Common rearrangements of the LDLR gene in the Czech population likely arise from one mutational event

Katerina Konecna1, Lukas Tichy1, Tomas Freiberger2

1University Hospital Brno, Centre of Molecular Biology and Genetics, Brno, Czech Republic; 2Center of Cardiovascular and Transplant Surgery, Brno, Czech Republic.
Background/Objectives: Mutations in the low-density lipoprotein receptor gene (LDLR) are the most common cause of familial hypercholesterolemia in the Czech Republic. Out of all Czech probands with an LDLR mutation, nearly 10% are carriers of a deletion or duplication spanning whole exons. We characterized the breakpoints of 8 large rearrangements of the LDLR gene. One of the goals was to analyze the breakpoint of all probands carrying a specific rearrangement to verify the hypothesis that all probands of each rearrangement have identical breakpoints inherited from a common ancestor.

Methods: The breakpoint sequence was determined by PCR amplification and Sanger sequencing.

Results: We sequenced the breakpoint of 8 rearrangements of the LDLR gene, including the four most common rearrangements in Czech population (number of probands ranging from 8 to 28), and four less common rearrangements (1-4 probands). For all analyzed rearrangements, all Czech probands with a specific rearrangement shared identical breakpoint position and sequence, suggesting shared origin from a common ancestor. All breakpoints except for one were located inside an Alu element. In 5 out of 8 breakpoints, there was high homology (>75%) between the two Alu repeats in which the break occurred.

Conclusion: Most common rearrangements of the LDLR gene in the Czech population likely arise from one mutational event. Alu elements likely played a role in generation of the majority of rearrangements within the LDLR gene, but not all.

References:

Grants: Supported by the Ministry of Health, Czech Republic, grant number NU20-02-00261.

Conflict of Interest: None declared.

P06.031.A Prenatal Long QT syndrome associated with homozygous KCNH2 pathogenic variants

Ana Grangeia1,2, Mário Baixaia3, Sofia Granja Da Silva4, Susana Guimarães5, Carla Ramalho6,7-8, Raquel Silva3, Sérgio Castedo9,10, Renata Oliveira1

1São João University Hospital Center, Genetics, Porto, Portugal; 2Faculdade de Medicina da Universidade do Porto - FMUP, Porto, Portugal; 3IPATIMUP - Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; 4São João University Hospital Center, Pediatric Cardiology, Porto, Portugal; 5São João University Hospital Center, Anatomic Pathology, Porto, Portugal; 6São João University Hospital Center, Obstetrics, Porto, Portugal; 7Faculdade de Medicina da Universidade do Porto - FMUP, Porto, Portugal; 813s, Instituto de Investigação e Inovação em Saúde, Porto, Portugal, Porto, Portugal.

Background/Objectives: Long QT syndrome type 2 is an inherited autosomal dominant disorder usually caused by heterozygous pathogenic variants in the KCNH2 gene. However, homozygous KCNH2 variants have been proposed to cause a more severe cardiac phenotype associated with QT prolongation and functional atrioventricular conduction disturbances before and immediately after birth. Only three families with homozygous KCNH2 variants have been reported so far.

Methods:

Results: We report an asymptomatic Portuguese consanguineous couple, whose first child, presented in the prenatal period chaotic foetal rhythm (periods of tachycardia and complete atrioventricular block) and hydrops. She was born at 33 weeks of gestation requiring a pacemaker implantation at day one of life. Postnatal echocardiogram showed left ventricular non-compaction cardiomyopathy. She died at 18 months of age from sudden death. Dilated cardiomyopathy NGS panel study did not identify any pathogenic variant. The second child was a healthy female, now 3 years old. During their third gestation, foetal hydrops was detected associated with global left ventricular dysfunction and cardiomegaly. The pregnancy was terminated at 24 weeks of gestation. Necropsy confirmed foetal hydrops and dilated cardiomyopathy. Considering a potential disease recurrence, a comprehensive cardiomyopathy NGS panel was performed in the index case and a homozygous frameshift pathogenic variant [c.785del, p.(Gly262Alafs*98)] was identified in the KCNH2. The same variant was found in the foetus (homozygous) and in the mother (heterozygous). Genetic screening of the father and healthy sister is ongoing.

Conclusion: This report illustrates the severe cardiac phenotype, of prenatal onset, associated with a homozygous KCNH2 pathogenic variant.
Abstracts from the 55th European Society of Human Genetics Conference

414

P06.033.C Mutations in the GTPBP3 are associated with hypertrophic cardiomyopathy with rapid progression to burn out phase complicated by severe systolic dysfunction and ventricular tachycardia

Petya Angelova1, Vasily Velchev2, Nikolay Stoyanov2, Slavena Atemin1, Vanya Mitev1, Albena Todorova1

1Medical University Sofia, Department of Medical Chemistry and Biochemistry, Sofia, Bulgaria; 2University Hospital “St. Anna”, Department of Cardiology, Sofia, Bulgaria; 3Genetic Medico-Diagnostic Laboratory “Genica”, Sofia, Bulgaria.

Background/Objectives: About 100 genes have been associated with cardiomyopathies with genotype-phenotype correlations cause of cardiovascular morbidity and mortality in both children and adults. Of these, hypertrophic cardiomyopathy (HCM) characterized by increased left ventricular wall thickness and dilated cardiomyopathy (DCM) displaying ventricular dilatation, are most common. Alpha-protein kinase 3 (ALPK3) plays an essential role in sarcomere organization. Its mutations have been recently reported to be causative of the recessively inherited severe pediatric-onset DCM and HCM, accompanied by skeletal involvement and facial dysmorphism, as well as of the dominantly inherited adult-onset cardiomyopathy. We have ascertained kindred with multiple family members affected by infantile or late onset cardiomyopathy and aimed to elucidate the genetic basis of cardiomyopathy in the affected individuals.

Methods: The family members underwent clinical assessment and genotyping using whole-exome sequencing and Sanger sequencing.

Results: Compound heterozygosity for two novel variants in ALPK3 has been identified in two identical twin sisters, with severe infantile onset HCM and facial dysmorphism. Both their father and grandfather died by sudden death at young age, without specific diagnosis. Their uncle was diagnosed with adult-onset cardiomyopathy at the age of 56, and has been found to be heterozygous for the truncating ALPK3 variant, identified in both of his nephews.

Conclusion: We report two novel variants in ALPK3 in a kindred with individuals affected by both infantile onset and adult onset cardiomyopathy, and provide additional evidence for the reported phenotypic spectrum of ALPK3-related cardiac disease.

References:

Grants: The Morris Kahn Family Foundation.

Conflict of Interest: None declared.

P06.035.C Mutations in the GTPBP3 are associated with hypertrophic cardiomyopathy with rapid progression to burn out phase complicated by severe systolic dysfunction and ventricular tachycardia

Petya Angelova1, Vasily Velchev2, Nikolay Stoyanov2, Slavena Atemin1, Vanya Mitev1, Albena Todorova1

1Medical University Sofia, Department of Medical Chemistry and Biochemistry, Sofia, Bulgaria; 2University Hospital “St. Anna”, Department of Cardiology, Sofia, Bulgaria; 3Genetic Medico-Diagnostic Laboratory “Genica”, Sofia, Bulgaria.

Background/Objectives: About 100 genes have been associated with cardiomyopathies with genotype-phenotype correlations often hard to establish. Genetic testing may help to confirm the genetic diagnosis and assess the risk of inheritance in the family.

Methods: A 26-year old Caucasian male with hypertrophic cardiomyopathy (HCM) and suspected Wolff-Parkinson-White syndrome was referred for genetic testing by his cardiologist. Whole-exome sequencing (WES) was performed, followed by Sanger sequencing segregation analysis in the family.

Results: The targeted PRKAG2 gene screening turned out to be negative. WES revealed the following variants: c.247G>C (p.Ala83Pro) and c.1265C>T (p.Thr422Met) in the GTPBP3 gene in heterozygous state, as well as c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu) in the POLG gene. Family segregation analysis showed that the patient’s mother is a carrier of the c.247G>C variant and the patient’s paternal grandmother is a carrier of the variant c.1265C>T in the GTPBP3 gene. The findings of the family segregation analysis are in accordance with an autosomal recessive model of inheritance of the disease. Both variants in the POLG gene are found paternally inherited in the patient’s healthy half-brother, thus are not considered disease-causing.

Conclusion: WES led to the detection of two heterozygous variants in the GTPBP3 gene. Variants in this gene have been reported in patients with HCM, associated with combined oxidative phosphorylation deficiency 23. These heterozygous variants represent the probable cause of the observed clinical symptoms in the patient.

References:

Grants: The financial support of Medical University Sofia, Grant № D-125/2021 is gratefully acknowledged.

Conflict of Interest: None declared.

P06.034.D Novel ALPK3 variants cause infantile and late onset hypertrophic cardiomyopathy in a single family

Tomer Poleg1, ofek freund2, Matan M. Jean3, Nadav Agam1, Amit Safran1, Vadim Dolgin1, Marina Eskin-Shwartz1,2, Ohad Shmuel Birk1,2

1The Morris Kahn Laboratory of Human Genetics, National Institute for Biotechnology in the Negev and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; 2Genetics institute, Soroka Medical Center, Ben-Gurion University, Beer Sheva, Israel.

Background/Objectives: Cardiomyopathies are clinically heterogeneous disorders that impair heart function and are the leading cause of cardiovascular morbidity and mortality in both children and adults. Of these, hypertrophic cardiomyopathy (HCM) characterized by increased left ventricular wall thickness and dilated cardiomyopathy (DCM) displaying ventricular dilatation, are most common. Alpha-protein kinase 3 (ALPK3) plays an essential role in sarcomere organization. Its mutations have been recently reported to be causative of the recessively inherited severe pediatric-onset DCM and HCM, accompanied by skeletal involvement and facial dysmorphism, as well as of the dominantly inherited adult-onset cardiomyopathy. We have ascertained kindred with multiple family members affected by infantile or late onset cardiomyopathy and aimed to elucidate the genetic basis of cardiomyopathy in the affected individuals.

Methods: The family members underwent clinical assessment and genotyping using whole-exome sequencing and Sanger sequencing.

Results: Compound heterozygosity for two novel variants in ALPK3 has been identified in two identical twin sisters, with severe infantile onset HCM and facial dysmorphism. Both their father and grandfather died by sudden death at young age, without specific diagnosis. Their uncle was diagnosed with adult-onset cardiomyopathy at the age of 56, and has been found to be heterozygous for the truncating ALPK3 variant, identified in both of his nephews.

Conclusion: We report two novel variants in ALPK3 in a kindred with individuals affected by both infantile onset and adult onset cardiomyopathy, and provide additional evidence for the reported phenotypic spectrum of ALPK3-related cardiac disease.

References:

Grants: The Morris Kahn Family Foundation.

Conflict of Interest: None declared.

P06.034.A Multidisciplinary and standardised post-mortem genetic analysis in a representative Czech cohort of sudden cardiac death (SCD) victims, together with genetic screening of their living relatives, yields high diagnostic yield in cases with positive family history and renders primary prevention of SD in affected families

Pavel Votyoka1, Petra Peladova1, Patricia Norambuena2, Stepanka Pohlova-Kucerova3, Terezia Tavacova4, Milan Macek5, Milian Maccek1, Jan Janousek4, Josef Kautzner2, Alice Krebsová2

1Charles University 2nd Faculty of Medicine and Motol University Hospital, Department of Biology and Medical Genetics, Prague, Czech Republic; 2Institute for Clinical and Experimental Medicine, Department of Cardiology, Prague, Czech Republic; 3Charles University Faculty of Medicine Hradec Kralove, Department of Forensic Medicine, Hradec Kralove, Czech Republic; 4Charles University 2nd Faculty of Medicine and Motol University Hospital, Children Heart Centre, Prague, Czech Republic.

Background/Objectives: Post mortem genetic analysis in SCD, together with the cardiologic examination of victim’s relatives, represents a multidisciplinary approach for its prevention. We assessed the molecular aetiology of SCD in a representative cohort and evaluated how its results facilitate prevention of SCD.

Methods: A total of 115 SCD cases (34 females/81 males; av. age 34.1 years; period 2016-2021) was ascertained. Following genetic consultation and cardiological examination of victims’ living relatives 100 candidate genes in 106/115 cases on the MiSeq platform (Illumina) followed by SOPHiA GENETICS DDM bioinformatics (Switzerland) were examined. Class IV-V variants representing the probable cause of the observed clinical symptoms in the patient.

Results: The targeted PRKAG2 gene screening turned out to be negative. WES led to the detection of two heterozygous variants in the GTPBP3 gene. Variants in this gene have been reported in patients with HCM, associated with combined oxidative phosphorylation deficiency 23. These heterozygous variants represent the probable cause of the observed clinical symptoms in the patient.

References:

Grants: The financial support of Medical University Sofia, Grant № D-125/2021 is gratefully acknowledged.

Conflict of Interest: None declared.
ventricular noncompaction (DCM/LVNC), 22 - arrhythmogenic right ventricular cardiomyopathy (ARVC), 7 - sudden infant death (SIDS) and 11 - acute aortic dissection were diagnosed. Positive family history (pFH) of cardiac disease or SCD was identified in 27/115 (23.4 %; median age 41.0 years) of victims, whereas in cases without pFH their median age was significantly lower – 30.0 years. Molecular aetiology (i.e. presence of Class 4 -5 variants) was detected in a total 21/106 cases (19.8%) in RYR2, KCNQ2, KCNQ1, SCN5A, FLNC, GLA, TTN, TNNT2, RBM 20, MYPN, MYBPC3, FHL1, TGFBR1 and COL3A1. Diagnostic yield in cases with pFA reached 13/27 cases (48.1 %).

Conclusion: We demonstrate the utility of post mortem cardiac-genetic examination in individuals older than 40 years of age.

References:

Grants: NV18-02-00237 and the Czech SCD Research Consortium.

Conflict of Interest: None declared.

P06.036.B Molecular analysis of cardiomyopathies using next generation sequencing technologies in Slovak patients

Jarmila Bernasovská1, Iveta Boronova1, Michaela Zigová1, Eva Petrejčíková1

1University of Presov, Institute of Biology, Presova, Slovakia.

Background/Objectives: The aim of the study was to analyze a panel of genes associated with dilated or hypertrophic cardiomyopathy based on previously published results in order to identify the subjects at risk.

Methods: The method of next-generation sequencing by IlluminaHiSeq 2500 platform was used to detect sequence variants in 28 individuals diagnosed with dilated or hypertrophic cardiomyopathy. Detected variants were filtered and the functional impact of amino acid changes was predicted by computational programs.

Results: DNA samples of the 28 patients were analyzed by whole exome sequencing. We identified six nonsynonymous variants that were shown to be pathogenic in all used prediction softwares: rs3744998 (EPG5), rs11551768 (MGME1), rs148374985 (MURC), rs78461695 (PLEC), rs17158558 (RET) and rs2295190 (MYBPC3). Two of the analyzed sequence variants had minor allele frequency (MAF)<0.01: rs148374985 (MURC), rs34580776 (MYBPC3).

Conclusion: Our data support the potential role of the detected variants in pathogenesis of dilated or hypertrophic cardiomyopathy; however, the possibility that these variants might not be true disease-causing variants but are susceptibility alleles that require additional mutations or injury to cause the clinical phenotype of disease must be considered.

References: Rocarati,M.,Latronico,M.V.G.,Musumeci,M. et al.: Unexpectedly low mutation rates in beta-myosin heavy chain and cardiac mioin finding protein genes in Italian patients with hypertrophic cardiomyopathy. J Cell Physiol, 226,2894-2900, 2011.

Yamada T, Nomura S. Recent Findings Related to Cardiomyopathy and Genetics. Int J Mol Sci. 2021 Nov 20;22(22):12522. https://doi.org/10.3390/ijms222212522. PMID: 34830403; PMCID: PMC8623065.

Grants: KEGA 032PU-4/2021.

Conflict of Interest: None declared.

P06.037.C Aortic rupture force in mice modelling hereditary aortic diseases

Nicolo Dubacher1,2, Kaori Sugiyama3,4, Jeffrey Smith5, Vanessa Nussbaumer1, Sylvan Caspar1, Marc Schönholzer1, Janine Meienberg1, Hiromi Yanagisawa2, Mary Sheppard4,5, Gabor Matyas1,3

1Center for Cardiovascular Genetics and Gene Diagnostics, Swiss Foundation for People with Rare Diseases, Schlieren-Zurich, Switzerland; 2Translation Cardiovascular Technologies, Department of Health Sciences, ETH Zurich, Zurich, Switzerland; 3Life Science Center for Survival Dynamics, Tsukuba Advanced Research Alliance, University of Tsukuba, Tsukuba, Japan; 4Institute For Advanced Research of Biosystem Dynamics, Research Institute for Science and Engineering, Waseda University, Tokyo, Japan; 5Saha Cardiovascular Research Center, University of Kentucky, Lexington, United States; Department of Family and Community Medicine, University of Kentucky, Lexington, United States; 6Saha Aortic Center, University of Kentucky, Lexington, United States; 7Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.

Background/Objectives: Individuals suffering from hereditary aortic diseases (ADs) are at increased risk for aortic dissections and ruptures. We established an objective approach to measure the rupture force of the murine thoracic aorta, thereby explaining the outcomes of clinical studies and assessing an added value of old drugs in vascular Ehlers-Danlos syndrome (vEDS). Here, we applied our approach to six additional mouse AD models.

Methods: We used two mouse models for Marfan syndrome (MFS) as well as one smooth-muscle-cell-specific Etemp2 knockout (SMKO) and three CRISPR/Cas9-engineered knock-in models (Ltbp1, Mlap4, and Timp1). Moreover, one mouse MFS model was subjected to 4-week-long losartan treatment previously shown to reduce aneurysm growth. As previously described, 1.5-mm-long sections of the murine thoracic aorta were mounted on a tissue puller and uniaxially stretched until rupture.

Results: The aortic rupture force was significantly lower in both MFS and SMKO models, but mice with knock-in mutations in the genes Ltbp1, Mlap4, and Timp1 did not present with an impaired aortic integrity. As expected, the losartan treatment of MFS-modelling mice led to the reduction of aneurysm formation, which, surprisingly, had no impact on the aortic rupture force.

Conclusion: We show for the first time that our read-out system is able to characterize the aortic biomechanical integrity of mice modelling not only vEDS but also related ADs. Furthermore, aneurysm progression alone may not be a sufficient read-out for aortic rupture, as blood-pressure-lowering therapies preventing aortic aneurysms might still not strengthen the weakened aortic wall. These results may contribute to better medical therapies of hereditary ADs.

References: None declared.

P06.038.D Functional characterization of iPSC-derived cardiomyocytes from Brugada syndrome patients of a genetically unresolved family reveals distinct underlying mechanisms

Dogan Akdeniz1, Aleksandra Nijak1, Eline Simons2, Bert Vanden-driesche2, Dieter Van de Sande3, Erik Fransen4, Ewa Sieliwonczyk5, Dorien Schepers1, Dirk Snyders1, Emilene Van Craenenbroeck6, Johan Saenen7, Alain Labro8, Maaike Alaeerts1, Bart Loey1

1University of Antwerp, Antwerp, Belgium; 2Antwerp University Hospital, Edegem, Belgium; 3Ghent University, Ghent, Belgium.

Background/Objectives: Brugada syndrome (BrS) is an inherited cardiac arrhythmia characterized by a specific ECG pattern of ST-segment elevation, predisposition to ventricular fibrillation and sudden cardiac death. Over 20 genes have been associated with the disorder, however roughly 70% of patients remains without a genetic diagnosis.

Abstracts from the 55th European Society of Human Genetics Conference
Methods: In a large family with six mutation-negative BrS patients, we performed a SNP-based linkage analysis and whole-genome sequencing (WGS) on three patients. From two patients, one unaffected relative and an unrelated healthy control individual iPSC-derived cardiomyocytes (iPSC-CMs) were created. Molecular and electrophysiological characterization of the iPSC-CMs was performed using qPCR, immunocytochemistry, patch-clamping and calcium imaging.

Results: We detected significant linkage with a chromosome 2 locus (LOD score 3.16). In the WGS-data, no interesting shared candidate variants were identified, also not in the linked locus. Studying the iPSC-CM models, one patient showed significantly reduced sodium current density, a positive shift in sodium channel voltage dependence of activation and reduced action potential amplitude and upstroke velocity. The second patient showed changes in calcium transient duration and rise time, while in both patients arrhythmia-like events occurred during the calcium recordings.

Conclusion: Characterization of iPSC-CMs of two patients from a BrS family showing significant linkage on chromosome 2, showed one patient with a sodium current loss-of-function phenotype consistent with previously reported BrS phenotypes, while the other one only showed calcium handling abnormalities. These results suggest different underlying disease mechanisms within one family, underscoring the complex nature of BrS.

References:

Grants: Research Foundation Flanders, University of Antwerp BOF, ERC.

Conflict of Interest: None declared.

P06.039.A WES and its application for diagnostic purposes in hypertrophic cardiomyopathy

Albena Todorova1, Petya Angelova1, Slavena Atemin1,2, Nikolay Stoyanov3, Tihomir Todorov2, Mila Slepsova2, Krasimira Hristova4, Mariana Gospodinova5, Vanyo Mitev3, Vasil Velchev2

1Medical University of Sofia, Department of Medical Chemistry and Biochemistry, Sofia, Bulgaria; 2Genetic Medico-Diagnostic Laboratory “Genica”, Sofia, Bulgaria; 3University Hospital “St. Anna”, Department of Cardiology, Sofia, Bulgaria; 4Medical Center for Cardiovascular Disorders, Sofia, Bulgaria; 5University Hospital “St. Ivan Rilski”, Sofia, Bulgaria.

Background/Objectives: Hypertrophic cardiomyopathy (HCM) is a common genetically heterogeneous disorder with an autosomal dominant inheritance and incomplete penetrance. More than 50 genes are associated with HCM and it is the most common cause of cardiac death due to cardiac failure. Genetic testing is strongly recommended for patients with clinically suspected HCM due to echocardiography/ECG data, family history for the disease and/or anamnestic data. The phenotype-genotype correlations are difficult to interpret: patients with the same genetic variant could express different clinical presentation, even in the same family.

Methods: A group of 20 HCM patients were screened for pathogenic variants by use of WES (Whole Exome Sequencing). The analysis included a panel of 242 genes associated with cardiomyopathy. The WES data is interpreted by GenesearchNGS software.

Results: The genetic diagnosis was clarified in 9 cases. Pathogenic variants were detected in the following genes: MYBPC3 - 4 variants; TNNI3; LAMP2; RBM20; MYLK2 and JPH2. The suspected clinical diagnosis of Danon disease was genetically confirmed by mutation in the LAMP2 gene. Severe hypertrophic and restrictive cardiomyopathy is provoked by TNNI3 mutation. The gene RBM20 seems to be a promising candidate gene for HCM.

Conclusion: The application of WES for diagnostic purposes in HCM cases turned out to be very useful in order to study the molecular bases of cardiomyopathies. In total 45% of our cases are genetically diagnosed. Moreover, the affected families are offered adequate genetic counseling and prenatal diagnostics.

References:

Grants: The financial support of Medical University-Sofia, Grant № D-125/2021 is gratefully acknowledged.

Conflict of Interest: None declared.

P06.040.B APOE molecular spectrum in a French cohort with primary dyslipidemia

Yara Abou Khall1,2, Oriane Marmontel3,4, Olivier Blureau2, Catherine Boileau1,2, Marianne Abi-Fadel1,2, Mathilde Di Filippo4,5, Alain Carrie6, Jean-Pierre Rabes8,9, Mathilde VARET1,2

1INSERM, Laboratory for Vascular Translational Science (LTVS), F-75018 Paris, France, Paris, France; 2Université de Paris and Université Sorbonne Paris Nord, Paris, France; 3Laboratory of Biochemistry and Molecular Therapeutics (LBTM), Faculty of Pharmacy, Pôle Technologies-Santé (PTS), Saint-Joseph University, Beirut, Lebanon; 4CarMen Laboratory, INSERM U1060, INRAE U1397, Université Lyon 1, Oullins, France; 5Hospices Civils de Lyon, Department of Biochemistry and Molecular Biology, bron, France; 6INSERM UMRs 1166, Faculty of Medicine Pitié-Salpêtrière, Sorbonne University, Paris, France; 7Genetic Department, AP-HP, Hôpital Bichat, F-75018 Paris, Paris, France; 8Department of Biochemistry and Molecular Genetics, Ambroise Paré University Hospital, APHP, Boulogne Bilancourt, France; 9UFR Simone Veil-Santé, University of Versailles-Saint-Quentin-en-Yvelines, Paris-Saclay University, Montigny-le-Bretonneux, France.

Background/Objectives: Primary hypercholesterolemia is characterized by elevated LDL-cholesterol (LDL-C) levels associated with autosomal dominant hypercholesterolemia (ADH) or associated with elevated triglycerides levels in case of familial combined hyperlipidemia (FCHL), both leading to cardiovascular diseases (CVD). Along with LDLR, APOB, PCSK9, rare APOE gene variants were reported in ADH and FCHL. We explored the APOE molecular spectrum in a French ADH/FCHL cohort of 5,743 unrelated probands.

Methods: NGS was performed on coding DNA sequence and flanking introns (exon padding +/- 30 bp) of the LDLR, PCSK9, APOB and APOE genes and on the 12 SNPs of the polygenic score.

Results: The LDLR, PCSK9, APOB and APOE sequencing revealed 76 carriers of a rare APOE variant, without a mutation in the first three genes. Among the 31 variants 5 were described in ADH/FCHL: p.Leu167del, p.Leu46Pro, p.Arg163Cys, p.Arg269Gly and p.Gly145Asp. Twelve novel missense, five synonymous, two intronic and seven variants in regulatory regions were also identified. Sixteen variants were predicted in silico pathogenic or likely pathogenic, and their carriers had a significantly lower polygenic risk score than carriers of predicted benign variants. We did not observe any correlation between the LDL-C levels and the polygenic risk score which is in favour of a major effect of APOE potentially pathogenic variants. The p.Leu167del carriers were associated with a more severe phenotype and our data suggest that APOE variant carriers are better responders to statins than carriers of a LDLR mutation.

Conclusion: Altogether, we show that the APOE variants account for a significant part of ADH and FCHL.

References:

None declared.

Conflict of Interest: None declared.
P06.041.C Discovery of rare variants associated with resting heart rate

Julia Ramirez1, Stefan van Duijvenboden1, Lahiru Thomas Sooriyabandara2, Andrew Tinker1, Patricia Munroe1

1Queen Mary University of London, William Harvey Research Institute, London, United Kingdom; 2University of Nottingham, Nottingham, United Kingdom.

Background/Objectives: Resting heart rate (RHR) is associated with cardiovascular disease. Genome-wide association studies (GWAS) have identified common variants at 437 loci, but their biological processes are not fully characterised. Identification of rare variants may help to pinpoint candidate genes.

Methods: We first performed a rare variant GWAS (RV-GWAS) for RHR in 388,223 individuals filtering by allele count > 10. Next, whole exome sequencing (WES) analysis in 161,539 individuals was done to explore consistency of findings and discover coding variants. All participants were of European ancestry from UK Biobank.

Results: The RV-GWAS identified 29 rare variants (9 at known RHR loci). At novel loci, we observe three missense variants in genes AKTIP, TBX5 and DBH. AKTIP encodes an AKT interacting protein, and a knockout mouse model has shown heart abnormalities. The rare variants at TBX5 and DBH are identical to those reported for blood pressure traits. The WES analysis identified 6 rare variants. Three variants overlapped the RV-GWAS and three variants were novel. We observe a missense variant in HIGD1B, a gene with no prior associations with cardiovascular phenotypes. At a second novel locus, a knockout mouse model of TBC1D32 demonstrates several cardiovascular abnormalities.

Conclusion: We identified 35 rare variants associated with RHR across the RV-GWAS and WES, highlighting potential novel candidate genes. Ongoing studies are focused on gene-based testing and validation.

References: (1) Mensah-Kane et al. Front Genet 18; 12:569323 (2021); (2) Lee et al. AJHG 95, 1, 5-23 (2014); (3) Silvestri V et al. Cancer 123, 210-8 (2017).

Grants: MRC grant MR/N025083/1, European Union-NextGenerationEU.

Conflict of Interest: None declared.

P06.042.D Cardiac Arrhythmia Syndrome with ST-Segment Depression

Enrica Marchionni1, Ruggiero Mango2, Valentina Ferradini3, Francesca Di Lorenzo1, Giovanni Parlapiano1, Giuseppe Novelli1,2, Federica Sangiuolo1,3

1Medical Genetics Unit, Tor Vergata University Hospital, Department of Oncohematology, Rome, Italy; 2Cardiology Unit, Department of Emergency and Critical Care, Tor Vergata University Hospital, Rome, Italy; 3Laboratory of Molecular Genetics, Department of Biomedicine and Prevention, Tor Vergata University Hospital, Rome, Italy.

Background/Objectives: We report a large three-generation Italian family presenting with a peculiar ECG pattern and sudden cardiac death (SCD) in several individuals.

Methods: The proband was referred at 59 y.o. after a resuscitated cardiac arrest. She presented with recurrent atrial fibrillation and an abnormal ECG pattern, showing a concave-upward ST-segment depression in leads I, II, aVL, aVF and V2-6. Coronary angiographic studies were normal. She soon after died of SCD as well as her younger sister and several other family members, including her son, father, paternal grandmother, two uncles and three cousins. The proband’s older sister and her son were clinically screened and presented similar ECGs patterns.

Results: Firstly, genomic DNA was extracted from peripheral blood of the proband and Next Generation Sequencing (NGS) analysis was performed through a targeted panel of 61 genes associated with channellopathies and cardiomyopathies. NGS analysis failed to evidence the underlying genetic cause in the proband. Secondly, genomic DNA was extracted from peripheral blood of the proband’s older sister, her affected son and the healthy father. Trio-based Exome Sequencing (ES) was performed but failed to evidence the underlying genetic cause.

Conclusion: The intriguing ECG pattern of the present family fulfilled the proposed clinical criteria of ST-segment depression syndrome recently observed in five other families and segregating as an autosomal dominant trait1. Extensive examination of the NGS data revealed no coding variants segregating with the disease in any of the families reported to date. Genome sequencing is ongoing to reveal the likely underlying genetic cause.

References: 1PMID:30380381.

Grants: None.

Conflict of Interest: None declared.

P06.043.A The genetic landscape and clinical implication of pediatric Moyamoya angiopathy in a multiethnic cohort

Paolo Zanoni1, Katharina Steindl1, Heinrich Sticht2, Beatrice Oneda1, Pascal Jost1, Ivan Ivanovski1, Anselm Horn1, Elena Cabello1, Alessandra Baumer1, Julia Laube1, Markus Zweier1, Anita Rauch1,2,4, Nadia Khan1

1University of Zurich, Institute of Medical Genetics, Schlieren-Zurich, Switzerland; 2Friedrich-Alexander University Erlangen-Nürnberg, Institute of Biochemistry, Erlangen, Germany; 3University of Zurich, Zurich Center for Integrative Human Physiology, Zurich, Switzerland; 4University of Zurich and ETH Zurich, Neuroscience Center Zurich, Zurich, Switzerland; 5University Children’s Hospital Zurich, Moyamoya Center, Zurich, Switzerland.

Background/Objectives: To perform a comprehensive genotype-phenotype analysis in paediatric Moyamoya Angiopathy (MMA)1,2 patients with focus on clinical implications.

Methods: We performed molecular karyotyping, exome sequencing and automated structural assessment of missense variants on a series of 88 paediatric MMA patients and correlated genetic, angiographic and clinical findings.

Results: The two largest subgroups consisted of RNF213 and neurofibromatosis patients. While deleterious RNF213 variants were associated with a severe MMA clinical course with early symptom onset, frequent posterior cerebral artery involvement and higher stroke rates in multiple territories, NF1 patients had a similar infarct burden compared to non-NF1 individuals and were often diagnosed incidentally during routine MRIs. Additionally, we found that MMA-associated RNF213 variants have lower predicted functional impact compared to those associated with aortic disease. We also raise the question of MMA as a feature of recurrent as well as rare chromosomal imbalances and further support the association of MMA with STAT3 deficiency.

Conclusion: We provide a comprehensive characterization at the genetic and clinical level of a large exclusively pediatric MMA population. Due to the clinical differences we found across genetic subgroups we propose genetic testing for risk stratification as part of the routine assessment of pediatric MMA patients.

References: 1. Scott RM, Smith ER. Moyamoya Disease and Moyamoya Syndrome. N Engl J Med. 2009;360(12):1226-1237. 2. Kim SK, Cho BK, Phi JH, et al. Pediatric moyamoya disease: An analysis of 410 consecutive cases. Ann Neurol. 2010;68(1):92-101.
**P06.044.B Prevalence and clinical consequences of multiple pathogenic variants in dilated cardiomyopathy**

Sophie Stroeks¹, Ida Lunde², Debby Hellebrekers³, Godelieve Claes³, Ingrid Krapel⁴, Hiroko Wakimoto⁵, Els Vanhoucke⁶, Arthur van den Wijngaard⁶, Michiel Henkens¹, Anne Raafs¹, Maurits Sikking¹, Jos Broers³, Miranda Nabben¹,⁴,⁵, Elizabeth Jones¹,⁶, Stephane Heymans¹,⁶, Han Brunner⁶,⁷, Job Verdonschot¹,⁴

¹Maastricht University, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, Netherlands; ²Harvard Medical School, Genetics, Boston, United States; ³Akershus University Hospital, Diagnostics and Technology, Oslo, Norway; ⁴Maastricht University Medical Center, Clinical Genetics, Maastricht, Netherlands; ⁵Maastricht University, Genetics and Cell Biology, Maastricht, Netherlands; ⁶KI Leuven, Cardiovascular Sciences, Leuven, Belgium; ⁷Radboud University Medical Center, Human Genetics, Nijmegen, Netherlands.

**Background/Objectives:** Dilated cardiomyopathy (DCM) was considered a monogenetic disease which can be caused by over 50 genes. Evidence suggests that the combination of multiple pathogenic variants leads to greater disease severity and earlier onset. So far, not much is known about the prevalence and disease course of multiple pathogenic variants in patients with DCM. To gain insight in these knowledge gaps, we 1) systematically collected clinical information of a well-characterized DCM cohort and 2) created a mouse model.

**Methods:** Complete cardiac pheno- and genotyping was performed in 854 consecutive DCM patients. Patients were followed for an average of 54 months. Endomyocardial biopsies were taken from patients for RNA-sequencing. Compound heterozygous digenic (LMNA/TTNΔ) and monogenic (LMNA/WT) and WT/WT mice were created and phenotypically followed over time. Heart tissue was used for RNA-sequencing.

**Results:** 131 (likely) pathogenic (LP/P) variants were found in 854 consecutive tested DCM patients (15.4%). Three of the 131 patients had a second LP/P variant (2.3%). These three patients had a comparable disease onset, disease severity, and clinical course compared to DCM patients with one LP/P. The LMNA/TTNΔ mice also had no functional differences compared to the LMNA/WT mice after 40 weeks of follow-up, although RNA-sequencing suggests increased cardiac stress and sarcomere insufficiency in the LMNA/TTNΔ mice.

**Conclusion:** 2.3% of DCM patients with one LP/P also have a second LP/P in a different gene. Although the second LP/P does not seem to influence the disease course of DCM in patients and mice, the finding of a second LP/P can be important for their relatives.

**References:**

**Conflict of Interest:** None declared.

**P06.045.C Specific de novo variants in RNF213 cause a monogenic early-onset multisystemic disease ranging from childhood stroke to Leigh-like syndrome**

Theresa Brunet¹,⁴, Victoria Liefthüchter¹, Dominic Lenz¹, Philipp Peters¹, Robert Kopajtich², Benedikt Zott³,⁶, Hanna Zimmermann⁶, Irina Hüning¹, Diana Ballhausen¹, Christian Stauffer, Alyssa Bianzano¹, Joanne Hughes¹, Robert Taylor¹,², Robert McFarland¹,², Tamara Zigman¹, Danijela Petkovic Ramadza¹,², Rohlfis Meino³, Ute Hehr¹,¹⁵, Neal Sondheimer¹,³,⁶,¹⁷,¹⁸, Stacy Hewson¹,², KIKOLAOS MARINAKIS¹,¹⁹, Konstantina Kosma¹, Jan Traeger-Synodinos¹,³, Holger Proksch¹,³, Thomas Meitinger¹, Ingo Borggräfe²,²², Juliane Spiegler²², Ivo Baric¹⁴, Marco Paolini¹⁷, Lucia Gerstl¹⁷, Mathias Wagner¹,²,²⁰

¹Technical University of Munich, School of Medicine, Institute of Human Genetics, Munich, Germany; ²Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany; ³Department of Pediatrics, Dr. von Hauner Children’s Hospital, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany; ⁴Centre of Child and Adolescent Medicine, Department of Pediatric Neurology and Metabolic Medicine, Heidelberg University Hospital, Heidelberg, Germany; ⁵Institute of Neuroscience, Technical University of Munich, Munich, Germany; ⁶Munich Cluster for Systems Neurology, Technical University of Munich, Munich, Germany; ⁷Department of Neuroangiology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany; ⁸Institute of Neuropathology, University Hospital, LMU Munich, Munich, Germany; ⁹Institute of Human Genetics, University of Lübeck, Lübeck, Germany; ¹⁰Pediatric Metabolic Unit, Pediatrics, Woman-Mother-Child Department, University of Lausanne and University Hospital of Lausanne, Lausanne, Switzerland; ¹¹National Centre for Inherited Metabolic Disorders, Children’s Health Ireland at Temple Street, Dublin, Ireland; ¹²National Centre for Inherited Metabolic Disorders, Children’s Health Ireland at Temple Street, Dublin, Ireland; ¹³Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute, Faculty of Medical Sciences Newcastle University Newcastle upon Tyne United Kingdom; ¹⁴NHS Highly Specialised Services for Rare Mitochondrial Disorders, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; ¹⁵Department of Paediatrics, University Hospital Center Zagreb and University of Zagreb School of Medicine, Zagreb, Croatia; ¹⁶Center for Human Genetics, and Department of Human Genetics, University of Regensburg, Regensburg, Germany; ¹⁷Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON, Canada; ¹⁸Program in Genetics and Genome Biology Program, Sick Kids Research Institute, Toronto, ON, Canada; ¹⁹Departments of Pediatrics and Molecular Genetics, University of Toronto, Toronto, ON, Canada; ²⁰Laboratory of Medical Genetics, St. Sophia’s Children’s Hospital, National and Kapodistrian University of Athens, Athens, Greece; ²¹Department of Pediatric Neurology, Developmental Medicine and Social Pediatrics, University of Munich, 80337 Munich, Germany; ²²Department of Radiology, University Hospital, LMU Munich, Munich, Germany; ²³Department of Pediatric Neurology, University Hospital of Würzburg, 97080 Würzburg, Germany; ²⁴Epilepsy Center, University of Munich, 80337 Munich, Germany.

**Background/Objectives:** RNF213, encoding a giant E3 ubiquitin ligase, has been recognized for its role as key susceptibility gene for Moyamoya disease (MMD). To date, only single case descriptions have implicated an association of specific variants in RNF213 with an early-onset form of MMD with full penetrance. We aimed to systematically elucidate the clinical spectrum associated with RNF213 and to evaluate genotype-phenotype correlations.

**Methods:** Patients were identified through reanalysis of exome sequencing data of an unselected cohort from a single tertiary care center. Additional patients were ascertained via Genematcher and ClinVar. Phenotypic characterization including cMRI analyses and segregation analysis were performed.

**Results:** Nine individuals from eight unrelated families with heterozygous (8 de novo, 1 inherited) missense variants in RNF213 clustering within or around the RING domain were identified. 6/9 individuals had ischemic stroke between the age of birth and 23 years, five of which showed MRI alterations suggestive of Moyamoya disease. In contrast, 2 individuals had bilateral basal ganglia
T2 hyperintensities and high CSF lactate. Additionally, five individuals had recurrent episodes of elevated liver enzymes and three cases had cardiomyopathy. Secondary structural epileptic encephalopathy was frequent (6/9) requiring antiepileptic medication.

Conclusion: De novo missense variants in RNF213 clustering in the E3 RING or a region distal to it lead to a monogenic syndrome with two clinical presentations. Most patients presented with neonatal or childhood onset stroke and Moyamoya alterations whereas a second group had a Leigh-like phenotype. Hereby, we establish RNF213 as a Mendelian Disease Gene with symptoms beyond MMD.

References:
Grants:
Conflict of Interest: None declared.

P06.048.B The challenging choice of gene panel size: our experience with hypertrophic and dilated cardiomyopathy

Sebastian Suchet1, Philippe Meyer1, Eva Hammar Bouveret1, Maurice Beghetti1, Frédéric Masciaux1, Michel Guipponi1, Julie Wacker1, Agathe Py1, Judith Schwaiger2, Marc Abramowicz1, Jean-Louis Blouin1, Christiane Gruner2, Siv Fokstuen1

1University Hospitals of Geneva, Geneva, Switzerland; 2University Hospital Zurich, Zurich, Switzerland.

Background/Objectives: Implementation of next generation sequencing (NGS) has led to a rapid expansion in the number of genes included in diagnostic genetic testing for cardiomyopathies. This tendency is changing with the evidence-based assessment of genes conducted by ClinGen. Our aim was to evaluate the mutation detection rate and the involved genes in patients with isolated hypertrophic or dilated cardiomyopathy (HCM and DCM) according to the gene panel size.

Methods: Our NGS approach consist of targeted exome sequencing. Between September 2019, we used in-house gene panels including 65/78 cardiomyopathy genes. Since October 2019, we switched to Genomics England PanelAPP, including 144/201 genes with causative variants. All the genes with pathogenic or likely pathogenic variants identified with the large PanelAPP were already included in our smaller in-house panels.

Results: Between 2015 and 2021, a total of 135 patients with non-syndromic HCM or DCM underwent genetic testing. Our mutation detection rate was 49 % (36/74) with the in-house panels, 38% (23/61) with the PanelAPP panel and 44 % (59/135) overall. Comparing the two panel sizes we didn’t see any difference in the genes found with causative variants. All the genes with pathogenic or likely pathogenic variants identified with the large PanelAPP were already included in our smaller in-house panels.

Conclusion: Our results confirm the lack of major clinical benefit of large panels in isolated HCM or DCM and support the recommendations of the 2021 European Society of Cardiology heart failure guidelines, which suggest to use small evidence-based panels and to consider additional large panel only if there is a clear family history or a specific phenotype.

References:
Grants:
Conflict of Interest: None declared.

P07.001.C Loss of centrosomal gene ALMS1 alters cell metabolism through the TGF-β pathway

Brais Bea Mascato1, Diana Valverde Pérez2

1University of Vigo, Vigo, Spain.

Background/Objectives: Alström syndrome (AS) is a rare autosomal recessive disease that is associated with mutations in the ALMS1 centrosomal gene. The main manifestations of this syndrome are retinitis pigmentosa, obesity and type 2 diabetes mellitus. The depletion of the ALMS1 gene has been associated with the alteration of different processes regulated through the primary cilium, such as the Notch signalling pathway or TGF-β. Despite this, little is known about which cellular processes associated with the TGF-β pathway can be altered in the absence of ALMS1.

Methods: In this study we analyse the gene expression profile by RNA-seq of a cell line hTERT-BJ-5ta deficient in ALMS1, after stimulating the TGF-β pathway. We also performed a LFQ proteomic analysis by LC-MS/MS under the same conditions, to integrate the level of gene and protein expression. Finally, we validate the data obtained by western blot and fluorescence microscopy.

Results: RNA-seq data showed an enrichment mainly associated with TGF-β coordinated pathways such as PI3K/AKT, MAPKs or p53. Proteomic analysis showed an association between ALMS1 deficiency and alterations in cell metabolism and the lumen of intracellular organelles such as the endoplasmic reticulum. Observing the overlap of both datasets reinforced the relationship of ALMS1 with the endoplasmic reticulum and lipid-dependent signalling pathways. Finally, an over-activation of the AKT pathway was observed in the absence of ALMS1.

Conclusion: ALMS1 deficiency disrupted cross-signalling between the TGF-β pathway and other dependent pathways in immortalised fibroblasts. Furthermore, altered cross-signalling has implications for cellular metabolism and leads to over-activation of the AKT pathway.

References:
Grants:
Conflict of Interest: None declared.

P07.002.D ASAH1-related disorders: Expanding phenotypic spectrum requires updated thinking on diagnostic testing

Kathleen Crosby1, Alexander Solyom2

1Aceragen, Durham, United States; 2Aceragen, Basel, Switzerland.

Background/Objectives: Pathogenic variants in the ASAH1 gene cause acid ceramidase deficiency, which causes a spectrum of phenotypes. Farber disease, with typical symptoms including joint disease, subcutaneous nodules, and dysphonia, along with other symptoms like osteolysis; and SMA-PME (spinal muscular atrophy with progressive myoclonic epilepsy) are included recent literature and the Observational and Cross-Sectional Cohort Study of the Natural History and Phenotypic Spectrum of Farber Disease (NCT03233841). This systematic clinical study of patients with Farber disease included prospective evaluations, with 45 patients enrolled.

Results: 266 cases of ASAH1-related disorders were reviewed for phenotypic classification. 129 cases were classified as severe Farber disease with onset of symptoms and death before the age of 4 years; 66 cases as moderate to attenuated Farber disease with symptom onset in childhood and survival ranging from late childhood to the 6th decade; and 17 cases as unclassified Farber disease. 46 cases were classified as SMA-PME. Additional patients included 3 cases of late-onset SMA without epilepsy, one case of PME without SMA, 2 cases of SMA who later developed Farber disease symptoms, and 2 cases with both SMA-PME and Farber disease symptoms in childhood.

References:
None declared.
Conclusion: ASAH1-related disorders including Farber disease, SMA-PME, or variations of these phenotypes, are likely under-diagnosed. The broad phenotypic spectrum highlights the need for increased clinical suspicion and expanded inclusion of the ASAH1 gene in genetic testing for individuals presenting without textbook symptoms of acid ceramidase deficiency.

References:

Grants:

Conflict of Interest: Kathleen Crosby Aceragen, Aceragen, Alexander Solyom Aceragen, Aceragen.

P07.003 A Use of whole genome sequencing to determine the genetic basis of suspected mitochondrial disorders

Katherine Schon1, Rita Horvath2, Wei Wei2, Claudia Calabrese2, Arianna Tucci1, Kristina Ibáñez3, Thiloka Ratnaike4, Robert Pitceathly5, Enrico Bugiardini6, Ros Quinlivan7, Michael Hanna8, Emma Clement9, Emma Ashton10, John Sayer10, Paul Brennan11, Dragana Josifova12, Louise Izatt13, Carl Fratter14, Victoria Nesbitt15, Timothy Barrett16, Dominic McMullan17, Audrey Smith18, Charulata Despande12, Sarah Smithson19, Richard Festenstein14, Natalie Canham15, Mark Caulfield20, Henry Houlden21, Shamina Rahman22, Patrick Chinnery23

1University of Cambridge, Department of Clinical Neurosciences, Cambridge, United Kingdom; 2University of Cambridge, Department of Clinical Neurosciences, Cambridge, United Kingdom; 3Queen Mary University London, William Harvey Research Institute, London, United Kingdom; 4University College London, Queen Square Institute of Neurology, London, United Kingdom; 5Great Ormond Street Hospital for Children NHS Foundation Trust, Department of Clinical Genetics and Genomic Medicine, London, United Kingdom; 6Great Ormond Street Hospital for Children NHS Foundation Trust, NH South Thames Genomic Laboratory Hub, London, United Kingdom; 7Newcastle University, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle, United Kingdom; 8Newcastle Hospitals NHS Foundation Trust, Northern Genetics Service, Newcastle, United Kingdom; 9Guy’s Hospital, Department of Clinical Genetics, London, United Kingdom; 10Oxford University Hospitals NHS Foundation Trust, NHS Highly Specialised Services for Rare Mitochondrial, Oxford, United Kingdom; 11Birmingham Women’s and Children’s NHS Foundation Trust, West Midlands, Oxford and Wessex Genomics Laboratory Hub, Birmingham, United Kingdom; 12Manchester Centre for Genomic Medicine, Manchester, United Kingdom; 13University Hospitals Bristol, Department of Clinical Genetics, Bristol, United Kingdom; 14Imperial College, Department of Brain Sciences, London, United Kingdom; 15Liverpool Women’s Hospital, Liverpool Centre for Genomic Medicine, Liverpool, United Kingdom; 16Great Ormond Street Hospital for Children NHS Foundation Trust, Metabolic Unit, London, United Kingdom.

Background/Objectives: Diagnosis of mitochondrial disorders is challenging because they are clinically and genetically heterogeneous. WES has been effective for diagnosing mitochondrial disorders and discovering new disease genes. However, it is not possible to make a diagnosis in ~40%. WGS can diagnose pathogenic variants affecting the mtDNA and the nuclear genome, so it has the potential to make diagnoses in more families and shorten the ‘diagnostic odyssey’.

Methods: 319 families with suspected mitochondrial disorders were referred to the 100,000 Genomes Project after excluding common genetic causes. Human Phenotype Ontology terms were recorded, median 7 per participant. Short read WGS was analysed. Variants were prioritised using phenotype-based gene panels, Exomiser and comparison to ClinVar. mtDNA variants were called using an in-house pipeline. Copy number variants and short tandem repeats for thirteen neurological disorders were analysed.

Results: A definite or probable genetic diagnosis was identified in 98 families (31%), with an additional 6 possible diagnoses (2%). In total, 95 different genes were implicated. 37.5% of families had a mitochondrial diagnosis and 62.5% had a non-mitochondrial diagnosis. Diagnostic yield was higher in trios/quads (62/148) compared to singletons (23/102) (p = 0.005) and in children (64/143) compared to adults (46/202) (p < 0.001).

Conclusion: WGS is a useful diagnostic test in patients with suspected mitochondrial disorders yielding a diagnosis in a further 31% after excluding common causes. The majority of diagnoses were non-mitochondrial disorders, including developmental disorders with intellectual disability, epileptic encephalopathies, metabolic disorders, cardiomyopathies and leukodystrophies. These would have been missed using a targeted approach, with some having specific treatments.

References: BMJ 2021;375:e066288.

Grants:

Conflict of Interest: Katherine Schon Addenbrooke’s Charitable Trust. Medical Research Council (MRC) International Centre for Genomic Medicine in Neuromuscular Disease (MR/S005021/1), Rita Horvath Wellcome Trust Investigator (109915/Z/15/Z). Medical Research Council (UK) (MR/N025431/1). European Research Council, Newton Fund (UK/Turkey, MR/N027302/1).

Evelyn Trust.

Lily Foundation, Wei Wei: None declared, Claudia Calabrese: None declared, Arianna Tucci: None declared, Kristina Ibáñez: None declared, Thiloka Ratnaike: None declared, Robert Pitceathly: Medical Research Council Clinician Scientist Fellowship (MR/ S002065/1).

Medical Research Council strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNDM) (MR/S005021/1), Enrico Bugiardini: None declared, Ros Quinlivan: None declared, Michael Hanna Medical Research Council strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNDM) (MR/S005021/1), Emma Clement: None declared, Emma Ashton: None declared, John Sayer: None declared, Paul Brennan: None declared, Dragana Josifova: None declared, Louise Izatt: None declared, Carl Fratter: None declared, Victoria Nesbitt: None declared, Timothy Barrett: None declared, Dominic McMullan: None declared, Audrey Smith: None declared, Charulata Despande: None declared, Sarah Smithson: None declared, Richard Festenstein: None declared, Natalie Canham: None declared, Mark Caulfield: None declared, Henry Houlden: None declared, Shamina Rahman: None declared, Patrick Chinnery: None declared, Thiloka Ratnaike: None declared, Robert Pitceathly: None declared, Dominic McMullan: None declared, Audrey Smith: None declared, Charulata Despande: None declared, Sarah Smithson: None declared, Richard Festenstein: None declared, Natalie Canham: None declared, Mark Caulfield: None declared, Henry Houlden MRC, Wellcome Trust, Shamina Rahman BioMedical Insights - Payment to institution.

Neurovive - Payment to institution.

Partners4Access - Payment to institution.

Pfizer - Payment to institution.

Epipirn - Consultancy fee.

Stealth Biotherapeutics - Payment to institution.

Taysha Gene Therapies, Inc. - Consultancy fee.

Modis Therapeutics, Inc., a wholly-owned subsidiary of Zogenix, Inc. - Consultancy fee.

Pretzel Therapeutics, Inc. - Consultancy fee.

Access Infinity - Payment to institution, Editor, Journal of Inherited Metabolic Disease.

Senior Editor, Annals of Human Genetics.

Special Adviser to HFEA, Patrick Chinnery PFC is a Wellcome Trust Principal Research Fellow (212219/2/18/Z), and a UK NIHR Senior Investigator, who receives support from the Medical Research Council Mitochondrial Biology Unit (MC_UU_00015/9), the Medical Research Council (MRC) International Centre for Genomic Medicine in Neuromuscular Disease (MR/S005021/1), the Leverhulme Trust (RPG-2018-408), an MRC research grant (MR/S035699/1), an Alzheimer’s Society Project Grant (AS-PG-18B-022) and the National Institute for Health Research (NIHR) Biomedical Research.
Background/Objectives: Fabry disease (FD) is an X-linked lysosomal disease due to alpha-galactosidase A deficiency. This enzyme is involved in glycosphingolipid metabolism and its alteration leads to cellular dysfunction and microvascular pathology. Different organs are involved with kidney as a main organ alteration leading to cellular dysfunction and microvascular pathobiology. This study aims to provide insights into the pathobiology of multifactorial complex diseases. We performed genome-wide expression analysis in an FD human podocyte model.

Methods: RNAseq-based genome-wide expression analysis was done on human immortalized alpha-galactosidase A deficient podocytes generated using CRISPR/Cas9 technology, and control podocytes. Differential expression analysis was performed using DESeq2 package.

Results: Two hundred and forty-seven genes were differentially expressed, with 111 genes overexpressed and 136 under-expressed in FD compared to controls. Genes known to be involved in angiogenesis (ITGB3), autophagy (TIA1, SMG1) and oxidative stress (CB4a, BLYRA) were among these genes. The STRIPAK complex, related to autophagy, and the NADP/NADPH pathway (oxidative stress) were among the most altered pathways. The downregulated genes included MOB1A linked to the Hippo pathway which participates in kidney podocytes homeostasis maintenance.

Conclusion: These preliminary results unveil Fabry disease-related transcriptomic expression patterns. Further characterization of these disrupted cellular pathways could enable deeper understanding of FD pathobiology.

References:

Grants: None.

Conflict of Interest: Sarah Sanoudj University Hospital of Rouen, University of Rouen Normandy, celine derambure University of Rouen Normandie, Celine Lesueur University Hospital of Rouen, Lenaïg Donval: None declared, Stéphane Marret University Hospital of Rouen, University of Rouen Normandy, Soumeya Bekri University Hospital of Rouen, University of Rouen Normandy, Abdellah Tebani University Hospital of Rouen, University of Rouen Normandy.

P07.004.B Genome-wide expression analysis in Fabry disease human podocyte cell line

Sarah Sanoudj1, celine derambure2, Céline Lesueur1, Lenaïg Donval1, Stéphane Marret2, Soumeya Bekri1, Abdellah Tebani1
1Department of Metabolic Biochemistry, UNIROUEN, INSERM U1245, CHU Rouen, Normandie University, Rouen, France; 2Normandie University, UNIROUEN, IRIB, Inserm U1245, Normandy Center for Genomic and Personalized Medicine, Rouen, France; 3Department of Neonatal Pediatrics, Intensive Care and Neuropediatrics, UNIROUEN, INSERM U1245, CHU Rouen, Normandie University, Rouen, France.

Background/Objectives: Fabry disease (FD) is an X-linked lysosomal disease due to alpha-galactosidase A deficiency. This enzyme is involved in glycosphingolipid metabolism and its alteration leads to cellular dysfunction and microvascular pathology. Different organs are involved with kidney as a main organ target. The rise of omics sciences has prompted a paradigm shift, in both research and medicine. These approaches may open new insights into the pathobiology of multifactorial complex diseases. We performed genome-wide expression analysis in an FD human podocyte model.

Methods: RNAseq-based genome-wide expression analysis was done on human immortalized alpha-galactosidase A deficient podocytes generated using CRISPR/Cas9 technology, and control podocytes. Differential expression analysis was performed using DESeq2 package.

Results: Two hundred and forty-seven genes were differentially expressed, with 111 genes overexpressed and 136 under-expressed in FD compared to controls. Genes known to be involved in angiogenesis (ITGB3), autophagy (TIA1, SMG1) and oxidative stress (CB4a, BLYRA) were among these genes. The STRIPAK complex, related to autophagy, and the NADP/NADPH pathway (oxidative stress) were among the most altered pathways. The downregulated genes included MOB1A linked to the Hippo pathway which participates in kidney podocytes homeostasis maintenance.

Conclusion: These preliminary results unveil Fabry disease-related transcriptomic expression patterns. Further characterization of these disrupted cellular pathways could enable deeper understanding of FD pathobiology.

References:

Grants: None.

Conflict of Interest: Sarah Sanoudj University Hospital of Rouen, University of Rouen Normandy, celine derambure University of Rouen Normandie, Celine Lesueur University Hospital of Rouen, Lenaïg Donval: None declared, Stéphane Marret University Hospital of Rouen, University of Rouen Normandy, Soumeya Bekri University Hospital of Rouen, University of Rouen Normandy, Abdellah Tebani University Hospital of Rouen, University of Rouen Normandy.

P07.004.B Genome-wide expression analysis in Fabry disease human podocyte cell line

Sarah Sanoudj1, celine derambure2, Céline Lesueur1, Lenaïg Donval1, Stéphane Marret2, Soumeya Bekri1, Abdellah Tebani1
1Department of Metabolic Biochemistry, UNIROUEN, INSERM U1245, CHU Rouen, Normandie University, Rouen, France; 2Normandie University, UNIROUEN, IRIB, Inserm U1245, Normandy Center for Genomic and Personalized Medicine, Rouen, France; 3Department of Neonatal Pediatrics, Intensive Care and Neuropediatrics, UNIROUEN, INSERM U1245, CHU Rouen, Normandie University, Rouen, France.

Background/Objectives: Fabry disease (FD) is an X-linked lysosomal disease due to alpha-galactosidase A deficiency. This enzyme is involved in glycosphingolipid metabolism and its alteration leads to cellular dysfunction and microvascular pathology. Different organs are involved with kidney as a main organ target. The rise of omics sciences has prompted a paradigm shift, in both research and medicine. These approaches may open new insights into the pathobiology of multifactorial complex diseases. We performed genome-wide expression analysis in an FD human podocyte model.

Methods: RNAseq-based genome-wide expression analysis was done on human immortalized alpha-galactosidase A deficient podocytes generated using CRISPR/Cas9 technology, and control podocytes. Differential expression analysis was performed using DESeq2 package.

Results: Two hundred and forty-seven genes were differentially expressed, with 111 genes overexpressed and 136 under-expressed in FD compared to controls. Genes known to be involved in angiogenesis (ITGB3), autophagy (TIA1, SMG1) and oxidative stress (CB4a, BLYRA) were among these genes. The STRIPAK complex, related to autophagy, and the NADP/NADPH pathway (oxidative stress) were among the most altered pathways. The downregulated genes included MOB1A linked to the Hippo pathway which participates in kidney podocytes homeostasis maintenance.

Conclusion: These preliminary results unveil Fabry disease-related transcriptomic expression patterns. Further characterization of these disrupted cellular pathways could enable deeper understanding of FD pathobiology.

References:

Grants: None.

Conflict of Interest: Sarah Sanoudj University Hospital of Rouen, University of Rouen Normandy, celine derambure University of Rouen Normandie, Celine Lesueur University Hospital of Rouen, Lenaïg Donval: None declared, Stéphane Marret University Hospital of Rouen, University of Rouen Normandy, Soumeya Bekri University Hospital of Rouen, University of Rouen Normandy, Abdellah Tebani University Hospital of Rouen, University of Rouen Normandy.
Clinical picture and severity of ATAD3A-related disorders are dependent on the type of mutation and correlate with predicted severity of variants and their combinations.

References: Yap et al., Genome Med 2021.

Grants: APVV-17-0296, AVZ MZCR NV19-07-00136.

Conflict of Interest: None declared.

P07.008.B Unraveling a case of Niemann-Pick disease using long read sequencing and adaptive sampling

Deniz Karadurmus1, Sylvain Brohéé1, Sandrine Mary1, Valérie Benoit1, Anne Destree1, Dominique Roland1, Pascale Hilbert1

1Institut de Pathologie et Génétique, Gosselies, Belgium.

Background/Objectives: These last years, Oxford Nanopore Technology (ONT) emerged as a promisingactor for structural variants identification and repetitive regions analysis by long read sequencing. Moreover, ONT recently added the adaptive sampling option on its sequencing devices, i.e. a software-controlled enrichment method which allows to target genomic regions of interest without any specific wet-lab enrichment procedure. This method has been shown to identify structural variants not detected by conventional genetic testing (1). Therefore, we used this approach to analyze the unsolved case of a patient affected by the autosomal recessive Niemann-Pick disease, but in whom only one pathogenic mutation was previously identified in NPC1 gene despite extensive genetic testing.

Methods: Adaptive sampling of ONT was performed using 1.5 μg of DNA, on the basis of a custom bed file targeting NPC1 and surrounding genes.

Results: We reached a mean fold-enrichment of 7 on targeted region, along with mean depth coverage of 25.5X. Our result suggested an inversion of 70kb, involving NPC1 and its adjacent gene ANKRD29. This was then confirmed by PCR and Sanger sequencing. Moreover, segregation study showed that this inversion was in trans with the known point mutation, confirming Niemann-Pick diagnostic at molecular level.

Conclusion: The adaptive sampling option proposed by ONT appears extremely flexible and allows easy case-by-case adjustment and analysis. While still perfectible, we believe that this approach could be a valuable help in daily practice of genetics experts, in conjunction with classic genetic testing.

References: 1. Miller et al., PMID: 34216551.

Grants: Institut de Pathologie et Génétique Research Funds.

Conflict of Interest: None declared.

P07.009.C Follow-up of family members of children with mtDNA-associated Leigh syndrome

Celia Azevedo Soares1,2, Margarida Paiva Coelho3,4, Anabela Bandeira3,4, Rute Martins4, Rosa Ribeiro4, Natalia Tkachenko1, Ana Maria Fortuna1,2, Esmeralda Martins2,3,4

1Centro Hospitalar Universitário do Porto, Serviço de Genética Médica, Porto, Portugal; 2Instituto de Ciências Biomédicas Abel Salazar/Universidade do Porto, Unit for Multidisciplinary Research in Biomedicine, Porto, Portugal; 3Centro Hospitalar Universitário do Porto, Serviço de Pediatrica Médica, Porto, Portugal; 4Centro Hospitalar Universitário do Porto, Centro de Referência de Doenças Hereditárias do Metabolismo, Porto, Portugal.

Background/Objectives: Diagnostics of ATAD3A-related disorders is challenging from two reasons. Firstly, the ATAD3 locus contains three paralogous genes, making it difficult target for both sequencing and CNV analysis. Secondly, the clinical picture and severity are heterogeneous, ranging from recessive neonatal-lethal pontocerebellar hypoplasia through milder dominant Harlequin syndrome to, again, neonatal-lethal but dominant cardiomyopathy. Fourteen different recessive variants in 17 families have been described with so far.

Methods: We report two families, each with two affected children. Patients and their parents were analysed using WES followed by CNV analysis (ExomeDepth). Variants were verified using Sanger sequencing and long-range PCR. Enzymological and biochemical studies were performed in muscle and cultivated fibroblasts of one proband.

Results: Decreased activity of complex IV and decreased levels of nuclear-encoded subunits of respiratory chain confirmed mitochondriopathy in the Family 1 proband. Compound heterozygous p.Leu77Val and exon 3-4 deletion in the ATATD3A gene were found in all four affected members of both families. The p.Leu77Val variant had previously been described as mild by functional studies (Yap et al., 2021), exon 3-4 deletion is considered loss-of-function with severe impact. This novel combination of high- and mild-impact variants resulted in strikingly homogenous phenotype in our patients - less severe and with longer life-span than in case of bi-allelic loss-of-function variants.

Conclusion: Clinical picture and severity of ATAD3A-related disorders are dependent on the type of mutation and correlate with predicted severity of variants and their combinations.

References: Yap et al., Genome Med 2021.

Grants: AVZ MZCR NV19-07-00136.

Conflict of Interest: None declared.
Background/Objectives: Leigh syndrome (LS) is a genetic neurometabolic disorder characterized by central nervous system degeneration. Some patients have missense pathogenic variants in mtDNA inherited from the matrilineal lineage. Disease’s expressivity is dependent on the heteroplasmy level at a given tissue. Given this variable expressivity, we reviewed the features of family members of a cohort of patients with mtDNA-associated LS (MALS) in their matrilineline lineage. With this revision, we aim to understand the necessity of a structured follow-up for extended family members.

Methods: We reviewed five families with children with MALS syndrome followed at Centro Hospitalar e Universitário do Porto.

Results: All mothers were asymptomatic at the time of their children’s diagnosis, but two mothers initiated potentiality mitochondrial-related complaints after their child diagnosis. The mother of a child with MALS associated to m.10191T>C variant, presented headaches and abnormal subcutical white-matter T2 MRI signal, suggestive of adult onset-LS, with exclusion of autoimmunity and infections. The familial variant was not detected in this woman peripheral blood. A mother of a child with MALS associated to m.8993T>G variant, showed a heteroplasmy level of 75%, and presented complaints of headaches and fatigue. Her MRI showed left cerebellar cortico-subcortical hypodense area, suggestive of previous ischemic event. In this second family, two family members by the matrilinelineage present complaints suggestive of neuropathy, ataxia, and retinitis pigmentosa.

Conclusion: Follow-up guidelines should be established for MALS family members at risk and genetic counseling should be offered to all family members in the matrilinelineage of an index case.

References:
Grants:
Conflict of Interest: None declared.

P07.010.D ATAD3 knockout model in zebrafish

Shlomit Ezer1,2, Nathan Ronin3,4, Shahar Rotem-Bamberger5,6, Shira Yanovsky-Dagan1, Adi Inbal1,2, Tamar Harel1

1Hadassah Medical Center, Department of Genetics, Jerusalem, Israel; 2Hebrew University, Faculty of Medicine, Jerusalem, Israel; 3Hebrew University of Jerusalem, Department of Medical Neurobiology, Jerusalem, Israel; 4The Institute for Medical Research Israel-Canada, Jerusalem, Israel.

Background/Objectives: ATAD3A encodes a mitochondrial expressed protein which spans the inner and outer mitochondrial membranes. It is involved in mitochondrial dynamics, mtDNA maintenance, cholesterol metabolism, ER-mitochondria interaction and more. ATAD3A pathogenic variants have been shown to cause distinct neurological diseases in humans and we aimed to test possible remedies.

Methods: Using CRISPR-Cas9 genome editing, we created two lines of heterozygous fish with frameshift variants which can be bred to produce atad3-null embryos. We examined the phenotype and mitochondrial content of the mutant embryos, and compared the transcriptome of wild-type and mutant embryos at 3 days post-fertilization (dpf) via RNAseq. Results were validated by quantitative real-time PCR at 3dpf and 5dpf.

Results: Atad3-null embryos demonstrated microcephaly, small eyes, pericardial edema and thinning of the musculature, closely correlating with the human disease. Mitochondrial content was reduced. Transcriptome analysis revealed an expected decline in most mitochondrial pathways in the mutant embryos. In addition, we witnessed an unexpected global upregulation of cytosolic tRNA synthetases, presumably secondary to ER stress.

Conclusion: Zebrafish atad3-null embryos can be used as a reliable model of human ATAD3A-associated disorders. ER stress signals seem to have a role in the pathogenesis, and blocking ER stress by small compounds may serve as a potential therapeutic pathway.

References: Harel, T., et al. (2016). Am J Hum Genet 99, 831-845.

Grants: ISF 1663/17 to TH.

Conflict of Interest: None declared.

P07.011.A Impact of GCSH-deficiency: a protein at the crossroad of one-carbon metabolism and cellular respiration

Laura Arribas1, Mike Swanson2, Elsebet Østergaard3, Cristina Dallabona4, kostas Tsikas5, Moja Hempe6, Cecile Acquaviva7, Joseph Farris8, Nicholas Stence9, Martina Magistrati10, Stefanos Koutsoukos10, Elaine Spector7, kathryn Krongquist11, Mette Christensen11, Helen Karsen11, Rene G. Fichtinger11, Melanie Achleitner11, Lawrence Merritt12, Belén Pérez1, Magdalena Ugarte1, Stephanie Grunewald13, Anthony Riela13, Natalia Juve14, Jean-baptiste Arnoux15, Hans A. May15, Kastouri Haldar16, René Santer16, Allan Lund1, Claudia Donnini1, Pilar Rodríguez1, Johan Van Hove1

1Université Autonoma Madrid, Centro de Diagnostico de Enfermedades Moleculares, Centro de Biologia Molecular Severo Ochoa, CBM-CSIC, Departamento de Biologia Molecular, Madrid, Spain; 2University of Colorado, Department of Pediatrics, Aurora, Colorado, United States; 3Rigshospitalet - Copenhagen University Hospital, Centre for Inherited Metabolic Diseases, Department of Clinical Genetics, Copenhagen, Denmark; 4University of Parma, Department of Chemistry, Life Sciences and Environmental Sustainability, Parma, Italy; 5Department of Pediatrics, University Medical Center Hamburg Eppendorf, Hamburg, Germany; 6Institute of human genetics, University Medical Center Hamburg Eppendorf, Hamburg, Germany; 7CHU de Lyon, Services Maladies Héréditaires du Métabolisme, Centre de Biologie Est, Lyon, France; 8University of Notre Dame, Boler-Parseghian Center for Rare and Neglected Disease, and Department of Biological Sciences, Notre Dame, Indiana, United States; 9University of Colorado, Radiology Department, Aurora, Colorado, United States; 10University of Colorado, Department of Pediatrics, Section of Clinical Genetics and Metabolism, Aurora, United States; 11University Children’s Hospital, Paracelsus Medical University, Salzburg, Austria; 12Great Ormond Street Hospital, Institute for Child Health, Department of Metabolic Medicine, London, United Kingdom; 13Texas Child Neurology, Piano, TX, United States; 14IMED Valencia Hospital, Department of Pediatrics, Valencia, Spain; 15Necker Enfants Malades Hospital, Centre de Reference des Maladies Hereditaires du Metabolisme, Paris, France.

Background/Objectives: Post-translational lipoylation of the 2-ketoacid dehydrogenases (2KDH) is essential in the bioenergetics metabolism of eukaryotes. The GCSH-protein, lipoylated subunit of the glycine cleavage enzyme, has been proposed as the only acceptor of lipoate for transferring to other 2KDH in mammals but, this dual function remains unproven. We present an extensive analysis of the nucleotide variations identified in a cohort of six patients with genetic confirmation of bi-allelic changes in the GCSH gene.

Methods: The patient’s phenotyping included clinical record evaluation, biochemical analysis and brain MRIs. Genetic analysis was based on exome sequencing. Pathogenicity of nucleotide changes was assessed by in silico modelling and functional analysis in patient’s cells, knock-down models and purified recombinant proteins.
Results: The clinical presentations ranged from very severe early presentation with a fatal outcome to late milder courses. Patients had increased glycine levels in plasma and cerebrospinal fluid and mostly normal lactate. Genetic analysis identified four missense changes, one nonsense and two genomic rearrangements. Functional studies showed decreases in GCSH-protein amount, lipoylation status and mitochondrial respiration either in patient’s cells or after overexpressing missense GCSH-proteins in two GCSH knock-down models generated in COS7 and S. cerevisiae. Purified recombinant GCSH protein studies resembled those results.

Conclusion: We unravel the final step in post-translational lipoylation in mammals and describe a cohort of patients with a known mitochondrial stressor, indicating impaired mitochondrial activity in fibroblasts.

Proteomic results demonstrated decreased levels of subunits of the mitochondrial respiratory chain complex I, and both the small and large subunits of the mitochondrial ribosome, suggesting a mitoribosomal defect.

Conclusion: Our findings support the critical role of PYROXD2 in human cells, suggest that the biallelic PYROXD2 variants are associated with mitochondrial dysfunction and are the likely cause of the proband’s clinical presentation.

References:

Grants: Australian Government GHF76747.

Conflict of Interest: None declared.

P07.013.C Biallelic variants in PYROXD2 cause a severe infantile metabolic disorder affecting mitochondrial function

Nicole Van Bergen1-2, Daniella Hock3, Lucy Spencer1, Samir Massey4, Tegan Stait5, Zornitza Stark2,3,6,7, Sebastian Lunke8,9,10, Aïn Roesley4,5, David Thorne5, Joy Lee2,11, Anna Le Fevre12, Olivier Heath13, Cristina Mignone8, Joseph Yang1,2,3,10, Monique Ryan11, Colleen D’Arcy1,2, Margot Nash1,2, Sille Smith1,3, Nikeisha Caruana2,1,15, David Thorslund5,14, David Stroud1,14, Sue White1,14, John Christodoulou1,2,16, Natasha J Brown1,4

1Murdoch Children’s Research Institute, Brain and Mitochondrial Research Group, Parkville, Australia; 2University of Melbourne, Department of Paediatrics, Parkville, Australia; 3University of Melbourne, Department of Biochemistry and Pharmacology and Biob1 Molecular Science and Biotechnology Institute, Parkville, Australia; 4Victorian Clinical Genetics Services, Murdoch Children’s Research Institute, Parkville, Australia; 5Australian Genomics Health Alliance, Parkville, Australia; 6University of Melbourne, Department of Pathology, Parkville, Australia; 7Royal Children’s Hospital, Department of Metabolic Medicine, Parkville, Australia; 8Royal Children’s Hospital, Medical Imaging Department, Parkville, Australia; 9Royal Children’s Hospital, Department of Neurosurgery, Neuroscience Advanced Clinical Imaging Service, Parkville, Australia; 10Murdock Children’s Research Institute, Developmental Imaging, Parkville, Australia; 11Royal Children’s Hospital, Neurology Department, Parkville, Australia; 12Royal Children’s Hospital, General Medicine, Parkville, Australia; 13Royal Children’s Hospital, Paediatric Intensive Care Unit, Parkville, Australia; 14Victoria University, Institute for Health and Sport, Footscray, Australia; 15University of Sydney, Discipline of Child and Adolescent Health, Camperdown, Australia.

Background/Objectives: Pyridine Nucleotide-Disulfide Oxidoreductase Domain 2 (PYROXD2) is a mitochondrial inner membrane/matrix-residing protein reported to regulate mitochondrial function. Little is known about the clinical importance or precise biological function of PYROXD2. We report biallelic variants in PYROXD2 in a patient with suspected mitochondrial disease.

Methods: A male infant presented with acute unresponive episodes and extreme metabolic acidosis. He developed progressive neurological deterioration on a background of postnatal-onset poor growth and microcephaly. He died at 6.5 months age. Magnetic resonance brain imaging showed changes resembling Leigh syndrome. The proband and his unaffected parents underwent genome sequencing and RNA-seq analysis. Functional assays were conducted to assess mitochondrial function using patient fibroblasts. Protemic differences between the proband and control fibroblasts were investigated with high-resolution tandem mass spectrometry and quantitative protein analysis.

Results: No causative variants were found through standard trio analysis of known disease-causing genes, including analysis of the mitochondrial genome. A genome-wide analysis identified compound heterozygous variants in PYROXD2.

Functional assays revealed increased mitochondrial superoxide levels and a heightened sensitivity to culturing in galactose media, a known mitochondrial stressor, indicating impaired mitochondrial activity in fibroblasts.

Proteomic results demonstrated decreased levels of subunits of the mitochondrial respiratory chain complex I, and both the small and large subunits of the mitochondrial ribosome, suggesting a mitoribosomal defect.

Conclusion: Our findings support the critical role of PYROXD2 in human cells, suggest that the biallelic PYROXD2 variants are associated with mitochondrial dysfunction and are the likely cause of the proband’s clinical presentation.

References:

Grants: Australian Government GHF76747.

Conflict of Interest: None declared.

P07.014.D MITODIAG: A French network of diagnostic laboratories for mitochondrial diseases

Cécile Rouzier1,2, Emmanuelle Pion3, Céline Briss4, Patrizia Bonneau5,6, Valérie Desquibret4,5, Jean-Paul BONNEFONT4,6, Giulia Barcia6, Alessandra Pennisi6, Julie Steffann4, Pauline Gaignard4, Elise Lebigot7, Samira Ait-el-mkadem Saaïdi1,2, Sylvie Bannwarth1,2, Konstantina Fragaki1,2, Benoît Rucheton1,2, Bruno Francou4, Marie-Laure Martin Négrier1, Aurélien Trimouille1, Cécile Acquaviva10, Céline Pagan1,2, Anne-Sophie Lèbre1,2, Gaëlle Hardy1,2, Stéphane Allouche13, Pascal Reynier5,6, Mireille Cossee1,2, Anamaria Molon1,5, Shahram Attar-ian1,2, Véronique Paquis-Fluckinger1,2, Vincent Procaccio6

1Service de génétique médicale, Centre de référence des maladies mitochondriales, CHU Nice, Nice, France; 2Université Côte d’Azur, CNRS, INSERM, IRCAN, Nice, France; 3Filnemus, laboratoire de génétique moléculaire, CHU Montpellier, Montpellier, France; 4Service de génétique, Institut de BioLogie en santé, Centre National de référence Maladies Neurodégénératives et Mitochondriales, CHU Angers, Angers, France; 5Service de biochimie, Institut de Biologie en santé, Centre National de référence Maladies Neurodégénératives et Mitochondriales, CHU Angers, Angers, France; 6Fédération de génétique médicale, Service de génétique moléculaire du GH Necker-enfants malades, Hôpital Necker-Enfants Malades, Paris, France; 7Laboratoire de Biochimie, Pôle BPP, CHU Paris Sud, Hôpital Bicêtre-le Kremlin Bicêtre, Paris, France; 8Pôle de biologie et pathologie, CHU Bordeaux, Bordeaux, France; 9Unité fonctionnelle d’histologie moléculaire, Service de pathologie, CHU Bordeaux-GU Pellegrin, Bordeaux, France; 10Service de biochimie et biologie moléculaire Grand Est, UM Maladies Héréditaires du Métabolisme, Centre de biologie et pathologie Est, CHU Lyon HCL, GH Est, Lyon, France; 11Laboratoire de génétique, Hématologie et Immunologie, CHU Reims, Reims, France; 12Laboratoire de génétique moléculaire: maladies héréditaires et oncologie, Service de biochimie, biologie moléculaire et toxicologie environnementale, CHU Grenoble et des Alpes, Institut de biologie et pathologie, Grenoble, France; 13Service de biochimie, Pôle Biologie, Pharmacie et Hygiène, CHU Caen, Hôpital de la Côte de Nacre, Caen, France; 14Laboratoire de Génétique Moléculaire, CHU Montpellier, PhyMedExp, Université de Montpellier, INSERM, CNRS, Montpellier, France; 15Filnemus, Assistance Publique Hôpitaux Marseille, Marseille, France; 16Service de Neurologie, FILNEMUS, Hôpital La Timone, CHU, Marseille, France.
Background/Objectives: Mitochondrial diseases (MD) are characterized by a huge heterogeneity which poses significant diagnostic challenges for clinicians and around 50% of patients are still undiagnosed. Since 2000, the French Network of Mitochondrial Diseases Diagnostic Laboratories, called MITODIAG, has been created and works in close collaboration with the two National Reference Centers, CARAMMEL and CALISSON, and the Neuromuscular rare disease network FILNEMUS, in order to improve the diagnosis and health care for patients with MD.

Methods: We describe here the organization of the MITODIAG network, the evolution of genetic diagnosis in MD in France these last years and the interactions with national platforms of genome core sequencing facilities named AURAGEN and SEQOIA.

We also report the first clinical and genetic description of a cohort of more than 400 patients tested by NGS, in whom a diagnosis could be confirmed by the identification of pathogenic variants in nuclearly-encoded genes.

Results: 3/4 of the patients are children under 18 with often early and severe phenotypes, of mostly autosomal recessive inheritance. In these patients, 30% of pathogenic variants are located in complex I genes or genes involved in mitochondrial translation. In adults, diseases are more heterogeneous, from moderate to very severe, mainly with neuromuscular symptoms due to pathogenic variants in mtDNA maintenance machinery.

Conclusion: These data will be implemented in the MITO-MATCHER database in order to improve phenotype-genotype correlations and facilitate development of therapeutic strategies. Collaborations between MITODIAG and FILNEMUS will also facilitate patient follow-up in diagnostic wandering and will facilitate the identification of diagnosis for these patients.

References:

Grants:

Conflict of Interest: None declared.

P07.015.A Interpreting the pathogenicity of genetic variants in rare diseases: lessons from Fabry disease

Dominique P. Germain1,2, Thierry Levade3,4, Eric Hachull4, Bertrand Knebelmann5, Didier LACOMBE2, Vanessa Leguy-Seguin6, Karine NGUYEN PHONG7, Esther Noel8, Jean-Pierre Rabes9,11

1French Referral Centre for Fabry Disease, AP-HP University Paris-Saclay, Medical Genetics, Garches, France; 2University of Versailles-Saint-Quentin-en-Yvelines, Medical Genetics, Montigny le Bretonneux, France; 3INSERM UMR1037, Cancer Research Center of Toulouse (CRCT) and Paul Sabatier University, Toulouse, France; 4Clinical Biochemistry Laboratory, Reference Center for Inherited Metabolic Diseases, Federative Institute of Biology, University Hospital of Toulouse, Toulouse, France; 5Claude Huriez Hospital, University of Lille, Internal Medicine and Clinical Immunology, Lille, France; 6AP-HP, Necker Enfants Malades Hospital, University of Paris, Nephrology-Dialysis Department, Paris, France; 7University Hospital of Bordeaux and INSERM U1211, Medical Genetics, Bordeaux, France; 8François Mitterrand Hospital, Dijon University Hospital, Internal Medicine and Clinical Immunology, Dijon, France; 9APHM, Timone Children Hospital, Medical Genetics, Marseille, France; 10Strasbourg University Hospital, Internal Medicine, Strasbourg, France; 11Ambroise Paré University Hospital, APHP, Université Paris-Saclay, Biochemistry and Molecular Genetics, Boulouges-Billancourt, France.

Background/Objectives: Fabry disease (FD) is an X-linked genetic disease due to pathogenic variants in GLA (Gene ID: 2717). Over 1,000 GLA variants were identified, a significant number through screening protocols in newborns and at-risk populations more susceptible to disclose variants of unknown significance (VUS). This, together with the non-specificity of symptoms, challenges physicians at the time of diagnosis. Here, a panel of FD specialists convened to study how expertise compares with the traditional approach in interpreting variants.

Methods: Several highly controversial GLA VUS (p.Ser126 Gly, p.Ala143 Thr, p.Asp313 Tyr), were re-analyzed through the review of patients’ records.

Results: Experts’ input was found to significantly contribute to an accurate interpretation of variants. The proper use of surrogate biomarkers can optimize the interpretation of variants. When a (likely) benign GLA variant is disclosed, other genes (e.g., sarcormic genes in case of HCM) should be investigated. Comparing allele frequencies (AF) of GLA VUS is useful in excluding VUS which AF is higher than the disease prevalence or the frequency of the most common pathogenic allele. While databases and in silico prediction softwares are useful tools, they may yield conflicting results.

Conclusion: In genetics, the traditional approach to interpreting the pathogenicity of variants was developed by the American College of Medical Genetics. Our data suggest that through their in-depth knowledge of disease phenotypes, biomarkers, alleles frequencies, and literature data, highly specialized experts bring an important additional value. These lessons from FD give insights for better interpreting the pathogenicity of allelic variants in other genetic diseases.

References:

Grants:

Conflict of Interest: None declared.

P07.016.B Detection of single nucleotide and copy number variants in the Fabry Disease-associated GLA gene using nanopore sequencing

Omer Murik1, Tzvia Mann1, David Zeew1, Albina Nowak2,3, gheona Altarescu1

1Shaare Zedek Medical Center, Medical Genetics Institute, Jerusalem, Israel; 2University Hospital of Zürich, Department of Endocrinology and Clinical Nutrition, Zürich, Switzerland; 3Psychiatric University Hospital Zürich (PUK), Zürich, Switzerland.

Background/Objectives: More than 900 variants have been described in the GLA gene. Some intronic variants and copy number variants in GLA can cause Fabry disease but will not be detected by classical Sanger sequence. We aimed to design and validate a method for sequencing the GLA gene using long-read Oxford Nanopore sequencing technology.

Methods: 57 male and 42 female Fabry patients were blindly analyzed, both by conventional Sanger sequence and by long-read sequencing of a 13kb PCR amplicon. We used minimap2 to align the long-read data and Nanopolish and Sniffles to call variants.

Results: All the variants (100%) detected by Sanger (including a deep intronic variant) were also detected by long-read sequencing.
One patient had a deletion that was not detected by Sanger sequencing but was detected by the new technology.

**Conclusion:** Our long-read sequencing-based method was able to detect multiple missense variants and an exonic deletion, with the added advantage of intronic analysis. It can be used as an efficient and cost-effective tool for screening and diagnosing Fabry disease. Furthermore, our approach can be easily implemented for other monogenic diseases and improve diagnostic precision and efficiency.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P07.018.D An interactive website visualizing newborn screening programs worldwide**

Eyyüb Selim Ünlü¹, Sümeeye Karakaya¹, Gülbin Gökcay², Gülden Gökcay²

¹Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey; ²Institute of Child Health, Istanbul University, Istanbul, Turkey; ³Istanbul Faculty of Medicine, Istanbul University, Department of Pediatric Nutrition and Metabolism, Istanbul, Turkey.

**Background/Objectives:** Newborn screening (NBS) strategies have been proven to be successful diagnostics for several life-threatening inherited metabolic disorders and other genetic conditions. Governments are expanding nationwide NBS programs to improve public health. However, due to various challenges, worldwide NBS programs are not yet optimal. Monitoring worldwide NBS programs could accelerate the ongoing efforts for optimization.

**Methods:** We reviewed the last 10 years of literature to reveal country-level NBS programs. A user-friendly website (www.nbsww.org), consisting of an interactive world map, a filter table, and individual pages for each country, has been developed. Data sources are available with a link to corresponding publications. A data collection form is placed to receive user contributions to keep the content of the website up-to-date.

**Results:** We identified 115 countries’ nationwide NBS programs. The current status of NBS programs is heterogeneous, covering conditions ranging from a minimum of 0 to a maximum of 41 conditions. Expanded NBS is implemented in 35 (30%) of these countries while 57 (50%) screens less than 5 conditions. Most screened conditions are primary congenital hypothyroidism, phenylketonuria, congenital adrenal hyperplasia, screened by 82 (71%), 75 (65%), 50 (43%) programs, respectively.

**Conclusion:** The nationwide NBS programs were reported by presenting a website that allows monitoring and facilitates evaluation of the current situation.

**References:** Martinez-Morillo, E., Prieto García, B., & Álvarez Menéndez, F. V. (2016). Challenges for Worldwide Harmonization of Newborn Screening Programs. Clinical chemistry, 62(5), 689–698.

**Grants:** The Scientific And Technological Research Council Of Turkey grant 2209-A.

**Conflict of Interest:** None declared.

**P07.020.B Mitochondrial encephalomyopathy stroke-like episodes and lactate acidosis (MELAS), disease spectrum, lessons from large cohort**

Ralitza Gavrilova¹, Benjamin Cox²

¹Mayo Clinic, Neurology, Clinical Genomics, Rochester, United States; ²Mayo Clinic, Neurology, Rochester, United States.

**Background/Objectives:** Evaluate MELAS mutation cohort clinical spectrum, clinical/genetic factors associated with severe or later presentation.

**Methods:** Retrospective review 81 Mayo Clinic patients with/without meeting MELAS criteria. Clinical, MRI characteristics, mutations/heteroplasmy reviewed. MELAS, standard onset SLE <40 or late >40.

**Results:** 42 MELAS, 30 symptomatic non-MELAS, and 9 asymptomatic. MELAS, significantly lower BMI (mean 18.6 vs 25.1, 22.0), trend higher heteroplasmy (means 39.3%, 29.3%, 21.8%). MELAS and non-MELAS had similar age of first symptom (mean 20.3 vs 21.5); non-MELAS higher SNHL presentation (51.6% vs 24.4%, p = 0.014). Neurologic: Seizures/SLE/ataxia/dementia common MELAS first symptom (39%), versus non-MELAS (19.4%). MELAS, significant seizure prevalence (88.1% vs 16.7%), and higher mortality (43% vs 13%). MELAS cohort, 13 late and 29 standard-
onset. Mean age of first symptom 14.2y in standard (range 0-36), 34.1 in late (range 16-53). Trend (p = 0.18) towards higher heteroplasmy in standard (mean 44.8% vs 25.3%). Late-MELAS, significantly longer time from first symptom to SLE (mean 16.6 vs 9.3y), no different duration to death. Longer life expectancy in late-MELAS (mean death 62 vs 30y). Standard-MELAS higher incidence neurologic symptoms at onset (51.7% vs 15.4%); late-onset higher prevalence diabetes (69.2% vs 13.8%), nephropathy (53.8% vs 10.3%). Late-MELAS tended more systems involved (mean 4.1 vs 2.7).

Conclusion: Standard-MELAS more likely to present with neurologic symptoms compared to later onset, who are more likely to suffer diabetes, nephropathy, greater organ-involvement. Many MELAS present late >40y. Non-MELAS suffer substantial neurologic symptoms. Lower BMI in MELAS and higher rates SNHL in non-MELAS may be useful differentiator at onset.

References: N/A.

Grants: N/A.

Conflict of Interest: Ralitza Gavrilova Mayo Clinic, Benjamin Cox Mayo Clinic, Neurology fellow.

P07.021.C Development and validation of a new neonatal screening test

Michaella Georgiadou1, Charalambs Loizides1, Skevi Kyriakou1, Achilles Achilleos1, Christos Lemesios1, Michalis Nicolaou1, Chrissovalando Soteriou1 NIPD Genetics, Charalambars Loizides NIPD Genetics, Skevi Kyriakou NIPD Genetics, Achilleas Achilleos NIPD Genetics, Christos Lemesios NIPD Genetics, Michalis Nicolaou NIPD Genetics, Chrissovalando Soteriou NIPD Genetics, Haris Kkoufou NIPD Genetics, Louiza Constantinou NIPD Genetics, Krystallo Christou NIPD Genetics, Antonia Matsentidou NIPD Genetics, Michalis Spyrou NIPD Genetics, Stelia Pissaridou NIPD Genetics, Demetra Panayiotou NIPD Genetics, Kyriakos Tsangaras NIPD Genetics, Elena Kypri NIPD Genetics, Marios Ioannides NIPD Genetics, George Koumbaris NIPD Genetics, Philippos Patsalis NIPD Genetics.

Background/Objectives: Many genetic conditions affect normal development in newborns, infants or young children. These disorders can cause death, serious life-long disability or chronic disease if not treated early. Also, they have a vast array of symptoms, orders can cause death, serious life-long disability or chronic disease. Prompt identification and timely treatment is essential to prevent or minimize the impact of the conditions. Our aim was to develop an NGS-based product, which tests for 106 neonatal conditions including: metabolic, endocrine, haemoglobin, hearing loss, pulmonary and musculoskeletal disorders.

Methods: Custom target capture sequences (TACS) were designed to capture all gene exons, and intron-exon boundaries. The TACS were immobilized on streptavidin-coated magnetic beads. Sequencing libraries were constructed and subjected to immunoprecipitation with the immobilized TACS. The captured sequences were amplified and sequenced using NGS. A blind validation study was performed to assess the sensitivity and specificity of single nucleotide variant (SNV), indel and copy number variant (CNV) detection.

Results: SNVs and indels were detected at sensitivity of 100% (CI: 87-100%) and specificity of 100% (CI: 99.8-100%). The algorithm was designed to detect CNVs at high-resolution with estimated high sensitivity and specificity when applied to single or few exon CNV. Each positive call was confirmed with an orthogonal method.

Conclusion: We have developed and validated a neonatal screening test for 106 disorders that when detected early, can prevent or reduce serious health consequences such as developmental delay, cognitive impairment, neurological and physical problems and premature death.

References: N/A.

Grants: N/A.

Conflict of Interest: Michaella Georgiadou NIPD Genetics, Charalambars Loizides NIPD Genetics, Skevi Kyriakou NIPD Genetics, Achilleas Achilleos NIPD Genetics, Christos Lemesios NIPD Genetics, Michalis Nicolaou NIPD Genetics, Chrissovalando Soteriou NIPD Genetics, Haris Kkoufou NIPD Genetics, Louiza Constantinou NIPD Genetics, Krystallo Christou NIPD Genetics, Antonia Matsentidou NIPD Genetics, Michalis Spyrou NIPD Genetics, Stelia Pissaridou NIPD Genetics, Demetra Panayiotou NIPD Genetics, Kyriakos Tsangaras NIPD Genetics, Elena Kypri NIPD Genetics, Marios Ioannides NIPD Genetics, George Koumbaris NIPD Genetics, Philippos Patsalis NIPD Genetics.

P07.022.D Beyond the exome: identification and characterization of non-coding variants in inborn errors of metabolism

Alejandro Soriano-Sexto1;2;3;4;5, Fátima Leal1;2;3;4;5, Patricia Alcande1;2;3;4;5, Magdalena Ugarte1;2;3;4;5, Pilar Rodríguez1;2;3;4;5, Belén Pérez1;2;3;4;5

1Centro de Diagnóstico de Enfermedades Moleculares, Madrid, Spain; 2Centro de Biología Molecular Severo Ochoa, Madrid, Spain; 3CIBERER, Madrid, Spain; 4IDIPAZ, Madrid, Spain; 5Universidad Autónoma de Madrid, Madrid, Spain.

Background/Objectives: Inborn errors of metabolism (IEM) are a large group of rare diseases that include more than 1450 defects. Historically, the search for mutations contributing to IEM has been limited to exons, whereas regulatory elements have remained poorly investigated. Our aim here consisted in applying a combination of multiple omics to identify non-coding variants responsible for disease-state which shape exome sequencing, thus reducing the diagnostic gap.

Methods: Genomic analyses by whole exome or whole genome sequencing and functional studies (minigenes and luciferase reporters) were carried out in DNA and RNA extracted from patients’ fibroblasts. The enzymatic activity was also evaluated in these cells when possible.

Results: We have selected a cohort of unsolved patients with clinical or biochemical diagnosis of different IEM (hyperphenylalaninemia, galactosemia, mucopolysaccharidosis or citrullinaemia among others). Human Phenotype Ontologies (HPO) and biochemical signatures were used to filter the obtained variants. We prioritized either no candidate variants or only one. Therefore, all remaining undiagnosed. We have attained a complete genetic diagnosis for several patients by combination of transcriptomic and genomic analyses and functional genomics. We have identified pseudoxenons insertions caused by deep intrinsic variants such as c.[83+658C>G;83+758T>A] in PTS or c.598-757G>A in ASS1 and novel variants located in promoter regions like c.-8271delins-103 in PTS or c.-877C in IDUA. The pathogenic role of all of these changes was assessed by minigenes studies or luciferase reporter studies confirming their clinical significance.

Conclusion: The non-coding portion of the genome should be interrogated when searching for disease-causing mutations.

References: None declared.

Grants: PI19/01155, ERT18TRL746, B2017/BMD3721.

Conflict of Interest: None declared.

P07.023.A Three novel SLC2A1 mutations in GLUT1DS pediatric patients

Alessia Mauri1,2, Alessandra Duse3, Sara Olivotto3, Stefania Bova3, Pierangelo Veggiotti1;3;4, Cristina Cereda2

1University of Milan, Department of Biomedical and Clinical Sciences, L. Sacco, Milan, Italy; 2Neonatal Screening and Metabolic Disorders
Background/Objectives: GLUT1 deficiency syndrome (GLUT1DS; #606777) is a rare genetic metabolic disease, characterized by infantile seizures, neurodevelopmental delay, and movement disorders. GLUT1DS is caused by homozygous (or rarely, heterozygous) mutations in the SLC2A1 gene, which encodes GLUT1, a glucose transporter across the blood-brain barrier. Most commonly these variants arise de novo resulting in sporadic cases, although several familial cases with AD pattern have been described.

Methods: We performed SLC2A1 sequencing analysis on 26 pediatric patients with clinical suspicion of GLUT1DS, and relatives.

Results: Herein, we reported three novel SLC2A1 mutations causing GLUT1DS: two sporadic cases (a, b), and one familial case (c).

In the proband of the first sporadic case (a), characterized by 3-months-onset epileptic encephalopathy, we found a novel de novo c.114+1G>A splicing variant in SLC2A1 gene. In silico analysis showed that the identified variant affects the donor splice-site of intron 2-3, leading probably to exon 2 skipping and exon 1-3 junction.

In the other sporadic case (b), which the proband presents epileptic discharges and movement disorders, the analysis revealed in SLC2A1 a novel de novo frameshift variant c.370delC (p.Leu124TrpfsTer12), predicted to result in NMD.

The proband of the familial case (c) shows febrile seizures, while the father and grandfather present paroxysmal exercise-induced dyskinesia without epilepsy. Despite the clinical familial heterogeneity, we identified a novel SLC2A1 heterozygous missense variant c.1363A>G (p.Thr455Ala), reported as disease causing in all three patients.

Conclusion: Our report described three novel variants in both sporadic and familial cases, thus expanding the genotypic spectrum of SLC2A1 mutations causing GLUT1DS.

References:

Grants:

Conflict of Interest: None declared.

P07.024.B Establishing the mutational spectrum of Hungarian patients with familial hypercholesterolemia

László Madar1,2, Lilla Juhász3, Zsusanna Szücs1, Lóránt Kerkovits4, Mariann Harangi2, Istvan Balogh5,6

1University of Debrecen, Department of Laboratory Medicine, Division of Clinical Genetics, Debrecen, Hungary; 2University of Debrecon, Division of Molecular Cell and Immune Biology, Debrecen, Hungary; 3University of Debrecen, Department of Internal Medicine, Division of Metabolic Diseases, Debrecen, Hungary; 4South-Budapest Center Hospital St. Imre Teaching Hospital, Department of Nephrology, Budapest, Hungary; 5University of Debrecen, Department of Laboratory Medicine, Division of Clinical Genetics, Debrecen, Hungary; 6University of Debrecen, Department of Human Genetics, Debrecen, Hungary.

Background/Objectives: Familial hypercholesterolemia (FH) is one of the most common autosomal dominantly inherited diseases affecting the cholesterol metabolism which, in the absence of treatment, leads to the development of cardiovascular complications. The disease is still underdiagnosed, even though an early diagnosis would be of great importance for the patient to receive proper treatment and to prevent further complications. No studies are available describing the genetic background of Hungarian FH patients.

Methods: In this work, we present the clinical and molecular data of 44 unrelated individuals with suspected FH. Sequencing of five FH-causing genes (LDLR, APOB, PCSK9, LDLRAP1 and STAP1) has been performed by next-generation sequencing (NGS). In cases where a copy number variation (CNV) has been detected by NGS, confirmation by multiplex ligation-dependent probe amplification (MLPA) has also been performed.

Results: We identified 47 causal or potentially causal (including variants of uncertain significance) LDLR and APOB variants in 44 index patients. The most common variant in the APOB gene was the c.10580G>A p.(Arg3527Gln) missense mutation, this being in accordance with literature data. We detected 40 mutations in the LDLR gene in a total of 37 patients of which 3 patients carried mutations in compound heterozygous form.

Conclusion: Our study revealed one novel mutation in the LDLR gene, while most of the mutations that are present in the Hungarian population, have already been described. Indicating the importance of establishing a genetic diagnosis, the timing of initiation of lipid-lowering therapies may greatly influence the onset and severity of expected complications.

References:

None declared.

P07.025.C Biochemical and clinical effects of vitamin E supplementation in Hungarian Smith-Lemli-Opitz syndrome patients

Katalin Koczok1, László Horváth2, Željka Korade3, Zoltán András Mezei4, Gabriella P. Szabó5, Ned A. Porter6, Eszter Kovács2, Károly Mimics7, Istvan Balogh2,8

1University of Debrecen, Department of Laboratory Medicine, Division of Clinical Genetics, Debrecen, Hungary; 2University of Debrecen, Department of Pharmaceutical Surveillance and Economics, Debrecen, Hungary; 3University of Nebraska Medical Center, Department of Pediatrics, Omaha, United States; 4University of Debrecen, Department of Laboratory Medicine, Debrecen, Hungary; 5University of Debrecen, Department of Pediatrics, Debrecen, Hungary; 6Vanderbilt University, Department of Chemistry, Nashville, United States; 7University of Nebraska Medical Center, Munroe-Meyer Institute, Omaha, United States; 8University of Debrecen, Department of Human Genetics, Debrecen, Hungary.

Background/Objectives: Smith-Lemli-Opitz syndrome (SLOS) is a severe monogenic inborn error of cholesterol biosynthesis resulting in low cholesterol and high 7-dehydrocholesterol (7-DHC) levels. 7-DHC-derived oxysterols likely contribute to disease pathophysiology, thus antioxidant treatment might be beneficial because of high oxidative stress.

Methods: In a 3-year prospective study we investigated the effects of vitamin E supplementation in six SLOS patients already receiving dietary cholesterol treatment. Plasma vitamin A and E concentrations were determined by a HPLC method. At baseline plasma 7-DHC, 8-DHC and cholesterol levels were determined by a LC-MS/MS method. The clinical effect of the supplementation was assessed by performing structured parental interviews.

Results: At baseline, patients were characterized by low or low-normal plasma vitamin E concentrations (7.19-15.68 μmol/L), while vitamin A concentrations were found to be normal or high (1.26-2.68 μmol/L). Vitamin E supplementation resulted in correction or significant elevation of plasma vitamin E concentration in all patients. We observed reduced aggression, self-injury, irritability, hyperactivity, attention deficit, repetitive behavior, sleep disturbance, skin photosensitivity and/or eczema in 3/6 patients, with notable individual variability. Clinical response to therapy was associated with a low baseline 7-DHC and a high cholesterol ratio (0.2-0.4).

Conclusion: We suggest that determination of vitamin E status is important in SLOS patients. According to our results, the lower
level of vitamin E is most likely attributable to increased consumption due to oxidative stress, rather than malabsorption. Supplementation of vitamin E should be considered and might be beneficial.

References:
Grants:
Conflicts of Interest: None declared.

P07.026.D Missense variant in PDK1 associated with severe developmental delay and epilepsy

Raquel Vaz1, Josephine Wincent1,2, Najla Elfissi3, Kristina Forsblad4, Maria Pettersson1,2, Karin Naess3, Anna Wedell5,6, Anna Wredenberg5,6, Anna Lindstrand1,2, Sofia Ygberg5,8

1Karolinska Institutet, Department of Molecular Medicine and Surgery, Stockholm, Sweden; 2Karolinska University Hospital, Department of Clinical Genetics, Stockholm, Sweden; 3Karolinska Institutet, Department of Medical Biochemistry and Biophysics, Stockholm, Sweden; 4Akademiska Sjukhuset, Uppsala, Sweden; 5Karolinska University Hospital, Centre for Inherited Metabolic Diseases, Stockholm, Sweden; 6Karolinska Institutet, Science for Life Laboratory, Department of Molecular Medicine and Surgery, Stockholm, Sweden; 7Karolinska Institutet, Molecular Medicine and Surgery, Stockholm, Sweden; 8Karolinska Institutet, Department of Women’s and Children’s Health, Stockholm, Sweden.

Background/Objectives: The pyruvate dehydrogenase complex (PDC), located in the mitochondrial matrix, is responsible for the conversion of pyruvate into acetyl-CoA, used for energy production in the cells. PDC activity is tightly regulated by phosphorylation, via kinases and phosphatases (PDK/PDP), that respond to, for example, the amount of substrate in the cell (e.g. pyruvate or NADH) and hypoxia. Mutations in all subunits of the PDC and in PDH1 (pyruvate dehydrogenase) resulting in abnormal PDC function for example, the amount of substrate in the cell (e.g. pyruvate or NADH) and hypoxia. Mutations in all subunits of the PDC and in PDH1 (pyruvate dehydrogenase) resulting in abnormal PDC activity. This, in turn, affects muscle activity, seen by reduced bouts of movement when compared to control embryos, and neuronal development delay.

Conclusion: Here, we report a missense mutation in PDK1, a gene not previously associated with disease.

Methods: Genetic analysis was done using trio genome sequencing. Functional studies in zebrafish were done by overexpressing human wild type and mutant PDK1 in early-stage embryos.

Results: A de novo missense variant in PDK1 (c.1139G>A, p.Gly380Asp) was identified in a patient with developmental delay and seizures. In zebrafish, mutant PDK1 fails to phosphorylate PDHE1 (pyruvate dehydrogenase) resulting in abnormal PDC activity which, consequently, affects mitochondria activity. This, in turn, affects muscle activity, seen by reduced bouts of movement when compared to control embryos, and neuronal development delay.

Conclusion: Here, we report genetic and functional evidence suggesting that loss of function of PDK1 causes a similar clinical presentation as other PDC genes.

References:
Grants:
Conflicts of Interest: None declared.

P07.028.B Discovery of Type 2 Diabetes genes using an accessible tissue

David Davtian1, Jochen Schwenk2, Mark McCarthy3, Anubha Mahajan4, Mun-Gwan Hong2, Emmanouil Dermitzakis5, Hae Kyung Im6, Ewan Pearson1, Ana Viñuela7, Andrew Brown8

1University of Dundee, Dundee, United Kingdom; 2KTH Royal Institute of Technology, Stockholm, Sweden; 3University of Oxford, Oxford, United Kingdom; 4Wellcome Centre for Human Genetics, Oxford, United Kingdom; 5University of Geneva, Geneva, Switzerland; 6University of Chicago, Chicago, United States; 7University of Newcastle, Newcastle, United Kingdom.

Background/Objectives: Transcriptome Wide Association Study (TWAS) methods use reference expression datasets to link genes to disease. Ideally, these should use samples from a disease relevant tissue. We recapitulate known T2D genes using a well powered whole blood expression reference against smaller reference datasets from disease relevant tissues, gene panels must absolutely cover the genes for storage diseases.

Methods: Predictive models were built using whole blood expression and proteomic data (DIRECT consortium, n = 3029), pancreatic islets eQTL data (INSPIRE consortium, n = 420) and eQTL data from 49 tissues (GTEx consortium). These models were combined with GWAS summary statistics (DIAGRAM consortium, n = 898,130) to calculate gene-T2D association scores using S-PrediXcan.

Results: We found 97 significant associations between T2D and predicted gene expression levels using whole blood from DIRECT. We recapitulate known T2D genes such as CAMK1D, PAM, and CKDN1C and find more associations using the larger reference datasets as a background.

References:
Grants:
Conflicts of Interest: None declared.
dataset (43 using islets and from 2 to 84 in GTEx). There is a correlation between the sample size and the discovery power ($R^2 = 0.9, p = 2e^{-16}$). We also find DIRECT implicated genes to be enriched around GWAS loci compared to GTEx tissue derived genes, meaning a higher proportion of DIRECT genes have supporting genetic evidence. However, the DIRECT reference also misses important T2D genes, such as TCF7L2 or IGF2BP2, which were only captured when using islets models.

**Conclusion:** Our findings indicate that large studies in non-relevant tissues identify disease causal genes but miss relevant tissue specific signals.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P07.029.C Mitochondrial ATP-synthase deficiency causes a clinical, biochemical and genetical disease spectrum**

Andrea Pietro1,2, Marco seri1,2, Leonardo Caporali3, Valerio Carelli4,5, Duccio Maria Cordelli6, Valentina Del Dotto4, Veronica Di Pisa2, Claudio Fiorini3, Emanuela Iovino1, Chiara La Morgia3, Francesca Montanari1,2, Giulia Olivucci1,2, Flavia Palombo3, Tommaso Pippucci2, Emanuela Scarano6, Giulia Severi2, Caterina Garone1

1Alma Mater Studiorum University of Bologna, Department of Medical and Surgical Sciences, Bologna, Italy; 2IRCCS Azienda Ospedaliera Universitaria di Bologna, UO Genetica Medica, Bologna, Italy; 3IRCCS Institute of Neurological Sciences, Neurogenetics Unit, Bologna, Italy; 4Alma Mater Studiorum University of Bologna, Department of Biomedical and Neuromotor Sciences, Bologna, Italy; 5IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC di Neuropsichiatria dell'Età Pediatrica, Bologna, Italy; 6IRCCS Sant'Orsola Hospital, Rare Diseases Unit, Department of Pediatrics, Bologna, Italy.

**Background/Objectives:** Mitochondrial Complex V is composed by 18 protein subunits of which 16 are nuclear DNA encoded and 2 mitochondrial DNA (mtDNA) encoded (MT-ATP8 and MT-ATP6). Damaging genetics variants in protein subunits causes enzymatic activity deficiency and, consequently, severe mitochondrial encephalomyopathy.

**Methods:** Biochemical, histochemical and molecular genetics analyses including next generation sequencing of the whole mitochondrial genome were performed in biological samples (skeletal muscle, urine epithelium and blood) of probands and relatives from two unrelated families.

**Results:** Proband of family 1, is a 9 years-old male presenting with cerebellar ataxia, psychomotor delay and hypertrophic cardiomyopathy; brain MRI imaging showed cerebellar vermian hypoplasia and corpus callosum dysmorphism. The latter were also present in the asymtomatic sister. Proband of family 2, is a 48 years-old male presenting with progressive retinitis pigmentosa, cataaract, sensorineural deafness and ataxia. Our analyses revealed in both patients a biochemical deficiency of mt-ATP-synthase confirmed by the inheritance of novel pathogenetic variants in MT-ATP8 gene in family 1 (m.8535A>G (p.Lys57Ter)) and MT-ATP6 gene (m.8858G>A (p.Gly111Asp)) in family 2 with high level of heteroplasmy (95-98%) in patients' tissues while absent or very low level of heteroplasmy in unaffected family members.

**Conclusion:** Our study identifies novel variants in a very rare mitochondrial disorder due mitochondrial ATP-synthase deficiency and describes a clinical spectrum with a common and predominant feature represented by cerebellar ataxia and a variable multisystemic involvement.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P07.031.A Biallelic SLC25A36 mutation causes hyperinsulinism/hyperammonemia syndrome**

Amir Safaran1, Regina Praskorovski-Ohayon1, Neta Loewenthal2, ona staretz-chacham3, Ohad Shmuel Birk4

1Ben Gurion University of the Negev, Faculty of Health of Studies, Beer Sheva, Israel; 2Pediatric Endocrinology Unit, Division of Pediatrics, Soroka Medical Center, Beer Sheva, Israel; 3Soroka Medical Center, Metabolic Clinic, Beer Sheva, Israel; 4Soroka University Medical Center, Genetics Institute, Beer Sheva, Israel.

**Background/Objectives:** Hyperinsulinism/Hyperammonemia (HIHA) syndrome, the second most common form of congenital hyperinsulinism, is characterized by recurrent symptomatic hypoglycemia combined with persistently elevated serum ammonia levels. HIHA syndrome has been shown to be caused by dominant activating mutations in GLUD1, encoding the mitochondrial enzyme glutamate dehydrogenase (GDH). In this study, we present four children from consanguineous Bedouin kindred that were diagnosed with an autosomal recessive consistent HIHA syndrome phenotype with no mutations in GLUD1.

**Methods:** Genome-wide linkage analysis of ten family members was performed using 750k SNP arrays, HomozosityMapper and SuperLink softwares. Whole exome sequencing was performed for one affected individual and analyzed using the Qiagen Clinical Insight software and our in-house database of ~700 samples.

**Results:** A single ~16 Mbp homozygous disease-associated locus was identified on chromosome 3, between rs6439033 and rs55940906 (maximal LOD score of 2.65). Using our filtering analysis pipeline only one homozygous variant was found within the locus: a novel highly conserved SLC25A36 c.284+3A>T splice site mutation. The variant was validated by Sanger sequencing and segregated as expected within the family. The mutation changes the 5' splice site consensus sequence and leads to exon 3 skipping.

**Conclusion:** In parallel to two recent independent studies, we report a homozygous mutation in SLC25A36 as causing HIHA syndrome phenotype. The SLC25A36/PNC2 encodes a mitochondrial transporter that imports/exports pyrimidine and guanine nucleotides. Our study reinforces the involvement of SLC25A36 in the development of the HIHA syndrome through a recessive mode of inheritance.

**References:**

**Grants:** The Morris Kahn Family Foundation.

**Conflict of Interest:** None declared.

**P07.032.B Reverse phenotyping enables diagnosis of Smith-Lemli-Opitz syndrome in an oligosymptomatic female**

Angela Abad Perez1, Natalie Weinhold2, Dorothea Haas3, Denise Horn4

1Charité – Universitätsmedizin Berlin, Institute of Medical Genetics and Human Genetics, Berlin, Germany; 2Charité – Universitätsmedizin Berlin, Department of Pediatrics Endocrinology, Gastroenterology and Metabolic medicine, Berlin, Germany; 3University Hospital Heidelberg, Division of Child Neurology and Metabolic Medicine, Center for Child and Adolescent Medicine, Heidelberg, Germany.

**Background/Objectives:** Smith-Lemli-Opitz syndrome (SLOS) is a multiple congenital malformation and intellectual disability syndrome. It is caused by biallelic sequence variants in DHCR7, which encodes the enzyme 7-dehydrocholesterol (7-DHC) reductase.
Biologically, cholesterol concentration is low, whereas concentration of 7- and 8-DHC is elevated. The spectrum of clinical severity of SLOS is wide and some patients with mild manifestations have been reported.

**Methods:** Next generation sequencing and analysis of the DHCR7 gene (NM_001360.2) by Sanger sequencing were performed on two siblings with clinically diagnosed SLOS and their parents. Analysis of 7- and 8-DHC in the affected individuals was performed using gas chromatography mass spectrometry.

**Results:** We describe a 33-year-old female with normal psychomotor development and apart from mild microcephaly no major or minor anomalies. Her two experiments were clinically diagnosed with SLOS. Analysis of DHCR7 revealed the same paternally inherited pathological variant c.452G>A;p.(Trp151*) in both affected daughters. Each daughter carried a different, maternally inherited pathogenic variant: c.89G>C;p.(Gly30Ala) and c.278C>T;p.(Thr93Met), for which the mother was compound heterozygous. Plasma concentrations of 7- and 8-DHC in this female were elevated, confirming the diagnosis of SLOS.

**Conclusion:** Biallelic pathogenic DHCR7 variants c.89G>C;p.(Gly30Ala) and c.278C>T;p.(Thr93Met), accompanied by the typical biochemical features are associated with mild microcephaly as sole manifestation for SLOS. Both variants have been previously described in combination with other pathogenic variants, respectively. The genotype of this female leading to only mild microcephaly has not been reported in the literature.

**References:** Opitz et al., 1987; Fitzky et al., 1998; Blahakova et al., 2007.

**Grants:**

**Conflict of Interest:** None declared.

P07.033.C Trio-exome sequencing reveals Infantile Liver Failure Syndrome Type 1 (ILFS1) in an infant with recurrent hepatoportal failure and status epilepticus

**Stefanie Beck-Wödl**1,2, Tobias Haack1,3, Olaf Ries1,3, Ute Graschhoff1,3, Mona Grimm1,3, Marc Sturm1, Marisa Mendes1, Ralf A. Husain1

1Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany; 2ZSE, Rare Disease Center, Tübingen, Germany; 3Institute of Medical Genetics and Applied Genomics, Tübingen, Germany; 4Metabolic Unit, Vrije Universiteit Amsterdam, Department of Clinical Chemistry, Amsterdam UMC, Netherlands; 5Jena University Hospital, Department of Neuropediatrics, Jena, Germany.

**Background/Objectives:** Biallelic variants in LARS1, coding for the cystolic leucyl-tRNA synthetase, cause infantile liver failure syndrome 1 (ILFS1), a rare disorder of aminoacylation. Especially in infancy-onset of inborn errors of metabolism an early diagnosis is crucial to guide downstream clinical management and treatment decisions.

**Methods:** We report on a female child born in the 32nd week of gestation with intrauterine growth restriction, metabolic acidosis, hypoglycemia showing in the further course failure to thrive, developmental delay, hepatomegaly, low albumin and microcytic anemia. Many metabolic and endocrine causes were ruled out. At the age of 12 and 16 months episodes of acute liver and renal failure occurred most probably after viral infections with extreme hyperglycemia under moderate diazoxide dosing (6 mg/kg/d) during the first episode and status epilepticus and prolonged encephalopathy during the second episode. A third episode with infection-triggered status epilepticus but without liver failure occurred at the age of 35 month. Trio exome sequencing was performed during the first episode and revealed compound-heterozygous variants of unknown significance in the LARS1 gene.

**Results:** With the exclusion of other probable causes and LARS1 activity in fibroblasts of 8% of control fibroblasts we concluded the pathogenicity of the LARS1 variants. A high-protein diet as recommended was probably protective.

**Conclusion:** In children with acute liver failure rare genetic causes should be considered early. Next generation sequencing shows advantages over a step-wise approach because even a distinct phenotype can be recognized only in retrospect in extremely rare disorders.

**References:** PMID: 30349989.

**Grants:** No affiliations.

**Conflict of Interest:** None declared.

P07.034.D Next-generation diagnosis in patients with suspected mitochondrial neuromuscular diseases through a deep phenotyping and a in silico panel approach

**Flavia Palombo1, Chiara La Morgia1, Claudio Fiorini1, Mariantonietta Capristo1, Maria Lucia Valentina2, Giulia Severi3, Leonardo Caporali1, Gaetano Cantalupo4, Caterina Garone5, Marco seri6, Valerio Carelli7,8**

1IRCCS ISNB, Bologna, Italy; 2DIBINEM UNIBO, Bologna, Italy; 3U.O. Genetica Medica, IRCCS Azienda Ospedaliero-Università di Bologna, Bologna, Italy; 4U.O.C. di Neuropsichiatria Infantile, Dipartimento ad Attività Integrata Materno Infante - AOU di Verona, Verona, Italy; 5Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.

**Background/Objectives:** Mitochondrial neuromuscular diseases are highly heterogeneous disorders occurring at any age and with several clinical features including neurologic, muscular, cardiac, visual and auditory symptoms. These characteristics make the traditional diagnostic approach long, expensive and often inconclusive. Whole Exome Sequencing (WES) has revolutionized the study of rare genetic diseases and has found a wide application in clinical setting allowing to end the diagnostic odyssey typical of many heterogeneous genetic disorders, such as mitochondrial diseases.

**Methods:** WES strategy analysis based on standardized phenotyping by the Human Phenotype Ontology (HPO) terms and the use of in silico gene panel, in a heterogeneous cohort of 153 patients with suspected mitochondrial neuromuscular diseases. The cohort can be subdivided in patients with isolated optic atrophy (AO, 54), syndromic optic atrophy (AOplus, 16), progressive external ophthalmoplegia isolated or syndromic (CPEO, 34), adult-onset (EM, 16) and neonatal-onset encephalomyopathy (EMped, 22) and myopathy (MIO, 11).

**Results:** This strategy allowed to reach a diagnostic yield of 46.4%. In patients who had already undergone pre-sequencing panel (79%), very rare genes were identified. In addition, candidate genes could be identified in 4.5% of patients. The diagnosis of mitochondrial disease was confirmed in 50% of patients. The phenotypic traits most associated with mitochondrial genes are optic atrophy and ptosis, while the presence of phenocopies was high in the EMped and in the MIO patients.

**Conclusion:** The application of WES and a diagnostic algorithm that relies on phenotyping and filtering by on silico panels represents an effective diagnostic strategy in patients with suspected mitochondrial diseases.

**References:**

**Grants:** GR-2016-02361449.

**Conflict of Interest:** Flavia Palombo: None declared, Chiara La Morgia P/SI for clinical trials sponsored by GenSight. Biologics and Santhera, Santhera Pharmaceuticals, Chiesi Farmaceutici, Regulatory Pharma Net, Theneway srl, First Class srl and Biologix, Chiesi Farmaceutici, Regulatory Pharma Net and Theneway srl,
P07.035.A Investigation of the role of the DNM2 gene in mitochondrial dynamics by siRNA gene silencing

Fruzsina Szabó1, Dominokos Trager2, András Gézsi2, Anna Súveges2, Emese Bato3, Krisztina Takács-Vellai4, Csilla Nemes5, Aniko Gal1

1Institute of Genomic Medicine and Rare Disorders, Semmelweis University, Budapest, Hungary; 2Budapest University of Technology and Economics, Budapest, Hungary; 3Xenovea Ltd, Szeged, Hungary; 4Biological Anthropology, Eötvös Loránd University, Budapest, Hungary; 5Dr. Renessey Albert Hospital, Balassagyarmat, Hungary.

Background/Objectives: The Dynamin2 protein (DNM2) has diverse roles in cell functions, including in clathrin mediated endocytosis at the plasma membrane and together with DRP1, in mitochondrial division. DNM2 depletion blocks mitochondrial division and results in an elongated, hyper-fused mitochondrial network.

Methods: The silencing was performed for 72 hours. The efficiency of siRNA gene silencing was analysed by real-time PCR and Western blotting. RNA sequencing was performed on the properly transfected samples on Illumina NextSeq platform. The bioinformatics analysis focusing on mRNA expression changes.

Results: Gene silencing of siRNA was performed in 3 parallel measurements with 3 different siRNAs. Scrambled siRNA and non-transfected HEk cells were used as controls for the experiments. After a bioinformatical analysis very strong significance for 12 genes were found. These genes are involved in regulation of cytoskeletal function and trafficking, muscle function, and steroid biogenesis.

Conclusion: In DNM2 depletion samples, the downregulation of the FBLIM1, KRT13, KRT19, TMEM139, TMEM45A genes are involved in cytoskeletal function and trafficking, muscle function, and steroid biogenesis. After a bioinformatical analysis very strong significance for 12 genes were found. These genes are involved in regulation of cytoskeletal function and trafficking, muscle function, and steroid biogenesis.

References: -

Grants: The study was supported by the Semmelweis University StartUp, NKFIH_132812 and UNKP-21-5 grants.

Conflict of Interest: None declared.

P07.036.B Correlation between GLA rare variants and phenotype in Hungarian patients with Fabry disease

Tamás Szlepák1, Robert Sepp2, Eva Rakoczí3, Krisztina Nemeth4, Tamás Gyimesi5, Sandor Molnar6, Gyorgy Fekete6, Maria Judit Molnár7

1Semmelweis University, Institute of Genomic Medicine and Rare Disorders, Budapest, Hungary; 2University of Szeged, Second Department of Internal Medicine and Cardiology Center, Szeged, Hungary; 3University of Debrecen, Department of Rheumatology, Debrecen, Hungary; 4Semmelweis University, 2nd Department of Paediatrics, Budapest, Hungary; 5University of Pécs, 2nd Department of Internal Medicine and Nephrological Center, Pécs, Hungary; 6Soproni Erzsébet Teaching and Rehabilitation Institute, Neurology-stroke, Sopron, Hungary.

Background/Objectives: Fabry disease (FD) is the second most common metabolic disorder with high morbidity and mortality. Hundreds of mutations and non-coding haplotypes in the GLA gene have been described; however, many are variants of unknown significance, prompting doubts about the diagnosis and treatment.

Methods: We identified GLA mutations in patients with suspicion of FD in Hungary for the last couple of decades. Identification of patients’ genotype was done with Sanger sequencing. Patients tested were participating in FD screening projects or showed typical signs of FD or had low enzyme activity. The detected variants were classified using the current ACMG guideline, Fabry databases and literature.

Results: We found 24 different rare variants in 51 patients overall, of which 16 were classified as pathogenic, 4 likely pathogenic and 4 likely benign. Of the identified variants, 13 cause classic and 7 later onset phenotype. We also identified 2 variants that have conflicting interpretations of pathogenicity. Four of the damaging rare variants were only found in Hungarian patients so far.

Conclusion: We present a descriptive clinical study including 51 patients with 24 different GLA variants. We identified 4 novel rare damaging variants of the GLA gene. In order to better characterise VUS, not only probands but also all asymptomatic variant carriers from Fabry families should be followed prospectively. Data sharing has great importance. These data, in the future, will help to distinguish symptoms attributable to FD from nonspecific comorbidities in benign GLA variants carriers.

References: -

Grants: Nothing to disclose.

Conflict of Interest: None declared.

P07.037.C Molecular diagnosis of Fabry disease in patients with chronic renal failure of unknown etiology

Marina Parezanovic1, Maja Stojiljkovic1, Marina Andjelkovic1, Nina Stevanovic1, Vesna Spasović1, Milena Ugrin1, Jovana Komazec1, Natasa Tošić2, Sonja Pavlović3, Dejan Celić3, Jelica Vucenovic4, Anita Skakic1

1Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia; 2Clinic for Nephrology and Clinical Immunology, Clinical Center of Vojvodina, University of Novi Sad, Novi Sad, Serbia; 3General Hospital Sremska Mitrovica, Hemodialysis Center, Sremska Mitrovica, Serbia.

Background/Objectives: Fabry disease (FD) is a rare X-linked disorder caused by variants in the GLA gene leading to the deficiency of lysosomal α-galactosidase-A and progressive accumulation of globotriaosylceramide affecting the heart, nervous system, and kidneys. FD has overlapping phenotypes and often remains undiagnosed. Therefore, the precise molecular-genetic diagnosis and the earliest possible treatment are essential to avoid significant disease progression.

Methods: We analyzed 95 (34 female and 61 male) hemodialysis patients with clinical suspicion of FD using Sanger sequencing of all coding exons (7) and flanking intron regions of the GLA gene, and measured the relative expression of the GLA gene in available samples.

Results: The genetic analysis revealed 3 patients with a missense variant (p.Asp313Tyr), and 10 patients with combinations of non-coding variants, described as complex intronic haplotypes (CIHs). CIH1 (c.-10C>T, c.370-81_370-77delCAGCC, c.640-16A>G, c.655+1G>A).

Grants: -

Conflict of Interest: None declared.
c.1000-22C>T), the most frequent haplotype, was detected in 7 (7.4%) patients. Lyso-Gb3 biomarker levels were within the normal range in each tested patient. However, RT-qPCR analysis revealed decreased relative expression of GLA gene in PBMC of 2 female patients with CIH1 and one female patient carrying only c.-10C>T variant by 9.1%, 7.4%, 46.3%, respectively, pointing out that further analyses are needed to confirm/exclude FD in these patients.

**Conclusion:** Because the effects of CIHs are not yet fully understood, our work highlights the importance of analyzing intronic regions of the GLA gene as genetic modifiers and the need to include expression analysis in the diagnostic algorithm.

**References:**

**Grants:** Genetic and biomarker analyses are sponsored by Takeda GmbH, Serbia.

**Conflict of Interest:** None declared.

### P07.038.D An unusual case of combined hypolipidaemia and premature peripheral vascular disease

Zuzana Pôs1;2;3, Milad Khedr4, Jan Radvanszky1;2;5, Rastislav Heke2;3;5, Tomas Szemes2;3;5, Adela Penesova2, Lakshminarayanan Ranganath4, Andrea Zatkova1

1Biomedical Research Centre of the Slovak Academy of Sciences, Institute of Clinical and Translational Research, Bratislava, Slovakia; 2Comenius University Science Park, Bratislava, Slovakia; 3Geneton Ltd., Bratislava, Slovakia; 4Royal Liver University Hospital, Department of Clinical Biochemistry and Metabolic Medicine, Liverpool, United Kingdom; 5Faculty of Natural Sciences, Comenius University, Department of Molecular Biology, Bratislava, Slovakia; 5Slovak Centre of Scientific and Technical Information, Bratislava, Slovakia; 6Biomedical Research Centre of the Slovak Academy of Sciences, Institute of Clinical and Translational Research, Bratislava, Slovakia.

**Background/Objectives:** Monogenic hypobetalipoproteinemias include a heterogeneous group of disorders characterized by very low plasma levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL), and apolipoprotein B (apoB) that are relatively uncommon in general population. It is thought that low LDL can protect from CVD, but this is not what we found in a case we present. We report on a 57 years old male patient (with BMI 21 kg/m2) with combined hypolipidaemia who presented with premature peripheral vascular disease. We also presented his two sons aged 32 and 27 years, who also manifested tendency to low lipid levels.

**Methods:** We used illumina exome analysis in all three individuals. Variant filtering by QCI was performed using two different approaches: one based on candidate genes and the other one based on clinical symptoms.

**Results:** No pathogenic or likely pathogenic variants within main hypcholesterolaemia/dyslipidaemia candidate genes (ANGPTL3, SART1, APOB, PCSK9 or MTTP) were found in any of them. However, all three individuals share a novel ABCA1 variant, possibly responsible for decreased HDL levels. The proband and one of his sons share also the splicing variant rs138326449 within the APOC3 gene, shown to be associated with decreased TG levels.

**Conclusion:** We can hypothesize that in our patient despite his low TGs and LDL levels obtained thanks to the presence of the protective APOC3 variant, atherosclerosis developed due to the impaired cholesterol efflux caused by ABCA1 variant.

**References:**

**Grants:** APVV-18-0319; VEGA_2/0167/20; VEGA_02/0040/20; ITMS: 313011V446 co-financed by the European Regional Development Fund (LISPER).

**Conflict of Interest:** None declared.

### P07.039.A Untreated PKU patients without intellectual disability: SHANK gene family as a candidate modifier

Kristel Klaassen1, Majd Djordjevic2;3, Anita Skakic1, Bozica Kecman7, Marina Parezanovic1, Marina Andjelkovic1, Nina Stevanovic1, Vesna Spasovski1, Milena Ugrin1, Radoje Drmanac4;5;6, Sonja Pavlovic1, Maja Stojiljkovic1

1Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia; 2Mother and Child Health Care Institute of Serbia „Dr Vukan Cupic“, Belgrade, Serbia; 3School of Medicine, University of Belgrade, Belgrade, Serbia; 4Complete Genomics Incorporated, San Jose, United States; 5MGI, BGI-Shenzhen, Shenzhen, China; 6BGI-Shenzhen, Shenzhen, China.

**Background/Objectives:** Phenylketonuria (PKU) is an inborn error of metabolism caused by variants in the phenylalanine hydroxylase (PAH) gene. Although PKU is a monogenic disease, decades of research and clinical practice have shown that the correlation between the genotype and corresponding phenotype is not simple at all. Attempts have been made to discover modifier genes for PKU cognitive phenotype but without any success so far.

**Methods:** We conducted whole genome sequencing of 4 subjects from unrelated non-consanguineous families who presented with pathogenic mutations in the PAH gene, high blood phenylalanine concentrations and near-normal cognitive development despite no treatment.

**Results:** We used cross sample analysis to select genes common for more than one patient. Thus, the SHANK gene family emerged as the only relevant gene family with variants detected in 3 of 4 analyzed patients. We detected two novel variants, p.Pro1591Ala in SHANK1 and p.Asp18Asn in SHANK2, as well as SHANK2:p.Gly465Ser, SHANK2:p.Pro1388_Phe1389insLeuPro and SHANK3:p.Pro1716Thr variants that were previously described. Computational analysis indicated that the identified variants do not abolish the function of SHANK proteins. However, changes in posttranslational modifications of SHANK proteins could influence functioning of the glutamatergic synapses, cytoskeleton regulation and contribute to maintaining optimal synaptic density and number of dendritic spines.

**Conclusion:** Our findings are linking SHANK gene family and brain plasticity in PKU for the first time. We hypothesize that variant SHANK proteins maintain optimal synaptic density and number of dendritic spines under high concentrations of phenylalanine and could have protective modifying effect on cognitive development of PKU patients.

**References:**

**Grants:** MESTD-RS 451-03-68/2022-14/200042.

**Conflict of Interest:** None declared.

### P07.040.B Clinical, genetic and therapeutic aspects in Menkes disease: study of a French cohort and systematic literature review

Paul Rollier1;2, Marie-Pierre Moizard3;4, Annick Toutain5, Sophie Blesson5, Eric Bieth6, Chryselle Bonnemains7, Aline Cano8, Brigitte Chabrol6, Annabelle Chaussoen6, Léna Damaj9, François Feillet10, Sylvie Joriot11, Manoelle Kossorotoff12, Christian Richelme13, Dominique Bonneau14, Sylvie Odent1, Magalie Barth14

1Rennes University Hospital, Clinical Genetics, RENNES, France; 2Rennes University Hospital, Molecular Genetics and Genomics, RENNES, France; 3Tours University Hospital, Molecular Genetics, TOURS, France; 4INSERM, U1253, TOURS, France; 5Tours University Hospital, Clinical Genetics, TOURS, France; 6Toulouse University Hospital, Medical Genetics, TOULOUSE, France; 7Nancy University Hospital, Pediatrics, NANCY, France; 8Marseille Public University.

**Background/Objectives:** Polyalanine expansions in the gene ATP7A cause Menkes disease (MENK), a rare recessive genetic disorder characterized by multi-organ involvement and severe developmental delay. Clinical heterogeneity is high and mutations in ATP7A can affect the structure and function of the ATP7A protein. The pathogenic mechanism involves failures in metal homeostasis and impairment of cell functions. The clinical presentations range from the absence of symptoms to severe neurodevelopmental abnormalities, with the most severe cases displaying severe neurologic impairment, death early in life or within the first year of life. Preventive treatment with the copper chelator trientine is the only currently available therapy, though it is not effective in all patients.

**Methods:** We conducted a national study of 39 French MENK patients. We included 24 men and 15 women from 25 families. The diagnosis was made by a neurologist and clinical, biochemical, and radiological evaluation was performed. Molecular genetic analyses were done in all cases. Genetic testing was performed using Sanger sequencing and Next Generation Sequencing (NGS) on the Illumina MiSeq platform. The study was conducted according to the principles stated in the Declaration of Helsinki.

**Results:** The study was conducted on a French cohort of 39 MENK patients. The results showed that the most common mutation was the 123insC in the ATP7A gene. The study also highlighted the importance of early diagnosis and genetic counseling in MENK patients. The variant analysis showed that the 123insC mutation was present in 19 patients, indicating its high prevalence in the French MENK population.

**Conclusion:** The study of the French MENK cohort and systematic review of the literature revealed the high prevalence of the 123insC mutation in the French population. This variant analysis is crucial for early diagnosis and genetic counseling in MENK patients. Further studies are needed to understand the pathogenic mechanisms of the 123insC mutation and develop effective therapeutic strategies.

**References:**

**Grants:** none.

**Conflict of Interest:** None declared.
Luká Vyhnáková, Markéta Havlovicová, Markéta Vlčková, Emilie Vyhndlková

Second Faculty of Medicine, Charles University and University Hospital Motol, Department of Biology and Medical Genetics, Prague, Czech Republic; 1Institute of Physiology, Czech Academy of Science, Prague, Czech Republic.

Background/Objectives: Gene MECR encodes a highly conserved mitochondrial trans-2-enoyl-coenzyme-A-reductase which has a crucial role in mitochondrial fatty acid synthesis (mFAS). Here we report a 12-year-old patient with recessive mutations in MECR who presented with childhood-onset dystonia, hypoplasia and atrophy of the optical nerves, and abnormal MRI signaling of basal ganglia and dorsal mesencephalon.

Methods: Family-based whole-exome sequencing of DNA extracted from peripheral blood lymphocytes was followed by bioinformatics analysis of the TRIO using the software VarAF. Functional measurements of mitochondrial oxidative phosphorylation (OXPHOS) were performed on skin fibrocytes via high-resolution respirometry (OroborosOxygraph). Western blot was used to detect individual mitochondrial proteins and to study the assembly of OXPHOS complexes.

Results: Within gene MECR, we found a novel variant c.610G>C p.(Ala204Pro) and previously described variant c.772C>T p.(Arg258Trp) in a compound heterozygous state. Functional measurements of OXPHOS on fibrocyte cell line found a statistically significant decrease of the mitochondrial electron transport chain (ETC) capacity, complex I and IV capacity, and overall mild decrease of respiration. Western blot showed a decreased quantity of complexes I and IV.

Conclusion: We described a novel variant c.610G>C in MECR in an individual with a phenotype consistent with previously described cases of the MECR-related neurologic disorder (1). The pathogenicity of the variant was confirmed by functional analysis.

References: 1. Heimer G, Kerätär JM, Riley LG, et al. MECR Mutations Cause Childhood-Onset Dystonia and Optic Atrophy, a Mitochondrial Fatty Acid Synthesis Disorder. Am J Hum Genet. 2016;99(6):1229-1244. https://doi.org/10.1016/j.ajhg.2016.09.021.

Grants: IGA MZCR (NT/13770-4/2012 to MM, NT/14200 to MH), Norway Grants (PDP3-NorwayGrants) and COST–LD14073. Conflict of Interest: None declared.

P07.042.D False positive newborn screening for maple syrup urine disease in patients with hydroxyprolinemia

Dimitar Gavrilov, Amy White, Faisal Asumda, Noemi Vidal Folch, Laura Davis-Keppens, Isum Ward, Kari Casas, Matthew Schultz, Devin Oglesbee, Silvia Tortorelli, Dietrich Matern

1Mayo Clinic, Rochester, United States; 2USD Sanford School of Medicine, Sioux Falls, United States; 3University of North Dakota School of Medicine and Health Sciences, Fargo, United States.

Background/Objectives: Newborn screening (NBS) for maple syrup urine disease (MSUD) by tandem mass spectrometry utilizes leucine as primary marker. The isobaric amino acids leucine, isoleucine, alloisoleucine and hydroxyproline (OH-Pro) are not distinguished by this method. Hydroxyprolinemia is an autosomal recessive benign condition (1) and therefore should not be identified by NBS.

Methods: Of six healthy newborns with NBS results presumptive positive for MSUD two were hospitalized until MSUD was excluded. The other four patients had plasma and urine collected for amino acid (PAA) and organic acid (UOA) analyses at an outpatient visit. Original NBS specimens of two cases were available for retrospective measurement of leptine, isoleucine, valine, alloisoleucine and OH-Pro (2).

Results: PAA and UOA analyses excluded MSUD and disclosed elevations of OH-Pro (237-424 mmol/L; controls <61) in all six cases. OH-Pro but not leucine, isoleucine, valine or allo-isoleucine, was elevated in the NBS specimens of two cases. Molecular genetic analysis of PRODH2 is underway.

Conclusion: MSUD is a critical condition that requires rapid initiation of treatment. However, hydroxyprolinemia is more common and therefore a cause of false positive NBS results (1). Total parenteral nutrition can also cause false positive results (2). Employing a second-tier NBS test in the original dried blood spot specimen to differentiate between branch-chain amino acids and OH-Pro can avoid the cost and anxiety associated with false positive results of NBS for MSUD.

References: 1. Stauffer et al. J Inherit Metab Dis. 2016;39:625-32. 2. Oglesbee et al. Clin Chem 2008;54:542-9.

Grants: Conflict of Interest: Dimitar Gavrilov: None declared, Amy White: None declared, Faisal Asumda: None declared, Noemi Vidal...
Folch: None declared, Laura Davis-Keppen: None declared, Jsum Ward: None declared, Kari Casas: None declared, Matthew Schultz: None declared, Devin Oglesbee: None declared, Silvia Tortorelli: None declared, Dietrich Matern Advisory board. Novogene, 4 hrs (honorarium passed on to my employer, Mayo Clinic).

P07.043-A Clinical and metabolomic peculiarities in monogenic disorders affecting urea cycle or mitochondrial ATP synthase

Botceatu Alina1, Adina Chis2,3, Calin Deleanu2,4, Cecilia Lazea5, Gabriella Horvath6, Melinda Baizat7, Lilia Blaga6, Simona Buczan6, Alina Nicolae6,7, Romana Vultur6,7

1Iuliu Hatieganu University of Medicine and Pharmacy, Medicine, Cluj-Napoca, Romania; 2Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, Department of Molecular Sciences, Cluj-Napoca, Romania; 3Babeș-Bolyai University Cluj-Napoca, Romania, 3-Cognitive Neuroscience Laboratory, Cluj-Napoca, Romania; 4P. Poni Institute of Macromolecular Chemistry, Romanian Academy, Cluj-Napoca, Romania, 5C. D. Nenitescu Centre of Organic Chemistry, Romanian Academy, Cluj-Napoca, Romania, Romania; 6I. Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, Ist Paediatric Clinic - Cluj Children Hospital, Cluj-Napoca, Romania; 7Faculty of Medicine, University of British Columbia, Vancouver, Canada, Division of Biochemical Diseases, Department of Pediatrics, Cluj-Napoca, Romania; 8Neonatology Department, Clinical Hospital Zalau, Cluj-Napoca, Romania; 9Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, Neonatology Department, Cluj-Napoca, Romania.

Background/Objectives: The clinical-biochemical findings in born errors of metabolism (IEMs) are sometimes nonspecific. A metabolomic approach involves a quantitative analysis of a set of metabolites present in urine or and plasma linking them to a selected metabolic pathway and/or particular metabolic condition.

Methods: Results from plasma and/or urine amino acids analyzed by a two-dimensional thin-layer-chromatography (2D-TLC) as an urgent selective screening in patients from pediatric clinical departments were compared with urinary NMR spectroscopic results in several IEMs. 1H-NMR urine spectroscopy constitutes a complementary technique in the diagnosis of several IEMs, providing an overall view of metabolism, giving a “fingerprint” of almost all hydrogen nuclei in a metabolite.

Results: We summarize clinical data and biochemical comparative markers obtained using these two methods in several urea cycle disorders (ornithine transcarbamylase - OTC and argininosuccinic aciduria - AAS), and a mitochondrial disorder - the TMEM70 defect evolving with mild or severe hyperlactataemia. In TMEM70 defect, several plasma amino acids were outside the normal ranges as nonspecific changes, but the diagnostic was established by molecular DNA investigation. Contrary, the orotic acid and argininosuccinic acid were rapidly detected using urinary NMR spectroscopy in ornithine transcarbamylase defect. In AAS, the urinary 2D-TLC method was useful for rapid identification of high concentration of argininosuccinic acid.

Conclusion: The 2D-TLC and 1H-NMR spectroscopy methods available for a rapid evaluation may be a versatile association for several specific molecules. Identification of such bio-markers demonstrated important potential for including more rare diseases into current national screening programme and research.

References:

Grants: None declared.

Conflict of Interest: None declared.

P07.045.C Shifting the border of pathogenicity with a DEL9 mutation in the CEL gene

Maria Grossmann1, Janek Wilk2, Andrea Bier3, Silke Reif3, Manuela Timmer1, Christian Jänecke1, Vivien Klaschka1, Beate Küchler2, Albrecht Kobelt3, Stefan Krüger1, Jens Plaschke1,2

1Gemeinschaftspraxis für Humangenetik, member of Praxisnetz Humangenetik Deutschland, Dresden, Germany; 2MEWIGEN, Dresden, Germany; 3Praxis für Medizinische Genetik, Zentrum für Diagnostik am Klinikum Chemnitz, Chemnitz, Germany.

Background/Objectives: Maturity-onset diabetes of the young (MODY) is a group of autosomal dominantly inherited disorders of non-autoimmune diabetes mellitus with usual onset in adolescence or young adulthood. Most MODY mutations are located in genes GCK, HNF1A, HNF4A and HNF1B. Rarely, mutations in other contributing genes (APPL1, ABC68, BLK, CEL, INS, KCNJ11, KLF11, NEUROD1, PAX4, PDX1) are causative for MODY.

Here we report two sisters (34 and 37 years) and their mother (61 years) affected by MODY.

Methods: NGS analysis for all above-mentioned 14 genes was performed.

Results: For all three patients we identified the CEL mutation NM_001807.6:c.1941delC, p.(Val648Cysfs*45) in a heterozygous state affecting VNTR repeat 9 (DEL9 regarding individual VNTR haplotype).

Conclusion: Due to co-segregation in this family we consider the CEL DEL9 as pathogenic. This shifts the previously assumed border of pathogenicity to a more 3’end of the gene.

References: Gravdal et al. J Biol Chem. Jan-Jun 2021;296:100661.

Grants: None.

Conflict of Interest: None declared.

P07.046.D MELAS: clinical and laboratory-based diagnostic algorithm

Sebastian Romeo Pintilie1, Ilina Maria Farcas2, Alina Botezatu1, Laura Damian1, Adina Chis2,3, Romana Vultur4,5

1Iuliu Hatieganu University of Medicine and Pharmacy, Medicine, Cluj-Napoca, Romania; 2University of Oxford, Oxford, United Kingdom; 3Emergency Clinical County Hospital, Rheumatology, Center for Rare Autoimmune and Autoinflammatory Diseases, Cluj-Napoca, Romania; 4Babes-Bolyai University, Cognitive Neurosciences Laboratory, Cluj-Napoca, Romania; 5Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Background/Objectives: Mitochondrial Encephalopathy with Lactic Acidosis Syndrome (MELAS) is a mitochondrial disease caused by point mutations or deletions in the mitochondrial or even nuclear genome. The pathogenesis of MELAS is not fully understood, so several hypotheses have been proposed. Some of the most obvious processes involved are related to the accumulation of RNA19 in active metabolic tissues, mitochondrial
proliferation due to energy and nitric oxide deficiency, impaired glucose metabolism with lactic acidosis.

Methods: Following a review of the current literature on the diagnosis methods and criteria of MELAS, we have developed a quick algorithm for helping clinicians in establishing the diagnosis of MELAS.

Results: The Hirano et al. (1992) and Yatsuga et al. (2012) criteria remain the benchmark for selecting patients suspected of MELAS, based on their clinical picture such as: seizures, headache with vomiting, and myopathy. However, to secure the diagnosis, performing PCR-RFLP in a common set of affected-genes, including the prevalent m.3243A>G substitution, should be done first on a MELAS-suspected, only then followed by full mitochondrial and even nuclear genomic testing or, if sequencing is not possible, by allele-specific oligonucleotide (ASO) dot blot hybridization, which is more sensitive than PCR.

Conclusion: Beside the proposed clinical algorithm, muscle biopsy/blood lactate cannot provide certain evidence for MELAS diagnosis, which is why molecular testing should be prioritized over other clinical tests when establishing a diagnosis; yet a genetic test positive for a mutation in the mitochondrial DNA should still be correlated with any of the first two tests.

References:

Grants:

Conflict of Interest: None declared.

P08

IMMUNOLOGY AND HEMATOPOIETIC SYSTEM

P08.001.A The value of genetic data from 665,460 individuals in predicting anemia and ability to donate blood

Jarkko Toivonen1, Johanna Castrén1, FinnGen Consortium2, Mikko Arvas1

1Finnish Red Cross Blood Service, Helsinki, Finland; 2FinnGen Consortium, Helsinki, Finland.

Background/Objectives: We aim to find out whether genetic information has significant effect in predicting iron deficiency anemia or blood donation ability.

Methods: Genetic data from FinnGen release 6 (230,000 participants), Blood Service Biobank (30,000 participants) and UK Biobank (400,000 participants) was analyzed. In addition, age, sex, weight, height, anemia status and blood donation histories were used when available.

We performed GWAS for anemia and blood donation ability and computed polygenic risk score weights for anemia, ferritin1 and hemoglobin2. A Bayesian logistic regression for anemia was fitted on all FinnGen participants and for donation ability on blood donors, stratified into three demographic groups.

Results: A single significant SNP rs199598395 in gene RNF43 was revealed by our anemia and deferral GWAS. The meta-analysis from FinnGen and UKBB for anemia provided three more significant lead SNPs. The largest effect of the genetic data in anemia model was by the RNF43 SNP for pre-menopausal females (OR 4.3, 95% CI 2.6 – 6.7) and in the deferral model again the RNF43 SNP for pre-menopausal females (OR 3.2, 95% CI 1.9 – 5.4). PRSs didn’t have significant effects in either model.

Conclusion: A single SNP can have a strong effect on prediction of both anemia and blood donation ability. PRSs are not yet informative enough to be usable predictors.

References: 1 Bell et al. A genome-wide meta-analysis yields 46 new loci associating with biomarkers of iron homeostasis. Commun Biol 4, 156 (2021).

2 Vuckovic et al. The Polygenic and Monogenic Basis of Blood Traits and Diseases. Cell. 2020 Sep 3;182(5):1214-1231.e11.

Grants:

Conflict of Interest: Jarkko Toivonen Full-time employee at Finnish Red Cross Blood Service. Significant contribution, Johanna Castrén Full-time employee at Finnish Red Cross Blood Service. Significant contribution. FinnGen Consortium: None declared, Mikko Arvas Full-time employee at Finnish Red Cross Blood Service. Significant contribution.

P08.002.B Added value of reanalysing whole exome- and whole genome sequencing data with an extended gene panel and structural variant calling in patients suspected of having primary immune deficiency

Sara Murup1, Lusine Nazaryan-Petersen2, Migle Gabrielaite2, Joanne Reekie3, Hanne V. Marquart4, Hans Jakob Hartling5, Rasmus Marvig5, Terese L. Katzenstein5, Tania N. Masmas5, Jens D. Lundgren5,5, Daniel D. Murray1, Marie Helleberg3,5, Line Borgwardt2

1Copenhagen university hospital, Rigshospitalet, Persimune, Centre of excellence for health, immunity, and infections, Copenhagen, Denmark; 2Copenhagen university hospital, Rigshospitalet, Center for genomic medicine, København Ø, Denmark; 3Copenhagen university hospital, Rigshospitalet, Centre of excellence for health, immunity, and infections, København Ø, Denmark; 4Copenhagen university hospital, Rigshospitalet, Department of clinical immunology, København Ø, Denmark; 5Copenhagen university hospital, Rigshospitalet, Department of infectious diseases, København Ø, Denmark; 6Copenhagen university hospital, Rigshospitalet, The child and adolescent department, København Ø, Denmark.

Background/Objectives: Knowledge of genetic variation underlying Primary Immune Deficiency (PID) is steadily increasing(1). Reanalysis of genome-wide sequencing data from patients suspected of PID may improve the diagnostic rate.

Methods: We included patients monitored at the Department of Infectious Diseases, Rigshospitalet, Denmark, for a suspected PID, who had been analysed during 2015-2020 using a targeted PID gene panel (457 PID-related genes) on whole exome- (WES) or whole genome sequencing (WGS) data. A literature review was performed to extend the PID gene panel used for reanalysis of single nucleotide variation (SNV) and small indels. Structural variant (SV) calling was added on WGS data.

Results: In total, genetic data from 94 patients (86 adults) was reanalysed a median of 23 months after the initial analysis (38 WES and 56 WGS). The extended gene panel included 208 additional PID-related genes. The total proportion of patients with ACMG class 3-5 variants increased from 43 (46 %) to 50 (53 %). The proportion of patients with a causal genetic diagnosis was constant, but after reanalysis 13 patients (14 %) had a new potentially disease causing/contributing variant of unknown significance (VUS) identified. Among these, 8 of 94 (9 %) had a SV and 5 of 56 (9 %) patients had a SV.

Conclusion: These data indicate a possible diagnostic gain of reassessing WES/WGS data from patients with suspected PID. Reasons for the possible gain included improved knowledge of genotype-phenotype correlation, expanding the gene panel, and adding SV analyses.

References: (1) PMID: 31953710.

Grants: This work is funded by Danish National Research Foundation (DNRF126).

Conflict of Interest: Sara Murup: None declared, Lusine Nazaryan-Petersen: None declared, Migle Gabrielaite: None declared, Joanne Reekie: None declared, Hanne V. Marquart: None declared, Hans Jakob Hartling: None declared, Rasmus Marvig: None declared, Terese L. Katzenstein: Gilead Sciences., Advisory
boards for Gilead Sciences, GlaxoSmithKline/Viiv and MSD. Teaching for Takeda and CSL Behring, Tania N. Masmas: None declared. Jens D. Lundgren: None declared. Daniel D. Murray: None declared, Marie Helleberg: Advisory boards for AstraZeneca, Gilead, GSK, MSD, Roche and Sobi., Teaching for Gilead and GSK., Line Borgwardt: None declared.

P08.003.C Copy number variants in pediatric patients with suspected inborn errors of immunity

Breanna Beers1, Morgan Similuk1, Magdalena Walkiewicz1, Michael Kamen1, Michael Setzer1, Colleen Jodarski1, Rachel Gore1, Bryce Seifert1, Rajarshi Ghosh1, Rylee Duncan1, Devin Hunt1, Madison Center, Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Nijmegen, Netherlands; 2Radboud University Medical Center, Laboratory Medicine, Laboratory for Medical Immunology, Nijmegen, Netherlands; 3University Medical Center Groningen, Department of Genetics, Groningen, Netherlands; 4Radboud University Medical Center, Department of Pediatric Immunology, Pediatrics, Nijmegen, Netherlands; 5Maastricht University Medical Center+, Department of Clinical Genetics, Maastricht, Netherlands; 6Leiden University Medical Center, Center for Human and Clinical Genetics, Leiden, Netherlands.

Background/Objectives: De novo variants (DNVs) are currently not routinely evaluated as part of diagnostic whole exome sequencing (WES) in patients with inborn errors of immunity (IEI). This study explored the additional value of systematic DNV assessment in a retrospective cohort of 123 patients with sporadic PIDs.

Methods: Patient-parent trios sequenced at the Radboud University Medical Center were eligible for inclusion when 1) the IEI in-silico gene panel was analysed and 2) the phenotype of the index patient suggested sporadic disease. Exome-wide analysis was performed to retain rare, coding, non-synonymous de novo SNVs. Variants were further prioritized based on gene and variant level metrics. In immune cells from one selected patient, functional validation experiments were performed at the level of DNA splicing, NF-κB signalling and cytokine production.

Results: Candidate DNVs were identified in 15 (12.2%) trios, in addition to 12 (9.8%) with inherited (likely) pathogenic mutations. These potentially disease-causing DNVs were identified in the known IEI genes NLRP3 and RELA, and novel candidate genes including PSMB10, DDX1, KMT2C and FBXW11. Furthermore, the FBXW11 canonical splice site DNV, carried by a patient with autoinflammatory disease, was shown to cause defective DNA splicing, increased NF-κB signalling and elevated IL-1β production.

Conclusion: This retrospective cohort study advocates the implementation of trio-based sequencing in routine diagnostics of patients with sporadic IEI to improve the solve rate. Furthermore, we have provided functional evidence in support of a causal role for FBXW11 loss-of-function mutations in autoinflammatory disease.

References:

Grants: This research was part of a Radboud Institute for Molecular Life Sciences PhD grant.

Conflict of Interest: None declared.

P08.005.A Genetic characterization of non-familial hemophagocytic lymphohistiocytosis patients: monogenic defects in HAVCR2, TNFRSF9 and MADD genes

Laura Batlle-Masó1,2, Clara Franco-Jarava3, Laura Viñas-Gimenez3, Marina García-Prat1, Alba Parra-Martínez1, Cristina Díaz-de-Heredia4, Anna Maria Cueto-González2, Marta Codina-Sola5, Berta Campos5, Eduardo Tizzano5, Jacques G Rivière1, Pere Soler-Palacin1, Laia Alisna6, Monica Martinez-Gallo1, Ferran Casals2,3, Roger Colobran1,5

1VHIR – Vall d’Hebron Institut de Recerca / HUVH – Hospital Universitari Vall d’Hebron, Pediatric Infectious Diseases and Immunodeficiencies Unit, Barcelona, Spain; 2Genomics Core Facility, Department of Experimental and Health Science - Universitat Pompeu Fabra (UPF), Barcelona, Spain; 3VHIR – Vall d’Hebron Institut de Recerca / HUVH – Hospital Universitari Vall d’Hebron, Immunology Division - Translational Immunology Research Group, Barcelona, Spain; 4HUVH – Hospital Universitari Vall d’Hebron, Department of Pediatric Hematology and Oncology, Barcelona, Spain; 5HUVH – Hospital Universitari Vall d’Hebron, Department of Clinical and Molecular Genetics, Barcelona, Spain; 6Institut de Recerca Sant Joan de Déu – Hospital Sant Joan de Déu, Clinical Immunology and Primary Immunodeficiencies Unit, Barcelona, Spain; 7Universitat de
Barcelona, Department of Genetics, Microbiology and Statistics, Barcelona, Spain.

Abstracts from the 55th European Society of Human Genetics Conference

Background/Objectives: Hemophagocytic lymphohistiocytosis (HLH) is a severe and life-threatening syndrome characterized by a strong hyperactivation of the immune system. Familial HLH (FHL) is caused by biallelic variants in the genes PRF1, UNC13D, STX11 and STXBPF2. Non-familial HLH (nFHL) may be caused by other genetic entities or may be sporadic or secondary to other conditions.

Methods: To elucidate other genetic mechanisms driving nFHL we studied a cohort of 31 nFHL patients (25 European, 5 North-African and 2 Asian). All cases had an immunological diagnosis of HLH but remained unsolved at a genetic level after excluding pathogenic variants in FHL genes.

Results: Using WES data, we first evaluated the possibility of the disease being caused by a monogenic defect. We found the genetic diagnosis for three of the patients: i) one patient who carried a compound heterozygous variant at HAVCR2, ii) one with a homozygous nonsense variant at TNFRSF9, and iii) one with a homozygous deletion at MADD. Next, we looked for pathogenic variants over-represented in our cohort in comparison to healthy populations, identified monoallelic variants that could be acting as risk factors, and explored the digenic model in genes of the cytotoxic pathway.

Conclusion: Altogether, we showed that WES is a valuable diagnostic tool in nFHL patients, providing new insights into the physiopathology of the disease, and insisted on the importance of a genetic diagnosis on the clinical management and genetic counseling of the patients and their families.

References:

Grants:

2018_FI_B00072 by Generalitat de Catalunya, RTI2018-096824-B-C22 by Spanish Government-ERDF, PI17/00660-PI20/00761 by Instituto de Salud Carlos III-ERDF.

Conflict of Interest: None declared.

P08.006.B First description of a bone marrow failure syndrome in Spain caused by compound heterozygous truncating mutations in ERCC6L2

Perla Bandini1,2, Nina Borràs1,2, Laura Martin-Fernandez1,2, Eugenia Fernández-Melid1, Paula Melero-Valentini1, Natalia Comes1,2, Lorena Ramirez1,2, Patricia Cadahia Fernández1, Matilde Rodriguez Ruiz1, Manuel Mateo Perez Encinas1, Francisco Vidal1,2, Irene Corrales1,2

1Banc de Sang i Teixits (BST), Coagulopaties Congènètes, Barcelona, Spain; 2Vall d’Hebron Institut de Recerca, Universitat Autònoma de Barcelona (VHIR-UAB), Medicina Transfusional, Barcelona, Spain; 3Hospital Clínico Universitario de Santiago de Compostela (CHUS – SERGAS), Servicio de Hematología, Santiago de Compostela, Spain; 4Instituto Carlos III (ISCIII), Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.

Background/Objectives: Biallelic variants in ERCC6L2 have been recently described to cause inherited bone marrow failure syndrome type 2 (BMFS-2) which is characterized by hypocellular bone marrow and, frequently, microcephaly. We describe the case of two siblings diagnosed at 8 and 14 years with medullary aplasia and thrombocytopenia (60-80e9platelets/L) without extra-hematopoietic manifestations. The aim was to identify the molecular defect associated with the patients’ phenotype using a whole exome sequencing (WES) strategy.

Methods: WES was performed using the DNA Prep with Enrichment protocol (Illumina) and sequenced in NextSeq500 system (Illumina). Variants were identified with BWA Enrichment and annotated and filtered with Variant Interpreter (Illumina). Family based trio analysis including the affected siblings and their parents (unaffected) was carried out using recessive inheritance pattern.

Results: Two truncating ERCC6L2 pathogenic variants, according to ACMG guidelines, were identified in both patients: 1) NM_020207.c.1930C>T (p.Arg644Ter) in exon 13, the second most recurrent variant, only found in homozygous state; 2) NM_020207.c.2156del (p.Gly719AspsTer50), located in exon 15, previously described in a single patient.

Conclusion: This is the first description in Spain of medullar aplasia caused by ERCC6L2 mutations. Our findings contribute to the small worldwide cohort of 20 families with BMFS-2, with only four caused by compound heterozygous mutations in ERCC6L2. Early detection of the genetic defect will help in clinical management, which is relevant due to the susceptibility of BMFS-2 patients to myelodysplastic syndrome and acute myeloid leukaemia.

References: PMID: 29633571; 29987015; 29146883; 30936069.

Grants: ISCIII (PI18/01492 and CIBERCV), co-funded by ERDF, “A way to make Europe”, Fundación Privada Catalana de l’Hemofília.

Conflict of Interest: None declared.

P08.007.C A homozygous STING1 gene variant causes STING-associated vasculopathy with onset in infancy (SAVI) in two patients

Rensheng Wan1, Sandra Von Hardenberg1, lisa isabel olfe1, Bernd Auber1, Martin Wetze1, Doris Steinemann2

1Hannover Medical School, Department of Human Genetics, Hannover, Germany; 2Hannover Medical School, Department of Pediatric Pneumology, Allergology and Neonatology, Hannover, Germany.

Background/Objectives: Stimulator of interferon response cGAMP interactor 1 (STING1) gain of function (Gof) variants cause STING-associated vasculopathy with onset in infancy (SAVI; AD inheritance). While most causative heterozygous variants arise de novo, Lin et al. (2020) showed that STING1 variant p.(R281W) causes SAVI only in homozygous state. Here we report two further patients carrying STING1 homozygous variant p.(R281W).

Methods: Whole exome sequencing (WES) and whole genome sequencing (WGS) were applied respectively to identify causative variant in patient 1 and 2.

Results: STING1 (NM_198282.3): c.841C>T p.(R281W) was identified in two patients and classified as “pathogenic”. Patient 1 presented with recurrent severe hypoxaemia, hypoventilation, diffuse alveolar hemorrhage, interstitial lung disease, without skin vasculitis. Segregation analysis within the consanguinuous family showed that healthy parents and one brother carried variant heterozygously. The interferon signature was highly elevated in patient 1 but not in healthy heterozygous family members. This correlates to published cases displaying that the heterozygous p.(R281W) variant did not affect the interferon signature. No significant improvement was observed after therapy with Janus kinase inhibitor Baricitinib. Patient 2 showed hyperventilation with scarring fibrotic changes, bronchiectasis, tachypnea, failure to thrive with marked dystrophy, hypocalcemia, and also no skin vasculitis.

Conclusion: Our report supports the possibility that p.(R281W) causes an atypical SAVI phenotype without demonstrating vasculopathy. It is important to consider an autosomal recessive inheritance pattern when evidence of STING-associated vasculopathy is given.

References: No references.

Grants: German Research Foundation (DFG) under Germany’s Excellence Strategy - EXC 2155 - RESIST project number 390874280.
Background/Objectives: The variability in β-thalassemia phenotype has been attributed to several genetic modifiers. The significance of the latter varies in different populations. The objective of the current study was to determine the significance of six genetic modifiers as they relate to phenotype in Iraqi β-thalassemia patients and to create a genetic scoring system that could predict phenotype in patients from this part of the world.

Methods: A total of 224 Iraqi patients homozygous or compound heterozygous for β-thalassemia were assessed for five polymorphisms at HbF QTLs, namely: rs7482144 C>T at HBG2, rs1427407 G>T and rs10189857 A>G at BCL11A, and rs28384513 A>C and rs9399137 T>C at HMIP.

Results: The enrolled patients had a median age of 14 years, with 96 males and 128 females. They included 144 thalassemia major (TM) and 80 thalassemia intermedia (TI) patients. Multivariate logistic regression revealed that three genetic modifiers, namely β, β⁺, and rs1427407, could significantly predict phenotype (TM versus TI) with an overall prediction rate of 82.1%. A cumulative favorable allele score based on these significant predictors had an area under curve of 0.862 (95% CI 0.816-0.909), which was highly significant (P = 3.2656E-19).

Conclusion: The current study identified three genetic predictors of phenotype in Iraqi patients with β-thalassemia, with an overall prediction rate of 82.1%. Furthermore, the population-specific cumulative favorable allele scoring system created had a good ability to discriminate between TM and TI. The application of the latter may help in providing more informed management and therapeutic options in this region.

References:

Grants:

Conflict of Interest: None declared.

P08.012.D Genetics in inborn errors of immunity: pediatric autoinflammatory phenotypes and the underlying genetic causes in 125 families

Yvonne Poker1, Sandra Von Hardenberg1, Winfried Hofmann1, Michelle Tang1, Ulrich Baumann2, Nicolaus Schwerzk, Martin Wetze2, Viola Lindenthal3, Bernd Aubert, Brigitte Schlegelberger, Hagen Ott4, Philipp von Bismarck5, Dorothee Viemann6, Frank Dressler2, Christian Klemann2, Anke Katharina Bergmann7

1Department of Human Genetics, Hanover, Germany; 2Department of Pediatric Pneumology, Allergology and Neonatology, Hanover, Germany; 3Department of Pediatrics and Pediatric Hematology/Oncology, Oldenburg, Germany; 4Division of Pediatric Dermatology, Children’s Hospital Auf der Bult, Hanover, Germany; 5Department of Pediatrics, University Medical Center Schleswig-Holstein, Hanover, Germany; 6Translational Pediatrics, Department of Pediatrics, Würzburg, Germany.

Background/Objectives: Generalized pustular psoriasis (GPP) is a severe psoriatic subtype characterized by epidermal neutrophil infiltration. Although variants in IL36RN and MPO have been shown to affect immune cells contributing to GPP’s pathogenesis, a systematic analysis of neutrophils and of a wide variety of PBMC subsets and their differential gene expression dependent on MPO genotypes was not performed yet.

Methods: We assessed transcriptomes of MPO-deficient patients using single cell RNA-sequencing (scRNAseq) of peripheral blood mononuclear cells (PBMCs) and RNA-sequencing of neutrophils in relatively stable disease state.

Results: Cell type annotation by multimodal reference mapping of scRNAseq data was verified by flow cytometry of surface and intracellular markers; proportions of CD4⁺ cytotoxic T-lymphocytes (CTLs) and other CD4⁺ effector cells were increased in GPP, while frequencies of naïve CD4⁺ T cells were
significantly lower. The expression of the marker gene for CD4+ CTLs and CD8+ effector memory T-cells (TEMs) FGFBP2 was elevated in GPP patients with disease-contributing variants compared to healthy and diseased non-carriers (p = 0.0015) based on quantitative RT-PCR. Differentially expressed genes (DEGs) involved in the complement system were enriched in the complement system were enriched in patients’ neutrophils.

**Conclusion:** Future studies assessing affected cell types and pathways will show their contribution to GPP’s pathogenesis, and indicate whether findings can be transferred to the situation in affected skin and whether depletion or inactivation of CD4+ CTLs may be a reasonable therapeutic approach.

**References:**

Grants: CRC1181, project A05.

**Conflict of Interest:** None declared.

**P08.014.B** Filaggrin loss-of-function mutations are associated with the persistence of egg and milk allergy

**Ingo Marenholz**1;2, Birgit Kalb2;3, Alexander CSN Jeanrenaud1;2, Lara Meixner1, Ahia Ghauri1;2, Alexi Arnau-Soler1;2, Katharina Blümchen4, Rupert Schlags5, Gesine Hansen6, Jürgen Seidenberg7, Susanne Lau3, Bodo Niggemann3, Kirsten Beyer3, Young-Ae Lee1;2

1Max-Delbrück-Center for Molecular Medicine (MDC), Berlin, Germany; 2Clinic for Pediatric Allergy, Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany; 3Department of Pediatric Respiratory Medicine, Immunology, and Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany; 4Department of Allergy, Pulmonology and Cystic Fibrosis, Children’s Hospital, Goethe University, Frankfurt, Germany; 5Department of Pediatric Pneumology and Allergology, Wendel Hospital, Wangel, Germany; 6Department of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany; 7Department of Pediatric Pneumology and Allergology, Neonatology and Intensive Care, Medical Campus of University Oldenburg, Oldenburg, Germany.

**Background/Objectives:** A genetic defect in the epidermal barrier protein filaggrin plays a major role in the etiology of eczema and associated allergic airways diseases. However, it is still controversial to what extend loss-of-function (LOF) mutations in the filaggrin gene (FLG) contribute to the development of food allergies. We tested association of FLG LOF mutations with allergic reactions to diverse foods and investigated their effect on the persistence of early food allergies.

**Methods:** We recruited 890 children with challenge-proven food allergy for the German Genetics of Food Allergy Study (GOFA). All children were genotyped for the four most common LOF mutations in FLG: R501X, 2282del4, R2447X, and S3247X. Associations between FLG mutations and food allergies were analyzed by logistic regression using the German Multicenter Allergy Study cohort as control population.

**Results:** FLG mutations were associated with allergies to diverse foods including hen’s egg (HE), cow’s milk (CM), peanut, hazelnut, fish, soy, cashew, walnut, and sesame with similar risk estimates. Effects remained significant after adjusting for the eczema status. Interestingly, FLG mutations increased the risk of a persistent course of HE and CM allergy.

**Conclusion:** Using the gold standard for food allergy diagnosis, we demonstrate that FLG LOF mutations confer risk of any food allergy independent of eczema. They predispose to the persistence of HE and CM allergy and should be considered in the assessment of tolerance development.

**References:**

Grants: The study was funded in part by the Federal Ministry of Education and Research (CHAMP, 01GL1742C), and the German Research Foundation (Clinical Research Group 339 “Food@”, Project B2).

**Conflict of Interest:** None declared.

**P08.015.C** Ethnicity-specific GWAS to explore the genomic architecture of platelet count in the Northeast Indian subcontinent

**Kate Burley**1, Dragana Vuckovic2, David van Heel3, Andrew Mumford4

1University of Bristol, School of Physiology, Pharmacology and Neuroscience, Bristol, United Kingdom; 2Imperial College London, School of Public Health, London, United Kingdom; 3Queen Mary University of London, Barts and The London School of Medicine and Dentistry, London, United Kingdom; 4University of Bristol, School of Cellular and Molecular Medicine, Bristol, United Kingdom.

**Background/Objectives:** Blood cell traits are highly heritable, yet most known genomic associations have been identified in broad population sub-groups. We compared the genomic determinants of platelet count (PLT) in Pakistanis and Bangladeshis, a genetically distinct population from the Northeast Indian subcontinent where thrombocytopenia (PLT<150 x 10^9/L) is reported in 35%.

**Methods:** Data were analysed from British Bangladesh (BAN, n = 20,292) and British Pakistani (PAK, n = 9,237) individuals (https://www.genesandhealth.org/). Associations between TOPMed-imputed genotypes and mean PLT were calculated using BOLT-LMM and LD score regression software. Variants were annotated using the Ensembl Variant Effect Predictor.

**Results:** PLT was slightly lower in BAN (mean 266.4 x 10^9/L) than PAK (mean 271.5 x 10^9/L, p = 1.16e15) but respective rates of thrombocytopenia (1.5% vs 1.8%) and trait heritability (0.214 vs 0.216) were comparable. PLT was lower (mean 255.2 x 10^9/L) and had higher heritability (0.230) in a previously reported European (EUR) population (n = 166,066). Genetic correlation for PLT was higher between BAN and PAK (r = 1.11, SE 0.2) than for BAN and EUR (r = 0.82, SE 0.07). GWAS-significant variants in BAN were in regions associated with PLT in EUR, except for a MAST2 intrinsic loci previously associated with PLT in East Asian populations.

**Conclusion:** Loci associated with PLT were concordant between BAN and PAK, and largely reproduced previous findings in EUR. Thrombocytopenia observed in the Northeast Indian subcontinent was not reproduced in the British BAN population in which there was also no discernible genomic explanation for lower PLT.

**References:** 1. Nania et al., J Thromb Haemost. 2005, 2, 2581-1582.
   2. Astle et al., Cell 2016, 167, 1415-1429.

**Grants:** None declared.

**P08.016.D** Italian ancestral HLA haplotype predisposing to severe COVID-19 by low spike and high IFNγ binding affinity

**Susanna Croci**1;2, Silvia Brugiapaglia3;4, Ticiana D.J. Farias5, Paola Magistrino6, Kristen Zugaro7, Claudia Curcio3;4, Chiara Fallerini1;2, Francesca Fava2;3, Francesco Pettinì, Margherita Baldassarri1;2, Mirella Bruttini1;2;3, Gen-Covid Multicenter Study7, Paul Norman5, Alessandra Renieri1;2,3, Ilaria Meloni1;2, Simone Furini1, Antonio Amoroso8, Franco Novelli9

1Medical Genetics, University of Siena, Siena, Italy; 2Med Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy; 3Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy; 4Laboratory of Tumor Immunology Center for Experimental Research
Background/Objectives: Validated association between COVID-19 and the most obvious candidate genes, e.g., HLA, is still missing. A weak association with class I HLA- C*04:01 was found for infection in Sardinians and for severity in another mixed population. Auto-antibodies to interferon type I have been implicated in severity between COVID-19 in two studies.

Methods: The binding affinity between HLA molecules and SARS-CoV-2 spike protein and IFNα subunits was evaluated in silico. The presence of antibodies against one or more of the 12 IFNα subunits was evaluated in 160 hospitalized COVID-19 patients. The 10 most frequent haplotypes in the Italian population were tested in 1.997 SARS-CoV-2 infected patients (hospitalized versus not hospitalized).

Results: The presence of auto-antibodies against at least one IFNα subunit was detected in 26% of patients. The haplotype A*24:02-B*35:02-C*04:01-DRB1*11:04-DBB1*03:01 was found to predispose to severity (p = 0.0018; p = 0.07 after Bonferroni correction) in patients <50 years. The haplotype includes alleles able to bind spike with low affinity (i.e. C*04:01 and DRB1*11:04) and IFNα with high affinity (i.e. DRB1*11:04).

Conclusion: One of the 10 most frequent ancestral haplotype of the Italian population predisposes to severity likely reducing both innate immunity through IFNα auto-antibodies induction and adaptive immunity through weaker spike protein presentation.

References: Daga S et al. Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research. Eur J Hum Genet. 2021 Jan 17:1-15.

Conflict of Interest: None declared.

P08.017.A High prevalence of Netherton syndrome in Latvian population caused by founder SPINKS variant

INGA NARTISA1,2, Lota Ozola3, Ineta Grantina3, Gita Taurina2, Rasa Insberga2, Linda Gailite1, Natalija Kurjane1,2

1Riga Stradins University, Riga, Latvia; 2Children’s Clinical University Hospital Clinic of Medical Genetics and Prenatal Diagnostics, Riga, Latvia; 3Children’s Clinical University Hospital, Riga, Latvia.

Background/Objectives: Netherton syndrome (NTS) is a rare autosomal recessive inborn error of immunity caused by biallelic SPINKS loss-of-function variants. NTS is characterized by skin and immune system abnormalities, but with variable expressivity. Therefore, we aimed to clinically and molecularly characterize NTS in individuals with homogenous genotype and ethnicity.

Methods: We selected all Latvian NTS patients diagnosed in Children’s Clinical University Hospital by using exome sequencing (ES). Unrelatedness, as well as haplotype length for variant's age estimation in individuals with homozygous pathogenic variant was analysed using high-quality variants from ES.

Results: We identified pathogenic biallelic variants in 9 individuals (age 1 month to 17 years) from 7 families, confirming NTS diagnosis. Clinically, all patients have ichthyosis, hair abnormalities, developmental delay, high total IgE levels (371-6977 kU/L), and recurrent skin and respiratory infections with variable severity. Surprisingly, 5/7 families had the same homozygous SPINKS variant (NM_006846.4:c.1048C>T,p.(Arg350*)) and two siblings carried the same variant in compound heterozygous state (c.1048C>T,p.(Arg350*); c.1430+1A>G,r.spl). Therefore, we suspected that the variant is founder in Latvian population. NTS prevalence in Latvian population is higher: 1:256,000 (vs. ~1:1,000,000 in France by Dreifus I. et. Al. 2014) and carrier frequency is estimated 1:300. Assuming a ‘correlated’ genealogy, the mutation arose 47.9(95%CI 14.9-167.2) generations and 1175 years (assuming one generation 25y) ago.

Conclusion: We report high prevalence of NTS in Latvia due to the presence of a founder variant that arose before 50 generations ago. Interestingly, despite similar ethnic and identical genotype, NTS expressivity was variable among the individuals.

References:

Grants: Latvian Council of Science project:lzp-2020/1-0269.

Conflict of Interest: None declared.

P08.018.B Microenvironmental determinants of clonal hematopoiesis expansion rate

Taralynn Mack1,2, Michael Raddatz3, Joshua Weinstock4, Jaiswal Siddhartha5, Alexander Bick2

1Vanderbilt University Medical Center, Vanderbilt Genetics Institute, Nashville, United States; 2Vanderbilt University Medical Center, Division of Genetic Medicine, Nashville, United States; 3University of California, Department of Medicine, Los Angeles, United States; 4University of Michigan School of Public Health, Department of Biostatistics, Ann Arbor, United States; 5Stanford University School of Medicine, Department of Pathology, Stanford, United States.

Background/Objectives: Clonal hematopoiesis of indeterminate potential (CHIP) is a clonal expansion of blood cells caused by somatic mutations. CHIP confers risk of multiple aging diseases including blood cancer and cardiovascular disease. It is presently unknown what causes CHIP clones with identical driver mutations to expand at different rates in humans. Here, we leverage genetically predicted traits to identify factors that modify CHIP clonal growth rate.

Methods: We used the passenger-approximated clonal expansion rate (PACER) method to quantify clonal growth rate for 4,370 individuals with CHIP mutations in the NHLBI TOPMed cohort. [1] We calculated polygenic risk scores (PRS) for DNA methylation clocks, inflammation related lab values, disease traits, and circulating protein levels. We tested for associations between PRS and PACER score with linear regression, controlling for covariates and correcting for multiple-hypothesis testing.

Results: CHIP clonal growth rate was significantly associated with both genetically predicted and measured methylation clocks (p < 0.01). No associations were identified with any of the inflammation-related lab values, proteins or diseases. An unbiased proteome wide search identified circulating levels of myeloid zinc finger 1, anti-müllerian hormone, TIMP metalloproteinase inhibitor 1 and glycine N-methyltransferase as altering CHIP clonal expansion rate (p < 4.1 x 10^-5).

Conclusion: An aging microenvironment was associated with increased CHIP expansion rate as well as four specific circulating micro-environment proteins. Contrary to prior murine models, we do not identify inflammation as a root cause of CHIP clonal expansion rate in humans.

References: [1] Weinstock (2021) bioRxiv https://doi.org/10.1101/2021.12.10.471810.

Grants: HBP1 T32 HL144446.

Conflict of Interest: Taralynn Mack: None declared, Michael Raddatz: None declared, Joshua Weinstock: None declared, Jaiswal Siddhartha: None declared, Alexander Bick: None declared.
P08.019.C Assessing new RNA-based biomarkers in multiple sclerosis

Giulia Cardamone1,2, Federica Ain3, Giuseppe Liberatore4, Giulia Soldo2,3, Valeria Rimoldi1, Eduardo Nobile-Orazio4,5, Rosanna Asselta1,3, Elvezia Maria Paraboschi1,3

1Humanitas University, Department of Biomedical Sciences, Pieve Emanuele, Italy; 2Institute of Biochemistry I, Goethe-University, Frankfurt, Germany; 3IRCCS Humanitas Research Hospital, Rozzano, Italy; 4Neuromuscular and Neuroimmunology Service, IRCCS Humanitas Clinical and Research Center, Rozzano, Italy; 5Milan University, Department of Medical Biotechnology and Translational Medicine, Milano, Italy.

Background/Objectives: Multiple sclerosis (MS) is an autoimmune neurodegenerative disease characterized by chronic inflammation, and demyelination. Accumulating evidence suggests a pathogenic link between MS and abnormalities in alternative splicing (AS) [1], a process that increases the information content of the transcriptome through the expression of different mRNAs from single genes [2]. Our objective is to define an AS-based signature able to discriminate patients from controls, starting from a blood sample.

Methods: RNA was extracted from peripheral blood mononuclear cells of 29 relapsing-remitting MS patients and 20 controls. Fluorescent RT-PCR assays, focusing on three specific AS events were performed, and PCR products were separated using capillary electrophoresis. The relative exon inclusion level (percent-spliced in, psi) was calculated for each sample.

Results: For each AS event, we divided the psi range in quartiles and we assigned each sample to its relevant class. We calculated a risk score for each sample, resulting from the sum of the quantiles they fit in each AS assay. We used this score to perform a ROC analysis. Using this 3-marker-AS signature, we obtained a good predictive model (AUC = 0.72, specificity = 0.9, sensitivity = 0.48). We are testing the predictive value of our model on an independent cohort (32 MS cases and 50 matched controls).

Conclusion: Considering that the current diagnostic methods for MS are based on complicated procedures, the implementation of a diagnostic test, centered on RNA biomarkers use, would be useful in a clinical perspective.

References: 1. https://doi.org/10.1016/j.autrev.2019.05.010. 2. https://doi.org/10.1146/annurev.biochem.72.121801.161720.

Grants: This work is supported by Fondazione Regionale per la Ricerca Biomedica (FRBB), Early Career Award.

Conflict of Interest: None declared.

P08.021.A Differential diagnostic algorithm for Inherited Macrothrombocytopenias enables the genetic characterization of 52 families in a single tertiary referral centre

Catarina Monteiro1,2,3,4, ana gonçalves1,3,4, mónica pereira2,3,4, catarina lau4,5, marta gonçalves4,5, eugenia cruz6,7, sara morais2,3,4, Rosário Santos1,2,4

1Centro de Genética Médica Jacinto Magalhães (CGMM), Centro Hospitalar Universitário do Porto (CHUPorto), Unidade de Genética Molecular, Porto, Portugal; 2Serviço de Hematologia Clínica, Centro Hospitalar Universitário do Porto (CHUPorto), Unidade de Trombose e Hemostase, Porto, Portugal; 3UMIB - Unidade Multidisciplinar de Investigación Biomédica, ICBAS - Instituto de Ciencias Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal; 4ITR - Laboratory for Integrative and Translational Research in Population Health, Porto, Portugal; 5Serviço de Hematologia Clínica, Centro Hospitalar Universitário do Porto (CHUPorto), Unidade de Diagnóstico Hematológico Margarida Lima, porto, Portugal.

Background/Objectives: Inherited Macrothrombocytopenias (IMTP) are platelet (PLT) disorders characterized by reduced PLT counts, increased PLT volume and often disproportionate bleeding, with up to 30 genes currently implicated. We aimed to develop an efficient diagnostic algorithm for IMTP, contributing towards the understanding of these disorders and their underlying defects in our population.

Methods: The proposed algorithm comprises three assessment steps: (i) clinical data (personal/family history, physical examination, bleeding tendency); (ii) preliminary laboratory tests including PLT counts and indices [mean PLT volume (MPV) and immature PLT fraction (IPF)], PLT morphology and function assays (occlusion time by PFA100/200 and lumi-aggregometry); (iii) flow cytometry to assess surface glycoproteins and PLT size (forward scatter indices). PLT phenotypic patterns orientate towards candidate gene(s); in the absence of a suspected underlying cause, targeted next-generation sequencing (NGS) is used.

Results: The algorithm distinguished patient subgroups, guiding appropriate molecular approaches. The genetic cause was
identified in 37 families by direct Sanger sequencing and in 15 families by NGS. Differential diagnosis achieved was: 4 balicelic Bernard-Soulier syndrome (BSS), 5 monoallelic BSS, 1 Platelet-type vWD, 13 ITGB3/ITGA2B-related thrombocytopenia (-RT), 9 ACTN1-RT, 9 TUBB1-RT, 3 GF11B-RT, 7 MYH9-related disease (-RD) and 1 DIAPH1-RT.

Conclusion: Knowledge emerging from new genotype-phenotype correlations, particularly by reassessment of PLT function and phenotype in NGS-diagnosed cases, will be incorporated into the algorithm for further refining. Genetic diagnosis is essential for prognosis and preventive treatments, to flag syndromic entities with probable multi-organ involvement, as well as for determining carrier status.

References:

Grants: FCT grants to CM (UI/BD/150741/2020), UMIB and ITR (UIDB/00215/2020; UIDP/00215/2020; LA/P/0064/2020).

Conflict of Interest: None declared.

P08.022.B Making the invisible visible: Understanding what’s helpful in learning to live with a suspected Inborn Error of Immunity

Madison Mixer1, Rylee Duncan1, Michael Setzer1, Morgan Similuk1

1National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda, United States.

Background/Objectives: Prior research has established the potential for negative quality-of-life consequences among individuals with suspected Inborn Errors of Immunity (IEI). Relatively underrepresented in this literature, however, are qualitative methods that explore patient perceptions of their challenges and opportunities. This study aims to interrogate psychosocial impacts of having an IEI to better understand how patients adapt to their condition.

Methods: A survey including open-ended questions was sent to patients enrolled on the Centralized Sequencing Protocol and were suspected of having an IEI. Here, we present responses to the question: What has been most helpful in learning to live with a suspected Inborn Error of Immunity?

Results: Out of 1038 invited participants, 252 (24% response rate) responses were coded and analyzed thematically (59% female, mean age = 48 years). Many patients reported that they benefit from competent providers with a nuanced understanding of their disease and who provide effective treatments. Patients also reported seeking support in coping from family, friends, and the disease community. Many also reported the benefit of lifestyle changes and reconceptualizing their illness to gain a sense of control. An important minority of individuals indicated they had not found anything helpful in living with their illness. And why?

Background/Objectives: Inflammatory bowel diseases (IBD) is a group of chronic pathologies of the digestive system with not well known etiology. Interleukin 8 encoded by the CXCL8 gene is a cytokine that is a chemotactic factor responsible for the targeted migration of leucocytes to the site of inflammation. Its pro-inflammatory properties suggest that it plays a key role in the development of the inflammatory process. The aim of this analysis was to examine the two variants rs4073 (c.-251A>T) and rs188378669 (c.91G>T, p.Glu31Ter) in CXCL8 gene distribution in a group of IBD patients and populations.

Methods: Using pyrosequencing, Competitive Allele-Specific PCR (CASP) and Sanger sequencing, the two variants, rs4073 (c.-251A>T) and rs188378669 (c.91G>T, p.Glu31Ter) of the CXCL8 gene were analyzed in a group of 353 IBD patients and 200 subjects from Polish population in order to check if there is any correlations of them with a disease.

Results: Polymorphism c.91G>T, located in exon 2 of CXCL8 gene, causing premature termination of the polypeptide chain and consequently forming a non-functional protein was observed significantly more often in a group of IBD patients (MAF of 2.12%)
---

**Abstracts from the 55th European Society of Human Genetics Conference**

**Francesca Ariani**1;4;5; **Robinson**1;2, **Bianca Tesi**1;2, **Fulya Taylan**1, **Ann Nordgren**1;2

---

1Medical Genetics, University of Siena, Siena, Italy, Siena, Italy; 2Med Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy, Siena, Italy; 3Medical Genetics, University of Siena, Siena, Italy, Siena, Italy; 4Medical Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy, Siena, Italy; 5Genetica Medica, Azienda Ospedaliera Universitaria Senese, Siena, Italy, Siena, Italy.

---

**Background/Objectives:** Variants in CNOT3 have been associated with intellectual developmental disorder with speech delay, autism, and dysmorphic features (IDDSADF). To date, 22 mutated patients are known, and the phenotype is poorly described.

**Methods:** Via Exome sequencing, we detected the first splice site mutation in intron 2 in CNOT3 (c.262A>G). In silicon tools revealed a damaging effect on the splicing due to an alteration on the canonical splice site at 3'end, no longer recognized. Analysis of the transcript confirmed its damaging effect, consisting of intron 2 retention and of an in-frame duplication of exons 1 and 2.

**Results:** This is the third family with an inherited mutation in CNOT3, associated with a condition displaying intrafamilial variability. In fact, the proband showed intellectual disability (ID), language delay, structural cerebral anomalies, cardiac defects, physical dysmorphisms, whereas his mother manifested a mild ID and shared her son’s dysmorphisms. The mutation was related to anorectal dysplasia, firstly detected in CNOT3-patients.

**Conclusion:** The rectum is generated from the differentiation of the endoderm in the primordial gastrointestinal tract during the 4th week of the fetal life. CNOT3 takes part in the mesendoderm differentiation, which originates mesoderm and endoderm, suggesting a connection between its alterations and rectal atresia. This study contributes to define the CNOT3 phenotypic spectrum and highlights its clinical variability.

**References:** R. Meyer, et al., Inherited cases of CNOT3-associated intellectual developmental disorder with speech delay, autism, and dysmorphic facies, Clinical Genetics 2020. Martin R, et al., De novo variants in CNOT3 cause a variable neurodevelopmental disorder. Eur J Hum Genet. 2019.

**Grants:** None.

---

**Conflict of Interest:** None declared.

---

**P09 INTELLECTUAL DISABILITY**

**P09.001.A Parental mosaicism is underestimated in rare intellectual disability syndromes**

**Sofia Frisk**1,2, **Alexandra Wachtmeister**3, **Tobias Laurell**1,3, **Anna Lindstrand**1,2, **Nina Jäntt1,2, **Helena Malmgren**1,2, **Kristina LeGesterd-Robinson**1,2, **Bianca Tesi**1,2, **Fulya Taylan**1, **Ann Nordgren**1,2

1Karolinska Institutet, Molecular Medicine and Surgery, Stockholm, Sweden; 2Karolinska University Hospital, Clinical Genetics, Solna, Sweden; 3Södersjukhuset, Hand surgery, Stockholm, Sweden.

**Background/Objectives:** De novo variants are a common cause to rare intellectual disability syndromes, associated with low recurrence risk. However, when such variants occur pre-zygotically in parental germ cells, the recurrence risk might be higher. Still, the recurrence risk estimates are mainly based on empirical data and the prevalence of germline mosaicism is often unknown.

**Methods:** To establish the prevalence of mosaicism in parents of children with intellectual disability syndromes caused by de novo variants, we performed droplet digital PCR on DNA extracted from blood (43 trios), and sperm (31 fathers).

**Results:** We detected low-level mosaicism in sperm-derived DNA but not in blood in the father of a child with Kleefstra syndrome caused by an EHMT1 variant. Additionally, we found a higher level of paternal mosaicism in sperm compared to blood in the father of a child with Gillespie syndrome caused by a IFTR1 variant.

**Conclusion:** By employing droplet digital PCR, we detected paternal germline mosaicism in two intellectual disability syndromes. In both cases, the mosaicism level was higher in sperm than blood, indicating that analysis of blood alone may underestimate germline mosaicism. Therefore, sperm analysis can be clinically useful to establish the recurrence risk for parents and improve genetic counselling.

**References:**

**Grants:** This work was supported by grants from the Swedish Research Council, the Region Stockholm (combined residency and PhD training program), Karolinska Institutet, the Swedish Brain Foundation, the Swedish Rare Diseases Research Foundation (Sällsyntafonden) and The Hällsten Research Foundation.

**Conflict of Interest:** None declared.

---

**P09.004.D Missense variants in ANKRD11 cause KBG syndrome by impairment of stability or transcriptional activity of the encoded protein**

**Elke de Boer**1,2, **Charlotte Ockeloen**1, **Rosalie A. Kampen**3, **Juliet Hampton**4, **Alexander Dingelmann**5,2, **Dmitrijs Rots**1,2, **Tazeen Ashraf**3,2, **Rachel Baker**2, **Mouna Barat-Houani**2, **Brad Angle**2, **Nicolas Chatron**1,2, **Anne-Sophie Denommé-Pichon**1,2, **Orrin Devinsky**13, **Christele Dubourguier**14,15, **Frances Elmslie**16, **Kristin Monaghan**17, **Houda Elloumi**17, **Laurence Faivre**17,18,19, **Sara Fitzgerald-Butt**20, **David Geneviève**1, **Jacqueline Goos**2,22, **Benjamin Helm**20,23, **Usha Kini**24, **Amaia Lasa-Aranzasti**25, **Gaetan Lesca**9,10, **sally ann Lynch**26, **Irene Mathijsen**27, **Ruth McGowan**27, **Sylvie Odent**28, **Audrey Putoux**29, **Jeroen van Reeuwijk**22, **Gijs Santen**29, **Erina Sasaki**24, **Arthur Sorlin**11,18, **Peter van der Spek**22, **Alexander Viora-Dupont**18, **Antonio Vitobello**11,12, **Stephanie Ware**20,32, **Mathys Weber**28, **Christian Gilsen**19, **Karen Low**21,22, **Simon Fisher**2,23, **Lisa Vissers**1,2, **Maggie Wong**1, **Tijetske Kleefstra**12,24

1Radboudumc, Human Genetics, Nijmegen, Netherlands; 2Donders Institute, Nijmegen, Netherlands; 3MPI for Psycholinguistics, Nijmegen, Netherlands; 4RIMLS, Nijmegen, Netherlands; 5Great Ormond St Hospital for Children NHS, London, United Kingdom; 6Guys and St Thomas’ NHS, London, United Kingdom; 7Advocate Children’s Hospital, Park Ridge, United States; 8CHU Montpellier, Montpellier, France; 9Hospices Civils de Lyon, Lyon, France; 10Institut
NeuroMyoGene, Lyon, France; 17Université de Bourgogne Franche-Comté, Dijon, France; 18Laboratoire de Génétique chromosomique et moléculaire, Dijon, France; 19NYU Grossman School of Medicine, New York, United States; 20Service de Génétique Moléculaire et Génomique, Rennes, France; 13University of Rennes, Rennes, France; 16St George’s, London, United Kingdom; 21GeneDx, Gaithersburg, United States; 22Centre de Génétique et de Centre Référence Anomalies du Développement et Syndromes Malformatifs de l’Interrégion Est, Dijon, France; 19Fédération Hospitalo-Universitaire Médecine TRANS-LAD, Dijon, France; 23Indiana University, Indianapolis, United States; 24Oxford University Hospitals George, Rennes, France; 15University of Rennes, Rennes, France; 20Indiana University, Indianapolis, United States; 21Montpellier University, Montpellier, France; 22Erasmus MC, Rotterdam, Netherlands; 23Indiana University Fairbanks School of Public Health, Indianapolis, United States; 24Oxford University Hospitals NHS, Oxford, United Kingdom; 20Vall d’Hebron, Barcelona, Spain; 26Children’s Health, Dublin, Ireland; 27Queen Elizabeth University Hospital, Glasgow, United Kingdom; 28CHU Rennes, Rennes, France; 29Centre de Recherche en Neurosciences de Lyon, Lyon, France; 30Leiden UMC, Leiden, Netherlands; 31Maastricht UMC+, azM, Maastricht, Netherlands; 32Indiana University School of Medicine, Indianapolis, United States; 33University Hospital Bristol Hospital, Weston NHS, Bristol, United Kingdom; 34Vincent van Gogh Institute, Venray, Netherlands.

**Background/Objectives:** Although haploinsufficiency of ANKRD11 is among the most common genetic causes of neurodevelopmental disorders [1], the role of rare ANKRD11 missense variation remains unclear. We characterized the clinical, molecular and functional spectra of ANKRD11 missense variants.

**Methods:** We collected clinical information of individuals with ANKRD11 missense variants and evaluated phenotypic fit to KBG syndrome. We assessed pathogenicity of variants by in silico analyses and cell-based experiments.

**Results:** We identified 29 individuals with (mostly de novo) ANKRD11 missense variants, who presented with syndromic neurodevelopmental disorders and were phenotypically similar to individuals with KBG syndrome caused by ANKRD11 protein truncating variants or 16q24.3 microdeletions. Missense variants significantly clustered in Repression Domain 2. Cellularly, most variants caused reduced ANKRD11 stability. One variant resulted in decreased proteasome degradation and loss of ANKRD11 transcriptional activity.

**Conclusion:** Our study indicates that pathogenic heterozygous missense variants in ANKRD11 cause the clinically recognizable KBG syndrome. Disrupted transcription capacity and reduced protein stability each independently lead to ANKRD11 loss-of-function, consistent with haploinsufficiency. This highlights the diagnostic relevance of ANKRD11 missense variants, but also poses diagnostic challenges, as the KBG-associated phenotype may be mild, and inherited pathogenic ANKRD11 (missense) variants are increasingly observed, warranting stringent variant classification and careful phenotyping.

**References:** 1. Ockelen, C.W., et al., Further delineation of the KBG syndrome caused by ANKRD11 aberrations. Eur J Hum Genet, 2015. 23(9): p. 1270.

**Grants:** Aspasia grants, Dutch Research Council (015.014.036, 015.014.066), Netherlands Organization for Health Research and Development (91718310), the Max Planck Society, Solve-RD project (Horizon 2020, No 779257).

**Conflict of Interest:** Elke de Boer: None declared, Charlotte Ockelen: None declared, Rosalie A. Kampen: None declared, Juliet Hampstead: None declared, Alexander Dingemans: None declared, Dmitrijs Rots: None declared, Tazeen Ashraf: None declared, Rachel Baker: None declared, Mouna Barat-Houri: None declared, Brad Angle: None declared, Nicola Chatron: None declared, Anne-Sophie Denommé-Pichon: None declared, Orrin Devinsky: None declared, Christele Dubourg: None declared, Frances Elmslie: None declared, Kristin Monaghan This co-author is an employee of GeneDx, Inc, Houda Elloumi This co-author is an employee of GeneDx, Inc, Laurence Faivre: None declared, Sara Fitzgerald-Butt: None declared, David Geneviève: None declared, Jacqueline Goos: None declared, Benjamin Helm: None declared, Usha Kini: None declared, Amaia Lasa-Anaranztii: None declared, Gaetan Lesca: None declared, sally ann Lynch: None declared, Irene Mathijssen: None declared, Ruth McGowan For this centre, the WGS data were generated in the Scottish Genomes Partnership. The Scottish Genomes Partnership was funded by the Chief Scientist Office of the Scottish Government Health Directorates [SGP/1] and The Medical Research Council Whole Genome Sequencing for Health and Wealth Initiative (MC/PC/15080)., Sylvie Odent: None declared, Rolf Pfundt: None declared, Audrey Putoux: None declared, Jeroen van Reeuwijk: None declared, Gijs Santen: None declared, Erina Sasaki: None declared, Arthur Sorlin: None declared, Peter van der Spek: None declared, Alexander Steegmann: None declared, Sigrid Swage-makers: None declared, Irene Valenzuela: None declared, Eléonore Viora-Dupont: None declared, Antonio Vitobello: None declared, Stephanie Ware: None declared, Mathys Weber: None declared, Christian Gilissen: None declared, Karen Low: None declared, Simon Fisher This work was financially supported the Max Planck Society, Lisenka Vissers* This work was financially supported by Aspasia grants of the Dutch Research Council (015.014.066). In addition, the collaborations in this study were facilitated by ERN ITHACA, one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States, co-funded by European Commission. The aims of this study contribute to the Solve-RD project which has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257.

**P09.005.A A novel pathogenic FMR1 splice site variant in a man with normal intelligence and Klinefelter syndrome - A case report**

Malou Schadeck¹, Nicole Meier¹, Eva Wohleber¹, Juergen Kohlhase¹

1SYNLAB Center for Human Genetics, Freiburg, Germany.

**Background/Objectives:** We describe a 30-year-old man referred to genetic counselling regarding a possible Marfan syndrome. He presented with marfanoid features such as tall stature, an aortic root enlargement, and a systemic score of 7 points.

**Methods:** We performed whole exome sequencing based on the marfanoid phenotype including HPO-terms for cardiac defects.

**Results:** No variants associated with Marfan syndrome were detected. The exome based CNV (copy number variation) analysis revealed a duplication of all X-chromosomal genes, strongly suggesting a Klinefelter syndrome (KS) (karyotype 47,XYX), that does not fully explain the patient’s phenotype. Exome analysis detected a novel splice-site variant c.1738-1G>A, p. in the FMR1 gene. The variant has not been described previously. Splice-site in silico prediction tools (SSF, MaxEnt, NNSplice and GeneSplicer) indicated a disrupted splice acceptor site of intron 16.

KS is a sex-chromosomal disorder with a frequency of ca. 1:500 men. Phenotypic features can include tall stature, gynecomastia and often azoospermia.

In more than 99% of patients diagnosed with a Fragile-X syndrome the mutational mechanism is a CGG-trinucleotid repeat-enlargement, and a systemic score of 7 points.
expansion in FMR1, whereas other types of FMR1 mutations, affecting the coding region or splicing of FMR1, account for less than 1% of cases. Males previously described to carry FMR1 splice mutations had moderate to severe mental retardation.

**Conclusion:** We describe a patient with normal intelligence despite a pathogenic splice variant in FMR1, probably due to a skewed X-inactivation because of his Klinefelter syndrome.

**References:** 1. Intragenic FMR1 disease-causing variants: a significant mutational mechanism leading to Fragile-X syndrome, Quartier et al. (2017).

**Grants:**

**Conflict of Interest:** None declared.

---

**P09.006.B Deep phenotyping of patients with developmental disorders and their relatives to support interpretation of rare inherited copy number variants**

**Elise Pelgrims**, 1, **Laurens Hannes** 1, 2, **Marta Atzori**, 1, **Catia Attanasio**, 1, **Jeroen Breckpot** 1, 2, **Ann Swillen** 1, 2

1KU Leuven, Department of human genetics, Leuven, Belgium; 2UZ Leuven, Centre for human genetics, Leuven, Belgium.

**Background/Objectives:** In patients with developmental disorders (DD), copy number variants (CNV) inherited from seemingly unaffected parents are typically disregarded in variant interpretation. However, understanding the phenotypic contribution of inherited rare variants is crucial for genetic counselling. Therefore, an extended family-oriented approach is proposed, including deep familial phenotyping and multi-omics in carriers and non-carriers.

**Methods:** Deep phenotyping (including medical, developmental, and behavioral, using standardized instruments) of carriers and non-carriers within the nuclear family, enables familial segregation analysis of a CNV with DD (sub)phenotypes. Trio whole genome sequencing is used to identify additional pathogenic variants, further delineating the associated phenotype and review genotype-phenotype correlations in individuals with a TRIP12 mutation -associated phenotype and review genotype-phenotype correlations. This combined approach was applied to interpret a rare paternally inherited deletion (IGRCh37:4:141693186-142147039x1) in a 15-year-old boy with moderate intellectual disability, ASD, DCD, hypotonia and facial dysmorphic features.

**Results:** CNV carriers (FSIQ; index 40, father 71) scored significantly lower on cognitive abilities compared to non-carriers (FSIQ; mother 100, sibling 92). Behavioral profiles of carriers were more overlapping than profiles of non-carriers. De novo, recessive, X-linked and paternally inherited variant analyses of SNV, indels and additional CNVs were negative. RNA-seq shows four differentially expressed genes in the CNV or flanking regions (INPP4B, SETD7, MAML3, ZNF330). Their contribution to DD is subject to further study.

**Conclusion:** This multi-omics approach and correlation through deep familial phenotyping is suggestive of a contributory effect of this CNV to DD in this family.

**References:**

**Grants:** This work is supported by a KULeuven grant (C24M/19/075).

**Conflict of Interest:** None declared.

---

**P09.007.C Establishing the neurodevelopmental phenotype and genotype-phenotype correlations in individuals with a TRIP12 mutation**

**Mio Aerden**, 1, **Anne-Sophie Denommé-Pichon** 2, **Saskia Koene** 2, **Amelie Piton** 4, **Eric Legius** 1, **Miel Theunis** 1, **Tzung-Chien Hsieh** 5, **Peter Krawitz** 2, **Mala Misra-Irié** 3, **Sandra Whalen** 2, **Dagnmar Wieczorek** 3, **Theresia Herger** 2, **Guillaume Debroy** 10, **Nuria Brämswig** 17, **Vanesa López González** 2, **Guillaume Jouret** 13, **Berta Almoguera Castillo** 14, **Maria Isis Atallah Gonzalez** 15, **Maria Kibaek** 16, **Lucia Bruno** 17, **Katrin Ounap** 18, **Fernando Santos-Simarro** 19, **Hilde Van Esch** 1

1University Hospitals Leuven, KU Leuven, Department of Human Genetics, Leuven, Belgium; 2Université de Bourgogne, INSERM UMR1231 Equipe GAD, Dijon, France; 3Leiden University Medical Center, Department of Clinical Genetics, Leiden, Netherlands; 4Hôpitaux Universitaires de Strasbourg, Laboratoire de Diagnostic Génétique, Strasbourg, France; 5University of Bonn, Institute of Genomic Statistics and Bioinformatics, Bonn, Germany; 6Amsterdam University Medical Center, Department of Clinical Genetics, Amsterdam, the Netherlands; 7226Fondation de Genétique Clinique, Centre de Référence des Anomalies du Développement et Syndromes Malformatifs, APHP, Hôpital Armand Trousseau, Paris, France; 8Heinrich-Heine-Universität, Institut für Humangenetik, Düsseldorf, Germany; 9Universitätsklinikum Hamburg-Eppendorf, Institut für Humangenetik, Hamburg, Germany; 10Centre Hospitalier Universitaire de Liège, Center of Human Genetics, Liège, Belgium; 11Universität Duisburg-Essen, Institut für Humangenetik, Essen, Germany; 12Hospital Clínico Universitario Virgen de la Arrixaca, Sección de Genética Médica, Servicio de Pediatria, Murcia, Spain; 13Laboratoire National de Santé, National Center of Genetics, Dudelange, Luxembourg; 14Fundación Jiménez Diaz Hospital, Department of Genetics and Genomics, Madrid, Spain; 15Lausanne University Hospital, Division of Genetic Medicine, Lausanne, Switzerland; 16Odense University Hospital, Department of Clinical Genetics, Odense, Denmark; 17University of Siena, Medical Genetics Unit, Siena, Italy; 18Tartu University Hospital, Department of Clinical Genetics, Tartu, Estonia; 19Hospital Universitario La Paz, Instituto de Genética Médica y Molecular, Madrid, Spain.

**Background/Objectives:** Haploinsufficiency of TRIP12 causes a neurodevelopmental disorder characterized by intellectual disability associated with epilepsy, autism and dysmorphism, also named Clark-Baraitser syndrome. Less than 25 individuals harboring pathogenic TRIP12 variants have been reported. We aim to further delineate the TRIP12-associated phenotype and review genotype-phenotype correlations. In addition, characteristic facial traits are objectified through image analysis based on deep-learning algorithms.

**Methods:** 37 individuals were recruited through a collaborative call via ERN-ITHACA. Clinical data was collected and the pictures of 21 individuals were uploaded into the GestaltMatcher database for analysis of facial morphology.

**Results:** One inherited and 35 de novo TRIP12 variants were identified, including frameshift (n = 16), nonsense (n = 6), missense (n = 5) and splice (n = 3) variants as well as intragenic deletions (n = 5) and a multigene deletion disrupting TRIP12. Though variable in severity, global developmental delay was noted in all individuals, with language deficit most pronounced. Half of the individuals showed autistic features, but there was no clear correlation with the mutation type. Susceptibility to obesity seemed to be a recurrent feature in older individuals. Seizures were reported in a minority and proved to be refractory in individuals with a missense variant.

Facial analysis shows a clear gestalt including deep-set eyes with narrow palpebral fissures, downturned corners of the mouth and large, low-set ears with prominent earlobes.

**Conclusion:** We report the largest cohort to date of individuals with pathogenic TRIP12 variants, further delineating the associated phenotype including introduction of a facial gestalt and expanding genotype-phenotype correlations. These findings will improve future counseling and patient guidance.

**References:** /

**Grants:** /

**Conflict of Interest:** None declared.
Background/Objectives: Thanks to more than 50% diagnostic yield the whole-exome sequencing (WES) has become an effective and powerful approach to identify molecular genetic causes of neurodevelopmental disorders (NDDs) and multiple congenital abnormalities (MCA).

Methods: We present our experience with WES as an effective tool for the detection of rare and novel pathogenic sequence variant using the commercial kit Human Core Exome (Twist Biosciences) and Illumina NovaSeq 6000. Our pilot study included 45 families (trios or quatrois) of children with severe NDDs and MCA.

Results: Using our in-hose bioinformatic pipeline and unique algorithm for variant prioritization we identified recurrent de novo pathogenic sequence variants in clinically relevant SHANK3, GRIN1, NSD1, CDK13 genes, novel de novo pathogenic variants in KDM1A, KMT2E, GNAI1, MEIS2, SMARCA2, RAI1 and CHD8 genes, pathogenic X-linked variants in EDA and OPHN1 genes of maternal origin, pathogenic sequence variants in ZGRF1 of paternal origin and biallelic pathogenic sequence variants in the BLM gene. Moreover, two pathogenic sequence variants in the CTNNB1 and DYNC1H genes were present as low-level mosaicism in healthy fathers. All clinically important variants including secondary findings (in “ACMG” genes) were manually verified using Sanger sequencing and interpreted based on relevant information in integrated databases of genomic variants, relevant scientific literature, and individual anamnesis.

Conclusion: With an achieved diagnostic yield of 37.5% (18/48 children with NDDs and MCA), trio-based WES represents as an effective first-tier diagnostic test in the genetic evaluation of children with NDDs.

References:

Grants: Supported by Ministry of Health of the Czech Republic, grant nr. NU20-07-00145. All rights reserved.

Conflict of Interest: None declared.

P09.009.D The clinical benefit of trio-based whole-exome sequencing for the detection of rare pathogenic sequence variants in pediatric patients with undiagnosed neurodevelopmental disorders

Marketa Wayhelova1,2, Vladimira Vallova1,2, Jan Smetana3, Petr Broz4, Aneta Mikulasova4, Renata Gaillyova4, Petr Kuglik1,2

1University Hospital Brno, Centre of Molecular Biology and Genetics, Brno, Czech Republic; 2Masaryk University, Department of Experimental Biology, Faculty of Science, Brno, Czech Republic; 3Newcastle University, Biosciences Institute, Newcastle upon Tyne, United Kingdom; 4University Hospital Brno, Department of Medical Genetics and Genomics, Brno, Czech Republic.

Background/Objetives: Thanks to more than 50% diagnostic yield the whole-exome sequencing (WES) has become an effective and powerful approach to identify molecular genetic causes of neurodevelopmental disorders (NDDs) and multiple congenital abnormalities (MCA).

Methods: We present our experience with WES as an effective tool for the detection of rare and novel pathogenic sequence variant using the commercial kit Human Core Exome (Twist Biosciences) and Illumina NovaSeq 6000. Our pilot study included 45 families (trios or quatrois) of children with severe NDDs and MCA.

Results: Using our in-house bioinformatic pipeline and unique algorithm for variant prioritization we identified recurrent de novo pathogenic sequence variants in clinically relevant SHANK3, GRIN1, NSD1, CDK13 genes, novel de novo pathogenic variants in KDM1A, KMT2E, GNAI1, MEIS2, SMARCA2, RAI1 and CHD8 genes, pathogenic X-linked variants in EDA and OPHN1 genes of maternal origin, pathogenic sequence variants in ZGRF1 of paternal origin and biallelic pathogenic sequence variants in the BLM gene. Moreover, two pathogenic sequence variants in the CTNNB1 and DYNC1H genes were present as low-level mosaicism in healthy fathers. All clinically important variants including secondary findings (in “ACMG” genes) were manually verified using Sanger sequencing and interpreted based on relevant information in integrated databases of genomic variants, relevant scientific literature, and individual anamnesis.

Conclusion: With an achieved diagnostic yield of 37.5% (18/48 children with NDDs and MCA), trio-based WES represents as an effective first-tier diagnostic test in the genetic evaluation of children with NDDs.

References:

Grants: Supported by Ministry of Health of the Czech Republic, grant nr. NU20-07-00145. All rights reserved.

Conflict of Interest: None declared.

P09.009.A RAB11B-associated neurodevelopmental disorder - confirmed and extended to milder manifestations through 13 individuals with 5 novel variants

Natalie Ahmad1, Walid Fazeli2, Sophia Schließke3, Gaeta Lesca4, Zeynep Gokce-Samar4, Kristopher Kahle5, Kedous Mekbib5, Jennifer Burton6, George Hoganson6, Andrea Petersen6, Sara Gracie6, Leslie Granger6, Enrika Bartels7, Henry Oppermann7, Sheng Chih Jin8, Adam Kundishora9, Marianne Till9, Shane Dangerfield10, Dave Viskochil10, Katherine Anderson11, George E Tiller12, Wolfram Kunz13, Sebastian Burkart14, Matias Simons14, Ingrid M Wentzensen15, Hui Yang15, Rami Abou Jamra1, Sonja Neuser1

1University of Leipzig Medical Center, Institute of Human Genetics, Leipzig, Germany; 2University Hospital Bonn, Department of Pediatric Neurology, Bonn, Germany; 3University Hospital, Department of Medical Genetics, Lyon, France; 4University Hospital, Department of Epileptology, Lyon, France; 5Yale University School of Medicine, Department of Neurosurgery, New Haven, United States; 6University of Illinois College of Medicine, Peoria, United States; 7Randall Children’s Hospital, Portland, United States; 8Institute of Clinical Genetics and Tumor Genetics, Bonn, Germany; 9Medical School, Washington University, Department of Genetics, St. Louis, United States; 10University of Utah, Salt Lake City, United States; 11University of Vermont Medical Center, Department of Pediatrics, Burlington, United States; 12Kaiser Permanente, Department of Genetics, Los Angeles, United States; 13University Hospital Bonn, Department of Epileptology, Bonn, Germany; 14University Hospital Heidelberg, Institute of Human Genetics, Heidelberg, Germany; 15GeneDx Inc., Gaithersburg, United States.

Background/Objectives: The family of Rab GTPase proteins are molecular switches acting through GDP/GTP-exchange and involved in vesicle trafficking. RAB11B has been associated with a Mendelian neurodevelopmental disorder (NDD) in 2017 as two recurrent de novo missense-variants (amino acids 22,68) were identified in five children with severe intellectual disability (ID), absent speech, ataxic gait, and decreased cortical white matter. No additional cases have since been reported. We aim at confirming the relevance of RAB11B and delineating the genotypical and phenotypical spectrum.

Methods: Through international matchmaking, we gathered eight individuals with RAB11B variants identified through exome sequencing or array CGH. Clinical details of novel and previously reported five individuals were standardized to HPO-terms. We performed a cross-sectional analysis regarding the clinical manifestations. Three-dimensional analysis using a ProteinDataBank structure was done by manual inspection of variant localization in PyMol as well as cluster calculation according to mutation3d-algorithm.

Results: The variant spectrum comprises six missense-variants (four novel; amino acids 21,33,72,75) as well as one 319kb duplication, all except one confirmed de novo. In silico parameters indicate damaging effects. All variants affect or lay close by the GTP-binding sites and five of them showed significant clustering. Data from 13 individuals confirm main clinical findings to be NDD/ID (75%), muscular hypotonia (75%) and small cerebral cortex (70%). However, cognitive function ranges from severe ID (67%) to few cases with normal cognitive development only with epilepsy.

Conclusion: Confirmation of RAB11B as an NDD gene and extension to milder manifestations, generally de novo-variants within the GTP-binding regions are highly suspicious as disease-causing.

References:

Grants: Supported by Ministry of Health of the Czech Republic, grant nr. NU20-07-00145. All rights reserved.

Conflict of Interest: None declared.

P09.010.A Comparison of methylation epi-signatures in KMT2B and KMT2D-related human disorders

Sunwoo Lee1, Eguzkine Ochoa2, Katy Barwick2, Laura Cif3, Fay Rodger1,4, France Docquier1,4, Benel Perez2, Graeme Clark1,4, Jose-

European Journal of Human Genetics (2023) 31:345 – 709

SPRINGER NATURE
Abstracts from the 55th European Society of Human Genetics Conference

Ezequiel Martin Rodriguez1, Siddharth Banka2, Manju Kurian2, Eamonn R Maher1

1University of Cambridge, Department of Medical Genetics, Cambridge, United Kingdom; 2UCL Great Ormond Street Institute of Child Health, Zayed Centre for Research into Rare Disease in Children, Developmental Neurosciences, London, United Kingdom; 3Unite des Pathologies Cérébrales Ressources, Unite de Recherche sur les Comportements et Mouvements Anormaux, Hôpital Gui de Chauliac, Centre Hospitalier R’ginal Montpellier, Department of Neurochirurgie, Montpellier, France; 4Stratifed Medicine Core Laboratory NGS Hub, Cambridge Biomedical Campus, Cambridge, United Kingdom; 5University of Manchester and Manchester Centre for Genomic Medicine, and Genomics, School of Biological Sciences, Faculty of Biology, Medicine, and Health, Manchester, United Kingdom.

Background/Objectives: Many neurodevelopmental disorders caused by mutations in genes regulating chromatin function and/or structural display abnormal DNA methylation patterns (episignatures) in peripheral blood. DYT-KMT2B is unique among “chromatin neurodevelopmental disorders” in that the most prominent clinical feature and most frequent presentation is childhood onset dystonia rather than developmental delay or congenital anomalies (as seen in many chromatin neurodevelopmental disorders such as Kabuki syndrome).

Methods: To investigate peripheral blood methylation episignatures in KMT2B-related dystonia (DYT-KMT2B), we undertook genome-wide methylation profiling of ~2M CpGs using a next-generation sequencing based assay and compared the findings to those in controls and patients with Kabuki syndrome Type 1 (KS1-KMT2D).

Results: Methylation profiling revealed 1,812 significantly differentially methylated CpG positions (DMPs) (FDR < 0.05) in 10 DYT-KMT2B samples compared to controls, covering 40 CpG. Multi-dimensional scaling analysis showed that the DYT-KMT2B samples clustered together and separately from 29 control individuals and 10 individuals with pathogenic variants in KMT2D. Most DMPs were specific to one disorder and that all (DYT-KMT2B) and most (KS1) methylation alterations in CpG islands were gain of methylation events. Analysis of genes associated with CpG islands suggested potential candidate genes for the molecular pathogenesis of DYT-KMT2B.

Conclusion: Using higher resolution methodology for methylation profiling, we confirmed a peripheral blood methylation signature for DYT-KMT2B. Methylation episignatures could be used to aid pathogenicity interpretation of KMT2B variants and can complement mechanistic investigations of the pathogenesis of DYT-KMT2B.

References:

Grants: This research was co-funded by the NIHR Cambridge Biomedical Research Centre and Rosetrees Trust.

Conflict of Interest: None declared.

P09.011.C Exome sequencing detects two novel variants in SNRPN in two patients with Prader-Willi/ Prader-Willi-like syndrome

Arrate Pereda1, Purvi Majethia2, Guiomar Perez de Nanclares3, Anju Shukla2

1Bioaraba Health Research Institute, Rare Diseases Research Group, Molecular (Epi)Genetics Laboratory, Araba University Hospital-Txagorritxu, Vitoria-Gasteiz, Spain; 2Kasturba Medical College, Department of Medical Genetics, Manipal Academy of Higher Education, Manipal, India.

Background/Objectives: Imprinting disorders (IDs) are a group of congenital disorders caused by (epi)genetic alterations in imprinted chromosomal regions. Prader-Willi syndrome (PWS) is one of the best known IDs, and is consequence of the loss of paternally expressed genes (MAGEL2, NDN, SNURF-SNRPN and SNORD116) within the 15q11.2-q13, caused either by a CNV (65–75% of cases), a upd(15)mat (20–30%), or an epimutation (1–3%) (1). Recently, point variants in SNRPN have been reported as causative of PWS in two independent families (2, 3) and in this report we describe two new cases.

Methods: Two independent probands were referred for genetic testing due to seizures, mild intellectual disability and obesity (1); and clinical suspicion of PWS (P2). After negative MS-MLPA testing for 15q11 region, exome sequencing (ES) was carried out. Variant confirmation and cosegregation studies were analysed by Sanger sequencing. Parental origin of the allele was tested by allele-specific RT-PCR amplification, and sequencing.

Results: ES studies identified a novel missense variant in SNRPN in each proband. Complementary studies determined that each variant was carried in the proband’s paternal allele.

Conclusion: According to these and previous results (2, 3), genetic testing for SNRPN point variants should be performed in PWS patients with negative results for classical causes.

References:

1. C. K. Cheon, Ann. Pediatr. Endocrinol. Metab. 21, 126 (2016).
2. K. Pellikkaan et al., Genes (Basel). 12, 875 (2021).
3. Y. Huang et al., J. Med. Genet. 6, 1–4 (2021).

Grants: ESPE RU Grant 2020 (UE19_RUPE); Institute of Health Carlos III (P1200950); Basque Department of Health (GV2021/111056).

Conflict of Interest: Arrate Pereda ESPE RU Grant 2020 (UE19_RUPE); Institute of Health Carlos III (P1200950), Purvi Majethia: None declared, Guiomar Perez de Nanclares ESPE RU Grant 2020 (UE19_RUPE); Institute of Health Carlos III (P1200950); Basque Department of Health (GV2021/111056), Anju Shukla: None declared.

P09.012.D LoF variants can cause TUBB-associated disorder

Olga Levchenko1, Elena Dodali1, Sabina Nagieva1, Alexander Lavrov1

1Research Centre for Medical Genetics, Moscow, Russian Federation.

Background/Objectives: TUBB encodes one of nine beta-tubulin proteins and is widely expressed in all tissues, especially in the developing brain. Pathogenic variants in TUBB are associated with two main phenotypes: cortical dysplasia, complex, with other brain malformations 6 (OMIM: 615771) and symmetric circumferential skin creases, congenital, 1 (OMIM: 156610). Both diseases are autosomal dominant and result in impaired intellectual development. There are only 10 pathogenic variants currently described and none of them demonstrate loss of function (LoF) effect. We report for the first time that LoF variants in TUBB may be responsible for impaired intellectual development.

Methods: Whole exome sequencing (WES) was performed using the IlluminaTruSeq® ExomeKit, IDT xGen® Exome Research Panel, and Illumina NextSeq 500.

Results: A 38-year-old man was born from a full-term pregnancy with a weight of 2600 g and length of 48 cm. Motor development was delayed: he could seat at 10 months, walk at 1 year 8 months. He cannot speak. On examination: normal height and weight, thoracolumbar kyphosis, strabismus, ocular hypertelorism, short filter, protruding lower jaw, no focal neurological symptoms. Karyotype is 47, XXY, normal methylation status of the FMR1 promoter. WES revealed variant of unknown significance.
P09.013.A Delineating the MAPK8IP3-related neurodevelopmental disorder reveals consistent variant specific phenotypes

Tobias Bartolomeus1, Rami Abou Jamra2, Johannes Lemke1, International Study Group Mapk8ip3⁎, Konrad Platzer1

1Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany; 2International Study Group MAPK8IP3, New York, United States.

Background/Objectives: We and others have recently described de novo variants in MAPK8IP3 gene as a cause of neurodevelopmental disorder (NDD) with intellectual disability (ID), seizures, microcephaly, and brain anomalies.

Methods: We present an overview of 18 published and 20 novel individuals with causative MAPK8IP3 variants and a HPO based phenotypic analysis.

Results: Missense variants were identified in 31 individuals, truncating variants in six, and whole gene deletion in one. About 58% (22/38) harbour one of the previously reported recurrent missense variants p.Arg578Cys (10), p.Leu444Pro (3), or p.Arg1146Cys/His (9). ID ranges from mild to profound. Additional symptoms encompass brain anomalies (22/26), obesity (9/16), spasticity or dystonia (16/21), seizures (10/27), ataxia (6/8), microcephaly (5/15), and precocious puberty (4/6). The recurrent variant p.Arg578Cys is consistently associated with severe ID, spasticity, hypoplastic corpus callosum, white matter abnormalities, seizures, small hands and feet and early-onset obesity with insatiable appetite. In contrast, recurrent variants affecting Arg1146 are less frequently linked with obesity or seizures but instead with autism and ataxia. Three individuals do not fall into the MAPK8IP3-related NDD spectrum: two brothers with the de novo variant p.Ser984Leu have recurrent pain during urination with one of them also mildly delayed. Another six year old boy with the de novo variant p.Pro822Ser initially showed infantile spasms, which subsequently resolved with normal development.

Conclusion: MAPK8IP3-related NDD encompasses ID and consistent variant-specific phenotypes including novel observations of obesity, precocious puberty and small hands and feet. Causality of novel de novo variants remain to be elucidated.

References:

Grants:

Conflict of Interest: None declared.

P09.014.B BAFfling: Microduplications of ARID1A and ARID1B cause a novel clinical and epigenetic distinct BAFopathy

Eline van der Sluijs1, Sebastien Moutton2,3, Denisa Weis4, Kym Boycott5,6, Claudia Arberas7,8, Margherita Baldassari3,8, Claire Bene- teau9-11, Charles Couton12,13, Tabib Dabir1, Koenraad Devriendt15, Laurence Faivre5,6, Khadije Jiz7,17,18, Jennifer Kerkhof9,19, Mira Kharbanda20, Katherine Lachlan21, Michael Levy19, Angelica Maris22, Nathalie Marie22,23, Haley McConkey19, Maria Antonietta Mencarelli20, David Mowat24,16, Claire Nicolas24,16, olivier pichon17, Julia Rankin25,26, Raissa Relator19, Jill A. Rosenfeld27,28, Norbert Winner29,30, Jeremy Woods31,32, Bekim Sadikovic19, Marielle Alders33, Gijs Santen1

1Leiden University Medical Center, Clinical Genetics, Leiden, Netherlands; 2FHU TRANSLAD, CHU Dijon, Centre de Référence Anomalies du Développement et Syndromes Malformatifs, Dijon, France; 3Maison de Santé Protestantte Bordeaux Bagatelle, CPDPN, Pôle mère enfant, Talence, France; 4Johannes Kepler University Linz, Institute of Medical Genetics, Linz, Austria; 5University of Ottawa, Children’s Hospital of Eastern Ontario Research Institute, Ottawa, Canada; 6Children’s Hospital of Eastern Ontario, Department of Genetics, Ottawa, Canada; 7Hospital de Niños Dr. Ricardo Gutierrez, Sección Genética Médica, Buenos Aires, Argentina; 8Azienda Ospedaliera Universitaria Senese, Genetic Medica, Siena, Italy; 9University of Siena, Medical Genetics, Siena, Italy; 10Centre Hospitalier Universitaire de Nantes, Service de Génétique médicale, Nantes, France; 11Centre Hospitalier Universitaire de Nantes, UF de Foetoapathologie et Génétique, Nantes, France; 12Université Grenoble-Alpes, Grenoble, France; 13Hôpital Couple-Enfant, CHU de Grenoble, Département de Génétique et Procréation, Grenoble, France; 14Belfast City Hospital, Department of Genetic Medicine, Belfast, United Kingdom; 15University Hospitals Leuven, Center for Human Genetics, Leuven, Belgium; 16NSERM - Bourgogne Franche-Comté University, Genetics of Developmental Disorders, Dijon, France; 17Université de Montréal, Department of Pediatrics, Montréal, Canada; 18Centre de recherche et Centre Hospitalier Universitaire Sainte-Justine, Montréal, Canada; 19Western University, Verspeeten Clinical Genome Centre, London Health Sciences Centre, and Department of Pathology and Laboratory Medicine, London, Canada; 20University Hospital Southampton, Princess Anne Hospital, Wessex Clinical Genetics Service, Southampton, UK, United Kingdom; 21University Hospital Southampton, Princess Anne Hospital, Wessex Clinical Genetics Service, Southampton, United Kingdom; 22Universidad Federal de Santa Catarina, Florianópolis, Brazil; 23CHU de Dijon, Dijon, France, Laboratoire de Génétique Chromosomique et Moléculaire, Pôle de Biologie, Dijon, France; 24Sydney Children’s Hospital, Center for Clinical Genetics, Randwick, New South Wales, Australia; 25University of New South Wales, School of Women’s and Children’s Health, Faculty of Medicine and Health, Kensington, New South Wales, Australia; 26Royal Devon and Exeter NHS Foundation Trust, Department of Clinical Genetics, Exeter, United Kingdom; 27Baylor College of Medicine, Department of Molecular and Human Genetics, Houston, United States; 28Baylor Genetics Laboratories, Houston, United States; 29Centre Hospitalier Universitaire de Nantes, Service de Gynécologie-Obstétrique, Nantes, France; 30Université de Nantes, NUN, INRAE, UMR 1280, PHAN, Nantes, France; 31Valley Children’s Hospital, Department of Genetics, Madera, CA, United States; 32Stanford University, Palo Alto, CA, United States; 33Amsterdam UMC, University of Amsterdam, Department of Human Genetics, Amsterdam, Netherlands.

Background/Objectives: The clinical relevance of ARID1B whole gene duplications has been unclear until now. ARID1B and ARID1A have the same role within the BAF complex and are mutually exclusive. ARID1A duplications appear to lead to a distinct clinical syndrome, while ARID1B duplications have not been linked to a clinical phenotype.

Methods: To investigate whether an ARID1B duplication phenotype exists, and how this relates to the ARID1A phenotype, we included patients with an ARID1A or ARID1B duplication, compared their phenotypes and determined DNA methylation.

Results: We included data of 9 ARID1A and 11 ARID1B duplication patients. Duplication size ranges between 0.1-1.2 Mb with 1-44 genes for ARID1A and 0.4-10.3 Mb with 2-101 genes for ARID1B. Main features shared by ARID1A and ARID1B patients were intellectual disability, microcephaly, growth delay and cryptorchidism. Even though there is overlap between the two groups, the phenotype of ARID1A patients appeared to be more severe compared to that of ARID1B patients. DNA methylation Episign analysis showed that ARID1A and ARID1B duplication patients have a similar DNA methylation pattern in blood, which is different from controls and opposite to the pattern of more common ARID1A or ARID1B loss-of-function variants.
**Conclusion:** We report for the first time that duplications of ARID1B lead to a clinical phenotype with significant overlap with ARID1A duplications, and that these patients have overlapping episignatures providing further evidence for an overlapping phenotype distinct from other BAFopathies. A new type of BAFopathy caused by a duplication, rather than haploinsufficiency, is emerging here.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P09.015.C Expanding Rett syndrome landscape: identification of candidate genes from a WES study**

Elisabetta Di Fede¹, Angela Peron³, Elisa Colombo³, Simone Tamburrì¹, Diego Pasini¹, Cristiana Gervasini¹, Aglia Vignoli¹, Renata Szalai²

¹Università degli Studi di Milano, Department of Health Sciences, Milan, Italy; ²ASST Santi Paolo e Carlo, Human Pathology and Medical Genetics, Milan, Italy; ³Università degli Studi di Milano, Child Neuropsychiatry Unit, Epilepsy Center, Department of Health Sciences, Milan, Italy; ⁴University of Utah School of Medicine, Department of Pediatrics, Salt Lake City, United States; ⁵IEO European Institute of Oncology IRCCS, Department of Experimental Oncology, Milan, Italy; ⁶Università degli Studi di Milano, Child Neurology Unit, Milan, Italy; ⁷ASST Grande Ospedale Metropolitano Niguarda, Child NeuroPsychiatry Unit, Milan, Italy.

**Background/Objectives:** Rett syndrome (RTT) is a neurodevelopmental disorder (incidence of 1:10,000 live female births) most frequently affecting girls during infancy, after an early normal development. The genetic cause is known for about 90% of patients (MECP2 mutations in the classic form, CDKL5 and FOXG1 mutations for the two variants), while the 10% remain without molecular diagnosis.

**Methods:** We applied whole exome sequencing (WES) analysis to Rett-like probands and their healthy parents. We enrolled in the study patients negative for mutations in RTT genes to identify the genetic cause and expand the knowledge of the pathogenetic mechanisms underlying RTT.

**Results:** We found one girl (#1) being compound heterozygote for two unreported variants in NBEA gene, encoding for a brain-specific protein involved in vesicle trafficking. In addition, patient #2 was found being carrier of a de novo missense mutation in DYNC1H1, known to be associated to a recently classified neurodevelopmental disorder. Finally, in patient #3 was identified a novel heterozygous missense variant in SLC35F1, mainly expressed in the brain and coding for a putative solute carrier whose role is currently under investigation.

**Conclusion:** The identification of new RTT genes could expand the genotype-phenotype correlation for RTT syndrome, and the characterization of new candidate RTT genes could give insights into the pathogenesis of this neurodevelopmental disorder.

**References:** Neul et al., 2010; Mulhern et al., 2018; Poirier et al., 2013; Szafranski et al., 2015; Di Fede et al., 2021.

**Grants:** Grant Aldo Ravelli Center for Neurotechnology and Experimental Brain Therapeutics and Intraunmal funding of Università degli Studi di Milano.

**Conflict of Interest:** None declared.

**P09.016.D A novel missense mutation in SLC2A1 gene responsible for Glut1 Deficiency Syndrome**

Renata Szalai¹, Agnes Tili², Judit Bene², Anita Maasz², Kinga Hadzisie², Rami Abou Jamra¹

¹Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany.

**Background/Objectives:** Glut1 Deficiency Syndrome (Glut1DS) is a brain energy failure disease caused by impaired glucose transport across brain tissue barriers. The definite diagnosis of Glut1DS is confirmed by the presence of characteristic clinical features, hypoglycorrhachia, and a pathogenic variant in SLC2A1 gene. The type of genetic mutation correlates with severity of disease; missense variants (mild severity); splice site, nonsense variants, insertions, deletions (moderate and severe severity); complete gene microdeletions (severe severity). Heterozygous de novo pathogenic variants in SLC2A1 responsible for the phenotype of 81-89% of Glut1DS patients. Ketogenic dietary treatment (KDT) can achieve seizure freedom within a couple of days with normalization of EEG changes, frequently allowing for the withdrawal of any antiepileptic medications.

**Methods:** We present a patient with positive family history (mother with intellectual disability and seizures) and characteristic features for Glut1DS, including mild microcephaly, developmental and speech delay, paroxysmal eye movement abnormality and starvation-induced atypical absence seizures. NGS-based targeted custom epilepsy gene panel analysis was performed using QIA-GEN QIAseq library kit and Illumina sequencing technology.

**Results:** NGS analysis identified a c.1288G>T (p.Gly430Cys) heterozygous, likely pathogenic variant in SLC2A1 gene. This alteration is a missense variant, has never been reported. Application of KDT resulted in marked clinical improvement of the motor and seizure symptoms in our patient.

**Conclusion:** Accurate molecular diagnosis is critical for the clinical management and prognosis of subjects suspected with Glut1 deficiency, especially in case of mild severity, where early diagnosis and intervention would substantially influence the cognitive and motor functions.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P09.017.A AutoCaSc: Prioritizing candidate genes for neurodevelopmental disorders**

Johann Lieberwirth³, Benjamin Büttner³, Chiara Klöckner³, Konrad Platz³, Maximilian Radtke³, Meret Wegler³, Bernt Popp³, Rami Abou Jamra¹

¹Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany.

**Background/Objectives:** Exome sequencing(ES) in individuals with developmental disorders (DD) remains inconclusive in ~50%. Evaluation unsolved cases to identify candidate genes is subjective, slow, and uncomparable between labs. We developed AutoCaSc to prioritize candidate genes.

**Methods:** webAutoCaSc was developed in Python and vcfAutoCaSc was designed for VCFs scoring from the command line. The tools automate our fine-tuned candidate scoring scheme (CaSc), which is composed of the four categories “Variant attributes”, “Inheritance”, “Gene constraint” and “Gene plausibility”. The first three categories were implemented as decision trees, while “Gene plausibility” is a precomputed score of expression, model organism, protein-protein interaction, literature, and de novo occurrence in DD cohorts.

**Results:** As a proof of principle, we injected into two public ES trios 79 variants in recently published DD genes, thus simulating the identification of candidate genes and variants. AutoCaSc consistently (94.5%) scored all variants and genes in the top three
P09.018.B Novel in-frame deletion in RBMX leads to X-linked intellectual disability by disturbed RNA processing, splicing regulation and potentially reduced SH3 binding

Josefin Johansson, Sarah Lidéus, Filip Mihalic, Mauno Vihinen, Carina Frykholm, Sanna Gudmundsson, Adam Ameur, Per Jemth, Marie-Louise Bondeson, Maria Wilbe

1SciLifeLab, Uppsala University, Immunology, genetics and pathology (IGP), Uppsala, Sweden; 2Uppsala University, Medical Biochemistry and Microbiology, Uppsala, Sweden; 3Lund University, Experimental Medical Science, Lund, Sweden; 4Broad Institute of MIT and Harvard, Program in Medical and Population Genetics, Boston, United States; 5Boston Children’s Hospital, Harvard Medical School, Division of Genetics and Genomics, Boston, United States.

Background/Objectives: RNA binding motif protein X (RBMX) encodes the heterogeneous nuclear ribonucleoprotein G (hnRNP G) important for regulation of splicing, sister chromatid cohesion and genome stability. Deletion of the RGG/RG motif in hnRNP G have been associated with Shashi syndrome, however other hnRNP G domains’ association to X-linked intellectual disability (XLID) remains unknown.

Methods: Whole exome sequencing, whole genome sequencing, and X-chromosome inactivation studies were used to genetically characterize a Swedish five-generation family with XLID. The variant effect on biological processes and alternative splicing events were investigated by transcriptomics analyses of an SH-SY5Y cell line overexpressing the mutant or wildtype RBMX. The variant effect on hnRNP G was investigated by using prediction tools and fluorescence polarization assays with SH3 domains and peptides spanning the variant.

Results: A novel in-frame RBMX deletion segregated with disease in this family, where affected individuals were hemizygous, and asymptomatic individuals were non-carriers or heterozygous females with skewed X-chromosome inactivation. The affected individuals presented poor phenotypic overlap with Shashi syndrome, suggesting a different disease mechanism. Transcriptomics analyses revealed differentially expressed splicing events and enrichment for genes involved in RNA processing and neurodevelopment. Protein analyses imply a novel SH3-binding motif in hnRNP G and potentially lower affinity binding to SH3 domains caused by the variant.

Conclusion: We present a novel in-frame deletion in RBMX as a cause to XLID, by disrupted RNA processing, splicing regulation and potentially reduced SH3-binding. The results implies that disruption of different motifs impact the severity of disease.

References:

Grants: Swedish Society for Medical Research and Sävstaholm Foundation.
Conflict of Interest: None declared.

P09.019.C Genome Sequencing is a sensitive first-line test to diagnose individuals with intellectual disability

Anna Lindstrand, Marlene Ek, Malin Kvarnang, Britt M. Anderlid, Erik Björck, Jonas Carlsten, Jesper Eiffeldt, Grede Grigelioniene, Peter Gustavsson, Anna Hammersjö, Hafdis Helgadottir, Maritta Hellström Piagg, Ekaterina Kuchinskaya, Kristina Lagerstedt-Robinson, Lars-Ake Levin, Agne Lieden, Hillevi Lindelöf, Helena Malmgren, DanielNilsson, Eva Svensson, Martin Paucar Acree, Elrika Sahlin, Bianca Tesi, Emma Thom, Johanna Winberg, Max Winerdal, Josephine Wincent, Maria Johansson Solle, Maria Pettersson, Ann Nordgren

1Karolinska Institutet, Department of Molecular Medicine and Surgery, Solna, Sweden; 2Karolinska University Hospital, Department of Clinical Genetics, Solna, Sweden; 3Science for Life Laboratory, Department of Molecular Medicine and Surgery, Solna, Sweden; 4Linköping University, Department of Health, Medicine and Caring Sciences, Linköping, Sweden; 5Karolinska University Hospital, Department of Pediatric Neurology, Huddinge, Sweden.

Background/Objectives: Individuals with intellectual disability (ID) and/or neurodevelopmental disorders (NDD) are currently investigated with several different approaches in clinical genetic diagnostics. A molecular diagnosis can facilitate better individualized health care, improved genetic counselling and quality of life.

Methods: We compare the results from three diagnostic pipelines in patients with ID/NDD: genome-first (n = 100), genome as a secondary test (n = 129) or chromosomal microarray (CMA) with or without FMR1 screening (n = 421).

Results: The diagnostic yield was 37% (genome-first), 26% (genome as a secondary test) and 12% (CMA/FMR1). Notably, the age of diagnosis was delayed by 1 year when genome was done as a secondary test and the cost per diagnosed individual was 36% lower with genome-first compared to CMA/FMR1. Furthermore, 91% of those with a negative result after CMA/FMR1 screening (338 individuals) have not yet been referred for additional genetic testing and remain undiagnosed.

Conclusion: Our findings strongly suggest that genome analysis outperforms other testing strategies and should replace traditional CMA and FMR1 screening as a first-line genetic test in individuals with ID/NDD. Genome is a sensitive, time- and cost-effective method that results in a confirmed molecular diagnosis in 37% of all referred patients.

References: None.

Grants: The Swedish Research Council, the Swedish Brain Foundation, the Swedish Rare Diseases Research Foundation, the Hälsten Research Foundation.
Conflict of Interest: None declared.

P09.020.D Characterization of de novo variants in PPP2R5C expands the spectrum of PP2A-related neurodevelopmental disorders

Iris Verbrinnen, Elise Bribmle, Lisa Lenaerts, David Genevieve, Laurence Faivre, Julien Thevenon, Jessica X. Chong, Mike Bamshad, Karynne Patterson, Elysia Marco, Dmitry Niyazov, Aldo Telegraf, Sumit Pung, Kimberly Foss, William Dobyns, Ghayyda Mirzaa, Chin-To Fong, Sue White, Lynn Pais, Emily O’Heir, Celia van der Merve, Raphaëla Itzikowitz, Kirsty Donald, Tony Roscicoll, Kerith-Rae Dias, Carey-Ann Evans, Alessandro Musa, Raffaella Cervini, Elisa Giorgio, Anna Ruiz, Juan Pablo Trujillo Quintero, Rachel Rabin, John Pappas, Xiaodong Wang, Hua Yuan, Maura R.Z. Ruzhnikov, Veerle Janssens

European Journal of Human Genetics (2023) 31:345 – 709
Background/Objectives: Protein Phosphatases of type 2A (PP2A) regulate brain function and development by catalyzing phosphatase activity, mediated by a de novo mutation in PPP2R5C, encoding the regulatory B56 subunit. The aim of this study was to investigate the clinical features and genetic variation in patients with PPP2R5C mutations.

Results: Besides ID/NDD, clinical features of PPP2R5C mutations showed varying defects in A, C and/or substrate binding, while phosphatase activity, measured on phospho-peptide substrates, did not seem majorly affected. Both variants of unsure inheritance behaved normally in these assays, and were thus classified as likely non-pathogenic (VUS).

Conclusion: We report the first cohort of patients with pathogenic de novo PPP2R5C variants that show impaired functionality and are a novel cause of ID/NDD, with high clinical and biochemical similarities to PPP2R5D-affected cases.

References:
None declared.

P09.021.A Copy number detection from exome sequencing data for patients with neurodevelopmental disorder: an effective approach

Erika D’haenens1, Sarah Delbaere2, Toon Rosseel2, Marijke De Bruyne1, Hannes Syryn1, Bert Callewaert1, Björn Menten1, Annelies Dheedene1

1Center for Medical Genetics Ghent - Ghent University Hospital, Department of Biomedical Medicine, Ghent, Belgium; 2Center for Medical Genetics Ghent - Ghent University Hospital, Department of Biomedical Medicine, Ghent, Belgium.

Background/Objectives: Copy number variant (CNV) sequencing and exome-based gene panel analysis became state-of-the-art in routine diagnostics. However, small CNVs may not be routinely detected or reported and in recessive disease, the combination of both a CNV and single nucleotide variant (SNV) affecting the causal gene may underlie the phenotype.

Methods: In our center, we implemented ExomeDepth, a read depth-based analysis tool (Pagnol, 2012) for CNV detection in exome sequencing data.

Results: ExomeDepth analysis established the molecular diagnosis in seven patients suffering from a neurodevelopmental disorder (NDD) for whom SNV and CNVseq analysis did not provide conclusive results. A patient with a clinical diagnosis of Johanson-Blizzard syndrome harboured a ~30 kb triplication in UBRI, with both parents carrying the mono-allelic intragenic UBRI duplication. In a second patient a de novo 350bp deletion of exon 9 of the MYT1L gene was detected and confirmed by qPCR. The deletion was not detected by former molecular karyotyping (CNVseq analysis). In five other patients read-depth analysis revealed a CNV in a gene related to an autosomal recessive NDD, following the identification of a pathogenic SNV on the other allele (FARS2, KIAA0586, MMACHC, VPS13B, SLC7A7).

Conclusion: We conclude that ExomeDepth is an efficient tool to detect CNVs in exome sequencing data, even for CNVs with sizes below the detection limit of CNVseq. Given the added value of exome-based CNV detection via ExomeDepth in the diagnostic yield for NDDs patients, we implemented this tool in our routine exome analysis strategy.

References:
None declared.

P09.022.B Retrospective analysis of molecularly diagnosed KBG syndrome in Estonia during 2015-2021

Helen Lokke1,2, Rita Teek1, Riina Żordania2, Laura Roht1,2, Kai Muru1,2, Ulvi Thomson2, Tiia Reimand1,2, Katrin Ounap1,2

1University of Tartu, Department of Clinical Genetics, Institute of Clinical Medicine, Faculty of Medicine, Tartu, Estonia; 2Tartu
Background/Objectives: KBG syndrome (MIM # 148050) is an autosomal dominant inherited syndrome characterized by cognitive impairment, behavioral issues, short stature, characteristic facial features and macrodontia of the upper central incisors. It is caused by a heterozygous variant in ANKRD11 gene or deletion of chromosomal region 16q24.3 that includes ANKRD11 gene.

Methods: Retrospective analysis of performed NGS analyses during 2015-2021 in order to obtain detection estimation and a clinical summary of all molecularly diagnosed KBG syndrome patients.

Results: We diagnosed KBG syndrome in 12 patients (7 males, 5 females). In all patients a frameshift pathogenic variant in ANKRD11 gene was identified; in 7/12 of them, the detected variant was a novel one. The age of diagnosis was 8 months - 41 years (average age 9 years). The following common clinical features were evaluated: cognitive impairment (6/7), speech delay (10/11), behavioral issues (4/6), hypertelorism (6/11), protruding ears (6/11), thin upper lip or thin lips (6/11), macrodontia (2/3), clinodactyly of F5 (5/11) and brachydactyly (4/11). Average age of autonomous walking was 16 months.

Conclusion: Clinically relevant variants in ANKRD11 gene were found in 8.2% (12/6076) of the total amount of NGS panels done in Estonia. KBG syndrome is one of the most common monogenic autosomal-dominant neurodevelopmental syndromes, which we have detected by NGS panel. We present a patient with a previously described pathogenic variant in ANKRD11 gene with no cognitive delay or behavioral problems.

References: N/A.

Grants: Estonian Research Council grant PRG471.

Conflict of Interest: None declared.

P09.023.C White matter abnormality as a rare feature in Helsmoortel-van der Aa syndrome

Gergely Büki1,2, Agnes Till1, Anna Zsigmond1, Attila Gyenesei2, Bence Galki1, Kinga Hadzsiev1,2, Judit Bene1,2

1University of Pécs Medical School, Department of Medical Genetics, Pécs, Hungary; 2University of Pécs, Szentagotai Research Centre, Pécs, Hungary.

Background/Objectives: Helsmoortel-Van der Aa syndrome (HVDAS) is a neurodevelopmental disorder caused by de novo mutations in the ADNP gene, characterized by autism spectrum disorder (ASD), impaired intellectual development, hypotonia and dysmorphic facial features. The global developmental delay is often associated with attention deficit-hyperactivity disorder and delayed speech. Among the heterogeneous clinical picture, numerous brain abnormalities have been described, although white matter abnormalities were less frequent. Hereby we demonstrate two patients with HVDAS who showed significant signal intensity change in their white matter.

Methods: Whole-exome sequencing (WES) and brain magnetic resonance imaging (MRI) was applied in both patients. Libraries were sequenced on Illumina NovaSeq 6000 instrument with 100bp paired-end chemistry. Library preparation was carried out with Twist Human Core Exom Kit Library Prep Kit. Targeted sequencing was applied for confirmation and verification.

Results: WES data analysis revealed two frameshift mutations, a known (c.64dupA) mutation in Patient 1, and a novel (c.1223dupA) mutation in Patient 2. Patient 1 presented ASD, delayed speech, psychomotor development. Patient 2 manifested ASD, delayed speech, psychomotor development, intellectual disability, facial dysmorphism, hypotonia, epilepsy, visual disturbance, hirsutism. MRI showed significant aspecific white matter signal intensity change in both patients, furthermore corpus callosum dysplasia in Patient 2.

Conclusion: ADNP is a human transcription factor essential in brain development, however, according to our current knowledge only a few cases have been associated with abnormality of the white matter so far. Both of our patients presented such abnormality, and it suggests that it could be a potential rare feature in HVDAS.

References:

Grants: None declared.

Conflict of Interest: None declared.
P09.025.A Low-level parental somatic mosaicism detected by exome sequencing in cohort of patients with neurodevelopmental disorders

Vladimíra Valkova1,2, Marketa Wayhelova1,2, Jan Smetana1, Petr Brož2, Aneta Mikulasova1, Renata GaIllyova4, Petr Kuglik1,2
1Masaryk University, Faculty of Science, Department of Experimental Biology, Brno, Czech Republic; 2University Hospital Brno, Centre of Molecular Biology and Genetics, Brno, Czech Republic; 3Newcastle University, Biosciences Institute, Newcastle upon Tyne, United Kingdom; 4University Hospital Brno, Department of Medical Genetics and Genomics, Brno, Czech Republic.

Background/Objectives: Low-level somatic mosaicism leading to neurodevelopmental disorders (NDDs) and autism is more prevalent than previously thought. Due to limitations in its detection by routine molecular techniques, e.g. chromosomal microarrays or Sanger sequencing, detected single-nucleotide variants (SNVs) or small indel variants are often misinterpreted as de novo in the affected offspring. However, low-level somatic mosaicism in parents may significantly increase the risk of passing pathogenic variants to the offspring. We present our experience with exome sequencing as an effective approach for the detection of low-level parental somatic mosaicism for clinically relevant SNVs in patients with NDDs.

Methods: Our study included 45 families (trios or quatrots) of infants with NDDs examined using the commercial kit Human Core Exome (Twist Biosciences) and Illumina NovaSeq 6000.

Results: Using a customized bioinformatic pipeline, we detected SNVs or indel variants classified as pathogenic or likely pathogenic in 18/48 children (37.5%). Two SNVs classified as pathogenic in probands were detected in parental blood samples as low-level mosaicism (10-15%), both in fathers. The father of patient with c.7059G>C variant in MED13L gene exhibited learning disabilities, a phenotype possibly related to the mosaic change. The father harbouing mosaic variant c.911dup in CTNNB1 gene was clinically unaffected.

Conclusion: Our data demonstrate the importance of considering the possibility of parental mosaicism whenever exome sequencing is performed for precise genetic counselling.

References: 
Grants: Supported by Ministry of Health of the Czech Republic, grant nr. NU20-07-00145. All rights reserved.
Conflict of Interest: None declared.

P09.026.B GenIDA, an international participatory database to better understand the natural history and comorbidities of genetic forms of neurodevelopmental disorders

Jean Louis Mandel1,2, Pauline Burger1, Axelle strehle1, Florent colin1, timothée mazzucotelli1, nicole Collot1, Sarah Baer3, Benjamin Durand3, Amelie Piton1,4, Romain Coutelle4, Elise Schaefer4, Pierre parrend4,5, Laurence Faire6,9, David Geneviève10, Valentin Ruault10, Roseline caumes17, Thomas Smol2, jalmon ghoudi11, Joost Kummeling13, Charlotte Ockeloen13, Tijets Kleefstra13, David Koolen14
1IGBM - Department of Neurogenetics and Translational Medicine, Université de Strasbourg, Illkirch, France; 2Institute for Advanced Studies of the University of Strasbourg (USIAS), Université de Strasbourg, Strasbourg, France; 3Service de génétique médicale, Institut de Génétique Médicale d’Alsace (IGMA), Hôpitaux Universitaires de Strasbourg, Strasbourg, France; 4Unité de Génétique Moléculaire, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; 5INSERM U-1114, Clinique Psychiatrique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; 12Unité de Neurogenétique, Institut de Génétique Médicale d’Alsace (IGMA), Hôpitaux Universitaires de Strasbourg, Strasbourg, France; 13Department of Human Genetics, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, Netherlands.

Background/Objectives: GenIDA is an international online research project initiated to better characterise the clinical manifestations and natural history of genetic forms of intellectual disability with or without autism or epilepsy.

Methods: Clinical information reported and updated by the patient’s family using a structured questionnaire is analysed to identify new medically relevant information for families and professionals concerned with a given condition. The current questionnaire consists of 41 multiple-choice questions exploring physical parameters, cognitive and behavioural aspects, the presence or absence of neurological disorders or problems affecting major physiological functions (cardiac, renal, etc.). Five open-ended questions explore families’ perception of the events that most affect their relative’s health and quality of life, the secondary effects of treatments, etc.

Results: Currently, the questionnaire is available in 7 languages and has been completed for 1415 patients, the main cohorts being Koolen-de Vries/KdVS (n = 244), Kleefstra (174) and KBG (43) syndromes. For the KdVS, epilepsy, which affects almost 50% of patients, is of much greater concern than sleep problems. Other cohorts have grown significantly over the past year (DDX3X: 45; MED13L: 43; DYRK1A: 23; KMT2A: 32; POGZ: 18). Comparing several aspects of these 5 conditions reveals major differences: behavioural problems and sleep disorders appear to be more frequent in KMT2A and POGZ patients, while movement disorders are more frequent in DDX3X patients.

Conclusion: This validates the interest of our participatory approach: through their direct involvement, families can reveal aspects of the pathology that were previously underestimated.

References: 
Grants: 
Conflict of Interest: None declared.

P09.027.C Optical Genome Mapping Analysis of FMR1 Expansions in Fragile X Syndrome and Multi-site Validation

Alessio Venier1, Martin Muggli1, Bahar Ramandi1, Neil Miller1, Joyce Lee1, Andy Wing Chun Pang1, Henry B. Sadowski1, Yannick Delpu1, Alex Hastie1, Mark Oldakowski1
1Bionano Genomics, San Diego, United States.

Background/Objectives: Fragile X syndrome (FXS) is associated with intellectual disability, and is usually due to CGG expansion in FMR1 [1]. Phenotype severity being correlated with expansion size, accurate sizing is crucial. The repetitive nature of these regions presents difficulties: 1. PCR is unable to traverse through long repeats; 2. Sequencing is limited short-read lengths; 3. Southern-blot is inaccurate, time-consuming, and expensive. Optical genome mapping (OGM) has the potential to address some of these shortcomings [2].

Methods: OGM images ultra-long DNA molecules, labeled at specific motifs linearized in nanochannel arrays, and can be used for SV and CNV calling. We developed a targeted analysis workflow for Strasbourg, Strasbourg, France; 2ECAM Strasbourg-Europe, ECAM Strasbourg-Europe, Schiltigheim, France; 8Centre de Référence des Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, Hôpital d’Enfants, CHU Dijon, Dijon, France; 9Inserm UMR1231 GAD, Génétique des Anomalies du Développement, Université de Bourgogne, Dijon, France; 10Université de Montpellier, Centre Hospitalier Universitaire Montpellier, CLAD Sud Languedoc- Roussillon, INSERM, Montpellier, France; 11Clinique de Génétique, CHU Lille, Lille, France; 12Institut de Génétique Médicale, CHU Lille, Lille, France; 13Department of Human Genetics, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, Netherlands.
protein domain involved.

Results: In annotated samples, we observed alleles consistent with annotation across the entire range of repeat counts. Sensitivity was measured at 97% with 100% PPV for expansions > 200 repeats [3]. The largest expansion detected was ~1000 repeats. In controls, we measured CN below the full mutation cutoff in all cases. Repeatability studies were carried out to show analytical consistency. EnFocus™ analysis report provides pass/fail for QC metrics as well as analytic measurement quality using internal control regions on each autosomal chromosome.

Conclusion: OGM performance for FMR1 repeat lengths show a much higher dynamic range compared to PCR, NGS, and higher precision compared to Southern-blot.

References: 1. Paulson, Handb. Clin. Neurol. 2018. 2. Sahajpal, Genes 2021. 3. https://bionanogenomics.com/wp-content/uploads/2021/11/30457-Bionano-Solve-Theory-of-Operation-Bionano-EnFocus-Fragile-X-Analysis.pdf.

Grants: Conflict of Interest: Alessio Venier Full-time employee Bionano Genomics, Martin Muggli Bionano Genomics Employee, Bahar Ramandi Bionano Genomics Employee, Neil Miller Bionano Genomics Employee, Joyce Lee Bionano Genomics Employee, Andy Wing Chun Pang Bionano Genomics Employee, Henry B. Sadowski Bionano Genomics Employee, Yannick Delpu Bionano Genomics Employee, Alex Hastie Bionano Genomics Employee, Mark Oldakowski Bionano Genomics Employee.

P09.028.D An atypical Rubinstein-Taybi syndrome 2 associated with EP300 exon 20 skipping

Silvia Carestiato1, Lisa Pavina1, Lorena Zorzi2, Simona Cardaro-poli2, Emily Todd4, Alessandro Bruselles2, Silvia De Rubeis4,8, Joseph Buxbaum5,5, Marco Tartaglia2, Giovanni Battista Ferrero10, Alfredo Brusco11,12

1University of Turin, Department of Medical Sciences, Torino, Italy; 2Santa Croce e Carle Hospital, Pediatrics, Cuneo, Italy; 3University of Turin, Department of Public Health and Pediatrics, Torino, Italy; 4UCHealth Adult Genetics Clinic - Anschutz Medical Campus, Adult Medical Genetics Clinic, Aurora, United States; 5Istituto Superiore di Sanità, Department of Oncology and Molecular Medicine, Roma, Italy; 6Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, United States; 7The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, United States; 8Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, United States; 9Ospedale Pediatrico Bambino Gesù IRCCS, Genetics and Rare Diseases Research Division, Roma, Italy; 10University of Turin, Department of Clinical and Biological Sciences, Orbassano, Italy; 11University of Turin, Department of Medical Sciences, Torino, Italy; 12Città della Salute e della Scienza University Hospital, Medical Genetics Unit, Torino, Italy.

Background/Objectives: EP300 gene encodes p300, a ubiquitously expressed histone acetyltransferase that regulates transcription via chromatin remodeling. EP300 haploinsufficiency is associated with Rubinstein-Taybi syndrome 2 (RSTS2, MIM#613684). The phenotypic and mutational spectrum of this condition is broad and genotype–phenotype correlations have been proposed, suggesting clinical features depend upon the protein domain involved.

Methods: Trio exome analysis and genematcher exchange were conducted. Splicing analysis on cDNA from patient#1-derived PBMCs and Sanger sequencing on single bands extracted from agarose gel were performed.

Results: We identified two unrelated patients with de novo heterozygous variants in EP300 (NM_001429.4) affecting exon 20 splicing: patient#1 with c.3671+5G>C, and patient#2 with c.3671+5_3671+8delGTAAA. Both patients presented a severe RSTS2-like clinic, including ASD, speech delay, hearing loss, microcephaly, developmental delay and intellectual disability, accompanied with ocular, respiratory and cardiovascular abnormalities. Patient#2 developed colorectal cancer and deceased at 35 years old. Both splicing variants were predicted to affect exon 20 donor site (splice site score: -39% and -41%, respectively; visual Alamut). Splicing analysis on cDNA from patient#1 showed an in-frame exon-20 skipping, also expected for patient#2. In silico 3D protein modeling showed that loss of exon 20 (27 a.a.) leads to a possible alteration of the protein structure surrounding the invariant donor/acceptors splicing sites.

References: None declared.

P09.029.A Heterozygous and homozygous variants in STX1A cause a neurodevelopmental disorder with or without epilepsy

Johannes Luppe1, Heinrich Sticht2, François Lecoquiere3, Alice Goldenberg3, Kathleen Gorman4, Emmanuelle Agolini5, Silvana Bru-glia6, Outi Kuismin7, Carla Marcelis8, Antonio Vitello9, Anne-Sophie Demonnem-Pichon3, Sophie Julia10, Johannes Lenke1, Rami Abou Jamra1, Konrad Platzer1

1Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany; 2Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nuernberg, Erlangen, Germany; 3Laboratory of Molecular Genetics, Hospital Center University De Rouen, Rouen, France; 4Temple Street Children’s University Hospital, Dublin, Ireland; 5Bambino Gesù Children’s Hospital, Rome, Italy; 6Clinic of Genetics, Messina, Italy; 7Institute for Molecular Medicine Finland, Helsinki, Finland; 8Department of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands; 9University of Burgundy-Franche Comté, Dijon, France; 10Federative Institute of Biology, CHU de Toulouse, Toulouse, France.

Background/Objectives: The neuronal SNARE complex is responsible for synaptic vesicle exocytosis. Therefore, one of its core proteins syntaxin 1A (STX1A) has long been suspected to play a role in neurodevelopmental disorders.

Methods: We assembled eight individuals harbouring single amino acid deletions, missense and splicing variants in STX1A who present with a spectrum of neurodevelopmental delay and epilepsy. For all missense variants and single amino acid deletions, we applied in silico modelling of functional effects on interaction with other SNARE components and STXBP1.

Results: In our detailed phenotypic description, we observed an epileptiform characterized phenotype in the individuals with missense variants in contrast to intellectual disability with autistic behaviour in carriers of both single amino acid deletions and the homozygous splicing variant. In silico modelling showed impaired interaction with STXBP1 due to missense variants and
impaired SNARE complex function caused by single amino acid deletions.

Conclusion: Different lines of evidence presented here support that rare heterozygous and homozygous variants in STX1A cause a neurodevelopmental disorder with two different phenotypic presentations: (1) an STX1A-related developmental epileptic encephalopathy and (2) an STX1A-related intellectual disability and autism spectrum disorder. Our description thus expands the group of disorders called SNAREopathies.

References:
Grants:
Conflict of Interest: None declared.

P09.030.B The performance of GS as a first-tier test for neurodevelopmental disorders

Bart van der Sanden1;2, Gaby Schobers1;2, Jordi Corominas Galbany3, David Koolen1;3, Margie Sinnema4, Jeroen van Reeuwijk1;2, Connie Stumpel4;5, Bart van der Sanden2, Gydoula Jansen6, Martina Ruiterkamp-Versteeg1, Piet van Os6, Helger Yntema1;2, Martina Ruiterkamp-Versteeg1, Nico Leijsten1, Michael Kwint1, Ronny Rinne1, Nicole de Leeuw1;2, Alexander Stegmann4, Servi Stevens4, Derks1, Hilde Swinkels1, Amber de Ouden1, Rolph Pfundt7, Tuula Rinne1, Nicole de Leeuw1;2, Alexander Stegmann8, Servi Stevens4, Arthur van den Wijngaard4, Han Brunner1;2,4;5, Helger Yntema1;2, Christian Gilissen1;3, Marcel Nelen1, Lisenko Vissers4;5;2

1Radboud university medical center, Department of Human Genetics, Nijmegen, Netherlands; 2Donders Institute for Brain, Cognition and Behaviour, Nijmegen, Netherlands; 3Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands; 4Maastricht University Medical Center, Department of Clinical Genetics, Maastricht, Netherlands; 5GROW School for Oncology and Developmental Biology, Maastricht, Netherlands.

Background/Objectives: Genome sequencing (GS) can identify novel diagnoses for patients who have exhausted routine diagnostic procedures. We tested whether GS is a better first-tier genetic diagnostic test than current exome-based standard of care (SOC) by assessing the technical and clinical validity of GS for patients with neurodevelopmental disorders (NDD).

Methods: Using a prospective parallel design, we performed both GS and exome sequencing in 150 consecutive NDD patient-parent trios. Diagnostic yield was calculated from disease-causing variants affecting exonic sequence of known NDD genes as primary outcome measure.

Results: GS (30%, n = 45) and SOC (28.7%, n = 43) had similar diagnostic yield. All 43 conclusive diagnoses obtained in SOC were also identified by GS. These 43 conclusive diagnoses included a mixture of single nucleotide variants (SNVs, n = 26), insertion-deletion variants (InDels, n = 13), copy number variants (CNVs, n = 3), and a repeat expansion (n = 1). All 31 possible diagnoses obtained by SOC were also identified by GS. SOC, however, required integration of multiple test results (average 1.5; range 1-6) to obtain these conclusive and possible diagnoses. GS yielded two more conclusive diagnoses, and four more possible diagnoses than ES-based SOC (35 vs 31). Interestingly, all six likely pathogenic variants detected only by GS were CNVs.

Conclusion: Our data provide the technical and clinical validity of GS to serve as routine first-tier genetic test for patients with NDD. The additional diagnostic yield from GS is limited. Still, GS comprehensively identified all variants in a single experiment, suggesting that GS could constitute a more efficient genetic diagnostic workflow for patients with NDD.

References:
Grants:
Conflict of Interest: None declared.

P09.031.C Systematic evaluation of EHMT1 protein altering variants uncovers unexpected insights on EHMT1 functions and Kleefstra syndrome pathogenesis

Dmitrij Rots1, Ayumi Yamada2, Aidin Foroutan3,4, Haley McConkey4, Jennifer Kerkhof5, Marielle Alders5, Isabelle Maystd5, Sarah Hold6, Meena Balasubramanian6,8,9, Giuseppe Merlo10, Gijs Santen11, Alyce Belonis12, Ariane Bouman1, Joost Kummeling1, Malou Heijligers13, Mieke van Haes14, Michael Parker1, Soo-Mi Park1, Kay Metcalfe15, David Geneviè16,17, Nicolas Chatron8,9, Audrey Putoux8,9, Laurent Pasquier6, Christelle Dubourg16, Gertrud Strobl-Wildemann17, Astrid Pomp6, Maaike Vreeburg18, Diana Baralle19, Nicola Foulds19, Ingrid Scurr20, Gerarda Cappuccio22, Nicola Brunnerti22, Annet Van Hagen1, Emilia Kljijasma21, Helen Firth3, Francesca Forzano26, Louisa Kalsner27, Janna A Hof28, Carolina Courage29, Els Vanhoutte28, Siddharth Banka30, Hanken Venselaar30, N. Nadif Kasri31, Hans van Bokhoven31, Han Brunner31, Lisenza Vissers31, Yoichi Shinkai31, Bekim Sadikovic32,33, Jitske Kleefstra31

1Radboud University Medical Center, Department of human genetics, Nijmegen, Netherlands; 2RIKEN CPR, Cellular Memory Lab, Wako, Japan; 3Western University, Department of Pathology and Laboratory Medicine, London, Canada; 4London Health Sciences Centre, Verspeeten Clinical Genome Centre, London, Canada; 5Amsterdam University Medical Centres, University of Amsterdam, Amsterdam, the Netherlands, Department of Human Genetics, Amsterdam, Netherlands; 6Institute of Pathology, And Genetics, Center for Human Genetics, Charleroi, Belgium; 7Cambridge University Hospital NHS Foundation Trust, Department of Clinical Genetics, Cambridge, United Kingdom; 8Sheffield Children’s NHS Foundation Trust, Sheffield Clinical Genetics Service, Sheffield, United Kingdom; 9University of Sheffield, Academic Unit of Child Health, Sheffield, United Kingdom; 10University of Naples Federico II, Department of Molecular Medicine and Medical Biotechnology, Napoli, Italy; 11Leiden University Medical Center (LUMC), Leiden, Netherlands; 12Cincinnati Children’s Hospital Medical Center, Division of Human Genetics, Cincinnati, United States; 13Maastricht University Medical Centre, Maastricht, Netherlands; 14Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands, Department of Clinical Genetics, Amsterdam, Netherlands; 15Manchester Centre for Genomic Medicine, Manchester, United Kingdom; 16Montpellier University, INSERM U1183, Montpellier, France; 17Génétique clinique, Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Centre de Référence Anomalies du Développement SOOR, ERMITHACA, CHU Montpellier, Montpellier, France; 18Hospices Civils de Lyon, Service de Génétique - Centre de Référence Anomalies du Développement, Bron, France; 19Institut NeuroMyoGene, CNRS UMR5310, INSERM U1217, Université Claude Bernard Lyon 1, Lyon, France; 20Hospices Civils de Lyon, Service de Génétique - Centre de Référence Anomalies du Développement, Bron, France; 21Centre de Recherche en Neurosciences de Lyon, Équipe GENDEV, INSERM U1028 CNRS UMR5292, Université Claude Bernard Lyon 1, Lyon, France; 22Reference Center for Rare Diseases “Intelllectual Deficiencies”, Hôpital Sud - CHU Rennes, Department of Medical Genetics, Rennes, France; 23Service de Génétique Moléculaire et Génomique, CHU, Rennes, F-35033, France, Univ Rennes, CNRS, IGDR, UMR 6290, Rennes, France; 24Praxis für Humangenetik, Ulm, Germany; 25University of Southampton and University Hospital Southampton, Faculty of Medicine, Southampton, United Kingdom; 26University Hospitals Bristol, Department of Clinical Genetics, Bristol, United Kingdom; 27Telethon Institute of Genetics and Medicine, Pozzuoli, Italy; 28Guy’s & St Thomas’ National Health System Foundation Trust, Clinical Genetics Department, London, United Kingdom; 29Connecticut Children’s Medical Center and University of Connecticut School of Medicine, Departments of Neurology and Pediatrics, Farmington, United States; 30Erasmus Medical Centre, Rotterdam, United
Background/Objectives: EHMT1 is a histone-3 lysine-9 (H3K9) methyltransferase acting in heterodimer with EHMT2. EHMT1 haploinsufficiency causes Kleefstra syndrome (KS), but the role of EHMT1 protein altering variants (PAVs) is unknown. Therefore, we have systematically collected and evaluated EHMT1 PAVs.

Methods: We collected 30 different EHMT1 PAVs, identified in 40 individuals with neurodevelopmental disorders (NDDs), and evaluated them on: 1) patients’ phenotype similarity to KS, 2) predicted effects on the protein’s 3D structure, and 3) KS-episignature on DNA methylation array. Additionally, we studied EHMT1-EHMT2 heterodimerization capacity and methyltransferase-activity in vitro for selected variants.

Results: Out of the 30 analysed PAVs, we concordantly classified nine as benign and 17 as pathogenic. All pathogenic PAVs located in the ANK-repeat domain (n = 11), a H3K9me1-2 “reader”, or in the pre-SET/SET-domain (n = 6), which is responsible for the EHMT1-EHMT2 heterodimerization and methyltransferase-activity. Surprisingly, in four individuals with non-KS NDD and without KS-episignature, we identified three clustering SET-domain PAVs (two de-novo and one sib-pair) predicted to disrupt methyltransferase-activity, but not EHMT1-EHMT2 heterodimerization. This suggests that loss of only EHMT1 methyltransferase-activity is not responsible for KS. Indeed, unlike other PAVs, only KS-causing SET-domain PAVs, disrupted EHMT1-EHMT2 heterodimerization in vitro. Finally, we identified one individual without KS-phenotype and KS-episignature but with a de-novo PAV that completely disrupted the RING-like domain (functions unknown).

Conclusion: Disruption of EHMT1 “reader” or EHMT1-EHMT2 heterodimerization functions is sufficient to cause KS. However, the effects of loss of EHMT1 methyltransferase-activity or of RING-like domain are unknown but may result in novel syndromic NDDs e.g. via loss of the recently-described EHMT1-mediated non-histone protein methylation.

References:

Grants:

Conflict of Interest: Dmitrijs Rots: None declared, Ayumi Yamada: None declared, Aidin Foroutan: None declared, Haley McConkey: None declared, Jennifer Kerkhof: None declared, Maritelle Alayes: None declared, Isabelle Maystadt: None declared, Simon Holdem: None declared, Meena Balasubramanian: None declared, Giuseppe Merla: None declared, Gijs Santen: None declared, Alyce Belonis: None declared, Arianne Bouman: None declared, and one sib-pair) predicted to disrupt methyltransferase-activity e.g. via loss of the recently-described EHMT1-mediated non-histone protein methylation.

Background/Objectives: Haploinsufficiency of TCF4 by deletions, truncating variants or loss-of-function missense variants clustering within the DNA-binding and protein interacting bHLH domain cause Pitt-Hopkins syndrome (PTHS). This specific neurodevelopmental disorder (NDD) is characterized by severe intellectual disability (ID), epilepsy, postnatal microcephaly, hyperbreathing and typical facial dysmorphism. Only few deletions and variants, mostly located in the very N-terminal part of TCF4 have been associated with milder or atypical phenotypes.

Methods: By personal communication, we now assembled four cases with the novel, recurrent, de novo missense variant c.1165C>T, p.(Arg389Cys) in TCF4. This variant was independently identified by diagnostic exome or ID panel sequencing in different centers and is located upstream of the bHLH domain.

Results: In three of the individuals, the variant was initially classified as of unknown significance due to its location outside the bHLH domain and a rather unspecific neurodevelopmental phenotype not suggestive of P THS. Recurrence of the identical variant in four individuals allowed reclassification to pathogenic. All four individuals presented with moderate to severe ID with prominent language delay and impaired speech. Microcephaly occurred only in one of the four individuals, and no breathing anomalies or epilepsy were reported. Facial gestalt was suspicious. Interestingly, the variant is located in the AD2 activation side the bHLH domain in four individuals with a rather non-specific phenotype not suggestive of PTHS. This specific neurodevelopmental disorder (NDD) is characterized by severe intellectual disability (ID), epilepsy, postnatal microcephaly, hyperbreathing and typical facial dysmorphism. Only few deletions and variants, mostly located in the very N-terminal part of TCF4 have been associated with milder or atypical phenotypes.

Conclusion: Our findings of a recurrent missense variant outside the bHLH domain in four individuals with a rather non-specific ID phenotype delineates a novel genotype-phenotype correlation for TCF4-related NDDs.

References:

Grants:

Conflict of Interest: None declared.

P09.033.A Update on the phenotype of symptomatic females with ARX pathogenic variants, including 9 new patients

Matthilde Gras1,2, Solveig Heide1,2, Boris Keren1,2, Sandra Whalen1,3, Stéphane Valence1,4, Anna Jansen3, Katrien Stooff3, Jennesson Mélanie4, Poirier Céline5, Gaetan Lescas6, Christel Depienne7,8, Rastetter Agnes7, Caroline Nava7, Céline Aureil8, Mathieu MILH1, Perrine Charles1,2, Cyril Mignot1,2, DELPHINE HERON1,2

1Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany; 2INSERM U1266, Institut de Psychiatrie et de Neurosciences de Paris, Université de Paris, Paris, France; 3Département de Génétique Médicale, INSERM Childhood Genetic Diseases, AP-HP, Sorbonne Université, Hôpital Trousseau, Paris, France; 4APHP, Service de neurologie pédiatrique, Hôpital Universitaire Bicêtre, Le Kremlin-Bicêtre, France; 5Institute of Human Genetics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg FAU, Erlangen, Germany; 6Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany; 7Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; 8Department of Human Genetics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Background/Objectives: The X-linked Aristless-Related Homeobox (ARX) gene encodes a transcription factor that is essential for brain development. ARX-related disorders are well-described in male patients and encompasses syndromic and nonsyndromic intellectual disability with or without brain malformations and epilepsy. By contrast, the phenotype in females is poorly delineated.

Methods: We report the clinical and molecular data of nine novel female patients with de novo ARX pathogenic variants and review the data of the 63 females with truncating or missense variants from our cohort.

Results: Half of the female carriers have a normal neurodevelopment, whereas the other half have a neurodevelopmental disorder (NDD) comprising: isolated learning disabilities (8.3%), whereas the other half have a neurodevelopmental disorder (NDD) comprising: isolated learning disabilities (8.3%), mild to moderate ID (20.8%), developmental and epileptic encephalopathy (19.4%). NDD was significantly more prevalent in the group of women carrying de novo variants (84%). Agénésis of the corpus callosum (ACC) was observed in 65% of cases and affected more significantly the group of patients with NDD. Among the 10 previously reported de novo variants in female patients, all but two were truncating variants. We report here five de novo missense variants, which are all located in the homeodomain of the protein, affecting the ARX transcriptional activity. None of the de novo cases from our cohort had skewed XCI in blood.

Conclusion: ARX pathogenic variants in female patients are characterized by a broad clinical spectrum ranging from no symptoms to DEE phenotype, frequently associated with ACC. These new data will help prenatal counseling when an ARX variant is found in a female fetus with corpus callosum anomaly.

References:

Grants:

Conflict of Interest: None declared.

P09.034.8 BRAT1 biallelic variations: phenotypic spectrum and genotype-phenotype correlation from 91 cases

Camille Engel1, Stéphanie Valence2, Geoffrey Delplanché1, Reza Maroofian1, Paul Kuentz2, Christelle Cabrol1, else brischoux-boucher1, Vincenzo Salpietro5;6, Laurent Villard2, Martine Doco-Fenzy1, Sylvie Odent1, Deborah Morris-Rosendahl1, Maha Zaki2, Marion Gerard1, Alfredo Brusco1, Audrey Putoux1, Cathryn Poulton1, Christine Coubé1, Cyril Mignot1, Farid Kraus2, Fowzan Alkuraya22, Ingrid Scheffer23, Hartmut Engels24, Johanna Wagner25, Céline Rougeot45, Enza Maria Valente 46, Henry Houlden1, Joanna Goffeney47, Ange-Line Brue1, Amy Schneider48, lionel vanmaldergem1, lydie BURGLEN49, Juilette Piard4.

1AP-HP, Sorbonne Université, Paris, France; 2Groupe Hospitalier Pitié Salpêtrière et Trousseau, Département de Génétique et CRMPE, Déficiences Intellectuelles de causes rares, Paris, France; 3Hôpital Trousseau, UF de Génétique Clinique, Paris, France; 4Hôpital Trousseau, Service de Neuropédiatrie, Paris, France; 5Universitair Ziekenhuis, Brussel, Belgium; 6CHU de Reims Champagne Ardenne, Service de génétique, Reims, France; 7Hospices Civils de Lyon (HCL), Service de génétique, Lyon, France; 8Institut für Humangenetik Universitätsklinikum, Essen, Germany; 9Sorbonne Université, Institut du Cerveau et de la moelle épinière (ICM), Paris, France; 10Hospices Civils de Lyon (HCL), Service de neuropédiatrie, Lyon, France; 11AP-HM, Hôpital La Timone, Service de neuropédiatrie, Marseille, France.

Abstracts from the 55th European Society of Human Genetics Conference

European Journal of Human Genetics (2023) 31:345 – 709
Background/Objectives: Biallelic variations in BRAT1 were described in 40 patients from 29 families, presenting with epileptic encephalopathy or cerebellar ataxia.

Methods: Thanks to an international collaboration, we collected data of 51 new patients, allowing us to describe a large series of 91 patients.

Results: Data analysis showed two distinct phenotypes and an intermediate one. In the first group, 43 patients exhibited a neonatal epileptic encephalopathy. Prenatal signs were present in 16 of them (57%). None of them had any psychomotor acquisition and all had epilepsy with neonatal onset. Neurological examination showed microcephaly (91%) and limb rigidity (90%). Brain MRI showed cerebral atrophy (58%). They all died prematurely.

In the second group, 36 patients presented cerebellar ataxia, with acquisition of walking (85%) and language (69%). Axial hypotonia was found in 23 patients (85%). Epilepsy was rare (14%). Brain MRI always showed cerebellar atrophy. No patient in this group died.

Study of phenotype-genotype correlation showed that patients with epileptic encephalopathy harbour two predicted amorphic variations in most cases (25/33; 76%) and a recurrent inframe deletion/duplication in a tenth of cases (4/33; 10%). In contrast, patients with cerebellar ataxia present at least one missense variation (23/27; 85%).

Conclusion: BRAT1 bi-allelic variations are associated with a broad phenotypic spectrum whose most severe end, observed in patients with two amorphic variations, is associated with epileptic encephalopathy and early death. On the opposite, patients with at least one missense variation seem to have a moderate phenotype including variable intellectual disability, ataxia and cerebellar atrophy.

References:

Grants:

Conflict of Interest: None declared.
phenotypes in addition to or in combination with effects of X-inactivation and functional mosaicism.

**Conclusion:** Our findings therefore further delineate the clinical and mutational spectrum of female BFLS and provide further insights into possible genotype-phenotype correlations between females and males.

**References:**

**Grants:** German Research Foundation ZW184/3-1.

**Conflicts of Interest:** None declared.

**P09.038.B The largest cohort of KBG patients: defining the evolving phenotype**

Lorenzo Loberti1,2, Lucia Bruno1,2, Stefania Granata1,2, Gabriella Dodatto1,2, Francesca Fava1,2, Michele Carullo1,2, Elisa Rahikkala3, Guillama Jouret6, Leonie Menke5, Damien Lederer5, Pascal Vrielinck7, Lukáš Ryba1,4, Nicola Brunetti-Pieroni1, Amaia Lasa-Aranaz1,4, Anna Maria Cueto-González10, Laura Carmen Trujillano Lidón10, Irene Valenzuela10, Eduard Tizzano11, Alessandro Spinelli11, Irene Brun12, Aurora Curto13, Francesco Stanzial13, Francesco Benedicenti13, Diego Lopergolo14, Filippo Maria Santorelli14, Constantia Aristidou15, Georgios Tanteles15, Isabelle Maystadt16, Tinatin Temadze16, Tiia Reimand17, Helen Lokke17,18, Annika Tihveräinen19, Rita Seek20, Ulvi Thomson21, Margherita Baldassarri21, Maria Antonietta Mencarelli21,22, Caterina Lo Rizzo21,22, Mineilla Bruttini21,22, Francesca Mari1,2,21, Francesca Ariani1,2,21, Alessandra Renieri1,2,21, Anna Maria Pinto1,2,21

1Medical Genetics, University of Siena, Siena, Italy; 2Med Biotech Hub and Competence Centre, Department of Medical Biotechnologies, University of Siena, Siena, Italy; 3PEDREGO Research Unit, University of Oulu MRC Oulu and Department of Clinical Genetics Oulu, Oulu University, Oulu, Finland; 4Médecin génétique - Conseil Génétique National Center of Genetics Laboratoire national de santé, Dudelange, Luxembourg; 5Department of Pediatrics, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; 6Instut de Pathologie et de Génétique; Centre de Génétique Humaune, Gosselies, Belgium; 7Institut de Pathologie et de Génétique a.s.b.l, Brussel, Belgium; 8Department of Biology and Medical Genetics, Prague, Czech Republic; 9University of Naples “Federico II”, Naples, Italy; 10Area of clinical and molecular genetics, Vall d’Hebron University Hospital, Vall d’Hebron, Barcellona, Spain; 11Regional Coordinating Center for Rare Diseases, Udine, Italy; 12Institute for Maternal and Child Health, IRCCS, Burlo Garofolo, Trieste, Italy; 13Genetic Counseling Service, Department of Pediatrics, Regional Hospital of Bolzano, Bolzano, Italy; 14IRCCS Stella Maris Foundation, Molecular Medicine for Neurodegenerative and Neuromuscular Disease Unit, Pisa, Italy; 15Clinical Genetic Clinic, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus; 16Molecular and Medical Genetics, Tbilisi State Medical University, Tbilisi, Georgia; 17Department of Clinical Genetics, United Laboratories, Tartu University Hospital, Tartu, Estonia; 18Institute of Clinical Medicine, University of Tartu, Tartu, Estonia; 19Department of Genomics and Clinical Genetics, Turku University Hospital, Finland, Turku, Finland; 20Centre for Neurological Diseases, West-Tallinn Central Hospital, Tallin, Estonia; 21Genetica Medica, Azienda Ospedaliera Universitaria Senese, Siena, Italy.

**Background/Objectives:** KBG syndrome is characterized by distinctive facial gestalt, skeletal features, short stature, and variable clinical findings. With aging, some clinical features become more recognizable, allowing a differential diagnosis. We aimed to better characterize KBG-associated clinical features progression.

**Methods:** In the context of an ERN ITHACA collaborative study, we collected the largest cohort of KBG patients (47) followed over time. A combined array-CGH and NGS approach on genomic DNA investigated both genomic CNV and SNV.

**Results:** Intellectual disability (81%) ranged from mild to moderate with severe ID identified in one patient. Epilepsy was present in 25%. Short stature was consistent over time, while OFC, about -2SD at birth, normalized over years. Macrocephaly, oligodactyly and dental agenesis was present in 30%, representing the second most relevant clinical feature along with skeletal anomalies (44%, 28% with 5th finger clinodactyly). Two patients presented microdactyly. Cerebral anomalies, among which enlarged cisterna magna and broad anterior fontanelle, were identified in 35%. Heart defects were reported in 16.3%. In 28% of cases prenatal ultrasound anomalies were reported (increased NT, polyhydramnios, IUGR). Except for three splicing variants, leading to a premature termination, mutations were almost all frameshift, scattered along ANKRD11.

**Conclusion:** Our results, broadening the spectrum of KBG phenotype progression, suggest to consider a wider range of dental anomalies including microdactyly before excluding diagnosis. Cerebral anomalies, previously sporadic reports, represent a moderately frequent feature. NGS approaches, following evidence of increased NT, should include ANKRD11.

**References:**

**Grants:** ERN-ITHACA, Regione Toscana CCRM, Estonian Research Council PRG471.

**Conflict of Interest:** None declared.

**P09.039.C Inherited pathogenic variants in neurodevelopmental disorders: a potential pitfall in trio-based analysis of clinical exomes**

Annelies Dheedene1, Erika D’haenens1, Evelien Poullie1, Sarah Delbaere1, Olivier Vanacker1, Bert Callewaert1, Björn Menten1

1Center for Medical Genetics, Ghent University & Ghent University Hospital, Department of Biomolecular Medicine, Ghent, Belgium.

**Background/Objectives:** The use of clinical exome sequencing (ES) has led to a steep increase in the diagnostic yield in patients with neurodevelopmental disorders (NDDs).

**Methods:** ES data of > 2000 patients and both parents (when available) were analyzed for a panel of 1441 NDD related genes. Variant classification was based on ACMG/AMP and ACGS guidelines.

**Results:** We identified a class 4 or 5 variant explaining the phenotype in 21% of cases. In 60% of these probands, the variant occurred de novo, while in 40% the causal variant(s) was/were inherited. Of the probands with inherited variants, 12.5% had an X-linked disorder, 46% an autosomal recessive disorder, and 41.5% an autosomal dominant disorder. Furthermore, we reported a variant of unknown significance (class 3) in an additional 25% of the probands.

**Conclusion:** With a diagnostic yield between 21% and 46%, we confirm that exome sequencing is a game-changer in the diagnostic workup of patients with NDDs. Although the majority of causal variants occurred de novo, several (likely) pathogenic variants were observed in seemingly healthy parents. Analysis pipelines focusing solely on de novo or bi-allelic defects, may therefore miss molecular diagnoses. Our data add evidence that reduced penetrance is currently underreported in several NDDs and we should be cautious to rely on the “de novo paradigm for neurodevelopmental disorders” both in laboratory analysis and genetic counseling.

**References:**

**Grants:**

**Conflict of Interest:** None declared.
P09.040.D Altered gene expression profiles impair the nervous system development in patients with 15q13.3 microdeletion

Marek Körner¹, Linnaeus Bundaliam², Akhil Velluva³, Maximilian Radtké⁴, Julia Hentschel⁴, Tobias Bartolomaeus⁵, Pia Zacher⁶, Rami Abou Jamra⁷, Diana Le Duc⁸

₁Institute of Biochemistry, Medical Faculty, University Leipzig, Leipzig, Germany; ₂Institute of Human Genetics, University Clinics Leipzig, Leipzig, Germany; ³Max Planck Institute for Evolutionary Anthropology, Genetics, Leipzig, Germany.

Background/Objectives: The 15q13.3 microdeletion has a wide range of pleiotropic effects ranging from apparently healthy to severely affected individuals with intellectual disability, epilepsy, and neuropsychiatric disorders. Previous studies have investigated several genes within the deletion as potential drivers, but the pathomechanism and the underlying basis of the variable phenotype remain elusive.

Methods: We analyzed the effects of the 15q13.3 microdeletion using native RNA-seq data from blood of 3 probands and 4 control subjects. We assessed differentially expressed genes (DEGs), gene ontology (GO) enrichment, protein-protein interaction (PPI) functional modules, as well as gene expression in different brain developmental stages.

Results: The haploinsufficiency of genes within the deleted region was not transcriptionally compensated, suggesting a dosage effect may contribute to the pathomechanism. We observed network-wide dysregulatory effects implying the phenotype is not caused by a singular critical gene. A significant proportion of DEGs, which are silenced in the adult brain, have maximum expression during the prenatal stage of brain development. Based on DEGs and their PPI partners we identified altered functional modules related to immune and inflammatory processes, as well as nervous system development.

Conclusion: 15q13.3 microdeletion has an ubiquitous impact on transcriptome pattern, especially dysregulation of genes involved in brain development. The impact on immune and inflammatory responses cannot be fully assessed based on the test material, i.e. blood. Possibly, the high phenotypic variability could stem from an increased vulnerability during brain development, without an underlying driving pathomechanism.

References:

Grants: Else Kröner-Fresenius-Stiftung 2020_EKEA.32 to DLD, "Clinician Scientist Programm, Medizinische Fakultät der Universität Leipzig".

P09.041.A Clinical description, molecular delineation, and genotype-phenotype correlation in KBG syndrome: 67 new patients and review of the literature

Elena Martinez-Cayuelas¹, Isabel Lorda²;³, Fiona Blanco-Kelly²;³, Rosario Lopez-Rodriguez⁴, Fermina Lopez-Grondona⁵, Saoud Tahsin-Swafri²;³, Rebeca Losada⁶, Beatriz Moreno⁶, Maria Rodrigo⁶, Carmen Ayuso⁶, Aireso Camacho⁷, Aitor Lopez-González⁸, Antonio Martinez-Monseny⁹, Irene Valenzuela Palafox⁹, Anna Maria Cueto-González⁹, Sixto García-Minauí⁹, Fernando Santos-Simarro⁹, Jaime Cruz⁹, Juan Francisco Quesada Espinosa⁹, Jaime Sánchez del Pozo⁹, Ana Rosa Arteche López⁹, Blanca Gener Quera³, Isabel Llano Rivas³, Alberto Fernández-Jaén³, Raquel Bernardo Fonz³, Sergio Aguilar Albesa³, Pablo Prieto³, Javier Lopez Pisón⁴, Vanessa Lopez³, Ignacio Málaga⁴, María Palomares Braña⁴, Sara Ramiro León⁴, Beatriz Martínez Menéndez⁴, Belén Gil-Fourier⁴, Jesús Eirís⁴, Juan José García Peñas⁴, Begónica De Azúa Brea⁴, Nadia Irazabal⁴, Irene Berta Almoguera Castillo²;³

¹Fundación Jiménez Díaz University Hospital, Department of Pediatrics, Madrid, Spain; ²Fundación Jiménez Díaz University Hospital, Department of Genetics and Genomics, Madrid, Spain; ³Center for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain; ⁴Sant Joan de Deu Hospital, Department of Genetic and Molecular Medicine. Pediatric Institute of Rare Diseases (IPER), Barcelona, Spain; ⁵Vall d’Hebron University Hospital, Department of Clinical and Molecular Genetics, Barcelona, Spain; ⁶La Paz University Hospital, Structural and Functional Genomics-INGEMM, Madrid, Spain; ⁷12 de Octubre University Hospital, Department of Genetics and Genomics, Madrid, Spain; ⁸Crues University Hospital, Barakaldo, Spain; ⁹Quirónsalud University Hospital, Department of Pediatric Neurology, Madrid, Spain; ¹⁰Navarra University Hospital, Pediatric Neurology Unit. Department of Pediatrics, Navarra, Spain; ¹¹Salamanca University Hospital, Department of Pediatrics, Salamanca, Spain; ¹²Miguel Servet University Hospital, Zaragoza, Spain; ¹³Virgen de la Arrixaca University Hospital, Department of Medical Genetics, Murcia, Spain; ¹⁴Asturias Central University Hospital, Pediatric Neurology Unit. Department of Pediatrics, Oviedo, Spain; ¹⁵Getafe University Hospital, Madrid, Spain; ¹⁶Santiago University Hospital, Santiago, Spain; ¹⁷Niño Jesús University Hospital, Madrid, Spain; ¹⁸Son Llàtzer University Hospital, Mallorca, Spain; ¹⁹Can Misses University Hospital, Ibiza, Spain; ²⁰Barcelona Clinic Hospital, Barcelona, Spain; ²¹NIMGenetics, Madrid, Spain.

Background/Objectives: KBG syndrome is a highly variable neurodevelopmental disorder caused by loss-of-function sequence variants and large deletions involving ANKR11. Despite several attempts, to date no correlation has been reported between KBG features and ANKR11 aberration. We present the clinical and molecular characteristics of 67 new patients with KBG syndrome and perform a genotype-phenotype correlation leveraging data on 273 patients previously published.

Methods: 67 patients with KBG syndrome were recruited through a Spanish collaborative effort. 43 clinical features were assessed using a phenotypic questionnaire developed for this project. The frequency of the features was calculated and those with a frequency >50% of the patients were used to perform a genotype-phenotype correlation in the 67 patients and 273 KBG patients from the literature comparing the main features of the syndrome in patients with four different types of ANKR11 variants.

Results: The most frequent features were those related to neurodevelopment (95%), comorbidities (82.8%), macrodontia (80.9%), triangular face (71%), characteristic ears (76%), nose (75.9%) and eyebrows (67.3%). The genotype-phenotype correlation yielded significant associations with the triangular face (71.1% in SNVs vs 45.2% in CNVs, p = 0.015), short stature (62.5% inside exon 9 vs. 27.8% outside: p = 0.009) and macrodontia (with larger deletions, p = 0.028). ID/ADHD/ASD (70.4% in c.1903_1907del vs. 89.4%; p = 0.012) and a higher phenotypic score in patients with SNVs (p = 0.005).

Conclusion: We present a detailed phenotypic description of KBG syndrome in the largest series of patients reported to date and provide evidence of a genotype-phenotype correlation between some KBG features and specific ANKR11 aberrations.

References:

Grants:

Conflict of Interest: Elena Martinez-Cayuelas: None declared, Isabel Lorda: None declared, Fiona Blanco-Kelly: None declared, Rosario Lopez-Rodriguez: None declared, Fermina Lopez-Grondona: None declared, Saoud Tahsin-Swafri: None declared, Rebeca Losada: None declared, Beatriz Moreno: None declared, Maria Rodrigo: None declared, Carmen Ayuso: None declared, Aireso Camacho: None declared, Aitor Lopez-González: None declared, Antonio Martinez-Monseny: None declared.
declared, Irene Valenzuela Palafoll: None declared, Anna Maria Cueto-González: None declared, Sixto García-Minaur: None declared, Fernando Santos-Simarro: None declared, Jaime Cruz: None declared, Juan Francisco Quesada Espinoza: None declared, Jaime Sánchez del Pozo: None declared, Ana Rosa Arteche López: None declared, Blanca Gener Querol: None declared, Isabel Llano Rivas: None declared, Alberto Fernández-Jaen: None declared, Raquel Bernardo Fonz: None declared, Sergio Aguilara Albesa: None declared, Pablo Prieto: None declared, Javier Lopez Písón: None declared, Vanessa Lopez: None declared, Ignacio Málag: None declared, María Palomares Bral: None declared, Soraya Ramiro León: None declared, Beatriz Martínez Menéndez: None declared, Belén Gil-Fourier: None declared, Jesús Eirí: None declared, Juan José García Peñas: None declared, Begoña De Azúa Brea: None declared, Nadia Irazabal: None declared, Irene Madrigal: None declared, María Isabel Alvarez: None declared, Sara ALVAREZ Full time employee at NIMGenetics, Maria García Full time employee at NIMGenetics, Berta Almoguera Castillo: None declared.

P09.042.B De novo missense variants in SLC32A1 cause a neurodevelopmental disorder with epilepsy due to impaired GABAergic neurotransmission

Konrad Platzer1, Heinrich Sticht2, Caleb Bupp1, Mathily Ganapathi4, Elaine Pereira5, Gwenaël Le Guyader6, Frederic Bilan6, Lindsay Henderson7, Holger Taschenberger8, Nils Brose8, Maximilian Radtke1, Rami Abou Jamra1, Sonja Wojcik8

1Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany; 2Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nuernberg, Erlangen, Germany; 3Spectrum Health Medical Genetics, Grand Rapids, United States; 4Department of Pathology and Cell Biology, Columbia University Medical Center, New York, United States; 5Department of Pediatrics, Columbia University Irving Medical Center, New York, United States; 6Department of Genetics, Poitiers University Hospital Center, Poitiers Cedex, France; 7GeneDx, Gaithersburg, United States; 8Department of Molecular Neurobiology, Max Planck Institute of Experimental Medicine, Göttingen, Germany.

Background/Objectives: Rare inherited missense variants in SLC32A1, the gene that encodes the vesicular GABA transporter (VGAT), have recently been shown to cause genetic epilepsy with febrile seizures plus. We aimed to clarify if de novo missense variants in SLC32A1 can also cause a neuro-velopmental disorder with epilepsy.

Methods: Using exome sequencing, we identified four individuals with a neurodevelopmental disorder with epilepsy and de novo missense variants in SLC32A1. To assess causality, we performed functional evaluation of the identified variants in a murine neuronal cell culture model.

Results: The main phenotype comprises moderate to severe intellectual disability, early onset epilepsy within the first 18 months of life and a choreatic, dystonic or dyskinetic movement disorder. In silico modeling and functional analyses reveal that three of these variants, which are located in helices that line the putative GABA transport pathway, result in reduced quantal size, consistent with impaired filling of synaptic vesicles with GABA. The fourth variant, located in the VGAT N-terminus, does not affect quantal size, but increases presynaptic release probability, leading to more severe synaptic depression during high frequency stimulation. Thus, variants in VGAT can impair GABAergic neurotransmission via at least two mechanisms, by affecting synaptic vesicle filling and by altering synaptic short-term plasticity.

Conclusion: This work establishes de novo missense variants in SLC32A1 as a novel cause for a neurodevelopmental disorder with epilepsy.

References:

Grants:

Conflict of Interest: None declared.

P09.044.D Whole exome sequencing for the diagnosis of genetically unexplained severe or syndromic neurodevelopmental disorders

Ilaria Palmieri1,2, Antonio Manuel Di Silvestre3, Valentina Serpieri1,2, Marta Di Biagio1,2, Simone Gana1, Enza Maria Valente1,2

1IRCCS Mondino Foundation, Neurogenetic Research Center, Pavia, Italy; 2University of Pavia, Department of Molecular Medicine, 27100, Italy; 3University of Pavia, Department of Internal Medicine and Medical Therapeutics, Pavia, Italy; 4IRCCS Mondino Foundation, Medical Genetics Unit, Pavia, Italy.

Background/Objectives: Neurodevelopmental disorders (NDDs), including intellectual disability (ID), global developmental delay (GDD), and autism spectrum disorder (ASD), represent the most prevalent chronic medical conditions encountered in pediatric primary care. Identification of an underlying genetic etiology may improve prognostic predictions, ensure personalized management, clarify recurrence risk, and direct patients and families to condition-specific resources and supports. Whole exome sequencing (WES) was reported to reach a definite diagnosis in about 40% NDD patients (1). Here we assess the diagnostic yield reached by WES in our diagnostic lab for unexplained severe non-syndromic and syndromic ID, GDD, or ASD patients, negative at array-GCH and fragile-X testing.

Methods: WES was performed on 30 patients with severe non-syndromic GDD/ID and/or level 3 ASD (12 complicated with epilepsy), and on 67 syndromic NDD patients recruited over a 3-year period regardless of their age (mean 13 years), gender and familial history.

Results: A definite genetic diagnosis was reached in 44/97 (45%) probands, including 9/30 (30%) with severe non-syndromic NDD, and 35/67 (52%) with syndromic NDD. Of note, for syndromic patients, the diagnostic rate increased linearly with the number of concurrent clinical features, raising from 48% (2 concurrent features) up to 75% (4 features).

Conclusion: This study confirms that WES is a powerful diagnostic tool for NDDs, especially in case of severe or syndromic presentations, and should therefore be included in the diagnostic workout for these common disorders.

References: 1. Srivastava S et al. 2014. https://doi.org/10.1002/anna.24251.

Grants:

Conflict of Interest: None declared.

P09.045.A Array-CGH in a large cohort of unexplained syndromic and non-syndromic neurodevelopmental disorders

Marta Di Biagio1,2, Simone Gana, Antonio Manuel Di Silvestre4, Edoardo Errichietti1,2, Enza Maria Valente1,2, Elena Rossi1,2

1IRCCS Mondino Foundation, Neurogenetics Research Center, Pavia, Italy; 2University of Pavia, Department of Molecular Medicine, Pavia, Italy; 3IRCCS Mondino Foundation, Medical Genetics Unit, Pavia, Italy; 4University of Pavia, Department of Internal Medicine and Therapeutics, Pavia, Italy.
Background/Objectives: Neurodevelopmental disorders (NDDs), including intellectual disability (ID), global developmental delay (GDD) and autism spectrum disorder (ASD), are non-progressive disorders typically diagnosed from infancy to adolescence, and characterized by deficits in cognition, language, behavior, and/or motor skills. Here we aimed at comparing the diagnostic yield of array-comparative genomic hybridization (aCGH) for the diagnosis of syndromic versus non-syndromic NDDs in our diagnostic laboratory.

Methods: aCGH was performed using a 180K platform (Agilent Technologies) on 156 patients with syndromic NDDs and 117 with non-syndromic NDDs recruited over a 3-year period regardless of their age (mean 11 years), gender (M:F = 174:96) and family history.

Results: 30 pathogenic unbalanced rearrangements (21 deletions, 9 duplication) were identified in 25 patients. The most frequent rearrangements affected chromosomes 15 and 16; four probands carried more than one pathogenic copy number variants. The overall detection rate was 9% (25/270), with a similar rate in syndromic (13/156, 8%) and non-syndromic cases (12/114, 10%). In three patients, a double diagnosis was achieved through an integrated approach which combined aCGH and whole-exome sequencing (WES).

Conclusion: Our data show that aCGH remains a cost-effective, rapid and powerful first-level diagnostic strategy, able to diagnose about 10% NDDs patients regardless of their clinical presentation.

References: None declared.

P09.046.B Genetics of anomalies of the corpus callosum: lessons from a cohort of 403 individuals

Solveig Heide1, Stéphanie Valence2, Christel Depienne3, Thierry Billette de Villemeur4, mourtad marie-laure4, Anne Sophie Pellen5, Anne Faudet6, des portes vincent6, Laurent Guibaud7, rivier francois8, Laurence Faivre9, elise brischoux-boucher9, Audrey Putoux10, Perrine Charles11, agnes guet12, Sandra Whalen13, cecile laroche14, Alexane Garel15, Cyril Courtin16, Perrine Anne Faudet17, des portes vincent18, Laurent Guibaud19, rivier francois20, Hôpital d’Enfants Armand-Trousseau, Service de Neurologie, 22023 SAINT-BRIEUC CEDEX 1, France; 16HU CEDEX 5, France; 7CHU Dijon Bourgogne - Hôpital François Hospices civils de Lyon, Bron, France;6CHU de Montpellier - Hôpital Mitterrand, Centre de génétique, DIJON, France;8CHRU de Besançon neurologie pédiatrique, BRON, France;5Hopital Femme Mere Enfant genetik, ESSEN, Germany; 4CHU de Lyon HCL - GH Est, Service de médecine - Unité de Génétique clinique, NANTES CEDEX 1, France; 3Universitätsklinikum Essen, Institut für Human-Genetik, ESSEN, Germany; 16HU CEDEX 5, France; 13CHU Paris Enfants Armand-Trousseau, Service de Neuropédiatrie, PARIS, France; 1APHP.Sorbonne Université, GH Pitié Salpêtrière, centre de génétique moléculaire et chromosomique, Paris, France; 20INSTITUT DU CERVEAU ET DE LA MOELLE, Genétique et physiopathologie de l’épilepsie, PARIS, France; 22APHP.Sorbonne Université - Hôpital des Enfants Armand-Trousseau, Service de radiologie, PARIS CEDEX 12, France.

Background/Objectives: The corpus callosum is the main cerebral commissure. Its complex development occurs between the 11th and 15th week of gestation and involves multiple cellular and molecular events. Anomalies of the corpus callosum (AnCC) are among the most common brain malformations in humans. Their etiologies are numerous and involve many different genetic causes.

Methods: We describe the clinical and genetic aspects of a cohort of 403 individuals with AnCC. 38 (9.4%) of them had a chromosomal anomaly and 105/292 (36%) had at least one sequence variant (found by exome/genome sequencing or by targeted sequencing) explaining the AnCC.

Results: In our series, genetic causes of AnCC were identified (50%) when it was associated with developmental delay and/or ID, mostly in genes responsible for monogenic syndromes with ID. In all “solved” cases, AnCC was a trait with incomplete penetrance. By contrast, when AnCC was associated with a normal neurodevelopment, the diagnosis rate falls with only few recurrent genes identified (including DCC).

Conclusion: This confirmed that AnCC may result from the disruption of multiple developmental steps from early midline telencephalic patterning to neuronal specification and guidance of commissural axons. Our poor knowledge of genetic causes of isolated AnCC leads us to consider other pathogenic mechanisms such as oligo/polygenic inheritance.

References: None declared.

P09.047.C Assessment of the transcriptomic consequences of NIPBL pathogenic variants in edited pluripotent stem cells

kevin cassiniard1, anne rovelet-lecrux1, celine derambure1, Myriam Dezain1, Sophie Coutant1, anne-claire richard1, nathalie drouot1, juliette coursimault1, Gabriella Vera1, Alice Goldberg1, Pascale Saugier-Veber2, Camille Charbonnier1, Gael Nicolas1

1Normandie Univ, UNIROUEN, Inserm U1245, CHU Rouen, FHU G4 Translational Medicine and Cancer Biology, CHU Rouen, France; 2Terre Rouge, Inserm U1245, CHU Rouen, France.

Background/Objectives: Cohesins play a critical role in gene expression regulation. Cornelia de Lange syndrome (CdLS) is a transcriptionopathy related to cohesin complex alterations. NIPBL, the main CdLS gene, encodes the cohesin loading factor. Gene expression consequences of NIPBL pathogenic variants might be used as potential CdLS biomarkers.

Methods: By CRISPR/Cas9, we introduced each of the following NIPBL variants in the corresponding exons. We assessed NIPBL total mRNA levels
by RT-ddPCR, performed RNAseq and measured protein levels of NIPBL and its partner MAU2 by western-blotting.

**Results:** Both RT-ddPCR and RNAseq showed a decrease in NIPBL RNA levels for all cells carrying premature stop codon variants, except for the p.Arg45* variant, where NIPBL mRNA level was slightly increased. The differential expression analysis highlighted a pattern of up or downregulated genes. For all conditions, including the missense variant, a 50% decrease of MAU2 protein levels was observed, without MAU2 mRNA modification.

**Conclusion:** We propose new edited iPSC models for CdLS. Our results support previously established data suggesting that variations in the 5’ end of NIPBL coding sequence escape nonsense mediated decay, possibly due to translation reinitiation. We will confront our results to RNAseq and MAU2 western blot on patients’ blood, to assess their diagnostic potential.

**References:** (1) Parenti et al., PMID 32433996.

**Grants:**

**Conflict of Interest:** None declared.

**P09.048.D Identification of a causal mutation in DLG3 in the MRX20 family**

**Jolien Huysgebaert**1, Ligia Monica Mateiu1, Ellen Elinck1, Kirsten Van Rossem1, Claudio D’Incalci1, Michael K. McCormack2,3, Alice Lazzarini1, Geert Vandeweyer1, Frank Kooy1

1University of Antwerp and University Hospital Antwerp, Department of Medical Genetics, Antwerp, Belgium; 2Rowan University School of Osteopathic Medicine, Department of Pathology, Stratford, New Jersey, United States; 3Rutgers Robert Wood Johnson Medical School, Department of Psychiatry, Piscataway, New Jersey, United States; 4Rutgers Robert Wood Johnson Medical School, Department of Neurology, New Brunswick, New Jersey, United States.

**Background/Objectives:** Here, we describe one of the 105 historical families that received MRX numbers. MRX20 is one of the larger pedigrees which presents with intellectual disability. In 1995 historical families that received MRX numbers. MRX20 is one of the largest pedigrees which presents with intellectual disability. Although the disease-causing genetic alterations are known, the molecular pathomechanism remains unknown. We aim to understand which are the molecular pathways altered in RTT and MDS.

**Methods:** DNA and RNA was extracted from Epstein-Barr virus (EBV) cell lines of 19 family members. Whole exome sequencing (WES) was performed on two affected and one unaffected sample. Results were confirmed using Sanger Sequencing in all available members of the pedigree.

**Results:** A causal c.194delC mutation in the DLG3 gene was identified, aside from two other variants of unknown significance that also segregated in the family; SSX1 (c.3586G>T and USP27x (c.56A>G). Fourteen differentially expressed genes were identified. Currently, 7 of those 11 were confirmed using qPCR: BCL11A, PPP1R16B, WWR1, LDHA, NMT2, PEX26 and CDC44. Pathway analysis resulted in 4 related networks.

**Conclusion:** A causal mutation in DLG3 was identified in the MRX20 family. Fourteen genes were found to be significantly differentially expressed, of which 7 out of 11 could be confirmed. Further research is ongoing.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P09.049.A Multiomics approach identifies altered molecular pathways in MECP2-duplication syndrome and Rett syndrome patients**

**Ainhoa Pascual-Alonso**1,2, Clara Xiol1,2, Dmitrii Smirnov3,4, Robert Kopatich3,4, Christina Ludwig5, Holger Prokisch3,4, Judith Armstrong2,6,7

1Fundació Per la Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain; 2Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain; 3Technical University of Munich, Institute of Human Genetics, Munich, Germany; 4Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany; 5Technical University of Munich, Bavarian Biomolecular Mass Spectrometry Center, Freising, Germany; 6Hospital Sant Joan de Déu, Genomic Unit, Molecular and Genetic Medicine Section, Esplugues de Llobregat, Spain; 7Instituto de Salud Carlos III (ISCIII), CIBER-ER (Biomedical Network Research Center for Rare Diseases), Madrid, Spain.

**Background/Objectives:** Methyl CpG binding protein 2 (MECP2), located in the Xq28, is a multifunctional gene. Loss-of-function mutations in MECP2 trigger Rett syndrome (RTT), whereas its duplication causes MECP2 duplication syndrome (MDS). Both syndromes are characterized by neurodevelopmental delay and intellectual disability. Although the disease-causing genetic alterations are known, the molecular pathomechanism remains unknown. We aim to understand which are the molecular pathways altered in RTT and MDS.

**Methods:** RNA and protein were extracted from skin fibroblasts of 18 MDS patients, 21 RTT patients and 15 healthy controls. We performed transcriptomics and proteomics analysis using DESeq and LIMMA in a case-control approach. Enrichment of the differentially expressed genes (DEG) was evaluated.

**Results:** Transcriptomics and proteomics analysis showed a number of pathways that are significantly altered in both syndromes. Since MECP2’s functionality is dysregulated in an opposed way, we checked whether significantly upregulated genes in MDS were downregulated in RTT. The analysis revealed pathways involved in DNA replication and RNA processing.

**Conclusion:** We present the multiomics analysis of one of the biggest cohorts of RTT and MDS patients described so far. We could identify altered pathways in RTT and MDS patients regulated in opposite direction and, hopefully, contribute to the understanding of these two syndromes.

**References:**

**Grants:** This research was funded with the grants 2020 FI-B00888 (Government of Catalonia and European Social Fund), FPU18/02152 and PI20/0289 (Spanish Government) and PCP/00282 (parent association “Sindrome duplicación MECP2: Miradas que hablan”).

**Conflict of Interest:** None declared.

**P09.050.B Uncovering BOD1 mutation effect and its correlation to syndromic intellectual disabilities**

**Nadine Hamdan**1, Olivier De Bacter1, Eliane Choueiry2, Cybel Meheawe2

1Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium; 2Department of Human Genetics, Gilbert and Rose-Marie Chagoury School of Medecine, Lebanese American University, Byblos, Lebanon.

**Background/Objectives:** We and others showed that inherited autosomal recessive nonsense mutations in BOD1 gene resulted a syndromic intellectual disability mostly combined with endocrine dysfunction. BOD1 has shown to: direct chromosome orientation
in mitosis, form a complex with a methyltransferase SET1B that regulates expression of some fatty acid metabolic genes and its downregulation showed also synaptic defects and learning deficiency is drosophila.

Our project aims to determine the consequences of p.R151* nonsense mutation and to start investigating at molecular, cellular and organism levels the mechanisms linking BOD1 deficiency to syndromic ID.

Methods: Two HEK293 cell models were obtained by either introducing p.R151* BOD1 mutation or deleting BOD1 coding region by CRISPR/Cas9. We are also developing BOD1 knockout mouse model to investigate its developmental and physiological function.

Results: HEK293 cells with p.R151* mutation express a truncated protein that was observed by Western blot analysis when proteasome is inhibited, indicating that mutated allele mutation is probably amorph, with complete loss of function. HEK293T clones with BOD1 KO display an altered morphology suggesting modified cell adhesion properties. The electrophoretic profile of BOD1 KO clones indicate an alteration of protein expression that remains to investigate. Contrary to what was observed, after RNA interference-mediated knockdown of BOD1, we didn’t observe alterations of ADIPOR1 expression in the KO cells.

Conclusion: Our observations indicate that p.R151* mutation corresponds to an amorpha allele. We showed that BOD1 is not essential for survival or proliferation of HEK293T cells but its deprivation leads to an altered colony morphology on uncoated plastic surface.

References:

Grants: University of Namur.

Conflict of Interest: Nadine Hamdan: None declared, Olivier De Backer Professor Full time Job, University of Namur, Eliane Choueiry: None declared, Cybel Mehawej: None declared.

P09.051.C MED13L missense variations cause multifaceted functional consequences underlying severe phenotypes

Thomas Smol1,2, Frederic Frenois1, Morgane Billotte1, Odile Boute1,3, Roseline caumes1,3, Leonie Menke4, Amara Nassar-Sheikh Rashid4, Caroline Thullier2, Samra Holuigue1, Didier Monte5, Catherine Roche2, Sylvie Manouvrier1,3, Florence Petit1,3, Alexis Verger5, jamal ghoudm1,3

1Univ. Lille, ULR 7364 - RADEME - Maladies Rares du Développement embryonnaire et du Métaboisme, Lille, France; 2CHU Lille, Institut de Génétique Médicale, Lille, France; 3CHU Lille, Cnille de Génétique, Lille, France; 4Department of Pediatrics, Emma Children’s Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; 5CNRS ERL 9002 Integrative Structural Biology, Inserm U 1167 – RIDGE, Univ. Lille, CHU Lille, Institut Pasteur de Lille, Lille, France.

Background/Objectives: Pathogenic MED13L variants cause a neurodevelopmental disorder characterized by a moderate-to-severe intellectual disability. The majority of the patients carry a protein-truncating variation leading to haploinsufficiency and a typical phenotype. Few patients with a missense variant were reported with a broader and more severe phenotype. The exact biological consequences underlying atypical phenotypes remain unknown.

Methods: We selected five MED13L reported pathogenic variants located in exon 15, 17, and 30, causing either a severe phenotype (p.Pro866Leeu, p.Pro869Ser and p.Cys1131Tyr) or a typical phenotype (p.Gly1899Arg and p.Thr2162Met). To unravel pathogenic mechanisms, we analyzed MED13L wild type and mutant subcellular localization, integration into CDK8-module (CKM) and core Mediator complex, proteasome-mediated degradation, and phosphorylation.

Results: The p.Pro866Leeu and p.Pro869Ser variants were likely to induce a hyper-phosphorylated status of the MED13L623-938 domain while residues Cys1131 and Thr2162 are predicted to be critical for MED13L proper folding. Cytoplasmic relocalization and reduced integration into CKM and core Mediator complex were observed only with the p.Gly1899Arg.

Conclusion: MED13L missense variants are likely to be responsible for different pathogenic mechanisms. MED13L variants associated with typical phenotypes (p.Gly1899Arg and p.Thr2162Met) probably induce a loss of function, while variants associated with severe phenotypes probably cause a dominant-negative effect. This study highlights potential novel MED13L functions that should now be properly deciphered.

References:

Grants: None declared.

Conflict of Interest: None declared.

P09.052.D Biallelic mutations in CACTIN encoding component of spliceosome machinery cause severe intellectual disability, speech impairment and epilepsy

Uzma Abdullah1, Maria Asif1, Maryam Anayat1, Ghulam Nasseer Udin1, Muhammad Saqib Hussain2

1Pir Mehr Ali Shah Arid Agriculture University Rawalpindi, University Institute of Biochemistry and Biotechnology (UIBB), Rawalpindi, Pakistan; 2University of Cologne, Cologne Center for Genomics (CCG), Cologne, Germany.

Background/Objectives: Intellectual disability (ID) is a condition of significant limitation of cognitive functioning and adaptive behaviour, with 50% of aetiology attributed to genetic predisposition.

Methods: We recruited two consanguineous Pakistani families (A an B) manifesting severe ID and developmental delay. The probands were subjected to whole exome sequencing (WES) and variants were further prioritized based on population frequency, predicted pathogenicity and functional relevance.

Results: The WES data analysis of family A identified a homozygous missense variant CACTIN (NM_001080543.1:c.1040A>T;fl: p.(Asp347Val)), co-segregating with the disease. The gene is highly intolerant to loss of function variants (pLOF = 0.14) and has never been implicated in any inherited disorder. Its encodes Cactin which is a critical component of post-catalytic spliceosome that mediates exon ligation by stabilizing the position of the branch helix. CACTIN depleted cells show global splicing defects, while its knock down in zebrafish leads to embryonic lethality or extensive dysmorphogenesis. Family B segregated a novel missense substitution (NM_024298.4:c.757G>A;p.(Glu253Lys)) of MBOAT7, a known gene of ED. Both of the identified variants were absent in gnomAD and 1000 Genomes and predicted to be ‘deleterious’ by several in silico tools.

Conclusion: Our findings indicate that CACTIN is novel gene that when disrupted leads to intellectual disability. These also provide additional evidence to the role of MBOAT7 in aetiology of ID.

References: Nil.

Grants: Nil.

Conflict of Interest: None declared.

P09.054.B Variability in Wolf-Hirschhorn syndrome: two cohorts side by side

Julian Nevado1,2,3, Raquel Blanco-Lago4, Cristina Bel-Fenélls5, Maria Angeles Moro1,2,3, Pilar Barraz-Galán4, Ignacio Málaga4, Harry Pachajado4, Franco Cammarata-Scalisi2, Elena Mansilla1,2,3, Fe Amalia García Santiago1,2,3, Jair Tenorio1,2,3, Isabel Vallcorba1,2,3, Pablo LAPUNZINA1,2,3

1Levels of Lelystad Hospital, Leiden, Netherlands; 2Department of Pediatrics, Emma Children’s Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; 3Department of Pediatrics, Emma Children’s Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; 4Department of Pediatrics, Emma Children’s Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; 5Department of Pediatrics, Emma Children’s Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.

Abstracts from the 55th European Society of Human Genetics Conference.
Abstracts from the 55th European Society of Human Genetics Conference

1Instituto de Genética Médica y Molecular (INGEMM)-IdiPAZ, Hospital Universitario La Paz, Madrid, Spain; 2CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain; 3JTHACA-European Reference Network-Hospital la Paz, Madrid, Spain; 4Hospital Universitario Central de Asturias (HUC), Servicio de Neuropediatría, oviedo (Asturias), Spain; 5Facultad de Educación, UCM, Dpto. Investigación y Psicología en Educación, Madrid, Spain; 6Universidad Icesi, Cali, Colombia; 7Hospital Regional de Antofagasta, Servicio de Pediatría, Antofagasta, Chile.

Background/Objectives: Wolf-Hirschhorn syndrome (WHS) results from the loss of genetic material at 4pter. It is a neurodevelopmental disorder of genetic cause that have great phenotypic heterogeneity, including global developmental delay, microcephaly, delayed/absent speech, dysmorphic features, and epilepsy. We compare clinical, genetics, and follow-up characteristics between the Spanish and Latin-American subpopulations.

Methods: We describe a cohort of 134 patients with WHS (Spain, 72; Latino-America, 62). Patients were characterized by deep phenotyping, SNP-arrays, and other genetic approaches. We estimated an individual severity score (The global functional assessment of the patients (GFAP)) in our two cohorts using different features taken from two questionnaires and weighed them by HPO-term frequencies, on a numerical scale. Principal Component analysis was performed to validate our GFAP scale.

Results: The whole cohort (134) has a mean age of 7.81 years and shows a predominance of female sex over males (2:1). Although no differences between the two cohorts were observed at neonatal variables nor dysmorphic traits or physical aspects, we do find significant differences at several comorbidities, different items affecting developmental delay and clinical management of the epilepsy, although both subpopulations showed similar GFAP functional numbers.

Conclusion: No great functional differences can be made comparing both subpopulations, but do see significant changes at some of the variables collected (mainly related to the clinical and genetic managements of the cases). We used our GFAP scale as a base to develop a potential Clinical Outcome Assessment for each individual.

References: None.

Grants: FIS P18/01433 from ISCIII. Ministry of Health. Spain.

Conflict of Interest: None declared.

P09.056.A Supporting evidence on the role of a novel STXBP1 variant underlying discordant phenotypes in a family with a commonly balanced translocation

Constantia Aristidou1,2, athina theodosiou1,2, angelas alexandrou1, ioannis papaevripidou1, paola evangelidou1,2, carolina sismani1,2

1The Cyprus Institute of Neurology and Genetics, Department of Cytogenetics and Genomics, Nicosia, Cyprus; 2The Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.

Background/Objectives: Familial apparently balanced translocations (ABTs) segregating with discordant phenotypes are challenging for interpretation and counselling. We report an individual with intellectual disability, epilepsy and a t(1;7)(p36.1;q22) inherited from his non-affected mother. All possible mechanisms that could explain the differential phenotypes were thoroughly investigated; whole-genome mate-pair sequencing further demonstrated that the common translocation was identical and truly balanced. Subsequent family-based Whole-Exome Sequencing (WES) revealed a novel, de novo splice donor variant (NM_003165.6:c.1110+1T>G) in the STXBP1 gene, which is essential for neurotransmitter release through syntaxin regulation.

Methods: In order to assess the impact of this candidate variant on mRNA splicing, RNA was extracted from lymphoblastoid cell lines of the patient and a control sample. Reverse transcription PCR (RT-PCR) was performed, using STXBP1-specific primers flanking the identified variant and β-actin primers, followed by bidirectional sequencing.

Results: The expected wild-type STXBP1 allele was observed in both samples but lower quantities were seen in the patient. However, when a primer specifically amplifying the mutated allele was used, a PCR product was obtained only in the patient, indicating the incorporation of intronic sequences into the STXBP1 transcript. Sequencing of the RT-PCR products revealed that fifteen new amino acids are eventually inserted at position 371 of the STXBP1 protein (NP_003156.1) followed by a premature stop codon.

Conclusion: This study supports our previous findings describing familial ABTs as coincidental in individuals with discordant phenotypes. The novel, de novo STXBP1 variant identified by WES affects normal splicing and segregates with the patient’s phenotypes, thus expanding the mutational spectrum of the STXBP1 gene.

References: None.

Grants: None declared.

Conflict of Interest: None declared.

P10 NEUROGENETIC AND PSYCHIATRIC DISORDERS

P10.001.D High diagnostic rate of trio exome sequencing in consanguineous families with neurogenetic diseases

AYSE SEMRA HIZ1,2,3, Yavuz Oktyay3,4 Ana Töpf5, Nora Szabo6, GÜNGÖR SERDAL7,8, Ahmet Yaramis7,9, Ece Sonmezler10, Leslie Matalonga10, Uluc Yis11, Katherine Schoen11,12, Ida Paramonov6, İpek Polat Kalafatçilar13,14, Fei Gao11,12, Aliz Rieger13, Nur Arslan15,16, Elmasuş Yilmaz17,18, Burcu Ekin19, Pınar Pulat Edem20, Mahmut Aslan20, Bilge Ozgor21, Ashwati Nair22, Reza Maroofian23,24, Henry Houlden17,25, Kiran Polavarapu17, Andreas Roos18,19,20, Juliane S. Müller21,22, Denisa Hathazi20,22, Patrick Chinney21,25, Steven Laurie9, Sergi Beltran9, Hanns Loehmuller26,27, Rita Horvath10,21,28

1Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir, Turkey; 2Dokuz Eylul University, School of Medicine, Department of Paediatric Neurology, Izmir, Turkey; 3Izmir Biomedicine and Genome Center, Dokuz Eylul University Health Campus, Izmir, Turkey; 4Dokuz Eylul University, School of Medicine, Department of Medical Biology, Izmir, Turkey; 5John Walton Muscular Dystrophy Research Centre, Institute of Translational and Clinical Research, Newcastle University, Newcastle upon Tyne, United Kingdom; 6Epilepsy-Neurology Polyclinic of Buda Children’s Hospital, New Saint John’s Hospital and Northern -Buda United Hospitals, Budapest, Hungary; 7İzmir University, Faculty of Medicine, Turgut Ozal Research Center, Department of Paediatric Neurology, Malatya, Turkey; 8Pediatric Neurology Clinic, Diyarbakir, Turkey; 9CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain; 10Department of Clinical Neurosciences, School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom; 11Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom; 12Department of Clinical Neurosciences, School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom; 13Rehabilitation Centre for the Physically Handicapped, Budapest, Hungary; 14Dokuz Eylul University, School of Medicine, Department of Paediatric Nutrition and Metabolism, Izmir, Turkey; 15Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir, Turkey; 16GKT School
of Medical Education, King’s College London, London, United Kingdom; 17 Neurogenetics Laboratory, National Hospital for Neurology and Neurosurgery, University College London, London, United Kingdom; 18 Children’s Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Canada; 19 Leibniz-Institut für Analytische Wissenschaften, ISAS e.V., Dortmund, Germany; 20 Department of Pediatric Neurology, University of Duisburg-Essen, Essen, Germany; 21 Department of Clinical Neurosciences, John Van Geest Centre for Brain Repair, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom; 22 Department of Clinical Neurosciences, John Van Geest Centre for Brain Repair, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom; 23 Department of Neuropediatrics and Muscle Disorders, Medical Center–University of Freiburg, Faculty of Medicine, Freiburg, Germany.

Background/Objectives: Consanguineous marriages are common in Turkey (~25%). They increase the risk for autosomal recessive genetic diseases most of which mainly affect the nervous system and muscles. Access to molecular diagnostic methods and other advanced diagnostic tools are limited in the majority of children with neurogenetic diseases in Turkey. Although the next-generation sequencing reduces the diagnostic odyssey, the diagnosis success rate is still low for neurogenetic diseases which impose a substantial clinical and economic burden.

Methods: We recruited 246 children with clinically undiagnosed neurogenetic diseases from 190 consanguineous families. All patients underwent deep phenotyping and trio exome sequencing. Advanced bioinformatics platforms were used to integrate the data (RD-Connect GPAP).

Results: We identified causative variants in 119 known disease genes (72%) and likely pathogenic variants in 27 novel genes (14%) with an 86% overall diagnostic yield. The majority of the causative variants were homozygous (82%) and the remaining were de novo (9.3%), X-linked recessive (5.2%), and compound heterozygous (3.5%) variants. Protein synthesis/degradation defects and metabolic disease-related pathways were mostly revealed by pathway analysis. We also provided prevention of transmission and targeted treatments in 24 patients (10%).

Conclusion: We generated an important genomic data resource to better understand the genetic causes of childhood neurogenetic disorders, provided improved diagnosis and targeted treatments. We also demonstrated the superiority of trio exome sequencing over singleton exome sequencing and targeted gene panels.

References: Kurul, S. H. et al. High diagnostic rate of trio exome sequencing in consanguineous families with neurogenetic diseases. Brain (2021). https://doi.org/10.1093/brain/awab395.

Grants: TUBITAK Newton-Katip Celebi Fund (2165771).

Conflict of Interest: AYSE SEMRA HIZ TUBITAK (The Scientific and Technological Research Council of Turkey) Project No. 2165771, Yazuv Oktay TUBITAK (The Scientific and Technological Research Council of Turkey) Project No. 2165771, Ana Topf: None declared, Nora Szabo: None declared, GÜNGÖR SERDAL TUBITAK (The Scientific and Technological Research Council of Turkey) Project No. 2165771, Ahmet Yaramis TUBITAK (The Scientific and Technological Research Council of Turkey) Project No. 2165771, Ece Sommezler: None declared, Leslie Matakolonga: None declared, Uluc Yis: None declared, Katherine Schon: None declared, Ida Winkelmann: None declared, Ikpe Polat Kafalcılar: None declared, Fei Gao: None declared, Alz Rieger: None declared, Nur Arslan: None declared, Elmasnur Yilmaz: None declared, Petra Pavlekova: None declared, Petra Havránková: None declared, Eugenia Tsoma: None declared, Elisabetta Indelicato: None declared, Evi Runkel: None declared, Valentin Heid: None declared, David Weise: None declared, Tibke Janzarik: None declared, Matthias Eckenweiler: None declared, Steffen Berweck: None declared, Volker Moll: None declared, Bernhard Haslinger: None declared, Robert Jech: None declared, Julian Winkelmann: None declared, Michael Zech: None declared, Sergi Beltran: None declared, Hanns Lochmüller Newton Fund [UK/Turkey, MR/N027302/1], Rita Horvath Newton Fund [UK/Turkey, MR/N027302/1].
and Development Agency; Operational Programme Integrated Infrastructure, ERDF; Else Kröner-Fresenius-Stiftung; German Research Foundation; and European Reference Network for Rare Neurological Diseases.

Conflict of Interest: None declared.

P10.003.B Contribution of schizophrenia polygenic burden to longitudinal phenotypic variance in 22q11.2 deletion syndrome

Alexandre Reynold1, Valentina Mancini2, Kristi Lääli3, Maude Schneider2,4,5, Luciana Romano2, Lili Milani5, Reedik Mägi6, Emma- nound Demitzakis6, Stephan Eliez2,6, Maris Alver1,2,5

1University of Lausanne, Center for Integrative Genomics, Lausanne, Switzerland; 2University of Geneva, Developmental Imaging and Psychopathology Laboratory, Geneva, Switzerland; 3Institute of Genomics, University of Tartu, Estonian Genome Center, Tartu, Estonia; 4University of Geneva, Clinical Psychology Unit for Intellectual and Developmental Disabilities, Faculty of Psychology and Educational Sciences, Geneva, Switzerland; 5University of Geneva, Department of Genetic Medicine and Development, Geneva, Switzerland.

Background/Objectives: While the recurrent 22q11.2 deletion is one of the strongest genetic risk factors for schizophrenia (SCZ), variability of its associated neuropsychiatric endophenotypes reflects its incomplete penetrance for psychosis development.

Methods: To assess whether this phenotypic variability is linked to common variants associated with SCZ, we studied the association between SCZ polygenic risk score (PRS) and longitudinally acquired phenotypic information of the Swiss 22q11.2DS cohort (n = 97, 50% females, mean age 17.7yr, mean visit interval 3.8yr).

Results: The SCZ PRS with the best predictive performance was ascertained in the Estonian Biobank (n = 201,146) with LDpred. The infinitesimal SCZ PRS model showed the strongest capacity in discriminating SCZ cases from controls with one SD difference in SCZ PRS corresponding to an odds ratio (OR) of 1.74 (95% CI 1.59–1.90, P = 2.99 × 10–33). Social anhedonia (OR = 2.09, P = 0.0002), avolition (OR = 1.61, P = 0.001) and ideational richness (OR = 1.78, P = 0.003) within negative symptoms course, and dysphoric mood (OR = 2.00, P = 0.002) and stress intolerance (OR = 1.76, P = 0.0002) within general symptoms course showed the strongest associations with SCZ PRS in 22q11.2 patients. Genetic liability for SCZ was additionally associated with full scale β-coefficient (β = −0.25, P = 0.02) and with longitudinal volumetric reduction of the right and left hippocampi (β = −0.28, P = 0.005; β = −0.23, P = 0.02, respectively).

Conclusion: Our results indicate that the polygenic contribution to SCZ acts upon the threshold-lowering first hit (i.e., the deletion). It modifies the endophenotypes of 22q11.2DS and augments the derailment of developmental trajectories for negative and general symptoms, cognition, and hippocampal volume.

References:

Grants: NCCR 51NF40-158776; SNP 1003A_182632; SNP 320030_179404; ETAg PUTJD901.

Conflict of Interest: Alexandre Reynold: None declared, Valentina Mancini: None declared, Kristi Lääli: None declared, Maude Schneider: None declared, Luciana Romano: None declared, Lili Milani: None declared, Reedik Mägi: None declared, Emmanouil Demitzakis: E.T.D. is currently an employee of GSK. The work presented in this manuscript was performed before he joined GSK, Stephan Eliez: None declared, Maris Alver: None declared.

P10.004.C Get your molar tooth right: Joubert syndrome misdiagnosis unmasked by whole exome sequencing

Fulvio D’Abruco1, Filippo Arrigoni2, Valentina Serpieri3, Romina Romaniello4, Caterina Caputi5, Filippo Mant1, Bosanka Jocić-Jakub4,6, Elisabetta Lucarelli6, Elena Panzeri6, Maria Clara Bona- glia1, Luisa Chiapparini1, Anna Pichiecchio12,13, Lorenzo Pinelli14, Andrea Righini15, Vincenzo Leuzzi2, Renato Borgatti13,16, Enza Maria Valente1,3

1University of Pavia, Dept. of Molecular Medicine, Pavia, Italy; 2Scientific Institute IRCCS Eugenio Medea, Neuroimaging Lab, Bossoi Parini, Italy; 3IRCCS Mondino Foundation, Neurogenetics Research Center, Pavia, Italy; 4Scientific Institute IRCCS Eugenio Medea, Neuropsychiatry and Neurorehabilitation Unit, Bossoi Parini, Italy; 5Università di Roma La Sapienza, Unit of Child Neurology and Psychiatry, Department of Human Neuroscience, Rome, Italy; 6Sultan Qaboos University Hospital, Child Health Department, Muscat, Oman; 7Clinical Center Nis, Pediatric Clinic, Child Neurology Department, Nis, Serbia; 8Scientific Institute IRCCS Eugenio Medea, Unit for Severe Disabilities in Developmental Age and Young Adults, Brindisi, Italy; 9Scientific Institute IRCCS Eugenio Medea, Molecular Biology Laboratory, Bossoi Parini, Italy; 10Scientific Institute, IRCCS Eugenio Medea, Cytogenetics Laboratory, Bossoi Parini, Italy; 11Fondazione IRCCS Istituto Neurologico Carlo Besta, Neuroradiology Unit, Milan, Italy; 12IRCCS Mondino Foundation, Neuroradiology Unit, Pavia, Italy; 13University of Pavia, Dept. Of Brain and Behavioral Sciences, Pavia, Italy; 14ASST Spedali Civili, Neuroradiology Unit, Pediatric Neuroradiology Section, Brescia, Italy; 15V. Buzzi Children’s Hospital, Paediatric Radiology and Neuroradiology Department, Milan, Italy; 16IRCCS Mondino Foundation, Child Neurology and Psychiatry Unit, Pavia, Italy.

Background/Objectives: Joubert Syndrome (JS) is a recessively inherited ciliopathy, characterized by a specific cerebellar and brainstem malformation recognizable on brain imaging as the “Molar Tooth Sign” (MTS). Clinical signs include infantile hypotonia, developmental delay and intellectual disability of variable degree, ataxia, ocular-motor apraxia and variable organ involvement. In recent years, the genetic diagnosis of JS has been mostly based on the analysis of next-generation-sequencing targeted gene panels. Recognition of the MTS is crucial to address the patient to the appropriate genetic testing. However, the MTS is not always properly diagnosed, resulting either in false negative diagnoses (patients with the MTS not addressed to JS genetic testing) or in false positive diagnoses (patients with a different brain malformation wrongly addressed to JS genetic testing).

Methods: We report on six cases referred for JS genetic testing based on inappropriate recognition of MTS.

Results: While the analysis of JS-related genes was negative, whole exome sequencing (WES) disclosed pathogenic variants in other genes causative of distinct brain malformations: LAMA1 (Poretti-Bolthshauser syndrome), SHANK3 (Phelan-McDermid syndrome), GTPBP2 (Jaberi-Elahi syndrome), NLGN4X (X-linked mental retardation and autism susceptibility) and 16p11.2 deletion. reassessment of brain MRIs confirmed that the initial suspicion of MTS was incorrect.

Conclusion: This study highlights that the diagnostic yield of NGS-based targeted panels is strictly related to the accuracy of the diagnostic referral based on clinical and imaging assessment, and that WES has an advantage over targeted panel analysis when the diagnostic suspicion is not straightforward.

References: PMID: 34846692.

Grants: Ricerca Corrente 2021, RF-2019-12369368, PADOARPT.

Conflict of Interest: None declared.
P10.005.D A complex chromosome 21 rearrangement causes APP triplication and autosomal dominant early onset Alzheimer disease

Emma Ehn1,2, Jesper Eisfeldt3, Hakån Thonberg4, José Laffita1,2, Jacqueline Schoumans5, Anne Remes6, Matti Viitanen7, Anna Lindstrand3,4, Inger Nennesemo8,9, Caroline Graff1,2

1Karolinska Institute, Division for Neurogeriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Stockholm, Sweden; 2Karolinska University Hospital Solna, Unit for Hereditary Dementias, Stockholm, Sweden; 3Karolinska Institute, Molecular Medicine and Surgery, Stockholm, Sweden; 4Karolinska University Hospital Solna, Department of Clinical Genetics, Stockholm, Sweden; 5Centre Universitaire Hospitalier Vaudois (CHUV), Département de Médecine de Laboratoire et Pathologie, Lausanne, Switzerland; 6University of Helsinki, Department of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Huddinge, Sweden; 7Karolinska Institute, Department of Laboratory Medicine, Stockholm, Sweden; 8Karolinska University Hospital, Department of Pathology, Stockholm, Sweden.

Background/Objectives: Amyloid-β precursor protein (APP) gene copy number variation can cause early onset autosomal dominant Alzheimer disease (EO-ADAD). We present a parent and a child with symptom onset at age 64 and 34 years respectively. Neuropathology confirmed the AD diagnosis with Braak stages V-VI and extensive cerebral amyloid angiopathy (CAA).

Methods: Array comparative genomic hybridization (array-CGH) of genomic DNA from blood identified increased APP copies, with seemingly more copies in the child. Follow-up analysis with genome sequencing (GS) allowed for a detailed analysis of the APP copy number and the breakpoint junctions in both individuals.

Results: The GS analysis, using FindSV (TIDDIT, CNVnator) and visualization in IGV, resolved the genomic architecture of the complex structural variant with novel breakpoints; a triplication with three APP copies that was mosaic in the parent (20% of cells). All involved segments, including an inverted middle segment, are in cis. Further characterization of mosaicism will be explored using digital droplet PCR on tissue from different body organs and brain regions.

Conclusion: Structural chromosomal rearrangements in neurodegenerative disorders (NDS) likely contribute to the missing heritability. A GS-first approach allows for efficient screening of structural variants and provides more patients with a genetic diagnosis. In our study, the presence of the triplication in 100% of the cells in the child, while the parent was mosaic, is the explanation for the anticipation with 20 years earlier onset of AD in the child.

References: None declared.

Grants: Emma Ehn was supported by the Region Stockholm (combined residency and PhD training program).

Conflict of Interest: None declared.

P10.007.B Intermediate and expanded HTT alleles and risk for α-synucleinopathies

Sergio Pérez Oliveire1, Israel David Duarte Herrera1, María Victoria Alvarez Martinez1,2, Pau Pastor2, Ignacio Alvarez Fernandez2, Laura Molina-Porcel3, Irene Rosas1, Manuel Menendez-Gonzalez4,5, Iban Aldecoa6,7, Marta Blázquez-Estrada6,7, Miguel Aguilar8, Daniela Cortè9, María J Martí10,11, Juan Pascual Sanchez10,11, Jon Infante10,11, Isabel Gonzalez Aramburu10,11, Maria Teresa Periñan10,11, Daniel Macías-García10,11, Laura Muñoz Delgado10,11, Pilar Gómez-Garré10,11, Pablo Mir Rivero10,11,12, Alberto Leo Bisa10,11, Daniel Alcolea10,12, Beatriz De la Casa Fages10,12, Francisco Grandas10,13, Jordi Clarimon10,13

1Central University Hospital of Asturias, Laboratory of Genetics, Oviedo, Spain; 2Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain; 3Hospital Universitari Mútua de Terrassa and Fundació Docència i Recerca Mútua de Terrassa, Movement Disorders Unit, Neurology, Terrassa, Spain; 4Hospital Clinic i Provincial de Barcelona and Institut d’Investigacions Biomèdiques August Pi i Sunyer, Alzheimer’s disease and other cognitive disorders unit, Neurology, Barcelona, Spain; 5Hospital Clinic de Barcelona, Pathology Department, Biomedical Diagnostic Center, Barcelona, Spain; 6Central University Hospital of Asturias, Neurology, Oviedo, Spain; 7Neurological Tissue Bank of the Biobank-Biopark-Bank Hospital-IDIBAPS, Barcelona, Spain; 8Central University Hospital of Asturias, Biobank of Principado de Asturias, Oviedo, Spain; 9Hospital Clinic de Barcelona, Parkinson’s disease and Movement Disorders Unit, Neurology, Barcelona, Spain; 10Carlos III Health Institute, CIBERNED, Madrid, Spain; 11Centro Alzheimer Fundación Reina Sofia Gestiòn

Background/Objectives: Spastic paraplegia type-64 (SPG64; OMIM615683) is an ultra-rare form of complicated hereditary spastic paraplegia. SPG64, caused by biallelic ENTPD1 mutations, is associated with impaired purinergic neurotransmission. Here, we report a novel ENTPD1 variant which adds novel dysmorphic findings, thalamus atrophy and sensorimotor polyneuropathy to the phenotypic spectrum of SPG64.

Methods: Clinical exome sequencing was conducted utilizing Illumina-TruSight-One panel and analyzed by SophiaDDM.

Results: The previously unreported nonsense ENTPD1 variant NM_001776: c.1174C>T (p.Gln392Ter) is located in the extracellular loop domain and is linked to a severe SPG64 phenotype in the proband, associated with early age-of-onset (2 years) and total loss of ambulation at 6 years. Segregation was in accordance with autosomal recessive inheritance in the family.

Conclusion: Only 9 individuals with SPG64 from 5 families have been described with clinical details and the full phenotypic spectrum remains inadequately characterized. Based on our comprehensive follow-up for 4 years and comparison with reported individuals, the clinical spectrum of SPG64 can include cognitive decline (9/10), speech abnormality (7/10), dystonia (3/10) and brain abnormalities (3/7). Additionally, presence of sensorimotor polyneuropathy in the proband, accompanied by thalamus atrophy possibly secondary to sensory neuropathy, suggests that the clinical spectrum of SPG64 is broader than previously reported. Early-stage neuropathy suspected in a previous individual with SPG64 supports that neuropathy may be an overlooked phenotypic component of SPG64. Moreover, neuropathy may also be associated with impaired purine metabolism since purines are acting as neurotransmitters in peripheral nervous system. Our study highlights the importance of evaluating all future patients for clues of neuropathy.

References: PMID33771085.

Grants: None declared.
Abstracts from the 55th European Society of Human Genetics Conference

P10.008.C Founder effect in Joubert syndrome: identification of four shared haplotypes enriched in distinct European geographical regions associated to recurrent variants

Valentina Serpieri1, Giulia Mortarini2, Tommaso Biagini3, Ilaria Palmieri4, Fulvio D'Abrusco5, Concetta Mazzotta6, Roberta Battini7, Enrico Bertini8, Eugen Boltshauser9, Renato Borgatti9-10, Stefano D'Arrigo10, Nardo Narducci11, Rita Fischetto12, Alfonso Romano13, Franco Stanziali14, Pietro Strisciuglio15, Tommaso Mazza16, Enza Maria Valente12,17

1IRCCS Mondino Foundation, Neurogenetic Research Center, Pavia, Italy; 2University of Pavia, Dept. of Molecular Medicine, Pavia, Italy; 3IRCCS Casa Sollievo della Sofferenza, Bioinformatic Lab, CSS-Mendel Institute, San Giovanni Rotondo, Italy; 4IRCCS Stella Maris Foundation, Pisa, Italy; 5University of Pisa, Dept. of Clinical ad Experimental Medicine, Pisa, Italy; 6Bambino Gesù Children Research Hospital IRCCS, Unit of Neuromuscular and Neurodegenerative Disorders, Rome, Italy; 7University Children’s Hospital, Zurich, Dept. of Pediatric Neurology (emeritus), Zurich, Switzerland; 8IRCCS Mondino Foundation, Child Neurology and Psychiatry Unit, Pavia, Italy; 9University of Pavia, Dept. of Brain and Behavioral Sciences, Pavia, Italy; 10Giovanni XXIII Children’s Hospital, Clinical Genetics Unit, Dept. of Pediatric Medicine, Bari, Italy; 11Fondazione IRCCS Istituto Neurologico Carlo Besta, Dept. of Developmental Neurology, Milan, Italy; 12Fondazione IRCCS Istituto Neurologico Carlo Besta, Dept. of Child Neurology, Milan, Italy; 13Giovanni XXII Children’s Hospital, Clinical Genetics Unit, Dept. of Pediatric Medicine, Bari, Italy; 14University Federico II Naples, Dept. of Medical Translational Sciences Section of Pediatrics, Naples, Italy; 15hospital de la Santa Creu i Sant Pau, Neurology, Barcelona, Spain; 16Instituto De Investigación Sanitaria Gregorio Marañon, Madrid, Spain; 17Regional Hospital of Bolzano, Genetic Counseling Service, Dept. of Pediatrics, Bozen, Italy.

Background/Objectives: Joubert syndrome (JS) is a neurodevelopmental ciliopathy characterized by peculiar mid-hindbrain malformation, the “molar tooth sign”. The >40 known causative genes account for 65-75% cases. While most pathogenic variants are novel or extremely rare, we report on 10 recurring variants in six genes, including three already known “founder variants”.

Methods: We compared the frequencies of these variants in two unrelated JS cohorts (one Italian-European and one from the United States), in three Italian control cohorts and in the gnomAD database.

Results: Six variants were markedly enriched in both JS cohorts compared to controls, while three others were enriched only in European JS. Genotyping of microsatellite markers across the gene loci identified four novel founder haplotypes: (1) a 2.29Mb Mediterranean haplotype across MKS1 c.1476T>G; (2) a 2.02Mb Sardinian haplotype around KIAA0586 c.1006C>T; (3) a ~1.4Mb European haplotype encompassing KIAA0586 exon 8-10 deletion; (4) a 747Kb Italian haplotype across PRGRIPI1L c.1843A>C.

Of note, we and others showed that at least two (MKS1 c.1476T>G and KIAA0586 c.428delG) are hypomorphic variants which do not cause JS when homozygous, but only when in trans with a more deleterious variant. Functional studies for MKS1 c.1476T>G, showed a similarly reduced percentage of ciliated cells between healthy homozygous parent and compound-heterozygous affected son, but a much more severe reduction of ciliary length in the patient, confirming the hypomorphic effect.

Conclusion: This study contributes to understand the complex genetic landscape of rare genetically heterogeneous diseases such as JS, and to explain their variable prevalence in distinct areas.

References:

Grants:

Conflict of Interest: None declared.

P10.010.A Perinatal stroke: the importance of genetic testing

Liene Thys1, Diane Belsey1, Sandra Kenis1, Katrien Janssens2, Marije Meeuwissen2

1Antwerp University Hospital, Paediatric neurology, Edegem, Belgium; 2Antwerp University Hospital, Medical genetics, Edegem, Belgium.

Background/Objectives: Perinatal stroke is a group of cerebrovascular disorders with an incidence ranging from 1/1600 to 1/4000 live births. It is related to several neonatal and maternal risk factors, such as coagulation disorders, infection, asphyxia, etc. However, in some patients no traditional risk factors can be identified, hence a genetic cause might underlie the pathophysiology of stroke in these patients.

Methods: In our cohort of 76 cases with (presumed) perinatal stroke, 36 cases with ischemic stroke and 40 cases with intracranial haemorrhage were identified. All cases underwent genetic investigations using single nucleotide polymorphism array and a whole exome sequencing based gene panel.

Results: A genetic diagnosis was confirmed in 7/76 cases (9.21%). The diagnostic yield was highest in cases with haemorrhagic stroke (6/40 patients, 15%), with an important contribution of COL4A1 pathogenic variants (4/6 diagnosed cases with haemorrhagic stroke, 66.67%). Furthermore, trisomy 12p and cardiofacio-cutaneous syndrome due to a de novo pathogenic BRAF variant were diagnosed in two haemorrhagic stroke cases. In the ischemic stroke group, only one diagnosis was made, comprising a de novo mosaic JAG1 variant in an atypical case of Alagille syndrome.

Conclusion: Our findings highlight the added value of genetic testing in cases with (presumed) perinatal stroke. A higher yield
was present in patients with haemorrhagic stroke, where we could establish a significant contribution of COL4A1 pathogenic variants. The added value in ischemic stroke seems less substantial, however needs further investigation.

References:

Grants: This work was supported by the Marguerite-Marie Delacroix support fund (RVC/B-458).

Conflict of Interest: Liene Thys This work was supported by the Marguerite-Marie Delacroix support fund (RVC/B-458), Diane Beyesen This work was supported by the Marguerite-Marie Delacroix support fund (RVC/B-458), Sandra Kenis: None declared, Katrien Janssens: None declared, Marije Meuwissen This work was supported by the Marguerite-Marie Delacroix support fund (RVC/B-458).

P10.011.B Evaluation of microRNA from serum extracellular vesicles in adolescents at risk for psychiatric disorders

Jessica Honorato Mauer1, Gabriela Xavier2, Vanessa Ota1, Amanda Bugiga1, Adrielle Martins1, Mirian Boim1, Paula Asapiro1, Samar Chehim1,6, Fernanda Mafra1,6, Renata Pellegrino5, Pedro Pan1, Rodrigo Bressan1, Giovanni Salum1, Sintia Belangero1, Marcos Santoro1

1Federal University of São Paulo (Unifesp), São Paulo, Brazil; 2Broad Institute of MIT and Harvard, Cambridge, United States; 3Massachusetts General Hospital, Boston, United States; 4Hospital Sírio-Libanês, São Paulo, Brazil; 5Center for Applied Genomics at Children’s Hospital of Philadelphia, Philadelphia, United States; 6University of Pennsylvania, Philadelphia, United States; 7Federal University of Rio Grande do Sul (Ufrgs), Porto Alegre, Brazil.

Background/Objectives: Exosomes are small extracellular vesicles (EVs) detected in body fluids, their content commonly enriched for microRNAs. They can cross the blood-brain barrier and therefore may be implicated in various neurological and psychiatric disorders. MicroRNA content in serum EVs from adolescents, to identify those microRNA expression associated with diagnosis of Major Depression cases (n=29); and persistent cases (N=32); remitted cases (N=29); and persistent cases (N=26). EVs were isolated from serum using differential centrifugation and precipitation kit. We characterized EV size, concentration and membrane proteins. microRNA was isolated from EV samples and sequenced.

Results: EV characterization indicated the presence of general and brain-associated EV protein markers. miR-4433b-5p, miR-584-5p, miR-625-3p, miR-432-5p and miR-409-3p were differentially expressed comparing Major Depression cases (n=38) vs. controls (n=56) in the second timepoint (FDR-adjusted p-value <0.1), miR-625-3p and miR-432-5p were previously associated with Schizophrenia and miR-409-3p with Major Depression and cognition. miR-382-5p, miR-625-3p, miR-134-5p and miR-15a-3p were differentially expressed longitudinally in male individuals regardless of diagnosis (n=66). miR-134-5p regulates synaptic plasticity processes, considered important in pubertal brain development.

Conclusion: We were able to observe differences in EV microRNA expression associated with diagnosis of Major Depression, as well as with age in males, and characterize EV samples. We expect to identify more microRNA associated with incidence and remission of PDs.

References: Salum, et al., IntJ MethodsPsychiatrRes. 2015; Geaghan M, Cairns MJ, BiolPsychiatry. 2015; Rao, et al., NeurosciBiobehav Rev. 2016.

Grants: NARSAD Young Investigator Grant 573974/2008-0; FAPESP 2020/02247-7; CAPES Scholarship.

Conflict of Interest: None declared.

P10.012.C Familial 1p36.31p36.23 deletion encompassing CAMTA1 associated with variable intellectual disability and ataxia phenotype

Mariana Soeiro e Sá1, rosário silveira-santos1, Ana Sousa1, Ana Berta Sousa1

1Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Department of Medical Genetics, Lisbon, Portugal.

Background/Objectives: Intragenic CAMTA1 rearrangements are rare and have been associated with varied neurobehavioural phenotypes, including developmental delay/intellectual disability (DD/ID) and nonprogressive cerebellar ataxia (OMIM#614756). From the few families reported, the phenotypic spectrum appears to be very variable, with cognition ranging from normal to moderate ID, and cerebellar signs from unsteady gait to overt ataxia.

Methods: The proband is a 9-year-old girl, referred due to autism spectrum disorder (ASD) and learning difficulties, with a history of impairment in gross and fine motor skills and unsteadiness while running. Brain MRI was normal. Her maternal half-sister had mild ID, ASD, attention deficit hyperactivity disorder (ADHD) and a diagnosis of intrauterine CMV infection causing postlingual unilateral deafness. She also had marked impairment of gross and fine motor skills; brain MRI showed possibly CMV-related abnormalities, but no cerebellar involvement. Their mother had no ID or ataxia, but reported mild global DD, learning difficulties, and ADHD in childhood, plus a history of frequent falls.

Results: ArrayCGH identified an interstitial deletion in 1p36.31p36.23 (6967159_8402554; hg19) encompassing exons 4 to 23 of CAMTA1. FISH studies confirmed the deletion to be maternally inherited and present in the proband’s half-sister.

Conclusion: This family illustrates the variable phenotype associated with intragenic rearrangements in CAMTA1, namely regarding cognition and motor impairment. Although, to our knowledge, the deletion found in this family is larger than previously reported (encompassing several genes downstream of CAMTA1), the phenotype is similar to other families, further contributing to establish CAMTA1 as a gene associated with a neurodevelopmental phenotype with variable cerebellar involvement.

References:

Grants:

Conflict of Interest: None declared.

P10.013.D Fine-mapping and transcriptome wide association study of anorexia nervosa prioritises WDR6 and immune pathways as potential causal factors

Danielle Adams1, William Reay1,2, Murray Cairns1,2

1The University of Newcastle, Newcastle, Australia; 2Hunter Medical Research Institute, Newcastle, Australia.

Background/Objectives: Anorexia nervosa is the leading cause of mortality among psychiatric disorders worldwide. Currently no medications are approved for anorexia treatment, and thus, identification of clinically actionable risk factors for this disease is pivotal to reducing disease burden.

Methods: We performed a transcriptome wide association study (TWAS) and conditional analysis across 17 tissues, leveraging mRNA, protein, and mRNA alternative splicing weights to identify genes, proteins, and transcripts, respectively, associated with anorexia risk. We utilised the largest anorexia GWAS available to date (N=72,517). Probabilistic fine-mapping was then applied to further prioritise genes that may represent true causal signals.

Results: TWAS identified 134 genes, 4 proteins, and 16 transcript isoforms significantly associated with anorexia after
Benjamini-Hochberg correction. A conditional analysis of these significantly associated genes considering other proximal genes resulted in 97 genes that remained independently associated. Moreover, finemapping prioritised five genes with strong evidence of a causal effect on anorexia (PIP > 0.8 in 90% credible set), with eight other genes exhibiting moderate evidence (PIP > 0.4). Upregulation of the gene encoding WD repeat domain 6 (WDR6) was identified as an anorexia risk gene through both finemapping and conditional analysis. Genes prioritised by finemapping were also overrepresented amongst the immune system process gene ontology pathway.

**Conclusion:** We identify novel candidate risk genes for anorexia through integration of anorexia genetic associations with models of genetically regulated mRNA, protein, and splicing. There was strong evidence to support a role for WDR6 in anorexia pathogenesis, whilst other prioritised genes were found to be plausibly linked to immunological function.

**References:**

**Grants:**

**Conflict of Interest:** Danielle Adams: None declared, William Reay Employee of the University of Newcastle, Murray Cairns Employee of the University of Newcastle.

**P10.017.C Evaluation of a nurse led care service for patients with neurofibromatosis**

_Gunjan Garg_1, Jane Fleming1, Yemima Berman1

1Bioaraba Health Research Institute, Molecular (Epi)Genetics Laboratory, Vitoria-Gasteiz, Spain; 2Bioaraba Health Research Institute, Department of Neurology, Vitoria-Gasteiz, Spain; 3Bioaraba Health Research Institute, Molecular (Epi)Genetics Laboratory, Vitoria-Gasteiz, Spain; 4Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain; 5ATLAS Molecular Pharma S. L., Derio, Spain; 6Ikerbasque. Basque Foundation for Science, Bilbao, Spain; 7Carlos III National Health Institute, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Madrid, Spain.

**Background/Objectives:** Chromosomal rearrangements in the 16p11.2 region are considered among the most frequent etiologies of neurodevelopmental and autism spectrum disorders with variable penetrance and highly pleiotropic clinical outcomes. Our study characterizes four cases diagnosed with reciprocal 16p11.2 CNVs and additional rare and novel variants in genes located outside the affected 16p11.2 region.

**Methods:** Four pediatric patients, two girls (A, B) and two boys (C, D), were referred to the clinic for various symptoms including global developmental delay, nonspecific dysmorphic features, early onset seizures, movement disorders and autistic traits. Brain MRI revealed abnormalities in three of them. Patients were recommended genetic investigations for diagnosis: A performed a WES test, B and C, an epilepsy gene panel test, and D, a chromosomal microarray analysis.

**Results:** 16p11.2 CNVs were revealed in all cases: microduplication for patient A and microdeletions for the rest. Additionally, VUS variants were detected: one heterozygous PRRT2 missense variant in trans to the CNV for each patient A and B, and a TUBB4A4 frame deletion variant for patient C. The additional variants detected for B and C have not been described to date. Testing is about to be continued for D.

**Conclusion:** Our study highlights the challenges encountered when establishing genotype-phenotype correlations in pediatric patients diagnosed with 16p11.2 CNVs associated with other rare gene variants, emphasizing that such diverse phenotypes are the result of CNVs interaction with the rest of the genome. To our knowledge, this is the first reported case presenting an association between a 16p11.2 CNV and a TUBB4A4 gene variant.

**References:**

**Grants:**

**Conflict of Interest:** None declared.
Background/Objectives: Neurofibromatoses (NF) are a group of complex genetic disorders requiring multidisciplinary care. Inconsistent and fragmented care has been reported to lead to disease complications that could have been prevented. We implemented a nurse led care (NLC) service to provide extra support to NF patients.

The aim of the study was to audit the consultations of the clinical nurse specialist (CNS) and evaluate patient experience, enablement and satisfaction with the NLC service.

Methods: The audit included 163 patient encounters with 114 patients with NF that received NLC (May 2020-May 2021). The 58-item anonymous online survey included validated scales and was distributed to all audit patients.

Results: The CNS’ main role was identified as ‘coordination of care’ (40%). 57 surveys were analysed (50% response-rate) with over 80% of patients reporting a positive or very positive experience. Mean patient satisfaction scores (50/75) were also favourable. Statistically significant association was found between patient satisfaction scores and patients’ views and concerns being listened to X 2 (2, (n = 50) = 6.34 (p = 0.04)); flexibility of getting a time with the nurse X 2 (3, (n = 57) = 12.13 (p = 0.007)); patients’ involvement in making decisions about their treatment plan X 2 (4, (n = 57) = 12.83 (p = 0.001) and being given enough information to manage their care at home X 2 (2, (n = 44) = 12.85 (p = 0.002).

Conclusion: This study shows nurse led care is associated with positive patient satisfaction and experience and supports its introduction as a model of care for management of patients with rare diseases.

References:
Grants:
Conflict of Interest: None declared.

P10.017D Genotypic spectrum and its clinical implication in disorders with epilepsy in Indian population: A preliminary experience

Purvi Majethia1, Vivekananda Bhat1, Karthik Nair1, Dhanya Lakshmi Narayanan1, Shikirin Aroor1, Ramesh Bhat1, Suvasini Sharma1, Praveen b1, Yatheesha b1, Siddaramappa J Patil1, Nutan Kamath1, Shahaney Siddiqui3, Rajagopal Kadavigere2, Stephanie Bielas3,9, Katta Girisha1, Anju Shukla1

1Department of Medical Genetics, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, India; 2Department of Paediatrics, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, India; 3Neurology Division, Department of Pediatrics, Lady Hardinge Medical College and Associated Kalawati Saran Children’s Hospital, New Delhi, India; 4Department of Pediatrics, Father Muller Medical College Hospital, Mangalore, India; 5Paediatric neurology, Dheemahi Child Neurology and Development center, Shimoga, India; 6Department of Paediatrics, Narayana Hrudayala Hospitals/ Mazumdar-Shaw Medical Center, Bangalore, India; 7Department of Paediatrics, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India; 8Department of Neuroimaging and Interventional Radiology, STAR Institute of Neurosciences, STAR Hospitals, Hyderabad, India; 9Department of Radiodiagnosis, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, India; 10Department of Human Genetics, University of Michigan Medical School, Ann Arbor, Michigan, United States.

Background/Objectives: Rapid advancement in identification of underlying genetic mechanisms in disorders with epilepsy has attributed to improved management including precision medicine as well as informed genetic counseling in families with these disorders.

Methods: We recruited 71 families (75 individuals) with neurodevelopmental disorders with epilepsy from October 2019 till date. Targeted testing and/or genomic testing after detailed clinical evaluation was carried out. The implications on genetic counseling and therapy were evaluated in individuals with definitive molecular diagnosis.

Results: Molecular diagnosis was achieved in a total of 54 out of 71 families (76%): two (4%) by targeted testing, ten (18%) by Mendelrome, and 42 (78%) by exome sequencing. Of these, monogenic disorders were identified in fifty-three families: autosomal recessive in 30 families (56%), autosomal dominant in 19 families (36%), X-linked in four families (9%), and imprinting/microdeletion syndrome (Angelman syndrome) in one family (Table 1). Thirty (55%) of 57 disease-causing variants were novel. One novel disease-gene association with pathogenic variants in GCDS was identified. We also report genotypic and phenotypic expansion of extremely rare and recently described disorders with pathogenic variants in SHMT2, SLC25A10, SNRPN, TRAPPC12, MINPP1 and FGF13. Reproductive counseling was offered to 72% (39/54) of families. Therapeutic implications were noted in 30% of individuals (16/54) with definitive diagnosis. Strong evidence of recommended therapies was available in 50% (8/16) families, emerging evidence in 6% (1/16), and sparse evidence in 44% (7/16) families.

Conclusion: The above-mentioned cohort is a part of an ongoing study of disorders with epilepsy.

References:
Grants: 1R01HD093570-01A1(NIH,USA).
Conflict of Interest: None declared.

P10.018.A Identity-by-descent analysis of a large Tourette’s syndrome pedigree from Costa Rica implicates genes involved in neuronal development and signal transduction

Niamh Ryan1, Cathal Ormond1, Yi-Chieh Chang2, Javier Contreras3, Henriette Raventos3, Michael Gill1, Elizabeth Heron1, Carol A. Mathews2, Aiden Corvin1

1Trinity College Dublin, Dublin, Ireland; 2University of Florida, Department of Psychiatry, Gainesville, United States; 3University Of Costa Rica Rodrigo Facio Campus, San Pedro, Costa Rica.

Background/Objectives: Tourette Syndrome (TS) is a poorly understood, substantially heritable neuropsychiatric disorder that typically begins in early childhood. Identifying rare variants that make a significant contribution to risk in affected families may provide important insights into the molecular aetiology of this disabling condition. We report data from a large pedigree (>500 individuals), densely affected by TS and co-morbid psychiatric disorders from a genetically isolated Costa Rican population. The pedigree spans 11 generations and shares ancestry from six founder-couples.

Methods: Whole genome sequencing (WGS) data was generated for 19 individuals from this pedigree. Identity-by-descent (IBD) analysis was performed, filtering haplotypes on the following criteria: >1MB in length; shared by at least three affected individuals sharing ancestry from the same founder couple(s); and absent in Costa Rican control samples.

Results: The IBD pipeline identified eleven haplotypes. Fine-mapping of these haplotypes using the WGS data identified rare (MAF< 0.01) and ultra-rare (MAF< 0.001) coding and non-coding variants in candidate genes. In particular we identified a rare deleterious missense variation in RAPGEF1 and two ultra-rare putatively deleterious intronic variants in ERBB4 and IKZF2.
Conclusion: RAPGEF1 has recently been implicated in a family study of neuropsychiatric symptoms, supported by a zebrafish model of this gene. ERBB4 participates in many critical functions, such as neurodevelopment and synaptic plasticity, while IKZF2 is a transcription factor shown to play a role in neuronal development. Together, these variants represent biologically relevant targets for investigation in other pedigree and population-based TS data.

References:

Grants: Project supported by the National Institute of Health and Science Foundation Ireland.

Conflict of Interest: None declared.

P10.019.B A different light on COL4A2 variant interpretation

Merlijn Nemegeer1, Dorien Schepers1, Bart Loeys1, Marijke Meuwissen1

1University of Antwerp, Center of Medical Genetics, Edegem, Belgium.

Background/Objectives: Pathogenic variants in COL4A1 and COL4A2 are known to cause a phenotype with a broad spectrum of neurological findings. COL4A1 variants are less frequent compared to COL4A1 variants. This has caused a biased representation, as COL4A2 is rarely considered separate from COL4A1 variants. In this study we re-assessed the current knowledge on COL4A2 variants.

Methods: After PubMed search, we collected all COL4A2 variants published until February 2022 and reviewed the LOVD and Clinvar database. All variants were reclassified using current ACMG guidelines.

Results: Twenty-three articles described 97 cases with 49 different COL4A2 variants. Remarkable was the discordance between published class and the classification using ACMG guidelines in more than 30% of the variant descriptions. In some cases, a strong discordance was noted between pathogenicity based on computational results, functional testing or population frequencies. A striking example is the COL4A2 variant, p.Glu1123Gly. Functional testing in 2012 showed a cellular phenotype, but current population frequency suggests this variant to be incompatible with monogenic disease.

Interestingly, the prevalence of confirmed de novo cases (12%) was distinctly lower compared to the previously reported 40% in COL4A1 variants. Screening of family members carrying the familial variant detected brain MRI abnormalities in 59% of the cases, even in clinically unaffected cases.

Conclusion: These results show that COL4A2 variant interpretation is complicated due to phenotypic variability, and conflicting predictions of pathogenicity. Additional research about the pathogenic mechanism of COL4A2 variants is imperative for correct interpretation of COL4A2 variants.

References:

Grants: Stichting ’t Trekpaert, Moordrecht, The Netherlands. DOCPRO grant, University of Antwerp.

Conflict of Interest: None declared.

P10.021.D Variant-specific changes in RAC3 function disrupt corticogenesis in neurodevelopmental phenotypes

Marcello Scala1,2, Masashi Nishikawa3, Hidenori Ito3, Hidenori Tabora4, Tatsuya Kon5, Andrea Accogli3, Laura Davids2, Anna Ruiz6, Pietro Chiurazzi3, Gabrielea Cericol6, Bjorn Schulte10, Kristin Monaghan11, Amber Begtrup11, Anna-Maria Margherita Manconi2, Michele Pinelli2, Anne-Sophie Denommé-Pichon14,15,16, Antonio Virotbello14,16, Caroline Racine14,15, Maria Margherita Manconi2, Courtney Kiss18, Andrea Guein18, Wendy Wu4,19, Elisabeth Gabau Vila20, Bryan C. Mak13, Julian A. Martinez-Agosto7,22,23, Michael B. Gorin21,24,25, Bugrahan Duz26, Yavuz Bayram27,28, Claudia M. B. Carvalho Fonseca29,30, Jaime Vengochea2, David Chitayat4, Bert Callewaert18, Anne-Sophie Denommé-Pichon14,15,16, Antonio Virotbello14,16, Caroline Racine14,15, Maria Margherita Manconi2, Courtney Kiss18, Andrea Guein18, Wendy Wu4,19, Elisabeth Gabau Vila20, Bryan C. Mak13, Julian A. Martinez-Agosto7,22,23, Michael B. Gorin21,24,25, Bugrahan Duz26, Yavuz Bayram27,28, Claudia M. B. Carvalho Fonseca29,30, Jaime Vengochea2, David Chitayat4, Bert Callewaert18, Anne-Sophie Denommé-Pichon14,15,16, Antonio Virotbello14,16, Caroline Racine14,15, Maria Margherita Manconi2, Courtney Kiss18, Andrea Guein18, Wendy Wu4,19, Elisabeth Gabau Vila20, Bryan C. Mak13, Julian A. Martinez-Agosto7,22,23, Michael B. Gorin21,24,25, Bugrahan Duz26, Yavuz Bayram27,28, Claudia M. B. Carvalho Fonseca29,30, Jaime Vengochea2, David Chitayat4, Bert Callewaert18, Anne-Sophie Denommé-Pichon14,15,16, Antonio Virotbello14,16, Caroline Racine14,15, Maria Margherita Manconi2

References:

Grants: None declared.

Conflict of Interest: None declared.

P10.020.C A novel autosomal dominant locus for essential tremor: when linkage analysis can still drive gene discovery

Verdiana Pullano1, Alessandro Brussino1, Maria Sofia Cotelli2, Orazio Palumbo3, Pietro Palumbo3, Paola Dimartino3, Simona Cardaropoli4, Elisa Giorgio6,6, Lisa Pavinato1, Tommaso Pippuccio1, Massimo Carella1, Barbara Borroni1, Alfredo Brusco1,10

1University of Turin, Department of Medical Sciences, Turin, Italy; 2Valle Camonica Hospital, Neurology Unit, Esine, Brescia, Italy; 3IRCCS “Casa Sollievo della Sofferenza”, Division of Medical Genetics, San Giovanni Rotondo, Italy; 4University of Bologna, Department of Medical and Surgical Sciences, Bologna, Italy; 5University of Turin, Department of Public Health and Pediatrics, Turin, Italy; 6University of Pavia, Department of Molecular Medicine, Pavia, Italy; 7IRCCS Mondino Foundation, Laboratory of Molecular Medicine and Cytogenetics, Pavia, Italy; 8Polyclinic Sant’Orsola-Malpighi University Hospital, Medical Genetics Unit, Bologna, Italy; 9Centre for Neurodegenerative Disorders, University of Brescia, Department of Clinical and Experimental Sciences, Brescia, Italy; 10Città della Salute e della Scienza University Hospital, Turin, Italy.

Background/Objectives: Essential tremor (ET) is a common movement disorder with a prevalence of approximately 1% worldwide. Although a considerable effort has been made in recent years trying to identify genomic markers for ET, the responsible genes have been elusive.

Methods: We studied a three-generation Italian family segregating early-onset autosomal dominant ET (7 affected, 4 unaffected cases, 1 spouse). Postural and action tremor started slowly and symmetrically in their twenties and progressed gradually with age; the neurological examination was otherwise unremarkable. We performed exome sequencing in two affected cousins, but no pathogenic variant was found. Using the CytoScan HD Arrays (Affymetrix), we performed SNP genotyping. Linkage analysis calculation was done using Merlin software.

Results: We identified an approx. 43 Mb region on chromosome 10p11.21-q23, between markers rs7477871 and rs12253494, containing several stretches of SNPs with a LOD score above 2 (up to 2.475). In the region, 313 unique encoding transcripts were identified, 161 of which are OMIM genes. Among them, 104 transcripts are expressed in brain, even if none was suggestive for ET pathology.

Conclusion: Our linkage analysis, even if below the significant threshold, highlighted a single region of 43 Mb on chromosome 10, as potentially in linkage with an autosomal dominant form of ET. An in-depth sequencing analysis of this region in two individuals of the family by whole genome sequencing is undergoing that hopefully will help us with this “gene hunt”.

References:

Grants: None declared.

Conflict of Interest: None declared.
Central Hospital, Department of Molecular Neurobiology, Institute for Developmental Research, Kasugai, Japan; 4The Hospital for Sick Children, Genetics and Genome Biology, Research Institute, Toronto, Canada; 5Emory Healthcare, Department of Human Genetics, Atlanta, United States; 6Universitat Autònoma de Barcelona, Genetics Laboratory, UDIAT-Centre Diagnòstic, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí 13PT, Bellaterra, Spain; 7Università Cattolica del Sacro Cuore, Dipartimento Universitario Scienze della Vita e Sanità Pubblica, Sezione di Medicina Genomica, Roma, Italy; 8Agostino Gemelli University Policlinic, Genetica Medica, Roma, Italy; 9Helios Klinikum Hildesheim, Neuropediatric Department, Hildesheim, Germany; 10Praxi dla Genetiki Tübingen, Tübingen, Germany; 11GeneDx, Gaithersburg, United States; 12Tigem, Pozzuoli, Italy; 13Seconda Università degli Studi di Napoli, Department of Precision Medicine, Caserta, Italy; 14Chu De Dijon, Laboratoire de Génétique Moléculaire, UFR Innovation en diagnostic génomique des maladies rares, Plateau Technique de Biologie, Dijon, France; 15Chu De Dijon, Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l’interrégion Est, Hôpital de l’Enfant, Dijon, France; 16university de Bourgogne Franche-Comté, INSERM UMR1231 Génétique des Anomalies du Développement, Dijon, France; 17Giannina Gaslini Institute, Unit of Child Neuropsychiatry, Department of Medical and Surgical Neuroscience and Rehabilitation, Genova, Italy; 18Queen’s University, Division of Medical Genetics, Department of Pediatrics, Kingston, Canada; 19Queen’s University, Kingston, Canada; 20Universitat Autònoma de Barcelona, Paediatric Unit, Parc Taulí Hospital Universitari, Institut d’Investigació e Innovació Parc Taulí 13PT, Bellaterra, Spain; 21University of California, Los Angeles, Department of Human Genetics, David Geffen School of Medicine, Los Angeles, United States; 22University of California, Los Angeles, Department of Pediatrics, David Geffen School of Medicine, Los Angeles, United States; 23University of California, Los Angeles, Department of Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine, Los Angeles, United States; 24University of California, Los Angeles, Department of Obstetrics and Gynecology, Mount Sinai Hospital, Toronto, Canada; 25University of California, Los Angeles, Department of Obstetrics and Gynecology, Mount Sinai Hospital, Toronto, Canada; 26University of California, Los Angeles, Department of Molecular Medicine, Los Angeles, United States; 27Children’s Hospital of Philadelphia, Division of Genomic Diagnostics, Department of Pathology and Laboratory Medicine, Philadelphia, United States; 28University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States; 29Pacific Northwest Research Institute, Seattle, United States; 30Bay College of Medicine, Houston, United States; 31University of Toronto, The Prenatal Diagnosis and Medical Genetics Program, Department of Obstetrics and Gynecology, Mount Sinai Hospital, Toronto, Canada; 32University of Toronto, Department of Molecular Genetics, Toronto, Canada; 33The Hospital for Sick Children, Division of Clinical and Metabolic Genetics, Department of Paediatrics, Toronto, Canada; 34University of Melbourne, Victorian Clinical Genetics Services, Murdoch Children’s Research Institute, and Department of Paediatrics, Parkville, Australia; 35Ghent University Hospital, Center for Medical Genetics, Gent, Belgium; 36Helios Klinikum Hildesheim, Neuropediatric Department, Hildesheim, Germany; 37University of California San Diego, Department of Pediatrics, La Jolla, United States; 38Rady Children’s Hospital – San Diego, Genetics/Dysmorphology, San Diego, United States; 39CeGaT, Tübingen, Germany; 40Harvard Medical School, Department of Biomedical Informatics, Boston, United States; 41Tigem, Telethon Undiagnosed Diseases Program, Pozzuoli, Italy; 42Giannina Gaslini Institute, Neuroradiology Unit, Genova, Italy; 43Giannina Gaslini Institute, Medical Genetics Unit, Genova, Italy; 44University of Toronto, Department of Paediatrics, Toronto, Canada; 45Nagoya University, Department of Neurochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Background/Objectives: Variants in RAC3, encoding the small GTPase RAC3 which is critical for the regulation of actin cytoskeleton and intracellular signal transduction, are associated with a rare neurodevelopmental disorder with structural brain anomalies and facial dysmorphism.

Methods: We investigated a cohort of 10 unrelated participants with neurodevelopmental phenotypes and an overlapping pattern of complex brain malformations. We performed exome sequencing and examined the pathophysiological significance of novel and previously reported RAC3 variants (p.P29L, p.P34R, p.A59G, p.Q61L, and p.E62K). We then focused on the four variants in the Switch II region (p.Q61L, p.E62del, p.D63N, and p.Y64C), variation hot spot and essential for the small GTPases biochemical activity.

Results: In vitro analyses revealed that all tested RAC3 variants were biochemically and biologically active to variable extent, showing different affinities to downstream effectors. Acute expression of the four Switch II variants in embryonic mouse brain using in utero electroporation caused defects in cortical neuron morphology and migration, leading to cluster formation during corticogenesis.

Conclusion: Our results indicate that RAC3 variants cause morphological and functional defects in cortical neurons during brain development through variant-specific mechanisms, leading to heterogeneous neurodevelopmental phenotypes.

References: [1] Stankiewicz, Front Cell Neurosci, 2014 [2] Dvorsky, EMBO Rep, 2004. [3] Azzarelli, Front Cell Neurosci, 2015. [4] de Curtis, Cells, 2019. [5] Rejnders, AJHG, 2017. [6] Costain, GIM, 2019. [7] Hiraide, JHG, 2019. [8] White, AJHG, 2018. [9] Nishikawa, Med mol morph, 2021. [10] Nishikawa, Cell sig, 2019.

Grants: JP19H03629; JP19K07059; JP20K22888; JP21K15895; 15ek0109040h0002; NHGRI/NHLBI U1HG006542; NHGRI U01HG011758.

Conflict of Interest: Marcello Scala: None declared, Masashi Nishikawa Japan Society for the Promotion of Science (JSPS) KAKENHI Grant-in-Aid for Scientific Research (B) (Grant Number JP19H03629), Grant-in-Aid for Scientific Research (C) (Grant Number JP19K07059), Grant-in-Aid for Research Activity Start-up (Grant Number JP20K22888), Grant-in-Aid for Early-Career Scientists (Grant Number JP21K15895), a grant-in-aid of the Practical Research Project for Rare/Intractable Diseases from Japan Agency for Medical Research and Development (AMED) (15ek0109040h0002), Hidenori Ito Japan Society for the Promotion of Science (JSPS) KAKENHI Grant-in-Aid for Scientific Research (B) (Grant Number JP19H03629), Grant-in-Aid for Scientific Research (C) (Grant Number JP19K07059), Grant-in-Aid for Research Activity Start-up (Grant Number JP20K22888), Grant-in-Aid for Early-Career Scientists (Grant Number JP21K15895), a grant-in-aid of the Practical Research Project for Rare/Intractable Diseases from Japan Agency for Medical Research and Development (AMED) (15ek0109040h0002), Hidenori Ito Japan Society for the Promotion of Science (JSPS) KAKENHI Grant-in-Aid for Scientific Research (B) (Grant Number JP19H03629).

Grants: JP19H03629; JP19K07059; JP20K22888; JP21K15895; 15ek0109040h0002; NHGRI/NHLBI U1HG006542; NHGRI U01HG011758.
Abstracts from the 55th European Society of Human Genetics Conference

Guerin: None declared, Wendy Wu: None declared, Elisabeth Gabau Vila: None declared, Bryan C. Mak: None declared, Julian A. Martinez-Agosto: None declared, Michael B. Gorin: None declared, Bugraham Duz: None declared, Yavuz Bayram: None declared, Claudia M. B. Carvalho Fonseca United States National Institutes of Health (NHGRI/NHLBI UM1HG006542; NHGRI U10HG011758), Jaime Vengoechea: None declared, David Chitayat: None declared, Tiong Yang Tan: None declared, Bert Callewaert: None declared, Bernd Kruse: None declared, Lynne M. Bird: None declared, Laurence Faire: None declared, Marcella Zollino: None declared, Saskia Biskup: None declared, Undiagnosed Disease Network: None declared, Telethon Undiagnosed Diseases Program: None declared, Pasquale Striano: None declared, Vincentino Negro: None declared, Maria Savina Severino: None declared, Valeria Capra: None declared, Gregory Costain: None declared, Kohichi Nagata Japan Society for the Promotion of Science (JSPS) KAKENHI Grant-in-Aid for Scientific Research (B) (Grant Number JP19H03629), Grant-in-Aid for Scientific Research (C) (Grant Number JP19K07059), Grant-in-Aid for Research Activity Start-up (Grant Number JP20K22888), Grant-in-Aid for Early-Career Scientists (Grant Number JP21K15895), a grant-in-aid of the Practical Research Project for Rare/Intractable Diseases from Japan Agency for Medical Research and Development (AMED) (15ek0109040h0002).

P10.022.A Elucidating the role of RLS-associated MEIS transcription factors during neural development

Volker Kitke1,2, Elena Dvoretckova2, Chen Zhao1, Nazanin Mirza-Schreiber1, Daniel Lam1,4, Barbara Schormair1,2, Konrad Oexle1, Christian Mayer2, Juliane Winkelmann1,2

1Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Institute of Neurogenomics, München, Germany; 2Technical University of Munich, School of Medicine, Institute of Human Genetics, Munich, Germany; 4Max Planck Institute for Biophysical Intelligence, Planegg, Germany; 5Boehringer Ingelheim Pharma GmbH & Co. KG, Global Computational Biology & Digital Sciences, Biberach an der Riß, Germany.

Background/Objectives: The strongest risk variant associated with restless legs syndrome (RLS) is located within the gene encoding the TALE homeobox transcription factor MEIS1. Both MEIS1 and its close homolog MEIS2 also located in a RLS risk locus, are expressed in various neuronal cell types throughout the developing and adult central nervous system. The functional role of MEIS in RLS pathogenesis, as well as the cell types involved, still remain elusive.

Methods: Using lentiviral vectors, we manipulated MEIS1 and MEIS2 expression in human neuronal stem cells in vitro and measured global changes in gene expression and DNA methylation. Furthermore, we performed single-cell RNA-sequencing in MEIS-deficient developmental mouse models and quantified the effects on gene expression in different neuronal subtypes. Direct target genes of MEIS transcription factors were identified by chromatin immunoprecipitation.

Results: We identified MEIS target genes active in early development in mouse models and human NSCs. In the mouse brain, preliminary results suggest MEIS transcription factors control the differentiation of striatal projection neurons. MEIS targets in hNSC were enriched for regulators of Wnt signalling and axon development.

Conclusion: We linked the genetic risk factors MEIS1 and MEIS2 to specific neuronal cell types and brain regions during development. This brings us one step closer to understanding the complex pathophysiology underlying RLS.

References:

P10.023.B De novo variants in ATP2B1 lead to neurodevelopmental delay

Meer Jacob Rahimi1, Nicole Urban2, Meret Wegler3, Heinrich Sticht3, Michael Schaefer2, Bernt Popp1, Frank Gauntz2, Manuela Moro1,6, Vincenzo Vincenzo Negro4, Maitz Silvia5, Grazia Mancini8, Claudia Ruivenkamp3, Eun-Kyung Suk10, Tobias Bartolomaeus5,12, Andreas Merkenschlager12, Daniel Koboldt13, Dennis Bartholomew14, Alexander Stegmann15, Margje Sippeling15, Irma Duyunseld15, Ramona Salvianova17, Simone Race17, Bert B.A. de Vries18, Aurélien Trimouille19, Sophie Naudon20, Daphne Marom21, Uri Hamiel21, Noa Henig21, Florence Demurger22, Nils Rhänner23, Enrika Bartels23, J. Austin Hamm23, Abbey M. Putnam23, Richard Person23, Rami Abou Jamra1, Henry Oppermann1

1Institute of Human Genetics, University of Leipzig Hospitals and Clinics, Leipzig, Germany; 2Rudolf-Boehm-Institute of Pharmacology and Toxicology, University of Leipzig Hospitals and Clinics, Leipzig, Germany; 3Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; 4Department of Neurosurgery, University of Leipzig Hospitals and Clinics, Leipzig, Germany; 5Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy; 6Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy; 7Clinical Pediatric Genetic Unit, Pediatric Clinic, Fondazione MBBM, San Gerardo Hospital, Monza, Italy; 8Erasmus MC University Medical Center, Department of Clinical Genetics, Rotterdam, Netherlands; 9Leiden University Medical Center, Clinical Genetics, Leiden, Netherlands; 10Praxis für Humangenetik-Friedrichstrasse, Berlin, Germany; 11CeGaT GmbH and Praxis für Humangenetik, Tübingen, Germany; 12Department of Neuropediatrics, University of Leipzig Hospitals and Clinics, Leipzig, Germany; 13Institute for Genomic Medicine at Nationwide Children’s Hospital, Columbus, United States; 14Division of Genetics and Genomic Medicine at Nationwide Children’s Hospital, Columbus, United States; 15Department of Clinical Genetics, Maastricht University Medical Center+ (MUMC+), Maastricht, Netherlands; 16Severinus Institute for Intellectual Disability, Veldhoven, Netherlands; 17Division of Biochemical Genetics, Department of Pediatrics, University of British Columbia, BC Children’s Hospital, Vancouver, Canada; 18Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud university medical center, Nijmegen, Netherlands; 19Service de Pathologie Centre Hospitalier Universitaire de Bordeaux, Bordeaux 33000, France; 20MRGM, Maladies Rares: Génétique et Métabolisme, INSERM U1211, Université de Bordeaux, Bordeaux, France; 21The Genetics Institute, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 22service de génétique, CHBA, Vannes, France; 23Institute for Clinical Genetics Bonn, Bonn, France; 24Pediatric Genetics, East Tennessee Children’s Hospital, Knoxville, United States; 25Clinical Genomics Program, GeneDx, Inc., Gaithersburg, United States.

Background/Objectives: We describe a cohort of 12 unrelated individuals with probable causative variants in ATP2B1 ascertained through international matchmaking efforts. All probands share the phenotype of mild to moderate global developmental delay and other common, but non-significant clinical features like autism (5/11), seizures (6/12), and distal limb abnormalities (4/12), such as clinodactyly and arachnodactyly. Nine probands had missense variants of which seven were in specific functional domains; the other

Grants: This work was supported by grants from the ERA-NET NEURON network (No. 01EW1605) and the German Research Foundation (No. 390857198).

Conflict of Interest: None declared.

P10.023.B De novo variants in ATP2B1 lead to neurodevelopmental delay

European Journal of Human Genetics (2023) 31:345 – 709

SPRINGER NATURE
three individuals carry nonsense variants. Nine variants in ATP2B1 were proven de novo, while the parents of the remaining three individuals were unavailable for segregation. ATP2B1 encodes a plasma membrane calcium-transporting protein, which plays a central role in calcium homeostasis and is mainly expressed in the central nervous system.

**Methods**: All missense variants were structurally analysed via 3D protein modelling. We introduced all nine missense variants in transfected HEK293 cells and investigated intracellular localization. Afterwards we performed Ca2+ imaging to investigate Ca2+ export capacity of the transfected cells.

**Results**: 3D structural protein modeling suggested that the variants have a destabilizing effect on the protein. All variants lead to a significant decrease in Ca2+-export capacity compared with the wild-type construct. These nine variants also exhibited incorrect intracellular localization of ATP2B1, which suggests a loss of function mechanism.

**Conclusion**: The genetic and phenotypic similarities among probands as well as the functional analyses imply that de novo variants in ATP2B1 cause a novel monogenic neurodevelopmental disorder.

**References**: None.

**Grants**: None.

**Conflict of Interest**: Meer Jacob Rahimi: None declared, Nicole Urban: None declared, Meret Wegler: None declared, Heinrich Sticht: None declared, Michael Schaefer: None declared, Bernt Popp: None declared, Frank Gaunitz: None declared, Manuela Morleo: None declared, Vincenzo Vincenzo Nigro: None declared, Malitz Silvia: None declared, Grazia Mancini: None declared, Claudia Ruivenkamp: None declared, Eun-Kyung Suk: None declared, Tobias Bartolomaeus: None declared, Andreas Merkenschläger: None declared, Daniel Koboldt: None declared, Dennis Bartholomew: None declared, Alexander Stegmann: None declared, Margje Sinnema: None declared, Irma Duynisveld: None declared, Ramona Salvinarova: None declared, Simone Race: None declared, Bert BA de Vries: None declared, Aurélien Trimouille: None declared, Sophie Naudion: None declared, Daphna Marom: None declared, Uri Hamiel: None declared, Noa Henig: None declared, Florence Demurger: None declared, Nils Rahner: None declared, Enrika Bartels: None declared, J. Austin Hamm: None declared, Abbey M. Putnam: None declared, Richard Person RP is an employee of GeneDX, Inc., Rami Abou Jamra: None declared, Henry Oppermann: None declared.

**P10.024.C GABBR1 monoallelic de novo variants linked to neurodevelopmental delay and epilepsy**

Lucia Cediel1, Michal Stawarski2, Xavier Blanc3, Lenka Nosková3, Martin Magner4,5,6, Konrad Platzer7, Janina Gburek-Augustat5, Dustin Baldridge5,6,7, John Constantino9, Emmanuelle Ranza10, Bernhard Bettler11, Stylianos Antonarakis12

1Medigenome, Swiss Institute of Genomic Medicine, Geneva, Switzerland; 2Pharmazentrum, University of Basel, Department of Biomedicine, Basel, Switzerland; 3Charles University and General University Hospital in Prague, Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Prague, Czech Republic; 4Charles University and University Thomayer Hospital in Prague, Czech Republic, Department of Paediatrics, Prague, Czech Republic; 5University of Leipzig Medical Center, Institute of Human Genetics, Leipzig, Germany; 6Washington University in St. Louis, St. Louis, United States.

**Background/Objectives**: GABAB receptors are obligatory heterodimers providing prolonged inhibition in the central nervous system. The two receptor subunits are encoded by the GABBR1 and GABBR2 genes. Variants in the GABBR2 gene have been associated with a Rett-like phenotype (OMIM 617903), epileptic encephalopathy (OMIM 617904) and milder forms of developmental delay with absence epilepsy. To date, however, the phenotypes associated with pathogenic variants of the GABBR1 gene remain to be established.

**Methods**: Through GeneMatcher, we have ascertained 4 patients each with a monoallelic GABBR1 de novo non-synonymous variant; these cases presented with neurodevelopmental delay (motor and/or language delay) ranging from mild to profound severity, and in one case, epilepsy. Further phenotypic features include varying degrees of intellectual disability, learning difficulties, psychiatric disorders including autism, ADHD, ODD, sleep disorders and muscular hypotonia.

**Results**: We functionally characterized the four de novo GABBR1 variants, E368D, A397V, A535T and G673D in transfected HEK293 cells. All four variants analyzed lead to a deficit in GBR-mediated inhibition that likely leads to an increase in the excitation/inhibition balance in the central nervous system. Variant G673D in TM3 renders the receptor completely inactive, consistent with failure of the receptor to reach the cell surface. E368D is located near the orthosteric binding site and reduces potency and efficacy of GABA at the receptor. GABA exhibits normal potency and decreased efficacy at A397V and A535T.

**Conclusion**: Characterization of GABBR1-related variants provides a rationale for understanding disease phenotypes and points to possible therapeutic strategies.

**References**: None.

**Grants**: None.

**Conflict of Interest**: None declared.

**P10.025.D Development of methods and tools in NPCs and zebrafish towards modeling of DNA sequence variants in patients with pachygyria by using genome editing technologies**

Aykut Kuruoglu1, Ayse Semra Hiz2,3, Ozge Cark1, Pinar Gencpınar1,2, Ramazan Ugray Bora1, Gokhan Karakulah1,2, Gunes Ozhan1,2, Yavuz Oktay1,2

1Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir, Turkey; 2Izmir Biomedicine and Genome Center, Dokuz Eylul University Health Campus, Izmir, Turkey; 3Dokuz Eylul University, School of Medicine, Department of Paediatric Neurology, Izmir, Turkey; 4Izmir Katip Celebi University, Department of Pediatric Neurology, Izmir, Turkey; 5Dokuz Eylul University, School of Medicine, Department of Medical Biology, Izmir, Turkey.

**Background/Objectives**: The main bottleneck in identification of DNA variants that cause neurogenetic diseases is functional analysis of VUS. The aim of this study was to develop a methodology for modelling candidate causative variants observed in patients with pachygyria by using CRISPR/Cas9 genome editing in NPCs and zebrafish.

**Methods**: DNA from 20 patients with pachygyria/lissencephaly were analyzed by an aCGH and WES, and variants were prioritized. Mutant lines were generated in NPCs and Zebrafish by using CRISPR/Cas9 genome editing, and compared to models where one of three key genes (TUBG1, LIS1, DAB1) that are known to play role in pachygyria/lissencephaly. Characterization of NPCs were performed with a 3D matrigel chamber system (IC-Chip) and phenotypic changes were observed in developing zebrafish at 3 dpf and 5dpf. The comparison of target mutant lines and selected variant lines was made with qPCR.

**Results**: A delay in migration was observed in mutant NPC lines of 3 selected genes compared to control group. WES identified two candidate variants, CGREF1 and NOL9. Expression changes of lissencephaly and microcephaly-related and neuronal differentiation
genes in CGREF1-KO-zebrafish and CGREF1-KO-NPCs were observed. A severe phenotype including small-head and eyes, and abnormal liver/gut development was observed in Tubb1 mutant zebrafish.

**Conclusion:** Our results provide evidence that variants that cause defects associated with NPC migration can be tested using NPC and zebrafish models in a time- and cost-efficient manner. Multi-omic analysis could further expand the use of this approach to other groups of neurogenetic defects.

**References:**

**Grants:** This Project was supported by TUBITAK-COST Action with 2175944 code number.

**Conflict of Interest:** Aykut Kuruoglu: None declared, AYSE SEMRA HIZ: None declared, Ozge Cark: None declared, Pinar Gencpinar: None declared, Ramazan Ugur Bora: None declared, Gokhan Karakaluh: None declared, Gunes Ozhakan: None declared, Yavuz Oktay TUBITAK-COST 2175944.

**P10.026.A** Rare compound heterozygous missense variants in *CSMD3* are associated with developmental delay, intellectual disability, and structural brain anomalies

**Kaisa Teele Oja**1,2, Sander Pajusalu1,2, Anneke Kievit1, Marjon van Slegtenhorst1, Gina Ravenscroft2,5, Vildan Göknur Haliloglu6, Ginevra Group, Nedlands, Australia;5University of Western Australia, School of Medical Research, QEII Medical Centre, Neurogenetic Diseases

**Background/Objectives:** CSMD1 and CSMD3 are associated with developmental delay, intellectual disability, and structural brain anomalies. Recent studies have indicated that CSMD1 and their connection to neurodevelopment has been suggested. Studies have also shown that CSMD3 regulates dendritic branching and might regulate dendritic morphology. Recently another gene, CSMD3, expressed in adult and fetal brain tissue, has been associated with neurodegenerative and psychiatric disorders and might regulate dendritic morphology. Recently another gene, CSMD3, has been associated with neurodegenerative and psychiatric disorders.

**Methods:** We have collected clinical information about 4 patients with rare biallelic variants in *CSMD3* gene.

**Results:** Three male and one female patient were all Caucasian and they were aged between 6 and 23 years during last evaluation. Phenotypes were varying with the common feature of motor development delay (ranging from mild to severe). Most patients (3/4) had hyotonopia. Two patients had mild intellectual disability (ID), one had moderate to severe ID and in one case this information was not available. Cerebral MRI was done in 2 cases – one had type 2 lissencephaly and polymicrogyria, and the other had cerebellar agenesis and hypoplasia of corpus callosum. Microcephaly was present in both cases, but was either not documented or not present in the other two. Whole exome sequencing revealed different compound heterozygous rare missense variants in *CSMD3* in all cases.

**Conclusion:** In conclusion, *CSMD3* gene is likely associated with neurodevelopmental phenotype and might be connected to brain structural anomalies as well as ID. Further research is needed to confirm this finding.

**References:**

**Grants:** Estonian Research Council grants PRG471, MOP175, P5G774.

**Conflict of Interest:** None declared.

**P10.027.B** A WDR47 variant suggests a phenotypic relation with microcephaly in humans

**Zafer Yüksel**1, Saeed Al Tala2, Ira Schwaab1, Berit Kerner5

1Bioscientia Healthcare GmbH, Division of Human Genetics, Ingelheim, Germany; 2Armed Forces Hospital Southern Region, Pediatric Directorate and Genetic Unit, Khamis Mushait, Saudi Arabia.

**Background/Objectives:** Microcephaly is defined by a head circumference of more than three standard deviations (SD) below the mean for age and gender. Most of the causative genes for microcephaly-related phenotypes encode proteins that play crucial roles in cellular processes, such as cytokinesis, centromere and kinetochore function, transmembrane or intracellular transport, and autophagy. WDR47 belongs to a group of genes that participate in key microtubule-mediated processes, including neural stem cell proliferation, radial migration, and growth cone dynamics.

**Methods:** Whole exome sequencing (WES) was performed in a blood sample of a 12-month-old male who presented with microcephaly, persistent head lag, abnormality of ocular smooth pursuit, myoclonic seizure and hyperreflexia. His older sibling died at six years of age due to a similar neurodevelopmental disease.

**Results:** WES revealed a homozygous missense variant in WDR47 (OMIM: 615734) [NM_001142550.1: c.1973C>T p.(Pro658-S944 code number).

**Conflict of Interest:** Zafer Yüksel Bioscientia Healthcare GmbH, Saeed Al Tala: None declared, Ira Schwaab Bioscientia Healthcare GmbH, Berit Kerner Bioscientia Healthcare GmbH.

**P10.029.D** Heterozygous UCHL1 is a novel cause of autosomal dominant neurodegeneration with spasticity, ataxia, neuropathy, and optic atrophy

**Joohyun Park**1, Arianna Tucci2, Valentina Cipriani2,3,4, German Demidov1, Clarissa Rocca2, Jan Senderek6, Michaela Butryn7, Ana Velic2, Tanya Lam8, Evangelia Galanaki2, Elisa Calì9, Letizia Vestito2, Reza Maroofan10, Natalie Deininger11, Maren Rautenberg12, Jakob Admard13, Gesa-Astrid Hahn13, Claudia Bartsch14, Nienke van Os15, Rita Horvath16, Patrick Chinnery17,18, May Yung Tiet17,18, Channa Hewamadduma19,20, Mario Hadjivasiliou17, George K Tofaris18, Nicholas Wood5, Stefanie Nicole Hayer20,21, Friedemann Bender20,21
Background/Objectives: Hereditary ataxias and hereditary spastic paraplegias are rare neurodegenerative disorders that often show overlapping clinical features as well as shared genetic basis. Bi-allelic variants in UCHL1 (Ubiquitin C-terminal hydrolase L1) have been associated with a progressive early-onset neurodegenerative disorder, autosomal recessive spastic paraplegia type 79. Our objective was to investigate candidate variants/genes in extended exome and genome datasets within national and international networks using cohort-based burden analyses.

Methods: Gene burden analyses were performed on exome and genome data in independent cohorts of hereditary ataxia and spastic paraplegia patients from Germany and the UK on a total of 3,169 patients and 33,141 controls. Detailed clinical information including in-depth neurological assessments on affected patients were subsequently collected, and additional independent families were ascertained through national and international collaborators. Mass-spectrometry-based proteomics was conducted on patients’ fibroblasts.

Results: Gene burden analysis prioritized UCHL1 in both independent cohorts from Germany and UK as a candidate gene for an autosomal dominant disorder. In total, we identified 33 cases from 17 unrelated families, carrying 12 heterozygous predicted loss-of-function variants (in 14 families) and an indel insertion (in 3 families). Affected individuals mainly presented with spasticity (23/30), ataxia (27/30), neuropathy (11/20) and optic atrophy (10/17). The mass-spectrometry-based proteomics data showed an approximately 50% reduction of UCHL1 expression in patients’ fibroblasts indicating haploinsufficiency as the likely pathological mechanism.

Conclusion: Our bioinformatic analysis, in-depth clinical and genetic work-up and functional studies establish haploinsufficiency of UCHL1 as a novel disease mechanism in spastic ataxia.

References:

Grants:

Conflict of Interest: Joohyun Park: None declared, Arianna Tucci MRC Clinician Scientist investigator (MR/S006753/1), Member of The Genomics England Research Consortium, Valentina Cipriani: None declared, German Demidov: None declared, Clarissa Rocca: None declared, Jan Senderek: None declared, Michaela Butryn: None declared, Ana Velic: None declared, Tanya Lam: None declared, Evangelia Galanaki: None declared, Elisa Cali: None declared, Letizia Vestito: None declared, Reza Maroofian: None declared, Natalie Deininger: None declared, Maren Rautenberg: None declared, Jakob Adnard: None declared, Gesa-Astrid Hahn: None declared, Claudius Bartels: None declared, Nienke van Os: None declared, Rita Horvath RH: a Wellcome Trust Investigator (109915/Z/15/2), who receives support from the Medical Research Council (UK) (MR/N025431/1 and MR/V009346/1), the European Research Council (309548), the Newton Fund (UK/Turkey, MR/ N027302/1), the Addenbrookes Charitable Trust (G100142), the Evelyn Trust, the Stoneygate Trust, the Lily Foundation and an MRC strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD) MR/ S005021/1. This research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care, Patrick Chinnery PFC is a Wellcome Trust Principal Research Fellow (212219/Z/18/Z), and a UK NIHR Senior Investigator, who receives support from the Medical Research Council Mitochondrial Biology Unit (MC_UU_00015/9), the Medical Research Council (MRC) International Centre for Genomic Medicine in Neuromuscular Disease (MR/S005021/1), the Leverhulme Trust (RPG-2018-408), an MRC research grant (MR/S035699/1), an Alzheimer’s Society Project Grant (AS-PG-18b-022). This research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care., May Yung Tiet: None declared, Channa Hewamadduma: None declared, Marios Hadjivassiliou: None declared, George K Tofaris MRC Senior Clinical Fellowship (MR/V007068/1), Nicholas Wood: None declared, Stefanie Nicole Hayler: None declared, Friedemann Bender: None declared, Benita Menden: None declared, Isabell Cordts: None declared, Joachim K. Krauss: None declared, Christian Blahak: None declared, Tim Strom: None declared, Marc Sturm: None declared, Bart Van De Warrenburg This project was sup-ported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) No 441040927, as part of the PROSPAX consortium under the frame of EJP RD, the European Joint Pro-gramme on Rare Diseases, under the EJP RD Cofund-EJP N° 825575 and by grant 779257 “Solve-RD” from the Horizon 2020
P10.030.A Link of disorders in the schizo-affective spectrum and comorbidity with neurobiological correlates

Lisa Sindermann¹, Udo Dannlowski², Susanne Meiners², Elisabeth Johann Lehle², Lena Weltemate², Hannah Lemke², Alexandra Winter³, Katharina Thiel³, Katharina Brosch³, Tina Meller³, Frederike Stein³, Per Hoffmann⁴, Axel Krug⁵, Til Kircher⁵, Till Andlauer⁶, Eva Beins¹, Markus M Nöthen¹, Andreas Forstner¹,²,⁶

¹Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany; ²Institute for Translational Psychiatry, Westphalian Wilhelms-University Münster, Münster, Germany; ³Department of Psychiatry and Psychotherapy, Philipps-University and University Hospital Marburg, Marburg, Germany; ⁴Human Genomics Research Group, Department of Biomedicine, University of Basel, Basel, Switzerland; ⁵Department of Neurology, School of Medicine, Technical University of Munich, Munich, Germany; ⁶Institute of Neuroscience and Medicine (INM-1), Research Center Jülich, Jülich, Germany.

Background/Objectives: Disorders of the schizoaffective spectrum may differ in their genetic architecture and brain phenotypes. The specific genetic architecture of these disorders has not been well characterized.

Methods: We focused on a subsample from the FOR2107 study comprising n = 470 patients with a single disorder in the schizoaffective spectrum (SD), n = 310 patients with additionally one or more comorbidities (COM), and n = 649 healthy controls (HC). We investigated group differences regarding a) the global severity index, b) a cross-disorder polygenic risk score (PRS) calculated with PRS-CS, using summary statistics of a large GWAS across mental disorders (Lee et al., 2019), and c) neurostructural alterations in gray matter using a whole-brain approach. An explorative subanalysis investigating only medication-free individuals (n = 246 patients) was also performed.

Results: The global severity index significantly differed between groups (COM > SD > HC). SD and COM patients displayed increased cross-disorder PRS compared to HC. However, they were not different from each other. Patients displayed decreased volume in the insula and the middle temporal gyrus compared to HC. These neurostructural associations did not withstand correction for multiple testing in the medication-free individuals.

Conclusion: Our analyses identified phenotypic and genetic differences between SD and COM compared to HC. They did not provide strong evidence that SD and COM patients differed significantly from each other at the genetic and brain structural levels. Future studies are needed to further assess the neurobiological correlates of comorbidity.

References: Lee et al., 2019, PMID:31835028.

Grants: DFG, grant FOR2107.

Conflict of Interest: Lisa Sindermann: None declared, Udo Dannlowski: None declared, Susanne Meiners: None declared, Elisabeth Johann Lehle: None declared, Lena Weltemate: None declared, Hannah Lemke: None declared, Alexandra Winter: None declared, Katharina Thiel: None declared, Katharina Brosch: None declared, Tina Meller: None declared, Frederike Stein: None declared, Per Hoffmann: None declared, Axel Krug: None declared, Til Kircher Dr. Kircher received unrestricted educational grants from Servier, Janssen, Recordati, Aristo, Otsuka, neuraxpharm. This funding is not associated with the current work., Till Andlauer: None declared, Eva Beins: None declared, Markus M Nöthen: None declared, Andreas Forstner: None declared.

P10.031.B The usefulness of array CGH for identification copy number variants in children with autism spectrum disorders

Agata Kucińska¹, Wanda Hawula¹, Lena Rutkowska¹, Agnieszka Gach¹

¹Polish Mother's Memorial Hospital - Research Institute, Department of Genetics, Lodz, Poland.

Background/Objectives: Autism spectrum disorder (ASD) is one of the most common neurodevelopmental disorders characterized by impairment in social interaction, communication and stereotypic behavior. Copy number variants (CNVs) are clinically relevant in the pathogenesis of ASD and occur in approximately 7-9% of cases. We aimed to demonstrate the clinical utility of dedicated array Comparative Genome Hybridization (aCGH) in isolated and complex ASD.

Methods: Array CGH was performed using 4x180k CytoSure Autism Research Array (OGT; UK). DNA was extracted from peripheral blood. The tested group comprised 155 pediatric patients divided in two cohorts: 93 patients with ASD and 62 patients with ASD and additional clinical features including dysmorphia, intellectual disability, epilepsy and psychomotor retardation.

Results: The strategy allowed for the identification of 38 rare exonic chromosomal imbalances classified as pathogenic or likely pathogenic in 13 of 155 patients (8.4%) and variants of uncertain significance (VUS) in 22 of 155 patients (14.2%). The range of CNVs size varies between 284 b and 4.04 Mb. In the group of isolated ASD 11 variants were classified as VUS and one as likely pathogenic. Among patients with complex ASD nine harbored pathogenic variants, three likely pathogenic and 10 VUS imbalances.

Conclusion: Overall, we have evaluated the usefulness of dedicated aCGH in the detection of clinically relevant CNVs in a cohort of 155 patients with ASD. Our results support the relevance of performing chromosomal microarray analysis especially in the case of complex ASD.
**P10.032.C A case with 9q33.3 microdeletion pointing to the existence of a new syndrome unrelated to STXBP1 gene deletion**

**Davit Babikyan**

1Center Of Medical Genetics And Primary Health Care, Yerevan, Armenia; 2Yerevan State Medical University, Yerevan, Armenia.

**Background/Objectives:** Several microdeletions of the 9q33.3-q34.11 chromosomal region have been reported with a range of clinical phenotypes mostly restricted on patients with seizures and STXBP1 gene point mutations or deletions. New cases showed a variable and incomplete penetrance of clinical features, including seizures in patients with or without STXBP1 gene deletion. Here we report a female patient with microcephaly, hypogenesis of corpus callosum, severe psychomotor development delay, absence of speech, but with no episode of seizures.

**Methods:** WES analysis was performed on DNA samples from the patient and her parents using the AgilentV6 WES and NEB DNA library preparation kits followed with data analysis using SophiaDDM platform.

**Results:** A 493 kb microdeletion was identified in the chr9q33.3 region (chr9: 126,914,782-127,407,898) encompassing 3 OMIM genes - RALGPS1, GARNL3 and SLC2A8 related to the region identified in patients with 9q33.3-q34.11 microdeletions. The clinical presentation of the patient was similar to the ones of previously reported cases with several common features including intellectual disability, psychomotor developmental delay with delayed or absent speech. The parents were not carriers of the microdeletion.

**Conclusion:** In addition to the previously reported cases, the microdeletion identified in our patient is one of the smallest and encompasses the minimal critical region with two genes RALGPS1 and GARNL3. This re-confirms that the minimal causative region responsible for the clinical spectrum with no seizures in patients with 9q33.3 microdeletion does not encompass STXBP1 and instead includes two other genes, and which could be considered as a new 9q33.3 microdeletion syndrome.

**References:**

1. None declared.

**P10.033.D DNA methylation analysis in precision medicine: Accurate biomarker and predictor of onset. The example of KMT2B-associated dystonia**

**Nazanin Mirza-Schreiber**, Michael Zech, Barbara Schormair, Juliane Winkelmann, Konrad Oexle

1Helmholtz Zentrum München, Institute of Neurogenomics, München, Germany; 2Technical University of Munich, School of Medicine, Institute of Human Genetics, München, Germany; 3Munich Cluster for Systems Neurology (SyNergy!), München, Germany.

**Background/Objectives:** Alterations of DNA methylation relate to disease-associated changes in cellular organization states. These alterations therefore allow for deriving disease-specific biomarkers. Here we report a blood biomarker for histone lysine methyltransferase (KMT2B)-deficient dystonia. Dystonia is a prevalent, heterogeneous movement disorder, and KMT2B-deficiency is a leading monogenic subtype.

**Methods:** The biomarker was derived by training a support vector machine classifier on an episignature of 113 DNA CpG sites showing significant epigenome-wide association with KMT2B deficiency.

To refine our classifier and to increase sensitivity we stepwise re-trained the classifier with previously classified VUS samples. With this approach we aim to capture KMT2B mutations with moderate epigenetic effects but still causing dystonia.

**Results:** All CpG sites of the episignature showed increased methylation levels in cases. The mean of their normalized methylation levels correlated well with the age at onset of dystonia (p = 0.003) – being lower in patients with late or incomplete penetrance – thus serving as a predictor of disease onset and severity. The SVM classifier was accurate both when tested on the general population and on samples with various other deficiencies of the epigenetic machinery. It was able to successfully evaluate variants of uncertain significance (VUS) from multiple batches.

**Conclusion:** Our data show that episignatures do not only function in diagnostics but may also provide predictors of disease course and, potentially, markers of therapeutic success. KMT2B-deficient patients are known to profit exceptionally well from deep brain stimulation. The episignature-based biomarker will serve to identify them with high accuracy.

**References:**

1. None declared.
understanding of the neurobiology of complex psychiatric disease.

References:

Grants:

Conflict of Interest: None declared.

P10.035.B The diagnostic yield of NGS-based gene panels in epilepsy

Laura Frey1, Anna Munzig-Schmidt1, Karin Mayer1, Sabine Lippert1, Oliver Wachter1, Sebastian Eck1, Julia Philippou-Massier1, Konstanze Hörtrogel1, Hanns-Georg Klein1, Imma Rost1

1MVZ Martinsried - Medcover, Martinsried, Germany.

Background/Objectives: We report the yield of NGS panels applied for routine diagnostics in suspected monogenic epilepsy syndromes during the years 2019-2021.

Methods: We analyzed 181 (23 adult and 158 pediatric) patients with epilepsy of unknown etiology who underwent diagnostic testing using targeted gene panels (range 3-143 genes). The pathogenicity of variants was assessed according to ACMG criteria. Diagnostic yield was determined for all individuals according to age at genetic diagnosis.

Results: Panel analysis identified pathogenic or likely pathogenic variants in 36 of 181 patients, resulting in an overall diagnostic yield of 19.9 %. The yield depended on the age of the patient at diagnosis as well as the epilepsy syndrome. The yield was highest among infants aged 6-12 months (72.7 %, 8/11) and toddlers aged 12-24 months (60 %, 9/15). Accordingly, benign familial infantile epilepsy (BFIE) exhibited the highest diagnostic yield among epilepsy syndromes (69.2 %, 9/13), followed by Dravet syndrome (50 %, 4/8). 17 different genes harbored pathogenic or likely pathogenic variants with PRRT2 (8 patients), PCDH19 (6 patients) and SCN1A (4 patients) being most frequently affected. Missense variants were the most common type contributing to diagnosis (44 %, 16/36). Frameshift variants, nonsense variants and CNVs accounted for 31 % (11/36), 14 % (5/36) and 11 % (4/36) of cases, respectively.

Conclusion: In our diagnostic setting NGS epilepsy gene panels have an overall diagnostic yield of approximately 20 %. We observed the highest probability of genetic diagnosis in infants whereas the detection rate decreased with increasing age at the time of genetic diagnosis.

References:

Grants:

Conflict of Interest: None declared.

P10.036.C Deciphering new genetic components of psychiatric disorders through multivariate association studies

Antoine Auvergne1, Traut Nicolas1, Hanna Julienne1, Lucie Troubat2, Toro Roberto1, Hugues Aschard2

1Institut Pasteur, Department of Computational Biology, Paris, France.

Background/Objectives: The study of imaging-derived phenotypes and their associated genetic and environmental factors has become central to mental disorder research. However, the dimensionality and high correlation of imaging phenotypes causes severe computational and analytical challenges. Here, we applied novel methods we recently developed to investigate shared genetic components between neuroanatomical phenotypes and psychiatric disorders.

Methods: We first performed multivariate genome-wide association study (GWAS) of brain volume phenotypes in 26,000 individuals from the UKBIOBANK and ENIGMA cohorts using JASS, a robust and computationally efficient multivariate analysis pipeline. We next conducted an unsupervised clustering of top univariate and multivariate association signals to identify clusters of variants displaying similar multivariate association patterns. Genetic variants from each cluster were then assessed for association with psychiatric disorders.

Results: Our multivariate analysis detected substantially more associated variants than univariate brain volume GWAS, with over 80% increase in power. Among top variants, we identified multiple clusters with marked enrichment for association with specific psychiatric diseases. In particular, a cluster of highly pleiotropic variants associated with all brain volumes considered was associated with bipolarity (P = 1.8e-7). Another cluster, capturing shared genetics between putamen, pallidum and caudate volume, showed strong association with schizophrenia (P = 1.5e-17), supporting the role of genetics in the previously reported association between basal ganglia and schizophrenia.

Conclusion: Our analyses demonstrate that data-driven multivariate analysis of imaging-derived phenotypes can help decipher the genetic components of psychiatric disorders.

References:

Grants:

Conflict of Interest: None declared.

P10.037.D Phenotypic spectrum overview of patients with neurodevelopmental disorders sharing one recurrent copy number variant (CNV) and carrying different additional CNVs

Martina Servetti1, Livia Pisciotta1,2, Elisa Tassano3, Maria Cermi-nara1,4, Marco Fontana4, Chiara Bagliani1, Lino Nobili2,3, Silvia Boeri1,3, Giulia Rosi1,4, Margherita Lerone1, Maria Teresa Divizia4, Federico Zara1,4, Patrizia Ronchetta1, Aldamaria Puli1,4

1University of Genoa, Dept. of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), Genova, Italy. 2ASST Fatebenefratelli Sacco, Child Neuropsychiatry Unit, Milano, Italy. 3IRCCS Istituto Giannina Gaslini, Human Genetics Laboratory, Genova, Italy. 4IRCCS Istituto Giannina Gaslini, Medical Genetics Unit, Genova, Italy. 5IRCCS Istituto Giannina Gaslini, Child Neuropsychiatry Unit, Genova, Italy.

Background/Objectives: Patients with neurodevelopmental disorders (NDDs) may have different clinical presentation even within the same diagnostic category. We aimed to characterize the phenotype of patients sharing one recurrent CNV and carrying additional different CNVs. To evaluate possible synergistic effects among multiple CNVs and their fall-out on patient’s phenotype.

Methods: We re-evaluated array-CGH results from 518 patients with NDDs with non-benign CNVs classified as pathogenic, likely pathogenic and variants of uncertain significance (1). Pathogenic variants included syndromic/recurrent CNVs (according to Decipher and SFARI databases), CNVs > 3 Mb and those < 3 Mb and encompassing known NDD-associated genes. Protein-protein interaction and gene enrichment analyses were used to show potential interplay among CNV-encumbered genes.

Results: We found that among patients with pathogenic variants (131), 8% (11) have one additional, inherited or de novo CNV. These double hits could explain the complex phenotypic spectrum of the patients. Among major results, three patients sharing a syndromic 15q13.3 deletion associated with additional different CNVs, and patients sharing one small CNV involving a known NDD
gene, in addition to different CNVs involving other NDD-associated genes with potential synergistic effects.

**Conclusion:** It is worth to further investigate patients with pathogenic CNVs and analyse modifier effects of multiple CNVs on patient’s phenotype. A better understanding and classification of these patients can be useful for disease prognosis, management of the patients, keeping with the developing idea of precision medicine.

**References:** 1. Servetti et al, Front. Genet. 2021.

**Grants:**

**Conflict of Interest:** None declared.

**P10.038.A Modelling the combined effects of rare and common genetic variants, with opposite effects on cognition, on autism spectrum disorder risk**

**Zoe Schmilovich**1,2, Elise Douard2,4, Guillaume Huguet2,4, Patrick Dion2,3, Sebastien Jacquetmon15, Guy Rouleau1,5

1McGill University, Human Genetics, Montreal, Canada; 2Montreal Neurological Institute, Montreal, Canada; 3Université de Montreal, Montreal, Canada; 4CHU Sainte-Justine, Montreal, Canada; 5McGill University, Neurology and Neurosurgery, Montreal, Canada.

**Background/Objectives:** Common and rare variants contribute to autism spectrum disorder (ASD) [1]. Rare de novo and inherited CNVs that substantially increase ASD-risk also have negative effects on cognition [2,3,4]. Conversely, there is a positive genetic correlation between ASD and cognition, such that common variants which increase ASD-risk also increase intelligence (IQ) in the general population [5].

**Methods:** Deletion and duplication CNVs, annotated by a constraint score (LOEUF), and PRS for intelligence (PRSIQ) were identified in 6,929 ASD cases and 32,663 unaffected individuals. The sum of LOEUF represented the individual-level burden of deleterious rare variants. A sliding window modelled the risk for ASD across LOEUF and PRSIQ categories. The cumulative risk for ASD across both LOEUF and PRSIQ categories was modelled using a double-sliding window approach.

**Results:** Intolerant (LOEUF<0.35) and tolerant (0.35cLOEUF<1) genes disrupted by gene dosage significantly increased ASD-risk, even after adjusting for their effects on cognition. High and low PRSIQ increased and decreased ASD-risk, respectively, and this effect was heightened after adjusting for cognition. A combination of highly intolerant genes (LOEUF < 0.2) and a high PRSIQ (>1 standard deviations from the control population mean) was associated with the highest risk for ASD for deletions (OR = 13.81;p = 2e-02) and duplications (OR = 1.81;p = 2e-02).

**Conclusion:** Our results suggest that a combination of genetic variants that both increase and decrease cognitive capacity may be key elements to ASD-risk.

**References:** 1-Weiner (2017); 2-Satterstrom (2020); 3-Huguet (2018); 4-Douard (2020); 5-Grove (2019).

**Grants:** Transforming Autism Care Consortium (Fonds de Recherche Québec - Santé).

**Conflict of Interest:** None declared.

**P10.040.C Generation and characterisation of induced pluripotent stem cell-derived microglia to study the influence of genetic risk for depression on microglial functions**

**Eva Beins**1, Ronja Hollstein1, Kerstin Ludwig1, Per Hoffmann1, Markus M Nöthen1, Andreas Forstner1,2

1Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany; 2Institute of Neuroscience and Medicine (INM-1), Research Centre Jülich, Jülich, Germany.

**Background/Objectives:** Microglia, the resident immune cells of the brain, have been implicated in the pathology of psychiatric disorders, including depression. These findings are mostly based on animal models, while results from humans are limited. Recent advances in induced pluripotent stem cell (iPSC) research provide new possibilities to study human microglia. Here, we established the differentiation of iPSC into microglia (iMG) to study the influence of genetic risk for depression on microglial function.

**Methods:** In pilot experiments, sequential differentiation of iPSC into primitive macrophage precursors (PMP) and iMG was established following published protocols.1 The progression of differentiation was monitored at several stages using flow cytometry, immunocytochemistry and transcriptomics (3’mRNA-Seq). Furthermore, iMG were stimulated with lipopolysaccharide (LPS) and/or dexamethasone to study inflammatory and glucocorticoid (“stress”) signalling. Prospectively, we plan to analyse iMG of depressed patients and healthy controls, selected based on

**P10.039.B GRIN2A null variants confer a high risk for early-onset mental disorders and potentially enable precision medicine approaches**

**Johannes Lemke**1, Ilona Krey1, Bernt Popp1, Vincent Strehlow1, Dirk Wittekind2, Tim Benke3, Steffen Syrbe4

1Institute of Human Genetics, Leipzig, Germany; 2Department of Psychiatry and Psychotherapy, Leipzig, Germany; 3Departments of Pediatrics, Pharmacology, Neurology, and Otolaryngology, Denver, United States; 4Division of Pediatric Epileptology, Center for Pediatrics and Adolescent Medicine, Heidelberg, Germany.

**Background/Objectives:** Mental disorders are considered complex and highly polygenic and numerous loci have been associated with a small risk increments for mental disorders, each. One of these loci is 16p13.2 spanning GRIN2A, a gene encoding the GluN2A subunit of the NMDA receptor.

**Methods:** Therefore, we investigated the presence of psychiatric diagnoses within our registry of 236 individuals with GRIN2A-related disorders.

**Results:** Carriers of null variants were significantly more likely to develop mental disorders compared to carriers of missense variants. GRIN2A-related mental disorders comprised the whole spectrum of psychiatric diseases, but most prominently mood and anxiety disorders followed by psychotic disorders. Literally all GRIN2A-related mental disorders manifested in childhood or adolescence and thus had a significantly earlier onset compared to the general population. In some individuals, the mental disorder appeared to be the foremost clinical diagnosis.

**Conclusion:** Thus, we identified GRIN2A to be the first gene ever associated with a monogenic mental disorder, demonstrating that the genetic background of this disease spectrum is not necessarily as polygenic or complex as previously thought. Likewise, we uncovered a completely novel phenotypic facet of this genetic entity, changing our perception of isolated seemingly non-syndromic mental disorders in general. Moreover, we recently observed that treatment with NMDA receptor co-agonists appears to be beneficial in GRIN2A-related disorders due to null variants, even with respect to psychotic features. Thus, the NMDA receptor appears to be a promising target of precision medicine approaches to ameliorate mental disorders due to GRIN2A null variants and maybe even beyond.

**References:**

**Grants:**

**Conflict of Interest:** None declared.
P10.041.D Eating disorders: Age of onset and its associated genetic risk factors

Helena Davies1, Christopher Hübel1,2,3, Jonathan Kelly4, Agnes Aytoun5, Rachel Bryant-Waugh5, Molly Davies1,2, Jessica Mundy1, Janet Treasure7, Gerome Breen1,2

1King’s College London, Social, Genetic and Developmental Psychiatry Centre, London, United Kingdom; 2UK National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health, South London and Maudsley Hospital, London, United Kingdom; 3National Centre for Register-based Research, Aarhus Business and Social Sciences, Aarhus University, Aarhus, Aarhus, Denmark; 4Beat, Norwich, United Kingdom; 5Oxford Health NHS Foundation Trust, Oxford, United Kingdom; 6Maudsley Hospital, Maudsley Centre for Child and Adolescent Eating Disorders, London, United Kingdom; 7King’s College London, Psychological Medicine, London, United Kingdom.

Background/Objectives: Eating disorders have a heritability of 16-83% and a median age of onset of 18 years1. UK-based studies on age of onset of eating disorders and how this is influenced by genetics are lacking.

Methods: Participants self-reported eating disorder diagnoses, symptoms, and age of onset in either the Eating Disorders Genetics Initiative UK (EDGI UK) or the Genetic Links to Anxiety and Depression (GLAD) Study (n = 8,945). We associated polygenic scores calculated with PRS-CS with age of onset.

Results: Median age of onset was younger in females than males: binge eating (18 vs. 21 years), low weight (18 vs. 20 years), and purging (16 vs. 19 years). More males reported onset older than 25 years for binge eating (41.3% vs. 18.4%), purging (29.1% vs. 10.3%), and low weight (33.2% vs. 17.6%), and onset below 10 years for low weight (2.9% vs. 0.3%). Preliminary polygenic score analyses indicate that a one standard deviation increase in educational attainment polygenic score was associated with earlier age of onset across all phenotypes: purging by 0.41 years (p = 0.04), low weight by 0.51 years (p = 0.04), and binge eating by 0.52 years (p = 0.01).

Conclusion: Eating disorders primarily begin in the 16-25 age group. Genetics driving educational attainment may be associated with younger age of onset. Our results highlight the need for sufficient investment into adult clinical services, increased awareness efforts about eating disorders in adulthood, and early screening.

References:

Grants: Funded by NIHR BioResource and the NIHR Maudsley Biomedical Research Centre.

Conflict of Interest: None declared.

P10.042.A Population-level study of CNVs and their associated risk of psychiatric disorders in a Danish case-cohort

Seyedmorteza Vaez1,2, Simone Montalbano1,2, Xabier Calle Sanchez1,2, iPSYCH Collaborators2, Armin Raznahan3, Wesley Kurt Thompson2,4, Thomas Verge1,2,5, Dorthe Helenius Mikkelsen2, Andres Ingason1,2

1Institute of Biological Psychiatry, Mental Health Services Capital Region of Denmark, Roskilde, Denmark; 2The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Copenhagen and Arhus, Denmark; 3Section on Developmental Neurogenomics, Human Genetics Branch, National Institute of Mental Health Intramural Research Program, Bethesda, United States; 4Herbert Wertheim School of Public Health and Human Longevity, University of California, San Diego, United States; 5Lundbeck Foundation Center for GeoGenetics, GLOBE Institute, University of Copenhagen, Copenhagen, Denmark.

Background/Objectives: Recurrent copy number variants (CNVs) have been shown to increase the risk of neuropsychiatric disorders in clinical case-control studies. Yet, little is known about their patterned impact at the level of an individual or an entire population. We sought to estimate the true population prevalence of recurrent CNVs and their associated risk of psychiatric disorders.

Methods: We applied the iPYSCH2015 case-cohort (1), including all individuals born in Denmark in 1981-2008 and diagnosed with a major psychiatric disorder by 2015, and a random comparison sample from the same birth cohort. Samples were genotype and recurrent CNVs at 30 loci called with PennCNV (2) and verified by visual inspection. Population-representative hazard ratios (HR) were derived using a Cox proportional hazard model with inverse probability of sampling (IPS) weights (3).

Results: The population prevalence of several CNVs was higher than in the UK Biobank (4). Overall, the carrier rate in cases was higher than in the comparison sample with HR varying widely across disorders and CNVs.

Conclusion: The population-based iPYSCH study enables estimating of true prevalence and associated risk conferred by CNVs of ascertainment psychiatric disorders, thus paving the way for implementing genetic predictions into clinical practice.

References: 1. Byberg-Grauholm et al., 2020 (https://doi.org/10.1101/2020.11.30.20237768). 2. Wang et al., 2007 (https://doi.org/10.1101/gr.6861907). 3. Barlow et al., 1999 (https://doi.org/10.1089/08954356(99)00102-x). 4. Crawford et al., 2019 (https://doi.org/10.1136/jmedgenet-2018-105477).

Grants: This work was supported by grants from the Lundbeck Foundation (R165–2013–15320, R155–2014–1724, and R248–2017–2003), and the NIH (R01 MH124789-01).

Conflict of Interest: None declared.

P10.043.B Investigation of polygenic scores in patients with social anxiety disorder

Angelina Vogelsang1, Man Long Chung2, Lisa Sindermann1, Friederike David1, Christina Elling1, Laura-Eth Seib-Pfeifer2, Stefanie Heilmann-Heimbach1, Per Hoffmann1,2, Stefan Herms1, Börge Schmidt2, Katharina Domschke2, Vanessa Nieratschker2, Udo Dannowski2, Elisabeth Krebs-Pfeifer1

Conflict of Interest: None declared.
Background/Objectives: Social anxiety disorder (SAD) is a common anxiety disorder (AD). It has a heritability of around 10-50% and is highly comorbid with depressive symptoms and major depressive disorder (MDD). Large AD genome-wide association studies (GWAS) have been conducted, but sample sizes in genetic analyses of SAD have been limited. Therefore, the genetic basis of SAD and its subphenotypes is still largely unknown.

Methods: We computed polygenic risk scores (PRS) using PRSice-2 and summary statistics of depression (Howard et al., 2019) and MDD GWAS (Wray et al., 2018). PRS were calculated in a large cohort comprising 1304 patients with SAD from our Social Phobia Research project and external collaborators, and n = 4140 controls from the Heinz Nixdorf Recall study. The association between the PRS and case-control status as well as SAD subphenotypes (depressive, SAD-specific, anxiety symptoms) was investigated by using R.

Results: Preliminary analyses revealed a significant association between the PRS of depression and SAD case-control status. The depression PRS was also nominally associated with depressive symptoms in SAD patients, but this association did not withstand stringent Bonferroni correction.

Conclusion: Our preliminary results suggest that the genetic risk for depression might contribute to depressive symptoms in SAD patients. Beyond that, we did not identify strong contributions of genetic risk factors for depression/MDD to SAD subphenotypes. Further systematic analyses of PRS of AD and additional subphenotypes (e.g., comorbid MDD) are currently ongoing and will be presented at the upcoming conference.

References: Howard et al. (2019), PMID: 30718901.
Wray et al. (2018), PMID: 29700475.
Grants: Else Kröner-Fresenius-Stiftung (2019_A127).
Conflict of Interest: None declared.

P10.045.D Whole exome sequencing followed by reverse phenotyping in patients with neurodevelopmental disorders identifies rare genetic syndromes and reveals novel clinical and genetic variants

Nevyana Ivanova1, Kalina Mihova1, Daniela Avdjieva-Tzavella2,3, Valentina Petcheva1, Ivan Litvinenko4,5, Genoveva Tacheva2,3, Iliyana Aleksandrova2, Velina Guergelcheva2,6, Veneta Bojinova-Tchamova7, Vanyo Mitev1, Ivanka Dimova1, Albena Jordanova1, Radka Kaneva1

1Medical University - Sofia, Molecular Medicine Center / Department of Medical Chemistry and Biochemistry, Sofia, Bulgaria; 2SBAL Children’s Hospital „Prof. Dr. Ivan Mitev“, Genetics Clinic, Sofia, Bulgaria; 3SBAL Children’s Hospital, Sofia, Bulgaria; 4SBAL Children's Hospital, Sofia, Bulgaria; 5SBAL Children’s Hospital, Sofia, Bulgaria; 6Medical University - Sofia, Pediatrics, Sofia, Bulgaria; 7SBAL Children’s Hospital, Sofia, Bulgaria.
Hospital „Prof. Dr. Ivan Mitev”, Neurologic Clinic, Sofia, Bulgaria; 2Medical University - Sofia, Pediatrics, Sofia, Bulgaria; 3SBAL Children’s Hospital „Prof. Dr. Ivan Mitev”, Pediatrics, Sofia, Bulgaria; 4Medical University - Sofia/ University Hospital for Neurology and Psychiatry “Sveti Naum”, Children Neurological Clinic, Sofia, Bulgaria; 5UMBAL „Sofnamed”, Neurology Clinic, Sofia, Bulgaria; 6Soﬁa University „St. Kliment Ohridski”, Medical Faculty, Sofia, Bulgaria; 7University Hospital for Neurology and Psychiatry “Sveti Naum”, Children Neurological Clinic, Sofia, Bulgaria; 8Medical University - Sofia, Medical Chemistry and Biochemistry, Sofia, Bulgaria; 9Medical University - Sofia, Molecular Medicine Center / Department of Medical Genetics, Sofia, Bulgaria.

Background/Objectives: The complex nature of neurodevelopmental disorders offers a real challenge when it comes to clinical and molecular diagnostics. The classical gene panel approach to the whole exome sequencing data analysis is hindered by the “blurred” clinical picture of complex, overlapping and variable clinical phenotypes. Looking outside a particular gene panel and back to clinical data made possible to “recognize” rare syndromes and to identify novel clinical and genetic variants.

Methods: Whole exome sequencing analysis using gene panels and non-targeted analysis followed by reverse phenotyping in 10 patients with neurodevelopmental disorders who had already been excluded for the common types of genetic defects for the suspected particular condition.

Results: We have identified potentially disease-causing variants in six cases. Three of them are due to de novo mutations in genes GFAP, KCNC3 and KMT2E. The other three were associated with homozygous or compound heterozygous variants in TTC3, RUBCN and ALDOA genes that relate to disorders with autosomal recessive inheritance. The patient carrying the KCNC3 variant exhibit non-characteristic for this locus clinical phenotype with a major clinical feature of focal epilepsy underlined by a mild developmental delay. A homozygous mutation in the ALDOA gene was found in patient with autism and mental retardation. Up to the moment, the role of this gene in autistic spectrum disorders has been only discussed but not established clear-cut.

Conclusion: The combined whole exome sequencing – reverse phenotyping approach is very effective method for the diagnostics that could provide new insides in of rare genetic disorders.

References: .

Grants: D83/04.06.2021, D01-285/17.12.2019, D01-395/18.12.2020, D01-382/17.12.2021.

Conflict of Interest: None declared.

P10.046.A Dysfunctional CTDP1 impairs the cell cycle indicating its essential role in neurodevelopment

Hamide Yildirim1, Boyan Dimitrov2, Elyssa Cannings3, Karen Sermon4, Alexander Gheldof5, Katrien Stouffs5, Anna Jansen6

1Vrije Universiteit Brussel, NEGE, Jette, Belgium; 2UZ Brussel, Jette, Belgium; 3Vrije Universiteit Brussel, Jette, Belgium; 4Antwerp University Hospital, Edegem, Belgium.

Background/Objectives: Malformations of cortical development (MCDs) constitute a diverse range of disorders that are common causes of neurodevelopmental delay and epilepsy. The underlying molecular mechanism of several MCDs have been elucidated, although many still remain unknown.

Methods: Trio exome analysis in a girl with congenital arthrogryposis, unilateral auditory neuropathy, absent optic chiasma and grey matter heterotopia revealed the presence of two novel variants in the C-terminal domain phosphatase 1 (CTDP1) gene. CTDPI functions as a phosphatase which dephosphorylates the C-terminus of RNA polymerase II (RNAPII) and may potentially be involved in MCD, re-enforced by its essential role for normal embryo development.

CTDP1 expression was analysed both on mRNA level using qPCR and protein (FCP1) level by western blot (WB) analysis. The protein’s phosphatase activity on the C-terminal domain was studied using WB. Finally, cell cycle analysis was performed by DNA staining using propidium iodide.

Results: qPCR data showed a significant downregulation of CTDPI expression in patient versus controls. WB revealed a decreased protein level and more phosphorylated RNAPII in patient cells. Lastly, a disturbed cell cycle was observed in the patient compared to the controls.

Conclusion: Our preliminary data show that the expression of CTDPI, as well as FCP1 and the phosphatase activity are altered in the patient. Alterations caused by abnormal FCP1 function in the cell cycle are associated with disturbed cell cycle proteins (p27, cyclin B). Together, these results provide us a preliminary evidence that FCP1 plays a role in early brain development and cell growth by regulating the cell cycle.

References: .

Grants: .

Conflict of Interest: Hamide Yildirim Marguerite-Maria Delacroix foundation, Boyan Dimitrov: None declared, Elyssa Cannings: None declared, Alexander Gheldof: None declared, Katrien Stouffs: None declared, Anna Jansen: None declared.

P10.047.B X-chromosome inactivation is an easy assay to further investigate another without a diagnostic exome sequencing

Chiara Giovenno1, Slavica Trajkova1, Lisa Pavinin1, Simona Cardaropoli1, Verdana Pullano1, Silvia Carestia1, Anthony Battaglia1, Paola Salmin1, Diana Cani1, Alessandro Musgra1, Silvia De Rubbi12,5,6, Joseph Buxbaum4,7,8, Tommaso Pipicci4, Paola Dimartino10, Alessandro Bruselles11, Marco Tartaglia12, Haley McConkey13,14, Jennifer Kerkkö15,16, Sadegheh Aghshenas13, Bekim Sadikovic13,15, Giorgia Mandriile15, Giovanni Battista Ferrero15, Alfredo Brusco1,3

1University of Turin, Department of Medical Sciences, Turin, Italy; 2University of Turin, Department of Public Health and Pediatrics, Turin, Italy; 3Città della Salute e della Scienza University Hospital, Turin, Italy; 4Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, United States; 5Icahn School of Medicine at Mount Sinai, Department of Psychiatry, New York, United States; 6The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, United States; 7Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic Sciences, New York, United States; 8Icahn School of Medicine at Mount Sinai, Department of Neuroscience, New York, United States; 9Sant’Orsola Malpighi University Hospital, Bologna, Bologna, Italy; 10University of Bologna, Department of Medical and Surgical Sciences, Bologna, Italy; 11Istituto Superiore di Sanità, Department of Oncology and Molecular Medicine, Roma, Italy; 12Ospedale Pediatrico Bambino Gesù IRCCS, Genetics and Rare Diseases Research Division, Roma, Italy; 13London Health Sciences Centre, Molecular Diagnostics Program, Verspeeten Clinical Genome Centre, London, Canada; 14Western University, Department of Pathology and Laboratory Medicine, London, Canada; 15University of Turin, Department of Clinical and Biological Sciences, Turin, Italy.

Background/Objectives: Non-random X-chromosome inactivation (skewed-XCI) is suggestive of an X-linked genetic disease if detected in mothers of affected males (skewing towards the normal allele) or affected females (skewing towards the
deleterious allele). We explored skewed-XCI in a cohort of unselected neurodevelopmental disease (NDD) cases, negative at FRAXA, array-CGH and triox Exome Sequencing (ES).

Methods: XCI test by methylation-sensitive fluorescent PCR screening on blood-extracted DNA. Episignature analysis using Episign.

Results: We examined 66 NDD females and 115 mothers of affected NDD males and found an excess of extreme XCI (>90%) in both groups (7/66: 11%; p = 0.03; 10/115: 9%; p = 0.04). We reanalyzed ES data and found overlooked causal X-chromosome variants in 6/17. Five occurred in genes encoding chromatin remodeling proteins; in four, we confirmed the corresponding episignature: (i) [c.1204G>A;p.(D402N)] likely pathogenic (LP) variant in KDM5C (female; 90:10 XCI); (ii) deletion of exons 3-4 in ATRX (male; mother 100:0 XCI); (iii) [c.1322G>A;p.(Arg441Glu)] LP variant in ZMYM3 (male; mother 100:0 XCI); (iv) [c.1526C>T;p.(Pro509Leu)] LP variant in OTUD5, a recently described novel disease gene (two brothers, mother 100:0 XCI).

We also found the de novo [c.890G>T;p.(Cys297Phe)] VoUS in PHF6 in a 10-year-old girl with DD/ASD whose episignature apparently did not confirm PHF6-associated disease. Finally, we found the TAF1 VoUS [c.805G>A;p.(Gly269Arg)] in a female (100:0 XCI) and her brother with ID, still under investigation, since no affected female has been described so far.

Conclusion: Our work recommends XCI as an easy assay to further study cases without a diagnostic ES, guiding molecular reevaluation and further analysis for X-linked genes.

References:

Grants:

Conflict of Interest: None declared.

P10.048.C Association of pathogenic variants in SCN2A and COL4A2 mimics the neurometabolic phenotype - a case of SCN2A-related encephalopathy and COL4A2-related brain small vessel disease

Katarzyna Polatynska1, Łukasz Kępczyński2, Małgorzata Rydzanicz2, Rafal Płoski1, Kinga Salacińska2, Łukasz Przysio1, Piotr Grzelak6, Agnieszka Gach2

1Polish Mother’s Memorial Hospital - Research Institute, Department of Developmental Neurology and Epileptogy, Łódź, Poland; 2Polish Mother’s Memorial Hospital - Research Institute, Department of Genetics, Łódź, Poland; 3Medical University of Warsaw, Department of Medical Genetics, Warszawa, Poland; 4Polish Mother’s Memorial Hospital - Research Institute, Department of Radiology, Łódź, Poland.

Background/Objectives: SCN2A gene encodes Na(v) alpha1.2 protein – alpha-2 subunit of voltage-gated type 2 sodium channel, expressed in central nervous system excitatory neurons. Pathogenic variants of SCN2A gene are associated with variable spectrum of neurodevelopmental and paroxysmal phenotypes as developmental and epileptic encephalopathy, benign familial infantile seizures, episodic ataxia, intellectual disability, and autism spectrum disorders with or without seizures. COL4A2 gene encodes alpha-2 chain of type IV collagen, ubiquitously present in basement membranes. COL4A2 pathogenic variants are associated with broad spectrum of systemic disorders affecting various systems; central nervous system affecting phenotypes include brain small vessel disease and intracerebral hemorrhages.

Methods: Here we report a case of male infant with neurometabolic-like presentation: drug-resistant epilepsy, pyramidal tetraplegia, creatine kinase and lactic acid elevation, abnormal NMR neuroimaging, the course was complicated by Rotavirus infection, Bordetella pertussis pneumonia, and Klebsiella pneumoniae sepsis.

Results: Whole exome sequencing (WES) in the proband revealed two clinically significant de novo variants (absent in both biological parents) in SCN2A (NM_021007.3): c.4972C>T (p.Pro1658Ser) and COL4A2 (NM_001846.4): c.2989G>A (p.Gly997Arg).

Conclusion: Congenital dysfunction of SCN2A and COL4A2 genes mimics neurometabolic-like phenotype in described patient. As both SCN2A- and COL4A2-related disorders are characterized by variable penetrance and diverse expression, clinical features and molecular findings presented here, broaden the knowledge of both disorders pathogenesis and their role as modifying factors for each other.

References:

Grants:

Conflict of Interest: None declared.

P10.049.D The influence of polymorphisms of selected genes on human chronotype

Roman Solc1

1Charles university, Faculty of science, Department of anthropology and human genetics, Prague, Czech Republic.

Background/Objectives: Circadian rhythms are the very important human biorhythms. Their disorders can have unpleasant health, psychological and social consequences. However, the rhythm of life in conflict with the physiological setting of the “biological clock” can also bring problems, including health problems. On the contrary, respecting these rhythms can be used positively in medicine, but also in economics. According to their individual settings, we can distinguish people of different chronotypes (so-called „larks“, „owls“ and neutral), whereas this chronotype is largely determined genetically.

Methods: We genotyped thirteen polymorphisms in seven candidate genes (clock genes CLOCK, PER1, PER2, PER3 and BMAL1 and clock-related metabolic genes SIRT1 and PGC-1α) in 57 probands with extreme chronotype (38 „larks“ and 19 „owls“) and analyzed the potential association between the polymorphisms and the probands chronotype (defined using MEQ score). We also used the relative risk ratio (RR).

Results: The analyzes show two results statistically significant at α = 0.05, and some more results at α = 0.1. We found a strong association between the minor allele A in rs3736265 (PGC-1α) and the extreme evening chronotype (p = 0.0331; RR = 2.98) and a strong association between the minor allele C in rs1801260 (CLOCK) and the extreme morning chronotype (p = 0.0165; RR = 1.17). From the other findings the most interesting is an association between the minor allele C in rs2640909 (PER3) and the extreme morning chronotype (p = 0.0683; RR = 2.06).

Conclusion: Our findings identify new polymorphisms associated with the human chronotype and confirm the need to focus not only on clock genes but also on clock-related metabolic genes.

References: No.

Grants: No.

Conflict of Interest: Roman Solc Charles university, Faculty of science.

P10.050.A Investigating the efficacy of combined ketogenic diet and anti-inflammatory therapy in a mouse model of early-onset Tay-Sachs disease

Orhan Kerim Incli1, Volkan Seyranetepe1

1Izmir Institute of Technology, Molecular Biology and Genetics, Izmir, Turkey.
Background/Objectives: Tay-Sachs disease is a rare genetic disorder caused by abnormal GM2 ganglioside accumulation predominantly in the central nervous system (CNS) due to β-hexosaminidase A (HEXA) enzyme deficiency. Recently, our research group generated Hexa-/-Neu3-/- mouse model that mimics neuropathology of early-onset Tay-Sachs disease (1). We showed that undegraded GM2 accumulation resulted in neuronal cell death and activated neuroinflammation inducing astroglia and microgliosis-induced pro-inflammatory cytokines and chemokines secretion (2). The high fat, low-carbohydrate ketogenic diet (KD) has broad potential usage in the treatments of neurological disorders and there is growing evidence that KD is also anti-inflammatory. In this study, we aim to show KD and anti-inflammatory drug therapy in the treatment of neuroinflammation in Hexa-/-Neu3-/-.

Methods: Hexa-/-Neu3-/- mice were fed until 4.5 months old under the following groups: (i) control diet (CD), (ii) ad-libitum KD (10-day), (iii) ad-libitum CD with propagermanium (8mg/kg/daily for 21-day) and (iv) KD with propagermanium (21-day). Neuroinflammation markers were analyzed by qRT-PCR and immunohistochemical (IHC) analysis.

Results: Administration of KD and propagermanium in Hexa-/-Neu3-/- mice significantly reduced the expression levels of Ccl2, Ccl3, Ccl5, Cxcl10 in the cortex and cerebellum compared to Hexa-/-mice. Consistent with qRT-PCR analysis, IHC staining for glial fibrillary acidic protein (GFAP) displayed decreased astroglia.

Conclusion: Altogether, our results clearly suggest that ketogenic diet and propagermanium can be potential combined therapeutic strategy to reduce neuroinflammation in an early-onset Tay-Sachs disease mouse model.

References: (1) Seyrantepe V et al 2018 (2) Demir SA et al 2020.

Conflicts of Interest: None declared.

P10.053.D Czech family confirms the new 1p36.13-1p36.12 microdeletion syndrome and the involvement of the critical region with UBR4 and CAPZB genes

Vlasta Cejnova1, Pavel Seeman2, Sarka Cerna1, Ladislava Rennerova1, Marie Trkova1, Jana Lastuvkova1

1Regional Health Corporation, Masaryk Hospital in Usti nad Labem, Department of Medical Genetics, Usti nad Labem, Czech Republic; 2nd Faculty of Medicine, Charles University and University Hospital Motol, Neurogenetic laboratory, Department of Paediatric Neurology, Prague, Czech Republic; 3Regional Health Corporation, Hospital in Teplice, Department of Pediatric Neurology, Teplice, Czech Republic; 4Gennet, Center for Fetal Medicine and Reproductive Genetics, Prague, Czech Republic.

Background/Objectives: In 2020 Aagaard Nolting and coauthors described a new 1p36.13-1p36.12 microdeletion syndrome characterized by learning disability, behavioral abnormalities and ptosis caused by a deletion of 1 Mb in the smallest region of overlap. They described seven patients from 5 families with these characteristic features and considered the genes UBR4 and CAPZB as the most likely candidate genes for the features of this new syndrome.

Methods: Clinical, molecular cytogenetic (array CGH; Agilent SurePrint G3 8x60K) and genotype-phenotype analysis.

Results: We present a Czech family where the daughter and her mother have congenital ptosis, intellectual subnormality and behavioral abnormalities and recently detected and electrophysiologically verified also demyelinating polyneuropathy. Array CGH revealed a 2.2 Mb microdeletion at 1p36.13 (chr1:17815790-20018021 (GRCh37/hg19)) in both patients affecting also the UBR4 and CAPZB genes. This deletion was not detected in the healthy grandmother of the daughter and the grandfather already died on cancer. Polyneuropathy was not reported in the seven patients in the original publication.

Conclusion: Our Czech family with two similarly affected patients, daughter and mother confirms the new 1p36.13-1p36.12 microdeletion syndrome and the involvement of the critical region with UBR4 and CAPZB genes. The demyelinating polyneuropathy detected in both our patients clinically and electrophysiologically may be part of this new syndrome, but may also have another independent cause in our family. The microdeletion at 1p36.13-1p36.1 seems to be very rare.

References: Aagaard Nolting et al. A new 1p36.13-1p36.12 microdeletion syndrome characterized by learning disability,
behavioral abnormalities, and ptosis. Clin Genet. 2020 Jun;97(6):927-932. https://doi.org/10.1111/cge.13739.

Grants:
Conflict of Interest: None declared.

**P10.054.A Polygenic relationships between human longevity and psychiatric disorders**

Kajsa-Lotta Georgii Hellberg, Seyedmorteza Vaez, Morten Krebs, Janith Don, Vivek Appadurai, Jesper Gådin, Thomas Perls, Paola Genomics Institute (TGEN), Phoenix, United States; 3Boston University, Boston, United States; 4Tufts Clinical Translational Science Institute, Boston, United States.

**Background/Objectives:** Psychiatric disorders (PD) have complex, polygenic architectures involving interrelationships among common and rare genetic factors and environmental exposures. There are broad genetic correlations among PDs and psychological and behavioral traits that represent risk (RF) or protective factors (PF). Psychiatric patients have increased mortality and genes associated with longevity (PLS) may capture PF. Genetic relationships among PDs, RFs, PFs, and longevity have not been fully described.

**Methods:** LD-score regression to estimated genetic correlations between PDs and RF, PF, and longevity using published GWAS. We estimate correlations among polygenic scores (PGS) from these GWAS in >100,000 individuals from the iPSYCH study. Multiple logistic regression and sequential model fitting estimate contributions of multiple PGS for PDs, RFs, PFs, and PLS in models for each PD.

**Results:** Most genetic correlations among PDs, RFs, PFs, and longevity are in expected directions (e.g., longevity negative with ADHD, but some are opposite (e.g., longevity positive with Autism). Each class of PGS makes significant, independent contributions in joint models predicting PDs, especially for ADHD and MDD, where PLS remain significant after adjustment for all other PGS.

**Conclusion:** We present genetic relationships among longevity and PDs, RFs, and PFs. We show PGS from multiple domains, including longevity, significantly increases explained variance. This has implications for the role of PF and PGS in psychiatric clinical and research applications.

**References:**
Grants: Lundbeck fellowship R335-2019-2318.
NIH grants: UH2 AG064706, U19 AG023122, U24 AG051129, U24 AG051129-0451.
Conflict of Interest: None declared.

**P10.056.C Deciphering the mechanism of a de-novo GRIA2 mutation related to a neurodevelopmental disorder**

Lina Berkun, Amit Porecki, Yael Stern-Bach, Reeval Segel

1Shaare Zedek Medical Center, Medical Genetics Institute, Jerusalem, Israel; 2The Hebrew University-Hadassah Medical School, Department of Biochemistry and Molecular Biology, Jerusalem, Israel.

**Background/Objectives:** GRIA2 encodes the GluA2 unit of the AMPA-type glutamate receptors. AMPA receptors are a major mediator of fast excitatory neurotransmission in the brain. They promote the formation of new synapses and trigger activity-dependent processes that underlie learning and memory. GRIA2 mutations cause intellectual disability (ID) and intractable seizure.

We studied a de-novo missense variant in GRIA2 (L772W) detected by exome sequencing in a 1.5-year-old girl with severe ID, microcephaly without seizures.

**Methods:** The GluA2(L772W) homomeric mutation was expressed in Xenopus laevis oocytes. Currents were recorded using the two-electrode voltage clamp configuration. Receptor maturation and surface expression were determined by Western-blot analysis, coupled with glycosylation (oocytes) and biotinylation (HEK293 cells) assays.

**Results:** The mutant protein was expressed normally, it reached the cell membrane and matured into functional receptor but had altered kinetics. This variant causes faster desensitization, thus limiting the duration of channel opening.

**Conclusion:** We believe that reduction of channel opening duration due to this GRIA2 mutation may explain the neurological phenotype, either by directly reducing neuronal excitability or by compensatory mechanisms which may cause a reactive increase in the calcium permeable GluA1 receptors, thus increasing the neuronal excitatory activity leading to cell death. We plan to investigate this variant in its natural surrounding using human induced pluripotent stem cells (iPSCs) derived from our patient and a healthy close relative.

**References:**
Grants: None declared.

**P10.057.D Identification of shared genes and pathways between psychiatric GWAS and monogenic neurodevelopmental disorders**

Philip Jansen,1 Eva van Walree,2 Siemon de Lange, Danielle Posthuma

1VU University, Amsterdam, Netherlands; 2Amsterdam UMC, locatie VUmc, Human Genetics, Amsterdam, Netherlands; 3VU University, Complex Trait Genetics, Amsterdam, Netherlands.

**Background/Objectives:** Large genome-wide association studies (GWAS) rapidly identified novel risk genes for psychiatric disorders. Mendelian neurodevelopmental disorders (NDD) caused by single gene mutations show overlapping behavioural symp- tomatology, however the extent to which genes are shared between psychiatric GWAS and monogenic NDD needs to be fully explored.

**Methods:** We carry out genetic overlap analyses between five large-scale psychiatric GWAS (ADHD, autism, bipolar disorder, depression, schizophrenia, sample size range: N = 46,077−807,553) and monogenic neurodevelopmental disorders (NDDs). Consistent gene-mapping was done in FUMA for each GWAS. Overlap analyses were carried out with monogenic disease genes in the Developmental Disease Gene - Phenotype (DDG2P) database. Using various bioinformatic resources, we analysed gene properties and gene-expression of genes implicated in psychiatric disorders, NDDs or both.

**Results:** We found significant enrichment of psychiatric GWAS genes in all monogenic NDDs (enrichment = 1.18, P = 1.70 × 10^-5), and NDDs related to abnormal brain development (enrichment = 1.39, P = 1.10 × 10^-6). Of all psychiatric disorders, ADHD showed the strongest overlap with NDDs (P = 0.009), and bipolar the lowest (P = 0.96). We show that differences in gene function (synaptic and neurogenesis), properties (pLI score, missense sensitivity) and expression patterns predict involvement of genes in GWAS, NDD or overlapping in both. No enrichment of psychiatric GWAS genes was observed in known copy number variant regions that are associated with a high risk of psychiatric symptoms.

**Conclusion:** Our findings demonstrate novel insights into partly shared genetic etiologies between polygenic psychiatric disorders and psychiatric GWAS.
Abstracts from the 55th European Society of Human Genetics Conference

**P10.058.A** PCDH19 is regulated by neurosteroids and their receptors

**Rebekah de Nys**¹², Tarin Ritchie¹²⁄², Rudarup Bhattacharje¹², Raman Kumar¹², Jozef Gecz¹²⁄²³

¹The University of Adelaide, Adelaide Medical School, Adelaide, Australia; ²The University of Adelaide, Robinson Research Institute, Adelaide, Australia; ³South Australian Health and Medical Research Institute, Adelaide, Australia.

**Background/Objectives:** Protocadherin 19 (PCDH19) Clustering Epilepsy (CE) is a disorder of cellular mosaicism. We and others have identified altered steroidogenesis and deregulated Nuclear Hormone Receptor (NHR)-related gene expression in the affected individuals. We reported PCDH19 as a co-regulator of Estrogen Receptor (ER) α activity on gene expression. Little is known if PCDH19 is regulated by steroids and what is the effect of protocadherins, not just PCDH19, on NHRs Androgen Receptor (AR) and/or Progesterone Receptor (PR). We utilised disease relevant models to investigate (a) the impact of neurosteroids on PCDH19 gene and (b) functional interaction between delta2 protocadherins and NHRs.

**Methods:** We treated T47D and embryonic mouse neurons with estradiol (E2), progesterone (P4) or dihydrotestosterone (DHT) separately or in combination and assayed PCDH19 expression via RT-qPCR, and performed RNA-sequencing on CE and control primary skin fibroblasts. We determined Protocadherin-NHR interactions by co-immunoprecipitation using epitope-tagged protocadherins (PCDH10, PCDH12, PCDH17 and PCDH19) and NHRs (ERα, AR or PR).

**Results:** PCDH19 expression was repressed in T47D cells treated with E2, P4 and DHT, and embryonic mouse neurons with E2. Congruent with this, RNA-sequencing of skin fibroblasts of CE girls revealed significant AR upregulation. AR (but not ERα or PR) co-immunoprecipitated with PCDH10, PCDH12, PCDH17 and PCDH19.

**Conclusion:** We show that NHRs play a major role in the regulation of PCDH19 expression and provide evidence of an interaction of PCDH19 with AR. This further supports our hypothesis that dysregulation of the steroid hormone receptor pathway contributes to CE pathogenesis.

**References:**

Grants: PCDH19 Alliance Grant, USA.

Conflict of Interest: None declared.

**P10.059.B** Relative prevalence of AD SCA subtypes in the Czech Republic – data from the Centre for Hereditary Ataxias in Prague

**Emílie Vyhnálková**¹, Martin Vyhnálek², Alena Zumrová², Jaroslav Jeřábek³, Jaroslava Paulasová Schwabová², Michaela Danková², Lucie Štovíčková², Markéta Havlovicová², Zuzana Musova¹

¹Institute of Biology and Medical Genetics, Motol University Hospital, Prague, Prague, Czech Republic; ²Centre for Hereditary Ataxias, Motol University Hospital, Prague, Prague, Czech Republic.

**Background/Objectives:** The classification of autosomal dominant spinocerebellar ataxias (AD SCA) is based on findings of specific gene variants. Testing of the most common forms of AD SCA has been introduced since 2000 in the Czech Republic.

**Methods:** Initial testing for SCA1-3, 6-8, 12, 17, and 28 is used routinely in patients with suspicion of AD SCA. We present a summary of AD SCA subtypes diagnosed in the Centre for Hereditary Ataxias in Motol University Hospital Prague, member of the ERN-RND network.

**Results:** The centre performed testing in 1700 probands with chronic and slowly progressive ataxia. In total, 162 patients from 111 unrelated families were diagnosed with AD SCA. The most common subtypes are SCA2 (70 patients from 39 families), SCA17 (22 patients from 14 families), and SCA1 (18 patients from 11 families). SCA28 was suspected in 9 patients from 6 families (1 patient with known pathogenic variant, rare variants of unknown significance in others). SCA8, a subtype with reduced penetrance, was detected in 30 patients from 28 families. Other SCA subtypes were rare (SCA6 was found in 9 patients, SCA3 detected in 3 patients, and SCA7 found in one patient). SCA12 has not been detected.

**Conclusion:** The most common AD SCA subtypes in the Czech Republic are SCA2, SCA17, and SCA1. The estimated prevalence of genetically confirmed AD SCA is 1.5 /100 000. Rare variants revealed in SCA28 gene need further investigation.

**References:**

Grants: The authors are members of the European Reference Network for Rare Neurological Diseases, Project ID 739510.

Conflict of Interest: Emilie Vyhnálková Motol University Hospital Prague, Martin Vyhnálek Motol University Hospital Prague, Alena Zumrová Motol University Hospital Prague, Jaroslav Jeřábek Motol University Hospital Prague, Jaroslava Paulasová Schwabová Motol University Hospital Prague, Michaela Danková Motol University Hospital Prague, Lucie Stošičková Motol University Hospital Prague, Markéta Havlovicová Motol University Hospital Prague, Zuzana Musova Motol University Hospital Prague.

**P10.060.C** Brain mosaic mutations as a cause of drug-resistant epilepsy including mesial temporal lobe epilepsy

**Katherine Benson**¹², Robert Carton³, **Michael Doyle**²³⁄⁴, **Hugh Kearney**²³, David Henshall², Gianpietro Cavallieri¹², Norman Delanty¹²³

¹Royal College of Surgeons in Ireland, School of Pharmacy and Biomolecular Sciences, Dublin, Ireland; ²Royal College of Surgeons in Ireland, FutureNeuro SFI Research Centre, Dublin, Ireland; ³ Beaumont Hospital, Epilepsy Programme, Department of Neurology, Dublin, Ireland; ⁴Royal College of Surgeons in Ireland in collaboration with Blackrock Clinic, Dublin, STAR MD Programme, Dublin, Ireland.

**Background/Objectives:** The contribution of somatic mutations in epilepsy is becoming apparent, in particular in malformations of cortical development (MCD). The aim of this study was to evaluate the diagnostic yield of brain somatic mutations in germline epilepsy genes, somatic epilepsy genes, and brain expressed pik3mt genes in drug-resistant epilepsy.

**Methods:** Surgical epilepsy cases, were clinically phenotyped and sub-divided based on the histopathology of resected brain tissue. Matched blood-derived and brain-derived DNA samples, were sequenced using high coverage (~500X) targeted next-generation sequencing for 229 genes. Variants were identified using MuTect-2 and annotated using ANNOVAR. Variants were filtered for those which had a variant allele frequency >0.05%, were absent in gnomAD, matched the inferred inheritance pattern and passed manual quality control inspection in Integrative Genome Viewer. Candidate variants were confirmed using high-coverage amplicon sequencing.

**Results:** 41 patients were successfully sequenced. 9 patients yielded 13 candidate somatic variants. 5 variants in 5 patients were validated using amplicon sequencing (genes: CBL, KCNB1,
ALG13, MTOR and FLNA). The overall diagnostic yield across 41 patients was 12%. Within the hippocampal sclerosis (HS), MCD and non-lesional focal patient subgroups, the yield was 13.6%/20%/0% respectively.

Conclusion: This study has provided new insights into the aetiology of HS, a condition not previously associated with somatic variants. The diagnostic yield in MCD is consistent with previous studies, confirming the importance of MTOR and related genes in this condition.

References:

Grants: Science Foundation Ireland (SFI) Grant Number 16/RC/3948 and co-funded under the European Regional Development Fund and by FutureNeuro industry partners.

Conflict of Interest: None declared.

P10.061.D Joint effects of rare GBA variants and polygenic risk score on Parkinson’s disease risk

Zied Landoulsi1, Sinhutha P Pachchek1,2, Dheeraj Bobbili2, Rejko Krüger1,2,3, Patrick May1

1Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg; 2Transversal Translational Medicine, Luxembourg Institute of Health (LIH), Strassen, Luxembourg; 3Department of Neurology and Parkinson Research Clinic, Centre Hospitalier de Luxembourg (CHL), Luxembourg, Luxembourg.

Background/Objectives: Rare homozygous mutations within the Glucocerebrosidase (GBA) gene were linked to lysosomal storage-disorder, whereas rare heterozygous mutations in GBA contribute to an increased risk for Parkinson’s disease (PD). We aimed to investigate how a polygenic risk scores (PRS) defined by common GWAS variants and different types of rare GBA (GBAr) variants (benign, mild, severe) jointly influence the PD risk.

Methods: We used genotyping and rare variants data from a Luxembourgish PD cohort of 805 controls and 792 patients, and stratified these samples based on PRS percentile and GBAr carrier status. The PRS was calculated Genome-wide (gPRS) and for genes involved in lysosomal (lysoPRS) and mitochondrial (mitoPRS) pathways. We compared GBAr carrier frequencies in each PRS category and different groups of PRS risk (low, intermediate, high), and assessed the combined effect of PRS and GBAr carrier status on PD risk.

Results: Overall GBAr carriers were more frequent in the high-risk compared to the low-risk group for gPRS and lysoPRS, but not for mitoPRS. For all types of PRS, severe GBAr were less frequent in the high-risk than in the low-risk PRS group. PD risk was higher among GBAr carriers than non-carriers in low-risk and high-risk for gPRS and lysoPRS. However, for mitoPRS, PD risk was higher among GBAr carriers compared to non-carriers in low but not in the high PRS group.

Conclusion: Our results indicate that the GBAr-conferred risk could be significantly influenced by PRS. Specifically, lysoPRS could give more insight into how lysosomal dysfunction leads to neurodegeneration in PD.

References:

Grants: None declared.

Conflict of Interest: None declared.

P10.062.A Unique Ataxia oculomotor apraxia 2 (AOA2, OMIM #606002) case in Israel: Expanding the phenotypic spectrum, highlighting novel variants and possible identification of a poison exon

Penina Ponger1, Alina Kurlop1, Hofit Gadot1, adi mory1, Yael Winai1, Nir Gildai1, Tatjana Gurevich1, Daphna Marom1, yuval yaron1, Hagit Baris Feldman1

1Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel.

Background/Objectives: SCAN2 is a rare progressive adolescent-onset cerebellar ataxia characterised by elevated serum alpha-fetoprotein (AFP) and oculomotor apraxia. SCAN2 is caused by bi-allelic variants in SETX, encoding senataxin, involved in DNA repair and RNA maturation.

Methods: WES trio was followed by SETX RNA analysis, extracted from peripheral blood mononuclear cells and converted to cDNA to enable splicing analysis. qRT-PCR was performed to assess overall and mutant SETX mRNA expression.

Results: Proband is of non-consanguineous Persian Jewish family. Phenotype includes early childhood clumsiness, functional deficits in late adolescence, oculapraxia, dystaxia, appendicular and truncal ataxia and cerebellar atrophy, especially of the vermis and anterior lobes in MRI. Serum AFP levels are within normal range. WES trio of proband and parents revealed two novel SETX variants in trans, maternal nonsense variant in exon 6 (c.568C>T; p.Gln190*), and paternal deep intronic variant in intron 12 (c.5549-107A>G). Intronic variant analysis and SETX mRNA expression revealed activation of a cryptic exon. This insertion introduces a premature stop codon (p.Met1850Lysfs*18). qRT-PCR analysis revealed that the intronic c.5549-107A>G variant induces aberrant splicing and leads to 20-30 times higher levels of cryptic exon activation compared to WT samples (mother and healthy controls). In combination with a second deleterious allele, this variant leads to low levels of SETX mRNA and disease manifestations.

Conclusion: Our case expands the phenotypic spectrum of SCAN2 and emphasizes the need for tailored molecular work-up to ensure timely diagnosis. Deep-intronic variant analysis reveals a previously undescribed poison exon in the SETX gene which may contribute to therapy development.

References:

Grants: None declared.

Conflict of Interest: Penina Ponger: None declared, Alina Kurlop: None declared, Hofit Gadot: None declared, adi mory: None declared, Yael Winai: None declared, Nir Gildai: None declared, Tatjana Gurevich: None declared, Daphna Marom: None declared, yuval yaron: Geenox, Hagit Baris Feldman: None declared.

P10.064.C CANVAS: molecular analysis, expansion size determination, and clinical features in Italian patients

Daniela Di Bella1, Stefania Magri1, Elisa Sarto1, Marinella Corbetta1, Maria Balzo1, cinzia geller1, Chiara Pisciotto2, Ettore Salsano3, Davide Pareyson2, Mario Fichera1, Lorenzo Nanetti1, Caterina Mariotti1, Franco Taroni1

1Fondazione IRCCS Istituto Neurologico Carlo Besta, Unit of Medical Genetics and Neurogenetics, Milan, Italy; 2Fondazione IRCCS Istituto Neurometabolic Diseases, Milan, Italy.

Background/Objectives: CANVAS is an adult-onset, slowly-progressive neurodegenerative disorder, whose phenotypic spectrum is expanding, ranging from late-onset ataxia to sensory neuropathy, caused by a biallelic intronic AAGGG expansion in the RFC1 gene. Expansions with alternative sequence conformations have been identified whose pathogenic role remains to be established.

Objectives: 1) To screen Italian patients with full or partial CANVAS phenotype (n = 223) or late-onset (n = 216) ataxia for RFC1 expansion; 2) to assess the frequency of RFC1 expansion carrier in a control population; 3) to sequence the expanded alleles to determine their repeat structure and role in disease.
Methods: The RFC1 locus was analysed by a PCR flanking the repeat, followed by fluorescent repeat-primed PCRs (Cortese, 2019). A long-read sequencing approach has been set up for the sequencing of the expanded allele.

Results: Biallelic RFC1 expansion was identified in 32.3% (72/223) probands with a CANVAS spectrum phenotype, and in 12.5% (27/216) of patients with ataxia. Heterozygous carrier rate was 10.6% in patients (16/151) and 10% (36/360) in controls. Approx. 5% of alleles showed complex repeat conformations with uncertain pathogenicity.

Conclusion: Biallelic RFC1 expansion accounts for a large proportion of ataxia phenotypes in Italian patients (12-32%), and should always be considered in the diagnostic algorithm of patients with sporadic ataxia, ranking first in late-onset cerebellar and sensory ataxia. Given the high carrier rate, RFC1 expansion might be the most common cause of ataxia in Italian patients. Sequencing data confirm the complex architecture of the expanded repeat which may have crucial implications for diagnosis and counseling.

References: Cortese A (2019) Nature Genetics 51:649-658.

Conflict of Interest: None declared.

P10.065.D A newly implemented NGS-based methods to detect GBA variants in patients with Parkinson disease

Giada Cuconato1, Ilaria Palmieri2, Edoardo Monfrini3, Marco Percetti2, Marco Morelli2, Ettore Zapparoli2, Alessio Di Fonzo2, Enza Maria Valente1,2

1University of Pavia, Molecular Medicine, Pavia, Italy; 2IRCCS Mondino Foundation, Pavia, Italy; 3IRCCS Foundation Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy; 4IRCCS San Raffaele, Milano, Italy.

Background/Objectives: Heterozygous variants in the GBA gene, encoding for the lysosomal enzyme β-glucocerebrosidase, are the commonest genetic risk factor for Parkinson disease (PD), accounting for 5-15% of all PD cases. Sequencing of the whole GBA coding region (11 exons) is a cumbersome task, both employing conventional techniques such as Sanger sequencing as well as more innovative strategies such as next-generation-sequencing (NGS). In particular, the high degree of homology (96-98%) between GBA and its pseudogene GBAP1 often leads to recombination events that eventually produce complex alleles which are misaligned through the standard NGS pipeline. Here we tested an implemented NGS-based technology on a selected pool of 22 patients, including 15 patients known to carry different GBA variants (identiﬁed through Sanger sequencing) and 7 controls.

Methods: The NGS experiment was designed starting from a long-range PCR to amplify a unique 12kb ampiclon encompassing GBA. This was used as template to create libraries, which were ampliﬁed using Nextera technology and then run on an Illumina MiSeq instrument. In parallel to standard bioinformatic analysis, we employed a custom pipeline, forcing the alignment of reads against the genomic coordinates of GBA gene only.

Results: All GBA variants were correctly called and identiﬁed using this approach; furthermore, comparing (*.bam) files obtained with standard vs forced alignment, the latter showed a signiﬁcant increase in read depth and mapping quality.

Conclusion: The proposed NGS-based approach appears a reliable and valid alternative for GBA sequencing, holding promise to increase the speed and the accuracy of variant detection compared to conventional strategies.

References: None declared.

P10.066.A Combining extended genealogies and genotypes for a unique view of the genetic architecture of major depressive disorder

Morten Krebs1, Kajsa-Lotta Georgii Hellberg1, Vivek Appadurai1, Henrik Olsson2, Xavier Calle Sanchez1, Bjarni Vilhjalmsson3, Silviu Bacanu4, Jonathan Flint5, Cai Na6, Noah Zaitlen7, Andres Ingason1, Alfonso Buil1, Andy Dahl8, Kenneth Kendler9, Thomas Werge1, Andrew Schork1

1Research Institute of Biological Psychiatry, Roskilde, Denmark; 2Family Medicine and Clinical Epidemiology, Lund, Sweden; 3Department of Economics and Business Economics - National Centre for Register-based Research, Aarhus, Denmark; 4Stat Gen, VIPBG, Dept of Psychiatry, Virginia Commonwealth University, Richmond, United States; 5Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, United States; 6Helmholtz Pioneer Campus, München, Germany; 7Departments of Computational Medicine and Neurology, Los Angeles, United States; 8University of Chicago, Department of Medicine, Section of Genetic Medicine, Chicago, United States; 9Virginia Commonwealth University, Virginia Institute for Psychiatric and Behavioral Genetics, Richmond, United States.

Background/Objectives: State-of-the-field complex disorder genetics leverages population-scale biobanks with broad demographic, health, survey, and genetic data. This presents an opportunity for Major Depressive Disorder (MDD), where genetic predictors underperform, clinical heterogeneity is etiologically enigmatic, and missing heritability persists. Combining genotypes, family history, and adjacent phenotypes in large data can advance each aim, but requires new approaches.

Methods: We introduce Pearson-Aitken framework for Family Genetic Risk Scores (PA-FGRS) to estimate individual liability scores from uniquely complex pedigrees of individuals in the iPSYCH case-cohort. We compute multiple psychiatric PA-FGRS and polygenic scores (PGS) for N = 37,555 MDD cases and 49,303 controls. We test discriminative utility of PA-FGRS and PGS with regression, compare GWAS on diagnoses and PA-FGRS, and compare multivariate PA-FGRS+PGS proﬁles of MDD cases with different clinical outcomes using multinomial regression.

Results: We construct genealogies including >2,000,000 relatives of iPSYCH individuals and show PA-FGRS has important advantages in simulations. Combining PA-FGRS with PGS explains as much additional variance in MDD as PGS alone (~3%). Clinical heterogeneity is widely associated with variability in genetic profiles, e.g., recurrent MDD increased PA-FGRS and PGS for MDD and bipolar. In iPSYCH, GWAS on PA-FGRS liabilities identiﬁed 3 more loci than binary diagnoses.

Conclusion: Approaches that integrate multiple data types in population biobanks give important new perspectives on genetic architectures of complex disorders like MDD. Clinical and research aims could be more data integrative and better attend to heterogeneity.

References: None declared.

P10.067.B Genetic variability of inflammation and oxidative stress in Alzheimer’s disease biomarkers

David Vogrinc1, Katja Gorcic1, Milica Gregorič Kramberger2, Vita Dolzan1

1Faculty of Medicine, University of Ljubljana, Institute of Biochemistry and Molecular Genetics, Pharmacogenetics Laboratory, Ljubljana.
haplotype, among LBD cases, PD patients, and healthy controls all second GBA variant; and evaluated the impact of the APOE-frequency <1%) in dementia-related genes; assessed the role of a GBA variant could eventually develop PD or LBD we focused on.

**Methods**: Our study included 54 AD patients, 14 MCI patients with pathological CSF biomarker levels and 20 MCI patients with normal CSF biomarker levels. Isolated DNA from blood was genotyped for polymorphisms in SOD2, CAT, GPX1, IL1B, MIR146A, IL6, TNF, CARD8, NLRP3, GSTP1, NOS1, KEAP1 and NFE2L2 using competitive allele-specific PCR. Association of polymorphisms with CSF biomarker levels and cognitive tests was evaluated using nonparametric tests.

**Results**: In the whole cohort, carriers of two polymorphic IL1B rs16944 alleles had higher CSF Aβ$_{42}$ and Aβ$_{40}$ (p = 0.025), while carriers of at least one polymorphic NFE2L2 rs35652142 allele had lower CSF Aβ$_{42}$ (p = 0.040) levels. In AD group, only IL1B rs16944 remained significant (p = 0.029). Significant associations with mini-mental state exam (MMSE) were observed for CAT rs1001179 (p = 0.022), GSTP1 rs1138272 (p = 0.005), KEAP1 rs1048290 and rs9676881 (both p = 0.019), NFE2L2 rs35652124 (p = 0.030). In AD group, significant association of IL1B rs1071676 (p = 0.004), KEAP1 rs1048290 and rs9676881 (both p = 0.035) with MMSE were observed.

**Conclusion**: Polymorphisms in inflammation and antioxidant genes may be associated with CSF biomarkers and cognitive test score and could serve as additional biomarkers contributing to early diagnosis of cognitive decline.

**References**: Grants: ARRIS P1-0170. Conflict of Interest: None declared.

**P10.068.C Genetic modulators of GBA expressivity in synucleinopathies**

**Giang Meliastico**, Letizia Straniero, Valeria Rimoldi, Alessio Di Fonso, Giulia Solda, Anna Zucchini, Gianni Pezzoli, Rossana Asselta

**Background/Objectives**: Heterozygous mutations in GBA are associated with an increased risk of the synucleinopathies Parkinson's disease (PD) and Lewy body dementia (LBD), which encompasses Parkinson's disease dementia and dementia with Lewy bodies (DLB). As it is not clear why individuals with the same GBA variant could eventually develop PD or LBD we focused on genetic modulators of GBA mutations expressivity. To this end, we: compared the burden of rare deleterious variants (minor allele frequency <1%) in dementia-related genes; assessed the role of a second GBA variant; and evaluated the impact of the APOE-e4 haplotype, among LBD cases, PD patients, and healthy controls all carriers of at least one GBA mutation.

**Methods**: We studied a cohort of 203 healthy individuals, 196 PD and 139 LBD patients heterozygous for at least a GBA mutation using an NGS custom panel including 10 dementia-related genes. The frequency of APOE haplotypes was assessed through a TaqMan™ Genotyping Assay.

**Results**: We showed a significantly increased burden of rare mutations in dementia-related genes in the DLB cohort compared to healthy controls (12.82% vs 3.86%, P = 0.02). We also found that a second GBA variant is more frequent in LBD vs PD patients (9.56% vs 3.96%, P = 0.04), and that the APOE-e4 allele is significantly enriched in the DLB cohort compared to healthy controls (17.57% vs 8.13%, P = 0.018).

**Conclusion**: Our data suggest that there is a correlation between the analyzed risk factors and the development of a dementia phenotype in GBA mutation carriers.

**References**: Grants: PRIN Grant no:2017228L3J. Conflict of Interest: None declared.

**P10.069.D Two de novo pathogenic variants in different genes identified by a whole exome sequencing TRIO approach explain and complement the phenotype in a patient with syndromic intellectual disability and autism**

**Eva Barroso**, Marina Martínez-Matilla, Gemma Cartagena, Jesús Ferre-Fernández, Alba Velo, Maria Berbel, Rocio Garcia-Jimenez, Iryna Boyko, Sandra García-Herrero, Carmen Fernández-Vizcaíno, Daniel Sanchez-Valero, Cristian Perez-García, Alberto Fernández-Jaén, Javier Garcia Planells

1Igenomix, Genomic Precision Diagnostic, Paterna, Spain; 2Hospital Universitario Quirónsalud Madrid, Pediatric Neurology, Pozuelo de Alarcón, Spain.

**Background/Objectives**: Five-years-old boy presented with a complex phenotype, including intellectual disability, autism, and attention deficit spectrum disorder with dysmorphic features as microcephaly and hypertelorism. CGH-array, karyotype and X-fragile tests were normal. Whole exome sequencing (WES) TRIO diagnostic was performed to elucidate the genetic cause underlying his phenotype.

**Methods**: WES for proband and progenitors were performed from DNA using Nextera DNA Flex Pre-Enrichment Library Prep and Illumina Exome Panel and sequenced on the NovaSeq 6000 System (Illumina). Raw data were processed by the Igenomix in-house bioinformatics pipeline. Detected variants were prioritised according to their possible pathogenicity following the recommendations of the American College of Medical Genetics using the in-house developed software GPDxViewer.

**Results**: Two de novo pathogenic variants were found in the proband: c.1139_1140delTT; p.(Phe380fs) in the CUL3 gene and c.1001 +2T>A in the NARST gene. CUL3 is associated with Neurodevelopmental disorder with or without autism or seizures (MIM#619239) and NARS1 with Neurodevelopmental disorder with microcephaly, impaired language, epilepsy, and gait abnormalities (MIM#619092), both with autosomal dominant inheritance pattern.

**Conclusion**: Each variant contributes to different parts of the complex phenotype present in the proband and as a result, the patient has a combination of two different disorders. These results also highlight the importance of being thorough in the variant analysis to avoid missing those variants that could complement or complete the explaination of the phenotype as a whole.

In disorders with such heterogeneous genetic basis as autism and intellectual disability, WES-TRIO emerges as the diagnostic approach with the highest efficiency.

**References**: Grants: PRIN Grant no:2017228L3J. Conflict of Interest: None declared.
P10.070.A Novel mutation in ENG causes autosomal dominant isolated cerebral arteriovenous malformation at young age

M atan M. Jean1, ofek freund1, Nadav Agam1, Amit Safran1, Tomer Poleg1, Marina Eskin-Shwartz2,2,3, Anat Horev3, Ohad Shmuel Birk1,2

1The Morris Kahn Laboratory of Human Genetics, National Institute for Biotechnology in the Negev and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel; 2Genetics institute, Soroka Medical Center, Ben Gurion University, Beer Sheva, Israel; 3Neurology Department, Soroka Medical Center, and Clalit Health Services, Ben Gurion University, Beer Sheva, Israel.

Background/Objectives: Cerebral arteriovenous malformation (CAVM) constitute abnormal vessels shunting blood from the arterial to the venous circulation, resulting in high flow lesions prone to rupture. CAVMs account for ~2% of all haemorrhagic strokes. Most CAVM cases are sporadic, although few are due to autosomal dominant inheritance of a genetic mutation, most commonly in the context of Hereditary HemorrhagicTelangiectasia (HHT), an autosomal dominant genetic disorder characterized by epistaxis, telangiectasias, and multiorgan vascular dysplasia. We studied a case of father and daughter with isolated CAVM ruptures at young age, aiming to identify mutations that cause CAVM.

Methods: Magnetic resonance angiography, whole exome sequencing and validation through PCR and Sanger sequencing.

Results: A father and daughter presented with isolated CAVM, with ruptures at an early age. Both were examined clinically and did not present telangiectasias. A frameshift mutation in ENG (endoglin) chr:9:127816006 AG>A HET. (hg38) was found in both affected father and daughter.

Conclusion: Mutations in ENG have been reported to cause HHT1, a subtype of HHT with higher risk for developing CAVM than other subtypes of the disease. This new mutation is unique in causing CAVM at a very young age and without skin presentation of telangiectasias. Thus, genetic testing is important for diagnosis of HHT in families with history of isolated CAVM ruptures.

References: 1) C. Stapf et. al. (2002). Cerebrovascular Diseases. 2) Abdalla, S. A., & Letarte, M. (2006). Journal of Medical Genetics.

Grants: The Morris Kahn foundation.

Conflict of Interest: None declared.

P10.071.B Genetic diagnoses for complex neurodevelopmental disorders in the international NeuroWES-Macedonia project

Slavica Trajkova1, Elena Sukarova-Angelovska², Aleksandar Petlichkovski³, Enza Ferrero¹, Simona Cardaropoli4, Chiara Giovenino5, Verdiana Pullano1, Lisa Pavinato1, Silvia Carestia1, Elisa Giorgio5, Alessandro Musso6, Tommaso Pippucci6, Paola Dimartino7, Ashkan Golshani8, Sarah Takallou8, Haley McConkey9,10, Jennifer Kerkhof9,10, Slavica Trajkova

1University of Turin, Department of Medical Sciences, Turin, Italy; 2University Clinic for Children’s Diseases, Department of Endocrinology and Genetics, Skopje, Macedonia; 3University “Sv. Kiril I Metodij”, Institute for Immunobiology and Human Genetics, Skopje, Macedonia; 4University of Turin, Department of Public Health and Pediatrics, Turin, Italy; 5University of Pavia, Department of Molecular Medicine, Pavia, Italy; 6Polyclinic Sant’Orsola-Malpighi University Hospital, Medical Genetics Unit, Bologna, Italy; 7University of Bologna, Department of Medical and Surgical Sciences, Bologna, Italy; 8Carleton University, Department of Biology and Ottawa Institute of Systems Biology, Ottawa, Canada; 9London Health Sciences Centre, Molecular Diagnostics Program, Verspeeten Clinical Genome Centre, London, Canada; 10Western University, London, Department of Pathology and Laboratory Medicine, London, Canada; 11Icahn School of Medicine at Mount Sinai, Seaver Autism Center for Research and Treatment, New York, United States; 12Icahn School of Medicine at Mount Sinai, Department of Psychiatry, New York, United States; 13Icahn School of Medicine at Mount Sinai, The Mindich Child Health and Development Institute, New York, United States; 14Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic Sciences, New York, United States; 15Icahn School of Medicine at Mount Sinai, Department of Neurosciences, New York, United States; 16University of Turin, Department of Clinical and Biological Sciences, Turin, Italy; 17University Hospital, Torino, Italy, Città della Salute e della Scienza, Turin, Italy.

Background/Objectives: Neurodevelopmental disorders (NDD) are genetically and clinically heterogeneous diseases that include Autism Spectrum Disorders (ASD), intellectual disability (ID), and epilepsy.

Methods: To improve Whole Exome Sequencing (WES) diagnostics in NDD, we exploited detailed clinical characterization, X-chromosome inactivation (XCI) profiles, epigenetic signatures and novel in vitro functional models.

Results: We collected and deeply phenotyped 203 NDD cases from Macedonia with ASD (69/203), ASD/ID (31/203), ID (42/203), or syndromic NDD (61/203). We solved 26% (52/203), with the highest diagnostic rate in syndromic NDD (31/61; 51%), and the lowest in ASD cases (5/69; 7%). Notably, we found two cases with a dual molecular diagnosis, and one family with two different de novo variants in two similarly affected brothers.

In three unrelated boys, whose mothers each had a 100% skewed XCI, we found variants in novel candidate genes, previously overlooked by WES analysis (ZMYM3:R441Q, PDD24K730N, and AMOT: G343R). Because chromatin remodeling genes were frequently mutated (14/52; 27%), we exploited episignatures, and confirmed the pathogenic role of variants in EZH2, HIST1H1, PBP1. We found 18 strong novel disease-gene candidates (8%), which included PHLP1, AARS1, UBE2I and CASK1. The PHLP1 mutated cases showed functional alteration of the AKT-mTOR pathway using dental pulp stem cells (SHED); the variants in AARS1, involved in aminoacyl-tRNA editing, caused growth impairment in a mutagenized yeast model.

Conclusion: The combination of deep phenotyping, XCI analysis and episignature profiling not only improved the WES diagnostic yield but identified several potentially novel NDD genes.

References:

Grants:

Conflict of Interest: None declared.

P10.072.C Novel de novo heterozygous H3-3A mutation causes neuro-developmental disorder

OHAD LANDAU1, Ginat Narkis2, Ohad Shmuel Birk1,2

1Ben-Gurion university of the Negev, Beer-sheva, Israel; 2 Genetics Institute, Soroka Medical Centre, Beer-sheva, Israel.

Background/Objectives: A non-consanguineous Jewish Moroccan family presented with a phenotype of a neuro-developmental disorder (NDD) of global developmental delay, low muscle tone and epilepsy, affecting an individual at the latest generation.
**Methods:** Whole exome sequencing data of the affected individual and healthy parents (Trio) were analyzed and filtered for known benign variants using our in-house databases along with open access databases (1000 genomes, NHLBI ESP, ExAC etc.).

**Results:** No mutations or likely-pathogenic variants were found in genes previously associated with NDDs. A novel de-novo heterozygous p.Q126R missense mutation in H3.3 Histone A (H3-3A) was identified. The mutation was verified by Sanger sequencing and was found to fully segregate in the affected kindred as expected for a dominant effect of a de-novo mutation. In-silico analysis of the p.Q126R variant showed putative multiple effects on the mature protein. Proliferation assay (XTT) of patient-derived fibroblasts versus matched controls indicated decreased proliferation of cells harboring the mutation.

**Conclusion:** Variants in H3-3A were mainly associated with cancer and only recent studies have shown H3-3A as a novel contributor to NDDs1. Our data suggest the de-novo p.Q126R mutation is the likely cause of the aforementioned NDD.

**References:** 1 - Bryant L et al. Histone H3.3 beyond cancer: Germline mutations in Histone 3 Family 3A and 3B cause a previously unidentified neurodegenerative disorder in 46 patients. Sci Adv. 2020 Dec 2;6(49): eabc9207.

**Grants:** None declared.

**Conflict of Interest:** None declared.

**P10.073.D Interaction between polygenic risk score and rare variants in amyotrophic lateral sclerosis**

**Jay Ross**1,2, Zoe Schmiliovich1,2, Karina Kwan3, Dan Spiegelman2,4, Angela Genge2, Nicolas Dupre3,6, Patrick Dion2,4, Sali Farhan1,4, Guy Rouleau1,2,4

1McGill University, Human Genetics, Montreal, Canada; 2McGill University, Montreal Neurological Institute and Hospital, Montreal, Canada; 3McGill University, Department of Epidemiology, Biostatistics and Occupational Health, Montreal, Canada; 4McGill University, Neurology and Neurosurgery, Montreal, Canada; 5Universite Laval, Division of Neurosciences, CHU de Quebec, Quebec, Canada; 6Universite Laval, Department of Medicine, Faculty of Medicine, Quebec, Canada.

**Background/Objectives:** The genetic background of amyotrophic lateral sclerosis (ALS) consists of common small-effect alleles and rare penetrant alleles. Here, we tested whether risk for ALS was affected by high polygenic risk score (PRS), carrying rare ALS-associated variants, or both.

**Methods:** 330 ALS cases and 349 unaffected controls from Quebec, Canada were included. SNP-chip genotyping was generated for all samples, and targeted or whole exome sequencing was used to screen 26 ALS genes. We used ALS GWAS summary statistics1 to estimate PRS for ALS. From sequencing, only protein-altering variants rarer than 0.1% were included. Individuals were subdivided into cases and controls, and rare variant carriers or non-carriers. Logistic regression was used to assess association of ALS risk with PRS and rare variant status.

**Results:** 4309 SNPs were included in the PRS, which explained 1.16% of phenotypic variation. The upper PRS quartile showed an odds ratio of 2.05 for ALS risk. Risk for ALS was significantly associated with PRS and rare variants independently (p = 2.58 × 10⁻⁵ and 4.90 × 10⁻³, respectively), but the interaction was not significant. PRS only differed significantly between non-carrier cases and non-carrier controls (p = 0.0087).

**Conclusion:** ALS PRS was informative only between cases and controls not carrying a rare variant, suggesting that rare variants in ALS genes have a substantial effect on disease risk. Rather than modifying the penetrance of rare risk variants, ALS PRS differentiates cases and controls only in the absence of these variants.

**References:** 1. van Rhenen. 2016. Nat Genet. Grants: Canadian Institutes for Health Research – FRN 159279.

**Conflict of Interest:** None declared.

**P10.074.A GIPR and GLP1R genetic polymorphisms and alcohol dependence**

Evangelia Eirini Tsermpini1, Anja Plemenita Iliješ2, Katja Goricar1, Vita Dolzan1

1University of Ljubljana, Faculty of Medicine, Institute of Biochemistry and Molecular Genetics, Ljubljana, Slovenia; 2University Clinical Centre Maribor, Department of Psychiatry, Maribor, Slovenia.

**Background/Objectives:** Alcohol dependence affects approximately 4% of the general population. It leads to decreased quality of life for patients and their families and present a huge burden to society. Gastric inhibitory polypeptide receptor (GIPR) and glucagon-like peptide one receptor (GLP1R) are expressed in the reward-related brain areas and modulate dopamine levels and glutamatergic neurotransmission, which results in behavioral changes. The present study investigated the association of common genetic polymorphisms in GIPR and GLP1R with alcohol dependence.

**Methods:** Three groups of male Slovenian participants have been included: 88 hospitalized alcohol-dependent patients, 96 abstinent alcohol-dependent patients, and 94 healthy blood donors and were genotyped for GLP1R rs10305420 and rs6923761 and GIPR rs1800437. In the statistical analysis, Kruskal-Wallis and Mann-Whitney tests were used for additive and dominant genetic models.

**Results:** Polymorphic GIPR rs1800437 GC+CC genotypes were more frequent in hospitalized alcohol-dependent than controls (P = 0.020). The association remained statistically significant after adjustment for age, education, smoking, environment, and partnership (P = 0.040). Similar associations were observed when comparing alcohol-dependent patients with controls (P = 0.047), but the significance was lost after adjustment (P = 0.086). Regarding psychosomatomatolog, rs1800437 GC+CC genotypes were associated with Yale-Brown Obsessive Compulsory Scale (YBOCS) obsession (P = 0.045), YBOCS compulsion (P = 0.032), and Buss-Durkee Hostility Inventory (BDHI) (P = 0.046) scores. No significant associations were observed for GLP1R rs10305420 and rs6923761.

**Conclusion:** Our data indicate that GIPR rs1800437 may play some role in susceptibility to alcohol dependence, and obsession, compulsion, aggression, and hostility symptoms. However, further studies with larger cohorts are needed to confirm these preliminary findings.

**References:**

**Grants:** ARRIS P1-0170.

**Conflict of Interest:** Evangelia Eirini Tsermpini: None declared, Anja Plemenita Iliješ: None declared, Katja Goricar: None declared, Vita Dolzan ARRIS P1-0170.

**P10.076.C Expanded phenotype of Snijders Blok-Campeau syndrome related to CHD3 pathogenic variant with precocious puberty and pituitary microadenoma**

radu parascán1, eric allain2,3,3,3, philippe pierre robichaud4, BEN AMOR MOUIN5

1Centre de formation médicale du Nouveau-Brunswick, moncton, Canada; 2Dr George L Dumont hospital, moncton, Canada; 3Dr George L Dumont hospital, moncton, Canada.

**Background/Objectives:** Snijders Blok-Campeau syndrome is an autosomal dominant genetic disorder often associated with missense mutations in the CHD3 gene that affects chromatin remodelling in human cells. This syndrome is also

**European Journal of Human Genetics (2023) 31:345 – 709**

**SPRINGER NATURE**
characterized by a distinct neurodevelopmental phenotype. Here, we present a case of a young female diagnosed with Snijders-Blok-Campeau syndrome with previously unreported clinical features, including precocious puberty and pituitary microadenoma.

**Methods:** The patient was investigated by a multidisciplinary team, she had extensive genetic testing, including CGH, metabolic work-up and targeted exome sequencing.

**Results:** Sequencing data revealed a heterozygous de novo likely pathogenic variant in the CHD3 gene and no other notable structural or punctual variants. This case demonstrates a unique clinical manifestation of Snijders Blok-Campeau syndrome related to a de novo likely pathogenic variant in the CHD3 gene: NM_00105271.2: c.5609G>A.

**Conclusion:** We believe that central precocious puberty can be part of the clinical manifestation of Snijders Blok-Campeau syndrome and this finding can expand the phenotypic spectrum of this disorder.

**References:** Snijders Blok, L., Rousseau, J., Twist, J., Ehresmann, S., Takaku, M., Venselaar, H., Rodan, L. H., Nowak, C. B., Douglas, J., Swoboda, K. J., Steeves, M. A., Sahai, I., Stumpel, C. T., Stegmann, A. P., Wheeler, P., Willing, M., Fiala, E., Kochhar, A., Gibson, W. T., ... Campeau, P. M. (2018). CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language. Nature Communications, 9(1). https://doi.org/10.1038/s41467-018-06014-6.

**Grants:** New Brunswick health research foundation.

**Conflict of Interest:** radu parascan: None declared, eric allain: None declared, philippe pierre robichaud: None declared, BEN AMOR MOUNA NBHRF clinical research scholarship.

**P10.078.A genetic testing in turkish pituitary adenoma patients: preliminary findings**

Ceren Alavanda, özcan sönmez, fatih bayrakli, ailter guney

1Faculty of Medicine, Marmara University, Department of Medical Genetics, Istanbul, Turkey; 2Faculty of Medicine, Marmara University, Department of Neurosurgery, Istanbul, Turkey.

**Background/Objectives:** Pituitary adenomas are the third most common intracranial tumors after meningioma and glioma. Its incidence was determined as 15%. There is no familial predisposition in 95% of the patients, while the remaining 5% is familial. Although germline mutations of genes such as NF1, RET, CDKN1B, SDHs position in 95% of the patients, while the remaining 5% is familial.

**Methods:** DNA was isolated from peripheral blood after obtaining informed consent from patients. AIP gene sequencing (Illumina Miseq) was performed to eight patients and customized panel (50 genes-Illumina NovaSeq) was performed to 32 patients. Variants with MAF <0.01 were filtered and retained variants were searched in Clinvar. ACMG classification was used to determine the pathogenicity.

**Results:** Forty patients (19 women and 21 men) with age range between 15-71 were included in our study. Five patients had microadenoma and 35 patients had macroadenoma. The most common pathological subtype was GHoma (14/37). Two patients had atypical adenomas with high Ki67 and p53 levels. In four patients pathogenic variants were detected in MEN1, AIP, MLH1 and MUTYH genes. In one patient who also hadpheochromocytoma, variant of unknown significance (VUS) was detected in SDHD gene. In another patient, missense VUS was detected in AIP gene.

**Conclusion:** We detected pathogenic variants in 10% of our patients, contributing to the follow-up and treatment of both patients and their families which implicate the importance of genetic testing in pituitary adenoma patients.

**References:** Afiorei ED, Karbonits M. Epidemiology and etiopathogenesis of pituitary adenomas. J Neurooncol. 2014;117(3):379-394. https://doi.org/10.1007/s11060-013-1354-5.

**Grants:** Conflict of Interest: None declared.

**P10.079.B Identification of molecular signatures and pathways involved in Rett syndrome-spectrum disorders using a multi-omics approach**

Clara Xiol1,2, Ainhoa Pascual-Alonso1,2, Dmitrii Smirnov3,4, Robert Kopatchik3,4, Christina Ludwig5, Holger Prokisch3,4, Judith Armstrong2,6,7

1Fundació per la Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain; 2Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain; 3Institute of Human Genetics, Technical University of Munich, München, Germany; 4Institute of Neurogenomics, Helmholtz Zentrum München, München, Germany; 5Bavarian Biomolecular Mass Spectrometry Center, Technical University Munich, Freising, Germany; 6CIBER-ER (Biomedical Network Research Center for Rare Diseases), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; 7Genomic Unit, Molecular and Genetic Medicine Section, Hospital Sant Joan de Déu, Barcelona, Spain.

**Background/Objectives:** Rett syndrome (RTT) is a severe neurodevelopmental disorder whose classical form is mainly caused by mutations in the MECP2 gene. There are also atypical forms, generally caused by mutations in CDKL5 or FOXG1 and RTT-like forms, with considerable clinical overlap with typical RTT but caused by mutations in other genes. Since the pathomechanism by which the dysfunction of these genes causes disease is not yet fully understood, there is no treatment available. Therefore, the aim of this study is to characterize the molecular alterations in RTT-spectrum patients to identify common and specific molecular signatures and discover pathways involved in the pathogenesis of these disorders.

**Methods:** Primary fibroblast cell cultures were obtained from 33 RTT-spectrum patients (21 with typical RTT, 6 with atypical RTT and 6 with RTT-like) and 15 healthy controls. RNA and protein were isolated and genome-wide differential expression was evaluated by RNAseq and quantitative TMT proteomics.

**Results:** Differential expression analysis revealed common molecular signatures in RTT-spectrum patients and enrichment analysis identified altered pathways associated with these signatures. Spliceosome components and genes involved in oxidative phosphorylation were significantly enriched within altered genes in all RTT-spectrum patients. Moreover, we found specific alterations that distinguish patients with mutations in certain genes from other RTT-spectrum patients with overlapping phenotypes.

**Conclusion:** Integrative multi-omics contribute to the understanding of the pathomechanisms behind RTT-spectrum disorders and could uncover new biomarkers to monitor disease status as well as potential therapeutic targets for treating these disorders.

**References:**

**Grants:** P120/0289, FPU18/02152, 2020/FI-B/00888, PCP/00282.

**Conflict of Interest:** None declared.

**P10.081.D Digenic inheritance of STUB1 variants and TBP polyglutamine expansions solves the enigma of SCA17 and SCA48 incomplete penetrance**

Stefania Magri1, Lorenzo Nanetti1, cinzia gellera1, Elisa Sarto1, Maria Balzo1, Elena Rizzo1, Alessia Mongelli1, Alfredo Brusco2,3, Caterina Mariotti1, Daniela Di Bella1, Franco Taroni1

1Fondazione IRCCS Istituto Neurologico Carlo Besta, Unit of Medical Genetics and Neurogenetics, Milan, Italy; 2Università degli Studi di
Background/Objectives: Spino cerebellar ataxia type 17 (SCA17), characterized by cerebellar-cognitive-behavioural features, is caused by a CAG/CAA repeat expansion in the TBP gene. TBP alleles with >49 CAG/CAA are fully penetrant. By contrast, intermediate TBP alleles with 41-49 CAG/CAA (TBP_{41-49}) are characterized by reduced penetrance, since ~50% of carriers in SCA17 families are healthy and ~1% of subjects in the general population carry TBP_{41-49} alleles. Objective: To unravel the genetic factors underlying missing heritability in SCA17.

Methods: Using NGS approaches, we investigated 40 TBP_{41-54} index patients, their affected (n = 55) and unaffected (n = 51) relatives, and a cohort of ataxia patients (n = 292).

Results: All but one (30/31) index cases with intermediate TBP_{41-46} alleles carried a heterozygous pathogenic variant in the STUB1 gene encoding the chaperone-associated E3 ubiquitin ligase CHIP. No STUB1 variant was found in patients carrying TBP_{47-54} alleles. TBP expansions and STUB1 variants cosegregate in all affected family members, while the presence of either one alone was never associated with disease. STUB1 pathogenic variants were previously associated with the autosomal recessive spino cerebellar ataxia SCAR16 and the autosomal dominant spino cerebellar ataxia SCA4A.

Conclusion: Our data reveal an unexpected interaction between STUB1 and TBP in the pathogenesis of SCA17 and raise questions on the existence of SCA4A as a monogenic disease, with crucial implications for diagnosis and counselling. They provide a convincing explanation for the incomplete penetrance of intermediate TBP alleles and demonstrate a dual inheritance pattern for SCA17, which is a monogenic dominant disorder for TBP_{47} alleles and a digenic TBP/STUB1 disease (SCA17-DI) for intermediate expansions.

References:

Grants: FRBB_CP2_2018.

Conflict of Interest: None declared.

P10.083.B Loss of C-terminal Mediator Complex subunit-11 impairs fetal brain development and cause severely progressive neurodegeneration

Elisa Cali¹, Clarissa Rocca¹, Yavuz Şahin², Aisha Mohamed Saeed Mohamed Al Shamsi³, Salima EL CHEHADÈ⁴, Myriam CHAABOUNI⁵, Kshitij Mankad⁶, Evangelia Galanaki⁷, Stephanie ETHYMIOU⁸, Sniya Sudhakar⁹, Alkyon Athanasiou-Fragkoul⁴¹, Tamer Celik¹, Nejat Narli⁹, Sebastiano Bianca⁶, David Murphy¹², Andrea ACCOGLI₁₀,¹¹, Masoud Edizadeh²¹, Rosaria Nardello¹², Rosaria Del Nardella¹³, Patrizia De Marco¹³, Martina Rug­hièr¹⁴, Federico Zara¹⁵,¹⁶, Pasquale Striano¹⁶, Yavuz Sahin⁷, Ilhadh algazali¹⁸, Marie Therese Abi warde¹⁶, Benedicte Geradin²⁰, Giovanni Zifarelli²¹, Christian Beetz²¹, Sara Fortuno²², Miguel Soler²³, Enza Maria Valente²⁴,²⁵, Reza Maroofian¹⁹, Vincenzo Salpietro¹⁸,¹⁹,²⁶, Henry Houlden²⁷

¹University College London, Department of Neuromuscular Diseases, London, United Kingdom; ²Genoks Genetic Laboratory, Department of Medical Genetics, Ankara, Turkey; ³Tawam Hospital, UAE, United Arab Emirates; ⁴Service de génétique médicale, Institut de Génétique Médicale d’Alsace (IGMA), Centre de Référence des Déficences Intelectuelles de Causes Rares, Centre de Recherche en Biomédecine de Strasbourg (CRBS), Hôpitaux Universitaires de Strasbourg, Strasbourg, France; ⁵Igcgenetics, Centre medical les Jasmins, Centre urbain nord, Tunis, Tunisia; ⁶Great Ormond Street Hospital for Children NHS Trust, Department of Radiology, London, United Kingdom; ⁷Department of Pediatric Neurology, Private Practice, Adana, Turkey; ⁸Department of Neuronal Pathology, Cukurova University, Adana, Turkey; ⁹Medical Genetics, Referral Center for Rare Genetic Diseases, ARNAS Garibaldi, Catania, Italy; ¹⁰Division of Medical Genetics, Department of Specialized Medicine, Montreal Children’s Hospital, McGill University Health Centre (MUHC), Montreal, Canada; ¹¹Department of Human Genetics, McGill University, Montreal, Canada; ¹²Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialities “G. D’Alessandro”, Palermo, Italy; ¹³Unit of Medical Genetics, IRCCS Istituto Giannina Gaslini, Via Geraldo Gaslini 5, 16147 Genoa, Italy, Genova, Italy; ¹⁴Unit of Rare Diseases of the Nervous System in Childhood, Department of Clinical and Experimental Medicine, Section of Pediatrics and Child Neuropsychiatry, AOU “Policlinico”, PO “G. Rodolico”, Catania, Italy; ¹⁵Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genova, Italy; ¹⁶Pediatric Neurology and Muscular Diseases Unit, IRCCS “Istituto Giannina Gaslini”, Genova, Italy, Genova, Italy; ¹⁷Department of Medical Genetics, Biruni University, Instanbul, Turkey; ¹⁸Department of clinical genetics & pediatrics, College of Medicine & Health Science, UAE, United Arab Emirates; ¹⁹Pediatric Neurology Department, CHU Strasbourg, Strasbourg, France; ²⁰Laboratories de Diagnostic Génétique, Unité de génétique moléculaire, Nouvel Hôpital Civil, Strasbourg, France; ²¹CENTOGENE, Rostock, Germany; ²²Department of Chemical and Pharmaceutical Sciences, University of Trieste, Trieste, Italy; ²³CONCEPT Lab, Italian Institute of Technology (IIT), Genova, Italy; ²⁴Neurogenetics Research Center, IRCCS Mondino Foundation, Pavia, Italy; ²⁵Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Background/Objectives: The Mediator (MED) is an evolutionarily conserved multi-subunit protein complex that modulates the activity of several transcription factors and different critical components of the overall transcriptional machinery. Genetic defects of different MED subunits have been implicated in severe brain developmental disorders with microcephaly and neurodegeneration.

Methods: Exome or genome sequencing were performed in five unrelated families identified via different research networks and Matchmaker Exchanges. Deep clinical and brain imaging evaluations were performed by pediatric neurologists and neuroradiologists. The functional impact of the candidate variant on both MED11 RNA and protein was assessed by RT-PCR and Western Blotting using patient-derived fibroblast cell lines and by computational approaches.

Results: A recurrent, segregating homozygous variant in MED11 (c.325 C>T, p.Arg109Ter) was identified in all affected children. The variant results in a premature stop codon and a putative protein lacking the last nine residues of MED11 C-terminal. The phenotype was characterized by microcephaly, profound neurodevelopmental delay, exaggerated startle reaction, refractory myoclonic epilepsy and diffuse severe brain degeneration with premature death. Semi-quantitative RT-PCR and Western blot revealed levels of protein and transcript similar to healthy carriers and age- and sex-matched controls, suggesting the variant does not cause non-sense mediated decay (NMD) but instead disrupts the C-terminal domain of MED11.

Conclusion: Loss of the C-terminal of MED11 may affect its binding efficiency to other MED subunits, thus impacting the complex stability and function and leading to a rare and severe prenatal-onset developmental and degenerative neurological condition.

References:

Grants: Wellcome Trust (WT093205MA and WT104033AIA).

Conflict of Interest: None declared.

P10.084.C The genetics of manic symptoms assessed by the Mood Disorder Questionnaire

Jessica Mundy¹, Christopher Hübel¹, jonathan colemant¹, Brett Aday¹, Gursharan Kalsi², Henry Rogers¹, Lee Sang Huyck¹, molly
Background/Objectives: Mania affects ~1% of the population. Together with depression, it is characteristic of bipolar disorder, a severe psychiatric disorder closely related to other disorders, including depression and schizophrenia [1-2]. The Mood Disorder Questionnaire (MDQ) is used to screen for manic symptoms in at-risk groups and the general population [3]. We investigated the heritability of mania and calculated genetic correlations with other traits.

Methods: We created a continuous mania trait using MDQ data from the Genetic Links to Anxiety and Depression Study and healthy volunteers in the NIHR BioResource (n = 26,450) in the UK. We performed a genome-wide association study of mania and calculated genetic correlations using Linkage Disequilibrium Score Regression, applying multiple testing correction.

Results: The continuous mania trait had a SNP-based heritability of 0.06 (SE = 0.02). Mania showed a significant, positive genetic correlation with major depressive disorder (r_g = 0.45, SE = 0.10, p = 4.5x10^-3), attention deficit hyperactivity disorder (r_g = 0.54, SE = 0.11, p = 8.8x10^-3), posttraumatic stress disorder (r_g = 0.61, SE = 0.12, p = 8.5x10^-3), alcohol dependence (r_g = 0.48, SE = 0.12, p = 8.6x10^-3), and number of sexual partners (r_g = 0.26, SE = 0.06, p = 1.6x10^-3). Mania showed a significant, negative genetic correlation with educational attainment (r_g = -0.44, SE = 0.06, p = 3.41x10^-3). However, mania did not show significant genetic correlations with bipolar disorder or its subtypes.

Conclusion: Caution should be paid when assessing bipolar disorder quantitative traits via the MDQ in epidemiological studies. When applied to the general population, the MDQ may capture symptoms of general distress rather than mania.

References: [1] Daly (1997).
[2] Mullins et al. (2021).
[3] Hirschfeld et al. (2000).

Grant: Funded by the NIHR Maudsley Biomedical Research Centre and the Lord Leverhulme Charitable Grant.

Conflict of Interest: Jessica Mundy: None declared, Christopher Hübner: None declared, Jonathan Coleman: None declared, Brett Adey: None declared, Gursharan Kalsi: None declared, Henry Rogers: None declared, Lee Sang Huyck: None declared, Molly Davies: None declared, Thalia Eley: None declared, Robin Murray: None declared, Evangelos Vassos: None declared, Gerome Breen: Prof Breen has received honoraria, research or conference grants and consulting fees from Illumina, Otsuka, and COMPASS Pathfinder Ltd., Prof Breen has received honoraria, research or conference grants and consulting fees from Illumina, Otsuka, and COMPASS Pathfinder Ltd., Prof Breen has received honoraria, research or conference grants and consulting fees from Illumina, Otsuka, and COMPASS Pathfinder Ltd.

P10.085.D Neuropsychiatric risk in children with intellectual disability of genetic origin: IMAGINE - The UK National Cohort Study

Jeanne Wolstencroft1, Marianne Van Den Bree2, Jeremy Hall2, Michael Owen4, David Skuse1, Imagine Consortium1-4, F. Lucy Raymond4

1NIHR BRC Great Ormond Street Institute of Child Health, London, United Kingdom; 2Cardiff University, Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff, United Kingdom; 3University of Cambridge, School of Clinical Medicine, Cambridge, United Kingdom.

Background/Objectives: Children with intellectual disability (ID) frequently have multiple co-morbid neuropsychiatric conditions and poor physical health. Genomic testing is increasingly recommended as a first-line investigation for these children. We aimed to determine the impact of genomics, inheritance and socioeconomic deprivation on neuropsychiatric risk in children with intellectual disability of genetic origin as compared to the general population.

Methods: IMAGINE is a prospective study using online mental health and medical assessments in a cohort of 2770 children with ID and pathogenic genomic variants, identified by the UK’s National Health Service.

Results: Assessments completed on 2397 young people with ID (4-19 years, M 9.2, SD 3.9) with a rare pathogenic genomic variant. 1339 (55.9%) were male. 1771 (73.9%) of participants had a pathogenic copy number variant (CNV), 626 (26.1%) a pathogenic single nucleotide variant (SNV). Participants were representative of the socioeconomic spectrum of the UK general population.

The relative risk of co-occurring neuropsychiatric diagnoses, compared with the UK national population, was high: Autism Spectrum Disorder 29.2 (95% CI 23.9 to 36.5), Attention Deficit Hyperactivity Disorder 13.5 (95% CI 11.1 to 16.3). In children with CNV, those with a familial variant tended to live in more socioeconomically deprived areas. Both inheritance and socioeconomic deprivation contributed to neuropsychiatric risk in those with a CNV.

Conclusion: Children with genomic variants and ID are at a greatly enhanced risk of neuropsychiatric difficulties. CNV variant inheritance and socioeconomic deprivation also contribute to the risk.

References:
[1] Daly (1997).
[2] Mullins et al. (2021).
[3] Hirschfeld et al. (2000).

Conflicts of Interest: Jeanne Wolstencroft: None declared, Marianne Van Den Bree Grant from Takeda Pharmaceuticals, Jeremy Hall Grant from Takeda Pharmaceuticals, Michael Owen Grant from Takeda Pharmaceuticals, David Skuse: None declared, Imagine Consortium: None declared, F. Lucy Raymond: None declared.

P10.086.A Single-cell deconvolution of cerebellar cortex uncovers increased proportions of astrocytes and granule cell loss in essential tremor

Charles-Etienne Castonguay1, Calwing Liao1, Miranda Medeiros1, Gabrielle Houle1, Alex Rajput2, Patrick Dion1, Guy Rouleau1

1McGill University, Montreal, Canada; 2University of Saskatchewan, Saskatoon, Canada.

Background/Objectives: Essential tremor (ET) is one of the most common movement disorders, affecting 1% of the worldwide population. Not much is known about its pathophysiology. Some histopathological studies of ET cerebellum have noted reduced numbers of Purkinje cells (PCs), but this finding remains controversial [1]. We sought to replicate these findings using deconvolution of bulk-RNA sequencing (bulk RNA-seq) data to compare cell type proportions between ET and healthy control cerebellar cortices.

Methods: MuSiC was used to deconvolute bulk RNA-seq of 16 ET and 16 control cerebellar cortex using cerebellar single-cell data [2]. A permutation test (100k iterations without replacement) was used to test cell type proportions between ET and control samples.
Results: Most cell types including both PC subtypes did not differ between ET and control samples. Astrocytes proportions were significantly increased in ET samples compared to controls (Beta = 0.0382, q-val = 0.0196). Granule cells were significantly decreased in ET cerebellum compared to control cerebellum (Beta = -0.0563, q-val = 0.0221).

Conclusion: Using deconvolution of bulk RNA-seq, we found increased proportions of astrocytes as well as decreased numbers of granule cells in ET cerebellum compared to controls. PC proportions did not differ between ET and control samples. Although astrogliosis has been previously described in ET, decreased numbers of granule cells is a novel finding in ET.

References: [1] Rajput, A.H., Parkinsonism Relat. Disord. (2013). [2] Lake B.B., Nature Biotechnology. (2018).

Grants: Canadian Institutes of Health Research - CGSM.

Conflict of Interest: None declared.

P10.090.A Biallelic variants in the ESCRT-II subunit SNF8 cause either early-onset leukoencephalopathy or childhood onset optic atrophy

Melanie Brugger1, Yan Zhen2, Leonardo Caporali3, Andreas Brech4, Vigidis Sørensen4, Robert Kopajtich1,5, Benedikt Zott6, Kornelja Kreiser7, Gertrud Strobl-Wildemann8, Francesca Clementina Radio9, Antonella Lauri9, Rosalba Carrozzo10, Claudio Fiorini11, Chiara La Morgia12, Luca Ziccardi12, Viviana Cordeddu13, Giuseppe Zumino14, Maria Arelin15, Christiane Blechschmidt16, Holger Proksch1,5, Rachel Michaelson-Cohen17, Hagit Daum17, Rami Abou Jamra18, Thomas Arzberger19, Juliane Winklmann20,21,22,23, Nikola; Sekulic24, Valerio Carelli25, Marco Tartaglia26, Harald Stenmark4, Matias Wagner1,5

1Institute of Human Genetics, Munich, Germany; 2Institute for Cancer Research, Oslo, Norway; 3IRCSc Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; 4Istituto per Cancer Research, Oslo University Hospital, Oslo, Norway; 5Institute of Neurogenomics, Munich, Germany; 6Klinikum rechts der Isar, Technical University of Munich, Department of Diagnostic and Interventional Neuroradiology, Munich, Germany; 7University Hospital Ulm, Department of Radiology and Neuroradiology, Ulm, Germany; 8Praxis für Human- genetik, Ulm, Germany; 9Ospedale Pediatrico Bambino Gesù, Genetics and Rare Diseases Research Division, Rome, Italy; 10Laboratory of Molecular Medicine, Bambino Gesù, Children’s Hospital, Department of Neurosciences, Rome, Italy; 11University of Bologna, Department of Biomedical and Neurosurgery Research, Bologna, Italy; 12IRCSc-Fondazione Berti, Rome, Italy; 13Istituto di Neurofisiologia, University of Bologna, Department of Neurosciences, Bologna, Italy; 14Institute of Human Genetics, Munich, Germany; 15Institute of Molecular and Molecular Cell Biology, Bambino Gesù, Children’s Hospital, Department of Neurosciences, Rome, Italy; 16Institute of Human Genetics, Munich, Germany; 17Center for Rare Diseases and Birth Defects, Department of Woman and Child Health and Public Health, Rome, Italy; 18Hospital for Children and Adolescents, Department for Women and Child Health, Leipzig, Germany; 19Hospital Nürnberg, Department of Neuropathology, Nürnberg, Germany; 20Shaare Zedek Medical Center, Department of Gynecology, Jerusalem, Israel; 21Hadassah Medical Organization and Faculty of Medicine, Department of Genetics, Jerusalem, Israel; 22University Medical Center Leipzig, Institute of Human Genetics, Leipzig, Germany; 23University Hospital Munich, Center for Neuropathology and Prion Research, Munich, Germany; 24Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany; 25Chair of Neurogenetics, Neurological Clinic and Polyclinic, Munich, Germany; 26Munich Cluster for Systems Neurology (SyNergy), Munich, Germany; 27Centre for Molecular Medicine Norway (NCMM), Oslo, Norway; 28University of Bologna, Department of Biomedical and Neurosurgery Research (DiBiNEM), Bologna, Italy; 29Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, Rome, Italy.

Background/Objectives: We report five individuals from three unrelated families presenting with severe leukoencephalopathy and three adults from two unrelated families presenting with mild developmental delay and optic atrophy in which biallelic variants in the gene encoding the ESCRT-II subunit SNF8 could be identified.

Methods: Exome sequencing was performed in affected individuals which were collected using GeneMatcher. Patients were phenotyped including MRI and neuropathologic examinations. Proteomic profiling of patient derived fibroblasts as well as immunofluorescence and electron microscopy studies were used to assess ligand-induced EGFR degradation and autolysosome formation.

Results: Cases with leukoencephalopathy had severe developmental delay and secondary microcephaly, three of four passed away within the first two years of life. Loss of ESCRT II subunits was confirmed in patient derived fibroblasts by proteomic profiling. Patient derived fibroblasts showed no detectable defects in cytokinesis or degradation of growth factor receptors but displayed an accumulation of autolysosomes which could be reproduced by knockdown of SNF8 in control fibroblasts. Electron microscopy showed accumulation of vesicular structures and immunohistopathological evaluation of brain tissue in one individual revealed increased LC3B staining both in line with autolysosome accumulation. Additionally, adult cases presented with loss of function variants in compound-heterozygosity with a recurrent missense variant. This variant could be observed in homozygosity in a control individual suggestive of a hypomorphic effect.

Conclusion: Loss of ESCRT II due to biallelic SNF8 variants is associated with two allelic diseases characterized by impaired autophagic flux: early-onset leukoencephalopathy and adult-onset optic atrophy the latter associated with a hypomorphic effect.

References:

Grants: 

Conflict of Interest: None declared.

P10.091.B Genetic abnormalities in neurodevelopmental disorders with multidimensional impairment

Cyril Hanin1, Paloma Torres1, Isabelle Millet1, Joanna Matos1, Marianna Giannitelli1, Cora Cravera1, Anne Sophie Pellen1,2, DELPHINE HERON2, Boris Keren3, Cyril Mignot2, Charline Grossard1, Ingrid Zammouri1, Astra De Foucaud4, Angele Consoli5, Claudine LAURENT-LEVINS01, David Cohen1

1Hôpital de la Pitié Salpêtrière, AP-HP.SU, Sorbonne Université, Referral Center for Rare Diseases with Psychiatric Expression, PARIS, France; 2Hôpital de la Pitié Salpêtrière, AP-HP.SU, Sorbonne Université, Referral Center for Intellectual Disability, PARIS, France; 3Hôpital de la Pitié Salpêtrière, AP-HP.SU, Sorbonne Université, Uf de génomique du développement, PARIS, France.

Background/Objectives: Many neurodevelopmental disorders (NDD) in children are complex with multiple domains of dysfunction (Xavier and Cohen, 2020). These cases have been termed Multidimensional Impairment (MDI), but they could be considered “diagnostically homeless” because DSM-5 does not include MDI. Here, we evaluate the prevalence of genetic abnormalities in MDI as a step toward establishing the utility of this diagnosis.

Methods: We evaluate complex NDD cases using both categorical and dimensional approaches (e.g. intelligence, language, motor coordination, executive functions). In 2016, we established a secure computerized database of genetic data for these cases. Between 2017 and 2019, we diagnosed MDI in 637 patients of whom 133 had a genetic assessment, using DNA microarrays to
**P10.094.A Investigation of causal association between ALS and Autoimmune disorders**

**Paria Alipour**, Konstantin Senkevich, Despoina Manousaki, Dan Spiegelman, Patrick Dion, Guy Rouleau

1Department of Human Genetics, McGill University, Montreal, Canada; 2Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada; 3Department of Neurology and Neurosurgery, McGill University, Montreal, Canada; 4Department of Biochemistry and Molecular Medicine, University of Montreal, Montreal, Canada; 5Department of Pediatrics, University of Montreal, Montreal, Canada; 6Research Center of the Sainte-Justine University Hospital, Montreal, Canada.

**Background/Objectives:** Amyotrophic Lateral Sclerosis (ALS) is reported to be associated with different autoimmune disorders according to epidemiological studies. This study aims to explore the causal relationship between ALS and these various traits.

**Methods:** Following selection of 11 different traits, we used largest available GWAS summary statistics of autoimmune disorders with European ancestry participants. Applying two-sample Mendelian randomization (MR) we investigated the causal association between exposures (autoimmune disorders) and an outcome (ALS in our case). MR uses the SNPs strongly associated with exposure to establish the causal association between exposure and outcome. The MR analysis was performed using R package TwoSampleMR.

**Results:** After applying Bonferroni correction for multiple testing, MR analyses show no causal relationship between autoimmune disorders and ALS. The variance in the exposure variables explained by SNPs ranged from 8.1E-04 to 3.1E-01. All instruments had F-statistics of >10, which is above the standard cut-off indicating sufficient instrumental strength. The SNPs within the human leukocyte antigen (HLA) region were excluded in the analyses. We also performed reverse MR between ALS and autoimmune disorders and did not find any causal relationship.

**Conclusion:** Our MR study did not support the direct causal relationship between ALS and autoimmune disorders in European population. The associations observed in epidemiological studies could be, in part, attributed to shared biology, confounders and bias.

**References:**

| Grant(s): |
| --- |
| Canada’s federal funding agency for health research. |

**Conflict of Interest:** None declared.

**P10.095.B A novel Adnp mutant mouse model reveals involvement of the WNT signaling pathway in the Helsmoortel-Van der Aa syndrome**

**Claudio D’Incal**, Elisa Cappuyns, Jolien Huyghebaert, Ellen Elinck, Debby Van Dam, Elke Callus, Peter De Deyn, Takuro Horii, Izuho Hatada, Wim Vanden Berghe, Frank Kooy

1University of Antwerp, Antwerp, Belgium; 2Centre of Medical Genetics (Genetic genetics) and Epigenetic Signalling lab, Antwerp, Belgium; 3University of Antwerp, Antwerp, Belgium; 4University of Antwerp, Antwerp, Belgium; 5Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Japan.

**Background/Objectives:** Loss-function mutations in the Activity-Dependent Neuroprotective Protein Homeobox (ADNP) gene have been linked to the Helsmoortel – Van der Aa Syndrome (HVDAS), a complex neurological disorder characterized by autism, intellectual disability amongst many additional abnormalities. Mutations in the ADNP gene are almost exclusively de novo with the p.Tyr719* being the two most frequent mutation.

**Methods:** We introduced a frameshift mutation in the murine Adnp gene with CRISPR/Cas9 technology to create a mouse model for the human disorder and we studied the effect of the Leu822HisFs*6 mutation in a heterozygous model. Mutant mice underwent a behavioural testing battery including Morris water maze, elevated plus maze test, and the marble burying test. RNA sequencing and differential proteome analyses were performed on the frontal cortex of mutant and wild-type littermate controls.

**Results:** Adnp mutant mice carry a 14 base pair deletion, resulting in a frameshift in exon 5, a mutation akin to that observed in patients. A 30% reduction of Adnp mRNA and protein levels were observed in the mutant mice. Behavioural testing showed an increased anxiety, cognitive impairments together and increased repetitive behaviour, a hallmark of autism. A combination of RNA sequencing and differential proteome analysis of the frontal cortex of Adnp mutant mice identified a downregulation of the WNT signalling pathway, impacting neuronal development and development.

**Conclusion:** Our findings constitute the baseline behavioural and molecular characterization of a new mouse model for the HVDAS, and identify the WNT signalling pathway as a potential target for future therapy of the disorder.

**References:**

| Grant(s): |
| --- |
| None declared. |

**Conflict of Interest:** Claudio D’Incal PhD student and Academic Assistant, Elisa Cappuyns: None declared, Jolien Huyghebaert: None declared, Ellen Elinck: None declared, Debby Van Dam: None declared, Elke Callus: None declared, Peter De Deyn: None declared, Takuro Horii: None declared, Izuho Hatada: None declared, Wim Vanden Berghe: None declared, Frank Kooy: None declared.
Background/Objectives: Constitutional thinness and anorexia nervosa both present with low weight (e.g., BMI <18.5 kg/m²). However, individuals with anorexia nervosa additionally fear gaining weight and engage in weight loss behaviours not seen in constitutional thinness. Body composition regulation and anorexia nervosa are both heritable. It is unclear how constitutional thinness differs from anorexia nervosa on a genomic level.

Methods: We calculated genetic correlations among constitutional thinness, anorexia nervosa and traits genetically correlated with anorexia nervosa, to investigate similarities and differences. Additionally, we identified individuals with constitutional thinness in the Avon Longitudinal Study of Parents and Children (ALSPAC) and performed polygenic score analyses.

Results: Our results suggest that, in contrast to anorexia nervosa, attention deficit hyperactivity disorder ($r_{GAN} = 0.02$ vs. $r_{GCT} = -0.24$) and alcohol dependence ($r_{GAN} = 0.07$ vs. $r_{GCT} = -0.44$) are significantly genetically correlated with constitutional thinness. A higher polygenic score for posttraumatic stress disorder is associated with an increased risk of constitutional thinness in the ALSPAC cohort ($OR = 1.27; Q = 0.03$) whereas posttraumatic stress disorder shows no genetic correlation with anorexia nervosa ($r = -0.02$).

Conclusion: Even though both anorexia nervosa and constitutional thinness are marked by low BMI, they differ on a genomic level.

References:

Grants: BRC at South London and Maudsley NHS Foundation Trust and King’s College London, G5TT Charity (TR130505), Maudsley Charity (980), MRF (ref: MR/R004803/1), Wellcome (Grant ref: 102221/2/13/2 and 217065/Z/19/Z), NIMH (R21 MH115397; R01MH121070; R01MH119084; R01MH118278; U01 MH109528), Vetenskapsrådet (award: 538-2013-8864), Lundbeck Foundation (Grant no. R276-2018-4581), MRC UK (MR/T027843/1)

Conflict of Interest: Christopher Hübel: None declared, Mohamed Abdulkarid: None declared, Moritz Herle: None declared, Alish Paimos: None declared, Gerome Breen NHIR UK, Maudsley Charity, Guy’s and St. Thomas’s Trust, Compass Pathways Ltd, Otsuka Ltd, Ruth Loos NIH US, Nadia Micali NIH, Cynthia M Bulik, Shire, Lundbeckfonden, NIH USA, Shire, Idorsia, Pearson (author, royalty recipient).

P11 NEUROMUSCULAR DISORDERS

P11.001.D Gene variant and neuromuscular findings from a Long-Chain Fatty Acid Oxidation Disorder gene panel program

Vanessa Rangel Miller1, Peter Baker II2, Omid K. Japalaghi3, Nicola Longo4, Deborah Marsden1, Heather McLaughlin5, Tom Pulles6, Kate Simmons7, Jillian Yong8, Nicole Miller1

1Ultragenyx Pharmaceutical Inc., Novato, United States; 2University of Colorado, Anschutz Medical Campus, Aurora, United States; 3University of Utah, Salt Lake City, United States; 4Invitae Corporation, San Francisco, United States; 5Ultragenyx Europe GmbH, Allschwil, Switzerland.

Background/Objectives: Long-chain fatty acid oxidation disorders (LC-FAOD) are rare, life-threatening, autosomal recessive conditions that can be diagnosed clinically with plasma acylcarnitine analysis and molecular testing. Undiagnosed LC-FAOD may present with hypoglycaemia, cardiomyopathy, cardiac arrhythmias, and neuromuscular symptoms.

Methods: Patients with a clinical diagnosis or suspicion of LC-FAOD are eligible for this no-charge NGS gene panel which includes 6 genes associated with LC-FAOD plus 18 genes associated with disorders that cause abnormal acylcarnitine profiles.

Results: As of 28 October 2021, LC-FAOD gene variants were identified in 153 (37%) of 417 patients tested, including 83 variants of uncertain significance (VUS), 8 likely pathogenic (LP), and 102 pathogenic (P) variants. Twenty-three patients had positive (2 P/LP) LC-FAOD results and 19 had potential positive (2 variants, at least 1 VUS) results. VUS resolution analysis led to the reclassification of 6 variants from VUS to LP or P. Five patients had variants in two or more LC-FAOD genes and 22 had variants in one LC-FAOD gene and one or more non-LC-FAOD genes. Fifty-one patients had only one LC-FAOD gene variant identified.

The most common neuromuscular symptoms among patients ages ≥13 (76 reported) were myopathy (42), elevated creatine kinase (36), and rhabdomyolysis (30), and among patients <13 years (83 reported) were elevated creatine kinase (22), and myopathy (12).

Conclusion: Program results demonstrate the diverse composition of gene variants in patients referred for LC-FAOD genetic testing. Approaches to resolve VUS and identify previously undetected variants in patients with suspected LC-FAOD are important and necessary.

References:

Grants: None, sponsored by Ultragenyx Pharmaceutical Inc.

Conflict of Interest: Vanessa Rangel Miller Ultragenyx Pharmaceutical Inc., Ultragenyx Pharmaceutical Inc., Peter Baker II Ultragenyx (ended 2021, unspent), Omid K. Japalaghi Ultragenyx, Nicola Longo Longo Clinical Trial Support: Aeglea, Amicus Therapeutics, Audentes/astrellas, AuroBio, BioMarin, Chiesi/Protalix, Genzyme/SanoBi, Hemoshear, Homology, Horizon Pharma, Moderna, Nestle’ Pharma, Pfizer, PTC Ther. /CENSA, Reneo, Retropath/Traverve Pharma, Shire/Takeda, Synlogic, Ultragenyx, Speaker: Cycle Pharmaceuticals, Alnylam, Amicus Therapeutics, BioMarin, BridgeBio/CoA Ther, Chiesi/Protalix, Genzyme/SanoBi, Hemoshear, Horizon Pharma, Jaguar Gene Therapy, Leadiant Biosciences, Moderna, Nestle’ Pharma, PTC Ther. /CENSA, Recordati, Reneo, Shire/Takeda Synlogic, Ultragenyx, Data Safety Monitoring Board: ACI Clinical (Applied Ther, Taysha), CTI-Clinical Trial (Vtesse), Deborah Marsden Ultragenyx, Ultragenyx, Heather McLaughlin Invitae, Invitae, Tom Pulles Ultragenyx, Ultragenyx, Kate Simmons Ultragenyx, Ultragenyx, Jillian Yong Invitae, Invitae, Nicole Miller Ultragenyx, Ultragenyx.

P11.002.A Extended clinical spectrum associated with de novo variant in CLTC gene

Kristi Tael1,2, Nadezda Sapovalova3, Eve Õiglane-Shlik4, Sanna Puusepp1,2, Bjarne Udd1,2, Katrin Ounap1,2

1Faculty of Medicine, University of Tartu, Department of Clinical Genetics, Institute of Clinical Medicine, Tartu, Estonia; 2Tartu University Hospital, Department of Clinical Genetics, United Laboratories, Tartu, Estonia; 3Tartu University Hospital, Children’s Clinic, Tartu, Estonia; 4Folkhalsan Research Center, Helsinki, Finland; 5Tampere Neuromuscular Center, Tampere, Finland.

Background/Objectives: De novo heterozygous variants in CLTC, which encode the clathrin heavy chain protein, are associated with a variable phenotype from mild to severe intellectual disability (ID), microcephaly, hypoplasia of the corpus callosum, and epilepsy. Congenital heart defects and kidney anomalies have also been described. No thorough muscle investigations are in published CLTC patients so far.
Methods: The boy is a second child of non-consanguineous parents born after 10 years infertility from in vitro fertilization. He was born at term by caesarean section, with normal growth parameters and Apgar scores (8/9). At 13 months, he was investigated due to developmental delay and muscular hypotonia, which was more prominent in proximal muscles. There was more subcutaneous tissue in the thighs and upper arms compared to other parts of the body. His motor development corresponded to 6 months and communication skills to 4 months. Magnetic resonance imaging (MRI) of the leg and pelvis muscles showed massive general muscular hypotrophy without clear dystrophic replacement and a peculiar amyloplasia of the medial gastrocnemius. Electroneuro-myography and muscular biopsy indicated a possible congenital myopathy or congenital myotonic dystrophy. MRI of the brain was normal.

Results: Trio exome sequencing revealed a pathogenic de novo missense variant NM_004859.4 (CLTC):c.2669C>T p.(Pro890-Leu), and was confirmed by Sanger sequencing.

Conclusion: Muscular hypotonia is a constant clinical finding in previously reported patients with CLTC gene variant. We present a patient with marked general muscular hypotonia, which may cause more pronounced delay in motor development.

References:

Grants: Estonian Research Council grant PRG471.

Conflict of Interest: None declared.

P11.004.C Three novel MTM1 pathogenic variants identified in patients with X-linked myotubular myopathy presented by severe neonatal hypotonia: diagnostic algorithm, genotype-phenotype correlations

Katarína Kušiková1, Martina Witsch-Baumgartner2, Martina Skapkova3, Daniela Gaspenkova4, Miroslav Kolnikov4, Ognian Kalev5, Serge Weis6, Denisa Weis7

1Department of Pediatric Neurology, Medical School, Comenius University and National Institute of Children’s Diseases, Bratislava, Slovakia; 2Institute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria; 3Department of Metabolic Disorders, Institute of Experimental Endocrinology, Biomedical Research Center SAS, Slovakia, Bratislava, Slovakia; 4Division of Neuropathology, Department of Pathology and Molecular Pathology, Kepler University Hospital Neuromed Campus, Johannes Kepler University Linz, Linz, Austria; 5Department of Medical Genetics, Kepler University Hospital Med Campus IV, Johannes Kepler University Linz, Linz, Austria.

Background/Objectives: X-linked myotubular myopathy (X-MTM, OMIM: 310400) is a rare neuromuscular disorder (prevalence 1:50,000 males), caused by mutations in the MTM1 gene (OMIM: 300415). The most severe is the classic form manifested in neonates as floppy infant, areflexia, and early ventilatory support dependence. Due to the severity of clinical manifestations with early mortality, and potential therapy options (current clinical trials for X-MTM6), early diagnosis is essential. According to previously published data it seems that severe genotype is related to the truncating mutation while non-truncating mutations are responsible for moderate or mild phenotype. However, an exact genotype-phenotype correlation still remains unclear.

Methods: We present 3 detailed case reports of patients (2 Austrian, 1 Slovakian) with severe neonatal hypotonia, where X-MTM was diagnosed according to diagnostic algorithm (in-house approach presented) using exact clinical evaluation, histopathological findings in muscle biopsy sample and molecular genetics approach using whole exome sequencing.

Results: 3 novel hemizygous pathogenic variants were found in MTM1 gene: (NM_000252.2): c.438_439delCA (p.His146GlnfsX10), (NM_000252.3): c.(342 +1_343-1)_(444 +1_445-1)del, and (NM_000252.3): c.(1053 +1_1054-1)_(1467 +1_1468-1)del (p.Leu352_Gln489). Histopathological findings in biopsied muscle (n = 2) were consistent with X-MTM.

Conclusion: A comprehensive diagnostic approach is essential for the early diagnosis of neonatal forms of NMDs. The easiest and time-saving approach is an immediate muscle biopsy in case of postnatal severe muscular hypotonia. Subsequent molecular examinations serve to confirm the diagnoses, render a prognosis and potential treatment.

References: 1. Lawor MW, Dowling JJ. Neuromuscular Disorders, 2021. 2. Oliveira J et al. European Journal of Human Genetics, 2013.

Grants: APVV-17-0296.

Conflict of Interest: None declared.

P11.005.D Interactome-based multi-omics approach to study disease activity in the early phases of Multiple Sclerosis

Valentina Nale1, Alice Chioldi1, Antonino Giordano2,3, Béatrice Pignonet2, Ferdinando Clarelli2, Elisabetta Mascia2, Silvia Santoro2, Laura Fera2,3, Miryam Cannizzaro2,3, Matteo Gnocchi2,3, Marco Moscatelli2,5, Kaatind Misra2, Melissa Sorosina2, Luciano Milanesi2, Massimo Filippi2,3, Roland Liblau4, FEDERICA ESPOSITO2,3, Ettore Mosca2

1Institute of Biomedical Technologies, National Research Council, Segrate (MI), Italy; 2IRCCS San Raffaele Scientific Institute, Division of Neurosciences, Milan, Italy; 3IRCCS San Raffaele Scientific Institute, Neurology, Milan, Italy; 4CHU Toulouse, Neurosciences, Toulouse, France; 5Territorial Research Area of Milan 4, Segrate (MI), Italy; 6Vita-Salute San Raffaele University, Milan, Italy.

Background/Objectives: Multiple Sclerosis (MS) is an autoimmune disease of the Central Nervous System (CNS), characterized by high clinical heterogeneity. Here, we analysed multi-omics data using molecular networks to disentangle the biological basis of MS inflammatory activity by identifying relevant gene networks and pathways implicated in disease activity [1].

Methods: Relapsing remitting MS patients were characterized as EDA (Evidence of Disease Activity) or NEDA (No-EDA) at 2 years of follow-up. GWAS (n = 1533): PLINK and MAGMA for gene-wise statistics. Differential methylation analysis (n = 243): minf; differential expression analysis (mRNA and miRNA) (n = 243): Deseq2. Gene-gene interactions: STRING and iRefIndex. Tissue-specific gene-gene interactions: HumanBase. miRNA-mRNA interactions: miTarbase and miRNet. Identification of gene networks supported by multi-omics evidences: dmfind and mND. Gene-pathway associations: MSigDB. Enrichment analysis and pathway cross talk analysis: Ullisese.

Results: We mapped the results of EDA-NEDA GWAS and EDA-NEDA differential methylation/expressions analysis onto genome-wide molecular networks. We found brain-specific and lymphocyte-specific networks of genes that carry variants associated with EDA, and interact with “core” (recurring) network regions. The integrative analysis revealed gene networks that are supported by genomics, epigenomics and transcriptomics. Network analysis shed light on key genes involved in multiple connections and/or connectors between diverse pathways.

Conclusion: Our network-based multi-omics analysis provides an in-depth knowledge of genes and pathways which appear to be associated with inflammatory activity in MS, including novel candidates that require further study.

References: [1] https://www.findingms.com.

Grants: MoH GR-2016-02363997, FRRB ERAPERMED2018-233 GA 779282.

Conflict of Interest: Valentina Nale: None declared, Alice Chioldi: None declared, Antonino Giordano: None declared,
Background/Objectives: The SLC12A6 gene encodes the potassium chloride cotransporter, KCC3, which is involved in maintaining cell volume and intracellular chloride levels in neurons [1]. Pathogenic variants in SLC12A6 are known to cause autosomal recessive motor and sensory neuropathy with corpus callosum agenesis and mental retardation (HMSN/ACC). In recent years, heterozygous de novo SLC12A6 variants have been described in patients with early onset predominantly motor neuropathy [2-4].

Methods: At two Norwegian centres performing genetic analysis of peripheral neuropathies, the SLC12A6 gene was analysed by next-generation sequencing as part of the diagnostic routine. Family members were examined by Sanger sequencing. For functional characterization, the mutant KCC3 cotransporter was modelled in Xenopus oocytes.

Results: In five families presenting with late onset peripheral neuropathy, the heterozygous SLC12A6 variant, NM_001365088.1 (c.1655G>A (p.Gly552Asp)) was found to segregate with the disease in ten affected patients and to be absent in two unaffected family members. Clinical and neurophysiological evaluations revealed a predominant sensory axonal polyneuropathy with slight to moderate motor components. Functional characterization of the p.(Gly552Asp) variant showed a significant reduction in function, demonstrated through reduction of potassium influx.

Conclusion: Our findings further expand the spectrum of SLC12A6 disease to involve late onset autosomal dominant axonal neuropathy with predominant sensory deficits.

References: 1. Flores, et al, Neurochem Int, 2019. 123.
2. Kahle, et al, Sci Signal, 2016. 9(439).
3. Park, et al, J Med Genet, 2020. 57(4).
4. Shi, et al, Neuroumuscular Dsord, 2021. 31(2).

Grants: HH received funds from the South Eastern Norway Regional Health Authority (HSO).

Conflict of Interest: None declared.

P11.008.C Mosaic collagen 6-related myopathy mimicking a hemihypotrophy syndrome

Miriam Elbracht1, Annette Lischka1, Stefan Nikolin2, Joachim Weis2, Ingo Kurth1, Katja Eggermann1

1Institute of Human Genetics, Medical Faculty, RWTH Aachen University, Aachen, Germany; 2Institute of Neuropathology, Medical Faculty, RWTH Aachen University, Aachen, Germany.

Background/Objectives: Somatic mosaicism as a cause of genetic-related disorders is well known but the detection in routine diagnostic workup of monogenic disorders is challenging.
Methods: We present a patient with hemihyptrophy and relevant leg/arm length and circumference difference (right > left). Mildly elevated CK levels, progressing muscular weakness and pain led to MRI examination which showed marked reduction and fatty degeneration of the muscles of the left side. Muscle biopsy in the affected area revealed a chronic myopathy with connective tissue and fat proliferation combined with a moderately chronic neurogenic muscle atrophy. Electron microscopy revealed fine filamentous, dense deposits in the extracellular matrix in close proximity to the sarcolemma, consistent with altered collagen synthesis.

Results: Exome sequencing of blood DNA showed no pathogenic variant using standard filter settings, but in exome sequencing of the affected muscle DNA the variant NM_004369.3:c.6210+1G>A in the COL6A3 gene was identified in approximately 18% of the reads. This canonical splice-site variant has already been described as pathogenic in the literature and in the ClinVar database (Bethleum myopathy, Ulrich congenital muscular dystrophy, OMIM: 120250). Further investigation of the exome data from the blood DNA revealed that the variant was present in about 13% of the reads, being slightly below the internal cut-off value. Sanger sequencing confirmed somatic mosaicism in both tissues.

Conclusion: Our findings show that mosaicism for a structural myopathy may not only manifest as milder generalized disorder, but may mimic a hemihyptrophy syndrome. Careful evaluation of NGS data with regard to low-grade and sometimes tissue-specific mosaicism is needed.

References:

Grants: -

Conflict of Interest: None declared.

P11.009.D Exome sequencing in understanding the etiology of hypotonia

Arya Shambhavi1, Amita Moirangthem2, Haseena Sair2, Somya Srivastava2, Renu Suthar2, Shubha Phadke2

1Sanjay Gandhi Postgraduate Institute of Medical Sciences, Medical Genetics, Lucknow, India; 2Sanjay Gandhi Postgraduate Institute of Medical Sciences, Medical Genetics, Lucknow, India; 2Post Graduate Institute of Medical Education & Research, Chandigarh, Chandigarh, India.

Background/Objectives: Hypotonia is a common feature in neuromuscular disorders having varied etiologies. NGS has a good diagnostic yield (upto 59%) given the phenotypic and genotypic variability seen in Hypotonia1-2. This study aims to provide information about the diagnostic yield and expand the genotypic spectrum in patients presenting with hypotonia in Indian population.

Methods: Patients with hypotonia with unknown etiology based on preliminary evaluation were enrolled. Exome sequencing was done followed by genotype-phenotype correlation.

Results: Forty cases (10 consanguineous) were recruited and exome sequencing was performed where causative variant(s) were identified in 34 cases, suggesting a diagnostic yield of 85%. Of these 34 cases, pathogenic/likely pathogenic variants were identified in 21 cases. Of the 34 cases, 22 novel variants were identified in 18 genes. Biallelic variations were identified in 17 autosomal recessive genes, heterozygous variations in 8 autosomal dominant genes and hemizygous variation in one X-linked gene. One patient was homozygous for two genes (PYCR1 and FBLN5) and the variants segregated in the family suggesting blended phenotype.

Conclusion: The diagnostic yield in our cohort is 85%. We have identified 22 novel variants in 18 genes. Additionally, our study expands the genotypic and phenotypic spectrum of the genetic forms of hypotonia.

References: 1. AlBanji, Mohammed H et al. “Utility of Hypotonia Diagnostic Investigations: A 12-year Single Center Study.” Molecular genetics and metabolism reports vol. 25 100665 (2020).

Conflict of Interest: None declared.

P11.010.A FSHD analysis pipeline by Bionano optical genome mapping - a field report

Monika Morak1, Constanze Kurschat2, Jenny Schiller3, Soheyla Chahrokh-zadeh3, Julia Philippou-Massier4, Imma Rost5, Hanns-Georg Klein5, Uwe Heinrich1

1MVZ Martinsried, Martinsried, Germany.

Background/Objectives: The autosomal-dominantly inherited facioscapulohumeral muscular dystrophy-1 (FSHD1) is caused by contractions of D4Z4 repeats to less than 10 on the permissive 4qA-haplotype on chromosome 4q35. We tested the practicability of the Bionano EnFocus™ FSHD Analysis pipeline.

Methods: Optical genomic mapping data were generated on Bionano Genomics Saphyr with data quality recommended (minimum 80x with total DNA =150 kb, output 1300 Gb, map rate 70.7-92.4%) from 80 patients with clinical indication not implicating FSHD diagnosis and two positive FSHD-controls, and were analysed by FSHD1.

Results: In our FSHD-negative patient dataset, the FSHD pipeline analysis was successful in 64 cases and gave normal results with repeats ranging from 11 to 61 on 4qA-alleles. Eleven cases had low coverage (<20 locus-spanning reads per allele), and five were not analysable, e.g. due to merged data. The reads were discriminated between chromosome 4 and the homologous region on chromosome 10, the respective haplotypes A or B were assigned, and for each allele the number of D4Z4 repeats was analysed.

In 14% of the cases, shorter/incomplete reads were called as additional alleles (++/-1-2 repeats) and were removed manually, whereas a third allele in two patients (3%) indicated a mosaicism of repeat length. Alleles with >30 repeats were underrepresented (65%). In two commercial FSHD1-positive samples, the respective repeat contractions on one 4qA-allele were correctly detected and distinguishable from chromosome 10.

Conclusion: A validated Bionano optical genomic mapping method allows a reliable analysis for FSHD1 with the Bionano EnFocus™ FSHD Analysis pipeline integrated in the software.

References: -

Grants: -

Conflict of Interest: Monika Morak: None declared, Constanze Kurschat: None declared, Jenny Schiller: None declared, Soheyla Chahrokh-zadeh: None declared, Julia Philippou-Massier: None declared, Imma Rost: None declared, Hanns-Georg Klein partner of IMGM laboratory, Uwe Heinrich: None declared.

P11.011.B Functional characterization of mutations causal to rare muscle disorders in genes encoding intermediate filament proteins

Shamita Sanga1, chandrayee mukherjee2, krishak sengupta2, moulinath acharya1

1National Institute of Biomedical Genomics, Kalyani, India; 2Saha Institute of Nuclear Physics, Biophysics and Structural Genomics Division, Kolkata, India.
Background/Objectives: Mutations in the DES gene encoding cytoplasmic desmin proteins and LMNA gene encoding A-type lamins, are a common cause of familial desminopathy and laminopathy. Here, we provide evidence of the pathological role of two novel desmin and lamin mutations occurring in two patients of Indian origin.

Methods: Exome sequencing was performed to identify pathogenic or likely pathogenic mutations in DES and LMNA gene in two Indian origin patients with muscle disorder. Two novel mutations, NM_001282625.1:c.590T>C; p.(Leu197Pro) in the LMNA gene leading to formation of truncated desmin protein and the missense mutation NM_001282625.1:c.590T>C;p.(Leu197Pro) in the LMNA gene were identified. The variants were validated by sanger sequencing and segregation analysis was also performed. The pathological role of these mutations were determined in cultured primary human skeletal muscle cells (HSKMC). Confocal imaging was performed to observe any defect in the localization of these two proteins.

Results: Analysis of the confocal micrographs elucidated the formation of aggregates and migration of truncated desmin proteins into the nucleus of the cells transfected with mutant desmin constructs. On the other hand, c.590T>C change in the LMNA gene also showed formation of aggregates and disappearance of laminar rims in the nuclei of the muscle cells.

Conclusion: The formation of desmin and lamin aggregates and absence of laminar rim in the nuclei of the muscle cells provides a clue to explain pathogenicity of c.448C>T and c.590T>C in desminopathies and laminopathies, respectively. The aggregates might disturb the cellular homeostasis and organelle positioning thereby impacting the mechano-transduction signalling.

References:

Conflict of Interest: None declared.

P11.014.A Non-invasive biomarker discovery in amyotrophic lateral sclerosis

Christa Caggiano¹, Marco Morsetti², Barbara Celona³, Robert Henderson⁴, Catherine Lomen-Hoerth⁵, Fleur Garton⁶, Matteo Pellegrini⁷, Noah Zaitlen¹

¹University of California, Los Angeles, Neurology, Los Angeles, United States; ²University of California, Los Angeles, Molecular and Developmental Biology, Los Angeles, United States; ³University of California San Francisco, Cardiovascular Research Institute, San Francisco, United States; ⁴Royal Brisbane and Women's Hospital, Neurology, Herston, Australia; ⁵University of California San Francisco, Neurology, San Francisco, United States; ⁶The University of Queensland, Institute for Molecular Biosciences, Saint Lucia, Australia.

Background/Objectives: Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease with complex pathogenesis. Although there are several candidates, there is no clinical biomarker for ALS. A biomarker, however, could expedite diagnosis, monitor disease progression, or prioritize patients for clinical trials. Here, we propose using cell-free DNA (cfDNA) as a non-invasive biomarker for ALS. CfDNA is an ideal candidate because it is enriched in ALS patients, is informative about tissue-specific cell death, and can be extracted from a standard blood draw.

Methods: To study cfDNA in ALS with the potential to be clinically relevant, we developed a capture panel technology that has a projected cost of under $300 per sample. The panel was designed to capture methylation sites that are informative for tissue status. Using this technology, we captured over four thousand regions and performed next-generation sequencing of 48 cases and 48 controls. Sequencing data was combined with supervised machine learning to predict ALS disease status using the methylation status of the reads and clinical covariates.

Results: With this approach, we replicated past findings of higher skeletal muscle cfDNA in ALS patients (logit p-value: 0.026). Furthermore, our model could accurately predict ALS disease status (cross-validated AUC: 0.95, AUPRC: 0.95), which may reach the level of clinical utility.

Conclusion: Together, these results demonstrate that cfDNA may be a valuable predictive biomarker in ALS.

References: 1. Bowser et al. (2011), 2. Taga & Maragakis (2018), 3. Caggiano et al. (2021).

Grants: NIH 1K01NS112358, ALS Finding a Cure, UCSF Weill Award.

Conflict of Interest: None declared.

P11.015.B SMN1 and SMN2 status in Georgian SMA patients

Dodo Agladze¹,², Lili Margvelashvili³, Saba Jordaniašvili, Nana Kvirkvelia⁴, Teona Shatirisvili⁵, Nana Tatishviii³,⁹

¹Pediatric Surgery Center (KidCo), Tbilisi, Georgia; ²Todua Clinic, Tbilisi, Georgia; ³Georgian Foundation for Genetic and Rare Diseases

Abstracts from the 55th European Society of Human Genetics Conference
Background/Objectives: Spinal muscular atrophy is an autosomal recessive inherited disorder affecting 1:10000 individuals, causing the progressive degeneration, muscle weakness and atrophy. It is considered to be one of the most life limiting condition in infants. The aim of the study was to determine the genotype of the Georgian patients diagnosed with SMA.

Methods: 51 patients clinically diagnosed with SMA were tested for SMN1 and SMN2 status. Quantitative RT-PCR was performed. Amplification of SMN1 exon 7/8 and SMN2 exon 7 was used to detect the number of copies.

Results: From tested 51 individuals only in 41 (80%) diagnose was confirmed, 1 (2%) was a carrier. 35 (85%) of confirmed cases were homozygous for SMN1 exon 7 and 8 deletion, 6 (15%) revealed 1 copy of exon 8. Patients with homozygous deletion showed heterogeneity in SMN2 copy number. From 41 patients 23 (56%) have 3 copies of SMN2 gene, 15 (36.5%) 2 copies and 3 (7.5%) 4 copies. From 11 patients who need palliative care, 100% (56%) have 3 copies of SMN2 gene, 15 (36.5%) 2 copies and 3 were homozygous for SMN1 exon 7/8 deletion and do not have more than 2 copies of SMN2 gene.

Conclusion: As well as in most other populations SMA phenotype in Georgian patients is highly dependent on the disease genotype. There is a strong correlation between the clinical features of the disorder and the number of SMN1 and SMN2 genes copies. Type 1 SMA is affecting nearly 30% of the patients. Implementation of National SMA screening program is highly recommended.

References:

Grants:

Conflict of Interest: None declared.

P11.016.C An unusual case of TP11 deficiency causing early-onset dystonia without hemolytic anemia

Arthur Sorlin1, Emmanuel Scalais2, Jimena Murgia3, Ben Flies1, Guillaume Jouret4, Fernand Pauly4, Richard van Wijk5, Christian Muller5, Philippe Theis6, Lucas Herissant1, Christophe Olinger1, Dominique Bourgeois1, Daniel Stieber7, Barbara KLINK8

1Laboratoire national de santé, National Center of Genetics, Dudelange, Luxembourg; 2Centre Hospitalier de Luxembourg, Neurologie pédiatrique, Luxembourg, Luxembourg; 3Centre Hospitalier de Luxembourg, Service National d’Evaluation et de Rééducation Fonctionnelles, Luxembourg, Luxembourg; 4Université Medisch Centrum Utrecht, Laboratorium voor Rode Bloedcel Onderzoek, Afdeling Klinische Chemie en Haematologie, Utrecht, Netherlands.

Background/Objectives: Triosephosphate isomerase deficiency (TPID) is a rare, severe autosomal recessive enzynopathy, characterized by congenital hemolytic anemia, progressive neuro-muscular dysfunction beginning in early childhood, cardiomyopathy, increased susceptibility to infections, and neurodegeneration (OMIM 615512).

Methods: We used trio exome sequencing to study DNA from a 10 years old girl affected with early-onset dystonia and epilepsy.

Results: Exome sequencing revealed two compound heterozygous mutation in the Triosephosphate isomerase gene, TP11. The pathogenicity of these two novel mutations (a frameshift variation and a missense in the first exon) was confirmed by an enzyme activity assay, showing a strongly decreased TP1 activity. However, this patient’s phenotype is unusual, as repeated exams showed the absence of nonspherical hemolytic anemia, which is considered a hallmark of TPID. Some phenotypic variability has been described, including patients with anemia without neurologic involvement, or severe forms with death in childhood due to respiratory failure, but an isolated dystonia without anemia was never reported two our knowledge.

Conclusion: The identification of these two novel variations, in association with an unusual phenotype, provides the opportunity to enhance the current knowledge about this rare and poorly understood disorder. We would like to gather data from more patients with classic or atypical TPID, which will pave the way towards a better comprehension of the disease mechanism.

References: None.

Grants: None.

Conflict of Interest: None declared.

P11.017.D Primary hypogonadism in a patient with CONDSIAS: coincidence or spectrum?

Gorjan Milanovski1, Iskra Bitovska2, Meri Kirija3, Boban Dobrevski1, Teodora Brnjarchevska Blazevska1, Ivan Barbov4, Aleksandar Petlichkovski1, Zoran Gucev5, Todor Arsov5,6

1Ss. Cyril and Methodius University in Skopje, Faculty of Medicine – Skopje, Institute of Immunobiology and Human Genetics, Skopje, Macedonia; 2Ss. Cyril and Methodius University in Skopje, Faculty of Medicine – Skopje, University Clinic for Endocrinology, Skopje, Macedonia; 3Ss. Cyril and Methodius University in Skopje, Faculty of Medicine – Skopje, University Clinic for Neurology, Skopje, Macedonia; 4Ss. Cyril and Methodius University in Skopje, Faculty of Medicine – Skopje, University Children Hospital, Skopje, Macedonia; 5Centre for Personalised Immunology, Australian National University, Canberra, Australia.

Background/Objectives: ADP-ribosylation is a posttranslational modification of proteins in response to cellular stressors, with excessive poly-ADP-ribose accumulation triggering the cell-death cascade. Two genes (ADPRHL2, PARG) encode specific PAR-degrading enzymes and bi-allelic pathogenic ADPRHL2 variants are reported to cause the ultra-rare autosomal recessive Childhood-onset, neurodegeneration, stress-induced, with variable ataxia and seizures (CONDSIAS, OMIM 618170).

Methods: We present a 34-year old male patient with a 20-year long history of progressive generalized hypotonia and hypotrophy, ataxia, reduced superficial and deep sensation, mild intellectual disability, hypogonadism, and normal brain MRI scan. Laboratory examination detected very low testosterone and high FSH levels and testicular MRI demonstrated profound testicular hypoplasia and DEXA scan confirmed significant osteoporosis.

Results: Trio whole-exome sequencing using Illumina NGS platform, identified a homozygous pathogenic missense ADPRHL2 variant c.1004T>G; p.Val335Gly. This variant has been previously reported in several unrelated patients with CONDSIAS and was shown to influence enzyme activity and reduce cell survival in the setting of oxidative stress. The variant is present within the gnomAD database with an extremely low frequency (0.0000954).

Conclusion: To our knowledge this is the first case of CONDSIAS associated with primary hypogonadism, raising the interesting question whether the hypogonadism is part of the underlying genetic spectrum, or whether it is a coincidental finding. This case also raises the question about the potential role of testosterone/steroid hormones in ADPRHL2 deficiency, given the milder phenotype, no history of seizures, normal brain MRI and the repeated history of adverse muscular effect of testosterone supplementation in our patient.

References: None.

Grants: None.
Background/Objectives: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis. In this study, we report a recurrent variant c.401A>G (p.Glu134Gly) in the SOD1 gene is the most frequent genetic cause for ALS with incomplete penetrance.

Methods: DNA samples of more than 10000 patients were tested by using clinical and whole exome sequencing.

Results: Among Russian patients variant c.401A>G in the SOD1 have been identified in 6 cases. In 3 of them (50%) the variant was identified in patients with ALS. Their ages ranged from 32 to 50 years. The variant was also identified in 3 patients with diagnosis unrelated to ALS. Two of them have not yet reached the middle age of manifestation of this disease. The mother of one of the probands with ALS, carrying the variant, had no clinical manifestations of the disease. A notable feature in our study is that three probands live in the same region.

Conclusion: The variant was classified as likely pathogenic according to the guidelines for massive parallel sequencing (ACMG) data interpretation (criteria PM1, PM2, PP3, PP5). Despite this the question of the pathogenicity of this variant remains open.

P11.021.D A recurrent variant in the SOD1 gene – is a frequent pathogenic or a rare benign variant?

Olga Shatkohina1, Ilya Kanivets2, Denis Pyankov4, Fedor Konovalev, Oksana Ryzhkova1

1Federal State Budgetary Institution «Research Centre for Medical Genetics, The Shared Resource Centre (SRC) "Genome", Moscow, Russian Federation; 2Genomed Ltd, Moscow, Russian Federation; 3Independent Clinical Bioinformatics Laboratory, Moscow, Russian Federation.

Background/Objectives: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis. In this study, we report a recurrent variant c.401A>G (p.Glu134Gly) in the SOD1 gene is the most frequent genetic cause for ALS with incomplete penetrance.

Methods: DNA samples of more than 10000 patients were tested by using clinical and whole exome sequencing.

Results: Among Russian patients variant c.401A>G in the SOD1 have been identified in 6 cases. In 3 of them (50%) the variant was identified in patients with ALS. Their ages ranged from 32 to 50 years. The variant was also identified in 3 patients with diagnosis unrelated to ALS. Two of them have not yet reached the middle age of manifestation of this disease. The mother of one of the probands with ALS, carrying the variant, had no clinical manifestations of the disease. A notable feature in our study is that three probands live in the same region.

Conclusion: The variant was classified as likely pathogenic according to the guidelines for massive parallel sequencing (ACMG) data interpretation (criteria PM1, PM2, PP3, PP5). Despite this the question of the pathogenicity of this variant remains open.

P11.018.A HINT1-Neuropathy in France: Let’s expand genotypic and phenotypic spectrum

Victor Morel1, Emmanuelle Campagna-Salort2, Florence Esselin3, Ulrike Walther-Louvier4, Giorgia Querin5, Philippe Latour6, Valérie Delague7, Nicolas Levy1;7, Tanja Stojkovic8, Shahram Attarian2;7, Nathalie Bonello-Palot1,7.

1APHM, CHU Timone, Génétique Médicale, Marseille, France; 2APHM, CHU Timone, Centre de référence des Maladies Neuromusculaires et de la SLA, Marseille, France; 3CHU Montpellier, Centre de référence des Maladies du Motoneurone et des Maladies Neuromusculaires, Montpellier, France; 4CHU Montpellier, Service de Neuropsychiatrie, Centre de référence des Maladies Neuromusculaires AOC (Atlantique-Occitanie-Caraïbe), Montpellier, France; 5APHP, Hôpital Pitié-Salpêtrière, Service de Neuropsychiatrie, Paris, France; 6CHU de Lyon, GH Est, Service de Biochimie et Biologie Moléculaire Grand Est, Bron, France; 7Aix Marseille Univ, Inserm, U1251-MMG, Marseille Medical Genetics, Marseille, France; 8APHP, Hôpital Pitié-Salpêtrière, Centre de Référence des Maladies Neuromusculaires Nord/Est/Île de France, Paris, France.

Background/Objectives: Inherited peripheral neuropathy (IPN) is a heterogeneous group of disorders due to mutations in more than 90 genes. In 2012, the first cases of IPN associated with HINT1 variants were described in 33 families sharing the same phenotype. A novel disease was discovered: Autosomal Recessive Axonal Neuropathy with Neuromyotonia (ARAN-NM #137200). HINT1 is involved in the regulation of transcription, cell-cycle control and possibly in neuropsychiatriy pathophysiology. To date, only 3127 patients have been described with neuropsychiatric symptomatology or neurodevelopmental disorder.

Methods: Herein, we report 6 French patients with ARAN-NM identified by Next Generation Sequencing. We conducted a literature review and compared phenotypic and genotypic features with our cohort.

Results: We identified a novel HINT1 mutation involved in ARAN-NM: c.310G>C (p.Gly104Arg) and the first African patient. This cohort is comparable with literature data regarding age of onset (8,5yo), neuronal involvement (sensorimotor 3/6 and motor 6 individuals).

Conclusion: We expand genotypic et phenotypic spectrum of ARAN-NM. Neuropsychiatric features could be part of HINT1-related disease and we should further study the clinical phenotype of the patients previously described.

References: 1. Zimova, M., Baets, J., … Jordanova, A. (2012). Loss-of-function mutations in HINT1 cause axonal neuropathy with neuromyotonia. Nature Genetics, 44(10), 1080–1083. 2. Varadarajulu, J., … Martins-de-Souza, D. (2012). Differential expression of HINT1 in schizophrenia brain tissue. European Archives of Psychiatry and Clinical Neuroscience, 262(2), 167–172.

Grants: Conflict of Interest: None declared.

P11.019.B Targeted screening of the C9orf72 and ATXN2 gene in Bulgarian amyotrophic lateral sclerosis patients

Slavko Ormandzhiev1, Tihomir Todorov1, Teodor Angelov2, Teodora Chamova2, Vanyo Mitev2, Albena Todorova1, Ilya Kanivets2, Denis Pyankov4, Fedor Konovalev, Oksana Ryzhkova1.

1Genetic Medico-Diagnostic Laboratory “Genica”, Sofia, Bulgaria; 2University Hospital Aleksandrovska, Clinic of Neurology, Sofia, Bulgaria; 3Medical University of Sofia, Department of Medical Chemistry and Biochemistry, Sofia, Bulgaria; 4New Bulgarian University, Department of Cognitive Science and Psychology, Sofia, Bulgaria.

Background/Objectives: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease, characterized by progressive degeneration of the upper and lower motor neurons, leading to muscle weakness, hypotrophy, swallowing and respiratory failure.

The cause of ALS is not fully elucidated, but there are 35 associated genes and 2 gene loci with an unidentified gene. The most common are C9orf72, SOD1, TARDBP and FUS found in approximately 10% of patients. It has been established that intermediate length polyglutamine (polyQ) expansions (~27–33 Qs) are a significant risk factor for ~4.7% of ALS cases.

Methods: Expansions in the C9orf72 and ATXN2 genes were analysed by in-house short PCR and triplet repeat-primed PCR assay (TP-PCR), followed by fragment analysis.

Results: From 200 ALS patients included in the current study, 7 (3.5%) were diagnosed with C9orf72 repeat expansion, carrying more than 145 GGGGCC repeats. In addition, 7 ATXN2 expansions ranging from 27 to 30 CAG repeats and 2 borderline expansions of 26 CAG repeats were identified. Furthermore, two asymptomatic family members were genetically proved to be ATXN2 expansion carriers.

Conclusion: Amyotrophic lateral sclerosis is a rare neurodegenerative disease for which there is a lack of genetic data for Bulgarian patients. The obtained results enrich the worldwide database and shed light onto genetically characterized Bulgarian ALS patients. Affected patients and their families can be offered adequate medical-genetic consultation and prenatal diagnostics.

References: Grants: The financial support of the Medical University Sofia, grant №PD-90/24.06.2020 and №PD-42/08.03.2021 is gratefully acknowledged.

Conflict of Interest: None declared.

Conflict of Interest: None declared.
open, due to the fact that half of the cases were found in one region, including in patients without ALS. Interpreting such variants beyond the primary cause of the disease can be challenging and time-consuming for both clinicians and labs.

References:

Grants:

Conflict of Interest: None declared.

P11.022.A The Middle Eastern Genomes Project: Leveraging consanguinity in inherited diseases

Alan Pittman1, Paria Najarzadeh Torbati2, Mina Zamani3, Luke Peacock1, Chris Carroll1, Kate Everett1, Ehsan Ghayoor Karimiani1,2, Hamid Galehdari3, Reza Maroofian4, Yalda Jamshidi5

1St George’s University of London, London, United Kingdom; 2Department of Medical Genetics, Next Generation Genetic Polyclinic, Mashhad, Iran; 3Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; 4UCL Queen Square Institute of Neurology, London, United Kingdom.

Background/Objectives: Consanguineous marriages are common in the Middle East and associated with an increased burden of autosomal recessive genetic conditions. We have characterised two thousand individuals with a variety of conditions including inherited neuromuscular disease. The variant frequency data, enriched for homozygous variants, and particularly homozygous loss of function variants, provides an invaluable opportunity to gain scientific and clinical insights into gene function, as well as providing support for candidate disease gene identification and variant interpretation.

Methods: Homozygosity mapping and whole exome/genome sequencing was carried out and analysed according to best practice and included single nucleotide, copy number and mitochondrial variant analysis. Candidate disease variants were assessed based on predicted effect on protein structure and function, amino acid conservation, and population frequency, and by family segregation using Sanger sequencing.

Results: We have detailed frequency and functional prediction data on 2.7 million coding variants, including approximately 100,000 putative loss-of-function variants and 1.5 million missense variants. Likely pathogenic/pathogenic variants were detected in 46% cases in different disease-causing genes, including novel genes first identified in this population.

Conclusion: Our results provide novel insights into genotype-phenotype relationships and identify high frequency disease variants in this unique population, suggesting the utility of population specific sequencing efforts. The availability of genetic data from the Middle East, currently an underrepresented group in large genomic databases, will support both local genetic diagnostics as well as facilitating the assignment of pathogenicity to variants found in other populations and provide opportunities for discovery of new disease-gene associations.

References:

Grants: The work was supported by the grant of AZV ČR NU21-06-00363.

Conflict of Interest: None declared.

P11.024.C Severe neonatal respiratory distress is part of the clinical spectrum of congenital myopathy with tremors associated with dominant MYBPC1 variants

Pierre-Louis Lanvin1, Solène Conrad1, Magot Aermelle2,3, Bertrand Isidor2, Mathilde Nizon1,4, Marie Vincent1,4, Damien Stemberg1,2, Xavier Micaelli2, Pereon Yann2, Sandra Mercier1,3,4

1CHU Nantes, Department of medical genetics, Nantes, France; 2CHU Nantes, Department of Clinical Neurophysiology, Nantes, France; 3Reference Centre for Neuromuscular Disorders AOC, Filnemus, Euro-NMDO, Nantes, France; 4Nantes Université, CNRS, INSERM, l’institut du thorax, Nantes, France; 5APHP, Metabolic Biochemistry Department, Genetics Center, Pitié-Salpêtrière Hospital, Paris, France; 6Group, Center of Research in Myology, APHP Sorbonne University, Paris, France; 7CHD Vendée, Service de Pédiatrie, La Roche Sur Yon, France.

Background/Objectives: Congenital myopathies are phenotypically and genetically heterogeneous. While MYBPC1 variants were previously described in Distal Arthrogryposis type 1B, Complex Congenital Arthrogryposis or Lethal Congenital Contractural Syndrome, heterozygous missense variants in the MYBPC1 gene have been recently identified in 11 patients from five families with congenital myopathy with tremor (MYOTREM, MIM 618524). All variants are located at highly conserved residues in the M-motif. We report one new patient with MYOTREM expanding the clinical spectrum to severe neonatal respiratory distress.

References:

Grants: The work was supported by the grant of AZV ČR NU21-06-00363.

Conflict of Interest: None declared.
Methods: Trio Whole Genome Sequencing has been carried out as part of the France Genomic Medicine 2025 Plan.

Results: The patient presented with neonatal respiratory distress due to stridor, severe axial and peripheral hypotonia, weak spontaneous movements and myogenic tremors of the jaw and four limbs on stimulation. We identified a de novo heterozygous missense variant in MYBP1: c.742G>A; p.(Glu248Lys) in a 16 month-old girl. This variant has been previously described as pathogenic in MYOTREM. Motor skill abilities improved over time as previously reported. She sat up unaided at 15 months and started crawling and standing at 16 months. Gastrostomy supplementation could be discontinued at 13 months. Despite gradual improvement, she remained highly dependent on non-invasive ventilation (12-hour daily dependence at 16 months).

Conclusion: This observation extends the clinical spectrum of MYOTREM, which should be considered in the differential diagnosis of neonatal hypotonia associated with severe respiratory distress. Early diagnosis is essential to reassure parents about good motor prognosis in adulthood.

References: 1 Stavusis et al, Ann Neurol, 2019.

Grants: None.

Conflict of Interest: None declared.

P11.025.D Deep intronic mutations, alternative splicing and complex chromosomal rearrangements in the DMD gene: genetic diagnosis of dystrophinopathies through mRNA analysis

Alba Segarra-Casas1, maria josé rodriguez1, aurelio hernández-lain2-3, María Teresa Sánchez Calvin1, cristina dominguez1-3, andrea campo-barosa1-6, Marcos Madruga2, eloy rivas8-9, Carlos Ortez2-10, Daniel Natera-de Benito1-6, anna codina1-6, Andrés Nascimento1-6, pia gallano1-6, lidia gonzalez-quereda1-6

1Hospital de Sant Pau, IIB-Sant Pau - UAB, Genetics Department, Barcelona, Spain; 2Hospital 12 de Octubre Research Institute (i+12), Madrid, Spain; 3Hospital Universitario 12 de Octubre, Department of Neuropathology, Madrid, Spain; 4Hospital Universitario 12 de Octubre, Genetics Department, Madrid, Spain; 5Center for the Biomedical Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain; 6Hospital Universitario Virgen Macarena, Pediatric Department, Sevilla, Spain; 7Hospital Universitario Virgen del Rocío, Pediatric Neurology Department, Seville, Spain; 8Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain; 9Hospital Universitario Virgen del Rocío, Pathology Department, Seville, Spain; 10Neuromuscular Unit, Hospital Sant Joan de Déu, Institut de Recerca Sant Joan de Déu - UB, Neuropediatrics Department, Barcelona, Spain.

Background/Objectives: Becker and Duchenne Muscular Dystrophy (BMD/DMD) are X-linked muscular dystrophies caused by alterations in the DMD gene. An early genetic diagnosis of the disease allows anticipatory care, an optimal management of the disease, be eligible for mutation-specific therapies and genetic and reproductive counselling. It has been estimated that 5-7% of the patients remain genetically undiagnosed despite an extensive study in the genomic DNA (1). Here, we evaluate the diagnostic utility of mRNA sequencing of the DMD gene in dystrophinopathy patients.

Methods: In eight patients with a clear clinical suspicion of dystrophinopathy supported by the presence of alterations in muscle biopsy and without a precise genetic diagnosis after MLPA and NGS, we extracted RNA from muscle biopsy and evaluated the whole mRNA of the DMD gene. Droplet Digital PCR was performed to quantify transcript isoforms.

Results: Through cDNA sequencing, we have identified alterations in DMD mRNA in all the patients. We have detected the presence of two novel pseudoexons, transcript isoforms related with mild BMD and chromosomal rearrangements.

Conclusion: The mRNA analysis of the DMD gene is a useful technique to fulfill the genetic diagnosis of dystrophinopathy patients. It enables the identification of alterations in mRNA processing that cannot be detected through MLPA and NGS.

References: 1. Dent KM, Dunn DM, Von Niederhausern AC, et al. Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort. Am J Med Genet. 2005;134A(3):295–8.

Grants: This study was granted by FIS P118/01585, funded by ISCIII. ASC was supported by FP20/06692 (Ministerio de Universidades).

Conflict of Interest: None declared.

P11.026.A Evaluation of molecular-genetic testing results of myotonic dystrophies in the last 30 years in Slovakia

Eva Tothova Tarova1-2, Zuzana Pös1, Ludevit Kadasi1-3, Peter Spalek4, Jan Radvansky1-3

1Biomedical Research Centre, Slovak Academy of Sciences, Institute for Clinical and Translational Research, Bratislava, Slovakia; 2Faculty of Education, J. Selye University, Department of Biology, Komarno, Slovakia; 3Faculty of Natural Sciences, Comenius University in Bratislava, Department of Molecular Biology, Bratislava, Slovakia; 4Centre for Neuromuscular Diseases, University Hospital Bratislava, Bratislava, Slovakia.

Background/Objectives: Myotonic dystrophies (DM) are genetic disorders with two known genetic forms and overlapping multi-organ symptomatology. DM1 and DM2 are caused by tandem repeat expansions in the DMPK and in the CNBP genes, respectively. We report the statistical results of molecular-genetic testing of DM suspected patients.

Methods: We retrospectively evaluated the findings of 739 individuals tested for DM1 and DM2 belonging to 610 families. They consisted of approved DM1 and DM2 patients and patients with no DM expansions detected. Symptomatology in all three groups was assessed; however, only the main complaints and clinical findings when ordering molecular-genetic testing, i.e., do not reveal the complex symptomatology of patients.

Results: DM1 expansion was confirmed in 69 families (102 patients). DM2 expansion was confirmed in 94 families (142 patients). 390 families remained without confirmed expansions. DM2 seems to be more common in Slovakia than DM1. The age of molecular diagnosis was a decade higher in the DM2 group (49.02 years) than in the DM1 group (40.97 years). DM1 and DM2 were identified in both sexes equally, while DM2 was more commonly identified among women. The most commonly reported symptoms, i.e., myotonic findings and myotonia on EMG, muscle weakness, and cataracts, were identified in all three groups, although slightly different frequencies.

Conclusion: No single symptom or combination of symptoms was identified that would differentiate between the DM1 and DM2 groups, or even patients suspected but not proved to have DM.

References: Grants: APPV-18-0319; VEGA-2/0167/20.

Conflict of Interest: None declared.

P11.027.B Neuromuscular disease diagnosis: the experience of a reference laboratory in Brazil

Fernanda Teixeira Belluccio1-2, Maria Arismendi Gonçalves3, Anelisa Gollo Dantas1-2, Ana Eduarda Campos3, Betânia Machado Loures4, Helena Ribeiro Barbosa5, Jacqueline H. R. Fonseca5, Márcio Gonçalves Ribeiro1-2, Mateus de Oliveira Torres5, Milene Mulatinho5,

1Hospital de Clínicas de Porto Alegre, Coordination of Neurology Department, Porto Alegre, Brazil; 2Faculdade de Medicina de Porto Alegre, Federal University of Porto Alegre, Porto Alegre, Brazil; 3Hospital Universitario de Brasilia, Institute of Neurology, Brasilia, Brazil; 4Hospital Municipal de São Paulo, Institute of Neurology, São Paulo, Brazil; 5Neuromuscular Unit, Instituto de Medicina Tropical Oscar studies, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
Background/Objectives: Neuromuscular diseases (NMD) are a group of disorders that involve injury or dysfunction of peripheral nerves or muscle. Many NMDs have a genetic origin, and around 600 genes related to more than a thousand neuromuscular diseases were described to date. Onset may occur in the neonatal period, childhood, or adult life, pointing to the importance of identifying these diseases’ etiology. We aim to describe genetic findings in molecular analysis of patients with symptoms of NMDs.

Methods: We performed a descriptive, cross-sectional study, with retrospective collection of DNA sequencing results performed in a clinical reference laboratory from Brazil, from 1996 to 2021. Four gene panels were carried out: mitochondrialopathies (196 genes); muscular dystrophies, myopathies and myasthenic syndrome (80 genes); myopathies and muscular dystrophies (200 genes) and neuromuscular diseases (82 genes).

Results: 79 patients (40 males/39 females) suspected of having NMDs with age ranging from 2 to 78 years old were evaluated. Pathogenic mutations were detected in 33 patients (41.8%), involving 27 different NMD-relates genes (ACTA1, ATP2A1, CAPN3, CHRNE, COL6A1, DMD, DOK7, ECHS1, GAA, HEXA, ITGA7, LAMA2, LMNA, MT-TL1, PDHA1, PNPLA2, POMT2, POMT1, PYGM, RAPSN, RYR1, SCGB, SURF1, OPAL, TPM2, TTN, WFS1). 32 patients carried variants of unknown significance (40.5%), and 1 patient (1.2%) had a pseudodeficiency variant.

Conclusion: High-throughput sequencing enables the genetic diagnosis of NMD patients, supports evidence-based treatment and the familiar genetic counseling. The identification and classification of these genetic variants are essential to improve the knowledge of the etiology of the NMD diseases.

References:

Grants: None.

Conflict of Interest: None declared.

P11.028.C GGPS1-associated muscular dystrophy with and without hearing loss

Clarissa Rocca1, Raouan Kairyzhanov1, Maha Zaki2, Heba Hosny3, Christian Beetz2, Mojtaba Movahedinia1, Arnaud Isapo3, Mohammad Yahya Vahidi Mehrjardi1, Nasrin Ghasemi1, Sandra Whalen4, Henry Houlden5, Reza Maroofian1

1UCL Queen Square Institute of Neurology, Department of Neuromuscular Diseases, London, United Kingdom; 2National Research Centre, Clinical Genetics Department, Human Genetics and Genome Research, Cairo, Egypt; 3Genetic Department, National Institute of Neuromotor Systems, Cairo, Egypt; 4CENTOGENE GmbH, Rostock, Germany; 5Pediatric Neurology Division, Myelin Disorders Clinic, Children’s Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran; 6Department of Biochemistry, AP-HP, Bichat Hospital, Paris, France; 7Service de Neurologie Pédiatrique, Hôpital Armand Trousseau, APHP, Sorbonne Université, Paris, France; 8Yazd Shahid Sadoughi University of Medical Sciences and Medical Research Center, Yazd, Iran; 9APHP UF de Génétique Clinique, Centre de Référence des Anomalies du Développement et Syndromes Malformatifs, APHP, Hôpital Armand Trousseau, ERN ITACA, Sorbonne Université, Paris, France.

Background/Objectives: Geranylgeranyl diphosphate synthase 1 (GGPS1) gene is a member of the prenyltransferase family encoding a protein with geranylgeranyl diphosphate (GGPP) synthase activity. Ultra-rare biallelic pathogenic variants in GGPS1 have been associated with Muscular Dystrophy/Hearing Loss/Ovarian Insufficiency Syndrome. We describe nine cases from two new families with defective GGPS1 gene and provide follow-up details from the previously reported family with two affected.

Methods: Two families were collected as part of the SYNAps Study Group collaboration, and the third family was followed up from the report by Tucker et al. (2020). Exome sequencing and segregation analysis by Sanger sequencing were utilized to identify and confirm the GGPS1 variants.

Results: More than 70% of cases presented with delayed motor milestones, short stature, hypotonia, progressive generalized or proximal muscle weakness, and muscular dystrophy. Sensorineural hearing loss was reported in three cases, while hearing remains clinically intact in the remaining eight cases. One 30-year-old female case reached puberty and had no clinical signs of primary ovarian insufficiency. Ultra-rare likely pathogenic homozygous missense GGPS1 variants (NM_004837:4;c.269A>G; p.(Asn90Ser) and c.439A>G; p.(Met147Val) were identified, which segregated with the phenotype within both families.

Conclusion: This report consolidates the disease-causing role of GGPS1 biallelic variants and demonstrates that hearing loss and ovarian insufficiency might be variable features of the GGPS1-associated muscular dystrophy.

References: Tucker EJ, Rius R, Jaillard S, et al. Genomic sequencing highlights the diverse molecular causes of Perrault syndrome: a peroxisomal disorder (PEX6), metabolic disorders (CLPP, GGPS1), and mtDNA maintenance/translation disorders (LARS2, TFAM). Hum Genet 2020; 139(10):1325-1343.

Grants: Wellcome Trust [WT093205MA, WT104033AIA].

Conflict of Interest: None declared.

P11.029.D New phenotype of myopathy in ASCC1-related disorder

Margarita Sharova1, Dariya Guseva1, Aysylu Murtazina2, Olga Novoselova2, Alexey Kurenkov3, Mikhail Skoblov1

1Research Centre for Medical Genetics, Moscow, Russian Federation; 2Genomed Itd, Genetic diagnostic lab, Moscow, Russian Federation; 3National Medical Research Center for Children’s Health the Russian Federation Ministry of Healthcare, Moscow, Russian Federation.

Background/Objectives: Spinal muscular atrophy with congenital bone fractures 2 (SMABF2) is a severe neuromuscular disorder caused by homozigous or compound heterozygous variants in the ASCC1 gene. There are only eight families described with the disease. We are presenting a case of a patient with the myopathy phenotype and two novel variants in ASCC1 gene.

Methods: 3 y.o. boy underwent neurological examination and genetic investigation in the RCMG. WES of proband’s DNA was performed on Illumina NextSeq500. The functional effect of splicing variant was investigated using RT-PCR analysis. The expression analysis was performed by qPCR.

Results: Probard was born with muscular hypotonia, ulna fracture. Early motor skills were delayed. Neurological examination at 3 y.o. revealed severe muscular hypotonia, hyporeflexia with muscular pitter on the NCS. WES identified two novel variants in ASCC1 gene: splicing variant c.311-2A>G and decreased coverage of exons 2 and 3 (ΔEx2,3) seemed as deletion. The analysis of c.311-2A>G by RT-PCR showed the presence of two isoforms: with truncated exon 5 without frameshift and exon 5 skipping. Splicing variant validated on proband’s and father’s DNA. The deletion was validated in heterozygous state in proband’s and mother’s cDNA. The increased expression of the transcript with ΔEx2,3 in 1.8 times was shown. Also, we suggested that ΔEx2,3 transcript could...
produce a new truncated protein p.Glu2_Met86del from new Kozak sequence in exon 4.

**Conclusion:** We believed that a detailed analysis of this case could explain new phenotype of the proband.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P11.030.A Mutational spectrum and clinical features of GNE myopathy in Russia**

**Aysylu Murtazina**¹, Sergey Nikitin¹, Galina Rudenskaya¹, Inna Sharkova¹, Olga Shchagina¹, Alena Chukhrova¹, Oksana Ryzhkova¹, Olga Shatokhina¹, Anna Orlova¹, Artem Borovikov¹, Ilya Kanivets²,³, Sergey Korostelev², Elena Dadali¹

¹Research Centre for Medical Genetics, Moscow, Russian Federation; ²Genomed LTD, Moscow, Russian Federation; ³FSBEI FPE RMACPE MOH, Moscow, Russian Federation.

**Background/Objectives:** GNE myopathy (MIM 605820) is the most common distal myopathy in several countries. However, the genetic and clinical spectrum of Russian patients is unknown. Here we summarized the mutational spectrum and clinical features of 30 patients with GNE myopathy from Russia.

**Methods:** Massive parallel sequencing was performed for all probands, followed by Sanger DNA sequencing for segregation analysis. Clinical data, including manual muscle testing and the GNE myopathy functional activity scale (GNEM-FAS), were collected for 24 patients from 20 families. Muscle MRI was performed in 8 patients.

**Results:** As a result of molecular genetic analysis, novel mutations were found: 2 frameshift mutations, 2 large deletions, and 4 missense variants. In other cases, 12 known missense mutations were identified. One novel missense mutation c.169_170delGCinsTT, p.Ala57Phe was identified in 4 families in a homozygous state and 3 unrelated patients in a compound heterozygous state. All families with this novel frequent mutation in our cohort were originally from the 3 neighboring areas of European Russia. GNEM-FAS scores were analyzed for 21 patients, and scores varied from 2 to 97 (mean (SD) 55 (31)). Two patients have atypical clinical features: one has severe quadriiceps atrophy, and another patient has a prominent asymmetry of muscle involvement, both cases were supported by muscle MRI.

**Conclusion:** We reported the clinical and genetic spectrum of the largest Russian group of patients with GNE myopathy. The novel variant c.169_170delGCinsTT is a frequent mutation in the European part of Russian Federation.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P11.031.B RFC1 intronic repeat expansions on a Spanish late-onset neuromuscular disorder cohort**

**Paula Fernández-Alvarez**¹, Desireé Martinez Cruz¹, Daniel Sánchez-Tejerina², Victoria Gonzalez-Martinez², Jorge Hernandez-Vara², Raúl Juntas Morales², Elena Garcia-Arumi², Eduardo Tizzano¹

¹Vall d’Hebron University Hospital, Department of Clinical and Molecular Genetics, Barcelona, Spain; ²Vall d’Hebron University Hospital, Department of Neurology, Barcelona, Spain.

**Background/Objectives:** CANVAS syndrome (Cerebellar Ataxia, Neuropathy, and Vestibular Areflexia Syndrome) is associated with biallelic AAGGG intronic expansions in RFC1. A pattern of progression from isolated sensory neuropathy to full CANVAS manifestations has been proposed.

**Methods:** We studied a cohort of 19 patients with late onset manifestations compatible with CANVAS. Conventional PCR (C-PCR) flanking the reference allele (AAAAAG)₁, was used to assert the presence of the wild-type allele. The screening of expansions of the non-pathogenic (AAAAAG and AAAGG) and pathogenic (AAGGG) alleles was performed by repeat-primed PCR (RP-PCR). We characterized the motif with Long-range-PCR (LR-PCR) and Sanger sequencing.

**Results:** C-PCR showed no product in 9 patients suggesting that they did not carry the wild-type allele, 3 patients had larger products, compatible with an expansion of the reference allele, and the remaining 6 had the reference allele (AAAAAG)₁. RP-PCR showed biallelic expansions of the AAGGG repeat in the 9 patients with failed C-PCR and confirmed the normal result in the 6 previously normal patients. RP-PCR of the remaining 3 patients showed that 2 were heterozygous for the expanded wild-type allele, whereas one (patient 11) showed an expansion of the pathogenic AAGGG allele and of an AAAGG allele, suggesting compound heterozygosity. LR-PCR confirmed RP-PCR results in all patients, except in patient 11, who carried a pathogenic AAAGG allele and an expanded AAGAG allele of unknown significance, previously described in Canadian and Brazilian populations.

**Conclusion:** We confirmed the clinical diagnosis in 47% (9/19) patients: 4 showed full CANVAS, whereas the remaining 5 presented with different PNS involvement.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P11.032.C Biallelic founder mutation in PDE2A causes paroxysmal dyskinesia with Intellectual disability in Pakistani families**

Hammad Yousaf¹, Ambrin Fatima², Saadia Maryam Saadi¹, Shahid M Baig¹,², Mathias Toft³,⁴, Zafar Iqbal¹

¹National Institute for Biotechnology and Genetic Engineering (NIBGE), college, PIEAS Islamabad, Pakistan, Faisalabad, Pakistan; ²Department of Biological and Biomedical Sciences, The Aga Khan University, Karachi, Pakistan; ³Department of Neurology, Oslo University Hospital, Oslo, Norway; ⁴Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

**Background/Objectives:** Intellectual developmental disorder with paroxysmal dyskinesia or seizures (IDDPADS, OMIM# 619150) is an ultra-rare childhood-onset movement disorder manifesting paroxysmal dyskinesia slowly progressive global developmental delay, impaired cognitive development and seizures (variable). We investigated three unrelated Pakistani families with six affected individuals born to cousin marriages. Belonging to diverse age groups (13 - 60 years), patients presented with severe developmental delay, cognitive abnormalities, speech impairment and seizures with onset in early years of age.

**Methods:** Whole exome sequencing (WES) was used to detect potentially pathogenic variants and identify shared regions of homozygosity.

**Results:** We identified a rare homozygous missense variant c.1490T>C (NM_002599.5), (p.Phe497Ser) in Phosphodiestrerase2A (PDE2A) gene. The identified variant segregates with the phenotype in all three families. To assess the possibility of a founder mutation, we performed homozygosity mapping which revealed a shared 5.5 Mb homozygous region at Chr11: q13.4-q13.5 among all three families. PDE2A is involved in hydrolysis of second messengers, cAMP and cGMP. It is activated by binding of cGMP to provide a new truncated protein p.Glu2_Met86del from new Kozak sequence in exon 4.

**Conclusion:** Aysylu Murtazina, Sergey Nikitin, Galina Rudenskaya, Inna Sharkova, Olga Shchagina, Alena Chukhrova, Oksana Ryzhkova, Olga Shatokhina, Anna Orlova, Artem Borovikov, Ilya Kanivets, Sergey Korostelev, Elena Dadali.

**References:**

**Grants:**

**Conflict of Interest:** None declared.
GAF-B domain of the protein. The function of PDE2A is very critical for temporal regulation of these second messengers consequently modulating critical cellular processes like proliferation, neuronal function, apoptosis and differentiation. So far, only five variants and five patients are reported with disrupted PDE2A.

Conclusion: Our findings add important details to the clinical and genetic spectrum of PDE2A, and highlight c.1490T>C, (p. Phe497Ser) as a founder mutation in Pakistani families.

References: n/a.

Conflict of Interest: None declared.

P11.033.D The rare case of a patient with neurodevelopmental disorder with epilepsy and hypoplasia of the corpus callosum and a homozygous LNPK gene mutation

Ouranio Anastasiou1, Andri Miltiadous1, Petroula Gerasimou1, Yiannos Kyripanou2, Jason Chi3, Paul Costeas4, Violetta Christofidou Anastasiadou5

1Karaiskakio Foundation, Molecular Genetics, Nicosia, Cyprus; 2Archbishop Makarios III Children’s Hospital, Clinical Genetics, Nicosia, Cyprus.

Background/Objectives: The endoplasmic reticulum (ER) has a variety of cellular functions that require the acquisition of distinct states. It is well established that ER dictates a tight regulation through a wide number of proteins. Perturbation of these ER-shaping proteins are known to cause distinct phenotypes such as Alzheimer’s and Hereditary Spastic Paraplegia. Lunapark (LNPK) is a recently discovered transmembrane protein which is involved in the regulation of ER-shaping. The protein consists of an N-terminal domain, two transmembrane domains, and a unique zinc-finger domain and has been shown to act as a stabilizer to the negative membrane curvature. However, even though the role of LNPK has been established, its association with disorders remains unexplored. A study by Breuss et al. found an association between homozygous mutations in LNPK with a neurodevelopmental disorder in three patients.

Methods: We have collected blood samples from over 50 patients with familial and sporadic ALS of Czech origin. After DNA extraction, samples were analysed for the most common genes causing ALS, such as C9ORF72 and SOD1.

Results: We found a typical distribution of about 10% of familial vs sporadic ALS in our cohort based on the patient’s history, and confirmed the findings by molecular genetic analyses of selected genes.

Conclusion: Our study shows the first preliminary data for Czech Republic, with a typical distribution of common pathogenetic variants causing ALS in Caucasians. Next we plan on enlarging the sample size and collecting the clinical data, and further genetic analyses.

References: 1. Cronin, et al (2007), Neurology, 68(13), 1002-1007. 2. Meijzini, et al (2019). Frontiers in Neuroscience 06 (2019).

P12 MULTIPLE MALFORMATION/ANOMALIES SYNDROMES

P12.002.D A novel FLCN-related syndrome that leads to intellectual disability, developmental delay and immunodeficiency

Fulya Taylan4,5, Carolina Maya Gonzalez4, Behzad Khoshnood3, Tessa Campbell6, Johan Bobek5, Yenan Bryceson4, Magnus Nordenskjold4,6, Ann Nordgren1,4,6,7,8

1Karolinska Institutet, Molecular Medicine and Surgery, Stockholm, Sweden; 2Karolinska University Hospital, Stockholm, Sweden; 3Karolinska Institutet, Department of Neurobiology, Stockholm, Sweden; 4Karolinska Institutet, Department of Medicine, Stockholm, Sweden; 5Kalmar County Hospital, Department of Pediatrics, Kalmar, Sweden.

Background/Objectives: FLCN forms complexes with the FLCN-interacting proteins 1 and 2 (encoded by FNIP1/2) that modulate mechanistic target of rapamycin complex 1 (mTORC1) and AMP-activated protein kinase (AMPK) which have opposite roles in cells[1]. The balance between mTORC1 and AMPK depends on the FLCN/FNIP complex[2]. Here, we present a 14-year-old boy with intellectual disability, short stature, dysmorphic features, late psychomotor development, hearing impairment and immunodeficiency, where whole genome sequencing (WGS) detected a homozygous ultra-rare variant in FLCN.

Methods: WGS analysis, quantitative real-time PCR and western blot were performed to identify the variant and investigate its effect on expression. Immune parameters were evaluated with flow cytometry analysis (FCA).

Results: WGS identified a homozygous, ultra-rare missense (NM_144997.7:c.43G>A; p.(Gly14Ser)) variant in FLCN fitting to autosomal recessive inheritance. In the patient fibroblasts, the
expressions of FLCN and FNIP1 were increased while no significant change at the protein level was observed. FCA showed hypogammaglobulinemia (IgM, IgG) and low B and NK cells.

Conclusion: Overexpression of FLCN and FNIP1 signals dysregulation of the balance between mTORC1 and AMPK pathways, resulting in disruption of homeostasis in the cells. Patients with FNIP1 mutations had a remarkable phenotypic overlap with our patient[3]. Therefore, we conclude that the FNIP1 variant causes a novel FLCN-related syndrome with phenotypic overlap with the FNIP1 immunodeficiency.

References: 1. Takagi, Y., et al., Oncogene, 2008. 27(40): p. 5339-47. 2. Gonzalez, A., et al., Cell Metab, 2020. 31(3): p. 472-492. 3. Saettini, F., et al., Blood, 2021. 137(4): p. 493-499.

Grants: The Swedish Childhood Cancer Fund.

Conflict of Interest: None declared.

P12.003.A Familial cleft tongue caused by a unique translation initiation codon variant in TP63
Julia Schmidt1, Gudrun Schreiber2, Janine Altmüller1,2,5,6, Holger Thiele1,2,5,6, Peter Nürnberg5,6, Peter Nürnberg5,6, Peter Nürnberg5,6, Yun Li1, Silke Kaulfuß1, Rudolf Funke2, Laer1, Bart Loeys1

1Institute of Human Genetics, University Medical Center Göttingen, Göttingen, Germany; 2Department of Pediatric Neurology, Klinikum Kassel, Kassel, Germany; 3Core Facility Genomics, Berlin Institute of Health at Charité, Berlin, Germany; 4Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany; 5Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany; 6Cologne Center for Genomics (CCG), University Hospital Cologne, Cologne, Germany; 7Cluster of Excellence Multiscale Bioimaging: from Molecular Machines to Networks of Excitable Cells (MBExC), University of Göttingen, Göttingen, Germany.

Background/Objectives: Variants in transcription factor p63 have been linked to several autosomal dominantly inherited malformation syndromes. These disorders show overlapping phenotypic characteristics with various combinations of the following features: ectodermal dysplasia, split-hand/foot malformation/syndactyly, lacrimal duct obstruction, hypoplastic breasts and/or nipples, ankyloblepharon filiforme adnatum, hypospadias and/or cleft lip/palate.

Methods/Results: We describe a family with six individuals presenting with a striking novel phenotype characterized by a type A dissection, while another 66-years old male underwent a Bentall procedure because of severe insufficiency of a bicuspid aortic valve and a sinus of Valsalva aneurysm (50mm, z-score = 5.2). Two other male mutation carriers presented with a pathologically enlarged ascending aorta or aortic root aneurysm at older age (75 and 80 years). None of the 25 other TP6G3 founder mutation carriers (10-84 years, 14 males/11 females) had aortic aneurysms. Additional cardiovascular observations were ventricular septal defect, valve insufficiency and variable conduction abnormalities. We also observed minor systemic involvement such as easy bruising, inguinal hernia and ruptured ligaments and tendons.

Conclusion: The low penetrance for aortic involvement suggests that the pathogenic TGFB3 variant is not sufficient to cause the aneurysm phenotype. No aggravating cardiovascular risk factors were documented in the aneurysm-presentation patients. Comparative whole genome- and RNA-sequencing of IPSVC-vascular smooth muscle cells of affected and unaffected variant carriers is currently being performed to pinpoint genetic modifiers.

References:

Conflict of Interest: Melanie Perik full, Emmanuela Govaerts full, Steven Laga full, Inge Govaerts full, Josephina (Jeanette) Meester full, Aline Verstraeten full, Lut Van Laer full, DOCPRO: FFB170247, Bart Loeys full, Genoma – ERC-COG-2017-771945.

P12.005.C Delineation of a KDM2B-related neurodevelopmental disorder and its associated DNA methylation signature
Marie-Claire Cornils1, Richard van Jaarsveld1, Jack Reilly2, Michael Hadders3, Emmanuela Agolini9, Kwame Anyane-yebod4, Marie-José Van den Bosch4, Ellen vanBinsbergen5, Raymond Caylor6, Andrea Colli8, Joke Verheij7, Paolo Fontana6, Saskia MJ Hopman7, Maria Iascone8, Margaret Mary Javier9, Erik-Jan Kamsteeg10, Jennifer Kerkhof11, Jun Kido14, Hyung-Goo Kim15, Tjitske Kleefstra12, Abbe Lai16, Dorit Levy17, Michael Levy13, Suzanne Lewis13, Angie Lichy4, Idit Mayo18, Haley McConkey13, Andre Megarbane19, Vincent Michaud20, Marcello Niceta21, Severine Audebert Bellanger21, Roberta Onesimo22, Rolph Pfundt23, Bernt Popp23, Eloise Prijoles6, Dmitrijs Rots24, Saada Ken25, Jolanda Schieving26, Marco Tartaglia27, Romano Tenconi28, Kevin Uguen21, Roberta Verheij7, Marielle Alders29, Renske Oegema3

1UMC Utrecht, Department of Genetics, Utrecht, Netherlands; 2London Health Sciences Centre, Molecular Genetics Laboratory, Molecular Diagnostics Division, London, Canada; 3UMC Utrecht, Oncoide Institute and Center for Molecular Medicine, Utrecht, Netherlands; 4Bambino Gesù Children’s Hospital, IRCCS, Translational...
Cytogenomics Research Unit, Rome, Italy; 5Columbia University, Division of Clinical Genetics, Department of Pediatrics, New York, United States; 6Greenwood Genetic Center, Greenwood, United States; 7Bambino Gesù Children’s Hospital, Genetics and Rare Diseases, Rome, Italy; 8UMCG, University of Groningen, Department of Genetics. In Memoriam., Groningen, Netherlands; 9A.O.R.N. San Pio, Medical Genetics Unit, Benevento, Italy; 10ASST Papa Giovanni XXIII, Laboratorio di Genetica Medica, Bergamo, Italy; 11The University of British Columbia, Medical Genetics, Vancouver, Canada; 12Radboud University Medical Center, Human Genetics, Nijmegen, Netherlands; 13London Health Sciences Centre, Vespisneen Clinical Genome Centre, London, Canada; 14Kumamoto University, Department of Pediatrics, Graduate School of Medical Sciences, Kumamoto, Japan; 15Neurological Disorders Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Doha, Qatar; 16Boston Children’s Hospital, Division of Genetics and Genomics and Howard Hughes Medical Institute, Boston, United States; 17Wolfson Medical Centre, Institute of Medical Genetics, Holon, Israel; 18Rabin Medical Center, Beilinson Hospital, The Raphael Recanati Genetic Institute, Petach-Tikva, Israel; 19Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Human Genetics, Beirut, Lebanon; 20CHU Bordeaux, Department of Medical Genetics, Bordeaux, France; 21Centre Hospitalier Regional Universitaire, Service de Genetique medicale et de biologie de la reproduction, Brest, France; 22Bambino Gesù Children’s Hospital, Department of Pediatric Hematology/Oncology and Cell and Gene Therapy, Rome, Italy; 23Friedrich-Alexander University of Erlangen-Nuremberg, Institute of Human Genetics, Erlangen, Germany; 24Yokohama City University Graduate School of Medicine, Department of Human Genetics, Yokohama, Japan; 25Radboud University Medical Center, Department of Child Neurology, Nijmegen, Netherlands; 26Università di Padova, Department of Pediatrics, Clinical Genetics, Padova, Netherlands; 27Université de Franche-Comté, Centre de Génétique Humaine, Besançon, France; 28Edith Wolfson Medical Centre, Molecular Genetic Laboratory, Holon, Israel; 29Boston Children’s Hospital, Department of Neurology, Boston, United States; 30Fondazione Policlinico Universitario A. Gemelli, Center for Rare Disease and Congenital Defects, Rome, United States; 31AmsterdamUMC, University of Amsterdam, Department of Clinical Genetics, Genome Diagnostics laboratory, Amsterdam, Netherlands.

Background/Objectives: Mutations in genes involved in the epigenetic machinery are an emerging cause of neurodevelopmental disorders (NDDs). Lysine-demethylase 2B (KDM2B) encodes an epigenetic regulator but has not been convincingly recognized as a NDD gene to date.

Methods: We assessed 24 heterozygous missense and loss-of-function variants in KDM2B in 33 individuals and reviewed their clinical data. We applied genome-wide methylation arrays on leukocyte-derived DNA samples to establish a KDM2B-specific epigenetic signature.

Results: For 21 individuals their variants were classified as pathogenic, in another 12 they remained variants of unknown significance. We observed a clustering of variants in the DNA-binding CXXC domain. Affected individuals presented with developmental delay and/or intellectual disability (20/21), autism (8/21), AD(H)D (7/21), cardiac anomalies (10/21), single kidney (4/21), ophthalmological abnormalities (6/21) and subtle facial dysmorphism. We established a KDM2B-specific epigenetic signature, characterized by hypermethylation of CpG-dinucleotides and with a stronger subsignature of the CXXC-domain variants. We identified two distinct epigenesignatures in individuals with concurrent deletions of SHANK3 or SETD1B respectively, confirming their dual diagnosis.

Conclusion: Heterozygous KDM2B variants cause a NDD with frequent congenital anomalies and a distinct DNA methylation signature. Importantly, we were able to detect the KDM2B epigenesignature in the context of a dual diagnosis, demonstrating the robustness of this assay.

References:

Grants: NM is supported by Japan Agency for Medical Research and Development (AMED). BP is supported by the Deutsche Forschungsgemeinschaft (DFG). CAW is supported by a grant from the National Institute of Neurological Disorders and Stroke (NINDS).

Conflict of Interest: None declared.

P12.006.D A novel missense variant in FLNC causes syndromic dominant cardiomyopathy in a large family

Ingrid E Christophsen1,2, Øyvind H Hald3,4, Yngve Sejersted1, Mari Ann Kulsseth1, Øyvind Evju1, Emily H Marshall1, Karoline B Rypdal1,5, Marit K Smedsrud1, Inga M Sara4, Andreas D Rosenberger3, Jens A Arntzen1,2, Jens Pahnke2,11, Nathan R Tucker5,17, Ida Lunde6,7, Marie Falkenberg Smeland4

1Oslo University Hospital, Department of Medical Genetics, Oslo, Norway; 2Bærums Hospital, Vestre Viken Hospital Trust, Department of Medical Research, Gjøtum, Norway; 3University Hospital of North Norway, Department of Medical Genetics, Tromsø, Norway; 4University Hospital of North Norway, Department of Oncology, Tromsø, Norway; 5Masonic Medical Research Institute, Utica, NY, United States; 6Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway; 7Akershus University Hospital, Division of Diagnostics and Technology, Lørenskog, Norway; 8Oslo University Hospital, ProCardio Center for Innovation, Department of Pediatric Cardiology, Oslo, Norway; 9University Hospital of North Norway, Department of Pediatrics, Tromsø, Norway; 10The University Hospital of North Norway, The National Neuromuscular Centre of Norway, Tromsø, Norway; 11University Hospital of North Norway, Department of Neurology, Tromsø, Norway; 12UIT - The Arctic University of Norway, Department of Clinical Medicine, Tromsø, Norway; 13University Hospital of North Norway, The National Neuromuscular Centre of Norway, Tromsø, Norway; 14University of Oslo and Oslo University Hospital, Department of Pathology, Section of Neuropathology, Translational Neurodegeneration Research and Neuropathology Lab, Oslo, Norway; 15LIED, University of Lübeck, Lübeck, Germany; 16University of Latvia, Department of Pharmacology, Faculty of Medicine, Riga, Latvia; 17Cardiovascular Disease Initiative, The Broad Institute of MIT and Harvard, Cambridge, MA, United States.

Background/Objectives: Pathogenic variants in FLNC (filamin C) cause cardiomyopathies and myopathies with known genotype-phenotype correlations (1). A few cases have been described with accompanying manifestations, such as congenital cardiac defects. We present a large family with dominant cardiomyopathy and extra-cardiac manifestations caused by a novel missense variant in FLNC.

Methods: Eleven affected individuals (age 0-73 years) in four generations underwent clinical evaluation. We performed whole-exome sequencing in three affected individuals, followed by Sanger sequencing of a shared variant in all other family members. Functional effects of the identified genetic variant were experimentally explored by overexpression in C2C12 myoblasts.

Results: Clinical evaluation revealed hypertrophic cardiomyopathy in children and adults, congenital but transient myopathy with contractures, and congenital malformations: cardiac defects, micrognathia, cleft palate, small/absent uvulas, short stature and hernias. Exome sequencing identified a novel missense variant in FLNC (NM_001458.4: c.7118A>C: p.Tyr2373Ser) in a highly conserved position in Ig-like domain 21. Overexpression of the variant versus wild-type FLNC showed intracellular accumulation of...
filamin C protein, suggesting misfolded protein aggregation as mechanism of disease.

**Conclusion:** We report a novel pathogenic missense variant in FLNC, causing syndromic cardiomyopathy and myopathy in a four-generation family. Our findings expand the clinical spectrum of FLNC related disease, and gives unique insight in the lifespan course of the disease.

**References:** 1) Verdonschot JAJ et al. A mutation update for the FLNC gene in myopathies and cardiomyopathies. Hum Mutat 2020 Jun;41(6):1091-1111.

**Grants:** The National Neuromuscular Centre of Norway, University Hospital of North Norway, Tromsø, Norway.

**Conflict of Interest:** Ingrid E Christophersen Recipient of research grant from The Norwegian Research Council.

Recipient of research grant from the South-Eastern Health Authorities.

Recipient of research grant from Vestre Viken Hospital Trust, Øyvind H Hald: None declared, Øyvind Hjulie: None declared, Mari Ann Kulseth: None declared, Øyvind Evju: None declared, Emily H Marshall: None declared, Karoline B Rypdal: None declared, Mari K Smedsrud: None declared, Inga M Sara: None declared, Andreas D Rosenberger: None declared, Kjell A Amtzen: None declared, Jens Pahnke: None declared, Nathan R Tucker: None declared, Mari Lunde: None declared, Marie Falkenberg Smeland: None declared.

**P12.007.A Investigating Rho dysregulation in Adams-Oliver syndrome as a model of vascular development**

**Clare Benson**, **Daniel Osborn**, **Laura Southgate**

1St George’s, University of London, Molecular and Clinical Sciences, London, United Kingdom.

**Background/Objectives:** Adams-Oliver syndrome (AOS) is a genetically heterogeneous developmental disorder, predominantly characterised by scalp, limb and cardiovascular anomalies. Of the six known causal genes, DOCK6 and ARHGAP31 encode Rho GTPase regulators of CDC42 and RAC1. In AOS, DOCK6 depletion or ARHGAP31 gain-of-function have been shown to inactivate CDC42/RAC1, affecting cytoskeletal dynamics. Nonetheless, the molecular mechanisms of CDC42 and RAC1 dysregulation in disease progression remain largely unexplored. AOS is hypothesised to be a disorder of vasculogenesis, therefore we sought to model Rho GTPase dysregulation in zebrafish to examine embryonic vascular development.

**Methods:** A novel Tg(dock6:mCherry) zebrafish reporter line was developed to examine dock6 expression during embryogenesis. Models of Rho dysregulation were generated by morpholino and CRISPR technology. Whole-mount in situ hybridisation was used to assess the expression of known endothelial markers kdrl and fltl in our disease models. Vascular analysis was conducted by microangiography.

**Results:** Depletion of dock6 and arhgap31 resulted in cardiovascular defects, with dock6 embryos additionally displaying eye abnormalities. Microangiography revealed asymmetric and truncated intersomitic vessels and impaired optic vessel formation in both models. In arhgap31 morphants, kdrl and fltl were diminished throughout the vasculature. Conversely, dock6 knockdown induced aberrant patterning of the trunk vasculature and reduced marker expression in the caudal vein plexus (CVP).

**Conclusion:** The observed defects in models of Rho dysregulation indicate a possible vascular origin to AOS. Specifically, dock6 depletion leads to compromised CVP patterning and intersomitic vessel development. Future work to investigate arhgap31-mediated regulation of fltl and kdrl may support the delineation of novel pathways driving AOS pathogenesis.

**References:**

1. Verdonschot JAJ et al. A mutation update for the FLNC gene in myopathies and cardiomyopathies. Hum Mutat 2020 Jun;41(6):1091-1111.

1. Verdonschot JAJ et al. A mutation update for the FLNC gene in myopathies and cardiomyopathies. Hum Mutat 2020 Jun;41(6):1091-1111.

**Conflict of Interest:** None declared.

**P12.008.B Luscan-Lumish syndrome: Nine new cases and review of the literature**

**Jair Tenorio**, **Pedro Arias**, **julian nevado**, **Natalia Gallego**, **fernando santos-simarro**, **ignacio arroyo**, **alfredo santana**, **teresa vendrell**, **mercedes artigas**, **gabriel martos**, **the sogri consortium**, **Pablo LAPUNZINA**

1La Paz University Hospital, INGEMM, Madrid, Spain; 2Hospital San Pedro de Alcántara, Pediatric department, Cáceres, Spain; 3Hospital Materno Infantil de Gran Canaria, Medical genetic unit, Las Palmas de Gran Canaria, Spain; 4Hospital Universitari Vall d’Hebron: Urgencies, Clinical and molecular genetic unit, Barcelona, Spain; 5Navarrabiomed, Genetic Unit, Pamplona, Spain; 6Hospital Infantil Universitario Niño Jesús, Pediatric department, Madrid, Spain.

**Background/Objectives:** Luscan-Lumish syndrome (LLS) is a relative recent overgrowth disorder. Clinical features of patients with LLS also included neurodevelopmental disorders such as intellectual disability, autistic behavior and epilepsy. Since the initial description, only few cases have been reported in the literature, with the lack of deep phenotyping and molecular underlying mechanism. LLS is caused by pathogenic variants in SETD2, which encoded a methyltransferase (MTs) protein involved in histone regulation, playing an important role in gene expression regulation.

**Methods:** Analysis by custom NGS panel, from a cohort of >2000 cases with overgrowth disorders from the Spanish Consortium. This panel was designed in-house and included 214 genes. We have also reviewed the clinical and molecular features of the cases described in the literature so far.

**Results:** Here, we report nine additional individuals with LLS, in which pathogenic or likely pathogenic variants. Most common clinical features of the patients included overgrowth, intellectual disability, and neurodevelopmental disorders with variable degree of severity. We have also seen that autism behaviour in quite common, and can appear without overgrowth.

At molecular level, we have detected nine new variants not reported previously in the literature, expanding the causative variants in LLS. The majority of the variants detected were nonsense and frameshift, which is in line with low tolerance of SETD2 for this kind of changes according to the pLI score (pLI = 1).

**Conclusion:** In summary, we report nine additional cases with LLS and reviewed clinical and molecular features of all cases described.

**References:**

1. Verdonschot JAJ et al. A mutation update for the FLNC gene in myopathies and cardiomyopathies. Hum Mutat 2020 Jun;41(6):1091-1111.

1. Verdonschot JAJ et al. A mutation update for the FLNC gene in myopathies and cardiomyopathies. Hum Mutat 2020 Jun;41(6):1091-1111.

**Conflict of Interest:** None declared.

**P12.009.C A large, ten-generation family with autosomal dominant preaxial polydactyly/triagonalpalmalge thumb: Historical, clinical, genealogical and molecular studies**

luis francisco gonzalez alvarez, **Jair Tenorio**, **fernando poletta**, **fernando santos-simarro**, **Pedro Arias**, **Natalia Gallego**, **lola olivi**, **Stefan Mundlos**, **Eduardo castilla**, **vctor martinez-glez**, **maria luisa martinez frias**, **vctor i. ruiz-pérez**, **julian nevado**, **Pablo LAPUNZINA**

1Cervera de Buitrago, Centro de Salud Area 6, Cervera de Buitrago, Spain; 2La Paz University Hospital, INGEMM, Madrid, Spain; 3CEMIC, Buenos Aires, Argentina; 4CENICET, Buenos Aires, Argentina; 5Max-Planck-Institut für molekuleare Genetik, Berlin, Germany; 6Carlos III Health Institute, esearch Center on Congenital Anomalies (CIAC),
Madrid, Spain; 2Instituto de Investigaciones Biomédicas “Alberto Sols”. IIBm (CSIC-UAM), Madrid, Spain.

Background/Objectives:

Methods:

Results: We present a large, ten-generation family of 273 individuals with 84 people having preaxial polydactyly/triphalangeal thumb due to a pathogenic variant in the ZRS domain. The causative change maps to position 396 of the ZRS, located at position c.423+4909C>T (chr7:156791480; hg38; LMBR1 ENST000003533442.10; rs606231153 NG_009240.2 in the intron 5 of LMBR1. The first affected individual with the disorder was traced back to mid-1700, when some settlers and workers established in Cervera de Buitrago, a small village about 82 Km north to Madrid. Clinical and radiological studies of most of the affected members have been performed for 42 years (follow-up of the family by LFGA). Recently, molecular studies have confirmed a pathogenic variant in the ZRS that segregates in this family. Currently, four affected individuals at child-bearing age have been included in a pre-implantation genetic diagnosis program with the aim to avoid the transmission of the disease.

Conclusion: To the best of our knowledge, this is the largest family with preaxial polydactyly/triphalangeal thumb reported so far.

References:

Grants:

Conflict of Interest: None declared.

P12.010.D Biallelic mutations in TIE1 in a family with congenital lymphedema, intestinal lymphectasia and cutis aplasia

Aasem Abu Shtaya1, Rivka Sukenik Halevy2,3, Illy bazak1, Gabriel Arie Lidzbarsky1, Claudia Gonzaga-Jauregui1, Yael Goldberg1,2, Lina basel-salmon1,3,6

1Rabin Medical Center, Recanati Genetic Institute, Petah Tikva, Israel; 2Meir Medical Center, Genetics Institute, Kfar Saba, Israel; 3Tel Aviv University, Sackler School of Medicine, Tel Aviv, Israel; 4Regenomer Genetics Center, Tarrytown, New York, United States; 5Schneider Children’s Medical Center of Israel, Pediatric Genetics Clinic, Petah Tikva, Israel; 6Felsenstein Medical Research Center, Petah Tikva, Israel.

Background/Objectives: Intestinal lymphangiectasia (ILA) is a very rare condition; it occurs due to dilatation of the intestinal lymphatic vessels resulting in lymphatic leakage to the bowel lumen leading to protein loss and edema.

Congenital cutis aplasia (CAA) is also a rare phenotype, occurring mainly on the scalp; up to 90% of cases present as sporadic isolated lesions, but can rarely be associated with additional abnormalities as part of a genetic disorder.

We report co-occurrence of IL, CAA and lymphedema in two male siblings. One sibling died in infancy due to sagittal sinus bleeding.

Methods: Exome sequencing performed in the proband, parents and two healthy siblings.

Results: Sequencing revealed compound heterozygosity for c.1502G>A; p.Ser501Asn and c.2536G>A; p.Gly846Arg (NM_005424.5) in TIE1 in the proband. Three asymptomatic family members were heterozygous for one or the other variant.

Conclusion: The TIE1 gene encoding TIE1 orphan receptor is associated with autosomal dominant (AD) Lymphatic malformation 11 (MIM #619401) characterized by peripheral edema, with onset in the second-third decade of life. Biallelic variants in this gene have been reported to cause extensive edema in knock-out mice suggesting a loss of function mechanism. To the best of our knowledge, this is the first report of possible autosomal recessive inheritance of this disorder in humans with a more severe phenotype than the AD form. However, the possibility of AD inheritance with incomplete penetrance cannot be excluded.

To conclude, we suggest that biallelic deleterious variants in TIE1 might lead to a more severe phenotype with previously unreported clinical features including CAA and IL.

References:

Grants:

Conflict of Interest: None declared.

P12.012.B Cardiac involvement and TBCK-related neurodevelopmental disorder: is it a new feature of this condition?

Gioia Mastromoro1, Daniele Guadagno1, Nader Khaleghi Hashemian1, Laura Bernardini1, Antonella Gianotti1, Antonio Novelli1, Viviana Caputo1, Cira di Gioia1, Gerardo Piacentini1, Antonio Pizzuti1

1Sapienza University of Rome, Experimental Medicine, Roma, Italy; 2Casa Sollevio della Sofferenza, San Giovanni Rotondo, Italy; 3Sapienza University of Rome, Roma, Italy; 4Bambino Gesù Pediatric Hospital, Roma, Italy; 5Fatebenefratelli San Giovanni Calibita Hospital, Roma, Italy.

Background/Objectives: TBCK (TBC1 Domain-Containing Kinase; MIM*616899) encodes a protein that plays a role in actin cytoskeleton organization, cell growth/proliferation by regulating the mTOR signaling pathway. Deleterious homozygous or compound heterozygous TBCK variants determine Hypotonia, infantile, with psychomotor retardation and characteristic facies 3 (MIM#616900). We report on three affected sibs, presenting also with cardiac malformations.

Methods: A couple of first cousins had previously been studied because their first child presented developmental delay, dysmorphisms, hyperthricosis and right-sided aortic arch, and a deceased daughter had showed similar features and Tetralogy of Fallot. Whole exome sequencing, performed on the infant detected the homozygous c.1532G>A,p.(Arg511His) pathogenic variant in the TBCK gene, resulting in a compatible clinical picture. The couple was referred again to perform prenatal diagnosis on their current pregnancy. The ultrasound scan had showed cystic hygroma and hypoplastic nasal bone, previously unreported in TBCK-related cases. We thereby requested chromosomal microarray analysis, whole exome sequencing and early fetal echocardiography.

Results: Chromosomal microarray analysis revealed 8.6% runs of homozygosity. The homozygous TBCK variant was detected by whole exome sequencing, without further pathogenic or candidate variants. Early fetal echocardiography identified hypoplasia of left ventricle and aortic arch. The couple opted for pregnancy termination. Fetopsy confirmed the sonographic findings and revealed a hypoplastic aorta arising from right ventricle and corpus callosum agenesis.

Conclusion: This is one of the very few families reported with TBCK mutations. Interestingly, the cardiac phenotype segregates with mutations and cardiac involvement could be considered a new feature of this variant causing Hypotonia, infantile, with psychomotor retardation and characteristic facies 3.

References:

Grants:

Conflict of Interest: None declared.

P12.013.C Mouse in vivo and in vitro models to understand neural pathobiology associated with ACTB loss of function

Andrew Thom1, Filipa Lopes2, Leo Zeef1, Catherine Lawrence3, Neil Roberts1, Adrian S. Woolf2, Siddharth Banka1,18

1Rabin Medical Center, Recanati Genetic Institute, Petah Tikva, Israel; 2Medical Center of Israel, Pediatric Genetics Clinic, Petah Tikva, Israel; 3Tel Aviv University, Sackler School of Medicine, Tel Aviv, Israel; 4Regenomer Genetics Center, Tarrytown, New York, United States; 5Schneider Children’s Medical Center of Israel, Pediatric Genetics Clinic, Petah Tikva, Israel; 6Felsenstein Medical Research Center, Petah Tikva, Israel.

Background/Objectives: The ACTB encoding actin, cytoplasmic gene have been reported to cause extensive edema in knock-out mice suggesting a loss of function mechanism. To the best of our knowledge, this is the first report of possible autosomal recessive

incidence of this disorder in humans with a more severe phenotype than the AD form. However, the possibility of AD heritability with incomplete penetrance cannot be excluded.

To conclude, we suggest that biallelic deleterious variants in TIE1 might lead to a more severe phenotype with previously unreported clinical features including CAA and IL.

References:

Grants:

Conflict of Interest: None declared.
Background/Objectives: Heterozygous loss of function variants in ACTB encoding β-actin cause a human syndrome featuring developmental delay. We hypothesised that mouse in vivo and in vitro models would further our understanding of the neural pathobiology of this human genetic disease.

Methods: We used two models: mice with a heterozygous Actb deletion in early embryogenesis, using Cre-Lox technology; and mouse N2a neuroblastoma cells with siRNA-mediated Actb knockdown. In each, Actb expression is predicted to be reduced but not absent, thus modelling ACTB haploinsufficiency.

Results: In wild type mouse brains, as assessed by immunohistochemistry, β-actin was widespread and was most prominent in microglial-like cells. Neonatal mice with heterozygous deletion of Actb had normal brain weights. Nevertheless, RNA sequencing identified significantly deregulated transcripts including, as expected, downregulated Actb, but with increased Acta2 (encoding a smooth muscle actin) and transcripts encoding filamin (an actin binding protein) and vinculin (another cytoskeletal protein). We exposed N2a cells to Actb siRNA, resulting in decreased Actb mRNA and β-actin protein. Versus cells exposed to control siRNA, knockdown cells showed slower migration, with increases in neurite length and number as well as prominent secondary branches. There was no effect on proliferation. These cells showed changed levels of several of the transcripts altered in Actb mutant mouse brains.

Conclusion: Actb knock-down neural cells provide clues regarding altered cell biology and we hypothesise that similar changes occur in vivo. In heterozygous deleted Actb brains, an altered signature at the transcript level may suggest druggable targets to ameliorate the pathobiology.

References:

Grants:

Conflict of Interest: None declared.

P12.016.B In vitro effect of TRAF7 germline and somatic missense variants on its subcellular localization and cell shape

Aina Prat-Planas1,2, Laura Castilla-Vallmanna1,2, Mónica Centeno-Piña1,2, Daniel Grinberg1,2, Raquel Rabionet1,2, Roser Urreizti2,3, Susanna Balcells1,2

1University of Barcelona, Department of Genetics, Microbiology and Statistics, Faculty of Biology (IBUB), Barcelona, Spain; 2Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain; 3Hospital Sant Joan de Déu, Clinical Biochemistry Department, Esplugues de Llobregat, Spain.

Background/Objectives: TRAF7 syndrome is an ultra-rare neurodevelopmental disorder characterized by intellectual disability, motor delay, cardiac alterations and dysmorphic features. It is caused by germline mutations in TRAF7, which codes for an E3 ubiquitin ligase acting in different signalling pathways. Somatic mutations in this same gene have been associated with tumorigenic processes. Our aim was to explore the effects of germline and somatic missense variants on TRAF7 subcellular localization.

Methods: We selected five TRAF7 variants (one benign (p.H478Y), 2 tumorigenic (p.L519P, p.N520S), 2 syndromic (p.L519F, p.R655Q)) and introduced them in a TRAF7 expressing vector by site-directed mutagenesis. We then transfected these constructs into HeLa cells and performed immunocytochemistry to study their effects on TRAF7 subcellular localization. We also assessed colocalization with its partner MEKK3.

Results: Wild-type TRAF7 was found throughout the cytoplasm in aggregate-like structures. Upon transfection with TRAF7 development delay, intellectual disability, neurological impairment, and abnormal thyroid hormone profile. It mainly affects males, as female carriers are usually asymptomatic or present only abnormal thyroid blood tests. In rare cases of symptomatic female carriers, X-chromosome abnormalities and skewed X-chromosome inactivation (XCI) may play a role in the expression of the phenotype.

Methods: We describe a 16-year-old female patient with mild intellectual disability, dysmorphic facial features, marfanoid habitus, joint hypermobility, lumbar hyperlordosis, mild thoracic scoliosis, genu recurvatum, high serum levels of 3,3',5'-triiodothyronine (T3), and normal to low levels of thyroxine and thyroid-stimulating hormone (TSH). Karyotyping, whole-exome sequencing, Sanger sequencing, and XCI analysis through Human Androgen receptor assay (HUMARA) were performed.

Results: The proposita and her parents presented normal karyotypes. Whole-exome sequencing revealed a de novo rare missense variant in SLC16A2: c.1388C>T:Pro463Leu, confirmed by Sanger sequencing. Haplotype analysis using a single nucleotide polymorphism (rs5537843) in cis with the variant showed that the missense variant was in the X chromosome originated from the father. HUMARA revealed the inactivation of the maternal and paternal alleles in ratios of 71% and 29%, respectively. Thus, the chromosome carrying the normal SLC16A2 allele was preferentially inactive.

Conclusion: Skewed XCI may have played a role in the expression of a mild AHDS phenotype in the patient. Together with SLC16A2 variants, skewed XCI may be investigated in females with AHDS phenotypic features even when X-chromosome abnormalities are absent.

References:

Grants: #2019/21644-0, #2020/16422-5 São Paulo Research Foundation (FAPESP).

Conflict of Interest: None declared.

P12.014.D Mildly skewed X-chromosome inactivation as a mechanism for the expression of Allan-Herndon-Dudley syndrome phenotype in a female patient

Bianca Pereira Favilla1, Caroline Oliva1,2, Erika Lopes Freitas3, Bibiana Santos4, Maria Isabel Melaragno4, Vera Ayres Meloni1,2, Flavia Balbo Piazzon5,6

1Universidade Federal de São Paulo, Department of Morphology and Genetics, São Paulo, Brazil; 2Rare Rosy Clinic, São Paulo, Brazil; 3Fleury Medicina e Saúde, São Paulo, Brazil; 4Mendelics Andróide Genômica, São Paulo, Brazil; 5University of Liège, Department of Pediatrics, Liège, Belgium; 6University of São Paulo, Neurometabolic Unit, São Paulo, Brazil.

Background/Objectives: Allan-Herndon-Dudley syndrome (AHDS) is an X-linked condition characterized by neuropsychomotor development delay, intellectual disability, neurological impairment, and abnormal thyroid hormone profile. It mainly affects males, as female carriers are usually asymptomatic or present only abnormal thyroid blood tests. In rare cases of symptomatic female carriers, X-chromosome abnormalities and skewed X-chromosome inactivation (XCI) may play a role in the expression of the phenotype.

Methods: We describe a 16-year-old female patient with mild intellectual disability, dysmorphic facial features, marfanoid habitus, joint hypermobility, lumbar hyperlordosis, mild thoracic scoliosis, genu recurvatum, high serum levels of 3,3',5'-triiodothyronine (T3), and normal to low levels of thyroxine and thyroid-stimulating hormone (TSH). Karyotyping, whole-exome sequencing, Sanger sequencing, and XCI analysis through Human Androgen receptor assay (HUMARA) were performed.

Results: The proposita and her parents presented normal karyotypes. Whole-exome sequencing revealed a de novo rare missense variant in SLC16A2: c.1388C>T:Pro463Leu, confirmed by Sanger sequencing. Haplotype analysis using a single nucleotide polymorphism (rs5537843) in cis with the variant showed that the missense variant was in the X chromosome originated from the father. HUMARA revealed the inactivation of the maternal and paternal alleles in ratios of 71% and 29%, respectively. Thus, the chromosome carrying the normal SLC16A2 allele was preferentially inactive.

Conclusion: Skewed XCI may have played a role in the expression of a mild AHDS phenotype in the patient. Together with SLC16A2 variants, skewed XCI may be investigated in females with AHDS phenotypic features even when X-chromosome abnormalities are absent.

References:

Grants: #2019/21644-0, #2020/16422-5 São Paulo Research Foundation (FAPESP).

Conflict of Interest: None declared.
pathogenic mutants, aggregate size was larger and cell shape was modified. TRAF7 syndromic mutations presented an aberrant behaviour, with 86-95% of transfected cells being rounded (compared to 27-37% in WT/benign conditions). Additionally, tumorigenic and syndromic mutations showed higher levels of large protein aggregates in comparison to WT/benign conditions. Finally, TRAF7 and MEKK3 presented a high degree of colocalization, and no differences were noted between TRAF7 variants.

Conclusion: The pathogenic mutations caused drastic cell shape and TRAF7 subcellular localization modifications after their transfection. These modifications could be used as biomarkers to test the pathogenicity of newly identified variants in patients with an unclear neurodevelopmental presentation.

References: None declared.

P12.017.C Two novel cases of IQSEC2 syndromic mental retardation revealed an intronic variant disrupting expression of different transcripts isoforms

Estrella Lopez-Martín1, Beatriz Baladron1, Lidia Mielu1, Jose Ignacio Alvarado1, Sara Monzon2, Saral Varona2, Isabel Cuesta de la Plaza2, Gema Gomez-Mariano1, Marina Gutierrez1, Lidia López1, Francisco Javier Alonso1,3, Eva Bermejo-Sanchez1, Manuel Posada1, Beatriz Martinez-Delgado1,3

1Instituto de Salud Carlos III, Instituto de Investigación de Enfermedades Raras, Madrid, Spain; 2Instituto de Salud Carlos III, Bionformatics Unit, Madrid, Spain; 3Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Grupo CIBERER 758, Madrid, Spain.

Background/Objectives: Pathogenic hemizygous or heterozygous mutations in the IQSEC2 gene cause X-linked mental retardation-1 (MRX1) characterized by a variable phenotype. It afflicts both males and females typically through loss of function in males and haploinsufficiency in heterozygous females. IQSEC2 gene is one of the described genes that scape X chromosome inactivation. It is expressed in neurons and participates in cytoskeletal organization, dendritic spine morphology, and excitatory synaptic organization.

Methods: The diagnostic activity of the SpainUDP (Undiagnosed Rare Disease Program) revealed two unrelated cases, one male and one female, with de novo IQSEC2 variants detected by trio-based whole exome sequencing. The female case had an undescribed frameshift mutation and the male case showed an intronic variant in intron 6, with unknown effect. IQSEC2 gene expression was analyzed by RT-PCR and QT-PCR specific for the three transcripts isoforms.

Results: Expression analysis revealed that the intronic variant created an alternative donor splicing site and an aberrant product, with the inclusion of 19bp leading to a frameshift and premature stop codon. Moreover, quantitative expression of the three different IQSEC2 transcripts in both cases comparing to their progenitors showed a higher reduction of all isoforms in the male, but expression was less reduced in the female case, with no decrease of the short IQSEC2 isoform expression.

Conclusion: Our study allowed us to establish an intronic variant in IQSEC2 as the cause of the disease leading to the diagnosis. Different expression level of the IQSEC2 isoforms might be implicated in the disease manifestations.

References: None declared.

P12.018.D Simpson-Golabi-Behmel syndrome type 1: How placental immunohistochemistry can rapidly predict the diagnosis

Giacomo Fiandrino1, Alessia Arossa2, Silvia Kalantar1, Elisa Giorgio3,4, Francesco Bassanese1,6,7, Annachiara Scattigno2,6,7, Anna Meroni2,7, Chiara Melito2,7, Stefania Cesari1, Gianacchino D’Ambrosio1, Stefania Longo6, Stefano Ghirardello9, Tiziana Angelica Figa9, Marco Pauli1,4, Arsenio Spinillo1,2, Enza Maria Valente1,2, Fabio Sirchia1,9

1IRCCS San Matteo Foundation, Neonatal Intensive Care Unit, Pavia, Italy; 2IRCCS San Matteo Foundation, Department of Obstetrics and Gynecology, Pavia, Italy; 3University of Turin, Medical Sciences, Turin, Italy; 4University of Pavia, Department of Molecular Medicine, Pavia, Italy; 5IRCCS Mondino Foundation, Pavia, Italy; 6IRCCS San Matteo Foundation, Pediatric Clinic, Pavia, Italy; 7University of Pavia, Pavia, Italy; 8IRCCS San Matteo Foundation, Neonatal Intensive Care Unit, Pavia, Italy; 9IRCCS San Matteo Foundation, Medical Genetics Unit, Pavia, Italy.

Background/Objectives: Glypican-3 (GPC3) is an oncofetal protein involved in cellular signalling, strongly expressed in placenta and absent or diminished in postnatal life, but often increased in human malignancies (i.e. hepatocellular carcinoma and germinal tumours). Germline loss-of-function variants of GPC3 gene are associated with Simpson-Golabi-Behmel syndrome type 1 (SGBS1), an exceedingly rare recessive X-linked overgrowth disease characterized by typical facial features, congenital abnormalities and an increased risk of tumours during childhood.

Methods: A clinical suspicion of SGBS1 was postulated for a newborn with prenatal history of overgrowth and polyhydramnios, presenting at birth with neonatal weight and length >99th centile, coarse face, iris coloboma, supernumerary nipples and splenomegaly. Prenatal genetic testing for Beckwith-Wiedemann syndrome (the most common genetic overgrowth syndrome) and SNP-arrays resulted normal. In order to support the diagnostic hypothesis, placental GPC3 immunohistochemical expression was investigated. In parallel, we assessed placental GPC3 expression in 20 probands representative of multiple disorders associated with fetal macrosomia and/or placentomegaly, including pregestational/gestational diabetes and placental mesenchymal dysplasia, as well as in healthy controls.

Results: Whole genome sequencing in the proband identified a likely pathogenic maternally inherited missense variant in GPC3: c.1645A>G; (p.Ile549Val).

GPC3 immunohistochemistry demonstrated full-thickness negativity on all parenchymal sections of the SGBS1 case. On the contrary, we demonstrated preservation of GPC3 placental antigenicity in all the other overgrowth conditions and in healthy controls.

Conclusion: Evaluation of GPC3 expression in the placenta may prove useful in the differential diagnosis of fetal macrosomia, allowing targeted genetic testing and earlier diagnosis both in prenatal and in neonatal setting.

References: https://doi.org/10.1186/s13023-014-0138-0, https://doi.org/10.14670/HH-16.71.

Grants: None declared.

P12.018.A TSC1/TSC2 mosaicism accounts for ~10% of all diagnoses of tuberous sclerosis and genome sequencing fails to identify a third causative gene

Angela Peron1,2,3, Rosa Maria Alfano1, Barry Moore4, Mark Neillass5, Brent Pedersen4, Francesca La Briola6, Luigina Spaccini7, Federica Natacci8, Maria Paola Recalcati9, Valentina Chiesa4, Rosangela Arancio4, Ugo Cavallari1, Chiara Vannicola6, Graziella Cefalo2

1University of Pavia, Department of Molecular Medicine, Pavia, Italy; 2IRCCS Mondino Foundation, Pavia, Italy; 3University of Turin, Medical Sciences, Turin, Italy; 4University of Pavia, Department of Molecular Medicine, Pavia, Italy; 5IRCCS Mondino Foundation, Pavia, Italy; 6IRCCS San Matteo Foundation, Pediatric Clinic, Pavia, Italy; 7University of Pavia, Pavia, Italy; 8IRCCS San Matteo Foundation, Neonatal Intensive Care Unit, Pavia, Italy; 9IRCCS San Matteo Foundation, Medical Genetics Unit, Pavia, Italy.

Background/Objectives: Tuberous sclerosis complex (TSC) is a dominantly inherited disorder affecting skin, kidneys, brain, and other organs.

Methods: A clinical suspicion of TSC in a newborn with prenatal history of overgrowth and polyhydramnios, presenting at birth with neonatal weight and length >99th centile, coarse face, iris coloboma, supernumerary nipples and splenomegaly. Prenatal genetic testing for Beckwith-Wiedemann syndrome (the most common genetic overgrowth syndrome) and SNP-arrays resulted normal. In order to support the diagnostic hypothesis, placental GPC3 immunohistochemical expression was investigated. In parallel, we assessed placental GPC3 expression in 20 probands representative of multiple disorders associated with fetal macrosomia and/or placentomegaly, including pregestational/gestational diabetes and placental mesenchymal dysplasia, as well as in healthy controls.

Results: Whole genome sequencing in the proband identified a likely pathogenic maternally inherited missense variant in GPC3: c.1645A>G; (p.Ile549Val).

GPC3 immunohistochemistry demonstrated full-thickness negativity on all parenchymal sections of the SGBS1 case. On the contrary, we demonstrated preservation of GPC3 placental antigenicity in all the other overgrowth conditions and in healthy controls.

Conclusion: Evaluation of GPC3 expression in the placenta may prove useful in the differential diagnosis of fetal macrosomia, allowing targeted genetic testing and earlier diagnosis both in prenatal and in neonatal setting.

References: https://doi.org/10.1186/s13023-014-0138-0, https://doi.org/10.14670/HH-16.71.

Grants: None declared.

Conflict of Interest: None declared.

Conflict of Interest: None declared.
Background/Objectives: Aims: 1. To investigate the molecular basis of tuberous sclerosis complex (TSC) in patients with no mutation identified (NMi); 2. To evaluate the rate of mosaicism in a real-world setting and delineate the phenotype of mosaic patients.

Methods: Pilot study: chromosomal microarray (8x60K), trio genome sequencing (60X), deep-coverage TSC1/TSC2 NGS (>2000X), and HaloPlex custom capture array of the TSC1/TSC2 genomic regions on 10 individuals with TSC and NMI. Complete study: deep-coverage TSC1/TSC2 sequencing on 200 patients and deep phenotyping of those with mosaicism.

Results: Pilot study: we identified mosaic pathogenic variants in TSC1/TSC2 in 8/10 patients and deep-intronic inherited VUSs in 2/10. Genome sequencing failed to identify causative variants in other relevant genes. Complete study: we identified 24 patients with mosaic pathogenic variants in TSC1 (n = 2) or TSC2 (n = 22), defining a rate of mosaicism of 12%. Mosaic variant allele frequency (VAF) was 1%-32% in blood, 2%-35% in saliva. Extensive phenotypic analysis showed that 82% of individuals with mosaic variants displayed normal cognitive level, and the number of several manifestations - although present - was often insufficient to meet diagnostic criteria. Notwithstanding, we observed a high frequency of pulmonary/renal manifestations, which were as severe as those seen in non-mosaic individuals. Notwithstanding, we observed a high frequency of pulmonary/renal manifestations, which were as severe as those seen in non-mosaic individuals.

Conclusion: We demonstrated for the first time that at least one in 10 individuals with TSC carries a mosaic pathogenic variant in TSC1/TSC2 and that mosaic patients have a distinctive phenotypic severity. We did not obtain evidence for a third TSC locus. Our findings have implications for surveillance and counselling.

References:

Grants:

Conflict of Interest: None declared.

P12.020.B Further delineation of SMG9-related heart and brain malformation syndrome

Amal Alhashem1,2, Norah Altuwaijiri3, Fowzan Alkuraya3

1Prince Sultan Military Medical City, Pediatric, Riyadh, Saudi Arabia; 2Alfaisal university, College of medicine, Riyadh, Saudi Arabia; 3King Faisal Specialist Hospital & Research Centre, Developmental medicine, Riyadh, Saudi Arabia.

Background/Objectives: SMG9-deficiency syndrome, (MIM #616920), is a recently described autosomal recessive disorder associated with intellectual disability and multiple malformations. To date, seven affected individuals have been reported. Here, we describe two previously unpublished cases that expand the phenotypic spectrum of SMG9-related heart and brain malformation syndrome.

Methods: The proband born with midbrain atrophy, interrupted inferior vena cava. Baby suffered from hypotonia, chronic lung infections, was on continuous positive airway pressure, and died after respiratory cardiac arrest at 25 months of age, he underwent exome sequencing which revealed homozygous variant in SMG9. He had another sister diagnosed antenatally to have a banana-shaped cerebellum, scoliosis, a narrow chest, and ectopia cordis with an anterior abdominal wall defect, died soon after birth. Her carrier testing for SMG9 showed the same homozygous mutation.

Results: Whole exome sequence for the boy revealed homozygous splicing variant in SMG9 (NM_019108.4: exon7: c.701+4A>G), which was also found in his sister. This is the first time ectopia cordis, jejunal atresia and involvement of brainstem and basal ganglia have been documented.

Conclusion: Since the severe phenotypic presentation observed in the proband’s sibling is the first to include ectopia cordis, a defect in the anterior abdominal wall, further characterization of the phenotypic spectrum of SMG9-related heart and brain malformation syndrome is imperative to conclude if a mutation in SMG9 alone is responsible for these major abnormalities. These new features should inform the management and anticipatory health supervision of children as we learn more about this newly emerging syndrome.

References:

Grants:

Conflict of Interest: None declared.

P12.021.C Novel variant in OTUDS detected in a patient with multiple congenital anomalies-neurodevelopmental syndrome and suggested in a fetus in the same family

Irina Hüning1, Inga Nägele2, Helga Rehder3, Malte Spielmann1,2

1Institute of Human Genetics, University of Lübeck, Lübeck, Germany; 2Institute of Human Genetics, University of Kiel, Kiel, Germany; 3Institute of Medical Genetics, Medical University of Vienna, Vienna, Austria.

Background/Objectives: The OTUDS gene at Xp11.23 encodes ovarian tumor deubiquitinase 5 protein, a deubiquitinating enzyme member of the ovarian tumor family. Recently 3 families with 16 male patients were reported with a new X-linked recessive disorder (Multiple congenital anomalies-neurodevelopmental syndrome).

References:

Grants:

Conflict of Interest: None declared.

SPRINGER NATURE
P12.021 Persistent urine excretion of D-2-Hydroxyglutaric acid in a patient with 2-Hydroxyglutaric Aciduria (MC-HGA)

Maura Valle1,8, Ilaria Musante1,2, Anna-Maria Binetti1,2, Maria Teresa Divizia1,2, Margherita Leron1,2, Michele Torre1,2, Anna Maria Romanina1,2, Simone Bossi1,2, Martina Servetti1,2, Renata Bocciardi1,2, Nicoletta Pedemonte1,2, Genny Del Zotto1,2, Filippo Maria Senes1,2, Maura Vallet1,2, Maria Grazia Calevo1,2, Maria Francesca Bedeschi1,2, Aldamaria Puliti1,2, Eradio Cittaro1,2, Davide Domini1,2, Anna Sabatini1,2, Teresa Divizia3, Margherita Leron3, Margherita Lerone3, Michele Torre3,4, Anna Maria Binetti3,2, Maria Teresa Divizia3,4, Maria Teresa Divizia3,4, Maria Francesca Bedeschi3,2, Aldamaria Puliti1,2, Anna Sabatini1,2, Teresa Divizia3, Aldamaria Puliti1,2, Maria Francesca Bedeschi3,2, Aldamaria Puliti1,2

Background/Objectives: In 1990 the mother of the patient had a spontaneous abortion at 14 weeks of gestation. The male fetus showed clinical features consisting with MCAND. Unfortunately fetal DNA was no longer available for molecular analysis.

Methods: The index patient presents with severe intellectual impairment, hypotonia, distinctive dysmorphic facial features, intrauterine growth retardation, scoliosis, strabismus, bifid tongue, tetralogy of Fallot, single transverse palmar crease, self-injurious behavior, hypoplasia of corpus callosum, cryptorchidism and short stature. Single exome analysis showed the hemizygous variant OTUD5: c.1492C>T; p.(Gln498*).

In 1990 the mother of the patient had a spontaneous abortion at 14 weeks of gestation. The male fetus showed clinical features consistent with MCAND. Unfortunately fetal DNA was no longer available for molecular analysis.

Conclusion: Here we report two additional patients with MCAND and a novel truncating variant in OTUD5 in the index patient, suggesting that also truncating variants in OTUD5 are responsible for MCAND and supporting the data on intrafamilial variability.

References:

Grants:

Conflict of Interest: None declared.

Results: Whole exome sequencing showed a de novo pathogenic variant c.395G>A, p.(Arg132His) in the IDH1 gene in somatic mosaicism. The variant was found in 59 of 152 reads (38,8%). This missense mutation is predicted to be likely pathogenic.

Conclusion: The phenotype of our patient overlaps with the phenotype of the previously reported three patients in the literature and thus marks the fourth case.

References:

Grants:

Conflict of Interest: None declared.

P12.023.A Whole exome sequencing (WES) and functional analyses suggest synergistic effects of deleterious variants in two candidate genes for Poland Syndrome

Maria Cerminara1,2, Carlotta Vaccari1, Ilaria Musante1,2, Maria Teresa Divizia1,2, Margherita Leron1,2, Michele Torre1,2, Anna Maria Romanina1,2, Simone Bossi1,2, Martina Servetti1,2, Renata Bocciardi1,2, Nicoletta Pedemonte1,2, Genny Del Zotto1,2, Filippo Maria Senes1,2, Maura Vallet1,2, Maria Grazia Calevo1,2, Maria Francesca Bedeschi3,2, Aldamaria Puliti1,2, Eradio Cittaro1,2, Davide Domini1,2, Anna Sabatini1,2, Teresa Divizia3, Aldamaria Puliti1,2, Maria Francesca Bedeschi3,2, Aldamaria Puliti1,2

Background/Objectives: Poland Syndrome (PS, OMIM 173800) is a rare congenital condition characterized by pectoral muscle agenesis/hypoplasia variably associated with ipsilateral thoracic and/or upper limb anomalies. Most cases of PS are sporadic, familial recurrence has been observed with phenotypic heterogeneity. Different inheritance patterns have been reported and polygenic/multifactorial mechanisms have been hypothesized in some cases. The genetic etiology of PS remains unknown. In this study we aimed at investigating the genetic mechanisms underlying PS.

Methods: A cohort of 30 PS patients were analysed by WES, and potentially deleterious variants prioritized by custom filtering strategies including the use of Oligogenic Resource for Variant Analysis Platform (ORVAL). Functional analyses of identified variants included in vitro mutagenesis followed by cell imaging and gene reporter assays.

Results: In a familial case with pectoral muscle hypoplasia, thoracic and mammary gland anomalies deleterious missense variants were found in two genes: MUSTN1, expressed in the nucleus and involved in the development of pectoral muscle and cartilage, and PARD3B localized at the cell membrane and involved in cell polarity, and mammary gland development. Both mutant proteins displayed altered cell localization likely impairing their function. One further PS sporadic patient, with a similar complex phenotype, showed a 5’UTR variant of MUSTN1 causing a reduced expression of MUSTN1.
Conclusion: These results suggest that PS may be due to a digenic inheritance mechanism with the MUSTN1 variant responsible for the pectoral muscle defects and PARDB substitution for the asymmetry and mammary gland anomalies.

References: Romani et al., Semin Pediatr Surg. 2018.

Grants: Conflict of Interest: None declared.

P12.024.B A fatal progeroid syndrome caused by a recessive RAF1 loss-of-function mutation

Nathalie Escande-Beillard1,2, Samantha Wong3, yu xuan tan1, kiat yi tan1, Abigail loh1, engin Ozkan3, Hülya Kayserili3, Bruno Reversade1,2

1Institute of Molecular and Cellular Biology, Singapore, Singapore; 2Koç University, Istanbul, Turkey; 3University of Chicago, Chicago, United States; 4Koç University Hospital, Istanbul (EUR), Turkey.

Background/Objectives: Somatic and germline gain-of-function point mutations in RAF, the first oncogene to be discovered in humans, delineate a group of tumor-prone syndromes known as RASopathies. In this study, we document the first human progerotype resulting from the germline loss-of-function of the proto-oncogene RAF1 (a.k.a. CRAF).

Methods: Whole exome sequencing followed by Sanger sequencing were performed. HEK293T wildtype and mutant were grown in Dulbecco’s modified Eagle’s medium. RAF1 mutant cells were generated with CRISPR/Cas9 method. Cell death was assessed by adding SYTOX® Green Nucleic Acid Stain. For western blotting, cells or Xenopus embryos were lysed in RIPA buffer supplemented with protease inhibitor cocktails and phosphatase inhibitors. RAF1 mutants mRNA were injected into 4-cell stage Xenopus laevis embryos, and harvested at various developmental stages for subsequent protein extraction or WISH analyses.

Results: In a consanguineous family, we uncovered a homozygous p.Thr543Met mutation segregating with a neonatal lethal progeroid syndrome with cutaneous, craniofacial, cardiac and limb anomalies. Structure-based prediction and functional tests using human knock-in cells showed that threonine 543 is essential to: 1) ensure RAF1’s stability and phosphorylation, 2) maintain its kinase activity towards substrates of the MAPK pathway and 3) protect from stress-induced apoptosis. When injected in Xenopus embryos, unlike RAF1WT, mutant RAF1TS433M failed to phenocopy the effects of overactive FGF/MAPK signaling confirming its hypomorphic activity.

Conclusion: Collectively, our data disclose the genetic and molecular etiology of a novel segmental progeroid syndrome, which highlights the importance of RAF1 for human development and homeostasis.

References: Grants: Conflict of Interest: None declared.

P12.025.C ATRIP-deficient patient expands molecular and clinical spectrum of Seckel syndrome

Lynn Backers1,2, Simon J Tavernier3,4, Mattias Van Heetvelde1,2, Bram Parton1,2, Ria Roelandt3, Evi Duthoo4, Elien Belys5, Marieke De Bruyne2, Kim De Leeerneer2, Ans Baeyens6, Anne Vraa6, Filomeen Haeryck7, Kathleen Claes1,2

1Ghent University, Department of Biomedical Medicine, Ghent, Belgium; 2Ghent University Hospital, Center for Medical Genetics, Ghent, Belgium; 3VIB-Ugent Center for Inflammation Research, Unit of Molecular Signal Transduction in Inflammation, Ghent, Belgium; 4Ghent University, Department of Biomedical Molecular Biology, Ghent, Belgium; 5VIB-UGent Center for Inflammation Research, VIB Single Cell Core, Gent, Belgium; 6Ghent University, Human Structure And Repair, Radiobiology Research Unit, Ghen, Belgium; 7Ghent University, Department of Internal Medicine and Pediatrics, Ghent, Belgium.

Background/Objectives: We report the second ATRIP-deficient patient clinically diagnosed with Seckel Syndrome (SS). The ATRIP protein is required for ATR stabilization by complex formation and is crucial for localization of the ATR-ATRIP complex to regions of DNA damage and ATR activation. Besides the typical clinical SS characteristics (primary dwarfism, facial dysmorphism, skeletal abnormalities, microcephaly and mental retardation), our patient suffers from an immunodeficiency. However a link between ATRIP and the immune system was not previously reported.

Methods: Whole exome sequencing (WES), transcriptomics, western blot, micronucleus assays, flow cytometry and single cell RNA-Sequencing.

Results: The patient is homozygous for a splice variant (c.829+5G>T) in ATRIP leading to out-of-frame exon 5 skipping. Western blot showed absence of ATRIP protein and analysis of microinuclei in response to DNA damage by mitomycin C and ionizing radiation revealed defective DNA repair. Downstream substrates of the ATR-ATRIP complex are currently investigated. WES ruled out a pathogenic variant in 460 genes linked to inborn errors of the immune system. Immunophenotyping reveals low absolute B cell numbers, aberrant T cell subsets, decreased plasmacytid dendritic cells, low CD56dimCD16+ natural killer cells and increased low density neutrophils. Additionally, a first look at scRNA-Seq data suggests a recombination deficiency during B and T cell development, as was published for ATR-deficient SS patients (1), and allows to further elaborate the immune phenotype.

Conclusion: We expanded the molecular and clinical spectrum of SS and further validations will provide insights into the link with the immune system and will contribute to the disease mechanism.

References: Grants: Conflict of Interest: None declared.

P12.026.D Differential alternative splicing analysis to link variation in ZRSR2 to a novel syndrome with oral, digital and brain anomalies

Laurens Hannes1,2, Marta Atzori1, Elise Pelgrims1, Ann Swillen1, Alejandro Sifrim1, Catia Attanasio1, Jeroen Breckpot1,2

1Katholieke Universiteit Leuven, Department of Human Genetics, Leuven, Belgium; 2University Hospitals Leuven, Center for Human Genetics, Leuven, Belgium.

Background/Objectives: ZRSR2, located on Xp22.2, is part of the minor spliceosome complex which recognises U12-type introns representing 0.35% of human introns. Minor spliceosome defects have been associated with developmental disorders. Somatic mutations in ZRSR2 are found in myelodysplastic syndromes, germline variation in ZRSR2 has not been implicated in impaired human development yet.

Methods: We describe a 24-months-old boy presenting upper limb bilateral postaxial polydactyly, doubled first ray of the feet, a tongue nodule, seizures, pituitary abnormalities and polymicrogyria. A maternal uncle died neonatally with holoprosencephaly, polydactyly and ambiguous genitalia. A son of a maternal aunt the mother died prenatally with brain and limbs anomalies. Unfortunately DNA of these male relatives was not preserved. Whole exome sequencing and segregation analysis of 6
informative males was performed, followed by whole transcriptome RNA-SEQ on fibroblasts from the extra digit and tongue nodule, and on EBV cell lines of the index and mother.

Results: WES showed a maternally inherited frameshift c.1207_1208delAG (p.Arg403Glyfs*24) in the last exon of ZRSR2, compatible with X-linked recessive inheritance. This variant is absent in reference databases, but has been described as a variant of unknown significance in a family with 5 male foetuses with holoprosencephaly. Whole transcriptome differential expression and alternative splicing analysis of minor spliceosome gene targets showed a similar effect on U12-dependant splicing as seen in somatic ZRSR2 mutations in meduloblastoma syndrome.

Conclusion: Genetic and functional data associate this ZRSR2 variant to a novel syndrome with variable expression of oral, digital and brain (holoprosencephaly) anomalies.

References:

Grants: KUL C24M/19/075.
Conflict of Interest: None declared.

P12.027.A Assessing the burden of rare CNVs on miRNA genes in CAKUT

Ivana Kolić1, Kristina Mitrović1, Ivan Zivotic1, Ana Djordjević1, Jelena Filipovic-Trickovic1, Maja Zivkovic1, Aleksandra Stankovic1, Ivan Jovanovic1

1Vinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, Department of radiobiology and molecular genetics, Belgrade, Serbia; 2Vinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, Department of physical chemistry, Belgrade, Serbia.

Background/Objectives: Rare copy number variants (rCNVs) are the common genetic cause of Congenital Anomalies of the Kidney and Urinary Tract (CAKUT). miRNAs located in rCNVs represent well-founded functional variants for human CAKUT research. However, the impact of rCNVs on miRNA genes in CAKUT is unknown. Thus, burden assessment was performed to identify chromosomes with non-random representation of miRNA genes in rCNVs associated with CAKUT.

Methods: A comprehensive literature mining of rCNV regions associated with CAKUT was performed. The total cumulative length of rCNVs per chromosome was the sum of corresponding CNV-DNA regions, taking into account overlapping. Mapping of miRNAs onto cumulative rCNV regions gave counts of affected miRNA loci. The correlation analysis was performed between the number of miRNA genes overlapping rCNVs, and the fractional lengths of cumulative rCNVs regions in relation to the chromosome size.

Results: A statistically significant positive correlation was observed for duplications and deletions respectively (Spearman correlation p < 0.0001, r = 0.9, r = 0.8). However, a deviation from the best fit line for chromosome 16, for both rare duplications and deletions, was observed due to the high overrepresentation of miRNA genes in identified rCNVs.

Conclusion: The current finding of the high overall burden of rCNVs on miRNA genes in chromosome 16 suggests that miRNAs located on this chromosome could serve as candidates for the investigation of miRNA role in CAKUT development.

References: Verbitsky, M. et al.(2019) J.Nat Genet. 51,117-127.
Grants: This research was supported by the Science Fund of the Republic of Serbia, PROMIS, #6066923, miFaDriCa, and Serbian Ministry of Education, Science and Technological development.
Conflict of Interest: None declared.

P12.028.B Heart defects, oral clefts, and polydactyly caused by novel compound heterozygous variants in WDPCP gene involved in ciliogenesis

Ana Rita Ferreira Pacheco Quental1, Carlos Mariz2, Carla Ramalho3-5, João Parente Freixo2-6, Pedro Louro7, Miguel Leão1

1Centro Hospitalar Universitário de São João, Serviço de Genética Médica, Porto, Portugal; 2Centro Hospitalar Universitário de São João, Serviço de Cirurgia Pediátrica, Porto, Portugal; 3Centro Hospitalar Universitário de São João, Serviço de Obstetrícia, Porto, Portugal; 4Faculdade de Medicina da Universidade do Porto, Porto, Portugal; 5I3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal; 6CGPP-IBMC, Universidade do Porto, Porto, Portugal.

Background/Objectives: Ciliopathies are a group of disorders with overlapping phenotypes, caused by dysfunctional cilia. WDPCP is a planar cell polarity protein, which is involved in the recruitment of molecules essential for ciliogenesis. Wdpcp mutant mouse exhibited developmental defects including anophthalmia, polydactyly, kidney cysts, heart defects, and facial clefts. In humans, only four patients with biallelic pathogenic variants in WDPCP gene have been reported, presenting with congenital heart defects, hamartomas of tongue, and polysyndactyly (CHDTHP), or Bardet-Biedl Syndrome 15.

Methods: In trio-whole exome sequencing (WES) was performed to identify candidate variants.

Results: We describe a 2-year-old girl born to non-consanguineous parents. Pregnancy was achieved by ICSI due to male infertility. Prenatal ultrasound revealed multiple anomalies including heart defects, cleft lip/palate, and polydactyly. Chromosomal microarray analysis and an Ellis-van Creveld Syndrome gene panel were negative. Delivery occurred at term and the newborn presented left cleft lip and palate, postaxial polydactyly of the left hand and hallux duplication bilaterally. Echodochiography revealed a large atrial septal defect and left ativoventricular regurgitation. WES identified two novel compound heterozygous variants in WDPCP gene: NM_001354044.1:c.1486T>G, p.(Cys496Gly), and NM_001354044.1:c.852_860delinsG, p.(Asp285Alafs*4).

Conclusion: Only two patients with CHDTHP have been reported so far. Interestingly, our patient is the first one presenting oral clefts, resembling the phenotype of the Wdpcp knockout mice. This study further expands the molecular and phenotypic spectrum of this rare and still poorly known disorder, contributing to a deeper understanding of WDPCP function in ciliogenesis. To the patient’s family, molecular diagnosis allowed proper genetic counselling and informed reproductive choices.

References:

Grants: None declared.

P12.029.C C20orf24: a potential novel gene responsible for Cerebrofaciothoracic Dysplasia

Esra İsık1, Durdurgül Ayyıldız Emecen2, Tahir Atik2, Özgur Cogulu2, Ferda Ozkınyay2

1Ege University, Pediatric Genetics, Izmir, Turkey; 2Ege Üniversitesi, Pediatric Genetics, Izmir, Turkey.

Background/Objectives: Cerebrofaciothoracic Dysplasia (CFTD) is a rare syndrome characterized by intellectual disability, dysmorphic facial features and skeletal anomalies. Biallelic loss of function variants in the TMCO1 were found to be responsible for CFTD. However, due to no mutations in the coding region of
TMCO1 could be identified in some patients, it has been considered that CFTD could be a genetically heterogeneous disorder.

**Methods:** The molecular etiology of CFTD was investigated using whole exome sequencing in Illumina NextSeq 550 platform.

**Results:** A 3 years old boy was the first child of consanguineous healthy parents. He had global developmental delay and dysmorphic facial features. Skeletal survey revealed craniosynostosis and rib anomalies. Regarding clinical and radiological findings CFTD was considered in the patient. Any TMCO1 variants could not be found via sequence analysis. WES revealed a homozygous variant (c.75G>A, p.Trp25Ter) in C20orf24 gene. In C20orf24 gene, the c.75G>A variant which causes a premature termination codon at 25th position of C20orf24 mRNA, a highly conserved amino acid during evolution, has not been reported in public databases to date.

**Conclusion:** C20orf24 is a protein coding gene, and its function has not yet been fully elucidated. Recently, Lewis and Hegde suggested that TMCO1 and C20orf24 seemed to be interaction partners to form an Oxa1 superfamily insertase complex. Regarding studies analyzing structure of integral membrane protein biogenesis, we consider that biallelic variants in the C20orf24 gene may cause similar phenotype with loss of function TMCO1 variants. However, functional studies are needed to show the relationship between C20orf24 variants and CFTD.

**References:**

**Conflict of Interest:** None declared.

**P12.030.D Pathogenicity assessment of DISP1 variants associated with midline anomalies spectrum**

**Alinoe Lavillaureix1,2, Paul Rollier1,2, Artem Kim1, Christele Dubourg1-2, Wilfried Carre3, Veranika Panasenkova1, Svetlana Mironov, Helene Guyodo1, Marjolaine Broekema1, Boris Keren1, Sandra Whalen2, Jeanne Médéric4, Laurence Faivre5, Clémence Vanlerbergh6, Luisa Mittendorf9, Fanny Laffargue11, Marie detryrac2, Valerie dupe12, Sylvie Odent12**

1South Hospital, Génétique clinique, Centre de Référence Maladies Rares CLAD-Ouest, ERN-ITHACA, CHU de Rennes, Rennes, France; 2University Rennes 1 - Ufr Médecine, Univ Rennes, CNRS, INSERM, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, ERL U1305, Rennes, France; 3CHU - Pontchaillou Hospital, Génétique Moléculaire et Génomique, CHU de Rennes, Rennes, France; 4Amsterdam UMC, locatie VUMc, Department of Human Genetics, clinical genetics, Amsterdam, Netherlands; 5University Hospitals Pitié Salpêtrière - Charles Foix, Département de génétique, Unité de génomique du développement, APHP, GH Pitié Salpêtrière, Paris, France; 6Hôpital Armand-Trousseau Ap-Hp, Unité Fonctionnelle de génétique clinique, Hôpital Armand Trousseau, Assistance publique-Hôpitaux de Paris, Centre de Référence Maladies Rares des anomalies du développement et syndromes malformatifs, Paris, France; 7CHU Hospitals Of Tours, Service de génétique clinique, Tours, France; 8CHU Dijon, Génétique clinique, Centre de Référence Maladies Rares CLAD, Dijon, France; 9CHU De Lille, Service de génétique clinique, Lille, France; 10Leipzig, Department of Human Genetics, clinical genetics, Leipzig, Germany; 11Clermont-Ferrand, CHU, Service de génétique clinique, Clermont-Ferrand, France.

**Background/Objectives:** Holoprosencephaly (HPE; MIM# 236100) results from incomplete midline division of the prosencephalon. The clinical spectrum is very wide, ranging from severe HPE with cyclopia to HPE microforms with midline craniofacial defects. HPE genes belong to the Sonic Hedgehog (SHH) pathway, a complex molecular cascade allowing ventralization during early central nervous system development. DISP1 is a positive factor necessary for the efficient secretion of the SHH morphogen and the establishment of its concentration gradient along the midline of the neural tube. We describe the first cohort of HPE patients with DISP1 variants.

**Methods:** We describe 22 individuals from 18 unrelated families, regrouping DISP1 variants retained during molecular diagnosis in our lab, along with collaborative and previously published findings.

**Results:** 13 patients have microform HPE or lobar HPE, 8/13 with orofacial cleft. 4/13 have single median incisor and pifiform aperture stenosis, a rare association described previously in patients with SHH variants. 9 additional patients from 6 families present with severe HPE (alobar or semilobar), 2/9 with cyclopia, 3/9 with orofacial cleft.

We further delineate the clinical spectrum of DISP1-related HPE, provide insight into the underlying pathomechanism and describe various factors modulating the phenotypic output of DISP1 variants.

**Conclusion:** DISP1 is major gene of holoprosencephaly. Autosomal recessive inheritance and haploinsufficiency lead to HPE microforms. Severe HPE can be caused by oligogenic transmission. The accumulation of rare and pathogenic variants in different genes negatively impact SHH and lead to HPE, more or less severe depending on the early role of the genes involved: “SHH-disorder”.

**References:**

**Conflict of Interest:** None declared.

**P12.031.A Losses and gains including PURA cause reciprocal ID syndromes: results of a large-scale study on 5q31.3 copy number variations**

**Margot Reijnders1, Laura Hamilton2,3, Diana Baralle2,3, David Hunt2, Nicole de Leeuw**

1Maastricht University Medical Center, Maastricht, Netherlands; 2University of Southampton, Southampton, United Kingdom; 3Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, United Kingdom; 4Radboud University Medical Center, Nijmegen, Netherlands.

**Background/Objectives:** Deletions in the 5q31.3 region have been occasionally reported to cause an intellectual disability (ID) syndrome. Previously, we reported a cohort of patients with PURA-syndrome caused by de novo nucleotide variants in PURA, located at 5q31.3.

**Methods:** To further investigate the contribution of PURA in copy number variants (CNVs) in the 5q31.3 region, we (1) re-analyzed available CNV data of ID patients available in South-apton (UK) and Nijmegen/Maastricht (Netherlands), (2) asked genetic centers in the UK and the Netherlands to re-evaluate diagnostic genetic data on 5q31.3 CNVs and (3) contacted clinicians of patients reported in the DECIPHER database.

**Results:** This led to the identification of eight patients with a de novo loss and eight patients with a de novo gain including PURA. Depending on the size and involvement of neighboring ID genes such as KDM3B, PPP2CA and PITX1, losses lead to severe ID, feeding difficulties with low weight, multiple congenital malformations and/or (prenatal) death. We show that gains cause a milder rec procal syndrome with moderate ID, aggressiveness and obesity as common features. Severe laryngomalacia is present in 3/8 microdeletion patients and in one patient reported in literature, but has never been observed in patients with PURA-syndrome before. By analyzing the smallest region of overlap, we suggest NRG2 and UBE2D2 as candidate genes for the development of laryngomalacia.

**Conclusion:** Close international collaboration led to the clinical delineation of 5q31.3 losses and identification of a novel,
reciprocal ID syndrome caused by 5q31.3 gains, showing the power of data sharing for studies on rare syndromes.

References:
Grants:
Conflict of Interest: None declared.

P12.032.B Homozygous NRP1 truncating variant in a multiplex family with conotruncal heart defects, lymphatic malformations and genitourinary anomalies

Umut Altunoglu1, Mert Kaya2, Tugba Kalayci3, Zehra Oya Uyguner4
1Koç University, School of Medicine, Medical Genetics Department, Istanbul, Turkey; 2Koç University, Graduate School of Health Sciences, Istanbul, Turkey; 3Istanbul University, Istanbul Medical Faculty, Medical Genetics Department, Istanbul, Turkey.

Background/Objectives: Neuropilins (NRP1 and NRP2) are cell surface proteins conserved across species, acting as coreceptors for signal proteins including members of semaphorin and VEGF families. They participate in a multitude of processes: development of the cardiovascular system, lymphangiogenesis, neuronal patterning and immune function. NRP1 deficient mice display embryonic lethality due to a severely abnormal cardiovascular phenotype, resembling those of Vegf and Vefgr2 knockouts. Shaheen et al. (2015) reported a homozygous null mutation in the proband of a multiplex family with truncus arteriosus.

Methods: Exome sequencing in the proband was performed in a consanguineous multiplex family with conotruncal anomalies. Affected and unaffected family members were screened for the candidate variant to reveal segregation.

Results: We present a 32-day-old girl born to 1st cousins once-removed, with a severe congenital heart defect comprising atrial and ventricular septal defects with patent ductus arteriosus, left microphthahmia with cystic lymphatic malformation, and renal anomalies. Weight was 3500 g (14p), height 52.5 cm (31p) and head circumference 37 cm (46p). Cranial MRI was unremarkable. The parents had a medical abortion due to a huge parapharyngeal lymphangioma, and two children deceased due to severe coarctation of the aorta and tetralogy of Fallot, respectively. Chromosomal array was normal. WES revealed homozygous nonsense c.1213C>T; p.(Arg405*) in NRP1 [NM_003873], segregating with the phenotype in unaffected parents and sister, and one deceased affected sibling. Parental echocardiograms were normal.

Conclusion: This is the second report of a family with homozygous truncating variants in NRP1, further supporting NRP1 as a human disease gene.

References: https://doi.org/10.1016/s0092-8674(00)80534-6, https://doi.org/10.1016/s0092-8674(00)81402-6, https://doi.org/10.1073/pnas.022017899, https://doi.org/10.1136/jmedgenet-2015-102992.

Grants: None.
Conflict of Interest: None declared.

P13 CANCER GENETICS

P13.001.C Development of genomic instability score for ovarian cancers from a limited panel of genes

Leman Raphael1,2, Etienne Muller1,2, Nicolas goardon1,2, Imène Chentli3, Aurore Tranchant2, Angelina Legros1, Laurent Castéra1,2, Alain Morel3, Christel Brunet3, Véronique Boly4, Eric Fernandez5, Florence Coulet5, Dominique Vaur1,2
1Normandie University, Inserm U1245, Rouen, France; 2Centre François Baclesse, Laboratoire de biologie et génétique des cancers, Caen, France; 3Institut de Cancérologie de l’Ouest - Paul Papin, Angers, France; 4Hôpital Pitié-Salpêtrière, Département de Génétique, UF d’Onco-Angiogénétique et Génomique des tumeurs solides, Paris, France.

Background/Objectives: High-grade serous ovarian cancers with a homologous recombination DNA repair (HRD) are sensitive to the combination of bevacizumab and olaparib as maintenance therapy. HRD status is determined by mutational scars within the tumor genome. To date, only the method developed by the commercial company Myriad Genetics® (MG) has been clinically validated to identify HRD status. In this study, we developed a new method to identify HRD status and suitable with the most of molecular biology laboratory constraints.

Methods: We computed a score from the genomic scars, i.e. chromosomal breaks, genomic deletion/duplication and allelic imbalance of polymorphisms. We used sequencing data from limited panel of 127 genes to detect these events. The score training was performed on a collection of 146 samples from ovarian cancer with HRD status previously defined by MG. Among these samples, 32 samples were managed and sequenced by another laboratory to assess the robustness of our method.

Results: Our new score reached an accuracy of 92.46 % (Chi-Square p-value < 0.00001) compared to MG HRD status, with a sensitivity of 95.38 % and specificity of 90.12 %. The Pearson coefficient between the two scores was 0.810 (p-value < 0.00001). We observed similar results for the 32 samples analyzed by the second platform.

Conclusion: Our score showed a significant correlation with MG data, confirmed on data from different platforms. Thus, our method is robust enough to be deployed in other molecular biology laboratories. The validation of the method on clinically characterized samples is in progress.

References: No references.
Grants: No grants.
Conflict of Interest: Leman Raphael Centre François Baclesse, Etienne Muller CERBA, Nicolas goardon Centre François Baclesse, Imène Chentli Centre François Baclesse, Aurore Tranchant Centre François Baclesse, Angelina Legros Centre François Baclesse, Laurent Castéra Centre François Baclesse, Alain Morel Institut de Cancérologie de l’Ouest, Christel Brunet Hôpital Pitié-Salpêtrière, Véronique Boly Hôpital Pitié-Salpêtrière, Eric Fernandez Hôpital Pitié-Salpêtrière, Florence Coulet Hôpital Pitié-Salpêtrière, Dominique Vaur Centre François Baclesse.

P13.002.D Imprinting relaxation of an ovarian dysgerminoma in a patient with Prader-Willi syndrome

Carolina Maya Gonzalez1, Sandra Wessman1,2, Bianca Tesi1,2,4, Fulya Taylan4, Glenn McCluggage5, Ekaterina Kuchinskaya6, Anna Poluha7,8, Stefan Holm1,9, Ricard Nargàrd7,9, Teresita Díaz de Stahl1,9, David Gisselsson Nord8, Kristina Lagerstedt1,3, Ann Nordgren1,3
1Karolinska Institutet, Department of Molecular Medicine and Surgery, Centre for Molecular Medicine, Stockholm, Sweden; 2Karolinska Institutet, Department of Oncology-Pathology, Stockholm, Sweden; 3Karolinska Institutet, Department of Clinical Pathology and Cytology, Stockholm, Sweden; 4Karolinska Institutet, Department of Clinical Genetics, Uppsala, Sweden; 5Karolinska Institutet, Department of Obstetrics and Gynecology, Stockholm, Sweden; 6Karolinska Institutet, Department of Gynaecological Oncology, Stockholm, Sweden; 7Belfast Health and Social Care Trust, Department of Pathology, Belfast, United Kingdom; 8Uppsala University Hospital, Department of Clinical Genetics, Uppsala, Sweden; 9Karolinska Institutet, Department of Women’s and Children’s Health, Stockholm, Sweden; 1Lund University, Division of Clinical Genetics, Department of Laboratory Medicine, Lund, Sweden.
Background/Objectives: Prader-Willi syndrome (PWS) is a rare intellectual disability syndrome characterized by dysmorphic features, short stature, obesity, hypotonia, hyperphagia and hypogonadism. PWS is caused by lack of expression of paternally inherited imprinted genes on chromosome 15q11-q13. Loss-of-imprinting has previously been reported in a testicular seminoma of a patient with PWS caused by maternal UPD[1]. Here, we present the genetic and microscopic findings of an ovarian tumour in a 13-year-old girl with PWS due to a paternal 15q11.2-13 deletion.

Methods: Microscopic examination of tumour tissue including immunohistochemical staining was performed. Tumour and germline DNA were analysed with 30X whole genome sequencing and germline genome was evaluated for pathogenic variants in 153 known childhood cancer predisposition genes. Methylation sensitive MLPA was carried out to assess the methylation status in the tumour-DNA at the PWS locus compared to a control imprinted region (11p15).

Results: Tumour morphology and immunohistochemical staining were consistent with a dysgerminoma. Additionally, bilateral microscopic sex-cord stromal tumours were found. MLPA analysis revealed that methylation was reduced by 50% in the PWS locus in the tumour compared to blood, while preserved in other imprinted regions. A somatic pathogenic activating KIT mutation was detected in the tumor (NM_000222.3:c.1676T>G AF:20%). No additional germline aberrations were found.

Conclusion: We present a second case of locus-specific loss-of-imprinting in a germ-cell tumour from a patient with PWS and propose imprinting relaxation as a possible mechanism of carcinogenesis in PWS.

References: [1] Eldar-Geva T, et al. Molecular Genetics and Genomic Medicine. 2018;6(5).

Grants: The Swedish Childhood Cancer Fund.

Conflict of Interest: None declared.

P13.003.A Primary mediastinal large B-cell lymphoma is hallmarked by large-scale copy-neutral loss of heterozygosity

Stefania Tuveri1, Koen Debackere2, Lukas Marcelis3, Nicolas DierckxSENS1, Jonas Demeulemeester1, Efychia Dimitriadou1, Daan Dierickx4, Pierre Lefesvre5, Karen Deraedt6, Carlos Graux7, Lucienne Michaux8, Jan Cools9, Thomas Tousseyn9, Joris Vermeesch10, Iwona Wlodarska11

1Katholieke Universiteit Leuven, Centre for Human Genetics, Leuven, Belgium; 2Katholieke Universiteit Leuven, Laboratory for Experimental Hematology, Leuven, Belgium; 3University Hospitals Leuven, Department of Pathology, Leuven, Belgium; 4University Hospitals Leuven, Department of Hematology, Leuven, Belgium; 5Free University Hospital, Department of Pathology, Brussels, Belgium; 6Hospital East Limburg, Anatomato-pathology, Genk, Belgium; 7Mont-Godinne University Hospital, Department of Hematology, Yvoir, Belgium.

Background/Objectives: Development of primary mediastinal B-cell lymphoma (PMBL), an aggressive subtype of non-Hodgkin lymphoma, is driven by cumulative genomic aberrations. To identify the driver mutational events, we screened PMBL cases by SNP arrays.

Methods: PMBL samples were investigated by SNP arrays (Illumina HumanCytoSNP-12v2.1 BeadChip), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), whole-exome sequencing (WES) and whole-genome sequencing (WGS) [NovaSeq 6000 (Illumina), Oxford Nanopore Technology sequencing].

Results: The screen uncovered an extreme burden of copy-neutral loss of heterozygosity (CN-LOH) in PMBL which distinguishes this tumour from other B-cell malignancies, including the biologically related diffuse large B-cell lymphoma (respectively on average per patient 4.04 and 1.8). We identified large-scale CN-LOH lesions in 90.9% (30/33) of diagnostic PMBLs and both investigated PMBL-derived cell lines. The cohort showed 133 extra-large (25.3-248.4 Mb) CN-LOH lesions affecting up to 14 chromosomes per case. Notably, CN-LOH stretches non-randomly clustered on chromosome 6p (60%), 15 (37.2%) and 17q (40%), and frequently co-occurred with homozygous mutations in MHC I (6p21), B2M (15q15) and GNA13 (17q23) genes, as yielded by preliminary whole-exome/genome sequencing data.

Conclusion: Altogether, our findings implicate large-scale CN-LOH as a novel mutational process contributing to the molecular pathogenesis of PMBL. The prevalent occurrence of segmental CN-LOH in a heterozygous diploid context, alongside the lack of common CNVs and/or recurrent scars in regions flanking CN-LOH regions revealed by long-read sequencing, points to a key role of mitotic homologous recombination. This mechanism usually follows DSB and likely acts as an errant DNA repair mechanism leading to CN-LOH.

References:

Grants: Conflict of Interest: Stefania Tuveri Research Foundation-Flanders (FWO 1574420N), Koen Debackere: None declared, Lukas Marcelis: None declared, Nicolas DierckxSENS: None declared, Jonas Demeulemeester Research Foundation-Flanders (FWO 12J6921N), Efychia Dimitriadou: None declared, Daan Dierickx Kom op tegen Kanker, Pierre Lefesvre: None declared, Karen Deraedt: None declared, Carlos Graux: None declared, Lucienne Michaux: None declared, Jan Cools: None declared, Thomas Tousseyn Mandate for Fundamental and Translational Research from the “Stichting tegen Kanker” (2’14-083), Joris Vermeesch KULeuven grant C1/018, Iwona Wlodarska: None declared.

P13.004.B Overview of cancer predisposition syndromes in a national, unselected cohort of 836 children with a neoplasm

Jette Bakhuizen1,2, Saskia MJ Hopman1,2, Machtedl I Bosscha3, Charlotte J Dommering4, Marry M van den Heuvel-Eibrink5, Janna A Hof6, Lennart A Kester7, Marco J Koudijs1, Karin PS Langenberg1, Jan LC Loeffen8, Annette C Moll9, Max M van Noesel1,2, Stephanie E Smetsers1, Johannes HM Merks1, Roland Kuiper1, Marjolijn Jongmans1,2

1Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; 2University Medical Center Utrecht, Department of Genetics, Utrecht, Netherlands; 3Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Department of Ophthalmology, Amsterdam, Netherlands; 4Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Clinical Genetics, Amsterdam, Netherlands; 5University Medical Center Utrecht, Division Imaging & Cancer, Utrecht, Netherlands.

Background/Objectives: The diagnostic approach of cancer predisposition syndromes (CPSs) in children with cancer is shifting from a phenotype-driven approach towards a genotype-first approach. To decide on best practice in CPS diagnostics, it is essential to evaluate the yield of universal germline sequencing and to compare it with targeted genetic testing based on clinical selection. However, a reliable comparison is difficult since recent reports on a phenotype-driven approach in large, unselected childhood cancer cohorts are lacking.

Methods: Medical records of newly diagnosed children with cancer in the Netherlands between 01/06/2018 and 31/12/2019 were screened for medical history and clinical genetic assessment. In this period, it was standard practice that pediatric oncologists checked for characteristics of CPSs and selected children for referral to clinical geneticists.

Results: In 72/836 patients (8.6%) a CPS was identified (26 different conditions), of which the majority (96%) was identified...
by a phenotype-driven approach. Down syndrome and NF1 were the most common CPSs diagnosed. In 42/72 patients (58%) a CPS was identified after these children had developed a neoplasm. The specific type of neoplasm was the most frequent indicator for referral to a clinical geneticist and targeted genetic testing, whereas family history played a small role.

**Conclusion:** The mostly phenotype-driven diagnosis of CPSs in our unselected cohort revealed a CPS prevalence similar to that in earlier genotype-based studies, but the spectrum of CPS diagnosis is clearly different. This study can be used as a reference cohort for future genotype-driven studies.

**References:** NA.

**Grants:** JJB was funded by KiKa (355).

**Conflict of Interest:** Jette Bakhuizen JJB was funded by the KiKa Foundation (project number 355). Saskia MJ Hopman: None declared, Machtedt I Bosscha: None declared, Charlotte J Dommering: None declared, Marry M van den Heuvel-Eibrink: None declared, Janna A Hol: None declared, Lennart A Kester: None declared, Marco J Koudijis: None declared, Karin PS Langenberg: None declared, Jan LC Loeffen: None declared, Annette C Moll: None declared, Max M van Noesel: None declared, Stephanie E Smetters: None declared, Johannes HM Merks: None declared, Roland Kuiper: None declared, Marjolijn Jongmans: None declared.

P13.005.D Constitutional mismatch repair deficiency (cmmrd) presentation in two unrelated saudi patients with early onset malignancies

**Al-Jouhara Asiri**, balsam almaarik, rasha saleh, saleh albanyan

**Background/Objectives:** Biallelic germline mismatch repair gene mutations are rare events that cause constitutional mismatch repair deficiency (CMMRD) syndrome. They frequently go undiagnosed and often presents with fatal pediatric malignant brain tumors, early onset colorectal cancer, leukemia, lymphoma, and other malignancies. CMMRD may also present with non-neoplastic features such as cafe au lait macules (CALMs).

**Methods:** Case series of two cases of CMMRD.

**Results:** We present two cases of CMMRD without prior established diagnosis. The cases were of two 13-year-old children who presented with Neurological and/or gastrointestinal symptoms, skin findings and suggestive family history of Lynch syndrome. Both cases were the product of consanguineous marriages. The first case of a 13-year-old boy, who has unfortunately passed away due to a high-grade brain glioma, and his testing revealed a homozygous pathogenic variant in MSH6 (c.2772_2773del). While the second case, is of a 13-year-old girl who has locally advanced rectal cancer has revealed a homozygous pathogenic variant in PM25 (c.1376C>G). She has a brother with multiple CALMs and a sister that passed away of a brain tumor at the age of 3 but she was not tested beforehand.

**Conclusion:** We hope to raise awareness of CMMRD and its phenotype. Such awareness is needed especially in regions where consanguinity is prevalent, in aims to identify similar cases and to provide familial counseling, surveillance and timely intervention. Prompt recognition and prevention is crucial due to its early age of presentation and the aggressiveness of the disease.

**References:** The abstract does not contain references.

**Grants:** The abstract does not contain grants.

**Conflict of Interest:** None declared.

P13.006.D Constitutional mosaicism: a critical issue in the definition of BRCA inherited cancer risk

**Elena Tenedini**, Simonetta Piana, Angela Toss, Marco Marino, Elena Barbieri, Lucia Artuso, Marta Venturelli, Elisa Gasparini, Vincenzo Dario Mandato, Isabella Marchi, Sara Castellano, Mario Luppi, Tommaso Trenti, Laura Cortesi, Enrico Tagliafico

**1University of Modena and Reggio Emilia, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy; 2Modena University Hospital, Department of Laboratory Medicine and Pathology, Diagnostic Hematology and Clinical Genomics Unit, Modena, Italy; 3Azienda USL-IRCCS Reggio Emilia, Pathology Unit, Reggio Emilia, Italy; 4Modena University Hospital, Department of Oncology and Hematology, Modena, Italy; 5Azienda USL-IRCCS Reggio Emilia, Oncology Unit, Reggio Emilia, Italy; 6Azienda USL-IRCCS Reggio Emilia, Unit of Obstetrics and Gynecology, Reggio Emilia, Italy.

**Background/Objectives:** Low-frequency constitutional variants represent alterations that inform the personal and familiar inherited cancer risk definition and precision medicine cancer strategies.

**Methods:** Following the standard procedure for BRCA diagnostic testing, peripheral blood and ovarian cancer FFPE sections were collected from a woman with a diagnosis of high-grade serous carcinoma. The tissue’s DNA was NGS-sequenced for BRCA genes and Sanger confirmation of the pathogenic variant was assessed in the blood. A second blood draw, a buccal swab along with sections from her previous triple negative breast carcinoma and from normal nasal mucosa were NGS-sequenced. Targeted Sanger sequencing was performed in parents and offspring.

**Results:** The DNA from the patient’s ovarian carcinoma was sequenced and a BRCA1 nonsense pathogenic variant was identified. Its presence was confirmed in her peripheral blood, though with lower-than-expected heterozygous frequency. Further analyses in secondary normal tissues revealed the patient as a constitutional mosaic for this variant. In addition, they showed that both her breast and ovarian neoplastic tissues harbored this variant with high frequency. A cascade screening of family members revealed that both parents were negative, but one of the daughters was a previously undiagnosed heterozygous carrier.

**Conclusion:** Constitutional mosaicism is a renowned mechanism for multiple hereditary cancer-associated genes and enables access to personalized therapies and preventive cancer strategies. To improve the current standard of constitutional analysis, we propose a new algorithm for the BRCA diagnostic routine to increase the sensitivity of germlinal assessment and decrease the number of false negatives when pathogenic or likely pathogenic variants occur at low frequencies.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

P13.008.B Yield of cancer surveillance in PTEN Hamartoma Tumour Syndrome

**Nicoline Hoogerbrugge**, Meggie Drissen, Kevin Kwinten, Alma Hoxha, Dorien Van der Biessen-van Beek, Tanya Bisseling, Anne van Altena, Joanne de Hullu, Iris Nagtegaal, Romana Teodora Netea-Maier, Martin Gotthardt, Ritse Mann, Janet Vos

**1Radboud University Medical Center, Human Genetics, Nijmegen, Netherlands; 2Radboud University Medical Center, Gynecology, Nijmegen, Netherlands; 3Radboud University Medical Center, Radiology, Nijmegen, Netherlands; 4Radboud University Medical Center,
Gastroenterology, Nijmegen, Netherlands; 2Radboud University Medical Center, Pathology, Nijmegen, Netherlands; 3Radboud University Medical Center, Endocrinology, Nijmegen, Netherlands.

Background/Objectives: Patients with PTEN Hamartoma Tumour Syndrome (PHTS) are at high hereditary cancer risk and advised surveillance for breast (BC), endometrial (EC), thyroid (TC) and colorectal (CRC) cancer. Current PHTS guidelines are expert opinion-based only. We aimed to assess the yield of cancer surveillance in patients with PTEN Hamartoma Tumour Syndrome (PHTS) are at high hereditary cancer risk and advised surveillance for breast (BC), endometrial (EC), thyroid (TC) and colorectal (CRC) cancer. Current PHTS guidelines are expert opinion-based only. We aimed to assess the yield of cancer surveillance.

Methods: A single-institution retrospective cohort study including adult PHTS patients between 2005-2021.

Results: BC: 39 women, median age first examination 38 yr, underwent 156 annual surveillance rounds with MRI and mammography. BC was diagnosed in 7/39 women (CDR: 45/1000 rounds) and benign breast lesions in 18/39 women.

EC: 25 women, median age first examination 39 yr, underwent 93 rounds with annual trans vaginal ultrasound, and endometrial biopsy. No EC was diagnosed. Endometrial hyperplasia with and without atypia was diagnosed in 28%.

TC: 85 patients, median age first examination 36 yr, underwent 324 annual surveillance rounds with ultrasound. TC was diagnosed in 2/85 patients (age 17, 22) and another 2/85 had a thyroid adenoma. Nodular progression occurred in 16%.

CRC: 35 patients, median age first examination 45 yr, underwent 58 rounds with max. 5 yearly colonoscopy. CRC was diagnosed in 1/35 patient (age 41), and no advanced adenomas were found. Polyps were detected in 30/35 (86%), including hamartomas (13/30), non-advanced adenomas (14/30) and ganglioneuromas (13/30).

Conclusion: Our unique data show that surveillance in PHTS contributes to early detection of cancer. Our findings support surveillance for BC, EC, TC and CRC, and offer guidance to optimize the age and frequency of current surveillance recommendations for this rare disease.

References: None.

Grants: None.

Conflicts of Interest: None declared.

P13.009.C POLE and POLD1 germline variants in familial glioma

Christine A. M. Weber1, Frank Brand1, Alisa Förster1, Robert Geffers2, Bernd Auber3, Amir Samii3, Joachim K. Krauss 4, Bettina Wiese4,5, Christian Hartmann6, Ruthild G. Weber1

1Hannover Medical School, Department of Human Genetics, Hannover, Germany; 2Helmholtz Centre for Infection Research, Genome Analytics Research Group, Braunschweig, Germany; 3International Neuroscience Institute, Department of Neurosurgery, Hannover, Germany; 4Hannover Medical School, Department of Neurosurgery, Hannover, Germany; 5Diakovere Krankenhaus gGmbH, Henriettenstift, Department of Neurology, Hannover, Germany; 6Hannover Medical School, Institute of Pathology, Department of Neuropathology, Hannover, Germany.

Background/Objectives: Pathogenic variants in the DNA polymerase genes POLE and POLD1 cause polymerase proofreading-associated polypsis, a dominantly inherited disorder with an increased risk of colorectal carcinomas and other tumors. Tumors with POLE/POLD1 variants, particularly in the exonuclease domain, commonly show an accumulation of somatic mutations, making them susceptible to checkpoint blockade immunotherapy. Here, we explored the role of POLE/POLD1 germline variants in glioma predisposition.

Methods: Whole-exome sequencing was performed on germline DNA of 53 tumor families with at least one glioma case each. For genotype-phenotype correlations, gliomas from patients with POLE/POLD1 germline variants are being characterized with respect to histology, immunophenotype, mutational burden and signature. Cellular assays are being performed to investigate the mutational rate in POLE/POLD1-deficient versus wildtype cells, and upon stable expression of POLE/POLD1 variants versus wildtype.

Results: Rare heterozygous POLE/POLD1 missense variants predicted to be deleterious were detected in eight patients diagnosed with glioblastoma, astrocytoma, or oligodendroglioma from 7/53 (13%) families, co-segregating with the tumor phenotype in both families with available DNA from two tumor patients. The other tumor types diagnosed in these families were breast, colorectal, lung, prostate and uterus cancer, and meningioma. In primary gliomas of POLE/POLD1 variant carriers, enlarged nuclei or multinucleated cells were observed in 3/8 cases, and evidence for hypermutation in 3/7 cases. Immunophenotyping is ongoing. An increased mutation rate in POLE-deficient versus POLE-wildtype LN-229 glioblastoma cells was observed in an HRPT1 mutation assay. The effects of the POLE/POLD1 variants are being investigated.

Conclusion: POLE/POLD1 variants may predispose to glioma and render patients susceptible to immunotherapy.

References: None.

Grants: None.

Conflict of Interest: None declared.

P13.010.D Investigating genetic susceptibility to male breast cancer by multigene panel testing: an Italian population-based case-control study

Agostino Bucalo1, Valentina Silvestri1, Giulia Conti1, Virginia Valenti1, Mina Karimi1, Ines Zannd2, Maria Grazia Tibiletti3, Antonio Russo3, Liliana Varesco3, Anna Coppa3, Daniele Calisti3, Laura Cortese4, Alessandra Vie1, Bernardo Bonanni10, Siranoush Manoukian11, Marco Montagna12, Paolo Radice13, Domenico Pali13, Paolo Peterlongo14, Laura Ottini1

1Sapienza University of Rome, Department of Molecular Medicine, Rome, Italy; 2Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy; 3ASST Settegelati and Centro di Ricerca per lo studio dei tumori eredo-familiari, Università dell’Insubria, Dipartimento di Patologia, Varese, Italy; 4Section of Medical Oncology, University of Palermo, Department of Surgical and Oncological Sciences, Palermo, Italy; 5IRCCS Ospedale Policlinico San Martino, Genoa, Italy; 6Sapienza University of Rome, Department of Experimental Medicine, Rome, Italy; 7Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy; 8University of Modena and Reggio Emilia, Department of Oncology and Haematology, Modena, Italy; 9Unità di Oncogenetica e Oncogenomica Funzionale, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy; 10Division of Cancer Prevention and Genetics, European Institute of Oncology (IEO), IRCCS, Milan, Italy; 11Unità di Medicina Genetica Medica, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Dipartimento di Oncologia Medica ed Ematologia, Milano, Italy; 12Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy; 13Unità di Ricerca Medicina Preditiva: Basi molecolari Rischio genetico e Test genetici, Dipartimento di Ricerca, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milano, Italy; 14Genome Diagnostics Program, IFOM – The FIRC Institute of Molecular Oncology, Milan, Italy.

Background/Objectives: About 20% of male breast cancer (MBC) patients report BC family history (FH) and personal history (PH) of cancer other than BC, suggesting a role of genetic susceptibility. BRCA1/2 pathogenic variants (PVs) are responsible for about 15% of MBCs. The aims of this study were to evaluate the role of PVs in...
non-BRCA1/2 genes in MBC susceptibility and to identify possible distinct clinical-pathologic features in PV carriers.

Methods: A population-based, case-control study including 725 BRCA1/2 PV negative MBCs and 917 healthy male controls, enrolled in the frame of the Italian multicenter study on MBC, was performed using a custom 50-gene panel in NGS. Statistical analyses were performed using chi-square test and logistic regression model.

Results: Overall, MBCs were more likely to carry PVs in cancer genes compared with controls (5% vs 2.3%, p = 0.003). PALB2 PVs were identified in 1% of MBCs and were significantly associated with increased MBC risk (OR: 4.6, 95% CI: 1.00-22.3; p = 0.04). BLM and FANCN emerged as possible genes associated with MBC risk in the case-control analysis (p = 0.02, each). PV carriers were more likely to have a PH of cancer (p = 0.02) and FH of cancer (p = 0.007), not limited to BC.

Conclusion: Our results support a central role of PALB2 in MBC susceptibility in the Italian population. Overall, our data indicate that a multigene testing approach may benefit from appropriately selected patients, particularly those with family and personal history of multiple cancers, with implications for clinical management of MBC patients and their relatives.

References:

Grants: Study supported by AIRC (IG21389) to LO.

Conflict of Interest: None declared.

P13.011.A Germline NGS gene panel testing in routine care of Breast and Ovarian cancer patients in Estonia 2016-2020

Mikk Tooming1;2, Kadri Rekker2, Kadri Toome2, Olga Fjodorova2, Hanno Roomere2, Piret Lairde2, Ülle Murumets2, Katrin Ounap1;2, Tiina Kahre1;2

1Institute of Clinical Medicine, Department of Clinical Genetics, Tartu, Estonia; 2Tartu University Hospital, Department of Clinical Genetics, Tartu, Estonia.

Background/Objectives: Targeted NGS gene panels have replaced the standard single-gene testing for hereditary cancer diagnostics of Breast cancer (BC) and Ovarian cancer (OC) in Estonia. The aim of this study was to investigate the prevalence of pathogenic variants (PV) in hereditary BC and OC patients and healthy individuals with positive family history (HI) from Estonia during the years 2016-2020.

Methods: The study included 2200 patients referred to the Department of Clinical Genetics at Tartu University Hospital for analysis of suspected hereditary BC and OC or HI carrier screening. Individuals were analyzed using Illumina TruSight Cancer or TruSight Hereditary Cancer gene panel.

Results: Analyzed group consisted of 1080 (49.1%) BC patients, 366 (16.6%) OC patients, 27 (1.3%) BC/OC patients and 727 (33%) HI group. NGS revealed PV findings in 263/2200 (16.5%) cases. Altogether, PVs were found in 195/1080 (18.1%) BC patients, 98/366 (26.7%) OC patients, 7/27 (26%) BC/OC patients and 63/727 (8.7%) HI group. Respectively, BRCA1/2 PVs were found in 113/1080 (10.4%) BC patients, 69/366 (18.9%) OC patients, 6/27 (22.2%) BC/OC patients and 39/727 (5.4%) HI. Furthermore, non-BRCA1/2 (ATM, BARD1, BRIP1, CDH1, CHEK2, NF1, PALB2, RAD51C, RAD51D, TP53) PVs were found in 93/1080 (8.6%) BC patients, 29/366 (7.9%) OC patients, 1/27 (3.7%) BC/OC patients and 29/727 (4%) HI.

Conclusion: The diagnostic efficacy of NGS gene panels is in between 18-26% in BC and OC cases, which is similar to the literature data. Detection rate with NGS panel is ~7% higher compared to BRCA1/2 gene testing.

References:

Grants: Estonian Research Council grant PRG471.

Conflict of Interest: None declared.

P13.012.B MLH1 variant c.836T>G, a Tyrolean hypomorphic founder mutation?

Sukanya Horpaopan1;2, Esther Schamschula1, Simon Schnaiter1, Heidi Fieg1, Susanne Sprung4, Ulrich Strasser3, Hannes Dapoiz, Pia Traumfellner1, Albert Amberger1, Renate Lunzer1, Ingrid Weber1, Johannes Zschocke1, Katrinara Wimmer1

1Medical University Innsbruck, Institute of Human Genetics, Innsbruck, Austria; 2Naresuan University, Faculty of Medical Science, Phitsanulok, Thailand; 3Medical University Innsbruck, Department of Obstetrics and Gynecology, Innsbruck, Austria; 4Medical University Innsbruck, Institute of Pathology, Neuropathology, and Molecular Pathology, Innsbruck, Austria; 5Tyropath Obrist Brunhuber GmbH, Zams, Austria.

Background/Objectives: Correct classification of mismatch repair gene variants is of utmost important for appropriate counseling, surveillance, and treatment of suspected Lynch syndrome patients and their entire families.

Methods: We used multiple lines of evidence to classify MLH1 variant NM_000249.3:c.836T>G, reported twice in ClinVar, as likely benign and of uncertain significance, respectively.

Results: NM_000249.3(MIH1):c.836T>G, found in five Tyrolean patients with cancers showing MLH1 and/or PMS2 expression loss and no MLH1 hypermethylation (PP4_Strong), is absent in GnomAD (PM2_Supporting). Full-length transcripts with c.836G predicted to cause p.(Val279Gly) with a MAPP+PolyPhen-2 p value below 0.001 and p.(His264fs+2), represented only ~25% of transcripts in blood lymphocytes of four carriers. Use of a novel 5' splice site created by the variant is observed in ~20% and skipping of exon 10 in <10% of transcripts. Minigene experiments confirmed both splice effects, which are predicted to cause loss of 16 amino acids, p.(Val279_Ser295delinsGly), in the MLH1 N-terminal domain and p.(His264fs+2), respectively. Ignoring that they are leaky, both splice effects render a very strong argument for pathogenicity (PV51).

Conclusion: Considering its missense and newly characterized splice effects, we classify c.836T>G according to the draft InSIGHT ACMG criteria as (likely) pathogenic. Ongoing studies explore whether this variant has an attenuated penetrance, which is suggested by the lack of a strong Lynch syndrome family history of the five patients and its accidental finding in one patient with a concomitant MSH6 pathogenic variant and two different cancers with MSH6 expression loss.

References:

Grants: Ernst Mach-Grant of Austrian Agency for Education and Internationalization (OeAD).

Conflict of Interest: None declared.

P13.013.C Molecular characterization of an embryonal rhabdomyosarcoma occurring in a patient with Kabuki syndrome: report and literature review in the light of tumor predisposition syndromes

Sietse Aukema1, Selina Glaser2, Mari van den Hout3, Sonja Dahlum2, Rien Blok1, Morten Hillmer2, Julita Kolarova4, Raf Scoit4, Dina Schott1, Reiner Siebert2, Connie Stumpel1

1Maastricht University Medical Centre, Department of Clinical Genetics, Maastricht, Netherlands; 2Ulm University and Ulm University Medical Center, Institute of Human Genetics, Ulm, Germany; 3Maastricht University Medical Center, Department of Pathology, Maastricht, Netherlands; 4University Hospital, University of Leuven, Department of Pathology, Leuven, Belgium.

Background/Objectives: Kabuki syndrome (KS) is a MCA/ID syndrome in which most patients have a KMT2D germline variant.
With the publication of several case reports of patients with KS and a concomitant malignancy the topic of tumor predisposition in KS has received increased attention. We describe a patient with KS who developed an ERMS. To get more insight into a potential tumor predisposition in KS we performed molecular (epi)genetic analyses on tumor tissue and a literature review.

**Methods:** Exome sequencing and DNA-methylation profiling (EPIC-array) was performed on tumor DNA. For DNA methylation-based sarcoma classification we used the DKFZ-Sarcoma classifier(1). We conducted a literature search for reports of patients with KS and a malignancy.

**Results:** DNA-methylation profiling mapped the case to ERMS. Exome sequencing revealed variants in ERCC5 and TP53. Copy number variant analysis revealed (partial) gains of chromosomes 2, 3, 7, 8, 12, 15, and 20, and focal deletions in 11p. Sanger re-sequencing of the germline variant suggested a gain of the wild-type KMT2D allele in the trisomy 12. Including our patient literature review identified 18 patients with KS and a malignancy. Overall, the landscape of malignancies in patients with KS was reminiscent of that of the pediatric population in general. No secondary malignancy, bilateral-/multifocal or meta-synchronous malignancies were reported. Histopathological and molecular data were infrequently reported and did not include next generation sequencing and/or DNA-methylation profiling.

**Conclusion:** Although, based on our (molecular) analyses and literature review, a tumor predisposition cannot be confirmed or ruled out we found no strong arguments pointing towards KS as a tumor predisposition syndrome.

**References:** (1) Koelsche,Nat.Commun.2021.

**Grants:**

**Conflict of Interest:** None declared.

P13.014.D Severe neurovascular manifestations in PTEN-related hamartoma tumour syndrome

Anna Gerasimenko1, Patrick Benusiglio1, Florence Coulet1, Olivier Naggar2,3, Mélanie Eyries1, Cyril Mignot1,4, Annouk Bisdorff5

1APHP, Sorbonne Université, Groupe Hospitalier Pitie-Salpêtrière, Département de Génétique, Paris, France; 2APHP - CHU Necker-Enfants Malades, Service de Radiologie Pédiatique, Paris, France; 3CH Sainte-Anne, Paris, Service de Neuroradiologie, Paris, France; 4Institut du Cerveau et de la Moelle Epinière, Paris, France; 5Service de Neuroradiologie, APHP- Hôpital Lariboisière, Paris, France.

**Background/Objectives:** PTEN-related hamartoma tumor syndrome (PHTS) is an overgrowth and cancer susceptibility syndrome associated with germline pathogenic variants (PV) in the PTEN gene. Brain anomalies such as dysplastic ganglioma of the cerebellum are common, although there are no central nervous system surveillance recommendations. Brain vascular anomalies in the context of PHTS were scarcely studied. The aim of our study was to systematically search for cerebral vascular anomalies in a series of PHTS patients, with a focus on cranial dural arteriovenous fistulae (dAVF) and their clinical consequences.

**Methods:** We retrospectively studied brain imaging in 58 adult and pediatric PHTS patient s (MRI in 57 patients) who underwent germline testing at the AP-HP.Sorbonne-University neurodevelopmental, vascular and cancer genetics laboratory.

**Results:** A benign developmental venous anomaly was observed in 6 patients and dAVF in two (3.4%) patients. The first patient was a 36 yrs old man with severe epilepsy with a fatal evolution after 6 years of repetitive endovascular embolizations. The second was a 21-year-old woman who presented with intracranial hypertension as a consequence of the dAVF, subsequently cured by embolization.

**Conclusion:** In the present observational study, occurrence of cranial dAVF, a condition that may be associated with debilitating or life-threatening evolution, seems to be higher than in the general population. A screening brain imaging may be discussed at diagnosis in PHTS, ideally using MRI with dynamic MR angiography and perfusion imaging. In parallel, clinicians should be wary of neurological symptoms in their PHTS patients.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

P13.015.A Searching for germinal variants of TET2, IDH1, SETD2, CHD1 and ASXL1 epigenetic genes in Polish prostate cancer patients - preliminary results

Marta Heise1, Piotr Jarzemski2, Aneta Bąk1, Anna Junkiert-Czarnecka1, Maria Pilarska-Deltow1, Maciej Borysiak2, Beata Pilarska2, Olga Haus1

1Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland, Department of Clinical Genetics, Faculty of Medicine, Bydgoszcz, Poland; 2Department of Urology, Faculty of Health Sciences, Jan Bieżi University Hospital in Bydgoszcz, Poland, Bydgoszcz, Poland.

**Background/Objectives:** The epigenetic variants are present in all human cancers and associated with genetic alterations to drive a cancer phenotype. Thus, we searched for germinal variants of five epigenetic genes in Polish prostate cancer patients.

**Methods:** The material of investigation was DNA from 97 men with prostate cancer (PC) from all over Poland. NGS and Sanger sequencing.

**Results:** In 11/97 (11.3%) PC patients 13 variants of analyzed genes were detected. These were eight missense variants of TET2 (2), IDH1 (1), SETD2 (3), CHD1 (1) and ASXL1 (1), four silent variants of TET2 (3) and CHD1 (1) and one duplication of ASXL1. Bioinformatic analysis of variants was performed using VarSome database. TET2 c.2218CG>T and ASXL1 c.1934dupG were predicted as pathogenic, ASXL1 c.3623CT>T, SETD2 c.3383CG>G, TET2 c.2370GG>A, c.4161CT>T and IDH1 c.565AA>G as VUS (variants of uncertain significance), CHD1 c.2321AT>T and c.1434CT>C, SETD2 c.1643CA>A and c.3229GA>G and TET2 c.972A>G were predicted as benign and TET2 c.3251AT>G as likely benign. Two prostate cancer patients were both carriers of two variants, one of them was a carrier of ASXL1 c.1934dupG and TET2 c.2370GG>A and the second one a carrier of CHD1 c.2321AT>T and TET2 c.972A>G.

**Conclusion:** The results of the preliminary investigation point at the need to study germinal variants of epigenetic genes to help fully understand the pathogenesis of prostate cancer, identify men at PC high risk and predict the disease recurrence risk after radical prostatectomy.

**References:** Soo You J, Jones PA: Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell. 2012, 22: 9-20.

**Grants:**MN-1/WL/2020.

**Conflict of Interest:** None declared.

P13.017.C Rapid progression to Richter’s syndrome in patient with chronic lymphocytic leukemia and near triploid karyotype

Marija Dencic Fekete1, Tatjana Terzic2, Ljubomir Jakovic2, Vladi-slava Djurasinovic3, Teodora Karan Djurasevic3, Milica Radojkovic4, Sonja Pavlovic5, Andrija Bogdanovic5

1Institute for pathology, Medical faculty of Belgrade, Belgrade, Serbia; 2Clinic for hematology, University Clinical Center, Serbia, Belgrade,
Background/Objectives: The presence of aneuploidy in patients with chronic lymphocytic leukemia (CLL), except for trisomy 12, is quite uncommon. The frequency of hyperdiploidy or near-tetraploidy occurs in 1-3% of the CLL patients and usually confer poor prognosis.

Methods: Cytogenetic, Fluorescent in situ hybridisation (FISH) and Polymerase chain reaction analyses were performed and complemented with immunophenotyping by flow cytometry and pathohistological examination.

Results: Our patient showed splenomegaly, more than three enlarged lymph node regions and elevated serum LDH and β2 microglobulin levels, at presentation. Highly progressive disease was proven by other diagnostic methods, including the surface expression of CD38 and CD49d in the immunophenotype. The FISH result revealed a trisomy of 13q14 region and the C-MYC gene as the most prevalent aberrations, followed by a trisomy of the 11q, CEP12, IGH gene disruption and a tetrasomy of chromosome 12. In the patient’s karyotype, multiple structural and numerical changes of chromosomes not covered with the FISH probes, were observed, as well. In addition, the mutational analysis of the TP53 gene was positive for the frameshift mutation in exon 6.

Conclusion: In our report, the presence of the near-triploid karyotype was designated as an uncommon and very rare event in both CLL and RS. Utilization of comprehensive diagnostic techniques is highly recommended in patients with a progressive phase of CLL, primarily due to adequate choice of management strategy. The current case confirms poor prognosis of the previously reported CLL patients with aneuploidy.

References:

Grants: Supported by RVO-VFN64165, NU21-04-00100, GIP-22- NL-02-846.

Conflict of Interest: None declared.
WNK2. Genetic variants c.2105C>T (p.Pro702Leu), c.4820C>T (p.Ala1607Val) and c.6157G>A (p.Val2053Ile) were functionally characterized, displaying higher phospho-PAK1/2 and phospho-ERK1/2 levels, increased CCND1 expression, higher clonogenic capacity and upregulated MOMP2 levels.

**Conclusion:** Potentially pathogenic variants in WNK2 were identified in 3.24% of SP5 patients (17/524). WNK2 genetic variants seem to disrupt ERK1/2 MAPK pathway, affecting cellular functions as cell cycle progression, survival and adhesion capacity, supporting the role of WNK2 as a new germline predisposition gene to SP5.

**References:** 1- Soares de Lima Y et al. Germline and Somatic Whole-exome Sequencing Identifies New Candidate Genes Involved in Familial Predisposition to Serrated Polyposis Syndrome. Cancers 2021; 13(4):1–21.

**Grants:** LCF/BQ/D118/11660058 (ID100010434) Marie Skłodowska-Curie no. 713673, Fundació La Marató 2019-202008-10, Fondo de Investigación Sanitaria/FEDER (17/00878, 20/00113), AECC (PRYGN2110858CAST), Generalitat de Catalunya (GRPRE 2017SGR21), COST Action CA17118, CIBEREHD, CIBERONC and CIBERER.

**Conflict of Interest:** None declared.

**P13.020.B Evaluating the potential of polygenic risk score to improve colorectal cancer screening**

**Coral Arnau-Collell**1, Ana Diaz-Villanueva2, Beatriz Bellosillo2, Josep M Augé6, Jenifer Muñoz5, Elisabet Guino2, Leticia Moreira1, Anna Serradesanferm1, Àngels Pozo1, Isabel Torà1, Laia Bonjoch1, Gemma Rebeca Sanz-Pamplona1, Carmen Márquez Márquez6, Rebeca Rueda1, Laura Butland6, Abhijit Dixit6, Marc Tischkowitz1;5, Eamonn R Maher1

1Gastroenterology Department, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, Barcelona, Spain; 2Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP) and University of Barcelona, Barcelona, Spain; 3Pathology Department, Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; 4Biochemistry and Molecular Genetics Department, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; 5Department of Preventive Medicine and Epidemiology, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; 6Gastroenterology Department, Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; 7Unitat de Prevenció i Registre del Càncer, Servei d' Epidemiologia i Avaluació, Hospital del Mar, Barcelona, Spain; 8CRIPREV, Barcelona, Spain; 9Department of Clinical Sciences, University of Barcelona and IDIBELL, Barcelona, Spain.

**Background/Objectives:** Colorectal cancer (CRC) has a high incidence and associated mortality worldwide. Screening programs are recommended for men and women over 50 y.o.. Intermediate screens such as fecal immunochemical testing (FIT) select patients for colonoscopy with suboptimal sensitivity. Additional biomarkers could improve the current scenario.

**Methods:** We included almost 3,000 individuals with a positive FIT test. They were classified as cases when a high-risk lesion for CRC was detected after colonoscopy, whereas the control group comprised individuals with low-risk or no lesions. Sixty-five CRC risk genetic variants were genotyped. Polygenic risk score (PRS) and additive models for risk prediction incorporating sex, age, FIT value and PRS were generated.

**Results:** Risk score was higher in cases compared to controls (per allele OR = 1.04; 95%CI 1.02-1.06; P-value < 0.0001). We also observed a 2-fold increase in CRC risk for subjects in the highest decile of risk alleles (≥65), compared to those in the first decile (≤54) (OR = 2.22, 95%CI 1.59-3.12, P-value <0.0001). The model combining sex, age, FIT value and PRS reached the highest accuracy for identifying patients with a high-risk lesion (cross-validated AUROC: 0.639; 95%CI 0.619-0.660).

**Conclusion:** This is the first investigation analyzing PRS in a two-step CRC screening program. PRS could improve current CRC screening. However, its capacity is limited and should be complemented by additional biomarkers such as microbiome or environmental factors.

**References:**

**Grants:** PERIS (SLT002/16/00398), Fondo de Investigación Sanitaria/FEDER (PI17/00878, PI20/00113), Fundació La Marató de TV3 (2019-202008), AECC (PRYGN2110858CAST), Generalitat de Catalunya (GRPRE 2017SGR21), CIBEREHD, CIBERESP and COST Action CA17118.

**Conflict of Interest:** None declared.

**P13.022.D Diagnostic uncertainties in hereditary leiomyomatosis: complementary role of genetic analysis and immunohistochemical staining**

**Avgi Andreou**1, Anne Warren2, Saba Sharif2,4, Beverley. Speight5, Laura Butland6, Abhijit Dixit6, Marc Tischkowitz1;5, Eamonn R Maher1

1University of Cambridge, Academic Department of Medical Genetics, Cambridge, United Kingdom; 2Cambridge University NHS Foundation Trust, Department of Histopathology, Cambridge, United Kingdom; 3Birmingham Women’s and Children’s NHS Foundation Trust, Clinical Genetics Department, Birmingham, United Kingdom; 4Great Ormond Street Hospitals, Clinical Genetics Unit, London, United Kingdom; 5Addenbrooke’s Hospital, East Anglian Medical Genetics Service, Cambridge, United Kingdom; 6Nottingham City Hospital, Department of Clinical Genetics, Nottingham, United Kingdom.

**Background/Objectives:** Multiple cutaneous and/or uterine leiomyomas are associated with hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome but also occur with other disorders or are sporadic. HLRCC is caused by heterozygous germline variants in FH and is an important diagnosis to make because of the RCC risk. Though mutation analysis of FH may detect a pathogenic variant, detection of a rare variant of unknown clinical significance (VUS) or negative testing can leave diagnostic uncertainty. Here we report our findings from a patient series with multiple leiomyomas in which genetic findings were inconclusive and the role of immunohistochemistry in resolving diagnostic uncertainty.

**Methods:** Eight individuals with multiple cutaneous and/or uterine leiomyomas were evaluated. Genetic analysis identified an FH variant (initially classified as a VUS) in 6 cases. Immunohistochemical (IHC) staining for FH expression and detection of S-(2-succino)-cysteine (2-SC) was performed [1].

**Results:** IHC on leiomyoma and normal tissue revealed 2-SC positivity in 100% (6/6) and FH protein loss in 67% (4/6) of cases with a germline FH variant. All variants with 2-SC tumour positivity were upgraded to likely pathogenic/pathogenic. Two individuals with multiple leiomyomas and a family history of leiomyomatosis but no detectable germline FH variant demonstrated retention of FH expression and negative staining for 2-SC and a diagnosis of HLRCC was excluded.

**Conclusion:** We propose a management pathway for the investigation of suspected HLRCC in individuals with multiple
leiomomas that incorporates genetic testing and IHC for 2-SC and FH in a complementary fashion to resolve diagnostic uncertainty.

References: 1. Bardella et al. 2011.

Grants: CRUK.

Conflict of Interest: Avgi Andreou: None declared, Anne Warren: None declared, Saba Sharif: None declared, Beverley Speight: None declared, Laura Butland: None declared, Abhijit Dixit: None declared, Marc Tischkowitz: None declared, Eamon R Maher Invited speaker fees from MSD.

P13.024.B Incidence of Pediatric Cancer Predisposition in Czechia

Lucie Slamova1,2, Michal Zapotocky2, Lucie Šrámková2, Martina Bittova1, Leona Cerna1, Monika Koudová1

1GENET - Center of Medical genetics and reproductive medicine, Department of Genetics, 17000, Czech Republic; 2Second Faculty of Medicine, Charles University and University Hospital Motol, Department of Pediatric Hematology and Oncology, Prague, Czech Republic.

Background/Objectives: Genetic predisposition plays important role in cancer development especially when environmental factors couldn’t be the key player. However the role in cancer development especially when enviromental factors may play a role is still not fully understood. Our main objective is determine the incidence of predisposing genetic variants in Czechia.

Methods: NGS analyses using targeted gene panels (226 genes) were redesigned for pediatric cohort (add 64 genes). The study of the variants was carried out with the help of the ClinVar, professional HGMD, as well as in silico predictions. The variants were classified as benign, likely benign, VUS (variant of uncertain significance), likely pathogenic, pathogenic. All patients enrolled in the study were referred to genetic counseling under hema-tooncology department between January 2020 and December 2021. 217 patients (M 111, F 104) fulfilled the criteria and agreed to participate in the study, all parents and/or patients signed informed consent.

Results: A pathogenic variant connected to cancer predisposition was detected in 31 patients (31/217;14%), in following genes TP53, NF1, RB1, PALB2, EXT2, BRCA1, WNR, ABRAXAS1, STK11, HOXB13, NBN, MUTYH, ATM, CHEK2, FANCA, SBDS, FANC, ESR1, FBXW7, FANCI, remarkable enrichment in neurooncology group for variants in MUTYH, CHEK2, WNR. Likely pathogenic variant was found in 14 patients (14/217;6,%). Reckon up the incidence to 20,7%. Interestingly variant of uncertain significance was discovered in 55 cases and needed to be futher validated (55/217;25%).

Conclusion: For the first time accurate incidence for cancer predisposition in Czech pediatric cohort was determined (20,7%).

References: 1. Bardella et al. 2011.

P13.026.D ENIGMA effort to standardize the classification of variants disrupting splicing of in-frame exons using BRCA1 exon 18 as an example

Joanna Domènech-Vivó1, Hélène Tubeuf2,3, Romy L.S. Mesman4, Aurelie Douzet5, Mélanie Girard2, María Concepción Alonso-Cerezo6, Diana Baralle6,7, Nadia Bautry-Krzyd6, Dave Bunyan8,9, Helen J Byers10,11, Kathleen Claes12, D. Gareth Evans13, Miguel de la Hoya14, Sophie krieger15,16,17, Conxi Lázaro16,18, Mélâne Leone6, Eva Machackova19, Mireia Menéndez18, Alejandro Mores-Fernández1, Gemma Montalban2,1, Elke van Veen13, JUDITH BALMANA12,22, Amanda B. Spurdle23, Orland Diez12,24, Maaite Vreeswijk4, Alexandra Martins3, Sara Gutiérrez-Enriquez2

1Hereditary Cancer Genetics Group, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain; 2Inserm U1245, UNIROUEN, Normandy University, Normandy Centre for Genomic and Personalized Medicine, FHU Génomique G4, Rouen, France; 3Interactive Biosoftware, Rouen, France; 4Department of Human Genetics, Leiden University Medical Center, Leiden, Netherlands; 5Genética Clínica, Servicio de oncología médica, Hospital Universitario de la Princesa, Madrid, Spain; 6Faculty of Medicine University of Southampton, Southampton, United Kingdom.

Background/Objectives: Recent recommendations from the USA state that most breast and ovarian cancer patients (BC/OC) should be offered germline testing. However, European oncogeneticists still need to select a subset of suggestive cases, as resources would not allow for near-universal testing. Clinical criteria, prediction models or scores are used in this context. We have adapted the Manchester Scoring System (MSS-P) to French practice and multigene panels, and report its performances in a large series of cases.

Methods: We included 1219 BC/OC patients referred between 2016 and 2020 to the AP-HP Sorbonne University Oncogenetics laboratory, Paris, and who underwent germline panel testing (BRCA1, BRCA2, PALB2, TP53, RAD51C, RAD51D, ATM, CHEK2, PTEN, CDH1, MMR). MSS-P correlation with the identification of pathogenic variants was assessed using AUC/ROC curves. For a subset of 210 patients, MSS-P was compared to BOADICEA. Curves were also re-calculated using the raking method as a correction, matching cases statistics to those of unsel ected BC/OC cases.

Results: MSS-P performances were average, with an AUC of 0.61. Sensitivity was 0.95, 0.75 and 0.55 at the 9, 12 and 15-point thresholds. Specificity was 0.14, 0.36 and 0.63, respectively. Negative and positive predictive values varied very little with thresholds, with estimations of 0.93-0.96 and 0.10-0.13, respectively. The BOADICEA AUC on a subset of cases was similar to MSS-P (0.61). MSS-P performances, though, were improved after raking, with an AUC of 0.74.

Conclusion: Improved performances after raking suggest that MSS-P should actually be used by gynaecologists and oncologists to select BC/OC patients for Oncogenetics referral.

References:

Grants: None declared.

Conflict of Interest: Patrick Benusiglio AstraZeneca, Lucas Ducrot: None declared, Jasmine Hasnaoui: None declared, Florence Coulet: None declared, Camille Desseignes: None declared, Geoffrey Canlorbe: None declared, Diarietou Gueye: None declared, Catherine Uzan: None declared, Erell Guillerm: None declared, Gregory Nuel: None declared.
Background/Objectives: BRCA1 germline pathogenic variants are associated with high risk of breast/ovarian cancer. Variants inducing complete skipping of in-frame exons or causing partial/leaky splicing defects are challenging to classify, due to lack of knowledge about the functionality of the generated in-frame proteins or the minimal level of full-length transcripts (FL) required for normal function. In the ENIGMA consortium, we performed a comprehensive study of variants affecting BRCA1 exon 18 (BRCA1e18) to identify those spliceogenic and characterize their severity to estimate the threshold of FL levels for sufficient normal BRCA1 function.

Methods: Patients’ RNA (n = 30), minigene (n = 160), and mouse embryonic stem cell (mESC) complementation assays were combined to determine the impact of BRCA1e18 variants on RNA splicing and the minimal level of BRCA1 FL required for function.

Results: Variants in which we detected a complete skipping of BRCA1e18(D18) were not functional by the saturation genome editing assay[1], and neither were those that induced 50% Δ18 in minigenes (25% expected in patients). In contrast, synonymous and intronic variants causing up to 10% of Δ18 were considered functional. Complete deletion of BRCA1e18 in mESC leads to a non-functional protein supporting that Δ18 is not a rescue transcript.

Conclusion: This data evidences that the leakiness rate of BRCA1e18 skipping and residual FL levels are critical to determine the pathogenicity of variants affecting this exon.

References: [1] G. Findlay et al., “Accurate classification of BRCA1 variants with saturation genome editing”, Nature, 2018, v562, pp. 217-222.

Grants: P119/01303, I3CII, Ministerio de Ciencia e Innovación, funded by FEDER funds-a way to build Europe-and AGAURFI-DGR2020.

Conflict of Interest: Joanna Doménech-Vivó: None declared, Hélène Tucheuf H. Tucheuf was employed by Interactive Biosoftware for the time period October 2015-September 2018 in the context of a public-private PhD project partnership between INSERM and Interactive Biosoftware (CIFRE fellowship #2015/0335), Romy L.S. Mesman: None declared, Aurelie Drouet: None declared, Mélanie Girardi: None declared, María Concepción Alonso-Cerez: None declared, Diana Baralle: None declared, Nadia Boutry-Kryza: None declared, Dave Bunyan: None declared, Helen J Byers: None declared, Kathleen Claes: None declared, D Gareth Evans: None declared, Miguel de la Hoya: None declared, Sophie krieger: None declared, Conxi Lázaro: None declared, Mélanie Leone: None declared, Eva Machackova: None declared, Mireia Menéndez: None declared, Alejandro Moles-Fernández: None declared, Gemma Montalban: None declared, Elke van Veen: None declared, JUDITH BALMAÑA: None declared, Amanda B. Spurdle: None declared, Orland Diez: None declared, Maaike Vreeswijk: None declared, Alexandra Martins: None declared, Sara Gutiérrez-Enríquez: None declared.

P13.027.A In vivo cancer co-driver identification and dependency mapping via evaluation of CRISPR-induced repair outcomes in Xenopus tropicalis cancer models

Dieter Tulken[1,2], Thomas Naert[1,2], Suzan Demuyck[1], Marthe Boeens[1,2], David Creytens[3], Pieter Van Vlierberghe[4,5], Kris Viemincx[1,2]

[1] Ghent University, Department of Biomedical Molecular Biology, Ghent, Belgium; [2] Ghent University, Cancer Research Institute Ghent, Ghent, Belgium; [3] Ghent University and Ghent University Hospital, Department of Pathology, Ghent, Belgium; [4] Ghent University, Center for Medical Genetics, Ghent, Belgium; [5] Ghent University, Department of Biomolecular Medicine, Ghent, Belgium.

Background/Objectives: With the emergence of CRISPR/Cas9 techniques, Xenopus is receiving increased attention with regard to modeling of human genetic diseases. X. tropicalis is especially uniquely placed for these applications because it combines the general amphibian features of large externally developing embryos, which are straightforward to inject with genome editing reagents, a relatively short life cycle and a true diploid genome.

Methods: We use targeted microinjections of multiplexed genome editing reagents in early developing embryos and rapid F2 screening of such mosaic mutant animals. This allows rapid identification of cooperative driver genes in specific cancer contexts. Additionally, we use an in-house developed methodology to identify cancer dependencies built on principles of Darwinian cell-clonal selection, opening possibilities for development of new treatments.

Results: Over the last couple of years, we built multiple genetically engineered Xenopus models (GEXMs) for several human cancers. Furthermore, in a model for Gardner syndrome, we validated an in vivo negative-selection screen that identified the epigenetic regulator EZH2 as a druggable dependency factor needed for desmoid tumor growth. A similar strategy is followed to identify vulnerabilities in other GEXM tumor models.

Conclusion: We provide findings and perspectives important for current and future (Xenopus) cancer research. The generation of GEXMs even more closely mimicking the patient situation, will be an extra valuable tool for a reliable and time-efficient screening of novel genetic dependencies and the discovery of extra potential inhibiting compounds.

References:

Grants:

Conflict of Interest: None declared.
Abstracts from the 55th European Society of Human Genetics Conference

P13.028.B Lung metastases and subsequent malignant transformation of a fumarate hydratase-deficient uterine leiomyoma

terhi ahvenainen1,2,3, Sara Khamaisheh1,2,3, amjad alkodu1, milka mehine1,2, rikka nevala4, anna ärväainen1,2,5, ralf bützow1,6, pia vahteristo1,2,3

1Applied Tumor Genomics Research Program, University of Helsinki, helsinki, Finland; 2Department of Medical and Clinical Genetics, University of Helsinki, helsinki, Finland; 3ICAN Digital Precision Cancer Medicine Flagship, helsinki, Finland; 4Comprehensive Cancer Center, Helsinki University Hospital (HUH) and Medical Faculty, University of Helsinki, Helsinki, Finland; 5Department of Obstetrics and Gynecology, Helsinki University Hospital, helsinki, Finland; 6Department of Pathology, University of Helsinki and Laboratory of Helsinki University Hospital (HUSLAB), Helsinki University Hospital, helsinki, Finland.

Background/Objectives: Uterine leiomyomas are common benign smooth muscle tumors. Their potential to metastasize or transform into leiomyosarcomas is extremely low. Here, we report a patient who was diagnosed with a uterine leiomyoma and seven and nine years later with pulmonary leiomyosarcomas.

Methods: Histopathological examination, whole-exome sequencing and 3′RNA sequencing.

Results: Histopathological re-evaluation confirmed the cellular leiomyoma diagnosis for the uterine tumor, whereas the pulmonary tumors met the criteria of a leiomyosarcoma. Somatic copy number analysis showed similar mutational profiles in all three tumors, including a homoygous deletion in a rare leiomyoma driver gene FH. Tumor evolution analysis confirmed their clonality. Pulmonary tumors harbored additional alterations affecting e.g. the cancer-associated genes NR11, MYOCD, and FGFR1. The uterine tumor showed similar gene expression patterns as other FH-deficient leiomyomas.

Conclusion: This data supports the occasional metastatic capability and malignant transformation of uterine leiomyomas with FH-deficiency and/or cellular histopathology. Identification of such tumors may provide early diagnosis and even cancer prevention.

References:

Grants: Sigrid Jusélius Foundation, Academy of Finland, Cancer Foundation Finland, ICAN Digital Precision Cancer Medicine Flagship.

Conflict of Interest: None declared.

P13.029.C Significance of ARID1A mutations in colorectal cancer

Dimitar Dimitrov1, Hristo Ivanov1, Nelly Miteva-Marcheva1, Gabriela Raycheva1, Jan Grudeva-Popova1, Alexandar Linev2, Ivan Zheliaskov2, Peter Shopov2, Monchil Topalov2, Vili Stoyanova2

1Medical University Plovdiv, Department of Pediatrics and Medical Genetics, Plovdiv, Bulgaria; 2St. George University Hospital, Department of Medical Genetics, Plovdiv, Bulgaria; 3Medical University Plovdiv, Department of Clinical Oncology, Plovdiv, Bulgaria; 4St. George University Hospital, Department of Medical Oncology, Plovdiv, Bulgaria; 5Creator of PGx R package, Sofia, Bulgaria.

Background/Objectives: Colorectal cancer (CRC) is one of the most common neoplasms and the leading cause of death worldwide. It is a complex heterogeneous disease, arising from the accumulation of many different genetic mutations.

Methods: The study included 15 patients with CRC. Circulating tumor DNA was extracted from blood plasma and a target sequencing of a panel of 484 target genes was performed.

Results: A somatic variant ARID1A/c.3999_4001delGCA was identified in 13 out of 15 patients. ARID1A is a tumor suppressor gene that encodes a protein involved in the SWI/SNF protein complex. Its function is to regulate the transcription of certain genes by changing the structure of the chromatin around them. The SWI/SNF protein complex acts as a tumor suppressor, preventing uncontrolled cell growth and division. The majority of mutations in the ARID1A gene are frame shifts or nonsense mutations that contribute to mRNA breakdown and loss of protein expression. 5% of ARID1A mutations are in-frame insertions or deletions (indels). Recent studies show that variants in the ARID1A gene have been found in many types of cancer, including colorectal cancer recent functional analysis revealed, that no or low expression of ARID1A is observed in CRC patients.

Conclusion: Clearly mutations in ARID1A are involved in CRC, but more research is needed to clarify their role in tumorigenesis.

References: Erfani M, et al., Altered ARID1A expression in colorectal cancer. BMC Cancer. 2020 Apr 25;20(1):350.

Grants: Project BG05M2OP001–1.002-0005 /29.03.2018 (2018–2023) – Center for Competence “Personalized Innovative Medicine (PERIMED)”.

Conflict of Interest: None declared.

P13.031.A Multi-gene panel testing of melanoma patients

Alessia Russo1, Paola Ogliaro2, Chiara Catalano3, Francesca Resticvo4, Francesca Vignolo5, Giovannino Birol6, Flavia Palermo5, Cecilia Bracco7, Debora Fiorito7, Francesca D’Alessio8, Guido Casalis Cavalcini9, Enrico Grosso10,11, Antonella Maffè12, Silvana Ungari9, Enrico Colombo10, Caterina Marchio13, Pietro Quaglino14, Simone Ribero15, Giuseppe Mattullo16, Barbara Pasini17

1University of Turin, Turin, Italy; 2AOU Città della Salute e della Scienza di Torino, Turin, Italy; 3USL di Aosta, Aosta, Italy; 4AO Santa Croce e Carle di Cuneo, Cuneo, Italy; 5University of Piemonte Orientale, Novara, Italy; 6IRCCS di Candiolo (Torino) – FPO, Candiolo, Italy.

Background/Objectives: Melanoma is characterized by a complex and heterogeneous etiology, which involves environmental, phenotypic and genetic risk factors. Approximately 5-10% of melanoma cases occurs in a familial context. Carriers of mutations in high-penetrance genes show a lifetime risk of 52%; however, in the majority of families no causative mutations are identified. The aim of our study is to find novel genetic alterations that could be useful to identify pathways involved in the development of the disease.

Methods: We tested 306 patients with a diagnosis of familial or multiple or juvenile malignant melanoma and belonging to cases referred for testing at the Genetic Unit of Città della Scienza e della Salute di Turin (Prof. B. Pasini).

Results: Patients firstly underwent screening of four established familial melanoma susceptibility genes: CDKN2A, CDK4, MITF, and TERT. Twenty-four out of 306 patients (7.8%) presented 24 pathogenic mutations in CDKN2A (19 cases) and MITF (4 cases) genes. As expected, the most frequent mutation was the missense variant CDKN2A c.301G>T present in 10 out of 19 patients. To understand the genetic etiology of wild-type cases, we will screen 21 low to high-risk genes plus 256 melanoma-associated SNPs through Next Generation Sequencing. Analysis of the first 101 cases revealed pathogenic variants in MC1R, OCA2, PTEN, TYR and SLC45A2 genes.

Conclusion: Extended testing beyond main high-risk genes could identify new potentially actionable deleterious mutation. Moreover, it allows investigating the combination effect of low to moderate variants.

References:
Background/Objectives: Paclitaxel (PTX) is an important first-line drug for the treatment of non-small cell lung cancer (NSCLC), but it leads to the development of resistance to many other structurally unrelated compounds. This phenomenon that is known as Multidrug Resistance (MDR) is frequently conferred by the overexpression of membrane-anchored ABC transporters capable of transferring xenobiotics across membranes. Furthermore, enhanced lysosomal function has been shown to be characteristic of paclitaxel resistance in cancer cells. ATP-dependent chromatin remodeling complexes are an important part of the epigenetic mechanism of transcriptional regulation. Knowing that ATPase BRG1 is involved in the expression of ABC transporters in breast cancer cells, we examined the role of BRG1 in the expression of genes responsible for MDR, paying particular attention to those that occur in the lysosomal membrane and may contribute to increased drug accumulation in lysosomes.

Methods: The expression of ABC transporters was analysed by qPCR and Western Blot. Enrichment of ABC genes promoters in BRG1 was measured by ChIP-qPCR. Drug accumulation was analysed by confocal microscopy.

Results: PTX exposure has been shown to promote the expression of MDR-associated ABC transporters and BRG1. Furthermore, BRG1 has been shown to interact with promoter sequences of genes for ABC proteins. The silencing of BRG1 expression decreases ABC transporter expression and reduces drug accumulation in lysosomes.

Conclusion: Our results suggest that specific BRG1 inhibitors may have potential applications in overcoming resistance acquired after paclitaxel therapy by reducing drug accumulation in lysosomes.

References:

Grants: National Centre for Research and Development: LIDER/22/0122-L-10/18/NCBR/2019.

Conflict of Interest: None declared.

P13.034.D Development of APC-specific ACMG/AMP variant classification guidelines

Xiaoyu Yin1,2, Isabel Spier3,4,5, Marcy Richardson6, Marta Pineda5,7,8, Deborah Ritter9,10, Tina Pesaran5, Gabriela Capellá2,7,8, Sean V. Tavtigian1, John-Paul Plazzer2,2, Andrea Lantry1, Andrew Latchford1, Ian M. Frayling1, Sharon E Plon1, Marg Greenblatt1, Finlay A. Macrae2,2, Stefano Aretx2,5,

1Royal Melbourne Hospital, Department of Colorectal Medicine and Genetics, Parkville, Australia; 2University of Melbourne, Department of Medicine, Parkville, Australia; 3University of Bonn, Institute of Human Genetics, Medical Faculty, Bonn, Germany; 4University Hospital Bonn, National Center for Hereditary Tumor Syndromes, Bonn, Germany; 5European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS), Project ID No 739547, Nijmegen, Netherlands; 6Amory Genetics, Aliso Viejo, United States; 7Institut Català d’Oncologia – IDIBELL, Hereditary Cancer Program, Barcelona, Spain; 8Instituto Salud Carlos III, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; 9Baylor College of Medicine, Houston, United States; 10Baylor College of Medicine, Texas Children’s Cancer Center, Houston, United States; 11University of Utah School of Medicine, Department of Oncological Sciences and Huntsman Cancer Institute, Salt Lake City, United States; 12Medical Genetics Center Munich, Department of Genomics, Munich, Germany; 13St Mark’s Hospital, Polypostsis Registry, London, United Kingdom; 14University Hospital of Wales, Institute of Medical Genetics, Cardiff, United Kingdom; 15University of Vermont College of Medicine, Vermont Cancer Center, Burlington, United States.

Background/Objectives: To resolve the interpretative challenges of constitutional variants in colorectal cancer predisposing genes, a Hereditary Colon Cancer/ Polyvariant Variant Curation Expert Panel (VCEP) was established as a collaborative effort between ClinGen and the International Society for Gastrointestinal Hereditary Tumours (https://clinicalgenome.org/affiliation/50099/). Under oversight of the ClinGen Sequence Variant Interpretation working group, our subcommittee reviews APC variants under-lying Familial adenomatous polyposis and aims to improve variant classification through the development of gene-specific specifications and the implementation of expert-reviewed pathogenicity assertions.

Methods: APC-specific specifications of the variant guidelines by the American College of Medical Genetics and the Association of Molecular Pathology (ACMG/AMP) were cross-examined in teleconferences based on database analyses, literature review and expert opinions. A balanced selection of 57 variants underwent pilot testing to further refine and finalise the APC-specific classification criteria.

Results: Three of the 28 original criteria were left unchanged (BS4, BP1, BP5), whilst eight were removed (PM1, PM3, PM4, PP2, PP4, PP5, BP3, BP6). Gene, disease-based and/or evidence strength modification were applied to the remaining 17 criteria. Major specifications were noted for PV51 (including variants at the 5’ and 3’ of the gene and splice variants) and allele frequency criteria (BA1, BS1 and PM2). Moreover, a point system for the phenotypic description of variant carriers was developed.

Conclusion: A list of prioritised APC variants will be classified by the VCEP regularly, whose consensus will represent the most authoritative classification of pathogenicity for widespread clinical use. The reclassifications will be publicly available through both ClinVar and the InSiGHT APC databases (www.lovd.nl/AMP).

References:

Grants:

Conflict of Interest: Xiaoyu Yin: None declared, Isabel Spier: None declared, Marcy Richardson: None declared, Marta Pineda: None declared, Deborah Ritter: None declared, Tina Pesaran: None declared, Gabriela Capellá: None declared, Sean V. Tavtigian: None declared, John-Paul Plazzer: None declared, Andreas Laner: None declared, Andrew Latchford: None declared, Ian M. Frayling: I am a member of CanVIG-UK https://www.ncbi.nlm.nih.gov/clinvar/submitters/506655/, Sharon E Plon Scientific Advisory Panel for Baylor Genetics, Marc Greenblatt: None declared, Finlay A. Macrae for the APC Councillor for InSiGHT, Stefano Aretx: None declared.

P13.035.A The interplay between pathology, molecular alterations and outcomes in esophageal adenocarcinoma

Arianna Orsini1, Isotta Bozzarelli1, Federica Isidori1, Roberto Fiocca2, Luca Mastracci2,3, Marialuisa Lugaresi2,4, Maria Antonietta D’Errico1,5, Deborah Malvi6, Paola Spaggiari6, Anna Tomезzoll6, Luca Albarello7, Ari Ristimäki8, Luca Battiglieri9, Sheila Krishnadath10, riccardo rosati10, Uberto Fumagalli Romario11, Giovanni di Manzoni12, Jari Räsänen16, Sandro Mattioli17, Elena Bonora17

1University of Bologna, Department of Medical and Surgical Sciences (DIMEC), Bologna, Italy; 2University of Genova, Department of Medicine, Pavia, Italy; 3Hospitals of Genoa, Department of Medicine, Genoa, Italy; 4University of Genoa, Department of Pathology, Genoa, Italy; 5University of Genoa, Department of Clinical Pathology, Genoa, Italy; 6Azienda Ospedaliero Universitaria Policlinico, University of Genova, Genoa, Italy; 7University of Genoa, Department of Medical Biology, Genoa, Italy; 8University of Oulu, Department of General Surgery, Oulu, Finland; 9University of Turku, Department of Clinical Pathology, Turku, Finland; 10Vaalhalla Medical Centre, Department of Gastroenterology, Helsinki, Finland; 11University of Verona, Department of Surgery, Verona, Italy; 12Istituto di Scienze Oncologiche di Roma, Department of Experimental Clinical Science, Rome, Italy; 13University of Turku, Department of Clinical Pathology, Turku, Finland; 14University of Turku, Department of Clinical Pathology, Turku, Finland; 15University of Turku, Department of Clinical Pathology, Turku, Finland; 16University of Turku, Department of Clinical Pathology, Turku, Finland; 17University of Turku, Department of Clinical Pathology, Turku, Finland.

Abstracts from the 55th European Society of Human Genetics Conference
Surgical and Diagnostic Sciences (DISC), Genova, Italy; 2Ospedale Policlinico San Martino IRCCS, Unit of Anatomic Pathology, Genova, Italy; 3Maria Cecilia Hospital, Division of Thoracic Surgery, Cotignola, Italy; 4IRCCS Azienda Ospedaliere-Universitaria di Bologna, Pathology Unit, Bologna, Italy; 6University of Bologna, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Bologna, Italy; 7Humanitas University, Unit of Anatomic Pathology, Milano, Italy; 8IRCCS Azienda Ospedaliere di Verona, Unit of Anatomic Pathology, Verona, Italy; 9San Raffaele Scientific Institute, Pathology Unit, Milano, Italy; 10HUSLAB and HUS Diagnostic Center, Department of Pathology, Helsinki, Finland; 11Istituto Europeo di Oncologia, Unit of Anatomic Pathology, Milano, Italy; 12European Institute of Oncology, Digestive Surgery, Milano, Italy; 13University of Verona, Department of Surgery, General and Upper G.I. Surgery Division, Verona, Italy; 14Helsinki University Hospital, Department of General Thoracic and Esophageal Surgery, Helsinki, Finland; 15IRCCS Azienda Ospedaliero-Universitaria di Bologna, Unit of Medical Genetics, Bologna, Unit, Italy.

Background/Objectives: Esophageal adenocarcinoma (EAC) is a severe malignancy with increasing incidence in Western countries over the past few decades. EAC pathogenesis is still poorly understood and the survival rate is low. Therefore, there is a need to better clarify EAC risk factors to improve patient identification and treatment.

Methods: 207 EAC cases classified according to EACGSE2 were included. DNA was extracted from formalin-fixed paraffin-embedded surgical specimens and sequenced for 26 cancer-related genes (#226722257; IDT) with high coverage on NextSeq (Illumina). Data analysis was performed using an in-house pipeline.

Results: A total of 353 variants were identified across the whole cohort. TP53 was the most frequently altered gene (134/500 (Illumina). Data analysis was performed using an in-house pipeline.

Conclusion: A specific type of mutations (missense changes in protein expression between NOMO1 Knockout and wild type cell lines by liquid chromatography-mass spectrometry (LC-IMS/MS).

References:

Conflict of Interest: None declared.

P13.037.C Protein expression analysis in NOMO1 knockout cells, a recurrent alteration in early-onset colorectal cancer

Abel Martel-Martel1,2,3, Paula García-Vallés1,2,4, Jésica Pérez-García3,4, Luis Antonio Corchete3, Diego Iglesias-Coral1,2,4, Juan-Luis García3,4, Manuel Fuentes1,2, Ana-Belén Herrero1,2,4, Jose Perea1,2, Rogello González-Sarmiento1,2,4

1Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; 2Molecular Medicine Unit, Department of Medicine, University of Salamanca (USAL), Salamanca, Spain; 3Medical Oncology Service, University Hospital of Salamanca, Salamanca, Spain; 4Institute of Molecular and Cellular Biology of Cancer (IBMCC), University of Salamanca-CSIC, Salamanca, Spain.

Background/Objectives: Early-onset colorectal cancer (EOCRC, age younger than 50 years) incidence has been steadily increasing over the last decades worldwide. Recently, we have detected a homoyzygous deletion of the NOMO1 gene in more than 70% of EOCRC patients, suggesting that it could be a molecular marker associated with EOCRC. However, the mechanisms of NOMO1 in EOCRC carcinogenesis are currently unknown. In this work, we analyzed the changes in protein expression between NOMO1 Knockout and NOMO1 wild type cell lines by liquid chromatography-mass spectrometry (LC-IMS/MS).
Methods: CRISPR/Cas9 technology was used to generate NOMO1-KO HCT116 (EOCRC) and HS-5 (bone marrow) cell lines. 0.5 μg of total protein was digested with trypsin and used for LC-IMS/MS analysis. Raw files were analyzed by MaxQuant software using Andromeda. Data search was against the Human UniProt Reference Proteome and WebGestalt tool was used for proteome data analysis.

Results: A total of 12 overexpressed (such as HMGA1) and 16 infraexpressed proteins (such as NOMO, NCLN, CTND1, HMGB1 and LMNB1) showed up in common between the two cell lines. Interestingly, CTND1, HMGA1 and LMNB1 alterations are associated with a modification to migration capability, which may explain the increased migratory ability that we observed in NOMO1 KO.

Conclusion: NOMO1 loss leads to protein expression changes that could explain its implication in the development of EOCRC. Further studies are being performed to explore other signaling pathways deregulated by the loss of NOMO1 that might play a relevant role in the pathogenesis of the disease.

References:

Grants: Study funded by P120/01569.

Conflict of Interest: None declared.

P13.038.D Combined conventional cytogenetic and genomic testing in hematological malignancies: the added value of the old and the new

TARA KELLY¹, Despoina Iakovaki¹, Pavlos Pollakis¹, Vasiliki Katsini¹, Stavroula Samara¹, Aikaterini Oikonomaki¹, Georgia Christopoulou¹, Pantelis Constantoulakis¹

¹Genotypos M.S.A., Athens, Greece.

Background/Objectives: Conventional karyotyping and FISH are the gold standards for the genetic diagnosis, monitoring and prognosis of hematological malignancies. Genomics have introduced new approaches to these clinical questions. We aim to show the synergistic value of traditional and exome sequencing approaches in hematological-patient management.

Methods: In 20 prospective cases, karyotype/FISH/exome analyses were requested to investigate hematological malignancies. Bone marrow or peripheral blood samples were processed with karyotype/FISH with standard procedures. Exome sequencing was performed on DNA extracted from the same samples: libraries preparation was performed with Clinical Exome (Sophia Genetics) or Whole Exome (Twist Bioscience) and sequenced on Illumina NextSeq-550 (Illumina). Bioinformatics analyses were conducted by SOPHIA DDM® bioinformatics pipelines.

Results: Exome sequencing single-nucleotide-variation (SNV) analysis revealed actionable variants in 17 cases, while copy number variation (CNV) analysis detected large deletions/duplications in 11 cases. Cytogenetic analyses revealed clinically significant findings in 13 cases. Discrepant results between exome and cytogenetic analysis were either due to balanced aberrations, limits of detection, the chromosomal constitution complexity, test failure or test not performed.

Conclusion: Chromosomal analysis is superior to exome sequencing CNV analysis due to its ability to detect clinically significant balanced abnormalities and complex clones. Nevertheless, exome CNV analysis may detect critical deletions/duplications thus complementing chromosomal analysis or even reveal crucial information where chromosome analysis is unavailable. On the other hand, incorporating exome sequencing in routine hematologic diagnosis, actionable gene variants can be detected allowing diagnosis/prognosis confirmation and most importantly, consist eligibility criteria for targeted therapies or inclusion in clinical trials.
Abstracts from the 55th European Society of Human Genetics Conference

Esther Schamschula

adenomatous polyposis- and colorectal cancer syndrome

P13.041.C Di-genically inherited highly penetrant
adenomatous polyposis- and colorectal cancer syndrome

Background/Objectives: Breast cancer (BC) is the leading female cancer worldwide. Some patients develop resistance to traditional treatments after a variable period of time and some subtypes of breast cancer, like triple negative breast cancer, lack targeted therapies. The androgen receptor (AR) is emerging as a novel factor in breast cancer. It has been demonstrated that both AR and its inducible proteins are expressed in 60-80% of BCs. Thus, we evaluated BC cell line response to enzalutamide, an AR inhibitor, as a potential therapeutic alternative.

Methods: AR+ BC cell lines (BCCLs): BT549, BT474 and MCF7 and AR- HCC1937 and HCC1569 were used. MTT and apoptosis assays were performed to test enzalutamide and dihydrotestosterone sensitivity. Stable AR-+ cell lines (HCC1937, HCC1569) were constructed using lentiviral vectors. Western blot and RT-qPCR were used to validate AR status.

Results: Our results show that enzalutamide inhibits cell growth and induces apoptosis in both AR-+ and AR- BCCLs. Additionally, dihydrotestosterone stimulation decreases enzalutamide-mediated cell viability inhibition regardless of AR status. Response to enzalutamide treatment is independent of AR status in AR- and AR+ HCC1937 and HCC1569.

Conclusion: Our study suggests that enzalutamide could mediate its action through AR-independent pathways.

References: Anestis, A., Zoi, I., Papavassiliou, A. G., & Karamouzis, M. V. (2020). Androgen receptor in breast cancer—clinical and preclinical research insights. Molecules, 25(2), 358.

Grants: This study was funded by FIS-FEDER P120/01569.

Conflict of Interest: None declared.

P13.041.D Tumour radio-sensibility by PX478, a hypoxia-inducible factor 1-alpha inhibitor

David Diez-Castro1,2, Pablo Berrocal2, Janet Sotolongo-Ravelo1,2, Luis Perez-Romasanta3, Ana-Belén Herrero1,2, Rogelio González-Sarmiento1,2,4

1Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; 2Molecular Medicine Unit, Department of Medicine, University of Salamanca, Salamanca, Spain; 3Oncology service, Hospital University of Salamanca, Salamanca, Spain; 4Institute of Molecular and Cellular Biology of Cancer (IBMCC), University-CIC, Salamanca, Spain.

Background/Objectives: Hypoxia is a common situation in the solid tumours’ microenvironment. It is associated with resistance to radiotherapy and with poor clinical results. The activation of Hypoxia-inducible Factor (HIF) signalling pathway plays a pivotal role in the tumour adaptation to hypoxia. HIF proteins regulate the transcription of several genes implicated in angiogenesis, apoptosis, metastasis or tumoral growth and their overexpression correlates with a poor prognosis after radiotherapy. So, HIF inhibitors are used to improve the cell response to radiotherapy. Here, we study the effects of PX478, a first-generation HIF-1-alpha inhibitor, on tumoral cell lines under hypoxic and normoxic conditions.

Methods: HT29 (Colon), MCF7 (Breast), HCC1937 (Breast), VCAP (Prostate), CAL33 (Head and Neck) cell lines were used to test PX478 radio-sensibility through MTT, cell cycle and apoptosis assays. Western blot was used to analyse the expression of HIF-1-alpha.

Results: Western blot analysis showed that the expression of HIF-1-alpha was partially inhibited by PX478 in a dose-dependent manner. PX478 inhibited cell proliferation and decreased cell survival in normoxia but especially in hypoxic conditions. In addition, the compound increased the radio-sensibility of HT29 and results in other cell lines are pending.

Conclusion: PX478 inhibited the expression of HIF-1-alpha in a dose-dependent manner. This drug had a strong effect on cell survival and increased radio-sensibility, especially in hypoxic conditions.

References: Albadari N; Deng S, Li W. Expert Opin. Drug Discov. 2019. https://doi.org/10.1080/17460441.2019.1613370.

Grants: This project was financed by Gerencia Regional de Salud, JCyL (GRF2171/A/2020).
Conflict of Interest: None declared.

P13.043.A Second-hit in ATM in a case of gallbladder cancer: hints at driver mechanism, therapeutic target and cancer susceptibility redefinition

Daniele Guadagnolo1, Gioia Mastromoro1, Nader Khaleghi Hashemian1, Camilla Savio2, Fabio Libi2, Sopa Sadeghi2, Aldo Germani2,3, Simona Petrucci2,3, Maria Piane2,3, Laura De Marchis4, Paolo Marchetti5, Simon Pisegna5, Antonio Pizzuti1

1Sapienza university of Rome, department of Experimental Medicine, Rome, Italy; 2Sapienza University of Rome, Department of Clinical and Molecular Medicine, School of Psychology, Rome, Italy; 3Sant’Andrea University Hospital, Rome, Italy; 4Sapienza University of Rome, Department of Radiological, Oncological and Pathological Sciences, Rome, Italy; 5Sapienza University of Rome, Department of Clinical and Molecular Medicine, Rome, Italy.

Background/Objectives: Invasive biliary cancers are severe neoplasms with limited therapeutic options. The molecular bases are far from fully elucidated, and targeted therapies are lacking.

Methods: A 65-year-old man presented with metastatic gallbladder cancer, biliary type. His father and his uncle had prostate cancer at age 70 and 63. Next Generation Sequencing (NGS) analysis of 324 genes implicated in cancer development and progression was performed on tumor sample to identify potential molecular therapeutic targets. Variants with possible germ-line origin were confirmed on DNA extracted from peripheral blood lymphocytes with Sanger sequencing.

Results: NGS on tumoral DNA identified the pathogenic c.4611_4611+9del, p.(Pro1480Tyrfs5*), rs80969040 and c.901+1G>A, variants in the ATM gene (MIM*607585;NM_000051;NP_000042.2). The c.4611_4611+9del was demonstrated to be of germ-line origin in heterozygosity. It has a frequency of 8/1000000 in GnomAD v.2.1.1. The presence of a germ-line mutation and a concurrent somatic pathogenic variant suggest a second-hit mechanism for ATM in this case. In accordance with recent cases published in the literature, this means that heterozygous ATM variants might lead to biliary/gallbladder cancer susceptibility and that ATM loss-of-function might be implicated in biliary/gallbladder cancer tumorigenesis. The finding led to the proposal a PARP-inhibitor drug in conjunction with standard chemotherapy protocols. This class of drugs might be considered even in sporadic cases with a history of ATM.

Conclusion: ATM variants might lead to biliary/gallbladder cancer susceptibility, and the gene might be a driver in biliary cancer development. This can lead to diagnostic and therapeutic changes.

References:

Grants:

Conflict of Interest: None declared.

P13.044.B Clinical and histopathological features predictive of BRCA1/2 pathogenic variants in ovarian cancer patients: single-center experience and meta-analysis

Giovanni Innella1,2, Lea Godino2, Giulia Erini1, Daniela Turchetti1,2

1University of Bologna, Department of Medical and Surgical Sciences, Center for Studies on Hereditary Cancer, Bologna, Italy; 2IRCCS Azienda Ospedaliero-Universitaria di Bologna, Unit of Medical Genetics, Bologna, Italy.

Background/Objectives: BRCA1/2 testing is currently recommended in almost-all ovarian cancer patients to inform treatment and prevention. In order to identify prior predictors of BRCA1/2 germine variants, we compared features of ovarian cancer patients carrying BRCA1/2 pathogenic variants versus non-carriers among our patient series and in the literature.

Methods: Features of ovarian cancer patients tested for BRCA1/2 at our laboratory were registered and analysed. A systematic literature review, performed according to PRISMA guidelines, was synthesized using meta-analysis (PROSPERO 2021: CRD42021271815).

Results: Among 869 ovarian cancer patients, 188 carried germline BRCA1/2 pathogenic variants (21.6%); young age at diagnosis (56.6±11.1 vs 60.4±12.1 years, p < 0.001), personal breast cancer history (23.0% vs 8.6%, p < 0.001), family history of breast/ovarian cancer (53.5%/29.3% vs 30.3%/5.6%, p < 0.001), serous histotype, (87.1% vs 68.1%, p < 0.001), high grade (97.6% vs 81.6%, p < 0.001) and advanced stage (76.3% vs 66.6%, p = 0.04) were significantly more frequent in germline BRCA1/2 carriers than in non-carriers, while there were no statistically-significant differences regarding personal history of non-breast/ovarian cancers. According to the meta-analysis of 34 papers, predictors of BRCA1/2 alterations were: personal breast cancer history (OR 4.45, 95% CI: 3.58-5.52, compared to no personal breast cancer history), serous histotype (OR 2.49, 95% CI: 2.20-2.82, compared to other histotypes), grade 3 (OR 2.43, 95% CI: 2.01-2.93, compared to grade 1-2) and stage III/IV (OR 1.87, 95% CI: 1.65-2.11, compared to stage I/II).

Conclusion: Our results reinforce previous evidence on features associated to BRCA variants, providing data on the prior probability of finding alterations that may prove helpful in counselling patients and prioritizing testing.

References:

Grants:

Conflict of Interest: None declared.

P13.045.C Barrett’s esophagus after esophageal atresia corrective surgery

Erwin Brosens1,2, Chantal ten Kate1,2,4, Tom Brands1,2, Rene Wijnen3, Annelyes de Klein1,2, Manon C.W. Spaander4

1Erasmus MC-Sophia Children’s Hospital, Department of Clinical Genetics, Rotterdam, Netherlands; 2Erasmus MC Cancer Institute, Department of Clinical Genetics, Rotterdam, Netherlands; 3Erasmus MC-Sophia Children’s Hospital, Department of Pediatric Surgery and Intensive Care, Rotterdam, Netherlands; 4Erasmus MC Cancer Institute, Department of Gastroenterology and Hepatology, Rotterdam, Netherlands.

Background/Objectives: The surgical correction of Esophageal Atresia (EA) can impact the natural reflux barrier many patients suffer from. The most common adult manifestations of EA are motility problems, chronic gastroesophageal reflux and reflux esophagitis. These are risk factors for the development of Barrett’s Esophagus (BE), a metaplastic lesion in which esophageal squamous epithelium is replaced with gastric columnar epithelium. EA patients have an increased population risk and earlier age of onset of BE. Recent advances have identified specific BE patient subclusters associations to the risk of developing esophageal adenocarcinoma (EAC). Interestingly, BE in EA patients seems to progress into EAC as well as esophageal squamous cell carcinoma and could represent a distinct subgroup.

Methods: We compared the transcriptomes of mucosal esophageal biopsies of adults born with EA who developed BE to those of BE patients who did not have EA/TEF in their medical history. Differential expression analysis was done using DESeq2 after deconvolution using Granulator. To evaluate differences in isoforms-exon usage we used DEXSeq, aberrant splicing was evaluated using FRASER (Find Rare Splicing Events in RNA-seq), Chromosomal stability using SuperFreq and mutational signatures
Background/Objectives: MicroRNAs (miRNAs) are small non-coding RNAs expressed in various tissues and cell types. They can help understanding the carcinogenesis of lung cancer and serve as potential diagnostic biomarkers for differentiating lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC). The aim of the present study is to analyse and compare the expression patterns of miRNAs in LUAD and LUSC samples.

Methods: The expression of 2549 human microarrays (Agilent Technologies) was performed on enlarged cohort (50LUAD, 50LUSC) by microarrays (Agilent Technologies). The validation of the selected miRNAs was performed on enlarged cohort (12LUAD, 12LUSC) by real-time PCR. GO and pathway enrichment analyses were performed using R version 3.0.2 and GSEA with the Python package, GSEApy (version 0.9.12).

Results: We assessed the expression levels of 2549 human mature miRNAs and found 107 to be significantly differentially expressed (FC > 2.0; p < 0.05) between the LUAD and adjacent normal tissues. 240 miRNAs were significantly differentially expressed (FC > 2.0; p < 0.05) between the LUSC and adjacent normal tissues. 26 miRNAs were common for LUAD and LUSC but showed different expression patterns. After bioinformatics analyses we chose the most suitable miRNAs and validated them in an extended cohort by qRT-PCR. GO and pathway enrichment analysis was performed to investigate the relationship between miRNA and targeted mRNA.

Conclusion: Our results were in agreement with previous observations that different panels of miRNAs including miR-375 and miR-21 have better potential to discriminate between LUAD and LUSC. The expression patterns of validated miRNAs and their target genes revealed both common and subtype specific signal pathways for LUAD and LUSC. However, further analysis in enlarged samples and validation is necessary to ascertain their diagnostic potential in NSCLC.

References: None.

Grants: DH03/14/19.12.2016, D01-285/17.12.2019, D01-395-18.12.2020, D01-302-17.12.2021.

Conflict of Interest: None declared.

P13.047.A Characterization of driver mutations in the erb-b2 receptor tyrosine kinase 2 (ERBB2) gene

Atena Yasari1, Theresa Mair1, Monika Heinzl1, Irene Tiemann-Boege1

1Institute of Biophysics, Johannes Kepler University, Linz, Austria.

Background/Objectives: We adapted duplex sequencing to screen a unique type of mutagenesis that confers a selective growth advantage in ERBB2 gene [1-3]. We hypothesize that a series of driver mutations in this oncogene are expanding in sperm and testis. Some of these mutations lead to aberrant ERBB signaling that could induce the clonal expansion of mutant germ cells with paternal age and testis specific-mosaicism.

Methods: Further, we characterized the clonal expansion of candidate hotspot mutations in the testis by droplet digital PCR (ddPCR), along with the analysis of the functional changes in the downstream activation of the ERBB2 signaling pathway by biological methods [4-7].

Results: Some of the mutations were identified as hotspot pathogenic variants that could be expanding at low, sub-clonal levels in the male germline. Further, the functional analysis showed that the selected variants have a significant activation increase compared to the wild-type constructs [6-8].

Conclusion: The identified variants found at low levels might contribute to tumor development creating a microenvironment that promotes malignancy.

References: 1 Arnheim, N. et al. Annu Rev Genomics Hum Genet 2016. 2 Goriely, A. et al. Am J Hum Genet 2012. 3 Shinde, D. N. et al. Hum Mol Genet 2013. 4 Kennedy, S. R. et al. PLoS Genet 2013. 5 Salk, J. J. et al. Nat Rev Genet 2018. 6 Salazar, R. et al. bioRxiv 2021.04.26.441422. 2022. 7 Lanzerstorfer, P. et al. PLoS One 2014. 8 Motsch, V. et al. Sci Rep 2019.

Grants: FWFP30867000, REGGEN ATC2207.

Conflict of Interest: None declared.
7p15.1, RAD51B, LRMADA and TRAF3IP2 as translocation partners. The SNV analysis revealed a high mutational burden comparable to cancers. Polyps carry recurrent low-allelic fraction mutations in cancer genes, including well-established cancer driver mutations in KRAS, PIK3CA, PIK3R1, and PTEN.

**Conclusion:** Most polyps harbor chromosomal alterations affecting HMGAI and HMGAI2. Cancer-associated driver mutations indicate that endometrial polyps may act as precursor lesions to cancer. These findings contribute to our understanding on polyphagogenesis, and provide tools for the development of personalized, non-invasive treatment options.

**References:**

**Grants:** Sigrid Jusélius Foundation, Academy of Finland; Cancer Foundation Finland, iCAN Digital Precision Cancer Medicine Flagship, Finnish Cultural Foundation.

**Conflict of Interest:** None declared.

**P13.049.C Digenic contribution of Cancer driver genes and TNFRSF13B rare variants in malignancies predisposition**

**Elena Pasquinelli1,2, Debora Maffeo1,2, Ludovica Mercuri1,2, Miriam Lista1,2, Luca Bruno1,2, Kristina Zguro2, Rossella Doddato2, Rossella Tita3, Mirella Bruttini1,2,3, Maria Antonietta Doddato1,2, Alessandra Fabbian1,2,3, Margherita Baldassarri1,2,3 Francesca Fava2,3, Catering Lo Rizzo2, Anna Maria Pinto3, Anna Carrea1,2, Lorenzo Loberto2,3, Pietro Iard2,3, Marianna Manara1,2,3, Francesca Mori2,3, Alessandra Renieri1,2,3, Francesca Ariani1,2,3

1Medical University of Siena, Siena, Italy; Siena, Italy; 2Med Biotech Hub and Competence Center, Department of Medical Biotechnology, University of Siena, Siena, Italy; 3Genetica Medica, Hub and Competence Center, Department of Medical Biotechnology, University of Siena, Siena, Italy; 4Genetica Medica, University of Porto, Porto, Portugal; 5Faculty of Medicine, University of Porto, Porto, Portugal; 6CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain; 7MGZ - Medizinisch Genetisches Zentrum, Munich, Munich, Germany; 8Campus Innenstadt, Klinikum der Universität München, Munich, Germany; 9Center for Hereditary Tumor Syndromes, University of Bonn, Bonn, Germany.

**Background/Objectives:** Colorectal polyposis syndromes are rare inherited disorders with a high colorectal cancer lifetime risk. The European Reference Network GENTURIS aims to uncover causal germline variants for unexplained polyposis in a large multicentre cohort. Therefore, whole-exome sequencing (WES) data from unsolved patients are re-analysed within the European Solve-RD project.

**Methods:** Germline-WES data from 211 unrelated patients with adenomatous or serrated polyposis from multiple centres in the Netherlands and Germany were re-evaluated to identify rare, (likely) pathogenic variants. Transcript analyses were performed to evaluate potential splice variants.

**Results:** In a first analysis of known polyposis genes, one truncating, pathogenic variant in SMAD4 c.1231_1232delAG (c.1231_1232delAG, p.Leu411fs*17), and two presumed splice variants c.677G>C and c.868+2dup in BMPR1A were identified. Abrupt splicing could be confirmed for c.868+2dup by RNA-Seq, and is likely for c.677G>C based on conventional transcript analysis. Surprisingly, the variants were found in three unrelated patients with an adenomatous polyposis phenotype. Histologic reclassification by an experienced gastrointestinal pathologist confirmed the adenomas, just the polyps in the SMAD4 variant carrier seemed likely juvenile when being aware of the affected gene.

**Conclusion:** Pathogenic germline variants in the BMPR1A and SMAD4 genes cause juvenile polyposis. In casuistic reports, single pathogenic BMPR1A variants were described as causative of a mixed or untypical polyposis. The observed genotype-phenotype discrepancy supports a broader disease spectrum of BMPR1A and SMAD4 germline variants and challenges to classify juvenile polyps correctly. Given the phenotypic variability, germline mutation screening in patients with a suspected adenomatous polyposis should be extended by other polyposis genes.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P13.050.D Identification and characterisation of BMPR1A and SMAD4 germline variants in patients with colorectal adenomatous polyposis**

**Anna Sommer1, Iris te Paske2, J. García-Peláez3,4,5, Leslie Mata-longa6, Dieter Wolf7, Rita Katharina Knaust7, Sophia Peters1, Verena Steinke-Lange7,8, Elke Holinski-Feder7,8, Andreas Laner7, Carla Oliveira3,4,5, Nicole Hoogerbrugge2, Richarda De Voer2, Isabel Spier1,9, Stefan Arez1,9

1Institute of Human Genetics, Medical Faculty, University of Bonn, Bonn, Germany; 2Department of Human Genetics, Radboud university medical center, Radboud Institute for Molecular Life Sciences, Nijmegen, Nijmegen, Netherlands; 3JPI, Instituto de Investigación e Inovação em Saúde, University of Porto, Porto, Portugal; 4Patimap, Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal; 5Faculty of Medicine, University of Porto, Porto, Portugal; 6CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain; 7MGZ - Medizinisch Genetisches Zentrum, Munich, Munich, Germany; 8Campus Innenstadt, Klinikum der Universität München, Munich, Germany; 9Center for Hereditary Tumor Syndromes, University of Bonn, Bonn, Germany.

**Background/Objectives:** Colorectal polyposis syndromes are rare inherited disorders with a high colorectal cancer lifetime risk. The European Reference Network GENTURIS aims to uncover causal germline variants for unexplained polyposis in a large multicentre cohort. Therefore, whole-exome sequencing (WES) data from unsolved patients are re-analysed within the European Solve-RD project.

**Methods:** By Exome Sequencing (ES) we analyzed a series of 60 individuals divided into a control group (30 patients) and an affected cohort from different forms of cancer (30 patients).

**Results:** We focused on cancer patients in whom at least one pathogenic or likely pathogenic variants in cancer genes belonging to ERN-GENTURIS panel have been detected. Simultaneously, data analysis in the same patients identified recurrent heterozygous stop-variants (c.431C>G, p.Ser144*; c.706G>T, p.Glu236*; c.868+2dup by RNA-Seq, and is likely for c.677G>C) in the TNFRSF13B gene, whereas its impairment might increment the likelihood of their signaling pathways safe-guards against the development of cancer. A normal function of immunity-related genes and proteins is of utmost importance for the development of cancers. Polyps carry recurrent low-allelic fraction mutations in cancer genes, including well-established cancer driver mutations affecting SMAD4, including well-established cancer driver mutations affecting SMAD4, BMI1, HRAS and TP53.

**Conclusion:** In conclusion, this study supports a major role of the immune system (and especially the cell-mediated system) in the malignancies predisposition. Analysis of additional cases and families will be necessary to more precisely assess the risk associated with TNFRSF13B variants.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P13.051.A Somatic variant PARP4 c.3509C>T identified in ctDNA in patients with colorectal cancer, preliminary results**

**Hristo Ivanov1,2, Gabriela Raycheva3,4, Janet Grudeva-Popova3,4, Peter Shopov5, Nelly Miteva-Marcheva1, Ivan Zhiiazkov1, Aleksandar Linev1, Dimitar Dimitrov1, Momchil Topalov1, Vili Stoyanova1,2

1Institute of Human Genetics, Medical Faculty, University of Bonn, Bonn, Germany; 2Department of Human Genetics, Radboud university medical center, Radboud Institute for Molecular Life Sciences, Nijmegen, Nijmegen, Netherlands; 3JPI, Instituto de Investigación e Inovação em Saúde, University of Porto, Porto, Portugal; 4Patimap, Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal; 5Faculty of Medicine, University of Porto, Porto, Portugal; 6CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain; 7MGZ - Medizinisch Genetisches Zentrum, Munich, Munich, Germany; 8Campus Innenstadt, Klinikum der Universität München, Munich, Germany; 9Center for Hereditary Tumor Syndromes, University of Bonn, Bonn, Germany.

**Background/Objectives:** Colorectal polyposis syndromes are rare inherited disorders with a high colorectal cancer lifetime risk. The European Reference Network GENTURIS aims to uncover causal germline variants for unexplained polyposis in a large multicentre cohort. Therefore, whole-exome sequencing (WES) data from unsolved patients are re-analysed within the European Solve-RD project.

**Methods:** We focused on cancer patients in whom at least one pathogenic or likely pathogenic variants in cancer genes belonging to ERN-GENTURIS panel have been detected. Simultaneously, data analysis in the same patients identified recurrent heterozygous stop-variants (c.431C>G, p.Ser144*; c.706G>T, p.Glu236*; c.868+2dup by RNA-Seq, and is likely for c.677G>C). In a first analysis of known polyposis genes, one truncating, pathogenic variant in SMAD4 c.1231_1232delAG (c.1231_1232delAG, p.Leu411fs*17), and two presumed splice variants c.677G>C and c.868+2dup in BMPR1A were identified. Abrupt splicing could be confirmed for c.868+2dup by RNA-Seq, and is likely for c.677G>C based on conventional transcript analysis. Surprisingly, the variants were found in three unrelated patients with an adenomatous polyposis phenotype. Histologic reclassification by an experienced gastrointestinal pathologist confirmed the adenomas, just the polyps in the SMAD4 variant carrier seemed likely juvenile when being aware of the affected gene.

**Conclusion:** Pathogenic germline variants in the BMPR1A and SMAD4 genes cause juvenile polyposis. In casuistic reports, single pathogenic BMPR1A variants were described as causative of a mixed or untypical polyposis. The observed genotype-phenotype discrepancy supports a broader disease spectrum of BMPR1A and SMAD4 germline variants and challenges to classify juvenile polyps correctly. Given the phenotypic variability, germline mutation screening in patients with a suspected adenomatous polyposis should be extended by other polyposis genes.
Abstracts from the 55th European Society of Human Genetics Conference

**Clinical Oncology, Plovdiv, Bulgaria; University Hospital St George, Metastasis: A Meta-analysis of In Vitro Studies.**

Demonstrating the role of PARP4 in CRC need to be performed.

María Ovejero-Sánchez

**Damage and inhibition of DNA repair in ovarian cancer**

Homologous End Joining inhibitors through induction of DNA damage and inhibition of DNA repair in ovarian cancer (OC) needed. We have previously shown that Chloroquine (CQ) and the three NHEJi was assessed using Chou-Talalay method.

**Results:** CQ induced DSBs that were completely repaired after the removal of this compound but persisted in the presence of NHEJi inhibitors. These results revealed that CQ-induced lesions are also repaired by this DNA repair mechanism. The combination of CQ with NHEJi caused a synergistic effect in all cell lines analyzed. The triple combination Chloroquine, NHEJi and an HR inhibitor, Panobinostat, exerted a stronger synergistic effect than the double combinations.

**Conclusion:** Our study suggests that the Chloroquine-NHEJi combination could be a novel therapeutic strategy against OC.

**References:** [1] M. Ovejero-Sánchez, R. González-Sarmiento, A. B. Herrero, Neoplasia. 23, 515–528 (2021).

**Grants:** This project was funded by FIS-FEDER PI20/01569 and project CS1264P20.

**Conflict of Interest:** None declared.

**P13.053.C Whole genome and transcriptome sequencing reveals a complex rearrangement involving MLH1 and LRRFIP2 in a family with Lynch syndrome**

Ulrike Faust, Dennis Witt, Kristin Bosse, Rebecca Buchert, Gertrud Strobl-Wildemann, Marc Sturm, Jakob Admard, Nicolás Casadei, Olaf Riess, Tobias Haack, Christopher Schroeder

**Background/Objectives:** Lynch syndrome is a highly penetrant autosomal dominant cancer predisposition syndrome associated with a high risk of colorectal, gynecological and other cancers. The purpose of this study was to use combined genome and transcriptome sequencing (GS, TS) to search for a potential causative genomic rearrangement in a family with suspected Lynch syndrome and no pathogenic germline variant in all four MMR genes MLH1, MSH2, MSH6, and PMS2 by conventional sequencing.

**Methods:** Genomic DNA and RNA from blood was used for GS and TS. Sequencing data was analyzed using an open-source bioinformatic data analysis pipeline (megSAP). An in-house software (GSvar) was used to further prioritize potentially clinically relevant DNA variants.

**Results:** We performed GS and TS in the 56-year-old index patient, diagnosed with colon cancer and cholangiocarcinoma and identified a complex structural variant containing exons 16-19 of MLH1 as well as a deletion of neighboring exons 28-4 in LRRFIP2. Subsequent TS revealed two fusion transcripts: MLH1 exon 1-15 and LRRFIP2 exon 29, and LRRFIP2 exon 1-3 fused with MLH1 exon 16-19, confirming our initial finding. Meanwhile additional family members were found to be carriers of the pathogenic variant by direct sequencing of the inversion breakpoints in MLH1 intron 15 and LRRFIP2 intron 3.

**Conclusion:** Genomic rearrangements in the MLH1 gene have been reported to account for an important proportion of the mutation spectrum in HNPCC. We demonstrate that GS and TS are an effective strategy for the characterization of genomic rearrangements in patients showing no mutation by conventional screening methods.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P13.054.D Pathogenic germline variants of TP53 gene are rare in patients with chronic lymphocytic leukemia**

Šárka Pavlova, Jitka Malcová, Johana Gombíková, Jana Smardová, Karla Plevová, Jana Kotašková, Barbara Dvořáčková

**Background/Objectives:** Ovarian cancer (OC) is the deadliest gynecological malignancy; therefore, new therapeutic strategies are needed. We have previously shown that Chloroquine (CQ) is induced DNA double strand breaks (DSBs) that are repaired by homologous recombination (HR) (1). The aim of this study was to analyze whether Non-Homologous End Joining (NHEJ), the other main pathway that repairs DSBs, was also involved in the repair of CQ-induced lesions and then, if the combination of CQ with NHEJ inhibitors (NHEJi) could be effective against OC.

**Methods:** OC cell lines (A2780, IGROV-1, OVCAR-8 and SK-OV-3) were used. DSBs were detected monitoring phosphorylation of H2AX by immunofluorescence. MIT, cell cycle and apoptosis assays were performed to test NHEJi (KU-55778, NU-7026, SCR7 pyrazine) anticancer activity. Synergistic interaction between

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P13.055.B Synergistic effect of Chloroquine and Non-Homologous End Joining inhibitors through induction of DNA damage and inhibition of DNA repair in ovarian cancer**

Maria Ovejero-Sánchez, Jorge Rubio-Heras, M. del Carmen Vicente de la Peña, Carmen Sicilia-Navarro, Rogelio González-Sarmiento, Ana-Belén Herrero

**Background/Objectives:** Ovarian cancer (OC) is the deadliest gynecological malignancy; therefore, new therapeutic strategies are needed. We have previously shown that Chloroquine (CQ) induced DNA double strand breaks (DSBs) that are repaired by homologous recombination (HR) (1). The aim of this study was to analyze whether Non-Homologous End Joining (NHEJ), the other main pathway that repairs DSBs, was also involved in the repair of CQ-induced lesions and then, if the combination of CQ with NHEJ inhibitors (NHEJi) could be effective against OC.
Background/Objectives: In chronic lymphocytic leukaemia (CLL), B-cell malignancy with the median age at diagnosis >65 years, TP53 defects are routinely examined. We analysed TP53 gene variants and their germline/somatic origin in 706 CLL patients.

Methods: Tumour and non-tumour gDNA were subjected to amplicon-based NGS. Variants were interpreted according to TP53Website and TP53Database; functional yeast assay (FASAY) was performed for germline variants.

Results: In 102/706 (15%) patients, exonic or splice site TP53 variants >10% VAF other than common population variants (Pro72Arg, Pro36) were identified. Six of them (6%) were non-pathogenic variants of germline origin (~50% VAF; Asp49--; Ile254Val; Arg283Cys; Arg290His; Gly360Ala). None was accompanied by a second allele defect, and the patients were free of personal or family history suggesting Li-Fraumeni syndrome. In a patient with Gly360Ala, another pathogenic TP53 variant expanded after treatment.

Of the remaining 96 patients, the variant origin could be assessed in 81. Germline origin was excluded in 80 cases, while it was confirmed in one patient carrying the heterozygous variant Arg158Cys. This variant has been reported with conflicting interpretations of pathogenicity due to contradictory results of functional assays. Our FASAY results showed intermediate functionality. CLL was the first tumour of the patient (aged 56) without a family history of cancer.

Conclusion: Germline (likely) pathogenic TP53 variants are infrequent in CLL, which corresponds to late disease onset but should be considered, especially if the activity of mutated protein is partially retained. Rare population variants should not be mis-interpreted as pathogenic.

References: MEYS-CZ_MUNI/A/1330/2021, MH-CZ_RVO_65269705, MH-CZ_AZV_NU21-08-000237, AZV_NU20-08-00137, AZV_NV19-03-00991.

Conflict of Interest: None declared.

P13.056.A Investigating the effect of estradiol levels on the risk of breast, endometrial and ovarian cancer: a mendelian randomization study

Weronica Ek1, Daniel Schmitz1, Julia Höglund1, Fatemeh Hadizadeh1, Torgny Karlsson1, Åsa Johansson1

1Uppsala University, Immunology, Genetics and Pathology and Science for Life Laboratory, Uppsala, Sweden.

Background/Objectives: High levels of estrogen are associated with increased risk of breast and endometrial cancer and have been suggested to also play a role in the development of ovarian cancer. Carcinogenic effects of estradiol, the most prominent form of estrogen, has been highlighted as a side effect of estrogen replacement therapy. However, whether high levels of endogenous estrogens, produced within the body, promote cancer development, has not been fully established.

Methods: Here we performed both two and one-sample Mendelian randomization (MR), using hitherto unexploited genetic instruments, to estimate the effect of endogenous estradiol on the risk of developing breast, endometrial and ovarian cancer.

Results: We showed that higher estradiol levels increase the risk of ER-positive breast cancer (OR = 2.43 [95% CI 1.07-5.51]), as well as ER-positive and negative breast cancers combined (OR = 1.99 [95% CI 1.02-3.87]). A significant effect was also identified for ovarian cancer (OR = 2.26 [95% CI 1.09-4.71]). However, we could not establish a clear link to the risk of endometrial cancer (OR = 1.93 [95% CI 0.77-4.80]).

Conclusion: Our results suggest that high production of estradiol in the body triggers the development of breast and ovarian cancer.

References: This work was funded by the Swedish Cancer Society 19 0383 Pj (ÅJ) and 21 0447 FE (WEE), and the Åke Wiberg Foundation M19-0349/M20-0057 (WEE).

Conflict of Interest: None declared.

P13.056.B In-frame deletions and insertions in TP53 gene identified in leukemia patients result in p53 protein inactivation

Jitka Malcikova1,2, Šárka Pavlová1,2, Johana Gombiková1, Jana Šmarďová1, Karla Plevová1,2, Jana Kotalková1,2, Barbara Dvořáková1, Eva Zapletalová1, Veronika Navrkalová1,2, Michael Doube1,2,4, Sarka Pospisilova1,2,4

1University Hospital Brno and Medical Faculty Masaryk University, Department of Internal Medicine - Hematology and Oncology, Brno, Czech Republic; 2Central European Institute of Technology, Masaryk University, Brno, Czech Republic; 3Faculty of Science, Masaryk University, Department of Experimental Biology, Brno, Czech Republic; 4University Hospital Brno and Faculty of Medicine Masaryk University, Institute of Medical Genetics and Genomics, Brno, Czech Republic.

Background/Objectives: TP53 defects are routinely examined. We analysed TP53 gene variants and their germline/somatic origin in 706 CLL patients.

Methods: Tumour and non-tumour gDNA were subjected to amplicon-based NGS. Variants were interpreted according to TP53Website and TP53Database; functional yeast assay (FASAY) was performed for germline variants.

Results: In 102/706 (15%) patients, exonic or splice site TP53 variants >10% VAF other than common population variants (Pro72Arg, Pro36) were identified. Six of them (6%) were non-pathogenic variants of germline origin (~50% VAF; Asp49--; Ile254Val; Arg283Cys; Arg290His; Gly360Ala). None was accompanied by a second allele defect, and the patients were free of personal or family history suggesting Li-Fraumeni syndrome. In a patient with Gly360Ala, another pathogenic TP53 variant expanded after treatment.

Of the remaining 96 patients, the variant origin could be assessed in 81. Germline origin was excluded in 80 cases, while it was confirmed in one patient carrying the heterozygous variant Arg158Cys. This variant has been reported with conflicting interpretations of pathogenicity due to contradictory results of functional assays. Our FASAY results showed intermediate functionality. CLL was the first tumour of the patient (aged 56) without a family history of cancer.

Conclusion: Germline (likely) pathogenic TP53 variants are infrequent in CLL, which corresponds to late disease onset but should be considered, especially if the activity of mutated protein is partially retained. Rare population variants should not be mis-interpreted as pathogenic.

References: MEYS-CZ_MUNI/A/1330/2021, MH-CZ_RVO_65269705, MH-CZ_AZV_NU21-08-000237, AZV_NU20-08-00137, AZV_NV19-03-00991.

Conflict of Interest: None declared.

P13.055.A Investigating the effect of estradiol levels on the risk of breast, endometrial and ovarian cancer: a mendelian randomization study

Weronica EK1, Daniel Schmitz1, Julia Höglund1, Fatemeh Hadizadeh1, Torgny Karlsson1, Åsa Johansson1

1Uppsala University, Immunology, Genetics and Pathology and Science for Life Laboratory, Uppsala, Sweden.

Background/Objectives: High levels of estrogen are associated with increased risk of breast and endometrial cancer and have been suggested to also play a role in the development of ovarian cancer. Cancerogenic effects of estradiol, the most prominent form of estrogen, has been highlighted as a side effect of estrogen replacement therapy. However, whether high levels of endogenous estrogens, produced within the body, promote cancer development, has not been fully established.

Methods: Here we performed both two and one-sample Mendelian randomization (MR), using hitherto unexploited genetic instruments, to estimate the effect of endogenous estradiol on the risk of developing breast, endometrial and ovarian cancer.

Results: We showed that higher estradiol levels increase the risk of ER-positive breast cancer (OR = 2.43 [95% CI 1.07-5.51]), as well as ER-positive and negative breast cancers combined (OR = 1.99 [95% CI 1.02-3.87]). A significant effect was also identified for ovarian cancer (OR = 2.26 [95% CI 1.09-4.71]). However, we could not establish a clear link to the risk of endometrial cancer (OR = 1.93 [95% CI 0.77-4.80]).

Conclusion: Our results suggest that high production of estradiol in the body triggers the development of breast and ovarian cancer.

References: This work was funded by the Swedish Cancer Society 19 0383 Pj (ÅJ) and 21 0447 FE (WEE), and the Åke Wiberg Foundation M19-0349/M20-0057 (WEE).

Conflict of Interest: None declared.
contribution of BRCA1 variants to HR proficiency and were also tested and validated in the HeLa system. c.32T>G and c.5202T>G, c.754_762del p.(Leu252_Ile254del) resulted in the loss of the transactivation function of p53 protein. Although we cannot exclude that functional in-frame deletions/insertions may occur, we showed that all tested in-frame deletions/insertions identified in patients with CLL resulted in the loss of the transactivation function of p53 protein.

**References:**

Grants: MEYS-CZ_MUNI/A/1330/2021, MH-CZ_RVO_65269705, MH-CZ_AZV_NU21-08-00237, AZV_NU20-08-00137, AZV_NV19-03-00091.

**Conflict of Interest:** None declared.

**P13.057.C Identification of new pathogenic mutations in BRCA1 through homologous recombination assays**

**Paloma Martín-Bejarano Soto**1-2, Nuria Arroyo-Garrapuchó1-2, Eva María Sánchez-Tapia1-2, Rosario Vidal-Tocino1,2, Teresa Martín-Gómez1-2, Raquel Seijas-Tamayo1-2, Rogelia González-Sarmiento1-2, Ana-Belén Herrero1-2

1Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain; 2Molecular Medicine Unit, Department of Medicine, University of Salamanca, Salamanca, Spain

**Background/Objectives:** BRCA1 is a tumor suppressor frequently mutated in breast and ovarian cancer syndrome that plays an essential role in homologous recombination (HR), a DNA double-strand break repair mechanism necessary to maintain genome integrity. Hundreds of mutations in BRCA1 are classified as variants of unknown significance (VUS), since their effect on protein function has not been determined. In this study, we use different functional assays to quantify the efficiency of HR of VUS identified in the Genetic Counselling Unit of Salamanca in the last 20 years.

**Methods:** VUS were re-analysed using ClinVar, VEP and Varsome databases. QuickChange II Site-directed mutagenesis kit was used to generate plasmids containing the studied VUS. BRCA1 through homologous recombination assay is a tumor suppressor frequently mutated in breast and ovarian cancer syndrome that plays an essential role in homologous recombination (HR), a DNA double-strand break repair mechanism necessary to maintain genome integrity. Hundreds of mutations in BRCA1 are classified as variants of unknown significance (VUS), since their effect on protein function has not been determined. In this study, we use different functional assays to quantify the efficiency of HR of VUS identified in the Genetic Counselling Unit of Salamanca in the last 20 years.

**Results:** 91 pathogenic BRCA1 variants were identified in 34 out 41 patients. The most frequently mutated genes were TP53, MET, PIK3CA, SMAD4 and BRCA1/2. We found a total of 91 pathogenic variants in 34 different genes. Our approach was also successful to identify somatic mutations with allele frequencies as low as 0.05% in patients who were not yet in an advanced clinical stage allowing a prompt therapeutic response against actionable genes.

**References:** 1. Palmieri M et al. J Cancer Metastasis Treat. 2020;6:55.

**Grants:** None declared.

**Conflict of Interest:** None declared.

**P13.059.A Overview of the genetic predisposition from a large cohort of medulloblastoma**

**Mathilde Fils**1, Adrien Borgel1, Alexandre Perrier2, Marie-Charlotte Villy2, Léa Guerrini-Rousseau3, Christine Bourenieux1, Mathilde Warcolin1, Marion Gauthier-Villars2, Fatoumata Simaga2, François Doz4, Olivier Delattre5, Chrystelle Colas2, Franck Bourdeaut4, Julien Masliah-Planchon1

1Institut Curie, Oncogenetic Department, Paris, France; 2Institut Curie, Clinical Oncogenetic Department, Paris, France; 3Gustave Roussy,
Mirjam de Hullu1, Iris Nagtegaal2, Nicoline Hoogerbrugge1, Richarda De Voer1, Marjolijn Ligtenberg1

**TP53** presents 60% of childhood intracranial embryonal tumours. In 2016, frequent brain neoplasia in the paediatric population and predisposition in medulloblastoma.

**Methods:** From our large cohort of 610 grouped medulloblastomas received at the Genetic Somatic laboratory since 2000, 404 benefited from a tumour genomic screening including the common medulloblastoma predisposition genes SUFU, PTCH1 and TP53.

**Results:** 36.6% (148/404) of our patients presented somatic alterations in those genes and the SHH subgroup was confirmed as the most frequent one (72.3%; 133/184). Among the 73 cases for which a germline analysis was possible, we identified nine cases of germline alterations of **SUFU**, four of **PTCH1** and two of **TP53**.

In addition, we described germline alterations in the following genes: **APC**, **ELP1**, **GPR161**, **MLH1**, **MSH2**, **MSH6**, **MUTYH**, **NF1**, **NF2**, **SMO** and **TCF4**.

**Conclusion:** Our study performed on a large panel of medulloblastomas confirms the previously published data regarding well characterized even though rare predisposition genes and highlights the need to orientate the patient in a genetic counselling, especially if presenting a SHH medulloblastoma. We also describe new predisposition genes that will be crucial to identify before deciding the treatment, to help the clinicians in their decision-making.

**References:** None.

**Grants:** None.

**Conflict of Interest:** None declared.

**P13.061.C The highest frequency of BRCA1 c.3700_3704del detected among Albanians from Kosovo**

Ivana Maleva Kostovska1, Simona Jakovichska1, Milena Jakimovska Özdemir1, Sanja Kiprijanovska1, Katerina Kubelka-Sabiti2,3, Dzenis Jasap2,3, Marina Iljovska1, Emilija Lazareva1, Snezhana Smichkoska1, Dijana Pleskas-Karanfilski1

1Macedonian Academy of Sciences and Arts, Research Centre for Genetic Engineering and Biotechnology “Georgi D. Eremov”; Skopje, Macedonia; 2Clinical Hospital Akibadem Sistina, Dept. of Histopathology and Cytology, Skopje, Macedonia; 3University “Goce Delcev”, Medical Faculty, Stip, Macedonia; 4Ss. Cyril and Methodius University, Medical Faculty, University Clinic of Radiotherapy and Oncology, Skopje, Macedonia.

**Background/Objectives:** The spectrum of BRCA1/2 mutations varies among populations; however some mutations may be frequent in particular ethnic groups due to the “founder” effect. The c.3700_3704del mutation was previously described as a recurrent BRCA1 variant in Eastern European countries. This study aimed to investigate the frequency of c.3700_3704del BRCA1 mutation in Albanian breast and ovarian cancer patients from North Macedonia and Kosovo.

**Methods:** A total of 327 patients with invasive breast and/or ovarian cancer (111 Albanian women from North Macedonia and 216 from Kosovo) were screened for 13 recurrent BRCA1/2 mutations. Targeted NGS with a panel of 94 cancer-associated genes including BRCA1 and BRCA2 was performed in a selected group of 118 patients.

**Results:** We have identified 21 BRCA1/2 pathogenic variants, 17 (14 BRCA1 and 3 BRCA2) in patients from Kosovo (7.9%) and 4 (1 BRCA1 and 3 BRCA2) in patients from North Macedonia (3.6%). All BRCA1/2 mutations were found in one patient each, except for c.3700_3704del BRCA1 mutation which was observed in 14 unrelated families, all except one originating from Kosovo. The c.3700_3704del mutation accounts for 93% of BRCA1 mutation positive cases and is present with a frequency of 6% among breast cancer patients from Kosovo.

**Conclusion:** This is the first report of BRCA1/2 mutations among breast and ovarian cancer patients from Kosovo. The finding that BRCA1 c.3700_3704del represents a founder mutation in Kosovo with the highest worldwide reported frequency supports the implementation of fast and low-cost screening protocol, regardless of the family history and even a pilot population-based screening in at-risk population.

**References:**

**Grants:**
Conflict of Interest: None declared.

**P13.062.D Cytogenetic evaluation in myelodysplastic syndrome**

**Can Berk Leblebicı**, Sule Altner, Arzu Vıcdnan, Nuket Y Kutlaur, TIMUR TUNCALI, Halil Gürhan Karabulut, Sadiye Ekinci, Hatile Ilgün Ruhi

1Ankara University, Medical genetics, Ankara, Turkey.

**Background/Objectives:** Myelodysplastic syndrome (MDS) is a hematological malignancy that is characterized by prolonged cytopenia in the bone marrow (BM) and has a risk of conversion to acute myeloid leukemia. Morphological changes in the bone marrow are often required for diagnosis, this also needs to be correlated with other laboratory tests such as cytogenetic analysis. Cytogenetic risk grouping according to IPSS-R (Revised International Prognostic Scoring System) is important in patient follow-up. In this study, conventional cytogenetic(CC) and fluorescent in situ hybridization(FISH) results of MDS are presented.

**Methods:** The results of cytogenetic analysis of BM materials of patients with MDS were evaluated retrospectively referred to our department, in the period of 2019-2021.

**Results:** A total of 152 patients were included in the study. Of these, 89 (58.5%) were male and 63 (41.5%) were female. The age range of the patients was 19-89 (mean age 65.2). CC and FISH results are summarized in the table below.

![Table 1: Outline of the cytogenetic results.](https://doi.org/10.5772/intechopen.97112)

**Conclusion:** CC findings provide important data for the diagnosis and prognosis of MDS, and additional cytogenetic methods, especially FISH, are clearly beneficial in the diagnosis and follow-up of disease.

**References:** 1- https://doi.org/10.5772/intechopen.97112.

**Grants:**

**Conflict of Interest:** Can Berk Leblebicı Ankara University Faculty of Medicine, Medical Genetics, Sule Altner Ankara University Faculty of Medicine, Medical Genetics, Arzu Vıcdnan Ankara University Faculty of Medicine, Medical Genetics, Nuket Y Kutlaur Ankara University Faculty of Medicine, Medical Genetics, TIMUR TUNCALI Ankara University Faculty of Medicine, Medical Genetics, Halil Gürhan Karabulut Ankara University Faculty of Medicine, Medical Genetics, Sadiye Ekinci Ankara University Faculty of Medicine, Medical Genetics, Hatile Ilgün Ruhi Ankara University Faculty of Medicine, Medical Genetics.

**P13.063.A Targeted gene panel investigations in chronic lymphocytic leukemia patients**

**Agnes Mosolygo-Lukacs, Maria Balogh, Aniko Ujfalusi**

**Background/Objectives:** Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease with various genetic abnormalities that can affect the treatment and survival of the patients. Next-generation sequencing (NGS) studies have described recurrently mutated genes in CLL. The aim of this study was to detect pathogenic variants of commonly mutated genes in CLL and to explore their associations with IGHV mutational status and cytogenetic abnormalities.

**Methods:** NGS analysis was performed on 75 blood samples from CLL patients using Twist Custom Panel kit and Illumina NextSeq according to the manufacturers’ instructions.

**Results:** Overall, 42 of 75 patients (56%) harbored at least one mutation, the majority of variants (63%) was clonal. The most frequently mutated gene was TP53, followed by NOTCH1, BRIC3 and SF3B1. Subclonal variants (5-10% VAF) were also detected in 17/75 patients (22%), particularly in BIRC3 and NOTCH1 genes. TP53 and NOTCH1 variants occurred mostly in unmutated-IGHV CLL cases. Patients with mutated-IGHV harbored mainly BIRC3 and FBXW7 variants. 17p deletions co-occurred with TP53 clonal mutations in 6 of 8 patients. SF3B1 and TP53 variants occurred with 11q deletions in 6 of 8 cases. BIRC3 clonal and subclonal variants were observed in 4 of 7 patients with favourable 13q deletions.

**Conclusion:** This study confirmed the presence of high number of clonal and subclonal variants in the most frequently mutated genes (TP53, NOTCH1, BRIC3, SF3B1) in CLL cases. These NGS results complementing the IGHV mutational status and cytogenetic data can contribute to better prognostic workup and management of patients with CLL.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P13.064.B Analysis of circulating miRNA profile in plasma samples of glioblastoma patients**

**Dóra Gécel**, Bálint Nagy, Melinda Szilágyi, András Penyige, Álmos Klekner, József Virga, Zsuzsanna Bíró

1University of Debrecen, Department of Laboratory Medicine, Debrecen, Hungary; 2University of Debrecen, Department of Neurosurgery, Debrecen, Hungary; 3University of Debrecen, Department of Oncology, Debrecen, Hungary.

**Background/Objectives:** Glioblastoma multiforme (GBM) is among the most aggressive cancers with a poor prognosis. Treatment options are limited, clinicians lack efficient prognostic and predictive markers. Liquid biopsy represents a great advance in this field because it can be useful to monitor the evolution and recurrence of the disease as well as the response of patients to therapy. Circulating miRNAs – besides being important regulators of cancer development – may have potential as diagnostic biomarkers of GBM.

**Methods:** In this study, profiling of 798 human miRNAs was performed on blood plasma samples from 6 healthy individuals and 6 patients with GBM, using a NanoString nCounter Analysis System. To validate our results, five miRNAs (hsa-mir-433-3p, hsa-mir-362-3p, hsa-mir-195-5p, hsa-mir-133a-3p and hsa-mir-29a-3p) were randomly chosen for RT-qPCR detection.

**Results:** 53 miRNAs were significantly differentially expressed in plasma samples of GBM patients when data were filtered for FC > 1 and FDR < 0.1. Target genes of the top 39 differentially expressed miRNAs were identified, and we carried out functional annotation and pathway enrichment analysis of target genes via GO and KEGG-based tools. General and cortex-specific
protein–protein interaction networks were constructed from the target genes of top miRNAs to assess their functional connections.

**Conclusion:** We demonstrated that plasma microRNA profiles are promising diagnostic and prognostic molecular biomarkers that may find an actual application in the clinical practice of GBM, although more studies are needed to validate our results.

**References:**

**Grants:** This study was supported by grant 2017-1.2.1-NKP-2017-00002 “National Brain Research Program NAP 2.0”.

**Conflict of Interest:** None declared.

**P13.065.C Study the significance of miR-30 family members in ovarian cancer**

Alexandra Beke-Varga1, Éva Márton1, András Penyige1;2, Istvan Balogh1;3, Bálint Nagy1, Melinda Szilágyi1

1University of Debrecen, Department of Human Genetics, Debrecen, Hungary; 2University of Debrecen, Faculty of Pharmacy, Debrecen, Hungary; 3University of Debrecen, Department of Laboratory Medicine, Debrecen, Hungary.

**Background/Objectives:** Estrogens are able to trigger cell pro- liferation and cell death in a dose dependent manner. MicroRNAs are considered to play an important role in estrogen response. Our aim was to characterize the function of miR-30s (tumor suppressors) in the response of ovarian cells to estradiol (E2).

**Methods:** The applied human ovarian cell lines were PEO1 (expressing Estrogen Receptor α and β) and A2780 (ERβ). The effect of high dose E2 was studied by determining cell proliferation, apoptosis, cellular lysis, mRNA and miR-30s expression.

**Results:** The basal expression of miR-30a-3p, miR-30a-5p, miR-30d-5p and miR-30e-5p proved to be higher in PEO1 than in A2780. The expression of miR-30a-5p, miR-30d-5p and miR-30e-5p was induced to high dose E2 treatment (>50 μM) where intensive cell death was observed according to the induction of apoptosis (TP53) and autophagy (BAG3, ATG28) related genes. ERα expressing PEO1 cells had higher tolerance to high dose E2 than A2780 what might be caused by the induction of ERα mediated estrogen response (GREB1, CA12). Bioinformatic analysis of miR-30s revealed that several targets are shared by miR-30a-5p, miR-30d-5p and miR-30e-5p that are involved in the regulation of cell proliferation and cell death related pathways. The application of miR-30d-5p mimic reduced cell proliferation and decreased the tolerance of PEO1 cells to high dose E2.

**Conclusion:** MiR-30a-5p, miR-30d-5p and miR-30e-5p might mediate the stress-response induced by high dose E2 in ovarian cells. MiR-30d-5p might be a promising therapeutic target in ovarian cancer.

**References:**

**Grants:** FK138021 (National Research Development and Innovation Office, Hungary) and EFOP-3.6.3-VEKOP-16-2017-00009 projects.

**Conflict of Interest:** None declared.

**P13.066.D Comparative analysis of transcriptomic changes including mRNA and microRNA expression induced by xenoestrogens in ovarian cells**

Alexandra Beke-Varga1, Éva Márton1, Fatime Grimplinyi1, András Takács1, Andrász Penyige1;2, Istvan Balogh1;2, Bálint Nagy1, Melinda Szilágyi1

1University of Debrecen, Department of Human Genetics, Debrecen, Hungary; 2University of Debrecen, Faculty of Pharmacy, Debrecen,

**Background/Objectives:** Xenoestrogens are natural (e.g. zearalenone; ZEA) or synthetic compounds (e.g. bisphenol A; BPA), which mimic the effect of physiological estrogens. The exposure to xenoestrogens increases the risk for ovarian cancer. The aim of our study was to compare the transcriptomic changes induced by physiological estradiol (E2) and xenoestrogens in ovarian cells.

**Methods:** PEO1 human ovarian cell line was treated with E2, ZEA and BPA. Transcriptomic changes were studied by mRNA and miRNA sequencing (Illumina NextSeq 500). Validation of data was made by qPCR.

**Results:** Estrogen exposure induced remarkable transcriptomic changes: 304, 283 and 62 genes were up-regulated (log2FC>1); 288, 255 and 44 genes were down-regulated (log2FC<-1) in response to E2, ZEA and BPA. Furthermore, the expression of 12 (E2), 11 (ZEA) and 10 (BPA) miRNAs changed significantly (log2FC>1, or log2FC<-1). Functional enrichment analysis revealed several pathways related to the regulation of cell proliferation, apoptosis and migration. The effect of xenoestrogens was highly comparable to E2: 319 genes were co-regulated in response to E2 and ZEA and the expression of 81 genes changed in response to all the three estrogens tested. Furthermore the expression of miR-197-5p, miR-5008-5p and miR-501-5p were down-regulated in response to at least to two treatments. Correlation proved to be high (r>0.9) between the data obtained from RNA sequencing and qPCR.

**Conclusion:** Xenoestrogens induce relevant transcriptomic changes that are comparable with E2. We identified key genes and miRNAs that might contribute to the carcinogenic effect of xenoestrogens.

**References:**

**Grants:** None declared.

**P13.067.A Disequilibrium between BRCA1 and BRCA2 circular and messenger RNAs plays a role in breast cancer**

Corentin Levacher1, Mathieu Viennot2, Ludwine Beausière1;2, Sophie Coutant1, Stéphanie Baert-Desurmont4, Marick Laé2;3, Philippe Ruminy1, Claude Houdayer4

1INSERM U1245, Normandie Univ, UNIROUEN, Normandy Centre for Genomic and Personalized Medicine, FHU-G4 Génomique, Rouen, France; 2INSERM U1245, Cancer Center Henri Becquerel, University of Normandy, UNIROUEN, FHU-G4 Génomique, Rouen, France; 3Department of Pathology, Cancer Center Henri Becquerel, University of Normandy, UNIROUEN, Rouen, France; 4Department of Genetics, Normandy Center for Genomic and Personalized Medicine, Normandy Univ, UNIROUEN, INSERM U1245 and Rouen University Hospital, FHU-G4 Génomique, Rouen, France.

**Background/Objectives:** Circular RNAs (circRNAs) are single-stranded covalent structures in closed loops produced by backsplicing. As backsplicing and linear splicing compete against each other, we hypothesize that a balance disruption between circRNAs and messenger RNAs (mRNAs) could promote tumorigenesis and used breast cancer and BRCA1 and BRCA2 as a model.

**Methods:** We develop a novel gene-targeted technique for simultaneous quantitative and qualitative analyses of circRNAs and mRNAs. A total of 114 probes, located at exon extremities, were designed to explore all reported alternative transcripts for BRCA1 and BRCA2. Following reverse transcription and probing on cDNA, nearby probes were ligated and the number of ligations quantified using unique molecular identifiers and
sequencing on a MiSeq. Hence, circRNAs and mRNAs were identified and quantified. This method was first validated on a set of 169 formalin-fixed, paraffin-embedded tumour samples harbouring various BRCA mutations (including splice mutations). Next, our hypothesis was tested using another test set of 95 pairs of tumour and adjacent normal breast tissues.

**Results:** On the validation set, all known circRNAs and mRNAs and those resulting from splice mutations were correctly identified. Four novel circRNAs were identified. On the test set, the ratio of BRCA1 and BRCA2 circRNAs/mRNAs were significantly lower in tumour breast tissue compared to normal tissue ($p = 6.9e-09$ and $p = 1.5e-06$ for BRCA1 and BRCA2, respectively).

**Conclusion:** We have validated an innovative method to study linear and backsplicing and showed for the first time that the disequilibrium between BRCA1 and BRCA2 circRNAs and mRNAs plays a role in breast cancer.

**References:**

**Grants:** Cancéropôle Nord-Ouest.

**Conflict of Interest:** None declared.

**P13.068.B Comprehensive RNA and protein functional assessments contribute to the clinical interpretation of MSH2 variants causing in-frame splicing alterations**

**Laëtitia Meulemans**

Stéphanie Baert-Desurmont, Marie-Christine Waill3, Gaia Castelain3, Audrey Killian1, Julie Hauchard1, Thierry Frebourg1,2, Florence Coulet1,2, Alexandre Martins1, Martine France; 4Inserm UMR-S 938, Centre de Recherche Saint-Antoine, GenOMics, Rouen University Hospital, Rouen, France; 3Department of Genetics, AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France; 4Inserm UMR-S 938, Centre de Recherche Saint-Antoine, CRSA, Paris, France.

**Background/Objectives:** Spliceogenic variants in disease-causing genes are often presumed pathogenic since most induce frameshift mutations resulting in loss-of-function. However, it was recently shown in cancer predisposition genes that some may trigger in-frame alterations that preserve function.

**Methods:** Eighteen MSH2 variants, mostly localized within canonical splice sites, were analyzed using minigene splicing assays. Then, the biological impact of the resulting protein alterations was assessed in a methylation tolerance-based assay. Clinicopathological characteristics of variant carriers were collected.

**Results:** Three in-frame RNA biotypes were identified based on variant-induced spliceogenic outcomes: exon skipping (E3/E4/E5/E12), segmental exonic deletions (E7/E15) and intrinsic retentions (I3/I6/I12/I13). The 10 corresponding protein isoforms exhibit either large deletions (49-93aa), small deletions (12/16aa) or insertions (3-10aa) within different functional domains. We showed that all these modifications abrogate MSH2 function, in agreement with the clinicopathological features of variant carriers.

**Conclusion:** Altogether, these data demonstrate that MSH2 function is tolerant to in-frame indels caused by the spliceogenic variants analyzed in this study, supporting their pathogenic nature. This work stresses the importance of combining complementary RNA- and protein-based approaches to ensure accurate clinical interpretation of in-frame spliceogenic variants.

**References:**

1. Meulemans et al, Skipping Nonsense to Maintain Function: The Paradigm of BRCA2 Exon 12. Cancer Research, 2020.

**References:**

1. University Hospital Virgen del Rocío/CSIC/University of Seville, Department of Maternofetal Medicine, Genetics and Reproduction, Institute of Biomedicine of Seville, Seville, Spain; 2Center for Biomedical Network Research on Rare Diseases (CIBERER), Seville, Spain; 3University Hospital Virgen del Rocío, Endocrinology Service, Seville, Spain.

**Background/Objectives:** Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor (2-5% of all thyroid cancer) derived from the parafollicular C-cells. About 75% of all MTCs are sporadic; the remaining 25% correspond to inherited cancer syndromes known as multiple endocrine neoplasia type 2 (MEN2), attributed to gain-of-function mutations of the RET proto-oncogene in >98% of cases. MEN2 includes three clinically distinguishable types: MEN2A, MEN2B, and familial MTC (FMTC). However, there are MTC cases in which RET is not affected and whose genetic cause remains unknown (non-MEN2 FMTC). In this study, we aimed at identifying possible causal variants involved in these rare familial forms.

**Methods:** We performed WES in nine non-MEN2 FMTC patients belonging to five different families, using an Illumina Nextseq550 sequencer. Multi-sample analyses were launched and annotated using the Varsome Clinical Platform to study SNVs and CNVs. After variant filtering and prioritization, based on pathogenicity predictors, functional evaluation, and expression profiles, candidate variants were segregated and evaluated by Sanger sequencing in additional family members.

**Results:** We have identified new pathogenic variants in heterogeneous, in genes not previously associated with the disease. They are involved in diverse molecular functions, such as DNA repair, post-transcriptional regulation and a phosphatase receptor that regulates cell growth and differentiation. Further studies are on-going to assess the role of the candidate variants in the onset of the disease.

**Conclusion:** The determination of new genes involved in non-MEN2 FMTC forms offers new pathways for further elucidation of the molecular mechanisms that lead to the disease.

**References:**

PMIDs:31717449;33407723.

**Grants:** ISCIII-ERDF/ESF(P119/01550;F120/00192;CD20/00171); Andalusian Government(PEER-0470-2019); I+D+i Funding-PADI2020(P20_00887).

**Conflict of Interest:** None declared.

**P13.069.C Whole exome sequencing reveals new candidate genes involved in non-MEN2 familial medullary thyroid cancer**

Carmen Muñoz1, Cristina Tou Rivera1, Elena Navarro2,1, Elena Lucena1, Raquel Fernández1,2, Guillermo Antiñolo1,2, Salud Borrego1,2

1University Hospital Virgen del Rocío/CSIC/University of Seville, Department of Maternofetal Medicine, Genetics and Reproduction, Institute of Biomedicine of Seville, Seville, Spain; 2Center for Biomedical Network Research on Rare Diseases (CIBERER), Seville, Spain.

**Background/Objectives:** Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor (2-5% of all thyroid cancer) derived from the parafollicular C-cells. About 75% of all MTCs are sporadic; the remaining 25% correspond to inherited cancer syndromes known as multiple endocrine neoplasia type 2 (MEN2), attributed to gain-of-function mutations of the RET proto-oncogene in >98% of cases. MEN2 includes three clinically distinguishable types: MEN2A, MEN2B, and familial MTC (FMTC). However, there are MTC cases in which RET is not affected and whose genetic cause remains unknown (non-MEN2 FMTC). In this study, we aimed at identifying possible causal variants involved in these rare familial forms.

**Methods:** We performed WES in nine non-MEN2 FMTC patients belonging to five different families, using an Illumina Nextseq550 sequencer. Multi-sample analyses were launched and annotated using the Varsome Clinical Platform to study SNVs and CNVs. After variant filtering and prioritization, based on pathogenicity predictors, functional evaluation, and expression profiles, candidate variants were segregated and evaluated by Sanger sequencing in additional family members.

**Results:** We have identified new pathogenic variants in hetrozygosis, in genes not previously associated with the disease. They are involved in diverse molecular functions, such as DNA repair, post-transcriptional regulation and a phosphatase receptor that regulates cell growth and differentiation. Further studies are on-going to assess the role of the candidate variants in the onset of the disease.

**Conclusion:** The determination of new genes involved in non-MEN2 FMTC forms offers new pathways for further elucidation of the molecular mechanisms that lead to the disease.

**References:**

PMIDs:31717449;33407723.

**Grants:** ISCIII-ERDF/ESF(P119/01550;F120/00192;CD20/00171); Andalusian Government(PEER-0470-2019); I+D+i Funding-PADI2020(P20_00887).

**Conflict of Interest:** None declared.

**P13.070.D Mutation Profile of Metastatic Castration-Resistant Prostate Cancer Patients Prior to Olaparib Treatment - EMA vs. FDA**

Vita Setrajcic Drašar1, Vida Stiegel1, Gasper Klancar1, Petra Škerl1, Anja Zagozžen Klasinc1, Šrdjan Novaković1

1Institute of Oncology Ljubljana, Department of Molecular Diagnostics, Ljubljana, Slovenia.

**Background/Objectives:** Olaparib has been approved by EMA and FDA for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). However, the indication for its clinical use in the USA (FDA) and in the EU (EMA) differs
significantly. Patients with mCRPC in the USA are eligible for treatment if they harbor a somatic/germline mutation in ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L gene, whereas in the EU only patients with BRCA1 or BRCA2 gene mutations are eligible.

Methods: During the year 2021, 98 consecutive prostate tumor samples have been routinely genotyped for the presence of the mutations in ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, RAD54L genes, using Illumina’s TruSightTumor 170 panel.

Results: Sequencing quality of 82% of samples was sufficient for data analysis. The most commonly mutated genes were BRCA2 (11%) and ATM (8%), followed by BRCA1 (3%), CHEK2 (2%) whereas RAD51B, RAD51C, and CDK12 were mutated in 1% of patients. More than half of patients (55%) did not harbor a mutation in any of the investigated genes.

Conclusion: Based on the tumor genotype, 14% of patients would be eligible for treatment with olaparib in the EU in comparison to 26% of patients in the USA.

References:

Grants: None declared.

Conflict of Interest: None declared.

P13.071.A Biallelic Pathogenic Variants in CHEK2 Predispose to Multiple Primary Tumours

Snezana Stankovic1, Janet Vos2, Rachel van der Post3, Fulvia Brugnoletti4,5, Saskia Koene6, Janneke Schuurs-Hoeijmakers1, Bianca Hilhorst1, Lilian Vreede1, D. Gareth Evans6, Katharina Wimmer7, Harada2, Alexander Mackinnon2

1 Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Department of Human Genetics, Nijmegen, Netherlands; 2Radboud Institute for Health Sciences, Radboud University Medical Center, Department of Human Genetics, Nijmegen, Netherlands; 3Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Department of Pathology, Nijmegen, Netherlands; 4Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Istituto di Medicina Genomica, Rome, Italy; 5Leiden University Medical Center, Department of Clinical Genetics, Leiden, Netherlands; 6The University of Manchester, Genomic Medicine, Manchester, United Kingdom; 7Institute for Human Genetics, Medical University of Innsbruck, Department of Genetics and Pharmacology, Innsbruck, Austria; 8Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 9Center for Medical Genetics, Ghent University and Ghent University Hospital, Ghent, Belgium; 10Oulu University Hospital, Department of Clinical Genetics, Oulu, Finland; 11UOC Genetica Medica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Background/Objectives: Biallelic germline pathogenic variants (PV) in CHEK2 are associated with an increased risk to develop breast cancers (BC) and suggested to predispose to other cancer types. Moreover, CHEK2-deficiency has been postulated to lead to homologous DNA repair deficiency (HRD). We aimed to elucidate the role of CHEK2-deficiency in the development of multiple primary tumours (MPT).

Methods: We collected individuals with a CHEK2-deficiency: i) from individuals who developed two or more tumours before 65 years (n = 94) who underwent germline whole-exome sequencing (WES), ii) by genotyping the CHEK2 c.1100delC PV in individuals who developed MPTs before the age of 60 (n = 787) and iii) identified through routine genetic testing, ERN GENTURIS centres and literature (n = 35 CHEK2-deficient cases). WES was performed on DNA from six tumour types (n = 16 tumours) and the somatic mutational signatures and cancer driver genes were analysed.

Results: We identified 3/94 (3%) and 3/787 (0.4%) MPT cases with CHEK2-deficiency in cohorts i and ii, respectively. In total, we collected 41 CHEK2-deficient cases, 85% were women (n = 35) and 76% developed at least one BC (n = 31). Next to BC, 51% of the cohort (n = 21) developed at least one benign (n = 9) and/or malignant (n = 19) tumour. CHEK2-deficient tumours harboured on average 3.14 variants/Mb (range 0.3–19.65). All tumours presented with clock-like SBS1 and SBS5 signatures and somatic PVs in cancer driver genes.

Conclusion: Individuals with CHEK2-deficiency are predisposed to develop MPTs. CHEK2-deficient tumours do not show HRD-associated mutational signatures. Our results suggest that individuals with MPTs should undergo germline genetic testing for CHEK2.

References:

Grants: KWF 12174.

Conflict of Interest: None declared.

P13.072.B MassARRAY-based diagnostics of hot spot mutations in IDH1/2 and TERT genes and allelic losses of 1p/19q deletions in gliomas

Edyta Borkowska1, Felipe Masiccano2, Robin Everts3, Shuko Harada4, Alexander Mackinnon2

1 Medical University of Lodz, Department of Clinical Genetics, Łódź, Poland; 2University of Alabama at Birmingham, Division of Genomic Diagnostics & Bioinformatics, Birmingham, United States; 3Agena Bioscience, San Diego, United States.

Background/Objectives: Multiplex genetic analysis, for example Next Generation Sequencing (NGS), is increasingly utilized for the routine identification of clinically significant biomarkers in cancer because it provides diagnostic, prognostic, and therapeutic guidance in a single workflow. However, NGS is expensive, laborious, and requires complicated bioinformatics analysis. The Agena MassARRAY system provides accurate, low cost, multiplexed analysis of hundreds of clinically relevant mutations with relatively simple analytics. In this study, we evaluated the utility of this system for the detection of somatic hotspot variants in the IDH1, IDH2 and TERT genes and the identification of deletions of chromosomes 1p and 19q in a cohort of glial tumors.

Methods: Our custom panel was designed to identify 65 genetic alleles important for the diagnosis of glial tumors. Purified DNAs from 60 routine formalin-fixed, paraffin embedded tissue specimens was analyzed. Results were compared to orthogonal testing (FISH, IHC and/or NGS). Visualization of the genetic data was achieved using custom develop scripts in the R programming environment.

Results: Results obtained using the MassArray were >95% concordant to orthogonal FISH and NGS analysis. Testing required less DNA, was simpler to perform, and turnaround time was faster. A custom pipeline developed in R allowed visualization of the data and facilitated accurate interpretation.

Conclusion: In the current study, we described an alternative, multiplex method to NGS that is robust, fast, and inexpensive for the identification of 1p/19q co-deletion and variants of IDH1/2 and TERT genes.

References:

Grants: Polish National Agency for Academic Exchange Grant No: PPN/WAL/2020/1/00017.

Conflict of Interest: Edyta Borkowska: None declared, Felipe Masiccano: None declared, Robin Everts Agena Bioscience, own
stock options, Shuko Harada: None declared, Alexander Mackinnon: None declared.

P13.073.C Systematic functional analysis by hybrid minigenes of CHEK2 splice-site variants detected in the BRIDGES project

Lara Sanoguera-Miralles1,2, Alberto Valenzuela-Palomo1,3, Elena Bueno-Martínez1,2, Ada Esteban-Sánchez4, Inés Llinares-Burguet1,3, Alicia Garcia-Álvarez1,3, Douglas F. Easton5, Peter Devilee6, Maaike Vreeswijk6, Miguel de la Hoya4, Eladio A. Velasco1,3

1Instituto de Biología y Genética Molecular (IBGM), Splicing and genetic susceptibility to cancer, Valladolid, Spain; 2Universidad de Valladolid (UVA), Valladolid, Spain; 3Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain; 4Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Molecular Oncology Laboratory CIBERONC, Madrid, Spain; 5Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 6Leiden University Medical Center (LUMC), Department of Human Genetics, Leiden, Netherlands.

Background/Objectives: CHEK2 germline inactivating variants moderately increase the risk of developing breast cancer. Our goal was to functionally analyse CHEK2 candidate spliceogenic variants identified in ~113,000 women in the large-scale sequencing project BRIDGES (https://bridges-research.eu/).

Methods: A total of 128 CHEK2 variants of the intron-exon boundaries were bioinformatically analysed. Fifty-two potentially spliceogenic variants were found with splicing prediction profiles that were further functionally characterised.

Results: The three wild type minigenes produced the full-length transcripts of the expected size and sequence, with several alternative transcripts, all of which had been previously reported length transcripts of the expected size and sequence, with several alternative transcripts, all of which had been previously reported.

Conclusion: At least 113 transcripts were detected, 95 of which (94.2%) impaired splicing and 34 out of them produced severe splicing anomalies. At least 113 transcripts were detected, 95 of which could be characterized (68 protein-truncating isoforms).

Conflict of Interest: None declared.

P13.075.A First estimates of diffuse gastric cancer risks for carriers of CTNNA1 germline pathogenic variants

Marie Coudert1, Youenn Drouet2,3, Helene Delhommelle1,4, Magali Svercek5, Patrick Benusiglio5, Florence Coulet6, Dana Farenco Clark7, Bryson Katona8, Liselotte P van Hest9, Lizet Van der Kolk10, Annemieke Cats11, Jolanda M van Dieren11,17, Bitia Nehoray12, Thomas Slavin13, Isabel Spie6,14, Robert Hübner6,15, Silvana Lobo16,17,18, Carla Oliveira16,17,19, Lise Boussenart20, Laure Masson21, Jean Chiesa22, MATHIAS SCHWARTZ23,24, Bruno Bucher1,4, Golmard Lisa1,4, Anne-Marie Bouvier23,24, Valérie Bonadonna23,25, Dominique Stoppa-Lyonnet1,4,26, Christine Lasse23, Chrystelle Colas1,4,26

1Institut Curie, Genetics, Paris, France; 2Centre Léon Bérard, Département Prévention et Santé Publique, Lyon, France; 3Université de Lyon, CNRS UMR 5558 LBBE, Villeurbanne, France; 4Full Member of the European Reference Network on Genetic Tumor Risk Syndromes, Paris, France; 5Sorbonne Université, AP-HP, Saint-Antoine hospital, Department of pathology, Paris, France; 6Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Département de Généétique Médicale, Paris, France; 7University of Pennsylvania Perelman School of Medicine, MS, LCGG, Division of Hematology and Oncology, Department of Medicine, University of, Philadelphia, United States; 8Medicine, University of Pennsylvania Perelman School of Medicine, Division of Gastroenterology and Hepatology, Department of Medicine, Philadelphia, United States; 9Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Clinical Genetics, Amsterdam, Netherlands; 10The Netherlands Cancer Institute, Family Cancer Clinic, Amsterdam, Netherlands; 11The Netherlands Cancer Institute, Department of gastrointestinal oncology, Amsterdam, Netherlands; 12City of Hope, Division of Clinical Cancer Genomics, Duarte, United States; 13City of Hope, Departments of Medical Oncology and Population Sciences, Duarte, United States; 14University Hospital Bonn, Institute of Human Genetics / National Center for Hereditary Tumor Syndromes, Bonn, Germany; 15University Hospital Bonn, Department of Internal Medicine /National Center for Hereditary Tumor Syndromes, Bonn, Germany; 16Instituto de Investigación e Investigación en Saúde, I3S, Porto, Portugal; 17University of Porto, IPATIMUP – Instituto de Molecular Pathology and Immunology, Porto, Portugal; 18Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, International Doctoral Programme in Molecular and Cellular Biotechnology Applied to Health Sciences (BiotechHealth), Porto, Portugal; 19University of Porto, Faculty of Medicine, Porto, Portugal; 20CHU de Nantes - Hôpital Dieu, Service de Dermatologie, Nantes, France; 21CHU de Rennes, Dermatologie, Rennes, France; 22CHRU Hôpital Caremeau, Génétique, Niimes, France; 23UMR 1231, Digestive cancer registry of Burgundy, Dijon, France; 24Réseau FRANCIM (réseau Français des registres du cancer), Toulouse, France; 25Centre Léon-Bérard, Unité Clinique d’Oncologie Génétique, Lyon, France; 26INSERM U830, Université de Paris, Paris, France.

Background/Objectives: Pathogenic variants (PV) of CTNNA1 are found in families evocative of hereditary diffuse gastric cancer (DGC) but no risk estimates were available until now. The aim of this study is to evaluate DGC risks for carriers of germline CTNNA1 PV.

Methods: Authors of published CTNNA1 families updated their data and unpublished families were identified through international collaborations. The cumulative risk of DGC by age for PV carriers was estimated with the Genotype Restricted Likelihood (GRL) method, taking into account non-genotyped individuals and conditioning on all observed phenotypes and genotype of the index case to obtain unbiased estimates. A non-parametric and the Weibull functions were used to model the shape of penetrance function with the GRL. Kaplan-Meier incidence curve and Standardized Incidence Ratios (SIR) were also computed. A “leave-one-out” strategy was used to evaluate estimate uncertainty.

Results: Thirteen families with 46 carriers of PV were included. The cumulative risks of DGC at 80 years for carriers of CTNNA1 PV are 4%, 57% and 77% respectively with the Weibull GRL, NP GRL and SIR methods. Risk ratios to population incidence reach particularly high values at early ages and decrease with age. At 40 years, they are equal to 65, 833 and 21,574 respectively with the Weibull GRL, NP GRL and SIR methods.

Conclusion: This large series of CTNNA1 families provides the first risk estimates of GC. It will help to improve management and
surveillance for these patients and support inclusion of CTNNA1 in germline testing panels.

References:

Grants:

Conflict of Interest: None declared.

P13.076.B Can genetic testing in healthy individuals prevent inherited cancer? Genetic data analysis of a Spanish cohort

Cristian Perez-Garcia1, Jordi Perez-Lopez2, Daniel Sanchez-Valero3, Rocío García-Jimenez4, Gemma Cartagena1, Eva Barroso5, Marina Martínez-Matilla1, Sandra García-Herrero1, Javier Garcia Planells1

1Igenomix, Genomic Precision Diagnostic, Valencia, Spain.

Background/Objectives: A hereditary cancer risk assessment is the key to identifying patients and families who may be at increased risk of developing certain types of cancer. Recent studies show that more than 50% of individuals at risk have not received genetic nor genetic counselling and have not been identified. Improving the knowledge and access to testing by individuals and families at high-risk for cancer provides significant improvements for prevention and early treatment of inherited cancer.

Methods: We analysed the carrier rate of pathogenic/likely-pathogenic variants in 31 genes associated to high risk of inherited cancer in 30582 Spanish healthy individuals between September 2015 to August 2021. Genetic data was obtained by WES and variants were pre-categorized using an in-house algorithm according to ACMG criteria.

Results: 867 individuals out of 30582 (2,83%) presented pathogenic/likely-pathogenic variants in 26 out of the 31 genes related with cancer.

148 likely pathogenic and 295 pathogenic different variants were identified in our cohort, being the most frequent genes BRCA2 (76 variants) and ATM (71 variants). Genes with the most presence in the population were ATM (111 carriers), BRCA2 (105 carriers) and CHEK2 (100 carriers).

Conclusion: We identified a moderate amount of healthy individuals carrying variants in cancer related genes. These individuals have a high-risk of developing cancer and can benefit from a preventive cancer detection, have a regular screening or preventive treatment.

Awareness of the result may reduce any stress and anxiety that comes from not knowing through an appropriate genetic counselling programme.

References:

Grants:

Conflict of Interest: Cristian Perez-Garcia IGENOMIX, Jordi Perez-Lopez IGENOMIX, Daniel Sanchez-Valero IGENOMIX, Rocío García-Jimenez IGENOMIX, Gemma Cartagena IGENOMIX, Eva Barroso IGENOMIX, Marina Martínez-Matilla IGENOMIX, Sandra García-Herrero IGENOMIX, Javier Garcia Planells IGENOMIX.

P13.077.C Triple-negative breast cancer in association with RAD51C pathogenic variants

Ana Blatnik1, Ksenija Strojnik1, Marta Banjač1, Vida Stegel1, Vita Setrajčic Dragos2, Petra Šker1, Gasper Klancar3, Srdjan Novakovic2, Mateja Klarić1

1Institute of Oncology Ljubljana, Department of Oncological Clinical Genetics, Ljubljana, Slovenia; 2Institute of Oncology Ljubljana, Department of Molecular Diagnostics, Ljubljana, Slovenia.

Background/Objectives: RAD51C pathogenic variants (PV) are associated with high risk of ovarian cancer (OC) in female carriers.

The association with breast cancer (BC) is less well established, but there is some evidence triple-negative disease is more common in RAD51C positive patients. The aim of our study was to investigate the tumour and mutation spectrum in Slovenian RAD51C carriers, with an emphasis on a possible association with specific BC subtypes.

Methods: In order to identify carriers of RAD51C PV tested at the Institute of Oncology Ljubljana, we analysed records for 5170 individuals who underwent genetic testing due to personal or family history of cancer using TruSight Cancer/TruSight Hereditary Cancer panels between January 2016 and December 2021. We then analysed personal and family history data obtained from medical records and the National registry of tested individuals from cancer families for our RAD51C PV carriers.

Results: We identified 22 RAD51C PV carriers from 17 different families, 20 female and 2 male. The majority of our probands (13/17) had a positive personal or family history of BC. Of the 20 female carriers, 10 had OC (aged 46-80, median 59.5) and 10 had BC (aged 34-65, median 50), with two carriers developing both BC and OC. Five carriers developed triple-negative BC (aged 36-65, median 53). Of our 17 families, 14 carried the c572-1G>C p.? PV, which appears to be a founder variant in the Slovenian population.

Conclusion: Triple-negative BC is disproportionately frequent in our RAD51C carriers and OC appears to be rare before age 50.

References:

Grants:

Conflict of Interest: None declared.

P13.078.D Alternative classification of pediatric oncology patients based on gut microbiota biomarker prediction with machine learning

Katarina Soltysová1,2, Sara Sandzikova2, Simona Ugrayova2, Ivan Hric2, Gabor Beke3, Ivan Mikula2, Adela Penesova5, Viktor Biliik5, Marian Grendár3, Lubos Klucar4, Peter Svec5, Alexandra Kolenová2

1Comenius University Science Park, Bratislava, Slovakia; 2Comenius University in Bratislava, Faculty of Natural Sciences, Department of Microbiology and Virology, Bratislava, Slovakia; 3Comenius University in Bratislava, Faculty of Physical Education and Sport, Department of Biological and Medical Science, Bratislava, Slovakia; 4Institute of Molecular Biology, Slovak Academy of Sciences, Bratislava, Slovakia; 5The Hebrew University, Faculty of Medicine, The Concern Foundation Laboratories at The Lautenberg Center for Immunology and Cancer Research, Israel-Canada Medical Research Institute, Jerusalem, Israel; 6Institute of Clinical and Translational Research Biomedical Center, SAS, Bratislava, Slovakia; 7Comenius University in Bratislava, Jessenius Faculty of Medicine, Biomedical Center Martin, Martin, Slovakia; 8Comenius University and National Institute of Children’s Diseases, Department of Pediatric Hematology and Oncology, Bratislava, Slovakia.

Background/Objectives: Pediatric oncology patients suffer not only from the disease itself but also from additional complications (febrile neutropenia, GvHD, gastrointestinal problems) associated with changes in gut microbiome composition. However, it is still not elucidated whether individual bacterial genera or higher taxonomical level group is responsible for functional differences.

Methods: 16S rRNA gene sequencing (V1-V9) of gut microbiome from feces was carried out on Illumina MiSeq (2x300bp). Healthy controls (n = 14) and pediatric oncology patients (n = 30), with prevailing ALL were involved. Pre-processing, taxonomic classification and diversity analysis were performed with QIIME2 Core 2020.8./DADA2/BLAST+. Functional profiles were predicted in R with Tax4Fun2 package. Statistical analysis was carried out using SPSS, machine-learning (ML) using...
randomForest SRC analysis and elastic network ML for biomarker discovery and obtaining ROC curve.

**Results:** The ML analysis discriminated healthy individuals from oncology patients receiving chemotherapy using joint predictors Blautia, Oscillibacter, Parabacteroides, Eubacterium hali group, Enterococcus, Streptococcus (AUC 0.962). We have identified significantly discriminant Firmicutes to Bacteroidetes ratio in oncology patients in conditioning regime before transplantation (allo-HSCT). The dominant effect of the therapy was supported by the best joint predictors – Enterococcaceae, Lachnospiraceae, Clostridiaceae and Lactobacillaceae (AUC 0.86) discriminating between children with ALL from oncology department and from Transplantation Unit, associated mainly but not exclusively with metabolism of cofactors and vitamins, glycan biosynthesis and genetic information processing.

**Conclusion:** We have shown the highest importance of family level gut microbiota structure in pediatric oncology patients as biomarkers that can predict the loss of gut microbiota function.

**References:**

**Grants:** APV17-0099, ITMS2014-1-3103021D075.

**Conflict of Interest:** None declared.

### P13.079.A Clinical, splicing and functional analysis of a predicted truncating BRCA1 variant that alters splicing, increasing an in-frame Δ11q naturally occurring isoform

**Lidia Feliciabaldò**1,2,3, Joanna Domènéch-Vivó4, Mireia Menéndez5, Alba Llop-Guevara5, Eva Tomoro6, Alejandro Moles-Fernández6, Montserrat de Miguel7, Miriam Potrony7, Marta Santamaria8,9,10, Alba Llop-Guevara5, Eva Tornero1, Alejandro Moles-Fernández4, tella, Spain;10Centro de Investigación en Red de Enfermedades Raras Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain; 8Fundación Pública Galega Medicina Xenómica (FPGMX), Genètica Molecular, Centre de Diagnòstic Biomèdic (CDB), Barcelona, Clínic de Barcelona, Genètica Molecular, Servei de Bioquímica i Cáncer Hereditario, Servei de Bioquímica, Madrid, Spain;7Hospital Universitario 12 de Octubre, Laboratorio Diagnóstico Genético de Cáncer Hereditario, Servicio de Bioquímica, Madrid, Spain; 3Hospital Clínic de Barcelona, Genética Molecular, Servei de Bioquímica i Genètica Molecular, Centre de Diagnòstic Biomèdic (CDB), Barcelona, Spain; 4Fundación Pública Galega Medicina Xenómica (FPGMX), SERGAS, Santiago de Compostela, Spain; 5Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain; 6Hospital Universitari 12 de Octubre, Laboratorio Diagnóstico Genético de Cáncer Hereditario, Servicio de Bioquímica, Madrid, Spain; 7Hospital Universitari 12 de Octubre, Laboratorio Diagnóstico Genético de Cáncer Hereditario, Servicio de Bioquímica, Madrid, Spain; 8Hospital Universitario 12 de Octubre, Laboratorio Diagnóstico Genético de Cáncer Hereditario, Servicio de Bioquímica, Madrid, Spain; 9Hospital Universitario 12 de Octubre, Laboratorio Diagnóstico Genético de Cáncer Hereditario, Servicio de Bioquímica, Madrid, Spain; 10Hospital Universitario 12 de Octubre, Laboratorio Diagnóstico Genético de Cáncer Hereditario, Servicio de Bioquímica, Madrid, Spain.

**1Catalan Institute of Oncology (ICO), Hereditary Cancer Program, L’Hospital de Llobregat/Girona/Badalona, Spain; 2IDIBELL, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), L’Hospital de Llobregat, Spain; 3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; 4Vall d’Hebron Institute of Oncology (VHIO), Hereditary Cancer Genetics Group, Barcelona, Spain; 5Vall d’Hebron Institute of Oncology (VHIO), Experimental Therapeutics Group, Barcelona, Spain; 6Hospital Universitario 12 de Octubre, Laboratorio Diagnóstico Genético de Cáncer Hereditario, Servicio de Bioquímica, Madrid, Spain; 7Hospital Clínic de Barcelona, Genética Molecular, Servei de Bioquímica i Genètica Molecular, Centre de Diagnòstic Biomèdic (CDB), Barcelona, Spain; 8Fundación Pública Galega Medicina Xenómica (FPGMX), SERGAS, Santiago de Compostela, Spain; 9Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain; 10Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain; 11ALTHAIA - Xarxa Assistencial Universitària Manresa, Manresa, Spain; 12Vall d’Hebron Hospital Universitari, Medical Oncology Department, Barcelona, Spain; 13Vall d’Hebron Hospital Universitari, Area of Clinical and Molecular Genetics, Barcelona, Spain.

**Background/Objectives:** Protein truncating variants are expected to produce loss of function by nonsense-mediated decay of the transcript and/or absence of critical domains. However, spliceogenic variants can rescue some function by causing in-frame deletions. Here we studied clinical, splicing, and functional effects of BRCA1 variant c.791_794del.

**Methods:** Cancer history was retrieved from available carrier families. Carrier RNAs underwent splicing analysis by Sanger sequencing and single-nucleotide primer extension. Homologous recombination repair (HRR) was determined by immunofluorescence-based detection of RAD51 and BRCA1 nuclear foci in tumours from carriers and a patient-derived xenograft (PDX).

**Results:** The variant was detected in 12 families with one or more cases of breast/ovarian cancer (BC/OC), most carrying also pathogenic variants in other BC/OC genes or showing poor variant segregation with disease or milder-than-expected phenotype. According to splicing in-silico predictions, c.791_794del increases the strength of a cryptic donor site used to generate the Δ11q, a BRCA1 naturally occurring in-frame splicing event. RNA analysis in blood of three carriers and one PDX’s tumour revealed that carrier alleles generate almost exclusively Δ11q transcripts. Tumour samples from one carrier and its PDX presented a RAD51 score compatible with a proficient HRR, supported by the presence of BRCA1 foci.

**Conclusion:** These results suggest that BRCA1 c.791_794del confers a lower cancer risk than classical BRCA1 truncating variants, driven by an increased Δ11q in-frame transcript. Further studies will help to fully ascertain its associated cancer risk.

**References:**

**Grants:** P119/00553-P119/01303, ISCIII, Ministerio de Ciencia e Innovación, funded by FEDER funds—a way to build Europe; AGAURFI-DGR2020.

**Conflict of Interest:** None declared.

### P13.081.C Driver genes for chronic lymphocytic leukemia can be affected not only by mutations but also by complex genomic rearrangements

**Karla Plešová1,2,3, Eva Ondrousková1, Natalie Kazdová1, Tobias Rausch2, Sárka Pavlová1,2, Jana Kotasová2,3, Kristýna Zavacká2,3, Jitka Malíková1,2, Karol Páč2, Jakub Hyný3, Michael Doubek1,2,3, Marie Jarosová1,2, Valdimir Beneš1, Sarka Pospíšilova1,2,3

1University Hospital Brno and Medical Faculty, Masaryk University, Department of Internal Medicine - Hematology and Oncology, Brno, Czech Republic; 2Central European Institute of Technology, Masaryk University, Brno, Czech Republic; 3University Hospital Brno and Faculty of Medicine, Masaryk University, Institute of Medical Genetics and Genomics, Brno, Czech Republic; 4European Molecular Biology Laboratory, Genomics Core Facility, Heidelberg, Germany.

**Background/Objectives:** In chronic lymphocytic leukemia (CLL), genomic complexity (GC) serves as an important prognostic marker and a high number of chromosomal defects (≥5; high-GC) is associated with an unfavorable prognosis. High-GC can be induced by chromothripsis and/or related mechanisms (high-GC-cth) (PMID: 34900721). This study aimed to characterize in detail high-GC-cth in CLL.

**Methods:** We analyzed 327 samples from 201 CLL patients using genomic arrays (CytoScanHD, ThermoFisher Sci.), 97 patients (48%) were tested at multiple time-points. iPSH for the most recurrent chromosomal changes in CLL and/or stimulated cytogenetics data were available for the cohort. Selected samples were subjected to WGS analysis.

**Results:** High-GC-cth was identified in 52 samples (16%) from 38 patients (19%). High-GC-cth occurred in initial samples of 20 cases and persisted during the follow-up in all nine patients tested repeatedly. In contrast, high-GC-cth newly developed at later time-points in 18 cases due to clonal evolution. Consistent with published data, high-GC-cth associated with TP53 gene aberrations (deletions/ mutations; 30 cases). In five of the remaining eight TP53-intact patients, high-GC-cth was linked to ATM gene aberrations. Chr6 was most frequently affected by high-GC-cth (10 cases), followed by chr8 and chr9 (eight cases each). Cytogenetics and WGS revealed additional chromosomes and loci involved in genomic rearrangements indicated by arrays. Genomic breakpoints occurred in the vicinity of genes known to be mutated in CLL, suggesting additional mechanisms of their activation or inactivation.
Conclusion: Our detailed analysis reveals another layer of genomic alterations shaping functions of genes essential for CLL phenotypes.

References:

Grants: MH-CZ_AZV_NU21-08-00237, MH-CZ_RVO_65269705, MEYS-CS_MUNI/Á/1330/2021.

Conflict of Interest: None declared.

P10.082.D Omic data integration for hereditary susceptibility to colorectal cancer

Anaël Lopez-Novo1, Andres Dacal2, David Remedios3, Joaquin Cubiella4, Maria Victoria Alvarez Sanchez4, Maria Jesús Ladra-González4, Fernando Fernandez-Lopez2, Ana Alvarez-Castro4, Jose Manuel Cameselle-Tejeiro5, Miriam Cuatrecasas4, Francesc Balamguer4, Sergi Castellvi-Bel9, Ceres Fernandez-Rozadilla1, Clara Ruiz-Ponte1,10

1Fundacion Publica Galega de Medicina Xenomica, Instituto de Investigacion Sanitaria de Santiago (IDIS), Grupo de Medicina Xenomica-Universidade de Santiago de Compostela, Santiago de Compostela, Spain; 2Servicio de Digestivo, Hospital Universitario Lucus Augusti, Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Lugo, Spain; 3Servicio de Digestivo, Complejo Hospitalario Universitario de Ourense, Centro de Investigacion Biomédica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd), Ourense, Spain; 4Servicio de Digestivo, Complejo Hospitalario de Pontevedra, Pontevedra, Spain; 5Servicio de Cirugia Digestiva-Unidad de Coloproctologia, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain; 6Servicio de Digestivo, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain; 7Servicio de Anatomia Patologica, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain; 8Servicio de Anatomia Patologica, Instituto D'Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigacion Biomédica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd) and Tumor Bank-Biobank, Hospital Clinic, Barcelona, Spain; 9Gastroenterology Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERERH), Hospital Clinic, Universitat de Barcelona, Barcelona, Spain; 10Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), Santiago de Compostela, Spain.

Background/Objectives: The identification of new colorectal cancer (CRC) susceptibility genes through whole exome sequencing (WES) has not been as successful as expected, possibly due to the genetic heterogeneity of CRC. Our aim is to identify novel candidate susceptibility genes by integrating WES and RNA-seq data.

Methods: WES and RNA-seq were performed on paired normal-tumor tissue from a phenotypically homogeneous cohort of 19 MMR-proficient CRC patients. Germline calling (Haplotype-Caller) and annotation (ANNOVAR) were carried out on WES, RNA-seq data, as well as GTex data as a control group. Somatic calling (MuTect2) and annotation (ANNOVAR) were also carried out on WES data. Aberrant expression, aberrant splicing and monoallelic expression analysis were performed following DROP pipeline (1). SKATO were carried out on our WES data and using 267 non-cancer individuals from the MGP Spanish (EGAC0001000222) as controls.

Results: None of the patients harbor germline pathogenic variants in already described Mendelian genes associated to hereditary CRC syndromes. We did not find rare variant (gnomAD <1%) recurrence in genes in our CRC cohort. At the individual level, RNA-seq expression analysis together with WES results reported some candidate genes previously involved in different types of cancers, metabolism of different metabolites or gastrointestinal physiology.

Conclusion: These results show the molecular heterogeneity underlying CRC in a phenotypically homogeneous cohort. The use of RNA-seq together with WES allows prioritizing variants at the individual level, increasing the probabilities to identify new CRC predisposition genes. As a result, a more personalized genetic diagnostic could be achieved.

References: 1. PMID: 33462443.

Grants: ISCIII and FEDER funds P117/00509.

Conflict of Interest: None declared.

P10.083.A Somatic variant landscapes of solid papillary and comedo subtypes of canine mammary tumors from a single dog

Sruthi Hundi1,2, Marjo Hytönen1, Hannes Lohi1

1University of Helsinki, Helsinki, Finland.

Background/Objectives: Breast cancer (BC) is still the most common cancer reported in women and mammary tumor (MT) is also the most common malignancy in intact female dogs. The key goal of this research is to study two rare and less explored subtypes of canine mammary tumor, i) solid papillary subtype and ii) comedo subtype and compare the findings with human discoveries.

Methods: An intact female dog diagnosed with simple invasive carcinoma of these two sub-type was selected and cell populations from respective tumor sites and normal lobular cells were isolated from the using the method of laser pressure catapulting microdissection. Libraries of the cells isolated were prepared with PicoPLEX tool kit and whole genome sequenced with about 15X coverage. Data was aligned to latest canFam4, somatic variants were called and analyzed.

Results: The number of non-silent mutations is sixfold higher in comedo sub-type than in solid papillary sub-type. Genes related to MAPK, mTOR and NF-kappaB signaling pathways and Adherens junctions were enriched in Solid papillary. Genes related to ECM receptor interaction, focal and cell adhesion, PI3K-AKT and cGMP-PKG signaling pathways were enriched in Comedo.

Conclusion: The tumor mutation burden co-relates with the already known fact in humans that comedo carcinoma is more pathogenic than solid papillary sub-type of carcinoma. The presence of variants in cell proliferation signaling pathways and junction is supporting the invasive nature of the tumor which was identified as HER+ and E Cadherin positivity.

References: PMIDs: 32680987; 33262909.

Grants: Partially supported by Cancer Foundation Finland.

Conflict of Interest: None declared.

P10.084.B Pan-cancer identification of signatures of survival-associated prognostic long non-coding RNAs

Lee Jin Lim1, Yu Jin1,2, Klara Chew3, Ashley Thenpandiyan3, Henry Yang3, Samuel Chong4, Caroline Lee1,2,5

1National University of Singapore, Biochemistry, Singapore, Singapore; 2National Cancer Centre, Cellular and Molecular Research, Singapore, Singapore; 3National University of Singapore, Singapore, Singapore; 4National University of Singapore, Pediatrics, Singapore, Singapore; 5Duke-NUS Medical School, Cancer and Stem Cell Biology, Singapore, Singapore.

Background/Objectives: Long non-coding RNAs (IncRNAs), which play key roles in modulating gene expression, are frequently
dysregulated in cancers. Their prognostic and therapeutic value currently remains unclear. Here, we aim to identify potentially actionable, survival-associated (PAS) lncRNAs as possible prognostic biomarkers in multiple cancers or therapeutic targets.

**Methods:** Survival-associated (SA) lncRNAs that are correlated with at least one SA-gene (|R| ≥ 0.8) in the same cancer and survival-endpoint represent PAS-IncRNAs. Profiles of IncRNAs, miRNAs and mRNAs of 33 cancer types from The Cancer Genome Atlas were associated with four survival endpoints (Overall survival (OS), Disease-free survival (DFS), Progression-free interval (PFI), Diseases free interval (DFI)). PAS-IncRNAs that are associated with ≥ 1 survival-endpoint in ≥ 3 different cancer-types represent potential pan-cancer prognostic biomarkers, while nodal PAS-IncRNAs in PAS-(lncRNA-miRNA-mRNA) co-expression network associated with ≥ 100 SA-mRNAs represent promising therapeutic targets. Pathways modulated by the SA-genes of these PAS-IncRNAs are then determined.

**Results:** Two prognostic pan-cancer PAS-IncRNAs capable of distinguishing between patients with good and bad prognosis in ≥ 3 cancers were identified. Two nodal PAS-IncRNAs that potentially modulate the expression of ≥ 100 SA-mRNAs in cancer-associated pathways through miRNAs in Uveal Melanoma were also identified.

**Conclusion:** These prognostic PAS-IncRNAs may facilitate the design of potential clinically useful biomarkers and therapeutic targets.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P13.085.C Insights from multigene panel testing in non-Ashkenazi breast cancer patients – carrier rates and variant classification in a genetically diverse population**

**sari Lieberman**1, Omer Murik2, Fouad Zahdeh2, Rachel Beer1, Pinhas Renbaum3, Michal Barzily4, tehilah klopstock5, Orit Freireich6, Malka BenUziyahu7, ariela tomer8, David Zeevi2, Oded Olsha3, Hadar Goldvaser4,5, Tal Hadar6,7, Shani paluch-shimon7,8, Shelley Shoval9, Eitan Friedman10,11, amnon lahad12,13, Rinat Bernstein-Molho1, Michal Barzily1, tehila klopstock1, Orit Freireich1, Malka BenUziyahu1, ariela tomer1, David Zeevi2, Tzvia Mann2, Oded Olsha3, Hadar Goldvaser4,5, Tal Hadar6,7, Shani paluch-shimon7,8, Shelley Shoval9, Eitan Friedman10,11, amnon lahad12,13, Rinat Bernstein-Molho1.

1 Shaare Zedeck Medical Center, Medical Genetics Institute, Jerusalem, Israel; 2 Shaare Zedeck Medical Center, Translational Genomics Lab, Medical Genetics Institute, Jerusalem, Israel; 3 Shaare Zedeck Medical Center, Department of Surgery, Jerusalem, Israel; 4 Shaare Zedeck Medical Center, Department of Medical Oncology, Jerusalem, Israel; 5 Hebrew University, the Faculty of Medicine, Jerusalem, Israel; 6 Hadassah Hebrew University Medical Center, Department of Breast Surgery, Jerusalem, Israel; 7 Hebrew University, Faculty of Medicine, Jerusalem, Israel; 8 Hadassah Hebrew University Medical Center, Breast Oncology, Jerusalem, Israel; 9 Sheba Medical Center, Oncology Division, Tel Hashomer, Ramat-Gan, Israel; 10 Sheba Medical Center, The Meiray Center High Risk Clinic, Tel Hashomer, Ramat-Gan, Israel; 11 Tel Aviv University, Sackler School of Medicine, Tel Aviv, Israel; 12 Hebrew University, Department of Family Medicine, Jerusalem, Israel; 13 Clalit Health Services, Jerusalem, Israel; 14 Sheba Medical Center, Department of Medical Oncology, Tel Hashomer, Ramat-Gan, Israel.

**Background/Objectives:** There is limited information on the landscape of inherited breast cancer (BC) in non-Ashkenazi Jews. This heterogeneous, little tested population can offer insights into novel variants in known BC-predisposition genes.

**Methods:** In 2015-2021 consecutively diagnosed non-Ashkenazi BC patients underwent multigene panel testing (MGPT). MGPT was also offered to a control group of unaffected non-Ashkenazi participants.

**Results:** Genetic testing was performed in 751 affected and 810 unaffected women. BRCA1/2 pathogenic variants (PV) were identified in 23 (3.3%) affected vs. 5 (0.6%) unaffected women (P < 0.0002). Only 3 BRCA1 PVs were recurrent. PVs in other genes were found in 30 (4.8%) affected vs. 8 (1%) unaffected women. This included PVs in ATM, CHEK2, BRIP1, TP53, MRE11, FANCM, NBN, PALB2 and PTEN.

9490 rare variants (<0.01 MAF) were observed in 28 genes: 695 (7.3%) exonic, 8789 (92.7%) non-coding. 541 exonic variants were previously in ClinVar. Using frequencies from this cohort enabled downgrading of 15 ClinVar variants of uncertain significance (VUSs) to Benign, based on MAF >0.01 among unaffected low-family history (FH) women. MAF by sub-ethnicity downgraded another 28 VUSs. Among non-coding variants, 68 were significantly more common in affecteds with significant FH, suggesting possible pathogenicity. Conversely, 52 non-coding variants were classified as benign based on higher frequency in controls.

**Conclusion:** Non-Ashkenazi women exhibit expected rates of PVs in known breast cancer genes, but low rates in affected with substantial FH. Genetic analysis in diverse populations can contribute to variant classification, especially of non-coding variants whose interpretation by standard tools is limited.

**References:**

**Grants:** BCRF-095.

**Conflict of Interest:** sari Lieberman Modest, AstraZenca Israel, Omer Murik: None declared, Fouad Zahdeh: None declared, Rachel Beer: None declared, Pinhas Renbaum: None declared, Michal Barzily: None declared, tehilah klopstock: None declared, Orit Freireich: None declared, Malka BenUziyahu: None declared, ariela tomer: None declared, David Zeevi: None declared, Tzvia Mann: None declared, Oded Olsha: None declared, Hadar Goldvaser: None declared, Tal Hadar: None declared, Shani paluch-shimon: None declared, Shelley Shoval: None declared, Eitan Friedman: None declared, amnon lahad: None declared, Rinat Bernstein-Molho: None declared, ephrat lahad: None declared.

**P13.086.D Expression of ST6GAL1 protein in thyroid cancers**

**Ivana Gunja**1, Benjamin Benzon1, mirjana babic leko1, Nikolina Pleic1, Valdi Pešutić Pisac1, Ana Barić1, ante punda1, Ozren Polasek1, Katarina Vukojević1, tatijana zemunik1

1 University of Split School of Medicine, split, Croatia; 2 University Hospital of Split, split, Croatia.

**Background/Objectives:** ST6 β-galactoside α2,6-sialytransferase 1 (ST6GAL1) is known as a cancer-associated glycosyltransferase. It plays important role in tumor progression where elevated expression of ST6GAL1 has been observed in several cancers, but not in thyroid cancers. Previously, our GWA studies identified that gene encoding ST6GAL1 was associated with plasma thyroglobulin (Tg) levels. In thyroid pathologies, Tg levels are altered, so the aim of the study was to analyze the expression of ST6GAL1 protein in papillary thyroid cancer (including follicular variant and microcarcinoma) and follicular thyroid cancer.

**Methods:** We performed immunohistochemical analysis using human thyroid tissue and analysed expression levels of ST6GAL1 protein in well-differentiated thyroid cancers in comparison to normal thyroid tissue. We examined 9 papillary thyroid carcinomas (PTC), 5 with classical papillary architecture and 4 follicular variants of papillary thyroid carcinoma (FVPTC), 3 microcarcinoma, and 9 follicular thyroid carcinomas (FTC).

**Results:** In human thyroid tumors, ST6GAL1 protein levels were higher in malignant thyroid tumors in comparison to normal thyroid tissue. The analysis showed high ST6GAL1 expression level in FVPTC (fold increase = 14.98, p = 0.0086) compared to normal
thyroid tissue, followed by classic PTC (fold increase = 7.55, p = 0.0093) and FTC (fold increase = 3.37, p = 0.0008). Microcarcinomas had the expression levels closest to control (fold increase = 2.38, p = 0.0055).

**Conclusion:** The results of this study showed that ST6GAL1 expression, compared to normal thyroid tissue, was increased in all examined thyroid tumors, with the highest expression in FVPTC.

**References:**

**Grants:** Research was funded by the Croatian Science Foundation, no. 2593.

**Conflict of Interest:** None declared.

**P13.087.A Germline intergenic duplications at Xq26.1 cause an inherited basal cell carcinoma susceptibility syndrome**

Yanshan Liu, Siddharth Banka, Yingzhi Huang, Jonathan Hardman, Derek Pye, Antonio Torrello, Glenda Beamam, Marcelo G. Kazaniez, Martin Baker, Carlo Ferrazzano, Chenfu Shi, Gisela Fischer, Zosia Miedzybrodzka, Faris Abuahra, Albert Ruebben, Sara Cuverino, Jamie Ellisford, Miriam Smith, D. G. Evans, Lilzelle Weppner-Paren, Maurice van steensel, Iskander chaudhry, D. Chas Mangham, John Lear, Ralf Paus, Jorge Jesus, Madrid, Spain; University of Pennsylvania, Philadelphia, USA; School of Medicine, University of Pennsylvania, Philadelphia, USA; Hospital Infantil Universitario Niño Jesús, Madrid, Spain; University of Pennsylvania, Philadelphia, USA; University of Manchester, Manchester Centre for Genomic Medicine, Manchester, United Kingdom; Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; University of Manchester, Manchester Centre for Genomic Medicine, Manchester, United Kingdom; Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Kings College London, London, United Kingdom; University of Manchester, Centre for Dermatology Research, Manchester, United Kingdom; Hospital Infantil Universitario Niño Jesús, Madrid, Spain; University of Pennsylvania, Philadelphia, USA; University of Manchester, Manchester Centre for Genomic Medicine, Manchester, United Kingdom; University of Manchester, Manchester, United Kingdom; University Hospital Maastricht, Maastricht, Netherlands; Odense University, Odense, Denmark; University of Freiburg, Freiburg, Germany; University of Aberdeen, Aberdeen, United Kingdom; Zaandam Medical Center, Zaandam, Netherlands; University Hospital of RWTH Aachen, Aachen, Germany; University of Manchester, Manchester, United Kingdom; Jeroen Bosch Hospital, Jeroen, Netherlands; Agency for Science, Technology and Research (A*STAR), Singapore, Singapore; The Royal Liverpool University Hospital, Liverpool, United Kingdom; Salford Royal Hospital, Salford, United Kingdom; University Medical Center Göttingen, Göttingen, Germany; University of Manchester, Manchester Centre for Genomic Medicine, Manchester, United Kingdom.

**Background/Objectives:** Bazex-Dupré-Christol syndrome (BDCS; MIM301845) is a rare X-linked dominant genodermatosis characterized by follicular atrophoderma, congenital hypotrichosis and multiple basal cell carcinomas (BCCs). Previous studies have linked BDCS to an 11.4 Mb interval on chromosome Xq25-27.1 and characterized by follicular atrophoderma, congenital hypotrichosis and multiple BCCs. To maximize success, we applied to exome sequencing data a specific strategy for variant prioritization, followed by gene burden tests for the selected genes.

**Methods:** Our variant prioritization strategy for the identification of hereditary CRC genes from exome sequencing data was based on different parameters, including, among standard criteria, the selection of predicted pathogenic variants affecting genes involved in pathways relevant in hereditary cancer, colorectal carcinogenesis, and/or acting as cancer drivers. The strategy was applied to exome sequencing data from 24 CRC-affected individuals from 15 families with CRC aggregation and/or early-onset CRC diagnoses. The selected genes were next studied in 465 additional familial CRC patients. The results, together with germline sequencing data from publicly available datasets of CRC and population controls, were included in gene-based burden analyses.

**Results:** We identified 20 candidate genes, all affecting TGF-beta or Wnt-pathways, six of which showed positive association with CRC in gene burden tests. We are currently performing the characterization of the candidate genes and carrier families, including the analysis of tumor molecular features.

**Conclusion:** The application of a well-designed variant prioritization strategy to exome sequencing data from familial/early-onset CRC patients, followed by gene burden tests including data from open-access repositories, facilitated the identification of candidate genes potentially involved in CRC predisposition.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P13.088.B Identification of new hereditary colorectal cancer candidate genes**

Mariona Terradas, Isabel Quinatana, Noemi Gonzalez-Abuin, Gemma Aiza, Paula Marceli, Fatima Marin, Pillar Mur, Matilde Navarro, Joan Brunet, Gabriel Capelló, Laura Valle

1IDIBELL Institut d’Investigació Biomèdica de Bellvitge, L’Hospitalet de Llobregat, Spain; 2Catalan Institute of Oncology, L’Hospitalet de Llobregat, Spain; 3Ico Institut Català d’Onkologia, Girona, Spain.

**Background/Objectives:** Despite the multiple initiatives to identify new hereditary non-polyposis colorectal cancer (CRC) genes, their yield has been extremely low. In the past decade, only RPS20, which explains less than 0.1% of familial CRC cases, has been unequivocally linked to the disease. To maximize success, we applied to exome sequencing data a specific strategy for variant prioritization, followed by gene burden tests for the selected genes.

**Methods:** Our variant prioritization strategy for the identification of hereditary CRC genes from exome sequencing data was based on different parameters, including, among standard criteria, the selection of predicted pathogenic variants affecting genes involved in pathways relevant in hereditary cancer, colorectal carcinogenesis, and/or acting as cancer drivers. The strategy was applied to exome sequencing data from 24 CRC-affected individuals from 15 families with CRC aggregation and/or early-onset CRC diagnoses. The selected genes were next studied in 465 additional familial CRC patients. The results, together with germline sequencing data from publicly available datasets of CRC and population controls, were included in gene-based burden analyses.

**Results:** We identified 20 candidate genes, all affecting TGF-beta or Wnt-pathways, six of which showed positive association with CRC in gene burden tests. We are currently performing the characterization of the candidate genes and carrier families, including the analysis of tumor molecular features.

**Conclusion:** The application of a well-designed variant prioritization strategy to exome sequencing data from familial/early-onset CRC patients, followed by gene burden tests including data from open-access repositories, facilitated the identification of candidate genes potentially involved in CRC predisposition.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P13.091.A Validation of genotype array analysis for the assessment of homologous recombination deficiency (HRD) in epithelial ovarian cancer**

Simon Schnaider, Esther Schamschula, Johannes Zschocke, Heidi Fiegli, Daniel U. Reimer, Alain Zeimet, Katharina Wimmer

**Background/Objectives:** Homologous recombination deficiency (HRD) is a genetic alteration associated with increased sensitivity to platinum-based chemotherapy. The routinely used multiplex ligation-dependent probe amplification (MLPA) assay for HRD screening in ovarian cancer is highly sensitive but has a low specificity. The use of microarray comparative genomic hybridization (aCGH) as well as fluorescent in situ hybridization (FISH) may improve HRD assessment in clinical practice.

**Methods:** We studied aCGH and FISH on cell lines with well-characterized HRD status. We compared the results of both methods and the sensitivity of the FISH assay for detection of homozygous deletions.

**Results:** We found that aCGH and FISH were highly concordant for the detection of deletions. FISH was more sensitive than aCGH for homozygous deletions, allowing the detection of additional cases of HRD.

**Conclusion:** The use of FISH as a supplementary assay for HRD screening in ovarian cancer can improve the accuracy of HRD assessment.

**References:**

**Grants:**

**Conflict of Interest:** None declared.
Background/Objectives: Genomic instability caused by homologous recombination deficiency (HRD) - in 40-50% of cases due to BRCA1/2 pathogenic variants (PVs) - is a predictive biomarker for the response of different tumors to PARP-inhibitor therapy. In epithelial ovarian cancer (EOC) it is also considered predictive for sensitivity of platinum-based therapies. Currently, diagnostic genomic instability testing is mostly based on the HRD-score by Myriad Genetics.

Methods: To determine HRD positivity we examined genome-wide copy number variation and loss of heterozygosity (LOH) by genotyping 89 ovarian cancers, 26 of which contained a BRCA1/2 PV, using the Global Screening Array (GSA-24 v3.0; Multi-Disease Content; Illumina). Data analysis was performed with Illumina GenomeStudio 1.6.3 (Genotyping Analysis Module) and NxClinical (Biodiscovery, SNP-FASST2-Segmentation Algorithm) software. For quantification of HRD a LOH-score based on Swisher et al (2017; PMID: 27908594) and an Aneuploidy Normalized Telomeric Imbalance-Score (ANTI-Score, unpublished) were defined.

Results: The group of BRCA1/2-PV samples had significantly higher median scores than BRCA1/2-wildtype samples. LOH-score and ANTI-scores were concordant (r = 0.83) with each other and with the HRD-Score by Myriad (rLOH/MYRIAD = 0.82; rANTI/MYR-IAD = 0.86). Based on the lowest scores determined in the BRCA1/2-PV samples, we defined the threshold for HRD-positivity as LOH-score ≥14 and/or ANTI-score ≥6. Current investigations focus on the correlation of the scores with the clinical outcome and in depth sequence and epigenetic analysis of BRCA-wildtype samples with positive LOH/ANTI-scores. Applicability of our scores in other tumor entities are tested.

Conclusion: Rapid and reliable HRD analysis is possible with a standard genotyping array on DNA from native tumor tissue.

References:

Grants:

Conflict of Interest: None declared.

P13.093.C Study the role of miR200s in the estrogen response of ovarian cells

Éva Márton1, Alexandra Beke-Varga1, Andráss Penyige1,2, Bálint Nagy1, Lajos Széles1, Istvan Balogh1,3, Melinda Szilágyi1,3

1University of Debrecen, Department of Human Genetics, Debrecen, Hungary; 2University of Debrecen, Faculty of Pharmacy, Debrecen, Hungary; 3University of Debrecen, Department of Laboratory Medicine, Debrecen, Hungary.

Background/Objectives: Ovarian cancer is the fifth most common form of cancer death among women. Exposure to physiological estrogens or xenoestrogens (zearalenone or bisphenol A) increases the risk for cancer. We present a comprehensive study about the effect of estradiol (E2), zearalenone (ZEA) and bisphenol A (BPA) of human epithelial ovarian cell lines.

Methods: We applied the PEO1 (expressing Estrogen Receptor α and β) and A2780 (ERβ) human ovarian cell lines. We studied the effect of estrogens to cell proliferation, migration, miRNA and miR200s expression.

Results: E2, ZEA and BPA induced cell proliferation and migration in physiologically relevant doses in the case of the PEO1 cell line, that was accompanied with the induction of estrogen-responsive genes (GREB1, CA12, DEPTOR, RBBP8). However, A2780 did not respond to estrogens. The basal intracellular and cell-free expression of miR200s was higher in PEO1, which was accompanied with low ZEB1 and high E-cadherin expression. These miRNAs showed a rapid but intermittent upregulation in response to estrogens that was diminished by an ERα-specific antagonist (MPP). MiRNA expression of cell lysates correlated well with cell-free miRNA expression. The role of ERα in the regulation of the miR200B-miR200A-MIR429 locus was further supported by publicly available ChIP-seq data. MiRNA expression of cell lysates correlated well with cell-free miRNA expression.

Conclusion: MiR200s might be regulated by ERα. Cell-free miR200s might be applicable biomarkers for estrogen sensitivity of ovarian cells that support therapy selection in ovarian cancer (e.g. the application of estrogen blocking agents).

References:

Grants:

Conflict of Interest: None declared.

P13.094.D Small non-coding RNA profile in esophageal squamous cell carcinoma patients

Nazerke Satvaldina1, Aigul Sharip2, Mukhtar Tuleutau3, Ulan Kozhamkulov4, Yuri Zhukov5, Marat Omarov6, Askhat Molkengov7, Ainur Akilzhanova8, Ulykbek Kairov9, Baktybai Orabekov9, Saule Rakhimova9

1PI “National Laboratory Astana”, Genomic and personalized Medicine, Center for Life Science, Nur-Sultan, Kazakhstan; 2PI “National Laboratory Astana”, Bioinformatics and Systems Biology, Center for Life Science, Nur-Sultan, Kazakhstan; 3Multidisciplinary medical center of the akimat of Nur-Sultan city, Department of Surgery №2, Nur-Sultan, Kazakhstan.

Background/Objectives: Esophageal cancer (EC) is the sixth among number of new deaths for 36 cancer types worldwide according to GLOBOCAN 2020 statistics. Among two main types of EC esophageal squamous cell carcinoma (ESCC) is the most frequent type. Lack of significant biomarkers complicates ESCC differentiation in the early stages. Mounting evidence indicates that small non-coding RNAs, especially microRNAs may serve as a potential biomarker.

Methods: Two total RNA samples (#36 and #38) extracted from tumor tissue of the patients with pathologically confirmed T3N0M0 ESCC. Small RNA libraries were prepared using NEXTFLEX Small RNA-Seq kit v3 protocol (Perkin Elmer). The microRNA control was included.

Results: Analysis and identification of small types of RNAs on COMPRSA pipeline has been implemented.The results of the further sequences annotation analysis of the absolute values distribution of small RNA types in #36 and #38 samples are pmIRNA -538,473 piRNA – 2335, 1938, TRNA – 386, 364, snoRNA – 444, 420, snRNA – 318, 322 and circRNA – 62733, 39748 respectively.

Conclusion: Recent findings reveal that differently expressed small RNA levels have correlation with clinicopathological characteristics of ESCC patients, may affect to proliferation of ESCC cells and advanced progression of cancer. Sequencing of non-coding regions of the genome may shed a light to distinguish new significant diagnostic markers for esophageal squamous cell carcinoma.

References:

Grants: This work was supported by NU CRP grant 021220CRP2222 and grant MES RK #A09058660.

Conflict of Interest: None declared.
P13.096.B Two different pathogenic variants affecting the translational initiation of the BMPR1A gene result in different phenotypes in patients with hereditary polyposis syndrome

Marjia Staninova Stojevska¹, Nadica Matevska-Geshkovska¹, Elizabeta Krshteva Bazzhinkovsk¹, Biljana Grozdanovska², Nenad Mitrevski², Milco Panovski³, Aco Kostovski¹, Aleksandar Dimovski¹

¹Faculty of Pharmacy, Ss. Cyril and Methodius University, Center for Biomolecular Pharmaceutical Analyses, Skopje, Macedonia; ²Faculty of Medicine, Ss. Cyril and Methodius University, Institute of Radiotherapy and Oncology, Skopje, Macedonia; ³Faculty of Medicine, Ss. Cyril and Methodius University, University Clinic for Abdominal Surgery, Skopje, Macedonia; ⁴Faculty of Medicine, Ss. Cyril and Methodius University, University Children’s Hospital, Skopje, Macedonia; ⁵Macedonian Academy for Sciences and Arts, Research Center for Genetic Engineering and Biotechnology, Skopje, Macedonia.

Background/Objectives: Juvenile polyposis syndrome (JPS) and hereditary mixed polyposis syndrome (HMPS) share common pathogenesis related to the disruption of the BMP pathway.

Methods: Using NGS we detected two germline pathogenic variants located in the 5’region of the BMPR1A gene in two unrelated patients with familial history of polyposis; one novel splice variant (c.152-2A>G, p. = ?) and one rare, start loss variant (c.1A>G, p.Met1>Val). The carrier of the splice variant presented a more severe phenotype reminiscent of JPS (>150 juvenile polyps at 9yrs of age) compared to the other patient which had a phenotype resembling the HMPS (~10 polyps of variable type and size at age of 35). The RNA analysis of the splice site variant confirmed the presence of an aberrant transcript lacking whole exon 3, resulting in a loss of the normal initiation codon. Additionally, this transcript was expressed at a reduced level, probably due to decreased stability. While both transcripts can be expected to result in an absent protein product, in silico analyses showed that a possible identical protein can be constructed via a rescue of translational initiation by the downstream in-frame methionine at codon 29 in exon 4. This truncated protein would lead to the loss of the signal peptide (residues 1-23), which is necessary for normal membrane localization of the BMPR1A.

Conclusion: Since both variants potentially result in the same truncated protein, the different clinical presentation of the disease in these two families might be due to the differences in the BMPR1A levels produced by the two different mutant alleles.

References: None declared.

Conflict of Interest: None declared.

P13.099.A Our experience with von Hippel-Lindau syndrome in Bulgarian patients

Maria Glushkova¹, Liliana Grozdanova¹, Tihomir Todorov¹, Albena Todorova²

¹Genetic Medico-Diagnostic Laboratory “Genica”, Sofia, Bulgaria; ²Medical University of Sofia, Department of Medical Chemistry and Biochemistry, Sofia, Bulgaria.

Background/Objectives: Von Hippel-Lindau syndrome (VHL) is an inherited disorder characterized by hemangioblastomas (HBS) which can develop in the brain and spinal cord and provoke headaches, vomiting, weakness and ataxia. Retinal angiomas can occur in the light-sensitive tissue and may cause vision loss. In total 17 Bulgarian VHL cases were genetically screened for mutations in the VHL gene. One prenatal diagnosis was performed.

Methods: DNA was isolated from blood for all patients and from chorionic villus sampling of the pregnant woman for prenatal testing. The molecular genetic testing included direct Sanger sequencing and MLPA.

Results: Eight of the patients turned out to be positive for mutations in the VHL gene (47%). The detected mutations are four missense, a nonsense mutation, an indel, a small deletion and a large deletion. Prenatal testing was performed in a twenty-eight year old patient with multiple retinal HBS and vision loss. Her father had the same phenotype but milder clinical presentation. The detected mutation was a deletion of exon 3 of the VHL gene. The fetus did not carry the maternal mutation. All patients have clinical symptoms typical for VHL.

Conclusion: In total 47% of the VHL Bulgarian patients were genetically verified. The detected mutations in our patients are already known in the literature. The genetic testing in VHL gene and high-risk (hr) human papilloma viruses (HPVs) in PCa was assessed.

Methods: Sixty urine specimens obtained after digital rectal investigation (DRI) from suspected PCa patients and 55 “tru-cut” PCa biopsies were analyzed. DNA isolation, DNA sequencing, bisulfite conversion of DNA, PCR-based hybridization method, cytological preparations and staining were applied.

Results: Fluctuations in the molecular profile were registered in most of the patients: neoplastic GSTP1 allele, PCA3 strongly elevated expression/hyperexpression. A positive TMPRSS2-ERG fusion status was detected in 4 cases. hrHPVs were detected in 34% of urine specimens, where 96% of hrHPVs are: 16, 33, 35, 31, distributed in the subgroup with highest oncogenic potential. The frequency of hrHPVs in the control group is significantly lower (11%). The cytological examination on hrHPVs positive urine specimens showed inflammation, atrophy, partially viral cytopathic effect and neoplastic findings (high-grade prostatic intraepithelial neoplasia (PIN), nuclear margination, tumor diathesis).

HPVs were detected in 9% of PCa “tru-cut” biopsies: low-risk HRVs 42, 54/55; hrHPVs 18, 51. Histological examination showed a presence of acinar adenocarcinoma in combination with benign prostatic hyperplasia (BPH), PIN and inflammation.

Conclusion: The selected molecular panel is useful for early diagnostics and molecular profiling of PCa. Long-term active infection with hrHPVs in prostate contributes to intraprostatic inflammation, precancerous lesions and BPH, later to malignancy.

References: None declared.

Conflict of Interest: None declared.
provides the possibility for adequate genetic counselling, family planning and prenatal diagnostics in affected families.

References: Glushkova M. et al. 2018 Int J Neurosci. 128(2):117-124.

Grants: Conflict of Interest: None declared.

P13.100.B microRNA profile in Bulgarian laryngeal squamous cell carcinoma

Gergana Stancheva1, Silva Kyurkchiyan1, Veronika Petkova1, Stiliiana Panova1, Diana Popova2, Radka Kaneva1, Todor Popov2

1Medical University - Sofia, Sofia, Bulgaria, Department of Medical Chemistry and Biochemistry, Molecular Medicine Center, Sofia, Bulgaria; 2UMHAT “Tsarica Yoanna-ISUL”, Sofia, Bulgaria, Department of Ear- Nose and Throat/ Clinic of Ear- Nose and Throat, Sofia, Bulgaria.

Background/Objectives: Laryngeal squamous cell carcinoma (LSCC) is an aggressive malignancy with poor prognosis, which despite modern treatment protocols, novel molecular markers are required to improve survival. Deregulation of miRNA expression plays key role in various pathological processes, as well as angiogenesis and hypoxia.

Methods: Expression of 2549 miRNA in fresh-frozen tumour materials and adjacent normal tissue was performed in 12 patients with advanced primary LSCC, by SurePrint G3 Human MiRNA r21 Microarray Kit, 8 x 60K(Agilent Technologies). The expression of miR-21-3p and miR-210-3p was evaluated in a group of 38 fresh frozen LSCC and adjacent normal samples by qRT-PCR analysis.

Results: Expression levels of 2549 miRNA were assessed and 242 of those were significantly dysregulated (cut-off-2.0(FC); BH-FDR<0.05). After the analysis, a subset of 14 miRNAs was selected- 8 upregulated(miR-18a-5p, miR-181a-5p, miR-181b-5p, miR-21-3p, miR-24-3p, miR-93-5p, miR-210-3p, miR-1246) and 6 down-regulated (miR-140a-3p, miR-145-5p, miR-148a-5p, miR-204-5p, miR-497, miR-874-3p), miR-21-3p and miR-210-3p revealed to be an important and related to pathways of tumour angiogenesis and hypoxia so they were investigated in a validation group of patients. It was confirmed increased expression levels of miR-21-3p and miR-210-3p, respectively 78.94% and 39.47%. The ROC curve analysis showed that miR-21-3p can distinguish laryngeal tumour from normal tissue (AUC = 0.816; 95% CI:0.720-0.917; p=1.76.10^-6) with sensitivity of 84.2% and specificity of 73.7% whereas miR-210-3p did not.

Conclusion: Our study revealed the subset of 14 miRNAs significantly deregulated in our LSCC group. miR-21-3p and miR-210-3p were significantly overexpressed in validation group but miR-21-3p only showed power to distinguish tumour from normal tissue.

References: None.

P13.101.C Country-specific calibration of Polygenic Risk Scores for Breast Cancer in European ancestry populations

Kristia Yangou1, Nasim Mavaddat2, Joe Dennis3, Andreas Hadjilambros1, Maria A. Loizidou4, Jacques Simard5, Antonis C. Antoniou6, Douglas F. Easton2,4, Kyriaki Michailidou7, Breast Cancer Association Consortium2

1The Cyprus Institute of Neurology and Genetics, Department of Cancer Genetics, Therapeutics and Ultrastructural Pathology, Nicosia, Cyprus; 2University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, United Kingdom; 3Centre Hospitalier Universitaire de Québec—Université Laval Research Center, Genomics Center, Québec City, Canada; 4University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, United Kingdom; 5The Cyprus Institute of Neurology and Genetics, Bioinformatics Unit, Nicosia, Cyprus.

Background/Objectives: The 313-SNP breast cancer polygenic risk score (PRS313), developed for women of European ancestry by the Breast Cancer Association Consortium (BCAC), can be used in predicting a woman’s risk of developing the disease. However, calibration of the PRS is important for providing valid risk estimates. Here we evaluated the distribution of PRS313 in different countries. Analyses were based on 111,814 breast cancer cases and 94,718 controls of European ancestry from studies participating in the BCAC, from 17 countries in Europe, together with Australia, Canada, Israel, and the USA.

Methods: All samples were genotyped using either the Oncoarray or iCOGS platforms. We computed the mean and standard deviation (SD) of PRS313 and evaluated the association between breast cancer risk and PRS313 in each country separately. Fixed-effect meta-analysis was performed to calculate the overall estimates for each country and across all countries. The country-specific estimates were compared to the overall values.

Results: Relative to the overall mean, the mean standardized PRS313 differed significantly across Europe (p-value for heterogeneity <0.01), being highest in Greece (0.22), and Italy (0.10), and lowest in Ireland (-0.12). The mean estimates for Australia, Canada, Israel, and the USA are close to the overall mean.

Conclusion: The results indicate that the implementation of the PRS313 for breast cancer risk prediction will require country-specific calibration, which can be achieved by adjusting for the population-specific mean.

References: None declared.

P13.102.D Development of combined somatic copy number alteration and fragmentation analysis for monitoring in colorectal cancer patients using liquid biopsy

Ariane Hallermayr1,2,3, Verena Steinke-Lange1,4, Anna Benet-Pagés1,5, Tobias Wohlfarth1,6, Florentine Scharf4, Ellen Heitzer7,8, Christoph Haberer1, Maite de Wit9,10, Holger Vogelsang12, Markus Rentsch13,14, Elke Holinski-Feder1,4, Julia Romic-Pickl1,4

1MGZ – Medizinisch Genetisches Zentrum, Munich, Germany; 2Pettenkofer School of Public Health, Munich, Germany; 3Institute for Medical Genetics, Ludwig Maximilian University, Munich, Germany.
Background/Objectives: Liquid biopsy (LB) for non-invasive disease monitoring of cancer patients is progressing towards routine clinical practice. Whole-genome sequencing (WGS) of ctDNA provides a promising tool for real-time monitoring of treatment response, as well as early diagnosis for all cancer patients.

Methods: For clinical validation of Liquid biopsy Fragmentation Analysis of downsampled data of a small cohort of 11 samples identified 5x coverage to be the minimal required coverage to reliably distinguish healthy controls from CRC patients based on SCNAS, global fragmentation profiles and epigenetic signatures. Although sensitivity increased with higher coverage, we show that 5x coverage is acceptable for sensitive analysis of ctDNA for routine clinical practice, by keeping costs per sample in the range of targeted hotspot assays. To determine the clinical validity of LIFE-CNA, ctDNA specific features were compared with clinical data of CRC patients over all disease stages which were treated with surgery and / or chemotherapy. We were able to show that changes in ctDNA signals can be associated with treatment response or disease progression.

Conclusion: We developed a cost-effective and sensitive method for untargeted ctDNA analysis, which may expand the detection of residual disease and recurrence, as well as treatment monitoring to all cancer patients. The cost-effectiveness and sensitivity of our approach form the basis to enable implementation of LIFE-CNA into routine clinical practice.

References:

Grants: None declared.

Conflict of Interest: None declared.

P13.103.A Hereditary cancer panels, beyond the expected

Jesús del Valle1,2, Lidia Feluxabadalo1,2, Roser Lleuger-Pujol1,2, Xavier Muñoz1,2, Eva Tomero1,2, Mónica Salinas1,2, Mireia Menéndez1,2, Noelia Torres1,2, Eva Montes1,2, Marta Pineda1,2, Ángela Velasco1,2, Sara González1,2, Joan Brunet1,2, Conxi Lázaro1,2

1Catalan Institute of Oncology, IDIBELL, Hereditary Cancer Program, Oncobell Program, Hospital de Llobregat, Spain; 2Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Abstracts from the 55th European Society of Human Genetics Conference

Conclusion: These variants increased the mutational yield in 1.8% in our cohort of patients. Although many variants are in genes of moderate/low penetrance, others are not, representing incidental findings or putative new genotype-phenotype correlations. In some instances, these findings could be used to improve clinical follow-up of carriers and may prevent unexpected cancers in these families.

References:

Grants: PI19/00553.

Conflict of Interest: None declared.

P13.105.C Variability in the size of del(5q) and its clinical implication in myelodysplastic syndromes (MDS)

Zuzana Zemanova1, Nikola Sejgunovova1, Karla Svobodova1, Halka Lhotska1, Denisa Vidlakova1, Tatiana Aghova1, Libuse Lízova1, Silvia Iza kova1, Iveta Mendlíková1, Sarka Ransdorfová1, Lucie Hodanova1, Lenka Pavlístová1, Monika Belickova1, Jana Brezinova2, Jaroslav Cermák1, Tomas Stopka1, Anna Jonasova1

1General University Hospital and First Faculty of Medicine, Charles University in Prague, Center of Oncogenomics, Prague, Czech

References:

Grants: PI19/00553.
Abstracts from the 55th European Society of Human Genetics Conference

Republic; 2Institute of Hematology and Blood Transfusion, Prague, Czech Republic; 3General University Hospital and First Faculty of Medicine, Charles University in Prague, 1st Medical Department, Prague, Czech Republic.

Background/Objectives: The most common cytogenetic abnormality in MDS is del(5q) occurring either as a sole aberration or as a part of complex karyotypes (CK). Isolated del(5q) is associated with favorable outcome, MDS with CK relate to poor prognosis. It remains unclear whether deletion size matters for different MDS phenotypes. The aim was to assess the relationship between del(5q) extent and TP53 gene mutations, and to evaluate the effect of deletion size on disease prognosis.

Methods: We performed a detailed analysis of the del(5q) extent in a large cohort of 348 newly diagnosed MDS patients using mBAND (MetaSystems) and aCGH/SNP (Illumina, Agilent). Sequence analysis of TP53 gene was performed using NGS on a 454 GS Junior system (Roche) or MiSeq sequencing instruments (Illumina).

Results: In the group of 175 cases with isolated del(5q), we observed a smaller extent of deleted segment. The deletion ranged between 5q14-5q33.3. TP53 mutations were found in 19.4% of cases. In the group of 173 cases with CK, deletion often involved entire long arm. Mutations of TP53 or LOH17p were detected in 49% of them. When both the prevalence of CK and the del(5q) extent were considered, only karyotype complexity had a significant effect on patient’s overall survival.

Conclusion: More extensive deletions were associated with CK, higher frequency of TP53 aberrations/mutations and poor prognosis. Karyotype complexity is the main factor that negatively affects the prognosis. However, we cannot exclude that isolated large del(5q) may pose a higher risk of clonal evolution and complex karyotype formation during the disease.

References:

Grants:

MH CZ-DRO-VFN64165, DRO-UKHT0023736.

Conflict of Interest: None declared.

P13.106.D miR-210 reveals strong association with nodal metastasis and HIF2a, but not HIF1a in advanced LSCC

Silva Kyurkchiyan1, Stiliana Panova1, Gergana Stancheva1, Veronika Petkova1, Diana Popova1, Radka Kaneva1, Todor Popov1

1Medical Faculty, Medical University of Sofia, Molecular Medicine Center, Department of Medical Chemistry and Biochemistry, Sofia, Bulgaria; 2Medical Faculty, Medical University of Sofia, Department of ENT, Sofia, Bulgaria; 3Medical Faculty, Medical University of Sofia, Department of ENT, Sofia, Bulgaria.

Background/Objectives: Hypoxia has role in invasion and metastasis pathways. Advanced laryngeal squamous cell carcinoma (LSCC) is a disease with poor prognosis and presence of locoregional metastases. Our aim was to study hypoxic-master miR-210 and its association with major hypoxia markers and nodal metastasis status.

Methods: In the study 30 advanced tumour and corresponding normal laryngeal samples were enrolled. Total RNA isolation, reverse transcription and real-time qPCR were performed with miRNeasy kit, miScript IRT kit, and SYBR based detection (Qiagen). SPSS v19 (IBM) was used in statistical analysis, and p-value less than 0.05 was taken as significant.

Results: Most of the patients were with positive nodal metastasis status (67.5%) and overexpression of miR-210 (75%). Elevated levels of miR-210 demonstrated strong association with the presence of nodal metastasis (p < 0.01). ROC analysis distinguish patients developed nodal metastasis from those who are N-stage negative with 75% sensitivity and 65% specificity at RQ = 2.001 (AUC = 0.694, p = 0.012). Moreover, Spearman correlation analysis reveal potential co-expression and significant correlation between miR-210 and HIF2a (r = 0.409, p = 0.001), but not HIF1a, which is most commonly expressed during hypoxia.

Conclusion: Our results reveal that one of best-studied hypoxic-miRNA, miR-210, potentially could take a key role in nodal metastasis development in advanced LSCC. Correlation analysis reveal, that miR-210 may participates in latter stage during hypoxia via HIF2 transcription factor, which molecule is accumulated in prolonged hypoxia.

References:

Grants: D-77/04.06.2021,DN13/12/20.12.2017; D01-285/17.12.2019,D01-395/18.12.2020,D01-302/17.12.2021.

Conflict of Interest: Silva Kyurkchiyan DN13/12/20.12.2017 - collaborator.

DN-285/17.12.2019 - collaborator, Stiliana Panova D01-285/17.12.2019,D01-395/18.12.2020,D01-302/17.12.2021 - collaborator, Gergana Stancheva D-77/04.06.2021 - collaborator.

DN13/12/20.12.2017 - collaborator.

D01-285/17.12.2019,D01-395/18.12.2020,D01-302/17.12.2021 - collaborator, Veronika Petkova DN13/12/20.12.2017 - collaborator, Diana Popova D-77/04.06.2021 principal investigator.

DN13/12/20.12.2017 - collaborator, Radka Kaneva D-77/04.06.2021 - collaborator.

DN13/12/20.12.2017 - collaborator.

D01-285/17.12.2019,D01-395/18.12.2020,D01-302/17.12.2021 - collaborator, Todor Popov D-77/04.06.2021 - collaborator.

DN13/12/20.12.2017 - principal investigator.

P13.107.A An insertion in the MSH2 gene detected by Bionano optical mapping and confirmed by Nanopore sequencing in a family with suspected Lynch Syndrome

Ragnhild Margethe Aaløkken1, June Åsheim1, Marianne Dalland1, Eli Marie Grindedal1, Arvind YM Sundaram1, Pål Marius Bjørnstad1, Wenche Sjursen2, Gregor Gillillian3

1Oslo University hospital Ullevål, Medical genetics, Oslo, Norway; 2St. Olav’s University Hospital, Trondheim, Norway.

Background/Objectives: Structural variants, also called SVs, are defined as a lesion of DNA approximately 1kb or larger in size. Humans harbour approximately 18 Mb of structural variants per diploid genome, and these variants are an important underlying cause of genetic diseases. Despite the importance of SVs, they are difficult to detect by sequencing-based technologies. Bionano is a unique technology for detecting lesions by combining Nano-Channel arrays with optical mapping to image high-molecular weight DNA.

Methods: In this study, we investigated blood sampled from a patient with a personal and family history of cancer that gave a strong suspicion of Lynch Syndrome, a hereditary cancer syndrome caused by germline mutations in one of the four Mismatch Repair genes MLH1, MSH2, MSH6 and PMS2. However, no diagnostic tests, including sequencing, RNA-analyses and analysis of MSH2 inversion, could confirm the diagnosis.

Results: We therefore used Bionano technology to look for structural lesions in the patient’s genome. The Bionano results showed a large (about 40 kb) heterozygous insertion in the MSH2 gene. This showed a large (about 40 kb) heterozygous insertion in the MSH2 gene. This caused by Nanopore sequencing in a family with suspected Lynch Syndrome.
P13.108.B Beyond BRCA Genes: Frequency of genes with breast cancer-associated variants in a single center

Ayşe Savaş1, Yusuf Bahap1, Hasan Huseyin Kazan1, Gulsum Kayhan1, Mehmet Ergun1

1Gazi University Hospital, Medical Genetics Department, Ankara, Turkey.

Background/Objectives: Breast cancer is a very common disease accounting for 11.6% of all new cancer cases. There is a hereditary predisposition in 5-10% of all breast cancer patients. Advances in next-generation sequencing technology have enabled the discovery of different genes other than BRCA1 and BRCA2, which are the most common breast cancer susceptibility genes. In this study, germline multigene panel results in breast cancer patients are presented.

Methods: A hereditary cancer panel including 27 genes was performed in 449 patients with breast cancer only and 18 patients with multiple cancer, aged 19-77 years.

Results: A total of 69 pathogenic (P)/likely pathogenic (LP) variants in 14 genes were detected in 67 (13.9%) patients with breast cancer only and 9 (50%) patients with multiple cancer. Both breast cancer only and 9 (50%) patients with multiple cancer, aged 19-77 years.

Conclusions: Breast cancer only patients have different genetic backgrounds than patients with multiple cancer. Mutations in other genes were predominant. All the mutant genes in addition to BRCA1/2 could be listed according to the number of mutations. The use of multigene panels promotes the rapid identification of individuals with cancer. In breast cancer, other genes in addition to BRCA genes should be scanned to explore the genetic background of the disease.

References: Clinical Cancer Research, 23(20), 6113-6119.

Grants: Conflict of Interest: None declared.

P13.109.C Preliminary evaluation of highly sensitive assessment of microsatellite instability in endometrial aspirates as a tool for cancer risk individualization in Lynch syndrome

Júlia Canet-Hermida1,2, Fátima Marín1,2, Eduard Dorca Duch2, Nuria Dueñas2, Laura Costas2, Mónica Salinas1, Angela Velasco1, Paula peraméриar trillas2, Sonia Payubi2, Jordi Ponce2, Laura Cárdenas2, Laia Alemany1, August Vidal1, Eugeni López Bonet1, Gabriel Capellá1, Joan Brunet1,2, Xavier Matias Guiu1, Marta Pineda1

1Catalan Institute of Oncology, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Hereditary Cancer Program, ONCOBELL Program, CIBERONC, L’Hospital de Llobregat (Barcelona), Spain; 2Hospital Universitari de Bellvitge, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Pathology Department, L’Hospital de Llobregat (Barcelona), Spain.

Background/Objectives: Lynch syndrome (LS) women are at increased risk of endometrial cancer (EC), characterized by mismatch repair deficiency (MMRd) and microsatellite instability (MSI). While risk-reducing gynaecological surgeries are effective there is a need to empower carriers in their decision regarding surgery timing. We aim at exploring the usefulness of highly sensitive-MSI (hs-MSI) assessment in endometrial aspirates for the individualization of gynaecological surveillance in LS carriers.

Methods: Hs-MSI was assessed in prospectively collected endometrial aspirates from 67 LS carriers, 30 controls with benign lesions and 26 sporadic-EC cases. MMR, PTEN and ARID1A expression patterns were evaluated in LS samples.

Results: High hs-MSI levels were detected in 20 aspirates from MMRd EC cases (4 of 4 LS and 16 of 16 sporadic) being negative in aspirates from controls and MMR-proficient EC cases. Interestingly, elevated hs-MSI scores were also detected in aspirates from LS women with complex hyperplasia (3 of 3). In addition, high hs-MSI was present in 10 of 49 aspirates from LS carriers showing histologically normal endometrium. In normal endometrium hs-MSI score positively correlated with density of MMRd-glands, presence of MMRd-clusters and PTEN and ARID1A loss. Hs-MSI levels increased in follow-up aspirates from 5 LS carriers.

Conclusion: Elevated hs-MSI scores were detected in aspirates from pre/malignant lesions and normal endometrium in LS carriers, correlating with MMR protein loss. Further analyses of sequential aspirates are needed to elucidate the predictive value of hs-MSI in the identification of LS carriers at higher risk of developing EC.

References:

Grants: P13.110.D Cancer cell line variant knowledge resource for facilitated cell line identification

Rahel Paloots1, Michael Baudis1

1University of Zurich, Zürich, Switzerland.

Background/Objectives: One of the known features of cancer is the instability of its genome. Vast changes in the genome lead to duplications and deletions in the chromosome, that can be detected in most types of cancer. These chromosomal aberrations are also called copy number variants. Cancer cell lines are necessary tools for understanding the disease mechanisms as well as the development of new cancer treatments. However, they may not always be the best representation of their neoplasm of origin, due to cell line contamination and misidentification, as well as higher numbers of accumulated mutations in the cancer cell line genome. The analysis and comparison of cancer cell line and their origin’s profiles provide information on how similar different instances of cancer and/or cancer cell lines are to each other.

Methods: We build a cancer cell line variant resource for easier cell line identification and to enable finding the best representation for the cell line. This resource is open-source and uses the Beacon protocol for facilitated data sharing. To make this cell line variant knowledge resource complete we have also included cell line metadata and known single nucleotide variants to our database.

Conclusion: None declared.
P13.111.A Development of a pan-cancer comprehensive genomic profiling assay for solid tumor cancers with integration of MSI and TMB immunotherapy biomarkers

Alexia Eliades1, Irene Hadjidemetriou1, Marilena Elpidorou1, Achilleas Achilles1, Charalambos Loizides1, Christos Lemesios1, Kyriakos Tsangaras1, Elena Kypri1, Marios Ioannides1, George Koumarbaris1, Alessandro De Luca2, Laura Papi7, Marco Tartaglia8, Paola Grammatico9, Sandra Giustini1, Stefania Cavone2, Emanuele Miraglia1, Francesca Piceci-Rotondo, Foggia, Italy; 3Department of Experimental Medicine, Fondazione IRCCS Casa Sollievo della Sofferenza, Medical Genetics Division, Rome, Italy; 4University of Florence, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, Florence, Italy; 5Ospedale Pediatrico Bambino Gesù, IRCCS, Genetics and Rare Diseases Research Division, Rome, Italy; 6Sapienza University of Rome, Department of Experimental Medicine, San Camillo-Forlanini Hospital, Laboratory of Medical Genetics, Rome, Italy.

Background/Objectives: Over the last few years, there is a significant increase in the availability of targeted therapies. As the field of precision therapy expands, there’s an increasing need for a highly accurate comprehensive assay for testing different types of genomic alterations such as single nucleotide variants (SNVs), small insertions and deletion (Indels), copy number alterations (CNAs) and rearrangements. In addition, new complex biomarkers such as microsatellite instability (MSI) and tumor mutational burden (TMB) can inform on eligibility to immunotherapy treatment. Herein, we describe the development of a 221-gene assay that can accurately detect all these therapy-associated biomarkers in a single assay.

Methods: DNA extracted from a set of FFPE and contrived samples was subjected to library preparation and hybrid capture enrichment with a 221-gene panel. Enriched libraries were then subjected to next generation sequencing (NGS) on a NovaSeq platform and analysed using in-house bioinformatics pipelines. A subset of FFPE samples were also subjected to WES for TMB assessment.

Results: A combination of FFPE tumour samples, reference material and contrived samples with known alterations and known MSI status were used to evaluate the performance characteristics for SNVs, Indels, CNAs and translocations. The assay demonstrated 100% sensitivity and 100% specificity for SNVs and Indels, CNAs, rearrangements and MSI. TMB assessment showed high concordance when compared with whole exome sequencing (WES).

Conclusion: Validation results demonstrate that the assay provides a sensitive and accurate tissue-based NGS method for assessing genomic alterations and immunotherapy biomarkers in a single assay.

References:

Grants:

Conflict of Interest: None declared.

P13.114.D The potential of high-throughput sequencing in the evaluation and monitoring of microsatellite instability by short homopolymer loci

Jakub Styk1,2,3, Jaroslav Budis1,2,4, Jan Radvanszky1,2,5,6, Marcel Kucharik1,2, Ondrej Post2,4, Zuzana Post2,4, Werner Kramer1,2,5, Natalia Forgacova1,5, Diana Rusnakova1,2,5, Tatiana Sedlackova1,2, Pavol Janega1, Vanda Repiska1,6, Tomas Szemes1,2,5,6

1Geneton Ltd., Bratislava, Slovakia; 2Comenius University Science Park, Bratislava, Slovakia; 3Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Bratislava, Slovakia; 4Slovak Center of Scientific and Technical Information, Bratislava, Slovakia; 5Department of Molecular Biology, Faculty of Natural Sciences, Comenius University, Bratislava, Slovakia; 6Institute for Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia; 7Institute of Pathological Anatomy, Faculty of Medicine, Comenius University, Bratislava, Slovakia.

Background/Objectives: Evaluation of microsatellite instability (MSI) has broad clinical applications in some cancer patients’ follow up treatment efficacy. Conventional methods for MSI screening have traditionally been low-throughput strategies for limited cancer types. Currently, in the era of massively parallel sequencing (MP5),
there is a great potential to improve capabilities of the methods, resulting in more reliable monitoring of MSI.

**Methods:** We designed a cost-effective PCR protocol to enrich a set of homopolymer loci ranging from 7 – 30 base pairs obtained from regions of the human genome associated with MSI across various malignancies. The proposed system was standardised for sequencing by Illumina MiSeq platforms. We annotated and genotyped the sequenced data using the tool Dante.

**Results:** Our initial validations have shown that optimized PCR conditions to enrich the homopolymer markers site can amplify FFPE samples, standardly problematic for similar purpose. We showed that biases resulting from the repetitive nature of homopolymers could be alleviated by pre-analytical steps, such as high fidelity DNA polymerases and reduced number of PCR cycles, and last but not least, by statistical and computational algorithms.

**Conclusion:** To sum it up, sequencing data can enable a more accurate evaluation of genomic MSI events. However, due to laboratory-induced biases caused by homopolymers, further laboratory and statistical improvements are required for MSI evaluation more precisely. With these promising results, we validate the proposed strategy also in the circulating cell-free tumour DNA.

**References:**

**Grants:** The presented work was supported by the OP Integrated Infrastructure for the projects ITMS: 313011V578 co-financed by the European Regional Development Fund.

**Conflict of Interest:** None declared.

**P13.115.A Beyond pathogenic RUNX1 germline variants: The spectrum of somatic mutations in RUNX1 familial platelet disorder with predisposition to hematologic malignancies**

**Alisa Förster**, **Melanie Decker**, **Brigitte Schlegelberger**, **Tim Ripperger**

1 Hannover Medical School, Human Genetics, Hannover, Germany.

**Background/Objectives:** Pathogenic germline variants in RUNX1 cause familial platelet disorder with predisposition to hematologic malignancies (RUNX1-FPD). Accumulation of somatic alterations is presumed to drive clonal hematopoeisis and, finally, malignant transformation. The interplay of predisposing germline variants and acquired variants remain to be elucidated to better understand leukemic transformation.

**Methods:** We retrospectively reviewed 104 individuals with causal RUNX1 germline variants who have been investigated for somatic gene variants, which were previously reported in the literature or the RUNX1 database.

**Results:** Out of 104 individuals, 29 (28%) were investigated in a non-malignant state (i.e., cytopenia). The majority of these patients had no or only a single variant (62%). Regarding malignant neoplasms, 45 (62%) were diagnosed with AML, 12 (16%) with MDS, 7 (10%) with MDS/AML, 6 (8%) with ALL, and 6 (8%) with other malignancies (i.e., CMMKL). On average, two somatic variants were identified per patient. No somatic variant was observed in only 10 (14%) patients with a hematologic malignancy. In MDS and/or AML, 26 (40%) samples displayed somatic RUNX1 alterations. BCOR, TET2, NRAS, PHF6 and BCO1L1 were most frequently mutated.

**Conclusion:** Retrospective analysis supports the theory of stepwise malignant transformation in RUNX1-FPD. It highlights the importance of somatic mutations in the development of frank leukemia. Different somatic variants may explain clinical heterogeneity. Detailed analyses will provide insights in synergistic effects of germline and somatic variants. This is key to enable better stratification during surveillance and may allow tailored chemoprevention studies to avoid malignant transformation in the future.

**References:**

**Grants:** BMBF MyPred (01GM1911B).

**Conflict of Interest:** None declared.

**P13.116.B Prognostic utility of targeted circulating cell-free DNA versus formalin-fixed paraffin-embedded DNA mutation analysis for advanced lung cancer**

**Madli Tamm**, **Mart Kals**, **Tarmo Annilo**, **Kersti Oselin**, **Katrin Keerma**, **Paula Ann Kivistik**, **Mirjam Nurmi**, **Margot Saare**, **Jana Jaal**, **Neeme Tonisson**

1 Institute of Genomics, University of Tartu, Estonian Genome Centre, Tartu, Estonia; 2 University of Helsinki, Institute for Molecular Medicine Finland, Helsinki, Finland; 3 Clinic of Oncology and Haematology, North Estonia Medical Centre, Department of Chemotherapy, Tallinn, Estonia; 4 State Agency of Medicines, Tartu, Estonia; 5 Institute of Technology, University of Tartu, Tartu, Estonia; 6 Diagnostic Clinic, East Tallinn Central Hospital, Central Laboratory, Tallinn, Estonia; 7 Haematology and Oncology Clinic, Tartu University Hospital, Tartu, Estonia; 8 Institute of Clinical Medicine, University of Tartu, Tartu, Estonia; 9 United Laboratories, Tartu University Hospital, Department of Genetics, Tartu, Estonia.

**Background/Objectives:** We evaluated the performance of circulating cell-free DNA (cfDNA) and formalin-fixed paraffin-embedded (FFPE) tissue DNA analyses using a commonly employed targeted therapeutic pathway in predicting the outcomes of patients with lung cancer.

**Methods:** Patients (n = 106) donated blood samples at baseline and progression (n = 22), with matched FFPE biopsy samples being available for 75 patients. We set up a targeted sequencing workflow for the analysis of mutations in nine cancer-related genes. CfDNA concentration, number of mutations, and mutation occurrence in specific genes were analyzed. To identify factors associated with overall survival (OS), a multivariate analysis was performed using Cox regression.

**Results:** Higher cfDNA concentrations were associated with poorer OS (HR = 1.670, 95% CI 1.108-2.516, P = 0.014). OS was better among patients with at least one mutation in cfDNA (HR = 0.477, 95% CI 0.313-0.727, P = 0.0006). In baseline cfDNA, patients with mutations of VAFs < 5% had significantly better OS (HR = 3.510, 95% CI 1.672-7.370, P = 0.009). Patients with slowly progressing disease had significantly more cfDNA mutations than did those with rapid cancer progression (P = 0.045).

**Conclusion:** Our key finding was that cfDNA analysis performs better than FFPE tissue analysis in the prediction of patients’ OS and disease progression.

**References:** Tamm M, et al. (2022) Prognostic Utility of Targeted Circulating Cell-Free DNA versus Formalin-Fixed Paraffin-Embedded DNA Mutation Analysis for Advanced Lung Cancer. Int J Oncol Res 5:033. https://doi.org/10.23937/2643-4563/1710033.

**Grants:** 2014-2020.01.15-0012, PRGS55, PUT726.

**Conflict of Interest:** None declared.

**P13.117.C Delineating Genotype and Parent of Origin Effect on the Phenotype in MSH6-Associated Lynch syndrome**

Anne-Sophie van der Werf-t’ Lam, **Mandy Villasmil**, **Msh6 study group**, **Diantha Terlouw**, **Mar Rodriguez Girono**, **Manon Suerink**, **Maartje Nielsen**

1 LUMC, Clinical Genetics, Leiden, Netherlands; 2 LUMC, Department of Medical Statistics and Bioinformatics, Leiden, Netherlands.

**Background/Objectives:** The reported severity in phenotype differs in Lynch syndrome is largely unexplained. Genotype and/or
Abstracts from the 55th European Society of Human Genetics Conference

Parent of origin effect (POE) have been suggested to influence CRC or EC risk in Lynch syndrome (1). Previous studies have focused on MLH1/MSH2 and PMS2. In this study we analyze this for families with germline MSH6 variants.

**Methods:** Dutch MSH6 (likely) pathogenic variant carriers were grouped based on RNA expression and parental origin. Genotype-phenotype correlation and POE was estimated using hazard ratios (HR) with a (weighted) cox regression. In total 1615 variant carriers from 310 families were included.

**Results:** Variant carriers with retention of RNA expression (group 1) did not have a significantly different mean age of CRC diagnosis compared to group 2 (no RNA expression) (59.71 years vs. 58.83 years, p = 0.209) or EC diagnosis (54.7 years vs. 56.2 years, p = 0.083). There was no association between genotype and CRC risk (HR = 1.08, 95% CI 0.72-1.62). However, a significant lower risk for EC was found in group 2 compared to group 1 (HR = 0.43, 95% CI 0.27-0.69). There was no association between POE and CRC risk (HR = 0.93, 95% CI 0.62-1.37), or EC risk (HR = 0.87, 95% CI 0.55-1.37).

**Conclusion:** These data show that retained RNA expression is associated with a higher lifetime risk for EC, but not for CRC. No correlation was found for POE. Further research is needed to elucidate the mechanism behind higher EC risk before variant specific surveillance can be implemented.

**References:** 1. Ryan et al JAMA Oncol, 2017.3(12).

**Grants:** Dutch Digestive Disease Foundation (FP16-06).

**Conflict of Interest:** None declared.

**Mar Rodriguez Girondo:** None declared, Manon Suerink: None declared, Marjae Nielsen: None declared.

**P13.118.D Predicting biology instead of disease risk by overlapping oncological polygenic risk scores**

**Jeroen van Rooij**1, Jard de Vries1, Bahar Sedaghati-khayat1, Joyce Van Meurs1, Linda Broer1, André Utterliinden1, Annemieke Verkerk6

1Erasmus Medical Center, Internal Medicine, Rotterdam, Netherlands.

**Background/Objectives:** Polygenic risk scores (PRS) have been constructed and validated for many cancer types. The most advanced, such as breast, lung or colon cancer PRS, are making its way into clinic and society. For example, through the “Genotyping on all patients” (GOALL) and “Societal impact of genetic science” (SENSE) personalized medicine and prevention programs in Rotterdam and the Netherlands, respectively. In this project, we combine PRS for different cancers and perform biological annotation and clustering to partition genetic risk into cancer-related biological pathways.

**Methods:** We extract PRS from literature for the most common cancers, and construct a network of disease-variant (GWAS results) and variant-variant (based on LD) associations. The network is soft clustered and visualized using R. All variants are annotated to biological pathways an individual’s risk is cause might have diagnostic and prognostic implications, e.g., altered treatment options for breast cancer caused primarily through DNA metabolism or hormone response variants.

**References:** NA.

**Grants:** NA.

**Conflict of Interest:** None declared.

**P13.119.A A collaborative multicenter approach for the classification of mismatch repair gene variants in Spain: results of a pilot study**

**Victor Lorca Castellanos1, Alysson Turcios2, Anaíl Lopez-Novo3, Maribel Gonzalez-Acosta3, Elisabet Munteş4, Zoiola Cavaeiro5, Daniel Rueda6, Montserrat de Miguel6, José Luis Soto7, Miguel Urioste Azcoar8,9, JUDITH BALMANA10, Gemma Llort11, Francesc Balaguer11, Teresa Ramon y cajal12, Carmen Guillén-Ponce12,13, Núria Rodríguez-Salas12, Conxi Lázaro12, Gabriel Capellá12, Clara Ruiz-Ponte12, Pilar Garre1, Trinidad Caldés1, Marta Pineda12

1Hospital Clínico San Carlos, Madrid, Spain; 2IDIBELL - Institut Català d’Oncologia, Hospital de Llobregat, Spain; 3Fundación Pública Gallega Medicina Xonómica, Santiago de Compostela, Spain; 4Hospital Universitario 12 de Octubre, Madrid, Spain; 5Hospital Universitario de Elche, Elche, Spain; 6Centro Nacional de Investigaciones Oncológicas, Madrid, Spain; 7Hospital Universitario Vall d’Hebron, Barcelona, Spain; 8gllort@tau1.cat, Sabadell, Spain; 9Hospital Clinic, Barcelona, Spain; 10Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 11Hospital Universitario Ramón y Cajal, Madrid, Spain; 12Hospital Universitario La Paz, Madrid, Spain.

**Background/Objectives:** Identification of germline pathogenic variants in mismatch repair (MMR) genes allows diagnosis of DNA MMR deficiency-associated syndromes. The identification of variants of unknown significance (VUS) precludes diagnosis. Recently, classification guidelines have improved reproducibility and transparence in variant classification. Our main aim is to accelerate and improve MMR variant classification based on the creation of a national registry of germline variants in Spain.

**Methods:** Twelve Spanish centers were invited to collaborate. Clinical and molecular data from MMR VUS carriers were submitted on a consensus template form. Collected data were curated. Monthly team conferences were held to update and review variant classification according to Insight v2.4 and Insight-ACMG v1 (pending to be approved by ClinGen) guidelines.

**Results:** A total of 255 VUS present in 324 index cases were collected. Fifty-two of whom were identified in 2 or more individuals. Classification was revisited in a subset of 161 VUS (enriched for recurrent, silent and splicing suspected variants). Update of available information allowed the reclassification of 20 variants according to Insight guidelines (8 class 1-2; 12 class 4-5). When using Insight-ACMG criteria 60 VUS were reassigned (43 class 1-2; 17 class 4-5), increasing the reclassification yield from 12 to 37%.

**Conclusion:** The Spanish variant registry has accelerated the exchange of revised data, essential to improve classification. The use of Insight-ACMG MMR-specific guidelines further increases reclassification yield, mainly of silent/intronic VUS to likely neutral variants.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P13.121.C A novel variation in PTCH1 gene causing Gorlin-Goltz syndrome**

**Ersa Dirimtekin1, esra arslan ates2, Hamza Polat1, bilgen bilge geçeklini1**

1, esra arslan ateş
Background/Objectives: Gorlin-Goltz Syndrome (GGS) also known as basal cell nevus syndrome, is a rare multisystemic autosomal dominant disorder. It's estimated population frequency is 1/150,000 to 1/570,000 worldwide. Multiple basal cell carcinomas of the skin, palmar and plantar pits, odontogenic keratocysts and skeletal anomalies are the major presentation of GGS. Pathogenic variations in PTCH1, PTCH2 and SUFU genes encoding components of Hedgehog/ Patched signaling pathway, are associated with GGS.

Methods: This index case was evaluated with detailed analysis, pedigree, physical examination, laboratory and imaging methods. Following DNA extraction from peripheral blood lymphocytes all coding exons and exon-intron boundaries of PTCH1, PTCH2 and SUFU genes were analysed via next generation sequencing (NGS). Segregation analysis of the identified variant was performed using Sanger sequencing.

Results: A 11-year-old girl was referred to us because of odontogenic keratocysts of jaws, palmar and plantar pits, multiple basal cell carcinomas of the skin and trichoblastoma. She was born to nonconsanguineous parents after an uneventful pregnancy. Anthropometric measurements and neurodevelopmental characteristics were compatible with her age. Frontal bossing and congenital melanocytic nevus on forearm were present. Arachnoid cyst of the brain and bifid ribs were detected on imaging studies. Molecular genetic studies revealed a de novo novel heterozygous PTCH1 variant (c.3076dupC; p.His1026Profs*119), expected to cause a truncated protein.

Conclusion: GGS is a tumor prone multisystemic disorder in which asymptomatic carriers and families may benefit from early molecular diagnosis and preimplantation genetic diagnosis. Here we report a novel pathogenic variation related to GSS contributing genotype-phenotype correlation.

References:
Grants:
Conflict of Interest: None declared.

P13.122.D Faecal metagenomics and Whole Genome Sequencing of patients with somatic APC variants suiting the mutation signature caused by colibactin

Diantha Terlouw1, Arnoud Boot2, Quinten Ducarmon3, Sam Noot4, Manon Suerink5, Alexandra Langers5, Romy Daniëlle Zwittink3, Tom adenomas, namely colibactin produced by E.coli revealed a possible additional explanation for the development of colorectal mucosa and presence of putative carcinogenic bacteria amongst others. More research into the impact of colibactin on formalin-fixed Paraffin-Embedded material of adenomas is challenging, the mutational signature (SBS88) was slightly enriched in patients with pks (4/8; 50%) compared to patients without pks in their feces samples (2/7; 29%). The negative controls did not show pks in their feces samples, nor the mutational signatures in their adenomas.

Conclusion: These results show subtle additional evidence for the carcinogenic influence of colibactin in patients with multiple adenomas. However, to draw firmer conclusions, additional negative controls will be analysed.

References:
Grants: Dutch Cancer Society (11292).
Conflict of Interest: None declared.

P13.124.B Variants of uncertain significance in DNA repair genes: Clinical relevance and impact on therapeutic strategies in Tunisian breast and ovarian cancer patients

Maroua Boujemaa1, Fatma Nouira2, Nouha Jandoubi1, Nesrine Mejri1,2, Hanen Bouaziz1,4, Sonia Ben Nass1,3, Sonia Abdelkhak1, Mohamed Samir Boubaker1,6, Hamouda Boussem1,3, Yosri Hamdi1,6

1Institut Pasteur de Tunis, Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Tunis, Tunisia; 2IBST, Biotechnopole Sidi Thabet, Laboratory (BVBGR)-LR11E531, Ariana, Tunisia; 3Abderrahman Mami Hospital, Faculty of Medicine Tunis, University Tunis El Manar, Medical Oncology Department, Ariana, Tunisia; 4Salah Azaiez Institute of Cancer, Surgical Oncology Department, Tunis, Tunisia; 5Military Hospital of Tunis, Department of Medical Oncology, Tunis, Tunisia; 6Institut Pasteur de Tunis, Laboratory of Human and Experimental Pathology, Tunis, Tunisia.

Background/Objectives: Variants of uncertain significance (VUS) in cancer predisposing genes pose a critical challenge in clinical care since their association with disease remains unclear. Here we aim to evaluate the contribution of VUS in DNA repair genes to hereditary breast and ovarian cancer in Tunisian families.

Methods: A total of 78 breast and ovarian cancer cases investigated by NGS and negative for BRCA mutations were included in this study. The pathogenicity of variants was assessed using several in silico predictions tools, the stability predictor DynaMut and molecular dynamics simulation with NAMD. Segregation of variants with disease within the investigated families was also evaluated.

Results: A total of 36 VUS were identified among of which 8 are likely to be deleterious affecting ATM, CHEK2, BRCC3, FANC, FANC and PMS2 genes. ATM_c.6115G>A and CHEK2_c.592+3A>T were the most clinically relevant variants identified in families with multiple breast cancer cases and segregation analysis has confirmed their cosegregation with disease. In addition, functional in silico analysis revealed that the ATM variant may lead to protein immobilization and rigidification decreasing hence its activity.

Conclusion: Our findings revealed that cancer predisposition may be linked to VUS that need to be reclassified as pathogenic for better disease management. This will help to improve the genetic diagnosis and therapeutic strategies of cancer patients not only in Tunisia but also in neighboring countries.

References: Monteiro, et al. Journal of medical genetics (2020).
Grants: Tunisian Ministry of Health, Tunisian Ministry of Higher Education and Scientific Research.
**Conflict of Interest:** None declared.

**P13.125.C Gene expression analysis on single cell level uncovers the subclonal architecture of chromosomes in a leukemia patient with multiple chromosomal aberrations**

Jana Kotasová1,2,3, Terézia Kurucová1, Kamila Rěblová1,2, Martina Vališová1,2, Andrea Marečková3, Michaela Bohunová4, Sarka Pavoľová1,2, Jitka Malčíková1,2, Veronika Navrátilová1,2, Michael Doubek1,2, Karla Plevová1,2, Sarka Pospisilová1,2,3

1Masaryk University, Central European Institute of Technology, Brno, Czech Republic; 2University Hospital Brno and Faculty of Medicine, Masaryk University, Institute of Medical Genetics and Genomics, Brno, Czech Republic; 3University Hospital Brno and Faculty of Medicine, Masaryk University, Department of Internal Medicine - Hematology and Oncology, Brno, Czech Republic.

**Background/Objectives:** In cancer cells, the chromosomal changes are often multiple/complex and can be present only in subclones prone to drive disease aggressiveness. Bulk analysis such as WGS, WES, or genomic array cannot precisely determine the occurrence of aberrations in individual cells. Therefore, we employed single-cell RNA sequencing (scRNAseq) technology to study subclonal changes in the malignant cells of a patient with relapsed/refractory chronic lymphocytic leukemia (CLL).

**Methods:** We identified a patient with multiple chromosomal changes based on the DNA analysis from separated CLL cells using a genomic array (ThermoFisher Scientific). Simultaneously, the transcriptome was analysed using scRNAseq (Chromium system, 10x Genomics) in 2330 cells. Detailed data analysis was carried out with Seurat package. In addition, we used InferCNV tool to detect the chromosomal aberrations in every tested cell.

**Results:** We detected several changes with a variable proportion of affected cells using a genomic array. Unsupervised clustering of scRNAseq data according to gene expression defined major clones bearing aberrations (loss on chromosomes 1, 9, 18, del13q, del17p). Moreover, these clones were composed of cells with additional aberrations defining number of separate subclones. The proportion of subclones was typically under the detection limit of the genomic array and showed extreme intraclonal heterogeneity of the relapsed/refractory CLL case.

**Conclusion:** Genomic alterations influence the expression of affected genes; this fact can be considered to reconstruct chromosomal disruptions on a single cell level using scRNAseq and to uncover the subclonal architecture of the malignancy.

**References:**

Grants: MH-CZ_AZV_NV20-08-00314, MH-CZ_AZV_NV19-03-00091, MEYS-CZ_MUNI/A/1330/2021, MH-CZ_RVO_65269705.

**Conflict of Interest:** None declared.

**P13.126.D A Retrospective Cross-Sectional Analysis of Familial Adenomatous Polyposis Coli Cases**

Elanur Yılmaz1,2,3, Esra Yücel4, Hilal-Piril Saracoğlu4, Emre Balık4, Şahin Avcı1, Serpil Eraslan2, Dursun Bugra3, Hülya Kayserili1,2,3

1Koc University, Research Center for Translational Medicine (KUT-TAM), Istanbul, Turkey; 2Koc University Hospital, Diagnostic Center for Genetic Diseases, Istanbul, Turkey; 3Koc University, School of Medicine, Department of Medical Genetics, Istanbul, Turkey; 4Koc University Hospital, General Surgery, Istanbul, Turkey.

**Background/Objectives:** Cancer is the second leading cause of death globally. 1.8 million people receive a new diagnosis each year. Colorectal cancers (CRC) constitute about 10% of all, and among them, 30% are familial. Among all familial cancer susceptibility syndromes, one of the best-known is Familial Adenomatous Polyposis Coli (FAP), inherited autosomally dominant caused by the germline variants in the APC gene located on chr5q22. The incidence of FAP is estimated as 1.8-15.000 and accounts for less than 1% of all CRC cases.

**Methods:** Between 2014-2020, 1024 patients have undergone colorectal surgery and diagnosed with CRC. In all the cases, only 24 were considered as FAP, female:male ratio was 3:7, and the mean age of diagnosis 31.6 (±7.1). Genetic testing and counseling were offered to all FAP cases; ten took APC and hereditary oncpanel testing.

**Results:** Pathogenic variants in APC were detected in six, and STK11 and SDHD variants of unknown significance (VUS) were detected in two. Cascade screening was offered to all the families, and only one with c.2510C>G(p.Ser837Ter) variant accepted the offer. In seven individuals tested, one was found to be the carrier for the pathogenic variant. Another patient with APC variant (c.4464_4468delATTAC/p.L1488fs), developed a desmoid tumor seven years after the colectomy operation, which is in correlation with the incidence of desmoid tumor occurrence (10-25%).

**Conclusion:** In conclusion, the risk of desmoid tumor development should be considered in families with hereditary cancer syndromes, especially in FAP. Furthermore, cascade screening should be supported worldwide for the effective follow-up of high-risk individuals in familial cancer syndromes.

**References:**

Grants: None.

**Conflict of Interest:** None declared.

**P13.129.C Comparative analyses of long non-coding RNA and associated microRNAs expression in plasma and ovarian tissue samples of patients with ovarian cancer**

Beata Soltesz1, Janos Lukacs2, Nikolett Nemeth3, András Penyige3, Robert Poka4, Istvan Balogh3, Bálint Nagy3

1University of Debrecen, Department of Human Genetics, Debrecen, Hungary; 2University of Debrecen, Institute of Obstetrics and Gynaecology, Debrecen, Hungary; 3University of Debrecen, Department of Human Genetics, Debrecen, Hungary.

**Background/Objectives:** Ovarian cancer is a leading cause of gynaecological cancer mortality among women, due to nonspecific symptoms and late diagnosis. Early diagnosis should be essential in the effective treatment. Some non-coding RNAs, as long non-coding RNAs (lncRNA) and microRNAs seem to be promising biomarkers in non-invasive diagnosis. Metastasis-associated long adenocarcinoma transcript 1 (MALAT1) is an IncRNA, which have a role in carcinogenesis and metastasis and can also be a prognostic factor in different types of cancer.

**Methods:** Nineteen ovarian cancer patients and six healthy controls were involved in the study. Blood samples and ovarian tissue were collected; the RNA was isolated and then cDNA was synthesised. The expression of MALAT1 and microRNAs were determined among Hungarian patients and controls.

**Results:** Pathogenic variants in APC were detected in 6, and STK11 and SDHD variants of unknown significance (VUS) were detected in 2. Cascade screening was offered to all the families, and only one with c.2510C>G(p.Ser837Ter) variant accepted the offer. In seven individuals tested, one was found to be the carrier for the pathogenic variant. Another patient with APC variant (c.4464_4468delATTAC/p.L1488fs), developed a desmoid tumor seven years after the colectomy operation, which is in correlation with the incidence of desmoid tumor occurrence (10-25%).

**Conclusion:** In conclusion, the risk of desmoid tumor development should be considered in families with hereditary cancer syndromes, especially in FAP. Furthermore, cascade screening should be supported worldwide for the effective follow-up of high-risk individuals in familial cancer syndromes.

**References:**

Grants: None.

**Conflict of Interest:** None declared.
women, our results are promising, but more samples and the extension of study are needed.

References: -.

Grants: -.

Conflict of Interest: None declared.

P13.130.B The effect of dietary habits on breast cancer development in patients with BRCA1/2 pathogenic/likely pathogenic variations

Gizem Keskin1, Hilal Irem Özdemir1, izen tuna1, özden hatırmaz ng2, Busra Unal2, Nhiath Buga Aqagolu4

1Bahcesehir University, Nutrition and Dietetics, Istanbul, Turkey; 2Acibadem University, Medical genetics, Istanbul, Turkey; 3Umranie Education and Research Hospital, Clinical Genetics, Istanbul, Turkey; 4Umranie Education and Research Hospital, Clinical Genetics, Istanbul, Turkey.

Background/Objectives: The effect of nutrition on cancer development has been proven. However, there is no concrete data on the role of nutrition in the cancer development among the patients with BRCA1/2 Pathogenic/Likely pathogenic variations (PVs). We evaluated distinctions in the dietary habits between breast cancer (BC) patients with BRCA1/2 PVs and healthy individuals (HI) with BRCA1/2 PVs.

Methods: We retrospectively screened 1000 patients that were referred to the Genetic Cancer Clinic at Umraniye Training and Research Hospital. Among these, 89 patients with germline PVs on BRCA1/2 genes were included to the study. Sixty-one out of 89 were diagnosed with BC, whereas the remaining 28 were HI. Dietary habits and anthropometric measures (AM) of these two groups were compared by using the food consumption frequency form and the Mediterranean Diet Score.

Results: We compared the eating habits of the BC patients with germline BRCA1/2 PVs and HIs with the germline BRCA1/2 PVs and found that the ratio of individuals who adhere to the Mediterranean Diet was higher among the HI (60.7%) than BC group (39.3%). Besides, among the AM, body mass index of the cancer patients was significantly higher (p = 0.033). Moreover, smokers were higher in BCs (p = 0.047).

Conclusion: To our knowledge this is the first study evaluating the dietary habits and AM in individuals with germline BRCA1/2 PVs. Our study suggests that there is a difference in nutritional habits between BC patients and HIs. However, studies with larger groups are needed to clarify the impact of nutritional habits on cancer development in patients with germline cancer susceptibility.

References: -.

Grants: -.

Conflict of Interest: None declared.

P14.001.D LRNF5 locus structure is associated with autism and influenced by the sex of the individual and locus conversions

Gunnar Houge1, Helle Lybæk1, Michael Robson2, Nicole de Leeuw3, Joanne H. Herir-Kwa4, Aaron R. Jeffries5, Bjørn Ivar Haukanes1, Siren Berland1, Diederik de Bruijn3, Stefan Mundlos2, Malte Spielmann6

1Haukeland University Hospital, Medical Genetics, Bergen, Norway; 2Max Planck Institute for Molecular Genetics, Berlin, Germany; 3Radboud University Nijmegen Medical Centre, Department of Human Genetics, Nijmegen, Netherlands; 4Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; 5University of Exeter, United Kingdom; 6UKSH, Institute for Human Genetics, Kiel, Germany.

Background/Objectives: LRNF5 is a regulator of synaptic development and the only gene in a 5.4 Mb topologically associating domain (TAD). The LRNF5 locus is highly conserved despite extensive copy number variation.

Methods: LRNF5 locus structure was studied by quantitative chIP-on-chip in fibroblasts, supplemented with capture-HiC determination of TAD structures. Locus interaction was indirectly studied by allele counting.

Results: An association between locus structural changes and developmental delay (DD) and/or autism was suggested by data from DECIPHER and own records. More significantly, we found that maternal inheritance of a specific LRNF5 locus haplotype segregated with an identical type of autism in distantly related males. This autism-susceptibility haplotype had a specific TAD pattern. We also found a male/female quantitative difference in the amount histone-3-lysine-9-associated chromatin around the LRNF5 gene itself (p < 0.01), possibly related to the male-restricted autism susceptibility.

To better understand locus behaviour, the prevalence of a 60 kb deletion polymorphism was investigated. Surprisingly, in three cohorts of individuals with DD (n = 8757), the number of deletion heterozygotes was 20-26% lower than expected from Hardy-Weinberg equilibrium. This suggests allelic interaction, also because the conversions from heterozygosity to wild-type or deletion homozygosity were of equal magnitudes. Remarkably, in a control group of medical students (n = 1416), such conversions were three times more common (p = 0.00001), suggesting a regulatory role of this allelic interaction.

Conclusion: LRNF5 regulation appears unusually complex and influenced by gender and inter-allelic interaction, and LRNF5 dysregulation could be an epigenetic cause of autism.

References: This work is in press in Autism Research (2022).

Grants: HelseVest grant #911459.

Conflict of Interest: None declared.

P14.002.A Combining cytogenetic and genomic technologies for deciphering challenging complex chromosomal rearrangements

Rachel Michaelson-Cohen1,2,3, Omer Murik4, Sharon Zeligson1, Orit Lobel1, Ormi Weiss5, Ellie Picard6, Tzvia Mann1, Omri Weiss2; 5Shaare Zedek Medical Center, Department of Obstetrics and Gynecology, Jerusalem, Israel; 4Shaare Zedek Medical Center, Pediatric Pulmonary Institute, Jerusalem, Israel; 3Shaare Zedek Medical Center, Department of Obstetrics and Gynecology, Jerusalem, Israel; 2Shaare Zedek Medical Center, Translational Genomics Laboratory, Jerusalem, Israel; 1Shaare Zedek Medical Center, Pediatric Pulmonary Institute, Jerusalem, Israel; 6Hadassah Medical Organization, Department of Genetics, Jerusalem, Israel.

Background/Objectives: Complex chromosomal rearrangements (CCR) are a class of structural variants (SVs) involving more than two chromosome breaks, classically thought to be extremely rare. As advanced technologies become more available, it has become apparent that CCRs are more common than formerly thought and are a substantial cause of human genetic disorders. Solving the mechanism of CCRs by precisely identifying sequence-level changes, and their order, are challenging, especially when repetitive sequences are involved.

Methods: Chromosomal microarray (CMA) and FISH analyses were used for interpretation of SVs detected by whole exome sequencing (WES). Breakpoint junctions were analyzed by

References: -.

Grants: -.

Conflict of Interest: None declared.
Nanopore sequencing, a novel long-read whole genome sequencing (WGS) tool.

**Results:** A large deletion identified by WES, encompassing the FOXF1 enhancer, was the cause of alveolar capillary dysplasia and respiratory insufficiency, resulting in perinatal death. CMA analysis of the deceased newborn’s mother revealed two duplications encompassing the deleted region in the proband, raising our hypothesis that the deletion resulted from CCR in the mother. Breakpoint junctions of complex SVs were determined at the nucleotide level using Nanopore long-read sequencing. According to the sequencing results of breakpoint junctions, the CCR in the newborn was considered as the consequence of at least one double-strand break (DSB) during meiosis and reassembly of DNA fragments by intra-chromosomal homologous recombination.

**Conclusion:** The combination of CMA, FISH and long read NGS enabled delineation of the exact breakpoints and proposed a mechanism in which the CCR arises. We suggest an integrative approach combining cytogenetic and genomic technologies for deciphering challenging CCRs.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

P14.003.B Hidden splice variants in stop-codons of the DMD gene in Duchenne/Becker muscular dystrophy

*Maria Orlova¹, Maria Bulakh¹, Alexander Polyakov¹, Oksana Ryzhkova¹*

¹Research Centre for Medical Genetics, Moscow, Russian Federation.

**Background/Objectives:** The most common cause of Duchenne/Becker muscular dystrophy (DMD/BMD) is gross deletions and duplications. Frameshift deletion exons form Duchenne muscular dystrophy phenotype, while non-frameshift mutations are milder and result in the Becker muscular dystrophy phenotype.

One of the mechanisms of the molecular pathogenesis of DMD/BMD are variants affecting splicing in the DMD gene. It is known that not only mutations in canonical regions, but also missense, nonsense and intronic variants can affect splicing.

The aim of the study was to investigate the mechanism of the influence of stop-codons on the mRNA sequence.

**Methods:** We performed the bioinformatic analysis of 656 variants leading to the formation of a premature termination codon from the HGMD Professional database 2020.4. The splice site prediction programs SpliceAI, SPiP, and NetGene2 were used.

**Results:** Out of 554 nonsense variants in DMD, 54 variants were predicted to affect splicing (9.7%). Of these, in 90% of cases a frameshift was predicted.

For variants associated with BMD 7 of 47 nonsense variants (14.8%) were predicted to affect splicing. For 100% splice variants the programs predicted inframe deletions part of exon or skipping of an exon entirely.

**Conclusion:** The results of the study are consistent with the concept of differences in the phenotypes of DMD/BMD and allow us to evaluate the mechanism of the influence of nonsense variants on DMD gene splicing. The lack of predictions about the effect of nonsense variants on splicing requires further study of the influence of these variants on the molecular mechanism of the pathogenesis of DMD/BMD.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

P14.004.C Identification of alternative transcripts of nsd1 gene responsible for sotos syndrome

*Giuseppina Conteduca¹, claudia cantoni², Giovanni Candiano², Alessia Arada¹, Chiara Baldo¹, Marina Grasso¹, Barbara Testa¹, Michela Malacarne¹, Domenico Covelli¹*

¹IRCCS Istituto Giannina Gaslini, Laboratory of Human Genetics, GENOVA, Italy; ²IRCCS Istituto Giannina Gaslini, Laboratory of clinical and experimental immunology, GENOVA, Italy; ³IRCCS Istituto Giannina Gaslini, Laboratory of Molecular Nephrology, GENOVA, Italy.

**Background/Objectives:** NSD1 gene (nuclear-receptor-binding-set-domain-protein) encodes a methyltransferase [1,] implicated in the transcription and methylation of histone H3 at lysine 36 (H3-K36), but the molecular mechanisms involved in these processes remain largely unknown. Pathogenetic variants in NSD1 gene lead to Sotos syndrome (SoS), and they have been involved also in cell proliferation and drug resistance of some type of cancers [2].

**Methods:** Sequence analysis and array CGH were performed to verify NSD1 alteration in 14 Sotos patients and NSD1 mRNA expression by Real Time PCR was performed on fibroblast cell lines obtained from patients and from 8 controls. We sequence NSD1 cDNA isoforms observed in patients and controls.

**Results:** We describe the presence of two shorter NSD1 mRNA isoforms not yet reported: NSD1 Δ5Δ7 (isoform2) and NSD1 Δ19-23 (isoform 3) both in healthy subjects and in patients. We show that the NSD1 mutations in patients were associated to a decreased level of NSD1 mRNA. In addition, one SoS patient, bearing the NSD1 variant c.6010-10G>A, expressed an additional transcript derived from an aberrant splicing. Protein structure prediction of NSD1 isoform 2 indicates the presence of a shorter protein displaying only the PWWP1 domain that lacks the catalytic SET domain, while Isoform 3 lacks PHD3 and PHD4 C-terminal domains.

**Conclusion:** These results provide a basis to better elucidate the role of alternative transcripts both in SoS and in tumor progression.

**References:**

1. Douglas J et al. 2003 Am J Hum Genet.
4. Mohanty S et al 2020 Cancers.

**Grants:** AssiGulliver and Fondazione Sardegna.

**Conflict of Interest:** None declared.

P14.005.D Exploring the obscure clinical significance of uncommon uni-parental disomy (UPD)

*Omri Weiss¹, Sharon Zeiligson¹, Orit Lobel¹, Malka BenUziyahu¹, Adi Ben Yehuda¹, Shachar Zuckerman¹, Shelly Lev-Hochberg¹, Rachel Beeri¹, Efret Burak¹, Shira Shaviv¹, Tal Dror¹, Miriam Patt¹, Reeval Segel²*

¹Medical Genetics Institute, Shaare Zedek Medical Centre, Jerusalem, Israel; ²The Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

**Background/Objectives:** The use of next generation sequencing and single nucleotide polymorphism based chromosomal microarray analysis (CMA) leads to detection of uniparental disomy (UPD) in both pre- and post-natal settings. UPD may lead to disease by abnormal expression of imprinted genes or loss of heterozygosity (LOH) of mutations in recessive genes.

The unknown clinical significance of many UPD segments is challenging, especially in prenatal settings. Sharing UPD segments detected in healthy individuals can resolve such uncertainty.
Methods: We identified regions of homozygosity (ROH) suggestive of UPD in CMA samples in Shaare Zedek Medical Centre and correlated them to the clinical information.

Results: In our cohort, 14 samples had ROH suggestive of UPD. Four causing UPD-imprinting disease and ten were ROH of uncertain significance. Of the ten, three were found in healthy individuals tested for unrelated conditions and one was done due to LOH of a mutation in the CASR gene, causing autosomal recessive neonatal hyperparathyroidism.

We report four ROH indicative of UPD of uncertain significance: chr3 maternal (iso)UPD detected in the patient with hyperparathyroidism; 18q12.1q22.3 (unknown parental origin) in a healthy individual; maternal segmental UPD of 5p13.3q21.3 and paternal mosaic (iso)UPD of chr22 in amniocenteses referred for advanced maternal age. Pregnancy follow-up was normal and exome sequencing validated UPD.

Conclusion: Our data, together with previously published UPD segments, establish that UPD of chromosomes 3, 5, 18 and 22 are not expected to cause imprinting-related disease. Further reports of UPD from healthy individuals are necessary for mapping imprinting free regions, allowing more informative genetic counselling.

References:

Grants:

Conflict of Interest: None declared.

P14.006.A Hereditary Hemorrhagic Telangiectasia: first demonstration of a branch point causative variant

Anna Sbalchiero1, Claudia Cantarini1, Chantal Nardiello1, Gennaro Mariano Lenato2, Patrizia Lastella2, Giuseppe Spinozzi2, Fabio Pagella3,4, Elina Matti3, Carla Olivieri1

1University of Pavia - Unit of General Biology and Medical Genetics, Molecular Medicine, Pavia, Italy; 2UOS Sovravissuolo di Assistenza e Ricerca per le Malattie rare - Policlinico di Bari, UOC medicina interna universitaria "C. Frugoni", Bari, Italy; 3Fondazione IRCCS Policlinico San Matteo, UOC of Otorhinolaryngology, Pavia, Italy; 4University of Pavia, Surgical Sciences, Pavia, Italy.

Background/Objectives: Hereditary Hemorrhagic Telangiectasia (HHT) is a rare autosomal dominant disease leading to vascular dysplasia caused by a pathogenic variant in one of the HHT gene: ENG, ACVRL1, SMAD4, GDF2. We present a large HHT family without a defined pathogenic variant; linkage analysis suggested the ACVRL1 involvement. The c.526-22 A>G VUS in this gene, located at a putative branch point, co-segregates with the disease in the family. This represents the first case of a branch point mutation in HHT.

By analyzing the ACVRL1 transcript we aimed to demonstrate the variant pathogenicity.

Methods: We performed WES (filtering for the HHT genes) and MLPA analysis on a clinically confirmed case of the family. Co-segregation of c.526-22 A>G was confirmed by Sanger Sequencing. To proof the variant pathogenicity, RNA was extracted from peripheral blood of the patient and five healthy controls. After retrotranscription and PCR, semi-quantitative and qPCR analyses were performed. Sanger sequencing was carried out too.

Results: The variant is not present in GnomAD. Bioinformatics and semi-quantitative analyses suggested a quantitative change in the canonical coding RNA and the exon-5 skipping isoforms, changing the ratio between the two. These data were confirmed by quantitative and sequencing analyses.

Conclusion: We report the first case of a branch point pathogenic variant in HHT. This is, to the best of our knowledge, the first HHT-related variant modifying the quantity rather than quality of the transcript.

References:

Grants: Italian Ministry of Education, University and Research to the DMM-University of Pavia “Dipartimenti di Eccellenza (2018-2022)”.

Conflict of Interest: None declared.

P14.007.B Characterization of the mitochondrial genome landscape in induced MSCs (iMSCs) derived from patients with osteoarthritis and healthy donors

Aspasia Destouni1, Evaftinia Moursou1, Vasileios Konteles1, Irene Sfougataki2, Ann Mertzianzian2, Thomas Brantzos5, Myrto Poulou1, Varvara Trachana1, Maria Tzitis4, Eugenios Goussetis2, Aspasia Tsezou1

1Laboratory of Cytogenetics and Molecular Genetics, Faculty of Medicine, University of Thessaly, Larissa, Greece; Larissa, Greece; 2Bone Marrow Transplantation Unit, Aghia Sophia Children’s Hospital, Athens, Greece, Athens, Greece; 3Laboratory of Medical Genetics, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece.

Background/Objectives: Osteoarthritis (OA) is an age-related disease. Heteroplasmic mitochondrial variants accumulate with advancing age, impairing respiration and cell metabolism. The present study characterized the mtDNA landscape in OA and healthy BM-MSCs, iPSCs and iPSCs-derived-MSCs (iMSCs).

Methods: Linearization of mtDNA, ultra-deep NGS and mtDNA analysis were used to determined homoplasmic and heteroplasmic SNVs and short deletions.

Results: Homoplasmic variants were not different between donors and cell types, while heteroplasmic variants were higher in OA-MSCs compared to healthy-MSCs. Differences were observed between OA-MSCS, -iPSCs and -iMSCs. Unsupervised hierarchical clustering showed a purifying effect for heteroplasmic variants in OA patients during re-programming to iPSCs. The decreased variant number remained stable during iPSCs differentiation while ~58% of heteroplasmic variants in OA and (~48%) in healthy donors are coding. In OA donors, the variants with the highest heteroplasmy fraction (HF~10%) are located in the control region (DLOOP1, DLOOP2), whereas in healthy donors (HF>90%) in ATP6 and a t-RNA gene TQ. The majority of the heteroplasmic variants fall in the r-RNA gene followed by ND1, ND2 genes in both groups.

Conclusion: We characterized the mtDNA landscape during generation of iMSCs from OA and healthy MSCS-donors, suggesting a decreased heteroplasmic variant load in OA-iPSCs, which remains stable during differentiation to iMSCS. The findings indicate that iMSCS might be valuable alternative to cell-based OA treatment.

References: Wei et al, Nat Commun, 2021, 12:5241.

Grants: The study co-financed by EU and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH–CREATE–INNOVATE (project code: T1EDK-00128).

Conflict of Interest: None declared.

P14.008.C Systematic characterisation of 5’untranslated regions reveals key difference between and across gene-sets

Nechama Wieder1, Alex Geary1, Frederik Lassen1, Elston D’Souza1, Maria Fernandes1, Robert Davies1, Nicola Whiffin1

1University of Oxford, Oxford, United Kingdom.

Background/Objectives: Untranslated regions (UTRs) flank the coding sequence of a gene. 5’ and 3’ UTRs are not translated but mediate post-transcriptional regulation via linear and structural
elements. To interpret 5'UTR variants in a clinical setting, further understanding of these regions is required; what they normally 'look like' and how they vary between different categories of genes.

**Methods:** We analysed 5'UTRs across all genes to determine their overall landscape. 5'UTRs of disease genes (developmental disorder (DD), cancer (C) and dosage sensitive (DS) genes sets) were explored to establish enrichment for 5'UTR features as they may be under tighter regulatory control. 5'UTR features investigated were length, introns and the number and type of upstream open reading frames (uORFs; cis-regulatory elements that down-regulate protein translation).

**Results:** 5'UTR lengths range from one to over 200 base pairs. 35% of genes have at least one intron. uORFs are present in 34% of genes. 5'UTRs of disease gene-sets were significantly longer (DD:P = 1.1x10-41, C:P = 1.8x10-05, DS:P = 1.1x10-98); have more uORFs (DDP = 2.6x10-23, C = 0.0002, DS = 2.4x10-56) and some have more introns (C:P = 0.03) than all gene 5'UTRs. DD recessive genes reflected the inverse trend - significantly shorter 5'UTRs (P = 1.6x10-05), significantly fewer introns (P = 0.001) and fewer uORFs (P = 0.002).

**Conclusion:** These disease gene-sets have more complex 5'UTRs and are enriched for cis-acting regulatory elements. 5'UTR features may be important to subtly regulate translation levels. Well-characterised 5'UTRs will aid in understanding of UTRs role and interpreting variants.

**References:**

**Grants:** Wellcome Trust.

**Conflict of Interest:** None declared.

**P14.009.D Genomic analysis of germline and somatic lesions at the FCGR locus; from reference genomes to clinico-biological implications**

**Sarah Frampton¹, Jade Forster², Marine Armand³, Helen Parker³, Khiyam Hussain⁴, Chantal Hargreaves⁵, Amatta Mirandari⁶, Nicolas Carey⁷, Daniel Rose⁷, Russell Fxalit⁸, Rosanna Smith⁹, Dean Bryant³, Steve Beers³, Mark Craggⁱ, Jane Gibsonⁱ, Jonathan Strefford⁻¹

¹University of Southampton, Cancer Genomics Group, Cancer Sciences, Southampton, United Kingdom; ²University Hospital Southampton, The Wessex Investigational Sciences Hub Laboratory, Southampton, United Kingdom; ³Centre for Cancer Immunology, Antibody and Vaccine Group, Southampton, United Kingdom; ⁴NIHR Oxford Biomedical Research Centre, Department of Clinical Immunology, John Radcliffe Hospital, Oxford, United Kingdom.

**Background/Objectives:** In cancer treatment, monoclonal antibodies (mAb) immunotherapies elicit their functional response by interacting with the Fc gamma receptors (FcγRs). The low-affinity locus (encoding FCGR2A, FCGR2B, FCGR2C, FCGR3A and FCGR3B) contains a 98% homologous 85kb segmental duplication and is highly polymorphic, harbouring multiple large copy number variations (CNVs) and single nucleotide polymorphisms (SNPs). Short sequencing reads often fail to map adequately, therefore we are generating accurate genomic maps of the FCGR locus using long-read Oxford Nanopore Technologies (ONT).

**Methods:** Utilising a healthy human cohort (n = 22) with different FCGR SNPs and CNV states, ONT adaptive sampling and cas9-mediated enrichment (tiling of 10 ROI) were employed to create comprehensive maps providing phased sequence, breakpoint and methylation information.

**Results:** Samples sequenced to an average of 200x (read N50 35kb) with some reads spanning >100kb. ONT adaptive sampling and cas9-targeting resulted in 6.2- and 500-fold increases in FCGR sequencing respectively, with enrichment as high as 967-fold. The bioinformatics pipeline of SNP and SV calling, phasing, de novo assembly and methylation calling has enabled the exact breakpoints of the CNVs to be identified, linkage disequilibrium relationships to be inferred and the connection between the FCGR (epi)genomic landscape and transcriptional regulation to be explored.

**Conclusion:** ONT transcriptomics for isoform quantification and expression analysis, and confirmation of large structural variants with BioNano optical mapping are both underway. ONT sequencing represents an exciting opportunity to overcome the difficulties of sequencing this complex region, facilitating greater understanding of FcγR regulation and how their function may be manipulated for the benefit of cancer patients.

**References:**

**Grants:**

Conflict of Interest: None declared.

**P14.010.A Whole-genome sequencing data reveals higher number of structural variants in Chernobyl catastrophe clean-up workers from Lithuania**

**Ingrida Domarkiene¹, Gabriele Zukauskaite², Alina Umikyte³, Laura Pranckenienė³, Svetlana Dauengauer-Kirlienė³, Justas Arasimavičius³, Alma Molytė³, Aušra Matulevičienė³, Ingrida Pilypienė³, Vaidutis Kucinskas³, Laima Ambrozaityte³

¹Department of Human and Medical Genetics, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania; ²Clinic of Children’s Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

**Background/Objectives:** Many of the Lithuanian Chernobyl catastrophe clean-up workers (LCCW) are already diseased, thus, we hypothesize that those, who experienced harsh exposures but survived and age relatively healthy, might have specific genomic variation which works in a protective way. Here we report initial structural variation (SV) analysis from whole-genome sequencing (WGS) data for 40 LCCW and 24 male control individuals of Lithuanian origin from the general population.

**Methods:** Short-read WGS data was of good quality (Q30 value: >90%) with the average coverage of ~38x. Structural variants were called on Illumina DRAGENv.3.6.4 using the same methods as Manta. SV (>49 bp) annotation was performed using AnnosV with default parameters. Wilcoxon rank sum test with continuity correction (α = 0.05) was performed using R 4.1.2.

**Results:** Deletions and insertions were more abundant than duplications in both groups. There were significant differences in average numbers of deletions (p = 0.007), duplications (p < 0.001), and insertions (p < 0.001) among LCCW and control groups. The average number of SV in LCCW group was 9640 compared to 8987 in control group, and about 95% of SV was new in both groups.

**Conclusion:** It is the first WGS SV data analysis of the Chernobyl catastrophe clean-up workers' and Lithuanian origin genomes. Further detailed SV characterization and integrative analysis will provide useful information on local human population and unique sample group of LCCW genomic variation. Current results complementation with greater sample size data would be beneficial for analysis.

**References:**

**Grants:** ADAPT (No.5-MIP-20-35) and ANELGEMIA (No.5-MIP-20-34) funded by the Research Council of Lithuania.

Conflict of Interest: None declared.
P14.011.B Mobile element insertions as potential cancer predisposition in high-risk HBOC patients

Janin Klein1, Annette Otto1, Gina Kastens1, Gunnar Schmidt1, Thilo Dörk2, Brigitte Schlegelberger3, Doris Steinemann1, Winfried Hofmann1

1Institute of Human Genetics, Hannover, Germany; 2Gynaecology Research Unit, Hannover, Germany.

Background/Objectives: In more than 60% of patients at risk for hereditary breast and ovarian cancer (HBOC), current diagnostic tests fail to identify the causative variant. A currently underestimated type of predisposing event is the disruption of gene structures by mobile element insertions (MEIs), since their systematic detection has not been possible before the implementation of high-throughput sequencing.

Methods: Panel sequencing data of 303 high-risk HBOC patients were reanalyzed using the bioinformatic tool Mobster. After filtering for rare, novel events proximal to HBOC-associated genes, one candidate MEI was further characterized by a minigene assay and fragment analysis.

Results: Of 55 novel MEI predictions, 13 located to HBOC-associated genes among which one predicted Alu element-insertion in intron 54 of ATM manifested as a true event and the most likely candidate to predispose for HBOC in two patients. Transcript analysis showed the expression of an alternative ATM transcript. Sanger sequencing revealed an exon skipping event resulting in the exclusion of exon 54 which was evident in up to 37% of total ATM mRNA in the patients. These results were reinforced by the minigene assay.

Conclusion: Since the aberrant transcript is unlikely to be translated into a functional protein due to a frameshift and subsequent premature stop codon in exon 55, the Alu element-insertion is a likely pathogenic variant associated with HBOC in two families. Our work has important implications for the treatment and surveillance of the patients and their families in addition to valuable insights into the detection and characterization of MEIs.

References:

Conflict of Interest: None declared.

P14.012.C Multisite de novo mutations after paternal exposure to ionizing radiation

Fabian Brand1, Manuel Holtgrewe2, Alexej Knaus1, Leonie Weinhold3, Dieter Beule2, Matthias C. Schmid2, Peter Krawitz2

1Institut für Genomische Statistik und Bioinformatik, Bonn, Germany; 2Berlin Institute of Health, Core Unit Bioinformatics, Berlin, Germany; 3Institut für medizinische Biometrie, Informatik und Epidemiologie (IMBIE), Bonn, Germany.

Background/Objectives: In our ongoing study we evaluate the effects of ionizing radiation on the offspring of exposed soldiers. Additionally, we identified ten candidates for large de novo SVs in the case cohort, including two translocations.

Methods: Panel sequencing data of 303 high-risk HBOC patients were reanalyzed using the bioinformatic tool Mobster. After filtering for rare, novel events proximal to HBOC-associated genes, one candidate MEI was further characterized by a minigene assay and fragment analysis.

Results: Of 55 novel MEI predictions, 13 located to HBOC-associated genes among which one predicted Alu element-insertion in intron 54 of ATM manifested as a true event and the most likely candidate to predispose for HBOC in two patients. Transcript analysis showed the expression of an alternative ATM transcript. Sanger sequencing revealed an exon skipping event resulting in the exclusion of exon 54 which was evident in up to 37% of total ATM mRNA in the patients. These results were reinforced by the minigene assay.

Conclusion: Since the aberrant transcript is unlikely to be translated into a functional protein due to a frameshift and subsequent premature stop codon in exon 55, the Alu element-insertion is a likely pathogenic variant associated with HBOC in two families. Our work has important implications for the treatment and surveillance of the patients and their families in addition to valuable insights into the detection and characterization of MEIs.

References:

Conflict of Interest: None declared.

P14.013.D Xq27.1 palindrome mediated interchromosomal insertion as the likely cause of familial congenital bilateral laryngeal abductor paralysis (Plott syndrome)

Felix Boschann1, Daniel Julian Acero-Moreno2, Martin Atta Mensah1, Henriek Szczakiel1, Karolina Skipalova1, Manuel Holtgrewe3, Stefan Mundlos1, Björn Fischer-Zirnsak1

1Charité – Universitätsmedizin Berlin, corporate member of Free University Berlin and Humboldt-Universität zu Berlin, Institute of Medical Genetics and Human Genetics, Berlin, Germany; 2Kliniken der Stadt Köln gGmbH, Division of Pediatric Critical Care Medicine, Cologne, Germany; 3Berlin Institute of Health Charité – Universitätsmedizin Berlin, Core Facility Bioinformatics, Berlin, Germany.

Background/Objectives: Bilateral laryngeal abductor paralysis is a common cause of stridor in newborns. No convincing genetic aberration has been reported for Plott syndrome (X-linked isolated bilateral vocal cord paralysis, MIM: 308850). We aimed to study the underlying cause in a large family with eight affected males, of whom seven died shortly after birth.

Methods: We performed short read whole genome sequencing (WGS) in an affected boy and his unaffected brother. FISH analysis was conducted to confirm the detected genomic rearrangement. Breakpoint specific PCRs and qPCR were used for segregation analysis.

Results: In the affected boy, we identified a 404 kb large non-coding insertion into the well-known intergenic region Xq27.1, originating from chromosome 10q21.3. This genomic rearrangement was confirmed by FISH analysis. Breakpoint junction analysis identified patterns likely resulting from replication based mechanisms like MMBlR/FoSTeS. Segregation analysis confirmed strictly matrilineal inheritance of the derivative chromosome X.

Conclusion: Our findings add Plott syndrome as a further disease entity caused by interchromosomal insertions into the intergenic region Xq27.1 and show that phenotypically distinct diseases can result from the introduction of different regulatory elements into the same genomic region. Thus demonstrating the utility of WGS in the diagnosis of previously unsolved cases.

References: Boschann F, Moreno DA, Mensah MA, Szcakiel HL, Skipalova K, Holtgrewe M, Mundlos S, Fischer-Zirnsak B. Xq27.1 palindrome mediated interchromosomal insertion likely causes familial congenital bilateral laryngeal abductor paralysis (Plott syndrome). J Hum Genet. 2022 Jan 31. https://doi.org/10.1038/s10038-022-01018-z. Epub ahead of print. PMID: 35095096.

Grants:

Conflict of Interest: None declared.
P14.014.A Unusual Suspects in hereditary melanoma: POT1, POLE and BAP1

Ellie Maas1, brigid betz-stablein1, lauren aoude2, Hans Peter Soyer3,4, Aiden McInerney-Leo2

1University of Queensland Diamantina Institute, Faculty of Medicine, WOOLLOONGABBA, Australia; 2The University of Queensland Diamantina Institute, Surgical Oncology Group, WOOLLOONGABBA, Australia; 3University of Queensland Diamantina Institute, Dermatology Research Centre, Brisbane, Australia; 4Princess Alexandra Hospital, Dermatology Department, Brisbane, Australia.

Background/Objectives: Three genes (POT1, POLE and BAP1), have been reported in association with familial melanoma in the past decade. Genotype-phenotype correlations of individuals with mutations in these genes have not been well described.

Methods: Systematic searches collated 273-variants pathogenic (BAP1 n = 136, POT1 n = 71, POLE n = 66) which were identified and annotated from 69-sources to identify genotype-phenotype correlations in these genes.

Results: Two high-cluster regions, predominantly associated with cutaneous melanoma (CM), were identified in POT1 in the oligonucleotide/oligosaccharide binding region one (292aa) and two (6aa). POT1 had one high-cluster variant region (929aa) in the exonuclease domain associated with diverse cancer types. The highest proportion of variants in this cluster were associated with endometrial cancer; however, there was one hotspot (spanning 55aa) associated with CM. BAP1 had six high-cluster regions with loss-of-function variants within 24aa associated exclusively with CM (between nuclear localisation signal domains). Two BAP1 clusters (31aa and 12aa) were both associated with CM and uveal melanoma (UM) (located in unspecified regions between the BRCA-1 associated ring domain (BARD) and the BRCA1 binding domain); another two clusters had the predominant phenotype of UM (74aa and 21aa) located in the ubiquitin carboxy-terminal hydrolase (UCH)/BARD crossover domain, and the BARD binding domain respectively. The remaining BAP1 cluster was associated with diverse cancer phenotypes of CM, UM and malignant mesothelioma, and was located in the UCH domain (11aa).

Conclusion: Genotype-phenotype correlations captured from this research can be used to identify patient disease predisposition based on mutation position and cluster regions in POT1, POLE or BAP1.

References:

Grants:

Conflict of Interest: None declared.

P14.015.B Genetic and epigenetic effect of 22q12 large deletions in rare NF2 patients

Viviana Tritto1, Marica Eoli2, Micaela Berni3, Rosina Paterra2, Luisa Chiapparini3, Serena Redaelli4, Paola Riva1

1University of Milan, Department of Medical Biotechnology and Translational Medicine, Segrate (Milan), Italy; 2IRCCS Foundation, Carlo Besta Neurological Institute, Unit of Molecular Neuro-Oncology, Milan, Italy; 3IRCCS Foundation, Carlo Besta Neurological Institute, Department of Diagnostics and Applied Technology, Neuroradiology Unit, Milan, Italy; 4University of Milano-Bicocca, School of Medicine and Surgery, Monza, Italy.

Background/Objectives: Neurofibromatosis type 2 is an autosomal dominant tumor-prone disorder, mainly due to point mutations or intragenic deletions of NF2 gene, encoding Merlin protein, that inhibits proliferation pathways. However, rare large 22q12 microdeletions have been found in patients with complex phenotype [1]. To identify the genetic and epigenetic mechanisms resulting from 22q12 microdeletions, we characterized three NF2 microdeletion patients, two with extended deletions and severe phenotype, including mental retardation, and one with a smaller deletion and milder phenotype.

Methods: We carried out MLPA, aCGH, in silico analysis, Long-Range PCR assays, and Sanger sequencing to characterize the deletions’ breakpoints. We performed in silico analysis of 22q12 TADs and regulatory elements, together with gene expression analysis of 19 genes flanking patients’ deletions by RT-PCR, to investigate a possible position effect generated by the chromatin 3D-structure alteration.

Results: Patient with milder phenotype shows 146 Kb deletion, involving three genes. In patients with more severe phenotype, deletions of 560 Kb and 1.8 Mb have been identified, counting 13 and 36 genes, respectively, and including AP1B1, a gene that could be linked to patients’ mental retardation. Furthermore, patients’ microdeletions alter from one to five TADs and the 22q12 regulatory landscape, and RT-PCR assays confirmed the position effect on some flanking genes. Interestingly, PIK3IP1 over-expression could be associated with the ischemic event occurred in patient with largest deletion.

Conclusion: Our results, providing new genotype-phenotype correlations in NF2 microdeletion patients, could have an impact on the identification of prognostic markers, useful for patient management, and potential therapeutic targets.

References: [1] PMID:10338003.

Grants: Academic fund.

Conflict of Interest: None declared.

P14.016.C A systematic annotation of the impact on splicing of all possible substitutions within the SPINK1 coding sequence

Hao Wu1,2, Jin-Huan Lin1,2, Wen-Bin Zou1,2, Emmanuelle Masson3,4, sachia schutz3,4, David N. Cooper5, Gerald Le Gac3,4, Claude Férec3, Zhao-Shen Li1,2, Zhuhan Liao1,2, Jian-Min Chen1

1Changhai Hospital, The Secondary Military Medical University, Department of Gastroenterology, Shanghai, China; 2Shanghai Institute of Pancreatic Diseases, Shanghai, China; 3Univ Brest, Inserm, EFS, UMR 1078, GGB, Brest, France; 4CRU Brest, Service de Génétique Médicale et de Biologie de la Reproduction, Brest, France; 5Institute of Medical Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom.

Background/Objectives: In addition to mutations within splice junctions, both missense and silent variants within the coding region may affect pre-mRNA splicing. However, there are currently no human genes for which the consequences for splicing of all possible substitutions within the coding sequence have been systematically annotated. Herein, we attempted to achieve such a goal in the context of SPINK1.

Methods: All possible substitutions within the entire SPINK1 coding sequence were subjected to SpliceAI prediction [1]. The accuracy of SpliceAI prediction was first evaluated in the context of 27 known variants previously analyzed using a Full-Length Gene Splicing Assay (FLGSA) [2,3]. All three possible substitutions in a dozen selected coding nucleotide sites were further subjected to FLGSA as described [3].
Results: SpliceAI prediction and experimentally obtained findings concurred exactly with the previously analyzed 27 SPINK1 variants. As for the prospectively analyzed variants, there was an excellent correlation between SpliceAI prediction and experimental validation. The use of FLGSA made it possible to correlate precisely the predicted and experimentally obtained aberrant splicing outcomes.

Conclusion: Having correlated SpliceAI-predicted and FLGSA-derived findings from a large number of known and prospectively generated variants, we were able to provide a systematic annotation of the splicing effects of all possible substitutions within the coding sequence of the SPINK1 gene with a high degree of accuracy.

References: [1]. Jaganathan et al. Cell. 2019;176:535. [2]. Zou et al. Gut. 2016;65:884. [3]. Wu et al. Genes. 2017;8:263.

Grants: The National Natural Science Foundation of China (81800569 [HW]; 82000611 [J-HL]); The Shanghai Pujiang Program (18PJD057 [HW]; 2020PD061 [J-HL]).

Conflict of Interest: Hao Wu Department of Gastroenterology, Changhai Hospital, the Secondary Military Medical University, Shanghai, China, The National Natural Science Foundation of China (no. 81800569); The Shanghai Pujiang Program, China (no. 18PJ0D057), Jin-Huan Lin Department of Gastroenterology, Changhai Hospital, the Secondary Military Medical University, Shanghai, China, The National Natural Science Foundation of China (no. 82000611); The Shanghai Pujiang Program (no. 2020PD061), Wen-Bin Zou Department of Gastroenterology, Changhai Hospital, the Secondary Military Medical University, Shanghai, China, Emma-nuelle Masson Service de Génétique Médicale et de Biologie de la Reproduction, CHRU Brest, F-29200 Brest, France, sacha schutz Service de Génétique Médicale et de Biologie de la Reproduction, CHRU Brest, F-29200 Brest, France, David N. Cooper Institute of Medical Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom, Gerald Le Gac Univ Brest, Inserm, EFS, UMR 1078, GGB, F-29200 Brest, France, Claude Férec Univ Brest, Inserm, EFS, UMR 1078, GGB, F-29200 Brest, France, Zhao-Shen Li Department of Gastroenterology, Changhai Hospital, the Secondary Military Medi-cal University, Shanghai, China, Zhuan Liao Department of Gastro-enterology, Changhai Hospital, the Secondary Military Medical University, Shanghai, China, Jian-Min Chen Univ Brest, Inserm, EFS, UMR 1078, GGB, F-29200 Brest, France.

P14.017.D Identification of a novel physiological LRIG2 splicing variant associated with the development of Urofacial Syndrome

Ornella Rondinone1, Alessia Mauri2, Giada Moresco2, Jole Costanza3, Carla Cantaniello3, Patrizia Colapietro4, Passalvina D’Ursi5, Matteo Uggeri2, Giovanni Marfia6, Laura Guarnaccia6, Stefania Novone6, Gianantonio Manzoni2, Dario Guido Minoli7, Dario Federico Grilli8, Donatella Milani9, Monica Mizio10, Laura Fontana1

1Università degli Studi di Milano, Medical Genetics, Department of Health Sciences, Milan, Italy; 2Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Research Laboratories Coordination Unit, Milan, Italy; 3Fondazione Istituto Nazionale di Genetica Molecolare, INGM, Milan, Italy; 4Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy; 5Institute for Biomedical Technologies, National Research Council (ITB-CNR), Milan, Italy; 6Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Laboratory of Experimental Neurosurgery and Cell Therapy, Neurosurgery Unit, Milan, Italy; 7Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Pediatric Urology Unit, Milan, Italy; 8Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Highly Intensive Pediatric Care Unit, Milan, Italy; 9ASST Santi Paolo e Carlo, Medical Genetics Unit, Milan, Italy; 10Universitätsklinikum Heidelberg.

P14.018.A BeSolveRD: The Belgian genome resource to resolve rare diseases

Mathilde Geyens1, Wouter Bossuyt1, Elfrid De Boer2, Kim De Leener2, Koenraad Devriendt1, Annelies Dheedene3, Aime Lumaka4, Jeroen Luyten5, Bert Matthys6, Björn Menter7, Marije Meuwissen7, Olivier Monestier8, Catharina Olsen9, Leonor Palmeira3, Nicole Revençu8, Julie Soblet1, Erika Souche1, Yves Sznajer8, Sonia Van Dooren10, Catheline Vilain11, Kris Van Den Bogaert1, Joris Vermeesch1

1University hospitals Leuven-KU Leuven, Center for Human Genetics, Leuven, Belgium; 2Ghent University Hospital, Center for Medical Genetics, Ghent, Belgium; 3Centre Hospitalier Universitaire de Liège, Center for Medical Genetics, Liège, Belgium; 4University of Leuven, Leuven Institute for Healthcare Policy, Leuven, Belgium; 5Université Antwerpen, Center for Medical Genetics, Antwerp, Belgium; 6Institut de Pathologie et Génétique, Center of Human Genetics, Gosselies, Belgium; 7Université Libre de Bruxelles, Machine Learning Group, Département d’informatique, Brussels, Belgium; 8Université Catho-lique de Louvain, Center for Human Genetics, Brussels, Belgium; 9Université Libre de Bruxelles, Center of Human Genetics, Brussels, Belgium; 10Wijme University Brussel, Center for Medical Genetics, Brussels, Belgium.

Background/Objectives: Despite the diagnostic implementation of chromosomal microarrays/shallow whole genome sequencing and whole exome sequencing (WES) for patients with intellectual disabilities/developmental disorders (ID/DD), approximately half remain undiagnosed using this standard of care (SoC). To (1) technically validate whole genome sequencing (WGS) at different genetic centers in Belgium, (2) investigate the clinical utility of WGS for ID/DD diagnosis and (3) to assess the health economic impact, the Belgian genetic centers engaged in a multicentric prospective randomized control trial, called BeSolveRD.
Methods: A total of 800 patients and both parents will be recruited of which half will be processed by SoC and half by WGS. We have performed ring trials to compare different methods to generate WGS libraries, allowing the optimization and validation of WGS in all centers. The WGS pipelines for SNV detection of all centers and their performance have also been assessed. Most pipelines use the same tools and perform very similarly despite the different implementation. Finally, we have created a federated database to share variant and sequence information.

Results: We will present the process of collaboration, the challenges and the intermediate output data.

Conclusion: Intermediate conclusions will be deduced from the results gathered until May 2022.

References: /.

Grants: Illumina sponsored study.

Conflict of Interest: None declared.

P14.019.B Method optimisation for structural variant detection in the human genome

Oguzhan KALYON1, Bilal Alobaidi1, Lois Batty1, Miguel Xavier1, Giles Holt1, Aneta Mikulasova1, Joris Veltman1

1Biosciences Institute, Faculty of Medical Sciences, Newcastle upon Tyne, United Kingdom.

Background/Objectives: Structural variation (SV) has been traditionally difficult to identify and characterize. Now, whole genome sequencing (WGS) and optical genome mapping (OGM) are both available for more comprehensive SV detection. Here, we compared and optimized the accuracy of SV detection by combining different bioinformatic tools and platforms into an integrated workflow and applied this to both simulated and real genomic data.

Methods: Two short-read WGS BAM files with gains and losses (n = 841, size range 2kb–1Mb) were simulated. Different bioinformatic tools were tested for SV detection in these simulated WGS data. In addition, we performed both WGS and OGM in 9 samples and compared SV detection.

Results: Simulated WGS data showed that the combination of a depth of coverage method (CNVRobot) and a method based on discordant read pairs and split reads (dysgu-SV) provided the most efficient and accurate method for SV detection. This combination resulted in a true positive rate of SV detection of 99.3% and a false discovery rate of 0.02%. Next, we applied this integrated approach in WGS data from 9 samples and identified 96 SVs on average (mean size 8kb). In addition, we identified 135 SVs on average (mean size 31kb) by OGM. Only 34% of SVs detected by the integrated WGS pipeline were supported by OGM, which in general detected larger and more complex SVs.

Conclusion: Our study demonstrates that combined bioinformatic approaches provide highly accurate SV identification in WGS. By combining WGS with OGM we were able to obtain a highly reliable SV dataset.

References:

Grants:

Conflict of Interest: None declared.

P14.020.C Review of secondary findings reported in the qGenomics patient cohort, analyzed by exome sequencing

Marta Carreño1, Maria Segura-Puimendon1, Raquel Garcia1, Lidia Carreño1, César Arjona1, Hector San Nicolás1, Célia Sintas1, Mónica Vail1, Olaya Villa Marcos1, Marina Viñas-Jornet1, LLuis Armengol1

1qGenomics, NGS Clinical Department, Esplugues de Llobregat, Spain.

Background/Objectives: A new update of the American College of Medical Genetics (ACMG) recommendations for the reporting of secondary findings (SF) in clinical exome and genome sequencing was published last year, along with the new list of 73 medically actionable genes ACMG SF v3.0. In it, an analysis of the impact of the use of the previous list (ACMG SF v2.0) is also exposed. The objective of our study was to calculate the frequencies of the SF report in our cohort and to compare it to previous studies in literature and with the frequencies obtained with the new list.

Methods: A retrospective investigation was carried out on 3638 patients, analyzed by whole exome sequencing during the period between the publication of both ACMG lists (2017-2021). Also, it was extended to 541 more patients, analyzed after the ACMG list update.

Results: In our cohort, SF have been reported in 98 cases (frequency of 2.69%), being BRCA2 and KCNQ1 genes the most frequently reported. As expected, this frequency has increased up to 3.51% with the use of the new list.

Conclusion: Although it is difficult to compare different studies, the frequencies obtained fit perfectly into the frequency ranges described in the update. Currently, the new expanded list has been implemented in our laboratory, continuing with the objective of preventing and reducing patient morbidity and mortality. Our purpose is to continue to analyze the diagnostic potential of SF with the new ACMG SF v3.0 list.

References:

Grants:

Conflict of Interest: Marta Carreño qGenomics, Maria Segura-Puimendon qGenomics, Raquel Garcia qGenomics, Lidia Carreño qGenomics, César Arjona qGenomics, Hector San Nicolás qGenomics, Célia Sintas qGenomics, Mónica Vail qGenomics, Olaya Villa Marcos qGenomics, Marina Viñas-Jornet qGenomics, LLuis Armengol qGenomics.

P14.022.A Genetic diagnosis can be missed by classical filtering criteria for WES in Mendelian Disorders – diagnostic strategies to approach challenging cases

Sarah L. Stenton1;2, Christiane Neuhofer1;2;3, Riccardo Berutti1;2, Robert Kopajtich1;2, Dmitrii Smirnov1;2, Holger Prokisch1;2

1Institute of Human Genetics, Technical University of Munich, Munich, Germany; 2Institute of Neurogenomics, Helmholtz Zentrum Munich, Munich, Germany; 3Department of Neurology, Friedrich-Baur-Institute, LMU Hospital, Ludwig Maximilians University, Munich, Germany.

Background/Objectives: More than 50% of patients with suspected hereditary disorders ultimately remain without molecular diagnosis. Variants with incomplete penetrance as well as heterozygous variants in autosomal recessive genes escape prioritzation despite being potentially causative.

Methods: In case of reduced penetrance, segregation of pathogenic variants doesn’t follow conventional Mendelian inheritance patterns. This required new filtering approaches, inclusion of gene burden tests in large cohorts and early integration of functional evidence.

Results: Variants of incomplete penetrance show higher allele frequency than expected from the incidence of the disease. We therefore eased the MAF filtering criteria, applied statistical analysis of gene burden and included functional evidence by transcriptome and proteome analysis to search for novel disease genes with incomplete penetrance[1].
In the absence of statistical evidence functional analysis is of paramount importance. In one family the unaffected grandfather was found to carry the same hemizygous variant in a complex I subunit gene as the index patient. Functional proteomics studies provided convincing evidence of the pathogenicity of the variant.

In another case a patient presented with a recognisable phenotype but unexpected inheritance pattern. Large scale proteomics analysis strongly argued for a heterozygous variant to cause the clinical presentation of a disease considered to be recessive.

**Conclusion:** From a large body of data and long-standing experience in molecular genetic diagnostics we show strategies to approach cases unsolved in first line diagnostics. We derive general recommendations to address variation in reduced penetrance genes and following unexpected inheritance patterns.

**References:**
1. Stenton et al. J Clin Invest. 2021 https://doi.org/10.1172/JCI147734.

**Conflict of Interest:** None declared.

---

**P15 CYTOGENETICS**

**P15.001.B International System for Human Cytogenomic nomenclature (ISCN) – the challenge of the nomenclature**

Ros Hastings¹, Melody Tabiner², Zandra Deans³

¹Oxford University Hospitals NHS Foundation Trust, Genomics External Quality Assessment (GenQA), Oxford, United Kingdom; ²Oxford University Hospitals NHS Foundation Trust, Genomics External Quality Assessment (GenQA), Oxford, United Kingdom; ³NHS Lothian, Genomics External Quality Assessment (GenQA), Edinburgh, United Kingdom.

**Background/Objectives:** ISCN is an essential tool for reporting cytogenomic and some molecular analysis results (e.g. QF-PCR, MLPA) in a consistent and accurate manner to enable effective communication between clinicians and scientists and use of databases. Educational webinars plus a pilot online ISCN external quality assessment (EQA) highlighting some key ISCN principles were delivered to support laboratories reporting results, following publication of ISCN 2020(1).

**Methods:** Ideograms and/or images plus written descriptions of abnormalities were provided online. Participants were required to input the correct ISCN for the result described. Each case focussed on different aspects of ISCN: Constitutional karyotyping; Constitutional FISH; Neoplasia karyotyping; Oncology FISH; Microarrays; Region specific assays (rsA).

**Results:** There were numerous errors, with some particularly challenging case scenarios. Sixty-six participants answered at least one case. Recurrent errors included:
- Using ‘mat’ instead of ‘dmat’ for a maternally derived unbalanced segregant;
- Including the normal control probe and/or cell numbers in non-mosaic constitutional FISH;
- Incorrect order for structural chromosome abnormalities;
- Inappropriate omission of breakpoints for metaphase FISH;
- Inconsistent use of terminology/punctuation.

**Conclusion:** This EQA highlighted the challenges of using ISCN. More centres gave the correct ISCN for rsa than the other cases. It was apparent from the submissions that FISH nomenclature was the most demanding and that the differences between constitutional and neoplastic ISCN were not fully understood.

This pilot demonstrated the continued need for training webinars and additional ISCN EQAs to educate and promote standardisation.

---

**References:**
1. McGowan-Jordan J., et al. (2020). ISCN 2020: An International System for Human Cytogenomic Nomenclature. S. Karger, Basel.

**Conflict of Interest:** None declared.

---

**P15.003.D Comparative benchmarking of optical genome mapping and chromosomal microarray reveals high technological concordance in CNV identification and structural variant refinement**

Dana Jaber¹, Hayk Barseghyan², Andy Wing Chun Pang¹,²,³, Alka Chaubey¹, Yannick Delpu¹, Alex Hastie¹

¹Bionano Genomics, Inc., San Diego, United States; ²Center for Genetic Medicine Research, Children’s National Hospital, Washington, United States; ³Genomics and Precision Medicine, School of Medicine and Health Sciences, George Washington University, Washington, United States.

**Background/Objectives:** Children with developmental delays and/or congenital anomalies with suspected genetic etiology are often tested for SVs by chromosomal microarray (CMA), karyotype, fragile X testing, and sequencing [1]. Because CNV and SV are often found to be causative, CMA is recommended as first tier testing for many indications [2]. Optical genome mapping (OGM) is a technology that can detect not only CNVs, but also balanced rearrangements compared with CMA [3-5]. We evaluated the performance of OGM for reported genomic variants in comparison with CMA for 61 chromosomal abnormalities from 55 patients with variable phenotypes.

**Methods:** OGM was performed on samples from 55 patients with CNVs previously identified by CMA. SVs identified by OGM were filtered by a control database to remove polymorphic variants and a gene list to prioritize biologically relevant findings before comparison against CMA and FISH.

**Results:** OGM successfully identified CNVs, SVs, and absence of heterozygosity (AOH) in samples previously tested with CMA. OGM results showed high concordance with CMA while also characterizing the structure that CMA was unable to define without FISH.

**Conclusion:** OGM has sufficient analytical validity to detect biologically relevant variants identified by CMA. OGM can also identify rearrangements observed with FISH within the same single assay in a genome-wide scale that may provide additional biological utility compared to CMA.

**References:**
1. https://omim.org/.
2. Miller, Am. J. Hum. Genet. 2010.
3. Cope, Mol. Genet. Genomic Med. 2021.
4. Mantere, Am. J. Hum. Genet. 2021.
5. Mostovoy, Genetics. 2021.

**Grants:**

**Conflict of Interest:** Dana Jaber Bionano Genomics, Hayk Barseghyan Bionano Genomics, Andy Wing Chun Pang Bionano Genomics, Alka Chaubey Bionano Genomics, Yannick Delpu Bionano Genomics, Alex Hastie Bionano Genomics.

---

**P15.004.A Structural and copy number variant detection, filtering, annotation, and classification by Optical Genome Mapping in research of constitutional disorders**

Dana Jaber¹, Ben Clifford¹, Hayk Barseghyan¹,²,³, Andy Wing Chun Pang¹, Alka Chaubey¹, Yannick Delpu¹, Alex Hastie¹

¹Bionano Genomics, Inc., San Diego, United States; ²Center for Genetic Medicine Research, Children’s National Hospital, Washington, United States; ³Genomics and Precision Medicine, School of Medicine and Health Sciences, George Washington University, Washington, United States.

**References:**
1. McGowan-Jordan J., et al. (2020). ISCN 2020: An International System for Human Cytogenomic Nomenclature. S. Karger, Basel.

**Grants:**

**Conflict of Interest:** None declared.
Background/Objectives: Identifying a breadth of variants and presenting actionable findings is key to disease research, classification and stratification. In contrast to methods like karyotyping, chromosomal microarray (CMA), FISH or sequencing, optical genome mapping (OGM) is sufficiently versatile to identify all classes of SVs with high sensitivity and specificity. Variant calls are managed within the Bionano Access software, where filters are applied to prioritize classification on variants likeliest to have a biological impact.

Here, we demonstrate a comprehensive and lab-ready workflow for whole genome OGM data analysis, alignment and annotation using GRCh38, variant evaluation, and classification.

Methods: For constitutional disorders, OGM data is analyzed with the Solve 3.7 De Novo Assembly pipeline, with sample data aligned to GRCh38 to resolve variants and annotate against a common reference.

Results: We apply a workflow to filter based on size (≥1.5 kbp), absence in assay-matched controls database (≤1%), and overlap with gene. The resulting prioritized variant list presents ~20-30 variants on average, added to a curation list. With the variant classifier visualization, we evaluate each variant captured as aligned to GRCh38, showing properties such as size and putative impact to genes. Multiple analysts may independently classify and supervisor can reconcile records to adjudicate classifications, record large-scale genomic irregularities, download a report.

Conclusion: OGM is suited to identify variants which are biologically relevant. The analytical approach annotates thousands of genome-wide variants accurately, and the filtering workflow directs focus to the most promising. The subsequent classification and reporting tools provide utility for communicating significance.

References:

Grants:

Conflicts of Interest: Aoxing Liu full employment, University of Helsinki, Giulio Genovese Biomedical Institute of Harvard and MIT, Yajie Zhao University of Cambridge, Po-ru Loh Broad Institute of MIT and Harvard, Andrea Ganna Institute for Medical Research Finland, John Perry University of Cambridge, Mitchell Machiela National Cancer Institute.

P15.006.C Multi-omics analysis of DNA and RNA identifies disruption of MINK1 in a balanced translocation carrier with congenital cataract and epilepsy

Jesper Eifelstøl, Jakob Schuy, Eva-Lena Stattin, Anna Lindstrand

1Karolinska Institute, Department of Molecular Medicine and Surgery and Center for Molecular Medicine, Stockholm, Sweden; 2Karolinska University Hospital, Department of Clinical Genetics, Stockholm, Sweden; 3Karolinska Institutet Science Park, Science for Life Laboratory, Stockholm, Sweden; 4Uppsala University, Science for Life Laboratory, Department of Immunology Genetics and Pathology, Uppsala, Sweden.

Background/Objectives: Genomic translocations are structural variants which are copy number neutral. Chromosomal segments are relocated forming fusing chromosomes which may result in genes disruption and/or fusion transcripts. The translocation breakpoints are commonly located in repetitive or insufficiently mapped regions of the genome complicating the process of resolving the rearrangement. In such cases, long-range information is required to precisely pinpoint the breakpoints. MINK1 (Misspliced-like kinase 1) has been linked to skeletal and neuronal impairments and has also been mentioned in phenotypes like cancer, platelet formation, Alzheimer and Rheumatoid arthritis.

Methods: The here presented case has been investigated with a cascade of methods including karyotyping, paired-end and linked-read as well as long-read genome sequencing.

Results: The presented case contains a balanced translocation t(17,19) of which one breakpoint is located in the centromere of chromosome 19. Only by the addition of long-read Oxford nanopore technology, the centromeric breakpoint on chromosome 19 could be detected. The translocation disrupts MINK1 leading to reduced levels of transcripts which is observed in patient-derived neuroepithelial stem cells.

Conclusion: Due to the unique translocation and the breakpoint’s phenotype matching the MINK1 linked literature, we suggest MINK1 as novel gene causing autism, epilepsy, and osteoporosis.

References: -

Grants: Swedish Research Council (2019-02078), Swedish Rare Diseases Research Foundation (Sällsyntafonden) and the Swedish Brain Foundation (FO2020-0351).
Conflict of Interest: None declared.

P15.007.D First Genome-first identification of a chromosomal balanced rearrangement responsible for a recessive disease: a case of renal tubular dysgenesis

Nicolas Chatron1,2, Claire Goursaud3, Charlotte Dubuc4,5, Jacqueline Aziza6, Stéphane Decramer6, Blandine Hougas7, Dominique Chauveau8, Julien Thevenon9,10, Damien Sanlaville1,2, Laurence Michel-Calemard3

1Hospices Civils de Lyon, Service de Génétique, Lyon, France; 2Univ Lyon, UCBL1, INMG, CNRS UMR5310, INSERM U1217, Lyon, France; 3Hospices Civils de Lyon, Service de Biochimie, Lyon, France; 4CHU de Toulouse, Service de Génétique médicale, Toulouse, France; 5IUCT Oncopôle, Service d’Anatomie et Cytologie Pathologiques, Toulouse, France; 6CHU de Toulouse, Service de Pédiatrie – Néphrologie Médecine Intére et Hypertension, Hôpital des Enfants, Toulouse, France; 7Centre d’échographie des Carmes, Toulouse, France; 8CHU Grenoble Alpes, Service de Génétique, Grenoble, France; 9Laboratoire AURAGEN, Lyon, France.

Background/Objectives: Sequence resolution of balanced structural variation is now possible at scale through genome sequencing. For recessive diseases, simultaneous detection of structural and nucleotide variants on both alleles makes genome sequencing an effective approach. Herein, we report the identification of a compound heterozygous case of renal tubular dysgenesis and paralogs which are responsible for an autosomal recessive form of frequently lethal RTD.

Methods: Genome sequencing was used as a first-tier cytogenetics test also able to identify a differential diagnosis. A maternally inherited balanced reciprocal translocation disrupting AGTR1 was identified through panel sequencing. Biallelic variants of AGTR1 are responsible for an autosomal recessive form of frequently lethal RTD.

Results: A custom-designed deep-dive template was used to extract relevant information from diverse sources including: OMIM morbidity, gnomAD allele counts, REVEL pathogenicity, and gnomAD Z / probability loss-of-function scores. Findings were reviewed collaboratively with clinical geneticists and academic research scientists from the NIGMC to identify plausible VUS. The kidney specific public database NephroSeq was utilised to further explore the biological function of genes with VUS.

Conclusion: Of the nine probands with unexplained ESRD, six phenotypically plausible VUS were identified within five individuals. This included splice donor variants within pseudohypoaldosteronism associated WNK1, missense / frameshift variants within the renal specific gene BB59 associated with Bardet-Biedl syndrome, and a splice region variant within LAMC1 which has prior associations with increased ESRD risk.

References:
Grants:
Conflict of Interest: None declared.

P16 NEW TECHNOLOGIES AND APPROACHES

P16.002.B Cost-effective, collaborative approach to prioritise variants of unknown significance from whole genome sequencing data: unexplained end stage renal disease exemplar

Katie Kerr1,2, Caomhie McKenna2, Diya Thomas1, Jill Kliner1, Cheryl Flanagan2, Shane McKee2, Amy Jayne McKnight1

1Queen’s University Belfast, Belfast, United Kingdom; 2Belfast Health & Social Care Trust, Northern Ireland Genomic Medicine Centre, Northern Ireland Genomic Medicine Centre, Belfast, United Kingdom.

Background/Objectives: The Northern Ireland Genomic Medicine Centre (NIGMC) recruited 444 rare disease probands to the 100,000 Genomes Project for whole genome sequencing. Forty-one probands had renal phenotypes, including nine participants with unexplained end-stage renal disease (ESRD) who remained undiagnosed following initial analysis by the NIGMC. We performed individual ‘deep-dives’ to prioritise variants of unknown significance (VUS) for follow-up analyses.

Methods: The top five ranked variants from Exomiser were prioritised for investigation. A custom-designed ‘deep-dive’ template was used to extract relevant information from diverse sources including: OMIM morbidity, gnomAD allele counts, REVEL pathogenicity, and gnomAD Z / probability loss-of-function scores. Findings were reviewed collaboratively with clinical geneticists and academic research scientists from the NIGMC to identify plausible VUS. The kidney specific public database NephroSeq was utilised to further explore the biological function of genes with VUS.

Results: Of the nine probands with unexplained ESRD, six phenotypically plausible VUS were identified within five individuals. This included splice donor variants within pseudohypoaldosteronism associated WNK1, missense / frameshift variants within the renal specific gene BB59 associated with Bardet-Biedl syndrome, and a splice region variant within LAMC1 which has prior associations with increased ESRD risk.

Conclusion: This study highlights the potentials of deeply reviewing VUS from WGS data for patients with unexplained ESRD, as well as the benefits of clinical and academic collaboration for capitalising on VUS which could not feasibly within routine clinical services. Further functional analysis of these VUS is underway, including long read sequencing and functional follow-up.

References:
Grants:
Conflict of Interest: None declared.
**Results:** Following limiting dilution and clonal expansion of CRISPR/Cas9-edited cells, four wells showed a single population. Unexpectedly, two of these were found to have an in-frame 13bp sequence alteration at the cut-site that resulted from gene conversion, with replacement of the targeted sequence of ATAD3A by a donor sequence from its paralog, ATAD3B. Chromosomal microarray did not show larger deletions or duplications at the locus.

**Conclusion:** We highlight the complexity of CRISPR/Cas9 design and recombination repair mechanisms when targeting genes that have paralogs or pseudogenes. Additionally, we suggest that endogenous gene conversion may be used to repair missense variants in genes with paralogs or pseudogenes.

**References:** Harel, T., et al. (2016). Am J Hum Genet 99, 831-845.

**Grants:** ISF 1663/17 to TH.

**Conflict of Interest:** Shira Yanovsky-Dagan: None declared, Ayala Frumkin: None declared, James Lupski: Stock ownership in 23andMe, J.R.L. is a paid consultant for Regeneron Genetics Center, and is a co-inventor on multiple United States and European patents related to molecular diagnostics for inherited neurofibromatosis, and is a co-inventor on multiple United States and European patents related to molecular diagnostics for inherited neurofibromatosis, eye diseases, and bacterial genomic fingerprinting. The Department of Molecular and Human Genetics at Baylor College of Medicine receives revenue from clinical genetic testing conducted at Baylor Genetics (BG) Laboratories. J.R.L serves on the Scientific Advisory Board of BG, Tamar Harel: None declared.

P16.004.D Application of droplet digital PCR to the molecular characterization of recurrent deletions of the NF1 locus

Laurence PACOT1,2, Dominique Vidaud1,2, Lucie Orhant1, Nicolas Vaucouleur1, Théodora Maillard1, Ingrid Laurendeau2, Juliette Nectoux1, Eric Pasman1,2

1Hôpital Cochin, Fédération de génétique et médecine génomique, AP-HP-Centre - Université de Paris, Service de médecine génomique des maladies de système et d’organe, Paris, France; 2Cochin Institute, Inserm U1016 - CNRS UMR8104 - Université de Paris, CARPEM, Paris, France.

**Background/Objectives:** Neurofibromatosis type 1 (NF1) is caused by loss-of-function variants in the NF1 gene, among which ~5-10% are deletion of the whole NF1 locus. Three recurrent types of deletions have been described this far. They are caused by non-allelic homologous recombination (NAHR) mediated by low-copy repeats (LCR) at the NF1 locus. Here, we describe a new approach using droplet digital PCR (ddPCR) to quickly and easily distinguish recurrent deletions of the NF1 locus from atypical deletions.

**Methods:** A total of 121 index cases with an NF1 deletion were included. All patients were phenotypically described and 109 had an MLPA typing (1). Seven ddPCR probe sets distributed along the NF1 locus were selected to closely delimitate the three recurrent deletion types.

**Results:** Among the 121 deletions analyzed: 74 were type-1 (61%), 22 type-2 (18%), 5 type-3 (4%), and 20 showed an atypical deletion types.

**Conflict of Interest:** None declared.

P16.005.A Next generation sequencing analysis in clinical practice of cardiomyopathies diagnostics

Ivetta Boronova1, Jarmila Bernasovská2, Eva Petrejčíková1, Michaela Zígová1

1University of Prešov, Biology, Prešov, Slovakia; 2University of Prešov, Biology, Prešov, Slovakia.

**Background/Objectives:** The aim of our study was application of NGS technology for evaluation of MYBPC3 gene sequence variants included in the pathogenesis of cardiomyopathies. We point out to advantages of NGS technologies and utilization of the modern methods of molecular diagnostics in clinical practice.

**Methods:** The next-generation sequencing technology by IlluminaHiSeq 2500 platform was used to detect sequence variants in 37 Slovak patients with diagnosed cardiomyopathy by whole exome sequencing. Detected sequence variants were evaluated using Polyphen-2, SIFT and MutationTaster algorithms.

**Results:** We identified 47 sequence variants of 27 genes. Our analyses were focused to evaluation of sequence variants of MYBPC3 gene. NGS analyses identified the novel MYBPC3 gene sequence variants: rs35078470, rs34580776, rs138753870 with minor allele frequency (MAF)<0.01.

**Conclusion:** The results of the study support the potential role of detected variants in Slovak patients with cardiomyopathy. These sequence variants may be susceptibility alleles determining clinical phenotype. The effect of this variant in pathogenesis of cardiomyopathies requires functional studies.

**References:** Yamada T, Nomura S. Recent Findings Related to Cardiomyopathy and Genetics. Int J Mol Sci. 2021 Nov 20;22(22):12522. https://doi.org/10.3390/ijms222212522. PMID: 34830403; PMCID: PMC8623065.

TANIORE, R. R., et al., 2008. MYBPC3 gene variations in hypertrrophic cardiomyopathy patients in India. Vol. 24, No. 2, p. 127-130. In: Canadian Journal of Cardiology. ISSN: 0828-282X.

**Grants:** KEGA 032PU-4/2021: “Innovation of the educational process - implementation of new knowledges of Virology and NGS technology in teaching of biological subjects”.

**Conflict of Interest:** Iveta Boronova University of Prešov, Grant KEGA 032PU-4/2021, project leader, Jarmila Bernasovská University of Prešov, Grant KEGA 032PU-4/2021, co-investigator of the project, Eva Petrejčíková University of Prešov, KEGA 032PU-4/2021, representative of the project manager, Michaela Zígová University of Prešov, KEGA 032PU-4/2021, co-investigator of the project.

P16.006.B Approaches for enhancing of HDR-based genome editing efficacy

Arina Anuchina1, Milyausha Zaynitdinova1, Anna Demchenko1, Nadezhda Evtushenko2, Olesya Mishina2, Svetlana Smirnikhina2, Alexander Lavrov2

1Research Centre for Medical Genetics, Laboratory of genome editing, Moscow, Russian Federation; 2Pirogov Russian National Research Medical University, Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Moscow, Russian Federation.

**Background/Objectives:** There are many types of genome editing enhancing approaches. They include cell cycle synchronization, activation of homology directed repair (HDR) and inhibition of non-homologous end joining (NHEJ), fusion of Cas9 with DNA repair participants, etc. In current study we decided to test...
different methods for HDR enhancing: HDR activation by SCAI protein, NHEJ inhibition through MAD2L2 knockdown, NUDT16L1 knockdown/overexpression and SCR7 treatment.

Methods: Experiments were performed in HEK293T cells with stably integrated eGFP gene with mutation c.337delG (eGFPmut). Genome editing by CRISPR-Cas9 (eSpCas9(1.1)) in combination with ssODN should recover wt eGFP by insertion G nucleotide. SCAI was used as Cas9-SCAI fusion protein, knockdown of MAD2L2 and NUDT16L1 was performed by siRNAs transfected 24h before CRISPR-Cas9 plasmid. NUDT16L1 overexpression was achieved by adding plasmid coding this gene 24h before CRISPR-Cas9 plasmid. SCR7 were added with CRISPR-Cas9 plasmid. HDR CRISPR-Cas9 plasmid. NUDT16L1 overexpression was achieved by siRNAs transfected 24h before SCAI was used as Cas9-SCAI fusion protein, knockdown of MAD2L2 and NUDT16L1 knockdown, respectively, and SCR7 treatment didn’t induce any differences in eGFP fluorescence. NUDT16L1 overexpression and Cas9-SCAI fusion did not affect percentage of corrected alleles, however, decreased the number of GFP-positive cells 2.5 times both.

Conclusion: Thus, we discovered that MAD2L2 and NUDT16L1 knockdown, and also SCR7 treatment enhance the efficiency of CRISPR-induced homology directed repair. These methods could possibly be combined in further experiments.

References:

Grants:

Conflict of Interest: None declared.

P16.007.C Solving a de-novo microdeletion PGT-M case by combining long and short range PCR with NGS

Orit Freireich1, shira shavi1, elina farhi1, David A Zeevi1, Omer Munk1, gheona Altarescu1

1Shaare zedeck medical center, jerusalem, Israel.

Background/Objectives: A 34yo endometrial cancer patient was referred for PGT-M of a de-novo microdeletion in MSH2. It was not possible to diagnose the deletion and to construct a haplotype with standard molecular PGT techniques (informative markers surrounding the deletion), as the microdeletion breakpoints were unknown.

Methods: Precise deletion breakpoints were mapped by transposase-based library prep and next generation sequencing (NGS) of a long PCR amplicon derived from the patient’s genomic DNA spanning exons 8-11 of MSH2. Forty single nucleotide polymorphic (SNPs) sites within the deletion were genotyped in the patient and spouse by high throughput short amplicon sequencing. Haplotype informative SNP sites were used for PGT-M of blastomere biopsies from the patient’s previously frozen embryos.

Results: Long amplicon analysis revealed a 18kb sized heterogeneous deletion in the patient with precise breakpoints in introns 8 and 10 of MSH2. Forty highly polymorphic SNPs within the deletion were then concurrently genotyped in both the patient and her spouse by targeted short amplicon sequencing resulting in the detection of 6 informative SNPs (i.e., hemizygous in patient vs homozygous opposite allele in spouse). Using these SNPs, together with informative deletion-flanking microsatellites, haplotype phasing of the de novo deletion was attained. PGT-M was performed and diagnosis was achieved all embryos.

Conclusion: We describe state-of-the-art NGS technologies in the detection of precise deletion breakpoints and in genotyping long segments of genomic DNA where traditional methodology made impossible to perform PGT-M. Accordingly, we highly recommend this approach as a general solution for de-novo PGT-M of microdeletions.

References:

Grants:

Conflict of Interest: None declared.

P16.008.D Assessing the digenic model in rare disorders using population whole-genome sequencing data

Nerea Moreno-Ruiz1,2, Genomics England Research Consortium3, Oscar Lao1, Juan Ignacio Aróstegui4,5, Hafid Layaouni1,6, Ferran Casals7-9

1Institute of Evolutionary Biology (UPF-CSIC), Department of Experimental and Health Sciences, Barcelona, Spain; 2Universitat Pompeu Fabra, Genomics Core Facility, Department of Experimental and Health Sciences, Barcelona, Spain; 3Genomics England, London, United Kingdom; 4Hospital Clinic - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Department of Immunology, Barcelona, Spain; 5Universitat de Barcelona, School of Medicine, Barcelona, Spain; 6ESCI-UPF, Bioinformatics Studies, Barcelona, Spain; 7Universitat de Barcelona, Department of Genetics, Microbiology and Statistics, Barcelona, Spain.

Background/Objectives: An important fraction of patients with rare disorders remains with no clear genetic diagnostic, even after whole-exome or whole-genome sequencing. This poses a difficulty in giving adequate treatment and genetic counseling. The analysis of genomic data in rare disorders mostly considers the presence of single gene variants in coding regions that follow a concrete monogenic mode of inheritance. A digenic inheritance, with variants in two functionally-related genes in the same individual, is a plausible alternative that might explain the genetic basis of the disease in some cases. If this is the case, digenic disease combinations should be absent or underrepresented in healthy individuals.

Methods: In this work, we develop a method to evaluate the significance of digenic combinations by interrogating whole-genome data from the Genomics England 100,000 Genomes Project cohort.

Results: We apply the method to previously reported digenic combinations successfully validating one that has been suggested to cause a rare immune disorder.

Conclusion: Beyond the validation of possible pathogenic associations, we also suggest that this approach will be relevant with the advent of new sequencing efforts in projects including hundreds of thousands of samples.

References: This research was made possible through access to the data and findings generated by the 100,000 Genomes Project; http://www.genomicsengland.co.uk.,

Grants: Grant Salf2015-68472-C2-2-R, Ministerio de Economía y Competitividad (Spain) (FC), RTI2018-096824-B-C22, Agencia Estatal de Investigación (Spain) (FC), Direcció General de Recerca Generalitat de Catalunya (2017SGR-702) (FC), CERCA Programme/ Generalitat de Catalunya (JIA), and RTI2018-096824-B-C21, Spanish Ministry of Science, Innovation and Universities co-financed by European Regional Development Fund (JIA).

Conflict of Interest: None declared.

P16.010.B Proximity extension assay in combination with Next-Generation Sequencing for high-throughput proteome-wide analysis in large population health studies

Cynthia Lawley1, Lotta Wik2, Niklas Nordberg3, John Broberg3, Johan Björksten4, Erika Assarsson2, Sara Henriksson2, Ida Grundberg5, Christina Westerberg2, Elin Liljeroth2, Adam Falck2, Martin Lundberg5, Sarantis Chlamydas5, Tala Khosroheidari5, Yan Chen5, Anders Malarstig3

1Institute of Evolutionary Biology (UPF-CSIC), Department of Experimental and Health Sciences, Barcelona, Spain; 2Universitat Pompeu Fabra, Genomics Core Facility, Department of Experimental and Health Sciences, Barcelona, Spain; 3Genomics England, London, United Kingdom; 4Hospital Clinic - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Department of Immunology, Barcelona, Spain; 5Universitat de Barcelona, School of Medicine, Barcelona, Spain; 6ESCI-UPF, Bioinformatics Studies, Barcelona, Spain; 7Universitat de Barcelona, Department of Genetics, Microbiology and Statistics, Barcelona, Spain.

Abstracts from the 55th European Society of Human Genetics Conference 579

European Journal of Human Genetics (2023) 31:345 – 709
Abstracts from the 55th European Society of Human Genetics Conference

Background/Objectives: Understanding the dynamics of the human proteome is crucial for identifying biomarkers to be used as measurable indicators for disease severity and progression, patient stratification, and drug development. The Proximity Extension Assay (PEA) is a technology that translates protein information into actionable insights across large sample sizes in both healthy and disease samples. The high-throughput nature of the assay is enabled by linking protein-specific antibodies to DNA-encoded tags that can be read out on a next generation sequencer.

Methods: We have combined the PEA technology described above with automated sample preparation and a high-throughput sequencing readout for parallel measurement of ~3,000 proteins for up to 384 samples at a time, generating over 1 million data points per run.

Results: Characterizing the proteome alongside genetic and clinical data enables a pQTL framework to not only validate known clinical targets and identify new clinical targets but to also suggest repurposing opportunities of clinical candidates for new indications.

Conclusion: Here we will summarize results where proteomics is impacting large population health studies (e.g., UK Biobank, SCALLOP) to advance precision and personalized medicine.

References:
Folkesen et al. 2020. Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals. Nature Metabolism, 2, 1135-1148. https://www.nature.com/articles/s42255-020-00287-2.
Wik et al. 2021. Proximity extension assay in combination with next-generation sequencing for high-throughput proteome-wide analysis. Molecular and Cellular Proteomics. Volume 20, 100168, January 01, 2021. https://doi.org/10.1016/j.mcp.2021.100168.

Grants:
Conflict of Interest: Cynthia Lawley Olink, Illumina, Lotta Wik Olink, Niklas Nordberg Olink, John Broberg Olink, Johan Björkestén Olink, Erika Assarsson Olink, Sara Henriksson Olink, Ida Grundberg Olink, Christina Westerberg Olink, Elin Liljeroth Olink, Adam Falck Olink, Martin Lundberg Olink, Sarantis Chlamydas Olink, Tala Khosroheidari Olink, Illumina, Yan Chen: None declared, Anders Malarstig Pfizer.

P16.011.A Blood RNA-seq in diagnostic medicine

Andrew Douglas1,2, Htoo Wai1, Carolina Jaramillo Oquendo1, Jenny Lord1, David Hunt3, N Simon Thomas4, Diana Baralle1,3

1University of Southampton, Human Development and Health, Southampton, United Kingdom; 2Oxford University Hospitals NHS Foundation Trust, Oxford Centre for Genomic Medicine, Oxford, United Kingdom; 3University Hospital Southampton NHS Foundation Trust, Wessex Clinical Genetics Service, Southampton, United Kingdom; 4Salisbury District Hospital, Wessex Regional Genetics Laboratory, Salisbury, United Kingdom.

Background/Objectives: RNA sequencing (RNA-seq) can identify changes in splicing not readily apparent through DNA analysis, allowing better functional interpretation of genetic variants of uncertain significance (VUSs). Blood is the most readily available clinical tissue for RNA analysis. However, the degree to which blood RNA-seq provides adequate coverage for analysing splicing in different genes has not been well studied. Here, we have investigated the sensitivity of RNA-seq for the detection of splicing and other abnormalities.

Methods: RNA was extracted from blood in 56 patients with likely genetic disorders, 33 with candidate VUSs. RNA-seq was performed in three batches at 70M 150-bp paired-end reads per sample with STAR alignment to GRCh38. Transcripts per million (TPM) values were calculated for all genes using stranded raw read counts. Splice junction and intronic reads were counted, filtered and annotated for skewed usage. UK Genomic Medicine Service (GMS) PanelApp gene panels were used to filter outputs.

Results: 72% of GMS genes had TPM>1 and 65% of observed annotated junctions had sufficient average coverage to detect alternative splicing occurring at a 0.5 usage level (55% at 0.25 usage, 42% at 0.1 usage). Genes with identified splicing abnormalities were not consistently down-regulated when compared across samples within the same RNA-seq batch. The RNA effects of previously identified chromosomal microdeletions were generally visible as contiguous regions of decreased gene expression. Skewed X-inactivation was identified in one case.

Conclusion: Blood RNA-seq can detect not only splicing abnormalities but also chromosomal microdeletions and skewed X-inactivation.

References:
Grants: NIHR Research Professorship awarded to Diana Baralle (RP-2016-07-011).

Conflict of Interest: None declared.

P16.013.A Medical costs of children admitted to the neonatal intensive care unit: the role and possible economic impact of rapid exome sequencing in early diagnosis

Richelle Olde Keizer1,2, A. Marouane3, A. Chantal Deden4, Wendy Van Zelst-Stams5, Willem de Boode6, Willem Keusters7, Lidewij Henneman5, Johannes Kristian Ploos van Amstel5, Gerardus Frederix5,6, Lisinka Vissers1,2

1Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands; 2Donders Institute for Brain, Cognition and Behaviour, Department of Human Genetics, Nijmegen, Netherlands; 3Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Human Genetics, Nijmegen, Netherlands; 4Radboud University Medical Center, Radboud Institute for Health Sciences, Amalia Children’s Hospital, Department of Neonatology, Nijmegen, Netherlands; 5Amsterdam UMC, Vrije Universiteit, Amsterdam, Department of Clinical Genetics, Amsterdam, Netherlands; 6University Medical Center, Department of Genetics, Utrecht, Netherlands.

Background/Objectives: Genetic disorders are likely under-diagnosed in neonates admitted to the neonatal intensive care unit (NICU) as testing is not always performed, not even for all neonates presenting with congenital anomalies (CA), despite their strong correlation with genetic defects. We modelled the cost impact of implementing of trio-based rapid exome sequencing (trio-rES) for neonates admitted at the NICU.

Methods: To determine baseline healthcare costs, we retrospectively collected postnatal healthcare data of neonates admitted to level IV NICU at Radboudumc (October 2013-October 2015), and linked these to unit costs. Next, scenarios were based on replacing current genetic tests by trio-rES, combined with clinical preselection of neonates based on the presence/absence of (multiple) CAs.

Results: Overall, on average €26,627 was spent per patient, of which 2.3% involved genetic testing. We next modelled four scenarios. First, implementing trio-rES for all neonates without clinical preselection will increase overall healthcare costs by 22.2%. Contrasting, implementation of trio-rES for neonates with multiple CAs, but leaving neonates with an isolated CA untreated, will be cost-neutral. We next modelled trio-rES for all patients with...
CAs, increasing the average per patient healthcare costs by 5.3%, with a maximum of 5.5% when correcting for genetic diagnoses that are undetectable by rES.

**Conclusion:** Implementation of trio-based rES for all neonates with CAs will lead to a limited increase in overall healthcare budget, but maximizes the potential for diagnosing neonates with rare genetic disorders and personalized treatment options.

**References:** Not applicable.

**Grants:** ZonMw; 843002608 and 846002003. European Union’s Horizon 2020; No. 779257.

**Conflict of Interest:** Richelle Olde Keizer: None declared. A. Marouane: None declared. A. Chantal Deden: None declared, Wendy Van Zelst-Stams: None declared, Willem de Boode: None declared, Willem Keusters: None declared, Lidewij Henneman: None declared, Johannes Kristian Ploos van Amstel: None declared, Gerardus Frederix: None declared, Lisenka Vissers* None declared, Johannes Kristian Ploos van Amstel: None declared, Willem Keusters: None declared, Lidewij Henneman: None declared, Wendy Van Zelst-Stams: None declared, Willem de Boode: None declared, Gerardus Frederix: None declared, Lisenka Vissers* None declared, Johannes Kristian Ploos van Amstel: None declared, Willem Keusters: None declared, Lidewij Henneman: None declared, Wendy Van Zelst-Stams: None declared, Willem de Boode: None declared.

**P16.014.B Proteofrom Detection in Deep Plasma Proteomics through Peptide Expression Correlation and Genomic Mapping**

Jian Huang1, Yingxiang Huang1, Margaret Donovan1, Daniel Hornburg1, Marwin Ko1, Ryan Benz1, Theo Platt1, Asim Siddiqui1, Serafim Batzoglou1, Omid Farokhzad1

1Seer Inc., Redwood City, United States.

**Background/Objectives:** Biological complexity exceeds what can be explained by the number of protein-coding genes, however, can be largely explained by alternative splicing and post-translational modifications of proteins yielding multiple molecular forms of a protein (proteofroms). The ability to perform quantitative proteomic experiments across a large cohort can improve proteofrom inference by using peptide quantitative profiles. In this work, we demonstrate the power of the Proteograph™ Product Suite, which leverages physiochemically distinct nanoparticles for unbiased, deep, and rapid proteomics at scale to systematically infer proteofroms from plasma samples using peptide abundances and genomic mapping.

**Methods:** Proteomes of 141 non-small cell lung cancer and control plasma samples were profiled using Proteograph and LC-MS/MS. For all detected peptides within a given protein group, we calculated the Pearson pairwise correlation of abundances. To identify clusters of similarly abundant peptides, we then applied the silhouette method to obtain the optimal number of clusters and used K-means clustering on the correlation of peptide abundances, followed by filtering to ensure clusters were distinct. Next, peptides were mapped to known protein isoforms from the Ensembl database. We then inferred the presence of a proteofrom if the known protein isoform explained the peptide clusters.

**Results:** Some identified proteofroms included BMP1, which has dual role in cancer possibly explained by short and long proteofroms, and Collagen XVIII, which has a short proteofrom byproduct with anti-angiogenic effects.

**Conclusion:** Overall, this work demonstrates Proteograph utility to generate unbiased and deep plasma proteome profiles enabling the inference of biologically important proteofroms.

**References:** Blume et al. Nat. Comm. (2020).

**Grants:**

**Conflict of Interest:** Jian Huang Significant. Employee of Seer Inc., Modest. Own stocks at Seer Inc, Yingxiang Huang Significant. Employee of Seer Inc, Modest. Own stocks at Seer Inc., Margaret Donovan Significant. Employee of Seer Inc, Modest. Own stocks at Seer Inc. Daniel Hornburg Significant. Employee of Seer Inc., Modest. Own stocks at Seer Inc., Marwin Ko

Significant. Employee of Seer Inc., Modest. Own stocks at Seer Inc., Ryan Benz Significant. Employee of Seer Inc., Modest. Own stocks at Seer Inc., Theo Platt Significant. Employee of Seer Inc., Modest. Own stocks at Seer Inc., Asim Siddiqui Significant. Employee of Seer Inc., Modest. Own stocks at Seer Inc., Serafim Batzoglou Significant. Employee of Seer Inc, Modest. Own stocks at Seer Inc., Omid Farokhzad Significant. founder of Seer Inc., Modest. Own stocks at Seer Inc.

**P16.015.C Genome-wide CpG methylation calling with standard HiFi whole genome sequencing**

Justin Blethrow1, Daniel Portik1, Kristofer Nyquist1, Aaron Wenger1, Richard Hall1

1Pacific Biosciences, Menlo Park, United States.

**Background/Objectives:** Both the genome and epigenome contribute to inherited disease. While genome sequencing has been applied at large scale, epigenome sequencing remains more difficult and expensive and less frequently used. Here we extend PacBio HiFi sequencing to simultaneously generate accurate genomes and epigenomes with a single library prep and sequencing experiment.

**Methods:** In PacBio sequencing, the nucleotide incorporation rate is sensitive to epigenetic modifications like 5-methylcytosine, but the signal is spread over multiple positions and is challenging to detect in single sequencing passes. HiFi sequencing observes the same molecule across multiple serial passes, opening new approaches to detect 5mC. We implemented a multilayer convolution neural network to combine kinetics from multiple passes and assign a probability of methylation to each CpG. We trained the model on fully unmethylated (whole-genome amplification) and fully methylated (M.SssI-treated) reads.

**Results:** HiFi methylation calling accuracy for individual CpG sites in single reads (i.e. 1X coverage) is around 85%. At 30X coverage for Genome in a Bottle samples, HiFi CpG methylation correlates >95% with bisulfite sequencing, or >99% at the level of CpG islands. HiFi methylation calling also recapitulates biologically-relevant hypomethylation in the undifferentiated haploid CHM13 cell line, including unique patterns across chromosomes. In diploid samples – including rare disease samples – HiFi reads can be phased by sequence to reveal parental imprinting for genes like GNAS and DIRAS3.

**Conclusion:** HiFi sequencing provides an approach to generate more accurate genomes than short-read sequencing while simultaneously providing the epigenome, offering the opportunity to understand new aspects of evolution, disease, and diversity.

**References:**

**Conflict of Interest:** Justin Blethrow Employed by Pacific Biosciences. Daniel Portik Employed by Pacific Biosciences. Kristofer Nyquist Employed by Pacific Biosciences. Aaron Wenger Employed by Pacific Biosciences. Richard Hall Employed by Pacific Biosciences.

**P16.016.D By enabling same day synthesis of hydrolysis probes on the SYNTAX System, Enzymatic DNA Synthesis (EDS) promises to unleash the development of multiplexed qPCR assays**

Benoit Derrien1, Nadège Tardieu2, Henri Lachaize2, Anaïs Vallette3, Erwan Grolleau4, Charles Rouillard5, Gabriel De Crozals6, Christine Pepounet7, Florence Mahé8, Xavier Godron8

1DNA Script, Application, Le Kremlin-Bicêtre, France; 2DNA Script, Synthesis Development, Le Kremlin-Bicêtre, France; 3DNA Script,
**Surface Chemistry, Le Kremlin-Bicêtre, France; 4DNA Script, Le Kremlin-Bicêtre, France.**

**Background/Objectives:** Quantitative PCR (qPCR) was first developed in the early 90’s and has remained one of the gold standard techniques used in modern day gene expression studies. By implementing the synthesis of hydrolysis probes on the SYNTAX System, DNA Script opens access to the rapid on demand synthesis of good quality qPCR probes.

**Methods:** Among the various qPCR approaches developed, the most popular techniques utilize intercalating dyes and hydrolysis probes. Compared to intercalating dyes, hydrolysis probes provide several advantages including high specificity and the possibility of multiplexing, thus enabling the detection of multiple target genes within a single reaction.

**Results:** In this study, we demonstrate the performance of hydrolysis probes generated using DNA Script’s proprietary enzymatic DNA synthesis (EDS) technology. By combining EDS and labelling chemistry within the SYNTAX System, we enable the fully automated synthesis of 32 hydrolysis probes and their associated primer pairs in less than 12 hours directly in the lab. The labelling reaction enables the user to position the labels inferentially at the 5’, 3’ or internally while blocking the 3’end of the probe. Our qPCR probes are available in 5 different colours and were tested within a multiplexed experimental design using two different gene expression models: 1) the validation of a shRNA cell line, 2) the analysis of the relative expression of two genes in breast cancer tumours.

**Conclusion:** By enabling same day synthesis of hydrolysis probes, the SYNTAX System alleviates one of the bottlenecks associated with hydrolysis probes, providing next-day results.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P16.017.A RNAseq from dried blood spots cards improves diagnosis in rare genetic diseases**

**Ruslan Al-Ali**1, Mandy Radefeldt1, Najim Ameziane1, Sabrina Lemke1, Christian Beetz1, Peter Bauer1

1CENTogene GmbH, Rostock, Germany.

**Background/Objectives:** A considerable fraction of genetic diagnostic analyses remains negative or ambiguous even when comprehensive approaches such as exome sequencing or genome sequencing are applied. This is largely due to non-coding causative variants escaping attention (false-negative reports) or misjudgement of in silico prediction tools (uncertain reports). Transcriptome analysis helps to solve these issues but faces challenges related to RNA stability in pre-analytical samples and logistics of those precarious samples. We established RNA-seq protocol that utilizes dried blood spots on easy-to-ship filter cards.

**Methods:** Several types of filter cards were probed with EDTA blood and stored under distinct conditions modelling typical shipment conditions for differing durations. Subsequently, compared protocols differed regarding RNA extraction, depleton unwanted RNA species, library preparation and next-generation sequencing.

**Results:** A tentatively optimized protocol applies a proprietary filter card (CentoCard®), uses four blood spots covering a total area of ~3 cm², and involves a hemoglobin RNA depletion and polyA-tail capture. Up to 10 days from sampling preparation, we obtain >100 ng RNA with RIN score of 3-6, and could generate 5-12 million uniquely mapped RNA-seq reads on average, respectively. The sequence coverage for genes typically expressed in blood was sufficient to detect the pathological mutations and thereby confirm rare genetic disorders in our test cohort.

**Conclusion:** Further optimization will enable us to offer an innovative genetic diagnostic service that combines DNA-based and RNA-based data from the very same specimen, i.e. dried blood spot filtercard for achieving higher diagnostic yield and more definite genetic diagnoses.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P16.018.B Integrated heteroduplex correction in PacBio’s circular consensus algorithm**

Derek Barnett1, John Harting1, Walter Lee1, Armin Töpfer1, Fritz Sedlacek2, Jenny Ekholm1, Nina Gonzalez3, Justin Blethrow1, James Drake1, Zev Kronenberg1

1Pacific Biosciences (PacBio), Menlo Park, United States; 2Baylor College of Medicine, Human Genome Sequencing Center, Houston, United States.

**Background/Objectives:** A heteroduplex is a double-stranded sequence comprised of two non-complementary strands that can form during PCR. These mixed-template artifacts produce misleading results in downstream analysis, e.g., false haplotypes during diplotyping. Unlike short-read technologies, PacBio Single-Molecule Real-Time sequencing produces strand-level base calls. Heteroduplex signatures can be directly observed and corrected using the stranded sub-read data. Our new method is integrated in the circular consensus sequence algorithm which generates accurate HiFi data from sub-reads.

**Methods:** The transformation of PacBio subreads into high accuracy HiFi reads is done by the circular consensus sequence (CCS) algorithm. During CCS, an intermediate draft sequence is generated, and subreads are mapped and aligned to the draft. The heteroduplex algorithm (hd-finder) takes the subread alignments and generates a read pileup whereby variants are identified. At each site, the bases are sorted and counted by strand. The 2x2 count data is subjected to a Fisher’s exact test. The fraction of significant sites across the draft is used to determine if a read contains heteroduplex. Heteroduplex flagged reads are split by strand and reprocessed resulting in two HiFi reads, one for each strand.

**Results:** We demonstrate the accuracy of the hd-finder algorithm is >94% by using a heteroduplex enriched amplicon library. We also show that applying the hd-finder to amplified datasets improves the quality of downstream analysis of important human genes.

**Conclusion:** The heteroduplex algorithm is a powerful new method for improving HiFi amplicon targets. The method has been released (v6.3) and is documented https://ccs.how/faq/mode-heteroduplex-filtering.html.

**References:**

**Grants:**

**Conflict of Interest:** None declared.
P16.019.C Characterizing genetic variants that affect splicing using CRISPR activation in easily accessible patient cells

Thorkild Terkelsen1,2, Nanna S Mikkelsen3, Ibēn B Bentsen1,2, Jenny Blechingberg1, Henning Andersen3, Rasmus O Bak2, Uffe B Jensen1,2

1Aarhus University Hospital, Department of Clinical Genetics, Aarhus, Denmark; 2Aarhus University, Department of Biomedicine, Aarhus, Denmark; 3Aarhus University Hospital, Department of Neurology, Aarhus, Denmark.

Background/Objectives: Analysis of cDNA is the primary method to study the impact of rare genomic variants on mRNA splicing. Many disease genes are not expressed in easily accessible patient cells such as skin fibroblasts. We hypothesized that CRISPR activation (CRISPRa) would allow splicing analysis of the myelin protein zero gene (MPZ), where the full-length transcript is exclusively expressed in Schwann cells of the peripheral nervous system.

Methods: CRISPRa induces gene expression directed by guide RNAs and a catalytically inactivated Cas9 protein fused to transcriptional activators (e.g., dCas9-VPR). Thus, to activate full-length MPZ expression in skin fibroblasts, cells were electroporated with dCas9-VPR mRNA and synthetic guide RNAs that targeted the first transcriptional start site of MPZ. Normal fibroblasts and fibroblasts from a patient with a disruptive consensus donor splice site variant in intron 2 of MPZ were analyzed by RT-qPCR and RNA-Seq. Cells were cycloheximide treated before RNA extraction to protect the transcripts from nonsense-mediated decay.

Results: CRISPRa strongly upregulated MPZ, including its full-length isoforms, during the initial days after treatment, followed by a normalization of gene expression. In patient fibroblasts with the disruptive splice donor site variant, we detected multiple novel transcript isoforms that bypassed the splice site. The abnormal transcripts were only detectable in patient fibroblasts after CRISPRa and absent from normal fibroblasts induced to express MPZ.

Conclusion: CRISPRa expands the application of cDNA analysis to disease genes not expressed in easily accessible patient cells.

References:

Grants: DFF grant number 9039-00378B.

Conflict of Interest: None declared.

P16.020.D Optical Genome Mapping in Routine Human Genetic Diagnostics - Lessons Learned

Paul Dremsek1, Anna Schacher2, Mateja Smogavec2, Maria Gerykova Bujaikova3, Franco Laccone1, Jürgen Neesen1

1Institute of Medical Genetics, Center for Pathobiochemistry and Genetics, Vienna, Austria.

Background/Objectives: Optical Genome Mapping (OGM) is an emerging method that promises to detect most classes of structural variants (SVs) of a nuclear genome in a single test. It holds unique potential where other current methods struggle, e.g. fine-mapping of translocations or covering repetitive regions. As OGM-systems are still in their infancy, their meaningful usage needs to be explored. Here, we present our experience with the Saphyr OGM-instrument (Bionano Genomics, CA, USA) in a human genetic setting.

Methods: We analyzed a panel of >100 diagnostic cases with the Saphyr OGM-instrument and other genetic methods (e.g. chromosomal analysis, microarray, long-range sequencing) with emphasis on chromosomal numerical aberrations, balanced and unbalanced SVs and mosaics of potential clinical significance.

Results: Comparison of the Saphyr-system to the other methods showed a high concordance of most variants. OGM characterized all SVs with a resolution of several kilobases and could localize rearranged genetic material in most instances. However, we also encountered several variants of potential clinical relevance that were systematically missed by the OGM-system, whereas they were detected by karyotyping or microarray. Among the reasons were insufficient coverage, incomplete calling and assembly artefacts.

Conclusion: While showcasing OGM’s unique advantages as physical DNA imaging platform in clinical samples, we also provide documentation of typical pitfalls scenarios. This is indispensable for a prior understanding to infer certain variants with detection biases. The results raise awareness for variation signatures that are challenging for OGM data analysis, relying on advanced interpretation beyond automated calling.

References:

Grants:

Conflict of Interest: None declared.
P16.022.B Efficient, high sensitivity detection of oncogenic variants with UMIs and target enrichment

Michael Bocck1, Lydia Bonar1, Jean Challacome1, Richard Gantt1, Derek Murphy1, Esteban Toro1

1Twist Bioscience, South San Francisco, United States.

Background/Objectives: Early detection can significantly improve clinical outcomes for a number of cancers, but many of the best current screening methods require invasive procedures. A promising alternative approach is a liquid biopsy of cell-free DNA (cfDNA) from plasma. Because tumors generally shed relatively large amounts of DNA into the circulation, cancer potentially be detected by identifying oncogenic variants in cfDNA. This process generally requires extremely deep sequencing, and in many cases is limited by the accuracy of next-generation sequencing (NGS).

Methods: One approach to overcoming this limitation is unique molecular identifiers (UMIs), short sequences that uniquely tag each input DNA molecule prior to preparing NGS libraries. The approach can further be improved by tagging each original strand of the DNA molecule, in a technique termed duplex sequencing, which can correct early PCR errors and/or single-strand DNA damage events. Here we describe a new library preparation system incorporating short, discrete UMI sequences to maximize sequence distances for error correction.

Results: We show that this system can determine the conversion efficiency of NGS libraries. Using the Twist cfDNA Pan-cancer Reference Standards to simulate a low fraction of tumor DNA in a healthy background, we demonstrate high sensitivity towards a variety of oncogenic substitutions, indels and structural variants. We validate the baseline error rate using unmodified human cfDNA, and use the system to determine the mutation frequency in a synthetic biology application.

Conclusion: In summary, this study demonstrates the utility of UMIs for a variety of applications in NGS.

References:

Grants:

Conflict of Interest: Michael Bocck Currently employed with Twist Bioscience, Lydia Bonar Currently employed with Twist Bioscience, Jean Challacome Currently employed with Twist Bioscience, Richard Gantt Former employee of Twist Bioscience, Derek Murphy Currently employed with Twist Bioscience, Esteban Toro Currently employed with Twist Bioscience.

P16.023.C Targeted nanopore sequencing ushers in the era of long-read sequencing in the clinic

Abderaouf Hamza1, Mathilde Filser1, Kevin Merchadou2, Laetitia Maillot1, Éléonore Frouin1, Élodie Girard3, Albain Chansangay4, Djihad Hadjhadj5, Eric Pasmand6, Franck Bourdeaut7, Tina Alanit8, Sonia Lameiras9, Sylvain Baulande10, Nicolas Servant11, Victor Renault12, Olivier Delatte13, Julien Masliha-Planchon14

1Institut Curie, Unité de Génétique Somatique - Genetics Department, Paris, France; 2Institut Curie, Unité de Bioinformatique Clinique - Genetics Department, Paris, France; 3Institut Curie, INSERM U900 – Bioinformatics, Biostatistics, Epidemiology and Computational Systems, Biology of Cancer, Paris, France; 4Cochin Hospital – Assistance Publique-Hôpitaux de Paris, Service de Génétique et Biologie Moléculaire, Paris, France; 5Cochin Institute, INSERM U1016-CNRS UMR8104, Paris, France; 6Institut Curie, SIREDO (Care, Innovation, Research in Pediatric, Adolescent and Young Adults Oncology), Paris, France; 7Institut Curie, INSERM U830 – Cancer, Heterogeneity, Instability and Plasticity (CHIP), Paris, France; 8Institut Curie, ICGex – NGS Platform, Paris, France.

Background/Objectives: Nanopore sequencing offers attractive prospects (e.g., methylation analysis and production of long reads, allowing variant phasing and reliable structural variant (SV) detection, including gene fusions), but its integration in clinical laboratory workflows has been hampered by its low throughput. Adaptive sampling (AS)(1), a novel modular target enrichment method made possible by recent technological advances, can offset this limitation. The goal of this study was to evaluate the use of AS in a diagnostic laboratory setting.

Methods: We analysed 24 tumour samples and 2 germline samples with AS, targeting 570 cancer genes. The analytical performance of SV detection on AS data was compared to nanopore whole genome sequencing (nWGS) and Pacific Biosciences HiFi whole genome sequencing (pWGS) on two samples.

Results: On-target median read depth was 12X (min = 6X, max = 30X) on a single flow cell, a four-fold improvement over baseline. Off-target reads were utilized to generate genome-wide copy number variant (CNV) profiles. Base-pair level characterization of causal SV was achieved for 24/26 samples. Relevant gene fusions (C11orf95-RELA, YAP1-MAML1, ETV6-NTRK3, MNI-BEND2) were detected in 5 samples. The analytical performance of AS was comparable to nWGS and pWGS. Input DNA quantity (2μg), library preparation time (1h30), turnaround time (48h) and computational requirements were compatible with diagnostic workflows.

Conclusion: Targeted nanopore sequencing is an exciting addition to the clinical laboratory arsenal, offering single- assay reliable SV and CNV detection. Long-read sequencing can now be offered as a routine diagnostic tool, promising novel biological insights and improved diagnostic yield.

References: 1.Payne, A. et al. (Nat. Biotechnol, 2020).

Grants:

Conflict of Interest: Abderaouf Hamza Received equipment used in this study from NVIDIA through its Academic Hardware Grant Program., Mathilde Filser: None declared, Kevin Merchadou: None declared, Laetitia Maillot: None declared, Éléonore Frouin: None declared, Élodie Girard: None declared, Albain Chansangay: None declared, Djihad Hadjhadj: None declared, Eric Pasmand: None declared, Franck Bourdeaut: None declared, Tina Alanit: None declared, Sonia Lameiras: None declared, Sylvain Baulande: None declared, Nicolas Servant: None declared, Victor Renault: None declared, Olivier Delatte: None declared, Julien Masliha-Planchon: None declared.

P16.024.D Automated tissue dissociation system for single cell sequencing

Yang Ni1, Khalil Abou Elardat2

1Singleron Biotechnologies GmbH, Service Lab, Cologne, Germany.

Background/Objectives: Getting high quality single cell suspensions is the first step and essential for all downstream sample processing procedures in single-cell, multi-omics studies today. An established tissue dissociation workflow should meet the following criteria: (1) high yield, (2) high cell viability, and (3) high reproducibility. These standards are particularly important for clinical researchers, as samples collected from patients are usually in low amounts.

Methods: The Singleron PythoN automated tissue dissociation system (abbreviated as PythoN) integrates tissue mincing, grinding, enzymatic dissociation and cell straining into one “click-of- button”, and has huge advantages over the traditional manual protocol.

Results: First, PythoN has a broad input range of sample weights, spanning from 10 to 500 mg. Internal testing data
showed that 660,000 single cells were successfully collected from a mouse liver tissue as small as 14 mg. Thus, PythoN is well suited for biopsy samples commonly seen in the clinic. Second, PythoN combines both mechanical and enzymatic tissue dissociation, being able to finish the whole procedure within 15 minutes, while keeping cells at a high viability (>90%). Third, PythoN is fully automated and programmable, which ensures the reproducibility of sample preparation. Up to 30 programs can be saved in PythoN. Key parameters, such as the motor speed of the grinder and the number of strokes, can be customized, leaving users free space to optimize their own protocols for new types of samples.

Conclusion: PythoN enables users to obtain high quality single cell suspensions in a reproducible manner.

References: More information can be found on https://www.singlerongbio.com/product/detail-19.html.

Grants: None declared.

Conflict of Interest: None declared.

References from the 55th European Society of Human Genetics Conference

P16.026.B Enablement of long-read targeted sequencing panels using Twist hybrid capture and PacBio HiFi sequencing

Sarah Kingan¹, John Harting¹, Ting Hon¹, Yu-Chih Tsai¹, Ian McLaughlin¹, Janet Ziegel², Tina Han², Leonardo Arbiza², Susan Kloet², Loes Busscher², Geoff Henno², Edd Lee³, Nina Gonzaludo¹

¹Pacific Biosciences, Menlo Park, CA, United States; ²Twist Bioscience, South San Francisco, CA, United States; ³Leiden University Medical Center, Leiden, Netherlands.

Background/Objectives: Targeted resequencing allows for high-resolution characterization of gene panels at a scale and cost that is more accessible than whole genome sequencing. While long-read PacBio HiFi sequencing has been shown to accurately and comprehensively interrogate complex clinically actionable loci, such as pharmacogenetic targets, studies have been primarily focused on single genes using PCR amplicon-based methods. We describe a method to leverage Twist Bioscience target enrichment probes for the design of custom gene panels sequenced with HiFi reads.

Methods: PacBio partnered with Twist Bioscience to develop a long-read hybrid capture protocol for custom gene panels of up to 2 Mb in size. The protocol follows a standard hybrid capture workflow with DNA shearing, barcoding, and sample handling optimized for long-read sequencing. The resulting enriched material is used to construct a SMRTbell library sequenced on the Sequel II system from PacBio. Up to 24 samples may be multiplexed with HiFi read length of 5-10 kb.

Results: We demonstrate that this method efficiently and comprehensively covers gene targets using Coriell samples run with multiple gene panels of varying sizes, which include complex regions like pharmacogene CYP2D6.

Conclusion: This protocol can be utilized with custom gene panels from Twist to efficiently capture genes of interest using long-read HiFi sequencing. The demonstrated method allows for scalable and cost-efficient hybrid capture with long read lengths, unbiased coverage, and high accuracy to fully capture all variant types, including structural variation that can be inaccessible to short-read sequencing and non-NGS technology.

References: None declared.

P16.027.C RMetSeq package for processing targeted MRE-seq

Aleksi Zarubin¹, Svitsev Aleksei², Irina Zhalsanova², Nikolay Skryabin³

¹Tomsk National Research Medical Center, Research Institute of Medical Genetics, Tomsk, Russian Federation.

Background/Objectives: Methylation-sensitive restriction enzyme sequencing or MRE-seq is one of the methods for determining the level of DNA methylation. It usually involves comparing the results of sequencing samples after exposure to methyl sensitive and insensitive enzymes targeting the same restriction sites. This approach has some limitations, which leads to the fact that this method has not found wide application. We propose a new approach to the design of experiments and analysis of MRE-seq data, which allows integration of this analysis with standard NGS sequencing of exome and target panels with probe enrichment.

Methods: DNA isolated from blood samples was sonicated in 300 and 500 bp modes. Thereafter, half of each sample was treated with the HpaII. All samples were enriched using SureSelect Custom DNA Target Enrichment Probes (which includes exomes of 37 genes of a total length of 168497 nucleotides) and sequenced using MiSeq. Genotyping analysis was performed using GATK4. The methylation level was assessed using the RMetSeq package published on github.com/aleksei zarubin/RMetSeq.

Results: The sequencing result of the fraction of the target region with coverage greater than 50x was 95.95% and 95.7% for the untreated and treated with restriction enzyme. But at the same time, combining 50% of random reads from these samples gave a fraction of 96.4%. These regions accounted for 573 restriction sites, with >50 x coverage.

Conclusion: Targeted MRE-seq and the RMetSeq package make it possible to simultaneously determine the level of DNA methylation without compromising the quality of genotyping in standard sequencing using probe enrichment.

References: None declared.

P16.029.A Molecular diagnostics of myotonic dystrophies from short-read whole genome sequencing data

Ingrid Lojová¹, Marcel Kucharík³, Zuzana Pös¹, Andrea Zatková¹, Jaroslav Budiš³, Ludevit Kadasi¹, Tomas Szemes³, Jan Radvanský¹, Zuzana Pös¹, Andrea Zatková¹, Jaroslav Budiš³

¹Institute of Clinical and Translational Research, Biomedical Research Center of the Slovak Academy of Sciences, Bratislava, Slovakia; ²Department of Molecular Biology, Faculty of Natural Sciences, Comenius University, Bratislava, Slovakia; ³Comenius University Science Park, Bratislava, Slovakia

Background/Objectives: Recently we are witnessing the spread and diversification of bioinformatic tools allowing tandem repeats (TRs) characterisation from short-read massively parallel sequencing (srMPS) data. The complexity of TRs, however, represents specific challenges when considering the diagnostic possibilities of repeat expansion disorders (REDs). We are reporting on specific
Abstracts from the 55th European Society of Human Genetics Conference

P16.032.D Optical genome mapping as a diagnostic tool in cases of unresolved rare diseases

Detlef TROST¹, Aicha Boughalem¹, Fernando Martin¹, Viorica Ciorna², Patricia Blanchet³

¹CERBA, Human genetics, St Ouen l'Armoué, France; °CHR Metz-Thionville, Genétique Médicale et Oncogénétique, Metz Cedex 03, France; ³CHU Hôpital Arnaud de Villeneuve, Département de Génétique Médicale, Centre de Référence « Anomalies du Développement et Syndromes Malformatifs », Montpellier Cedex 5, France.

Background/Objectives: The usefulness of optical genome mapping (OGM) for genetic testing in patients presenting with a rare genetic disease is currently evaluated. For patients for whom all previous genetic testing did not identify an underlying genetic variant, OGM might provide information that allows to end this diagnostic odyssey.

Methods: In this cohort OGM was performed on cases of rare diseases for 28 patient-parents TRIOs. All patients had normal or inconclusive results for chromosomal microarray and diagnostic exome sequencing.

Results: OGM identified putative disease related structural variants in 3 of these cases (10.7%). The identified variants overlap with known disease genes that correlate to the patient’s phenotype. The size of the identified variants was below the resolution of the diagnostic chromosomal microarray and difficult to detect with NGS testing. One patient was found to be composite heterozygous for a structural variant and a pathogenic single nucleotide variant within a recessive disease gene and biparental inheritance.

Conclusion: OGM allowed the identification of putative disease related variants in 10.7% of our patients with negative chromosomal microarray and NGS testing.

References:

Grants: APVV-18-0319; VEGA 2/0167/20.

Conflict of Interest: None declared.

P16.033.A Pilot study demonstrates the feasibility, the diagnostic power and the utility of rapid whole genome sequencing for critically ill pediatric patients in Belgium

Aimé Lumaka¹, Corinne Fasquelle², Guillaume Debray², Serpil Alkan³, Adeline Jacquinet⁴, Julie Harvengt², François Boemer⁴, Leonor Palmeira⁵, Benoit Charloteaux⁵, Anne Brysse⁶, Saskia Bulk⁷, Vincent Rigo⁸, Vincent Bours¹²

¹University of Liège, Human Genetic Laboratory, GIGA Institute, Liège, Belgium; °Centre Hospitalier Universitaire, Center for Human Genetics, Liège, Belgium; ²CHU de Liège - CHR de la Citadelle, Neuropediatric Division, Liège, Belgium; ³CHU de Liège - CHR de la Citadelle, Neonatology Division, Liège, Belgium.

Background/Objectives: Genetic diseases are an important causes of admission and death in pediatric intensive care units. Early diagnostic orient the care and prevent irreversible harms. Whole Genome Sequencing in short turnaround time (wGS) represents a valuable exploration in critically ill pediatrics patients. We evaluated the feasibility, the efficiency and the utility of the wGS in Belgium.

Methods: We leveraged the collaboration between two pediatric institutions and the center for human genetics of the University of Liège. Cloud-based computing data analysis services and a high-throughput NGS platform to develop a wGS workflow intended to deliver diagnostics to critically ill pediatric patients before hospital discharge. WGS was performed on NovaSeq PE300cy in trio for 9 and in duo for 1 proband. The study was approved by the Ethical Committee.

Conclusion: Genetic diseases are an important causes of admission and death in pediatric intensive care units. Early diagnostic orient the care and prevent irreversible harms. Whole Genome Sequencing in short turnaround time (wGS) represents a valuable exploration in critically ill pediatrics patients. We evaluated the feasibility, the efficiency and the utility of the wGS in Belgium.

References:

Grants: APVV-18-0319; VEGA_2/0167/20.

Conflict of Interest: None declared.

P16.031.C Implementation of the GA4GH Beacon protocol for discovery and sharing of genomic copy number variation data

Michael Baudis¹²

¹University of Zurich, Department of Molecular Life Sciences, Zürich, Switzerland; ²Swiss Institute of Bioinformatics, Zürich, Switzerland.

Background/Objectives: Genomic copy number variations (CNV) are frequent, causative events in rare diseases and represent the majority of the mutational landscape in the most malignancies. However, the complexity of genomic CNV patterns requires large amounts of well-defined genomic profiles for meaningful meta-analyses.

Methods: The “Beacon” protocol of the Global Alliance for Genomics and Health (GA4GH) represents an emerging standard for an “Internet for Genomics”. While the initial version of the protocol provided access to the public and private genomic datasets from around the world, version 2 of the protocol provides extended, metadata-rich interactions various access scenarios. Here, the Progenetix cancer genomics resource (progenetix.org) - comprising the largest publicly accessible set of cancer CNV data - has served as a testbed for Beacon v2 features.

Results: With Beacon v2 API as backbone of Progenetix - serving genome-wide CNV profiling data from more than 130’000 - we demonstrate the use of the GA4GH Beacon v2 protocol for the sharing vast amounts of genomic profiles, using a documented, open API.

Conclusion: After the acceptance of the Beacon v2 protocol as GA4GH standard, work will focus on its implementation in a wide set of use cases, from clinical information systems to public research databases. Importantly, an ELIXIR-supported study by members of the ELIXIR h-CNV community (cnvar.org) explores Beacon v2 powered CNV implementations by European genomics resources, in human genetics / rare diseases and cancer genomics.

References: Huang Q et al. (2021). The Progenetix oncogene resource in 2021. Database (Oxford), 2021 Jul 17.

Grants: ELIXIR Community-led Implementation Study (2021-2023).

Conflict of Interest: None declared.
Results: Ten unrelated critically ill patients without any clear diagnostic were recruited from the Neonatal Intensive Care Unit (4), the Pediatric Intensive Care Unit (4) and the neonopediatrics unit (2). A definite diagnostic was reached in 6 out of 10 patients in 39.29 hours (95% CI 38.3 - 40.3), including six clinically unsuspected diagnosis. rWGS-guided multidisciplinary care was implemented in 5 patients and disease specific care in 1. Time constraints and cost were identified as the main limitations to the broad introduction of rWGS for critically ill pediatric patients.

Conclusion: We successfully implemented the fastest rWGS platform in Europe. Our workflow has one of the highest rWGS yields. This study establishes the path for a nation-wide semi-center rWGS network in Belgium.

References:

Grants: Government of Wallonia, Belgium: WALGEMED/RIWAL170180.

Conflict of Interest: Aimé Lumaka Sequencing reagents for 5 patients were donated by Illumina Inc., Corinne Pasquelle: None declared, Guillaume Debray: None declared, Serpi Alkan: None declared, Adeline Jacquetin: None declared, Julie Harvengt: None declared, François Boemer: None declared, Leonor Palmeira: None declared, Benoît Charlotteaux: None declared, Anne Brysse: None declared, Saskia Bulk: None declared, Vincent Rigo: None declared, Vincent Bours: None declared.

P16.034.B Non-invasive preimplantation genetic testing for optimizing of IVF treatments

Sabrina Frederiksen,1 Christina D. Fenger,1 Mads Fruensgaard,1 Steen B. Laursen,1 Hans Atli Dahl2

1Amplexa Genetics, Odense, Denmark; 2Fertilitetsklinik IVF-SYD, Fredericia, Denmark.

Background/Objectives: The major contributor for unsuccessful IVF cycles has been found to be embryo aneuploidy. The percentage of aneuploidy rate is known to increase with maternal age increasing the problem of unsuccessful IVF treatments. Preimplantation genetic testing for aneuploidies (PGT-A) is a widely used method to screen embryos for chromosomal abnormalities. Until now the method has required a TE biopsy making the method invasive and thereby limited to few. The discovery of cell free DNA (cfDNA) in the spent culture media (SCM) has made it possible for the development of a non-invasive PGT-A screening of the blastocysts.

Methods: Amplexa Genetics has implemented and validated the nPGT-A method. The generated WGA is sequenced using the Illumina sequencing platform and processed to identify chromosomal abnormalities.

Results: Amplexa Genetics has demonstrated that we can use cfDNA SCM samples and generate WGA from all SCM samples obtained. Clear calls could be obtained in 93% of all cases as either euploid or aneuploid. We observed that increased maternal age correlated with increased percentage of aneuploidy rate as expected. Moreover, the identified aneuploidy is evenly distributed between losses and gains of all 23 autosomal chromosomes.

Conclusion: The nPGT-A method can be used to screen embryos for chromosomal abnormalities to the same extent as the former and invasive PGT-A method.

References: Scott et al 2012, Hassold T, Hunt P et al 2001, Nature Rev.

Grants: No Grants.

Conflict of Interest: Sabrina Frederiksen Amplexa Genetics, Christina D. Fenger Amplexa Genetics, Mads Fruensgaard: None declared, Steen B. Laursen Fertilitetsklinik IVF-SYD, Hans Atli Dahl Amplexa Genetics.

P16.035.C A novel enzymatic fragmentation library preparation workflow that prevents sequencing artifacts and increases scalability

Ross Wadsworth1, Zane Jaafar2, Josh Haines2, Thomas Harrison2, Lindsay Peterkin1, Kristin Scott3, Martin Ranik2, Kristina Giorda2, Eric van der Walt1, Brian Kudlow2

1Watchmaker Genomics, Cape Town, South Africa; 2Watchmaker Genomics, Boulder, United States; 3Colorado State University, Fort Collins, United States.

Background/Objectives: There has been extraordinary progress towards translational research and clinical genomics in the era of NGS — throughput has grown while sequencing costs have gone down. Now, gold standard sonication methods are being reevaluated in light of increased sequencing capacity and the need for highly accurate and scalable workflows. Our goal was to create an automation-friendly workflow and reduce sequencing artifacts to enable highly sensitive clinical and translational applications.

Methods: Here, we utilized sophisticated enzyme engineering and a multidimensional Design of Experiment approach to develop a novel enzymatic library preparation method and ultra-high fidelity amplification module. To assess performance, our solution was compared to conventional enzymatic library preparation workflows using samples ranging from 100 pg to 500 ng of gDNA.

Results: Libraries generated using our optimized workflow reduced chimeric reads and terminal hairpin artifacts 10-fold compared to other enzymatic methods, and reached comparable levels to mechanically sheared DNA controls. Library insert sizes were highly tunable from 150 bp to 550 bp and were consistent across the input titration. To assess the utility of ultra-low input samples, libraries were prepared using a titration from 100 ng to sub-nanogram inputs. Copy number variations (CNVs) were detected across the titration with high sensitivity and specificity using Hidden Markov Model analysis method.

Conclusion: Taken together, this enzymatic fragmentation and library preparation workflow avoids library preparation artifacts that convolute variant calling, is highly scalable, and suitable for ultra-low input samples.

References:

Grants: Government of Wallonia, Belgium: WALGEMED/RIWAL170180.

Conflict of Interest: Ross Wadsworth Watchmaker Genomics, Zane Jaafar Watchmaker Genomics, Josh Haines Watchmaker Genomics, Thomas Harrison Watchmaker Genomics, Lindsay Peterkin Watchmaker Genomics, Kristin Scott Watchmaker Genomics, Martin Ranik Watchmaker Genomics, Kristina Giorda Watchmaker Genomics, Eric van der Walt Watchmaker Genomics, Brian Kudlow Watchmaker Genomics, Watchmaker Genomics.

P16.036.D Improved transcript detection sensitivity utilizing a novel, rapid whole transcriptome sequencing workflow

Travis Sanders1, Lee French2, Julie Walker1, Jennifer Pavlica1, Clara Ross1, Thomas Harrison1, Ross Wadsworth2

1Watchmaker Genomics, BOULDER, United States; 2Watchmaker Genomics, Cape Town, South Africa.

Background/Objectives: mRNA-seq is a powerful tool for transcriptome profiling but is not applicable to many clinically relevant sample types. Template damage in FFPE samples generates 3'-bias, while overabundant globin mRNAs in blood-derived samples are uninformative. Whole transcriptome sequencing, where overabundant transcripts are depleted, supports these sample types and offers a comprehensive view of the transcriptome - including
biologically relevant non-coding transcripts. However, these workflows are typically long, labor-intensive, and difficult to automate. To address this need, we aimed to develop a highly streamlined and automatable solution tailored for challenging samples.

**Methods:** To simplify the protocol while minimizing off-target effects, we built algorithms for optimal probe design and streamlined probe hybridization. We specifically engineered enzymes and reformulated buffers in parallel to improve yields. A novel de-crosslinking step was integrated to improve FFPE performance. Combining reactions, reducing incubation times, and eliminating purifications streamlined the overall workflow. With RNA extracted from whole blood and five FFPE blocks, we compared our solution to commercial products using inputs ranging from 10 to 500 ng.

**Results:** Libraries generated using our solution resulted in improved library yields, unique transcript identification, strand specificity, and rRNA depletion efficiency on a per-FFPE-block basis. Technical replicates showed excellent transcript abundance correlation. Additionally, we observed less than 1% residual rRNA and globin mRNA with no measurable off-target effects using a blood-derived, high-quality sample with as little as 10 ng.

**Conclusion:** Our novel, simplified workflow delivers robust and reproducible performance while enabling library construction within five hours.

**References:** N/A.

**Grants:** N/A.

**Conflict of Interest:** Travis Sanders Watchmaker Genomics, Lee French Watchmaker Genomics, Julie Walker Watchmaker Genomics, Jennifer Pavlica Watchmaker Genomics, Clara Ross Watchmaker Genomics, Thomas Harrison Watchmaker Genomics, Ross Wadsworth Watchmaker Genomics.

**P16.037.A Comprehensive de novo variant discovery with HiFi long read sequencing**

**Erði Kucuk**¹, Bart van der Sanden¹, Luke O’Gorman¹, Michael Kwint¹, Aaron Wenger², William Rowell³, Zev Kronenberg⁴, christine lamber⁵, shreyasee chakraborty⁶, primo baybayan⁶, Han Brunner¹, Alexander Hoischen¹, Lisenka Vissers⁷, Christian Gilissen¹

¹Radboud University Medical Center, Human Genetics, Nijmegen, Netherlands; ²Pacific Biosciences (PacBio), Menlo Park, United States.

**Background/Objectives:** Current technologies fail to accurately explain almost half of neurodevelopmental disorder cases. Long read sequencing (LRS) is promising to comprehensively identify almost half of neurodevelopmental disorder cases. PacBio sequencing technology achieves single base accuracies that are sufficient to robustly identify genome-wide de novo mutations, including in regions missed by SRS.

**Methods:** We sequenced the genomes of 8 trios with unresolved cases. PacBio sequencing achieves single base accuracies that are sufficient to robustly identify genome-wide de novo mutations, including in regions missed by SRS. Long read sequencing (LRS) is promising to comprehensively identify almost half of neurodevelopmental disorder cases. PacBio sequencing technology achieves single base accuracies that are sufficient to robustly identify genome-wide de novo mutations, including in regions missed by SRS.

**Results:** We sequenced the genomes of 8 trios with unresolved cases. PacBio sequencing achieves single base accuracies that are sufficient to robustly identify genome-wide de novo mutations, including in regions missed by SRS. Long read sequencing (LRS) is promising to comprehensively identify almost half of neurodevelopmental disorder cases. PacBio sequencing technology achieves single base accuracies that are sufficient to robustly identify genome-wide de novo mutations, including in regions missed by SRS.

**Conclusion:** Our results show that current PacBio HiFi sequencing technology achieves single base accuracies that are sufficient to robustly identify genome-wide de novo mutations, including in regions missed by SRS.

**References:**

**Grants:**

**Conflict of Interest:** Erði Kucuk: None declared, Bart van der Sanden: None declared, Luke O’Gorman: None declared, Michael Kwint: None declared, Aaron Wenger Pacific Biosciences, William Rowell Pacific Biosciences, Zev Kronenberg Pacific Biosciences, christine lamber: None declared, shreyasee chakraborty Pacific Biosciences, primo baybayan Pacific Biosciences, Han Brunner: None declared, Alexander Hoischen: None declared, Lisenka Vissers*: None declared, Christian Gilissen: None declared.

**P16.038.B Melter: towards achieving efficient semi-automatic reanalysis in rare disease**

**Henning Onspring¹, Daniel Nilsson²,³, Henrik Stranneheim¹,⁴,⁵, Valtteri Wirta¹,²,⁶

¹Karolinska Institutet, Science for Life Laboratory, Department of Microbiology, Tumour and Cell Biology, Stockholm, Sweden; ²Karolinska Institutet, Science for Life Laboratory, Department of Molecular Medicine and Surgery, Stockholm, Sweden; ³Karolinska University Hospital, Department of Clinical Genetics, Stockholm, Sweden; ⁴Karolinska University Hospital, Genomic Medicine Center Karolinska, Stockholm, Sweden; ⁵Karolinska University Hospital, Centre for Inherited Metabolic Diseases, Stockholm, Sweden; ⁶KTH Royal Institute of Technology, Science for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, Stockholm, Sweden.

**Background/Objectives:** Through introduction of comprehensive genomic analyses, the proportion of rare disease patients receiving a molecular diagnosis has dramatically increased. However, the majority of cases still remain without molecular diagnosis after a primary analysis¹, despite suspicion of an underlying genetic disease. Reanalyses of manually selected cases have several times led to identification of a disease-causing variant that was missed in the initial analysis. The accumulated pool of unsolved cases constitutes a great opportunity for disease gene discovery.

**Methods:** We present a concept for systematic, automated reanalysis of unsolved cases using specific triggers to initiate the reanalyses. Such triggers include e.g., updates in clinical features (HPO terms), in phenotype-specific gene panels, or in bioinformatic tools or databases used for annotations. New variants not seen in previous analyses and fulfilling predefined threshold in our variant prioritization scheme are presented for further manual clinical inspection.

**Results:** Testing an automated approach for reanalysis of previously unsolved cases in a pilot setting will allow measuring the computational resources needed and allows for estimating the effort needed for inspecting variants passed on to manual inspection.

**Conclusion:** Comparing the change in diagnostic yield with costs will determine if automated reanalysis of unsolved rare diseases cases should be implemented in clinical routine.

**References:**

¹Stranneheim, H et al. Integration of whole genome sequencing into a healthcare setting: high diagnostic rates across multiple clinical entities in 3219 rare disease patients. Genome Med. 2021;13(1):40. https://doi.org/10.1186/s13073-021-00855-5.

**Grants:**

**Conflict of Interest:** None declared.
P17 DIAGNOSTIC IMPROVEMENTS AND QUALITY CONTROL

P17.002.D Dried blood spot testing with AmplideX SMA Plus Kit resolves SMN1 and SMN2 exon 7 copy numbers and more
Sarah Edelman1, Walairat Laosinchai-Wolf2, Laura Blasco-Pérez2, Mar Costa-Roger2, Ivon Cuscó2, Gary Latham1, Eduardo Tizzano2, John Milligan1

1Asuragen a Bio-Techne brand, Research and Development, Austin, Texas, United States; 2University Hospital Vall d’Hebron, Clinical and Molecular Genetics, Barcelona, Spain.

Background/Objectives: Spinal Muscular Atrophy (SMA) is an autosomal recessive disorder commonly caused by homozygous absence of SMN1, SMN2, an SMN1 paralog, modulates SMA severity. Breakthrough therapies rely on rapid quantification of SMN1 and SMN2 copies, and newborn screening using dried blood spot (DBS) samples has become a public health priority. However, most screening assays only determine presence/absence of SMN1 exon 7, excluding copy numbers (CN) for SMN1 and SMN2 and disease-modifier variants (c.859G>C).

Methods: We tested 42 DBS samples with three DNA isolation methods on three genetic analyzer models (378 measurements total) using the AmplideX® SMA Plus® Kit, which quantifies SMN1 and SMN2 exon 7 CN and detects c.859G>C in a single-tube workflow. Genotypes were determined using AmplideX PCR/CE Reporter software. Reference values were determined using matched whole blood (n = 20) or MLPA and sequencing (n = 22).

Results: For each platform, SMN1 and SMN2 exon 7 CN and variant status were 95-100% concordant with reference results, including 10 SMA samples with no SMN1 copies. Confirmed heterozygous or homozygous samples for 859G>C had unique peak profiles, suggesting concordance for zyosity.

Conclusion: These data demonstrate that the AmplideX Kit can accurately resolve SMN1 and SMN2 CN and variant status from DBS samples. Further, the ability to generate complete results in under 4 hours may improve the time-to-result over current screening approaches, which rely on follow-up confirmatory diagnostic tests. Given the narrow therapeutic window for maximum treatment efficacy, these benefits may enable earlier decision on treatment and improved patient outcomes.

References: *CE-IVD. For US export only.

Grants: Not applicable.

Conflict of Interest: Sarah Edelman Asuragen, a Bio-Techne brand, Asuragen, a Bio-Techne brand, Walairat Laosinchai-Wolf Asuragen, a Bio-Techne brand, Asuragen, a Bio-Techne brand, Laura Blasco-Pérez: None declared, Mar Costa-Roger: None declared, Ivon Cuscó: None declared, Gary Latham Asuragen, a Bio-Techne brand, Asuragen, a Bio-Techne brand, Eduardo Tizzano: None declared, John Milligan Asuragen, a Bio-Techne brand, Asuragen, a Bio-Techne brand.

P17.003.A Standardising the variability of variant classification

Zandra Deans1, Dave Creggen1, Jennifer Fairley1, Farrah Khawaja1, Mark Sales1, Melody Tabiner2, Rebecca Treacy3, Ross Hastings2

1GenQA, Edinburgh, United Kingdom; 2GenQA, Oxford, United Kingdom.

Background/Objectives: Expansion of genome-wide testing for disease-causing changes has increased the requirement to classify variant pathogenicity. Multiple classifications are available for different variant types, and clinical settings. GenQA has globally delivered laboratory external quality assessments (EQAs) for variant interpretation to aid standardisation of classification.

Methods: EQAs were provided for classification of single nucleotide variants (SNVs), copy number variants (CNVs) in prenatal and postnatal settings, and somatic variants. Variant details were provided and laboratories were expected to classify them according to the clinical scenarios. Assessment was based on correct classification, evidence provided and, where appropriate, the actionability of the variant.

Results: Nine germline SNV EQAs have been delivered since 2013, during which time the ACMG classification system was introduced. Data from 26 cases will be presented highlighting changes in practice, and the different applications of evidence. A summary of the prenatal and postnatal CNV classification pilots will show consistency in approach, by either using local justification, or applying the ACMG/ClinGen guidelines. They demonstrate how uncoupling evidence-based classification from potential implications for an individual can assist in standardisation of variant classification. Two solid tumours variant classification pilot EQAs have also been delivered. Laboratories used AMP/ACO/CAP tiering guidelines (actionability) and ACMG guidelines1 (pathogenicity). Both showed variability reflecting differences in guideline application.

Conclusion: Accuracy of variant classification is essential to ensure the patient receives the correct result and clinical management. The EQAs demonstrated variability in the use and application of the guidelines, and the continued need for EQAs to educate and promote standardisation.

References:

Grants:

Conflict of Interest: Zandra Deans NHS Lothian, Dave Creggen NHS Lothian, Jennifer Fairley NHS Lothian, Farrah Khawaja NHS Lothian, Mark Sales NHS Lothian, Melody Tabiner Oxford University Hospital NHS Trust, Rebecca Treacy NHS Lothian, Ross Hastings Oxford University Hospital NHS Trust.

P17.004.B Increasing genomics diagnostic success for Indigenous families in Canada with rare diseases

Tatiana Marollo1,2,3, Arezzo Mohajeni1,4,5, Jill Mwenifumbo3, Vladimir Avramovic1,2, Karen J. Jacob6, Sarah McIntosh4, Solenne Correard6,7, Wyeth W. Wasserman4,8, Nadine R. Caron7,8,9, Laura Arbour4, Anna Lehman4, Maja Tarailo-Graovac1,2

1Cumming School of Medicine, University of Calgary, Departments of Biochemistry, Molecular Biology and Medical Genetics, Calgary, Canada; 2Alberta Children’s Hospital Research Institute, University of Calgary, Calgary, Canada; 3contributed equally., Canada; 4University of British Columbia, Department of Medical Genetics, Vancouver, Canada; 5BC Children’s Hospital and BC Women’s Hospital Vancouver, Department of Pathology and Laboratory Medicine, Vancouver, Canada; 6BC Children’s Hospital Research Institute, Centre for Molecular Medicine and Therapeutics, Vancouver, Canada; 7Canada’s Michael Smith Genome Sciences Centre at British Columbia Cancer, Vancouver, Canada; 8University of British Columbia, Centre for Excellence in Indigenous Health, Vancouver, Canada; 9University of British Columbia, First Nations Health Authority Chair in Cancer and Wellness, Vancouver, Canada.

Background/Objectives: Genomics has the potential to transform health care by facilitating precision medicine. However, individuals who identify as Indigenous (First Nations, Inuit, and Métis) have limited access to genomics. Background genetic variation for Indigenous Peoples is largely unknown, reducing the chance of accurate interpretation of variants and diagnosis of genetic conditions. The Silent Genomes Project (SGP) aims to increase access
to genomics for Indigenous Peoples in Canada, in a culturally safe way.

Methods: We analysed rare disease (RD) patients’ genomes with two independent pipelines. The automated diagnosis pipeline (Level1) implements state-of-the-art methods aligned with clinical standards. The research-based pipeline (Level2) re-analyses genomes with no/uncertain/partial findings. It implements different tools and newly developed approaches to explore complex diagnostic scenarios such as non-coding variations and complex genomic rearrangements (CGR), later experimentally validated (PCR, transcriptomics).

Results: Level1 has analysed 33 probands with suspected undiagnosed RD and reported clinically confirmed pathogenic/likely pathogenic variants for 12 of them (36%). Level1 has also reported 17 variants of uncertain significance (VUS). In total, 20 probands are eligible for Level2. Level2 analysis of seven probands has detected four new findings including novel gene, CGR and translocation.

Conclusion: To facilitate VUS interpretation, the SGP plans to build the first Indigenous Background Variant Library (IBVL) by enrolling Indigenous participants with no RD. With the IBVL and two analytical pipelines, the SGP has the potential to increase diagnostic success in Indigenous patients with RD and reduce disparities in health care. This effort could become a model for other underrepresented populations, addressing gaps in genomic medicine.

References:

Grants:

Conflict of Interest: None declared.

P17.005.C Delivery of a multi-distribution external quality assessment for severe combined immunodeficiency newborn screening

David Cregeen¹, Becky Treacy², Stuart Adams³, Zandra Deans²

¹GenQA, Edinburgh, United Kingdom; ²GenQA, Edinburgh, United Kingdom; ³Great Ormond Street Hospital, Haematology, London, United Kingdom.

Background/Objectives: Newborn screening for severe combined immunodeficiency (SCID) by measurement of T-cell receptor excision circles (TRECs) continues to be evaluated and implemented globally. This requires concomitant implementation of external quality assessment (EQA) distributed regularly throughout the year. GenQA has developed and delivered a 2-year pilot EQA consisting of multiple sample distributions.

Methods: Newborn blood spot cards were prepared using blood samples with either normal or absent TRECs and validated to confirm the levels of TRECs using commercially available TREC assays prior to the global distributions. Assessment was carried out by independent expert advisors against peer rated criteria. Pilot year 1 provided eight samples across two distributions. Pilot year 2 delivered 12 samples across six distributions.

Results: Participants were split evenly between the two commercially available TREC assays with some variation in cut-off levels and the units used to describe results. Over the course of the pilot the quality of result submission improved with ultimately only a few participating laboratories omitting essential information such as assay units, cut-off levels and reference gene results. Older blood spots prepared from normal blood could give results in the affected range despite reference gene results appearing acceptable; therefore, samples for subsequent EQAs were sourced, validated, and distributed within as short a time as possible.

Conclusion: The development of a comprehensive newborn screening EQA is challenging when samples need to be sourced from patients. An EQA format consisting of regular distributions throughout the year of samples suitable for SCID newborn screening analysis has been successfully implemented.

References:

Grants:

Conflict of Interest: None declared.

P17.006.D Deep phenotyping – symptom annotation made simple with SAMS

Robin Steinhaus¹,², Sebastian Proft¹,², Evelyn Seelow³, Tobias Schalau¹, Peter N. Robinson⁴,⁵, Dominik Seelow¹,²

¹Berliner Institut für Gesundheitsforschung, Exploratory Diagnostic Sciences, Berlin, Germany; ²Charité – Universitätsmedizin Berlin, Institut für medizinische Genetik und Humangenetik, Berlin, Germany; ³Charité – Universitätsmedizin Berlin, Medizinische Klinik mit Schwerpunkt Nephrologie und Internistische Intensivmedizin, Berlin, Germany; ⁴The Jackson Laboratory for Genomic Medicine, Farmington, United States; ⁵University of Connecticut, Institute for Systems Genomics, Farmington, United States.

Background/Objectives: Precision medicine needs precise phenotypes. The Human Phenotype Ontology (HPO) structures clinical signs and symptoms and has become the standard annotation for patient phenotypes when describing single gene disorders. However, use of the HPO in other fields than human genetics is not widespread.

Methods: SAMS (Symptom Annotation Made Simple) brings deep phenotyping to routine clinical care, hospital patients, and outpatients. Our web-based application provides three widely used annotation systems: HPO, OMIM, and Orphanet. It also offers a guided differential diagnosis towards a disease when clinical signs (as HPO terms) are entered.

Results: Whilst data can be stored in our database, phenotypes can also be imported and exported as GATK Phenopackets without using the database. The web interface can easily be integrated into local databases, e.g., clinical information systems. SAMS offers users the ability to share their data with others, empowering patients to record their own signs and symptoms (or those of their children) and thus provide their doctors with additional information.

Conclusion: We think that our approach will lead to better characterised patients which is not only helpful for finding disease mutations but also to better understand the pathophysiology of diseases and to recruit patients for studies and clinical trials. SAMS is available at https://www.genecascade.org/SAMS/.

References:

Grants:

Conflict of Interest: None declared.

P17.007.A Implementation of genomic medicine in Stockholm healthcare region – update on first 10,000 samples

gmck-RD consortia¹,²,³, Anna Lindstrand¹,²,³, Henrik Stranneheim¹,²,³, Kristina Lagerstedt-Robinson¹, Nicole Lesko¹, Daniel Nilsson¹,², Sofie Vonlanthen¹, Jesper Eifsfält¹,², Malin Kvarnungs¹,², Martin Engvall¹,³, Helena Malmgren¹, Britt-Marie Anderlid¹, Chiara Ras², Anders
Background/Objectives: In healthcare clinical genetics is transitioning to clinical genomics and especially rare disease diagnostics is increasingly done through panel, exome and genome sequencing. At Karolinska we have formed Genomic Medicine Center Karolinska Rare Diseases (GMCK-RD), a joint unit between healthcare and academia, enabling large-scale genome sequencing of patients. GMCK-RD brings together experts from various medical disciplines with clinical geneticists, bioinformaticians and researchers.

Methods: To facilitate clinical implementation of genome sequencing, we have developed a number of bioinformatic tools and processes covering steps such as variant calling, workflow management, variant prioritization and interpretation, multomics support, data sharing and quality assurance.

Results: Over 10,000 individuals across a broad spectrum of rare diseases have been analyzed, enabling a diagnosis as well as personalized prediction, prognosis, and treatment in thousands of patients.

Conclusion: Challenges include big data processing, ethical and legal issues as well as rigorous quality control while at the same time enabling continuous development of analysis pipelines and tools. The rapid increase in genomic testing also brings along a high need for scaling up interpretation, including recruitment and training of highly specialized "genomicists" and development of new support solutions. We also need integrated units where highly specialized clinicians work closely together with laboratory experts, enabling patient selection, correct interpretation and rapid translation to individualized treatment. These interactions have also enabled a large number of new disease gene discoveries. By overcoming these issues, we at GMCK-RD have moved healthcare in our region towards precision diagnostics and precision medicine.

References: None.

Grants: None.

Conflict of Interest: None declared.

P17.008.B Genetic genome sequencing: one lab flow for all

Gaby Schobers1,2, Ronny Derks1, Ermanno Bosgoed1, Debby Hellebrekers1, Nicole de Leeuw1, Alexander Stegmann1, Erik-Jan Kamsteeg1, Aimee D.C. Paulussen2, Marjolijn Ligtenberg1, Arthur van den Wijngaard1, Christian Gliessen3,4, Rien Blok1, Anna Wedell1,2, Helger Yntema1,2, Marjolijn Ligtenberg1, Arthur van den Wijngaard1, Christian Gliessen3,4, Rien Blok1, Anna Wedell1,2, Helger Yntema1,2, Kinsteeg1, Aimee D.C. Paulussen3, Marjolijn Ligtenberg1, Arthur van Hellebrekers3, Nicole de Leeuw1, Alexander Stegmann3, Erik-Jan work1

1Karolinska Institute, Stockholm, Sweden; 2SciLifeLab, Solna, Sweden; 3Karolinska University Hospital, Stockholm, Sweden.

Background/Objectives: Genetic laboratories maintain numerous genetic workflows to diagnose the full spectrum of hereditary and congenital diseases, including traditional approaches and advanced technologies. A single generic workflow would increase efficiency quite dramatically. We therefore assessed whether genome sequencing (GS) can replace all existing workflows supporting germline genetic diagnoses.

Methods: We performed GS (NovaSeq6000TM; 37x mean coverage) on 1,000 cases with 1,271 clinically relevant variants, selected from one year’s diagnostic yield in a tertiary referral center, identified through 15 different workflows. Variants were binned by size and type: small variants (SNVs/indels <50 bp), large variants (CNVs and repeat expansions) and other variants (SVs and aneuploidies). VCFs were queried per variant and assessed in Trusight Software Suite (DRAGEN Germline Pipeline, TSS, Illumina).

Results: Overall, 93.9% (1,194/1,271) of variants were detected with GS. Detection rates differed per type, with small variants detected in 95.2% (825/867), large variants in 91.9% (328/357), and other variants in 87.2% (41/47). Importantly, variants were identifiable through routine clinical interpretation strategies, including disease-based clinical filters or gene-specific searches in TSS. Variants that remained undetected were mosaic or located in homologous/repetitive regions.

Conclusion: GS is an efficient generic workflow to capture clinically relevant germline variants in a ‘one-test-fits-all-strategy’. Besides those already known for short-read sequencing, no new challenges in variant detection were identified. GS can therefore not only replace exome sequencing, but also >99% of Sanger sequencing, allele specific PCRs, smMIP, MLPA, array, and cyto-genetic analyses including karyotyping and FISH. These results provide perspective on how genetic laboratories will evolve in the near future.

References: None.

Grants: None.

Conflict of Interest: None declared.

P17.009.C How can entire CFTR genotyping contribute in genetically unsolved Cystic Fibrosis cases?

Simone Ahting1, Lutz Nährlich2, Julia Hentschel2

1University Hospital Leipzig, Institute of Human Genetics, Leipzig, Germany; 2Universitätsklinikum Giessen-Marburg GmbH, Zentrum für Kinderheilkunde und Jugendmedizin, Abteilung Allgemeine Pädiatrie und Neonatologie, Giessen, Germany.

Background/Objectives: Genotyping Cystic Fibrosis (CF) patients is crucial for diagnosis confirmation and treatment options. Recent modulator therapies allow for correction of malfunctioning CFTR, but depend on the underlying genotype. Still 5.4% of patients [1] remain undiagnosed after conventional genetic testing and can therefore benefit from entire CFTR-genotyping.

Methods: 731 patients with clinically confirmed CF-diagnosis, but ambiguous genotype were assembled using the German CF Registry. Variants were identified and re-classified, if required using ClinVar, HGMD and CFTR1/2 and corrected in the registry database. Genetic testing was offered to all patients whose variants were inconclusive and further patients lacking genetic CF-confirmation were called for testing. Patient samples were analysed using a Next-Generation-Sequencing-custom-design-panel covering all 27 exons including intrinsic and regulatory regions.

Results: Identification of inconclusive variants led to the discovery of 48 variants not formerly reported in the context of CF. 20 samples with previously unknown or incomplete CFTR genotype were sequenced via NGS with an overall success rate of 70%. All results were uploaded to ClinVar and previously unknown variants were reported to CFTR1/2 for database completion.

Conclusion: Entire CFTR-genotyping can greatly increase the genetic diagnostic rate of CF-patients and should therefore be considered as a replacement for the current strategies in routine diagnostics. Still unclear cases might further benefit from transcriptome sequencing on nasal epithelial cells to analyse the CFTR-mRNA and better assess intrinsic variants.

References: [1] German CF Registry annual report 2020 (https://www.muko.info/fileadmin/user_upload/angebote/qua/qualitaetsmanagement/register/berichtsband/ Berichtsband_2020.pdf).
Grants: Vertex Pharmaceuticals funded this project through the 'Charitable Grant Vertex'.
Conflict of Interest: None declared.

P17.010.D Periodic automated reanalysis and reevaluation of exome data to improve its clinical utility
Cyrielle Kint1, Sara Haers1, Linde Proost1, Alexandra Obregon-Tito1, Jeanne Leisk1

1Invitae, Leuven, Belgium.

Background/Objectives: As more genetic data become available, gene-disease associations and phenotypes are clarified. From June-November 2021 alone, our internal gene-disorder database grew by 184 new rare disorders associated with genetic variation. Additionally, phenotypic associations with genes increased by 28,478 Human Phenotype Ontology terms. Therefore, patients for whom no diagnosis is available today, might be diagnosable next year, next month or even sooner. Similarly, the phenotype of an individual may change over time resulting in the need to adjust analysis to include newly available clinical information. However, leveraging the clinical benefit of this new genetic and phenotypic information is largely contingent on computational tools that can evaluate and integrate it.

Methods: Despite the clinical potential of integrating continuously expanding genetic and clinical information, reanalysis and reevaluation efforts for unsolved whole exome sequencing (WES) tests remain largely manual. This restricts access to the most recent gene-phenotype knowledge, and limits the utility of a WES test to the evaluation of phenotypes present in an individual at the time of testing. To address these deficits, we present an automated reanalysis pipeline utilizing the Moon software that runs every six months, integrating both the most up-to-date gene-phenotype associations and the evolving clinical phenotype of a patient when available.

Results: Automating regular reanalysis of cases has increased the diagnostic utility of our WES tests and provides patients better answers at no additional cost.

Conclusion: This pipeline has been validated and can be used as part of a larger system, as presented here, or as a stand-alone tool (Invitae’s Moon).

References:
Grants:
Conflict of Interest: Cyrielle Kint Invitae, Sara Haers Invitae, Invitae, Linde Proost Invitae, Invitae, Alexandra Obregon-Tito Invitae, Invitae, Jeanne Leisk Invitae, Invitae.

P17.011.A Low-coverage genome sequencing is an efficient approach for the detection of clinically relevant copy-number variants and mtDNA variants
Sander Pajusalu1,2, Kaisa Oja1,2, Ustina Samarina2, Mikko Tooming1,2, Tiina Kahre1,2, Katrin Ounap1,2

1Tartu University, Institute of Clinical Medicine, Department of Clinical Genetics, Tartu, Estonia; 2Tartu University Hospital, United Laboratories, Department of Clinical Genetics, Tartu, Estonia.

Background/Objectives: Compared to exome sequencing, high-coverage genome sequencing is widely appreciated for its superior ability to detect a wide range of genetic variations including copy-number variants (CNVs) and mitochondrial (mtDNA) variants. However, the high cost is still limiting the use of genome sequencing. We aimed to assess whether low-coverage genome sequencing, a considerably cheaper approach, would detect clinically relevant CNVs and mtDNA variants and would thus be a cost-efficient approach to supplement exome sequencing in rare disease diagnostics.

Methods: To assess the level of sequencing depth needed for variant detection, first, 30x mean coverage genome sequencing data were subsampled to 0.5x, 1x, 2x, and 4x coverage files in silico. CNVs were detected using Control-FREEC and the mtDNA variants were detected using the GATK4 mitochondrial pipeline. Five disease-causing deletions (sized 3.4kb, 4.6kb, 7.2kb, 16kb, and 90kb) and one possibly pathogenic heteroplasmic (14.7%) mtDNA variant was used to assess sensitivity.

Results: For CNV calling, 2x coverage was sufficient to detect all heterozygous CNVs greater than 10kb in size, for smaller CNVs even 4x coverage data did not suffice for CNV detection. Regarding mtDNA variants, 2x coverage resulted in >99% theoretical sensitivity for heteroplasmcy levels >10%. The possibly pathogenic heteroplasmic variant was detected without significant change in heteroplasmcy estimation in all low-coverage data (0.5x to 4x coverage).

Conclusion: Low-coverage genome sequencing may be used to complement exome sequencing for simultaneous mtDNA variant and CNV detection.

References:
Grants: Estonian Research Council grants PRG471, MOBTP175, PSG774.
Conflict of Interest: None declared.

P17.012.B MorbidGenes panel: a monthly updated list of diagnostically relevant genes derived from diverse sources
Robin-Tobias Jauss1, Bernt Popp1, Konrad Platzer1, Rami Abou Jamra1

1Institute of Human Genetics, University Hospital Leipzig, Leipzig, Germany.

Background/Objectives: Identifying clinically relevant genetic variants is crucial for a fast and reliable genetic diagnosis. With exome sequencing now standard, diagnostic labs are in need of a, in principle, to-the-day-accurate list of genes associated with rare diseases. Manual curation efforts are slow and often disease specific, while efforts relying on single sources are too inaccurate and may result in false-positive genes.

Methods: We established the MorbidGenes panel based on a list of publicly available databases: OMIM, PanelApp, SysNDD, ClinVar, HGMD and GenCC. A simple logic allows inclusion of genes with sufficient evidence based on a voting algorithm. By providing an API endpoint, users can directly access the list and metadata for all relevant information on their genes of interest.

Results: The panel currently includes 4,677 genes (v.2022-02.1, as of February 2022) with minimally sufficient evidence on disease causality to classify them as diagnostically relevant. Reproducible filtering and versioning allow the integration into diagnostic pipelines. In-house implementation successfully removed false positive genes and reduced time requirements in routine exome diagnostics. The panel is updated monthly, and we will integrate novel sources on a regular basis. The panel is freely available at https://morbidgenes.org/.

Conclusion: The MorbidGenes panel is a comprehensive and open overview of clinically relevant genes based on a growing list of sources. It supports genetic diagnostics labs by providing diagnostically relevant genes in a QM conform format on a monthly basis with more frequent updates planned. Once genomes are standard, diagnostically relevant non-coding regions will also be included.

References:
Grants:
Conflict of Interest: None declared.
P17.013.C Who am I? Donor DNA in Patients after Stem Cell Transplantation

Mareike Mertens1, Mona Sadlo1, Julia Hentschel1

1Philipp-Rosenthal-Straße, University of Leipzig Medical Center, Leipzig, Germany.

Background/Objectives: In Germany, 3,500 persons per year receive a stem cell transplantation resulting in a chimeraism. Therefore, germline testing of blood samples is not feasible. The presence of donor DNA in various tissues recipients has previously been documented (Thiede et al. 2000; Imanishi et al. 2007). Yet, the literature lacks a statistical sound assessment of quantitative extend of donor DNA in various tissues.

Methods: We performed a pilot trial with six patients who received an allogeneic stem cell transplant. We analyzed DNA from buccal swabs, nails and reference material (collected before transplantation) with two different approaches: a short tandem repeat (STR) assay containing 28 STR markers (custom-made) to detect donor derived DNA and a NGS-RC-PCR-based SNP-Assay including 34 Loci (Nimagen).

Results: Our study showed that DNA of the stem cell donor could be detected in both buccal swabs and nail samples after transplantation. The detected donor proportion varies between 11 % and 44 % in the buccal swabs and nail samples.

Conclusion: The study confirms the presence of donor DNA in buccal swabs and documents a donor DNA percentage in nail samples of the recipient after allogeneic stem cell transplantation. Currently, we extent the study to additional patients, additional tissue types and adress the question how donor DNA proportion varies over time after transplantation to derive more robust conclusions, to provide guidance for germline testing after stem cell transplantation.

References:

Grants:

Conflict of Interest: Mareike MertensUniversitätsklinikum Leipzig, Mona Sadlo Universitätsklinikum Leipzig, Julia Hentschel Universitätsklinikum Leipzig.

P17.014.D Challenges and lessons learned for automated variant interpretation pipelines in clinical whole genome sequencing

Kevin Savage1, Susan Walker2, Katherine Smith1, Antonio Rueda1, Javier Lopez1, Liam Abrahams1, Emma Baple1, Smedley Damien1, Ellen Thomas1, Matt Brown1, Richard Scott1, Augusto Rendon1, Rachael Mein2, Zandra Deans2, Sue Hill2, Mark Caulfield2, Dalia Kaspersavicute1

1Genomics England, London, United Kingdom; 2NHS England, London, United Kingdom; 3Queen Mary University of London, London, United Kingdom.

Background/Objectives: During the 100,000 Genomes Project, Genomics England developed an automated variant interpretation framework called Tiering. Tiering prioritises variants most likely to be clinically relevant for individual patients based on known gene-disease association, predicted variant consequence type, population frequency and variant segregation with the phenotype in the family. Here, we investigate the performance of tiering.

Methods: We analysed 938 small variants that were classified as pathogenic or likely pathogenic, and considered diagnostic by NHS Genome Medicine Centres, but not prioritised by Tiering at the time of the first interpretation. We identified the reasons these variants were not prioritised.

Results: The most frequent reasons diagnostic variants were not prioritised were:

- No gene/disease association data known at time of analysis (43%).
- Observed variant segregation with phenotypes in a family did not match mendelian patterns associated with the disease (21%).
- Complexities, such as skewed X inactivation, mosaicism, assumed complete variant penetrance or phenocopies, may account for some segregation errors. Sensitivity can be improved by discarding all information from family members (recovered 63 out of 191 variants) or allowing reduced penetrance, assuming family members may have the diagnostic variant but not be affected (recovered 54 out of 191 variants). Such gains are at the cost of specificity, but given the impact on diagnostic yield this needs to be explored further.

Conclusion: Known gene-disease association data poses the largest challenge for automated variant prioritisation. We show that accommodating complex inheritance patterns with automated variant prioritisation pipelines is particularly challenging.

References:

Grants:

Conflict of Interest: Kevin Savage Employed by Genomics England, Susan Walker Employed by Genomics England, Katherine Smith Employed by Genomics England, Antonio Rueda Employed by Genomics England, Javier Lopez Employed by Genomics England, Liam Abrahams Employed by Genomics England, Emma Baple: None declared, Smedley Damien: None declared, Ellen Thomas Employed by Genomics England, Matt Brown Employed by Genomics England, Richard Scott Employed by Genomics England, Augusto Rendon Employed by Genomics England, Rachael Mein: None declared, Zandra Deans: None declared, Sue Hill: None declared, Mark Caulfield Employed by Genomics England, Dalia Kaspersavicute Employed by Genomics England.

P17.015.A A Prostate-enriched circulating cells from semen as a source for prostate cancer liquid biopsy: setting and challenges

Ilaria De Simone1, Marinella Corbetta1, Chiara Chierghin2, Piergiuseppe Colombo1-3, Federico Colombo2, Vittoria Fasulo2, Cesare Saitta1, Alessio Benetti1, Rodolfo Hurle1, Alberto Saita1, Nicolò Maria Buin1,2, Giovanni Lughezzani1-2, Paolo Casile2, Giorgio Guazzoni1,2, Rosanna Asselta1,2, Massimo Lazzeri1,2, Giulia Solda1,3

1Humanitas Research, Department of Biomedical Sciences, Humanitas University, Milan, Italy; 2IRCCS Humanitas Research Hospital, Milan, Italy.

Background/Objectives: Prostate cancer (CaP) diagnosis relies on prostate-specific antigen and invasive trans-rectal/perineal biopsy, with a significant rate of false negatives and complications. Hence, there is a growing interest in the development of novel approaches for non-invasive CaP detection. We implemented a protocol to enrich prostate-derived cells from seminal fluid (SF) and urine, to test the hypothesis that liquid biopsy (LB) of SF can be used for CaP diagnosis/prognosis.

Methods: The study cohort included 86 CaP patients scheduled for radical prostatectomy. The day before surgery, we collected a sample of SF; post-ejaculation urine, and peripheral blood from each patient. For 43 patients, CaP specimen was also obtained. After centrifugation, prostate-derived cells were enriched from SF and urine by FACS with the following markers: 7AAD+ (cell viability), Syto-16+ (nuclear staining), CD45- (leucocyte antigen), PSMA+ (prostate-specific antigen), EpCAM+ (epithelial marker).
Results: We obtained on average ≈67,000 and ≈23,000 prostate-enriched cells from semen and urine, respectively. No correlation between the number of collected cells and Gleason Score was observed. Although a critical point of implementation concerns the quantity/quality of nucleic acids (RNA, DNA) obtainable from these cells, we were able to confirm the presence of PCA-specific lesions (TMPRSS2-ERG fusion and a somatic mutation in the SPOP gene) in CTCs from SF and urine, respectively.

Conclusion: The number of prostate-enriched cells in semen/urine alone cannot be used for non-invasive PCA grading. A molecular analysis of the obtained cells could be implemented to identify tumor markers for PCA diagnosis.

References:

Grants: Ricerca Finalizzata, grant RF-2018-12367080, is acknowledged.

Conflict of Interest: None declared.

P17.016.B A tailored stepwise strategy for improving diagnostic yield in intellectual disability and developmental disorders

Nuno Maia1,2, Arjan PM de Brouwer3, Paula Jorge1,2

1Centro de Genética Médica Jacinto de Magalhães (CGM), Centro Hospitalar Universitário do Porto (CHUPorto), Porto, Portugal; 2Unit for Multidisciplinary Research in Biomedicine (UMiB), Institute of Biomedical Sciences Abel Salazar (ICBAS), and ITR - Laboratory for Integrative and Translational Research in Population Health, University of Porto, Porto, Portugal; 3Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen, Nijmegen, Netherlands.

Background/Objectives: Intellectual disability (ID) / developmental disorders (DD) describe a clinical and genetic heterogeneous group of conditions. Herein, a molecular diagnostic strategy for ID/DD will be illustrated using a singular cohort of patients.

Methods: Exome (ES) and target sequencing were applied in the investigation of a diverse cohort of ID/DD patients with putative autosomal recessive inheritance and a previous normal genetic investigation, namely Fragile-X, conventional karyotype, and chromosomal microarray analysis.

Results: The investigational odyssey of our cohort suggests that (i) targeted sequencing is effective in clinically recognizable forms of ID, e.g. X-linked Optiz G/BBB syndrome; (ii) ES contributes to disclose genetic contribution of complex phenotypes, e.g. in a patient with Usher syndrome and muscle complaints (iii) deep phenotyping is important, e.g. in the synergic contribution of heterozygous variants in genes linked to DNA repair, (iv) CNVs and genomic rearrangements can be unnoticed by ES, which we will explain by a genomic rearrangement in SNX14, and (v) interlaboratory collaborations are key for the identification of new ID/DD gene(s) by using MAN2C1 as an example.

Conclusion: According to some authors ES should be used as first-tier test in ID/DD. Despite this trend, the definition of a diagnostic strategy is still difficult even in case with a clear inheritance pattern. To define the best strategy for each patient, communication between medical and laboratory communities is fundamental. In the absence of well-defined guidelines, we propose a stepwise tailored approach for molecular diagnosis, which should be periodically reviewed.

References:

Grants: UIDB/00215/2020, UIDP/00215/2020) and LA/P/0064/2020.

Conflict of Interest: None declared.

P17.017.C Analytical validation of gene coverages for Newborns Whole Genome Sequencing Pilot programme

Dasha Deen1, Susan Walker1, Gabriel Adams1, Alex Stuckey1, Javier Lopez1, Alice Tuff-Lacy1, Matt Brown1, Richard Scott1, Augusto Rendon1, David Bick1, Dalia Kasperavici1, Genomics England Research Consortium1

1Genomics England, London, United Kingdom.

Background/Objectives: The Newborn Whole Genome Sequencing (WGS) programme is an NHS-embedded research pilot in the UK that aims (1) to evaluate the feasibility, utility and impact on the NHS of screening for childhood-onset rare actionable genetic conditions; (2) understand how, with consent, genomic and healthcare data could be used to enable research to develop new diagnostics and treatments; and (3) explore the implications of storing an individual’s genome for use over their lifetime. Here we present an approach for analytical validation of the coverages of genes for childhood-onset rare actionable conditions in short-read WGS data.

Methods: Statistical modelling was used to define the required coverage. Then the empirical distributions of the coverage for coding regions of 689 genes for rare treatable conditions1 for SNP and CNV variant calling were assessed in 1,000 test WGS samples sequenced at average depth of 50X.

Results: We defined low coverage positions as the positions that are expected to be covered with less than 16 reads in more than 5% of the samples. We classified the regions of systematic low coverage into three categories: (1) inherently prone to undersequencing; (2) low coverage due to reads with poor base quality and (3) low coverage due to the presence of homology regions.

Conclusion: Our work provides a basis to inform decisions about technology, pipeline and gene selection for Newborn WGS screening. It will also support monitoring of performance and tailoring of approaches to enhance fidelity in error-prone regions by bespoke solutions, reference masking or blacklisting.

References: Bick et al. Am.J.Med.Genet.C.Semin.Med.Genet 187(1):48-54(2021).

Grants:

Conflict of Interest: Dasha Deen Full time employee of Genomics England, Susan Walker Full time employee of Genomics England, Gabriel Adams Full time employee of Genomics England, Alex Stuckey Full time employee of Genomics England, Javier Lopez Full time employee of Genomics England, David Bick Full time employee of Genomics England, Richard Scott Full time employee of Genomics England, Augusto Rendon Full time employee of Genomics England, Dalia Kasperavici Part-time employee of Genomics England, Alice Tuff-Lacy Full time employee of Genomics England, Javier Lopez Full time employee of Genomics England, Gabriel Adams Full time employee of Genomics England, David Bick Full time employee of Genomics England, Richard Scott Full time employee of Genomics England.

P17.018.D Multiplex Ligation-Dependent Probe Amplification (MLPA) is a powerful tool for screening of different CNVs and loci methylation status of various genetic conditions: 7 years’ experience

Ola Eid

1National Research Centre, Egypt, Human Cytogenetic, Cairo, Egypt.

Background/Objectives: Multiplex ligation-dependent probe amplification is a rapid, reliable, robust and cost-efficient technique to screen the clinically relevant aberrations in routine diagnostics. It is a multiplex polymerase chain reaction-based method...
that can detect changes in the gene copy number status, DNA methylation, and point mutations simultaneously. MLPA is an efficient tool to analyze genomic copy number aberrations at 55-60 different genomic loci. MLPA allows the profiling of prognostic and predictive markers.

**Methods:** Here, we are going to explore the MLPA results of more than 1500 sample form various genetic conditions such as intellectual disabilities/multiple congenital anomalies (ID/MGA), autism spectrum disorders (ASD), short stature (SS), breast cancer, chronic lymphocytic leukemia (CLL), retinoblastoma (RB), imprinting diseases and prenatal screening for aneuploidies.

**Results:** MLPA positive results were detected in 3 (22.9%) out of 144 ID/MGA patients, in 7 (17.5%) out of 40 ASD patients, in 11 (22%) out of 50 SS children, in 12 out of 72 RB patients (16.67%). Moreover, MLPA detected 14 foetuses having trisomy out of 48 amniotic fluid samples in addition of their sex determination. Furthermore, MLPA detected 26 genomic abnormalities in 30 CLL patients. There are other interesting results.

**Conclusion:** Our conclusion about this technology that it has considerable advantages in that it is highly versatile in its applications, malleable in its target loci, highly automated, appropriate for high-throughput testing, competent, and cost effective.

**References:**

**Conflict of Interest:** None declared.

**P17.019.A Efficiency and clinical utility of trio-based whole exome sequencing in patients with suspected rare mendelian disorders**

Sandra Von Hardenberg1, Gunnar Schmidt1, Manuela Richter2, Hannah Wallaschek1, Brigitte Schlegelberger1, Christoph Jacob1, Alexander von Gise2, Bernd Aubert1

1Department of Human Genetics, Hannover Medical School, Hannover, Germany; 2Department of Neonatology, Children’s and Young Hospital Auf der Bult, Hannover, Germany; 3Department of Pediatric Pulmonology and Neonatology, Hannover Medical School, Hannover, Germany; 4Department of Pediatric Cardiology and Intensive Care Medicine, Hannover Medical School, Hannover, Germany.

**Background/Objectives:** Rare genetic diseases are a major cause for severe illnesses in children. Whole exome sequencing (WES) is a powerful tool for identifying the underlying genetic cause. A simultaneous examination of the patient and his/her parents (tWES) has been proven to be a time saving method. To shorten the process of identifying the correct genetic diagnosis is of utmost importance for precise, evidence-based treatment decisions.

**Methods:** We assessed diagnostic rate and clinical utility of tWES in 224 children with a suspected genetic condition in the German in- and out-patient public healthcare system.

**Results:** tWES provided a diagnosis in 63 (28%) of all analysed children and in 18 (35%) children treated in intensive care units (ICUs). Due to vigorous improvements in sample processing and data analysis the evaluation time of tWES data has been reduced significantly during the last three years from 41 days in 2019, 34 days in 2020 to 23 days in 2021. Several genes could be identified to be causative, three of them (GAD1, TMEM222 and ZNF3X1) were previously not associated with a clinical condition. It is worth emphasizing that 15% of children with a genetic diagnosis had larger copy number variations (CNV) that were detected via WES.

**Conclusion:** tWES has been proven to have a high diagnostic yield in critically ill children. It has a high impact for classification of de novo or compound heterozygous variants and therefore on management and family counselling. We recommend initiating tWES as early as possible, especially or children on ICU.

**References:**

**Grants:** /

**Conflict of Interest:** None declared.

**P17.020.B DeepVariant as a variant caller to diagnose rare diseases**

Ramprasad Neethiraj1, Anders Jemt2,3, Valterri Wirta1,2,3, Henrik Stranneheim1,2,4

1Science for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm, Sweden; 2Genomic Medicine Center Karolinska, Karolinska University Hospital, Stockholm, Sweden; 3Science for Life Laboratory, Department of Microbiology, Tumour and Cell Biology, Karolinska Institutet, Stockholm, Sweden; 4Centre for Inherited Metabolic Diseases, Karolinska University Hospital, Stockholm, Sweden.

**Background/Objectives:** GATK best practices workflow is widely used to identify variants to diagnose rare diseases, but studies have shown that DeepVariant (DV) can generate more accurate variant calls. DV also generates biologically relevant genotype quality (GQ) scores, a parameter used to evaluate the quality of the variants. The primary goal of this study was to assess DV’s performance against that of GATK in a clinical diagnostics pipeline. Additionally, we have also attempted to understand the relationship between genotype quality (GQ) scores from the two variant callers.

**Methods:** In this study, we used 2 cases; one is a trio of Ashkenazi Jewish ancestry from NIST reference sample collection that was used to evaluate precision and sensitivity metrics of the pipeline, and one is a synthetic dataset spiked with data from 503 known disease-causing SNVs which we used to assess recall rate on clinical samples and understand the effect of changing the variant caller on GQ scores.

**Results:** We observed that DV outperformed GATK in terms of both precision (99.92% vs. 98.88%) and sensitivity (99.84% vs. 99.41%) for variants in the high-confidence regions. All 503 SNVs were correctly recalled, and approximately 90% of the SNPs called by GATK had a GQ score of >90, whereas SNVs from DV had a relatively better spread with 90% of the variants between 30 and 60.

**Conclusion:** Our results show that switching from GATK to DV for variant calling can improve the overall quality of variant calls.

**References:**

**Grants:** /

**Conflict of Interest:** None declared.

**P17.021.C Development of an amplicon-based NGS test for evaluating MLH1 promoter methylation**

Sara Iolanda Oliveira da Silva1, Tabata Domingos1, Bruna Catin Kupper1, Samuel Aguiar Junior1, Dirce Carraro1, Giovana Torrezan1

1A.C.Camargo Cancer Center, Sao Paulo, Brazil.

**Background/Objectives:** Detecting loss of expression of DNA mismatch repair (MMR) proteins is highly relevant to identify Lynch syndrome patients. However, MLH1 inactivation due to promoter hypermethylation occurs in 15% of sporadic colorectal cancers (CRCs), and it is correlated with BRAF somatic mutations. Here, we aimed to develop a diagnostic test for assessing MLH1 promoter methylation based in next generation sequencing (NGS), and to evaluate the concordance of MLH1 methylation and BRAF-V600 mutation status in CRC.
**Methods:** For MLH1 methylation analysis DNA from FFPE tumors and saliva was treated with bisulfite, amplified by PCR and evaluated by amplicon sequencing on Ion Proton platform. Sequences were analyzed in CLC Genomics Workbench to evaluate the frequencies of cytosine/thymine bases of four CpGs.

**Results:** The average percentage of MLH1 methylation was 2.49% in 20 saliva samples, 2.1% in 6 tumors with MSH2/MSH6 loss and 29.6% (ranging from 1.0% to 91.3%) in 20 tumors with MLH1/PMS2 loss. We confirmed the reproducibility and accuracy of MLH1 promoter analysis performing a serial dilution experiment with completely methylated and unmethylated control DNAs. For MLH1/PMS2 deficient tumors, the MLH1 methylation status was concordant with the BRAF mutation status in 90% (18/20) of the cases.

**Conclusion:** Our amplicon based NGS test showed a great sensitivity and specificity for detecting MLH1 methylation in CRC samples, with a high agreement with the evaluation of BRAF mutation. This simple and affordable test could be used as a reflex test to identify patients with sporadic causes of MLH1/PMS2 deficiency in CRC and endometrial cancer.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P17.022.D Automated decision support for the clinical interpretation of copy number variants**

Tomáš Sládeček1,2, Michaela Gažiová1,2, Marcel Kucharík1,2, Zuzana Póš1,2, Ondrej Pos1,2, Werner Krampl1,2, Rastislav Hekel1,2, Ján Radvánszky1,2, Jaroslav Budíš1,2, Tomas Szemes1,2,4

1Geneton Ltd, Bratislava, Slovakia; 2Comenius University Science Park, Bratislava, Slovakia; 3Faculty of Mathematics, Physics and Informatics, Comenius University, Department of Computer Science, Bratislava, Slovakia; 4Faculty of Natural Sciences, Comenius University, Bratislava, Department of Molecular Biology, Bratislava, Slovakia; 5Biomedical Research Center, Slovak Academy of Sciences, Institute of Clinical and Translational Research, Bratislava, Slovakia; 6Slovak Centre of Scientific and Technical Information, Bratislava, Slovakia.

**Background/Objectives:** Clinical interpretation of copy number variants (CNVs) is a complex process that often leads to different decisions between diagnostic centers. In order to alleviate this obstacle, technical standards for the interpretation and reporting of variants have been developed, called ACMG guidelines. Several semiautomatic computational methods have been proposed to recommend appropriate choices. Alternately, the emerging machine learning based tools showed promising ways of even fully automated predictions.

**Methods:** We evaluated state-of-the-art computational prediction tools on CNV records collected from the ClinVar database. We compared their accuracy and showed the superior accuracy of their combination. We also tweaked the key parameters and underlying data sources to demonstrate their impact on the overall prediction.

**Results:** We demonstrate that the choice of underlying data sources significantly affects the prediction of CNV pathogenicity. We also show how automated prediction tools, especially their combination, further improve the evaluation of ACMG guidelines and thus lead to more reliable clinical decision support for clinicians.

**Conclusion:** Modern clinical decision support tools for the clinical interpretation of CNVs are able to provide valuable guidance to clinicians, relieving them of a great share of tedious annotation and interpretation processes.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P17.023.A Completing MANE Select, A Joint NCBI and EMBL-EBI Transcript Set for Clinical Genomics and Research**

Adam Frankish1, Joannella Morales1, Shashikant Pujar2, Jane Loveland3, Alex Astashyn4, Ruth Bennett1, Andrew Berry1, Eric Cox2, Claire Davidson1, Olga Ermolaeva1, Catherine Farrell2, Reham Fatima1, Laurent Gill5, Tamara Goldfarb6, Jose M Gonzalez6, Diana Haddad6, Matt Hardy1, Toby Hunt1, John Jackson5, Vinita Joardar2, Michael Kay1, Vamsi Kodali5, Kelly McGarvey7, Aiofe McMahon1, Jonathan Mudge1, Michael Murphy5, Bhanu Rangwala6, Lillian Riddick6, Françoise Thibaud-Nissen6, Anjana Vatsan6, Craig Wallin5, David Webb6, Fiona Cunningham5, Terence Murphy6

1European Molecular Biology Laboratory, European Bioinformatics Institute, Cambridge, United Kingdom; 2National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, United States.

**Background/Objectives:** Understanding the impact of clinically relevant variants requires comprehensive gene annotation. However, the historic lack of a standard for clinical reporting complicates the process of consistent interpretation and reporting.

**Methods:** Ensembl/GENCODE and ReSeq launched the Matched Annotation from NCBI and EMBL-EBI (MANE) collaboration to converge on human gene and transcript annotation and jointly define a high-value set of transcripts and corresponding proteins for use as a universal standard for variant reporting. Each MANE transcript represents an exact match between the exonic sequence of an Ensembl/GENCODE transcript and its counterpart in ReSeq, such that the identifiers can be used synonymously. The MANE Select set identifies a representative transcript for each human protein-coding gene. The MANE Plus Clinical set provides additional transcripts at loci where the Select alone is not sufficient to report all currently known clinical variants.

**Results:** With MANE release 1.0 we have now released MANE Select transcripts for 99.7% of human protein-coding genes, including all ACMG SF v3.03 genes.

**Conclusion:** MANE transcripts are accessible from major genome browsers and key resources. Widespread adoption will increase consistency of reporting, facilitate exchange of data regardless of annotation source, and help streamline clinical interpretation.

**References:**

**Grants:** This work is supported by: Wellcome Trust-WT200990/Z/16/Z; EMBL-Core-Funds; NIH-U41HG007234 and Intramural Research Program of the National Library of Medicine, National Institutes of Health.

**Conflict of Interest:** None declared.
P17.024.B Detection of Turner Syndrome in newborn screening: validation of a fragment-analysis based approach

Ruth Luschka1, Ivonne Bedei1, Johannes Becker-Follmann2, Axel Weber2, Zeynep Agirman2, Tarrin Khairi-Taraki2, Ramon Enriquez Schaefer2, Roland Axt-Fliedner3

1Justus-Liebig University Giessen, Department of Prenatal Medicine and Fetal Therapy, Giessen, Germany; 2Justus-Liebig-Universität Gießen, Institute of Human Genetics, Gießen, Germany.

Background/Objectives: Turner syndrome (TS) affects one in 1,900 newborn girls. Late diagnosis impairs a timely treatment and limits improvement of the outcome. Various experts have been advocating for including TS in newborn screening (NBS) programs (1). Existing methods are not suitable for use in NBS, partly because they fail to work with material from dried blood spots (DBS), fail to detect mosaics or because of elevated costs. Our objective was to overcome these constraints and develop a screening method suitable for public NBS programs.

Methods: We defined 6 STR and 3 SD (segmented duplication) markers, all mapping to the X chromosome, the latter additionally mapping to chromosomes Y, 3, and 16, respectively. The distribution of the STR markers along the X chromosome allows to detect aneuploidies of both chromosomal arms separately. The SD markers allow to compare the copy number of the X chromosome with that of the Y chromosome and the autosomes. Fragments were amplified by multiplex-PCR and separated by capillary electrophoresis. 20 TS patients, confirmed by karyotyping were analyzed and compared against 60 controls. The capability to distinguish 46,XX from discrepant karyotypes was evaluated applying statistics.

Results: All 60 controls and 20 TS cases were correctly identified from DBS, gDNA from whole blood and buccal smears, respectively.

Conclusion: Our SD-STR-QF-Multiplex-PCR system allows to screen for TS, including mosaics and is in line with requirements for NBS programs concerning tissue, ease of use, costs, turn-around-time and scalability.

References: (1) Gravholt, CH, et al: Eur J Endocrinol 2017;177:G1-G70.

Grants:

Conflict of Interest: Ruth Luschka: None declared, Ivonne Bedei: None declared, Johannes Becker-Follmann Employee of Eluthia, Axel Weber: None declared, Zeynep Agirman Employee of Eluthia, Tarrin Khairi-Taraki Employee of Eluthia, Owns stocks in Eluthia, Ramon Enriquez Schaefer Employee of Eluthia, Owns stock in Eluthia, Roland Axt-Fliedner: None declared.

P17.026.D Sequencing and Commercial Intelligible Ratio based Real-Time PCR Outperform Multiplex Ligation-Dependent Probe Amplification in Prenatal Diagnosis for Spinal Muscular Atrophy

Gülten Tuncel1, Aysegul Bostanci2, Burcin Sanlidag3, Eray Dirik3, SEHIME TEMEL4, Mahmut Ergören1,5

1Near East University, DESAM Research Institute, Nicosia, Cyprus; 2Near East University, Department of Medical Microbiology and Clinical Microbiology, Faculty of Medicine, Nicosia, Cyprus; 3Near East University, Department of Pediatrics, Faculty of Medicine, Nicosia, Cyprus; 4Bursa Uludag University, Department of Medical Genetics, Faculty of Medicine, Nicosia, Cyprus; 5Near East University, Department of Medical Genetics, Faculty of Medicine, Nicosia, Cyprus.

Background/Objectives: Spinal muscular atrophy (SMA) is a rare, recessively inherited neurodegenerative disorder arising from deterioration of motor neurons in the anterior horn of the spinal cord that in turn results in muscle weakness and atrophy. SMA is mostly caused by deletion or point mutations in the SMN1 gene. As current therapies are only applicable to patients below two years of age and are expensive, screening tests are of high importance for prevention and early detection of cases. Currently, multiple ligation probe analysis (MLPA) is often considered as the gold standard method for diagnosis, providing an easy and high throughput system for analysing the critical regions in affected patients and carriers.

Methods: Here we report the case of an SMA type I patient with a novel SMN1 mutation that was misdiagnosed in prenatal screening. She was admitted to the hospital with symptoms of muscle weakness recognised from birth on. The diminished movements were mostly recognised on her hands and arms. Further genetic analysis was performed with next generation sequencing and by SNP Biotechnology SMA Real-Time PCR Detection Kit.

Results: NGS revealed the novel heterozygous SMN1 c.835_5_835delTCCTTinsTG(IVS7-5_5IVS7-9delTCCTTinsTG) mutation in combination with heterozygous SMN1 exon 7-8 deletion. The novel mutation could also be detected by SNP Biotechnology SMA Real-Time PCR Detection Kit.

Conclusion: In this context we conclude that the use of MLPA analysis may not be the gold standard in SMA screening as less frequent mutations or mutations in the ligand binding regions can be missed.

References:

Grants:

Conflict of Interest: None declared.

P18 BIOINFORMATICS, MACHINE LEARNING AND STATISTICAL METHODS

P18.001.A GestaltMatcher 2.0: Open access database and open source software toolkit for facial phenotype descriptors

Alexander Hustinx1, Behnam Javanmardi1, Peter Kowitz2, Tzung-Chien Hsieh3

1Institute for Genomic Statistics and Bioinformatics, University Hospital of Bonn, Bonn, Germany.

Background/Objectives: Many next-generation phenotyping approaches, such as GestaltMatcher and DeepGestalt, have shown that they can assist in finding a diagnosis for individuals with rare genetic disorders. However, most of these tools are based on deep convolutional neural networks that were developed for a broad range of object identification. We aimed to improve the performance by using recent network architectures for facial images, more data augmentation, and ensemble models. Besides, we introduce GestaltMatcher Database (GMDB) to the research community which can be used to train and compare further deep learning models.

Methods: We utilized 4750 frontal face photos of 350 different disorders in GMDB for training and benchmarking. We first replaced the old architecture with a recent one that performs better on face recognition. Afterward, we improved the base model’s performance for transfer learning and addressed the data scarcity when training the new GestaltMatcher model. Lastly, we applied test time augmentation and model ensembles to maximize the robustness and accuracy of our model.

Results: We first benchmarked each proposed change and showed that they improve the diagnostic performance on the frequent and rare subsets of GMDB. Moreover, we compared the performance between the old model, the new model, and
an ensemble of models. The modernized models significantly improved the performance on both subsets compared to the old model’s performance on GMDB by up to 45%.

Conclusion: In Conclusion GestaltMatcher 2.0 is not only a significant update with respect to performance, but it is the first open source effort for next-generation phenotyping and FAIR data use.

References:

Grants.

Conflict of Interest: Alexander Hustinx: None declared, Behnam Javanmardi: None declared, Peter Krawitz Modest; FDNA, Tzung-Chien Hsieh: None declared.

P18.002.B Scalable integration of multiomic single-cell data using generative adversarial networks

Valentina Giananti\textsuperscript{1,2}, Marco Antoniotti\textsuperscript{1,3}, Davide Cittaro\textsuperscript{2}

\textsuperscript{1}Università degli Studi di Milano-Bicocca, Department of Informatics, Systems and Communication, Milan, Italy; \textsuperscript{2}IRCCS San Raffaele Institute, Center for Omics Sciences, Milan, Italy; \textsuperscript{3}Università degli Studi di Milano-Bicocca, Bicocca Bioinformatics Biostatistics and Bioimaging Centre – B4, Milan, Italy.

Background/Objectives: The amount of single-cell datasets, their size and the diverse modalities they describe is continuously increasing, prompting the need to develop robust methods to integrate multiomic datasets, whether paired from the same cells or, most challenging, from unpaired separate experiments. Most methods allow the integration of a limited number of omics and make assumptions about the relationships between them. We introduce a deep-learning model to integrate multimodal data supporting high number of modalities and agnostic about their relationships.

Methods: We prototyped our approach on public data for which paired and unpaired experiments exist. Each modality is embedded into feature spaces with same dimensionality across all modalities. The embeddings are used to train a Wasserstein embedded into feature spaces with same dimensionality across all modalities. The embeddings are used to train a Wasserstein generative adversarial network to understand the couplings between multiple modalities. The output is integrated with the original data and can be used to bridge information across omics.

Results: We introduce “informative training” so that mini-batches include locally similar cells. This paradigm increases the performances in coupling while keeping global structure invariant. Performance of label transfer between unpaired data using performances in coupling while keeping global structure invariant.

Conclusion: We propose an approach for coupling unpaired multimodal data, ready for the large diversity of single cell technologies available. Our method doesn’t make assumptions on crosstalk among modalities nor needs anchors to match them. Moreover, it can be easily extended to an unlimited number of omics.

References:

Grants.

Conflict of Interest: Valentina Giananti: None declared, Marco Antoniotti Università degli Studi di Milano-Bicocca Milan, Italy, CRUK Accelerator Award #22790, Single Cell Cancer Evolution in the Clinic, coPI. Fondo Ateneo Quota Competitiva, Università degli Studi di Milano-Bicocca, Davide Cittaro Ospedale San Raffaele (employer).

P18.003.C Converting single nucleotide variants between genome builds: from cautionary tale to solution

Cathal Ormond\textsuperscript{1}, Niamh Ryan\textsuperscript{1}, Aiden Corvin\textsuperscript{1}, Elizabeth Heron\textsuperscript{1}

\textsuperscript{1}Trinity College Dublin, Dublin, Ireland.

Background/Objectives: Next-generation sequencing studies are dependent on a high-quality reference genome for single nucleotide variant (SNV) calling. Position information is not directly comparable between builds, so tools such as liftOver and CrossMap are used to convert data from one build to another. However, the positions of converted SNVs do not always match SNVs derived from aligned data, and in some instances, SNVs are known to change chromosome when converted.

Methods: We describe a novel algorithm to identify positions that are unstable when converting between human genome reference builds GRCh37 and GRCh38. We also examine the overlap between these unstable positions and various annotation sets in the genome to explain the source of the instability. Finally, we apply this method to sequencing data to benchmark the accuracy of the converted data with aligned data.

Results: We identified 11.3Mbp of unstable positions on GRCh37 and 20Mbp on GRCh38, all of which are determined by the chain file and independent of the conversion tool. The majority of these positions overlap segmental duplications and/or assembly updates between builds. Pre-excluding SNVs at these positions prior to conversion results in SNVs that are stable to conversion. SNVs at unstable positions had worse accuracy metrics than SNVs at stable positions.

Conclusion: We have identified all positions which are unstable to conversion between GRCh37 and GRCh38 and provided a simple framework to remove these instabilities. This work highlights the care that must be taken when converting SNVs between genome builds.

References: Ormond et al., Brief Bioinform, 2021.

Grants: NIH [S01MH109499-04] and SFI [16/SPP/3324].

Conflict of Interest: None declared.

P18.004.D Distribution analysis of missense variants in the human genome reveals widespread gene-specific clustering patterns and improves prediction of pathogenicity

Quinodoz Mathieu\textsuperscript{1,2,3}, Virginie Peter\textsuperscript{1,2,3,4}, Katarina Cisarova\textsuperscript{5}, Béryl Royer-Bertrand\textsuperscript{3}, Peter D. Stenson\textsuperscript{6}, David N. Cooper\textsuperscript{6}, Sheila Unger\textsuperscript{5}, Andrea Superti-Furga\textsuperscript{3}, Carlo Rivolta\textsuperscript{1,2,3}

\textsuperscript{1}Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland; \textsuperscript{2}University of Basel, Department of Ophthalmology, Basel, Switzerland; \textsuperscript{3}University of Leicester, Department of Genetics and Genome Biology, Leicester, United Kingdom; \textsuperscript{4}Lausanne University Hospital (CHUV), Institute of Experimental Pathology, Lausanne, Switzerland; \textsuperscript{5}University of Lausanne and Lausanne University Hospital (CHUV), Division of Genetic Medicine, Lausanne, Switzerland; \textsuperscript{6}Cardiff University, Institute of Medical Genetics, Cardiff, United Kingdom.

Background/Objectives: Identifying variants that underlie Mendelian phenotypes and cancer represents a major challenge in genetic medicine. However, current criteria still leave many rare missense variants classified as “variants of uncertain significance” (VUS). Many in silico tools have been developed to help with this problem. However, existing tools did not take into account that mutations appear to cluster within specific regions.

Methods: In this work, we address the question of within-gene distribution of pathogenic and benign missense variants, discover significant clustering across the whole coding genome, and use this information to build a positional score. We used a machine learning approach to analyze the within-gene distribution of missense variants observed in hereditary conditions and cancer.

Results: When applied to 840 genes from the ClinVar database, this approach detected a significant non-random distribution of
pathogenic and benign variants in 387 (46%) and 172 (20%) of them, respectively, revealing that variant clustering is widespread. We then developed a pathogenicity predictor, MutScore, that integrates qualitative features of DNA substitutions with the new additional information derived from this positional clustering. Using a random forest approach, MutScore was able to identify pathogenic missense mutations with very high accuracy, outperforming existing predictive tools.

**Conclusion:** Within-gene clustering of pathogenic and benign DNA changes is an important and previously underappreciated feature of the human exome, which can be harnessed to improve the prediction of pathogenicity and disambiguation of VUS.

**References:**

**Grants:** This work was supported by the Swiss National Science Foundation (grants #176097 and #204285 to C.R.).

**Conflict of Interest:** Quinodoz Mathieu: None declared, Virginie Peter: None declared, Katarina Cisarova: None declared, Béryl Royer-Bertrand: None declared, Peter D. Stenson Research performed by QIAGEN Inc., David N. Cooper Research performed by P.D.S. was partly supported by QIAGEN Inc., Sheila Unger: None declared, Andrea Superti-Furga: None declared, Peter D. Stenson Research performed by P.D.S. was partly supported by QIAGEN Inc., Katarina Cisarova: None declared, Béryl Royer-Bertrand: None declared, Pierre-Emmanuel Sugier 1, Taban Baghfalaki 1, Yazdan Asgari 1

1 CESF (Center for Research in Epidemiology and Population Health), INSERM, Paris-Saclay Université, Paris-Sud University, Gustave Roussy, Villejuif, France, Paris, France; 2Laboratoire de Mathématiques et de leurs Applications de Pau, Université de Pau et des Pays de l’Adour, UMR CNRS 5142, E2S-UPPA, France, Paris, France; 3School of Mathematical and Physical Sciences, Macquarie University, Sydney, Australia, Sydney, Australia.

**P18.005.A Component-wise L2-boosting for polygenic risk scores based on large cohort data**

**Hannah Klinkhammer**1,2, Christian Staerk2, Carlo Maj1,3, Peter Krawitz1, Andreas Mayr2

1 Institute for Genomic Statistics and Bioinformatics, University Hospital Bonn, Bonn, Germany; 2 Institute of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany; 3 Center for Human Genetics, Philipps University of Marburg, Marburg, Germany.

**Background/Objectives:** Polygenic risk scores (PRS) evaluate the individual genetic liability to a certain trait and play an increasingly important role in the field of risk stratification. Most often, PRS models are based on summary statistics of univariate effects derived from genome-wide association studies. To improve the prediction performance of PRS, it is desirable to fit multivariable models directly on the genotypic data. Due to the large and high-dimensional data, efficient algorithms have to be developed to overcome the computational burden.

**Methods:** We implemented a component-wise L2-boosting algorithm to fit genotyped data from large cohort studies to continuous outcomes using the genotypic variants as linear base-learners. Similar to the snpnet approach for the lasso we iteratively work on smaller batches of variants.

**Results:** By restricting the set of possible base-learners in a data-driven way in each boosting step, we can increase the computational efficiency without losing prediction accuracy. Furthermore, we show both in a simulation study and via different traits from the UK biobank data, that our method yields competitive results in comparison to other methods such as the lasso.

**Conclusion:** We introduced a L2-boosting algorithm to effectively derive sparse PRS directly from genotypic data. Due to the modular structure of boosting, the method can be extended to construct PRS for different outcomes such as binary or time-to-event data.

**References:** Qian J et al. (2020) A fast and scalable framework for large-scale and ultra-high-dimensional sparse regression with application to the UK Biobank. PLoS 16(10): e1009141. https://doi.org/10.1371/journal.pgen.1009141.

**Grants:**

**Conflict of Interest:** None declared.

**P18.007.C Investigating microRNA-associated variation in Multiple Sclerosis**

**Ifeolutemi Fashina**1,2, Ngoc Thanh Nguyen3, Simon J. Furney4, Claire McCoy5

1 SFI Centre for Research Training in Genomic Data Science (NUIG), Galway, Ireland; 2 Royal College of Surgeons in Ireland, Department of Molecular Cellular Therapeutics, Dublin, Ireland; 3 Royal College of Surgeons in Ireland, Department of Physiology Medical Physics, Dublin, Ireland; 4 Royal College of Surgeons in Ireland, Genomic Oncology Research Group, Department of Physiology Medical Physics, Dublin, Ireland.

**Background/Objectives:** Genome-wide association studies (GWAS) have highlighted over 200 autosomal variants associated with Multiple Sclerosis (MS). However, variants in non-coding regions such as those encoding microRNAs have not been explored adequately, despite strong evidence of microRNA dysregulation in MS patients and model organisms. This work explores microRNA associated variants within MS GWAS studies.

**Methods:** SNPs within the coordinates of microRNA mature, precursor and flanking sequences and within 3’UTR microRNA-binding sites were collated from six open-access catalogues. These microRNA-associated SNPs were intersected with the 200 susceptibility SNPs and summary statistics from the most recent MS GWAS.

**Results:** TargetScan7.0, a target-prediction algorithm was used to calculate potential miRNA loss and gain for each candidate SNP.

**Conflict of Interest:** None declared.
Background/Objectives: Cross-phenotype association at gene- or pathway-level can help to detect pleiotropic genes, i.e. the fact that one gene can affect multiple traits, and inform about common mechanisms between diseases. However, the lack of proper pipelines to apply gene-set analysis in this context using GWAS data in a reasonable running time could prevent researchers to apply such methods.

Methods: We designed a user-friendly pipeline to perform cross phenotype association using GCPBayes method [1], a cross-phenotype gene-based method developed by our team. We illustrated the application on publicly available GWAS summary statistics on breast cancer (BC) and ovarian cancer (OC) from BCAC and OCAC consortia and compared the results with previous studies used SNP-level analysis or transcriptome data.

Results: Previous studies suggested 40 pleotropic genes but only one (RCCD1) was replicated by two studies. Our method retrieved seven of these genes: TERT, BAMB1, CPNE1, RGS19, SMC2, CLIC6, and RCCD1. Besides, we also detected additional 140 new genes with potential pleiotropic signals for BC and OC. However, we are working on a suitable way to narrow our large list of candidate genes for further experimental analyses.

Conclusion: Our method replicated some genes previously found associated to both BC and OC using gene-set rather than SNP-level approach. User-friendly tutorials are available on our group's GitHub page.

References: 1. Baghfalaki et al. 2021, Stat. Med., 40, 1498–1518.

Grants: This work was supported by ‘Ligue contre le Cancer’, INSERM Cancer, INSERM Cross-Cutting Project GOLD.

Conflict of Interest: None declared.

P18.009.A GenOtoScope: Towards automated ACMG classification of genetic variants associated with congenital hearing loss

Christian Landgraf1, Damianos Melidis2, Gunnar Schmidt1, Anja Schönner-Heinisch1, Sandra Von Hardenberg1, Alisa Förster1, Anna-Lena Katze1, Anke Lesinski-Schiedat1, Wolfgang Nejd12, Bernd Auber1

1Hannover Medical School (MHH), Department of Human Genetics, Hannover, Germany; 2Leibniz University Hannover, L3S Research Center, Hannover, Germany.

Background/Objectives: Consistent interpretation of a large number of genomic variants is a key challenge of today’s clinical genetics. This is particularly relevant for hearing loss (HL). HL is the most common sensory disorder with a vast genetic heterogeneity. Variant assessment can be highly standardized using the “Expert Specification of ACMG/AMP Variant Interpretation Guidelines for Genetic Hearing Loss”. However, manual analyses remain time-consuming and prone to inconsistent interpretation and could, therefore, massively benefit from automated variant (pre-)assessment.

Methods: GenOtoScope is an open-source bioinformatics tool written in Python programming language. Two types of interfaces are provided: a freely accessible website to classify single variants, and a command line application capable of processing large variant sets (e.g. full WES data sets).

GenOtoScope automates all 12 ACMG/AMP criteria that can be assessed without further individual patient information or human curator investigations. We benchmarked the performance against two other variant classification tools using two manually curated HL data sets: ClinGen expert clinical validation curation of 164 hearing loss gene-disease pairs (158 variants in 9 genes) and a local data set from Hannover Medical School’s Department of Human Genetics (118 variants in 36 genes).

Results: GenOtoScope achieved the best average accuracy and precision for both data sets: Compared to the second best tool, GenOtoScope improved accuracy metrics by 25.75% and 4.57% and precision metrics of 52.11% and 12.13% on the two data sets, respectively.

Conclusion: GenOtoScope has proven capable of standardizing the process and significantly reducing the time of variant assessment and interpretation for HL.

References:

Grants: Funded by Volkswagen Foundation.

Conflict of Interest: Christian Landgraf Volkswagen Foundation (Understanding Cochlear Implant Outcome Variability using Big Data and Machine Learning Approaches), Damianos Melidis Volkswagen Foundation (Understanding Cochlear Implant Outcome Variability using Big Data and Machine Learning Approaches), Gunnar Schmidt: None declared, Anja Schönner-Heinisch: None declared, Sandra Von Hardenberg: None declared, Alisa Förster: None declared, Anna-Lena Katzke: None declared, Anke Lesinski-Schiedat: None declared, Wolfgang Nejd: None declared, Bernd Auber: None declared.

P18.010.B Using the central dogma to quantify the precision and recall of colocalisation methods

Ralf Tambets1, Anastassia Kolde1, Kaur Alasoo1

1University of Tartu, Tartu, Estonia.

Background/Objectives: Colocalisation is a fundamental approach for identifying candidate genes that causally mediate complex trait associations. However, benchmarking different colocalisation methods is challenging due to potentially unrealistic assumptions in simulated data and a lack of ground truth about causal associations in real data. We overcame this problem by using cis gene expression and protein quantitative trait locus (QTL) data, assuming that the most likely causal gene for each cis-pQTL is the gene coding for the protein.

Methods: We compared three Bayesian colocalisation methods: coloc v3 and coloc v5 operating at the locus level; and CAVIAR’s colocalisation posterior probability (CLPP) defined at the variant level. We used cis-eQTL data from the eQTL Catalogue (103 datasets) and blood plasma cis-pQTLs from the INTERVAL study.

Results: Using the same threshold (PP4 > 0.8), v5 detected 157 additional colocalisations (36% more) relative to v3 and missed only 29 colocalisations (7%) that v3 detected. Of the 851 proteins analysed, v5 found 441 to colocalise with the corresponding coding gene (52% recall), compared to 315 found by v3 (37% recall). However, v5 also detected colocalisations with additional genes, giving it slightly lower precision (32% vs 40%). Both versions of coloc detected more true positive signals than CLPP at its standard threshold (>0.1, 24% recall, 57% precision).

Conclusion: Our results indicate that using fine-mapping-based coloc v5 can significantly improve the yield of colocalisation analysis, but false positives introduced by co-regulation of neighboring genes should be carefully considered.

References:

Grants: PSG415 “Inferring gene regulatory networks from large-scale gene expression and genotype datasets” (01.01.2020-31.12.2023).

Conflict of Interest: None declared.

P18.011.C A phenotype-gene based graph for symptoms description harmonization and clinically-driven genomic analysis

Kevin Yaun2, Nicolas Dufourt-Frebourg2, Quentin Testard2, Sacha Beaumeunier1, Yannis Duffourd3, Jerome Audoux2, Nicolas Chatron2

1Université Paris-Sud, CNRS, Ligue contre le Cancer ; 2Université Paris-Sud, CNRS, Centre national de recherche scientifique (CNRS) ; 3Ligue contre le Cancer Paris-Sud, Université Paris-Sud, Centre national de recherche scientifique (CNRS) ; 4Centre national de recherche scientifique (CNRS), Université Paris-Sud, Ligue contre le Cancer Paris-Sud.

Background/Objectives: Phenotypic analysis in genetic research is an essential but challenging process that requires the development of tools to help researchers to systematically identify and describe symptoms in a standardized manner.

Methods: We developed a phenotype-gene based graph (PGBG) tool that integrates symptoms and genes into a single network. The tool uses a cross-phenotype association approach to identify symptom-gene networks, allowing researchers to systematically identify and describe symptoms in a standardized manner.

Results: The PGBG tool was evaluated using a set of real-world genetic data. The results showed that the tool was able to identify symptom-gene networks that were consistent with known genetic associations.

Conclusion: The PGBG tool is a valuable tool for genetic research, as it allows researchers to systematically identify and describe symptoms in a standardized manner.

References:

Grants: None declared.

Conflict of Interest: None declared.
Background/Objectives: Identical symptoms observed in patients may heterogeneously be described by physicians, even though relying on the same Human Phenotype Ontology (HPO). Several tools explore the accuracy of generating diagnostic hypotheses based on HPO terms associations and vicinity in the ontology, although bearing common methodological limitations.

Methods: We build a phenotype-gene graph weighted by consensus of associations identified on both structured and free-text databases extracted by ElasticSearch. To manage the diversity of physicians’ descriptions, dimensionality reduction of HPO terms was obtained through Non-Negative Matrix Factorization. Based on this graph, we developed a phenotype-gene matching algorithm called PhenoGenius. We evaluated our approach on a multicentric cohort of 316 patients recruited from a French consortium and 444 patients from literature.

Results: The graph presents more than 2 million phenotype-gene associations, covering 4,974 genes and 9,687 symptoms, whereas the Monarch database contains nearly 640,000 associations. PhenoGenius performances allow a median diagnostic gene frequency 1:68). This work explored a weighted phenotype-gene association graph, dissociated from the HPO developmental-based ontology, although bearing common methodological limitations.

Conclusion: This work explored a weighted phenotype-gene association graph, dissociated from the HPO developmental-based hierarchy used to describe patients’ phenotypes. PhenoGenius presents an original method that harmonizes and maximizes the usage of clinical symptoms in bioinformatic processes, outperforming currently published approaches.

References:

Conflict of Interest: Kevin Yaay SeqOne Genomics (part time), Nicolas Duforet-Frebourg SeqOne Genomics (full time), Quentin Testard: None declared, Sacha Beaumenuier SeqOne Genomics (full time), Yannis Duffour: None declared, Jerome Audoux SeqOne Genomics (full time), Nicolas Chatron: None declared, Sophie Nambot: None declared, Cédric Le Maréchal: None declared, Jean-Francois Taly: None declared, Wilfrid Carre: None declared, Gaëtan Lesca: None declared, Claire Bardel: Frederic Tran Mau Them: None declared, Marc Planes: Marie-Pierre Audrezet: None declared, Laure Raymond: Charles Coutton: None declared, Véronique Satre: Pauline Le Tanno: None declared, Marjolaine Willems: Thomas Guignard: Dimitri Larue: Denis Bertrand: Virginie Bernard: Marie De Tayrac: Sylvie Odent: Laurent Mesnard: Damien Sanlaville: Laurence Faivre: David Geneviève: Nicolas Philippe: Julien Thevenon: 1,2,8

1Institute of Advanced Biosciences, Université Grenoble Alpes, La Tronche, France; 2SeqOne Genomics, Montpellier, France; 3CHU Dijon, Dijon, France; 4Hospices Civils de Lyon, Lyon, France; 5CHU Brest, Brest, France; 6Eurofins Biomnis, Lyon, France; 7CHU Rennes, Rennes, France; 8CHU Grenoble Alpes, La Tronche, France; 9CHU Montpellier, Montpellier, France; 10Assistance Publique - Hopitaux de Paris, Paris, France.

Results: The graph presents more than 2 million phenotype-gene associations, covering 4,974 genes and 9,687 symptoms, whereas the Monarch database contains nearly 640,000 associations. PhenoGenius performances allow a median diagnostic gene frequency 1:68). This work explored a weighted phenotype-gene association graph, dissociated from the HPO developmental-based hierarchy used to describe patients’ phenotypes. PhenoGenius presents an original method that harmonizes and maximizes the usage of clinical symptoms in bioinformatic processes, outperforming currently published approaches.

References:

Grants:

Conflict of Interest: Kevin Yaay SeqOne Genomics (part time), Nicolas Duforet-Frebourg SeqOne Genomics (full time), Quentin Testard: None declared, Sacha Beaumenuier SeqOne Genomics (full time), Yannis Duffour: None declared, Jerome Audoux SeqOne Genomics (full time), Nicolas Chatron: None declared, Sophie Nambot: None declared, Cédric Le Maréchal: None declared, Jean-Francois Taly: None declared, Wilfrid Carre: None declared, Gaëtan Lesca: None declared, Claire Bardel: Frederic Tran Mau Them: None declared, Marc Planes: Marie-Pierre Audrezet: None declared, Laure Raymond: Charles Coutton: None declared, Véronique Satre: Pauline Le Tanno: None declared, Marjolaine Willems: Thomas Guignard: Dimitri Larue SeqOne Genomics (full time), Denis Bertrand SeqOne Genomics (full time), Virginie Bernard: None declared, Marie De Tayrac: None declared, Sylvie Odent: None declared, Laurent Mesnard: None declared, Damien Sanlaville: None declared, Laurence Faivre: None declared, David Geneviève: None declared, Nicolas Philippe SeqOne Genomics (full time), Julien Thevenon: None declared.

P18.012.D Community data-driven approach for generating cross-ethnic population carrier screening panel

Yaron Einhorn1, Moshe Einhorn1, Yuval Yaron2, Dror Steinberg1, Noa Henig2, Adi Mory2, Illy Bazak3, Erez Tsur4, Karin Weiss5, Tamar Paperna6, Julia Grinshpun-Cohen6, Amihood Singer6, Lina Basel-Salmon6, Hagit Baris Feldman7

1Genoox, Tel-Aviv, Israel; 2The Genetics Institute and Genomic Center, Tel-Aviv Sourasky Medical center, Israel, Tel-Aviv, Israel; 3Recanati Genetics Institute, Bellinson Hospital, Rabin Medical Center, Petach Tikva, Israel; 4Maccabi Health care Services, Tel-Aviv, Israel; 5The Genetics Institute, Rambam Health Care Campus, Haifa, Israel; 6Community Genetic Services, Ministry of Health, Tel-Aviv, Israel.

Background/Objectives: The ACMG has recently published tier-based recommendations for carrier screening. While many pan-ethnic conditions are well established, some genes carry pathogenetic founder variants (PFVs) prevalent only in specific ethnic groups, and may therefore not be assigned into the correct tier or not represented at all. Using an interconnected, data-driven repository including a cohort of cases from the Israeli population we created a workflow for assistance in generating a cross-ethnic carrier screening panel.

Methods: The dataset included de-identified WES data from a cohort of 2792 Israeli patients. Frequencies of pathogenic/likely pathogenic variants were calculated for each subpopulation and compared with existing carrier screening panels used in Israel. Manual curation was done for suspected variants using evidence from Franklin community members.

Results: We detected a number of relevant PFVs not included in existing carrier screening panels. These included two variants that should be included in Tier 2 (carrier frequency >1:100) and nine variants for Tier 3 (1:100-1:200). We detected two PFVs of autosomal recessive traits, a PFV in PTPN23, associated with a severe neurodevelopmental disorder (carrier frequency 1:53) as well as a PFV in WFS1 associated with Wolfram syndrome (carrier frequency 1:68).

Conclusion: Community data-driven and sharing approaches may detect PFVs missing from currently available panels. Moreover, with the increasing use of next generation sequencing for carrier screening, it is expected to result in a deluge of variants falsely classified as P/LP. Such data-sharing approaches will facilitate proper classification of frequent variants that have no clinical implications, thereby reducing unnecessary workload and patient anxiety.

Conflict of Interest: Yaron Einhorn Genoox, Moshe Einhorn Genoox, Yuval Yaron Genoox, Dror Steinberg: None declared, Noa Henig: None declared, Adi Mory: None declared, Illy Bazak: None declared, Erez Tsur: None declared, Karin Weiss: None declared, Tamar Paperna: None declared, Julia Grinshpun-Cohen: None declared, Amihood Singer: None declared, Lina Basel-Salmon: None declared, Hagit Baris Feldman: None declared.

P18.013.A A Benchmarking of long-read structural variant callers using in-house generated Oxford Nanopore data

Griet De Clercq1, Bram Van Gaeve1, Lies Vantomme1, Annelies Dhuedene1, Björn Menten1

1Center for Medical Genetics, Ghent University, Ghent University Hospital, Department of Biomolecular Medicine, Ghent, Belgium;
Abstracts from the 55th European Society of Human Genetics Conference

Dysplasia

Digenic variants interpretation: a case study of skeletal dysplasia

Lecca2, Ivan Limongelli1, Susanna Zucca1

Performances (sensitivity 92%, specificity 99%). Among the large cohort of samples tested with DIVAs, here we focus on two fetuses (from independent pedigrees) with skeletal dysplasia. In both cases DIVAs unveiled a digenic inheritance model. In particular, the algorithm prioritized DYNC2H1 as first gene, combined with IFT140 and TCTN1 in the first fetus, whereas with IFT172 in the second one. In the first case, familial segregation analysis allowed refining the digenic combination between DYNC2H1 and TCTN1, thus discarding IFT140. For DYNC2H1-IFT172 combination segregation analysis is ongoing.

Conclusion: Our algorithm proved to be reliable to define a likely digenic inheritance in a large cohort of unsolved clinical WES cases with heterogeneous phenotypes, such as skeletal dysplasia, here adopted as paradigm of a typical monogenic condition.

References: PMID:26481352. PMID:26432245.

Grants:

Conflict of Interest: None declared.

P18.014.B DIVAs, a jump forward in the phenotype-driven digenic variants interpretation: a case study of skeletal dysplasia

De Paoli1, Giovanna Nicora1, Edoardo Errichelli2,3, Mauro Lecca2, Ivan Limongelli1, Susanna Zucca1

1enGenome, Pavia, Italy; 2University of Pavia, Department of Molecular Medicine, Pavia, Italy; 3IRCCS Mondino Foundation, Pavia, Italy.

Background/Objectives: As long-read sequencing (LRS) technologies mature, several bioinformatics tools designed to identify structural variants (SVs) have been developed. To allow validation of these tools, Zook et al.1 published a highly curated SV truth set of Genome in a Bottle sample NA24385, consisting of deletions and insertions. We performed a benchmarking analysis with five LRS SV callers against this set utilising in-house generated Oxford Nanopore reads.

Methods: SVs are called with cuteSV, SVIM, snifles, pbsv, and nanovar. The callers are assessed in terms of resource usage, reproducibility, and calling performance. The latter is evaluated with Truvari giving recall and precision statistics on SV detection. We further investigate the influence of read support, sequencing coverage, SV type and length, and integration of call sets with Jasmine.

Results: CuteSV achieves overall best performance, while nanovar lags behind in both resource usage and calling statistics. A coverage greater than 20x offers no additional advantage for reliable SV detection, while the recommended read support of one third of the coverage proves to be too stringent. Integration of call sets with Jasmine should include three callers to compete with stand-alone call sets.

Conclusion: We propose a minimum coverage of at least 15x for optimal sensitivity and specificity. Read support should be set at one fifth of the coverage to obtain optimised calling performance. CuteSV performs best in both sensitivity and specificity, and resource usage. Further work is however needed to assess results for different SV types and more complex regions.

References: 1. Zook et al. Nat Biotechnol 38, (2020).

Grants:

Conflict of Interest: None declared.

P18.015.C Ulisse: beyond the pathway boundaries towards cross-talk and cell-cell communication

Alice Chiiodi1, Valentina Nale1, Ali Ehsan2, Matteo Bersanelli3, Matteo Della Porta4,5, Paride Pelucchi1, Ettore Mosca1

1Italian national research council, Institute for biomedical technologies, Segrate (Milan), Italy; 2University of Milan, Department of Biosciences, Milan, Italy; 3Humanitas University, Department of Biomedical Sciences, Milan, Italy; 4Humanitas Research Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy; 5Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Laboratory of Geriatric Neuropsychiatry, Department of Neuroscience, Milan, Italy.

Background/Objectives: Functional analysis is typically based on testing the enrichment of a series of pathways, each defined as a gene set. However, at the molecular level, information flows by means of a complex network of biochemical processes in which pathways do not have clear boundaries, and are highly interconnected, within cells and between cells. We present Ulisse[1], a tool for the analysis of relations between intracellular pathways (pathway cross-talk, PCT) as well as cell-cell communication (CCC).

Methods: Statistical significance is assessed using a permutation-based approach. Molecular interactions: various sources (i.e.: STRING, iRefIndex). Gene-pathway associations: MSigDB. Ligand-receptor interactions (LRI): Omnipath. Single cell expression data: Single Cell Expression Atlas. Lidag-receptor interactions (LRI): Omnipath. Single cell expression data: Single Cell Expression Atlas[2], Single cell Portal[3].

Results: We used Ulisse to study the PCTs affected by the most frequently mutated genes in 10 major cancer types and found cancer-specific and recurring PCTs. We classified the genes involved in these PCTs considering their functional relevance, that is, the number of different PCTs in which a gene is involved in relation to its interactors. We used Ulisse to calculate the CCC using LRI and LR expression between cell types in each tumor sample considered.

Conclusion: Ulisse complements the typical pathway analysis assessing whether the studied genes take part in interactions between pathways. Ulisse can be applied to any gene list emerging from studies in genomics as well as other gene-centered "omics". It can also be applied to quantify cell-cell communication in single cell data.

References: [1] https://doi.org/10.7490/f1000research.1118917.1. [2] https://www.ebi.ac.uk/gxa/sc/home. [3] https://singlecell.broadinstitute.org/single_cell.

Grants:

Conflict of Interest: None declared.
P18.016.D Improved detection of functionally relevant aberrant splicing with FRASER2

Ines Scheller1,2, Karoline Lutz1, Christian Mertes1,3, Vicente Yépez1, Julien Gagneur1,2,3
1Technical University of Munich, Department of Informatics, Garching, Germany; 2Helmholtz Zentrum München, Institute of Computational Biology, Neuherberg, Germany; 3Technical University of Munich, Munich Data Science Institute, Garching, Germany.

Background/Objectives: As aberrant splicing is a major cause of rare diseases, detection of aberrantly spliced genes from RNA-seq data is an active research topic. We have recently developed FRASER1, a denoising autoencoder-based method that outperformed alternative approaches for detection of aberrant splicing on precision-recall analyses. When systematically investigating FRASER results on more than 300 rare disease RNA-seq samples and GTEx v8 samples, we noticed however that many of the detected events captured aberrant weak and cryptic splice site usage that did not result in substantial major isoform usage variation.

Methods: We introduced a new intron excision metric that integrates alternative donor, alternative acceptor and intron retention signal and, therefore, reflects variations in major isoform usage more closely. As with FRASER, we modelled this ratio using a beta-binomial based denoising autoencoder thereby controlling for potential confounding sources of variations.

Results: On a mitochondrial rare disease dataset (N = 303), FRASER2 considerably reduced the number of splicing outliers (by 25% to 75%) for a mild loss of sensitivity (only 1 out 26 pathogenic cases not recovered). Moreover, FRASER2 splice outliers were 5 times more enriched for rare splice affecting variants. Also, FRASER2 is less sensitive to sequencing depth and benefits from a reduced multiple testing burden.

Conclusion: By introducing a new splicing metric, FRASER2 is able to maintain the sensitivity of FRASER while providing more functionally relevant outlier calls.

References: 1 Mertes, Scheller et al., Nat Commun (2021).
2 Yépez, Gusic, et al., Genome Med (2022).

Conflict of Interest: None declared.

P18.017.A Identification of clinically relevant variants in homologous regions in 41,755 exomes

Wouter Steyaert1,2, Marloes Steehouwer1, Lonneke Haer-Wigman1, Rolf Plundt1, Sander Stegmann1, Elke de Boer1,4, Helger Yntema1, Han Brunner1, Alexander Hoischen1,2,3, Christian Gilissen1,2,3
1Radboud University Medical Center, Department of Human Genetics, Nijmegen, Netherlands; 2Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands; 3Maastricht University Medical Center, Department of Clinical Genetics, Maastricht, Netherlands; 4Radboud University, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, Netherlands; 5Radboud University Medical Center, Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Nijmegen, Netherlands.

Background/Objectives: Altogether, homologous regions comprise 3.5% of the exome but are difficult to analyse.

Methods: We devised a new method (Chameleolyser) that identifies single nucleotide variants (SNVs), copy number variants (CNVs) and gene conversion events in homologous regions based on exome sequencing data.

Results: Application to a cohort of 41,755 whole exome sequencing samples yielded 2,191,707 SNVs, 20,432 homozygous deletions and 22,600 homozygous gene conversions with ≤ 10% frequency in the cohort. Validation with PacBio high-fidelity genomes of variants identified in 20 samples confirmed 678/769 SNVs (88.2%), 8/8 gene conversions (100%) and 11/15 homozygous deletions (73%).

Conclusion: In conclusion, we developed a novel method that can accurately identify clinically relevant copy number and single nucleotide variations in homologous coding regions from diagnostic exome sequencing data.

References: 1 Grants: Solve-RD (Horizon 2020 grant agreement No. 779257).

Conflict of Interest: None declared.

P18.018.B Meta-analysis of human retinal transcriptome data: a powerful tool to gain insight into the genomic organization of inherited retinal disease genes

Karla Alejandra Ruiz Ceja1, Dalia Capasso1,2, Diego Di Bernardo1, Sandro Banfi1,3
1Telethon Institute of Genetics and Medicine, Pozzuoli, Italy; 2School of Advanced Studies, Federico II, Genomics and Experimental Medicine, Napoli, Italy; 3University of Campania, “Luigi Vanvitelli”, Precision Medicine, Napoli, Italy.

Background/Objectives: Eye diseases are among the most common inherited human retinal disorders (IRDs). Around 279 genes have been associated with the genetic diversity of IRDs. Over 30% of patients do not harbour mutations in coding regions of IRD genes. We aimed to gain insight into the genomic organization and transcript composition of IRD genes using human retina RNA-Seq datasets.

Methods: We retrieved 177 bulk RNA-Seq human retina data from non-visual impaired post-mortem donors. RNA-Seq alignments were assembled at a single-sample level and merged to generate a set of assembled transcripts. Transcript expression was quantified by scaling TPM abundance estimates and filtered out transcripts with less than one median TPM. A subset of newly identified candidate transcripts was validated RT-PCR.

Results: We focused our analysis on 219 IRD genes and identified 3367 putative novel transcripts. The latter were the results of a) partial intron retentions, b) exon skipping and extension, c) novel exon and d) connections with other transcriptional units. RT-PCR analysis revealed an overall 50% rate of experimental validation.

Conclusion: To the best of our knowledge, this is the most comprehensive and extended meta-analysis of IRD genes carried out on RNA-Seq data. Our work yielded a reliable expression quantification of IRD transcripts in the human retina, including the identification of novel ones, and paves the way towards a better understanding of the organization of their transcriptional unit and, possibly, of the molecular mechanisms underlying inherited retinal diseases.

References: 1 Grantees: SIRP (Horizon 2020 grant agreement No. 779257).

Conflict of Interest: None declared.
Abstracts from the 55th European Society of Human Genetics Conference

P18.019.C Alignment-free method for gene copy number estimation from raw next generation sequencing data

Fanny-Dhelia Pajuste\textsuperscript{1,2}, Maito Remm\textsuperscript{2}

\textsuperscript{1}University of Tartu, Institute of Genomics, Tartu, Estonia; \textsuperscript{2}University of Tartu, Institute of Molecular and Cell Biology, Department of Bioinformatics, Tartu, Estonia.

Background/Objectives: Copy variable genes in human genome are often associated with phenotypic traits and susceptibility to diseases. Methods for exact copy number estimation from sequencing data require mapping reads to the reference genome which is time-consuming and often prone to mistakes especially in complex repetitive regions. K-mers (small substrings of DNA with length k) have been successfully used for efficiently handling huge amounts of genomic data and could be used for fast alignment-free copy number estimation.

Methods: For an accurate copy number estimation, a list of k-mers is carefully composed for the gene of interest as well as a flanking single-copy reference region. K-mers are selected based on region specificity, uniqueness in the genome and GC content value. The frequencies of these k-mers are obtained from raw sequencing data and used for copy number estimation.

Results: The copy numbers have been estimated for amylase genes AMY1, AMY2A and AMY2B for 40 individuals from Estonian Biobank. The results showed high correlation (R = 0.9932) with the copy numbers measured experimentally using Droplet Digital PCR and the proportion of concordant results was 93.33%, these numbers were slightly lower when using a read-depth based approach (R = 0.9925 and 87.6%). The similar parity of AMY1 and AMY2A copy numbers (95%) corresponds to previous studies.

Conclusion: A k-mer based method is not only fast, but accurate approach for gene copy number estimation.

References:

Grants: EU ERDF grant No. 2014-2020.4.01.15-0012, the cost of the sequencing was partly covered by the Broad Institute (MA, USA).

Conflict of Interest: None declared.

P18.020.D Performance of ACMG/AMP guidelines to tackle digenic variants interpretation: do we need a digenic interpreter?

Giovanna Nicora\textsuperscript{1}, Federica De Paoli\textsuperscript{1}, Susanna Zucca\textsuperscript{1}, Ivan Limongelli\textsuperscript{1}, Paolo Magni\textsuperscript{1,2}

\textsuperscript{1}enGenome Srl, Pavia, Italy; \textsuperscript{2}University of Pavia, Department of Electrical, Computer and Biomedical Engineering, Pavia, Italy.

Background/Objectives: As monogenic hypothesis is sometimes insufficient to diagnose rare diseases, digenic models are increasingly evaluated. Yet, digenic variant interpretation (DVI) guidelines are still missing. We explore whether the mono-digenic ACMG/AMP standard guidelines can support interpretation of digenic pairs types (True Digenic (TD), Composite (CO), Dual Molecular Diagnosis (DMD)), highlighting potential utility and drawbacks.

Methods: 121 TDs, 85 C0s and 78 DMDs, along with 10,000 benign pairs were collected and interpreted according to the ACMG/AMP guidelines using the eVai software. The eVai score, proportional to the number of triggered ACMG/AMP criteria, was used to develop a digenic classifier (ACMG-based DVI): if both variants’ scores exceed a threshold, the pair is predicted pathogenic. We compared ACMG-based DVI against a machine learning (ML) approach tailored for DVI (DIVAs, enGenome).

Results: 58% of DMD are classified as Pathogenic/Likely-Pathogenic according to ACMG/AMP guidelines, 42% of CO are Pathogenic/Likely Pathogenic, 34% of TD are Pathogenic/Likely Pathogenic, and up to 15% of variants (in case of TD) are Benign/Likely Benign. The Area Under the Precision-Recall Curve (PRC) of the ACMG-based DVI is 30% for TD, 46% for CO and 78% for DMD. On the other hand, DIVAs shows 93% mean PRC on TD, 96% on CO and 95% on DMD.

Conclusion: ACMG/AMP guidelines show acceptable performance only for DMD classification. ML-based DVI outperforms the ACMG-based DVI in all categories. New approaches are required to expand variant interpretation towards more complex inheritance patterns, such as digenicity.

References: PMID28911095, PMID30298955.

Grants:

Conflict of Interest: Giovanna Nicora enGenome Srl, Federica De Paoli enGenome Srl, Susanna Zucca enGenome Srl, Ivan Limongelli enGenome Srl, Paolo Magni enGenome Srl, Paolo Magni enGenome Srl.

P18.021.A Bioinformatic approach to the detection of genetic variants through next generation sequencing in genes and their pseudogene counterparts

Jairo Rodríguez\textsuperscript{1}, Nacho Coca\textsuperscript{1}

\textsuperscript{1}qGenomics, R&D department, Esplugues de Llobregat, Spain.

Background/Objectives: Current short-read NGS methods hinder the precise calling of clinically relevant variants in genes that have pseudogene counterparts. We aim at developing a bioinformatic method that, using Illumina short reads, allows to precisely map variants of interest in the gene CYP21A2 and its pseudogene, which is of great relevance in the diagnostic of congenital adrenal hyperplasia (CAH). We aim at designing a method broadly applicable to other gene/pseudogenes with minimal customization.

Methods: We develop proprietary bioinformatic methods that are capable of phasing long haplotypes from short-read Illumina data. The automated, basic steps of the method are: (i) identify all variant positions that discriminate a gene and its pseudogene/s; (ii) identify all possible haplotypes within the reads in a genomic window; (iii) merge overlapping reads with compatible haplotypes; (iv) compute copy number status for all haplotypes; (v) provide graphical/tabular results for interpretation.

Results: Although our method can identify variants across CYP21A2 here we focus on the clinically relevant, hard to map variant c.C955T, p.Q319X. We have produced results for 49 samples for which we have performed Sanger sequencing. For 10 samples we were not able to reach a clear conclusion of concordance (20%, 10/49). For the rest (n = 39), our software was in agreement with Sanger sequencing in 37 samples (94%) and for two samples (5%) we obtained discordant results.

Conclusion: Our haplotype phasing strategy using Illumina short reads has proven capable of precisely identifying when the clinically relevant variant c.C955T, p.Q319X (NM_000500) is present in the CYP21A2 gene or its pseudogene.

References:

Grants:

Conflict of Interest: Jairo Rodríguez qGenomics, Nacho Coca qGenomics.
P18.022.B IdefcSV - towards a clinician-friendly tool for the identification and clinical annotation of structural variants in whole-exome sequencing data

Anja Hess¹, Henrike Szczakiel²,³, Felix Boschmann²,³, Uwe Kornak⁴, Björn Fischer-Zimskak²,³, Dominik Seelow²,²

¹Max Planck Institute for Molecular Genetics, Department of Genome Regulation, Berlin, Germany; ²Charité Universitätmedizin Berlin, Institute of Medical Genetics and Human Genetics, Berlin, Germany; ³Max Planck Institute for Molecular Genetics, RG Development & Disease, Berlin, Germany; ⁴Universitätsmedizin Göttingen, Institute of Human Genetics, Göttingen, Germany; ⁵Berlin Institute of Health, Bioinformatics and Translational Genetics, Berlin, Germany.

Background/Objectives: Structural variants (SVs) constitute a core cause for genetic variation and may lead to genetic disease or cancer. It is generally assumed that SVs are detectable only by Whole Genome Sequencing (WGS), leading to re-sequencing efforts of ‘failed’ Whole Exome Sequencing (WES) projects. However, WES can detect SVs at base-pair resolution if a breakpoint lies in the enriched region. Despite its extensive application in clinical practice there is currently no public software with user-friendly graphical interfaces for detection, clinical annotation, and prioritization of SVs in WES data. To make SV analysis accessible for non-bioinformaticians, we have developed IdefcSV, a fast, user-friendly tool for the identification of Structural Variants in WES and optionally WGS data.

Methods: IdefcSV provides an intuitive interface for Windows and Linux for high-throughput screening of BAM files. It detects breakpoints using split-read, paired-end, and read-depth information without requiring reference genome downloads. A 10GB BAM-file is analyzed in ~20 minutes on a typical PC. Results can be exported in popular BED format but we also provide a human-friendly web interface offering candidate SVs prioritization based on clinical phenotypes. IdefcSV also renders IGV screenshots for visual inspection of SVs.

Results: We tested the software on more than 300 NGS data-sets and confirmed detected SVs by PCR and Sanger sequencing. We generated a consensus black list of alignment artifacts by annotating frequently present SVs in our cohort. Users can easily provide their own blacklist.

Conclusion: We hope that our tool will foster the recognition of clinically relevant SVs in WES data.

References: -

Grants: -

Conflict of Interest: None declared.

P18.023.C Gene-environment interaction effects of early-life stress (ELS) program neurocognitive development in children

hee-hwan wong¹, seo-yoon moon¹, kakyong kim¹, hyun-jin kim¹, woo-young ahn¹, jook cha¹, Yoonjung Joo²

¹Seoul National University, Seoul, Korea, Rep. of South; ²Korea University, Seoul, Korea, Rep. of South.

Background/Objectives: Early-life stress (ELS) has well-known associations with low cognitive outcomes and brain functional and structural representations, yet it remains unclear how exactly ELS affects cognitive capacity in humans. Moreover, it is unknown how ELS interacts with genetic influences on development of the brain and cognition in children. We hypothesized that ELS is likely to interact with genetic influences that impact brain development as well as cognitive development in preadolescents.

Methods: We leveraged multimodal data consisting of DNA genotypes, brain imaging (MRI), and neuropsychological assessments (NIH Toolbox) from 4,276 children (ages 9 to 10, European ancestry) from the Adolescent Brain Cognitive Development study. Regression and mediation analyses were used to systematically examine the underlying causal relationships among genome-wide polygenic scores of cognitive capacity, brain structure, and ELS in their influence on child neurodevelopment.

Results: Our analyses revealed significant causal interaction of ELS and genetic factors in modulating child neurodevelopment. In particular, we found genetic influences on cognitive development to be mediated by brain structure development (partial mediation effect = 0.016, Pr(Δ<=0.001)), and this gene-to-brain pathway to be significantly moderated by ELS (abuse) (Index of Moderated Mediation = -0.007; 95% CI = -0.012 – -0.002; Pr(Δ<=0.05)).

Conclusion: Our findings indicate ELS to be a negative modulator of genetic influence on brain structural development, thereby leading to disadvantageous neurocognitive development in prepubertal children.

References: Wang, Hee-Hwan, et al. “The Impact of Early Life Stress on the Genetic Influence on Brain and Cognitive Development in Children,” medRxiv (2021).

Grants: Funded by the National Research Foundation (NRF) of South Korea (2021R1I1A1A01054995).

Conflict of Interest: None declared.

P18.025.A MANCOR, a powerful test based on correlation to detect predictors of the gut microbiome variability

Christophe Boetto¹, Violeta Basten Romero¹, Etienne Patin², Marius Bredon³, Darragh Duffy⁴, Lluis Quintana-murci², Harry Sokol³;⁵;⁶;⁷, Hugues Aschard¹,⁸

¹Institut Pasteur, Université de Paris, Department of Computational Biology, Paris, France; ²Institut Pasteur, Université de Paris, Department of Genomes and Genetics, Paris, France; ³INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Sorbonne Université, Saint Antoine Hospital, Gastroenterology Department, Paris, France; ⁴Institut Pasteur, Université de Paris, Department of Immunology, Paris, France; ⁵Paris Center for Microbiome Medicine, Fédération Hospitalo-Universitaire, Paris, France; ⁶Carenity, Paris, France; ⁷INRAE, UMR1319 Micalis & AgroParisTech, Jouy en Josas, France; ⁸Harvard TH Chan School of Public Health, Department of Epidemiology, Boston, United States.

Background/Objectives: Multivariate analysis are becoming central in studies investigating features associated with host-gut microbiome relationship. However, statistical methods to assess predictors associated with gut microbiome composition and other meta-parameters are severely lacking. Here we present MANCOR (Multivariate Analysis of Correlation), an innovative and flexible method that addresses this challenge, allowing to test the effect of any predictor on the joint distribution of a multivariate outcome, as measured by its correlation matrix.

Methods: We first compared the performance of MANCOR against existing correlation-based (BoxM, Mantel, etc) methods using simulated data. We then conducted a screening of a hundred predictors (diet, medical history, etc) on 165-derived gut microbiome data in 1,000 healthy participants from the Milieu Interieur cohort, and compared the results of MANCOR against both standard univariate and multivariate (MANOVA) tests, and diversity-based (alpha) approaches.

Results: In all simulations mimicking microbiome data, existing correlation-based methods display severe type I error rate inflation, and only MANCOR showed both valid calibration and high statistical power. In the Milieu Interieur our test strongly outperformed univariate and multivariate tests, confirming associations with age and sex but with higher power (up to 200% power increase), while detecting additional signals with smoking and diet...
Abstracts from the 55th European Society of Human Genetics Conference

P18.028.D Variant effect prediction based on custom long-read transcriptomes

Renee Sale1, Caspar van der Made2, Mark Quinton-Tulloch2, Sarah Hunt5, Alexander Hoischen2, Peter-Bram ‘t Hoen1

1 Radboud University Medical Center, Centre for Molecular and Biomolecular Informatics, Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands; 2 Radboud University Medical Center, Department of Human Genetics, Radboud University Medical Center for Infectious Diseases (RUC), Department of Internal Medicine, Radboud Institute for Molecular Life Sciences, and Radboud Expertise Center for Immunodeficiency and Autoinflammation, Nijmegen, Netherlands; 3 EMBL’s European Bioinformatics Institute (EMBL-EBI), Hinxton, United Kingdom.

Background/Objectives: Our knowledge of transcript annotations is still incomplete and may result in a failure to detect disease-causing variants. For example, in patients with primary immunodeficiencies it could be valuable to annotate transcripts that are only expressed under certain conditions such as host-pathogen interactions. Current variant annotation software uses only precomputed pathogenicity prediction scores based on reference transcripts. The pipeline presented here is designed to annotate variants with custom transcript annotations for downstream prioritization.

Methods: The input of the pipeline is a sample-specific/non-reference long-read transcriptome in fasta format, variant file(s) derived from unsolved exome data of patients with suspected inborn errors of immunity (IEI) in VCF format, and a reference genome build. The Ensembl Variant Effect Predictor is used in conjunction with Polyphen-2 to provide custom variant annotations. Our pipeline is available at https://github.com/cmbi/VEP_custom_annotations.

Results: The input long-read transcriptome contained 37,434 novel transcripts detected through PacBio IsoSeq on peripheral blood cells exposed to various immune stimuli. The re-annotation pipeline was tested on 148 undiagnosed IEI patient’s exomes. Out of a total of 802,352 variants, 6.2% had a more severe effect in the novel transcript annotation than in the reference.

Conclusion: Genetic variant annotation may benefit from long-read sequencing approaches that discover novel transcripts. This benefit can be reaped without extensive bioinformatic knowledge using this pipeline. Our pipeline outputs crucial information for further prioritization of potentially disease-causing variants, and will become increasingly useful due to the rising number of long-read RNAseq datasets.

References:

Grants: French National Research Agency: ANR-18-CE37-0002-02.

Conflict of Interest: None declared.

P18.030.B ILIAD: the E RN-ITHACA federated registry of rare diseases with intellectual disability and anomalies of development

Klea Vyshka1,2, Morris Swertz3, Fernanda De Andrade4, Joeri Van Der Velde4, Lennart Jönhoff5, Dieuwke Prins6, Dorica Dan7, Sofia Douzou HOUGE8, Andreas Dufke9, Agnies van Eeghen9, Laurence Faivre10, Tiziana Franchin10, Andrew Green11, Roaul Hennekam12, Anne Hugon13, Sylvia Huismans14, Marianne Le Dref15, Tijske Kleefstra16, David Koolen17, Andrea Manunta18, Jukka Molilainen19, Giovanni Mosiella20, Mahsa Shabani20, Ammi Sundqvist21, Nicholas Szeto22, Marco Tartaglia23, Zeynep TÜMER24, Birute Tumiene25, Lisenna Visser26, Helger Yntema27, Dagmar Wiescorz28, Giuseppe Zamper29, Alessandra Renieri30, Alain Verloes30,31, Erinithaca consorti30,31

1Assistance Publique-Hôpitaux de Paris - Université de Paris, Department of Genetics, Paris, France; 2CERCID, UMR 5137, “Centre de Recherches Critiques en Droit”, Université de Lyon, Lyon, France; 3University Medical Center Groningen, Dept. of Genetics, Genomics

Abstracts from the 55th European Society of Human Genetics Conference

European Journal of Human Genetics (2023) 31:345 – 709

variables. Diversity-based test were only able to detect variability with age. Host-genetics screening is ongoing.

Conclusion: Our approach will provide the community a robust and efficient tool to study the role of host-factors (genetics, environment) on a range of microbiome meta-parameters including taxa composition, metagenomic and metatranscriptomic profiles.

References:

Grants: Research supported by Agence Nationale pour la Recherche (ANR-20-CE15-0012-01).

Conflict of Interest: None declared.
P18.031.C Predicting chromatin loop status from local DNA sequence alone

Lyam Baudry¹, Cyril Mathey-Doret², Axel Cournac², Romain Koszul³, Alexandre Reymond¹

¹University of Lausanne, Center for Integrative Genomics, Lausanne, Switzerland; ²Institut Pasteur, Genomes and Genetics, Paris, France.

Background/Objectives: The recent flurry of omics technologies and cutting-edge protocols has brought about an increased understanding on the fundamental structure of chromatin. However, specific mechanisms behind the formation of structures of interest such as loops and domains remain elusive and only partially elucidated. While a complex and multifactorial mechanistic nature of loop formation is being unveiled, it is still unclear whether and to which extent the basic DNA sequence contributes to loop formation.

Methods: We use a variety of machine learning models (SVM, neural network) to predict loop status from short 5000 bp fragments. We build these predictions through a new and extensive positioning of loops on the recently-released telomere-to-telomere human genome sequence, combined with a specific embedding inspired from natural language processing models (dna2vec).

Results: Loop status can be correctly predicted with up to 80% accuracy. In contrast with other, highly-performing models (e.g. basenji, akita), our predictions are established independently of the context of the assessed sequence, i.e. locus position or extraneous data like ChiP-seq andRNA-seq.

Conclusion: As recent findings further confirm that chromatin loops are multi-faceted in nature and origin (e.g. cohesin vs non-cohesin mediated), shedding light on the information provided by biological latent variables of interest may prove crucial to investigate regulation mechanisms. Our method paves the way to a generalized use of language-based frameworks to predict DNA structure from its sole sequence.

References:

Grants: None declared.

P18.032.D Enhanced molecular consequence prediction and variant annotation with the Ensembl Variant Effect Predictor

Diana Lemos¹, Nuno Saraiva-Agostinho¹, Ola Austine Orimoloye², Andrey Azov³, Diego Marques-Coelho³, S. Nakib Hossain³, Helen Schullenburg³, Jamie Allen³, Stephen Trevanian³, Sarah Hunt³, Paul Flick³, Fiona Cunningham³

¹European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, United Kingdom.

Background/Objectives: The comprehensive annotation of genomic variation is key to interpreting potential impact on molecular function, thus important in understanding disease aetiology and diagnosis.

Methods: The Ensembl Variant Effect Predictor (VEP) is a powerful toolset for the annotation and prioritisation of genomic variants. We have extended its functionality to incorporate additional protein annotations and variant pathogenicity predictions.

Results: The effect of genetic variation on a protein function depends on the location of the variant in the protein structure. The protein domains a variant falls within are reported alongside matching UniProt protein isoforms. VEP now optionally reports matching UniProt protein isoforms. VEP now optionally reports matching UniProt protein isoforms. VEP now optionally reports matching UniProt protein isoforms.

Conclusion: We are well underway to share ERN-ITHACA patient data, yielding high-quality epidemiological insights and expert consensus statements, informing policy decisions that impact rare disease patients in general and care for ERN-ITHACA patients in particular.

References:

Grants: None declared.

European Journal of Human Genetics (2023) 31:345 – 709
Abstracts from the 55th European Society of Human Genetics Conference

P18.033.A Implementing RNA-fusion detection in routine cancer diagnostics

Annick Renevey¹, Martin Proks², Maxime Garcia³, Rickard Hammersén⁴, Praveen Raj⁵, Philip Ewels⁶, Anders Jemt⁷, Valtteri Wirta¹

¹Science for Life Laboratory, Karolinska Institutet, Department of Microbiology, Tumour and Cell Biology, Solna, Sweden; ²University of Copenhagen, Centre for Stem Cell Research and Developmental Biology, Copenhagen N, Denmark; ³Karolinska Institute, Department of Oncology-Pathology, Stockholm, Sweden; ⁴Uppsala University, Department of Organismal Biology, Human Evolution, Uppsala, Sweden; ⁵Science for Life Laboratory, Stockholm University, Department of Biochemistry and Biophysics, Solna, Sweden.

Background/Objectives: Healthcare is increasingly relying on massively parallel sequencing in clinical genomics diagnostics. In particular, cancer diagnostics and therapy selection can be assisted by the detection of gene fusions, as an increased number of fusions are observed in common cancer types. However, to operate in a clinical setting, a robust, scalable and portable data analysis pipeline is necessary.

Methods: We have developed the rnafusion pipeline designed to examine gene fusions in RNA sequencing. The pipeline is built within nf-core, a community-based framework to build and maintain bioinformatics analysis pipelines. The rnafusion pipeline uses multiple callers (e.g. STARfusion, fusioncatcher) to generate a combined comprehensive report of all fusion events, which aids interpreting results.

Results: rnafusion has an easily maintainable codebase assembled into a continuous integration environment. Containerisation ensures reproducibility and portability of the analyses. Combining results from different sources grants confidence in fusion events repeatedly identified by different tools and increases the chances of identifying novel fusions.

Conclusion: Maintaining analysis pipelines to the state-of-the-art in terms of software and databases is challenging. As computing capacities and technical achievements advance, a high turnover in data and methods is to be expected, highlighting the need for a fast, reliable and continuous maintenance of analysis pipelines, as well as regular validation procedures. Achieving this gold standard is facilitated within the nf-core framework, enabling a multitude of analyses to be accessible for patient care.

References: Ewels, P.A. et al. The nf-core framework for community-curated bioinformatics pipelines. Nat Biotechnol 38, 276–278 (2020).

Grants: None declared.

Conflict of Interest: None declared.

P18.034.B Evaluating validation approaches for whole exome sequencing based CNV calling in a diagnostic setting

Lisa Lüer¹, Sónia Font Tellada¹, Jenny Schiller², Sebastian Eck¹, Daniel Becker¹

¹MVZ Martinsried, Bioinformatics R&D, Planegg, Germany; ²MVZ Martinsried, Cytogenetics, Planegg, Germany.

Background/Objectives: The detection of genomic rearrangements such as copy-number variants (CNV) from Next-generation sequencing (NGS) data is an attractive alternative to the time consuming and costly MLPA and aCGH. Many different tools for CNV detection from NGS data have been developed over the last years. However, the validation of the NGS based CNV calls in a clinical setting is a major challenge, due to the high portion of false-positive calls and the lack of reference material.

Methods: We set up a patient cohort based on 23 samples and used filter settings as well as parameter modification for CNV calls to achieve an accessible number of calls. Here, we aim to evaluate CNV calling performance by comparing NGS based data to various orthogonal methods.

Results: The optimal validation methods differ, depending on the validation parameter of interest. The GIAB dataset is suitable as a truth set for precision calculation while the multitude of different methods used in generating the data makes it difficult to include it in sensitivity calculation based on short-read data. On the other hand, aCGH data is too imprecise to generate viable sensitivity values and MLPA cohorts are usually too small.

Conclusion: We show that the combination of a wide variety of validation methods as a reference system made it possible to compensate for the weaknesses of the individual technologies.

References: Zook, J.M., Hansen, N.F., Olson, N.D. et al. A robust benchmark for detection of germline large deletions and insertions. Nat Biotechnol 38, 1347–1355 (2020). https://doi.org/10.1038/s41587-020-0538-8.

Grants: None declared.

Conflict of Interest: None declared.

P18.036.D Evaluation of in silico pathogenicity predictor tools for the classification of small inframe indels

Stuart Cannon¹, Minnie Williams¹, Adam Gunning¹, Caroline Wright²

¹University of Exeter, Institute of Biomedical and Clinical Science, Exeter, United Kingdom.

Background/Objectives: The use of in silico pathogenicity predictions as evidence when interpreting genetic variants is widely accepted as part of standard reporting guidelines. Although numerous algorithms have been developed and evaluated for classifying missense variants, inframe insertions/deletions (indels) have been much less well studied.

Methods: We created a dataset of 3964 small (<100bp) indels predicted to result in inframe amino acid insertions or deletions using data from gnomAD v3.1 (minor allele frequency of 1-5%), ClinVar and the Deciphering Developmental Disorders (DDD) study. We used this dataset to test ten pathogenicity predictor tools (CADD, CAPICE, EXOMISER, FATHMM-indel, MutPredIndel, MutationTaster2 Proven, SIFT-INDEL, VEST and VDP).

Results: Our dataset consisted of 2224 benign/likely benign and 1740 pathogenic/likely pathogenic variants from gnomAD (n = 809), ClinVar (n = 2882) and, DDD (n = 273). We were able to generate scores across all tools for 95% of the variants, with areas under the ROC curve (AUC) of 0.81-0.96 based on the published thresholds. To avoid biases caused by inclusion of our dataset in...
the tools’ training data, we also evaluated just DDD variants not present in either gnomAD or ClinVar (70 pathogenic and 81 benign). Using this subset, the AUC of all tools decreased substantially. Overall, VEST performed best, with AUCs of 0.93 (full dataset) and 0.87 (DDD subset).

**Conclusion:** Diagnostic laboratories and genomic scientists should note that numerous tools now exist for predicting the pathogenicity of inframe indels, which perform on a par with similar tools designed for classifying missense variants, though ease of use varies substantially.

**References:**
[1] Mendelian, Clinical Operations, London, United Kingdom.

**Background/Objectives:** Hereditary haemorrhagic telangiectasia (HHT) is a rare multisystemic disease. Underdiagnosis is common due to the disease’s complexity and low physician awareness.

**Methods:** A cohort of HHT patients was identified in the Optimum Patient Care Research Database (OPCRD), a database of 11 million patients’ primary care electronic health records (EHR). Cases were identified by the presence of the SNOMED-CT code for HHT. HHT clinical features were mapped to the appropriate SNOMED-CT codes. Clinical features were examined in advance of their diagnostic date for HHT. Descriptive statistics was performed including patient count and time before diagnosis summarized by median of months.

**Results:** EHR with HHT diagnostic code: 1119

### Clinical features

| Clinical features                | # EHR | Months before diagnostic code (Median) |
|---------------------------------|-------|---------------------------------------|
| Epistaxis                       | 190   | -38                                   |
| Microcytic anaemia              | 90    | -37                                   |
| Migraine                        | 81    | -72                                   |
| Telangiectasia of the skin      | 54    | -5                                    |
| Arteriovenous malformation      | 28    | -8                                    |
| Seizure                         | 23    | -74                                   |
| Spontaneous hematoma            | 20    | -37                                   |
| Cavernous haemangioma           | 20    | -23                                   |
| Intestinal polyposis            | 17    | -24                                   |
| Haematuria                      | 17    | -56                                   |
| Stroke                          | 12    | -41                                   |
| Gastrointestinal haemorrhage    | 12    | -5                                    |
| Haemoptysis                     | 11    | -11                                   |
| Visceral angiomatosis           | 8     | -33                                   |

**Conclusion:** Clinical features of HHT can be identified in patients’ primary care EHR in advance of diagnosis. These may be used to develop phenotypical prediction tools to help identify patients at risk of HHT. Further work is needed to validate these results in other data-sets and control comparisons.

**References:**
[1] McDonald, J., & Stevenson, D. A. (2000). Hereditary Hemorrhagic Telangiectasia. In M. P. Adam (Eds.) et al., GeneReviews®. University of Washington, Seattle.
[2] Grants: VW Stiftung – NWK ZN3432.

**Conflict of Interest:** None declared.

---

**P18.038.B Phenotyping Hereditary hemorrhagic telangiectasia using UK primary care Electronic Health Records**

**Orlando Buendia**

**Abstracts from the 55th European Society of Human Genetics Conference**
P18.041.A Synthesized dysmorphic portraits can protect privacy while maintaining the benefits of data sharing

Tzung-Chien Hsieh1, Alexander Hustinx1, Behnam Javanmardi1, Peter Krawitz2

1Institute for Genomic Statistics and Bioinformatics, University Hospital of Bonn, Bonn, Germany.

**Background/Objectives:** The performance of next-generation phenotyping (NGP) approaches depends highly on the size and diversity of the training dataset. Because collecting a large number of images from individuals with rare disorders at a single institution is not feasible, data sharing between different sites is crucial, and this is usually done through publication. However, since we are re-identifiable by our faces, only about one out of ten patients gives consent. Therefore, we propose synthesizing portraits of rare disorders based on real data that can remain local to overcome this barrier.

**Methods:** We trained generative adversarial networks on 4,538 frontal images with 139 disorders from GestaltMatcher Database to synthesize faces with rare disorders. We then trained deep convolutional neural networks on the real and synthetic images separately to classify 139 disorders and benchmarked these two models on 360 test images.

**Results:** We first showed that the model trained on synthetic images achieved comparable performance as that trained on the real images. The saliency map was further utilized to visualize feature importance contributing to the classification, and dysmorphologists confirmed that the key dysmorphic features were preserved in the synthetic images. Lastly, face verification showed that the synthetic images cannot re-identify the underlying individuals.

**Conclusion:** We conclude that algorithms can benefit from synthetic facial images, representing an alternative to classical means of data sharing. Moreover, facial portraits are still the best teaching material for clinicians in medical genetics. Therefore, beyond the deep learning purpose, it is also of interest to educate the next generation of physicians.

**References:**

**Grants:**

**Conflict of Interest:** Tzung-Chien Hsieh: None declared, Alexander Hustinx: None declared, Behnam Javanmardi: None declared, Peter Krawitz Modest.

P18.042.B New RD-Connect GPAP features implemented in collaboration with Solve-RD, EJP-RD and ELIXIR enable the diagnosis of rare disease patients with previously negative WES/WGS

Leslie MataIonga1, Davide Piscia1, Alberto Corvo1, Anastasios Papakonstantinou1, Carles Hernandez-Ferrer1, Steven Laurie1, Carles Garcia1, Luca Zalatnai1, Raul Tonda1, Ida Paramonov1, Daniel Piscia1, Marcos Fernandez-Callego1, Dylan Spalding2, Coline Thomas2, Thomas Keane1, Hanns Lochmuller1, Rita Horvath1, Holm Graessner1, Alexander Hoischen1, Peter Krawitz1, Luca Zalatnai1, Peter Krawitz1

1European Bioinformatics Institute (EMBL-EBI), Hinxton, United Kingdom; 2Children’s Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Canada; 3Department of Clinical Neurosciences, School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom; 4Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany; 5Department of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands.

**Background/Objectives:** The RD-Connect Genome-Phenome Analysis Platform (GPAP, https://platform.rd-connect.eu/) is an IRDiRC recognised resource for diagnosis and gene discovery in Rare Diseases (RD). The interface allows clinical scientists to collaboratively analyse integrated genome-phenome data under controlled access. The GPAP is a key resource for Solve-RD (http://solve-rd.eu/), EJP-RD (https://www.ejprrdiseseuses.org/) and the ELIXIR RD Community (https://elixir-europe.org/communities/rare-diseases).

**Methods:** New features have been implemented in the RD-Connect GPAP which processes and indexes pseudonymised genome-phenome data from over 26,000 individuals.

**Results:** Recent developments facilitate data submission and integration, as well as the analysis and visualisation of the data. The developments include an innovative web interface that improves user experience and analysis capabilities, a module to collate and export phenotypic information using broadly used standards (e.g. HPO, ORDO, OMIM, GA4GH Phenopackets) and a user-friendly tool to create in-silico patient cohorts based on phenotypic and experimental information, a programmatic module to automate genomic analysis and the ability to remotely visualise sequence alignments archived at the European Genome-Phenome Archive (EGA). Some of these developments have contributed to diagnose the first 437 patients through the reanalysis of previously inconclusive WES/WGS data within the Solve-RD project.

**Conclusion:** New developments in the GPAP have contributed to the identification of hundreds of disease-causing variants in patients with RD and confirm diagnosis hypotheses through patient matchmaking approaches.

**References:**

**Grants:** EU projects (FP7-305444,H2020-779257,H2020-825575), ISCIII (PT13/0001/0044,PT17/0009/0019), INB and ELIXIR.

**Conflict of Interest:** None declared.

P18.042.D BAMdelbee: novel software enabling detection of midsize homozygous deletions through unsequenced NGS data analysis

Noam Hadar1, Baruch Yerushalmi2, Galina Ling2, Ismael Alshaafee1,3, Amit Nahum1, Ohad Shmuel Birk1,3

1Morris Kahn Laboratory of Human Genetics, NIBN and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel; 2Pediatric Gastroenterology Unit, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; 3Pediatrics Department A, Soroka University Medical Center, and The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.

**Background/Objectives:** Microdeletions between 70bp and 20,000bp can be disease causing, yet are often too small for detection through chromosomal microarrays (CMA) analysis and too large for standard NGS such as whole-exome-sequencing (WES) and whole-genome-sequencing (WGS) data analyses. Therefore, specialized methods are needed for investigating this troublesome range.
Methods: We created BAMdelbee, a novel tool for discovery of homozygous deletions in WES and WGS data, that is effective also in this troublesome range. WES or WGS samples generated by the same method produce BAM files with similar alignment coverage across the genome. BAMdelbee locates homozygous deletions by pinpointing regions sequenced in all samples but the ones in question.

Results: We demonstrate how our application can spot homozygous deletions not identified in WES and WGS variant analysis for being too vast, yet undetectable by CMA for being too small.

Conclusion: BAMdelbee is unique, being freely available on our website and capable of running on a regular laptop (https://fohs.bgu.ac.il/BirkLab/BAMdelbee). Furthermore, the high specificity of BAMdelbee results in scarcity of false positives, a common pitfall in such analyses in existing software. Therefore, it can be easily and effectively integrated into WES and WGS interpretation pipelines for recessive diseases.

References:

Conflict of Interest: None declared.

P18.045.A AION: an artificial intelligence platform for automated variant interpretation

Kristina Ibáñez Garikano¹, Andrea Bertana¹, Carla Glassl², David Alberto Neville¹, Rocio Acuna Hidalgo¹

¹Nostos Genomics, Berlin, Germany.

Background/Objectives: Variant interpretation is critical to the success of diagnostic tests such as Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS), as it identifies genetic variant(s) causing a patient’s clinical features. However, variant interpretation remains time-consuming and costly, requiring ~12 hours per case and causing long turnaround times. Furthermore, manual interpretation is prone to variability in results, potentially impacting diagnostic yield.

Methods: We developed AION, a variant interpretation software platform for diagnostic WES and WGS. AION consists of a pipeline for variant annotation, classification, and prioritization using a white-box machine learning approach. AION performs exhaustive variant interpretation providing a classification and confidence score for each variant in coding regions, and combinations of molecular and clinical diagnoses ranked according to the genetic and clinical data provided per patient.

Results: The performance of AION’s classification algorithm was tested in a prospective study of 122,208 variants classified in ClinVar, showing 96% accuracy, 92% sensitivity, and 96% specificity. AION was subsequently tested on 5,062 exomes from simulated patients with different monogenic diseases (including intellectual disability, hereditary cancer, heart disorders…). AION correctly identified the disease-causing variant in 96% of cases (4,845/5,062), outperforming automated ACMG guidelines which identified the pathogenic variant(s) in 61% of cases (3,108/5,062).

Conclusion: AION provides fast, accurate, and interpretable variant interpretation. AION identified pathogenic variants in >95% of cases, increasing diagnostic yield by more than 50% compared to ACMG rule-based classification. Exomes were analysed in 2 minutes, leading to quick turnaround times and the opportunity to increase throughput.

References:

Conflict of Interest: Kristina Ibáñez Garikano Nostos Genomics, Andrea Bertana Nostos Genomics, Carla Glassl Nostos Genomics, David Alberto Neville Nostos Genomics, Rocio Acuna Hidalgo Nostos Genomics, Nostos Genomics.

P18.046.B Search for complex alleles leading to disruption of mRNA splicing

Mikhail Skoblov¹, Mikhail Gatupov², Ivan Reveguk³, Igor Bychkov⁴, Ksenia Davydenko¹, Peter Sparber⁵, Andrey Marakhonov⁵, Alexandra Filatova¹

¹Research Centre for Medical Genetics, Laboratory of Functional Genomics, Moscow, Russian Federation; ²Moscow Institute of Physics and Technology, Dolgoprudny, Moscow Region, Russian Federation; ³École Polytechnique, Laboratoire de Biologie Structurale de la Cellule, Paris, France; ⁴Research Centre for Medical Genetics, Laboratory of hereditary metabolic diseases, Moscow, Russian Federation; ⁵Research Centre for Medical Genetics, Laboratory of Genetic Epidemiology, Moscow, Russian Federation.

Background/Objectives: It is well known that single nucleotide polymorphisms (SNPs) in the human genome are mostly neutral. However, if a mutation appears near to a frequent SNP their cooperative impact on splicing regulatory sequences can be very significant. At the same time, the effect of mutation could be different depending on the allelic states of SNP.

Methods: Bioinformatics analysis was performed using MaxEntScan and SpliceAI. The functional effect of the complex alleles on pre-mRNA splicing using a minigene assay.

Results: We attempted a genome-wide search for such “complex alleles”. For this, we created an “alternative” version of the human genome (hg19 assembly) where every frequent SNP contains its alternative allele. We also generated a dataset representing results of an in silico mutagenesis of the human genome sequence within the 10 nucleotides window flanking each SNP. Using the modified SpliceAI algorithm applied on both reference and “alternative” genome versions, we predicted those mutations which could change the splicing pattern in one version of the genome but not in another. As a result, we found about 41 thousand mutations. A detailed analysis of these mutations has shown various mechanisms of disruption of normal splicing patterns. Using the minigene system, we carried out experimental validation of some cases which could be relevant to medical genetics.

Conclusion: This work demonstrates that pathogenic complex alleles are common in the population and can lead to the appearance of hereditary diseases.

References:

Conflict of Interest: None declared.

P18.047.C Comparison of Polygenic Risk Scores for Coronary Artery Disease in an Italian prospective cohort: the EPICOR study

Alessandro De Gregorio¹, Carla Debernardi¹, Elisabetta Casalone¹, Giovanni Cugliari¹, Alessandra Allione², Licia Iacoviello³, Rosario Timuno³, Vittorio Krogh³, Paolo Vineis⁴, Salvatore Panico⁵, Carlotta Sacerdote⁶, Giuseppe Matteu³,⁷

¹University of Turin, Department of Medical Sciences, Turin, Italy; ²University of Insubria, Department of Medicine and Surgery, Varese, Italy; ³IRCCS Neuromed, Department of Epidemiology and Prevention, Isernia, Italy; ⁴Azienda Ospedaliera “Civile-M.P. Arrezo”, Cancer Registry and Histopathology Unit, Ragusa, Italy; ⁵Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Predictive and Preventive Medicine, Milan, Italy; ⁶Imperial College London, MRC-PHE Centre for Environment and Health, London, United Kingdom; ⁷University Federico II, Department of Clinical and Experimental Medicine, Naples, Italy; ⁸Piedmont Reference Centre for Epidemiology
Abstracts from the 55th European Society of Human Genetics Conference

P18.048.A Phivea: a novel platform for real-time detection of chromosomal aberrations using long-read sequencing and artificial intelligence

Carmen Garrido Navas1,2,3, David Galevski4,5, Anne Kristine Schack6,7, Gorgji Madjarov8, Aleksandar Nikov9, Lukasz Krych10, Chris Kyräkiidis11, Zoran Velkoski12

1GENYO Centre for Genomics and Oncological Research, Liquid Biopsy and Cancer Interception Group, Granada, Spain; 2University of Granada, Faculty of Sciences, Genetics, Granada, Spain; 3ConGen, Genetic Counselling Services, Granada, Spain; 4University Ss Cyril & Methodius, Skopje, Macedonia; 5Netcetera, Zurich, Switzerland; 6University of Copenhagen, Frederiksberg, Denmark; 7gMendel, Copenhagen, Denmark.

Results: We found striking differences in performance between tools when comparing WGS and ES results. MELT and Scramble performed best on ES data with a sensitivity (0.72;0.63) and precision (0.84;0.76), respectively. Application of both methods to the Solve-RD cohort identified a total of 375,082 MEIs, of which 1,647 (0.4%) were found in 2 or less individuals, absent in the dbRIP database and affecting OMIM genes. Patient phenotype matching has so far resulted in the identification of 3 causal pathogenic MEIs (0.03%), but interpretation is ongoing.

Background: Genetic diagnosis of chromosomal abnormalities is done through karyotyping/FISH or chromosomal microarrays (CMA) (1). Resolution, although sufficient for large anomalies, is limited for small chromosomal rearrangements and mosaicism. Recently, Optical Genome Mapping (OGM) showed 100% concordance with karyotype and CMA (2)(3) and was able to detect mosaicism (3); however computational analysis is challenging and cost-effectiveness needs to be demonstrated (4). Also, analysis methodology based on CMA, cannot efficiently detect triploidy (5). Oxford Nanopore Technology (ONT) uses long-read fragments facilitating identification of aneuploidies and mosaicism (6)(7) in a rapid and inexpensive way although bioinformatics analysis is under development.

Methods: We developed an end-to-end solution for mass, real-time, and cost effective screening of chromosomal aberrations based on ONT. As proof-of-concept, we evaluated diagnostic ability for Klinefelter syndrome (KS) patients (N = 2), healthy donors (N = 2) and other chromosomal abnormalities (N = 10). DNA libraries were prepared and loaded on the GridIONx5. Analysis and diagnosis was performed on Phivea1, a proprietary software solution enabling real-time detection of chromosomal aberrations using state-of-the-art data-driven modelling.

Results: We simultaneously analyzed 48 to 192 replicate samples, reducing costs and increasing throughput. We achieved 98.3% and 97.0% diagnostic specificity and sensitivity respectively for KS, with a LoD below 30%.

Conclusion: Our solution demonstrated a novel approach for detecting chromosomal abnormalities that can reduce costs, increasing throughput and facilitating analysis. Our technology was validated on KS, but results can be directly extrapolated for screening of any other chromosomal aberration.
References: 1. https://doi.org/10.1038/sj.ejhg.5201896. 2. https://doi.org/10.3390/genes12030398. 3. https://doi.org/10.1016/j.ejgh.2021.05.012. 4. https://doi.org/10.1081/E-ECHP-140000148. 5. https://doi.org/10.3390/genes12121958. 6. https://doi.org/10.1534/genesics.115.182311. 7. https://doi.org/10.1016/j.fertnstert.2018.06.014.

Conflict of Interest: Carmen Garrido Navas I am member of the advisory board as Clinical Specialist at gMendel, David Galevski Consultant, Data Scientist, Anne Kristine Schack Employment, Full-time, Gjorgji Madjarov Advisory Board, AI/ML Advisor, Aleksandar Nikov Consultant, AI/ML, Lukasz Krych Advisory Board, Genomics Advisor, Chris Kyrilakis Employment, Full-time, Zoran Velkoski Employment, Full-time.

P18.050.B Structurally informed epistatic features improve variant effect assessment in clinically actionable genes

Federica Luppino1,2, Ivan A. Adzhubei1, Christopher Cassa4,5, Agnes Toth-Petroczy1,2

1Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany; 2Center for Systems Biology, Dresden, Germany; 3Harvard Medical School, Biomedical Informatics, Boston, United States; 4Brigham and Women’s Hospital Division of Genetics, Boston, United States.

Background/Objectives: As genetic testing becomes more relevant to support clinical diagnoses, the interpretation of rare single nucleotide variants (SNVs) remains a major challenge for genetics research. Variant effect predictors (VEPs) are used to inform variant effect assessment. Yet their thresholds to classify a variant as pathogenic are often set for high sensitivity, that results in the misclassification of benign variants. Here, we developed DeMAG (Deciphering Mutations in Actionable Genes), a supervised classifier for interpreting missense variants in actionable genes.

Methods: DeMAG predictor uses conservation-based features and structural features derived from AlphaFold2 3D models. In addition, we designed the “partners feature” that captures epistasis both in sequence and 3D space of the protein. It is a probabilistic score that predicts pathogenicity based on the phenotypic effect of co-evolving residues and spatially close residues of the protein.

Results: DeMAG reached high performance for almost all genes considered and high sensitivity and specificity overall. DeMAG yielded the top performance across clinical and common population validation sets among different VEP tools. The novel partners feature assigns a score to more than 60% of residue positions that lack a clear clinical interpretation. We provide classification of all 1.3 million missense mutations for 59 actionable genes available at demag.org.

Conclusion: DeMAG expands the traditional conservation paradigm to epistatic and structural features to predict variants’ effect. DeMAG’s high specificity will reduce the number of misdiagnoses due to false positives and it might be better suited to prioritize variants for association studies.

References:
Grants: NIH grant (R01-HG010372), Max Planck Society MPRGL funding.

Conflict of Interest: None declared.

P18.051.C Hybrid de novo genome assembly of a Kazakh individual

Danyar Karabayev1, Asset Daniyarov1, Askhat Molkenov2, Saule Rakhimova1, Diana Samatkyzy1, Aidana Gadbulkyayum2, Ulan Kozhamkulov2, Ainur Akizhanova4, Ulykke Kairov2

1Digital Health Center, Hasso Plattner Institute, University of Potsdam, Potsdam, Germany; 2Digital Health Center, Hasso Plattner Institute, University of Potsdam, Potsdam, Germany; 3Hasso Plattner Institute for Digital Health at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, United States.

Background/Objectives: Chronic Kidney Disease (CKD) is a condition that causes a gradual loss of kidney function and affects approximately 9.1% of the global population. The disease is highly complex, and its genetic disease-causing mechanisms are not entirely understood. In this work, we use different soft-clustering approaches to deconstruct CKD heterogeneity.

Methods: First, we applied two soft-clustering methods to identify overlapping clusters of 493 independent CKD variants and 935 associated traits, identified from published genome-wide association studies (GWAS). Second, we tested whether the novel clusters have any broad clinical consequence by performing a cluster-specific polygenic Risk Scores (CRS) and comparing them to the CKD prevalence (cases = 2871, controls = 2737). Eventually, to further investigate each cluster’s mechanistic biology, we
performed a pathway analysis extracting the genes mapped to the top variants.

**Results:** The two clustering methods identified six comparable clusters whose diversity reflects different aspects of CKD: protective traits, type-2 diabetes, slow eGFR decline, anemia, hypertension, and hemolytic-uremic syndrome. The PheWAS confirmed the top-weighted traits in most of the clusters. Although the clustering results were comparable, Non-negative Matrix Factorization (NMF) performed better in yielding significant PheWAS results. Furthermore, despite having used only CKD risk-increasing alleles, the clusters showed different correlations between an increasing CRS and the prevalence of CKD.

**Conclusion:** Besides improving the understanding of disease biology, these results support using genetics to reduce CKD complexity by identifying disease subtypes.

**Conflict of Interest:** None declared.

**P18.054.B Venus: Elucidating the impact of amino acid variants on protein function beyond structure destabilisation**

**Matteo Ferla**1, Alistair Pagnamenta1, Jenny Taylor1, Brian Marsden2

1University of Oxford, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, Oxford, United Kingdom; 2University of Oxford, Centre for Medicines Discovery, Nuffield Department of Medicine, Oxford, United Kingdom.

**Background/Objectives:** Exploring functional effects of a missense variant at the protein level requires multiple pieces of information to be interpreted appropriately. This is particularly important when studying a potentially pathogenic variant linked to a rare or monogenic disease. Whereas accurate stability predictions alone are generally informative, other effects, such as disruption of post-translational modifications or weakened ligand binding, may also contribute to the disease phenotype. Furthermore, consideration of nearby variants that are found in the healthy population may strengthen or refute a given mechanistic hypothesis. Whilst there are several bioinformatics tools available that score the deleteriousness of variants, post-translational modifications etc., Venus empowers other researchers.

**Methods:** Venus (https://venus.cmd.ox.ac.uk) is a webapp which, given a protein substitution, rapidly estimates the predicted effect on protein stability of the variant, flags if the variant affects a post-translational modification site, a predicted linear motif or known annotation, and determines the effect on protein stability of variants which affect nearby residues and have been identified in healthy populations. Venus is built onto Michelangelo and the results can be exported to it, allowing them to be annotated and shared with other researchers.

**Results:** Venus (https://venus.cmd.ox.ac.uk) rapidly estimates the predicted effect on protein stability of the variant, flags if the variant affects a post-translational modification site, a predicted linear motif or known annotation, and determines the effect on protein stability of variants which affect nearby residues and have been identified in healthy populations. Venus is built onto Michelangelo and the results can be exported to it, allowing them to be annotated and shared with other researchers.

**Conclusion:** By presenting interactively multiple sources of information on a protein structure (stability, human population variants, post-translational modifications etc.), Venus empowers the investigation into the effects a variant of interest may have on a protein function.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P18.055.C A community developed pipeline for rare disease diagnostics**

**Anders Jemt**1,2, Ramprasad Neethiraj3, Mei Wu2, Lauri Mesilaakso4, Annick Renevey1, Gwenna Breton2, Subazini Thankaswamy Kosala1, Sima Rahimi2, Emil Bertilsson3, Viktor Hennyy2, Valtteri Wirta1,2,3, Henrik Stranneheim1,2,8

1Science for Life Laboratory, Karolinska Institute, Department of Microbiology, Tumour and Cell Biology, Solna, Sweden; 2Karolinska University Hospital, Genomic Medicine Center Karolinska, Solna, Sweden; 3Science for Life Laboratory, KTH Royal Institute of Technology, School of Engineering Sciences in Chemistry, Biotechnology and Health, Stockholm, Sweden; 4Linköping University Hospital, Department of Clinical Microbiology, Linköping, Sweden; 5Gothenburg University, Clinical Genomics Gothenburg, Sambio core facilities, Gothenburg, Sweden; 6Örebro University Hospital, Department of Laboratory Medicine, Örebo, Sweden; 7Skåne University Hospital, Lund, Sweden; 8Karolinska University Hospital, Centre for Inherited Metabolic Diseases, Solna, Sweden.

**Background/Objectives:** Genome sequencing has become a mainstay in rare disease (RD) diagnostics, enabling medical professionals to diagnose challenging cases. However, computational pipelines are getting increasingly complex, resource demanding and are often tightly tied to local computational infrastructure. The community driven nf-core initiative aims to develop and maintain a curated set of open-source best practice bioinformatic pipelines1. Herein we describe the development of the nf-core rare disease pipeline.

**Methods:** The pipeline aligns fastq files, calls and annotates SNV/indels and structural variants. Furthermore, it calls uniparental disomy, runs of homozygosity, repeat expansions and SMN1/SMN2 copy numbers. Variants are ranked according to their predicted pathogenicity using a weighted sum rank model.

**Results:** The pipeline is an extension of the workflow used in the Stockholm healthcare region to analyze >10,000 samples, with a diagnostic yield of 40% in a first cohort of 3219 patients2. The development is a collaborative effort within Genomic Medicine Sweden, aiming to establish this as the national pipeline for RD diagnostics.

**Conclusion:** Pipelines developed within the nf-core community adhere to strict guidelines ensuring that they will install, run and perform on most computing infrastructure, including cloud. The nf-core rare disease pipeline enables a broad utilization across the diagnostic RD community.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P18.056.D Automated prioritization of copy number variants with ACMG/ClinGen standards**

**Jiri Ruzicka**1, Kevin Yaay1, Nicolas Duforet-Freborg3, Laure Raymond2, Melanie Brouin1, Jerome Audoux1, Sacha Beaumeunier1, Nicolas Philippe1, Denis Bertrand3

1SeqOne, Montpellier, France; 2Eurofins Biomnis, Ivry-sur-Seine, France.

**Background/Objectives:** With the rising adoption of long-read sequencing technologies, previously undetected and numerous CNVs (copy-number variants) are accessible and their prioritization becomes necessary for the clinical evaluation. ACMG and ClinGen published guidelines for clinical interpretation of such variations, which allow more consistent prioritization of CNVs.
Methods: We present an original implementation of the recommendations of the ACMG/ClinGen framework, adapted to both small and large CNVs. Classifications were processed using dosage map sensitivity, general population frequency, phenotype matching and disease inheritance patterns. The performance of the model was compared with the published ACMG/ClinGen dataset consisting of 114 CNVs evaluated by two independent experts.

Results: Our classification tool achieved 96.7% specificity for pathogenic variant identification, identifying correctly 15 of 23 CNV assessed as pathogenic by the two evaluators. 2 additional CNV could be classified as pathogenic when phenotypes were available. In 84.2% of CNVs, the prediction was the same as the prediction of at least one evaluator. For the 15.8% of predictions in disagreement, no variants classified as benign were predicted pathogenic and vice-versa.

Conclusion: This implementation of ACMG/ClinGen standards provides an automated and confident classification of CNVs which accelerates the clinical interpretation of structural variants.

References:
Grants:
Conflict of Interest: None declared.

P18.058.B Bone2Gene: deep learning-based diagnosis of rare skeletal disorders
Sebastian Rassmann1, Alexander Hustinx1, Kyra Skaf2, Miguel Ibarra-Arellano3, Tzung-Chien Hsieh1, Alexandra Keller4, Ruth Gausche5, Klaus Mohnike6, Peter Krawitz1, Behnam Javanmardi1
1Institute for Genomic Statistics and Bioinformatics, Bonn, Germany;
2Otto von Guericke University Magdeburg, Medizinische Fakultät, Magdeburg, Germany;
3Heidelberg University, Institute for Computational Biomedicine, Heidelberg, Germany; 4Children’s Center am Johanniskrankenhaus, Leipzig, Germany; 5Leipzig University, Medizinische Fakultät, Leipzig, Germany.

Background/Objectives: Rare skeletal disorders are an important group of genetic disorders that are highly heterogeneous, making their accurate diagnosis a very challenging process. In this project, we have (so far) collected more than 700 hand X-Ray images from patients diagnosed with 6 different skeletal disorders which we are using to build a diagnostic tool based on Deep Learning (DL).

Methods: DL usually requires massive amounts of training data. However, data for rare genetic disorders is inherently sparse which is further exacerbated by difficulties collecting and digitizing the X-Ray imagery. We address this issue by employing transfer learning from a public bone age dataset. Furthermore, varying data sources e.g. using differing imprinted labels or images showing digitization artifacts potentially induces biases. To eradicate these, we trained DL models to extract only the hands concealing the origin of the X-Ray.

Results: Our bone age DL models trained on the bone age dataset reach a competitive accuracy with a mean age difference (MAD) of ~4.5 months (compared to 5-7 months from human experts). Furthermore, our models achieve a MAD of ~7.5 months (w.r.t. a single human rater) on our skeletal disorder dataset which demonstrates generalizability to (1) unseen datasets and (2) disordered patients. Upon fine-tuning our models on disorder classification, we build a preliminary classifier. However, prediction accuracies widely depend on the class frequency in our dataset (0-95%).

Conclusion: By growing our database we aim to increase the performance and, consequently, deploy Bone2Gene as a clinical assistance tool.

References:
Grants:
Conflict of Interest: None declared.

P18.060.D Analyzing clinical RNAseq data with machine learning models greatly improves the genetic diagnosis in pediatric acute lymphoblastic leukemia
Michelle Tang1,2, Zeljko Antic1, Stefan Pietzsch1, Jana Lentes1, Winfried Hofmann1, Gunnar Cario1, Gabriele Escherich1, Udo zur Stadt1, Brigitte Schlegelberger1, Martin Horstmann1,2, Martin Stannu1,2, Anke Katharina Bergmann1
1Hannover Medical School, Department of Human Genetics, Hannover, Germany; 2L3S Research Center, Hannover, Germany; 3University Hospital Schleswig-Holstein, Department of Pediatrics, Kiel, Germany; 4University Medical Center Hamburg-Eppendorf, Clinic of Pediatric Hematology and Oncology, Hamburg, Germany; 5Research Institute Children’s Cancer Center Hamburg, Hamburg, Germany; 6Hannover Medical School, Department of Pediatric Hematology and Oncology, Hannover, Germany.

Background/Objectives: Since tumour genetics greatly influence the risk stratification and treatment of acute lymphoblastic leukaemia (ALL), Next Generation Sequencing (NGS) technologies have been incorporated into routine diagnostics with the cost-
effective targeted RNA sequencing being particularly appealing. However, the analysis and integration of large amounts of NGS data in diagnostic settings remains challenging since a systematic tool is lacking.

**Methods:** We performed targeted RNAseq on ~1500 pediatric ALL patients from the German pediatric ALL study groups. The megSAP pipeline was applied to analyze the gene expression and fusions. We then combined UMAP (Uniform Manifold Approximation and Projection) and supervised machine learning algorithms to build an interactive tool for visualization and prediction of patients’ diagnostic subgroups.

**Results:** Our tool provides a user-friendly interface for analyzing large cohorts as well as individual cases. New patient data is uploaded weekly. The UMAP visualization and subgroup prediction are generated immediately (~1 minute) and accurately (F1=95%).

Using this tool, we are able to: (1) identify patients with DUX4 fusion, when fusion calling and conventional cytogenetic methods failed; (2) stratify patients without aberrant fusion or aneuploidy, e.g., Ph-like; (3) pinpoint individual outlier cases that need special attention or are usually difficult to distinguish, e.g., masked-hypodiploidy; (4) validate the results from conventional diagnostic methods.

**Conclusion:** We present a systematic AI tool that easily integrates into the routine diagnostics. Its application helps to improve risk stratification and brings novel insights to research. Our workflow has the power to replace some traditional methods and pave the way for personalized oncology.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

P18.061.A Recent updates in the VarFish platform for collaborative variant data analysis

**Manuel Holtgrewe,1 Oliver Stolpe,1 Henrike Szczakiel,2 Björn Fischer-Zirnsak,2 Felix Boschmann,2 Nadja Ehmk,2 Dieter Beule1**

1Berliner Institute of Health, Berlin, Germany; 2Charité – Universitätsmedizin Berlin, Berlin, Germany.

**Background/Objectives:** VarFish is a web-based for the collaborative analysis of DNA variant data. VarFish is freely available under a permissive open source license.

**Methods:** We have continuously developed the application further together with our clinical partners and extended it in terms of features and usability.

**Results:** We present recent advancements in VarFish features including support for easily exporting annotated variants for submission to Clinvar, the analysis of stratural variants, and the support for large cohorts.

**Conclusion:** VarFish continues to be a versatile and powerful tool for variant analysis in our research and diagnostics applications.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

P18.062.B Identification of unknown environmental factors that mediate eQTLs using principal interaction component analysis

**Martijn Vochteloo,1 Patrick Deelen1,2, Britta Vink1,2, Bios Consortium4, Sergio Andreu-Sánchez2, Jingyuan Fu1,2, Alexandra Zhernakova1, Ellen A. Tsai6, Heiko Runz6, Harm-Jan Westra1, Lude Franke1,2**

1University Medical Center Groningen, University of Groningen, Department of Genetics, Groningen, Netherlands; 2Oncode Institute, Utrecht, Netherlands; 3Hanze University of Applied Sciences, Institute for Life Science & Technology, Groningen, Netherlands; 4BIOS Consortium, Utrecht, Netherlands; 5University Medical Center Groningen, University of Groningen, Department of Pediatrics, Groningen, Netherlands; 6Biogen Inc., Translational Biology, Research & Development, Cambridge, MA, United States.

**Background/Objectives:** Expression quantitative trait loci (eQTL) help explain the regulatory mechanisms of trait associated variants. eQTL effect sizes are often dependent on observed and unobserved biological contexts, such as cell type composition and environmental factors. Here, we introduce PICALO (Principal Interaction Component Analysis through Likelihood Optimization) which is an unbiased method to identify known and hidden contexts that influence eQTLs.

**Methods:** PICALO uses expectation maximization to identify latent components, referred to as Principal Interaction Components (PICs), which maximally affect eQTL effect-sizes. Here we applied PICALO to bulk RNA-seq eQTL datasets in both blood (n = 2,932) and brain (n = 2,439).

**Results:** We identified 33 PICs in blood. These PICs interact with 4,533 (35%) unique eQTLs. We identified 21 PICs in brain, which interact with 3,996 (39%) unique eQTLs (FDR<0.05). These PICs capture both RNA quality, cell type composition, and environmental influences.

For instance, a PIC interacting with 375 blood eQTLs is correlated to the presence of prior Cytomegalovirus infection (r = 0.31, p-value = 5x10^-17). Several of these eQTLs overlap asthma GWAS risk variants, corroborating a previously reported role of Cytomegalovirus in asthma.

We observed that PICALO is robust to heterogeneous datasets, yielding biologically highly informative and reproducible interaction components.

**Conclusion:** PICALO is a novel method that allows for the identification of context dependent eQTLs without any prior knowledge, and which outperforms methods that use cell counts or expression-based principal components. PICALO therefore has the potential to aid in better understanding the environmental components that play a role in common diseases.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

P18.063.C Using CADA – a phenotype-driven gene prioritization tool for custom panel definition in diagnostics of rare disorders using exome sequencing – a retrospective analysis of 380 patients

**Gaber Bergant,1 Aleš Mavor1, Klemen Žiberna2, Borut Peterlin1**

1University Medical Centre Ljubljana, Clinical Institute of Genomic Medicine, Ljubljana, Slovenia; 2Faculty of Medicine, University of Ljubljana, Institute for Biostatistics and Medical Informatics, Ljubljana, Slovenia.

**Background/Objectives:** Phenotype-driven gene target definition using gene panels and known phenotype-gene associations represent an established practice in next-generation sequencing data analysis. In patients with complex phenotypes target selection can be difficult, often resulting in the analysis of multiple
genes not associated with the observed phenotype pattern. We propose using CADA, a phenotype-driven gene prioritization tool for custom panel definition and report on the results of a retrospective analysis in 380 patients.

**Methods:** Phenotype of 380 patients examined, sequenced and diagnosed at our institution was described in human phenotype ontology (HPO) terms and served as CADA input. We performed a statistical analysis of the results and report on CADA rankings and score distribution for genes with diagnostic findings. We defined custom gene panels using CADA scores at different cut-off values and provide comparison with the standard gene panel approach using Genomics England PanelApp.

**Results:** Genes with diagnostic findings in our patient cohort had an average CADA rank of 54.6 (SD = 81.8, max = 484) and a median score of 60.5 (SD = 24.6, min = 14.7). Average number of genes in gene panels selected by clinical geneticist was 470. Using CADA score at 5th percentile in our cohort as cut-off value for gene inclusion in custom gene panel would have provided us with smaller target sizes (mean = 324 genes) compared with gene panels selected by a clinical geneticist.

**Conclusion:** We conclude that using CADA for phenotype-driven gene target definition would lead to smaller gene targets compared to the standard approach using gene panels.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

P18.064.D Comprehensive copy number variant analysis of 11,000 previously unsolved rare disease exome sequencing datasets within the Solve-RD project results in diagnoses being reached for 2% of previously unsolved cases

German Demidov1, burcu yaldiz2, Francesca Musacchia3, Lennart Johansson6, Ida Paramonov5,6, J. Garcia-Pelaez7,8,9, Elisa Benetti10, Gemma Bullich Vilanova1,6, Elke de Boer2, Nika Schuermans3, Ana Töpf4,5, Liedewei van de Vondel13, Jana Vandrovcova14, Carla Oliveira7,8,9, Lisenha Vissers9,11, Stephen Ossowsky15,15, Steven Laurie5,6

1Institute of Medical Genetics and Applied Genomics, Tübingen, Germany; 2Department of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands; 3Center for Human Technologies, Italian Institute of Technology (IIT), Genova, Italy; 4University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, Netherlands; 5CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona, Spain; 6The Barcelona Institute of Science and Technology, Barcelona, Spain; 7i3S, Instituto de Investigación e Inovación en Saúde, University of Porto, Porto, Portugal; 8Ipatimup, Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal; 9Faculty of Medicine, University of Porto, Porto, Portugal; 10Med Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy; 11Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium; 12John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle, United Kingdom; 13Translational Neurosciences, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium; 14Department of Neuromuscular Diseases, Institute of Neurology University College London, Queen Square, London, United Kingdom; 15Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.

Background/Objectives: A key objective of the H2020 Solve-RD project is the exhaustive reanalysis of 19,000 exome sequencing (ES) datasets to reach diagnoses that have previously proven elusive. For some of these datasets only limited, if any, copy-number variant (CNV) analyses may have been previously undertaken. The Solve-RD CNV working group is reanalysing all submitted data using a variety of algorithms in order to identify candidate disease-causing CNVs. Here we report on reanalysis of the success of the first 11,000 experiments representing 6,000 families.

**Methods:** Raw ES reads were realigned to the hs37d5 reference genome and four CNV calling algorithms applied to the new alignments to maximise sensitivity: ClinCNV, Conifer, ExomeDepth, and VarGenius-HZD. Putative CNVs in candidate gene lists provided by four European Reference Networks submitting to Solve-RD, and all CNVs over 500kb in length, were prioritised for further investigation. QC measures were applied to reduce the number of false positive events identified, and IGV track screenshots generated for all candidate CNVs, to facilitate visual inspection and interpretation by clinical researchers.

**Results:** Analyses to date have already resulted in the identification of CNVs that are fully, or partially explanatory for the disease phenotype in >2% of cases, some of which have remained undiagnosed for more than a decade, and this number is expected to grow further as further events are confirmed.

**Conclusion:** Disease causing CNVs were identified in an important proportion of patients likely because thorough CNV analysis of exome data remains challenging and thus has not been routinely performed in the past.

**References:**

**Grants:** EU H2020-779257.

**Conflict of Interest:** None declared.

P18.066.B Fast and powerful statistical method for context-specific QTL mapping in multi-context genomic studies

Andrew Lu1, Mike Thompson1, Gracie Gordon2, Andy Dahl3, Chun Jimmie Ye1, Noah Zaitlen1, Brunilda Balliu

1University of California Los Angeles, Los Angeles, United States; 2University of California San Francisco, San Francisco, United States; 3University of Chicago, Chicago, United States.

**Background/Objectives:** Recent studies suggest that context-specific eQTLs underlie genetic risk factors for complex diseases. However, methods for identifying them are still nascent, limiting their comprehensive characterization and downstream interpretation of disease-associated variants.

**Methods:** Here, we introduce FastGxC, a novel statistical method that leverages the correlation structure of multi-context studies to efficiently and powerfully map context-shared and context-specific eQTLs. We prove through analytical derivation and empirical examination that FastGxC shared and context-specific eQTL effect size estimates are a re-parametrization of the standard eQTL effect size estimates in each context and the eQTL-by-context interaction effect size estimates from a linear mixed model with a genotype-by-context effect.

**Results:** We show via simulations that FastGxC is orders of magnitude more powerful and computationally efficient than previous approaches. We apply FastGxC to bulk multi-tissue RNA-Seq data from the GTeX Consortium and PBMC single-cell RNA-Seq data from CLUES to produce the most comprehensive tissue- and cell-type-specific eQTL maps to date. We validate these maps by establishing that context-specific eQTL variants are enriched in corresponding functional genomic annotations. Finally, we examine the relationship between context-specific eQTLs and human disease and show that FastGxC context-specific eQTLs provide a three-fold increase in precision to identify relevant tissues and cell types for GWAS variants and a two-fold improvement in their rank than standard eQTLs.

**Conclusion:** In summary, FastGxC enables the construction of context-specific eQTL maps that can be used to understand the
context-specific gene regulatory mechanisms underlying complex human diseases.

References:

Grants:

Conflict of Interest: Andrew Lu: None declared, Mike Thompson: None declared, Gracie Gordon: None declared, Andy Dahl: None declared, Chun Jimmie Ye C.J.Y. has received research support from Chan Zuckerberg Initiative, A3 Chan Zuckerberg Biohub, and Genentech, C.J.Y. is a Scientific Advisory Board member for and hold equity in A35Related Sciences and ImmunoAI, a consultant for and hold equity in Maze Therapeutics, and a436consultant for TrEx Bio, Noah Zaitlen: None declared, Bru- nildá Balliu: None declared.

P18.067.C DGH-GO: Dissecting the Genetic Heterogeneity of complex diseases using Gene Ontology, an interactive and user-friendly web application

Muhammad Asif1,2, Hugo Martiniano3, Francisco Couto1

1LASIGE, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal, Lisbon, Portugal; 2CENTURI Multi Engineering Platform, Aix Marseille University France, Marseille, France; 3Instituto Nacional de Sau de Doutor Ricardo Jorge, Avenida Padre Cruz, Lisboa, Portuga, Lisboa, Portugal.

Background/Objectives: Neurodevelopmental disorders (NDDs) are phenotypically heterogeneous and dif- ferent NDDs share biological mechanisms that age. The genetic heterogeneity of NDDs matches to their clinical-variability. The different NDDs share biological mechanisms that further complex the patient's stratification, thus, limiting the applica- tions of personalized medicine for NDDs. Existing studies have employed biological networks and machine-learning methods to dissect the genetic heterogeneity. Such methods suffer from many parameter tuning and lack biological interpretations, resulting in the reduced generalizability of the proposed method.

Methods: Here, we presented an interactive and user-friendly application, DGH-GO that allows biologists to dissect the genetic heterogeneity of complex diseases by stratifying the genes, disrupted by any type of genetic variants (SNV, CNVs). The application can also be used to study the shared etiology of complex-diseases.

Results: DGH-GO creates a functional similarity matrix of puta- tive disease-causing genes or known-disease genes for multiple disorders using Gene Ontology (GO). The resultant matrix can be visualized in a 2D space using different dimension reduction methods (T-SNE and Principal-Coordinate-Analysis). Functional similarities from GO and projected space coordinates from dimen- sion reduction methods can be used to identify clusters by employing four different clustering methods (K-means, Hierarchical, Fuzzy and PAM). The user may change the clustering parameters and see their effect on stratification results immediately.

Conclusion: In summary, functional-similarities, dimension-reduction and clustering, coupled with interactive-visualization and control over analysis allows biologists to explore and analyze their datasets, without knowing the execution of complex meth- ods. The proposed application and its application to NDDs is available at https://github.com/Muh-Asif/DGH-GO.

References: Asif et al. 2018, 2019, 2020.

Grants:

Conflict of Interest: None declared.

P18.068.D Whole-Genome Sequencing: The Long and the Short of It

Sylvan Caspar1, Patricia Stoll1, Siro Fritzmann1, Gilles Gut1, Daniel Salerno1, Janine Meienberg1, Gabor Matyas1,2

1Foundation for People with Rare Diseases, Center for Cardiovascular Genetics and Gene Diagnostics, Schlieren, Switzerland; 2Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.

Background/Objectives: Whole-exome sequencing (WES), short-read whole-genome sequencing (SR-WGS) and long-read WGS (LR-WGS) enable the detection of sequence variants at unprece- dented scale, leading to new challenges in variant calling. Indeed, the calling of all clinically-relevant ClinVar/HGMD variants is challenging due to the limitations of sequencing and data analysis platforms. Here, we provide new insights into the performance of the most recent sequencing, alignment, and variant-calling pipe- lines in the detection of ClinVar/HGMD variants.

Methods: We used raw data of SR-WGS (PE150, ~60×) of ≥50 in-house samples as well as SR-WGS (PE150, ~60×) and LR-WGS (PacBio HiFi, ~30×) of 4 publicly available samples (HG0001-HG0004). We implemented 12 state-of-the-art analysis pipelines for SR-WGS, LR-WGS, or the combination of both as well as developed a workflow to assess the pipelines’ performance in the detection of ClinVar/HGMD variants.

Results: For a ~60× genome, accelerated pipelines decreased the runtime of BWA/GATK from ~2.5 d to ~2-5 h, enabling the analysis of multiple samples. LR-WGS outperformed SR-WGS, particularly in regions with mappability <1, while WES failed to detect variants in non-exonic or GC-rich regions. However, no pipeline alone detected all ClinVar/HGMD variants. By analyzing read depth, strand bias, variant allele fraction, and population-based allele-frequency, we identified a substantial number of false-positive calls and ClinVar/HGMD entries.

Conclusion: Sequencing, alignment, and variant-calling pipe- lines can significantly influence the detection of all ClinVar/HGMD variants, leading to both false-negative and false-positive results. Owing to its inherent advantages in variant detection/calling, LR- WGS should be implemented in clinical practice as soon as it is affordable.

References:

Grants:

Conflict of Interest: None declared.

P18.069.A Hybrid semi-automated approach for neonatal screening using whole exome sequencing

JEKATERINA SHUBINA1, Ekaterina Lozier1, Vladislav Tkachuk2, Igor Sadelov1, Dmitry Trofimov1

1FSBI «National medical research center for obstetrics, gynecology and perinatology named after academician V.I.Kulakov» ministry of healthcare of the Russian federation, Moscow, Russian Federation; 2DNA-technology, Moscow, Russian Federation.

Background/Objectives: The advances in high-throughput sequencing technologies have provided powerful tools for the analysis of genomic variants and allowed for newborn screening that included a huge amount of rare hereditary disorders that would not be detected using conventional screening methods. However the step of variant interpretation remains time and labor consuming and requires a highly qualified specialist. Therefore, a manual analysis of every sample is impossible for routine screening. At the same time, a fully automated approach is not the best decision due to the huge amount of variant data with ambiguous clinical relevance. Therefore, we decided to apply a combined approach that allows for automated analysis of samples with no “suspicious” variants followed by manual analysis of those samples that carry variants of interest.

Methods: The variants were called using GATK best practices pipeline. The automated variant prioritization was performed for
more than 2000 genes associated with severe childhood-onset diseases considering the inheritance type, variant significance information from ClinVar, HGMD, and local databases, variant frequency in gnomAD and local databases. For autosomal recessive disorders we only reported potential homozygotes and compound heterozygotes.

**Results:** Automated variant prioritization resulted in 45% of cases that carried no variants for manual interpretation. The remaining cases carried “suspicous” variants in 1-3 different genes, that significantly reduced the time needed for analysis.

**Conclusion:** A combination of automated and manual variant analysis allowed us to speed up data analysis for neonatal screening without sacrificing the sensitivity.

**References:**

**Grants:** The study was carried out within the framework of State Assignment 121092400060-5.

**Conflict of Interest:** None declared.

### P18.070.B Clinically-driven, multi-layered, and interpretable machine learning model for assisted variant interpretation

Jiri Ruzicka¹, Nicolas Duforet-Frebourg², Laure Raymond², Jerome Audoux², Sacha Beaumeunier¹, Denis Bertrand², Laurent Mesnard³, Nicolas Philippe⁴, Julien Thevenon⁵, Kevin Yauy⁴

¹SeqOne, Montpellier, France; ²Biomnis-eurofins, Lyon, France; ³Assistance Publique – Hôpitaux de Paris, Paris, France; ⁴CHU Grenoble, Grenoble, France.

**Background/Objectives:** With the great expansion of sequencing technologies and artificial intelligence tools, the demand for interpretable classification of variants rises rapidly and highlights the need for a personalized approach based on the clinical context. Unfortunately, the low interpretability of machine learning black-box models limits their adoption in the community.

**Methods:** We created a multi-layered machine learning model called ClassifyML which scores the pathogenicity of genomic variants and prioritizes their importance for the clinical context. Called ClassifyML which scores the pathogenicity of genomic variants and prioritizes their importance for the clinical context.

**Results:** The model proposes an interpretable output in the form of a continuous importance scale for each criterion, which assists the clinical interpretation of variants. We evaluated our method with a multi-centric cohort consisting of 310 patients. The model was trained firstly on the ClinVar variant classification dataset, followed by a second training on a cohort of 316 deep-phenotyped patients recruited from a French consortium.

**Conclusion:** ClassifyML is an interpretable machine learning model for pathogenicity prediction and variant prioritization. It allows variant classification prediction, patient context integration, and yields human-explainable classifications.

**References:**

**Grants:** The study was carried out within the framework of State Assignment 121092400060-5.

**Conflict of Interest:** None declared.

### P18.071.C Gene prioritization for rare diseases integrating genotype, RNA-seq and phenotype - lessons from a CAGI 6 challenger team

Vicente Yépez¹, Christian Mertes¹, Nicholas H. Smith¹, Ines Scheller¹, Julien Gagneur¹

¹Technical University of Munich, Munich, Germany.

**Background/Objectives:** RNA sequencing emerges as a complementary tool to DNA sequencing for rare disease diagnostics. However, gene prioritization methods integrating genotype, RNA-seq and phenotypes have been lacking. To address this need, the SickKids Genome Clinical released a CAGI 6 diagnostics challenge with nearly 80 genomes and RNA-seq samples.

**Methods:** We developed a gene prioritization model integrating variant annotations, mono-allelic expression, gene expression and splicing outliers (through our workflow DROP), together with HPO-encoded phenotypes. The model is a gradient tree boosting machine (XGboost) trained on a cohort of 209 mitochondrial disease patients from which half are diagnosed.

**Results:** On the mitochondrial disease dataset, our model prioritizes the causal gene first for almost half of the diagnosed cases, and among the top 5 in more than 70% of them. Application to the CAGI6 SickKids cohort revealed a known splice-disrupting pathogenic variant and reported several promising candidates (CAGI6 evaluation pending as of now).

**Conclusion:** Our approach and publicly available software can help find and prioritize candidates found by DNA and RNA sequencing and can be especially useful to reduce the burden of manual inspection in cohorts of hundreds of samples.

**References:**

1. http://genomeinterpretation.org/cagi6-sickkids.html.
2. Brechtmann et al, AJHG (2018).
3. Mertes et al, Nat Commun (2021).
4. Yépez et al, Nat Protoc (2021).
5. Yépez, Gusic et al, Genome Med (2021).
6. https://github.com/gagneurlab/cagi6_sickkids.

**Grants:**

**Conflict of Interest:** Vicente Yépez Technical University of Munich, Christian Mertes Technical University of Munich, Nicholas H. Smith Technical University of Munich, Ines Scheller Technical University of Munich, Julien Gagneur Technical University of Munich.

### P18.073.A Whole genome sequencing for copy number variation and structural variant analyses

Nicolas Chatron¹, Virginie Bernard², Céline Richard³, Gaelle Salaun³, Laetitia Gouas³, Laurence Michel-Calemard¹, Quentin Charret², Valentin Klein², Laura Fancellò³, Laura Nicolas³, Alain Vian¹, Anthony Ferrarit, Jean Yves Blay³, Marianne TILL³, Renaud Touraine³, François Bermond³, Ines Harzallah³, Rodol Harbuz³, Véronique Sattre³, Caroline Schluth-Boland³, Philippe Vago³, Charles Couton⁷, Christinevinciguerra⁷,⁹, Damien Sanlaville¹;⁵, Julien Thevenon⁵;⁷

¹Service Genetic - Hcl, Bron, France; ²auragen, Grenoble, France; ³CHU Clermont-Fd Estaing, Clermont-Ferrand, France; ⁴Léon Bérard Center, Lyon, France; ⁵auragen, Lyon, France; ⁶CHU Nord Saint-Étienne, Saint-Priest-en-Jarez, France; ⁷CHU Grenoble Alpes - Service de Génétique, La Tronche, France; ⁸CHU Strasbourg, Strasbourg, France; ⁹ISPB - Faculté de Pharmacie de Lyon, Lyon, France.

**Background/Objectives:** WGS is widely spreading as a first line diagnostic test, both for detecting small variants (SNVs/indels), Copy-Number Variants and Structural Variants (CNVs/SVs). Through the Auragen program, we have validated a routine for CNVs/SVs calling, annotation, and prioritizations devoted to rare mendelian disorders diagnostics. Literature data and reference samples are missing gold standards for such variants, hence we developed an internal analytical validity assessment.

**Methods:** A reference dataset was constituted through 82 CNVs (52 losses, 30 gains) identified by array-CGH from various...
Abstracts from the 55th European Society of Human Genetics Conference

P18.075.C OpenCB: an Open Source BigData clinical genetics platform that scales for large health and research system organizations

Will Spooner1, Pablo Marin2, Jacobo Coll2, Pedro Furio2, Phillip Hamid1, Junfe Sanahuja1, Joaquin Tarrega1, Laura Lopez1, Marta Bleda1, Jose Miguel Juanes2, Rodiel Martinez2, Ignacio Medina1-3

1Zetta Genomics Ltd, Cambridge, United Kingdom; 2Zetta Genomics Ltd, Valencia, Spain; 3University of Cambridge, Computational Biology Lab, Cambridge, United Kingdom.

Background/Objectives: Current large-scale clinical genomics studies consisting of thousands of whole-genome sequences require a platform with the ability to analyze billions of variants over Terabytes of data. This platform should take into account performance, scalability, flexibility, robustness, accuracy and security under a SAS model based on Big data. Here we present the latest version of OpenCB, an Open Source project that implements a full-stack solution for genomics data management, analysis and visualization for both population genomics and clinical interpretation of rare diseases and cancer.

Methods: OpenCB is based on three main projects: (1) CellBase, a MongoDB database used for querying genomic annotations, (2) OpenCGA, a variant and clinical data store based on MongoDB and HBASE with Solr indexing and (3) IVA, a web-based analysis client of OpenCGA.

Deployment is based on Docker and Kubernetes under CI/CD.

Results: OpenCB is an open-source suite of interoperable software components that enable genomic data management and analysis at an unprecedented scale. Functionality includes population-scale and clinical interpretation analysis for rare diseases and cancer under a strict data access authorization model, and data visualization modules.

Conclusion: OpenCB provides a scalable and flexible solution for biomedical researchers, clinical scientists, and geneticists. Both genomic and clinical data is stored in one single platform and allow real-time query and analysis. OpenCB is a successful clinical Open Source project that works well from small research genomics centres to big genomic and pharmaceutical companies, and national health and research systems.

Public repository: https://github.com/opencb.

Conflict of Interest: Will Spooner Zetta Genomics, Zetta Genomics, Pablo Marin Zetta Genomics, Jacobo Coll Zetta Genomics, Zetta Genomics, Pedro Furio Zetta Genomics, Philip Hamid Zetta Genomics, Junfe Sanahuja Zetta Genomics, Joaquin Tarrega Zetta Genomics, Laura Lopez Zetta Genomics, Marta Bleda Zetta Genomics, Jose Miguel Juanes Zetta Genomics, Rodiel Martinez Zetta Genomics, Ignacio Medina Zetta Genomics, University of Cambridge, Zetta Genomics.

P18.076.A Identification of a non-canonical transcription factor binding site using deep learning

Sebastian Proft1,2, Janna Leiz3,4, Robert Opitz2, Minie Jung1, Udo Heinemann5, Dominik Seelow1,2, Kai Schmidt-Ott3,4, Maria Rutkiewicz5,7

1Berlin Institute of Health, Exploratory Data Sciences, Berlin, Germany; 2Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Medical and Human Genetics, Berlin, Germany; 3Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Nephrology and Intensive Care Medicine, Berlin, Germany; 4Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Molecular and Translational Kidney Research, Berlin, Germany; 5Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Nephrology and Intensive Care Medicine, Berlin, Germany; 6Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Nephrology and Intensive Care Medicine, Berlin, Germany.
Background/Objectives: Most approaches for the detection of transcription factor binding sites are based on position-weight matrices (PWM). These require that one or more common sequence motifs be present in the DNA. Here we show that also allow the identification of motifs that were hitherto unknown.

Methods: We trained a convolutional-recurrent neural network on SELEX data for GRHL1 binding. The classifier was then applied to 7,857 sequences containing GRHL1 binding sites obtained from ChIP-Seq experiments (length > 197 bp).

Results: The neural network identified 46 potential binding sites for which the PWM-based approach did not suggest any binding at all. Using isothermal titration calorimetry (ITC), we validated binding between a non-canonical DNA sequence motif predicted by our network and the GRHL1 protein. We could confirm correlation between predicted binding scores and real binding affinity by introducing variants into the binding sites and measuring binding strength by ITC.

Conclusion: Our results show that neural networks do not only outperform PWMs but can also be used to discover unknown TF binding motifs. We will apply our approach to a wider array of transcription factors to identify novel binding sites with a special focus on known disease mutations in promoter regions.

References:

Grants:

Conflict of Interest: None declared.

P19 PERSONALIZED MEDICINE AND PHARMACOGENOMICS

P19.001.D Polygenic risk prediction, how far can it go?

Léo Henches1, Jihye Kim7, Clara Albiñana1, Florian Privé1, Bjarni Vilhjalmsdóttir7, Hugues Aschard2

1Institut Pasteur, Université de Paris, Department of Computational Biology, Paris, France; 2Harvard School of Public Health, Department of Epidemiology, Boston, France; 3National Centre for Register-Based Research, Aarhus University, Aarhus, Denmark.

Background/Objectives: Polygenic risk scores (PRS) based on thousands of genetic variants have become a central tool for genetic prediction in multifactorial diseases, and the prospect of using these PRS in clinical care has received increasing attention. The accuracy of PRS will likely continue to increase with increasing sample size of genome-wide association (GWAS) and the development of new powerful methods. However, questions remain on how much prediction can be achieved in the future and how performances depend on the many parameters involved. Here, we used real data and theoretical models to provide a global perspective on PRS performances.

Methods: We used GWASs from multiple common diseases and published since 2010 to derive PRSs using a harmonized pipeline. The PRSs were then applied to independent datasets to assess performances as a function of sample size, genetic effect size distribution, genomic coverage, and heterogeneity in disease definition and population ancestry. We then use state-of-the-art methodologies to investigate future improvement and expected maximum prediction conditional on multiple parameters.

Results: Among outcomes displaying a clear increase with sample size, some showed a convergence toward the expected maximum, while others suggest important future gain with increasing sample size. For several outcomes, diagnosis heterogeneity (age at onset, self-reported vs doctor diagnosed, etc) induces substantial variability in prediction accuracy. Future improvements appear to be highly dependent on the inclusion of denser variants data with smaller frequencies.

Conclusion: Our harmonized and thorough analyses provide a unique perspective on the potential utility of current and future PRS.

References:

Grants:

Conflict of Interest: None declared.

P19.002.A Pharmacogenetic association of diabetes associated genetic risk score with rapid progression of coronary artery calcification following treatment with HMG-CoA-reductase inhibitors — results of the Heinz Nixdorf Recall Study

Dominik Jung1, Sonali Pechlivanis1,2, Susanne Moebus2,3, Nils Lehmann2, Amir A, Mahabdi2, Per Hoffmann2,3, Raimund Erbel4, Markus M Nöthen7,8, Hagen Sjard Bachmann1

1Witten/Herdecke University, Centre for Biomedical Education and Research, Institute of Pharmacology and Toxicology, Witten, Germany; 2Heinrich-Heine-University, Düsseldorf, Germany; 3Medical Faculty of Heinrich-Heine-University, Düsseldorf, Germany; 4Institut für Herzinfarktforschung (IHF), Cologne, Germany; 5Research Center for Medical Genetics, University Hospital Muenster; 6Research Center for Medical Genetics, University Hospital Muenster; 7Research Center for Medical Genetics, University Hospital Muenster; 8German Research Center for Biomedical Sciences, Muenster, Germany.

Background/Objectives: Polygenic risk scores (PRS) based on thousands of genetic variants have become a central tool for genetic prediction in multifactorial diseases, and the prospect of using these PRS in clinical care has received increasing attention. The accuracy of PRS will likely continue to increase with increasing sample size of genome-wide association (GWAS) and the development of new powerful methods. However, questions remain on how much prediction can be achieved in the future and how performances depend on the many parameters involved. Here, we used real data and theoretical models to provide a global perspective on PRS performances.

Methods: We used GWASs from multiple common diseases and published since 2010 to derive PRSs using a harmonized pipeline. The PRSs were then applied to independent datasets to assess performances as a function of sample size, genetic effect size distribution, genomic coverage, and heterogeneity in disease definition and population ancestry. We then use state-of-the-art methodologies to investigate future improvement and expected maximum prediction conditional on multiple parameters.

Results: Among outcomes displaying a clear increase with sample size, some showed a convergence toward the expected maximum, while others suggest important future gain with increasing sample size. For several outcomes, diagnosis heterogeneity (age at onset, self-reported vs doctor diagnosed, etc) induces substantial variability in prediction accuracy. Future improvements appear to be highly dependent on the inclusion of denser variants data with smaller frequencies.

Conclusion: Our harmonized and thorough analyses provide a unique perspective on the potential utility of current and future PRS.

References:

Grants:

Conflict of Interest: None declared.
Background/Objectives: Familial hypercholesterolemia (FH) is one of the most common inherited disorders worldwide. Characterised by elevated LDL cholesterol levels since birth, FH confers an increased risk of premature cardiovascular disease (CVD). Therefore, an early diagnosis and adequate treatment is essential. Mutations in LDLR, APOB and PCSK9 are known to cause autosomal dominant FH, but variants in other genes and polygenic inheritance have also been described. The objective of this study is to personalise the management of FH to prevent CVD, by using genomic and clinical data.

Methods: 507 individuals with LDL>190 mg/dl and ≤65 years old were recruited, and genome sequencing was performed. We analysed genetic variants in 43 genes linked to FH and dyslipidemia, LDL polygenic risk scores (PRS), and pharmacogenetic markers of statins, among others.

Results: A preliminary analysis of 300 genomes revealed: 35% of cases carried pathogenic variants in LDLR, APOE or ABCG8 (monogenic cause), 24% had high LDL-PRS (polygenic cause) and 6% presented with both monogenic FH and elevated LDL-PRS. Some individuals had VUS in typical genes or pathogenic variants in novel genes, requiring further characterisation. Pharmacogenomic findings showed 27% of individuals carried variants in LpA and 32% in SLC01B1.

Conclusion: A genetic cause of severe hypercholesterolemia was detected in 65% of cases, as well as variants associated with statin treatment. These data are helping us tailor patient care. The role of non-coding and structural variants, novel FH genes and cardiovascular risk alleles will be evaluated.

References:
Grants: Navarra Government R&D project call 2019-2021 (0011-1411-2019-000049), "laCaixa" fellowship (LCF/BQ/PI21/11830009) and H2020-MSCA-COFUND-2018 (No847648).
Conflict of Interest: Maria Apellaniz-Ruiz MAR received the support of a fellowship from "la Caixa" Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska Curie grant agreement No 847648. The fellowship code is LCF/BQ/PI21/11830009.

P19.003.B Nagencol project: personalised medicine in familial hypercholesterolemia

Maria Apellaniz-Ruiz1, Monica Arasanz Armengol1, Luna Delgado de Mora2, Anne Sagardia Fernandez3, Alberto Maillo4, Maria Miranda Perez5, Irazu Gonzalez Borja5, Steven Laurie6, Oscar Teijido Hermida7, Edurne Urrutia Lafuente8, Gonzalo Etayo Nagore9, Sergio Beltran10, David Gomez Cabrero11, Juan Jose Beloqui Lizaso9, Angel Alonso Sanchez2,8, Juan Pablo Martinez de Esteban9, Ander Ernaga Lorea2.

1Navarrabiomed - IdSNA - HUN, Genomics Medicine Unit, Pamplona, Spain; 2INGEMM - Hospital Universitario La Paz, Madrid, Spain; 3Navarrabiomed - IdSNA, Translational Bioinformatics Unit, Pamplona, Spain; 4Centre for Genomic Regulation (CRG), Bioinformatics Unit, Barcelona, Spain; 5NASERTIC - Navarra De Servicios Y Tecnologias S A - Servicios Generales, Data processing center & distributed systems area, Pamplona, Spain; 6King Abdullah University of Science and Technology, Biological and Environmental Science and Engineering Division, Thuwal, Saudi Arabia; 7Hospital Universitario De Navarra (HUN), Pharmacy Department, Pamplona, Spain; 8Hospital Universitario De Navarra (HUN), Genetics Department, Pamplona, Spain; 9Hospital Universitario De Navarra (HUN), Endocrinology and Nutrition Department, Pamplona, Spain.
furosemide resistance may occur. UGT1A1 enzyme play role in furosemide metabolism therefore in this study it was aimed to investigate the effects of UGT1A1 mutations to furosemide resistance in HF patients.

Methods: Thirty healthy individuals and 50 HF patients who used furosemide during their treatment were enrolled into the study as control and patients groups, respectively. Patient group was also divided into 2 subgroups as responders (n = 25) and non-responders (n = 25) according to the presence of furosemide resistance. After DNA was isolated from peripheral blood, UGT1A1 mutations were investigated by direct sequencing. For understanding the effects of the mutations to three dimensional protein structure, homology modelling and docking studies were applied.

Results: Totally ten mutations were detected at which eight of them are novel and nine of them cause amino acid change. Three mutations were found deleterious and five mutations were detected as probably damaging of protein functions. The binding angles of furosemide with wild type and mutant types were determined. Changes of binding sites and bond structures were detected in five of the mutant types.

Conclusion: UGT1A1 mutations may cause furosemide resistance. Therefore it may possible to prevent the harmful effects of furosemide resistance by using personalized diagnosis and treatment strategies.

References: -

Grants: -

Conflict of Interest: None declared.

P19.005.D Polygenic risk score comparator (PRScomp): tested population vs. worldwide populations

Joan Fibla1, Leandre Palau2, Jose Nunes3, Oscar Lao4, Ricard López2, Marina Laplana6

1Universitat de Lleida - IRBLleida, Complex Genetic Diseases, Lleida, Spain; 2Grup Globalia, Lleida, Spain; 3Grup Globalia, Lleida, Spain; 4Institut de Biologia Evolutiva -UPF-CSIC, Population Genetics, Barcelona, Spain; 5Hospital Universitari Arnau de Vilanova, Unidad de Citogenética i Genética Médica, Lleida, Spain; 6Universitat de Lleida, Ciència Animal, Lleida, Spain.

Background/Objectives: We developed a Polygenic risk score comparator (PRScomp), which allows users to evaluate polygenic risk score of a tested population and compare it with worldwide populations.

Methods: A disease/trait database is constructed from GWAS catalog(1) summary statistics data of genetic risk of disease and traits. Genotype data of the tested population is uploaded to the platform and merged with genotype data of reference data set, in order to obtain a merged file including common disease associated SNPs of both datasets. Reference data set comprise geno- genic and epidemiologic data of 3269 individuals from 1000 Genome Project (1Kg)(2) and Human Genome Diversity Project (HGDP)(3), belonging to 8 worldwide superpopulations and 75 subpopulations.

User can select a desired disease/trait from database, to be assessed on tested population. A curated set of risk markers is associated SNPs of both datasets. Reference data set comprise geno- genic and epidemiologic data of 3269 individuals from 1000 Genome Project (1Kg)(2) and Human Genome Diversity Project (HGDP)(3), belonging to 8 worldwide superpopulations and 75 subpopulations.

User can select a desired disease/trait from database, to be assessed on tested population. A curated set of risk markers is obtained and used to calculate summatory polygenic risk score (PRS) by plink software(4). Values obtained are normalized along worldwide map (mean values) and barplot (percentile distribution).

Conclusion: PRScomp offers the opportunity to evaluate population associated risk to disease and traits that could be of great interest in planning and monitoring public health strategies.

References: (1) Buniello A, et al. Nucleic Acids Res. 2019 J8;47 (D1):D1005-D1012. (2) 1000 Genomes Project Consortium, Nature. 2015 Oct 1;526(7571):68-74. (3) Bergström A, et al. Science. 2020 Mar 20;367. (4) Purcell S, et al. Am J Hum Genet. 2007 Sep;81(3):559-75.

Grants: -

Conflict of Interest: None declared.

P19.006.A Predictive polygenic score for outcome from first-line oxaliplatin-based chemotherapy in colorectal cancer patients using supervised principal component analysis

Hanna Park1,2, Dominic Edelmann3, Federico Canzian4, Tabitha Harrison5, Xinwei Hua6, Qian Shi6, Allison Silverman7, Martin Schneider8, Richard Goldberg9, Steven Alberts10, Michael Hoffmeister11, Hermann Brenner12,13, Andrew Chan14,15, Ulrike Peters16,19, Polly Newcomb17,18, Jenny Chang-Claude1;20

1German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany; 2University of Heidelberg, Medical Faculty, Heidelberg, Germany; 3German Cancer Research Center (DKFZ), Division of Biostatistics, Heidelberg, Germany; 4German Cancer Research Center (DKFZ), Genomic Epidemiology Group, Heidelberg, Germany; 5Fred Hutchinson Cancer Research Center, Public Health Sciences Division, Seattle, United States; 6Massachusetts General Hospital and Harvard Medical School, Department of Gastroenterology, Boston, United States; 7Massachusetts General Hospital, Clinical and Translational Epidemiology Unit, Boston, United States; 8Mayo Clinic, Department of Quantitative Science, Rochester, United States; 9Fred Hutchinson Cancer Research, Epidemiology Program, Seattle, United States; 10University of Heidelberg, Department of General, Visceral and Transplantation Surgery, Heidelberg, Germany; 11West Virginia University Cancer Institute, Morgantown, United States; 12Mayo Clinic, Medical Oncology, Rochester, United States; 13German Cancer Research Center (DKFZ), Division of Clinical Epidemiology and Aging Research, Heidelberg, United States; 14National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Division of Preventive Oncology, Heidelberg, Germany; 15German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany; 16Brigham and Women's Hospital, Channing Division of Network Medicine, Department of Medicine, Boston, United States; 17Harvard T.H. Chan School of Public Health, Department of Epidemiology, Boston, United States; 18Massachusetts General Hospital, Department of Medicine, Boston, United States; 19University of Washington, School of Public Health, Seattle, United States; 20University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Cancer Epidemiology Group, Hamburg, United States.

Background/Objectives: Associations between candidate germline genetic variants and treatment outcome of oxaliplatin, a drug commonly used for colorectal cancer patients, have been reported but not robustly established. This study aimed to construct a polygenic hazard score (PHS) as a predictive marker for oxaliplatin treatment outcome by using a supervised principal component approach.

Methods: Genome-wide association analysis of interaction terms (SNP*type of treatment) was conducted using two phase III trials, 3,098 resected stage III colon cancer patients of NCCTG N0147, and 506 metastatic colorectal cancer (mCRC) patients of NCCTG N9741, separately. SNPs showing interaction with genome-wide significance (P < 5 × 10-8) were selected for principal component analyses to derive a PHS. We performed replication in an independent, population-based cohort, DACHS.
Results: The PHSs based on the first two principal components of significant NPs (15 SNPs in resected stage III colon cancer and 13 SNPs in mCRC) in the discovery cohorts showed significant interaction with treatment type in models adjusted for clinical covariables. However, clinical models including PHS interaction terms were not replicated in DACHS. The prediction error of the 3-year survival remained unchanged when comparing clinical models to clinical models including interaction terms as 0.04 in resected stage III colon patients and 0.18 in mCRC patients.

Conclusion: Integration of the PHS with clinical factors did not provide a statistically significant improvement in the prediction of patient benefit from the oxaliplatin-containing regime. Our negative results highlight the challenges in providing evidence for a potential polygenic score for oxaliplatin efficacy.

References:

Grants:

Conflict of Interest: Hanla Park: None declared, Dominic Edelman: None declared, Federico Canzian: None declared, Tabitha Harrison: None declared, Xinwei Hua: None declared, Qian Shi Celine: None declared, Roche/Genentech, Janssen, Novartis., Shanghai Pharmaceutical Co., Ltd, Johnson & Johnson, Argen, and Merck & CO., Yviva Inc, Boehringer Ingelheim Pharmaceuticals, Inc, Regeneron Pharmaceuticals, Inc., Hoosier Cancer Research Network., Allison Silverman: None declared, Martin Schneider: None declared, Richard Goldberg: None declared, Steven Alberts: None declared, Michael Hoffmeister: None declared, Hermann Brenner: None declared, Andrew Chan: None declared, Ulrike Peters: None declared, Polly Newcomb: None declared, Jenny Chang-Claude: None declared.

P19.007.B Whole genome germline genetic testing: a pilot of its role as an additional tool to general health screening in General Practice, the first in the UK

Ann-Britt Jones1,2, Michael Sandberg3, Gabriella Pichert4, Lucy Side5, Tessa Hombrey6, Sophie Hicks7, Matthew Dixon5, Vincenzo Circigliano4, Bibiana Palao8, Luis Izquierdo9, Elizabeth Bancroft10, rosalin elies12,4,

1Institute of Cancer Research, Oncogenetics, London, United Kingdom; 2Royal Marsden Hospital, Oncogenetics, London, United Kingdom; 390 Sloane Street General Practice, London, United Kingdom; 490 Sloane Street General Practice, London, United Kingdom; 5Veritas Interscience, Madrid, Spain

Background/Objectives: Whole genome sequencing (WGS) is now possible due to improvements in next generation sequencing technology. This allows opportunity to incorporate genetic data into primary care health screening. This study aimed to set up a model pathway to undertake WGS for actionable findings and assess its role in enhancing health screening.

Methods: We have undertaken WGS in 100 individuals as part of a medical screen. To date, 20 have been analysed. Individuals were recruited from a private general practice. We reviewed past medical and family history from electronic health records (EHR). Germline genetic testing consisted of 84 cancer and 77 cardiac genes and WGS, including higher penetration monogenic mutations, recessive carrier alterations and pharmacogenomics. A multidisciplinary clinical team reviewed integrated results through an iterative process.

Results: Twenty-five percent (5 out of 20) individuals had an actionable genetic variant in either cancer or thromboembolic genes. No cardiovascular risk associated variants were found. Eighty percent of the participants had an autosomal recessive carrier variant. Pharmacogenomics results yielded significant variants in seven individuals (DPYD; CYP2C19). Forty percent of patients had a significant change in management.

Conclusion: WGS in this pilot study altered risk-reducing measures in 25% of individuals and altered the screening programme in 40% of individuals. We identified clinically significant actionable variants in unaffected participants and showed integrating genetic screening into primary care is clinically valuable.

References:

Grants: The Oppenheimer Foundation; anonymous donors to Prof Eeles’ Research Fund, 90 Sloane Street Ltd, The Biomedical Research Centres at The Institute of Cancer Research and Royal Marsden NHS Foundation Trust.

Conflict of Interest: None declared.

P19.008.C Selection of biomarkers for determining the degree of aggression of bladder tumors - strategy and a flexible workflow

Olga Antonova1, Zora Hammoudeh2, Boris Mladenov3, Zornitsa Yordanova4

1Medical University of Sofia, Department of Medical Genetics, Sofia, Bulgaria; 2Medical University of Sofia, Sofia, Bulgaria; 3UMBASL "N. I. Pirogov", Department of Urology, Sofia, Bulgaria; 4University of National and World Economy, Sofia, Bulgaria.

Background/Objectives: Bladder cancer is a heterogeneous group with several subgroups with different clinicopathological features. Low-grade non-infiltrating progressive and non-progressing cancers, High-grade muscle-invasive cancer with relatively good prognosis and those with poor prognosis. This required improving the current knowledge that underlies this variation in tumour behavior. The aim of our study was to select potential bladder cancer biomarkers and to test the methodology for biomarkers development.

Methods: A total of 87 bladder cancer samples staged pTa to pt4 and 4 negative controls were collected. Pool gene expression analysis of 168 genes involved in pathways for Cancer drug resistance and metabolism (PAHS-004) as well as for Cancer drug targets (PAHS-507). Qiagene was performed on 40 samples staged pTa, pT1 and pT2. Conformational analyses were performed on 12 individual samples (4 per stage). The subsequent analyzes selected genes for tumor invasion. Further validation on the selected genes was performed in a cohort of additional 40 bladder cancer samples from all tumor stages pTa to pt4.

Results: The four genes: AP1S1, FIGF, HDAC11 and CDK9 were selected for gene-expression analysis based on differences in the expression levels between invasive and non-invasive bladder carcinoma. The results revealed 4-12 fold change difference in the expression level between pT2 and pTa/pT1 non-invasive tumors for FIGF, HDAC11 and CDK9 genes. AP1S1 failed to show significant difference in expression levels between tumor stages.

Conclusion: FIGF, CDK9 and HDAC11 can be considered as potential biomarkers for the characterization of invasive tumor phenotype.

References: No.

Grants: BG NSF No KP-06-OPR01/3-2018.

Conflict of Interest: Olga Antonova BG NSF No KP-06-OPR01/3-2018, Zora Hammoudeh BG NSF No KP-06-OPR01/3-2018, Boris Mladenov BG NSF No KP-06-OPR01/3-2018, Zornitsa Yordanova BG NSF No KP-06-OPR01/3-2018.

P19.009.D Utilising drug switches as a proxy for angiotensin-converting enzyme inhibitor-induced cough discovers novel genetic signals

Kayesha Coley1, David Shepherd1, Catherine John1, Richard Packer1, Robert Free1,2, Edward Hollox3, Louise Wain1,2, Martin D Tobin1,2, Chiara Batini1
Background/Objectives: Switching drugs from one class to another is often indicated in response to adverse reactions. Approximately 15% of patients taking angiotensin-converting enzyme inhibitors (ACEIs) experience persistent dry cough, resulting in switches from ACEIs to angiotensin-II receptor blockers (ARBs). Drawing on previously validated electronic health record-based phenotypes, we used such drug switches as a proxy to study genetic determinants of ACEI-induced cough.

Methods: Using EXCEED Study and UK Biobank primary care data, cases switched from ACEIs to ARBs within 12 months of initiating ACEIs, and controls were continuous users of ACEIs. In a two-stage meta-analysis, stage 1 included all cohort and ancestry-specific genome-wide association analyses. Variants reaching suggestive significance (p-value <5 x 10^{-6}) were meta-analysed with publicly-available summary statistics of ACEI-induced cough in stage 2.

Results: A total of 39,871 individuals (5,435 cases; 34,436 controls) from 4 ancestral groups (African, Asian, Chinese and European) were included in the stage 1 meta-analysis of ~17M variants. In stage 2, we identified nine genome-wide significant (p-value <5 x 10^{-8}) risk loci for which positional and gene expression analyses implicated 35 protein-coding genes, one of which (KCNA2) has been previously associated with ACEI-induced cough. Novel genes included KCN2A2, supporting the importance of potassium ion channels in cough reflex modulation, and NTSR1, highlighting the role of neuropeptides in neurogenic inflammation and cough hypersensitivity.

Conclusion: In this multi-ancestry meta-analysis we have identified associated genes for which functional follow-up has given insight to the currently unclear mechanism of ACEI-induced cough, and will help identify candidates for predictive pharmacogenetic biomarkers.

References:

Grants:

Conflicts of Interest: Kaye Coley: None declared, David Shepherd: None declared, Catherine John: None declared, Richard Packer: None declared, Robert Free: None declared, Edward Hollox: None declared, Louise Wain Research grants from GlaxoSmithKline (as principal investigator) and Orion Pharma (as co-principal investigator), Consultancy/advisory board for Galapagos, Martin D Tobin: None declared, Sebastian Lunke: None declared, Zornitza Stark: None declared.

Conflict of Interest: None declared.

P19.011.B Homozygous CYP2C9*14 allele resulting in profound warfarin sensitivity

Mark Cleghorn1, Lesley McGregor2, Anna Le Fevre1, Rowenne Smith1, Gemma Crigthon1, Jacob Mathew1, Mohamad Kaddour1, Sebastian Lunke1,2,3, Zornitza Stark1,2,3

1Victorian Clinical Genetics Services, Parkville, Australia; 2Women’s and Children’s Hospital, Paediatric and Reproductive Genetics Unit, North Adelaide, Australia; 3The Royal Children’s Hospital Melbourne, Parkville, Australia; 4Australian Genomics, Parkville, Australia; 5University of Melbourne, Parkville, Australia.

Background/Objectives: Rapid genomic testing facilitates early genetic diagnosis, while the data generated also provides opportunity for additional analyses in future, as clinical features evolve. We describe a neonate who initially presented with cleft lip/palate and congenital heart disease and underwent exome sequencing (ES) in 2018 without a diagnosis being made. Re-analysis of the ES data was performed after the clinical presentation evolved to severe dilated cardiomyopathy. Clinical management was complicated by profound sensitivity to warfarin and significant bleeding.

Methods: Clinical rapid trio ES was performed in 2018 on DNA extracted from peripheral blood using Agilent Sureselect QT CREv1 kit, following by sequencing on Illumina NextSeq500. Re-analysis using updated clinical information and updated phenotype-driven virtual gene panels was performed in 2021.

Results: A homozygous pathogenic variant in PPP1R13L (c.1068dupC; p.(Ser357Leufs*49)) was identified as causing the primary clinical features (dilated cardiomyopathy and cleft lip/palate), this gene-disease association having been described in 2020 in five unrelated families. In addition, homozygosity for the well-established CYP2C9*14 (p.Arg125His) warfarin sensitivity allele was identified, explaining the extreme warfarin hypersensitivity. Alternate anticoagulation with intravenous bivalirudin and low molecular weight heparin successfully preventing thromboembolic complications.

We hypothesize that the unbiased selection of these individuals in an experienced medical check-up unit would add value to standard check-up findings.

Methods: 361 patients attended to the Medical Check Up Unit of the Clínica Universidad de Navarra and underwent a “genomic check-up” consisting in a complete medical interview, biochemistry, low-intensity whole body scan and selected genome analysis, curated with a proprietary platform (myGenome, Veritas Intercontinental).

Results: Seventy-one clinically relevant genetic variants were identified in 64 of 361 patients (17.7%), including 7 patients with 2 variants. The detected variants were related to hemochromatosis (8.3%), hereditary cancer predisposition (6.9%), hereditary cardiovascular disease (2.2%), and other diseases (2.2%). Clinical phenotype-genotype associations were made based on the available clinical data. In addition, 66.2% patients were carriers of one or more recessive conditions, 88.6% presented risk alleles for multifactorial diseases and relevant pharmacogenomics associations were detected in all patients.

Conclusion: The inclusion of elective genomic sequencing in a structured medical consultation optimizes the identification of primary and secondary genetic findings and enables a better correlation of the genetic findings with the real clinical scenario of patients and their follow up.

References: Senol-Cosar O, et al. Genet Med 21:2765-2773 (2019); Hou YC, et al. Proc. Natl Acad. Sci. 117(6):3053-3062 (2020).

Grants: None significant to the purpose of this research.

Conflict of Interest: None declared.
Conclusion: Heterozygosity for the CYP2C9*14 allele has been described in individuals with increased sensitivity to the anticoagulant effects of warfarin. This is the first case report of an individual homozygous for the CYP2C9*14 allele with profound warfarin sensitivity. In addition to expanding the phenotypic spectrum associated with the CYP2C9*14 allele, this case report highlights the value of genomic data as a healthcare resource.

References:
Grants: Australian Government GHFM76747.
Conflict of Interest: None declared.

P19.012.C Genetic and environmental determinants of drug adherence

Mattia Cordioli¹, Andrea Corbetta¹, Sakari Jukarainen¹, Tuomo Kiiskinen¹, Samuli Ripatti²,⁵, Andrea Ganna¹,²,⁵

¹Institute for Molecular Medicine Finland, Helsinki, Finland; ²Broad Institute of MIT and Harvard, Cambridge, United States; ³Department of Public Health, University of Helsinki, Helsinki, Finland; ⁴Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, United States; ⁵Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, United States.

Background/Objectives: One of the major factors behind the efficacy of pharmacological treatments is patients adherence to the prescribed therapy regimen. While demographic and socioeconomic factors play a role in determining adherence, there have been few investigations on the potential effects of genetic variation on drug adherence. By using genetic data from the FinnGen study (N = 356,077), data from Finnish nation-wide health registries and the drug purchase registry (68,826,654 total purchases), we provide a systematic investigation of adherence determinants across multiple medications.

Methods: We looked at adherence (ratio between the total purchased quantity and total days of purchasing) and early discontinuation (stopping after one purchase) for six different class of medications: statins, blood pressure (BP) medications, breast cancer medications, antiplatelets, anticoagulants and glaucoma medications.

For each, we run a GWAS of adherence and early stopping vs good adherence. We estimated genetic correlation \( r_g \) between these and 29 publicly available traits.

Results: Adherence to BP medications or statins positively associated with psychological or behavioural traits such as educational attainment, participation to follow-up questionnaires, subjective well-being and with predisposition to type2 diabetes, higher BMI, higher systolic BP. Negative associations were observed between adherence and risk tolerance, loneliness and schizophrenia. Similar association patterns were observed for early discontinuation of BP medications.

Conclusion: Overall, results suggest adherence is related to behavioural aspects and perception of underlying risk factors or disease severity rather than to biologic determinants, allowing for a better identification of patients at high risk of non-adherence in drug taking.

References:
Grants: None declared.
Conflict of Interest: None declared.

P19.013.D Polygenic scores for cardiovascular disease - how could they be implemented?

Tanya Bridge¹, Saskia Sanderson², Joanna Janus¹, Chantal Babb de Villiers¹, Sawmya Moorthe¹, Mark Kroese¹, Alison Hall²

¹PHG Foundation, University of Cambridge, Cambridge, United Kingdom; ²Our Future Health, Manchester, United Kingdom.

Background/Objectives: With the increased interest in the possible use of polygenic score analysis for clinical care, we explored the implications arising from the possible implementation and delivery of polygenic score analysis for cardiovascular disease in practice, specifically in the context of the NHS Health Check programme. Underpinning our analysis is the assumption that a robust polygenic score model has been developed, suitable for implementation.

Methods: We adopted a mixed methods research approach, including a literature review of peer-reviewed publications and grey literature and semi-structured interviews with domain specific experts.

Results: Our analysis suggests that polygenic score analysis could be incorporated into NHS Health Checks with only modest changes relating to the interface between healthcare professionals and patients. However, such implementation will be contingent on a robust testing infrastructure being in place.

Looking forward, incorporating polygenic scores may generate opportunities for developing personalised risk assessments targeted at individuals or sub-groups.

Conclusion: More evidence is needed on the impact of polygenic score analysis on healthcare provider behaviour, particularly the impact of a high polygenic score on the likelihood of a health professional offering a prescription or recommending lifestyle change. If health systems choose to adopt personalised risk assessment incorporating polygenic score analysis, a key priority will be to address any inequalities and inequities that might arise.

References: T Bridge, S Sanderson, J Janus, C Babb de Villiers, S Moorthe, M Kroese, A Hall, Implementing polygenic scores for cardiovascular disease into NHS Health Checks, PHGF 2021.

Grants: None declared.

Conflict of Interest: None declared.

P19.014.A High throughput genetic characterization of Italian patients affected by multi-drug resistant rheumatoid and psoriatic arthritis

Paola Tesolin¹, Francesca Bertinetti²,³, Arianna Sonaglia⁴, Maria Pina Concas¹, Anna Morgan⁵, Giuseppe Giovanni Nardone⁶, Alen Zabotti⁴, Paolo Gasparini¹,⁵, Antonio Amoroso²,³, Luca Quattrocchio⁴, Giorgia Girotto¹,³

¹University of Trieste, Department of Medicine, Surgery and Health Sciences, Trieste, Italy; ²University of Turin, Department of Medical Sciences, Turin, Italy; ³Immunogenetics Service AOU “Città della Salute e della Scienza di Torino”, Turin, Italy; ⁴University of Udine, Clinic of Rheumatology, Department of Medicine (DAME), ASUFC, Udine, Italy; ⁵Institute for Maternal and Child Health – IRCCS, Burlo Garofolo, Trieste, Italy.

Background/Objectives: Rheumatoid and Psoriatic arthritis (RA and PsA) are multifactorial autoimmune diseases for which very few susceptibility genes have been described so far. We genetically characterised a highly selected cohort of non-responder patients.

Methods: The accurate clinical examination of eleven patients affected by refractory RA/PsA was followed by several high-throughput genetic testing:

1. Targeted resequencing focused on HLA genes.
2. WES to detect rare and pathogenic variants. T-test was employed to compare variants burden of RA/PsA group with a WGS control cohort.
3. SNP-arrays to identify CNV.

Results: As regards 1) the 11 patients carry at least one HLA allele that might predispose to those diseases (i.e. HLA-DRB1*04; DRB1*1001 and DRB1*01). Two subjects also carry...
a particular ancestral haplotype (i.e. HLA-A*033:01 B*14:02 C*08:02 DRB*1:01:02 DQB*1:05:01). For analysis 2), 27 rare variants (MAF<0.01) within 22 candidate RA/Psa genes have been detected and checked in the WGS control cohort. For example, two patients carry different pathogenic variants (i.e. heterozygous missense and homozygous truncating) within UGT2B17, a gene involved in hormones and drug metabolisms. Other two carry pathogenic heterozygous missense variants within SERPING1 and VPS13D, having a role in complement-cascade and IL6-signaling, respectively. Further, we identified four heterozygous missense variants within HACE1, IRF2BP2 and DVL1, which might modulate TNFα signalling. In analysis 3) we identified CNVs within genes involved in crucial mechanisms of RA/Psa (e.g. MSR1).

Conclusion: This multistep approach allowed the discovery of novel RA/Psa candidate genes and the definition of genotype-phenotype correlations. Thus, we highlighted new molecular targets to help clinicians define the best therapeutic approach.

References:

Grants:

Conflict of Interest: None declared.

P19.015.B Transferrability of genetic loci and polygenic scores for cardiometabolic traits in British Pakistanis and Bangladeshis from a real-world healthcare cohort

Qiing Huang1, Neeneh Sallah2, Diana Dunca2, Bhavi Trivedi3, Karen Hunt1, Sam Hodgson2, Samuel Lambert3, Elena Arciero4, John Wright4, Chris Griffiths4, Richard Trembath5, Harry Hemingway6, Michael Inouye5, Sarah Finer3, David van Heel3, Hilary Martin6, Karoline Kuchenbäcker2

1Wellcome Sanger Institute, Cambridge, United Kingdom; 2University College London, London, United Kingdom; 3Queen Mary University of London, London, United Kingdom; 4University of Southampton, Southampton, United Kingdom; 5University of Cambridge, Cambridge, United Kingdom; 6Bradford Institute for Health Research, Bradford, United Kingdom; 7King’s College London, London, United Kingdom.

Background/Objectives: Individuals with South Asian ancestry have a higher risk of heart disease than other groups in Western countries. However, most genetic research has focused on European-ancestry individuals and it is largely unknown whether the findings are applicable to other groups.

Methods: Using data from 22,000 British Pakistanis and Bangladeshis with linked electronic health records from the Genes & Health cohort (G&H), we conducted genome-wide association studies (GWAS) of coronary artery disease (CAD) and its key risk factors, body mass index (BMI), lipid biomarkers and blood pressure. We estimated power-adjusted transferrability (PAT) ratios, a new technique to assess the extent to which loci are transferable. We tested how well polygenic scores (PGS) developed in European ancestry studies performed in G&H.

Results: We observed high transferrability for cardiometabolic loci from European GWAS that were sufficiently powered to replicate in G&H: the PAT ratios were all ≥1 for the risk factor traits, but only 0.62 for CAD (binomial p = 0.05). The relative accuracy of PGS compared to European ancestry was ≥0.95 for HDL-C, triglycerides, and blood pressure, but lower for BMI (0.78) and CAD (0.42). We observed additional predictive power of PGS beyond clinical risk factors (QRISK3) for CAD, with a significant net reclassification index (NRI) = 3.9% (95% CI 0.9 – 7.0).

Conclusion: Transferrability of GWAS loci and PGS was high for lipid and blood pressure traits but lower for BMI and CAD. Our analyses indicate clinical validity for adding PGS to existing clinical risk prediction tools in primary prevention settings for this population.

References:

Grants:

Conflict of Interest: None declared.
from Letrozole, an aromatase inhibitor, which restores normal testosterone levels, reducing inflammation and which rescues male golden hamsters from severe COVID-19.

Conclusion: By adding these commonly used drugs to standard of care of selected patients, the rate of intubation is expected to decrease consistently, especially in patients with high penetrance rare genetic markers, mitigating the effect of the pandemic with a significant impact on the healthcare system.

References: Fallerini C et al. Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity. Hum Genet. 141(1):147-173 (2022).

Grants: FISR 2020 / Tuscany Region COVID-19 / INTERVENE - GA No. 101016775 / Soka Gakkai PAT-COVID.

Conflict of Interest: None declared.

P19.017.D Input of PRS313 for breast cancer risk stratification in patients with atypical breast lesion

Manon Réda1,2, Aurélie Bertaut3, Juliette Sauge4, Laura Guyard4, Sandy Chevrier5, Romain Boidot6, Emilie Courcet7, Laurent Arnauld1, Juliette Albuisson1,7

1Centre G.F. Leclerc, Oncologie médicale, Dijon, France; 2Centre G.F. Leclerc, Plateforme de Transfert en Biologie Cancérogénique, Dijon, France; 3Centre G.F. Leclerc, Unité de Méthodologie et de biostatistiques, Dijon, France; 4Centre G.F. Leclerc, Département de Biologie et de Pathologie des tumeurs, Dijon, France; 5Centre G.F. Leclerc, Unité de Biologie moléculaire, Dijon, France; 6Cypath Dijon, Dijon, France; 7Centre G.F. Leclerc, Laboratoire de biologie moléculaire, Dijon, France.

Background/Objectives: The genetic architecture of breast cancer (BC) susceptibility implies Mendelian inheritance related to "high-risk" genes like BRCA1/2, and polygenic inheritance estimated through GWAS. Polygenic risk scores (PRS) derived from GWAS help assessing such polygenic inheritance. PRS contribution to BC risk estimation was demonstrated in several Caucasian female populations, including women with high/moderate risk due to BRCA and CHEK2 mutations1-3. Atypical breast Lesions (AL) confer high risk of BC to carriers, but no routine prognostic markers are defined.

In this single-center study, we retrospectively evaluated the performances of PRS313 to refine BC risk within a cohort of patients with AL.

Methods: PRS313 was determined in non-tumor breast samples in 150 cases and 150 controls, defined respectively by history of AL and BC within 5 years, and history of AL without BC. Fluidigm® Micro-fluidic genotyping was performed. We assessed (1) the reproducibility of genotyping on FFPE compared to frozen tissues (2) the performances of PRS to detect high-risk women within this population, through sensitivity, specificity and area under the curve (AUC), and (3) evaluated odds-ratios between first and last decile of patients.

Results: Performance's parameters are currently under evaluation; results in our population will be discussed compared to patients with BC risk factors from literature.

Conclusion: PRS313 is a promising tool to better refine BC risk in specific female populations with moderate to high risk and may help clinical decisions.

References: 1- Mavaddat &al, Am J Hum Genet 2019. 2- Lakeman &al, Genet Med 2021. 3- Muranen &al, Genet Med 2017.

Grants: AOR-BFC-Plateforme-2020. AOI-Biocollection-2020.

Conflict of Interest: None declared.

P19.020.C Automated identification of a cancer patient treatment: from sequencing to treatment prioritisation

Nicolas Soirat1,2, Denis Bertrand3, Sacha Beaumennier1, Nicolas Philippe3, Dominique Vaur4, Sophie krieger2, Anne-Laure Bougé1, Laurent Castéra4

1SeqOne, Montpellier, France; 2Caen-Normandy University, Caen, France; 3Centre Francois Baclesse, Inserm U1245, Caen, France.

Background/Objectives: The emergence of sequencing allowed the scientific community to gather a tremendous amount of cancer genomic data, characterising biomarkers responsible for tumorigenesis that might indicate potential treatments. The use of short-read sequencing to identify cancer patient treatment is becoming a more common practice in hospitals. To standardise the treatment identification some prediction frameworks have been developed, but they mostly focus on a single alteration type and very few have been implemented.

Methods: We design a targeted DNA and RNA panel covering 639 cancer genes and 57 fusion genes to obtain a comprehensive patient genomic landscape. We developed a decisional algorithm which prioritises all known variant-therapy associations. Several rules give a score for each association based on more than 20 variant features indicating the variant impact in cancer, the patient indication and similarity of patient variant with variant in therapeutic databases.

Abstracts from the 55th European Society of Human Genetics Conference

European Journal of Human Genetics (2023) 31:345 – 709

SPRINGER NATURE

1Institute for Molecular Medicine Finland, FIMM, HILIFE, University of Helsinki, Helsinki, Finland; 2Clinicum, Department of Public Health, University of Helsinki, Helsinki, Finland; 3Department of Mathematics and Statistics, University of Helsinki, Helsinki, Finland; 4FinnGen Project, Helsinki, Finland; 5Broad Institute of MIT and Harvard, Cambridge, MA, United States.
Results: We generated a thousand simulated tumours, each containing passenger mutations and a targetable mutation from the Civic database. Our method correctly classifies the targetable mutation in its top predictions (average rank 2.19). Furthermore, on a cohort of 12 patients, we obtain similar results as 2 clinical routine approaches using our fully automated protocol. Currently, we are expanding our validation to a pan-cancer cohort of 500 patients.

Conclusion: We design a complete framework for multiple variant drug association identification in order to make easier therapeutic choices for a clinician. We succeed to integrate it into our variant calling workflow and show good performance of our method to prioritise targetable variants.

References:
Grants: None.
Conflict of Interest: None declared.

P19.021.D Quantifying the causal impact of modifiable risk factors and biomarkers on total healthcare burden via Mendelian randomization

Jiwoo Lee1, Sakari Jukarainen2, Pradeep Natarajan1, Andrea Ganna2

1Broad Institute of MIT and Harvard, Cambridge, United States; 2Institute for Molecular Medicine Finland, Helsinki, Finland.

Background/Objectives: Public health aims to reduce the burden of modifiable risk factors to improve population health and decrease healthcare burden. Previous studies have attempted to quantify the total healthcare burden (e.g. total healthcare expenditure) associated with certain modifiable risk factors such as body mass index (BMI), systolic blood pressure (SBP), or cholesterol. However, such studies are based on observational data or single disease clinical trials. Thus, they are likely to suffer from confounding or ignoring the impact of modifiable risk factors on broader healthcare burden, which is mediated by multiple diseases.

Methods: Here, we address these limitations by using genetic instruments to assess the causal impact of modifiable risk factors on healthcare burden and expenditure. We leveraged primary care, hospital visit, and medication costs for 236,101 FinnGen participants able risk factors on total healthcare burden, which is mediated by multiple diseases.

Results: We found that a SD increase in SBP, body mass index (BMI), and low-density lipoprotein cholesterol (LDL-C) was causally associated with an increase in observed healthcare costs of 27.6% [11.7%–30.6%], 5.2% [2.2%–8.2%], respectively, while high-density lipoprotein cholesterol (HDL-C) was associated with a decrease in observed healthcare costs by 5.2% [1.8%–8.5%].

Conclusion: Taken together, we quantified the causal impact of modifiable risk factors and biomarkers on total healthcare burden.

References: None.
Grants: None.
Conflict of Interest: None declared.

P19.022.A Genome-wide association studies of advanced cancer patients loci associated with opioid-induced nausea-vomiting

Francesca Minnai, Morena Shkodra, Sara Noci, Cinzia Brunelli, Alessandra Pignì, Frank Skorpen, Pål Klepstad, Stein Kaasa, Oscar Corfi, Maria Caterina Pallotti, Marco Cesare Maltoni, Augusto Caraceni, Francesca Colombi

1Institute for Biomedical Technologies, National Research Council, Segrate, Italy; 2Fondazione IRCCS Istituto Nazionale Tumori, Palliative care, Pain therapy and Rehabilitation Unit, Milan, Italy; 3University of Oslo, Oslo, Norway; 4Fondazione IRCCS Istituto Nazionale Tumori, Genetic Epidemiology and Pharmacogenomics Unit, Milan, Italy; 5Norwegian University of Science and Technology, European Palliative Care Research Center, Trondheim, Norway; 6Norwegian University of Science and Technology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Trondheim, Norway; 7Oslo University Hospital, Department of Oncology, Oslo, Norway; 8IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; 9IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” - IRST, Meldola (FC), Italy; 10Università degli Studi di Milano, Department of Clinical Sciences and Community Health, Milan, Italy.

Background/Objectives: Advanced cancer patients usually receive opioids to treat cancer pain; unfortunately, 10-20% do not benefit from treatment and even higher percentages experience side effects such as nausea and vomiting. Previous studies suggested a possible role of genetics in determining individual variability in the response to opioids. The aim of this genome-wide association study is to identify new genetic markers of opioid toxicity.

Methods: The study included 1,038 European cancer patients receiving morphine, oxycodone, buprenorphine or fentanyl. The patients were included in one cross-sectional and two longitudinal studies. Nausea and vomiting was measured by the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQ-C30). A composite nausea-vomiting score (NVS), ranging from 0 to 100, was calculated. Patients were genotyped using Axiom PMRA arrays. Genome-wide linear regressions between NVS and the genotypes of 432,087 variants were performed using PLINK software.

Results: NVS significantly associated (P < 5.0x10-8) with the genotype of 12 variants (six, five, and one on chromosome 2, 6 and 15, respectively). The top-significant variants at each locus were rs6723108 (beta = 7.26, P = 7.47x10-11), rs2596503 (beta = 10.0, P = 2.96 x10-11), and rs1129138 (beta = -5.81, P = 1.65 x10-8), respectively. The gene nearest to rs6723108 is TMEM163, encoding a transmembrane protein transporting zinc ions, whereas variants on chromosomes 6 mapped in the HLA locus.

Conclusion: These results indicate that opioid induced nausea and vomiting are regulated by germline variants. However, further studies are needed to validate these results and to identify the molecular mechanisms underlying the observed associations.

References: [None]
Grants: AIRC MFAG 2019 - ID. 22950 project.
Conflict of Interest: None declared.

P19.024.C Typing CYP2D6 star alleles from fully phased variants using PacBio HiFi reads

John Harting1, Zev Kronenberg2, Nina Gonzaludo1, Jenny Ekholm4, Geoff Henno5, Edd Lee6

1Pacific Biosciences (PacBio), Computational Research, Menlo Park, United States; 2Pacific Biosciences (PacBio), Bioinformatic Engineering, Menlo Park, United States; 3Pacific Biosciences (PacBio), Market Development, Menlo Park, United States; 4Pacific Biosciences (PacBio), Segment Marketing, Menlo Park, United States; 5Pacific Biosciences (PacBio), Precision Health Segment Marketing, Menlo Park, United States; 6Pacific Biosciences (PacBio), Human Genomics Segment Marketing, Menlo Park, United States.

Background/Objectives: The CYP2D6 locus is well known for its importance to pharmacogenetics as well as for its high diversity and complex genomic setting. Resolving individual alleles at this locus using short-read sequencing technologies requires inference-based methods due to ambiguous mapping in the presence of highly homologous pseudogenes. In contrast, long-range sequencing with...
Abstracts from the 55th European Society of Human Genetics Conference

PacBio HiFi reads directly resolves and phases a wide range of complicated and difficult genetic loci without inference. We present a novel bioinformatics workflow using PacBio HiFi reads which enables rapid and precise diplotyping and star(*)-allele classification of CYP2D6.

**Methods:** In this work we designed a set of primers to amplify full CYP2D6 genes and flanking sequence. A multi-primer approach was used to separately amplify primary CYP2D6 genes, duplicate genes, hybrid genes, and fully deleted *S* alleles. We applied this targeted strategy to 22 samples from Coriell and sequenced the amplicons on a PacBio Sequel II System. To generate resolved CYP2D6 *-allele diplotypes we describe a two-step process: 1) Cluster and consensus of PacBio HiFi reads, 2) Direct comparison of phased variant sets from consensus sequences to star-alleles described in PharmVar. Additional information regarding fusion alleles is also provided to further identify hybrid categories.

**Results:** Direct CYP2D6 *-allele typing generated by this workflow resulted in concordant results compared to orthogonal technologies. Differences between previous technologies' results and PacBio HiFi sequencing were due to higher resolution and improved calls via our method, including better CNV calls, *S* deletion calling, and high resolution subtyping for all alleles.

**Conclusion:**

**References:**

**Conflict of Interest:**

**Grants:**

**P19.026.A Modelling the patient journey of osteoarthritis in the context of obesity, using longitudinal health care data and genetics**

Rikke Linnemann Nielsen1, Thomas Monfeuga1, Zahra McVey1, Luis G. Leal1, Line E. Lund1, August Thomas Hjortshøj Schreyer2, Carol Sun1, Marianne Helenius2, Robert Kitchen1, Ramneek Gupta3

1Novo Nordisk Research Centre Oxford, Computational Biology, Oxford, United Kingdom; 2Technical University of Denmark, Kgs. Lyngby, Denmark.

**Background/Objectives:** Osteoarthritis (OA) is a chronic degenerative joint disease, causing decreased quality of life and a high economic health-care burden. The utility of known OA risk factors for predicting OA progression is insufficiently understood [1,2]. We developed predictive risk models of OA progression, across patient subgroups, to improve understanding of the heterogeneous OA aetiology and contribute to early diagnosis and treatment.

**Methods:** UK biobank data was explored using machine learning (ML) models to predict onset and progression of OA (N~100,000). The ML models integrated longitudinal information across primary and secondary health care data, as well as basic anthropometrics, lifestyle and nutrition, socioeconomic status, and genetic data. Several approaches were explored for incorporating genetic features. These included focusing on known common risk variants either associated with OA [3] or located within functionally relevant OA genes, and genetic risk scores.

**Results:** A subgroup of people with obesity had increased risk of OA compared to a normal weight population (OR: 2.95). In this subgroup, XGBoost predicted people with a risk of rapid progression to OA following obesity (1-6yrs) with ROC-AUC0.66 with age, walking pace, BMI and health rating as the most predictive features. People with slower progression to OA following obesity (6-10yrs) were predicted with similar performance (ROC-AUC0.65). Genetic risk scores of selected OA-associated genes were important for prediction of slow progression.

**Conclusion:** Predictive models of OA progression identify people who would most benefit from early intervention and enable the discovery of drug target candidates.

**References:**

[1] PMID:26904959.
[2] PMID:30523334.
[3] PMID:34450027.

**Conflict of Interest:** Rikke Linnemann Nielsen Novo Nordisk, full-time employment, Thomas Monfeuga Novo Nordisk, full-time employment, Zahra McVey Novo Nordisk, full-time employment, Luis G. Leal Novo Nordisk, full-time employment, Line E. Lund Novo Nordisk, full-time employment, August Thomas Hjortshøj Schreyer: None declared, Carol Sun Novo Nordisk, full-time employment, Marianne Helenius: None declared, Robert Kitchen

**P19.025.D Clinicians’ perceptions towards precision medicine tools for cardiovascular disease risk stratification in South Africa**

Michelle Kamp1,2, Oliver Pain2,4, Cathryn Lewis3,4, Michele Ramsay1,2

1Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; 2Division of Human Genetics, National Health Laboratory Service and School of Pathology, Faculty of Health Sciences, The University of the Witwatersrand, Johannesburg, South Africa; 3Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom; 4NIHR Maudsley Biomedical Research Centre, South London and Maudsley NHS Trust, London, United Kingdom.

**Background/Objectives:** Cardiovascular disease (CVD) risk stratification in African populations could improve with the inclusion of genetic risk to develop a clinically relevant precision medicine (PM) approach. African genetic data are scarce and current stratification approaches remain unvalidated. Successful PM implementation requires medical fraternity support. This study assessed clinicians’ knowledge, perceptions, and confidence towards implementing a PM tool for CVD risk stratification in the South African public health setting.

**Methods:** Electronic self-administered questionnaire was provided to clinicians in public hospitals in Johannesburg. Knowledge, perception, and confidence towards PM-based CVD risk stratification and perceived barriers were evaluated. Bivariate analysis assessed the effect of clinicalspeciality, practice level, research involvement, postgraduate study, clinical experience, exposure to genetics training and traditional CVD risk stratification on mean scores.

**Results:** Of the 94 respondents, 23.4% currently use clinical genetic testing, and 14.1% have formal genetics education and training. 79.5% had a low mean knowledge score, with higher scores associated with genetic training (p < 0.005) and research involvement (p < 0.05). 56.3% felt confident in applying the PM-based CVD risk stratification, with significantly higher scores amongst those involved in research (p < 0.005) or already undergoing CVD risk stratification (p < 0.005). Despite limited knowledge, 83.3% of respondents perceive PM approaches positively, with screening approaches tailored to African populations being the most valued benefit. Cost and limited access to genetic services were considered the greatest barriers to implementation.

**Conclusion:** Addressing the gap in genetic training is necessary to increase confidence in utilising and effectively implementing PM in South Africa.

**References:**

**Conflict of Interest:** Michelle Kamp: None declared, Oliver Pain: None declared, Cathryn Lewis Advisory board member, Myriad Neuroscience, Michele Ramsay: None declared.

SPRINGER NATURE

European Journal of Human Genetics (2023) 31:345 – 709
P19.027.B Pharmacogenetic analysis of a protein-protein interaction network in cyclosporine pathway in Greek patients with psoriasis under cyclosporine treatment

Charalabos Antonatos1, Eleana Staurou F.1,2, Evangelos Evangelou3,4, Andreas Liaropoulos1, Dani Bank J.5, Angeliki Roussaki-Schulze6, Alkaterini Patsatsi5, Dimitris Sotiriadis5, Sophia Georgiou7, Nicholas Moschonas2,8, Ioannis Vasilopoulos1, Dimitris Sotiropoulos1, Eikaterini Patsatsi6, Sofialousi6, Sothischkowitz1,8, Nicoline Hoogerbrugge4;12, Carla Oliveira1;2;3;12, Lou3,4, Andreas Liaropoulos1, Danai Digka1, Efterpi Zazigri

1University Of Patras, Biology, Panepistimioupoli Patron, Greece; 2University Of Patras, Medicine, Panepistimioupoli Patron, Greece; 3University of Ioannina, Hygiene and Epidemiology, Ioannina, Greece; 4Imperial College London, Epidemiology & Biostatistics, London, United Kingdom; 5University of Thessaly, Dermatology, Volos, Greece; 6Aristotle University of Thessaloniki, Dermatology, Thessaloniki, Greece; 7University Of Patras, Dermatology, Panepistimioupoli Patron, Greece; 8Foundation of Research & Technology, Institute of Chemical Engineering Science, Panepistimioupoli Patron, Greece.

Background/Objetives: Psoriasis is a chronic, inflammatory skin disease that affects 2-3% of the population worldwide. Although cyclosporine is a well-established systemic therapy for moderate to severe psoriasis, patients show important heterogeneity (~70%) in their response to treatment. The aim of our study was the pharmacogenetic analysis of Greek patients with psoriasis based on the construction of the cyclosporine-pathway Protein-Protein Interaction (PPI) network.

Methods: The cyclosporine related protein interactome was constructed through the PICKLE meta-database (www.pickle.gr). Based on this, we selected 30 single nucleotide polymorphisms mapped on 22 of the key molecular nodes in the cyclosporine signaling cascade, filtered through their functional significance and/or MAF ≥ 5%. Forward, reverse and the appropriate iPLEX extension PCR primers were designed using the ADS software. SNP genotyping of the 200 patients included in our study was performed through the iPLEX GOLD panel of the MassARRAY System (Agen Biosciences). In addition to single-SNP analysis carried out in Stata 13.1, haplotypic analysis was constructed with the Hapstat 3.0 software.

Results: Preliminary single-SNP analyses showed statistically significant associations between PPP3R1 rs1868402 (P = 0.02) and MALTI rs2874116 (P = 0.003) polymorphisms with positive response to cyclosporine therapy, but also a trend for association for 9 more genetic biomarkers. Haplotype analysis further enhanced the predictive value of rs1868402 as a pharmacogenetic biomarker for cyclosporine therapy (P = 0.0197).

Conclusion: Our findings have the potential not only to improve our prognosis of cyclosporine therapy in psoriasis patients but more importantly to be applied as a methodological approach in the pharmacogenetics of biological therapies in complex diseases.

References:

12.3: Instituto de Investigación e Inovação em Saúde, Porto, Portugal; 2Ipatimup, Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal; 3University of Porto, Faculty of Medicine, Porto, Portugal; 4Radboud Institute for Molecular Life Sciences, Department of Human Genetics, Radboud university medical center, Nijmegen, Netherlands; 5Institute of Human Genetics, Medical Faculty, University of Bonn, Bonn, Germany; 6The Barcelona Institute of Science and Technology, CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona, Spain; 7Institute of Medical Genetics and Applied Genomics, Tübingen, Germany; 8Centro Hospitalar Universitário São João (CHUSJ), Porto, Portugal; 9University of British Columbia, Department of Pathology and Laboratory Medicine, Vancouver, Canada; 10MGZ - Medizinisch Genetisches Zentrum, Munich, Germany; 11Campus Innenstadt, Klinikum der Universität München, Munich, Germany; 12European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTRIS) – Project ID No 739547, Nijmegen, Netherlands; 13University of Bonn, Center for Hereditary Tumor Syndromes, Bonn, Germany; 14University of Cambridge, Medical Genetics, Cambridge, United Kingdom.

Background/Objectives: Hereditary diffuse gastric cancer (HDGC), is the major gastric cancer tumour risk syndrome (GC-TRS) and is caused by loss-of-function germline variants in CDH1 or CTNNNA1, which predisposes for diffuse gastric cancer (DGC) and/or lobular breast cancer (LBC). Overall, >50% of all clinically diagnosed HDGC remain unsolved. We hypothesise that other tumour risk syndrome (TRS) genes explain unsolved GC-TRS cases.

Methods: We systematically searched the literature for individuals/families with cancer-history fitting clinical criteria for GC-TRS and bearing Pathogenic/Likely pathogenic variants (PVs) in TRS genes. Within the SOLVE-RD project, we re-analysed germline WES from 61 unsolved GC-TRS suspected families from the Netherlands and Canada. A cohort of 23 unsolved Portuguese GC-TRS cases was used to validate actionable candidate single nucleotide variants (SNVs) or copy number variants (CNVs).

Results: The literature search returned 28 PVs affecting 16 TRS-genes in 27 GC-TRS families, with PALB2 pathogenic SNVs occurring in 7/27 (26%) families dominated by DGC and LBC. SOLVE-RD re-analysis identified 1/61 (1.6%) GC-TRS family bearing a PALB2 pathogenic CNV, and a further case with LBC (1/23;4.3%) was identified in the validation cohort, bearing a PALB2-PV, and no other candidate variants.

Conclusion: GC-TRS families may be explained by non-classical genes, with PALB2 as the most frequently mutated gene found here (2.4%) in families fulfilling HDGC criteria and unsolved by CDH1 or CTNNNA1. This study supports the role of PALB2 SNVs and CNVs in the predisposition for DGC and/or LBC, and widening of genetic testing for GC-TRS suspected-families.

References:

Grants: EU H2020-779257 & PTDC/BTM-TEC/6706/2020.

Conflict of Interest: None declared.

P19.030.A Functional characterization of RUNX1 germline variants enhances translation of genetic data into personalized care

Melanie Decker1, Alena Wittstock1, Aliia Förster2, Anupriya Agrawal3, Andreas Benneche3, Jane Churpek4, Nicolas Duployez5, Adam S. DuVal7, Miriam Erlacher1, Martin P. T. Ernst6, Andreas Flom7, Alina Fester7, Hildeguern Høberg Vetli18, Inga Hofmann17, Tim Lammers17, Michelle Nos6, Charlotte Niemeyer7, Roajmakers Marc5, Doris Festermann1, Tor H. A. Tvedt16, Adrianna Vachos3, Ayami Yoshimi12, Brigitte Schlegelberger1, Thomas Illig10,15, Tim Ripperger8,9

1Hannover Medical School, Department of Human Genetics, Hannover, Germany; 2Oregon Health & Science University Knight Cancer Institute, Division of Hematology and Medical Oncology, Portland, United States; 3Haukeland University Hospital, Department of Medical Genetics,
Background/Objectives: Familial platelet disorder with predisposition to hematologic malignancies (RUNX1-FPD) is caused by heterozygous pathogenic RUNX1 germline variants. Following current variant classification guidelines, RUNX1 missense variants must frequently be classified as variants of uncertain significance (VUS) allowing no clinical conclusions. To support variant classification, we have established, validated and clinically applied a set of functional assays addressing various aspects of RUNX1.

Methods: We analyzed RUNX1’s heterodimerization with CBFB using FRET, its phosphorylation by western blotting, and its ability to activate transcription in transactivation assays in HEK293T and HEL cells. Individual assay results were combined in a functional score and integrated into variant classification.

Results: To date, we investigated 11 (likely) pathogenic controls, one benign control, and 19 RUNX1 variants of interest. We showed that the majority of RUNX1 variants detected in RUNX1-FPD can be evaluated by our functional assays and demonstrated that transactivation assays are suitable first-line screening tools. Integrating functional data led to reclassification of five RUNX1 VUS to likely pathogenic, two RUNX1 VUS to likely benign and supported the (likely) pathogenic classification of four additional variants.

Conclusion: Functional assays support RUNX1 variant classification and can be key to obtain a genetic diagnosis. These assays facilitate translation of genetic data into personalized medical care for patients and relatives at risk. Currently, we analyze additional missense VUS (n = 16) and aim to establish functional high-throughput assays as well as test tools for N-terminal RUNX1 variants to further enhance RUNX1 variant classification.

References:

Grants: EHA John Goldman Clinical Research Grant 2017; BMBF MyPred (01GM19111B).

Conflict of Interest: None declared.

P19.031.B Costs and diagnostic yield of whole genome sequencing in neurodevelopmental disorders

Maria Soller1,2, Hannes Runheim3, Ann Nordgren4, Maria Pettersson1, Anna Hammersjö1, Martin Henrikssoon1, Lars-Ake Levin3, Anna Lindstrand1,2

1Karolinska University Hospital, Clinical Genetics, Stockholm, Sweden; 2Karolinska Institutet, MMK, Stockholm, Sweden; 3Linköping University, Department of Health, Medicine and Caring Sciences, Linköping, Sweden.

Background/Objectives: Whole genome sequencing (WGS) has the potential to be a comprehensive genetic test, especially relevant for individuals with neurodevelopmental disorders, syndromes and congenital malformations. However, the cost consequences of using WGS as a first-line genetic test for these individuals are not well understood. The study objective was to compare the healthcare costs and diagnostic yield when WGS is performed as the first-line test instead of chromosomal microarray analysis (CMA).

Methods: Two cohorts were analyzed retrospectively using register data, cohort CMA (418 patients referred for CMA at the department of Clinical Genetics, Karolinska University Hospital, during 2015) and cohort WGS (89 patients included in a WGS-first prospective study in 2017). The analysis compared healthcare consumption over a two-year period after referral for genetic testing and diagnostic yield over a two- and three-year period after referral.

Results: The mean healthcare cost per patient in cohort WGS was $2,339 lower compared to cohort CMA ($2,339, 95%CI, -12,238-7,561; P = 0.64) including higher costs for genetic investigations ($1,065, 95%CI, 834-1,295; P < 0.001) and lower costs for outpatient care ($2,330, 95%CI, -3,992-(-669); P = 0.006). The diagnostic yield was 23% higher for cohort WGS (cohort CMA 20.1%, cohort WGS 24.7%) (0.046, 95%CI, -0.053-0.145; P = 0.36).

Conclusion: WGS as a first-line diagnostic test for individuals with neurodevelopmental disorders is associated with statistically non-significant lower costs and higher diagnostic yield compared with CMA. This indicates that prioritizing WGS over CMA in healthcare decision making will yield positive expected outcomes as well as showing a need for further research.

References:

Grants:

Conflict of Interest: None declared.

P19.032.C Polygenic risk scores for disease progression in clinically related events

Julian Wanner1,2, Nina Mars3, Bradley Jenney4, FinnGen Consortium2, Intervene Intervene1, Andrea Ganna3, Samuli Ripatti2, Henrike Heyne1,2,5

1Hasso Plattner Institute, Digital Health Center, Potsdam, Germany; 2Finnish Institute for Molecular Medicine (FIMM), Helsinki, Finland; 3Hasso Plattner Institute, Mount Sinai School of Medicine, New York, United States.

Background/Objectives: Predicting who is at elevated risk of developing a severe disease remains an important task in many clinical disciplines to optimize screening and prevention.

Methods: Here, we test the utility of polygenic risk scores (PRSs) in a potentially actionable clinical setting where a patient presents with an unspecified symptom using electronic health records of 356,077 Finns. Examples for such scenarios are individuals with an unclear possible seizure at risk to develop epilepsy or individuals with unclear stomach complaints (irritable bowel syndrome) at risk to develop an autoimmune inflammatory bowel disease (IBD).

Results: In 7,083 individuals with irritable bowel syndrome, we found that individuals with the top 10% of IBD-PRS showed an increased risk (HR 2.24, 95% CI 1.60-3.15) of developing IBD after 10 years compared to individuals with lower IBD-PRS. In young adults (age < 40) the effect of IBD-PRS was larger: the top 10% of IBD-PRS had a risk of developing IBD of ca. 14%. Individuals in the bottom 25% of IBD-PRS were consistently at low risk (<5%) to develop IBD. Disease-specific PRS had a more modest benefit in scenarios of high genetic correlation between two endpoints such as predicting myocardial infarction in individuals with angina pectoris or onset of type 2 diabetes in women with gestational diabetes. Analyses are replicated in a biobank network (n = 1.2 Million).

Conclusion: We are thus presenting scenarios and methods to improve the utility of PRSs for predicting disease progression.

References:
**Grants:** Horizon 2020(101016775).

**Conflict of Interest:** None declared.

**P19.033.D SwissGenVar: A genetic data-sharing platform and knowledge-database for harmonization and up-scaling of clinical grade interpretation of genetic variants to foster personalized health care in Switzerland**

Dennis Kraemer1, Dilenn Terumalai2, Livia Famiglietti3, Stephanie Meier4, Javier Sanz5, Samuel Koller6, Pascal Jost7, Fabienne Maurer7, Thierry Nouspikel8, André Schaller5, Isabel Filges4, Andrea Superti-Furga5, Marc Abramowicz8, Wolfgang Berger5, Sven Cichon8, Valérie Barbié2, Anita Rauch1

1Institute of Medical Genetics (IMG), University of Zurich, Schlieren-Zürich, Switzerland; 2Swiss Institute of Bioinformatics (SIB), Geneva, Switzerland; 3Swiss Institute of Bioinformatics (SIB), Geneva, Switzerland; 4Institute of Medical Genetics and Pathology, University Hospital Basel, Medical Genetics, Basel, Switzerland; 5Division of Human Genetics, Inselspital, Bern University Hospital, Bern, Switzerland; 6Institute of Medical Molecular Genetics (IMMG), University of Zurich, Schlieren-Zürich, Switzerland; 7Medical Genetics Service/Division of Genetic Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland; 8Medical Genetics Service/Center for Genetic Medicine, Geneva University Hospitals (HUG), Geneva, Switzerland.

**Background/Objectives:** Representing an effort of all Swiss academic centers for Medical Genetics under the umbrella of the Swiss Personalized Health Network (SPHN), SwissGenVar aims to create the infrastructure for a scalable and user-friendly Swiss-wide depository and sharing platform of genetic variant data generated during routine diagnostic procedures and research projects. SwissGenVar intends to provide an environment for expert knowledge-sharing to harmonize and up-scale the significance interpretation of genetic variants at clinical-grade. Broader visibility will be gained by interfacing with international databases, thus supporting global initiatives in personalized health care.

**Methods:** For the operationalisation of the genomic and related phenomic data, SwissGenVar cross-expert working groups defined a set of variant (type)-related genetic and clinical data by utilizing an interchangeable data format for direct platform implementability. Furthermore, the database structures and functionalities required for fulfilling the objectives of SwissGenVar were elaborated by dedicated operational teams.

**Results:** Based on this, SwissGenVar database covering variant- and patient-centered query interfaces was designed. Its ontology refers to established external and custom data catalogs reflecting the different variant annotations as well as the demographical and phenotypical features consented by the individual variant carriers. After a preliminary testing phase, the database was fed by research vcf-files using an established encrypted data transfer tool and secure access management system. Further exploration of the platform functionality and required adjustments are ongoing.

**Conclusion:** SwissGenVar will be a necessary first step to scale-up clinical-grade genetic testing in Switzerland and will foster personalized health research involving genetic risk stratification and disease classifications.

**References:** [https://pages.sib.swiss/project/swissgenvar/Project.](https://pages.sib.swiss/project/swissgenvar/Project)

**Grants:** SPHN Infrastructure development project.

**Conflict of Interest:** None declared.

**P19.034.A MicroRNAs as biomarkers for radiotherapy toxicity in breast and prostate cancer patients**

Ester Aguado-Flor1, Petra Seibold2, Miguel E. Aguado-Barrera3,4, Manuel Altabas5, Ananya Choudhury6,7, Orland Diez8,9, Noelia Docampo Azuaga1, Sandrine Ducornet1, David Gibon2, Alexandra Giraldo1, Renan Gomes3, Antonio Gomez-Caamaño4,10, Maarten
Background/Objectives: Late adverse effects caused by radiotherapy (RT) are a common cause of morbidity amongst cancer survivors and are determined in part by genetic susceptibility. The international RADprecise project aims to personalize RT for cancer patients. One of its objectives is to identify differentially expressed microRNAs as novel biomarkers for radiosensitivity in whole blood of prostate (PC) and breast cancer (BC) patients.

Methods: We used data and RNA samples from a large established cohort of BC and PC patients from the REQUITE European project (www.requite.eu). Patients with moderate/severe toxicity were matched to patients without, two years after RT: 62 and 61 patients for BC, and 76 and 52 for PC, respectively. MicroRNA libraries were prepared with whole blood RNA using NEBNext® Small RNA Library for Illumina sequencing in a HiSeq sRNAtoolbox (https://arn.ugr.es/srnatoolbox) was used to perform the bioinformatics analysis.

Results: The first results show that in BC patients there are 75 microRNAs under- and 68 over-differentially expressed (FDR < 0.05) between toxicity and non-toxicity groups. However, significant differences were observed between the two centers where the PC patients were treated. A multivariate analysis including clinical data, treatment and location will be performed.

Conclusion: MicroRNAs may be a good indicator of RT-induced late toxicity in BC patients. The most differentially expressed microRNAs according to RT toxicity in this discovery analysis will be validated in another 400 RADprecise patients using NanoString technology.

References:

Grants: ERAPERMED2018-244 (ERAPerMed JTC2018), SLT011/18/00005 and FP7 #601826.

Conflict of Interest: None declared.
Background/Objectives: Neuronal differentiation of pluripotent stem cells is an established method to study physiology, disease and medication safety. However, the sequence of events in human neuronal differentiation and the ability of in vitro models to recapitulate early brain development are poorly understood. Moreover, the role of epigenetic regulation on the establishment and maintenance of cellular identity during early neuronal differentiation processes is not delineated.

Methods: We developed a protocol optimized for the study of early human brain development and neuropharmacological applications. We performed RNA-seq, global DNA methylation, single-cell RNA-seq and ATAC-seq data integration across time-points (4D analysis), to correlate the expression of transcription factors with time- and population-specific chromatin states in hESCs, and during differentiation.

Results: Gene expression and epigenetic profiles were comprehensively characterized at four time-points, as the cells differentiate from embryonic stem cells towards a heterogenous population of progenitors, immature and mature neurons bearing telencephalic signatures. A multi-omics roadmap of neuronal differentiation, combined with searchable interactive gene analysis tools, allows for extensive exploration of early neuronal development and the effect of medications.

Conclusion: In this study, we describe the generation of a novel neuronal differentiation protocol where we used the unparalleled power of multi-omics to understand early events of anterior neuroectodermal fate specification. We assessed the functional regulation of transcription factors and developmentally regulated genes, from loss of pluripotency towards neuronal differentiation.

References:
Grants: None declared.
Conflict of Interest: None declared.

P19.038.A Genetic variability in vitamin D receptor gene may influence the kidney graft function

Tanja Blagus¹, Katja Goricar², Dimitar Stefanovski², Emilija Reshko², Gjoko Risteski², Miha Amor³, Gregor Mlinšek², Vita Dolzan¹

¹University of Ljubljana, Faculty of Medicine, Institute of Biochemistry and Molecular Genetics, Pharmacogenetics laboratory, Ljubljana, Slovenia; ²University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia; ³University Medical Centre Ljubljana, Department of Nephrology, Ljubljana, Slovenia.

Background/Objectives: Vitamin D is crucial for the functioning of several organ systems. Vitamin D deficiency has also been associated with an increased risk of chronic kidney disease and worse outcomes in kidney transplantation. Since vitamin D elicits its actions by binding to vitamin D receptor (VDR), polymorphisms within VDR gene may also result in impaired regulation of genes involved in immune response and kidney graft function. Our aim was to evaluate the association of VDR polymorphisms with kidney graft function in the first year after transplantation.

Methods: We performed a retrospective study in 143 Slovenian patients with functional kidney graft. All patients were genotyped for common VDR polymorphisms: rs11568820 (Cdxz2), rs4516035 (GATA), rs2228570 (FokI), rs1544410 (BsmI), rs731236 (TaqI) and rs739837 (BglII). Nonparametric tests and logistic regression were used for statistical analysis.

Results: VDR rs4516035 polymorphism was associated with increased serum creatinine and decreased eGFR at the end of the first year after transplantation in the additive (P = 0.001 and P = 0.008, respectively) and dominant (P < 0.001 and P = 0.003, respectively) genetic models. VDR rs2228570 was associated with occurrence of BK polyomavirus and cytomegalovirus infections in the first year after transplantation, with carriers of two polymorphic rs2228570 alleles having a lower infection rate (OR = 0.31, 95% CI = 0.10-0.99, P = 0.047) than carriers of two normal alleles. None of the investigated VDR polymorphisms was associated with overall rejection in the first year after transplantation.

Conclusion: VDR polymorphisms may be associated with worse kidney graft function and lower risk of graft viral infection.

References: Grants: ARR5, grants P1-0170 and P3-0323.
Conflict of Interest: None declared.

P19.039.B Association of genetic polymorphisms in glucocorticoid pathway with dexamethasone treatment in COVID-19 patients

Patricija Štampar¹, Tanja Blagus¹, Katja Goricar³, Petra Bogovic², Gabriele Turel⁴, Franc Stie¹, Vita Dolzan¹

¹Institute of Biochemistry and Molecular Genetics, University of Ljubljana, Ljubljana, Slovenia; ²Faculty of Medicine, University of Ljubljana, Slovenia; ³Pharmacogenetics Laboratory, Faculty of Medicine, University of Ljubljana, Slovenia; ⁴Institute of Biochemistry and Molecular Genetics, Pharmacogenetics laboratory, Ljubljana, Slovenia.

Background/Objectives: The glucocorticoid pathway is crucial for the functioning of several organ systems and glucocorticoids are widely used for the treatment of inflammatory diseases. However, the glucocorticoid response to dexamethasone treatment in COVID-19 patients is not well understood.

Methods: We performed a retrospective study in 143 Slovenian patients with functional kidney graft. All patients were genotyped for common SNPs: HTR1A rs6295, HTR1B rs13212041, HTR2A rs1843809, HTR2B rs3705115, HTR3A rs4290270, HTR4 rs4570625, HTR7 rs5-HTTPLR rs25531, 5-HTTLPR S (OR = 0.52; 95% CI = 0.28-0.96; p = 0.037) or at least one 5-HTTLPR L allele (OR = 0.37; 95% CI = 0.14-0.97; p = 0.044) had decreased odds for VH. Carriers of the TPH2 TAAT haplotype had increased risk for VH (OR = 1.94; 95% CI = 1.06-3.55; p = 0.032) compared to the TPH2 TGTG carriers. Gene-gene interactions did not show any associations with VH.

Conclusion: The genetic variants in serotonergic system should be further investigated as predictive biomarkers of VH as they could contribute to better and more personalized care of PD patients.

References: Grants: ARR5, grants P1-0170 and P3-0323.
Conflict of Interest: None declared.
Background/Objectives: Corticosteroids are widely used for the treatment of coronavirus disease (COVID-19) caused by SARS-CoV-2 as they attenuate the immune response with their anti-inflammatory properties. Genetic polymorphisms of glucocorticoid receptor, metabolizing enzymes or transporters may affect treatment response to dexamethasone. The aim of this study was to evaluate the association of polymorphisms in glucocorticoid pathway with disease severity and duration of dexamethasone treatment in COVID-19 patients.

Methods: Our study included 107 hospitalized COVID-19 patients treated with dexamethasone. We isolated DNA from peripheral blood and genotyped all samples for polymorphisms in NR3C1 (rs6198, rs33388), CYP3A4 (rs35599367), CYP3A5 (rs776746), GSTP1 (rs1695, rs1138272), GSTM1/GSTT1 deletions and ABCB1 (1045642, rs1128503, rs2032582) Fisher’s and Mann-Whitney tests were used in statistical analysis.

Results: The median (min-max) age of the included patients was 62 (26-85) years, 69.2 % were male and 30.8 % female and they had moderate (1.9 %), severe (83 %) or critical (15.1 %) disease. NR3C1 rs6198 polymorphism was associated with more severe disease in additive genetic model (P = 0.022). NR3C1 rs6198, ABCB1 rs1045642 and ABCB1 rs1128503 polymorphisms were associated with a shorter duration of dexamethasone treatment in additive (P = 0.048, P = 0.047 and P = 0.024, respectively) and dominant genetic models (P = 0.015, P = 0.048 and P = 0.020, respectively), while carriers of the polymorphic CYP3A4 rs35599367 allele required longer treatment with dexamethasone (P = 0.033). Other polymorphisms were not associated with disease severity or dexamethasone treatment duration.

Conclusion: Genetic variability of glucocorticoid pathway genes was associated with the duration of dexamethasone treatment of COVID-19 patients.

References:
1. Grants: ARR S P1-0170 and P3-0296.
2. Conflict of Interest: None declared.

P19.040.C The NUDT15 and TPMT genes variants in Polish IBD patients treated with thiopurines

Joanna Żuraszek1, Maryam Dangana2, Oliwia Zakierska-Banaszak1, Aleksandra Zielińska1, Michał Walczak1, Marlena Szalata1, Ryszard Słomski1, Marzena Skrzyczak-Zielińska1

1. Institute of Human Genetics, Polish Academy of Sciences, Department of Nucleic Acid Function, Poznan, Poland; 2. Poznan University of Life Sciences, Department of Biochemistry and Biotechnology, Poznan, Poland.

Background/Objectives: For years, thiopurines have been essential immunomodulatory agents in maintaining inflammatory bowel disease (IBD) remission. However, nearly one-third of patients had modified or discontinued medication due to numerous side effects. Genetic polymorphism of the TPMT and NUDT15 genes is related to enzyme activity, patients’ reaction to thiopurine therapy, and drug dosing. We aimed to determine the NUDT15 and TPMT gene variants in a Polish cohort in the context of personalized medicine.

Methods: A group of 88 Polish IBD patients treated with thiopurine agents was enrolled. The coding region of the NUDT15 gene was analyzed using Sanger sequencing, and four common loci c.238G>C, c.292G>T, c.460G>A, and c.719A>G of the TPMT gene using pyrosequencing were genotyped.

Results: Obtained results found four variants of the NUDT15 gene; two in the first exon: c.36A>G (p.Pro12Pro, rs61746486) and c.123A>C (p.Gly41Gly, rs138959770) with minor allele frequency (MAF) of 0.57%, one in the first intron: c.515-1G>A (rs41284205) with MAF of 1.7% and one in the 3’ untranslated region: c.7G>A (rs61973267) with MAF of 2.84%. For the TPMT gene, two polymorphisms: c.460G>A (p.Ala154Thr) in exon 6 and c.719A>G (p.Tyr240Cys) in exon 9, as compound heterozygous were detected, which corresponds to the presence of the TPMT*3A allele with a frequency of 3.41%.

Conclusion: This study confirmed the importance of the TPMT gene in the pharmacogenetics of Polish IBD patients treated with thiopurines. However, it did not demonstrate thiopurine-related toxicity variants in the NUDT15 gene.

References:
1. Grants: Polish National Science Centre, grant no. 2016/23/D/NZ2/01620.
2. Conflict of Interest: Joanna Żuraszek Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland, Maryam Dangana Department of Biochemistry and Biotechnology, Poznan University of Life Sciences, Poznan, Poland, Oliwia Zakierska-Banaszak Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland, Aleksandra Zielińska Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland, Michal Walczak Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland, Marlena Szalata Department of Biochemistry and Biotechnology, Poznan University of Life Sciences, Poznan, Poland, Ryszard Słomski Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland, Marzena Skrzyczak-Zielińska Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland, Polish National Science Centre, grant no. 2016/23/D/NZ2/01620.

P19.041.D INTERVENE: exploring the generalizability of polygenic risk scores on disease

Bradley Jermy1, Kristi Laid2, Brooke Wolford3, Tuomo Hartonen1, Zhifu Yang4, Remo Monti5, Stravoula Kanoni6, Ying Wang7,8, Kristina Zguro9, Henrike Heyne10, Julian Wanner11,12, Omar Youssef11,12, FinnGen Consortium1, Alicia Martin6,7,8, David van Heel13, Kristian Hveem1, Reedik Mägi2, Arno Palotive1, Nina Mars1, Andrea Ganna1,14, Samuli Ripatti1,14

1. Institute for Molecular Medicine Finland, FIMM, HILIFE, University of Helsinki, Helsinki, Finland; 2. Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia; 3. K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health, Norwegian University of Science and Technology, Trondheim, Norway; 4. Hasslo Plattner Institute, Digital Health Center, University of Potsdam, Potsdam, Germany; 5. William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom; 6. Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, United States; 7. Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, United States; 8. Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, United States; 9. Med Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy; 10. Hasslo Plattner Institute, Mount Sinai School of Medicine, New York, United States; 11. Helsinki Biobank, Joint Authority of Hospital District of Helsinki and Uusimaa (HUS), Helsinki, Finland; 12. Pathology Department, University of Helsinki, Helsinki, Finland; 13. Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom; 14. Massachusetts General Hospital and Broad Institute of MIT and Harvard, Cambridge, United States.

Background/Objectives: The INTERVENE project is a collaboration between 7 biobank projects, harmonizing data on 1.3 million
participants. We aimed to estimate absolute risk by disease specific PRS strata and to understand the incremental benefit in prediction by phenotypic risk factors.

**Methods:** 38 diseases were selected to have high heritability, powerful GWAS data and contribution to global burden of disease. This includes diseases such as type 1 diabetes (T1D), rheumatoid arthritis (RA), and diseases less explored in the PRS literature such as melanoma and glaucoma. Analytical consistency is reached through comprehensive endpoint harmonization and systematic PRS deployment through Docker software.

**Results:** 32 disease specific PRS were tested for association in at least one of either FinnGen, Estonian Biobank or UK Biobank. Association strength varied by disease, however, two notably strong associations were prostate cancer (meta-analysis: OR per SD = 1.95, 95%CI = 1.92-1.98) and T1D (meta-analysis: OR per SD = 2.25, 95%CI = 2.17-2.32).

While estimates for most diseases showed agreement across the biobanks, some showed high variability, such as gout, inflammatory bowel disease and RA. Indeed, RA differed in association across all three biobank projects (Estonian Biobank: OR = 1.41, 95%CI = 1.33-1.49; FinnGen: OR = 1.64, 95%CI = 1.60-1.68; UK Biobank: OR = 1.98, 95%CI = 1.82-2.16). These analyses are now being replicated in other ancestries and across more biobanks.

**Conclusion:** Through our multi-biobank collaboration, we have developed an efficient replication machinery for studies on polygenic risk. Through this, we show variation in PRS association exists for specific diseases. Understanding such variation will be a vital step towards PRS’s clinical implementation.

**References:**

1. NeoGenomics, Biomedicine and Translation Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.

**Background/Objectives:** Triple-negative breast cancer (TNBC) has the worst survival rate reported to other breast cancer subtypes. Resistance mechanisms are based on the interplay between numerous factors and signaling pathways, which crosstalk and feedback.

**Methods:** To understand the interplay between the signaling pathways was downloaded the NCBI gene list related to pathway in cancer, mitogen-activated protein kinase(MAPK) and phosphatidylinositol 3-kinase(PI3K)/protein kinase B(AKT) signaling. The next step was to overlap the genes list using Venn diagram, then was evaluated the overall survival using online tools, based on a patient cohort of 176 TNBC patients from TCGA.

**Results:** The Venn diagram among the selected gene list emphasis a common signature of 52 genes; among this, 23 were correlated with overall survival rate, these genes being related to the EGFR tyrosine kinase inhibitor resistance, as KEGG gene ontology classification shows.

Although epidermal growth factor receptor (EGFR) is overexpressed and correlated with overall survival rate in TNBC, most of the clinical trials with EGFR inhibitors in TNBC have heretofore been unsuccessful. To develop effective EGFR-targeted therapy for TNBC, the specific mechanisms of EGFR signaling and the interconnection with MAPK and PI3K/AKT signaling mediated immune response in TNBC need to be elucidated. Additional key immune response regulators (IL1A, IL4, IL6, JGF2, VEGFAB/BC, EGFR, FGR2) were proved to be connected with overall survival rate in TNBC.

**Conclusion:** Our work provides the important role of the crosstalk among the MAPK and PI3K/AKT signaling; this paving the way to precision TNBC care.

**References:**

1. This project was financed by PN-III-P4-ID-PCE-2020-1625-ORIENT.
2. None declared.

**Conflict of Interest:** None declared.
Karume: None declared, Adam Wang: None declared, Miguel Almalvez: None declared, Yulong Fu: None declared, Désiré Musasa: None declared, Johanna Nsibu: None declared, Matthew Bramble: None declared, Erick Kamangu: None declared.

References:

Grants:

Conflict of Interest: None declared.

P19.044.C Gene editing in human iPSC models derived from patients affected by inherited retinal dystrophies

Laura Siles1,2, Arnau Navinés-Ferre1,2, Sheila Ruiz-Nogales1,2, Esther Pomares1,2

Background/Objectives: Inherited retinal dystrophies (IRD) are caused by mutations in more than 300 genes. Previous work in our lab reported the generation of several human induced pluripotent stem cell (iPSC) lines from patients carrying mutations in different IRD-associated genes. These genes comprise ABCA4, BEST1, PDE6A, PDE6C, RHO and USH2A. The aim of this study is to correct the identified mutations through gene editing and to revert the phenotype observed in the unedited cells as a source of cells for potential iPSC-mediated therapy.

Methods: We used CRISPR/Cas9 and transcription activator-like effector nuclease (TALEN) in patient derived human iPSCs to correct the variants from each subject. For that we designed specific sgRNAs and TAL mRNA pairs to target the mutation. Results: We have found differences in DNA cleavage efficiency in the different iPSC lines used depending on the type of the mutation and the gene. We also observed differences in editing efficiency between CRISPR and TALEN approaches among iPSC lines.

Conclusion: There is an unmet need to develop therapies to treat IRD. Genome editing allows correcting the disease mutations directly in patient’s DNA. By using CRISPR/Cas9 or TALEN-mediated genome editing we are able to specifically cut the DNA at the desired location and to revert the mutation with a corrected DNA template.

References:

Grants:

Conflict of Interest: None declared.

P19.046.A Genotype-first breast cancer prevention: transferring monogenic findings from a population biobank to clinical setting

Hannes Jürgens1,2, Laura Roha2,3, Liis Leitsalu4, Margit Nõukas4, Marili Palover5, Tiit Nikopensis6, Anu Reigo6, Mart Kals7, Kersti Kallak1, Riina Küntr7, Vahur Valver6, Piret Laide1, Kadri Toome1, Kadi Rekker3, Mikk Tooming2,3, Ülle Murumets2, Tiina Kahre2, Krista Kruuv-Kao7, Katrin Ounap2, Peeter Padrik2,3, Andres Metspalu4,7, Tõnu Esko8, Neeme Tonisson2,4

Background/Objectives: Although hereditary breast cancer (BC) screening and management is well established in clinical settings, it only captures a fraction of genetic predisposition at the population level. We have addressed this gap by returning data on BC predisposing monogenic variants to female participants of the Estonian Biobank (EstBB).

Methods: We describe our experience from a national pilot study (2018–2021) in collaboration with two Estonian regional hospitals. We screened the EstBB cohort (n = 154,201 of whom 66.1% were female) to identify carriers (22-79y) with monogenic variants conferring high or moderate BC risk in any of 11 genes listed in clinical guidelines (BRCA1, BRCA2, ATM, CHEK2, NBN, NFI). 180 female carriers were recontacted and 109 (61%) consented for further clinical management by clinical geneticists and oncologist. That included confirmation of genetic variant, cascade screening, imaging studies, laboratory testing, preventive surgery etc.

Results: Our results show that only one-third of participants were eligible for BC screening according to the current clinical criteria. 16 participants had previous cancer history. Only 10% were aware of their genetic information. BC was diagnosed in six participants.

Conclusion: Our results support population-based genomic screening for hereditary BC prevention.

References:

Grants: This research was funded by the Estonian Research Council–RITA programme, by the European Regional Development Fund in accordance with Directive no. 1.1-2/17/15 and by...
Background/Objectives: The only proven effective treatment of primary open-angle glaucoma (POAG) is to reduce the intraocular pressure (IOP). Treatment with prostaglandin analogues (PGAs) such as latanoprost eye drops leads to highest IOP reduction. However, in some patients sufficient IOP reduction may not be achieved or the disease may progress despite low IOP. The aim of our study was to search for pharmacogenetic markers of treatment response to latanoprost in patients with POAG and ocular hypertension.

Methods: Our pilot study included 52 treatment naive patients with POAG or ocular hypertension. Response to latanoprost was evaluated as IOP reduction in the most affected eye after 6 weeks of treatment. Patients were genotyped for polymorphisms in genes of latanoprost activation (CES1P1 rs3785161), transport (SLCO2A1 rs43550074 and rs4241366), and receptor (PTGFR rs3753380) and in antioxidative (SOD2 rs1001179, GPX1 rs1050450) and inflammatory (TNF rs1800629, IL1B rs16944 and rs1143623, IL6 rs1800795) pathways.

Results: SOD2 rs4880 CT (Padd = 0.036), CAT rs1001179 TT (Padd = 0.012) and TNF rs1800629 GG (Pdod = 0.012) genotypes were significantly associated with a decrease in absolute IOP after latanoprost treatment in the additive model, while carriers of at least one GSTT1 gene copy achieved higher percentage of IOP reduction in the dominant model (P = 0.024). The other investigated polymorphisms were not statistically significantly associated with response to latanoprost treatment.

Conclusion: Pharmacogenetic biomarkers associated with treatment response to latanoprost may contribute to more effective and personalized treatment of POAG and ocular hypertension.

References:
Grants: ARR grants P1-0170 and P3-0333.
Conflict of Interest: Makedonka Atanasovska Velkovska: None declared, Tanja Blagus: None declared, Katja Goricar: None declared, Barbara Cvenkel: None declared, Vita Dolzan: None declared.

P19.048.B NAGENpediatrics: Rapid Whole Genome Sequencing in Neonatal/Pediatric Intensive Care in Navarra, Spain

Monica Arasanz Armengol1, Sara Ciria Abad1, Leslie Mataclonga2, Gemma Bullich Vilanova3, Ida Paramonov2, Edurne Urutxu Lafuente1, Oscar Teijido Hermida1, Alberto Mailllo1, Maria Miranda Perez1, Iranzu Gonzalez Borja2, Gonzalo Etago Nagore3, Mercé Artigas Lopez2, Juan Jose Beloqui Lizaso2, Angel Alonso Sanchez2, Nerea Gorria-Redondo1,2, Josune Hualde Olascoaga1,2

Background/objectives: Whole-genome sequencing (WGS) is a rapid and cost-effective technique that significantly impacts the clinical setting, particularly in the paediatric context. Approximately 2-3% of newborns have a congenital anomaly, and at least 50% of these have a genetic cause. According to the literature, rapid genomic testing (2-3 weeks) allows the diagnosis of around 21-26% of critically ill children, influencing clinical outcomes. This pioneering study at regional level aims to evaluate the diagnostic and therapeutic utility of rapid WGS in acutely unwell children.

Methods: This ongoing study involved the participation of a multidisciplinary team and the recruitment of 34 trios over one year. A specialized paediatric clinical team initially assessed their eligibility and each family received a detailed genetic counselling consultation, provided by a registered genetic counsellor. WGS was performed on germline DNA, and variants were filtered and reported by extensive bioinformatic analysis.

Results: We identified pathogenic variants in genes in line with the clinical manifestations in 14 families, reaching a diagnostic yield of 41%. Genetic results, delivered in an average time of 2-3 weeks, significantly reduced the diagnostic odyssey and influenced clinical decisions.

Conclusion: We demonstrate the implementation of precision medicine through rapid WGS in the paediatric context in the region of Navarra, Spain, with potential extensive benefits for patients, clinicians and the Regional Health System. We describe new genetic variants associated with rare diseases, not identifiable by other diagnostic methods in rapid turnaround times.

References: Stark, Z et al., 2022.
Grants: Proyecto estratégico I+I-D53 2020-2022. GEMAIV Gobierno de Navarra.
Conflict of Interest: None declared.
Background/Objectives: Among non-European populations, it is an urgent task to construct a PRS (polygenic risk score) and to assess its utility with a combination of traditional risk factors. We aimed to examine the associations between genome-wide PRS and hypertension prevalence and interaction with conventional risk factors in a general Japanese population.

Methods: This cross-sectional study included 11,252 Japanese individuals who participated in the J-MICC Study (ten nationwide study sites). By leveraging publicly available GWAS results from the BioBank Japan, we developed PRS in the Target dataset using PRSice-2 and evaluated its performance in the Test dataset. Hypertension was defined as systolic blood pressure (SBP) > 130 mmHg, diastolic blood pressure (DBP) > 85 mmHg, or taking an antihypertensive drug.

Results: Compared with the middle PRS quintile, the OR (95% CI) of hypertension at the bottom and top PRS quintiles were 0.74 (0.57–0.97) and 1.73 (1.32–2.27), respectively. For continuous outcomes, differences (95% CI) between the middle and the top quintile were 4.55 (2.26–6.85) mmHg for SBP and 2.53 (1.80–3.26) mmHg for DBP. The OR (95% CI) of non-drinkers in the top PRS quintile (1.70, 1.11–2.61) were lower than drinkers in the top quintile (2.53, 1.70–3.79), although interaction term was not significant.

Conclusion: Our findings highlighted that a combination of PRS and traditional risk factors could be useful for risk stratification of hypertension in a Japanese population.

References:

Grants: Grants-in-Aid for Scientific Research for Priority Areas of Cancer [No: 17015018], Innovative Areas [No: 22150001], and JSPS KAKENHI [Nos: 16H06277, 15H02524, and 20K18943].

Conflict of Interest: None declared.

P20.003.A Pursuing public health benefit within national genomic initiatives: learning from different policies

Suzanne Onstwedder1,2, Marleen Jansen1,2, Teresa Leonardo Alves1, Martina Cornel2, Tessel Rigter1,2

1National Institute for Public Health and Environment, Centre for Health Protection, Bilthoven, Netherlands; 2Amsterdam UMC, locatie VUmc, Department of Human Genetics, Amsterdam, Netherlands.

Background/Objectives: Substantial public health benefits are expected of population-based genomic endeavours, such as national genomics initiatives. To date, little is known about the actual public health benefit that is yielded. We explore to what extent and how public health benefit is pursued in national genomics initiatives.

Methods: A mixed-method study was conducted, comprising a literature-based comparison of 11 purposively sampled national genomics initiatives (Belgium, Denmark, Estonia, Finland, Germany, Iceland, Qatar, Saudi Arabia, Taiwan, United Kingdom (UK), and United States of America (USA), and five semi-structured interviews with experts (Denmark, Estonia, Finland, UK, USA). The results were analysed using an adapted public health policy cycle: agenda setting, governance, (research) strategy towards health benefit, implementation, evaluation.

Results: Public health benefit within national genomics initiatives was pursued in all initiatives and in all phases of the public health policy cycle. The operationalization of public health benefit seemed dependent on the outcomes of agenda setting, as well as design of governance. Some initiatives focus on a research-based strategy to contribute to public health, while others focus on research translation into healthcare, or a combination of both. Both quantitative and qualitative methods were reported to evaluate public health benefits. However, the created health benefit for the general public, both short- and long-term, appears difficult to determine.

Conclusion: Genomics initiatives hold the potential to deliver health promises of population-based genomics. To ensure effective research translation, implementation, and ultimately improve public health, development of evaluation tools and clarity in roles and responsibilities of stakeholders is crucial.

References:

Grants: No grants were received.

Conflict of Interest: Suzanne Onstwedder Part-time employed at National Institute for Public Health and the Environment (the Netherlands), part-time employed at Amsterdam UMC, Marleen Jansen Part-time employed at National Institute for Public Health and the Environment (the Netherlands), part-time employed at Amsterdam UMC, Teresa Leonardo Alves Fulltime employed at National Institute for Public Health and the Environment (the Netherlands), Fulfills a position in the Advisory Board of a not-for-profit organization called Mieux Prescrire, but receives no financial payment., Martina Cornel Fulltime employed at Amsterdam UMC, the Netherlands, Tessel Rigter Part-time employed at National Institute for Public Health and the Environment (the Netherlands), part-time employed at Amsterdam UMC.
P20.004.B The contribution of rare whole genome sequencing variants to plasma protein levels and to the missing heritability

Marcin Kierczak1, Nima Rafati2, Julia Höglund2, Hadrien Gourlé3, Valeria Lo Faro2, Daniel Schmitz2, Veronica Ek2, Ulf Gyllensten2, Stefan Enroth2, Diana Ekman3, Björn Nystedt4, Torgny Karlsson4, Åsa Johansson1,2

1Uppsala university, Science for Life Laboratory, Uppsala, Sweden; 2Uppsala university, Immunology, Genetics and Pathology, Uppsala, Sweden; 3Stockholm University, Science for Life Laboratory, Stockholm, Sweden.

Background/Objectives: Despite the success of genome-wide association studies, much of the genetic contribution to complex traits remains unexplained. Here, we analysed high coverage whole-genome sequencing data, to evaluate the contribution of rare genetic variants plasma protein concentrations and to the heritability.

Methods: Whole-genome sequencing was performed using Illumina short read technology (X-ten) and protein levels for 460 putative biomarkers was measured using the Olink Proseek Multiplex panels (CVD II, CVD III, INF I, ONC II and NEU I) and the protein extension assay. Association analyses were performed using SKAT with different weights and minor allele frequency cut-offs.

Results: The frequency distribution of genetic variants was skewed towards the rare spectrum, and damaging variants were more often rare. We estimated that less than 4.3% of the narrow-sense heritability is expected to be explained by rare variants in our cohort. Using a gene-based approach and SKAT, we identified Cis-associations for 237 of the proteins, which is slightly more compared to a GWAS (N = 213), and we identified 34 loci in Trans. Several associations were driven by rare variants, and rare variants had on average larger phenotypic effects.

Conclusion: We conclude therefore that rare variants could be of importance for precision medicine applications, but have a more limited contribution to the missing heritability of complex diseases.

References:
Grants: This work was funded by the SciLifeLab, the Swedish Medical Research Council (2019-01497) and the Swedish Heart-Lung foundation (nr. 20200687).
Conflict of Interest: None declared.

P20.005.C The effect of LPA p.Thr1399Pro on lipoprotein(a) concentrations and coronary artery disease is modified by an interaction with the LPA splice site variant IVS-2 4925G>A

Rebecca Grüneis1, Claudia Lamina1, Silvia Di Maio1, Sebastian Schoenher1, Peter Zösch1, Lukas Forer1, Annette Peters2, Christian Gieger2, Anna Köttgen2, Florian Kronenberg2, Stefan Coassin2

1Medical University of Innsbruck, Institute of Genetic Epidemiology, Innsbruck, Austria; 2German Center for Diabetes Research (DZD), München-Neuherberg, Germany; 3Helmholtz Zentrum München - German Research Center for Environmental Health, Institute of Epidemiology, Neuherberg, Germany; 4University of Freiburg, Institute of Genetic Epidemiology, Freiburg, Germany; 5German Chronic Kidney Disease study, Erlangen, Germany.

Background/Objectives: High Lipoprotein(a) [Lp(a)] concentrations are a major genetic risk factor for coronary artery disease (CAD) in the general population[1]. Lp(a) variance is determined by the complex LPA gene, with a coding CNV (“KIV-2 repeat”) encompassing up to 70% of the coding region and determining 30-70% of Lp(a) variance[1]. Additionally, many LPA variants further contribute to Lp(a) variance[1].

Methods: The effect of the interaction between the largely investigated but ambiguous coding SNP rs41272110 (pThr1399Pro) and the splice variant 4925G>A located in the KIV-2 repeat was investigated by quantile regression in 10,405 individuals from three German studies (GCKD, KORA F3 and KORA F4). Survival analysis was used to assess the impact of both variants on CAD risk in UKBiobank (n = 186,088 exomes).

Results: We observed a highly significant SNP interaction (p < 3.03e-04). Rs41272110 alone showed no impact on Lp(a) (β = -0.06 [-0.79;0.68], p = 0.879) and CAD risk (HR = 1.01 [0.97;1.04], p = 0.731), but in a model containing both variants, rs41272110 was associated with markedly increased Lp(a) (β = +4.90 mg/dL, [6.45;12.34], p = 4.07E-10) and higher CAD risk (HR = 1.10 [1.04;1.16], p = 6.9e-04). The effect of rs41272110 is seen only in carriers of rs41272110 not carrying 4925G>A (i.e. sizeable 4% of the population), but at population level it is masked by partial association (R2 = 0.836-0.872, D’ = 0.984-0.985) and interaction with IVS-2 4925G>A.

Conclusion: We identify a SNP interaction and a novel CAD risk variant in the LPA gene. Our work emphasizes that missed SNP interactions in the genome may lead to inaccurate determination of phenotypic effects.

References:
[1]Coassin S et al, 2017, https://doi.org/10.1093/eurheartj/ehx174.

Grants: Austrian Science Fund (FWF) P31458-B34.
Conflict of Interest: Rebecca Grüneis: None declared, Claudia Lamina: None declared, Silvia Di Maio: None declared, Sebastian Schoenher: None declared, Peter Zösch: None declared, Lukas Forer: None declared, Annette Peters: None declared, Christian Gieger: None declared, Anna Köttgen: None declared, Florian Kronenberg served on the advisory boards and has received lecture fees from Novartis and Amgen, Stefan Coassin: None declared.

P20.006.D Functional differences between the modern human and Neandertal aryl hydrocarbon receptor

Nelly Helmbrecht1, Martin Lackner1, Svante Pääbo1,2

1Max Planck Institute for Evolutionary Anthropology, Leipzig, Germany; 2Okinawa Institute of Science and Technology, Onna-son, Japan.

Background/Objectives: The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor important in the response to toxins. AHR in modern humans differs from the AHR of Neandertals, Denisovans or other primates by having an alanine to valine substitution at position 381. Previous studies where these variants were overexpressed have yielded contradictory results. Here, we investigate the activity of the two versions of AHR by genome editing.

Methods: We introduced the codon for the Neandertal-like amino acid in human cells using CRISPR/Cas genome editing, exposed the edited and non-edited cells to AHR ligands and measured the expression of the AHR target genes cytochromes P450 1A1 and P450 1B1 with real-time quantitative PCR and additional target genes by RNA-Sequencing.

Results: We show that the induction of the transcription of the AHR target genes does not differ in cells expressing the ancestral and modern versions of AHR when they are exposed to the microbiome-derived metabolite indirubin. In contrast, the ancestral AHR variant induces a transcriptional response at >1000-fold lower concentrations than the modern human AHR variant when cells are exposed to the environmental pollutant benzo(a)pyrene and the endogenous tryptophan metabolite kynurenic acid.
Furthermore, the ancestralized cells are similar to comparable chimpanzee cells in that they express higher levels of AHR target genes when no ligands are added.

**Conclusion:** Compared to the ancestral variant seen in archaic hominins, modern human AHR activates its target genes to a lesser extent when exposed to kynurenic acid and benzo(a)pyrene. This may be advantageous in that less DNA adducts might be formed.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P20.007.A Phenome-wide association studies of genetic variants in microRNAs**

**Rima Mustafa**$^1$, Mohsen Ghanbari$^2$, Marina Evangelou$^3$, Abbas Dehghani$^{1,3}$

$^1$Imperial College London, Department of Epidemiology and Biostatistics, London, United Kingdom; $^2$Erasmus MC, Department of Epidemiology, Rotterdam, Netherlands; $^3$Imperial College London, Department of Mathematics, London, United Kingdom; $^4$Imperial College London, Dementia Research Institute, London, United Kingdom; $^5$Imperial College London, MRC Centre for Environment and Health, London, United Kingdom.

**Background/Objectives:** Genetic variants in microRNAs (miRNAs) can affect their biogenesis or functionality. Previous research showed these variants could be associated with disease, but their implication on a wide range of phenotypes remains unknown. Here we aim to study the effects of those variants on human phenotype.

**Methods:** We utilized genotype and hospital episode statistics data to investigate associations between genetic variants in miRNAs and clinical diagnoses in 423,419 participants in the UK Biobank. We extracted 346 genetic variants in seed, mature, or precursor genes of miRNAs. We included 905 diagnoses with at least 200 cases. Phenome-wide association studies were conducted for each genetic variant separately, adjusting for age, sex, genotyping array, and the first five principal components.

**Results:** At FDR<0.05, we identified 122 associations between 42 genetic variants (6 in seed, 9 in mature, and 27 in precursor genes of miRNAs, respectively) and 63 diagnoses across 14 disease groups. Of those, 47 associations (38.5%) were genome-wide significant. The strongest associations were reported between genetic variants in the major histocompatibility complex (MHC) region, including rs4285314 in the precursor gene of miR-3135b and celiac disease ($P = 1.80e-162$) and other immune-related disorders. Excluding MHC region, rs368791729 and rs370955537 in mature miR-3939 remain the most significant findings associated with hypothyroidism ($P = 8.06e-11$ and $P = 4.17e-10$, respectively).

**Conclusion:** Our study shows that genetic variants in miRNAs could have clinical implications and offers an opportunity to investigate their clinical importance. Further studies are needed to validate the findings, assess their causality, and explore the underlying mechanism.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P20.008.B Genetics and material culture support repeated expansions into paleolithic Eurasia from a population hub out of Africa**

**Leonardo Vallini**$^1$, Giulia Marciani$^{2,3}$, Serena Aneli$^{4,6}$, Eugenio Bortolini$^2$, Stefano Benazzi$^{2,5}$, Telmo Plevani$^7$, Luca Pagani$^{1,6}$

$^1$University of Padova, Department of Biology, Padova, Italy; $^2$University of Bologna, Department of Cultural Heritage, Ravenna, Italy; $^3$University of Siena, Department of Physical Sciences, Earth and Environment, Siena, Italy; $^4$University of Torino, Department of Public Health Sciences and Pediatrics, Torino, Italy; $^5$Max Planck Institute for Evolutionary Anthropology, Department of Human Evolution, Leipzig, Germany; $^6$University of Tartu, Institute of Genomics, Tartu, Estonia.

**Background/Objectives:** The population dynamics that followed the Out of Africa expansion of Homo sapiens and the whereabouts of the early migrants before the differentiation that ultimately led to the formation of Oceanian, West and East Eurasian macro populations have long been debated. Shedding light on these events may, in turn, provide clues to better understand cultural evolution in Eurasia 50,000-35,000 years ago.

**Methods:** Here we analyze the available Eurasian Paleolithic aDNA to provide a comprehensive population model (primarily using admixture graphs) and validate it in light of available material culture.

**Results:** We show that the genetic modeling of Paleolithic genomes largely matches the material culture evidence and suggests multiple waves of colonization of Eurasia. The only representative of the first expansion has been recovered in Europe and might be linked with the so called “transitional cultures” documented there 48,000-43,000 years ago. A second, major, population wave is broadly associated with Initial Upper Paleolithic lithics and populated West and East Eurasia around 45,000 years ago, before getting largely extinct in Europe. Another expansion, started before 38,000 years ago, is broadly associated with Upper Paleolithic industries and repopulated Europe with sporadic admixtures with the previous wave and more systematic ones while moving through Siberia.

**Conclusion:** Leveraging on our integrated approach we propose that, starting from a Eurasian population Hub, the broader colonization of the continent occurred through multiple events of expansion and local extinctions; with each expansion characterized by distinct chronologies, genetics and lithic technologies.

**References:**

**Grants:** UniPd PRID 2019, EU Horizon 2020 (N.724046–SUCCESS).

**Conflict of Interest:** None declared.

**P20.009.C Heterogeneity of lung function signals and genetic risk score in predicting Chronic Obstructive Pulmonary Disease in a multi-ancestry study of 580,869 individuals**

**Jing Chen**$^1$, Nick Shrine$^1$, Abril Izquierdo$^1$, Anna Guyatts$^1$, Richard Packer$^1$, Chiara Batini$^2$, Xiaowei Hu$^2$, Ain W Manichaikul$^2$, Brian Hobbs$^2$, Michael Cho$^3$, Tamar Sofer$^2$, Karsten SuHre$^2$, Alfred Pozarickij$^9$, Robin G Walters$^{6,7}$, Stephanie London$^9$, Andrew Morris$^9$, Louise Wain$^{1,7}$, Ian P. Hall$^{1,7}$, Martin D Tobin$^{1,7}$

$^1$Department of Health Sciences, University of Leicester, Leicester, United Kingdom; $^2$Center for Public Health Genomics, School of Medicine, University of Virginia, Charlottesville, United States; $^3$Channing Division of Network Medicine and Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, United States; $^4$Division of Sleep and Circadian Disorders, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Harvard University, Massachusetts, United States; $^5$Bioinformatics Core, Weill Cornell Medicine-Qatar, Education City, Doha, Qatar; $^6$Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; $^7$MRC Population Health Research Unit, University of Oxford, Oxford, United Kingdom; $^8$Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, NC, United States; $^9$Department of Medicine, Harvard Medical School, Boston, United States; $^{6,7}$Department of Health Sciences, University of Leicester, Leicester, United Kingdom; $^9$Department of Health Sciences, University of Leicester, Leicester, United Kingdom.

**Background/Objectives:** The Out of Africa expansion of Homo sapiens and the whereabouts of the early migrants before the differentiation that ultimately led to the formation of Oceanian, West and East Eurasian macro populations have long been debated. Shedding light on these events may, in turn, provide clues to better understand cultural evolution in Eurasia 50,000-35,000 years ago.

**Methods:** Here we analyze the available Eurasian Paleolithic aDNA to provide a comprehensive population model (primarily using admixture graphs) and validate it in light of available material culture.

**Results:** We show that the genetic modeling of Paleolithic genomes largely matches the material culture evidence and suggests multiple waves of colonization of Eurasia. The only representative of the first expansion has been recovered in Europe and might be linked with the so called “transitional cultures” documented there 48,000-43,000 years ago. A second, major, population wave is broadly associated with Initial Upper Paleolithic lithics and populated West and East Eurasia around 45,000 years ago, before getting largely extinct in Europe. Another expansion, started before 38,000 years ago, is broadly associated with Upper Paleolithic industries and repopulated Europe with sporadic admixtures with the previous wave and more systematic ones while moving through Siberia.

**Conclusion:** Leveraging on our integrated approach we propose that, starting from a Eurasian population Hub, the broader colonization of the continent occurred through multiple events of expansion and local extinctions; with each expansion characterized by distinct chronologies, genetics and lithic technologies.

**References:**

**Grants:**

**Conflict of Interest:** None declared.
Background/Objectives: Eurocentric biases in genome-wide association studies have risked exacerbating health disparities. We aimed to: (i) investigate genetic ancestry-related heterogeneity in effect sizes of lung function associated loci; (ii) develop and assess a multi-ancestry genetic risk score (GRS) for lung function (the ratio of forced expiratory volume in 1 second to forced vital capacity, FEV/FVC); and (iii) evaluate the performance of the multi-ancestry GRS in prediction of chronic obstructive pulmonary disease (COPD).

Methods: We assessed the heterogeneity of lung function genetic signals using MR-MEGA. We constructed two GRS both including 442 SNPs associated with lung function in 580,869 individuals across five ancestry groups: (i) using ancestry-specific weights estimated from a fixed-effects meta-analyses across cohorts (discovery dataset) within the same ancestry group; (ii) using weights estimated from a multi-ancestry meta-regression (MR-MEGA) across all cohorts. We evaluated GRS performance over ancestry-matched groups in UK Biobank (independent testing datasets).

Results: We observed 109 (11.4%) signals with nominal evidence of ancestry-correlated heterogeneity (binomial test $p = 5.17 \times 10^{-15}$). In UK Biobank, the multi-ancestry GRS consistently outperformed ancestry-specific GRS in association with FEV/FVC and COPD. The variance of FEV/FVC explained in European ancestry individuals by multi-ancestry GRS has increased from 5.02% to 7.77% compared to our previously published GRS derived in European samples; from 0.74% to 2.35% for African ancestry and from 2.02% to 3.84% for East Asian ancestry.

Conclusion: 11% of lung function loci exhibit ancestry-related heterogeneous effects. Multi-ancestry GRS for FEV/FVC better predicts COPD compared to a GRS based on same-ancestry GRS.

References:

Grants:

Conflict of Interest: None declared.

P20.010.D Estimating diagnostic noise in panel-based genomic analysis

Robin Beaumont 1, Caroline Wright 1

1University of Exeter, Exeter, United Kingdom.

Background/Objectives: Gene panels with strict variant filtering rules are often used for clinical analysis of exomes and genomes. Panels sizes vary, depending upon the genetic heterogeneity of the clinical presentation, affecting the sensitivity and specificity of the test. We investigated diagnostic variant filtering in a population setting using gene panels developed to diagnose a range of heterogeneous monogenic diseases.

Methods: We used the Genotype-2-Phenotype database with the Variant Effect Predictor plugin (VEP-G2P) to identify rare non-synonymous variants in exome sequence data from 200,643 individuals in UK Biobank. We evaluated five clinically curated gene panels: developmental disorders (DD; 1716 genes), heritable eye disease (536 genes), skin disorders (293 genes), cancer syndromes (91 genes) and cardiac conditions (49 genes). We used phenotypic data to evaluate potential clinical overlap between individuals in UK Biobank and gene-disease panels.

Results: As expected, bigger gene panels resulted in more prioritised variants, from $-0.3$ per person in the smallest panel (cardiac) to $-3.5$ using the largest panel (DD) with more in individuals of non-European ancestry. The number of prioritized variants increased with gene length, with some notable outliers. Most prioritized variants were missense, but the number can be reduced by applying REVEL score thresholds or ClinVar pathogenicity assertions, or phasing heterozygotes in biallelic genes.

Conclusion: Although large gene panels may be the best strategy to maximize diagnostic yield in genetically heterogeneous diseases, they will frequently generate false positives. Extreme caution should therefore be applied when interpreting candidate diagnostic variants found incidentally.

References:

Grants: MR/T00200X/1.

Conflict of Interest: None declared.

P20.011.A Reidentifying canonical metabolic networks using observational data

Adriaan van der Graaf 1, Kaido Lepik 1, Zoltan Kutalik 1

1Université de Lausanne, Department of Computational biology, Ecublens, Switzerland.

Background/Objectives: Molecular traits are interesting candidates for causal inference as they can be biomarkers for disease. Mendelian randomization (MR) identifies causal relationships between complex traits. Unfortunately, application of MR to molecular traits is difficult due to lack of instruments and the fact that these networks are only partially observed leading to confounding or pleiotropy.

Methods: We assessed multivariable MR (MVMR) performance in complex network scenarios through simulations of the caffeine metabolism network (KEGG ID has000232). In order to test how well KEGG metabolite networks can be recovered in general, we applied MVMR to metabolite QTLs (mQTL) obtained from two studies comprising up to 30,724 individuals. For this, we first identified 76 metabolites (with 190 reactions between them) in KEGG for which we have mQTLs and then tested how well MVMR can distinguish confirmed reactions from unsupported links.

Results: In various simulation settings, MVMR with Steiger-filter re-identified the caffeine metabolic network edges with well-controlled false positive rates (mean: 0.050, min: 0.030, max: 0.080) and high power (mean: 0.695, min: 0.652). MVMR based on mQTLs successfully reidentified the caffeine network (AUC 0.77), even when mQTLs for many (9/19) metabolites are unavailable. When extending the network to all 76 matching KEGG metabolites, we found slightly attenuated discriminative ability (AUC: 0.69). Extending the network to all 76 matching KEGG metabolites, we found slightly attenuated discriminative ability (AUC: 0.69).

Conclusion: We show that metabolic networks can serve as ground truth for causal inference. MVMR demonstrated discriminative ability for these networks. Our results can also be used to understand why often MVMR fails when applied to molecular traits.

References:

Grants: None declared.

P20.012.B Characterization of Danube Swabian samples on a high-resolution genome-wide basis

Zsolt Bánsai 1,2, Erzsébet Kővesdi 2,3, Katalin Sümegi 1,2, Valerián Adam 1, Ferenc Pálás 1, Attila Miseta 2, Miklós Kásler 2, Bela Melegh 1,2

1Abstracts from the 55th European Society of Human Genetics Conference
Abstracts from the 55th European Society of Human Genetics Conference

P20.013.C Population genetic profiling of hereditary transthyretin amyloidosis in Bulgaria and possible non-coding genetic modifiers

Zornitsa Pavlova\textsuperscript{1,2,3}, Tihomir Todorov\textsuperscript{1,3}, Teodora Chamova\textsuperscript{4}, Mariana Gospodinova\textsuperscript{5}, Vanyo Mitev\textsuperscript{5}, Iaylo Tournev\textsuperscript{4}, Albena Todorova\textsuperscript{1,2,3}

\textsuperscript{1}Genetic Medico-Diagnostic Laboratory Genica, Sofia, Bulgaria; \textsuperscript{2}Medical University Sofia, Medical Chemistry and Biochemistry, Sofia, Bulgaria; \textsuperscript{3}Independent Medico-Diagnostic Laboratory Genome Center “Bulgaria”, Sofia, Bulgaria; \textsuperscript{4}UMBAL Aleksandrovskia, Medical University Sofia, Department of Neurology, Clinic of Nervous Diseases, Sofia, Bulgaria; \textsuperscript{5}University Hospital “St. Ivan Rilski”, Sofia, Bulgaria.

Background/Objectives: In Bulgaria there is high prevalence of vATTR and founder effect for Glu89Gln TTR variant. Haplotype analysis of the other known TTR mutations, located in exons 2 and 3 and screening of exons 1 and 4 in suspected patients is important for exploration of the vATTR diversity. The search of genetic modifiers with possible effect on the manifestation of vATTR could have impact on the disease heterogeneity research.

Methods: Haplotype analysis was performed with microsatellite markers on chromosome 18. DNA samples from vATTR patients and their healthy relatives were analysed. TTR screening in exons 1 and 4 of other suspected patients, DBS screening of Roma newborns for Gly47Glu and regulatory SNP detection in Glu89Gln cohort were performed via Sanger sequencing. All samples were selected from our DNA bank.

Results: Founder effect was proved for the variants Val30Met and Ser77Phe. The results from the DBS screening of newborns for Gly47Glu were negative. We didn’t find any TTR pathogenic variants in exons 1 and 4 in the tested patients. Two of the selected regulatory SNPs in the Glu89Gln cohort are linked in haplotype and hypothetically could correlate to the late disease onset with cardiac manifestation.

Conclusion: Bulgaria has several endemic loci with founder effect for vATTR with distinct genetic background. The presence of Gly47Glu is sporadic event. TTR exons 2 and 3 are proven hot-spot for vATTR in Bulgaria. More studies should be done in order to reach statistical significance for the hypothesis of the effect of regulatory SNPs.

References:

Grants: WI241542 2018 GLOBAL ASPIRE TTR Amyloidosis.

Conflict of Interest: None declared.

P20.014.D Validation of low-pass sequencing approach for HGDP populations

Christian Daviaud\textsuperscript{1}, Zuzana Gerber\textsuperscript{1}, Claire dandine-roulland\textsuperscript{1}, stéphane meslage\textsuperscript{1}, delphine bacq-daian\textsuperscript{1}, Vincent Meyer\textsuperscript{1}, Edith Le Floch\textsuperscript{1}, Anne Boland\textsuperscript{1}, Robert Olaso\textsuperscript{1}, Jean-François Deleuze\textsuperscript{1,2}

\textsuperscript{1}CEA, Centre National de Recherche en Génomique Humaine, EVRY, France; \textsuperscript{2}Centre d’Etude du Polymorphisme Humain (CEPH) Fondation Jean-Dausset, PARIS, France.

Background/Objectives: Low-pass sequencing is whole genome sequencing to an average depth 1× combined with genotype imputation. It has been proposed as a cost-effective alternative to genotyping arrays to identify genetic variants \cite{1}. Most genotyping arrays best capture variation common in populations of European ancestry, while low-pass sequencing mitigates this ascertainment bias and can therefore be applied in under-represented populations. Furthermore, unlike genotyping arrays, it allows effective identification of novel variation. In this study, we applied low-pass sequencing to over 1000 individuals from 52 world populations from the HGDP panel \cite{2}, to evaluate the performance compared to standard 30× whole genome sequencing.

Methods: Libraries from 1062 HGDP individuals (CEPH, Fondation-Jean-Dausset) have been prepared with a miniaturized assay (adapted from Illumina), optimized and fully automated in our laboratory. Libraries (N = 720) were pooled to obtain low coverage (target 1×) and sequenced on a NovaSeq S4 flowcell (Illumina). Coverage metrics were assessed using our custom pipeline. Haplotype imputation was performed on a subset of libraries with a dedicated pipeline (Gencove).

Results: We obtained homogeneous results for all libraries, with mean depth of coverage 1.0× (inter quartile range: IQR = 0.2) and mean breadth of coverage 55.4% (IQR = 7.0%). Coverage was relatively homogeneous across all chromosomes.

Conclusion: This is a proof-of-principle study to evaluate low-pass sequencing approach and test its benefits and limits by analyzing genomes of individuals from populations under-represented in genome reference panels.

References: [1] Li et al. 2021. Genome Res 31(4):S29-S37; [2] Bergström et al. 2020. Science 370(6516):S57-S64.

Grants: LabEx GenMed (grant number ANR-10-LABX-0013).

Conflict of Interest: None declared.
P20.017.C Using non-linear and stratified Mendelian randomisation to explore relationships between body mass index and the plasma proteome

Lucy Goudswaard1, David Hughes1, Adam Butterworth2, Nicole Soranzo3, Ingeborg Hers1, Nicholas Timpson1

1University of Bristol, Bristol, United Kingdom; 2University of Cambridge, Cambridge, United Kingdom; 3Wellcome Sanger Institute, Cambridge, United Kingdom.

Background/Objectives: Elevated body mass index (BMI) raises the risk of diseases such as Type 2 Diabetes (T2D). The circulating proteome has been explored as an intermediate between adiposity and disease, where alterations in growth hormone receptor (GHR) and insulin-like growth factor binding proteins (IGFBP1/2) likely mediate some risk. These associations are often modelled using linear methods but recent studies have indicated that such relationships may be non-linear. This is important when measuring the effect of BMI on protein levels as it may have implications for understanding how weight loss interventions influence disease risk reduction.

Methods: We estimated linear and non-linear associations between BMI and protein (SomaLogic, N>3600) levels using observational and Mendelian randomisation (MR) frameworks in INTERVAL, a UK blood donor cohort (N = 2737). To estimate non-linear associations, an R package was developed (‘glsmr’ - generalized additive model (GAM) and linear stratified MR). Non-linear effects were identified by comparing the observational linear model and non-linear GAM models using a F-test. In addition, BMI stratified (BMI = 18.5-25kg/m², 25-30kg/m² and 30-40kg/m²) linear observational and MR analyses were performed to estimate BMI-protein associations in each stratum.

Results: We observed attenuated estimates for BMI on levels of proteins including leptin, GHR and IGFBPs when comparing the obesity stratum with normal-weight and overweight strata.

Conclusion: These analyses suggest weight loss interventions may be less effective at higher BMIs where plateauing associations between BMI and protein level is observed. This could have implications for weight loss interventions and disease risk reduction.

References:
Grants: University of Bristol alumni, BHF, EPSRC Prostanoid programme, Wellcome Trust.
Conflict of Interest: None declared.

P20.020.B Variation at ADH1B-ADH1C is associated with alcohol and drug dependence in Ukrainians and has pleiotropic effects on metabolic traits

Vitalina Bashynska1,2, Oksana Zahorodnia1,4, Yuliia Borysovyych1,5, Yaroslav Zaplatnikov1,2, Valeria Yasylevych4, Ihor Arefyev4, Darina Osichanskaya1, Anna Pastyr1, Dmytro Krashenikers1, Oksana Zubuga1, Kateryna Murlanov1,2, Alexander Kolida1,2, Artur Karapetov1, Oleksandra Melnychuk1, Olenna Boiko1,2, Gennady Zibereb1, Natalia Slobodianyuk1, Larysa Bal-Pylypko1, Inga Prokopenko1,2, Marika Kaakinen1,2,4

1National University of Life and Environmental Sciences of Ukraine, Faculty food technologies and quality management of agricultural products, Kyiv, Ukraine; 2LightGene LLC, RB&D, Kyiv, Ukraine; 3Taras Shevchenko National University of Kyiv, Institute of High Technologies, Kyiv, Ukraine; 4Otto von Guericke University Magdeburg, Institute of Biology, Faculty of Natural Sciences (FNW), Magdeburg, Germany; 5Heidelberg University, German Cancer Research Center, Heidelberg, Germany; 6Taras Shevchenko National University of Kyiv, EDUCATIONAL AND SCIENTIFIC CENTER “Institute of Biology and Medicine”, Kyiv, Ukraine; 7University of Bonn, Institute of Molecular Physiology and Biotechnology of Plants (IMBIO), Bonn, Germany; 8MedLux Rehabilitation Center, Kyiv, Ukraine; 9BioLabTech LTD, Kyiv, Ukraine; 10Cherobariov Institute of Gerontology, National Academy of Medical Sciences, Laboratory of Epigeneics, Kyiv, Ukraine; 11Diagen Genetic Laboratory, Kyiv, Ukraine; 12Kyiv City Psychoneurological Hospital N3, Psychiatric department for the treatment of patients with alcohol dependence, Glevakha, Ukraine; 13University of Surrey, Department of Clinical and Experimental Medicine, Guildford, United Kingdom; 14Imperial College London, Department of Metabolism, Digestion and Reproduction, London, United Kingdom.

Background/Objectives: Substance use disorders (SUDs), including drug (DD), alcohol (AD) and nicotine (ND) dependence, are global public health threats. SUDs are highly co-morbid with each other and there is evidence for co-morbidity with other health-related traits, including psychiatric and metabolic traits. This suggests underlying shared genetic effects. We investigated variation at the mainly alcohol-associated region ADH1B-ADH1C for a range of SUDs in Ukrainians and the potential pleiotropic effects on other traits.
Methods: We genotyped rs1789891 at ADH1B-ADH1C in 507 individuals with and without SUDs from Ukraine (mean age 32.6±9.6 years). The individuals’ case/control statuses were defined for each phenotype depending on their ICD-10 diagnosis and the standard questionnaire measures. We performed logistic regression for DD (in general and for opiate (OD)/stimulators (AmphD) dependence), AD, and ND, adjusting for sex and other SUDs phenotypes. We further conducted a phenome-wide association study of rs1789891 in UK Biobank (UKBB) data using GeneATLAS.

Results: rs1789891 in Ukrainians was associated with AD (P=0.0087) and DD (P=0.0321), specifically with AmphD (P=0.0261), with the direction of effect corresponding to the established results, but not with OD, ND, or alcohol consumption. rs1789891 showed an association in the UKBB with alcohol intake frequency (P=2.45x10⁻⁴⁴) and suggestive evidence for associations with F10 AD (P=3.27x10⁻⁴), Waist/Hip circumference ratio (P=3.02x10⁻⁴), and Non-insulin-dependent diabetes mellitus (P=3.03x10⁻⁴).

Conclusion: Our results suggest variation at ADH1B-ADH1C may have pleiotropic effects on multiple SUDs as well as metabolic phenotypes.

References:

Grants: University of Surrey Faculty Research Support Fund, US-Ukraine Biotech Initiative Small Research Grant, CrowdScience, Diagen genetic laboratory.

Conflict of Interest: Vitalina Bashynska Lightgene LLC, part-time employment (modest contribution) - scientific consultant in molecular biology, PI and co-l in several research grants (those relevant to the research are declared in the ‘Grants’ section, have received in-kind support (availability of equipment) from Diagen genetic laboratory (2018-2020) and Institute of Genontology NAMS Ukraine (2021-2022), Oksana Zaborhodna: None declared, Yuliia Borysovych: None declared, Yaroslav Zaplatnykov: None declared, Valeria Vasylieva: None declared, Ihor Areiev: None declared, Darina Osichanska: None declared, Anna Pastyria: None declared, Dmytro Krasnienkov: None declared, Oksana Zubuga: None declared, Kateryna Murlanova: None declared, Alexander Koliada: None declared, Artur Karapetov: None declared, Oleksandra Melnychuk: None declared, Olena Boiko: None declared, Gennady Zilberblat: None declared, Nataliia Slobodianyk: None declared, Larysa Bal-Prylypko: None declared, Inga Prokopenko Pi and co-l in several research grants (those relevant to the research are declared in the ‘Grants’ section, Marika Kaakinen Pi and co-l in several research grants (those relevant to the research are declared in the ‘Grants’ section.

P20.021.C Haplotype graph assembly using Swedish individuals

Kristine Bilgrav Saether1, Anna Lindstrand1,2, Jesper Eifeldt1,2,3

1Karolinska Institute, Molecular Medicine and Surgery, Stockholm, Sweden; 2Karolinska University Hospital, Clinical Genetics, Karolinska University Laboratory, Stockholm, Sweden; 3SciLifeLab, Stockholm, Sweden.

Background/Objectives: Next generation sequencing (NGS) methods such as short-read whole genome sequencing (SR-WGS) has transformed clinical analysis, solving complex genomic rearrangements. Regardless, capturing the complexity of the genome and relating phenotype-genotype is challenging using SR-WGS, resulting in patients remaining without a molecular diagnosis. Using long-read data to create a Swedish haplotype graph will allow association of single-nucleotide polymorphisms (SNPs) with haplotypes, easing prediction of disease susceptibility and phenotype-genotype interactions in Swedish patients.

Methods: To enable phasing of SNPs we built a haplotype graph using 62 Swedish individuals sequenced with linked-read sequencing. A custom de Bruijn graph-algorithm was applied to assemble the graph. Using 1000 additional Swedish genomes from the Swegen1 dataset sequenced with mostly short-, but also long-read WGS, we identified common haplotypes in the Swedish population. The haplotypes were compared to phased genomes from the 1000 Genomes Project (1KGP)2 and haplotype reference consortium (HRC)3.

Results: The de Bruijn graph with a kmer length of 2 SNPs is represented by nodes and edges, where traversal will result in a de Bruijn sequence representing a haplotype. We identified >1000 haplotypes, covering 90% of the genome. Using haplotype panels from the 1KGP and HRC, we distinguished population-specific haplotypes and inheritance patterns.

Conclusion: We built a population-specific haplotype graph of Swedish individuals, capturing local genetic diversity. The graph enables accurate phasing and genomic imputation in clinical analysis, as well as GWAS and linkage analysis studies of complex SNPs.

References:

1) Ameur, A., et al., https://doi.org/10.1038/ejhg.2017.130.
2) 1000 Genomes Consortium, https://doi.org/10.1038/nature15393.
3) Haplotype Reference Consortium, https://doi.org/10.1038/ng.3643.

Grants:

Conflict of Interest: None declared.

P20.022.D Lessons learned from the first national population-based carrier-screening program for Duchenne Muscular Dystrophy

Lena Sagi-Dain1, Amihood Singer2, julia grinshpun-cohen2

1Carmel Medical Center, Genetics Institute, Haifa, Israel; 2Israel Ministry of Health, Jerusalem, Israel.

Background/Objectives: The Israeli Ministry of Health genetic screening program for reproductive purposes is mainly aimed at severe incurable diseases with high rates of infant and childhood morbidity and/or mortality, a carrier frequency of at least 1:60 and/or a disease frequency of 1 in 15 000 live births. Recently, Duchenne Muscular Dystrophy (DMD) testing was included in pan-ethnic screening tests, and our objective was to summarize the results of first year implementation of this test.

Methods: Data acquisition for this study was performed by retrospective search of Ministry of Health database, encompassing the reports of all national laboratories performing genetic screening tests. Deletion and duplication testing of the 79 DMD exons was performed by multiplex ligation-dependent probe amplification technology. In case of single exon deletion, sequencing of the specific exon was performed to rule out underlying single nucleotide polymorphism (SNP).

Results: Of overall 35,830 DMD tests, 49 female carriers were noted (0.14%, 1:731). Of these, 41 constituted in-frame deletions and duplications, and only 8 (0.02%, 1:4479) were out-of-frame variants. Additional 201 single exon deletions were subsequently defined as false-positives due to underlying SNP (0.56%, 1:178), the majority of these are exon 8 deletion in North African Jewish population, and exon 48 deletion in Arab Muslim population.

Conclusion: Interpretation of population-based DMD carrier-screening might be highly complex, occasionally requiring
additional genetic testing methods and ethical considerations. Multicenter data registry, including ethnic origin and familial segregation in selected cases, is crucial for optimal definition of the results and informed decisions regarding prenatal testing.

References:

Conflict of Interest: None declared.

P20.024.B A genome-wide screening of plasma circulating microRNAs associated with obesity, body fat distribution and fat mass: the Rotterdam Study

Yasir J. Abozaid1, Xiaofang Zhang1, Michelle Mens2, Fariba Ahmadianz2, Marlou Limpens3, Arfan Ikrar1, Fernando Rivadeneira4, Trudy Voortman1, Maryam Kavousi1, Mohsen Ghanbari1

1Erasmus MC University Medical Center, Epidemiology, Rotterdam, Netherlands; 2Harvard T.H. Chan School of Public Health, Epidemiology, Boston, United States; 3University Utrecht Medical Center, Utrecht, Netherlands; 4Erasmus MC University Medical Center, Internal Medicine, Rotterdam, Netherlands.

Background/Objectives: MicroRNAs represent a class of small non-coding RNAs that regulate gene expression post-transcriptionally and are implicated in the pathogenesis of different diseases. However, limited studies have investigated the relationship between circulating miRNAs and obesity-related traits in large-scale using population-based data.

Methods: We conducted a genome-wide profile of circulating miRNAs in plasma, collected between 2002 and 2005, in 1208 participants from the Rotterdam Study. Obesity was measured by body mass index (BMI) and waist-to-hip ratio (WHR) and body composition including fat mass index (FMI) and android-fat to gynoid-fat ratio (AGR) were measured using Dual X-ray Absorptiometry. Multivariable linear regression models were used to assess the association of 591 miRNAs well-expressed in plasma with BMI, WHR, FMI and AGR adjusted for potential covariates. We further sought for the association of identified miRNAs with cardiovascular and metabolic diseases in previous studies.

Results: Plasma levels of 12 miRNAs were associated and overlapped between all four traits (at Bonferroni-corrected P < 8.46 × 10^-3). The most significant association was with miR-193a-5p, which was also associated with type 2 diabetes and hepatic steatosis in the Rotterdam Study. Besides, 4 miRNAs were particularly associated with fat mass and body fat distribution; among them, three miRNAs were associated with FMI, and miR-378i only with AGR. Five of the obesity-related miRNAs and two of the fat distribution-associated miRNAs have been linked previously to cardiovascular disease.

Conclusion: This study indicates that plasma levels of several miRNAs are associated with obesity traits and body fat distribution that may serve as potential biomarkers for obesity-related diseases.

References:

Grant:

Conflict of Interest: None declared.

P20.026.D Multiple occurring copy number variants that matter

Michaela Hyblová1,2, Marcel Kucharík3, Martina Sekelská1,2, Gabriel Minarík1,2

1Medirex Group Academy n.p.o., Nitra, Slovakia; 2Trisomy test Ltd., Nitra, Slovakia; 3Geneton Ltd., Bratislava, Slovakia.

Background/Objectives: NIPT has proven its efficacy, reliability, and high positive predictive value (PPV) in common aneuploidy screening, sex chromosomal aneuploidy, or even copy number variants. Simultaneously, they may be a precious source of information on maternal genome variation. Large CNVs are usually not an issue to interpret, however, many small and frequent CNV remain ambiguous. We reviewed our NIPT data on such CNV and determine which are the most common, compare them with frequencies in Gnomad. We defined them as multiple occurring variants (movs).

Methods: Paired end whole genome sequencing with low coverage on NextSeq was performed on pregnant plasma samples with at least 5 million reads. CNV detection algorithm was applied to more than 6000 unique analyses.

Results: We identified 20 movs not surprisingly most of them are duplications (16) and 4 deletions. Few of them have conflicting interpretations, and almost none of them is a clear benign variant. The frequencies varied from 0.2-1.9%. In 4 cases there was no match, in 3 cases partial overlay and 13 cases with almost complete different or comparable frequency compared to Gnomad, respectively.

Conclusion: We attempted to assess CNVs marked as movs in the context of genomic content and allele frequency.

References:

Grant:

Conflict of Interest: None declared.

P20.027.A Genetic ancestry supports cultural history of northwestern Himalayan Muslims

Abhishek Singh1, mukesh thakur2, vivek sahaipal3, satish kumar4

1National Forensic Sciences University, Forensic Biotechnology, Gandhinagar, India; 2Zoological Survey of India, molecular systematics division, New Alipore, India; 3State Forensic Science Laboratory, Directorate of forensic services, Shimla, India.

Background/Objectives: The Himalayas, a linguistic and cultural metacenter inhabiting diverse human populations has also been a focal point of invasions from both the west and south-eastern regions. With the varied and complex pattern of human settlements, the northwestern Himalaya has majorly evolved under the influence of Afghan-Iranian cultures from the west blending with the Tibetan culture from the north and Indic culture from the south. Despite the social amalgamation, the Muslim populations are believed to retain their distinct genetic signature due to restricted gene flow.

Methods: To establish the influence of social amalgamation on the genetic makeup, we investigated population structure based on 20 highly polymorphic autosomal STR markers in 187 individuals comprising three Muslim populations (Kashmir, Ladakh, and Himachal Pradesh) inhabiting northwestern Himalaya, India. Further, we evaluated the previous theories about the social structure and subsistence of cultures and identified the genetic affinities with 16 different Muslim populations comprising 3610 individuals.
Results: Overall, the phylogenetic analysis demonstrated Kashmiri Muslims in close affinity with other Muslim populations of the neighbouring countries, while the Muslims of Ladakh and Himachal Pradesh showed two different lineages. The Bayesian and Non-Bayesian clustering analysis revealed diverse population genetic structures between the three Muslim populations of western Himalaya, India.

Conclusion: These genetic patterns suggest that the genetic signature of all three populations corroborate with the historic patterns of human settlements and the Muslim populations still retain their genetic signature despite social amalgamation over the centuries.

References:

Grants:

Conflict of Interest: None declared.

P20.028.B Homozygosity predominantly affects hypertrophic cardiomyopathy minor genes in an Egyptian clinical cohort

Mona Allouba1, Roddy Walsh2, Aala Afly3, Sarah Halawa1, Aya Galal1, Mohammed Hosny4,5, Mariam Fathy1, Pantazis Theotokis5, Amany Ellithy1, Rachel Buchanan5,6,7, Risha Govind7,8, Shehab Anwer9, Ahmed El Guindy3, James Ware5,6,11, Paul Barton5,6,11, Yasmine Aguib1,5, Magdi H. Yacoub6,12,13

1Aswan Heart Centre - Magdi Yacoub Heart Foundation, Life Sciences, Aswan, Egypt; 2Amsterdam University Medical Center, Department of Experimental Cardiology, Amsterdam, Netherlands; 3Aswan Heart Centre, Magdi Yacoub Heart Foundation, Department of Cardiology, Aswan, Egypt; 4Ksar Al-Aini Medical School, Cairo University, Department of Cardiology, Cairo, Egypt; 5National Heart and Lung Institute, Imperial College London, London, United Kingdom; 6Royal Brompton and Harefield Hospitals, London, United Kingdom; 7Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom; 8National Institute for Health Research (NIHR) Biomedical Research Centre, South London and Maudsley NHS Foundation Trust and King's College London, London, United Kingdom; 9Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom; 10Aswan Heart Centre, Magdi Yacoub Heart Foundation, Aswan, Egypt; 11MRC London Institute of Medical Sciences, Imperial College London, London, United Kingdom; 12Aswan Heart Centre, Magdi Yacoub Heart Foundation, Aswan, Egypt; 13Harefield Heart Science Centre, United Kingdom, London, United Kingdom.

Background/Objectives: Consanguinity is prevalent in Egypt (35%) resulting in a high incidence of homozygosity. The influence of homozygosity on the genetics of hypertrophic cardiomyopathy (HCM) has not been adequately studied. The aim of this study is to define the genetic architecture of HCM in Egypt using ethnically-matched case and control cohorts.

Methods: Prospective Egyptian patients (n = 514) and controls (n = 400) were recruited to Aswan Heart Centre for clinical phenotyping and genetic testing for 174 genes implicated in inherited cardiac conditions (Illumina). Rare variation (gnomAD nototyping and genetic testing for 174 genes implicated in inherited cardiac conditions) was filtered according to the American College of Medical Genetics (ACMG) guidelines and compared with a prospective HCM cohort of predominantly European ancestry (n = 684).

Results: Significantly fewer rare variants detected in Egyptian patients could be classified as (likely) pathogenic compared to Europeans (40.8% vs. 61.6%, p-value = 1.6x10-5). Incorporating analysis from these Egyptian case-control cohorts into the ACMG guidelines increased this yield to 53.8%. Homozygous variants were more frequently observed in Egyptian patients (4.1% vs 0.1%, p-value = 2x10-7), with variants in the minor HCM genes MYL2, MYL3 and CSRP3 more likely to present in homozygosity than the major genes (MYH7, MYBPC3 and troponins), suggesting such variants are less penetrant in the heterozygous state.

Conclusion: The integration of Egyptian-specific genetic and phenotypic data significantly improves variant interpretation in HCM and consequently the precision of genetic testing. The observed prevalence of homozygosity and rare variation in minor HCM genes in Egyptian patients provides important insights into its disease-mechanisms and genetics.

References:

Grants:

Conflict of Interest: None declared.

P20.030.D Deamination of adenine to guanine is a signature of oxidative damage in mitochondrial DNA

Alina Mikhailova1,2, Alina Mikhailova3, Evgenii Tretiakov4, Victor Shamanskiy5, Dmitrii Illushchenko5, Valerian Yuurov5, Vsevolod Makeev6, Dmitriy Knoorre7, Alexandre Reymond6, Konstantin Khrapko8, Konstantin Gunbin9, Konstantin Popadin10,11

1Vavilov Institute of General Genetics, Moscow, Russian Federation; 2Immanuel Kant Baltic Federal University, Kaliningrad, Russian Federation; 3University of Münster, Münster, Germany; 4Medical University of Vienna, Vienna, Vienna, Austria; 5Moscow State University, The A.N. Belozersky Institute Of Physico-Chemical Biology, Moscow, Russian Federation; 6University of Lausanne, Center for Integrative Genomics, Lausanne, Switzerland; 7Northeastern University, Boston, United States; 8Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.

Background/Objectives: Since mitochondria maintain the oxidative metabolism, it has been traditionally assumed the mitochondrial DNA is affected by the oxidative damage. However, the classical signature of the oxidative damage, G>T, is extremely rare in mtDNA, suggesting that either there is no oxidative damage in mitochondria or it has another - mitochondrial specific and yet unknown signature.

Methods: Since oxidative damage is a normal byproduct of oxidative metabolism, which in turn is associated with different life-history traits, we performed a large-scale comparative-species study analyzing somatic mtDNA mutations with life-history traits. We reconstructed mtDNA mutational spectra for thousands of vertebrate species analyzing all available intraspecies mitochondrial polymorphisms at fourfold degenerate synonymous sites.

Results: First, within mammals, we correlated mtDNA mutational spectrum of hundreds species with their life-history traits and observed that the fraction of Ah>Gh transitions (heavy chain notation) is higher in species with longer generation length (https://doi.org/10.1101/2021.12.03.460832). Second, focusing on cold-blooded fishes (Actinopterygii) we observed that the frequency of the same transition Ah>Gh positively correlates with the ambient temperature (https://doi.org/10.1101/2020.07.25.221184). Finally, analyzing somatic mtDNA mutations in different human tissues we observed that Ah>Gh is more common in normoxic tissues, enriched in molecular oxygen.

Conclusion: Aging in mammals, high ambient temperature in fishes and normoxia in human tissues can be similar in terms of the increased oxidative damage. Thus we propose that Ah>Gh is a mitochondria specific mutational signature of the oxidative damage.

References:

Grants: Supported by RSF №21-75-20143.

Conflict of Interest: None declared.
P21 FUNCTIONAL GENOMICS AND EPIGENOMICS

P21.001.A Gene regulation in T-cells from PsA patients differs between peripheral blood and the inflamed joints: implications for the interpretation of GWAS signals

Chenfu Shi1, Danyun Zhao1, James Ding1, Carlo Ferrazzano1, Charlotte Wynn1, Antonios Frantzeskos1, John Bowes1, Pauline Ho2, Anne Barton1,3,4, Magnus Rattray2,5, Gisela Orozco1,3,4

1The University of Manchester, Centre for Genetics and Genomics Versus Arthritis, Manchester, United Kingdom; 2Manchester University NHS Foundation Trust, The Kellgren Centre for Rheumatology, Manchester Royal Infirmary, Manchester, United Kingdom; 3Manchester University NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom; 4The University of Manchester, Lydia Becker Institute of Immunology and Inflammation, Manchester, United Kingdom; 5The University of Manchester, Division of Informatics, Imaging and Data Sciences, Manchester, United Kingdom.

Background/Objectives: GWAS studies have identified the variants associated with complex diseases. Most of these affect regulatory elements which are cell type and state specific, and can affect distally located genes via chromatin interaction mechanisms.

We and others have used functional genomics techniques in cell lines to provide putative mechanisms for many loci with previously unknown function. It is known that significant differences exist between cell lines and primary cells. However, differences between between samples from healthy volunteers and patients, in particular from the affected tissue, have not been exhaustively investigated. Here we assess the impact of using primary cells derived from PsA patients in functional genomics studies.

Methods: RNA-seq and ATAC-seq were performed on CD4+ and CD8+ T cells isolated from blood from 10 controls and 48 PsA patients and from 6 synovial fluid samples.

Results: We find subtle differences between PsA patients and healthy controls in cells isolated from blood. In contrast, T cells isolated from synovial fluid showed substantially more differences compared to those isolated from patient’s blood. Interestingly, we find that CD4+ T cells display more DE genes compared to CD8+ T cells. These genes also enriched more strongly for immune pathways compared to synovial CD8+ T cells.

Conclusion: This study indicates the importance of not only studying GWAS loci in relevant primary cells from patients, but also that attention needs to be given to cells isolated from the affected site.

References:

Grants: Funded by the Wellcome Trust (207491/Z/17/Z, 215207/Z/19/Z), Versus Arthritis (21754), NIHR Manchester Biomedical Research Centre, Medical Research Council (MR/N00017X/1).

Conflicts of Interest: None declared.

P21.003.C DNA methylation signature for JARID2-neurodevelopmental syndrome

Liselot van der Laan1, Eline Verberne1, Sadegheh Haghshenas2, Kathleen Rooney3, Michael Levy4, Marielle Alders5, Saskia M. Maas6, Sandra Jansen1, Agne Lieden3, Britt M. Anderlid3, Louise Rafael-Croes4, Philippe M. Campeau4, Ayeshah Chaudhry5, David Koolen7, Rolph Punt1, Anna C.E. Hurst4, Frédéric Tran Mau-Them9, Laetitia Lambert10, Ange-Line Bruel11, Bertrand Isidor12, Marcel Mannens1, Bekim Sadikovic1, Peter Henneman1, Mieke van Haelst13

1Amsterdam UMC, Human Genetics, Amsterdam, Netherlands; 2Western University, Department of Pathology and Laboratory Medicine, London, Canada; 3Karolinska University Hospital, Department of Clinical Genetics, Stockholm, Sweden; 4Dr. Horacio E. Oduber Hospital, Department of Pediatrics, Oranjestad, Aruba; 5University of Montreal, Department of Pediatrics, Montreal, Canada; 6Trillium Health Partners, Department of Laboratory Medicine and Genetics, Mississauga, Canada; 7Radboud Institute for Molecular Life Sciences and Donders Institute for Brain, Cognition and Behaviour, Radboud university medical center, Department of Hum Genet, Nijmegen, Netherlands; 8University of Alabama at Birmingham, Department of Genetics, Birmingham, United States; 9CHU Dijon-Bourgogne, Equipe Génétique des Anomalies du Développement (GAD, Dijon, France); 10CHRU Nanc, Service de Génétique Clinique, Nancy, France; 11Université de Bourgogne, Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (TRANSALD), Dijon, France; 12CHU de Nante, Service de génétique médicale, Nantes, France.

Background/Objectives: JARID2 encodes a deglutamylase that regulates functional tubulin glutamylation levels in cilia. Mutations are associated with Retinitis Pigmentosa (RP). However, disease mechanisms associated with JARID2 variants require further investigation. This study investigated the effect of patient JARID2 mutations in JARID2 knockout ARPE19 cells to identify the potential molecular function of JARID2 and mechanisms causing retinal dysfunction.

Methods: Immunofluorescence confocal imaging, western blotting, transfection with an JARID2-eGFP expression construct and site-directed mutagenesis were used to investigate cillum structure modifications and protein expression in wild-type (WT) ARPE19 cells and CRISPR knockout cells JARID2+/−, and to characterise the effect of variants in patients with RP. RNA-seq data was used to investigate transcriptomic changes.

Results: JARID2+/− cells have reduced levels of JARID2 expression, hyperglutamylation, significantly shorter cilia, and lower percentage of ciliated cells than WT cells (p<0.001). WT JARID2-eGFP expression in mutant cells rescues the ciliary phenotype, whilst mutated versions affect ciliogenesis at variable levels, ranging from increased ciliogenesis to loss of cilia. Gene ontology (GO) analysis of genes overexpressed in JARID2−/− cells shows enrichment of genes with GO terms glutamate receptor signalling, nervous system development and negative regulation of neuron apoptotic process.

Conclusion: This work reports a clear phenotype of JARID2 deficient human cells consisting of hyperglutamylation, short cilia and reduced ciliogenesis, provides functional and transcriptomic data that could be used as a basis for investigating targets for treatment of retinal degeneration and supports the use of mutant cells models to obtain functional data of patient mutations.

References:

Grants:

Conflict of Interest: None declared.
Background/Objectives: JARID2 pathogenic variants cause a neurodevelopmental syndrome, that is characterized by developmental delay, cognitive impairment, hypotonia, autistic features, behavior abnormalities and dysmorphic facial features. JARID2 encodes a transcriptional repressor protein that regulates the activity of various histone methyltransferase complexes (1).

Methods: DNA methylation (DNAm) profiles were generated. Raw data was qC processed and analyzed in R. A Linear model (limma) was applied to obtain differential methylated positions between patients and controls. An unsupervised model was applied in order to assess the robustness of the JND classifying probes, wherein we followed an eight round cross-validation. Subsequently we applied a support vector machine to construct the final JND DNAm signature.

Results: Genome-wide DNAm analysis indicated a clear and robust separation between patients with pathogenic variants and controls. Cross-validation analysis confirmed the findings of a distinct and reproducible epigenotype. Patients carrying a Variation of Uncertain Significance (VUS) clustered with the control group.

Conclusion: We identified a highly specific genome-wide DNAm signature for patients with JARID2-neurodevelopmental syndrome. The signature can be used to assess and reclassify JARID2 genomic variants. In addition, the JARID2 signature can be added to the growing list of syndromes that can be confirmed by EpiSign analysis (LHSC Epigenetics), thus further confirming the value of EpiSign as a diagnostic tool in patients with suspected genetic disorders.

References: 1. Verberne EA, Goh S, England J, van Ginkel M, Rafael-Croes L, et al. JARID2 Haploinsufficiency is associated with a clinically distinct neurodevelopmental syndrome. Genet Med. 2021;23(2):374-83.

Grants: No Grants.

Conflict of Interest: Liselot van der Laan part time, Eline Verberne full, Sadegheh Haghsenas full, Kathleen Rooney (full or part-time), Michael Levy (full or part-time), Marielle Alders full, Saskia M. Maas (full or part-time), Sandra Jansen (full or part-time), Michael Levy (full or part-time), Agne Lieden (full or part-time), Britt M. Anderlid (full or part-time), Louise Rafael-Croes (full or part-time), Philippe M. Campeau (full or part-time), Ayeshah Chaudhry (full or part-time), David Koolen (full or part-time), Ángel Carracedo (full or part-time), Rafael-Croes L, et al. JARID2 Haploinsufficiency is associated with a clinically distinct neurodevelopmental syndrome. Genet Med. 2021;23(2):374-83.

P21.004.D The effect of polymorphic inversions on DNA methylation and its modulation by the early-life exposome

Natalia Carreras Gallo1, Alejandro Cáceres1,2,3, Laura Balagüé1, Carlos Ruiz Arenas4, Sandra Andrusaitë5, Ángel Carracedo1,2,3, Maribel Casas1,2,8, Leda Chatzi9, Regina Graziulevičiūnė,9 Kristine Gutzkow10, Johanna Lepeule11, Lea Maitre1,2,8, Mark Nieuwenhuijzen1,2,8, Remy Slama11, Nikos Stratakis12, Cathrine Thomsen13,2, José Urquiza12,2,8, John Wright12, Tiffany Yang12,2,8, Geórgia Escaramís2,9,13,14, Mariona Bustamante12,8, Martine Vrijheid12,8, Luis Pérez-Jurado15,16, Juan Ramón González1,1,16

1ISGlobal, Barcelona, Spain; 2CIBERESP - Centro de Investigación Biomédica en Red en Red Enfermedades Raras, Santiago de compostela, Spain; 3Department of Medicine of USC, Department of Preventive Medicine, Los Angeles, United States; 4ISGlobal, Barcelona, Spain; 5Keck School of Medicine of USC, Department of Preventive Medicine, Los Angeles, United States; 6Folkehelseinstituttet, Department of Environmental Health, Oslo, Norway; 7Institute for Advanced Biosciences, Team of Environmental Epidemiology applied to Reproduction and Respiratory Health, La Tronche, France; 8Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom; 9Facultad de Medicina - Universitat de Barcelona, Department of Biomedical Science, Barcelona, Spain; 10University of Girona - UdG, Research Group on Statistics, Econometrics and Health (GRECS), Girona, Spain; 11Hospital del Mar Research Institute (IMIM), Genetics Service, Barcelona, Spain; 12Universitat Autònoma de Barcelona, Bellaterra, Spain.

Background/Objectives: Polymorphic genomic inversions are chromosomal variants that play important roles in chromosome evolution, environmental adaptation, and complex traits. Although their effect on local gene expression is demonstrated, it is less known the extent to which inversions influence DNA methylation and how this influence depends on environmental exposures.

Methods: We analysed data of 1,009 children from the Human Early Life Exposome (HELIX) project and 39 prenatal heart tissue samples. We investigated the DNA methylation patterns in blood of three common human inversions, at 8p23.1, 16p11.2, and 17q21.3, and the modulation of these patterns by 64 early-life exposures.

Results: We found inversion-state specific methylation patterns that extended across the three inversion regions in both datasets. Additionally, at CpG level, we identified several inversion-exposure interactions on methylation levels for the early-life exposome. Within these interactions, we observed, for instance, that children homozygous for inv-8p23.1 and exposed to higher meat intake hypermethylated the TDH gene; while those exposed to higher manganese hypomethylated GATA4; and those exposed to parental smoking hypomethylated TRMT9B. These genes have been associated with obesity, heart development, and respiratory disease, respectively.

Conclusion: Although numerous significant inversion-exposure interactions in important genes deserve further scrutiny, our data suggest that the effect of numerous environmental exposures in childhood depends on the individual genetic background given by the inversions via allele-specific methylation patterns.

References: Puig et al, Brief. Funct. Genom. (2015). Ruiz-Arenas et al, PLoS Genet. (2019).

Grants: FP7/2007-2010/308333 (HELIX); H2020-EU.3.1.2./874583 (ATHLETE); ISCIII (PI17/01225 and PI17/01935); PERIS-GenCat/SLT017/20/000061 (Carreras-Gallo fellowship).

Conflict of Interest: None declared.

P21.005.A Ago-RIP sequencing identifies new microRNA-449a-5p target genes increasing sorafenib efficacy in hepatocellular carcinoma

Thea Reinkens1, Amelie Stalke2, Nicole Hugé3, Beate Vajan4, Marlies Eilers2, Vera Schäffer5, Oliver Dittrich-Breiholz2, Brigitte Schlegelberger2, Thomas Illig6, Britta Skawran7

1Hannover Medical School, Hannover, Germany; 2Hannover Medical School, Hannover, Germany.

Background/Objectives: Multi-tyrosine kinase inhibitor sorafenib has been used as standard treatment in advanced hepatocellular carcinoma (HCC) for the last fourteen years. Unfortunately, drug resistance develops in many cases. Therefore, we aimed to
mitigate drug resistance and to improve sorafenib efficacy in HCC. MicroRNAs play a significant role in targeting genes involved in tumor control suggesting microRNA/sorafenib combination therapy as a promising treatment option in advanced HCC.

Methods: MiR-449a-5p target genes were identified by Ago-RIP-sequencing and validated by luciferase reporter assays and expression analyses. Target gene expression and survival data were analyzed in public HCC datasets. Tumor-relevant functional effects of miR-449a-5p and its target genes as well as their impact on the effects of sorafenib were analyzed using in vitro assays. A transwell co-culture system was used to survey anti-angiogenic effects of miR-449a-5p.

Results: PEAI5, PPP1CA and TUFT1 were identified as direct target genes of miR-449a-5p. Overexpression of these genes correlated with a poor outcome of HCC patients. Transfection with miR-449a-5p and repression of miR-449a-5p target genes inhibited cell proliferation and angiogenesis, induced apoptosis and reduced AKT and ERK signaling in HLE cells. Importantly, miR-449a-5p potentiated the efficacy of sorafenib in HCC cells via downregulation of PEAI5, PPP1CA and TUFT1.

Conclusion: This study provides detailed insights into the targetome and regulatory network of miR-449a-5p. Our results demonstrate that targeting PEAI5, PPP1CA and TUFT1 via miR-449a overexpression could have significant implications in countering sorafenib resistance suggesting miR-449a-5p as a promising candidate for a microRNA/sorafenib combination therapy.

References:

Grants: Deutsche Krebshilfe: 70113683.
Conflict of Interest: Thea Reinkens: None declared, Amelie Stalke: None declared, Nicole Hude: None declared, Beate Vajen Deutsche Krebshilfe: 70113683, Marlies Eilers: None declared, Vera Schäffer: None declared, Oliver Dittrich-Breiholz: None declared, Brigitte Schlegelberger: None declared, Thomas Illig: None declared, Britta Skawran Deutsche Krebshilfe: 70113683.

P21.006.B Differential gene expression by sex in skeletal muscle cell types

Dan Ciotlos1;2, Sarah Hanks1;2, Juhyun Kim1;2, Arushi Varshney3, Nandini Manickam3, Michael Erdos4, Anne Jackson1;2, Heather Stringham3, Michael Boehnke1;2, Heikki Koistinen5;6;7, Francis Collins5, Stephen Parker3;4, Laura Scott1;2

1University of Michigan, Department of Biostatistics, Ann Arbor, United States; 2University of Michigan, Center for Statistical Genetics, Ann Arbor, United States; 3University of Michigan, Department of Computational Medicine and Bioinformatics, Ann Arbor, United States; 4National Institutes of Health, National Human Genome Research Institute, Bethesda, United States; 5Finnish Institute for Health and Welfare, Department of Public Health and Welfare, Helsinki, Finland; 6University of Helsinki and Helsinki University Hospital, Department of Medicine, Helsinki, Finland; 7Minerva Foundation Institute for Medical Research, Helsinki, Finland; 8University of Michigan, Department of Human Genetics, Ann Arbor, United States.

Background/Objectives: Skeletal muscle differs in size and fiber-type composition by sex. Identifying sex differences in cell-type gene expression will point to mechanisms underlying these differences.

Methods: We performed bulk tissue and single nucleus RNA-sequencing from skeletal muscle biopsies from live Finnish FUSION Tissue Biopsy Study donors (n = 258, 41.5% female). We clustered nuclei into 13 cell types. We tested for differential gene expression by sex in bulk tissue and cell types using linear regression, adjusting for age and technical covariates. We identified gene sets with higher expression levels in one sex using gene set enrichment analysis (FGSEA).

Results: Across cell types, type 1, 2A, and 2X muscle fibers had the highest proportion of genes differentially expressed by sex (9.4-16.4%), with smaller proportions in satellite cells (muscle progenitor cells) (2.0%). In bulk tissue, 32.6% of genes were differentially expressed by sex (FDR<0.05), likely reflecting greater power. Gene sets differentially expressed by sex were found in fiber types (2.4-4.3% of tested gene sets), satellite cells (0.03%), and bulk tissue (16.0%). The majority of gene sets showed consistent enrichment by sex across cell types and in bulk tissue; however, a small subset showed enrichment in opposite directions. In satellite cells, cell-cell adhesion genes were enriched for higher expression in males (ES = 0.34, p = 8.7x10−12), but enriched for higher expression in females in fiber types (min p = 0.003, FDR > 0.05) and bulk tissue (ES = −0.37, p = 4.2 x 10−12).

Conclusion: We identified gene sets with similarities and differences in expression by sex between muscle fibers and satellite cells, which may point to cell-type regulatory differences by sex.

References:

Grants: DK062630, T32 HG000040.
Conflict of Interest: Dan Ciotlos: None declared, Sarah Hanks University of Michigan, F31 HG011186, Juhyun Kim University of Michigan, Arushi Varshney University of Michigan, Nandini Manickam University of Michigan, Michael Erdos National Institutes of Health, Intramural research support ZIA HG000024-28, Anne Jackson University of Michigan, Heather Stringham University of Michigan, Michael Boehnke University of Michigan, DK062370, Heikki Koistinen Finnish Institute for Health and Welfare; University of Helsinki and Helsinki University Hospital, Francis Collins National Institutes of Health, Intramural research support ZIA HG000024-28, Stephen Parker University of Michigan, Laura Scott University of Michigan, DK062370, Training Grant T32 HG000040.

P21.007.C Profiling genome-wide DNA methylation patterns in human aortic and mitral valves

Sarah Halawa1;2, najma latif3;4, Yuan-Tsan Tseng1;4, Ayman M. Ibrahim1;3, Adrian H. Chester3;4, Ahmed Moustafa2;6, Yasmine Aguib1;4, Magdi H. Yacoub1;3;4

1Magdi Yacoub Aswan Heart Centre, Cairo, Egypt; 2Biotechnology Graduate Program, American University in Cairo, New Cairo, Egypt; 3Magdi Yacoub Institute, Heart Science Centre, Harefield, United Kingdom; 4NHLI, Imperial College London, London, United Kingdom; 5Zoology Department, Faculty of Science, Cairo University, Cairo, Egypt; 6Department of Biology, American University in Cairo, New Cairo, Egypt.

Background/Objectives: Cardiac valves exhibit highly complex structures and specialized functions. Valvular gene expression is tightly regulated by a variety of mechanisms including epigenetic factors such as DNA methylation. To date, methylation fingerprints of non-diseased human aortic and mitral valves have not been adequately studied.

Methods: Twelve non-diseased valves free from calcification (6 aortic, 6 mitral valves, 10 males:2 females, age range 42–64 years) were de-endothelialised and subjected to reduced representation bisulphite sequencing (RRBS) on Illumina HiSeq2500. Upon FastQC, reads were trimmed via Trimgalore and mapped to hg19 using Bismark. Extracted methylation levels were analyzed using methylKit. Genes with differentially methylated (DM) promoters were categorized using PANTHER and used for network construction using NetworkAnalyst.

Results: Analysis of methylation detected at 1601 promoters genome-wide revealed 584 DM promoters, of which 13 were reported in endothelial mesenchymal trans-differentiation (EMT), 37 in aortic and mitral valve disease and 7 in ECM remodeling. Genes associated with the DM promoters were enriched for WNT, Cadherin-, Endothelin-,- PDGF- and VEGF- signaling implicated in
valvular physiology and pathophysiology and for TGFβ, NOTCH- and Integrin- signaling involved in EMT and ECM remodeling.

**Conclusion:** This data provides the first insight into differential regulation of human aortic and mitral valve tissue and identifies candidate genes linked to DM promoters. This study will contribute to the understanding of valve biology, valve tissue engineering approaches and to the identification of relevant drug targets.

**References:**

**Grants:** This was funded by Magdi Yacoub Institute (MYI) and Magdi Yacoub Foundation (MYF). S.H. was partially supported by Al Ali Foundation.

**Conflict of Interest:** None declared.

**P21.008.D Sex differences in DNA methylation underlay sex differences in children’s gene expression**

Carlos Ruiz Arenas1,2, Alejandro Cáceres2,3, Mariona Bustamante2,3, Martine Vrijheid2,3,4, Luis Pérez-Jurado1,2,5, The HELIX Consortium6

1Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain; 2Universitat Pompeu Fabra – DCEXS, Barcelona, Spain; 3ICibersalud, Barcelona, Spain; 4CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain; 5Hospital del Mar, Genetics Service, Barcelona, Spain.

**Background/Objectives:** Sex differences in gene expression in childhood, which could explain differences in prepubertal development, behaviour and health risks between boys and girls, remain largely unknown.

Here, we aim to (i) identify genes with sex-specific gene expression in children and to (ii) determine whether these differences in gene expression can be explained by sex-specific DNA methylation patterns.

**Methods:** Using data from the HELIX project (823 6-9-year-old children from 6 European cohorts), we have performed transcriptome and epigenome-wide association studies of 23,054 autosomic coding genes and 386,518 autosomic CpGs on sex. The model was adjusted for cohort, age and 6 blood cell types.

**Results:** A total of 2,051 autosomic coding genes (8.9%) and 120,952 autosomic CpGs (31.3%) were significantly associated with sex (FDR < 0.05). 980 genes (47.8%) and 44,081 CpGs (36.4%) showed higher expression or methylation in boys. Of the 2,051 genes with sex differences, 1,339 (65.3%) could be explained by sex differences in DNA methylation. These 1,339 genes were enriched in 114 GO terms (FDR < 0.05), 48 of them directly associated with immune response.

**Conclusion:** Girls and boys present genome-wide differences in gene expression in autosomal chromosomes. These transcriptomic differences can be partly explained by sex differences in DNA methylation and can lead to differences in immune response and associated phenotypes.

**References:**

**Grants:** FP7/2007-2008/308333 (HELIK project); H2020-EU.3.1.2./874583 (ATHLETE project); & FIS PI21/00050.

**Conflict of Interest:** Carlos Ruiz Arenas: None declared, Alejandro Cáceres: None declared, Mariona Bustamante: None declared, Martine Vrijheid: None declared, Luis Pérez-Jurado Stock options in QGenomics, Advisory Board in QGenomics, The HELIX Consortium: None declared.

**P21.009.A Characterisation of new key cis-regulatory elements of the CFTR gene**

Clara Blotas1,2,3, Mégane COLLOBERT1,2,3, Ozvan Bocher1,2,3, Anaïs LE NABEC1,2,3, Emanuelle Génin1,2,3, Claude Férec1,2,3,4, Stéphanie Moisan1,2,3,4

1INSERM UMR1078, GBB, Brest, France; 2University of Bretagne Occidentale, BREST, France; 3French Blood Institute, BREST, France; 4CHRU Brest, Laboratory of Molecular Genetics and Histocompatibility, BREST, France.

**Background/Objectives:** Chromatin is a dynamic structure that determine gene expression. Long-range interactions between promoter and cis-regulatory elements (CREs) regulate this expression. Dysregulation of these interactions can lead to diseases, called “enhanceropathies”. Some patients with cystic fibrosis or CFTR-related disorders (CFTR-RD) have incomplete genotypes or present extreme phenotypes. This project aims to explain these unresolved cases by first identifying CREs in CFTR locus and in a second part by highlighting dysfunctions in the latter.

**Methods:** In order to study the regulation of the CFTR gene, reporter gene activity and chromatin immunoprecipitation tests in intestinal cells (Caco-2) allowed us to characterize new CREs. To validate the purpose, invalidation assays with CRISPR/dCas9 are developed. Then, the chromatin interactions (DNA loops) have to be confirmed by using chromatin study techniques (4C). A second part is dedicated to the detection of variants within CREs by NGS sequencing of the CFTR locus in CFTR-RD patients.

**Results:** CREs at introns 24 and 26 were newly identified with cooperative enhancer activity, in addition to the CREs identified in introns 1 and 12. This has allowed us to propose a three-dimensional model of CFTR gene regulation within the locus. Furthermore, an enrichment of transcription factors HNF1α, p300, FOXA1/2, and CDX2 was shown. By sequencing CBAVD patients, eight variants within CREs were identified and confirmed by functional tests.

**Conclusion:** Thus, this work allows a better understanding of the three-dimensional organization of the CFTR locus in order to improve the care of patients.

**References:**

**Grants:** Vaincre la mucoviscidose, Association Gaetan Saleun.

**Conflict of Interest:** None declared.

**P21.010.B Functional characterization of a JAG1 5'UTR variant in a patient with clinically observed Alagille Syndrome**

Nicole Buhl1,2, Eva-Doreen Pfister1, Jens Bohne1, Ulrich Baumann1, Björn Hartleben1, Brigitte Schlegelberger2, Thomas Illig5, Britta Skawran2, Amelie Stalke1,2

1Hannover Medical School, Pediatric Gastroenterology and Hepatology, Hannover, Germany; 2Hannover Medical School, Department of Human Genetics, Hannover, Germany; 3Hannover Medical School, Institute of Virology, Hannover, Germany; 4Hannover Medical School, Institute of Pathology, Hannover, Germany; 5Hannover Medical School, Hannover Unified Bank (HUB), Hannover, Germany.

**Background/Objectives:** Alagille Syndrome (ALGS) is an autosomal dominant multisystemic disease predominantly affecting liver, heart, kidney, vertebrae and eyes. Two NOTCH-Signaling pathway members -JAG1 and NOTCH2- are known to be associated with ALGS. Pathogenic variants exclusively affecting the JAG1 5’UTR have not been described so far. We report on a female patient with clinically distinct ALGS carrying a 5’UTR JAG1 variant. We performed segregation and functional analyses to assess the variant’s pathogenicity.

**Methods:** We compared the activity of the 5’UTR variant with the wild type 5’UTR via luciferase assay after transfecting HEK293T or HuH7 cells. RNA was analyzed by northern blot. Segregation analysis was done by Sanger sequencing and short tandem repeat (STR) analysis.
Results: The patient developed neonatal cholestasis at 4 weeks of age. With cardiac defects, butterfly vertebrae and histological ductopenia, the girl was clinically diagnosed with ALGS. We identified the heterozygous JAG1 5'UTR variant NM_000214.3: c.-100C>T, not detected in population database gnomAD. Luciferase assays showed, compared to the wildtype, a significantly reduced luciferase activity in both cell lines. The mutation slightly decreased total luciferase RNA levels. Sanger sequencing and STR analysis revealed the patient’s variant to be de novo allowing a classification as likely pathogenic.

Conclusion: To our knowledge, this is the first description of a disease-associated JAG1 variant located in the 5'UTR in a pediatric patient with a clinically diagnosed ALGS. Going forward, genetic testing of JAG1 or NOTCH2 in patients with suspected ALGS should include detailed 5'UTR characterization of JAG1 or NOTCH2.

References:

Conflict of Interest: Nicole Buhl: None declared, Eva-Doreen Pfister Albireo, Mirum, Alexion, Orphanal, Univar, Albireo, Mirum, Alexion (Modest), Orphanal, Univar, Albireo, Mirum, Alexion (Modest), Jens Bohne: None declared, Ulrich Baumann Albireo, Mirum, Alexion, Orphanal, Albireo, Mirum, Alexion, Nestle, Vivet, Astellas (Modest), Orphanal, Albireo, Mirum, Alexion, Nestle, Vivet, Astellas (Modest), Björn Hartleben: None declared, Brigittie Schlegelberger: None declared, Thomas Illig: None declared, Britta Skawran: None declared, Amelie Stalke: None declared.

P21.012.D Methylome-wide association studies of major depressive disorder, bipolar disorder and schizophrenia spectrum disorders in the German FOR2107 cohort

Friederike David1, Fabian Streit2, Josef Frank2, Lea Sirignano2, Lea Zillich2, Stefan Hermes1,1, Per Hoffmann1,2, Till Andlauer2, Tilo Kircher2,5, Udo Dannowski1, Stephanie Witt5,8, Marcella Rietschel2, Markus M Nöthen1, Andreas Forster1,5

1Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany; 2Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; 3Department of Biomedicine, University of Basel, Basel, Switzerland; 4Department of Neurology, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany; 5Department of Psychiatry and Psychotherapy, University of Marburg, Marburg, Germany; 6Center for Mind, Brain and Behavior, University of Marburg, Marburg, Germany; 7Institute for Translational Psychiatry, University of Münster, Münster, Germany; 8Center for Innovative Psychiatry and Psychotherapy Research, Central Institute of Mental Health, Medical Faculty Mannheim / Heidelberg University, Mannheim, Germany; 9Institute of Neuroscience and Medicine (INM-1), Research Center Jülich, Jülich, Germany.

Background/Objectives: Epigenetic modifications such as DNA methylation (DNAm) are important regulators of gene expression, influenced by both genetic and environmental factors. In major psychiatric disorders, previous studies have suggested that alterations in DNAm profiles may contribute to pathogenesis and represent potential biomarkers. Thus, we here examined differential methylation in patients with major depressive disorder (MDD), bipolar disorder (BD), and schizophrenia spectrum disorders (SSD) in comparison to healthy controls (HC) that were matched to the diagnostic groups in regard to sex and age.

Methods: Methylation profiling was conducted with the Infinium MethylationEPIC array using DNA from peripheral blood of 886 individuals (MDD: 345, BD: 100, SSD: 101, HC: 340) of the German FOR2107 cohort (https://for2107.de/). After quality control and preprocessing of the methylation data set using the minfi R package, methylome-wide association studies (MWAS) of case-control status were performed for each diagnostic group.

Results: During quality control, a total of 7 individuals were excluded. In the preliminary MWAS for MDD, no differentially methylated CpG sites could be detected that remained significant after Bonferroni correction for multiple testing. Final results for all diagnostic groups will be presented at the conference.

Conclusion: The investigation of DNAm profiles is a promising approach for understanding molecular changes in major psychiatric disorders. As the differential methylation signals typically have small effect sizes, larger sample sizes are needed to increase statistical power and any identified MWAS results should be replicated in meta-analyses of large international consortia.

References:

Conflict of Interest: None declared.

P20.013.A Tissue- and ethnicity-independent hypervariable DNA methylation states show evidence of establishment in the early human embryo

Maria Derakhshan1, Noah Kessler2, Miho Ishida3, Charalambos Demetrios3, Nicolas Bruccato4, Gudrun Moore5, Caroline Fall6, Giriraj Chandak6, Francois-Xavier Ricaut4, Andrew Prentice7, Garrett Helenthal6, Matt Silver1,7

1London School of Hygiene and Tropical Medicine, London, United Kingdom; 2University of Cambridge, Cambridge, United Kingdom; 3UCL Great Ormond Street Institute of Child Health, London, United Kingdom; 4Université de Toulouse Midi-Pyrénées, Toulouse, France; 5MRC Life-course Epidemiology Unit, University of Southampton, Southampton, United Kingdom; 6Genomic Research on Complex Diseases (GRG Group), CSIR-Centre for Cellular and Molecular Biology, Hyderabad, India; 7Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, Gambia; 8UCL Genetics Institute, University College London, London, United Kingdom.

Background/Objectives: Intergenerational variation in DNA methylation (DNAm) has been linked to both environmental exposures and phenotypic variation. However, methylation states are generally tissue-specific, making the identification of environmentally sensitive variable DNA states in disease-relevant tissues a challenge.

Here, we search for hypervariable CpGs (“hvCpGs”) on the widely-used Illumina450K array that show high interindividual methylation variation across multiple tissues and ethnicities and test the hypothesis that hvCpGs may have been established in the early human embryo.

Methods: We leverage 30 large-scale datasets that include 19 tissues and 8 ethnicities to identify hvCpGs falling into the top 5% of interindividual methylation variation in >65% of datasets. We explore hvCpG properties, including cross-tissue DNAm correlation, using unpublished multi-tissue fetal methylation data and other resources. We also analyse genetic effects on DNAm at hvCpGs using data from a large meta-analysis of methylation quantitative trait loci (mQTL).

Results: We identify 4143 hvCpGs and show that DNAm at hvCpGs is not driven by genetic variation, probe reliability, sex or cell heterogeneity effects. Instead, hvCpGs show cross-tissue correlation and are strongly enriched for CpGs previously implicated in methylation establishment in the early embryo, including loci sensitive to periconceptional environment.

Conclusion: Our findings position hvCpGs as strong candidates for using DNAm from any tissue to study how stochastic and/or
environmental effects on DNA methylation in the early embryo can influence life-long health and disease.

References:
- **Grants:** BB/M009513/1; MR/M01424X/1; MC_PC_MR/RO20183/1; MR/N006208/1; ANR/OC0EADAPTO; ANR/PAPUAÉVOL; BT/IN/DBT-MRC/D/FID/24/GRC/2015–16.
- **Conflict of Interest:** None declared.

P21.014.B Novel diagnostic DNA methylation epigenotypes expand and refine the epigenetic landscapes of Mendelian disorders

Michael Levy1, Haley McConkey1, Jennifer Kerkhof1, Aidin Foroutan2, Sadegeh Haghshehenas3, Jack Reilly3, Raissa Relator4, Kathleen Rooney15, Dimitar Azmanov5, Tugce Balci6, Siddharth Banka7, Zofia Gecz7, Peter Henneman6, Jennifer Lee7, Marcel Mannens5, Tony Roscioli5, Victoria Sia3, David Amor5, Gareth Baynham16, Nicola Brunetti-Pierri17, Eric Bend3, Kym Boycott18, Philippe M. Campeau19, John Christodoulou20, David Dymter21, Natacha Esber22, Jill Fahm16, Mark Fleming23, David Geneviève24, Barb DuPont25, Kristin Kristin D. Kerrmohan26, Aisidair McNeill27, Leonie Menke28, Laurence Faivre19, Giuseppe Merla29, Paolo Prontera30, Cheryl Rockmarr31, Charles Schwartz32, Steven Skinner33, Roger Stevenson34, Antonio Vitobello10, Marco Tartaglia13, Marielle Alders6, Matthew Tedder7, Bekim Sadikovic1

1London Health Sciences Centre, Teras Genomics, London, Canada; 2Western University, London, Canada; 3PathWest Laboratory Medicine, QEII Medical Centre, Perth, Australia; 4The University of Manchester, Manchester, United Kingdom; 5University of Adelaide, Adelaide, Australia; 6Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; 7Greenwood Genetic Center, Greenwood, United States; 8University of New South Wales, Sydney, Australia; 9King Edward Memorial Hospital, Perth, Australia; 10Federico II University of Naples, Naples, Italy; 11PreventionGenetics, Marshfield, United States; 12University of Ottawa, Children’s Hospital of Eastern Ontario Research Institute, Ottawa, Canada; 13University of Montreal, Montreal, Canada; 14KAT6A Foundation, West Nyack, United States; 15Johns Hopkins University, Baltimore, United States; 16Boston Children’s Hospital, Boston, United States; 17Montpellier University, Montpellier, France; 18University of Sheffield, Sheffield, United Kingdom; 19CHU Dijon Bourgogne, Dijon, France; 20University of Perugia Hospital SM della Misericordia, Perugia, Italy; 21University of Manitoba, Winnipeg, Canada; 22Ospedale Pediatrico Bambino Gesù, Rome, Italy.

Background/Objectives: Overlapping clinical phenotypes and an expanding breadth and complexity of genomic associations are a growing challenge in the diagnosis and clinical management of Mendelian disorders. The functional consequences and clinical impacts of genomic variation may involve unique, disorder-specific, genomic DNA methylation epigenotypes.

Methods: In this study, we describe 19 novel episignature disorders and compare the findings alongside 38 previously established episignatures for a total of 57 episignatures associated with 65 genetic syndromes. New episignatures were established through bioinformatic assessment of genome-wide methylation data of patient cohorts with a molecular diagnosis for a given disorder against unaffected controls to generate a specific and sensitive classifier.

Results: We demonstrate increasing resolution and specificity ranging from protein complex, gene, sub-gene, protein domain, and even single nucleotide-level Mendelian episignatures. We show the power of multiclass modelling to develop highly accurate and disease-specific diagnostic classifiers.

Conclusion: This study significantly expands the number and spectrum of disorders with detectable DNA methylation episignatures, improves the clinical diagnostic capabilities through the resolution of unsolved cases and the reclassification of variants of unknown clinical significance, and provides further insight into the molecular etiology of Mendelian conditions.

References: Levy, Michael A et al. “Novel diagnostic DNA methylation episignatures expand and refine the epigenetic landscapes of Mendelian disorders.” HGG advances vol. 3,1 100075. 3 Dec. 2021, https://doi.org/10.1016/j.xhgg.2021.100075.
- **Grants:** This work was funded by the government of Canada through Genome Canada and the Ontario Genomics Institute (OGI-188).
- **Conflict of Interest:** None declared.

P21.015.C DNA methylation episignature testing improves molecular diagnosis of Mendelian chromatinopathies

Jennifer Kerkhof1, Gabriella Maria Squeo2, Haley McConkey1, Michael Levy1, Maria Rosaria Piemontese1, Marco Caston1, Maria Accadia1, Elsa Bianmino1, Matteo Della Monica1, Marilena Carmela Di Giacomo2, Cristina Gervasi2, Maitz Silvia2, Daniela Melis3, Danatell4, Milani13, Massimo Ciccarese14, Paolo Prontera3, Angelo Selicour15, Giuseppe Merla15, Bekim Sadikovic1,16

1London Health Sciences Centre, Molecular Diagnostics, Verspeeten Clinical Genome Centre, London, Canada; 2Fondazione IRCCS Casa Sollievo della Sofferenza, Laboratory of Regulatory and Functional Genomics, San Giovanni Rotondo, Italy; 3Fondazione IRCCS Casa Sollievo della Sofferenza, Division of Medical Genetics, San Giovanni Rotondo, Italy; 4Hospital Cardinale G. Panico, Medical Genetics Service, Tricase, Lecce, Italy; 5University of Turin, Department of Pediatrics, Turin, Italy; 6Cardarelli Hospital, Medical Genetics Unit, Napoli, Italy; 7AOR San Carlo Hospital, UOC Anatomia Patologica, Potenza, Italy; 8Università degli Studi di Milano, Division of Medical Genetics, Department of Health Sciences, Milan, Italy; 9Hospital San Gerardo, Clinical Pediatric Genetics Unit, Pediatrics Clinic, MBBM Foundation, Monza, Italy; 10Università degli Studi di Salerno, Medical Surgical and Dental Department, Salerno, Italy; 11Mangiagalli Clinic IRCCS Ca Granda Foundation Ospedale Maggiore Policlinico, Milano, Italy; 12University of Palermo - Scuola Politecnica, Medical Genetics Unit Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Palermo, Italy; 13University of Perugia, Hospital SM della Misericordia, Medical Genetics Unit, Perugia, Italy; 14ASST Lariana, Sant’Anna General Hospital, Pediatric Department, Como, Italy; 15University of Naples Federico II, Department of Molecular Medicine and Medical Biotechnology, Naples, Italy; 16Western University, Department of Pathology and Laboratory Medicine, London, Canada.

Background/Objectives: Mendelian chromatinopathies result from disruption of genes involved in chromatin structure and function. To date, over 50 chromatinopathies have been described and many exhibit unique genome-wide DNA methylation profiles known as episignatures. In this study, we evaluated the DNA methylation profile of 129 individuals with either a confirmed or suspected chromatinopathy for detection of an episignature.

Methods: DNA methylation profiles were generated with the Illumina Infinium MethylationEPIC kit on DNA specimens extracted from peripheral blood and analyzed with the EpiSign classifier for 42 episignatures.

Results: Samples were grouped into discovery, validation, uncertain and negative cohorts based on their genotype and phenotype description. Both the discovery and validation cohorts consisted of patients carrying a pathogenic or likely pathogenic variant with a matching (discovery) or unknown (validation) phenotype. The DNA methylation profiles of all discovery and validation cases matched the expected episignature. The uncertain cohort consisted of individuals with an identified VUS by sequence analysis and 10.7% (3/28) matched a defined episignature, resulting in...
variant reclassification to likely pathogenic. EpiSign analysis in the negative cohort directed a clinical diagnosis in 3/33 (9.1%) cases where molecular investigations were previously negative.

**Conclusion:** EpiSign analysis provides utility in the diagnosis of chromatinopathies and should be considered as part of the clinical testing cascade.

**References:** Kerkhof J, Squeo GM, McConkey H, et al. DNA methylation epigenotype testing improves molecular diagnosis of Mendelian chromatinopathies. Genet Med. 2022;24(1):51-60.

**Grants:** Telethon – Italy (GGP13231), LHSC Molecular Development Fund, Genome Canada Genomic Applications Partnership Program.

**Conflict of Interest:** None declared.

**P21.016.D Investigation of SCN1A poison exons in epilepsy**

**Peter Sparber**¹, Igor Bychkov¹, Denis Pyankov², Mikhail Skoblov¹

¹Research Centre for Medical Genetics, Moscow, Russian Federation; ²Genomed Ltd., Moscow, Russian Federation.

**Background/Objectives:** Loss of function pathogenic variants in the SCN1A gene are associated with Dravet syndrome (DS) – a devastating childhood-onset epileptic syndrome. Recent works described several potential “poison exons” (PE) in SCN1A – an alternatively spliced in frame exons containing premature stop codon. Such PE when included to SCN1A mRNA leads to haploinsufficiency. However, a valid functional approach for SCN1A PE is not routinely available.

**Methods:** Bioinformatic analysis was performed using MaxEntScan and SpliceAI. All 3 PE in the SCN1A gene were cloned to pSp3-Flu2 splicing vector. Investigated variants were introduced using site directed mutagenesis. Splicing analysis was performed using RT-PCR after transfection to HEK293T cells. Knockdown of SRSF1 and hnRNP A1 was performed using siRNA.

**Results:** We created a minigene systems for investigation of SCN1A PE inclusion. Wild-type constrictions showed no inclusion for PE2 and PE3 and only 8.9% inclusion for PE1. We demonstrated the pathogenic effect of PE by introduction previously reported and artificial variants into minigene results in significant inclusion of PE. Analysis of 2000 WGS data revealed a potential causative variant in PE2. To investigate the regulation of PE inclusion we performed knockdown of SRSF1 and hnRNP A1 with siRNA. U7 snRNA oligonucleotides were used to correct the splicing pattern of PE in mutant constructions.

**Conclusion:** We created and validated a minigene-based functional assay for investigation of inclusion and regulation of PE in SCN1A. U7 snRNA oligonucleotides can be used as a promising approach for future therapy in SCN1A-based epilepsy.

**References:**

**Grants:** The reported study was funded by RFBR. Project number 20-315-90042.

**Conflict of Interest:** None declared.

**P21.017.A Identifying genetic mechanisms that uncouple leanness from a favorable body fat distribution**

**Jonathan Belanich**¹, Tuomas Kilpeläinen¹, Mario Urena²

¹Copenhagen University, The Novo Nordisk Foundation Center for Basic Metabolic Research, Copenhagen, Denmark.

**Background/Objectives:** Leanness is associated with a favorable body fat distribution, indicated by lower waist-hip ratio (WHR). However, many genetic variants show the opposite pattern – they are associated with lower body mass index (BMI) but higher WHR. The variants also show association with an adverse cardiometabolic risk profile. The underlying biological mechanisms remain incompletely understood. We aimed to elucidate the cellular mechanisms of action of genetic variants associated with lower BMI but higher WHR, and increased risk of cardiometabolic disease.

**Methods:** We took forward all genome-wide significant SNPs associated with BMI, WHR or WHR adjusted for BMI in the largest GWAS published to date, and identified SNPs that are associated with lower BMI (P < 0.05) but higher WHR (P < 0.05). We prioritized candidate causal genes in the corresponding genetic regions, and assessed the genes’ roles in differentiation and maturation of mouse and human preadipocytes by microscopy and quantitative methods.

**Results:** Altogether 252 independent loci showed an association with lower BMI but higher WHR. We prioritized six candidate causal genes for initial perturbation studies using siRNA. The studies showed an inhibition of adipogenesis for four of the six tested genes: ADAMTS9, ABHD15, EMILIN2 and COL18A1. In further experiments, we will determine the effects on lipid metabolism and insulin signalling through downregulation and dCas9 overexpression, and will examine the resulting expression profile data.

**Conclusion:** Our findings implicate four novel gene candidates linked to a leaner phenotype but an unfavorable body fat distribution, playing a role in adipogenesis.

**References:**

**Grants:** Novo Nordisk Foundation (NNF18CC0034900, NNF20OC0063707).

**Conflict of Interest:** None declared.

**P21.019.C Rare variant in CCN1 leads to a lean-to-fat switch in body composition by controlling cell differentiation**

**Sophia Metz**¹, Katja Thorae Michler¹, Jonathan Belanich¹, Trisha Jean Grevengoed², Matthew Gillum¹, Tuomas Kilpeläinen¹

¹The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

**Background/Objectives:** Obesity is a major contributor to the global burden of chronic disease. Unravelling the complex aetiology of obesity is key for developing effective therapies. Genome-wide association studies provide unique opportunities for identifying novel therapeutic targets. We examined the adipose tissue mechanisms that underlie the association of Ser316Cys missense variant (MAF = 0.8%) in CCN1 with body fat percentage.

**Methods:** We assessed the role of CCN1-Ser316 by a phenome-wide association study (PheWAS), receptor-binding assays, in vitro gene knockdown experiments, and in vivo adipose tissue-specific gene overexpression studies.

**Results:** The CCN1-Ser316 allele reduced the binding of CCN1 to its integrin-avb3 membrane receptor by 50% (p = 0.0003). The PheWAS suggested an association with lean mass and fat mass, in opposing directions, but showed no significant association with other disease risk traits. Gene knockdown in MSCs reduced proliferation by 30% (p = 0.0007), whereas treatment with CCN1 reduced adipocyte differentiation significantly. In mice, adipose tissue-specific overexpression of CCN1 led to a higher BF% (p = 0.0002) after a high fat diet, but did not affect bodyweight, indicating a lean-to-fat switch in body composition. The mean area of mouse adipocytes increased (p = 0.009), suggesting an effect of CCN1 on adipocyte hypertrophy.

**Conclusion:** Our data indicates a key role of CCN1 during adipocyte commitment from stem cells and an effect on adipocyte number, size, and body composition. Our ongoing experiments
Abstracts from the 55th European Society of Human Genetics Conference

P21.020.D Coregulation within Epigenomic Systems

Oliver Chukwuma Orji1, Rupert Fray2, Helen Knight1

1Division of Cells, Organisms and Molecular Genetics, School of Life Sciences, Nottingham, United Kingdom; 2School of Biosciences, University of Nottingham, Loughborough, United Kingdom.

Background/Objectives: Post-transcriptional and post-translational regulation by N-6-methyladenosine (m6A) and 5-methylcytosine (m5C) modification of ribonucleotides is essential for biological function. Dysregulation of m6A and m5C RNA methylation processes and changes in ‘writer’, ‘reader’ and ‘eraser’ effector protein abundance, is proposed to be important for the development of cancers and neurological conditions.

Methods: Here we analysed human brain tissues’ m6A and m5C sequence datasets, as well as studied protein coregulation of m6A and m5C effector proteins using a newly developed mass spectrometry protein database, ProteomeHD, which clusters proteins showing co-regulated abundance after cellular perturbations. Using a correlation cut-off ≥0.8, coregulated proteins for each set of m6A and m5C effector proteins was retrieved and examined by gene ontology (GO) analysis.

Results: We found co-regulation patterns between the two RNA methylation systems. For example, the m6A mRNA writer METTL14, was found to be coregulated with the m5C RNA writers, NSUN4 [percentile score, (PS) = 0.94] and NSUN5 (PS = 0.92). Furthermore, the m5C readers, ALYREF and YBX1 showed coregulation with m6A writer, and reader and eraser proteins (PS > 0.9) suggesting that they are central hub proteins in such RNA regulatory systems. GO analysis indicated that specific biological functions were significantly enriched between coregulated methylation proteins, e.g. the class of writer proteins and mitochondrial function.

Conclusion: The findings of the current study provide evidence of the existence of a co-regulatory cross talk between RNA modification systems and suggest that biological function may be context-specific to localised cellular domains.

References: Shown in paper.

Grants: Nonapplicable.

Conflict of Interest: None declared.

P21.022.B From patient to function: modeling CRIM1 in xenopus tropicalis

OZLEM AKGUN DOGAN1,2,3, Stephen Viviano3, Ozden Hatirmaz Ny8,9, Nihat Bugra Agaoğlu1,2, Weizhen Ji1, Tasmin Jeffries, Uğur Özbek8,9, Saaqib Lokhari1, Mustafa Khokhar1,7, Engin Deniz8,9, Yasemin Alanay1,2,3

1Acibadem Mehmet Ali Aydinlar University School of Medicine, Department of Pediatrics, Istanbul, Turkey; 2Acibadem Mehmet Ali Aydinlar University, Rare Diseases and Orphan Drugs Application and Research Center (ACURARE), Istanbul, Turkey; 3Yale University School of Medicine, Pediatric Genomics Discovery Program, Department of Pediatrics, NEW HAVEN, United States; 4Acibadem Mehmet Ali Aydinlar University School of Medicine, Department of Medical Biology, Istanbul, Turkey; 5Acibadem Mehmet Ali Aydinlar University School of Medicine, Department of Medical Genetics, Istanbul, Turkey; 6University of Health Sciences Umranliye Training and Research Hospital, Department of Medical Genetics, Istanbul, Turkey; 7Yale University School of Medicine, Department of Genetics, NEW HAVEN, United States; 8Yale University School of Medicine, Pediatric Genomics Discovery Program, Department of Pediatrics, NEW HAVEN, United States.

Background/Objectives: CRIM1 is a transmembrane protein that plays a role in organogenesis, angiogenesis, and kidney disease, yet the function of CRIM1 has not been fully elucidated especially in the context of human disease. Here, we report a patient with compound heterozygous missense variants in CRIM1 presenting with holoprosencephaly, facial asymmetry, coloboma, cleft palate, and extremity defects. We sought to establish an animal model for these phenotypes, test whether the CRIM1 variants are detrimental to function, and provide additional support for disease causality.

Methods: We used whole-exome sequencing and identified CRIM1 as a candidate gene. To model, we utilized loss-of-function assays using CRISPR/Cas9 mediated genome-editing in the Xenopus model system. We designed two non-overlapping CRISPRs, generated G0 tadpoles, and verified genomic edits using CRISPR edits analysis inference. Embryos then were raised to

P21.021.A Genome wide methylation profiling in diagnostics; the results of 3 years EpiSign testing

Marielle Alders1, Jennifer Kerkhof2,3, Peter Henneman1, Michael Levy2,3, Andrea Venema1, Raissa Relator2,3, Egbert Redeker1, Bekim Sadikovic2,3, Marcel Mannens1

1Amsterdam UMC, University of Amsterdam, Human Genetics, Amsterdam, Netherlands; 2Verspreet Clinical Genome Centre, London Health Sciences Centre, London, Canada; 3Western University, Department of Pathology and Laboratory Medicine, London, Canada.

Background/Objectives: A growing number of neurodevelopmental syndromes are shown to have unique genomic DNA methylation profiles, episignatures, which can be used as a diagnostic tool.

Methods: We have implemented genome wide methylation profiling as a diagnostic test, named EpiSign, in our laboratory in June 2019. The first version of this test, was able to recognize 22 conditions, which expanded to 45 conditions in v2 (2020) and to 64 conditions in v3 (2021). This latest version consist of 54 episignatures, 9 imprinting disorders and Fragile X syndrome.

Results: Between July 2019 and February 2022, 537 diagnostic EpiSign test have been requested at AUMC. In 318 cases the test was requested because the patient carried a VUS in one of the genes in the EpiSign panel. In 110 of these (35%), the methylation profile matched that of the associated syndrome, supporting pathogenicity of the variant. EpiSign was requested for 217 patients with neurodevelopmental disorder without a known cause. In 17 (8%) of these cases a positive epigenetic signature was found. These were imprinting disorders in 4 cases, FraX in one case and positive episignatures in 12 cases. In at least 6 of these episignature positive patients the causal mutation was identified after targeted and detailed (re)analysis of the associated genes.

Conclusion: These results shows that EpiSign is a powerful diagnostic tool, in particular for patients for whom conventional genetic testing was inconclusive. The number of conditions with an identified specific episignature is growing rapidly, increasing the diagnostic capabilities of this test.

References: None declared.

Grants: None declared.
be evaluated for neural tube defects (NTDs), craniofacial, and eye abnormalities using brightfield/fluorescence microscopy and optical coherence tomography. To test the function of the variants, we used a gain-of-function assay with overexpression.

**Results:** Crim1-G0 mutant Xenopus embryos recapitulated patient phenotype closely and showed severe/moderate NTDs (50%), unilateral microphthalmia/coloboma (30%), and facial dysmorphism (20%). Cleft palate was present in 23% of the embryos with facial dysmorphism. The overexpression of wild-type human mRNA resulted in more frequent NTDs than the overexpression with the patient variants indicating that the variants are detrimental to protein function.

**Conclusion:** We present the first evidence that homozygous variants in CRIM1 are associated with congenital abnormalities in humans and Xenopus tropicalis.

**References:**

**Conflict of Interest:** OZLEM AKGUN DOGAN Ozlem Akgun-Dogan is a Fulbright scholar in the “Fulbright Visiting Scholar Program”.

**OZLEM AKGUN DOGAN**

1, Dan Kent1,2, Marco Trevisan-Herraz1, Nefeli Karataraki1, Kent F.M. Fung2, Cody Ashby1, Agata Cieslak1, Shmuel Yaccoby3, Frits van Rhee5, Maurizio Zangari5, Sharmilan Thanen-Darajan5, Jack Reilly5, Kathleen Rooney5, Dimitar Azmanov1, Tugce Balci4, Siddharth Banaka1, Jozef Gecc2, Peter Henneman7, Jennifer Lee6, Marcel Mannens7, Tony Roscioli9, Victoria Siu8, David Amor10, Gareth Baynham11, Eric Bend12, Kym Boycott13, Nicola Brunetti-Pierri14, Philippe M. Campeau15, John Christodoulou10, David Genevieve16, Kristin Kristin D. Kermoian13, Alisdair McNeill20, Leonie Menke17, Laurence Fairve17, Giuseppe Merla22, Paolo Prontera23, Cheryl Rockman24, Charles Schwartz8, Steven Skinner8, Roger Stevenson9, Barb Du Pont3, Antonio Vitobello21, Marco Tartaglia25, Marielle Alders17, Matthew Tedder8, Bekim Sadikovic13

1Newcastle University, Biosciences Institute, Newcastle upon Tyne, United Kingdom; 2Newcastle University, Translational and Clinical Research Institute, Newcastle upon Tyne, United Kingdom; 3University of Arkansas for Medical Sciences, Department of Biomedical Informatics, Little Rock, AR, United States; 4L’Université de Paris (Descartes), Institut Necker-Enfants Malades, Paris, France; 5University of Arkansas for Medical Sciences, Myeloma Center, Little Rock, AR, United States; 6NYU Langone Health, NYU Langone Medical Center, Perlmutter Cancer Center, New York City, NY, United States; 7Aix-Marseille University, Inserm, Theories and Approaches of Genomic Complexity, Marseille, France; 8University of Edinburgh, School of Physics and Astronomy, Edinburgh, United Kingdom; 9Babraham Institute, Lymphocyte Signalling and Development Programme, Cambridge, United Kingdom; 10Newcastle upon Tyne Hospitals NHS Foundation Trust, Great North Children’s Hospital, Newcastle upon Tyne, United Kingdom; 11Indiana University, Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology Oncology, Indianapolis, IN, United States.

**Background/Objectives:** Chromosomal translocations are important drivers of haematological malignancies whereby proto-oncogenes are activated by juxtaposition with enhancers, often called enhancer hijacking. H3K4me3 is a histone mark characteristic of active promoters, but broad domains (H3K4me3-BDs) can cover entire genes, providing consistent expression. We present a new model of `epigenomic translocation`, where enhancer hijacking results in the relocalization of a wild-type H3K4me3-BD into the target oncogene.

**Methods:** We investigated 118 samples including B-cells (15 healthy, 32 malignant), T-cells (17 healthy, 4 malignant) and myeloid cells (50 healthy). Chromatin states were determined using ChromHMM (H3K4me1, H3K4me3, H3K9me3, H3K27me3, H3K27ac, H3K36me3), chromosomal translocations by targeted-genome sequencing and gene expression by RNA-seq.

**Results:** We studied the epigenomic consequences of IGH-CCND1 rearrangements. We detected an H3K4me3-BD within the IGH locus of healthy B-cells that was absent in samples with IGH-CCND1. Relocation of super-enhancer from IGH to CCND1 locus associated with the appearance of H3K4me3-BD over CCND1, resulted in overexpression and extensive chromatin accessibility. We observed similar cancer-specific H3K4me3-BDs associated with hijacking of super-enhancers of other oncogenes in B-cell (MAF, MYC, FGFR3/NSD2) and T-cell malignancies (LMO2, TLX3, TAL1). Co-occurrence of H3K4me3-BD and super-enhancer was identified genome-wide in healthy cells and associated with cell identity genes. Additionally, we predicted the 3D genome structure of the interactions between H3K4me3-BDs and super-enhancers using in-silico simulation models.

**Conclusion:** Our analysis suggests that H3K4me3-BDs can be created by super-enhancers and supports the new concept of epigenomic translocation, where the relocation of H3K4me3-BDs from wild-type location to oncogenes accompanies the translocation of super-enhancers.

**References:** PMID:34939339, bioRxiv:2021.03.12.434963.

**Conflict of Interest:** None declared.
Background/Objectives: An expanding range of genetic syndromes are characterized by genome-wide disruptions in DNA methylation profiles referred to as episignatures. Episignatures are distinct, highly sensitive and specific biomarkers that have recently been applied in clinical diagnosis of genetic syndromes. Episignatures are contained within the broader disorder-specific genome-wide DNA methylation changes which can share significant overlap amongst different conditions.

Methods: In this study we performed functional genomic assessment and comparison of disorder-specific and overlapping genome-wide DNA methylation changes related to 65 genetic syndromes with previously described episignatures.

Results: We demonstrate evidence of disorder-specific and recurring genome-wide differentially methylated probes (DMPs) and regions (DMRs). The overall distribution of DMPs and DMRs across the majority of the neurodevelopmental genetic syndromes analyzed showed substantial enrichment in gene promoters and CpG islands, and under-representation of the more variable intergenic regions. Overrepresentation analysis showed significant enrichment of the recurring DMPs and DMRs in gene pathways and networks related to neurodevelopment, including neuronal generation and differentiation and axon guidance.

Conclusion: This study expands beyond the diagnostic utility of DNA methylation episignatures by demonstrating correlation between the function of the mutated genes and the consequent genomic DNA methylation profiles as a key functional element in the molecular etiology of genetic neurodevelopmental disorders.

References: Levy, Michael A et al. “Novel diagnostic DNA methylation episignatures expand and refine the epigenetic landscapes of Mendelian disorders.” HGG advances vol. 3, 100075. 3 Dec. 2021, https://doi.org/10.1016/j.xhgg.2021.100075.

Conflicts of Interest: None declared.

P21.024.A Modelling the earliest stages of gliomagenesis using iNPCs in a three-dimensional alginate-based matrix

Burcu Ekinci1, Tutku Yaraş2, Yavuz Oktay2,3

1Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, izmir, Turkey; 2Izmir Biomedicine and Genome Center, Dokuz Eylul University Health Campus, izmir, Turkey; 3Dokuz Eylul University, School of Medicine, Department of Medical Biology, izmir, Turkey.

Background/Objectives: The development of gliomas is believed to be triggered by isocitrate dehydrogenase (IDH1/2) mutations, which confer a new enzymatic activity that leads to production of the oncometabolite 2-hydroxyglutarate (2-HG). However, current cellular models of early gliomagenesis frequently use transformed cells, or normal stem cells with driver mutations. In the present study we aimed to develop an induced neural progenitor cell (iNPC) model to study the earliest stages of gliomagenesis in 3D.

Methods: Human induced pluripotent stem cells (hiPSCs) were differentiated into NPCs. 2-HG was applied to NPCs embedded in a alginate-based 3D matrix for 2, 7, and 14 days. RNA was isolated from NPCs after day 2, 7, 14 and key genes previously reported to be altered in IDH1-mutant gliomas were assessed by qPCR. The time distribution of changes in the expression of key genes (L1CAM, MEOX2, etc.) were determined to identify the time-dependency of 2-HG effects in this particular model. RNA-seq analysis at selected time point were performed and compared to data from other models to identify model-specific transcriptomic changes. 4C-seq analysis is under way to characterize the alterations in promoter interactions of select genes.

Results: Optimal culturing conditions were identified and expression of key genes were monitored over different time points. RNA-seq analysis identified genes that are altered in response to 2-HG in a model-dependent manner.

Conclusion: Our model for the first time characterizes transcriptomic and epigenomic changes caused by IDH1/2 mutations at the earliest stages of gliomagenesis.

References:

Conflicts of Interest: Burcu Ekinci: None declared, Tutku Yaraş: None declared, Yavuz Oktay TUBITAK-ARDEB 117Z981 project.

P21.025.B Optimization of assay for transposase-accessible chromatin using sequencing of neutrophils

Janine Klima1, Arif B Ekici1, Steffen Uebe1, Christian Schmid2, Ulrike Hüffmeier1

1University Hospital Erlangen, FAU, Institute of Human Genetics, Erlangen, Germany; 2University Hospital Regensburg, RCI Regensburg Centre for Interventional Immunology, Regensburg, Germany.

Background/Objectives: Psoriasis is a chronic, inflammatory skin disease. Palmoplantar pustular psoriasis (PPP) is one rarer subtype of this clinically and genetically heterogeneous condition. It is characterized by hyperkeratosis, and clusters of sterile, neutrophil-filled pustules of the palms and soles. In contrast to other forms of psoriasis, there is not a single validated genetic risk factor for PPP. In our group, we aim to identify genetic risk factors for PPP. Therefore, among other things, we employ the assay for transposase-accessible chromatin using sequencing (ATAC-seq) on neutrophils, a cell type playing a crucial role in PPP. In order to do so, we developed an optimized ATAC-seq protocol.

Methods: For efficient ATAC-seq on neutrophils we combined the classic protocol1 with a dead cell removal step and a cell fixation step2.

Results: Using our modified ATAC protocol we were able to obtain all the desired DNA fractions including the nucleosome-free fraction.

Conclusion: Instead of using a standard procedure, one should always run proper quality controls throughout the whole ATAC-seq protocol and if necessary, optimize the workflow.

References:

1 Buenrostro JD, Wu B, Chang HY, Greenleaf WJ. ATAC-seq: A Method for Assaying Chromatin Accessibility Genome-Wide. Curr Protoc Mol Biol. 2015;109:21.29.1-21.29.9. Published 2015 Jan 5. https://doi.org/10.1002/0471142727.mb2129s109. 2 Chen X, Shen Y, Draper W, et al. ATAC-seq reveals the accessible genome by transposase-mediated imaging and sequencing. Nat Methods. 2016;13(12):1013-1020. https://doi.org/10.1038/nmeth.4031.

Conflicts of Interest: None declared.

P21.026.C Epigenomic and transcriptomic analysis of the intrinsic and extrinsic molecular mechanisms at the earliest stages of gliomagenesis in precancerous cell models

Tutku Yaraş1, Burcu Ekinci1, ebru diler2, Yavuz Oktay2,3

1Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, izmir, Turkey; 2Izmir Biomedicine and Genome Center, Dokuz Eylul University Health Campus, izmir, Turkey; 3Dokuz Eylul University, School of Medicine, Department of Medical Biology, izmir, Turkey.
Background/Objectives: Gliomas are the most common tumours of the brain. Point mutations in IDH1 and IDH2 genes are believed to be the earliest genetic defects in gliomagenesis and result in the production of oncometabolite 2-HG, which alters cellular metabolism as well as the epigenome. Our aim in this study was to elucidate the mechanisms underlying the genetic predisposition associated with SNP rs55705857 in the 8q24.21 locus, both cell-intrinsic and extrinsically.

Methods: Doxycycline-inducible, immortalized human astrocyte cells (IHA) with IDH1-R132H expression were used to mimic the earliest stages of gliomagenesis. To determine which loci in the genome rs55705857 physically interacts, we used the chromosome conformation capture technique (4C-seq). Media collected from these cells at different time points were applied to primary monocytes differentiating to macrophages, and transcriptomic changes were assessed by RNA-seq and qPCR.

Results: While 4C-Seq analyses showed that the rs55705857 locus interacts with a proximal MYC enhancer that binds TRIM28, RNA-seq showed that differentially expressed genes were significantly enriched in the list of genes that were altered as a result of loss of TRIM28. RNA-seq of differentiated macrophages showed that the complement system was negatively regulated in the presence of 2-HG-containing medium.

Conclusion: For the first time, a mechanistic relationship was established between the 8q24.21 associated glioma risk locus and the control of MYC expression. Also, mutant but untransformed astrocytes have effects on monocyte differentiation, primarily via complement system and the mevalonate pathway.

References:

Grants: This study was carried out with the support of TÜBITAK-ARDEB 2145097 and 1172981 projects.

Conflict of Interest: Tutku Yarar: None declared, Burcu Ekinci: None declared, Ebru Diler: None declared, Yavuz Oktay TÜBITAK-ARDEB 2145097 and 1172981 project.

P21.028.D Epigenetic adaptations of the masticatory mucosa to periodontal inflammation

Gesa Richter1, Jochen Kruppa2, Gencay Keceli2, Emel Tuğba Ataman-Durusel3, Christian Graetz2, Nicole Piscon2, Gunar Wagner2, Carsten Rendenbach2, Yvonne Jockel-Schneider3, Orlando Martins4, Corinna Bruckmann5, Ingrid Staudenbauer6, Andre Franke1,2, Rahime Nohutcu1, Saren Jepsen12, Henrik Domnisch1, Anke Schäfer1

1Charité Center of Dento-Maxillo-Facial Medicine, Dept. of Periodontology, Oral Medicine and Oral Surgery, Berlin, Germany; 2Institute of Medical Informatics, Charité – Universitätsmedizin Berlin, Berlin, Germany; 3Faculty of Dentistry, Hacettepe University, Ankara, Turkey; 4Clinic of Preventive Dentistry and Periodontology, University Medical Center Schleswig-Holstein, Kiel, Germany; 5Private Practice, Schönefeld, Germany; 6University Medical Center Leipzig, Leipzig, Germany; 7Charité – Universitätsmedizin Berlin, Berlin, Germany; 8Clinic of Preventive Dentistry and Periodontology, University Medical Center of the Julius-Maximilians-University, Würzburg, Germany; 9Institute of Medicine and Oral Surgery, University of Coimbra, Coimbra, Portugal; 10Medical University Vienna, Vienna, Austria; 11Hannover Medical School, Hannover, Germany; 12Institute of Clinical Molecular Biology, Kiel, Germany; 13University of Bonn, Bonn, Germany.

Background/Objectives: Exposure to environmental stressors during pregnancy plays a powerful role in influencing later susceptibility to certain chronic diseases of the newborn through modulation of epigenetic mechanisms, including DNA methylation [1]. Our aim was to explore the connections among environmental exposures during gestation with placenta, maternal and neonatal buccal cell DNA methylation by applying artificial neural networks (ANNs).

Methods: 28 mother-infants couples have been enrolled. Information on lifestyle and environmental exposure during gestation were obtained by the administration of a questionnaire. Concentrations of heavy metals and dioxins in placenta were analyzed by means of mass spectrometry. Global and gene specific DNA methylation were performed.

Results: ANNs analysis revealed that low birth weight associated with placental H19 methylation, maternal stress during pregnancy with placental NR3C1 and maternal BDNF methylation, and exposure to air pollutants with maternal MGMT methylation. Associations among placenta concentrations of lead, chromium, cadmium and mercury with placental OXTR, maternal and neonatal HSD11B2, maternal MECP2 and maternal MTHFR methylation, respectively, as well as among concentrations of dioxins and placental RELN, neonatal HSD11B2 and maternal H19 methylation were also observed.
Conclusion: Current results show that methylation levels of genes involved in different pathways important for the embryonic development are sensitive to various environmental stressors during pregnancy and are altered in placenta, potentially affecting foetal development, and in peripheral tissues of mothers and neonates, potentially providing peripheral biomarkers of environmental exposure.

References: Gluckman et al., N Engl J Med. 359(1):61-73, 2008.

Grants: CCM Program 2017 - CUP E72F1700390001.

Conflict of Interest: None declared.

P21.030.B A highly structured diet in Greek individuals reveals molecular signatures linked to growth hormone signalling

Anargyros Skoulakis1, Dimitris Zisis1, Vasiliki Zarkou1, Maria Anezaki1, Konstantinos Rouskas2, Antigone Dimas1

1Institute for Bioinnovation, Biomedical Sciences Research Center Alexander Fleming, Athens, Greece; 2Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece.

Background/Objectives: Dietary restriction extends healthspan in multiple species and likely has beneficial effects for human health. To address the molecular impact of a structured diet in humans, we established the FastBio project. FastBio comprises 199 individuals following a structured diet specified by the Orthodox Christian Church (temporal abstinence from meat, dairy products and eggs for 200 days annually) and 212 individuals following a general-population, unstructured diet. FastBio explores multiple omics levels at fasting and nonfasting timepoints to capture acute and long-term effects of diet.

Methods: gDNA was genotyped and PCA on genotypes was performed to map FastBio relative to 1KG individuals. Whole blood RNA was sequenced and differentially expressed genes (DEGs) and eQTLs were detected using DESeq2 and FastQTL respectively.

Results: FastBio individuals map closest to TSI, with a gradient moving away from 1KG populations implying additional ancestry. Most DEGs (N = 386) were detected across dietary groups during the fasting timepoint. We report enrichment of pathways linked to: a) growth hormone receptor signalling, a pathway modulated by diet, whose downregulation has beneficial effects on health, b) action of beta-blockers, c) immune and metabolic processes. We also report ~8,500 eGenes for each dietary group and timepoint.

Conclusion: We reveal key signatures driven by a highly structured diet in humans. Integration of incoming data on: 250 plasma metabolites, 1,536 plasma proteins, the gut microbiome, and base modifications are lost. Genetic variation analysis on isoform usage on 17,046 annotated isoforms expressed in 50% of our samples identified 70 cis-isoform-QTLs (FDR 5%), among these, nine were not previously observed cis-eQTLs.

Conclusion: Furthermore, to understand the effect of common and rare genetic variants on specific transcript alterations, we are currently evaluating allele-specific expression analysis and identifying direct-RNA modifications.

References: Tang, Nature Communications, 2020.

Grants: ERC Starting Grant to Dr Dimas.

Conflict of Interest: None declared.

P21.032.D Adenosine-to-inosine m502b-3p editing as a novel oncogenic process in high-grade serous ovarian cancer

Magdalena Niemira1, Anna Skwarska2, Karolina Chwiałkowska3, Agnieszka Bielska1, Gabriela Sokolowska1, Anna Szalkowska1, Anna Erol1, Iwona Sidorkiewicz1, Justyna Raczkowska2, Mirosław Kwasniewski3, Mariusz Kuzmiński3, Jacek Szamatawicz4, Michał Ryń5, Paweł Knapp6, Joanna Reszec6, Marcin Moniuszko7, Adam Kretowski1;8

1Medical University of Białystok, Clinical Research Centre, Białystok, Poland; 2The University of Texas M.D. Anderson Cancer Centre, Department of Leukemia, Houston, United States; 3Medical University of Białystok, Centre for Bioinformatics and Data Analysis, Białystok, Poland; 4Medical University of Białystok, Department of Gynecology and Gynecological Oncology, Białystok, Poland; 5Medical University of Białystok, University of Oncology Centre, Białystok, Poland; 6Medical University of Białystok, Department of Medical Pathomorphology, Białystok, Poland; 7Medical University of Białystok, Department of Regenerative Medicine and Immune Regulation, Białystok, Poland; 8Medical University of Białystok, Department of Genetic Medicine and Development, Geneva, Switzerland; 9University of Geneva Medical School, Department of Genetic Medicine and Development, Geneva, Switzerland; 10University of Geneva Medical School, Department of Medicine/Department of Pathology and Immunology, Geneva, Switzerland; 11International Centre for Life, Institute of Genetic Medicine, Newcastle University, Newcastle, United Kingdom; 12University of Geneva Medical School, Department of Basic Neuroscience, Geneva, Switzerland.

Background/Objectives: RNA-seq technologies increased our knowledge of gene expression and transcript isoform signatures. However, current short-read RNA-seq methods have limitations in identifying complex transcript isoforms as full-length transcripts and base modifications are lost.

Methods: In this study, we use long-read native poly(A) RNA-seq using the Oxford Nanopore Technologies (ONT) platform, which measures the full length of mRNA molecules. We independently sequenced 60 unrelated lymphoblastoid cell lines from the 1000 Genomes/Geuvadis dataset, to investigate the effect of genetic variation on expression, splicing and structure within a population.

Results: Sequenced samples had on average 1.7 million reads with a median read length of 823 bp. We detected 11,123 protein-coding genes expressed in at least 50% of the samples. For these, we observed a good correlation of 0.61-0.79 with gene expression from the same samples sequenced with Illumina (~50M reads/sample). However, using the p“I” computed on genes with significant eQTLs in Illumina (317 samples), the estimate of Illumina-eQTLs detectable with ONT technology was only 10.7%. Isoform analysis using the FLAIR pipeline [1] identified 250,987 isoforms, of which 98,056 were not associated to any annotated gene. Overall, over 77% of isoforms associated to a gene were not previously annotated. Genetic variation analysis on isoform usage on 17,046 annotated isoforms expressed in 50% of our samples identified 70 cis-isoform-QTLs (FDR 5%), among these, nine were not previously observed cis-eQTLs.

Conclusion: Furthermore, to understand the effect of common and rare genetic variants on specific transcript alterations, we are currently evaluating allele-specific expression analysis and identifying direct-RNA modifications.

References: Nature Communications, 2020.

Grants: ERC Starting Grant to Dr Dimas.

Conflict of Interest: None declared.
Background/Objectives: Deamination of adenosine to inosine in double-stranded microRNAs (miRNAs) affects their function as oncospessors or oncogenes. Consequently, edition of miRNAs may play a key regulatory role in multiple signalling pathways altering cancer cell growth and survival. Therefore, edited miRNAs represent a novel and promising therapeutic strategy, especially for traditionally undruggable cancer's targets.

Methods: Here, we investigated a profile of miRNA editing through small RNA sequencing followed by miRge 2.0 analysis of 36 high-grade serous ovarian cancer (HGSOC) samples paired with 34 normal ovarian tissues. For functional studies, human ovarian cancer OVCAR3 and CAOV3 cell lines were treated with siADAR1 and 8-azaadeno sine to inhibit miRNA editing or transfected with wild-type/edited miRNAs mimics and subjected to RNA-seq and proteomics analysis to identify altered biological pathways and the critical targets of edited miRNAs.

Results: We found that the tumour suppressor miR-200b-3p was overedited in HGSOC samples compared to the normal ovarian tissue. Mechanistically, edited miR-200b-3p promoted cell proliferation, colony formation, migration and formation of 3D spheroids in ovarian cancer cell lines. RNAseq and GSEA analysis revealed that whereas wild-type miR-200b-3p, consistent with its tumour suppressor function, induced apoptotic signalling pathways (NES = 2.4; FDR = 0), edited miR-200b-3p significantly inhibited G1 to S cell cycle control (NES = 1.89; FDR = 0.01) and cell cycle checkpoint (NES = -0.89; FDR = 0.002) pathways.

Conclusion: Our results suggest that edited miR-200b-3p can be a novel therapeutic target for the treatment of HGSOC.

References: Not included.

Conflict of Interest: None declared.

P21.034.A Artificial intelligence reveal connections among sex, gene methylation, maternal risk factors and disease severity in Autism Spectrum Disorder

Andrea Stoccaro1, Roberta Gallo1, Sara Calderoni2, Romina Cagiana2, Filippo Muratori1, Lucia Migliore1, Enzo Grossi1, Fabio Coppede1

1University of Pisa, Translational Research and of New Surgical and Medical Technologies, Pisa, Italy; 2IRCCS Stella Maris Foundation, Calambrone (PI), Italy; 3Villa Santa Maria Foundation, Tavernello, Italy.

Background/Objectives: Increasing evidence points to a contribution of environmental and epigenetic factors in autism spectrum disorder (ASD), but their connections are still largely unexplored [1-3]. In the present study we used machine learning tools to unravel connections among ASD-related gene methylation levels, maternal ASD risk factors and ASD severity.

Methods: The methylation levels of MEC2P, OXTR, RELN, BDNF, EN2, BCL2 and HTR1A genes have been assessed in blood DNA samples of 58 ASD children (23 males and 35 females). We then used machine learning approaches (Auto-CM) to connect gene methylation levels with maternal ASD risk factors and with disease severity (ADOS-2 score).

Results: Sex differences were observed in DNA methylation levels of the studied genes, with MEC2P, HTR1A, and OXTR methylation connected to females, and EN2, BCL2, and RELN methylation connected to males. BDNF methylation was not linked to sex, but rather to maternal risk factors. Maternal pre-pregnancy BMI, gestational weight gain and living context were among factors linked to disease severity.

Conclusion: The present study highlights the power of artificial intelligence tools to unravel connections among different variables in complex disorders, revealing links among maternal risk factors and disease severity or gene methylation levels, as well as sex differences in gene methylation levels that warrant further investigation in ASD.

References: [1] Wisniowiecka-Kowalnik B, et al. J. Appl. Genet. 60(1), 37–47 (2019).
[2] Coppede F. Epigenomics 13(20), 1587–1590 (2021).

P21.033.A Epigenetic study: an aid in the diagnostic impasse of Kabuki syndrome

Mouna Barat-Houari1, Nathalie PALLARES-RUIZ2, Aref-Eshghi Erfan2, Bekim Sadikovic2, Olivier Arduin1, David BAUX1, Thomas Guignard1, Kevin Yauy3, Marine Legendre4, Stanislas Lyonnet5, Jean-Philippe Granger6, Guillaume Boursier1, David BAUX1, Thomas Bagioui7, Guilaine Boursier1, David Geneviève1

1CHU de Montpellier, Genetic, Montpellier, France; 2London Health Sciences Centre, Molecular Genetics Laboratory, Molecular Diagnostics Division, London, Canada; 3Inserm U 1209, CNRS UMR 5309, Institute of Advanced Biosciences, Centre de recherche UGA, Grenoble, France; 4CHU de Bordeaux, Genetic, Bordeaux, France; 5Hôpital Necker-Enfants Malades, Genetic, Paris, France; 6CHD Félix-Guyon, Pediatric, Saint-Denis, France; 7CHU de Caen – Hôpital Clémenceau, Genetic, Caen, France; 8CHU de Saint Etienne - Hôpital Nord, Genetic, Saint-Etienne, France; 9CHU Nice - Hôpital l’Archet2, Genetic, Nice, France; 10CHU Rouen - Hôpital Charles Nicolle, Genetic, Rouen, France; 11AP-HP - Hôpital La Pitié-Salpêtrière, Genetic, Paris, France; 12CHRU de Strasbourg, Genetic, Strasbourg, France.

Background/Objectives: Kabuki syndrome (KS) is a rare genetic disorder with a prevalence of 1/32,000 births. Clinical KS diagnosis is difficult in the first year of life or with atypical facial features. Currently, only molecular confirmation by identification of de novo pathogenic variants in KMT2D and KDM6A allow to confirm KS. Our laboratory offers a NGS targeted analysis of genes involved in DNA methylation pathway, including KS genes. We confirmed KS diagnosis in 29/41 cases (70.7%). However, the absence of molecular diagnosis in 12/41 (29.3%) individuals raises the question of a possible non-detected variant.

Methods: After a careful clinical data review, we classified these patients into two groups: a “typical KS” (n = 3) and “atypical KS” (n = 8). We obtained DNA methylation profiles for 11 “negative” by a collaboration with Dr B.Sadikovic, (EpiSign-CAN).

Results: Unlike “atypical KS” patients, “typical KS” displayed KS epigenotype as previously established for KMT2D or KDM6A patients. Thanks to a more efficient bioinformatic analysis, we identified KMT2D variants and confirmed molecular diagnosis for two “typical SK” with KS epigenotype: a 20 nucleotides deletion and a deletion of exon 35. An extended molecular analysis of the deep intronic and regulatory regions would help to identify the causal variant in the third patient.

Conclusion: It would be interesting to replicate this result in a larger sample. Such approach would provide a valuable and complementary aid to NGS, and would allow the exit from diagnostic impasse for KS patients and probably for patients with other chromatinopathies.

References: Aref-Eshghi, 2020, https://github.com/mobidic/MobiDL.

Grants: Conflict of Interest: None declared.

Abstracts from the 55th European Society of Human Genetics Conference
Abstracts from the 55th European Society of Human Genetics Conference

[3] Gallo R, et al. Epigenomics 2022. https://doi.org/10.2217/epi-2021-0494.

Grants: University of Pisa Grant (PRA 2017-61).

Conflict of Interest: None declared.

P21.035.C A CRISPR and FACS-based assay to assess allele-specific gene regulation by transcription factors

Laura Duran-Lozano1, Jenny Mattsson1,2, Caterina Cafaro1, Maroulio Pertesi1, Ram Ajore1, Ludvig Ekdahl1, Aitzkoa Lopez de Lapuente Portilla1, Björn Nilsson1,3

1Lund University, Lund, Sweden; 2Biolinvent International AB, Lund, Sweden; 3Broad Institute, Cambridge, United States.

Background/Objectives: GWAS-identified variants are often found in large intergenic or noncoding regions. Understanding the regulatory effects of such variants is key to understanding their functional role in a given phenotype. Allele-specific transcription factor (TF) binding could explain the association of a noncoding variant with a given phenotype as a result of differences in gene expression.

Methods: We elaborated an extensive and curated list of 1719 TF and produced a lentiviral transcription factor knock out (TF KO).

We used fluorescence-activated cell sorting (FACS) to examine which TF were key for the expression of our gene of interest.

We did that by staining cells transfected with the TF KO library with a specific antibody against the protein of interest and then sorted the 5% lowest expressing cells. We then sequenced the sorted cells to find which TF KO caused loss of expression of the gene of interest.

Examining cell lines with opposite genotype provides insight TFs that affect gene expression differentially according to genotype.

Results: We applied our library to two different phenotype models: a) key transcription factors for a known gene in Multiple myeloma, ELL2; and b) regulators in a hematopoietic stem cell model by studying the transcriptional regulators of recently discovered ITGA9.

Conclusion: We provide with a CRISPR-based library that is easy to use in vitro cellular models and can be used to study key transcription regulators of cell surface proteins as well as intracellular and nuclear proteins.

References: 1. https://doi.org/10.1038/ncomms8213.
2. https://doi.org/10.1182/blood.2021013220.

Grants:
- EU-MSCA-COFUND754299.
- Knut och Alice Wallenberg Foundation.
- Swedish Cancer Society.

Conflict of Interest: Laura Duran-Lozano: None declared.
Jenny Mattsson employed by Biolinvent International AB, Caterina Cafaro: None declared, Maroulio Pertesi: None declared, Ram Ajore: None declared, Ludvig Ekdahl: None declared, Aitzkoa Lopez de Lapuente Portilla: None declared, Björn Nilsson: None declared.

P21.036.D Epigenome-wide association study of gestational age at birth using DNA methylation data measured on the Illumina MethylationEPIC BeadChip microarray

Kristine Lekås Haftorn1, William Denault1,2, Yun Sung Lee1, Christian Page1,2, Julia Romanowska1,2, Per Magnus1, Sri Häger1, Jan Bohlin1,2, Astanand Jugessur1,4

1Norwegian Institute of Public Health, Centre for Fertility and Health, Oslo, Norway; 2University of Chicago, Department of Human Genetics, Chicago, United States; 3University of Oslo, Department of Mathematics, Oslo, Norway; 4University of Bergen, Department of Global Public Health and Primary Care, Bergen, Norway; 5Norwegian Institute of Public Health, Department of Method Development and Analytics, Oslo, Norway.

Background/Objectives: Although shorter gestational age (GA) has been linked to increased risk of disease early and later in life, the mechanistic underpinnings are not well understood. Previous studies have shown a strong association between DNA methylation (DNAm) and GA. However, these studies analyzed DNAm measured on the Illumina HumanMethylation 450K array. The more recent 850K (’EPIC’) array covers almost twice as many CpGs as the 450K array and includes more CpGs in regulatory regions that may be more relevant to GA. We therefore wanted to investigate the relationship between GA and CpGs on the EPIC array.

Methods: We conducted an epigenome-wide association study (EWAS) of GA using EPIC-derived DNAm data from cord blood of 953 randomly selected newborns from a sub-study of the population-based Norwegian Mother, Father and Child Cohort (MoBa) study. Adjustments for child sex, maternal age and smoking, cell type proportions and batch effects were included in the analysis.

Results: 13,660 CpGs were associated with GA at Bonferroni significance, 7639 of which were specific for the EPIC array. Functional enrichment analysis further revealed that these CpGs were located near genes playing a role in development and regulation of the cytoskeleton.

Conclusion: We identified numerous differentially methylated CpGs that were associated with GA and specific for the EPIC array.

References:
- Grants: Research Council of Norway (grant 262700) and National Institutes of Health (NIH) (grant R01 1HL134840-0).
- Conflict of Interest: None declared.

P21.037.A The impact of functional characterization of variants in calcium sensing receptor gene (CASR) on the clinical diagnosis

Andrea Apetrei1, Richard Nicolas1, Stéphane Allouche2, Gros Anthony2, Fontaine Paul1, Resbeut Antoine1, Nicolas Gruchy1, Arnaud Molin1

1Normandy University, UNICAEN, Caen University Hospital, Department of Genetics, Reference Center of Rare Diseases of Calcium and Phosphorus Metabolism, EA 7450 BioTARGen, Caen, France; 2Normandy University, UNICAEN, Caen University Hospital, Department of Biochemistry, Caen, France; 3Normandy University, UNICAEN, EA 7450 BioTARGen, Caen, France.

Background/Objectives: The human calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that signals via intracellular calcium mobilization and MAPK pathway to regulate extracellular calcium homeostasis. Loss- or gain-of-function heterozygous CASR variants lead to familial hypocalciuric hypercalcaemia type 1 (FHH1) or autosomal-dominant hypocalcaemia (ADH), respectively.

Methods: We analysed the CASR gene in ten unrelated families presenting abnormalities of the calcium and phosphate metabolism. The missense variants of unknown significance were induced by site-directed mutagenesis into a wild-type (WT) CaSR-expressing plasmid vector. HEK293 cells were transfected with either the WT, the variant or cotransfected with both CaSR-containing vectors. We conducted two luciferase reporter gene assays using NFAT and SRE response elements to measure the function of CaSR on the two major CaSR-associated pathways.

Results: Eleven heterozygous CASR genetic variants were identified in eight different FHH1 families, one ADH family and
one patient presenting nephrolithiasis and hypercalciuria. In two families we identified two different variants in cis (complex allele) and in trans (compound heterozygote), respectively. The functional assays allowed to classify the eleven variants as gain of function (1/11), loss of function (8/11) and without impact (2/11) and to do a genotype-phenotype association.

**Conclusion:** We report and characterize eleven CASR variants in ten families with various clinical presentations. We were able to resolve two complex cases, with two variants presented in cis and in trans respectively and hypothesize on their implication in the observed phenotype. Our work enlarged the spectrum of pathogenic variants of CASR gene.

**References:**

**Grants:** This research received a grant from Normandy region (RIN Normandy Genomic Medicine).

**Conflict of Interest:** None declared.

**P21.038.B** Analysis of the effect of thiopurine drugs on the DNA methylation profile in IBD patients

Marlena Szalata1, Katarzyna Bzdęga2,3, Oliwia Zakerska-Banaszak2, Joanna Zuraszek3, Marcin Gabryel4, Aleksandra Zielinska3, Liliana Łykovska-Szuber4, Agnieszka Dobrowolska1, Ryszard Slomski3, Marzena Skrzypczak-Zielińska1

1Department of Biochemistry and Biotechnology, University of Life Sciences, Poznan, Poland; 2Chair and Department of Genetics and Pharmaceutical Microbiology, Poznan University of Medical Sciences, Poznan, Poland; 3Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland; 4Department of Gastroenterology, Dietics and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland.

**Background/Objectives:** Thiopurines, used in immunosuppressive treatment i.a. of inflammatory bowel disease (IBD), are purine analogs that via incorporation into the DNA strands, inhibit replication. It is hypothesized that thiopurines may cause epigenetic effects. Our aim was to analyze the impact of azathioprine (AZA) on the DNA methylation using the in vitro model of T lymphocytes and NK cells obtained from peripheral blood samples from 15 IBD patients and subjected to 6-day culture with 10 μM AZA addition. The control group consisted of 12 healthy individuals.

**Methods:** DNA methylation profile analyzes were carried out including 1) CpG islands by using bisulfite conversion and pyrosequencing of mitochondrial D loop sequence and ALU repetitive sequence, 2) global methylation analysis by detection of 5-methylcytosines using enzyme-linked immunosorbent assay (ELISA).

**Results:** Pyrosequencing results show no statistically significant differences in the methylation level of the D-loop mitochondrial DNA fragment and ALU sequence between in vitro cell cultures with and without 10 μM AZA supplementation, and also between patients and controls. However, for both loci, there were differences in the methylation level of the individual CpG positions (p < 0.0001). ELISA results showed that the average 5-mC level was at 4.35% for the cultured cells of patients without AZA supplement and 4.15% for those with AZA, and it did not differ significantly, even compared to the results for the control group (3.95% and 4.23% respectively).

**Conclusion:** The presence of 10 μM AZA addition in 6-day T lymphocytes and NK cells culture does not influence DNA methylation.

**References:** [https://doi.org/10.1016/j.crohns.2012.06.020](https://doi.org/10.1016/j.crohns.2012.06.020).

**Grants:** Polish National Science Centre, grant-no. 2016/23/D/NZ2/01620.

**Conflict of Interest:** None declared.

**P21.039.C** DNA methylation in 22q11.2 deletion syndrome and risk to develop schizophrenia

Chuan JIAO1, Fanny Demars1, Qin He1, Oussama Kebir1,2, Anushree Tripathi1, Hugo Turbé3, Caroline Demily3, Marie-Odile Krebs1,2, Thérèse Jaÿ1, Boris Chaumette1,2

1Université de Paris, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Paris, France; 2GHU Paris Psychiatrie et Neurosciences, Paris, France; 3GénoPcy Centre Hospitalier Le Vinatier, Lyon, France; 4McGill University, Montreal, Canada.

**Background/Objectives:** Schizophrenia is a severe psychiatric disorder resulting from the interaction of genetic and environmental factors. One of the highest genetic risks is 22q11.2 deletion. 25% of 22q11.2 deletion syndrome (22q11.2DS) carriers will develop schizophrenia in their lifetime. We hypothesized that environmental factors such as stress increase the risk of schizophrenia for 22q11.2DS carriers through epigenetics.

**Methods:** We explored the DNA methylation difference in nine 22q11.2DS carriers affected by schizophrenia and five carriers without schizophrenia. One pair of discordant monzygotic twins was included. Besides, 30 mice were separated into four groups: wildtype (WT), Df(h22q11)/+ (G), WT_stress (E), and Df(h22q11)/+ stress (GxE). Blood samples from humans and prefrontal cortex samples from mice were sequenced by RRBS. Differentially methylated probes (DMPs) and regions (DMRs) were detected (FDR<0.05 & Δm>25%).

**Results:** A total of 3,895 DMPs and 1,562 DMRs were significant, corresponding to 3,773 unique genes. They were highly expressed in the brain and significantly enriched in schizophrenia GWAS hits. The most significant pathways were neuroactive ligand-receptor interaction, calcium, and focal adhesion. Meanwhile, 10,076 DMPs and 167 DMRs (Δm>50%) were identified in twins; 3,030 genes were colocalized. For mice, more genes were detected in stress influence on Df(h22q11)/+ than in WT. Same groups of pathways were enriched. In total, 42 overlapped genes were highly expressed in neurons and astrocytes.

**Conclusion:** Stress matters in the emergence of schizophrenia for 22q11.2DS carriers. These target genes can help us to study the mechanism and therapy further.

**References:** J.R. Zinkstok et al., 2019, The Lancet Psychiatry.

**Grants:** ANR EPI-YOUNG, and Fondation Bettencourt Schueller.

**Conflict of Interest:** None declared.

**P2NEW TREATMENTS FOR GENETIC DISORDERS**

**P22.001.D** Papillon-Lefèvre syndrome: Alveolar bone regeneration using customized 3D printed poly-l-lactic acid scaffold and autologous bone marrow mononuclear cells

ahmad abd Elazeem1, hatem mattar2, mohamed elmasry3, mohsena abderazik4, Nermeen Ahmed3

1Human Genetics and Gnome Research Institute, National Research Centre, oro-dental genetics, Giza, Egypt; 2New Cairo Hospital, Oral and Maxillofacial unit, Cairo, Egypt; 3Ganzoni Specialized Hospital, Cairo, Egypt; 4Faculty of Dental Medicine for Girls, Al-Azhar University, Orthodontic Department, Cairo, Egypt.

**Background/Objectives:** Papillon LeFevre syndrome (PLS) is an autosomal recessive disorder that is characterized by early-onset severe periodontitis and consequently premature loss of teeth. Early teeth loss is followed by progressive bone resorption,
atrophied ridges, and reduced vertical dimension of occlusion that will hinder the construction of a suitable prosthesis. Tissue engineering is a field of medicine that uses a combination of; cells, engineered biomaterials, and suitable biochemical factors to replace biological tissues. Bone mononuclear cells (BM-MNCs) have been used for bone regeneration as they contain a fraction of stem cells. Recent technologies, such as 3D printing, have revolutionized the field of tissue engineering and provided the ability to design and fabricate patient-specific complex 3D scaffolds. Here, an innovative regenerative approach is proposed to provide a step forward towards regenerative therapy.

**Methods:** This study included 3 patients diagnosed with PLS. Autologous BM-MNCs were seeded on a patient-specific 3D printed poly-l-lactic acid (PLLA) scaffold. A combination of; autologous platelet-rich fibrin (PRF) and nano-hydroxyapatite was used for bone regeneration. Clinical and radiographic assessment was be performed at 6 and 12 months postoperatively.

**Results:** All patients healed probably without any complications. During the 12-month follow-up, no donor site morbidities have been reported. Cone beam radiographs showed successful bone regeneration in all cases.

**Conclusion:** This proposed approach may help to improve the lifestyle and health of patients with PLS.

**References:**

**Grants:** This work was supported by the Science and Technology Development Funding Authority (STDF), young Researcher Grant (STDF - YRG– Call 10, Grant number 33438, 2019).

**Conflict of Interest:** ahmad abd Elazeem Science and Technology Development Funding Authority (STDF), young Researcher Grant (STDF - YRG– Call 10, Grant number 33438, 2019), hatem mattar Science and Technology Development Funding Authority (STDF), young Researcher Grant (STDF - YRG– Call 10, Grant number 33438, 2019), mohamed elmasry Science and Technology Development Funding Authority (STDF), young Researcher Grant (STDF - YRG– Call 10, Grant number 33438, 2019), mohamed hamed Science and Technology Development Funding Authority (STDF), young Researcher Grant (STDF - YRG– Call 10, Grant number 33438, 2019), Nermek Ahmed Science and Technology Development Funding Authority (STDF), young Researcher Grant (STDF - YRG– Call 10, Grant number 33438, 2019).

**P22.002.A Periodontal management for patients suffering from Papillon–Lefevre syndrome**

yasmin khalil1, Nermek Ahmed2, Phoebe M. Abdelmassih3, Heba Mustafa4, mohsena abderazik5

1National Research Center, Department of Oro-Dental Genetics, Human Genetics and Genome Research institute, cairo, Egypt; 2Azhar university for girls, orthodontic department, faculty of dental medicine, cairo, Egypt.

**Background/Objectives:** Papillon–Lefevre syndrome (PLS) is an autosomal recessive disorder caused by Cathepsin C gene mutation. Patients suffer from palmoplantar keratosis, periodontitis, and early loss of teeth. Few periodontists have attempted to preserve natural dentition and avoid total clearance of both primary and permanent teeth which causes severe psychological trauma, indigestion problems and sabotages future attempts for prosthetic intervention. As a continuation of a previous study, this study aims to assess the best intervention to preserve natural dentition and delay bone loss in patients with PLS.

**Methods:** 5 patients aged 8 to 14 years diagnosed with PLS by molecular and biochemical analysis. All patients received 1 year treatment divided into 2 successive phases as in the following table

| Treatment                  | 1st phase (6month) | 2nd phase (6month) |
|----------------------------|--------------------|--------------------|
| Scaling and root planning  | Every 3 month      | Every 3 month      |
| Diode laser pocket disinfection | Twice per month | Once per month |
| Local chlorhexidine gel application | non             | Once per month |

Periodontal condition was assessed clinically and by cone beam x-ray at the beginning and the end of each phase.

**Results:** Gingival indices showed marked stability during both phases. No teeth were lost or showed increased mobility. Bone level and density were more stable only during the second phase.

**Conclusion:** Oral hygiene measures aided by diode laser can stabilize the clinical dental condition in PLS patients. Adding chlorhexidine gel was more effective in controlling bone loss.

**References:**

**Grants:** This work was supported by the Science and Technology Development Funding Authority, young researcher grant CALL 10 Grant number 33438,2019.

**Conflict of Interest:** yasmin khalil This work was supported by the Science and Technology Development Funding Authority (STDF), young researcher grant (STDF-YRG-CALL 10 Grant number 33438,2019), Nermek Ahmed This work was supported by the Science and Technology Development Funding Authority (STDF), young researcher grant (STDF-YRG-CALL 10 Grant number 33438,2019), Phoebe M. Abdelmassih This work was supported by the Science and Technology Development Funding Authority (STDF), young researcher grant (STDF-YRG-CALL 10 Grant number 33438,2019), Heba Mustafa This work was supported by the Science and Technology Development Funding Authority (STDF), young researcher grant (STDF-YRG-CALL 10 Grant number 33438,2019), mohsena abderazik This work was supported by the Science and Technology Development Funding Authority (STDF), young researcher grant (STDF-YRG-CALL 10 Grant number 33438,2019).

**P22.003.B L-Serine treatment is associated with improvements in behavior, EEG and seizure frequency in individuals with GRIN-related disorders due to null variants**

Ilona Krey1, Sarah von Spiczak2,3, Katrine Marie Johannesen4, Rikke Steensbjerg Moeller5, Christiane Hikel6, Gerard Kurlermann6, Hiltrud Muhr2, Diane Byesen7, Tobias Dietel8, Johannes Lemke9, Steffen Syrbe10

1Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany, Leipzig, Germany; 2DRK-Northern German Epilepsy Center for Children and Adolescents, Schwientental, Germany, Schwientental, Germany; 3Department of Neuropediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany, Kiel, Germany; 4Department of Epilepsy Genetics and Personalized Medicine, The Danish Epilepsy Centre, Dianalund, Denmark, Dianalund, Denmark, Denmark; 5Department of Children and Adolescents, GFO Kliniken Niederrhein, Dinslaken, Germany, Dinslaken, Germany; 6Hospital for Children, Bonifatius Hospital Lingen, Germany, Lingen, Germany; 7Department of Paediatric Neurology, Antwerp University Hospital, Antwerp, Belgium, Antwerp, Belgium; 8Epilepsy Center Kork, Medical Faculty of the University of Freiburg, Kehl, Germany, Kehl, Germany; 9Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany, Leipzig, Germany; 10Division of Paediatric Epileptology, Centre for Paediatrics and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany, Heidelberg, Germany.
Background/Objectives: Pathogenic missense variants in GRIN2A and GRIN2B may result in gain or loss of function (GoF/LoF) of the N-methyl-D-aspartate receptor (NMDAR). This observation gave rise to the hypothesis of successfully treating GRIN-related disorders due to LoF missense variants.

Methods: In this respect, we describe a retrospectively collected series of ten individuals with GRIN2A- or GRIN2B-related disorders who were treated with L-serine, each within an independent n-of-1 trial.

Results: Our cohort comprises one individual with a LoF missense variant with clinical improvements confirming the above hypothesis and replicating a previous n-of-1 trial. A second individual with a GoF missense variant was erroneously treated with L-serine and experienced immediate temporary behavioral deterioration further supporting the supposed functional pathomechanism. Eight additional individuals with null variants (that had been interpreted as loss-of-function variants despite not being missense) again showed clinical improvements. Among all nine individuals with LoF missense or null variants, L-serine treatment was associated with improvements in behavior in eight (89%), in development in four (44%) and/or in EEG or seizure frequency in four (44%). None of these nine individuals experienced side effects or adverse findings in the context of L-serine treatment.

Conclusion: In summary, we describe first evidence that L-serine treatment may not only be associated with clinical improvements in GRIN-related disorders due to LoF missense but particularly also null variants.

References:

Grants: Steffen Syrbe received funding from the Dietmar-Hopp-Stiftung (Grant 1DH1813319).

Conflict of Interest: None declared.

P22.004.C Development of a method for permanent skipping of exons 11 and 12 in the DMD gene for the treatment of Duchenne Muscular Dystrophy

Irina Panchuk1, Olga Levchenko1, Milyausha Zaynitdinova1, Yana Slesarek1, Sabina Nagieva1, Konstantin Kochergin-Nikitisky1, Vyacheslav Tabakov1, Alexander Lavrov1, Svetlana Smirnikhina1

1Research Centre for Medical Genetics, Moscow, Russian Federation.

Background/Objectives: Duchenne muscular dystrophy (DMD) is an X-linked recessive disease with mutations in DMD gene, coding dystrophin. Skipping one or more exons is a widely used approach for frame restoration in the DMD gene. Mutations in exons 11 and 12 of DMD are typical for 1% of patients. Purpose of the work: to evaluate the possibility of 11-12 exon skipping in the DMD using CRISPR-Cas9.

Methods: Eight sgRNAs (4 for SpCas9 and 4 for SaCas9) for introns 10 and 12 of DMD were cloned into plasmids with eSpCas9(1.1) (Addgene #71814) or SaCas9 (Addgene #61591). Plasmids were individually or pairwise transfected into HEK293T (lipofection) and immortalized healthy myoblasts (electroporation), DNA and RNA were isolated 72 hours after transfection, and PCR was performed to detect editing products. Amplified fragments were sequenced according to Sanger and analyzed by TIDE method.

Results: Experiments on HEK293T made it possible to identify two of the most active sgRNAs for SaCas9 (with efficiency 20% and 8%) and SpCas9 (with efficiency 30% and 25%). This pairs of sgRNAs were capable to create a target deletion in HEK293T and myoblasts, which confirmed by MLPA and Sanger sequencing. In addition, the formation of an inversion of exons 11-12 and a circular DNA consisting of deleted product were confirmed in both cell lines. At the RNA level, only 2 products were detected: a normal transcript and a transcript with a deletion.

Conclusion: The study shows the possibility of skipping exons 11 and 12 of the gene DMD in several cell lines.

References:

Grants: None declared.

Conflict of Interest: None declared.

P22.005.D The Dutch Center for RNA Therapeutics: a center to develop antisense oligonucleotide therapies for patients with nano-rare mutations

Marlen C. Lauffer1, Annemieke Aartsma-Rus1, Rob W.J. Collin2, Ype Elgersma3, Willeke van Roon-Mom1

1Leiden University Medical Center, Department of Human Genetics, Leiden, Netherlands; 2Radboud University Medical Center, Department of Human Genetics and the Donders Institute for Brain, Cognition and Behavior, Nijmegen, Netherlands; 3Erasmus University Medical Center Rotterdam, Department of Clinical Genetics and The ENCORE Expertise Center for Neurodevelopmental Disorders, Rotterdam, Netherlands.

Background/Objectives: Antisense oligonucleotides (AONs) offer the potential to treat patients with genetic diseases. Notably, for tissues allowing local injection, such as the brain and eye where high local exposure can be achieved with 3-4 infusions of low amounts of AONs annually. Proof-of-concept has been shown for example in spinal muscular atrophy and Leber congenital amaurosis. This approach can also benefit patients with private mutations, as was recently evidenced by the development of the custom-made AON milasen for a patient with Batten’s disease. This underlines the potential of AONs as personalized medicines, specifically for patients with private mutations that are associated with brain or eye phenotypes. However, pharmaceutical companies are usually not interested in the development of such approaches, due to the extreme rarity of these variants.

The Dutch Center of RNA Therapeutics (DCRT) is a collaboration of Dutch academic centers with a track record in AON development that aims to develop therapies for patients with nano-rare variants and to offer these therapies in a not-for-profit manner. The DCRT works in alignment with the N-of-1 collaborative (global) and the 1 mutation 1 medicine (1M1M, European) initiatives. In the first two years, we have identified several patients with mutations that are suitable for splice modulation by AONs. Here, we outline the pre-clinical development of AON-based splice correction for a cryptic splicing mutation underlying Stargardt disease affecting the eye, and Beta-propeller Protein-Associated Neurodegeneration (BPN) affecting the brain. We describe the Dutch roadmap towards clinical implementation, highlighting also the efforts to align developments internationally.

Methods:

Results:

Conclusion:

References:

Grants: None declared.

Conflict of Interest: None declared.

P22.006.A The Abcc6a Knockout Zebrafish Model as a Novel Tool for Drug Screening for Pseudoxanthoma Elasticum

Matthias Van Gils1, Andy Willaert1, Paul Coucke1, Olivier Vanacker1

1Ghent University Hospital, Center for Medical Genetics, Ghent, Belgium.
Background/Objectives: Pseudoxanthoma elasticum (PXE) is a currently intractable ectopic mineralization (EM) disorder due to bi-allelic ABCC6 mutations. PXE patients have multisystemic EM, while heterozygous carriers present mainly cardiovascular EM. Rapid, cost-effective discovery of therapeutic drugs can be done by compound screening in zebrafish, but this approach is unavailable in PXE. We validated a stable CRISPR/Cas9 abcc6a knockout zebrafish model – which has spinal column hypermineralization as primary phenotypic feature – as a model system for compound screening in EM.

Methods: We evaluated the anti-mineralization potential of five compounds, which has (anecdotal) positive effects reported in Abcc6a/-/- mice or PXE patients. Abcc6a/-/- zebrafish larvae were treated from 3 to 10 days post-fertilization with vitamin K1, sodium thiosulfate (STS), etidronate, alendronate or magnesium citrate and compared to untreated fish. Following alizarin red staining, alterations in spinal hypermineralization were semiquantitated.

Results: Vitamin K1 (80μM), etidronate (100μM) and alendronate (100μM) reduce hypermineralization by 42%, 33% and 39% respectively compared to untreated fish (P < 0.05). We show for the first time in a PXE model that 20μM STS reduces mineralization by 55%, but higher doses paradoxically result in EM. Magnesium citrate (10mM) reduces mineralization by 45% and, as only compound, also has an anti-mineralizing effect in heterozygous zebrafish (hyper-mineralization reduction of 77%). Physiological bone mineralization was not affected by any of the compound screens.

Conclusion: We demonstrate that the use of abcc6a/-/ zebrafish model is a promising strategy for drug discovery against EM.

References: N/A.

Grants: GOA019-21 grant – Ghent University.

Conflict of Interest: None declared.

P22.007.B Towards a home management solution for phenylketonuria patients

Giuseppe Bonapace, Ennio Tasciotti, Antonio Valentini, Joseph Toaff, Mauro Nasini, Vittorio Rossetti, Chiara Settanni, Stefano Alessandro Vismara, Azzurra Matarazzo, Nicole Vignaroli, Emiliano Binotti, Antonio Maiolo, Luca De Angelis, Maria Teresa Moricca, Giovanna Scozzafava, Onorina Marasco, Maria Pittelli, Teresa Greto, Nicola Perrotti, Marco Flavio Michele Vismara

1Magna Græcia University, Pediatrics, Catanzaro, Italy; 2lightScience s.r.l. - Modest, Rome, Italy; 3IRCCS San Raffaele Rome, Human Longevity Program, Roma, Italy; 4Azenda Ospedaliero Universitaria Mater Domini, Neonatal screening, Catanzaro, Italy; 5Magna Græcia University, Health Sciences, Catanzaro, Italy.

Background/Objectives: We aim to measure Phenylalanine using a machine-learning-based chemometric calibration model to process Near-Infra-Red (NIR) spectra from a Dried-Blood-Spot (DBS) card [1, 2]. Here we present the results obtained with our new prototype.

Methods: All data were obtained using a Texas-Instruments NIRScan Nano-EVM, bound in a custom-built 3d printed case run by a proprietary software built to manage the spectra. We used DBS-calibrators to obtain samples matched with values published by an independent third party and established a spectral pre-analytical data treatment. A dataset of 101 samples was populated with at least 6 scans from each sample. After scrubbng, 75 spectra were used to train a machine-learning-based chemometric model and 26 as a Test-set. The model was tested on a New-set of 30 samples.

Results: For this application, the optimal optical calibration is 990-1368 nm, with Digital resolution of 150 and auto-correction gain of 64. The pre-analytical data treatment pipeline was optimized to: Kubelka-Munk function, SNV, Smoothing_Detrend, and 2nd_derivative.

Training-set (n = 75) Test-set (n = 26)

|  | Training-set | Test-set |
|---|---|---|
| R | 0.96 | 0.96 |
| R2 | 0.93 | 0.92 |
| SPD | 3.75 | 3.43 |
| RMSEC | 1.48 | 1.46 |
| SEC | 1.49 | 1.47 |

Conclusion: An RPD of 3.43 in the Test-set means a good rating for real-world applications.

An RMSE of 1.46 explains the lack of measurement accuracy found when analyzing the new set, and gives room for improvement.

These findings support the feasibility of a NIR-based home Phenylalanine measurement system.

References: ESHG2019, Poster-ID 14.090.A. ESHG2020, Poster-ID P16.57.C.

Grants: .

Conflict of Interest: Giuseppe Bonapace lightScience srl - Modest, lightScience srl - Modest, Ennio Tasciotti lightScience srl - Modest, Antonio Valentini lightScience srl - modest, lightScience srl - modest, lightScience srl - modest, Joseph Toaff lightScience srl - modest, Mauro Nasini lightScience srl - modest, lightScience srl - modest, Vittorio Rossetti lightScience srl - modest, lightScience srl - modest, lightScience srl - modest, Chiara Settanni lightScience srl - modest, Stefano Alessandro Vismara lightScience srl - Modest, Azzurra Matarazzo modest, lightScience srl, Nicole Vignaroli lightScience srl, Emiliano Binotti lightScience srl - Modest, Antonio Maiolo lightScience srl - Modest, Luca De Angelis lightScience srl, Maria Teresa Moricca: None declared, Giovanna Scozzafava: None declared, Onorina Marasco: None declared, Maria Pittelli: None declared, Teresa Greto: None declared, Nicola Perrotti: None declared, Daniela Concolino: None declared, Marco Flavio Michele Vismara lightScience srl - Modest, lightScience srl - modest, lightScience srl - Modest, lightScience srl - Modest.

P22.008.C Genome editing for beta-haemoglobinopathies without double-strand DNA cleavage

Nikoletta Papaioannou, Petros Patsali, Panayiota Papasavva, Carsten W. Lederer, Marina Kleanthous

1The Cyprus Institute of Neurology and Genetics, Molecular Genetics and Thalassaemia Department, Nicosia, Cyprus.

Background/Objectives: Beta-thalassaemia, is marked by low adult haemoglobin (αβ) owing to defective β-globin (HBB) expression. Increased foetal haemoglobin (α2γ2/HBF) can ameliorate the severity of the disorder and may be achieved by erythroid reduction of γ-globin repressor. This can be achieved by catalysing base editors (BEs), which has (anecdotal) positive effects reported in silico design of guide RNAs to apply BE technology by nucleofection in erythroid
cells, to modify targets of relevance for β-haemoglobinopathies. Editing efficiency and functional studies at the DNA, RNA and protein level were carried out.

**Results:** Initial plasmid-based delivery of BEs resulted in high toxicity and poor performance, prompting us to establish in vitro mRNA synthesis for mRNA/gRNA-based delivery of BEs instead. Resulting precision editing with up to 86% bulk efficiency indicated differential same-target efficiency of different BEs for the clinically relevant BCL11A target. Finally, DSB-independence prompted us to evaluate duplex base editing of both, trans-acting factors and corresponding cis-regulatory elements, which resulted in elevated γ-globin induction by duplex compared to simplex BE application.

**References:**

**Grants:** RPF - Excellence /1216/0092.

**Conflict of Interest:** None declared.

**P22.009.D MEK-inhibitor successful treatment on a patient with NRAS-related cutaneous skeletal hypophosphatemia syndrome**

**Diana Carli**1,2, Daniele Tessaris1, Emilia Parodi1, Simona Cardaropoli1, Paola Coppo1, Jessica Munarin1, Roberta La Selva1, Gianpaolo Di Rosa1, Verdiana Pullano2, Martina Palumbo2, Alfredo Brusco2,3, Ugo Ramenghi1, Enzo Medic6,7, Luisa De Sanctis1, Giovanni Battista Ferrero2, **Alessandro Mussa**1

1University of Torino, Department of Public Health and Pediatrics, Torino, Italy; 2Città della Salute e della Scienza di Torino, Pediatric Oncology-Hematology, Regina Margherita Children’s Hospital, Torino, Italy; 3Città della Salute e della Scienza di Torino, Pediatric Dermatology, Regina Margherita Children’s Hospital, Torino, Italy; 4Città della Salute e della Scienza di Torino, Pediatric Radiology Unit, Regina Margherita Children’s Hospital, Torino, Italy; 5University of Torino, Department of Medical Sciences, Torino, Italy; 6Candiolo Cancer Institute, FPO-IRCCS, Laboratory of Oncogenomics, Candilo, Italy; 7Città della Salute e della Scienza di Torino, University of Medical Genetics, Torino, Italy; 8University of Torino, Department of Oncology, Torino, Italy; 9University of Torino, Department of Clinical and Biological Sciences, Orbassano, Italy.

**Background/Objectives:** Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS) is a RASopathy caused by postzygotic somatic activating variants in HRAS, NRAS, or KRAS genes. We treated a patient with NRAS-associated CSHS with the MEK inhibitor trametinib.

**Methods:** A 5-year-old boy with lipomatous nevus of the head, eye choristoma, multiple hamartomas, epidermal nevus, hypotrophy of the left hemisphere, pleural lymphangioma and relapsing chylothorax, developed in the last year severe hypophosphatemic rickets unresponsive to phosphate and calcitriol treatment. DNA testing from nevus biopsy showed a somatic c.182A>G, p.(Gln61Arg) variant in NRAS. We administered trametinib, a RAS/MAPK pathway inhibitor, for six months. Transcriptome analysis from patient’s PBMCs was performed at time 0, week 1, 4 and 12 from treatment start.

**Results:** Trametinib administration led to a prompt normalization of phosphatemia and phosphaturia. During the follow-up, we noted a growth improvement, the regression of the lymphangioma and chylothorax, and increase in bone mineral density with enhanced bone architecture; we also observed reduction of the epidermal nevus and hamartomas. The sole adverse events were a mild and asymptomatic increase in serum potassium and CPK. RNA-seq analysis indicated a down-modulation of the upregulated RASopathy-specific transcriptional signatures.

**Conclusion:** Our CSHS case is the first effectively treated with a MEK inhibitor allowing an almost complete recovery of the metabolic bone disease with practically no complication. Transcriptome data provide evidence that the altered RAS/MAPK pathway of the disease is reversed under the MEK-inhibitor treatment.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P22.010.A maxillofacial regeneration using customized 3D printed patient specific poly-l-lactic acid scaffold and autologous bone marrow mononuclear cells**

ahmad abdelazeem1, hatem mattar2, mohsena abderazik3, Inas Sayed4, Nermee Ahmed5

1National research center, cairo, Egypt; 2New cairo hospital oral and maxillofacial unit, cairo, Egypt; 3azhar university for girls, cairo, Egypt.

**Background/Objectives:** We report using patient specific 3D printed scaffolds for two applications in two cases of craniofacial disorders: cleft lip and palate patient with persistant alveolar fistula and 1 case of ectodermal dysplasia with progressive bone resorption, atrophied ridges, and reduced vertical dimension of occlusion. Using a combination of; cells, engineered biomaterials, and suitable biochemical factors to replace biological tissues combined with recent technologies, such as 3D printing revolutionized the field of tissue engineering and provided the ability to design and fabricate patient-specific complex 3D scaffolds.

**Methods:** This study report 2 patients with two craniofacial deformity.First a case diagnosed ectodermal dysplasia, and the other with unilateral cleft lip and palate with persistant alveolar deformity causing oronasal stula... Autologous BM-MNCs were seeded on a patient-specific 3D printed poly-l-lactic acid (PLLA) scaffold. A combination of; autologous platelet-rich fibrin (PRF) and nano-hydroxyapatite was used for bone regeneration. Clinical and radiographic assessment was be performed at 6 and 12 months postoperatively.

**Results:** Both patients healed probably without any complications. During the 12 month follow-up, no donor site morbidities have been reported. Cone beam radiographs showed successful bone regeneration in those cases.

**Conclusion:** This proposed approach may help to improve the complex maxillofacial repair for patients with Maxillofacial anomalies.

**References:**

**Grants:** This work was supported by the Science and Technology Development Funding Authority (STDF), young Researcher Grant (STDF - YRG– Call 10, Grant number 33494, 2019).

**Conflict of Interest:** ahmad abdelazeem This work was supported by the Science and Technology Development Funding Authority (STDF), young Researcher Grant (STDF - YRG– Call 10, Grant number 33494, 2019), hatem mattar This work was supported by the Science and Technology Development Funding Authority (STDF), young Researcher Grant (STDF - YRG– Call 10, Grant number 33494, 2019), mohsena abderazik This work was supported by the Science and Technology Development Funding Authority (STDF), young Researcher Grant (STDF - YRG– Call 10, Grant number 33494, 2019), Inas Sayed This work was supported by the Science and Technology Development Funding Authority (STDF), young Researcher Grant (STDF - YRG– Call 10, Grant number 33494, 2019), Nermee Ahmed This work was supported by the Science and Technology Development Funding Authority (STDF), young Researcher Grant (STDF - YRG– Call 10, Grant number 33494, 2019).
Abstracts from the 55th European Society of Human Genetics Conference

Alessandra Renieri
Angel Raya5, Maria Antonietta Mencarelli6, Silvo Conticello4;7, Neil Marta Somorai

syndrome ambulance within a social pediatric center
allows genetic manipulation to either insert or correct a mutation.

neurodevelopmental disorder (CDD, OMIM#300203). CRISPR/Cas9

patient (1). An isogenic cell line was generated from iPSCs derived from

the mouse model was performed by standard tests. The CRISPR/

CDD were found. Brain transcriptome pro

nized region surrounding the c.1090G>T (p.Glu364*) mutation

Background/Objectives: Mutations in CDKL5 cause an incurable

neurodevelopmental disorder (CDD, OMIM#300203). CRISPR/Cas9

allows genetic manipulation to either insert or correct a mutation.

Methods: The mouse model was generated by CRISPR/Cas9-

based Homologous Recombination. Behavioral characterization of the

mouse model was performed by standard tests. The CRISPR/

Cas9-based correction tool in human cells was built as described

(1). An isogenic cell line was generated from iPSCs derived from

patient's fibroblasts.

Results: A knock-in mouse model harboring a 40 bp huma-
nized region surrounding the c.1090G>T (p.Glu364*) mutation was generated. Motor and behavioral anomalies compatible with

CDD were found. Brain transcriptome profile revealed a lower expression of GABRA5, suggesting an impairment of GABA circuits,
in line with the reduced GAD1 expression in patient-derived neurons. In parallel, correction of the mutation was achieved in

in vivo correction.

Conclusion: We have generated a new Cdkl5 mouse model available for the scientific community. We achieved correction and biological rescue using CRISPR/Cas9 in vitro. Experiments are ongoing for the in vivo correction.

References: 1-Croci S et al, High Rate of HDR in gene editing of p.(Thr158Met) MECP2 mutational hotspot Eur J Hum Genet

2020.

Grants: CDKL5—associazione di volontariato onlus.

Conflict of Interest: None declared.

P23 GENETIC COUNSELLING/SERVICES/EDUCATION

P23.002.D Spectrum of medical care for pediatric patients with neurogenetic disorders – early experiences of a syndrome ambulance within a social pediatric center

Marta Somorai1, Volker Mall12

1kbo-Kinderzentrum, Social Pediatric Center, Munich, Germany; 2TUM School of Medicine, Chair of Social Pediatrics, Munich, Germany.

Background/Objectives: Our social pediatric center provides medical services for ca. 9,000 children pro year, mainly patients with neurodevelopmental disorders. We perform genetic analysis for around 250 patients/year, incl. >200 trio-ESI-analysis/year, making us one of the largest neurogenetic diagnostic centers in the state of Bavaria, Germany.

Establishing a state-of-the-art care for our patients with classical syndromic disorders as well as rare and ultra-rare neurogenetic diseases we started our interdisciplinary syndrome ambulance 3,5 years ago. The rapid development of this ambulance caring for over 200 patients 3 years after its foundation mirrors the recent large development in the human genetics.

We present our experience in three distinctive areas:

1. The different interdisciplinary structures for appropriate patient care depending on the age of the patient as well as the type and severity of the underlying neurogenetic condition.

2. The set-up of genetic counselling in straight-forward diagnostic courses through qualified pediactrians in collaboration with geneticist.

3. The search for approved, on-trial and novel therapeutic approaches through scheduled literature researches for all patients, and subsequently offering support to receive approved treatment or to be admitted in a clinical-trial as well as initiating compassionate-use drug-repurposing.

The goal of our presentation is to facilitate the communication and collaboration between pediatricians, geneticists and researchers on the field of neurogenetics.

In case of an invitation to an oral presentation we would also present unpublished cases of compassionate-use drug-repurposing.

Methods:

Results:

References:

Grants:

Conflict of Interest: None declared.

P23.003.A Telemedicine versus traditional consultations in clinical genetics: comparison of patient satisfaction rates

Uri Hamiel12, Audelia Eshel Fuhrer12, Nitsan Landau2, Hagit Baris Feldman12, Daphna Maromi12

1Tel Aviv Sourasky Medical Center, Genetics Institute and Genomics Center, Tel Aviv, Israel; 2Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel.

Background/Objectives: Telemedicine is a service delivery model in which credentialed specialists provide care remotely to clients. Data regarding patient satisfaction with telemedicine consultations in the field of clinical genetics, and specifically paediatric genetics is lacking. We aimed to compare patient satisfaction rates from telemedicine versus traditional, face-to-face genetics consultations during the COVID-19 pandemic.

Methods: A cross-sectional survey, sent to 1672 parents of minors (patients<18years), or adult patients, who received counselling through the Tel-Aviv Souraski Medical Center Genetics Institute between 1/1/2020-1/6/2020. Data were collected through REDCap and converted to Microsoft EXCEL Database Program(v16.0) and STATA(v14.1).

Results: Full responses were collected from 457 patients (27.3%). Of them, 330 patients (72.2%) had face-to-face consultations, 80 (17.5%) were counselled through telemedicine, and 47 had both (10.3%). Satisfaction or high satisfaction were reported in

European Journal of Human Genetics (2023) 31:345 – 709
Background/Objectives: Telemedicine consultations in the genetics clinic during the COVID-19 pandemic, and specifically in paediatric genetics, were associated with high satisfaction rates, non-inferior to traditional consultations satisfaction rates.

References: N/A.

Conflict of Interest: None declared.

P23.004.B First German Language Master of Science in Genetic and Genomic Counselling

Gunda Schwaninger1, Sabine Rudnik1, Johannes Zschocke1

1Institute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.

Background/Objectives: While Genetic Counsellors (GCs) are well-established around the globe, they have met resistance in the German language countries due to a perceived conflict of competencies with medical geneticists (Schwaninger et al. 2021, PMID: 33797821). In 2019, the Medical University of Innsbruck, Austria introduced the first MSc programme in Genetic and Genomic Counselling for the German-speaking countries.

Methods: Here we report the experiences from the first cohort graduating in spring 2022.

Results: The Innsbruck MSc programme follows the European standards and is EBMG accredited. This allows graduates with an additional two year training to apply for registration as a European Certified Genetic Counsellor, granting international reciprocity and freedom to move workplace within Europe and abroad. The five-semester part-time programme is currently graduating the first cohort and has started a second year group with twelve students from Germany, Austria and Switzerland.

The implementation of the master programme has commenced a lively discussion about the future of genetic counselling in all German-speaking countries. The programme team, in conjunction with the first graduates, works to establish an evidence-based implementation of the occupational profile for the region. Research projects on the professional scope of practice, the separation of the professional role of genetic counsellors and the service of genetic counselling, issues around the job title, remuneration concepts and the integration of GCs into genetic services are undertaken.

Conclusion: Most crucial will be a close integration of GCs into teams together with medical geneticists, building trust in their education and skills from genetics knowledge to psychological attending.

References: N/A.

Conflict of Interest: None declared.

P23.005.C Reasons for forgoing carrier testing among relatives of pathogenic variant carriers of Hereditary Breast and Ovarian Cancer and Lynch Syndrome

Mahesh Sarki1, Günther Fink2, Souria Aissaoui3,4, Nicole Bürki5, Rossella Graffeo-Galbiati7, Ursina Zürrer-Härdi1, Manuela Rabagli6, Karl Heinimann1,10, Pierre O. Chappuis1,12, Maria Katapodi1

1University of Basel, Department of Clinical Research, Basel, Switzerland; 2Swiss Tropical and Public Health Institute, Basel, Switzerland; 3Cantonal Hospital Fribourg, Breast Center, Fribourg, Switzerland; 4Hirslanden Clinique de Granges, Geneva, Switzerland; 5University Hospital Basel, Women’s Clinic, Basel, Switzerland; 6Oncology Institute of Southern Switzerland, Breast Unit of Southern Switzerland, Bellinzona, Switzerland; 7Cantonal Hospital Winterthur, Department of Medical Oncology, Winterthur, Switzerland; 8Bern University Hospital, Department of Medical Oncology, Inselspital, Bern, Switzerland; 9University of Basel, Department of Clinical Research, Basel, Switzerland; 10University Hospital Basel, Institute for Medical Genetics and Pathology, Basel, Switzerland; 11University Hospitals of Geneva, Unit of Oncogenetics, Service of Oncology, Geneva, Switzerland; 12University Hospitals of Geneva, Service of Genetic Medicine, Geneva, Switzerland.

Background/Objectives: Cascade screening of Hereditary Breast and Ovarian Cancer (HBOC) and Lynch Syndrome (LS) is important for prevention and clinical management of hereditary cancer syndromes. The study aims to find out reasons for forgoing carrier testing among relatives of known carriers of HBOC- or LS-associated pathogenic variants, and compare factors at the personal, family, and healthcare system levels between relatives who did not have genetic testing (GT(-)) and those who had genetic testing (GT(+)).

Methods: Data are part of the Swiss CASCADE cohort and were collected with self-administered surveys collected between September 2017 and December 2021.

Results: In total 115 relatives submitted baseline data and 38% did not have carrier testing. Compared to the GT(+) group, the GT(-) group included a higher proportion of males, who were significantly less likely to have a personal cancer diagnosis, fewer number of relatives tested in the family, less care from specialist and more likely to receive care by multiple (>3) healthcare providers. Being female (OR:2.77, 95%CI:1.10 – 7.10), having had personal history of cancer (OR:4.47, 95%CI:1.03-19.42) and higher number of family members tested (OR:1.42, 95%CI:1.09-1.83) had higher odds of getting carrier testing.

Conclusion: Carrier testing promotion among individuals with cancer, and men and family focused interventions may help increase carrier testing.

References: N/A.

Conflict of Interest: None declared.
P23.006.D Differences in intention to inform relatives and rates of cascade testing in families concerned with hereditary breast and ovarian cancer and Lynch syndrome: The Swiss CASCADE cohort

Mahesh Sarki1, chang ming2, Souria Aissaoui3,4, Nicole Burk3, Maria Caiata-Zufferey3, Tobias E. Erlanger6, Rossella Grafeo-Galbiati7, Karl Heinimann8,9, Viola Heinzelmann9, Christian Monnerat10, Nicole Probst-Hensch11, Viola Heinzelmann9, Christian Monnerat10, Nicole Probst-Hensch11, Manuela Rabaglio12, Ursina Züner-Härdi13, Pierre O. Chappuis14,15, Maria Kapadaki1

1University of Basel, Department of Clinical Research, Basel, Switzerland; 2Cantonal Hospital Fribourg, Breast Center, Fribourg, Switzerland; 3Hirslanden Clinique de Grange, Geneva, Switzerland; 4University Hospital Basel, Women’s Clinic, Basel, Switzerland; 5University of Applied Sciences and Arts of Southern Switzerland, Department of Business Economics, Health and Social Care, Lugano, Switzerland; 6University Hospital Basel, Basel, Switzerland; 7Oncology Institute of Southern Switzerland, Breast Unit of Southern Switzerland, Bellinzona, Switzerland; 8University Hospital Basel, Institute for Medical Genetics and Pathology, Basel, Switzerland; 9University of Basel, Department of Biomedicine, Basel, Switzerland; 10Hospital of Jura, Department of Medical Oncology, Delémont, Switzerland; 11Swiss Tropical and Public Health Institute, Basel, Switzerland; 12Inselspital, Bern University Hospital, Department of Medical Oncology, Bern, Switzerland; 13Cantonal Hospital Winterthur, Department of Medical Oncology, Winterthur, Switzerland; 14University Hospitals of Geneva, Unit of Oncogenetics, Service of Oncology, Geneva, Switzerland; 15University Hospitals of Geneva, Service of Genetic Medicine, Geneva, Switzerland.

Background/Objectives: Cascade testing and identification of individuals carrying pathogenic variants in causative genes associated with hereditary breast and ovarian cancer (HBOC) and Lynch syndrome (LS) is significant public health interventions. However, cascade rates of LS are much lower than HBOC, while a pronounced gender disparity exists for HBOC. We describe cascade testing in relatives from HBOC and LS families, and compare predictors of intention to invite relatives to a family-based cohort.

Methods: The Swiss CASCADE is a family-based, open-ended cohort, including carriers of HBOC- and LS-associated pathogenic variants and their relatives. Participating index cases are asked to invite their relatives.

Results: Currently 304 index cases and 115 relatives provided baseline information. We identified on average 10 relatives per index case potentially eligible for cascade testing. The family pathogenic variant was excluded in 14.7% of relatives (true negatives), while 13.9% are untested. Approximately 65% of index case potentially eligible for cascade testing. The family environment predict intention to invite relatives for both syndromes, while additional predictors were identified for HBOC.

Conclusion: Information can help optimize delivery of genetic services.

References:

Grants: Swiss Cancer Research Foundation KFS-5293-02-2021, the Swiss Cancer League – KLS-4294-08-2017 and by the University of Basel, Office of the Vice Rector of Research (2016), and the Department of Clinical Research (2021).

Conflict of Interest: None declared.

P23.007.A APOGeE (A Practical Online Genetics e-Education): a European medical genetics e-textbook by ERN-ITHACA

Nicholas Szeto1, jonathan berg2, Maurizio Genuardi3, Martin Krahn4,5, Ute Moog6, Edward S. Tobias7, Peter Turnpenny8, Johannes Zschocke9, Mutaz Amin10, Jill Clayton-Smith11,12, Dorica Dan13, Sofia Dougozou HOUGE14, Marianne Le Dref15, Laurence Faivre15,16, Raoul Hennekam17, Anne Hugon1, Jean-Marie Jouannic18, Tijtske Kleefstra19, David Koolen20, Giovanni Mosiello21, Alessandra Renieri22,23, Marco Tartaglia24, Zeynep Türker25, Birute Tumiene26, Agnieszka van Eeghen17, Lisinka Vissers27,28, Klea Vyshka29, Dagmar Wiecezek29, Giuseppe Zampino30, Christiane Zweier1, Ithaca Consortium1, Alain Verloes1

1Hôpital Robert Debré, Department of Genetics, Paris, France; 2School of Medicine - University of Dundee, Department of Clinical Genetics, Dundee, United Kingdom; 3AgostinoGemelli University Policlinic, UOC Genetica Medica, Rome, Italy; 4Hôpital Timone Enfants, Département de Genétique Médicale, Marseille, France; 5Aix-Marseille University, Inserm, U1251-MMG, Marseille, France; 6Heidelberg University, Clinical Genetic Department, Heidelberg, Germany; 7Queen Elizabeth University Hospital, Academic Unit of Medical Genetics and Clinical Pathology, Glasgow, United Kingdom; 8Royal Devon and Exeter Hospital, Clinical Genetics Department, Exeter, United Kingdom; 9Medizinische Universität Innsbruck, Institute of Human Genetics, Innsbruck, Austria; 10Inserm US14 Orphanet, Paris, France; 11The University of Manchester, Manchester centre for Genomic Medicine, Manchester, United Kingdom; 12Manchester University Hospitals NHS Foundation Trust, Manchester centre for Genomic Medicine, Manchester, United Kingdom; 13Prader Willi Patient Organisation, Zalau, Romania; 14Haukeland University Hospital / Health Bergen, Aveling for medisinsk genetikk, Haukeland, Norway; 15FHFU TRANSLAD and GIMI Institute, University Hospital Dijon, Dept of Genetics and Centres of Reference for Development disorders and intellectual disabilities, Dijon, France; 16UFR Des Sciences de Santé FHFU-TRANSLAD, INSERM-Université de Bourgogne UMR 1231 GAD « Génétique des Anomalies du Développement », Dijon, France; 17Academic Medical Centre Amsterdam UMC, Department of Pediatrics, Amsterdam, Netherlands; 18Hôpital Armand-Trousseau Ap-Hp, Service de Médecine Faitale, Paris, France; 19Radboud University Nijmegen, Department of Pediatrics, Nijmegen, Netherlands; 20Radboud University Medical Center, Department of Human Genetics, Nijmegen, Netherlands; 21Bambino Gesù ospedale pediatrico, Department of Surgery, Urology and Neuro-Urology, Roma, Italy; 22Med Biotech Hub and Competence Center, Università di Siena, Dept of Medical Biotechnologies, Siena, Italy; 23Università di Siena, Medical Genetics, Siena, Italy; 24Bambino Gesù ospedale pediatrico, Genetics and Rare Diseases Research Division, Roma, Italy; 25Copenhagen University Hospital, Rigshospitalet, Department of Clinical Genetics, Copenhagen, Denmark; 26Vilnius University Hospital Santaros klinikos, Vilnius, Lithuania; 27Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, Netherlands; 28Université de Lyon CERCRID, UMR 5137 “Centre de Recherches Critiques en Droit”, Lyon, France; 29Heinrich Heine University Düsseldorf, Institute of Human Genetics and Anthropology, Düsseldorf, Germany; 30Università Cattolica del Sacro Cuore, Department of Woman and Child Health, Center for Rare Diseases and Birth Defects, Institute of Pediatrics, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; 31Inselspital, Das Tumorzentrum University Cancer Center, Bern, Switzerland.

Background/Objectives: APOGeE (A Practical Online Genetics e-Education) will be launched in 2022 as a free online interactive medical genetics textbook built with Moodle, written by various authors from the ITHACA network and other ERNs. APOGeE will cover topics about biological genetics, formal genetics, a clinical and physiological approach to genetic diseases, precision medicine, and treatment of genetic diseases.

Methods: Whilst original content is being written by authors from various European countries and is produced by a renowned international editorial committee, the book will be further
enriched with existing up-to-date documents and courses in the network.

Results: As a companion for the European Certificate in Medical Genetics and Genomics (ECMGG) examination organised by the European Union of Medical Specialists (UEMS), the main content will be supplemented by almost 200 medical vignettes of diseases as pedagogical references, all linked to their relevant chapters. Moreover, the Moodle platform will include links to external reference materials such as articles and guidelines for further reading.

Conclusion: By contributing to a structured postgraduate education programme in the field of human genetics and rare diseases, the project aims to provide a free and open source of interactive and asynchronous medical genetics learning materials: doctors and researchers from Europe and beyond, from all socioeconomic backgrounds, will be able to access the online platform with different learning modules, self-evaluation tools and discussion forums.

References:

Grants: The project is co-funded by the CEF, Connecting Europe Facility of the European Union, under the action number 2020-FR-IA-0128.
Conflict of Interest: None declared.

P23.009.C Genetic first results: Lessons learned from pediatric secondary findings

Colleen Jodarski1, Alexander Katz2, Rajarshi Ghosh1, Leila Jama1, Jia Yan1, Bryce Seifert1, Michael Kamen1, Michael Setzer1, Kathleen Jevtich1, Yunting Yu1, Steven Holland1, Magdalena Walkiewicz1, Morgan Similuk1

1National Institute of Allergy and Infectious Diseases, Division of Intramural Research, Bethesda, United States; 2National Human Genome Research Institute (NHGRI), Bethesda, United States; 3National Institutes of Health, Department of Bioethics/National Cancer Institute, Bethesda, United States.

Background/Objectives: As clinical genomic testing becomes more common, so will receiving “genetic-first” results, defined as pathogenic/likely pathogenic variant(s) in a gene that is unrelated to the primary indication for testing, including a secondary finding (SF) recommended by the American College of Medical Genetics. A SF management framework has been articulated for adults; however, there is little, and often conflicting, guidance for how SFs should be managed in minors.

Our tertiary care sequencing program returns SF from exome and genome sequencing in minors by default. Here we synthesize our findings and present cases emphasizing the nuances of such findings.

Methods: A total of 864 minors received exome or genome sequencing from 2017-2021.

Results: Seventeen SFs were returned in 16 minor participants (1.9%). Most SFs (13/17, 76.5%) were associated with potential childhood-onset of disease.

Illustrative cases emphasize the following themes:

1. SFs do not necessarily lead to clinical diagnosis or active disease mitigation. Follow-up is uncertain and at clinician discretion.
2. Considerations for results disclosure: family understanding and adaptation.
3. Age-related penetrance and cascade testing opportunity for at-risk relatives.

Conclusion: These findings highlight opportunities and challenges of genetic first results. As genomic approaches become better integrated into clinical practice, thoughtful evaluation and tailored follow-up will be essential in translating such findings into meaningful recognition and mitigation of disease.

References:

Grants: No grants.
Conflict of Interest: None declared.

P23.010.D Role of the genetic counsellors in oncology settings, an European survey

Christophe Cordier1, Marie Met Domestici2, Amel Tsalamli3, Heidi Carmen Howard4, Kelly Ormond5,6, Nicolas Taris7

1SYNLAB Suisse SA, Department of genetics, Lausanne, Switzerland; 2CHUV Lausanne, Department of genetics, Lausanne, Switzerland; 3Centre Léon Bérard, Unité Clinique d’Oncologie Génétique, Lyon, France; 4Lund University, Researcher Medical Ethics, Lund, Sweden; 5ETH-Zurich, Health Ethics & Policy Lab, Dept of Health Sciences and Technology, Zurich, Switzerland; 6Stanford University School of Medicine, Stanford, CA, United States; 7Institut de Cancérologie Strasbourg Europe, Department of genetics, Strasbourg, France.

Background/Objectives: For several decades now, the inclusion of non-physician genetic counsellors (GC) has been shown to be an effective way to deliver genetic counselling services in many countries including USA, Canada, UK and France. The need for appropriately trained GC to support genetic healthcare is acknowledged all around Europe and Master Degrees specialized in genetic counselling are available across Europe (eg: UK, Spain, France). Although the profession is gaining recognition globally, associations and institutions are still needed to achieve true recognition of the practice itself (billing for consultation, recognized professional title, ability to work autonomously). This is especially true in the field of oncology genetics, where the practice of the profession is often regulated by national and international guidelines.

Methods: Based on review of the academic and grey literature, we discuss the barriers, challenges and facilitators to the integration of GC in oncogenetics as well as priorities for further action

Results: While GC provide a valuable service within an oncology practice, playing a pivotal role in bringing the benefits of oncogenetics and precision medicine, a concerted global effort is required to transform GCs’ policy and practice.

Conclusion: This discussion is critical to inform professionals in genetics of the work still needed to ensure that GC are appropriately involved in the offer of oncogenetics for the best care of patients. This work will also form the basis for further empirical studies and we hope to obtain input from 2022 ESHG conference attendees in real-time through mentimeter questions.

References:

Grants: No grants.
Conflict of Interest: None declared.
Abstracts from the 55th European Society of Human Genetics Conference

P23.011.A De Novo Experience of Individuals with Li-Fraumeni Syndrome: “Sometimes the people in your family are never going to be the ones who understand best”

Ashley S. Thompson1, Camella J. Rising1, Patrick Boyd1, Catherine Wilsnack2, Alix G. Sleight3, Rowan Forbes Shepherd4, Payal P. Khincha1, Allison Werner-Lin4

1National Cancer Institute, Division of Cancer Epidemiology and Genetics, Clinical Genetics Branch, Rockville, United States; 2University of Texas at Austin, Steve Hicks School of Social Work, Austin, United States; 3Cedars-Sinai Medical Center, Department of Physical Medicine & Rehabilitation, Los Angeles, United States; 4University of Pennsylvania, School of Social Policy and Practice, Philadelphia, United States.

Background/Objectives: Li-Fraumeni Syndrome (LFS) is a rare hereditary cancer predisposition syndrome characterized by high lifetime risks for multiple primary malignancies. Although most individuals with LFS inherit a pathogenic TP53 variant from a parent, approximately 20% have de novo variants with no suggestive family cancer history. This may result in an LFS experience distinct from individuals with affected relatives. This multi-case study report examines the unique psychosocial experiences of three young adults with de novo TP53 variants.

Methods: The National Cancer Institute’s LFS study (NCT01443468) recruited adolescents and young adults (AYAs; aged 15-39 years) with LFS for qualitative interviews. Three participants had a de novo TP53 variant and a personal cancer history. An interprofessional team analyzed interview data using extended case study and narrative methods.

Results: De novo participants lacked familiarity with LFS to situate a cancer diagnosis, interpret genetic test results, or adjust to chronic cancer risk. Communicating with and receiving support from family was challenged by their lack of common experience. De novo participants experienced socioemotional isolation, which was amplified during the COVID-19 pandemic. To cope, they sought support in online rare disease communities or through mental health providers.

Conclusion: Individuals with de novo variants may lack familial guides and familiar providers to address disease management and uncertainty. Specialty health and mental health providers may support de novo patients across hereditary cancer syndromes by validating their uncertainties and connecting them with disease-specific patient advocacy groups that support adjustment to chronic cancer risk.

References:
Grants:
Conflict of Interest: None declared.

P23.012.B Blood chimerism – more common than you would think: Practical implications in genetic counseling

teilha klopstock1, Orit Lobel1, Miriam Patt1, Omri Weiss1, Rachel Beer1, Ilhi amit1, Doris Goldschmidt1, Reeval Segel1,2

1Shaare Zedek Medical Center, Medical Genetics Institute, Jerusalem, Israel; 2The Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.

Background/Objectives: Blood chimerism (BC) result from blood transfusion between dizygotic twins through a shared placenta. Such chimerism is usually limited to blood cells, and doesn’t involve other cell types or organs. In the past, chimerism was estimated to be extremely rare, but nowadays it’s believed that BC exists in approximately 8% of dizygotic-monochorionic twins. We referred a 27-years old female for oncogenetic gene panel due to breast cancer diagnosis. Two blood samples were sent to the lab consecutively, yielding no results. Existence of different blood cells in the samples was offered as an explanation. In combination with the fact that the patient has a twin brother, the suspicion of chimerism arose.

Methods: QF-PCR (using Anuefast quantitative flourescent PCR kit) was performed on DNA from the patient’s blood, buccal cells and fibroblasts, and compared to her male twin and parents’ blood samples.

Results: We found 70% chimerism (XY markers) in the patient’s blood, 30% in her buccal cells and no chimerism in fibroblasts. Her twin’s blood sample had 50% chimerism (XX markers).

Conclusion: These results support the hypothesis of chimerism, confined to blood cells, most likely due to placental blood transfusion. The diagnosis of blood-confined chimerism enabled completing the genetic testing by using DNA from fibroblasts (no known pathogenic variants were detected). In addition, her fibroblast sample may be used in future genetic testing, such as prenatal carrier screening. Since chimerism can have medical, social, forensic, and legal implications, raising awareness to the issue is highly important.

References:
Grants:
Conflict of Interest: None declared.

P23.013.C Additive diagnostic yield of homozygosity regions identified during chromosomal microarray testing in children with developmental delay, dysmorphic features or congenital anomalies

Mohamed Ali1, Abdelrahman Madian2

1Ain Shams university, Biochemistry department, Cairo, Egypt; 2National Research Center, Cairo, Egypt.

Background/Objectives: Chromosomal microarray (CMA) has emerged as a robust tool for identifying microdeletions and microduplications, termed copy number variants (CNVs). Nevertheless, data regarding its utility in different patient populations with developmental delay (DD), dysmorphic features (DF) and congenital anomalies (CA), is a matter of dense debate. Although regions of homozygosity (ROH) are not diagnostic of a specific condition, they may have pathogenic implications. Certain CNVs and ROH have ethnically specific occurrences and frequencies. We aimed to determine whether CMA testing offers additional diagnostic information over classical cytogenetics for identifying genomic imbalances in a pediatric cohort with idiopathic DD, DF, or CA.

Methods: 169 patients were offered cytogenetics and CMA simultaneously for etiological diagnosis of DD (n = 67), DF (n = 52) and CA (n = 50).

Results: CMA detected 61 CNVs (21 [34.4%] pathogenic, 37 [60.7%] variants of uncertain clinical significance and 3 [4.9%] benign) in 44 patients. CMA identified one or more ROH in 116/169 (68.6%) patients. When considering pathogenic CNVs and aneuploidies as positive findings, 9/169 (5.3%) received a genetic diagnosis from cytogenetics, while 25/169 (14.8%) could have a genetic diagnosis from CMA. The identification of ROH was clinically significant in two cases (2/169), thereby, adding 1.2% to the diagnostic yield of CMA (16% vs. 5.3%, p < 0.001).

Conclusion: CMA uncovers additional genetic diagnoses over classical cytogenetics. Our findings convincingly demonstrate the additive diagnostic value of clinically significant ROH identified during CMA testing, highlighting the need for careful clinical interpretation of these ROH.

References:
Grants:
Conflict of Interest: None declared.
P23.014.D Patient Journey Common Needs: Rare congenital malformations syndromes with intellectual and other neurodevelopmental disorders affect one child in a million

Anne Hugon1,2, Dorica Dan3,4, Ammi Andersson5, Joel Detton5, Marianne Le Dref5, Gabor Pogany6, Sue Routledge4, Nicholas Szeto1, Klea Vyshka1, Lenja Wiehe2, Ernithaca consortium7, Alain Verloes1

1Assistance Publique-Hôpitaux de Paris - Université de Paris, Dept. of Genetics, Paris, France; 2Eurordis rare disease europe, Paris, France; 3Patient organisation, Prader Willi, Zalau, Romania; 4Patient organisation, Pitt Hopkins Syndrome, UK, United Kingdom; 5Patient organisation, Noonan Syndrome, Paris, France; 6Patient organisation, Williams Syndrome, HU, Hungary; 7Assistance Publique-Hôpitaux de Paris - Université de Paris, Dept. of Genetics ERN ITHACA, Paris, France.

Background/Objectives: The heterogeneous nature of clinical presentation and huge variation in the onset of the first symptoms can, as early as the neonatal period, lead to misdiagnosis, thus to the absence of early treatment. With over 5000 rare and complex syndromes, how can ERN ITHACA meet their diverse needs? In response, patient representatives (ePAGs) have described the individual needs of their children in a syndrome-specific “patient pathway”, which serves as a personal testimonial and describes the natural history of each of these rare syndromes Rett, Williams, Prader Willi, Spina Bifida and Pitt-Hopkins.

Methods: Patient representatives presented their syndrome-specific ‘patient journeys’ (Bolz-Johnson et al. 2019) in a workshop and identified the characteristics and needs that were common. A position paper describing relevant elements for all syndromes was presented to the Board in Düsseldorf, 2019.

Results: Genetics is the key for many ITHACA syndromes. However, it is only one aspect of child’s situation and ERN ITHACA needs to go beyond genetic diagnosis and think about the holistic needs of patient communities.

Conclusion: An agreement with experts on introducing common needs in all the work packages of ERN ITHACA have been achieved, as well as developing a standard of care in a Clinical Pathway.

New patient journeys will be developed in the future.

References: Bolz-Johnson, M., Meek, J., & Hoogerbrugge, N. (2020). “Patient Journeys”: improving care by patient involvement. European Journal of Human Genetics, 28(2), 141-143.

Grants: ERN-IITHACA [EU Framework Partnership Agreement ID: 3HP-HP-ERP-ERN-01-2016/739516].

Conflict of Interest: Anne Hugon APHP Paris Nord Université Robert DEBRE, Dorica Dan: None declared, Ammi Andersson: None declared, Joel Detton: None declared, Marianne Le Dref APHP Paris Nord Université Robert DEBRE, Gabor Pogany: None declared, Sue Routledge: None declared, Nicholas Szeto APHP Paris Nord Université Robert DEBRE, Klea Vyshka APHP Paris Nord Université Robert DEBRE, Lenja Wiehe: None declared, Ernithaca consortium: None declared, Alain Verloes: None declared.

P23.015.A Views and experiences of clinical geneticists concerning unsolicited findings in next-generation sequencing: “a great technology creating new dilemmas”

Vyne van der Schoot1, Carlijn Damste2, Helger Yntema3, Han Brunner4, Anke Oerlemans5

1Erasmus MC, Clinical genetics, Rotterdam, Netherlands; 2Radboud Institute For Health Sciences, IQ healthcare, Nijmegen, Netherlands; 3Radboud University Medical Center, Human genetics, Nijmegen, Netherlands.

Background/Objectives: Unsolicited findings (UFs) from diagnostic genetic testing are subject of debate. There is emerging consensus that UFs from genetic testing should be disclosed, but recommendations on UF disclosure generally leave room for practice variation. This study aimed to explore the views and experiences of clinical geneticists concerning counseling UFs pre-test and UF disclosure.

Methods: We interviewed 20 medical specialists certified in clinical genetics and residents in clinical genetics working in seven national genetic centers.

Results: Participants expressed that discussing the probability of detecting UFs is an integral part of pre-test counseling. However, they had doubts about to what extent and about what to inform patients. They argued that the contents of their counseling ought to depend on the individual patient’s capacity to understand information. While ‘medical actionability’ is broadly accepted as an important criterion for UFs to be disclosed, participants experienced substantial uncertainty regarding the concept.

Conclusion: These results direct towards tailored pre-test counseling in order to optimize genetic consultations. This study underscores the need for further demarcation of what exactly constitutes medical actionability. Installation of an expert panel to help to decide which variants to disclose, will support genetic counselors to face the dilemmas UFs present.

References:

Grants: Not applicable.

Conflict of Interest: None declared.

P23.016.B The role of the Genetic Counsellor in the multidisciplinary team: the perception of geneticists in Europe

francesca catapano1, mohamed el hachmi1, Natacha Ketterer-Heng2, Francesca Mari3, Alessandra Renieri1, Michael Morris4, Christophe Cordier5

1University of Siena, Department of Medical Biotechnology, Siena, Italy; 2SYNLAB Suisse SA, Department of Genetics, Lausanne, Switzerland; 3SYNLAB Suisse SA, Department of Genetics, Lausanne, Switzerland.

Background/Objectives: Genetics is becoming fundamental in the understanding and management of pathologies; thus, it is necessary to understand what is the most effective way of taking care of people affected by or at risk of genetic pathologies. Indeed, the team dealing with such patients has evolved especially with the emergence of the Genetic Counsellor figure. This profession is still much debated and not yet recognized in all European countries. Thus, the aim of this research is to investigate both how a team should be composed in the care of patients affected by or at risk of genetic pathologies and what the role of the Genetic Counsellor should be – his field of action and competences.

Methods: A research at European level was carried out, submitting an online questionnaire, over a period of six months, to geneticists who, expressing their opinion, can identify strengths and potential areas for improvement in genetic care.

Results: 147 responses were collected from all over Europe, highlighting the importance of the counsellor’s presence in the multidisciplinary team and what the counsellor’s skills and qualifications should be. It was also possible to study differences between different parts of Europe.

Conclusion: Although this new profession has difficulties in recognition in some countries, it seems clear that these highly competent professionals are essential in-patient care. To the authors’ knowledge this is one of the few – if not the only – study on the subject and we hope that it can pave the way to the recognition of the Genetic Counsellor profession.

References:
Abstracts from the 55th European Society of Human Genetics Conference

Grants: None declared.

Conflict of Interest: None declared.

P23.017.C Mainstreaming genomic testing for children with undiagnosed inborn errors of immunity

Tatiane Yanes1,2, Anna Sullivan1, Pasquale Barbara3,4, Kristian Brion5, Jane Peake1,6, Peter McNaughton1,6

1Children’s Health Queensland Hospital And Health Service, Queensland Paediatric Immunology and Allergy Service, South Brisbane, Australia; 2The University of Queensland, The University of Queensland Diamantina Institute, Brisbane, Australia; 3Children’s Health Queensland Hospital And Health Service, Queensland Paediatric Haematology Service, South Brisbane, Australia; 4Pathology Queensland, Queensland Children’s Hospital Laboratory, South Brisbane, Australia; 5Pathology Queensland, Department of Molecular Genetics, Brisbane, Australia; 6The University of Queensland, Department of paediatrics and child health, Brisbane, Australia.

Background/Objectives: Genetic diagnosis of paediatric inborn errors of immunity (IEI) influences management decisions, and can alter clinical outcomes through hematopoietic stem cell transplantation (HSCT). Historically, children with undiagnosed IEI in Queensland, Australia were referred to a state-wide clinical genetic service, delaying access to genomic testing and increasing the burden on the genetic clinic. To address this issue, we developed and evaluated a mainstreamed model of care for genomic testing for paediatric IEI.

Methods: This state-wide program included a genetic counsellor embedded within the paediatric immunology service, fortnightly multidisciplinary team meetings (MDT), and variant prioritisation meetings. Informed by the literature, 21 different virtual gene lists were developed for whole-exome sequencing. Additionally, parents completed pre- and post-testing survey assessing understanding of, and impact of genomic testing. Recruitment occurred between Nov 2020–Sep 2021.

Results: Of the 34 children with results, nine received a genetic diagnosis, and four accessed HSCT. Five children were also referred for further investigations of suspicious VUS. On average, 14 healthcare providers attended the state-wide MDT, including adult and paediatric immunologists, genetic pathologists, genetic healthcare professionals, and other non-genetic-healthcare providers. Parents demonstrated understanding of the implications of testing and reported minimal decisional regret.

Conclusion: Genomic testing can be mainstreamed for paediatric IEI. Our program improved access to genomic testing, facilitated treatment decision-making, and was acceptable to parents and clinicians alike.

References: 1. Tangye SG, et al. J Clin Immunol. 2020;40(1):24-64; 2. Bousfiha A, et al. J Clin Immunol. 2020;40(1):66-81.

Grants: Queensland Genomic Health Alliance; TY funded by NHMRC(APP1194646).

Conflict of Interest: None declared.

P23.019.A What does a genetic counsellor do in the university hospital of Liègue?

Léna Kukor1, Sabrina Bertoli1, Julie Crèvecoeur1, Vincent Bours1, Saskia Bulk1

1University Hospital of Liège, Human Genetics, Liège, Belgium.

Background/Objectives: Lately, the University Hospital of Liège has faced a growing demand for genetic consultations. In addition to increasing the number of clinical geneticists, the University Hospital opened a first position of Genetic Counsellor (GC) in 2013, followed by a second one in 2017 and a third one in 2020. The GC profession, although recognized in many countries around the world, is not official yet in Belgium. Since 2015, a national working group has been set up and a procedure is underway to create an MSc in genetic counselling. The aim of this study was to characterize and evaluate the activities of GCs in our hospital.
**Methods:** We performed a retrospective observational study of the patients from the University Hospital of Liège who had consulted with a GC between 2016 and 2021. We also analyzed the other interventions/tasks of the GCs. We performed a descriptive statistical analysis.

**Results:** The main task of the GCs is to receive patients in consultation either in pair with a geneticist or in “genetic counseling” consultation under the supervision of a geneticist. Other tasks are mainly administrative. The number of consultations has increased by 707.5% between 2016 and 2021 and the number of administrative interventions has also increased by 5740% between 2013 and 2020.

**Conclusion:** The number of specific “genetic counseling” consultations and the administrative interventions have increased significantly between 2016 and 2021. The tasks of the GCs are varied and essential for the overall care of the patient, in collaboration with the rest of the (para)medical team.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P23.020.B** Awareness of prostate cancer risk associated with deleterious mutations in DNA damage repair genes: a “reverse” gender gap?

Monica Zuradelli$^{1,2}$, Carla Barbara Ripamonti$^{2}$, Monica Barile$^{2}$, Ilaria De Simone$^{2,3}$, Vittorio Fasulo$^{1,2}$, Giuseppe Chiarelli$^{2}$, Rodolfo Hurle$^{2}$, Alberto Saita$^{2}$, Giovanni Lughezzani$^{1,2}$, Nicolò Maria Buffi$^{1,2}$, Giorgia Guazzoni$^{1,2}$, Paolo Casale$^{2}$, Armando Santoro$^{1,2}$, Rosanna Asselta$^{1,2}$, Massimo Lazzeri$^{2}$, Giulia Solda$^{1,2}$

$^{1}$Humanitas University, Milan, Italy; $^{2}$IRCCS Humanitas Research Hospital, Milan, Italy.

**Background/Objectives:** Germline pathogenic mutations in DNA damage repair genes (DDRG) are found in 5% of localized and up to 16% of metastatic Prostate Cancer (PCa) patients. BRCA1/BRCA2 are the most frequently mutated and associate with aggressive disease and poorer outcome. Despite available European guidelines for BRCA/DDRG testing, marked country-to-country differences exist in implementation in clinical practice, potentially excluding a not negligible number of PCa patients from genetic analysis. Here we investigate existing gaps in early diagnosis for PCa patients with familial history of DDRG mutations.

**Methods:** BRCA1/2+ families were selected from women with breast/ovarian cancer who attended our Genetic Counselling Clinic from January 2016 to May 2021. All healthy men, aged 35-75, were proposed genetic counselling and testing, and subsequent dedicated “enhanced” screening based on digital rectal examination, PSA/Prostate Health Index (PHI) blood test, and multiparametric MRI plus biopsy in suspected cases.

**Results:** In more than half of 139 families (of $>$1000 retrospectively analyzed) positive for DDRG mutations, the male member(s) rejected to be tested. In 28 families (20%) at least one male relative was interested in DDRG screening. Overall, 86 men performed genetic analysis, of which 35 tested positive and started the annual “enhanced” screening, together with additional 20 DDRG carriers recruited from other hospitals. About one third (16/55) had a PHI $\geq$20 and underwent MRI; one patient required biopsy (negative) based on imaging results.

**Conclusion:** Surprisingly, awareness in the male population about the risk for PCa in DDRG mutation carriers, and possible implications for early diagnosis/therapy, seems low.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P23.021.C** GeNotes: A pan-specialty, pan-profession “just in time” genomic education tool for clinicians

Amy Frost$^{1}$, Aine Kelly$^{1}$, Michelle Bishop$^{1,2}$, Kate Tatton-Brown$^{1,3}$

$^{1}$Health Education England, Genomic Education Programme, London, United Kingdom; $^{2}$Wellcome Genome Campus, Wellcome Connecting Science, Cambridge, United Kingdom; $^{3}$St George’s University Hospitals NHS Foundation Trust, Medical Genetics, London, United Kingdom.

**Background/Objectives:** Genomic medicine is at the vanguard of healthcare but many healthcare professionals lack the knowledge and skills to integrate genomic data into their clinical practice. It is therefore imperative that we upskill this workforce at scale and pace.

**Methods:** Health Education England’s Genomic Education Programme (GEP) has developed a flagship, two-tier “just in time” online educational tool to meet the genomic educational needs of the healthcare workforce. Tier 1 (‘In the Clinic’, requesting tests and receiving results) resources are specialty-specific, succinct, written to a strict template and aligned to England’s Genomic Test Directory. ‘In the Clinic’ links to tier 2 (‘Knowledge Hub’). The pan-specialty ‘Knowledge Hub’ offers extended genomic learning opportunities from ‘In the Clinic’ and comprises numerous individual resources (each representing 15-20 minutes of learning) that can be accessed standalone or assembled to create bespoke learning journeys (which can be aligned to curricula/training needs).

Following discovery and alpha phase testing, GeNotes has recently completed a private beta phase qualitative ($n=11$) and quantitative ($n=21$) evaluation.

**Results:** GeNotes received excellent feedback across the four tested domains: expected use, ease of access, navigation, and resource content. It scored 90/100 in system usability scale (SUS) testing (compared with an average score for digital services of 68$^{1}$).

**Conclusion:** GeNotes fulfills a previously unmet genomic educational need and will launch for oncology (as public beta) in the first quarter of 2022. It will be available for paediatrics soon after and for all working group specialties by summer 2022.

**References:** 1Lewis et al, International Journal of Human-Computer Interaction, 2018.

**Grants:**

**Conflict of Interest:** Amy Frost: None declared, Aine Kelly: None declared, Michelle Bishop: None declared, Kate Tatton-Brown KTB is a principal investigator of a research study to investigate new mechanisms of the overgrowth-intellectual disability syndromes. She is in receipt of two grants, KTB has many times been asked to speak at conferences and received honoraria for these. This is not applicable for this conference.

**P23.022.D** Assessing risk in genetics services: developing and piloting a clinical genetics-specific risk assessment tool

Deborah Lambert$^{1}$, Alana J Ward$^{1}$, Deborah Behan$^{2}$, Dearbhla Butterfly$^{1}$, Sally Ann Lynch$^{1,3}$

$^{1}$University College Dublin, School of Medicine, Dublin, Ireland; $^{2}$Children’s Health Ireland, Quality, Safety and Risk Management, Dublin, Ireland; $^{3}$Children’s Health Ireland - Crumlin, Department of Clinical Genetics, Dublin, Ireland.

**Background/Objectives:** Whilst using the national hospital assessment process to evaluate risks arising from long waiting lists in Clinical Genetics, it became apparent that adaptation was required for out-patient clinical genetic use.
Methods: The ISO3001-based Irish Health Service Executive’s risk assessment matrix was reviewed and the domains of risk impact adapted. Genetics context-specific criteria were established for impact severity scores of negligible (1) to extreme (5) across domains. The new matrix was piloted to chronicle consequences to 20 women who became pregnant while awaiting appointments to discuss diagnosis/recurrence risk because of family history or previous affected child.

Results: 10 domains of risk impact were identified: Harm to the patient and family; Harm to staff; Service user experience, Compliance with professional guidance and SOPs; National strategic objectives, Service disruption; Adverse publicity; Financial cost to hospital; Financial cost to patient; Environmental impact. Clinic waiting times in pilot charts (n = 20) ranged from 2-35 months; 4/20 had a recurrence of the condition in subsequent child while on the waiting list. All charts showed risks in multiple domains (range 1-10), with 17/20 rated moderate (3) to extreme (5) in patient/pregnancy harm.

Conclusion: The risk tool was usable by both clinical genetics and non-genetic personnel. Domains of impact for patient harm, service disruption, and financial cost to hospital varied independently between situations. Use of the new tool standardises risk assessment and clarifies areas where control measures could be implemented to improve care.

References: 1. Health Service Executive Integrated Risk Management Policy 2017. https://bit.ly/3J4mNoh.

Conflict of Interest: None declared.

P23.023.A An online genetic counselling narrative group as a tool for supporting patients with hereditary ataxias in Portugal

Milena Paneque1,23, Mariana Policarpo1,4, Maria Barbosa1,5, Marina Lemos3,5, Álvaro Mendes2,2

1IBMC - Institute for Molecular and Cell Biology, i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, CGP - Centre for Predictive and Preventive Genetics, Porto, Portugal; 2ICBS - Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal; 3UniGNE - Unit for Genetics and Epidemiological Research on Neurological Diseases, Porto, Portugal; 4ICBAS - Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal; 5ICBAS - Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal; 6FPCEU - Faculty of Psychology and Educational Sciences, Universidade do Porto, Porto, Portugal, Porto, Portugal; 7Centre of Psychology, Universidade do Porto, Porto, Portugal.

Background/Objectives: Genetic counselling interventions aimed to provide psychosocial support to individuals at-risk or with hereditary ataxias are very scarce. No interventions of this kind have been reported in Portugal so far. We aimed at implementing a service improvement intervention offering a group intervention of a structured narrative exercise (already implemented with people who tested gene-positive for Huntington disease).

Methods: Tree of life intervention was delivered remotely. In parallel, it was conducted a study to explore, respectively, i) the experiences of participants in the narrative intervention, and ii) to assess the impact of the intervention in their psychological well-being. Data collection involved observations and a post-intervention focus group.

Results: The Portuguese Hereditary Ataxias Association advertised the narrative group and 13 individuals stated their interest in participating. Of these, 9 people took part in preliminary session aimed to present the goals and nature of the intervention. Six of those participants (mean age 48; 39-53, 3 men) attended the narrative session (2.5 hours), with different types of ataxia (mostly Machado-Joseph Disease). A focus group took place 2 weeks after the narrative session aiming to collect the participants’ views and experiences with the intervention. Participants reported high levels of satisfaction as they had the opportunity to build new social relations that brought them different perspectives, and gained new insights to understand their biopsychosocial circumstances.

Conclusion: This intervention has potential to be extended and adapted for other types of genetic conditions and populations, and may be used as a follow-up support in genetic counseling protocols.

References:

Background/Objectives: When a patient has hereditary cancer he/she is recommended to disclose information to healthy at-risk relatives (ARRs), who can then themselves ask for assessment, eventually access surveillance and even risk-reducing surgery. The Swedish multicenter randomized controlled trial DIRECT evaluates weather information letters directly from healthcare may increase the proportion of ARRs contacting an oncogenetic unit. This study explores how healthy ARRs perceive receiving such a healthcare-mediated letter.

Methods: Patients with hereditary cancer included in the DIRECT study identified ARRs to whom we sent letters with an invitation to genetic counselling. ARRs who contacted an oncogenetic unit was invited to qualitative in-depths interviews. The interviews (n = 13) were recorded, transcribed, coded, categorized and analyzed inductively.

Results: The ARRs receiving a letter thought of it as tolerable, however when contacting the oncogenetic clinic, they wanted prompt accessibility and familiarity with the matter. They expressed ambivalence around their right to know, empowerment regarding one’s own health, versus the right not to know and true benefits of surveillance. They wanted a shared responsibility between the healthcare system and patients; neither an authoritarian praxis of disclosure nor that an individual could keep the information solely to himself.

Conclusion: Healthcare-assisted disclosure of hereditary risk for cancer by sending a letter to ARRs is a tolerable method. However, the corresponding clinic has to be highly accessible for re-contact and the ARRs expressed ambivalence regarding benefits and disadvantages from being contacted.

References:

Background/Objectives: Genetic counselling interventions aimed to provide psychosocial support to individuals at-risk or with hereditary ataxias are very scarce. No interventions of this kind have been reported in Portugal so far. We aimed at implementing a service improvement intervention offering a group intervention of a structured narrative exercise (already implemented with people who tested gene-positive for Huntington disease).

Methods: Tree of life intervention was delivered remotely. In parallel, it was conducted a study to explore, respectively, i) the experiences of participants in the narrative intervention, and ii) to assess the impact of the intervention in their psychological well-being. Data collection involved observations and a post-intervention focus group.

Results: The Portuguese Hereditary Ataxias Association advertised the narrative group and 13 individuals stated their interest in participating. Of these, 9 people took part in preliminary session aimed to present the goals and nature of the intervention. Six of those participants (mean age 48; 39-53, 3 men) attended the narrative session (2.5 hours), with different types of ataxia (mostly Machado-Joseph Disease). A focus group took place 2 weeks after the narrative session aiming to collect the participants’ views and experiences with the intervention. Participants reported high levels of satisfaction as they had the opportunity to build new social relations that brought them different perspectives, and gained new insights to understand their biopsychosocial circumstances.

Conclusion: This intervention has potential to be extended and adapted for other types of genetic conditions and populations, and may be used as a follow-up support in genetic counseling protocols.

References:

Background/Objectives: When a patient has hereditary cancer he/she is recommended to disclose information to healthy at-risk relatives (ARRs), who can then themselves ask for assessment, eventually access surveillance and even risk-reducing surgery. The Swedish multicenter randomized controlled trial DIRECT evaluates weather information letters directly from healthcare may increase the proportion of ARRs contacting an oncogenetic unit. This study explores how healthy ARRs perceive receiving such a healthcare-mediated letter.
Background/Objectives: The purpose of the European Society of Human Genetics - Young Committee (ESHG-Y) is to support the next generation of geneticists. Under the guidance of the ESHG, our committee aims to develop strategies and programs for a better education of human genetics and the creation of a strong network of geneticists in all European countries. We are focused on: organizing scientific events, achieving equal access to educational opportunities and promoting collaboration and leadership. We present all the projects that the ESHG-Y has been involved in since its conception in 2019.

Methods: We assessed all the ESHG-Y projects between 2019 and 2022. The role of the ESHG-Y was categorized as decisive, coordinating or supportive.

Results: Since 2020 ESHG-Y has created its own educational sessions at the ESHG Annual Conference. The ESHG-Y social media platforms have regularly promoted relevant activities like a virtual session in collaboration with the European Board of Medical Genetics (EBMG). A scientific event in which we had a coordinating role is the European Dysmorphology Meetings. In the last 4 years our representatives have had a supportive role in the ESHG Board, the ESHG Scientific Programme Committee, the ESHG Education Committee and the EBMG. We have also supported organizations like: ERN-Ithaca, Unique, Orphanet, EuroGEMS and MOOC BIG.

Conclusion: In the short span of almost 4 years the ESHG-Y has successfully implemented projects that have engaged young geneticists across Europe. For the near future, we will be seeking to build on and develop further activities such as the “ESHG Observership for Young Geneticists”.

References:
Grants: None declared.

Conflict of Interest: None declared.

P23.026.D Good enough embryo: Prioritization of Preimplantation genetic testing (PGT) embryos in the era of genomic medicine

Shachar Zuckerman, Orit Freireich, rahel beeni, Pinhas Renbaum, elinor Hakami, shira Shaviu, elina farhi, anat yadin, meirav ben shlomo, tali azar, gheona Altareescu

Background/Objectives: New technologies of expanded carrier screening (ECS), chromosomal microarrays (CMA) and whole-exome sequencing (WES) produce extensive information regarding variants’ carrier status, complicating the decisions of couples and professionals for testing and prioritizing embryos in PGT.

Methods: We describe the challenges of transferring embryos for multiple conditions.

Results: A woman carrier of two X-linked disorders; her spouse carries AD PAX9-hypodontia; both carry AR deletion. Couple decided to transfer an embryo with PAX9-hypodontia and freeze female embryos carriers of the X-linked disorders.

- Couple carriers of Canavan and each parent a different VUS microduplication, detected by CMA in amniocentesis. They opted of transferring only non-carrier embryo for the three conditions.
- Woman carrier of GREB1L mutation, detected after WES done for a fetus with Potter, was found out to be a carrier of ACAN mutation causing short stature. Couple decided to transfer WT GREB1L but ACAN mutant embryo.
- Woman with Laing myopathy caused by AD MYH7 mutation; both partners detected by ECS as carriers of congenital adrenalhyperplasia (CAH). Linkage for paternal allele was impossible since both his parents were carriers. The couple opted to transfer WT of MYH7 and carrier of maternal CAH mutation without knowing the status of paternal allele.

Conclusion: These cases demonstrate the challenges couples and professionals are faced with multiple genetic variants when unaffected embryos for all the tested genetic diseases are unavailable. Appropriate genetic counseling discussing medical and biochemical consideration and guidelines for PGT prioritization is crucial before decisions are being made regarding tests and embryos’ selection.

References:
Grants: None declared.

Conflict of Interest: None declared.

P23.027.A Rare disease families’ experience of accessing genetic testing and clinical genetics services in the Republic of Ireland

Alana J Ward, Deborah Lambert, Vicky McGrath, James O’Byrne, Dearbhla Buttery, sally ann Lynch

1School of Medicine, University College Dublin, Dublin, Ireland; 2School of Medicine, University College Dublin, Dublin, Ireland; 3Rare Diseases Ireland, Carmichael House, Dublin 7, Ireland; 4Mater Misericordiae University Hospital, National Centre for Inherited Metabollic Disorders, Dublin 7, Ireland; 5School of Medicine, Trinity College Dublin, Dublin, Ireland; 6Children’s Health Ireland, Crumlin, Dublin 12, Ireland.

Background/Objectives: National waiting times for Clinical Genetics approach three years. We aimed to identify consequences to families accessing services.

Methods: An online survey was distributed via Rare Diseases Ireland patient organisation alliance social media.

Results: Of 144 respondents 90% (129/144) were people with a rare disease and 10% (15/144) relatives. 95% (128/135) had genetic testing, 70% (88/125) leading to a diagnosis. Those where a diagnosis was made by the Clinical Genetics appointment reported higher levels of satisfaction (z = 3.94; p < 0.01).

77% (99/128) of participants had their genetic test arranged by a non-Genetic healthcare professional. The 24% (31/111) who had their genetic test result explained by a different physician/team than the one who arranged the test were more likely to report dissatisfaction (z = 3.07; p < 0.01). 55% (70/127) of respondents waited >3 months for genetic test results.

81% (80/99) of respondents accessed public appointments and 18% (18/99) private. 82% (93/114) of respondents indicated that being on the waiting list impacted their personal life and plans.

32% (37/114) of respondents said waiting for a Clinical Genetics appointment placed tension on relationships with partner/family members/friends. 23% (26/114) indicated wider impact on relatives’ family planning/relationships/education/employment plans. 25% (28/114) delayed future pregnancies and 15% (17/114) expressed impact on decisions around education/employment/mortgage.
Abstracts from the 55th European Society of Human Genetics Conference

Conclusion: Longer waiting times to access genetic services have significant impact on patients’ and carers’ personal and family lives. This highlights that current national waiting times increase the disadvantage already experienced by families with rare genetic conditions.

References:
- Grants: Adelaide Health Foundation R22808.
- Conflict of Interest: None declared.

P23.028.B Experiences and preferences of Healthcare Professionals using telegenetics in a UK Clinical Genetics centre during the COVID-19 pandemic

Beatriz Bustillo1,2, stephnie oates1, kathryn lubasch1, charlotte tomlinson1, vishakha tripathi1, sarah rose1

1Guy’s Hospital, Clinical Genetics, London, United Kingdom; 2School of Biological Sciences University of Manchester, Faculty of Biology, Manchester, United Kingdom.

Background/Objectives: The changes and restrictions precipitated by the COVID-19 pandemic have led to innovation in Clinical Genetics service delivery worldwide. At the Guy’s and St Thomas’ (GSTT) Clinical Genetics Service, telegenetics was implemented at the beginning of the pandemic using the AttendAnywhere videoconferencing platform. We subsequently designed a qualitative study to capture experiences and preferences of Healthcare Professionals (HCP) using this service delivery model.

Methods: We conducted semi-structured interviews with seven HCPs working at the GSTT Clinical Genetics Service, including Genetic Counsellors, Clinical Geneticists and a Clinical Psychologist. Interview content was analysed using a thematic analysis approach.

Results: We present HCPs’ experiences of transitioning between virtual and in-person appointments and their appraisal of the technical and practical aspects of telegenetics. We also present themes that emerged about how HCPs’ attitudes towards virtual appointments when compared to in-person encounters. Future considerations will be shared regarding the suitability of telegenetics for Clinical Genetics appointments.

Conclusion: Based on their experience at GSTT, HCPs interviewed would welcome the addition of telegenetics to the Clinical Genetics toolkit beyond the COVID-19 pandemic, and we will provide considerations for future guidelines.

References:
- Grants: The project was partially supported from Institute of Mother and Child intramural grant 510-18-17.
- Conflict of Interest: Monika Gos Modest, Magdalena Frączyk: None declared, Joana Wasiluk: None declared, Aleksandra Landowska: None declared, Mariola Jurzyk: None declared, Katarzyna Đurda: None declared, Natalia Szczerba: None declared, Wioletta Wafer: None declared, Paulina Kubiszyn: None declared, Maria Jędrzejowska Modest, Mariusz Oltarzewski: None declared.

P23.030.D Clinical description of families with Li-Fraumeni syndrome in a third level hospital in Barcelona

Lorena Moreno Calle1, Belen Pastor Piñera1, Elia Grau Garces1, Aurora Sánchez Díaz2, Miriam Potrony1, Josep Oriola1, Maria Isabel Alvarez1, Celia Badenas3, Lydia Gaba3, Adela Rodriguez4, Barbara Adamo5, Aleix Prat6, Francesc Balaguer6

1Hospital Clinic of Barcelona, Gastroenterology, Barcelona, Spain; 2Hospital Clinic of Barcelona, Biochemistry and Molecular Genetics Department, Barcelona, Spain; 3Hospital Clinic of Barcelona, Medical Oncology Department, Barcelona, Spain.

Background/Objectives: Li-Fraumeni Syndrome (LFS) is a rare cancer predisposition syndrome that increases multiple cancers risk. Recent studies suggest an overestimation in LFS penetrance due to identical of patients with TP53 pathogenic variants without fulfilling clinical criteria. It is imperative to understand risk-modifying factors, genotype-phenotype correlation and clinical effect of variant type to offer a correct follow-up and genetic counselling.

The study objective is to describe clinical and genetic LFS families’ characteristics and assess clinical criteria compliance.

Methods: It is a descriptive, observational and retrospective study of genetically diagnosed LFS families between 2014-2021. Clinical manifestations, variant type and accomplishment of clinical criteria are described.

| Results | Case | Cancer(s) band, age | Diagnosis | Study criteria | Genetic diagnosis | Pathogenic variant | Variant type |
|---------|------|---------------------|-----------|----------------|-------------------|--------------------|-------------|
| 1       | Osteosarcoma,9 | LFS-classic | 9 | c.637C>T | LF |
| 2       | Stomach,34 | HDGC | 35 | c.636S_366delTG | LF |
NG: negative dominance, LF: loss of function.

Conclusion: Our results agree with latest research that considers LFS penetrance and expressivity. It is not always possible to identify the variant type and, therefore, to use this data to personalize follow-up. Although our data is limited, it reveals the high phenotypic variability and the need to manage LFS families within a multidisciplinary team, as well as to rethink the LFS study criteria and the follow-up offered. It would be interesting to carry out multicenter studies to obtain more robust conclusions.

References:

Grants:

Conflict of Interest: None declared.

P23.031.A Observational study on lifestyle behaviors and nutrition in individuals undergoing genetic counselling for breast or colorectal cancer risk

Lea Godino1,2, Donatella Fabbro2, Benedetta Bertonazzi2, Daniela Turchetti1,2

Centro di Studio sui Tumori Ereditari, Università di Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna, Dipartimento di Scienze Mediche e Chirurgiche, Bologna, Italy; 2UOC Genetica Medica, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy, Bologna, Italy.

Background/Objectives: Healthy lifestyles are associated with cancer risk reduction. We aimed at exploring modifiable lifestyle behaviours among individuals at increased risk of breast/colorectal cancer.

Methods: We conducted a cross-sectional study of patients undergoing breast or colorectal cancer risk assessment. A questionnaire was administered, including: Italian validated MEDI-Lite and International Physical Activity questionnaires, items on socio-demographic and physical features and questions on risk perception and smoke and alcohol habits.

Results: Forty-two women and 8 men (age: 19-80 years) were recruited; 19 were affected by breast cancer, 4 by colorectal cancer, 27 were unaffected but had a family history of breast (23) or colorectal (4) cancer.

Fourty-four respondents (88%) perceived their general lifestyle as very or enough healthy. However, 16 (32%) were smokers (current or former), 37 (74%) drank alcohol and 18 (36%) were overweight or obese; 21 (42%) showed low adherence to Mediterranean diet and 7 (14%) reported low exercise. Low adherence to Mediterranean diet was significantly more frequent in participants of low education level (67%) compared to those with high education level (17%; p = 0.044). Participants with higher cancer risk were significantly more likely to smoke: 63% of those at high risk, 40% of those at intermediate risk and 14% of those at standard risk were current or former smokers (p < 0.05).

Conclusion: The results of this pilot study support a need for raising awareness on the role of the lifestyle in cancer risk modification among counselors, possibly tailoring information according to their literacy.

References:

Grants: None.

Conflict of Interest: None declared.

P23.032.B Non-genetic health professionals’ knowledge, attitudes, and behaviors towards medical genetics in Croatia

Tea Mladenvić1, Marina Mavrinac2, Sanja Dević Pavlić3, Anna Mnar1, Matea MAtić1, Sara Mikić1, Sasa Ostojic1, Nina Periza1

1Faculty of Medicine, University of Rijeka, Centre for Genetic Education, Rijeka, Croatia; 2Faculty of Medicine, University of Rijeka, Medical Informatics, Rijeka, Croatia.

Background/Objectives: The main objective of this study was to examine the knowledge, behavior, and attitudes toward medical genetics among physicians who encounter the largest number of patients with specific genetic disorders, in their daily practice.

Methods: The cross-sectional study involved 175 residents and specialists in the Republic of Croatia, who completed the online questionnaire anonymously and voluntarily. The validated questionnaire consisted of five groups of questions: general information, knowledge, behavior in practice, attitude toward genetic testing, and additional education in medical genetics.

Results: The median score of total knowledge in medical genetics was 70.2% among obstetrician-gynecologists, 80.5% among pediatricians, and 76.7% among neurologists. A statistically significant difference was found between the groups, with obstetrician-gynecologists having higher total knowledge than the other physicians (P < 0.001). Many patients with genetic disorders remain undiagnosed in respondent’s daily practice and not recognizing such patients is the main reason why patients are not referred for genetic testing often enough. In addition, the respondents showed a positive attitude toward genetic testing, but they do not feel educated enough to interpret the results of genetic testing.

Conclusion: The results obtained highlight the need for further education of non-genetic health professionals in medical genetics, which would lead to greater confidence and ability of physicians to recognize patients with genetic disorder, choose the right genetic testing method and to clearly convey information.

References:

Cargonja et al. The impact of needs-based education on the change of knowledge and attitudes towards medical genetics in medical students. Eur J Hum Genet. 2021;29(5):726-735.

Grants:

Conflict of Interest: None declared.

P23.033.C Art & genomics: teaching next generation scientists how to connect science and society by using art & design

Diewertje Houtman1, Mirte de Wit1,2, Sam Riedijk1, Bertrand Burgers3, Boy Vlijbriel4

1Erasmus Medical Center, Clinical Genetics, Rotterdam, Netherlands; 2Mirte de Wit, Inclusive design and design research, Den Haag, Netherlands; 3Bertrand Burgers, Social designer and science communicator, Utrecht, Netherlands.

Background/Objectives: The potential large societal impact of developments in the field of genomics asks for a new generation of scientists who are not afraid to step out of their ivory tower and into society. For most scientists (in training) this is a step out of their comfort zone, requiring new skills and tools. The course Art & Genomics (A&G) was developed by two PhD students and two designers. It aims to provide students with the skills and tools that help them connect (with) a broad public, in dialogue about the societal impact of genomic science, on an emotional and experiential level.

References:
Methods: Students go through the non-linear process of design thinking. Although this process asks for continuous iteration, the following successive steps can be distinguished: empathetic understanding, defining the problem, coming up with creative ideas, developing prototypes, and testing. At the end of this process, students showcase their dialogue-provoking art/design piece at an exhibition.

Results: Six students from the minor Genetics in Society participated in a pilot. They indicated that A&G required them to get out of their comfort zone at first, but then gave them the tools they needed to spark broad public dialogue about the societal impact of scientific research. Exhibited art/design pieces included a new fashion clothing line with your personal DNA printed on it, and a game revealing who has your genetic data.

Conclusion: Using art/design methods can build academic students’ competency and confidence to connect science and society.

References:

Grants: Impact at the Core.

Conflict of Interest: Diewertje Houtman Part-time employment at Erasmus MC, Educational support and educational materials by Impact at the Core, a program of the Erasmus University stimulating impact-driven education., Mirte de Wit Educational and financial support and educational materials from impact at the core, a program of the Erasmus University stimulating impact-driven education., Sam Riedijk Fulltime employment at Erasmus University stimulating impact-driven education., Erasmus University stimulating impact-driven education.

P23.034.D Worldwide use of EuroGEMS.org, the ESHG’s guide to online educational resources, and its new full Spanish translation

Adam P. Tobias1, Irene Esteban2, Anna Esteve Garcia3, Elena Avram4, Ana Raquel Gouveia Freitas da Silva1, Juliana Xavier de Miranda Cerqueira3, Edward S. Tobias1,2,8

1Medical School, University of Edinburgh, Edinburgh, United Kingdom; 2West of Scotland Centre for Genomic Medicine, Queen Elizabeth University Hospital, Glasgow, United Kingdom; 3Clinical Genetics, Bellvitge University Hospital, Barcelona, Spain; 4Medlife Clinics, Bucharest, Romania; 5Serviço de Genética Médica, Departamento de Pediatria, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal; 6Coeliac Disease Research Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; 7Faculty of Nutrition and Food Science, University of Porto, Porto, Portugal; 8Medical Genetics and Genomics, University of Glasgow, Glasgow, United Kingdom.

Background/Objectives: Access for individuals at all educational levels to reliable online educational genomics-related resources has been increasingly required, worldwide. A website (www.EuroGEMS.org) (1) was therefore created for the European Society of Human Genetics (ESHG), providing a user-friendly English-language guide to 110 high-quality online worldwide resources for genetics specialists, non-genetics-professionals, students and the public (2). Subsequently, its translation into other languages has been suggested by the ESHG. As Spanish is the first language of approximately 480 million people worldwide, Spanish translation was initiated (3).

Methods: EuroGEMS.org was fully translated (and carefully cross-checked) by two bilingual genetics professionals. The resulting Spanish web-pages were launched in June 2021.

Results: The www.EuroGEMS.org website has been visited from 128 countries. It has been endorsed by the ESHG Board and, in 2022, by the Human Genome Organisation (HUGO-International). The new Spanish-language pages have been accessed from 28 countries (including 12 in South and Central America) with a marked (6.3-fold) increase in the number of Spanish speakers using EuroGEMS (from January 2021 to January 2022).

Conclusion: EuroGEMS.org is used worldwide and has been endorsed by two major international societies (the ESHG and HUGO-International). Its new Spanish-language pages have greatly increased its accessibility and readership, particularly in Spain and South America but also elsewhere (including the USA). A Portuguese translation, now underway, should further increase genetics and genomics knowledge acquisition, internationally.

References: 1. https://www.eurogems.org/index.html. 2. Tobias AP and Tobias ES (December 2020): Human Mutation 41: 2021-2027. PMID: 32906220. 3. Tobias ES et al. (September 2021) Frontiers in Genetics 12: 693952. PMID: 34539735.

Grants: Conflict of Interest: None declared.

P23.035.A Community-driven co-creation of an educational genetics app

Ang Davies1, Naz Khan2, Alan Davies1, Norina Gasteiger3, Amy Vercell4, Dawn Dowding5

1The University of Manchester, Division of Informatics, Imaging & Data Sciences, School of Health Sciences, The University of Manchester, Manchester, United Kingdom; 2Manchester University NHS Foundation Trust, Manchester Centre for Genomic Medicine, Manchester, United Kingdom; 3The University of Manchester, Division of Nursing, Midwifery and Social Work, School of Health Sciences, University of Manchester, Manchester, United Kingdom; 4The Christie NHS Foundation Trust, Manchester, United Kingdom.

Background/Objectives: Previous studies have found lack of access to culturally sensitive genetic information creates an unmet genetics-education need within Pakistani communities in the UK, where incidence of consanguineous marriage is high, increasing risk of rare genetic diseases. Mobile apps may help to raise genetic literacy and signposting to clinical services in a sensitive, engaging and accessible manner.

Methods: A mixed methods study was undertaken to co-create a genetics app with the South Asian Pakistani community (Blackburn with Darwen, UK). Including: semi-structured interviews with community members (7), exploring understanding of genetics; systematic review of current genetics apps using the Mobile App Rating Scale (MARS); and systematic literature review of genetics apps.

Results: During the interview phase participants indicated use of the potential app either alone or with family members to educate themselves/others and make informed choices. Other preferences included: privacy, lack of connection to genetics in the app logo and requirement for high quality/trusted branding (e.g. NHS logo). Participants indicated a strong preference for video content of both patients and genetics health-professionals from the same ethnicity as themselves. During the app review phase, 22 apps met eligibility criteria, all intended to inform/educate users, 32% analysed genetic data and 18% helped to diagnose genetic conditions, though readability scores were poor.

Conclusion: Community-driven co-creation allowed the collection of users’ requirements and prioritisation of features,
creating a prototype genetics app. The community were integral to the design process, working together with researchers, app developers and health-professionals.

References:

Grants: Funding from Blackburn with Darwen Council.

Conflict of Interest: None declared.

P23.036.B Development of the CME training course in clinical laboratory genetics in Georgia

Eka Kvaratskhelia1, Maia Zarandia1, Tinatin Tkemaladze1, Elene Abzianidze1

1Tbilisi State Medical University, Department of Molecular and Medical Genetics, Tbilisi, Georgia.

Background/Objectives: A number of genetic diagnostic laboratories have been established in Georgia in recent years, offering different types of genetic tests including diagnostic testing for monogenic and common complex diseases, predisposition testing for cancer causing genes, and reproductive genetic testing [1]. The growing availability of genetic tests in Georgia raises the question regarding a shortage of laboratory geneticists and technicians. The first CME course in Laboratory Genetics has been developed at the Tbilisi State Medical University for healthcare professionals.

Methods: The aim of this postgraduate-level course entitled "Molecular genetic testing in a clinical practice" is to provide laboratory training in the field of molecular genetics for MDs. The course has been approved by the Ministry of Education and Science of Georgia for 15 CME category I credits.

Results: The course format is hands-on laboratory exercises including, but not limited to, molecular diagnostic techniques with standard and real-time quantitative PCR and application of these techniques in various areas of molecular genetic testing. A typical class module begins with a lecture on a specific laboratory topic (e.g. DNA chemistry, gene expression, PCR methodology, 1 hour), followed by lab exercises to demonstrate principles discussed in the lecture (2 hours). The course ends with a written multiple choice exam and post-course evaluation survey.

Conclusion: We believe that this course will help healthcare professionals to understand genetic technologies, and their application to clinical practice.

References: 1. Kvaratskhelia, E., Chokoshvili, D., Kvintradze, M. et al. Public attitudes towards the genetic testing in Georgia. J Community Genet 12, 407–414 (2021).

Grants: -

Conflict of Interest: None declared.

P23.040.B The communication chain: a qualitative analysis of patient-provider and patient-family communication in hereditary cancers

Carla Pedrazzani1, Monica Aceti1, Reka Schweighoffer1, Burki Nicole2, Rossella Graffeo-Galbiati1, Olivia Pagani1, Maria Katapodi1, Maria Caiata-Zufferey1

1University of Basel, Clinical Research, Basel, Switzerland; 2University Hospital Basel, Basel, Switzerland. 

Background/Objectives: In hereditary cancers, family-communication on genetics is crucial for family members’ decision making about genetic risk assessment. Healthcare-providers have an important role in supporting family-communication but this is still limited and unclear. The study aims to explore how healthcare-providers address family-communication with mutation carriers and how this may affect mutation carriers’ decision to communicate about genetic risk to family members.

Methods: In this qualitative study, data were collected with focus groups and interviews with 12 unaffected and 8 affected female carriers of hereditary breast and ovarian cancer ( HBOC)-associated mutations. Data were collected in Italian, German and French in three linguistic areas of Switzerland.

Results: Data show an inconsistent management of family-communication before, during and after genetic counselling with the perception of an overall negligence of the health-system, a low level of healthcare-providers’ involvement and the lack of continuity. Dynamic, contradictory, implicit logics such as responsibility, self-preservation, protection and respect of the
other, drive mutations carriers’ decision to (and how) communicate or not, genetic risk to family members. Many individual and family factors influencing communication such as gender, geographical and affective distance, illness experience, interact systematically with the different logics.

**Conclusion:** The study innovatively frames family-communication proceeding along a communication chain from health-care providers to at-risk relatives. It highlights the need for supporting family-communication on genetic risk and potential providers’ new roles.

**References:** Schwiter R. et al. (2018) How can we reach at risk relatives? Efforts to enhance communication and cascade testing uptake: a mini-review. Current Genetic Medicine Reports. 6:21-27.

**Conflict of Interest:** None declared.

---

**P24 ETHICAL, LEGAL AND PSYCHOSOCIAL ASPECTS IN GENETICS**

**P24.001.C Systematic reanalysis for genome diagnostic laboratories? ELSI/ethical, economical, legal and (psycho) social implications: Scoping review**

**Marije A. van der Geest**¹, Marielle E. van Gijn¹, Els Maeckelbergh², Anneke Lucassen³,⁴, Morris Swertz³, Mirjam Plantinga¹, Irene van Langen⁴

¹University Medical Center Groningen, Department of Genetics, Groningen, Netherlands; ²University Medical Center Groningen, Institute for Medical Education, Groningen, Netherlands; ³University of Southampton, Faculty of Medicine, Clinical Ethics and Law, Southampton, United Kingdom; ⁴University of Oxford, Centre for Personalised Medicine, Welcome Centre for Human Genetics, Nuffield Department of Medicine, Oxford, United Kingdom.

**Background/Objectives:** With the introduction of NGS techniques increasing numbers of disease-associated variants are being identified. This ongoing progress might lead to diagnoses in formerly undiagnosed patients and novel insights in already solved cases. Therefore, many studies suggest introducing systematic reanalysis of NGS data in routine diagnostics. Introduction will, however, also have ELSI implications that Genetic Health Professionals (GHPs) from laboratories should consider before possible implementation of systematic reanalysis.

**Methods:** To get a first impression we performed a scoping literature review. After searching PubMed for relevant literature between 2008 and 2021, we included 54 publications.

**Results:** Our findings show that for the vast majority of included articles ELSI aspects were not the main focus. However, some aspects were raised implicitly. In total, we identified nine ELSI aspects, such as (perceived) responsibilities, implications for consent and cost-effectiveness.

**Conclusion:** The identified ELSI aspects brought forward necessary trade-offs for GHPs to consciously take into account when considering implementation of systematic reanalysis of NGS data in routine diagnostics, balancing the various strains on their laboratories and personnel while creating optimal results for patients. Some important aspects are not well explored yet. For example, our study shows GHPs see the values of systematic reanalysis but also experience barriers, often mentioned as being practical and/or financial only, but in fact (also) being ethical and/or psychosocial. These results are in line with our previous study on recontacting (Otten et al., 2015). Engagement of these GHPs in further research on ELSI aspects is important for sustainable implementation.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

---

**P24.002.D The effect of Down syndrome on parents’ daily life**

**Leila Dardour**¹, Amira M’hamed², Amel Tefj², Asma Ben cheikh³, Hassen Kamoun³, Mediha Trabelsi⁵, Ramzi Zemni¹

¹Faculty of Medicine of Sousse, Department of Medical Genetics, Sousse, Tunisia; ²Farhat Hached University Hospital, Department of Pediatrics, Sousse, Tunisia; ³Faculty of Medicine of Sousse, Department of Community Medicine, Sousse, Tunisia; ⁴Hedi Chaker University Hospital, Department of Medical Genetics, Sfax, Tunisia; ⁵Charles Nicolle University Hospital, Department of congenital and hereditary diseases, Tunis, Tunisia.

**Background/Objectives:** Down syndrome (DS) is the most common genetic cause of intellectual disability. Having a child with DS can be an unexpected event that challenges parents’ ability to adapt. In Tunisia, there is no available data on the impact of DS on parents’ daily life. The objective of this study is to evaluate the quality of life of these parents and determine the associated factors.

**Methods:** This is a cross-sectional analytical multicentric study (Medical Genetics Services of University hospitals of Tunis and Sfax, “Awdalouma” Association, Tunisian Union of Assistance to Persons with Intellectual Disabilities in Sousse, and Pediatrics department of Farhat Hached hospital, Sousse, carried out between November 1 and December 31, 2018. The measurement instrument was a questionnaire: the Distress thermometer for parents.

**Results:** Of 131 participants, 74.8% were women. DS was diagnosed postnataally in 92% of cases, which shows the need to raise awareness among general population about prenatal screening methods. The feeling of distress was present in 57.3% of parents. Practical problems (especially professional and financial problems), emotional difficulties (depression, anxiety, and nervousness), and physical problems (fatigue, pain, and sleep disturbance) were all statistically associated with the overall distress score. There were few social problems since most of parents expressed their satisfaction with their family and friends support.

**Conclusion:** Almost all different aspects of daily life were associated with parents’ distress, particularly the emotional and practical domains. Adapted and structured psychosocial care of these parents would allow improving their quality of life and thus that of their children with DS.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

---

**P24.003.A Ethical Issues in Prenatal Genetic Diagnosis: new guidance of the British Society for Genetic Medicine**

**Ruth Horn**¹, Alison Hall², Anneke Lucassen³

¹University of Oxford, Oxford, United Kingdom; ²PHG Foundation, Cambridge, United Kingdom; ³University of Oxford, Wellcome Centre for Human Genetics, Oxford, United Kingdom.

**Background/Objectives:** New British Society for Genetic Medicine (BSGM) guidance considers the ethical issues that can arise in prenatal genetic testing. Building on the Joint Committee for Genomic Medicine’s Consent and Confidentiality document of 2019, it focusses on key steps of the prenatal testing pathway: and in particular in the interpretation and communication of results and subsequent clinical implications. By incorporating relevant legal principles, professional guidelines, and practical sources for support, it aims to facilitate the decision-making processes for both professionals and patients.
Methods: Based on a workshop with a multidisciplinary working group in 2019 and ongoing collaboration virtually during the pandemic, the three authors produced this report which incorporates illustrative case studies. The guidance was considered and approved by the BSGM Executive Committee in 2022.

Results: This guidance focusses on potential ethical issues related to 5 key-aspects in prenatal genetic testing: 1. Consent to investigations during pregnancy; 2. Communication and decision-making; 3. Implications of prenatal genetic testing for others; 4. Broader aspects of patient care including equal access and justice; 5. Ongoing management and post-pregnancy follow-up. The report offers case-based practical approaches and key-messages.

Conclusion: It is hoped that these clinically focused ethical guidelines are an accessible resource for any healthcare professional who utilise genetic and genomic tests.

References: N/A.

Conflicts of Interest: Ruth Horn UK Economic and Social Research Council Grant (ES/T00908X/1), Alison Hall: None declared, Anneke Lucassen: None declared.

P24.004.B Trust in different offers of expanded carrier screening: a qualitative study among Dutch potential users

Mirjam Plantinga1, Bonita Bazuin1, Donald van Tol2, Reinder Broekstra1, Erwin Birnie1, Irene van Langen1

1UMCG, genetics, groningen, Netherlands; 2University of Groningen, sociology, groningen, Netherlands.

Background/Objectives: Expanded carrier screening (ECS) is aimed at detecting carrier states for many, mainly autosomal recessive (AR) conditions in couples from the general population planning a pregnancy. Different ECS offers exist worldwide, amongst others in the Netherlands, Belgium and Australia. Acceptance of using new technologies requires high levels of trust. Investigating which characteristics of different ECS offers contribute to high trust levels is therefore important for implementation.

Methods: A heterogeneous sample of Dutch potential users was interviewed about trust in different ECS offers (n = 9). Subsequently they rated their level of trust in different ECS offers and ranked different aspects in terms of fostering trustworthiness (survey, n = 8).

Results: Table 1 displays which ECS aspects are associated with high and low trust.

| ECS aspect | High trust | Low trust |
|------------|------------|-----------|
| Test performance (1) | High sensitivity/high specificity | Low sensitivity/low specificity |
| Pre-test counselling (2) | Health care professional | Commercial company |
| Analysis of ECS test (3) | Scientific institute, hospital | Commercial company |
| Test panel (4) (number of AR conditions tested) | Limited number that can be overseen | Large (> 100) |
| Test with blood/saliva (5) | Blood | Saliva |
| Price (6) | Expensive | Cheap |

Trust was further found to be influenced by misunderstandings (e.g., that larger test panels have lower test performance).

References: 1. N. J. Smelser, American Sociological Review. 63, 1 (1998).
2. J. Pols, Sociology of Health & Illness. 25, 320–347 (2003).
Grants: KU Leuven C1 funding.
Conflict of Interest: None declared.

P24.005.C Ambivalence in the practice of advanced genetic healthcare

Janneke M.L. Kuiper1, Ine Van Hoyweghen1

1KU Leuven, Centre for Sociological Research, Leuven, Belgium.

Background/Objectives: The clinical implementation of next-generation sequencing (NGS) has heightened the chance of finding a genetic diagnostic answer. However, NGS results are also often more complex and uncertain and call for multidisciplinary and multifaceted decision-making. Conflicting expectations, interests, and demands in healthcare practice can fuel tension and ambivalence on both an individual and structural level. This paper uses the concept of ‘ambivalence’ as a lens to characterise the tensions found in dealing with NGS techniques in clinical practice (1).

Methods: We conducted extensive multi-sited qualitative research at two large European human genetics centres. Transcripts from clinical genetic consultations and semi-structured interviews with patients and healthcare professionals and field-notes from observations in multidisciplinary team meetings were inductively coded using Nvivo.

Results: Our analysis makes visible the tension, negotiation, and compromise involved in navigating the different modes of ‘doing good care’ at play in genetic healthcare practice (2). We show how research and clinical practice informed interests, demands, and concerns are intertwined in everyday practice and structure. We demonstrate how the experience of ambivalence creates tension in what care is offered and how care is experienced by patients.

Conclusion: Providing insight into how practices and structures are shaped by ‘the dynamics of ambivalence’ (1) can help to more consciously give direction to the future of genetic care.

References: 1. N. J. Smelser, American Sociological Review. 63, 1 (1998).
2. J. Pols, Sociology of Health & Illness. 25, 320–347 (2003).
Grants: KU Leuven C1 funding.
Conflict of Interest: None declared.

P24.006.D Conversational agents in genetic healthcare: an overview of ethical aspects

Marlies van Lingen1, Noor Giesbertz2, Annelien Bredenoord2, Lieke van den Heuvel1, Peter van Tintelen1, Karin Jongsmaj.

1University Medical Center Utrecht, Genetics, Utrecht, Netherlands; 2Erasmus University Rotterdam, School of Philosophy, Rotterdam, Netherlands; 3University Medical Center Utrecht, Julius Center, Utrecht, Netherlands.
Background/Objectives: Conversational Agents (CAs) are a form of Artificial Intelligence (AI) technology and mimic human interaction using text, speech and/or virtual embodied expressions. In the medical field, CAs are attracting increasing interest because of their efficiency, scalability, and flexibility. Considering the central role of conversation in genetic care, genetic counselling is a particularly suited field for implementation. However, little is known about the ethical aspects of the introduction of CAs in genetic care. The urgency to address this issue is underlined by the recent development of several chatbot-like CAs for genetic counselling practice.

Methods: We conducted a narrative review on ethical literature related to CAs and medical AI in healthcare. Key ethical aspects were categorized by genetic counselling phase.

Results: Different phases of genetic counselling attribute different roles and responsibilities for CAs. CAs could play a role in (1) information provision, (2) guiding informed consent, (3) provide test results or (4) emotional support, and (5) support with clinical assessment of a clinician. For each phase, key ethical aspects are identified at the crossroads of ethical debates in data science and healthcare.

Conclusion: Introduction of CAs in genetic care comes with promises and challenges. CAs impact existing care relations and introduce new dimensions of interaction and governance. Careful evaluation of the impact in each counselling phase is crucial to promote a morally sound and meaningful implementation in the clinical context.

References: -

Grants: This project is financially supported by ZonMW/IMDI and the Dutch Heart Foundation. Grant number 104021006 (ZonMW) 2019B012 (Dutch Heart Foundation).

Conflict of Interest: Marlies van Lingen: None declared, Noor Giesbertz: None declared, Annelien Breedenoord: None declared, Lieke van den Heuvel: None declared, Peter van Tintelen UMC Utrecht Fulltime, Netherlands Heart Foundation/ PLN Foundation/ Leducq Foundation, Cardiac Tissue Bank, Netherlands Heart Institute, Utrecht, the Netherlands (unpaid), Karin Jongma: None declared.

P24.007.A Parents’ views about newborn bloodspot screening (non-)participation and expansion

Jasmijn Klapwijk1, Sylvia Van der Paal2, Sophie Wins2, Tessa Van Dijk1, Adriana Kater-Kuipers2, Catharina P. B. Van der Ploeg2, Suze Jans2, Stephan Kemp2, Rendelien K. Verschoof-Puite2, Lion J. M. Van den Bosch2, Lidewij Henneman1

1 Amsterdam UMC, locatie VUMc, Department of Human Genetics and Amsterdam Reproductive & Development research institute, Amsterdam, Netherlands; 2 TNO, Child Health, Leiden, Netherlands; 3 Amsterdam UMC, locatie AMC, Laboratory Genetic Metabolic Diseases, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam Gastronérology Endocrinology Metabolism, Amsterdam, Netherlands; 4 National Institute for Public Health and Environment, Department of Vaccine Supply and Prevention Programmes, Bilthoven, Netherlands; 5 National Institute for Public Health and Environment, Centre for Population Screening, Bilthoven, Netherlands.

Background/Objectives: Neonatal bloodspot screening (NBS) aims at early detection of treatable disorders to offer early intervention. The number of conditions being screened for is expanding worldwide, which may affect public acceptance of NBS. This study explored views of NBS participants and non-participants on (expanding) NBS in the Netherlands.

Methods: Cross-sectional survey data was collected from 804 (605 invited; 13%) parents whose newborns participated in NBS in the Netherlands in the last two weeks of December 2019, and 48 (1162 invited; 4%) NBS non-participants in 2019 and 2020.

Results: For NBS participants, the most important reason to participate was preventing health problems. For NBS non-participants, the most important reasons to decline were belief that the heel prick would be painful for the child and parents’ viewpoint on life (more actively religious, considered alternative medicine/life-style more important, less inclined to vaccinate their child). NBS participants made an informed decision more often than NBS non-participants (83% vs 44%), with NBS participants showing more knowledge regarding NBS than NBS non-participants (86% vs 62%). Ninety-five percent of NBS participants were positive about NBS expansion, agreeing to include conditions that were incidentally found in the mother instead of the child (86), late-onset (84%), or untreatable (61%).

Conclusion: Most parents made an informed decision about NBS participation and were positive about NBS and its expansion. Insights into parents’ views on (non-)participation and expansion of NBS can help to ensure a program that suits population needs while safeguarding ethical principles for screening.

References: Grants: ZonMW Netherlands (no. 543002006).

Conflict of Interest: Jasmijn Klapwijk Employed part-time on Netherlands Organisation for Health Research and Development (ZonMw) grant no. 543002006), Sylvia Van der Pal Partly supported by Netherlands Organisation for Health Research and Development (ZonMw) grant no. 543002006), Netherlands Organisation for Health Research and Development (ZonMw) grant no. 543002006); collaborator, Sophie Wins Partly supported by Netherlands Organisation for Health Research and Development (ZonMw) grant no. 543002006), Tessa Van Dijk Partly supported by Netherlands Organisation for Health Research and Development (ZonMw) grant no. 543002006), Adriana Kater-Kuipers Partly supported by Netherlands Organisation for Health Research and Development (ZonMw) grant no. 543002006), Catharina P. B. Van der Ploeg: None declared, Suze Jans: None declared, Stephan Kemp: None declared, Rendelien K. Verschoof-Puite: None declared, Lion J. M. Van den Bosch: None declared, Lidewij Henneman Netherlands Organisation for Health Research and Development (ZonMw) grant no. 543002006); Principal Investigator.

P24.008.B Ethical issues raised by prenatal genetic testing in England, France and Germany: findings from a comparative study

Adeline Perrot1, Ruth Hom1

1 Ethox Centre, Nuffield Department of Population Health, Oxford, United Kingdom.

Background/Objectives: Recently, a number of countries such as England, France and Germany, have started offering NIPT as a publicly funded second tier test for common chromosomal aneuploidies (trisomy 21, 18 and/or 13). Despite the benefits, the implementation of NIPT in healthcare systems raises a number of ethical issues. These issues are discussed differently across countries, echoing different political particularities and value-systems. Our study aims to shed new light on different meanings of reproductive autonomy within various socio-cultural contexts and how this impacts on the use and regulations around prenatal genetic testing.

Methods: As part of a wider research project, which is involving semi-structured interviews with women, health professionals and policy-makers, we conducted a comprehensive literature review to compare arguments about, and regulations governing NIPT in the three countries. Between December 2020 and April 2021, we reviewed approximately 250 sources in legal and regulatory texts; public reports; parliamentary debates; medical press; academic literature, bioethics, social sciences; and daily press.
Results: Although reproductive autonomy is valued in each country, it is understood and implemented differently depending on the socio-cultural context and on what other principles (e.g., disability rights, human dignity, or professional duties to promote health and reduce technology-related risks) are evoked, and how they are defined and weighed against each other.

Conclusion: To further unpack these values and principles, further qualitative research is required to investigate various stakeholders’ positions and motivations. Such an in-depth understanding will contribute to both the ethical and societal debates on NIPT and other new prenatal genetic technologies.

References:
Grants: ES/T00908X/1.
Conflict of Interest: Adeline Perrot Full time, Ruth Horn Full time, PI - ES/T00908X/1 (Economic and social research council); Non-invasive prenatal genetics and genomics in England, France and Germany - Exploring practical ethical issues ‘on the ground’, Ruth Horn is a member of Oxford Tropical Research Ethics Committee, the French CNRS Ethics Committee, and of the scientific advisory board of the German Human Genome-Phenome Archive. She is President of the European Association of Centre of Medical Ethics (EACME).

P24.009.C Awareness, expectations, and concerns regarding whole-genome sequencing studies: a survey of cancer patients, families, and the public in Japan

Izen Ri1, Junichi Kawata1, Akiko Nagai1, Koari Muto1
1The Institute of Medical Sciences, The University of Tokyo, Department of Public Policy, Tokyo, Japan.

Background/Objectives: Whole-genome sequencing (WGS) is being increasingly used in research and clinical settings in cancer genomics. Studies show that cancer patients generally have positive attitudes toward genomic tumor profiling tests (Shirdareh et al. 2021); however, few works have revealed patients’ attitudes toward WGS. This study clarifies cancer patients’, families’, and public awareness, expectations, and concerns regarding WGS studies in Japan.

Methods: Cross-sectional anonymous online surveys were distributed to Japanese subjects, aged 20–69 years in March 2021, that registered in the survey company panel.

Results: The 10,077 respondents (response rate: 26.5%) were divided into those with a history of cancer (CPs, n = 1,204), those with family history (FMs, n = 5,968), and general adults (GAs, n = 2,915); 56.6% of CPs, 61.2% of FMs, and 70.6% of GAs had never heard of the WGS study. CPs had the highest expectations among the three groups; over 70% evaluated that it would lead to diagnosis, cure, or development of medicine by building a large-scale database. FMs had a higher level of concern than CPs; half were concerned about the accuracy or utility and the possibility of being treated unfavorably if germline findings were detected. About 60% of both CPs and FMs were concerned about the privacy of their genetic information.

Conclusion: Despite low awareness toward WGS studies, CPs had high expectations from it. Since a national project to sequence 80,000 cancer patients started in Japan, measures to prevent issues arising from misuse of genetic information and to protect genetic privacy are urgently needed.

References:
Grants: AMED JP21cm0106001, MHLW JPMH20AD0101, JSPS KAKENHI JP18K09940.
Conflict of Interest: None declared.

P24.010.D The Australian moratorium on genetics and life insurance fails to meet Parliamentary recommendations against genetic discrimination

Jane Tiller1, Paul Lacaze1, Margaret Otlowski2
1Monash University, Melbourne, Australia; 2University of Tasmania, Hobart, Australia.

Background/Objectives: Genetic discrimination is an issue of international concern to clinicians, researchers, and policy-makers. In Australia, genetic discrimination in life insurance is legal. In 2018, following a Parliamentary Joint Committee Inquiry into the Life Insurance industry, the Committee recommended an urgent ban on the use of genetic test results in Australian life insurance underwriting, in a form similar to the UK Code on genetic testing and life insurance. The Australian government has not responded to the recommendations. In 2019, the Australian life insurance industry implemented a self-regulated moratorium that applies only to policies up to certain financial limits until 2024. The moratorium will be reviewed by the industry in 2022, but has no government oversight.

Methods: We analysed the Australian moratorium from a policy perspective to measure its adherence to the Parliamentary recommendations.

Results: The Australian moratorium has failed to follow a number of Parliamentary recommendations. Importantly, it differs from the UK Code in a number of key areas (Table 1), including the financial limits, the tests included, the involvement of government, the end date, and the inclusion of research results. On each of these points of difference, the Australian moratorium offers less protection to consumers than the UK Code.

Conclusion: While the FSC moratorium is a step forward for Australia, it fails to meet the expectations of the Parliamentary recommendations. This analysis is instructive for Australian stakeholders, as well as stakeholders in other jurisdictions who are interested in the impact of genetic discrimination and the mechanisms for regulation that are being implemented internationally.

References:
Grants: None declared.

Table 1: Comparison of UK code and Australian moratorium

| Financial limits | UK Code on genetic testing and insurance | FSC moratorium on insurance and genetics | Consistent? |
|------------------|----------------------------------------|---------------------------------------|-------------|
| Tests included  | Only Huntington disease predictive results must be disclosed above the monetary limits for life cover. Currently, no genetic test results must be disclosed for any other type of policy. | All genetic test results must be disclosed once the monetary limit is reached for all types of life insurance policies. | × |
| Tests excluded  | | | |
| Regulation/ government involvement | A formal agreement between the UK government and the Association of British Insurers. Industry-led and self-regulated, without any agreement or involvement with the Australian government. | | × |
| End date | No end date (although it is reviewed periodically) | Currently due to end in 2024 (may be extended following review in 2022). | × |
| Ability to choose to disclose negative genetic test results | Yes | Yes | ✓ |
| Research results excluded from disclosure | Yes | No, unless the applicant does not receive the result. | × |
life insurance and genetics moratorium, Margaret Otolowski MO is an investigator of a project supported by a grant from the Australian Government’s Medical Research Future Fund (MRFF), ref 76721, monitoring the effectiveness of the Australian life insurance and genetics moratorium.

P24.011.A To share or not to share: public perspectives on genomic data sharing

Danya Vears1,2,3, Fiona Lynch4, Stephanie Best4,5, Yan Meng5,6,7, Ilia Goranitis5,6,7, Christopher Gyngell1,8

1Murdoch Children’s Research Institute, Biomedical Ethics Research Group, Parkville, Australia; 2University of Melbourne, Melbourne Law School, Carlton, Australia; 3K.U.Leuven, Centre for Biomedical Ethics and Law, Leuven, Belgium; 4Australian Institute of Health Innovation, Macquarie University, North Ryde, Australia; 5Australian Genomics, Murdoch Children’s Research Institute, Parkville, Australia; 6Melbourne School of Population and Global Health, University of Melbourne, Health Economics Unit, Centre for Health Policy, Carlton, Australia; 7Murdoch Children’s Research Institute, Parkville, Australia; 8University of Melbourne, Department of Paediatrics, Parkville, Australia.

Background/Objectives: Storage and sharing of genomic data following diagnostic sequencing is critical to the future of genomic medicine. Data sharing increases the chance of finding a diagnosis for both current and future patients and can benefit clinical and pharmaceutical research. Yet, few studies have explored public perspectives on how and where data should be stored, with whom it should be shared, and how to obtain meaningful consent to do so.

Methods: To address this issue, we conducted 7 online focus group with 39 members of the Australian public. Focus groups were recorded, transcribed, and analysed using inductive content analysis.

Results: Participants (mean age = 37 years; range 18-67) were overall in favour of storing genomic data, although they raised several concerns, particularly relating to data security and ensuring adequate regulation and standardised application processes to gain access to the data. Sharing data with clinicians and researchers was generally supported because it could provide clear medical benefit. Yet, views on sharing with pharmaceutical companies varied; some participants felt this would lead to better treatments whereas others saw companies as untrustworthy and predatory. Participants generally viewed sharing with insurance companies as inappropriate. Consent was seen as key, with many participants favouring a dynamic consent model which bolstered choice regarding the uses of the data.

Conclusion: Our findings have helped elucidate the complexities associated with developing a one-size-fits-all approach to data sharing and storage through the eyes of the Australian public. These results can be used to help guide policy development on these issues.

References:

Grants: Australian Government GFMH#76749.

Conflict of Interest: None declared.

P24.012.B Are couples making informed choices when opting for reproductive genetic carrier screening?

Eva Van Steijvoort1, Hilde Peeters2, Hilde Vandecruys3, Jasper Verguts2, Karen Peeraer4, Gert Matthijis3, Pascal Borry1

1KU Leuven, Public Health and Primary Care, Leuven, Belgium; 2UZ Leuven, Human Genetics, 3000, Belgium; 3Jessa Ziekenhuis, Hasselt, Belgium; 4UZ Leuven, Development and Regeneration, Leuven, Belgium.

Background/Objectives: Reproductive genetic carrier screening (RGCS) allows to identify couples who have an increased risk of conceiving a child with a particular genetic condition. Professional organizations have emphasized that the success of RGCS should not solely be measured by the uptake of screening. An assessment of whether or not individuals are making informed choices with regard to RGCS free from coercion from others is considered to be as important.

Methods: Women visiting a gynaecologist practice were asked to consider participation in a research study where RGCS was offered for free to them and their male partner. A modified Multidimensional Measure of Informed Choice was used to determine whether couples who opted for RGCS made an informed choice.

Results: A minority of participants perceived their risk to conceive a child with a hereditary condition (1.2%) to be (very) high. In total, 82% of participants (n = 77) made an informed choice with regard to RGCS according to the modified MIMIC. Thirteen participants (16.9%) made an uninforme choice due to insufficient knowledge and one participant (1.3%) due to insufficient knowledge and value-inconsistency. Anxiety scores were elevated for three participants (3.8%, n = 80). Two participants (2.4%, n = 81) presented with decisional conflict.

Conclusion: Our study results show high rates of informed choice among couples who were offered RGCS in a research study where participants received up to 30 minutes of pre-test counseling.

References:

Grants: Research Fund Flanders (FWO) - grant number G094518N.

Conflict of Interest: None declared.

P24.013.C Mental health of adolescents and young adults with Li-Fraumeni syndrome: Results from a mixed method study

Rowan Forbes Shepherd1, Camella J. Rising1, Patrick Boyd1, Alix G. Sleigh2, Catherine Wilsnack3, Ashley S. Thompson4, Payal P. Khincha5, Allison Werner-Llin4

1National Cancer Institute, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, Rockville, United States; 2Cedars-Sinai Medical Centre, Department of Physical Medicine & Rehabilitation, Los Angeles, United States; 3University of Texas at Austin, Steve Hicks School of Social Work, Austin, United States; 4University of Pennsylvania, School of Social Policy and Practice, Philadelphia, United States.

Background/Objectives: Li-Fraumeni syndrome (LFS) is an inherited cancer syndrome with whole body cancer risks from birth. Adolescents and young adults (AYAs) with LFS may experience significant physical and psychosocial burdens during critical periods of development early in life, increasing vulnerability to poor mental health. This study examined AYAs’ reported mental health and the intersection of LFS- and lifespan-related factors affecting ongoing mental health outcomes.

Methods: Eligible AYAs (aged 15-39 years) recruited from the National Cancer Institute’s LFS study (NCT01443468) completed an online survey, with validated mental health measures, and/or qualitative interviews. Descriptive statistics and correlation coefficients were calculated using SPSS. An interprofessional team thematically analyzed interview data using Dedoose.

Results: Thirty-seven AYAs completed surveys (78% female) and 38 AYAs completed interviews (71% female) (11 completed both). AYAs self-reported past emotional problems (n = 26, 70%),
depression or anxiety diagnoses (n = 25, 68%), and suicidal ideation (n = 16, 43%). Past suicidal ideation was significantly correlated with younger age at awareness of LFS (r = -0.391, p < 0.05). Participants described LFS-related cancer diagnoses, cancer worry, grief, and loss (e.g., family deaths, identity, occupations) that challenged their mental health. Although most (n = 29, 78%) reported previously receiving mental health counseling, fewer (n = 11, 30%) reported receiving counseling currently.

Conclusion: AYAs with LFS, especially those who learn of LFS at younger ages, may be at risk of poor mental health. These experiences may align with acute periods of LFS-related or developmental change leading to uncertainty and loss in multiple domains of life. Future studies could investigate the effect of an LFS- and youth-specific mental health support intervention.

References:

Grants: 
Conflict of Interest: None declared.

P24.014.D Genomic research on indigenous peoples in Asia: A comparative study on Japan and Taiwan

Momoko Sato1, Yusuke Inoue2, Koari Muto3

1The University of Tokyo, Graduate School of Interdisciplinary Information Studies, Tokyo, Japan; 2The Institute of Medical Science, The University of Tokyo, Department of Public Policy, Tokyo, Japan.

Background/Objectives: In 2021, the ESHG announced its opposition to the misuse of biobanks against vulnerable minorities (Forzano 2021). Many Asian jurisdictions have established biobanks emphasising the uniqueness of their genomes on the basis that genomic research has been West-biased. However, this premise can lead to the disregard of indigenous populations. The purpose of this paper is to understand the ethical considerations for genomic research on indigenous populations in Asia by focusing on major biobanks in Japan and Taiwan.

Methods: The authors conducted a literature review on the laws and guidelines regulating genomic research on indigenous populations, policies of biobanks and articles on ethical issues.

Results: The Taiwan Biobank collected nationwide biological samples, including indigenous populations. Although the group consent rule was introduced under the Free, Prior and Informed Consent (FPIC) of indigenous populations (United Nations 1997), concerns about stigmatisation remain. Biobank Japan has not mentioned the inclusion of the Ainu people, who are legally approved as the only indigenous population in Japan. Three academic societies and the Ainu Association on Hokkaido are preparing ethical guidelines on Ainu research. The Okinawa Bio-Information Bank states that Okinawans are ‘genetically different from mainlanders’, although Okinawans are not legally indigenous. In both jurisdictions, there were few examples or discussions on benefit sharing.

Conclusion: The legal statuses of indigenous populations in Japan and Taiwan are reflected in their positions in genomic research and in the number of ethical considerations. Further discussion of benefit sharing is required.

References:

Grants: This research received no specific grant from any funding agency.

Conflict of Interest: None declared.

P24.015.A Building a better mobile app marketplace: an ethical and legal toolkit for app mediated genomics research

Kyle McKibbin1, Mahsa Shabani1

1The University of Tokyo, Graduate School of Interdisciplinary Information Studies, Tokyo, Japan.

Background/Objectives: Genomics mobile apps are set to become an important data collection tool for biomedical researchers. However, app-mediated research raises questions regarding the responsibilities of researchers, app developers, and platforms in protecting the rights of research participants. Here, we explore the specific roles and responsibilities of the two major mobile platform providers, iOS and Android, in mediating genomics research on their platforms.

Methods: We reviewed current literature and regulatory guidance addressing the status of platform providers under the GDPR and examined two new regulatory proposals, the Digital Services Act and Digital Markets Act. We analysed the impact of each on app-mediated genomics research. We then looked at the contractual obligations that mobile platforms impose on developers in the context of health and genomics research.

Results: Mobile platforms play a significant role in the ethical governance and design of app-mediated research studies, but they have few clear obligations to do so under the GDPR. As a result, research on these platforms can lead to concerns regarding privacy, transparency, conflicts of interest, and diffusion of responsibilities. New regulatory proposals are set to introduce new obligations for mobile platforms and present opportunities for promoting ethical research on platforms.

Conclusion: Taking advantage of proposed obligations for platform providers to enforce their developer policies diligently, address systemic risks, implement notice and removal procedures for illegal content, and separate various platform services, we offer a toolkit for stakeholders interested in building a better app marketplace for genomics research.

References:

Grants: FWO Flanders-Quebec grant.

Conflict of Interest: None declared.

P24.016.B Development of a digital risk prediction tool based on family history for the general population: ethical and legal challenges

Tetske Dijkstra1, Irene van Langen1, Boudien Sieperda2, Jacolene Zaal3, Corrette Ploem4, Imke Christaans5

1University Medical Centre Groningen / University of Groningen, Genetics, Groningen, Netherlands; 2University Medical Centre Groningen, Legal Affairs, Groningen, Netherlands; 3Amsterdam UMC (location AMC) / University of Amsterdam, Ethics, Law and Medical Humanities, Amsterdam, Netherlands.

Background/Objectives: Both inherited and familial cardiovascular diseases pose a risk of early and preventable cardiovascular events relatives. Implementing a risk prediction tool to facilitate individuals from the general population to evaluate their potential cardiovascular risk based on their family history could serve as a responsible solution. However, the development and use of such a risk prediction tool gives rise to legal and ethical challenges.

Methods: At the start of our project experts mapped its legal and ethical framework. Especially EU-regulations provided potential obstacles for development and broader availability/use of the tool. To illustrate, according to the General Data Protection Regulation, collecting health data of relatives of a tool user -from the general population, so outside a health care environment- is only allowed after relatives’ consent or anonymously. This requirement has substantial consequences for the usefulness of the tool and raises the ethical dilemma “who is the owner of family data”. A second example: it follows from the Medical Device Regulation that software that generates a health risk or advice requires a CE-mark...
from a ‘notified body’ at development, and yearly check-ups, which are expensive. In our presentation we will illustrate main bottlenecks and discuss possible solutions.

**Conclusion:** Besides national law, European law heavily impacts on the development of digital tools collecting family data to provide information on health risk. Direct involvement of experts in law and ethics before and during development of a tool is advised to anticipate and tackle legal and ethical challenges.

**References:**
Grants: Dutch Heart Foundation 2019T111.
Conflict of Interest: Tetske Dijkstra: None declared, Irene van Langen: None declared, Boudien Sieperda: None declared, Jacolienne Zaal: None declared, Corrette Ploem: None declared, Imke Christiansa Dutch Heart Foundation (2019T111).

Netherlands Cardiovascular Research Initiative, an initiative with support of the Dutch Heart Foundation (2015-12 eDETECT).

**P24.017.C ePAGs’ (European Patient Advocacy Groups) role in the European Reference Network ITHACA on Intellectual disability, TeleHealth, Autism and Congenital Anomalies: How patients’ voices improve care**

Anne Hugon1, Dorica Dan2,3, Ammi Andersson4, Joel Detton5, Marianne Le Dref6, Jill Clayton-Smith7, Sofia Douzgou HOUGE7, Laurence Faivre8,9, Roaul Hennekam10, Jean-Marie Jouannic11, Tjitske Kleefstra12, David Koolen13, Giovanni Mosiello14, Gabor Pogany15, Alessandra Renieri16,17, Sue Routledge18, Nicholas Szeto19, Marco Tartaglia20, Zeynep Tuner21, Birute Tumiene22, Agnes van Eeghen23, Lisinka Vissers24,25, Klea Vyshka10, Dagmar Wieczorek25, Lenja Wiehe26, Giuseppe Zampino25, Christiane Zweier26, Emrithaca consortium27, Alain Verloes28

1Assistance Publique-Hôpitaux de Paris - Université de Paris, Dept. of Genetics, Paris, France; 2Patient organisation, Prader Willi, Zalau, Romania; 3Eurodis rare disease europe, Paris, France; 4Patient organisation, Pitt Hopkins Syndrome, UK, United Kingdom; 5Patient organisation, Association Noonan, Paris, France; 6Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Avdeling for Medisinsk genetikk, Haukeland universitetssjukehus, Haukeland, Norway; 8UFR Des Sciences de Santé, INSERM-Université de Bourgogne UMR 1231 GAD « Génétique des Anomalies du Développement », FUH-TRANSALD, Dijon, France; 9Dept of Genetics and Centres of Reference for Development disorders and intellectual disabilities, FUH TRANSALD and GIMI Institute, University Hospital, Dijon, France; 10Department of Pediatrics, Academic Medical Centre, Amsterdam UMC, Amsterdam, Netherlands; 11Service de Médecine fœtale, Assistance Publique-Hôpitaux de Paris - Hôpital Armand-Trousseau, Paris, France; 12Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands; 13Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands; 14Department of Surgery, Urology and Neuro-Urology, Bambino Gesù Pediatric Hospital, Rome, Italy; 15Patient organisation, Williams Syndrome, HU, Hungary; 16Genetica Medica, Azienda Ospedaliero-Universitaria Senese, Siena, Italy; 17Med Biotech Hub and Competence Center, Dept of Medical Biotechnologies, University of Siena, Siena, Italy; 18Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy; 19Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet, Denmark; 20Vilnius University Hospital Santaros Klinikos, Santariskiu 2, LT-08661, Vilnius, Lithuania; 21Donders Institute for Brain, Cognition and Behaviour, Radboudumc, Nijmegen, Netherlands; 22Dept of Human Genetics, Radboudumc, Nijmegen, Netherlands; 23Institute of Human Genetics and Anthropology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany; 24Eurodis rare disease europe, Paris, France; 25Department of Woman and Child Health, Center for Rare Diseases and Birth Defects, Institute of Pediatrics, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy; 26University Cancer Center Inselspital UCI – Das Tumorzentrum Bern, Bern, Switzerland; 27Assistance Publique-Hôpitaux de Paris - Université de Paris, ERM ITHACA, Dept. of Genetics, Paris, France; 28INSERM UMR 1141 NeuroDiderot, Hôpital R Debre, Paris, France.

**Background/Objectives:** The importance of patients’ voices is essential. However, this is the challenge for the ERM ITHACA, a patient-centred network, which aims to develop closer cooperation with ePAGs and member patient organisations. Our Patient Council is empowered through formal roles in the governance and participate through deep interaction in each or across Work Groups. All activities of ITHACA include patients, their families, and patients’ organisations as equal partners. ITHACA covers more than 5000 rare and complex genetic disorders and its name is a reference to the diagnostic Odyssey on which families embark with their children affected by rare developmental diseases.

**Methods:** Our approach is based on patient involvement in several projects in collaboration with the EUORDIS network, in particular on the impact of patient engagement on ERNs, to highlight the value of patient-clinician partnership (Rare Dis Orphan Drugs J 2021;1:2).

**Results:** The expected results are, through these tools and reflections to improve the partnership involvement, a common understanding of ePAGs in the daily activities of ERM ITHACA.

**Conclusion:** The UN has formally adopted, on 16 December 2021 with the consensus of all 193 UN Member States, the Resolution on Addressing the Challenges of Persons Living with a Rare Disease and their Families. This recognition of the voices of patients with rare diseases requiring complex care pathways in health care systems is increasingly understood at the EU level and by patient organisations across ERNs.

**References:** Rare Dis Orphan Drugs J 2021;1:2.
Grants: ERM-ITHACA [EU Framework Partnership Agreement ID: 3HP-HP-FPA ERN-01-2016/739516].

**Conflict of Interest:** Anne Hugon APHP Paris Nord Université Robert DEBRE - ERM ITHACA, Dorica Dan: None declared, Ammi Andersson: None declared, Joel Detton: None declared, Marianne Le Dref APHP Paris Nord Université Robert DEBRE, Jill Clayton-Smith: None declared, Sofia Douzgou HOUGE: None declared, Laurence Faivre CHU DIJON, Raoul Hennekam: None declared, Jean-Marie Jouannic APHP Paris, Tjitske Kleefstra: None declared, David Koolen: None declared, Giovanni Mosiello: None declared, Gabor Pogany: None declared, Alessandra Renieri: None declared, Sue Routledge: None declared, Nicholas Szeto APHP Paris Nord Université Robert DEBRE, Marco Tartaglia: None declared, Zeynep Tuner: None declared, Birute Tumiene: None declared, Agnes van Eeghen: None declared, Lisinka Vissers*: None declared, Klea Vyshka: None declared, Dagmar Wieczorek: None declared, Lenja Wiehe: None declared, Giuseppe Zampino: None declared, Christiane Zweier: None declared, Emrithaca consortium: None declared, Alain Verloes APHP Paris Nord Université Robert DEBRE.

**P24.019.A Psychological adjustment, cancer worry and personality traits: a preliminary survey in a group of women undergoing genetic test for cancer susceptibility**

Lucia Lombardi1, Liborio Stuppi2,3, Ivana Antonucci2,3, Carmen Trumello2, Alessandra Babore2

1University “G. d’Annunzio” of Chieti-Pescara, Department of Psychological, Health and Territorial Sciences, Chieti, Italy; 2University of Chieti-Pescara, Department of Psychological, Health and Territorial Sciences, Chieti, Italy; 3University of Chieti-Pescara, Department of Psychological, Health and Territorial Sciences, Chieti, Italy.
Background/Objectives: Individuals who undergo genetic test may have to deal with psychological consequences such as high levels of stress, anxiety, depression (Lombardi et al., 2019) and worries about becoming ill. Personality traits may have an influence on psychological adjustment to risk condition (Mellon et al., 2008). This study aimed to analyze if worries about cancer were associated with psychological adjustment and age. Furthermore, we investigated if personality characteristics could predict cancer worries. Finally, we evaluated differences in cancer worry and psychological adjustment between cancer affected and healthy females.

Methods: A total of 70 females (mean age = 47.19 years; s.d.=10.82; 63%, n = 44, cancer affected; 37%, n = 26, familiarity with mutation), after genetic testing, completed a set of questionnaires about psychological adjustment, personality traits and cancer worry.

Results: We found that cancer worry was positively associated with levels of anxiety (r = 0.548, p = 0.000), depression (r = 0.503, p = 0.000), stress (r = 0.371, p = 0.002), but not with age (r = 0.160, p = 186). Regarding personality traits, vulnerability predicted higher levels of cancer worries (Adjusted R2 = 0.118; F = 10.258; P < 0.001). No differences were found between affected and healthy females.

Conclusion: This preliminary study highlighted the importance of considering anxiety, depressive symptoms and stress during genetic counseling regardless of age and the importance of vulnerability trait in worries about cancer.

References: Lombardi L et al. 2019. Psychological aspects, risk and protective factors related to BRCA genetic testing: a review of the literature. Supportive Care in Cancer. Mellon S et al. 2008. Risk perception and cancer worries in families at increased risk of familial breast/ovarian cancer. Psycho-Oncology.

Grants: No.

Conflict of Interest: None declared.

P24.020.B To do or not to do: Population survey on forensic familial DNA searching in the Low Countries

Sofie Claerhout1,2,3

1KU Leuven, Forensic Genetics, Leuven, Belgium; 2KU Leuven KULAK, Interdisciplinary Research Facility, Kortrijk, Belgium; 3KU Leuven, Centre of Sociological Research, Leuven, Belgium.

Background/Objectives: Forensic familial DNA searching is a powerful tool to provide a last resort opportunity to solve criminal (cold) cases. Although the benefits are strong, strict regulations are required to address the doubts expressed by opponents concerning privacy and ethical issues. Therefore, we aimed to investigate the public opinion.

Methods: Through an online survey distributed through social media, population information of 578 participants living in the Low Countries was analysed. The survey was divided into three parts: (1) personal information to check data reliability (2) general DNA knowledge questions and (3) personal opinions on forensic DNA analysis.

Results: Our population graduated cum laude with an average score of 71%. A significantly higher score was observed for highly educated participants. Surprisingly, 95% of the participants is willing to cooperate in a forensic familial search. Important factors for participation are painless sampling and privacy security. Moreover, we saw that people with a failed DNA score were significantly more afraid to cooperate in forensic DNA analysis. Nevertheless, almost all participants (96%) agreed to use online DNA databases to resolve crimes with violence, but half of them stated that member informed consents should be obtained prior to the search.

Conclusion: To conclude, the ‘fear of the unknown’ combined with strong feelings towards privacy are two major influencing factors to not cooperate in a forensic familial DNA search. Yet, the highly positive attitude towards forensic DNA analysis was a pleasant surprise and point towards people’s high empathy and willingness to help justice.

References: None declared.

P24.021.C Rapid decisions: A qualitative analysis of health professionals’ experiences using ultra-rapid genomic sequencing in critically ill children

Katie Arkell1, Christopher Gyngell1,2,3, Zornitza Stark1,4,5, Danya Vears2,3

1The University of Melbourne, Department of Paediatrics, Parkville, Australia; 2Murdoch Children’s Research Institute, Biomedical Ethics Research Group, Parkville, Australia; 3The University of Melbourne, Melbourne Law School, Parkville, Australia; 4Murdoch Children’s Research Institute, Victorian Clinical Genetics Services, Parkville, Australia; 5Australian Genomics, Parkville, Australia.

Background/Objectives: Although ultra-rapid genomic sequencing (urGS) can provide life-saving results for patients in neonatal and paediatric intensive care units, it can create unique ethical challenges for healthcare professionals (HPs), particularly when the diagnosis raises the possibility of redirection of care towards palliation. Few studies have explored experiences of HPs to understand the impact of urGS on decision-making in this setting.

Methods: We conducted four focus groups and two interviews online with HPs who use urGS in critically ill paediatric patients. We explored the challenges they experience when making decisions about treatment or redirection of care towards palliation following urGS. Data was analysed using inductive content analysis.

Results: Nineteen HPs participated (8 Clinical Geneticists/Paediatric Specialists with Genetic Training; 9 Genetic Counsellors; 2 Intensivists). Participants noted the increasing prioritisation of urGS over other tests to guide patient management. They expressed concern that the timing of urGS may affect parent-child bonding in this setting. Participants described the need for more complex pre-test counselling with families, to prepare for a poor prognosis. HPs found that instances where parents chose to palliate, despite a treatment being available, were particularly distressing.

Conclusion: Our findings suggest that urGS is changing clinical practice and that HPs are gradually adapting their practices to accommodate this shift. These results will assist training of the intensive care workforce to prepare for wider implementation of urGS.

References: None declared.

Conflict of Interest: None declared.
P24.022.D Ethical aspects of population scale reproductive genetic carrier screening: Insights from the Mackenzie's Mission project

Ainsley Newson¹, Lisa Dive¹

¹University of Sydney, Sydney Health Ethics, Sydney, Australia.

Background/Objectives: Genetic carrier screening to inform reproductive decisions has existed for over half a century but is now being scaled up for broader implementation. Australia is trialling a large-scale population offer of reproductive genetic carrier screening (RGCS). ‘Mackenzie’s Mission’ is offering RGCS to up to 8,500 Australian couples. However, the move to large-scale population offers of RGCS generates numerous ethical considerations.

Methods: We analyse the overarching ethical issues in population-scale RGCS, drawing on bioethics literature and critically assessing concepts and arguments. We identify insights for policy-makers and funders to consider when delivering an ethically robust RGCS programs.

Results: A range of ethical issues arise when carrier screening moves from the clinic to the population, including: the selection of genes to screen for (e.g., how to deal with variable expressivity), the relevance of public health rather than clinical ethics approaches, and ensuring RCS programs reflect and support wider community values. An essential consideration is scalability – approaches in clinical or targeted screening are not always suitable for populations. It is also vital to maintain a constant dialogue between program-level design and how its implementation is experienced by participants.

Conclusion: Ethical population offers of RGCS require a broad public health pluralistic approach. This provides the best balance of individual and societal considerations.

References:

Grants: Mackenzie’s Mission is funded by the Australian Medical Research Future Fund, grant GHFM73390.

Conflict of Interest: Ainsley Newson Professor, University of Sydney, Prof. Newson is a current recipient of grant funds from government funders in Australia: the Australian Research Council, the National Health and Medical Research Council and the Medical Research Futures Fund., Prof. Newson received a small honoraria for a talk at a bioethics department in Hong Kong in 2021., Prof. Newson sits on a range of committees. All are government or professional societies; none are commercial., Lisa Dive Research Fellow, University of Sydney (grant-funded).

P24.024.B Dynamic informed consent system, citizen science data management, quality control and integration for Latvian Genome Database

Normunds Kante¹, Anastasija Nikiforova¹,², Katrina Kaleja¹, Alise Svandere¹, Signe Mežinska¹, Raitis Pečulis¹, Vita Rovite¹

¹Latvian Biomedical Research and Study Centre, Riga, Latvia; ²University of Latvia, Faculty of Computing, Riga, Latvia

Background/Objectives: Dynamic informed consent is used to ensure that an individual participating in biobank can modify his decision about the research that is conducted with his sample and data and actively follow research results that could be of importance to him or his immediate relatives.

Our aim is to develop a dynamic consenting and survey system prototype to integrate academic research conducted in Latvian Genome Database with citizen science initiatives maintaining data credibility via hierarchical metadata harmonization and assessing ELSA aspects.

Methods: Working groups of experts in fields of ethics, data science, biobanking and interested stakeholders from patients’ organizations and the pharma industry are involved in the following tasks: (1) create “information-wise” data management algorithms for dynamic informed consent and survey system; (2) develop ELSA guidelines for implementation of “ethics by design” in the ICT system; (3) create an IT system prototype for biobank activities and citizen science initiative integration.

Results: The prototype IT design have been created that consist of registration, consent, survey, result reporting and quality control models employing different access levels of several user types – biobank donors, citizen science enthusiasts, doctors/nurses and researchers. The “ethics by design” guidelines have been generated to ensure the best ELSA compliance of ICT system prototype.

Conclusion: Integrative approach is to develop a user-centred ICT system for biobank and citizen science data integration that will enhance data utilization in various health-related areas and serve as basis for communication with participants of Latvian Genome Database.

References:

Grants: Research was supported by the European Regional Development (Project no. 1.1.1.1/20/A/047).

Conflict of Interest: None declared.

P24.025.C Exploring Ethical Futures of NIPT: Stakeholder Perspectives from Belgium

Zoë Claesen¹, Lidewij Henneman², Joris Vermeesch¹, Pascal Barry¹

¹KU Leuven, Leuven, Belgium; ²Amsterdam UMC, VUmc, Amsterdam, Netherlands.

Background/Objectives: Non-invasive prenatal testing (NIPT) is currently primarily aimed at trisomy 21, 18, and 13. Expanded NIPT could significantly increase the number of conditions and non-medical traits the fetus can be tested for. This expansion reinforces ethical concerns about what can be considered the justifiable scope of prenatal screening. In Belgium, NIPT is available to all prospective parents, genome-wide NIPT is standard, fetal sex is reported, and women only co-pay €86.88. In a context where NIPT is reimbursed by public health care, the question about the scope is especially pertinent. The general aim of this research project is to identify and review: (1) the arguments and ethical principles used to determine the scope of NIPT; and (2) the ethical challenges connected to the widening scope of NIPT.

Methods: We will address the research objectives by performing a literature review and qualitative semi-structured interview studies in Belgium with several stakeholder groups such as healthcare professionals and (expectant) parents.

Results: Expanded NIPT is a clear example of the way technological developments challenge existing norms. There is likely great diversity among and across stakeholder groups about the desirable scope of NIPT. Implementing expanded NIPT needs to be carefully deliberated and multiple stakeholder views need to be considered.

Conclusion: The current climate of rapid technological developments in prenatal screening challenge the existing framework regarding the scope of NIPT as well as the current models of consent and prompt the need to rethink them.

References:  -.

Grants:  -.

Conflict of Interest: None declared.
P24.026.D Exploring policy approaches to cases of nondisclosure of genetic risk

Amicia Phillips1, Pascal Borry1, Ine Van Hoyweghen2, Danya Vears1

1KU Leuven, Public Health and Primary Care, Leuven, Belgium; 2KU Leuven, Leuven, Belgium.

Background/Objectives: Genetic risk information is relevant not just to patients but also their relatives. Disclosing genetic risk information to relatives can play an essential role in initiating genetic testing to determine their risk, thus enabling them to seek treatment and access reproductive screening technologies. When a patient does not inform their relatives, the interests and rights of patients and family members can come into conflict. While this ethical issue cannot easily be resolved, several countries have guidelines or legislation addressing nondisclosure. There are three main policy approaches to the disclosure: it is the obligation of the patients or clinicians, or it is within the clinician’s purview to decide. More commonly, countries have no specific guideline or law, meaning it is unclear what duties patients and clinicians have towards relatives.

Methods: Using Belgium as an example, we analyzed existing national and European legislation and compared it with international precedent. We then explored ethical arguments for and against various policy approaches. This ethical analysis is supported by data from our empirical research in which Belgian clinicians were asked their opinions regarding potential national policies.

Results: There is strong ethical, legal, and empirical support for a policy that obliges patients to inform their at-risk relatives, however, there are concerns regarding the legal enforcement of such a policy.

Conclusion: Clear policy is required to address the issue of nondisclosure, and further research is required to determine which policy approach is best in a given context.

References:
None declared.

Conflict of Interest: None declared.

P25 GWAS

P25.001.A A polygenic risk score to predict sudden cardiac arrest in patients with cardiovascular disease

Eleonora Porcu1, Christian Thorball1, Alessandra Pia Porretta2, Etienne Pruvo2,3, Kim Wiskott4, Federica Gilardi5, Aurelien Thomas6, Claire Redin1, Zoltan Kutalik5,6,7, Tony Fracasso4, Olivier Muller2, Jacques Fellay1,5,8

1KU Leuven, Public Health and Primary Care, Leuven, Belgium; 2KU Leuven, Leuven, Belgium; 3Swiss Institute of Bioinformatics, Lausanne, Switzerland; 4University of Ulm, Ulm, Germany; 5Department of Computational Biology, University of Lausanne, Lausanne, Switzerland; 6School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.

Background/Objectives: Cardiovascular disease (CVD) is a leading health problem representing the main cause of death globally. Even when causative factors are known, we often do not understand why a cardiovascular condition causes premature death in a victim while others can live longer with the same condition.

Methods: Here we propose a combined polygenic risk score (metaPRS) based on myocardial infarction (MI), coronary artery disease (CAD) and low-density lipoprotein (LDL) to predict the risk of sudden cardiac arrest (SCA) in patients affected by severe cardiovascular conditions. For this, we collected 2,114 patients with reported history of myocardial infarction from the Centre hospitalier universitaire vaudois (CHUV) Genomic Biobank (BGC) and extracted data from the UK Biobank (UKB) on 13,696 participants with similar medical history. Among those, 303 and 932 are affected by SCA or ventricular tachycardia/fibrillation, respectively.

Results: We found that metaPRS is significantly associated with SCA in both cohorts (OR_BGC = 1.18, P_BGC = 0.006 and OR_UKB = 1.14, P_UKB = 1.1 x 10−04). Furthermore, using the diagnosis based on the International Classification of Diseases (ICD-10) codes available in the UKB, we found that our metaPRS exhibits a strong association with the presence of aortocoronary bypass graft (OR_UKB = 1.20, P_UKB = 1.04 x 10−16) and coronary angioplasty implant (OR_UKB = 1.11, P_UKB = 1.05 x 10−08).

Conclusion: These results show that genetic risk score for CVD and associated risk factors has the potential to predict the occurrence of SCA in patients with CVD, hence to identify patients who could benefit from further preventive measures.

References:
None declared.

P25.002.B Genome-wide association studies of childhood steroid-sensitive nephrotic syndrome in Japanese and South Korean populations

Katsushi Tokunaga1, Xiaoyuan Jia1, Yosuke Kawai1, Tomoko Horinouchi1, Kandai Nozue1, Seulgi Jung1, Kyuysong Song1, Hae Il Cheong1, Kazumoto Iijima1,5

1National Center for Global Health and Medicine, Genome Medical Science Project, Tokyo, Japan; 2Kobe University Graduate School of Medicine, Pediatrics, Kobe, Japan; 3University of Ulm College of Medicine, Biochemistry and Molecular Biology, Seoul, Korea, Rep. of South; 4Seoul National University Children’s Hospital, Pediatrics, Seoul, Korea, Rep. of South.

Background/Objectives: Idiopathic nephrotic syndrome is the most common glomerular disease in children. To understand the genetics of steroid-sensitive nephrotic syndrome, we conducted genome-wide association studies (GWASs) in Japanese and Korean populations.

Methods: In total, 1,018 children with SSNS and 3,331 healthy adults with Japanese ancestry, 249 children with SSNS and 4,041 adult controls with Korean ancestry were recruited. Japanese samples were genotyped using Affymetrix Japonica Array. Whole-genome imputation was performed using phase 2 reference panel of 2,036 healthy Japanese individuals. Korean patients and healthy controls were genotyped using Axiom Genome-Wide AS1 array and HumanOmni1-Quad BeadChip, separately. Whole-genome imputation was performed using 1000 Genome project phase 3 as reference panel.

Results: After quality control steps, Japanese GWAS was performed in 987 childhood SSNS patients and 3,206 controls (6,834,340 variants). HLA-DR/DQ (rs6901541, P = 2.80E−33, odds ratio [OR] = 2.49), NPHS1-KIRREL2 (rs56117924, P = 4.94E−20, OR = 1.90) and TNFSF15 (rs6478109, P = 4.65E−08, OR = 1.83) achieved genome-wide significance. Korean GWAS was conducted in 243 SSNS patients and 4,041 controls after QC processes (2,912,342 variants). HLA-DR/DQ region (rs9272518, P = 1.04E−14, OR = 2.63) and NPHS1-KIRREL2 (rs412175, P = 4.65E−08, OR = 1.83) achieved genome-wide significance. Meta-analysis was conducted under fixed effects by “METAL”. Four loci showed significant associations with SSNS in both populations.
Abstracts from the 55th European Society of Human Genetics Conference

Paynton1, Stephan Ossowski2, Ian Sayers3, Louise Wain1,4, Edward Hollox5

TNFSF15 are associated with childhood steroid-sensitive nephrotic syndrome. Katherine Fawcett

Centre, School of Medicine, Biodiscovery Institute, University of Nebraska Medical Sciences, NIHR Respiratory Biomedical Research Centre, United Kingdom. 2Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany; 3Translational Medical Sciences, NIHR Respiratory Biomedical Research Centre, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, United Kingdom; 4National Institute for Health Research, Leicester Respiratory Biomedical Research Centre, Glenfield Hospital, Leicester, United Kingdom; 5Department of Genetics and Genome Biology, University of Leicester, Leicester, United Kingdom.

Background/Objectives: The role of copy number variants (CNVs) in asthma susceptibility is not well understood. This study aimed to analyse exome-wide CNVs for association with asthma in UK Biobank.

Methods: We called common CNVs from UK Biobank whole-exome sequencing and tested them for association with asthma in a stage 1 cohort of 7,098 cases and 36,578 controls. Nominally-associated CNVs were meta-analysed in the stage 1 cohort and an additional 17,280 cases and 115,562 controls. Results: Five of 189 high-quality CNVs were associated with asthma at a Bonferroni-corrected P-value threshold, including a deletion overlapping the HLA-DQA1 and HLA-DQB1 genes, a duplication of CHROM1/PKRA, deletions within MUC22 and TAP2, and a duplication in FBRSI1. In silico analyses indicated that the deletion overlapping HLA-DQA1 and HLA-DQB1 is an artefact arising from under-mapping of reads from non-reference HLA haplotypes, and that the CHROM1/PKRA and FBRSI1 duplications represent presence/absence of pseudogenes within the human leukocyte antigen (HLA) region. Bayesian fine-mapping of the HLA region suggested that there are two independent asthma association signals, and that single-nucleotide missense changes in the HLA-DQA1, HLA-DQB1 and/or HLA-DRB1 genes are likely to account for these. No CNVs were present in the credible sets.

Conclusion: These results suggest that CNVs in the HLA region are associated with asthma, but that the association is driven by amino acid changes. Identification of artefactual CNVs in the HLA region provides a cautionary tale for future analyses of sequencing data.

References:

Grants: This work was supported by KF’s Asthma UK Fellowship (AUK-CDA-2019-414).

Conflict of Interest: Katherine Fawcett University of Leicester, Asthma UK fellowship (AUK-CDA-2019-414), German Demidov: None declared, Nick Shrine: None declared, Megan Paynton: None declared, Stephan Ossowski: None declared, Ian Sayers: None declared, Louise Wain GSK/British Lung Foundation Chair in Respiratory Research (C17-1) and funding from GSK and Orion Pharma, Galapagos, Edward Hollox: None declared.

P25.004.B Germline variants associated with immunotherapy-related adverse events

Stefan Groha1, Sarah Abou Alaiwi1, Wenxin Xu1, Vivek Naranbhai2, Amin Nassar1, Ziad Bakouny1, Elio Adib1, Pier Nuzzo3, Andrew Schmidt1, Chris Labaki1, Talal El Zarif1, Biagio Ricciuti1, Joao Victor Alessi4, David Braun1, Sachet Shukla1, Tanya Keenan1, Eliezer Van Allen1, Mark Award1, Michael Manos2, Osama Rahma1, Leyre Zubiri1, Alexandre-Chloe Villani2, Christian Hammer3, Zia Khan4, Kerry Reynolds3, Yeveryn Semenov3, Deborah Schrag1, Kenneth Kehl1, Matthew Freedman1, Toni Choueim1, Alexander Gusev1

1Dana Farber Cancer Institute, Boston, United States; 2Massachusetts General Hospital, Boston, United States; 3Genentech, South San Francisco, United States.

Background/Objectives: Immune checkpoint inhibitors (ICIs) have yielded remarkable responses in patients across multiple cancer types, but often lead to immune related adverse events (irAEs). Although a germline cause for irAEs has been hypothesized, no individual variants have been identified, which is the focus of our study.

Methods: We carried out a Genome-Wide Association Study (GWAS) of 1,751 patients on ICIs across 12 cancer types, with replication in an independent cohort of 196 patients and independent clinical trial data from 2275 patients. We investigated two irAE phenotypes: (i) high-grade (3-5) events defined through manual curation and (ii) all detectable events defined through electronic health record (EHR) diagnosis followed by manual confirmation.

Results: We identified three genome-wide significant associations (p < 5 x 10-8) in the discovery cohort associated with all-grade irAEs: rs16906115 near IL7 (combined p = 1.6x10-11; hazard ratio (HR) = 2.1), rs75824728 near IL22RA1 (combined p = 6.6 x 10-9; HR = 1.9), and rs113861051 on 4p15 (combined p = 1.3 x 10-8, HR = 2.0); with rs16906115 replicating in two independent studies. The association near IL7 colocalized with the gain of a novel cryptic exon for IL7, a critical regulator of lymphocyte homeostasis. Patients carrying the IL7 germline variant exhibited significantly increased lymphocyte stability after ICI initiation than non-carriers, and this stability was predictive of downstream irAEs and improved survival.

Conclusion: We carried out a GWAS of irAEs and identified a genome wide association replicating in two independent cohorts. We hypothesize a functional relationship with irAEs through a change in IL7, which is predictive of patient outcome.

References:

Grants: NIH R01CA244569. NIH R21HG010748.

Conflict of Interest: Stefan Groha: None declared, Sarah Abou Alaiwi: None declared, Wenxin Xu: None declared, Vivek Naranbhai: None declared, Amin Nassar: None declared, Ziad Bakouny: None declared, Elio Adib: None declared, Pier Nuzzo: None declared, Andrew Schmidt: None declared, Chris Labaki: None declared, Talal El Zarif: None declared, Biagio Ricciuti: None declared, Joao Victor Alessi: None declared, David Braun LM Education/Exchange Services, Bristol Myers Squibb, MDedge, Exelixis, Octane Global, Defined Health, Dedham Group, Adcet Field Solutions, Slingshot Insights, Blueprint Partnerships, Charles River Associates, Trinity Group, and Insight Strategy, Sachet Shukla Agenus Inc., Agios Pharmaceuticals, Breakbio Corp., Bristol-Myers Squibb and Lumos Pharma, Bristol-Myers Squibb, Tanya Keenan: None declared, Eliezer Van Allen: None declared, Mark Award

SPRINGER NATURE

European Journal of Human Genetics (2023) 31:345 – 709
Genentech, Bristol-Myers Squibb, Merck, AstraZeneca, Lilly, personal fees from Genentech, Bristol-Myers Squibb, Merck, AstraZeneca, Maverick, Blueprint Medicine, Syndax, Ariad, Nektar, Gritstone, ArcherDX, Mirati, NextCure, Novartis, EMD Serono, Panvaxial/Novavax outside the submitted work: Michael Manos: None declared, Osama Rahma Merck, BMS, Merck, Merck, Celgene, Five Prime, GSK, Bayer, Roche/Genentech, Puretech, Imvax, Sobi, Boehringinger Ingelheim, Patent “Methods of using pembrolizumab and trebananib“ pending, Leyre Zubiri: None declared, Alexandria-Chloe Villani: None declared, Christian Hammer: None declared, Zia Khan imCORE Network on behalf of Genentech, Inc. and Bristol-Myers Squibb, UpToDate, Kerry Reynolds: None declared, Yevgeniy Semenov: None declared, Deborah Schrag: None declared, Kenneth Kehl IBM and Roche, Matthew Freedman: None declared, Toni Choueiri Dana-Farber/Harvard Cancer Center Kidney SPORE and Program, the Kohlberg Chair at Harvard Medical School and the Trust Family, Michael Brigham, and Loker Pinard Funds for Kidney Cancer Research at DFCI, Pionyr, Tempeast, AstraZeneca, Aveo, Bayer, Bristol Myers-Squibb, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVIA, Ipsen, Kanaph, Lilly, Merck, Nikang, Novartis, Pfizer, Roche, Sanofi/Aventis, Takeda, Tempest, Up-to-Date royalties, CME-related events (e.g.: OncLive, PVI, MJH Life Sciences) honorarium, Alexander Gusev: None declared.

P25.006.B Shared genetic aetiology of osteoarthritis and type 2 diabetes

Ana Arruda1,2,3, April Hartley4, Konstantinos Hatzikotoulas5, William Rayner6, Andrea Barysenka7, Georgia Katsoula1,2,3, George Davey Smith4, Andrew Morris3,5, Eleftheria Zeggini1,2,3

1TUM school of medicine, Technical University Munich and Klinikum Rechts der Isar, Munich, Germany; 2Munich School for Data Science, Helmholtz Association Munich, Neuherberg, Germany; 3Institute of Translational Genomics, Helmholtz Association Munich, Neuherberg, Germany; 4MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom; 5Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom.

Background/Objectives: Osteoarthritis (OA) and type 2 diabetes (T2D) are two of the most prevalent chronic health disorders worldwide. Observational studies report a positive epidemiological association between the diseases beyond their common risk factors, such as obesity and increasing age. Taking into consideration that the world’s obesity rates, and average age are rising, this comorbidity pair can be considered an increasing global health challenge. Thus, in this research project, we aim to disentangle the genetic correlation between OA and T2D.

Methods: Using summary statistics of large-scale GWAS from T2D (n = 898,130) and knee or hip related OA phenotypes (n = 490,345), we investigate the genetic intersection between the traits by performing statistical colocalization analysis of established association signals. For colocalizing regions, we derive a set of high confidence likely effector genes based on biological lines of evidence, including colocalization with molecular QTLs from disease-relevant tissues. Additionally, for each of those genes, we perform Mendelian randomization analyses between expression QTLs and each disease.

Results: 18 genome regions show robust evidence of colocalization between T2D and at least one OA phenotype. 27 genes were defined as high confidence likely effector genes, including TCF7L2 and the obesity-related FTO gene. TCF7L2 is among the leading signals for T2D risk but had not been identified as associated with OA at genome-wide significance levels yet. Genetic variants associated with expression levels of TCF7L2 in pancreatic islets are causal for T2D and protective for knee-related OA phenotypes.

Conclusion: Our shared common effector genes support the epidemiologically known link between BMI and the investigated comorbidity.

References:

Grants:

P25.008.D Genome wide association study of long-term toxicity 2 years following radiotherapy for breast cancer–results from the REQUITE cohort study

Harkeran Jandu1, Colin D Veal1, David Azria2, Jenny Chang-Claude3, Ananya Choudhury4, Alison M Dunning5, Dirk R. de Ruyscher6, Laura Fachal7, Sara Gutiérrez-Enríquez8, Philippe Lamber9, Tiziana Rancati10, Barry S Rosenstein11, Maria C de Santis9, Petra Sebold9, Elena Sperek11, R Paul Symonds1, Ana Vega12, Liv Veldeman13, Adam Webb1, Catharine West14, Christopher J Talbot1, Tim Ratty1

1University of Leicester, Leicester, United Kingdom; 2ICM Institut du Cancer Montpellier, Montpellier, France; 3German Cancer Research Center, Heidelberg, Germany; 4University of Manchester, Manchester, United Kingdom; 5University of Cambridge, Cambridge, United Kingdom; 6University Hospitals Leuven, Leuven, Belgium; 7Vall d’Hebron Institute of Oncology, Barcelona, Spain; 8MAASTRO Clinic, Maastricht, Netherlands; 9Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 10Mount Sinai School of Medicine, New York, United States; 11Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; 12Fundacion Publica Galega Medicina Xenomica, Santiago de Compostela, Spain; 13Universiteit Ghent, Ghent, Belgium.

Background/Objectives: Up to a quarter of breast cancer patients treated by surgery and radiotherapy experience clinically significant toxicity. This study was designed to identify common single nucleotide polymorphisms (SNPs) associated with toxicity 2 years following whole breast radiotherapy.

Methods: A genome-wide association study (GWAS) was performed in 1,635 breast cancer patients with complete SNP, clinical, treatment and toxicity data, recruited across 27 centres in Europe and the US into the prospective REQUITE study (www.requite.eu). All patients were genotyped using Illumina OncoArrays with ~600,000 SNPs. Datasets were imputed according to OncoArray Network methods. A total of 7,097,340 SNPs with minor allele frequency >0.05 and imputation score >0.3 were tested for association with the residuals of toxicity endpoints at 2 years.

Results: Quantile-quantile plots for association with toxicity showed more associations above the p < 5 x 10^{-4} level than expected by chance. Five SNPs reached genome-wide significance. Nipple retraction (10.0%≥G1) was associated with the rs188287402 intron variant on the X chromosome (p = 2.80 x 10^{-8}); breast oedema (11.1%≥G1) with the Chr5 rs12657177 (p = 1.12 x 10^{-10}) and the Chr13 rs61966613 variants (p = 1.06 x 10^{-10}); induration (6.5%≥G2) with Chr1 rs77311050 (p = 2.54 x 10^{-8}) and Chr arm lymphoedema (3.4%≥G1) with the Chr1 rs643644 variant (p = 3.54 x 10^{-8}). Heritability estimates across different endpoints ranged from 13% to 39%. Several previously significant SNP associations with late breast toxicity were validated at the nominal 0.05 significance level.

Conclusion: This largest GWAS to date for long-term breast radiation toxicity provides evidence for genome-wide significant association of common SNPs with distinct toxicity endpoints.

References:

Grants:
Conflict of Interest: Harkeran Jandu: None declared, Colin D Veal: None declared, David Azria: None declared, Jenny Chang-Claude: None declared, Ananya Choudhury: None declared, Alison M Dunning: None declared, Dirk R. de Ruyschcer: None declared, Laura Fachal: None declared, Sara Gutierrez-Enriquez: None declared, Philippe Lambin: None declared, Tiziana Rancati: None declared, Barry S Rosenstein: None declared, Maria C de Santos: None declared, Petra Seibold: None declared, Elena Sperk Dr Elena Sperk: none related to the current manuscript. Outside the current manuscript: General speakers bureau Zeiss Meditec, travel support Zeiss Meditec., R Paul Symonds: None declared, Ana Vega: None declared, Liv Veldeman: None declared, Adam Webb: None declared, Catharine West: None declared, Christopher J Talbot: None declared, Tim Rattay: None declared.

P25.009.A Gene-based burden scores to improve polygenic models for blood and urine biomarkers

Rana Aldisi1, Emadeldin Hassanin7, Hannah Klinkhammer2, Andreas Mayr2, Holger Fröhlich8, Sugirthan Sivalingam4, Andreas Buness3, Peter Krawitz2, Carlo Moj8

1University Hospital of Bonn, IGSB, Bonn, Germany; 2University Hospital of Bonn, Institut für Medizinische Biometrie, Informatik und Epidemiologie (IMBIE), Bonn, Germany; 3University of Bonn, Bonn-Aachen International Center for Information Technology (B-IT), Bonn, Germany; 4Fraunhofer Institute for Algorithms and Scientific Computing, Sankt Augustin, Germany; 5University Hospital of Bonn, Core Unit for Bioinformatics Data Analysis (CUBA), Bonn, Germany; 6University of Marburg, Centre for Human Genetics, Marburg, Germany.

Background/Objectives: Integration of common and rare functional variants for a more comprehensive genetic risk modelling in complex phenotypes.

Methods: We analyzed the genetic component of 32 blood and urine biomarkers in 200,000 samples with exomes and genotyping data from UKBiobank. We computed: 1. polygenic risk score (PRS) based on the effect of common variants as previously obtained using multivariante snpnet multivariate framework; 2. gene-based risk scores (GBRS) for each biomarker obtained by weighting each gene-based burden score in a training dataset according to the association signal obtained in a test dataset. The GBRS and PRS were then used to generate prediction models, both individually and in combination.

Results: PRS are generally more associated with the phenotype than GBRS corroborating a predominant role for common variants in the genetic liability for complex traits as metabolic biomarkers levels. However, GBRS are also strongly associated with blood and urine biomarkers suggesting that the burden of rare deleterious variants in coding regions can also substantially influence the biomarkers levels and interestingly the combination of PRS and GBRS improved the prediction performance as measured by the R2 for 25 out of 32 biomarkers.

Conclusion: Our findings suggest the analysis of exome data and the computation of gene-based risk scores assessing the burden of rare deleterious variants can improve the current PRS model predictions.

Conflict of Interest: None declared.

P25.010.A Novel loci and Loss-of-Function genes associated with prediabetes provide insights into biological mechanisms leading to diabetes

Jessica Van Setten1, Chris Finan1,2,3, Katarzyna Dziopa4, Abdurrahman Alasiri1,5, Marion van Vuigt1, Folkert Asselbergs1,2,4, Amand Schmidt1,2,3

1University Medical Center Utrecht, Utrecht University, Cardiology, Utrecht, Netherlands; 2University College London, Institute of Cardiovascular Science, London, United Kingdom; 3UCL BHF Research Accelerator Centre, London, United Kingdom; 4University College London, Institute of Health Informatics, London, United Kingdom; 5King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Medical Genomics Research Department, Riyadh, Saudi Arabia.

Background/Objectives: Prediabetes is a precursor of type 2 diabetes (T2D), and while still reversible, up to 70% of patients eventually develop diabetes. People with prediabetes have elevated glycated haemoglobin (HbA1C) and plasma glucose concentrations, and are often overweight and hypertensive. In this study we explored genetic and biological mechanisms responsible for prediabetes.

Methods: We included up to 7,748 prediabetics, 23,626 diabetics, and 286,132 controls from UK Biobank. Prediabetes and diabetes patients were identified using Hba1C values and a previously published algorithm. We tested prediabetes (vs diabetes and vs healthy controls) in a GWAS setting including >38 million variants, and examined ~8600 Loss-of-Function genes using the Loss-of-Function toolkit (LoFTK).

Results: The GWAS analyses using healthy controls identified thirty prediabetes loci. Of these, 26 had been previously associated with diabetes. Out of the 4 loci specific to prediabetes we found support from previous GWAS on Hba1C for three, and one novel locus near GLI3. We identified eleven loci associated with prediabetes vs diabetes, including ten known diabetes loci and a novel locus in LPCAT1. Loss-of-Function analyses highlighted SHPK, a novel gene associated with both prediabetes vs controls and vs diabetes.

Conclusion: We identified novel genes associated with prediabetes, which may lead to new insights into the biological mechanisms involved in prediabetes and diabetes.

References:

Grants:

Conflict of Interest: None declared.

P25.011.C Dissecting the genetic bases of Color Vision Defects (CVDs) through Genome-Wide Association Study (GWAS) in Silk Road populations

Giuseppe Giovanni Nardone1, Maria Pina Concas1, Domenico Laperlidio2, Anna Morgan3, Maurizio Battaglia Parodi4, Paolo Gasparini1,4, Giorgia Girotto1,4

1Institute for Maternal and Child Health – IRCCS, Burlo Garofolo, Trieste, Italy; 2University of Trieste, Department of Life Sciences, Trieste, Italy; 3Vita-Salute San Raffaele University, Ophthalmology Department, Milano, Italy; 4University of Trieste, Department of Medicine, Surgery and Health Sciences, Trieste, Italy.

Background/Objectives: Color perception relies on the brain’s response to the stimuli produced by light-activated cone photoreceptors. To date, apart from three major genes (OPN1L, OPN1MW,OPN1SW) involved in Mendelian CVDs, nothing is known for multifactorial CVDs forms.

Methods: 520 individuals from Silk Road populations were genotyped and phenotypically characterized for CVDs using the Famsworth D-15 color test and results interpretation was performed by a certified ophthalmologist. CVDs analysed traits were the following: Deutan-Protn (DP) and Tritan. GWAS for both traits was performed; results were filtered for MAF≥5%. Gene expression of final candidates was defined using a published human eye dataset.
Results: GWAS analysis revealed several interesting hits within genes involved in eye physiology and pathologies that show high expression levels in several eye tissues. As regards DP, LRRC8D gene resulted significantly associated (p-value = 3.41x10-8) whose protein is expressed in Müller cells of the retina. Concerning Tritan, three genes (MYL3, p-value = 1.77x10-8; PDE3A, p-value = 6.64x10-9; MCSR, p-value = 6.17x10-10) were associated. MYL3 is a gene modulated by MERTK, whose mutations have been associated with retinitis pigmentosa; PDE3A encodes phosphodiesterase 3A, a protein involved with hypertension and MCSR encodes melanocortin receptor type 5, a receptor involved in ocular immune regulation. Interestingly, drugs targeting phosphodiesterases and melanocortin receptors are known to cause temporary alterations in color vision.

Conclusion: We described, for the first time worldwide, a GWAS on multifactorial CVDs identifying four genes potentially playing a crucial role in CVDs pathogenesis. Next step will include external replication in independent populations and functional in vitro/in vivo studies to define the mechanisms underlying these clinical traits.

References:

None declared.

P25.012.D Genome Wide Association Studies of severe mental disorders reveal shared and disorder specific risk loci

Vivek Appadurai1, Morten Krebs1-2, Jesper Gådin1, Kajsa-Lotta Georgii Hellberg1, John Shorter1, Joeri Meijsen1, iPSYCH Consortium1,2,3,4,5, Thomas Werge1-2, Andrew Schork1,6

1Research Institute of Biological Psychiatry, Roskilde, Denmark; 2Copenhagen University, København, Denmark; 3Aarhus University, Aarhus, Denmark; 4Gentofte Hospital, Hellerup, Denmark; 5Statens Serum Institut, København, Denmark; 6Translational Genomics Research Institute, Flagstaff, United States.

Background/Objectives: Mental disorders (MD) are pleiotropic, sharing genetic origin1-3, likely expressed in early brain development. Descriptions of this genetic overlap are not consistent across studies. Several genetic loci associated with MDs have been identified through genome wide association studies (GWAS)4-6, but loci delineating individual disorders from shared liability are not well described. We aim to understand the genetics underlying the similarity as well as the differences among MDs.

Methods: We use the iPSYCH2012 and 2015i cohorts, independent samples from the population of Denmark born between 1980 and 2007 with follow up until 2015. Cases are ascertained for diagnosis of at least one of six severe MDs. Genetic correlations (rg) and heritabilities are calculated using phenotype correlation genotype correlation. GWAS are performed using mixed linear models (MLM) and genomeric structural equation modeling (GSEM). MLMs estimated within iPSYCH are consistently higher than external estimates. GWAS identify novel loci associated with the shared and individual risk of MDs. GSEM reveals structure of rg between MDs, replicates findings from MLMs, and estimates heterogeneity in associations between the shared and disorder specific risk.

Conclusion: Higher rg between iPSYCH cohorts for MDs suggest diagnoses obtained from national registers are meaningfully different from those in meta-analyses pooling data from diverse, non-uniformly ascertainment studies. Biological follow up of loci delineating disorder specific and shared risk factors can reveal genetic causes for differences among MDs.

References: 1. Schork 2019. 2. Gandal 2018. 3. Brainstorm 2018.

4. Demontis 2019. 5. Grove 2019. 6. Howard 2019.

Grants: iPSYCH. Lundbeck foundation fellowship R335-2019-2318.

Conflict of Interest: None declared.

P25.013A A Genome-wide meta-analysis identifies novel loci for positive thyroid Peroxidase and thyroglobulin antibodies

tatijana zemunik1, nikolina pleič1, mirjana babić leko1, ivana Gunjača1, vesela torlak1, ante punda2, ozren polašek3, thibaud boutin5, caroline hayward4

1University of Split, School of Medicine, Department of Medical Biology, Split, Croatia; 2University Hospital Split, Department of Nuclear Medicine, Split, Croatia; 3University of Split, School of Medicine, Department of Public Health, Split, Croatia; 4University of Edinburgh, Institute of Genetics and Cancer, MRC Human Genetics Unit, Edinburgh, United Kingdom.

Background/Objectives: The presence of antibodies to thyroid peroxidase (TPOAb) and thyroglobulin (TgAb) is an early indicator of autoimmune thyroid disease (AITD). However, thyroid antibodies are not only frequently detected in patients with AITD but also in patients without diagnosed thyroid dysfunction. This study aimed to replicate the significant findings from our discovery genome-wide association study (GWAS) and to increase statistical power to detect novel genetic variants associated with plasma antibody positivity by including over 1,500 new individuals.

Methods: Participants with elevated plasma TPOAb and/or TgAb were defined as cases (N = 341) and those with TPOAb and TgAb within reference values were defined as controls (N = 1253). We performed individual-level genome-wide association mapping using a linear mixed model (LMM) of 7,609,054 variants, imputed using the Haplotype Reference Consortium (HRC) panel, in 1,594 European-ancestry participants of the Croatian Biobank. In the meta-analysis, we combined these data with our discovery GWAS from three independent cohorts consisting of 2,613 individuals. In these 4,207 individuals, analysis was performed using the random-effects method.

Results: Meta-analysis identified ERBIN gene intron variant rs34540954 (p = 5.3 x 10-8) as the top association signal, including another 122 variants passing the suggestive genome-wide significance threshold of 5 x 10-6.

Conclusion: This study adds to the knowledge of genetic background of thyroid antibodies and will lead to better understanding of biological pathways and clinically relevant disorders related to their function.

References: None declared.

P25.014.B Rare variant associations and novel loci for eosinophil count - a UK Biobank whole-exome sequencing study

Julia Höglund1, Fatemeh Hadizadeh1, Weronica Ek1, Torgny Karlsson1, Åsa Johansson1

1Uppsala University, Immunology, Genetics and Pathology, Uppsala, Sweden.

Background/Objectives: Eosinophils play important roles in the release of cytokine mediators in response to inflammation. Many
associations between common genetic variants and eosinophils have already been reported, using SNP array data. However, there is a need to further investigate the role of rare variants altering eosinophil count as this might have considerable implications in the pathogenesis of inflammatory diseases.

Methods: Here, we have utilized 200 000 whole exome sequences (WES) from the UK Biobank cohort to perform gene-based analyses of eosinophil count. We defined five different variant weighting schemes to incorporate information on both deleteriousness and frequency.

Results: A total of 220 genes in 55 loci, were found to be associated with eosinophil count, of which seven genes (ALOX15, CSF2RB, IL17RA, IL33, JAK2, S1PR4, and SH2B3) are driven by rare variants, independent of common variants identified in genome-wide association studies. Two additional genes, NPAT and RMI1, have never been associated with eosinophil count before and are considered novel eosinophil loci.

Conclusion: The genes driven by rare variants can be of importance for further studies identifying therapeutic targets or biomarkers for eosinophil related traits. Additionally, rare variants with larger effects may have a large impact at an individual level. These results increase our knowledge about the effect of rare variants on eosinophil count.

References:

Grants: This research was funded by the Swedish Research Council (2019-01497), the Swedish Heart and Lung Foundation (20200687) and the Åke Wiberg, Marcus Borgström, A and M Rudbergs, Hedströms K and O F Foundations.

Conflict of Interest: None declared.

P25.016.D Benchmarking of univariate pleiotropy detection methods, with an application to epilepsy phenotypes

Oluwomi Adesoji1, Michael Nothnagel1,2

1Cologne Center for Genomics, University of Cologne, Cologne, Germany; 2University Hospital Cologne, Cologne, Germany.

Background/Objectives: Complex traits have been found to share genetic relationship in separate GWAS studies and the joint identification of these loci or variants via pleiotropy analysis improves gene discovery. Pleiotropy is the phenomenon of a hereditary unit affecting more than one trait. Joint analysis of sub-phenotypes improve power to discover association however, due to separate individual data collection for each trait, application of multivariate approaches is often not feasible. Therefore, to identify these switch-like or shared loci in more than one trait, we applied univariate pleiotropy detection approaches to epilepsy sub-phenotypes.

Methods: Firstly, we benchmarked five pleiotropy detection classical meta-analysis, cFDR, ASSET, CPBayes and PLACO, via simulation to identify the most powerful approach while keeping type 1 error low.

Results: ASSET method which gave a good trade-off between power and false -positive rate (FPR) is then applied to summary statistics of focal and genetic generalized epilepsies provided by the ILAE Consortium on complex epilepsies, thereby identifying a new putative pleiotropic locus at 17q21.32 and confirmed locus 2q24.3 which had already been identified via mega-analysis. Classical meta-analysis performed poorly in terms of FPR.

Conclusion: ASSET method yielded good power while keeping FPR low but, classic meta-analysis is not recommended.

References: International League Against Epilepsy Consortium on Complex Epilepsies (2018). Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies. Nat Commun 9, 5269. https://doi.org/10.1038/s41467-018-07524-z.

Grants: This study received support from the Research Unit FOR-2715 of the German Research Foundation and the 710 Fonds National de la Recherche.

Conflict of Interest: None declared.

P25.018.B Genetic overlap study between idiopathic pulmonary fibrosis and COVID – 19

Beatriz Guillen-Guio1, Richard Allen1, Emma Croot2, Luke M Kraven1, Samuel Moss3, Iain Stewart4, Gisli Jenkins5, Louise Wain1,2,4

1University of Leicester, Department of Health Sciences, Leicester, United Kingdom; 2University of Leicester, Department of Genetics and Genome Biology, Leicester, United Kingdom; 3National Heart and Lung Institute, Imperial College London, London, United Kingdom; 4National Institute for Health Research, Leicester Respiratory Biomedical Research Centre, Glenfield Hospital, Leicester, United Kingdom.

Background/Objectives: Genetic factors influence COVID-19 susceptibility and outcomes, including the development of pulmonary fibrosis (i.e. lung scarring). Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease and the most common cause of pulmonary fibrosis in the general population. Genome-wide association studies (GWAS) of COVID-19 and IPF revealed genes associated with both diseases, suggesting these share genetic risk factors. Here we performed a genetic overlap study between COVID-19 and IPF.

Methods: Summary statistics from an IPF 5-way meta-GWAS and from the COVID-19 Host Genetics initiative GWAS meta-analysis (v6) were used. We performed genetic correlation analyses and assessed individual genetic signals to identify those variants shared between both traits. We conducted colocalisation analyses to determine whether the same causal variant was driving both traits. Finally, the association of overlapping variants with gene expression was assessed and a phenome-wide association study was performed.

Results: There was a positive genetic correlation between severe COVID-19 and IPF. We found four genetic loci with likely shared causal variants between both traits, including one novel risk locus at 7q22.1 that colocalised with decreased ZKSCAN1 and TRIM4 expression in blood. The other three loci colocalised with MUC5B, ATP11A and DPP9 expression. The locus associated with increased ATP11A expression was also associated with higher HD1AC levels, a biomarker used in diabetes.

Conclusion: Results suggest there are shared biological processes driving IPF and severe COVID-19 phenotypes.

References:

Grants: Action for Pulmonary Fibrosis, Wellcome Trust (221680/Z/20/Z), GSK/British Lung Foundation (C17-1), NIHR Leicester Biomedical Research Centre.

Conflict of Interest: Beatriz Guillen-Guio B Guillen-Guio is supported by Wellcome Trust grant 221680/Z/20/Z, Richard Allen R Allen is an Action for Pulmonary Fibrosis Mike Bray Research Fellow, Emma Croot: None declared, Luke M Kraven: None declared, Samuel Moss: None declared, Iain Stewart: None declared, Gisli Jenkins G Jenkins is a trustee of Action for Pulmonary Fibrosis and reports personal fees from AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, Dae-woong, Galapagos, Galecto, GlaxoSmithKline, Hexaptes, NuMedii, PatientMPower, Pliant, Promedior, Redx, Resolution Therapeutics, Roche, Veracyte and Vicore., Louise Wain L Wain holds a GSK/British Lung Foundation Chair in Respiratory Research (C17-1), L
Background/Objectives: Genome-wide association study (GWAS) meta-analyses of complex traits have identified thousands of loci, whose biological characterization is underway. In meta-analyses, variant effect sizes vary across contributing studies due to environmental or genetic differences. However, how much study-specific features can be exploited to elucidate the underlying mechanisms is unclear. As a case study, we compared a GWAS of estimated glomerular filtration rate (eGFR) in a population-based study from the Alps, where thyroid disease is common, versus a meta-analysis on >1 million individuals that previously identified 147 kidney function relevant loci.

Methods: We performed a GWAS of age- and sex-adjusted In(eGFR) on 10,146 participants in the Cooperative Health Research in South Tyrol (CHRIS) study, accounting for genomic kinship (genomic inflation λ = 1.02). We assessed direction-consistent replication at any variant strongly correlated with the focal phenotype. For each variant, we assessed the impact on the eGFR log-transformed response. Replicated variants underwent phenotype-wide mediation analysis across 72 health biomarkers.

Results: We replicated 10 loci. The variants’ effect magnitudes were 1.3- to 5.8-times larger than in the meta-analysis, at similar minor allele frequencies (MAF). Free triiodothyronine and thyroxine, measured in individuals with low or high thyroid stimulating hormone levels, resulted as potential mediators for most loci. We observed potential interactions with hyperthyroidism at SHROOM3 (p = 0.03) and with hypothyroidism at PIP5K1B (p = 0.03) and GAB2 (p = 0.04).

Conclusion: Similar MAF, same ancestry and loci independency suggest the larger effects on eGFR in the CHRIS study being probably of environmental origin. The potential modifier role of thyroid disease warrants independent replication.

References:

Grants: H2020-MSCA-ITN-2019 ID:860977 (TrainCKDis).

Conflict of Interest: None declared.
Conflict of Interest: None declared.

P25.023.C A novel multi-components mixed model based bacterial-GWAS method and its application to Listeria monocytogenes

Frouin Arthur1, Fabien Laporte1, Hafner Lukas2, Maury Mylène2, Marc Lecuit2, Chikhi Rayan1, Hugues Aschard1

1Institut Pasteur, Université de Paris, Department of Computational Biology, Paris, France; 2Institut Pasteur, Université de Paris, Department of Cell Biology & Infection, Paris, France.

Background/Objectives: Genome-wide Association Studies (GWAS) have been central to study the genetics of complex human phenotypes, and there is now tremendous interest for implementing GWAS-like approaches to study pathogenic bacteria. However, bacterial genomes harbour complex structures making such analyses extremely challenging. Diverse and heterogeneous strategies have been proposed to define genetic variants (kmer, SNP, ...), and account for population structure (phylogeny, mixed model,...), but their relative performances have not been studied, and fundamental genetic modelling aspects have been surprisingly seldom discussed.

Methods: We used real bacterial sequence data and simulated phenotypes to conduct a formal comparison of alternative methods for modelling genetic structure, estimating heritability, and testing association. We leverage those results to develop a robust and powerful approach which we applied to the MONALISA cohort, a national prospective repository that systematically collects Listeria Monocytogenes strains in France, currently including whole genome sequencing of 3718 strains.

Results: We demonstrate that the classic human heritability model, commonly assumed in existing bacterial GWAS methods, is strongly unadapted to study highly structured organisms such as Listeria. The most efficient approach consists in a multi-component linear mixed model applied to unitigs, where components are inferred from a hierarchical clustering of the genetic relatedness matrix. Our analysis of virulence biomarkers in hypervirulent strains from MONALISA was able to identify promising targets, along clone-specific estimates of heritability.

Conclusion: We demonstrate that our refined genetic structure modelling can greatly improve power and robustness of bacterial GWAS.

References:

Grants: We thank the Inception program (Investissement d’Avenir grant ANR-16-CONV-0005) for funding this work.

Conflict of Interest: None declared.

P25.024.D The genetics of Parkinson’s Disease and the loss of dopaminergic neurons

Ann-Kathrin Schalkamp1, Cynthia Sandor2

1UK Dementia Research Institute at Cardiff University, Division of Psychological Medicine and Clinical Neuroscience, Cardiff, United Kingdom; 2UK Dementia Research Institute at Cardiff University, Division of Psychological Medicine and Clinical Neuroscience, Cardiff, United Kingdom.

Background/Objectives: Polygenic risk scores (PRS) for Parkinson’s Disease (PD) based on case/control genome-wide association study (GWAS) statistics show a low predictive value, possibly due to the high heterogeneity within PD or misdiagnoses. As quantitative traits achieve better reproducibility in genetic studies and better capture the phenotypic heterogeneity within a disorder, exploring the genetics of a biomarker could improve our understanding of the genetics of disease mechanisms. Striatal binding ratio (SBR) as measured through DaTscan could be such a marker. SBR is a good diagnostic biomarker and is a proxy for the loss dopaminergic neurons, a neuropathological hallmark of PD. We explore to what extend SBR is related to the genetics of PD and what the genetic basis of SBR is.

Methods: We calculate PD PRS and cell specific PD PRS, compare their performances, and correlate them with SBR. We investigate differences in SBR progression and severity between PD mutation carriers. We perform a GWAS for SBR and evaluate the predictive performance of SBR PRS in an independent cohort.

Results: SBR and PD PRS are correlated regardless of the applied p-threshold for PRS computation. The dopaminergic neuron specific PRS for PD is significantly associated with SBR and has the highest predictive performance. SNCA carriers have lower SBR at diagnosis. Some loci are associated with SBR and the predictive performance of SBR PRS on the independent cohort looks promising.

Conclusion: SBR is not only a good diagnostic biomarker for PD, but it also allows us to study the genetic basis of dopaminergic neuron loss across disorders.

References: None declared.

P25.025.A The genetic architecture of skull shape

Nishal Mewasingh1, Maria Knol1-2, Sander Lamballais1, Edith Hofer1-4, Reinhold Schmidt1, Marieke van Dooren1, Mikolaj Pawlak1,5,6, Hieab Adams1,5,6, Tavia Evans1,5,6

1Erasmus MC University Medical Center, Department of Clinical Genetics, Rotterdam, Netherlands; 2Erasmus MC University Medical Center, Department of Epidemiology, Rotterdam, Netherlands; 3Medical University Graz, Department of Neurology, Clinical Division of Neurogeriatrics, Graz, Austria; 4Medical University Graz, Institute of Medical Informatics, Statistics and Documentation, Graz, Austria; 5Medical University Graz, Department of Neurology, Clinical Division of Neurogeriatrics, Graz, Austria; 6Erasmus MC University Medical Center, Department of Clinical Genetics, Rotterdam, Netherlands; 7Poznan University of Medical Sciences, Department of Neurology and Cerebrovascular Disorders, Poznan, Poland; 8Erasmus MC University Medical Center, Department of Radiology and Nuclear Medicine, Rotterdam, Netherlands; 9Latin American Brain Health (BrainLat), Universidad Adolfo Ibáñez, Santiago, Chile.

Background/Objectives: The human skull forms an essential layer of protection for craniofacial areas, yet the genetic basis of skull shape remains largely unknown. Here, we perform the first genome-wide association study (GWAS) seeking to find genetic determinants underlying different skull shape dimensions.

Methods: We defined 19 MRI-derived linear and ratio skull shape measures including cranial length and width and a variety of novel (geometrically derived) measures. We estimated family-based heritability (ASPS-Family, N = 368) and single-nucleotide polymorphisms-based heritability (UK Biobank, N = 38,029), and performed a GWAS (UK Biobank, N = 38,029) controlling for batch effects (study center and genotyping array) and covariates (age, sex, height, intracranial volume, and 20 principal components).
Results: Skull shape measures were heritable to varying extents, ranging from 3% to 26% (standard error = 1-26) for SNP-based heritability, and 10% to 81% (standard error = 21-34) for family-based heritability. We identified 59 genome-wide significant loci for 15 skull shape measures including loci nearby genes involved in embryonic development (e.g., BMP3, FGFB) and craniofacial abnormalities (e.g., craniosynostosis, JAG1, KANSL1; Coffin-Siris syndrome, ARID1B).

Conclusion: Individual skull shape measures contain genetic information that could aid the understanding of the complex mechanisms underlying craniofacial development.

References:
Grants: Table 1 Number of loci and heritability estimates per skull shape measure

| Measure | Number of loci* | SNP-based (SE) | Family-based (SE) |
|---------|----------------|---------------|------------------|
| Front-Back | 19 | 0.24 (0.02) | 0.33 (0.13) |
| Front-Mid | 4 | 0.25 (0.02) | 0.47 (0.13) |
| Back-Mid | 7 | 0.17 (0.02) | 0.39 (0.12) |
| Right-L | 15 | 0.26 (0.02) | 0.75 (0.14) |
| Right-M | 5 | 0.17 (0.02) | 0.75 (0.14) |
| Left-M | 11 | 0.19 (0.02) | 0.33 (0.14) |
| FrontRight+FrontLeft | 19 | 0.26 (0.02) | 0.38 (0.14) |
| FrontRight+Back | 12 | 0.22 (0.02) | 0.39 (0.14) |
| TopRight+TopLeft | 9 | 0.23 (0.02) | 0.28 (0.11) |
| Height | 6 | 0.23 (0.02) | 0.71 (0.12) |
| Front-Top | 3 | 0.26 (0.02) | 0.78 (0.12) |
| Back-Top | 11 | 0.20 (0.02) | 0.20 (0.12) |

SE, standard error. *Loci overlap between measures

S25.027.C Liabilideep: a flexible, deep neural network approach for constructing genetic liabilities and conditioning on covariates without the need for prevalence or heritability estimates

Mike Thompson1,2 Jamie Matthews1, Andrew Schork3,4, Srim Sankararaman5,6,7, Noah Zaitlen1,3,7

1University of California, Los Angeles, Bioinformatics, Los Angeles, United States; 2University of California, Los Angeles, Computer Science, Los Angeles, United States; 3Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Aarhus, Denmark; 4Institute of Biological Psychiatry, MHC Sct. Hans, Mental Health Services, Copenhagen, Denmark; 5University of California, Los Angeles, Computational Medicine, Los Angeles, United States; 6University of California, Los Angeles, Human Genetics, Los Angeles, United States; 7University of California, Los Angeles, Neurology, Los Angeles, United States.

Background/Objectives: Recent GWAS methods use family history and population-level estimates of prevalence and heritability to improve power[1]. While there have been extensions to include covariates such as sex, age, and age-of-onset, these approaches require explicit changes to the generative model and additional prevalence information per covariate[2].

Methods: We develop a neural network—Liabilideep—with a flexible input layer that takes any set of covariates (including family history, related diseases, age, sex, etc.) and outputs a genetic liability that considers all covariates at the step of liability generation. The method optimizes a loss function that uses known GWAS SNPs and does not require estimates of heritability or prevalence.

Results: In simulations, Liabilideep reached over a median 3.5% increase in causal GWAS association statistics. On real data, using only age, sex and BMI, we observe an increase in chi-square statistics as high as 10% in GWAS of UKBB traits. Further, in simulations, we show that Liabilideep can optimally condition on covariates in ascertainment data, leading to a 9.5% increase over previous approaches. Notably, aside from age and sex, current approaches cannot condition on covariates at the liability generation step, and therefore lose power in ascertainment data when the covariate is causal and included in the association framework.

Conclusion: We present a flexible framework to generate genetic liabilities while leveraging covariates. Our approach is fast and can handle any number of covariates. Studies with ascertainment data and GWAS with more extensive family history available may benefit from Liabilideep without needing to adjust models.

References:
[1] https://doi.org/10.1038/s41588-020-0613-6.
P25.029.A Multi-tissue TWAS identifies 137 novel gene associations with ageing outcomes in humans

Georgina Navoly1, Olga Giannakopoulou1, Stefanie Mueller1, Linda Partridge2, Nazif Alic2, Karoline Kuchenbäcker1

1UCL Genetics Institute, London, United Kingdom; 2Institute of Healthy Ageing, London, United Kingdom.

Background/Objectives: Previous genome-wide association studies (GWAS) have identified multiple genetic variants associated with human lifespan, however, only a few genome-wide significant (P ≤ 5 x 10^-8) loci affecting lifespan have been pinpointed. An alternative approach to study human lifespan is through a gene-based association analysis called transcriptome-wide association study (TWAS), which integrates GWAS with gene expression data (eQTL), to boost statistical power and help narrow down GWAS loci, to identify causal gene candidates.

Methods: In this study, we performed a multi-tissue TWAS on human lifespan, using >1 million parental lifespans from the UK Biobank and the LifeGen Consortium as our discovery study, and two replication TWASes on human longevity and healthspan (morbidly-free lifespan) traits, using S-MultiXcan software.

Results: Here we show the successful application of the TWAS approach to validate previous GWAS findings, and to identify several novel genes associated with ageing: 137 novel replicating genes (replication threshold p < 0.05) associated with either longevity or healthspan and 9 novel genes, including HTR3B, VARS, VWA7 and COASY associated with all the three ageing outcomes. We identified 109 unique gene clusters, of which 16 gene clusters were successfully fine-mapped (using FOGS), identifying the putative causal gene in the region.

Conclusion: Our results support the role of TWAS in uncovering novel trait-associated genes, and through our prioritised, putatively causal gene set, we provide novel insights into the mechanisms of human ageing.

References: Grants: This work was supported by the Biotechnology and Biological Sciences Research Council (BBSRC) [grant number BB/M009513/1].

Conflict of Interest: None declared.

P25.030.B Polygenic scores for multiple definitions of depression explain independent variance in iPSYCH MDD

Aleksander Ring1, Vivek Appadurai2, Kaisa-Lotta Georgii Hellberg2, Morten Krebs2, Thomas Verge3, Cai Na4, Andrew Schork2

1Institute of Biological Psychiatry, Roskilde, Denmark; 2Institute of Biological Psychiatry, Roskilde, Denmark; 3Helmholtz Pioneer Campus, München, Germany.

Background/Objectives: Major Depressive disorder (MDD) is a complex, heterogeneous mental disorder with contributions from multiple genetic and environmental factors. Gene-mapping efforts have accelerated thanks to the rapid expansion of sample sizes, enabled by including lightly phenotyped cases. This approach has implications for both gene-mapping and trait prediction, and debates about the best approaches for each goal are on-going.

Methods: We collected published GWAS for multiple definitions of MDD. We then computed polygenic scores (PGS) using each MDD GWAS in N ~ 60,000 individuals genotyped as a part of the iPSYCH case-cohort study. We applied two PGS algorithms, pruning and thresholding (P + T) and SBayesR. We then used logistic regression to predict MDD in two iPSYCH cohorts, ranking the performance of each MDD GWAS + algorithm combination. Finally, we jointly fit all PGS in one multivariate logistic model to predict iPSYCH MDD.

Results: Consistent with previous reports, we saw clinical definitions of MDD predict less well out of sample, perhaps owing to their reduced sample sizes. Broad, shallow phenotyping and augmented phenotyping out-performed clinical MDD GWAS, perhaps because of expanded sample sizes. Importantly, when fit jointly, multiple PGS explain significant independent variance.

Conclusion: Multiple MDD PGS may capture independent components of etiology and can be combined to improve predictions. When performing gene-mapping it is important to identify definitions of MDD that are not ‘too sticky’ - they separate populations on core disease etiology. Strict predictions, however, can relax this requirement and should consider multiple, integrated predictors.

References: Grants: Lundbeck fellowship R335-2019-2318.

Conflict of Interest: None declared.

P25.032.D Non-coding rare variant trait associations in 127,724 UK Biobank genomes

Diogo Ribeiro1,2, Rick Wertenbroek1,2,3, Robin J. Hofmeister1,2, Olivier Delaneau1,2

1University of Lausanne, Department of Computational Biology, Lausanne, Switzerland; 2Swiss Institute of Bioinformatics, Lausanne, Switzerland; 3University of Applied Sciences Western Switzerland (HES-SO), Delémont, Switzerland.

Background/Objectives: The recent growth of available whole genome sequences (WGS) offers an unprecedented opportunity to assess the contribution of rare genetic variation to a multitude of human traits and diseases. Although rare variation in exonic regions has been associated with hundreds of traits, the study of rare variation in non-coding regions – where most GWAS hits are found – is lagging behind. Indeed, as non-coding regions represent ~98% of the genome, the identification of genomic regions to focus on is crucial. In this respect, recent studies identified regulatory domains (e.g. groups of enhancers) orchestrating the expression of nearby genes, which could be key in aggregating the signal across multiple pertinent genomic regions.

Methods/Results: Here, we develop new approaches to perform rare variant association tests on non-coding regions of 127,724 genomes from the UK Biobank. In practice, we perform rare variant (MAF<0.1%) collapsing analyses on a plethora of regulatory element annotations with the relevant traits, such as blood cell-types with blood biomarkers. To further refine our search for relevant regulatory regions per gene, we use public multimodal single cell data (scRNA-seq + scATAC-seq in the same cells) to identify >5000 groups of regulatory elements that synchronously regulate gene expression.

Conclusion: By utilising functionally-relevant genomic annotations we are able to scan the non-coding human genome and pinpoint context-specific genetic variation that contributes to human traits and disease and aid the development of pertinent therapeutic agents.

References: Delaneau et al. 2019 Science.

Grants: Marie Sklodowska-Curie n°885998, SNF PP00P3_176977.

Conflict of Interest: None declared.
P25.034.B Identification of shared molecular signatures of ageing and metabolic diseases using multi-omic data

Theodora Dafi Micaletto1, Mun-Gwan Hong2, Juan Fernandez3, Sapna Sharma4, Caroline Anna Brorsson2, Robert Koivula3,6, Jerzy Adamski4, Sören Brunak5, Emmanouil Dermitzakis7, Paul Frank3, Mark McCarthy3, Ewan Pearson8, Jochen Schwenk2, Mark Walker1, Sapna Sharma4, Caroline Anna Brorsson5, Robert Koivula3,6, Jerzy Adamski4, Søren Brunak5, Emmanouil Dermitzakis7, Paul Frank3, Mark McCarthy3, Ewan Pearson8, Jochen Schwenk2, Mark Walker1, Diabetes Research on Patient Stratification (DIRECT) Consortium8, Andrew Brown9, Ana Viñuela1

1Biosciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom; 2SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden; 3WTCHG, University of Oxford, Oxford, United Kingdom; 4Institut of Experimental Genetics, Neuherberg, Germany; 5Department of Health Technology, Technical University of Denmark, Kgs. Lyngby, Denmark; 6Department of Clinical Science, Lund University, Lund, Sweden; 7Genetic Medicine & Development, University of Geneva, Geneva, Switzerland; 8Population Health and Genomics, University of Dundee, Dundee, United Kingdom.

Background/Objectives: Many of the well-defined hallmarks of ageing are often observed in age-related diseases such as Type 2 Diabetes (T2D). By utilising multi-omic data from human tissues and clinical datasets we can identify molecular phenotypes associated with ageing towards better understanding the link between ageing and disease.

Methods: We utilised data from the DIRECT consortium including genotypes (N~9.2e5), transcriptomic (16,209 genes), targeted proteomic (373 proteins) and metabolomic (116 targeted metabolites) data from whole blood and plasma (3,029 participants). We evaluated the influence of age, T2D status, sex and BMI on each of the molecular phenotypes along with shared effects.

Results: We found 11,938 genes (73.7%) and 287 proteins (60.6%) differentially expressed with age (Qvalue < 5%). Of those, 163 transcripts and their corresponding proteins were associated with age, of which 78 pairs (~50%) demonstrated an opposite direction of effect of age. For example, REG4 expression significantly decreases with age (Pval = 3.85e-50) while increasing in its protein abundance (Pval = 4.49e-14). However, the molecular phenotypes most affected by age were metabolites (81% of targeted metabolites). We additionally evaluated that sex had the greatest influence in gene expression (13,669 associated genes), while BMI greatly influenced protein abundance (304 proteins). Significantly associated proteins such as IGFBP1 and FABP4 were also independently associated with age, sex and T2D.

Conclusion: Most measured phenotypes are associated with age and sex in an independent manner. We are currently evaluating the changes of molecular phenotypes over time with longitudinal measurements spanning up to 48 months.

References:

1. Martin et al., 2021. LAD Wave 1, 2017-18, India Report, IIPS, Mumbai. Rubinacci et al., 2021.
2. U01 AG064946, R01 AG05112.
3. Conflict of Interest: Ankita Srivastava Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland. Yuk Yee Leung Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Gerald Schellenberg Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Jinkook Lee University of Southern California, Los Angeles, CA, USA, Samuel Jones Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, Andrea Ganna Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.

P25.036.D A Genome Wide Association Study to investigate genetic risk modifiers of leg ulcers in adults with sickle cell disease

Jordan Connors1, Candace Middlebrooks1, Ashley Buscetta2, Catherine Minniti3, Anthony Musolf1, Joan Bailey-Wilson1, Vence Bonham2

1National Human Genome Research Institute, Computational and Genomics Branch, Baltimore, MD, United States; 2National Human Genome Research Institute, Social and Behavioral Research Branch, Bethesda, MD, United States; 3Albert Einstein College of Medicine, Bronx, NY, United States.

Background/Objectives: Sickle cell disease (SCD) is an inherited recessive disorder that leads to abnormal sickle-shaped red blood cells. There are a range of clinical manifestations that result from this disease, including the leg ulcers sub-phenotype, which negatively impacts the quality of life of SCD patients. There may be genetic variants that modify the risk of developing SCD associated leg ulcers. SCD patients develop leg ulcers at a higher rate than those in the general population. However, not every patient with SCD will develop leg ulcers. The INSIGHTS study seeks to understand what...
environmental or genetic factors are contributing to the increased risk of developing this sub-phenotype. The current project aims to detect modifier loci that may affect the risk of developing leg ulcers in a dataset of 264 SCD patients from the INSIGHTS study.

Methods: Whole genome sequencing was completed at NHGRI using the Illumina NovaSeq 6000 platform. Variant calling using GATK and association testing using PLINK has been completed on the first 121 samples (N = 53 with leg ulcers, N = 68 without leg ulcers).

Results: The strongest interin associations were on chromosome 21 near the TIAM1 gene (P-val = 1.01E-4) and on chromosome 20 near the ZFP64 gene (P-val = 1.08E-4).

Conclusion: Results from processing an additional 143 samples with this same pipeline will be reported in order to gain further insight into genetic variants that may modify the risk of developing leg ulcers in patients with SCD.

References:
Grants: This work was supported by the Intramural Research Program of NIH/NHGRI.
Conflict of Interest: None declared.

P25.037.A An innovative approach to link genomic data with electronic administrative health databases, focused on the investigation of shared genetics among autoimmune diseases

Alessandro Pizzino1, Ilenia Eboli2, Paolo Emilio Alboini3, Nadia Barirzone1, Roberta Picariello3, Carmen Marciano3, Paola Cavallà3, m. f. Grassi4, Paola Richiardi4, Antonio Bertolotto5, Domizia Vecchio4, sandra d’alfonso1

1University of Eastern Piedmont, Laboratory of human genetics, Health sciences, Novara, Italy; 2ASL TO3, Servizio Sovravionale di Epidemiologia, Regione Piemonte, Turin, Italy; 3IRCCS Casa Sollievo della Sofferenza, Neurology Unit, San Giovanni Rotondo, Italy; 4ASL TO3, Servizio Sovravionale di Epidemiologia, Regione Piemonte, Turin, Italy; 5San Giovanni Rotondo, Clinical Trial Office, San Giovanni Rotondo, Italy; 6Turin, S.C. Neurologia I e Centro Sclerosi Multipla, Dipartimento di Neuroscienze e di Salute Mentale, AOU Città della Salute e della Scienza di Torino, Turin, Italy; 7Cuneo, UO Neurologia, Ospedale Santa Croce e Carle, Cuneo, Italy; 8Turin, UO Neurologia, ASL Città di Torino, Ospedale San Giovanni Bosco, Turin, Italy; 9Orbassano, Neurologia-CRESM (Centro Riferimento Regionale Sclerosi Multipla), AOU San Luigi Gonzaga, Orbassano, Italy; 10University Hospital “Maggiore della Carità”, Neurology, Novara, Italy.

Background/Objectives: Multiple Sclerosis (MS) is a complex inflammatory-degenerative disease. GWASes identified >200 susceptibility loci, but they have poorly contributed to understand how genetics influences the phenotype as the reported comorbidity with other autoimmune diseases (ADs). Several AD loci were reported.

Aims:
- a) explore an innovative approach of linkage of genomic data with a large array of electronic administrative health databases (EAHDs) to test if genotype/phenotype associations can be successfully analyzed using EAHDs as well as in traditional studies.
- b) test the hypothesis that MS patients share a common genetic susceptibility with other ADs, leading to the presence of comorbidity with several of them.

Methods: We constructed several algorithms to identify MS or other ADs patients from EAHDs. To explore the common genetic susceptibility among ADs we are comparing a battery of weighted genetic risk scores (wGRSs) constructed using known genetic susceptibility variants for several ADs in MS patients with or without autoimmune comorbidity.

Results: We created: 1)an algorithm capable of ascertain prevalent MS cases, validated by matching with a clinical cohort of 685 genome-wide genotyped MS patients with confirmed diagnosis (95.9% sensitivity, 99.97% specificity); 2) algorithms to identify other 14 ADs and evaluated their co-morbidity with MS.

We identified 8850 MS cases, 16.2% show a comorbidity with at least one AD: eight of these are significantly associated with MS (P < 0.05). Linkage with genotypic data and the AD wGRS construction is ongoing.

Conclusion: EAHDs can be successfully used to test associations in complex diseases. MS patients show comorbidity with other ADs.

References:
Grants: Italian Ministry of Health (RF-2016-02361294 grant).
Conflict of Interest: None declared.

P25.038.B Deconstructing the genetic component of reported trauma with genomic structural equation modelling

Abigail ter Kuile1,2, Rosa Cheesman3, jonathan coleman1,2, Christopher Hübel1,2,4, alicia peel1, daniel levey5,6, murray stein7, joel gelernter5,6, christopher rayner1, Thalia Eley1,2, Gerome Breen1,2

1King’s College London, London, United Kingdom; 2National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, United Kingdom; 3PROMENTA Research Center, Department of Psychology, University of Oslo, Oslo, Norway; 4National Centre for Register-based Research, Aarhus Business and Social Sciences, Aarhus University, Aarhus, Denmark; 5Department of Psychiatry, Yale School of Medicine, New Haven, United States; 6Veterans Affairs Connecticut Healthcare System, West Haven, United States; 7Department of Psychiatry and School of Public Health, University of California, San Diego, La Jolla, United States.

Background/Objectives: Self-reports of trauma are partly heritable. Heritable behaviours also influence reports of or exposure to environmental factors. Identifying heritable behavioural factors of self-reported trauma could improve our understanding of the interpretation of life events.

Methods: We calculated genetic correlations of childhood maltreatment (reporting of emotional, sexual, and physical abuse, and emotional, and physical neglect) and >700 traits to identify phenotypes that might explain the heritability of reported childhood maltreatment. We retained traits with r|p| >0.25. We used genomic structural equation modelling to detect residual genetic variance in childhood maltreatment once genetically correlated traits were accounted for.

Results: More than half of the genetic component of childhood maltreatment could be accounted for by genetic correlations with twelve health traits (59%) and nine psychiatric disorders (57%). General risk tolerance, subjective well-being and autism spectrum disorder were the only traits independently associated with the genetic component of childhood maltreatment. These three traits alone explained 50% of the SNP-heritability of childhood maltreatment.

Conclusion: Our findings offer an explanation of the heritability of childhood maltreatment. The key contribution of three independently associated traits to the SNP-based heritability of reported trauma suggests that aspects of these phenotypes may be involved in gene-environment correlations or the retrospective reporting of trauma. Elucidating how these are linked with vulnerability or the subjective experience of trauma has the potential to improve trauma prevention and posttraumatic intervention strategies.

References:
Grants: None declared.
Conflict of Interest: None declared.
P25.039.C Understanding the genetics of autoimmune hypothyroidism

**Melissa Bujnis**, Rosalie Sterenberg,2 Bjørn Olav Asvold,3,5 Ana Barić,6 Luka Brčić,7 Jan Freudenberg8, Lars Fritsche9,10 Masahiro Kano11,12,13 Graham Leese14, Eirini Marouli15, Andres Metspalu16, Marta Riise Moksnes16, Bhramar Mukherjee9,10,17 Yukinori Okada11,18,19 Colin Palmer20, Areti Papadopoulou15, Vesna Boraska Perica,21 ante punda22, Monzeza Siddiqui23, Enrique Soto-Pedre22, Sundararajan Srinivasan22, Maris Teder-Laving16, Marco Medici3,18,19, Kanai, Graham Leese14, Eirini Marouli15, Andres Metspalu16, Johan Zvrskovec1,2, Abigail ter Kuile1,2, Christopher Hübel1,2, Thalia Eley1, Gerome Breen1,2

1University of Utah, Department of Human Genetics, Salt Lake City, United States; 2Erasmus University Medical Center, Rotterdam, Netherlands; 3Radboud University Medical Center, Nijmegen, Netherlands; 4NTNU, Norwegian University of Science and Technology, Trondheim, Norway; 5Trondheim University Hospital, Department of Endocrinology, St. Olavs Hospital, Trondheim, Norway; 6University Hospital of Split, Department of Nuclear Medicine, Split, Croatia; 7University of Split, Department of Medical Biology, School of Medicine, Split, Croatia; 8Regeneron Genetics Center, Regeneron Pharmaceuticals, Inc., Tarrytown, United States; 9University of Michigan, Department of Biostatistics, Ann Arbor, United States; 10University of Michigan, Center for Statistical Genetics, Ann Arbor, United States; 11RIKEN Center for Integrative Medical Sciences, Laboratory for Statistical Analysis, Yokohama, Japan; 12Massachusetts General Hospital, Analytic and Translational Genetics Unit, Boston, United States; 13Harvard Medical School, Department of Biomedical Informatics, Boston, United States; 14University of Dundee - Ninewells Hospital & Medical School, Dundee, United Kingdom; 15William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, London, United Kingdom; 16Institute of Genomics University of Tartu, Estonian Genome Centre, Tartu, Estonia; 17University of Michigan, Department of Epidemiology, Ann Arbor, United States; 18Osaka University Immunology Frontier Research Center (WPI-IFRc), Laboratory of Statistical Immunology, Osaka, Japan; 19Osaka University Graduate School of Medicine, Department of Statistical Genetics, Suita, Japan; 20University of Dundee - Ninewells Hospital & Medical School, Department of Endocrinology and Diabetes, Dundee, United Kingdom; 21University of Dundee - Ninewells Hospital & Medical School, Division of Population Health & Genomics, Dundee, United Kingdom; 22Ninewells Hospital and Medical School University of Dundee, Division of Molecular and Clinical Medicine, School of Medicine, Dundee, United Kingdom; 23Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany.

Background/Objectives: Autoimmune hypothyroidism is common, with a prevalence of 3-5% in the general population1. Hypothyroidism is associated with an increased risk of various diseases and mortality1. Despite its estimated high heritability, little is known about the genetic basis of autoimmune hypothyroidism1. For this reason, we have performed the largest GWAS meta-analysis of autoimmune hypothyroidism to date.

Methods: We obtained GWAS summary statistics from nine cohorts, where cases and controls were defined using ICD9/10 codes. Reference genomes were used to impute missing genotype data2,3. We adjusted for covariates including age, sex, population structure, and related individuals. METAL was used to perform the meta-analysis4.

Results: We performed the largest GWAS meta-analysis to date on autoimmune hypothyroidism, including 64,545 cases and ~500,000 controls. We identified more than 350 independent SNPs passing the GWAS significance threshold (p = 5x10E-8). Pathway analyses suggest involvement of known immune pathways as well as enrichment of associations in chromatin structure regulation.

Conclusion: Identification of novel genetic determinants is a key step in advancing the understanding of this common disease. These data will be a rich resource for future projects focusing on disease prediction, and personalized management, and treatment of autoimmune hypothyroidism.

References: 1. Chaker L, et al. Lancet. 390, 1550-1562 (2017). 2. Auton, A. et al. Nature. 526, 68-74 (2015). 3. McCarthy, S. et al. Nat. Genet. 48, 1279–1283 (2016). 4. Willer, C., et al. Bioinformatics 26, 2190–2191 (2010).

Grants: T32 - Training Program in Computational Approaches to Diabetes and Metabolism Research. R35 - Human Genetic Variation and Diseases.

Conflict of Interest: None declared.

P25.041.A The joint phenotypic and molecular genetic architecture of major depressive disorder and anxiety disorders

**Johan Zvrskovec**,1,2 Abigail ter Kuile1,2, Christopher Hübel1,2, jonathan coleman1,2, Thalia Eley1, Gerome Breen1,2

1Institute of Psychiatry, Psychology & Neuroscience, King’s College London, Social, Genetic & Developmental Psychiatry Centre, London, United Kingdom; 2National Institute For Health Research, Biomedical Research Centre for Mental Health, South London and Maudsley Hospital, London, United Kingdom.

Background/Objectives: Anxiety and mood disorders occur comorbid and are main contributors to the burden of disability worldwide. By using factor analytical methods, we characterise latent genetic constructs underpinning anxiety and mood disorders.

Methods: We performed genomic structural equation modelling (gSEM) on European ancestry genome-wide association study (GWAS) summary statistics of 20 behavioural traits. To retain genetic signal we 1.) generated expanded linkage disequilibrium (LD) scores from the European subset of 1000 Genomes Phase 3 (excluding Finnish ancestry) genetic reference panel, and 2.) imputed missing genetic effect estimates based on LD structure in summary statistics. We obtained GWAS with each latent genetic factor by regressing individual variant effects on factors in a synthetic GWAS using gSEM, including 3,935,493 individuals and more than 7.7M genetic variants per putative factor trait. We annotated genes and performed pathway analysis, using MAGMA and FUMA.

Results: We identified six correlated latent genetic factors (AIC = 3591, SRMR = 0.053), explaining 59% of the variance. We identified 1,296 novel genetic variant associations and 281 gene associations not previously detected in univariate GWAS. Factor neuroticism and factor depression were both enriched in genes expressed in brain tissue: frontal cortex, anterior cingulate cortex, hypothalamus, putamen, nucleus accumbens, hippocampus, caudate nucleus, cortex, and amygdala. Factor neuroticism was additionally enriched in genes expressed in substantia nigra.

Conclusion: Our work uncovers specific biological processes, such as chromatin organisation, gene regulation, synaptic signalling, neuronal development and neurogenesis, potentially involved in anxiety and affective aetiology.

References: [Grants:](https://www.guysandstthomassbrc.nihr.ac.uk/researchers/funding-acknowledgement-policy/).

Conflict of Interest: None declared.
P26 COVID-19

P26.002.C Germline rare variants of lectin pathway genes predispose to asymptomatic SARS-CoV-2 infection in elderly individuals

Giuseppe D'Alterio, Vita Alessandro Lasorsa, Ferdinando Bonfiglio, Sveva Cantalupo, Barbara Eleni Rosato, Immacolata Andolfi, Roberta Russo, Umberto Esposito, Giulia Frisso, Pasquale Abete, Gian Marco Cassese, Giuseppe Servillo, Ivan Gentile, Carmelo Piscopo, Matteo Della Monica, Giuseppe Fiorentino, Angelo Boccia, Giovanni Paolella, Veronica Ferrucci, Pasquale Carmelo Piscopo, Matteo Della Monica, Giuseppe Fiorentino, Achille Iolascon, Mario Capasso, Angelo Boccia, Giovanni Paolella, Veronica Ferrucci, Pasquale Carmelo Piscopo, Matteo Della Monica, Giuseppe Fiorentino, Andolfo, Roberta Russo, Umberto Esposito, Giovanni Paolella, Veronica Ferrucci, Pasquale Carmelo Piscopo, Matteo Della Monica, Giuseppe Fiorentino, Achille Iolascon, Mario Capasso

1University of Milan, Milan, Italy; 2CEINGE Biotecnologie Avanzate, Naples, Italy; 3University of Naples Federico II, Department of Molecular Medicine and Medical Biotechnology, Naples, Italy; 4COVID Hospital, P.O.S. Anna e SS. Madonna della Neve di Boscorecace, Ostipadi Riuniti Area Vesuviana, Naples, Italy; 5University of Naples Federico II, Department of Neurosciences and Reproductive and Odontostomatologic Sciences, Naples, Italy; 6University of Naples Federico II, Department of Medicine and Surgery, Naples, Italy; 7Medical and Laboratory Genetics Unit, A.O.R.N. ‘Antonio Cardarelli’, Naples, Italy; 8AORN dei Colli Presidio Ospedaliero Cotugno, Naples, Italy; 9Instituto Zooprofilattico Sperimentale del Mezzogiorno, Naples, Italy; 10University of Salerno, Salerno, Italy.

Background/Objectives: Emerging evidence suggests that complement system infection-dependent hyperactivation may worsen COVID-19 outcome. We investigated the role of predicted high impact variants - referred as Qualifying Variants (QVs) - of complement system genes in predisposing asymptomatic COVID-19

Methods: Exploiting Whole-Exome Sequencing (WES) data and 56 complement system genes, we performed a gene-based collapsing test between 164 asymptomatic subjects (age ≥ 60 y.o.) and 56,885 European individuals from the gnomAD database. We replicated this test comparing the same asymptomatic individuals with 147 hospitalized COVID-19 patients.

Results: We found an enrichment of QVs in three genes (MASP1, COLEC10 and COLEC11), which belong to the lectin pathway, in the asymptomatic cohort. Moreover, individuals with QVs showed lower serum levels of MASP1 and of prothrombin activity compared to controls while no differences were observed for CH50 and AH50 levels that measure the activity of classical and alternative complement pathways, respectively. Finally, integrative analyses of genome-wide association study and expression quantitative loci traits data showed a correlation between polymorphisms associated with asymptomatic COVID-19 and decreased expression of MASP1, COLEC11 and COLEC10 genes in lung tissue.

Conclusion: This study suggests that rare genetic variants can protect from severe COVID-19 by mitigating the activation of lectin pathway and prothrombin activity.

References:

Grants: This research was funded by the project “CEINGE TASK FORCE COVID19”, grant number DE4120003800, by Regione Campania for the fight against Covid-19 (DGR n. 140 del 17 Marzo 2020).

Conflict of Interest: None declared.

P26.003.D SARS-CoV-2 sequencing: A comparison of high-throughput methods

Zuzana Gerber, Christian Daviaud, Damien Delafos, Florian Sandron, Enagnon Alidjinar, Jonathan Mercier, Sylvain Gerber

1CEA, Centre National de Recherche en Génomique Humaine, Evry, France; 2Centre Hospitalier Universitaire de Lille, Laboratoire de Virologie, Lille, France; 3Muséum national d’Histoire naturelle, Institut de Systématique, Evolution, Biodiversité, Paris, France.

Background/Objectives: The COVID-19 pandemic continues to threaten public health and burden healthcare systems worldwide. Whole SARS-CoV-2 genome sequencing has become essential for epidemiological monitoring and identification of new variants, which could represent a risk of increased transmissibility, virulence, or resistance to vaccines or treatment. In this study, we assess the performance of various target enrichment methods for whole SARS-CoV-2 sequencing.

Methods: We applied three target enrichment methods – two multiplex amplification methods and one hybridization capture – to the same set of nasopharyngeal patient samples (N = 93) in high-throughput mode. SARS-CoV-2 genome was obtained using short-read next-generation sequencing.

Results: All three methods provided excellent breadth of coverage of SARS-CoV-2 genome (above 99%), albeit with vastly different sequencing depth (5-fold difference) and uniformity of coverage (20% difference in coefficient of variation). Poor local coverage has negative impact on variant calling in the concerned region, leading to an occasional allele drop-out (1.2% SNPs affected for one method).

Conclusion: We discuss the performance of each target enrichment method and their potential for scaling up, in order to promote prospective programs of large-scale genomic surveillance of SARS-CoV-2 worldwide. Genomic surveillance will be crucial to overcoming the ongoing pandemic of COVID-19, despite its successive waves and continually emerging variants.

References:

Grants: LabEx GENMED (grant number ANR-10-LABX-0013).

Conflict of Interest: None declared.

P26.005.B Design of a cost-effective diagnosis tool for SARS-CoV-2 variant detection through a next generation sequencing (NGS) based strategy

Mª Mercedes Montero-Vale, Pau Rodriguez-Sodupe, Marina Alguacil-Guillén, Mateu Espasa-Soley, LLuis Armengol, Juan Ramón González, Jairo Rodríguez

1Quantitative Genomics Medicine Laboratories (qGenomics), Esplugues de Llobregat (Barcelona), Spain; 2Barcelona Institute for Global Health (ISGlobal), Bioinformatic Research Group in Epidemiology, Barcelona, Spain; 3Hospital Parc Taulí, Sabadell, Spain.

Background/Objectives: Current pandemic situation, together with the continuous emergence of new SARS-CoV-2 variants reveal the need to develop a more versatile tool than PCR-based methods that allows both high throughput COVID-19 diagnostic and specific variant detection at reduced cost and fast turnaround times. Thus, with the aim of overcoming current test limitations and providing a strategy with these characteristics arises our novel next generation sequencing based approach.

Methods: The developed strategy works with RNA samples obtained from nasopharyngeal swabs. RNA samples are processed with our custom laboratory protocol and can be sequenced with any Illumina platform to generate results within a 24h timeframe. A tailored bioinformatic pipeline analyzes the data and generates a clinical-level report.

Results: Clinical validation results have shown that the designed solution, sensitively and specifically identifies negative
and positive samples that display a broad range in viral loads and readily identifies the following major SARS-CoV-2 variants of concern (VoC): Alpha, Beta, Gamma, Delta, Lambda and Omicron (BA.1 and BA.2).

**Conclusion:** The versatility of our solution allows the capability of identifying the presence of other common respiratory viruses as well as identifying patients at risk through the identification of susceptibility human variants in the host. This, together with the possibility of easily adding new VoC as they emerge, will make VoC monitoring in entire populations feasible, providing a new perspective on the application of NGS methods in the field of clinical microbiology.

**References:**

**Grants:** This project is supported by the Generalitat de Cataluña through an Industrial PhD grant.

**Conflict of Interest:** M. Mercedes Montero-Vale Pre-doc student, full-time, qGenomics, Pau Rodriguez-Sodupe Pre-doc student, full-time, qGenomics, Marina Alguacil-Guillén: None declared, Mateu Espasa-Soley: None declared, Lluís Armengol CSO, full-time, qGenomics, Juan Ramón González: None declared, Jairo Rodríguez R&D director, full-time, qGenomics.

**P26.006.C** A survival genome-wide association study to identify variants associated with COVID-19 risk of death

Francesca Minnai, Filippo Biscarini, Tommaso A. Draganii, Chiara Fallerini, Kristina Zguro, Simone Furini, Gen-Covid Multicenter Study, Alessandra Renieri, Francesca Colombo

1Institute for Biomedical Technologies - National Research Council, Segrate (MI), Italy; 2Institute of Agricultural Biology and Biotechnology - National Research Council, Milan, Italy; 3Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 4University of Siena, Siena, Italy.

**Background/Objectives:** SARS-CoV-2 infection clinical manifestations hugely vary among patients, ranging from no symptoms, to life-threatening conditions. This variability is also due to host genetics: COVID-19 Host Genetics Initiative identified six loci associated with COVID-19 severity in a previous case-control genome-wide association study. A different approach to investigate the genetics of COVID-19 severity is looking for variants associated with mortality, e.g. by analyzing the association between genotypes and time-to-event data.

**Methods:** Here we perform a case-only genome-wide survival analysis, of 1,777 COVID-19 patients from the GEN-COVID cohort, 60 days after infection/hospitalization. Case-only studies has the advantage of eliminating selection biases and confounding related to control subjects. Patients were genotyped using Illumina Infinium Global Screening Arrays. PLINK software was used for data quality check and principal component analysis. GeneAbel R package was used for survival analysis and age, sex and the first four principal components were used as covariates in the Cox proportional hazard model.

**Results:** We found four variants associated with COVID-19 patient survival at a nominal P < 1.0 x 10-6. Their minor alleles were associated with a higher mortality risk (i.e. hazard ratios (HR)>1). In detail, we observed: HR = 1.03 for rs28416079 on chromosome 19 (P = 1.34 x 10-7), HR = 1.15 for rs72815354 on chromosome 10 (P = 1.66 x 10-7), HR = 2.12 for rs2785631 on chromosome 1 (P = 5.14 x 10-7), and HR = 2.27 for rs2785631 on chromosome 5 (P = 6.65 x 10-7).

**Conclusion:** The present results suggest that germline variants are COVID-19 prognostic factors. Replication in the remaining HGI COVID-19 patient cohort (EGAS000001005304) is ongoing at the time of abstract submission.

**References:**

https://doi.org/10.1038/s41586-021-03767-x.
https://doi.org/10.1038/s41431-020-00793-7.

**Grants:** “PATCOVID” - 2020-2016_Ric_3 - Istituto Buddista Italiano Soka Gakkai.

**Conflict of Interest:** None declared.

**P26.007.D** Transcriptomic analysis in patients with SARS-CoV-2 virus infection. Identification of the association of risk/protective profiles against the disease

Israel David Duarte Herrera1, Elias Cuesta Llavona1,2, Guillermo Muñiz Albaiceta1,2, Marta García Clemente1, Eliecer Coto1,2, Juan Gómez1,2

1Central University Hospital of Asturias, Oviedo, Spain; 2Health Research Institute of Asturias (ISPA), Oviedo, Spain.

**Background/Objectives:** SARS-CoV2 causes the COVID-19 disease, capable of producing a severe acute respiratory syndrome. Several clinical variables and genetic variants have been related to a worse prognosis. The aim of this study is to measure if differences in the gene expression are associated with COVID-19 severity.

**Methods:** We performed RNA-seq Transcriptome in RNA extracted from lymphoblastoid cell line in 20 patients who require hospitalization (10 from the intensive care unit) in a GeneStudio SS Plus Sequencer (Ion Torrent Technology). FASTQ files were obtained and trimmed using BBtools, BBduk for cutting, filtering and masking the data, and Dedupe for the elimination of duplicates.

Mapping and counting matrix was done in bash using the Salmon program. Differential expression analysis and subsequent functional enrichment was performed using Rstudio (DESeq2, ClusterProfiler, GO and KEGG).

**Results:** We observed that 2042 differentially expressed genes (1996 overexpressed, LFC>0 and 406 underexpressed, LFC<0) were obtained between patients who require hospitalization versus those in the intensive care unit. We found some genes previously SARS-CoV-2 associated (PGLYRP1, HDAC9 and FUT4). Furthermore, genes involved in the activity of the immune system and in inflammatory processes showed significant differences between cohorts (ABCF1 (LFC = -25.14, padj = 1.05e-13), ABHD16A (LFC = 25.00, padj = 1.05e-13) and IER3 (LFC = -24.45, padj = 2.43e-13)).

**Conclusion:** We described differential expression in genes of the immune system and inflammatory processes that might be have a role in the risk of develop severe symptoms of COVID-19, including admission in the intensive care unit. This results should be validated by additional functional studies.

**References:**

**Grants:**

None.

**Conflict of Interest:** None declared.

**P26.008.A** A prospective study to evaluate the role of cholesterol metabolism related genes expression in predicting clinical outcome of patients with severe COVID-19

Katerina Basharova1, Tatiana Usenko1,2, Anastasia Bezrukova1, Daria Bogdanova1, Michael Nikolaev2,3, Artem Izumchenko1, Elena GavriloVa2, Irina Shlyk2, Yuri Polushin2, Petr Slominsky1, Sofya Pchelina1,2

1Petersburg Nuclear Physics Institute Named by B.P. Konstantinov of National Research Center “Kurchatov Institute”, Gatchina, Russian Federation; 2Pavlov First Saint-Petersburg State Medical University, Saint Petersburg, Russian Federation; 3Petersburg Nuclear Physics Institute Named by B.P. Konstantinov of National Research Center “Kurchatov Institute”, Gatchina, Russian Federation; 4Institute of
**Abstracts from the 55th European Society of Human Genetics Conference**

**Background/Objectives:** Latest studies have stressed the relevance of cholesterol metabolism with susceptibility to COVID-19 and its severity. We have previously shown downregulation of low-density lipoprotein particle receptor pathway in severe COVID-19 patient surviving compared to non-surviving(1). We aimed to assess the over-time expression changes of its relevant genes in severe COVID-19 patients with different outcomes (survivors/non-survivors).

**Methods:** Blood samples were taken from 39 severe COVID-19 patients without chronic diseases twice: on the day of admission to the intensive care (T1) and in one week (T2). Within 30-day follow-up 18 patients recovered and 21 patients died. 20 individuals never previously infected with COVID-19 were also enrolled. Expression levels of studied genes in peripheral blood lymphocytes were analyzed by real-time PCR with TaqMan assay.

**Results:** Increased expression of \( \text{STAB1} \) at T2, \( \text{PPAR}\gamma \) at T1 and \( \text{CD36} \) at T1 and T2 were revealed in COVID-19 patients regardless of the outcome compared to controls (\( p < 0.05 \)). Interestingly, that in respective groups of COVID-19 patients increased \( \text{STAB1} \), decreased \( \text{PPAR}\gamma \) and in survivors decreased \( \text{LRP6} \) expression were revealed at T2 compared to T1 (\( p < 0.01 \)). Also, \( \text{STAB1} \) expression was decreased in survivors compared to non-survivors at T2 (\( p = 0.017 \)).

**Conclusion:** Our study revealed, that patients with severe COVID-19 are characterized by increased expression of cholesterol metabolism related genes, with pronounced decrease of expression of these genes over time for survivors. Increased \( \text{STAB1} \) expression may be considered as a predictor of poor COVID-19 prognosis.

**References:** 1. Vlassov, I. et al. Transcriptomic Profiles Reveal Downregulation of Low-Density Lipoprotein Particle Receptor Pathway Activity in Patients Surviving Severe COVID-19. Cells 10,3495 (2021).

**Grants:**

**Conflict of Interest:** None declared.

**P26.010.C Mid-density Gene Expression profiling of SARS-CoV-2 infected samples using Applied Biosystems™ TaqMan™ Flexible Array Panels**

rui yang\(^1\), Kelly Li\(^1\), allan chen\(^1\), phillip kilgas\(^1\), katherine kirchmeier\(^1\), Archana Gupta\(^1\)

\(^1\)Thermo Fisher Scientific, south san francisco, United States.

**Background/Objectives:** The broad spectrum of clinical manifestations from SARS-CoV-2 infection and observed risk factors for severe disease highlight the importance of understanding molecular mechanisms underlying SARS-CoV-2 associated disease pathogenesis. Research studies have identified a large number of host proteins that play roles in viral entry, innate immune response, or immune signalling during infection. The ability to interrogate subsets of these genes simultaneously within SARS-CoV-2 infected samples is critical to understanding how their expression contribute to phenotypic variability of the disease caused by the pathogen.

**Methods:** 30 Nasopharyngeal swab were obtained and included SARS-CoV-2 infected and control samples. RNA was extracted, reverse transcribed and loaded onto flexible TaqMan array panels designed specifically for targeting the most cited genes related to SARS-CoV-2 entry and restriction factors as well as cytokines, chemokines, and growth factors involved in the pathogenesis.

**Results:** Our data indicated that not only were the levels of several of these host factors differentially modulated between the two study groups, but also that SARS-CoV-2 infected subjects presented with greater frequency of several important inflammatory cytokines and chemokines such as CCL2, CCL3, IFNG, entry receptors such as ACE2, TMRPS11A, and host restriction factors including LY6E and ZBP1.

**Conclusion:** TaqMan array plates provide a fast, mid-throughput solution to determine the levels of several virus and host-associated factors in various cell types and add to our understanding of how the pathogenesis may vary depending on gender, age, infection site etc.

**References:**

**Grants:**

**Conflict of Interest:** rui yang Thermo Fisher Scientific, Kelly Li Thermo Fisher Scientific, allan chen Thermo Fisher Scientific, phillip kilgas Thermo Fisher Scientific, katherine kirchmeier Thermo Fisher Scientific, Archana Gupta Thermo Fisher Scientific.

**P26.009.B Persistent chemosensory dysfunction in COVID-19 patients: a deep dive into the psychophysical and genetic characterisation of an Italian cohort**

Beatrice Spedicati\(^1\), Giuseppe Giovanni Nardone\(^2\), Aurora Santin\(^1\), Anna Morgan\(^2\), Maria Pina Concas\(^2\), Giancarlo Tirelli\(^1\), Paolo Gasparini\(^1\)\(^2\), Paolo Boscolo-Rizzo\(^1\), Giorgia Girotto\(^2\)\(^3\)

\(^1\)University of Trieste, Department of Medicine, Surgery and Health Sciences, Trieste, Italy; \(^2\)Institute for Maternal and Child Health – I.R.C.C.S. Burlo Garofolo, Medical Genetics, Trieste, Italy.

**Background/Objectives:** Chemosensory dysfunction is a hallmark of SARS-CoV-2 infection; nevertheless, the genetic factors predisposing to long-term smell and taste loss are still unknown. This study aims to identify candidate genes possibly involved in persistent smell/taste loss through Whole Genome Sequencing (WGS) analysis of a large cohort of 130 fully characterised Italian individuals, previously diagnosed with COVID-19.

**Methods:** DNA of all analysed patients was used to perform WGS analysis, and a detailed personal anamnesis was collected. Moreover, orthonasal function was assessed through the extended Sniffin’ Sticks test, retronasal function was tested with 20 powdered tasteless aromas, and taste was determined with validated Taste Strips. Self-reported smell and taste alterations were assessed via Visual Analog Scales plus questionnaires.

**Results:** The clinical evaluation allowed to classify the patients in two groups: 88 cases affected by persistent smell dysfunction (median age, 49) and 42 controls (median age, 51). Among cases, 26.1% (\( n = 23 \)) were functionally anosmic and 73.9% (\( n = 65 \)) were hyposmic. Within cases, 77 underwent the taste strip test: 53.2% (\( n = 41 \)) presented hypogeusia and 46.8% (\( n = 36 \)) were normogeusic. Preliminary WGS results on a first subset of 76 samples confirmed the important role of \( \text{UGT2A1} \) gene, previously described as involved in smell loss. Interestingly, we identified a nonsen se variant (rs111696697, MAF 0.046) significantly associated with anosmia in males (p-value: 0.0183).

**Conclusion:** Here, for the first time a large cohort of patients, fully characterised through a comprehensive psychophysical evaluation of smell and taste, have been analysed to better define the genetic bases of COVID-19-related persistent chemosensory dysfunction.

**References:**

**Grants:**

**Conflict of Interest:** None declared.

**P26.011.D Gain and loss of function CFTR alleles modulate COVID-19 clinical outcome**

Margherita Baldassarri\(^1\)\(^2\), Chiara Fallerini\(^1\)\(^2\), Francesca Favai\(^1\)\(^2\)\(^3\), Kristina Zgura\(^4\), Nicoletta Pedemonte\(^5\), Valeria Tomati\(^5\), Cristina
Background/Objectives: We previously demonstrated that carrying a single pathogenic CFTR allele increases the risk for COVID-19 severity and mortality rate. We now aim to clarify the role of several uncharacterized rare alleles, including complex (cis) alleles, and in trans combinations.

Methods: LASSO logistic regression was used for the association of sets of variants, stratified by MAF, with severity. Immortalized cystic fibrosis bronchial epithelial cell lines and Fischer Rat Thyroid cells were transfected by plasmid carrying specific CFTR mutations. YFP-based assays were used to measure CFTR activity.

Results: Here we functionally demonstrate that the rare (MAF = 0.007) complex G576V/R668C allele mitigates the disease by a gain of function mechanism. Several novel CFTR ultra-rare (MAF <0.001) alleles were proved to have a reduced function; they are a gain of function mechanism. Several novel alleles were also shown to be associated with reduced CFTR activity.

Conclusion: CFTR is a bidirectional modulator of COVID-19 outcome. At-risk subjects do not have open cystic fibrosis before viral infection and therefore are not easily recognisable in the general population unless a genetic analysis is performed. As the CFTR activity is partially retained, CFTR potentiator drugs could be an option as add-on therapy for at-risk patients.

References: Baldassarri M et al. Severe COVID-19 in Hospitalized Carriers of Single CFTR Pathogenic Variants. JPM.11,6 558. 15 Jun. 2021.

Grants: FISR 2020/Tuscany Region COVID-19/INTERVENE - GA No. 101016775/Soka Gakkai PAT-COVID.

Conflict of Interest: None declared.

P26.013.C COVID-19: How to analyze data from whole-exome sequencing?

Natalia Forgacova1,2, Zuzana Holesova3, Juraj Gazdarica1,3,4, Rastislav Heke1,3,4, Tatiana Sedlackova1,3, Diana Rusnakova1,2,3, Pavel Janega4, Kristina Mikus Kuracinova5, Lucia Krivosikova5, Pavel Babal5, Zuzana Pos1,2,3, Jakub Styk1,3,5, Ondrej Pos1,3, Rosanna Asselta2,3

1Comenius University in Bratislava; 2Slovak Academy of Sciences; 3Faculty of Mathematics, University of Pavia, Pavia, Italy; 4University of Siena, DIISM-SAILAB, Siena, Italy; 5Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden.

Background/Objectives: COVID-19 can affect anyone with the disease’s symptoms ranging from mild to very severe. Although environmental, clinical, and social factors play an important role in the disease process, host genetic factors are not negligible either. In the present article, we attempted to elaborate on the spectrum of risk variants and genes identified in different ways and their possible relationship to COVID-19 severity and/or mortality.

Methods: We present three different approaches to search host genetic risk factors that influence the development of COVID-19 disease. First, we analyzed the exome sequencing data obtained from Slovak patients who died of COVID-19. Second, we selected risk factors/genes that were associated with COVID-19. Finally, we compared the genetic background of 215 severe COVID-19 patients with 1764 individuals from the general population, worldwide public data of the Non-Finnish European population from the gnomAD database, and genetic data from Non-invasive prenatal testing in the Slovak population.

Results: We illustrate the utility of genomic data showed strong association in meta-analyses conducted by the COVID-19 HGI Browser.

Conclusion: To our knowledge, the present study is the first population analysis of COVID-19 variants worldwide and also in the Slovak population that provides different approaches to the analysis of genetic variants in whole-exome sequencing data from patients who have died of COVID-19.

References: This publication is the result of support from the Operational Programme Integrated Infrastructure for the project: Pangenomics for personalized clinical management of infected persons based on identified viral genome and human exome (Code ITMS:513011ATL7), co-financed by the European Regional Development Fund.

Conflict of Interest: None declared.

P26.014.C Identification of genetic determinants of COVID-19 severity by exome sequencing

Claudia Cappadona1, Valeria Rimoldi2, Sandro Bottaro2,3, Giulia Cardamone2,3, Humanitas COVID-19 Task Force2, The Humanitas Gavazzeni COVID-19 Task Force2, Elvezia Maria Paraboschi2,3, Rosanna Asselta2,3

1Humanitas University, Department of Biomedical Sciences, Pieve Emanuele, Italy; 2Humanitas University, Department of Biomedical Sciences, Pieve Emanuele, Italy; 3IRCCS Humanitas Research Hospital, Rozzano, Italy; 4Goethe-University Frankfurt, Institute of Biochemistry I Faculty of Medicine, Frankfurt, Germany; 5Humanitas Gavazzeni Castelli, Bergamo, Italy.

Background/Objectives: The severity of the symptoms of coronavirus disease 2019 (COVID-19) has been associated to age, comorbidity, and male sex. Besides virus characteristics, host genetic factors influence the infection outcome. Different genome-wide association studies and meta-analyses investigated the contribution of common variants, whereas the role of rare variants just started to be elucidated. Our goal is to determine the contribution of rare variants to the development of severe COVID-19 in the Italian population.

Methods: We compared the genetic background of 215 severe COVID-19 patients with 1764 individuals from the general population. Rare variants (minor allele frequency <1%) from whole-exome sequencing data were retrieved using a bioinformatics variant discovery pipeline. We tested the impact of rare variants (classified according to their predicted effect on the gene product) both using a burden test design, and an iterative machine learning (ML) approach.

Results: We identified a total of 690,000 rare variants in the entire examined population. Among them, 250 were associated with COVID-19 severity at a nominal P < 0.05. Gene-based burden test revealed a gene with an excess of loss-of-function mutations
Abstracts from the 55th European Society of Human Genetics Conference

Zoia Korobova2;3, Natalia Liubimova3, Michael Nikolaev1;2, Artem Izumchenko1, Elena Gavrilova 2, Irina Shlyk 2, Yuri Polushin 2, Areg Totolian2;3, Sofya Pchelina1;2

were higher in survivors with COVID-19 compared to controls (p < 0.0001, respectively). Receiver operating characteristic (ROC) analysis has been conducted for IL-15 and IL-27. Cut-off value was estimated as 25.50 pg/ml for IL-15 and 1.51 pg/ml for IL-27.

Conclusion: Our study demonstrated a more pronounced immune response in non-surviving patients with severe COVID-19. IL-15, IL-27 could be considered as a sensitive biomarker of the fatal outcome from COVID-19.

References:
Grants: Banca Intesa Sanpaolo is acknowledged.

Conflict of Interest: None declared.

P26.016.A Plasma cytokine profile in patients with severe COVID-19

Anastasia Bezruckova1, Tatiana Usenko1;2, Katerina Basharova1, Zoia Korobova2, Natalia Liubimova2, Michael Nikolaev1;2, Artem Izumchenko1, Elena Gavrilova 2, Yuri Polushin 2, Areg Totolian2;3, Sofya Pchelina1;2

Background/Objectives: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease (COVID-19) enters the lung tissue through exocytosis, leading to the release of a large amount of pro-inflammatory cytokines called 'cytokine storm'. The aim was to provide more insight into relationships between plasma cytokines profile and fatal outcome of COVID-19.

Methods: Plasma cytokines (IL-17F, GM-CSF, IFNγ, IL-10, CCL20/MIP3α IL-12, IL-17A, IL-22, IL-9, IL-1b, IL-33, IL-2, IL-21, IL-4, IL-23, IL-5, IL-6, IL-17E, IL-25, IL-27, IL-31, TNFα, TNFβ, IL-28A) were detected in 30 patients with severe COVID-19 by a LumineX assay system with Milliplex Human Th17 Magnetic Premix 25 Plex Kit (HT17MG-14K-PX-25, Merck-Millipore, USA) according to the instructions. Patients were followed up for 30 days since admission to intensive care. 18 patients died and 12 patients survived during the period of observation. The control group comprised 10 individuals who had never been diagnosed with COVID-19.

Results: IL-10 and CCL20/MIP3α plasma levels were elevated in non-survivors patients with COVID-19 compared to controls (p = 0.0027, p = 0.012, respectively). IL-15, IL-6, IL-27 plasma levels were higher in survivors with COVID-19 compared to controls (p = 0.049, p = 0.026, p = 0.00032, respectively). Interestingly, IL-15, IL-27 plasma levels were increased in non-survivors with COVID-19 compared to controls and survivors with severe COVID-19 (IL-15: p = 0.00098, p = 0.00014, respectively; IL-27: p = 0.011, p < 0.0001, respectively). Receiver operating characteristic (ROC) analysis has been conducted for IL-15 and IL-27. Cut-off value was estimated as 25.50 pg/ml for IL-15 and 1.51 pg/ml for IL-27.

Conclusion: Our study demonstrated a more pronounced immune response in non-surviving patients with severe COVID-19. IL-15, IL-27 could be considered as a sensitive biomarker of the fatal outcome from COVID-19.

References:
Grants: Sequencing was funded by the DFG, AS was funded by BONFOR.

Conflict of Interest: None declared.

P26.017.B Whole genome sequencing of a German cohort to understand host genetics in COVID-19

Axel Schmidt1;2, Eva C. Schulte2;3;4, Susanne Matomény2;5, Nicolas Casadei6;7;8, Fabian Brand9, Michael Nothnagel2, Elaheh Vojgani2;5, German Demidov2;6;7, Kerstin Becker2;5, Janine Altmüller2, André Heimbach1;2;5, Markus M Nöthen1;2;9, Peter Nürnberg2;5, Stephan Ossowski2;6;7, Olaf Ries2;6;7, Kerstin Ludwig1;2

1University Hospital Bonn, Institute of Human Genetics, Bonn, Germany; 2German COVID-19 OMICS Initiative (DeCOI), Host Genetics Group, Germany, Germany; 3University Hospital, LMU Munich, Institute of Psychiatric Phenomics and Genomics (IPPG), Munich, Germany; 4University Hospital Munich, Department of Psychiatry and Psychotherapy, Munich, Germany; 5University of Cologne, Cologne Center for Genomics, Cologne, Germany; 6University of Tuebingen, Next Generation Sequencing (NGS) Competence Center Tuebingen (NCC), Tübingen, Germany; 7University of Tuebingen, Institute of Medical Genetics and Applied Genomics, Tübingen, Germany; 8University of Bonn, Institute for Genomic Statistics and Bioinformatics, Bonn, Germany; 9University of Bonn, West German Genome Center (WGGC), Bonn, Germany.

Background/Objectives: The disease course upon SARS-CoV-2 infection is highly variable and comprises a range from asymptomatic infection to severe (and even lethal) COVID-19. Genetic factors substantially contribute to this variability, as evidenced by epidemiological studies and recent results from genome-wide association studies (GWAS) as well as sequencing-based approaches. The host genetics group of the German COVID-19 OMICS Initiative (DeCOI) has been founded with the aim to identify additional genetic variants that influence COVID-19 severity through whole genome sequencing (WGS) analyses.

Methods: Until January 2022, WGS has been performed on approximately 1200 individuals affected by COVID-19. The most recent data freeze comprised 952 individuals. In this dataset, no carrier of a deleterious protein-altering variant has been detected in TLR7, which is the only conclusive risk gene for severe COVID-19. Applying a gene-based association test of rare variants to the subcohort of European individuals (n = 752, mean age: 56 years, females: 44%), including 199 severely affected individuals, we did not observe any significant association after correction for multiple testing. Exome-wide association analysis of common variants in this subcohort replicated the GWAS-locus on chromosome 3.

Conclusion: With this ongoing work, we are contributing to international efforts to elucidate the host genetics of COVID-19, also by sharing our summary statistics for meta-analyses. Currently, we are sequencing additionally severely affected individuals and we are refining analytical strategies, which will also include the joint analysis of common and rare variants at genome-wide scale.

References:
Grants: None declared, Kerstin Ludwig: None declared.

Conflict of Interest: None declared.

P26.018.C Strong impact of the COVID-19 pandemic on fetal development and chromosomal abnormalities

Mahmut Ergen2, Gulten Tuncel2

European Journal of Human Genetics (2023) 31:345 – 709
Background/Objectives: To date, not many studies have been conducted to examine the role of COVID-19 on gestation and fetal development. During COVID-19, pregnant women had difficulty accessing prenatal screening and care due to pandemics restrictions and lockdowns. In this retrospective study we aimed to assess the effect of the SARS-CoV-2 outbreak on fetal development in both prenatal and postnatal outcomes pre- and pre-COVID-19 pandemics in Northern Cyprus.

Methods: A total number of 61 aborted materials were karyotyped during the pre-pandemic period (January 2017 and March 2020) whereas 24 samples were analysed during the peri-pandemic period (March 2020-November 2021). On the other hand, 25 new-borns blood samples during the pre-pandemic and 44 samples during the pre-pandemic period were analysed.

Results: No statistically significant difference found in health and abnormal aborted material karyotypes between two periods. On the other hand, a statistical significance was observed in postnatal chromosomal abnormalities ($P = 0.04$) after two long pandemic lockdowns, which are known as the first and the second waves, dramatically indicating that no baby with Down syndrome was between 2017-2020 whereas seven babies with Down Syndrome were born as consequences of without taking precaution against lockdowns.

Conclusion: Overall, prenatal care is failed which resulting increased postnatal chromosomal abnormality due to heavy flight restrictions, economic inflation instability, limited access to medical services during COVID-19 pandemic lockdowns in Northern Cyprus.

References:

Grants:

Conflict of Interest: None declared.

P26.019.D Carnosic acid as potential anti-SARS-CoV-2 therapeutics: a mechanistic insight

Havva Ozgen Kilgoz1, erol eyupoglu2, Sepideh Hassanpour Khodaei1, Prof. Dr. Şükrü Tüzmen1,2

Background/Objectives: Rosmarinus Officinalis L.(Rosemary) extract Carnosic acid(CA) has been investigated for its antimicrobial and antioxidative properties(1). Only limited number of publications reported the utilization of this extract in SARS-CoV-2 infection. Also, the mechanistic understanding of CA remains to be determined. Our goal was to elucidate the potential role of CA in COVID19. To obtain mechanistic insight of pharmacogenomic action of CA, comprehensive in silico analyses were performed. Further in vitro experiments were done to illustrate the cytotoxicity of CA and confirm in silico findings.

Methods: CA was extracted from Rosmarinus Officinalis L. by HPLC. Stimulation assays were performed using the COVID19 samples. In silico pharmacogenomic properties of CA were performed by using SwissADME. SwissTargetPrediction tool was utilized to define the possible targets. SARS-CoV-2-interacting proteins were evaluated using STRING(2). To verify in silico findings, gene expression levels were analyzed using qPCR.

Results: Among the top 15 SwissTargetPrediction target molecules(out of 100), Prostaglandin E synthase(PTGES) had the highest probability for CA. Among 332 proteins identified using the STRING, PGES2 was found to be interacting with the nsp7, important molecule for viral replication. The stimulation assays and gene expression analyses confirmed the viral inhibitory role of CA through PTGES pathway.

Conclusion: To our knowledge, our work is the first to reveal the inhibitory role of CA in COVID19 through PTGES pathway. Given the crucial role of PTGES in inflammation, it is noteworthy to examine CA as potential anti-SARS-CoV2 therapeutics.

References: 1. Bauer et al. J Pharmacol Exp Ther.2012 Jul;342(1):169–176.
2.Gordon et al. Nature.2020 Apr;583:459-468.

Grants:

Conflict of Interest: None declared.